The Renal Drug Handbook
The Ultimate Prescribing Guide for Renal Practitioners

5th Edition

Edited by
Caroline Ashley and Aileen Dunleavy
UK Renal Pharmacy Group

Foreword by
Professor Sir John Cunningham
Professor of Nephrology
University College London

CRC Press
Taylor & Francis Group
Boca Raton  London  New York

CRC Press is an imprint of the
Taylor & Francis Group, an Informa business
Foreword to the fifth edition

The Renal Drug Handbook has developed into an essential resource for nephrologists, specialist nurses and pharmacists engaged in the care of these patients. As the field moves forward so also do the therapeutic opportunities, and pitfalls. Fortunately successive editions of the handbook have kept pace with these advances - the present Fifth Edition includes over 900 drug monographs, each containing synoptic but important information for the target audience. A particularly strong point to this series is that, rather than trying to be clever, the authors have stuck with a simple alphabetical organisation which makes finding one’s way around extremely easy. Having found the desired entry, the reader is then confronted with a logical, clear and consistently structured body of information on the relevant drug, including criteria for use, dosing issues in patients with normal, reduced and severely reduced renal function, drug interactions, metabolism, pharmacokinetics and practicalities of administration. It is this combination of utility and accessibility that enables the Fifth Edition of The Renal Drug Handbook to set an exceptionally high crossbar. The book will continue to be available online and for this Fifth Edition will be also downloadable to smartphones. There really is nothing else quite like it.

Professor Sir John Cunningham
Professor of Nephrology, University College London
April 2018
Preface

Welcome to the fifth edition of The Renal Drug Handbook. The information contained in this book has been compiled from a wide range of sources and from the clinical experience of the editorial board of the UK Renal Pharmacy Group, all of whom are involved in the pharmaceutical care of renally-impaired patients. As such, some of the information contained in the monographs may not be in accordance with the licensed indications or use of the drug.

The Handbook aims to:

- provide healthcare professionals with a single reference of easily retrievable, practical information relating to drug use, sourced from the practical experience of renal units throughout the UK. By referring to the monographs, the user is guided in how to prescribe, prepare and administer the drug with due regard to potentially serious drug interactions and to any renal replacement therapy the patient may be undergoing
- provide a practice-based review of drug utilisation in renal units across the UK indicating, where appropriate, any local methods of use, licensed or otherwise.

In recent years, the classification for chronic kidney disease (CKD) has changed, now being described as CKD stages 1–5. Each stage is defined by the patient’s eGFR (or estimated GFR) which is calculated using the MDRD (modification of diet in renal disease) equation. One point to note is that the eGFR is normalised to a standard body surface area of 1.73 m². There is relatively good correlation between the two equations for calculating renal function in patients of average weight, and either could be used for the majority of drugs. However, eGFR should not be used for calculating drug doses in patients at extremes of body weight nor for drugs with a narrow therapeutic window unless it is first corrected to the actual GFR for that patient. Actual GFR can be calculated from the following equation:

$$\text{Actual GFR} = (\text{eGFR} \times \text{BSA}/1.73)$$

At extremes of body weight neither the MDRD nor the Cockcroft-Gault equation is particularly accurate. If an accurate GFR is required, e.g. for chemotherapy, then an isotope GFR determination should be performed.

The information on dosage adjustments in renal impairment given in this book is based on Cockcroft-Gault creatinine clearance and not eGFR, since the majority of published information available is based on creatinine clearance.

The Handbook is not intended to offer definitive advice or guidance on how drugs should be used in patients with renal impairment, nor is it a comprehensive and complete list of all drugs licensed in the UK.

The range of drugs covered will continue to grow with subsequent editions. The Handbook is not a guide to diagnosis nor to a drug’s side-effect profile, except where adverse drug events are more pronounced in the presence of renal impairment. For more in-depth information, users are advised to refer to the Summary of Product Characteristics, the British National Formulary, package inserts or other product data.

The use of drugs in patients with impaired renal function can give rise to problems for several reasons:

- Altered pharmacokinetics of some drugs, i.e. changes in absorption, tissue distribution, extent of plasma protein binding, metabolism and excretion. In renal impairment these parameters are often variable and interrelated in a complex manner. This may be further complicated if the patient is undergoing renal replacement therapy.
- For many drugs, some or even all, of the altered pharmacokinetic parameters and modified interrelationships are unknown. In such circumstances, the informed professional judgement of clinicians and pharmacists must be used to predict drug disposition. This must be based on knowledge of the drug, its class, chemistry and pharmacokinetics in patients with normal renal function.
- Sensitivity to some drugs is increased, even if elimination is unimpaired.
- Many side-effects are particularly poorly tolerated by renally impaired patients.
- Some drugs are ineffective when renal function is reduced.
- Renal function generally declines with age, and many elderly patients have a GFR less than 50 mL/min which, because of reduced muscle mass, may not be reflected by an elevated creatinine. Consequently, one can justifiably assume mild renal impairment when prescribing for the elderly.

Many of these problems can be avoided by careful choice and use of drugs. This Handbook seeks to assist healthcare professionals in this process.
Preface

Using the monographs

- Drug name: The approved (generic) name is usually stated.
- Clinical use: A brief account of the more common indications in renally impaired patients is given. Where an indication or route is unlicensed, this is usually stated.
- Dose in normal renal function: The doses quoted for patients with normal renal function are generally the licensed dosage recommendations stated in the Summary of Product Characteristics for each drug. Where a product is not licensed in the UK, dosage guidelines are provided by the relevant drug company.
- Pharmacokinetics: Basic pharmacokinetic data such as molecular weight, half-life, percentage protein-binding, volume of distribution and percentage excreted unchanged in the urine are quoted, to assist in predicting drug handling in both renal impairment and renal replacement therapy.
- Metabolism: Very few drugs are 100% excreted via either the liver or the kidneys. Many are metabolised by the liver to either active or inactive metabolites, and some of these may be excreted via the kidneys. Pharmacologically active metabolites that undergo renal excretion must be considered when prescribing the parent drug in patients with renal impairment.
- Dose in renal impairment: The level of renal function below which the dose of a drug must be reduced depends largely on the extent of renal metabolism and elimination, and on the drug's toxicity. Most drugs are relatively well tolerated, have a broad therapeutic index or are metabolised and excreted hepatically, so precise dose modification is unnecessary. In such cases, the user is instructed to 'dose as in normal renal function'.

For renally excreted drugs with a narrow therapeutic index, the total daily maintenance dose may be reduced either by decreasing the dose or by increasing the dosing interval, or sometimes by a combination of both. Dosing guidelines for varying degrees of renal impairment are stated accordingly.

- Dose in renal replacement therapy: Details are given for dosing in automated peritoneal dialysis/continuous ambulatory peritoneal dialysis (APD/CAPD), intermittent haemodialysis (HD), intermittent haemodiafiltration (HDF), continuous venovenous haemodialysis/haemodiafiltration (CVV HD/HDF), and continuous arteriovenous haemodialysis/haemodiafiltration (CAV HD/HDF), where known. Drugs are categorised into dialysable/not dialysable/dialysability unknown, to aid the practitioner in making an informed decision for dosing within a particular form of renal replacement therapy. Only a few specific guidelines are given for dosing in continuous arteriovenous/venovenous haemofiltration (CAV/VVH). In general, dosing schedules are the same as those quoted for CAV/VVHD, although it should be borne in mind that CAV/VVH may have a lower drug clearance capacity. Thus the clinician or pharmacist should use informed professional judgement, based on knowledge of the drug and its pharmacokinetics, when deciding whether to further modify dosing regimens.

It should be noted that HDF removes drugs more efficiently than HD, although there is limited information in this area.

- Important drug interactions: The interactions listed are those identified by a black spot in Appendix 1 of the British National Formulary. They are defined as those interactions which are potentially serious, and where combined administration of the drugs involved should be avoided, or only undertaken with caution and appropriate monitoring. Users of the monographs are referred to Appendix 1 of the British National Formulary for a more comprehensive list of interactions deemed to be not so clinically significant.
- Administration: Information is given on reconstitution, route and rate of administration, and other relevant factors. Much of the information relates to local practice, including information on the minimum volume that drugs can be added to. Only the most commonly used and compatible reconstitution and dilution solutions are stated. The product literature should always be consulted for the most up to date information.
- Other information: Details given here are only relevant to the use of that particular drug in patients with impaired renal function or on renal replacement therapy. For more general information, please refer to the Summary of Product Characteristics for that drug.

Your contribution to future editions is vital. Any ideas, comments, corrections, requests, additions, local practices, etc. on the drugs in the Handbook should be put in writing to the Editors-in-Chief: Caroline Ashley, Pharmacy Department, Royal Free Hospital, Hampstead, London NW3 2QG or Aileen Dunleavy, Pharmacy Department, Crosshouse Hospital, Kilmarnock KA2 0BE.

Caroline Ashley
Aileen Dunleavy
March 2018
The following texts have been used as reference sources for the compilation of the monographs in this book:

- electronic Medicines Compendium www.medicines.org.uk/emc
- Drug Information Handbook. 22nd ed. Lexicomp; American Pharmacists Association; 2013
- Cyclosporin Interaction File (Novartis Pharmaceuticals UK).
- Drugdex Database. Micromedex 2.0 Inc., USA.
- Drug company information.
- www.rxlist.com
- medsafe.govt.nz
- www.medicinescomplete.com
- http://www.drugbank.ca/drugs
About the editors

Caroline Ashley is the Lead Specialist Pharmacist for Renal Services at the University College London Centre for Nephrology and Transplantation, Royal Free Hospital. She has over 25 years’ renal experience, and her major areas of interest are transplantation and auto-immune renal disease. Caroline was involved in the development of the Renal National Service Framework, and the NICE guidelines on Immunosuppression in Renal Transplantation, Renal Anaemia, and Acute Kidney Injury. She is the co-editor of both The Renal Drug Handbook and the Introduction to Renal Therapeutics, and sits on the editorial board of the British Journal of Renal Medicine. She was the Chair of the UK Renal Pharmacy Group from 1996 to 2017, and was made Associate Professor of Pharmacy Practice, UCL School of Pharmacy in 2011. She was 2017 recipient of the BRS Mallick Lecture Award for lifetime services to the renal community.

Aileen Dunleavy is the Senior Specialist Pharmacist for Renal Services at the University Hospital Crosshouse, NHS Ayrshire and Arran, with over 20 years’ renal experience. Her major areas of interest are dialysis, anaemia and CKD. She became an independent prescriber in 2008. She is the co-editor of The Renal Drug Handbook and has contributed to the Introduction to Renal Therapeutics, Drugs in Use and Adverse Drug Reactions. She has been a committee member of the UK Renal Pharmacy Group for more than 15 years.
List of abbreviations

5-ASA  5-aminosalicylic acid
ABC   advanced breast cancer
ACE   angiotensin-converting enzyme
ACS   acute coronary syndrome
ADH   antidiuretic hormone
AIDS  acquired immunodeficiency syndrome
ALG   antilymphocyte immunoglobulin
ALT   alanine transaminase
APD   automated peritoneal dialysis
APTT  activated partial thromboplastin time
ARBS  angiotensin receptor blockers
ARF   acute renal failure
AST   aspartate transaminase
ATG   antithymocyte immunoglobulin
AT-II  angiotensin-II
ATN   acute tubular necrosis
AUC   area under the curve
AV    atrioventricular
bd    twice daily
BP    blood pressure
BUN   blood urea nitrogen
CAPD  continuous ambulatory peritoneal dialysis
CAVH  continuous arteriovenous haemofiltration
CAVHD continuous arteriovenous haemodialysis
CKD   chronic kidney disease
CLL   chronic lymphocytic leukaemia
CMV   cytomegalovirus
CNS   central nervous system
COX-2 cyclo-oxygenase-2
CRCL  creatinine clearance
CRF   chronic renal failure
CRIP  constant-rate infusion pump
CSF   cerebrospinal fluid
CSM   Committee on Safety of Medicines
CVVH  continuous venovenous haemofiltration
CVVHDF continuous venovenous haemodialysis
CyA   ciclosporin
CYP   cytochrome pigment
DIC   disseminated intravascular coagulation
DVT   deep-vein thrombosis
E/C   enteric coated
ECG   electrocardiogram
ECT   electroconvulsive therapy
ED    erectile dysfunction
EDTA  edetic acid
eGFR  estimated glomerular filtration rate
ERF   established renal failure
ESAs  erythropoiesis-stimulating agents
ESRD  end-stage renal disease
ESRF  end-stage renal failure
FSGS  focal segmental glomerulosclerosis
G-6-PD glucose-6-phosphate dehydrogenase
GFR   glomerular filtration rate
GI    gastrointestinal
GTN   glyceryl trinitrate
HCL   hairy cell leukaemia / hydrochloride
HD    intermittent haemodialysis
HDF   intermittent haemodiafiltration
HIT   heparin-induced thrombocytopenia
HMG CoA 3-hydroxy-3-methyl-glutaryl coenzyme A
HUS   haemolytic uraemic syndrome
ICU   intensive care unit
IM    intramuscular
INR   international normalised ratio
IP    intraperitoneal
IV    intravenous
LFT   liver function test
LHRH  luteinising hormone-releasing hormone
LMWH  low molecular weight heparin
LVF   left ventricular failure
M/R   modified release
MAO   monoamine oxidase
MAOI  monoamine oxidase inhibitor
MI    myocardial infarction
MMF   mycophenolate mofetil
MPA   mycophenolic acid
NHL   non-Hodgkin's lymphoma
NSAID non-steroidal anti-inflammatory drug
NSLC  non-small cell lung cancer
NYHA New York Heart Association
OD    daily
PAH   primary arterial pulmonary hypertension
PCA   patient-controlled analgesia
PCI   percutaneous coronary intervention
PCP   Pneumocystis jiroveci pneumonia
PCR   polymerase chain reaction
PD    Parkinson's disease / peritoneal dialysis
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE</td>
<td>phenytoin equivalent / pulmonary embolism</td>
<td>SIADH</td>
<td>syndrome of antidiuretic hormone secretion</td>
</tr>
<tr>
<td>PO</td>
<td>orally</td>
<td>SLE</td>
<td>systemic lupus erythematosus</td>
</tr>
<tr>
<td>PR</td>
<td>rectally</td>
<td>SPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>PRCA</td>
<td>pure red cell aplasia</td>
<td>SR</td>
<td>sustained release</td>
</tr>
<tr>
<td>prn</td>
<td>when required</td>
<td>SSRI</td>
<td>selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td>PTH</td>
<td>parathyroid hormone</td>
<td>SVT</td>
<td>symptomatic non-sustained ventricular tachy-arrhythmias</td>
</tr>
<tr>
<td>PTLD</td>
<td>post transplant lymphoproliferative disorder</td>
<td>T½</td>
<td>elimination half-life</td>
</tr>
<tr>
<td>PVC</td>
<td>polyvinyl chloride</td>
<td>T3</td>
<td>tri-iodothyronine (liothyronine)</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis</td>
<td>T4</td>
<td>thyroxine (levothyroxine)</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cells</td>
<td>TADs</td>
<td>tricyclic antidepressants</td>
</tr>
<tr>
<td>RhG-CSF</td>
<td>recombinant human granulocyte colony-stimulating factor</td>
<td>TDM</td>
<td>therapeutic- drug monitoring</td>
</tr>
<tr>
<td>RHuEPO</td>
<td>recombinant human erythropoietin</td>
<td>TPN</td>
<td>total parenteral nutrition</td>
</tr>
<tr>
<td>SBECO</td>
<td>sulphobutylether-beta-cyclodextrin sodium</td>
<td>UTI</td>
<td>urinary-tract infection</td>
</tr>
<tr>
<td>SC</td>
<td>subcutaneous</td>
<td>WM</td>
<td>Waldenström's macroglobulinaemia</td>
</tr>
</tbody>
</table>
Contents

Abacavir .................................................. 1
Abatacept .................................................. 2
Abciximab .................................................. 3
Abiraterone acetate ....................................... 4
Acamprosate calcium ..................................... 5
Acarbose ................................................... 6
Acebutolol ................................................... 7
Aceclofenac ............................................... 9
Achenoumarol (nicoumalone) ......................... 10
Acetazolamide ............................................ 12
Acetylcysteine ............................................ 13
Aclidin IV ................................................... 14
Aclidir oral .................................................. 16
Acipimox .................................................... 17
Acitretin .................................................... 18
Acrivastine ................................................ 19
Adalimumab ............................................... 20
Adefovir dipivoxil ........................................ 21
Adenosine .................................................. 22
Adrenaline (epinephrine) ............................... 23
Afatinib ..................................................... 24
Aflibercept ............................................... 25
Agalsidase alfa (Replagal) ............................. 26
Agalsidase beta (Fabrazyme) ......................... 27
Agomelatine .............................................. 29
Albendazole (unlicensed product) ................. 30
Albiglutide ............................................... 31
Aldesleukin ............................................... 32
Alemtuzumab (MabCampath) ....................... 33
Aldosterone ............................................... 34
Alfaldicidol ............................................... 35
Alfentanil .................................................. 36
Alfuzosin hydrochloride ................................ 38
Alimemazine tartrate (trimeprazine) ............ 39
Alirocumb ............................................... 40
Aliskiren fumarate ...................................... 41
Allopurinol ............................................... 42
Almotriptan .............................................. 43
Alogliptin .................................................. 44
Alteplase (Rt-Pa) (recombinant human tissue-
type plasminogen activator) ....................... 45
Aluminium hydroxide ................................... 47
Amanthine hydrochloride .............................. 48
Ambrisentan .............................................. 49
Amikacin ................................................... 50
Amiloride hydrochloride ................................ 52
Aminophylline ........................................... 53
Amitodarone hydrochloride ......................... 55
Amisulpride .............................................. 57
Amitriptyline hydrochloride ......................... 58
Amlodipine ............................................... 60
Amoxicillin ............................................... 61
Amphotericin IV — Abelcet (lipid complex) .... 62
Amphotericin IV — AmBisome (liposomal) ...... 64
Amphotericin IV — Fungizone ....................... 66
Ampicillin .................................................. 68
Anagrelide ............................................... 69
Anakinra ................................................... 70
Anastrozole .............................................. 71
Anidulafungin ............................................ 72
Apixaban ................................................... 73
Apomorphine hydrochloride ......................... 75
Apremilast ................................................ 76
Aprepitant ................................................ 77
Argatroban ............................................... 78
Aripiprazole .............................................. 80
Arsenic trioxide ......................................... 82
Artemether with lumefantrine ....................... 84
Ascorbic acid ............................................. 85
Asenapine ................................................ 86
Aspirin ..................................................... 87
Atazanavir ............................................... 89
Atezolol .................................................... 91
ATG (rabbit) (thymoglobuline) ..................... 93
Atorvastatin ............................................. 95
Atovaquone ............................................. 97
Atracurium besilate ..................................... 98
Avanafil ................................................... 99
Axitinib ..................................................... 100
Azacitidine .............................................. 101
Azathioprine ............................................ 102
Azilsartan medoxomil ................................. 103
Azithromycin ............................................ 104
Aztreonam ............................................... 105
Baclofen .................................................. 107
Balsalazide sodium .................................... 109
Baricitinib ............................................... 110
Basiliximab ............................................. 111
Bedaquiline fumarate .................................. 112
Belatacept ............................................... 113
Belimumab ............................................... 114
Bendamustine hydrochloride ....................... 115
Bendroflumethiazide .................................. 116
Benzbromarone (unlicensed product) ........... 117
Benzylpenicillin ........................................ 118
Betahistine dihydrochloride ....................... 119
Betamethasone ......................................... 120
Betaxolol hydrochloride .............................. 121
Bevacizumab ............................................ 122
Bexarotene .............................................. 123
<table>
<thead>
<tr>
<th>Drug</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bezafibrate</td>
<td>124</td>
</tr>
<tr>
<td>Bezlotoxumab</td>
<td>125</td>
</tr>
<tr>
<td>Bicalutamide</td>
<td>126</td>
</tr>
<tr>
<td>Bilastine</td>
<td>127</td>
</tr>
<tr>
<td>Bisacodyl</td>
<td>128</td>
</tr>
<tr>
<td>Bisoprolol fumarate</td>
<td>129</td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>130</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>131</td>
</tr>
<tr>
<td>Boceprevir</td>
<td>133</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>135</td>
</tr>
<tr>
<td>Bosentan</td>
<td>136</td>
</tr>
<tr>
<td>Bosutinib</td>
<td>138</td>
</tr>
<tr>
<td>Brentuximab vedotin</td>
<td>140</td>
</tr>
<tr>
<td>Brivaracetam</td>
<td>141</td>
</tr>
<tr>
<td>Brodalumab</td>
<td>142</td>
</tr>
<tr>
<td>Bromocriptine</td>
<td>143</td>
</tr>
<tr>
<td>Budesonide</td>
<td>144</td>
</tr>
<tr>
<td>Bumetanide</td>
<td>145</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>147</td>
</tr>
<tr>
<td>Bupropion hydrochloride (amfebutamone HCL)</td>
<td>148</td>
</tr>
<tr>
<td>Buserelin</td>
<td>149</td>
</tr>
<tr>
<td>Buspirone hydrochloride</td>
<td>150</td>
</tr>
<tr>
<td>Busulfan</td>
<td>151</td>
</tr>
<tr>
<td>Cabazitaxel</td>
<td>152</td>
</tr>
<tr>
<td>Cabergoline</td>
<td>153</td>
</tr>
<tr>
<td>Cabozantinib</td>
<td>154</td>
</tr>
<tr>
<td>Calcitonin (salmon) / salcaton</td>
<td>155</td>
</tr>
<tr>
<td>Calcitriol</td>
<td>156</td>
</tr>
<tr>
<td>Calcium acetate</td>
<td>157</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>158</td>
</tr>
<tr>
<td>Calcium gluonate</td>
<td>159</td>
</tr>
<tr>
<td>Calcium resumon</td>
<td>160</td>
</tr>
<tr>
<td>Canagliflozin</td>
<td>161</td>
</tr>
<tr>
<td>Candesartan cilexetil</td>
<td>162</td>
</tr>
<tr>
<td>Cangrelor</td>
<td>163</td>
</tr>
<tr>
<td>Capcitabine</td>
<td>164</td>
</tr>
<tr>
<td>Capreomycin</td>
<td>165</td>
</tr>
<tr>
<td>Captopril</td>
<td>166</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>168</td>
</tr>
<tr>
<td>Carbimazole</td>
<td>170</td>
</tr>
<tr>
<td>Carboplatin</td>
<td>171</td>
</tr>
<tr>
<td>Carfilzomib</td>
<td>172</td>
</tr>
<tr>
<td>Carmustine</td>
<td>173</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>174</td>
</tr>
<tr>
<td>Caspofungin</td>
<td>175</td>
</tr>
<tr>
<td>Cefaclor</td>
<td>176</td>
</tr>
<tr>
<td>Cefadroxil</td>
<td>177</td>
</tr>
<tr>
<td>Cefalexin</td>
<td>178</td>
</tr>
<tr>
<td>Cefixime</td>
<td>179</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>180</td>
</tr>
<tr>
<td>Cefradine</td>
<td>181</td>
</tr>
<tr>
<td>Cefaroline fosamil</td>
<td>182</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>183</td>
</tr>
<tr>
<td>Cefotibiprole medocaril sodium</td>
<td>185</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>186</td>
</tr>
<tr>
<td>Cefuroxime (oral)</td>
<td>187</td>
</tr>
<tr>
<td>Cefuroxime (parenteral)</td>
<td>188</td>
</tr>
<tr>
<td>Celexobx</td>
<td>189</td>
</tr>
<tr>
<td>Celirol hydrochloride</td>
<td>191</td>
</tr>
<tr>
<td>Ceritinib</td>
<td>192</td>
</tr>
<tr>
<td>Certolizumab pegol</td>
<td>194</td>
</tr>
<tr>
<td>Cetirizine hydrochloride</td>
<td>195</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>196</td>
</tr>
<tr>
<td>Chloral hydrate</td>
<td>197</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>198</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>199</td>
</tr>
<tr>
<td>Chlordiazepoxide hydrochloride</td>
<td>200</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>201</td>
</tr>
<tr>
<td>Chlorphenamine maleate (chlorpheniram)</td>
<td>203</td>
</tr>
<tr>
<td>Chlorpromazine hydrochloride</td>
<td>204</td>
</tr>
<tr>
<td>Chlortalidone (chlorthalidone)</td>
<td>206</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>207</td>
</tr>
<tr>
<td>Cidofovir</td>
<td>209</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>210</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>211</td>
</tr>
<tr>
<td>Cinacalcet</td>
<td>213</td>
</tr>
<tr>
<td>Cinnarizine</td>
<td>214</td>
</tr>
<tr>
<td>Ciprofibrate</td>
<td>215</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>216</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>218</td>
</tr>
<tr>
<td>Citalopram</td>
<td>220</td>
</tr>
<tr>
<td>Cladribine</td>
<td>222</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>223</td>
</tr>
<tr>
<td>Clemastine</td>
<td>225</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>226</td>
</tr>
<tr>
<td>Clozapine</td>
<td>235</td>
</tr>
<tr>
<td>Co-amoxiclav (amoxicillin / clavulanic acid)</td>
<td>237</td>
</tr>
<tr>
<td>Co-beneldopa (Madopar)</td>
<td>239</td>
</tr>
<tr>
<td>Co-careldopa (Sinemet)</td>
<td>240</td>
</tr>
<tr>
<td>Co-codamol (paracetamol and codeine phosphate)</td>
<td>241</td>
</tr>
<tr>
<td>Co-dyramol (paracetamol and dihydrocodeine)</td>
<td>242</td>
</tr>
<tr>
<td>Co-trimoxazole (trimethoprim + sulfamethoxazole)</td>
<td>243</td>
</tr>
<tr>
<td>Cobicistat</td>
<td>245</td>
</tr>
<tr>
<td>Cobicinitin</td>
<td>247</td>
</tr>
<tr>
<td>Codeine phosphate</td>
<td>248</td>
</tr>
<tr>
<td>Colchicine</td>
<td>249</td>
</tr>
<tr>
<td>Colecalciferol</td>
<td>251</td>
</tr>
</tbody>
</table>
Colestipol hydrochloride ........................................ 253
Colestyramine (cholestyramine) ................................ 254
Colistimethate sodium (Colistin) ................................. 255
Crisantaspase ......................................................... 257
Crizotinib ............................................................. 258
Cyclizine ............................................................... 259
Cyclophosphamide .................................................. 261
Cyclophosphamide .................................................. 261
Cycloserine ........................................................... 263
Cyproheptadine hydrochloride .................................... 264
Cypreterone acetate .................................................. 265
Cytarabine ............................................................. 266
Cytomegalovirus (CMV) human immunoglobulin (unlicensed product) .................................................. 268
Dabigatran etexilate .................................................. 269
Dabrafenib .............................................................. 271
Dacarbazine ........................................................... 272
Dactactasvir ............................................................ 273
Dacilizumab ............................................................. 274
Dactinomycin .......................................................... 275
Dalteparin sodium (LMWH) ......................................... 276
Danaparoid sodium .................................................... 278
Dantrolene sodium .................................................... 280
Dapagliflozin ........................................................... 281
Dapsone ................................................................. 282
Dapomycin ............................................................... 283
Daratumumab .......................................................... 285
Darbepoetin alfa ........................................................ 286
Darifenacin .............................................................. 288
Darunavir ............................................................... 289
Dasabuvir ............................................................... 290
Dasatinib ................................................................. 291
Daunorubicin .......................................................... 292
Decitabine ............................................................... 293
Deferasirox ............................................................. 294
Deferiprone ............................................................. 296
Deflacazocort .......................................................... 297
Degarelix ............................................................... 298
Delamanid ............................................................... 299
Demeclocycline hydrochloride ..................................... 300
Denosumab ............................................................ 301
Desferrioxamine mesilate ........................................... 302
Desirudin (unlicensed product) ..................................... 304
Desloratadine .......................................................... 305
Desmopressin (DDAVP) .............................................. 306
Dexamethasone ........................................................ 307
Dexibuprofen .......................................................... 309
Dexketoprofen ........................................................ 311
Dexrazoxane .......................................................... 312
Diamorphine hydrochloride ........................................ 313
Diazepam .............................................................. 314
Diazoxide .............................................................. 315
Diluclorex sodium .................................................... 316
Didanosine ............................................................. 318
Digoxin ................................................................. 319
Dihydrocodeine tartrate ............................................. 321
Diltiazem hydrochloride ............................................. 322
Dimethyl fumarate .................................................... 324
Dipryramide .......................................................... 325
Disodium pamidronate ................................................. 326
Disopropylmamine .................................................... 327
Disulfiram .............................................................. 329
Dobutamine ............................................................ 330
Docetaxel ............................................................... 331
Dolasetron ............................................................. 332
Domperidone .......................................................... 333
Donepezil hydrochloride ............................................. 335
Dopamine hydrochloride ............................................. 336
Dopamine hydrochloride ............................................. 337
Dornase alfa ........................................................... 338
Doxilepin hydrochloride (dothiepin) ............................... 339
Doxapram hydrochloride ............................................. 341
Doxazosin .............................................................. 342
Doxepin ................................................................. 343
Doxorubicin hydrochloride .......................................... 345
Doxycycline ............................................................ 346
Dronedaron ............................................................. 347
Droperidol ............................................................... 349
Dulaglutide .............................................................. 351
Duloxetine .............................................................. 352
Dutasteride ............................................................. 353
Eculizumab ............................................................. 354
Edoxaban tosilate ....................................................... 355
Efavirenz ............................................................... 357
Eletiriptan .............................................................. 359
Eltroambloc ............................................................. 360
Eluxadoline ............................................................. 361
Empagliflozin .......................................................... 362
Emtricitibatine ........................................................ 363
Enapril maleate ........................................................ 364
Enfuviartide ............................................................ 366
Enoxaparin sodium (LMWH) ........................................ 367
Entacapone ............................................................. 369
Entecavir ............................................................... 370
Enalalamide ............................................................ 371
Epirubicin hydrochloride ............................................. 372
Epleronone ............................................................. 374
Epoetin alfa (Eprex) .................................................. 376
Epoetin beta (Neoreconorm) ........................................ 377
Epoprostenol (prostacyclin) .......................................... 378
Eprosartan ............................................................. 379
Eptifibatide ............................................................. 380
Eribulin ................................................................. 381
Erlotinib .................................................. 382  
Ertapenem ............................................. 383  
Erythromycin ......................................... 384  
Escitalopram ........................................... 386  
Eslicarbazepine acetate ........................... 388  
Esmolol hydrochloride ............................... 389  
Esomeprazole .......................................... 390  
Estramustine phosphate ............................. 391  
Etamsylate ............................................. 392  
Etanercept .............................................. 393  
Etelcalcetide .......................................... 394  
Ethambutol hydrochloride ......................... 395  
Ethosuximide .......................................... 396  
Etodolac .................................................. 397  
Etomideate ............................................... 399  
Etoposide ............................................... 400  
Etoricoxib ............................................... 402  
Etravirine ............................................... 404  
Evetolimus ............................................... 405  
Evolocumab ............................................. 407  
Exemestane ............................................ 408  
Exenatide ............................................... 409  
Ezetimibe ............................................... 410  
Famiclovir ............................................... 411  
Famotidine ............................................. 413  
Febuxostat ............................................. 414  
Felodipine ............................................... 416  
Fenofibrate ............................................. 417  
Fenoprofen ............................................. 418  
Fentanyl ................................................. 419  
Ferric carboxymaltose ................................ 421  
Ferrous fumarate ..................................... 422  
Ferrous gluconate .................................... 423  
Ferrous sulphate ..................................... 424  
Fesoterodine fumarate ............................... 425  
Fexofenadine hydrochloride ....................... 426  
Fidaxomicin ............................................ 427  
Filgrastim ................................................ 428  
Finasteride ............................................. 429  
Fingolimod .............................................. 430  
Flecainide acetate .................................. 431  
Flucloxacillin ......................................... 433  
Fluconazole ............................................ 434  
Flucytosine ............................................. 436  
Fludarabine phosphate .............................. 437  
Fludrocortisone acetate ............................ 438  
Flumazenil ............................................. 439  
Fluorouracil ............................................ 440  
Fluoxetine ............................................... 441  
Flupentixol ............................................. 443  
Fluphenazine decanoate ............................ 445  
Flurbiprofen ............................................ 446  
Flutamide ............................................... 448  
Fluvastatin .............................................. 449  
Fluvoxamine maleate ................................ 450  
Folic acid ............................................... 452  
Folinic acid (calcium folinate) ................... 453  
Fondaparinux sodium ............................... 454  
Formoterol fumarate (eformoterol) ............ 455  
Fosaprepitant .......................................... 458  
Foscarnet sodium ..................................... 459  
Fosfomycin ............................................. 461  
Fosinopril sodium ..................................... 463  
Fosphenytoin sodium ................................ 464  
Frovatriptan ........................................... 466  
Fulvestrant ............................................. 467  
Fumaric acid esters (fumaderm) .................. 468  
Furosemide (frusemide) ............................. 469  
Gabapentin .............................................. 471  
Galantamine ............................................ 472  
Ganciclovir ............................................. 473  
Gatifloxacin ........................................... 474  
Gemcitabine ............................................ 476  
Gemfibrozil ............................................. 478  
Gentamicin ............................................. 479  
Glipizide ................................................ 484  
Glyceryl trinitrate ................................... 485  
Goserelin ................................................ 486  
Granisetron ............................................. 487  
Grazosulphate ........................................ 488  
Guanethidine monosulphate ....................... 489  
Haloperidol ............................................. 490  
Heparin .................................................. 492  
Hydralazine hydrochloride ....................... 493  
Hydrocortisone acetate ............................. 494  
Hydrocortisone sodium succinate .............. 495  
Hydromorphone hydrochloride .................... 496  
Hydroxyamide (hydroxyurea) ..................... 497  
Hydroxychloroquine sulphate ..................... 498  
Hydroxyurea ............................................ 499  
Hyoscine butylbromide ............................. 500  
Hyoscin hydrobromide ................................ 501  
Ibandronic acid ....................................... 502  
Ibrutinib ............................................... 504  
Idarubicin hydrochloride ......................... 507  
Idelalisib ............................................... 509  
Iodosamide ............................................. 511
<table>
<thead>
<tr>
<th>Item</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iloprost</td>
<td>513</td>
</tr>
<tr>
<td>Imatinib</td>
<td>514</td>
</tr>
<tr>
<td>Imidapril hydrochloride</td>
<td>516</td>
</tr>
<tr>
<td>Imipramine hydrochloride</td>
<td>517</td>
</tr>
<tr>
<td>Indapamide</td>
<td>519</td>
</tr>
<tr>
<td>Indinavir</td>
<td>521</td>
</tr>
<tr>
<td>Indometacin</td>
<td>523</td>
</tr>
<tr>
<td>Indoramin</td>
<td>525</td>
</tr>
<tr>
<td>Infliximab</td>
<td>526</td>
</tr>
<tr>
<td>Inosine pranobex</td>
<td>527</td>
</tr>
<tr>
<td>Inositol nicotinate</td>
<td>528</td>
</tr>
<tr>
<td>Insulin – soluble (Actrapid or Humulin S)</td>
<td>529</td>
</tr>
<tr>
<td>Interferon alpha-2A (Roferon A)</td>
<td>530</td>
</tr>
<tr>
<td>Interferon alpha-2B</td>
<td>531</td>
</tr>
<tr>
<td>Interferon beta</td>
<td>533</td>
</tr>
<tr>
<td>Interferon gamma-1B (Immukin)</td>
<td>534</td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>536</td>
</tr>
<tr>
<td>Irbesartan</td>
<td>537</td>
</tr>
<tr>
<td>Irinotecan hydrochloride</td>
<td>538</td>
</tr>
<tr>
<td>Iron dextran 5% solution</td>
<td>539</td>
</tr>
<tr>
<td>Iron isomaltoside 1000</td>
<td>540</td>
</tr>
<tr>
<td>Iron sucrose</td>
<td>541</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>543</td>
</tr>
<tr>
<td>Isosorbide dinitrate</td>
<td>544</td>
</tr>
<tr>
<td>Isosorbide mononitrate</td>
<td>545</td>
</tr>
<tr>
<td>Isotretinoin</td>
<td>546</td>
</tr>
<tr>
<td>Ispaghula husk</td>
<td>547</td>
</tr>
<tr>
<td>Isradipine</td>
<td>548</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>549</td>
</tr>
<tr>
<td>Ivabradine hydrochloride</td>
<td>551</td>
</tr>
<tr>
<td>Ixazomib citrate</td>
<td>552</td>
</tr>
<tr>
<td>Ketamine</td>
<td>553</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>555</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>557</td>
</tr>
<tr>
<td>Ketorolac trometamol</td>
<td>559</td>
</tr>
<tr>
<td>Ketotifen</td>
<td>561</td>
</tr>
<tr>
<td>Klean-prep</td>
<td>562</td>
</tr>
<tr>
<td>Labetalol hydrochloride</td>
<td>563</td>
</tr>
<tr>
<td>Lacidipine</td>
<td>565</td>
</tr>
<tr>
<td>Lacosamide</td>
<td>566</td>
</tr>
<tr>
<td>Lactulose</td>
<td>567</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>568</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>569</td>
</tr>
<tr>
<td>Lanreotide</td>
<td>570</td>
</tr>
<tr>
<td>Lansoprazole</td>
<td>571</td>
</tr>
<tr>
<td>Lanthanum carbonate</td>
<td>572</td>
</tr>
<tr>
<td>Lapanib</td>
<td>573</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>574</td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>575</td>
</tr>
<tr>
<td>Lenograstim</td>
<td>576</td>
</tr>
<tr>
<td>Lenvatinib mesilate</td>
<td>577</td>
</tr>
<tr>
<td>Lercanidipine hydrochloride</td>
<td>578</td>
</tr>
<tr>
<td>Letrozole</td>
<td>579</td>
</tr>
<tr>
<td>Leuprorelin acetate</td>
<td>580</td>
</tr>
<tr>
<td>Levamisole (unlicensed product)</td>
<td>581</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>582</td>
</tr>
<tr>
<td>Levoctrizine hydrochloride</td>
<td>583</td>
</tr>
<tr>
<td>Levofoxacin</td>
<td>584</td>
</tr>
<tr>
<td>Levofolic acid</td>
<td>586</td>
</tr>
<tr>
<td>Levomepromazine (methotrimethazine)</td>
<td>587</td>
</tr>
<tr>
<td>Levothyroxine sodium (thyroxine).</td>
<td>589</td>
</tr>
<tr>
<td>Lidoigaine hydrochloride (Lignocaine)</td>
<td>590</td>
</tr>
<tr>
<td>Linagliptin</td>
<td>591</td>
</tr>
<tr>
<td>Linezolid</td>
<td>592</td>
</tr>
<tr>
<td>Lithothryonine sodium (tri-iodothyronine)</td>
<td>594</td>
</tr>
<tr>
<td>Lipecfilgrastim</td>
<td>595</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>596</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>597</td>
</tr>
<tr>
<td>Lithium carbonate</td>
<td>598</td>
</tr>
<tr>
<td>Lixisenatide</td>
<td>600</td>
</tr>
<tr>
<td>Lofepramine</td>
<td>601</td>
</tr>
<tr>
<td>Lomipratide</td>
<td>603</td>
</tr>
<tr>
<td>Lomustine</td>
<td>604</td>
</tr>
<tr>
<td>Loperamide hydrochloride</td>
<td>605</td>
</tr>
<tr>
<td>Lopinavir</td>
<td>606</td>
</tr>
<tr>
<td>Loratadine</td>
<td>608</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>609</td>
</tr>
<tr>
<td>Lorazepamol</td>
<td>610</td>
</tr>
<tr>
<td>Losartan potassium</td>
<td>611</td>
</tr>
<tr>
<td>Loxapine</td>
<td>612</td>
</tr>
<tr>
<td>Lurasidone hydrochloride</td>
<td>613</td>
</tr>
<tr>
<td>Lymecycline</td>
<td>614</td>
</tr>
<tr>
<td>Macitentan</td>
<td>615</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>616</td>
</tr>
<tr>
<td>Mebendazole</td>
<td>617</td>
</tr>
<tr>
<td>Medroxyprogesterone acetate</td>
<td>618</td>
</tr>
<tr>
<td>Mefenamic acid</td>
<td>620</td>
</tr>
<tr>
<td>Mefloquine</td>
<td>622</td>
</tr>
<tr>
<td>Megestrol acetate</td>
<td>623</td>
</tr>
<tr>
<td>Melatonin</td>
<td>624</td>
</tr>
<tr>
<td>Meloxicam</td>
<td>625</td>
</tr>
<tr>
<td>Melfalan</td>
<td>627</td>
</tr>
<tr>
<td>Memantine</td>
<td>629</td>
</tr>
<tr>
<td>Mepacrine hydrochloride (unlicensed product)</td>
<td>630</td>
</tr>
<tr>
<td>Mepolizumab</td>
<td>631</td>
</tr>
<tr>
<td>Meptazinol</td>
<td>632</td>
</tr>
<tr>
<td>Mercaptopurine</td>
<td>633</td>
</tr>
<tr>
<td>Meropenem</td>
<td>635</td>
</tr>
<tr>
<td>Mesalazine</td>
<td>637</td>
</tr>
<tr>
<td>Mesna</td>
<td>638</td>
</tr>
<tr>
<td>Metaraminol</td>
<td>639</td>
</tr>
<tr>
<td>Metformin hydrochloride</td>
<td>640</td>
</tr>
</tbody>
</table>
Methadone hydrochloride ........................................ 641  
Methenamine hippurate ........................................ 643  
Methotrexate ....................................................... 644  
Methyldopa .......................................................... 646  
Methyldprednisolone .............................................. 647  
Metoclopramide hydrochloride ............................... 648  
Metolazone (unlicensed) ......................................... 649  
Metoprolol tartrate ............................................... 650  
Metronidazole ...................................................... 652  
Mexiletine hydrochloride (unlicensed) ....................... 653  
Mianserin hydrochloride ......................................... 654  
Micafungin ............................................................ 655  
Miconazole ........................................................... 656  
Midazolam ............................................................ 657  
Midodrine hydrochloride ........................................ 659  
Mifamurtide .......................................................... 660  
Minocycline .......................................................... 661  
Minoxidil .............................................................. 662  
Mirabegron ........................................................... 663  
Miricera ............................................................... 664  
Mirtazapine ........................................................... 665  
Misoprostol ............................................................ 666  
Mitomycin ............................................................. 667  
Mitotane ............................................................... 668  
Mirtroxantrone ........................................................ 669  
Mivacurium ............................................................ 670  
Mizolastine ............................................................ 671  
Moclubemide .......................................................... 672  
Modafinil ............................................................... 673  
Moexipril hydrochloride ......................................... 674  
Montelukast ........................................................... 675  
Morphine .............................................................. 676  
Movicol (active ingredient is the osmotic laxative polyethylene glycol) ........................................ 678  
Moxifloxacin .......................................................... 679  
Moxisylyte (thymoxamine) ....................................... 680  
Moxonidine ............................................................ 681  
Muromonab CD3 (OKT3) (unlicensed) ......................... 682  
Mycophenolate ........................................................ 683  
Nabilone ............................................................... 685  
Nabumetone ........................................................... 686  
Nadolol ................................................................. 688  
Naftidrofuryl oxalate .............................................. 689  
Nalidixic acid ........................................................ 690  
Nalmefene hydrochloride dihydrate ........................ 691  
Naloxone hydrochloride ......................................... 692  
Naltrexone hydrochloride ....................................... 693  
Naproxen ............................................................... 694  
Naratriptan ............................................................ 696  
Natalizumab ........................................................... 697  
Nateglinide ............................................................ 698  
Nebivolol ............................................................... 699  
Necitumumab ........................................................ 700  
Nefopam hydrochloride (nortriptyline bitartrate) .......... 701  
Nelarabine ............................................................. 702  
Neomycin sulphate ................................................. 703  
Neostigmine .......................................................... 704  
Nevirapine ............................................................ 705  
Nicardipine hydrochloride ........................................ 707  
Nicorandil ............................................................. 709  
Nicotinic acid (unlicensed) ....................................... 710  
Nifedipine ............................................................. 711  
Nilotinib ............................................................... 713  
Nimodipine ............................................................ 714  
Nintedanib ............................................................. 715  
Nitrazepam ............................................................ 716  
Nitrofurantoin ........................................................ 717  
Nivolumab ............................................................. 718  
Nizatidine ............................................................... 720  
Noradrenaline acid tartrate (norepinephrine bitartrate) ... 721  
Norethisterone ........................................................ 722  
Norfloxacin ............................................................ 723  
Normal human immunoglobulin ................................ 724  
Nortriptyline .......................................................... 726  
Nystatin ............................................................... 727  
Obinutuzumab ........................................................ 728  
Ocetreotide ............................................................. 729  
Oestrogen, conjugated (unlicensed product) ................. 730  
Olbatumab ............................................................. 731  
Ofloxacin ............................................................... 732  
Olanzapine ............................................................. 733  
Olaparib ................................................................. 734  
Olaratumab ............................................................ 735  
Olmesartan medoxomil ............................................ 736  
Olsalazine sodium ................................................. 737  
Omacetaxine methil esters ........................................ 738  
Ombitasvir / paritaprevir / ritonavir ......................... 739  
Omega-3-acid ethyl esters ........................................ 741  
Omeprazole ............................................................ 742  
Ondansetron .......................................................... 743  
Oritavancin ............................................................ 744  
Orlistat ................................................................. 745  
Orphenadrine hydrochloride .................................... 746  
Oseltamivir ............................................................ 747  
Osimertinib mesilate .............................................. 749  
Oxaliplatin ............................................................. 750  
Oxazepam ............................................................... 751  
Oxcarbazepine ........................................................ 752  
Oxenpilin hydrochloride ......................................... 753  
Oxybutynin hydrochloride ....................................... 754  
Oxycodone hydrochloride ....................................... 755  
Oxytetracycline ...................................................... 756  
Paclitaxel ............................................................... 757
<table>
<thead>
<tr>
<th>Substance</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palbociclib</td>
<td>758</td>
</tr>
<tr>
<td>Paliperidone</td>
<td>759</td>
</tr>
<tr>
<td>Palonosetron</td>
<td>760</td>
</tr>
<tr>
<td>Pancreatin</td>
<td>761</td>
</tr>
<tr>
<td>Pancuronium bromide</td>
<td>762</td>
</tr>
<tr>
<td>Panitumumab</td>
<td>763</td>
</tr>
<tr>
<td>Panobinostat</td>
<td>764</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>766</td>
</tr>
<tr>
<td>Papaveretum</td>
<td>767</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>768</td>
</tr>
<tr>
<td>Parathyroid hormone</td>
<td>769</td>
</tr>
<tr>
<td>Parecoxib</td>
<td>770</td>
</tr>
<tr>
<td>Paricalcitol</td>
<td>772</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>773</td>
</tr>
<tr>
<td>Pasireotide</td>
<td>775</td>
</tr>
<tr>
<td>Patiromer sorbitex calcium</td>
<td>776</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>777</td>
</tr>
<tr>
<td>Pegfilgrastim</td>
<td>778</td>
</tr>
<tr>
<td>Peginterferon alfa</td>
<td>779</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>780</td>
</tr>
<tr>
<td>Pemetrexed</td>
<td>781</td>
</tr>
<tr>
<td>Penicillamine</td>
<td>782</td>
</tr>
<tr>
<td>Pentamidine isetionate</td>
<td>783</td>
</tr>
<tr>
<td>Pentoctin</td>
<td>785</td>
</tr>
<tr>
<td>Pentoxifylline (expentifylline)</td>
<td>786</td>
</tr>
<tr>
<td>Perampanel</td>
<td>787</td>
</tr>
<tr>
<td>Pergolide</td>
<td>788</td>
</tr>
<tr>
<td>Perindopril</td>
<td>789</td>
</tr>
<tr>
<td>Pertuzumab</td>
<td>791</td>
</tr>
<tr>
<td>Pethidine hydrochloride</td>
<td>792</td>
</tr>
<tr>
<td>Phenelzine</td>
<td>793</td>
</tr>
<tr>
<td>Phenindione</td>
<td>794</td>
</tr>
<tr>
<td>Phenobarbital (phenobarbitone)</td>
<td>795</td>
</tr>
<tr>
<td>Phenoxybenzamine hydrochloride</td>
<td>797</td>
</tr>
<tr>
<td>Phenoxyethylpenicillin (penicillin V)</td>
<td>798</td>
</tr>
<tr>
<td>Phentolamine mesilate (unlicensed)</td>
<td>799</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>800</td>
</tr>
<tr>
<td>Phosphate supplements</td>
<td>803</td>
</tr>
<tr>
<td>Phytomenadione (vitamin K)</td>
<td>804</td>
</tr>
<tr>
<td>Pimozide</td>
<td>805</td>
</tr>
<tr>
<td>Pindolol</td>
<td>806</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>807</td>
</tr>
<tr>
<td>PIPERAZINE</td>
<td>808</td>
</tr>
<tr>
<td>Piracetam</td>
<td>809</td>
</tr>
<tr>
<td>Piroxicam</td>
<td>810</td>
</tr>
<tr>
<td>Pivmecillin hydrochloride</td>
<td>811</td>
</tr>
<tr>
<td>Pixantrone</td>
<td>812</td>
</tr>
<tr>
<td>Pizotifen</td>
<td>813</td>
</tr>
<tr>
<td>Plerixafor</td>
<td>814</td>
</tr>
<tr>
<td>Pomalidomide</td>
<td>815</td>
</tr>
<tr>
<td>Ponatinib</td>
<td>816</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>817</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>819</td>
</tr>
<tr>
<td>Pramipexole</td>
<td>820</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>821</td>
</tr>
<tr>
<td>Pravastatin sodium</td>
<td>822</td>
</tr>
<tr>
<td>Praziquantel (unlicensed product)</td>
<td>823</td>
</tr>
<tr>
<td>Prazosin</td>
<td>824</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>825</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>826</td>
</tr>
<tr>
<td>Primidone</td>
<td>827</td>
</tr>
<tr>
<td>Procarbazine</td>
<td>828</td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>829</td>
</tr>
<tr>
<td>Procyclidine hydrochloride</td>
<td>830</td>
</tr>
<tr>
<td>Proguanil hydrochloride</td>
<td>831</td>
</tr>
<tr>
<td>Promazine hydrochloride</td>
<td>832</td>
</tr>
<tr>
<td>Promethazine hydrochloride</td>
<td>833</td>
</tr>
<tr>
<td>Propafenone hydrochloride</td>
<td>834</td>
</tr>
<tr>
<td>Propiverine hydrochloride</td>
<td>835</td>
</tr>
<tr>
<td>Propofol</td>
<td>836</td>
</tr>
<tr>
<td>Propranolol hydrochloride</td>
<td>837</td>
</tr>
<tr>
<td>Propylthiouracil</td>
<td>838</td>
</tr>
<tr>
<td>Protamine sulphate</td>
<td>839</td>
</tr>
<tr>
<td>Pseudoephedrine hydrochloride</td>
<td>840</td>
</tr>
<tr>
<td>Pyrazinamide (unlicensed product)</td>
<td>841</td>
</tr>
<tr>
<td>Pyridostigmine bromide</td>
<td>842</td>
</tr>
<tr>
<td>Pyridoxine hydrochloride</td>
<td>843</td>
</tr>
<tr>
<td>Pyrimethamine</td>
<td>844</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>845</td>
</tr>
<tr>
<td>Quinagolide</td>
<td>846</td>
</tr>
<tr>
<td>Quinapril</td>
<td>847</td>
</tr>
<tr>
<td>Quinine</td>
<td>848</td>
</tr>
<tr>
<td>Rabeprazole sodium</td>
<td>849</td>
</tr>
<tr>
<td>Racecadotril</td>
<td>850</td>
</tr>
<tr>
<td>Rasagiline</td>
<td>851</td>
</tr>
<tr>
<td>Rasburicase</td>
<td>852</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>853</td>
</tr>
<tr>
<td>Ranolazine</td>
<td>854</td>
</tr>
<tr>
<td>Rasagiline</td>
<td>855</td>
</tr>
<tr>
<td>Rasburicase</td>
<td>856</td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>857</td>
</tr>
<tr>
<td>Racemic acid</td>
<td>858</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>859</td>
</tr>
<tr>
<td>Raifortamide</td>
<td>860</td>
</tr>
<tr>
<td>Ramipril</td>
<td>861</td>
</tr>
<tr>
<td>Ramucirumab</td>
<td>862</td>
</tr>
<tr>
<td>Ranitidine sodium</td>
<td>863</td>
</tr>
<tr>
<td>Ranolazine sodium</td>
<td>864</td>
</tr>
<tr>
<td>Rasagiline</td>
<td>865</td>
</tr>
<tr>
<td>Rasburicase</td>
<td>866</td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>867</td>
</tr>
<tr>
<td>Reboxetine</td>
<td>868</td>
</tr>
<tr>
<td>Regorafenib</td>
<td>869</td>
</tr>
<tr>
<td>Remifentanil</td>
<td>870</td>
</tr>
<tr>
<td>Repaglinide</td>
<td>871</td>
</tr>
<tr>
<td>Reslizumab</td>
<td>872</td>
</tr>
<tr>
<td>Retelplase</td>
<td>873</td>
</tr>
<tr>
<td>Ribavirin (tribavirin)</td>
<td>874</td>
</tr>
<tr>
<td>Ribociclib</td>
<td>875</td>
</tr>
<tr>
<td>Rifabutin</td>
<td>876</td>
</tr>
</tbody>
</table>
Strontium ranelate .............................................................. 894
Sodium nitroprusside ......................................................... 926
Sodium fusidate ................................................................. 928
Sodium valproate ............................................................... 931
Sotalol hydrochloride ......................................................... 936
Spiranolactone ................................................................. 938
Stavudine ......................................................................... 940
Streptokinase ................................................................. 941
Streptomycin (unlicensed) .................................................... 942
Strontium ranelate ............................................................. 944
Sucralfate (aluminium sucrose sulphate) ............................. 945
Sucroferric oxyhydroxide (Velphor) ................................. 946
Sulindac .............................................................. 950
Sulfinpyrazone .............................................................. 949
Sulphadiazine ................................................................. 947
Sulphasalazine (sulphasalazine) ........................................... 948
Sulphafoxanthine ............................................................ 951
Sulphadione ................................................................. 952
Sulphadiazinone ............................................................. 953
Sulfadiazine ................................................................. 954
Sulfasalazine ................................................................. 955
Sulfasalazine (sodium) ....................................................... 956
Sulfadiazine ................................................................. 957
Sulfadiazinone ............................................................... 958
Sulfacetamide ............................................................... 959
Sulfacetamide sodium ....................................................... 960
Sulfacetamide sodium (sodium) ........................................... 961
Sulfadiazine ................................................................. 962
Sulfadiazinone ............................................................... 963
Sulfacetamide sodium (sodium) ........................................... 964
Sulfacetamide sodium (sodium) ........................................... 965
Sulfacetamide sodium (sodium) ........................................... 966
Sulfacetamide sodium (sodium) ........................................... 967
Sulfacetamide sodium (sodium) ........................................... 968
Sulfacetamide sodium (sodium) ........................................... 969
Sulfacetamide sodium (sodium) ........................................... 970
Sulfacetamide sodium (sodium) ........................................... 971
Sulfacetamide sodium (sodium) ........................................... 972
Sulfacetamide sodium (sodium) ........................................... 973
Sulfacetamide sodium (sodium) ........................................... 974
Sulfacetamide sodium (sodium) ........................................... 975
Sulfacetamide sodium (sodium) ........................................... 976
Sulfacetamide sodium (sodium) ........................................... 977
Sulfacetamide sodium (sodium) ........................................... 978
Sulfacetamide sodium (sodium) ........................................... 979
Sulfacetamide sodium (sodium) ........................................... 980
Sulfacetamide sodium (sodium) ........................................... 981
Sulfacetamide sodium (sodium) ........................................... 982
Sulfacetamide sodium (sodium) ........................................... 983
Sulfacetamide sodium (sodium) ........................................... 984
Sulfacetamide sodium (sodium) ........................................... 985
Sulfacetamide sodium (sodium) ........................................... 986
Sulfacetamide sodium (sodium) ........................................... 987
Sulfacetamide sodium (sodium) ........................................... 988
Sulfacetamide sodium (sodium) ........................................... 989
Sulfacetamide sodium (sodium) ........................................... 990
Sulfacetamide sodium (sodium) ........................................... 991
Sulfacetamide sodium (sodium) ........................................... 992
Sulfacetamide sodium (sodium) ........................................... 993
Sulfacetamide sodium (sodium) ........................................... 994
Sulfacetamide sodium (sodium) ........................................... 995
Sulfacetamide sodium (sodium) ........................................... 996
Sulfacetamide sodium (sodium) ........................................... 997
Sulfacetamide sodium (sodium) ........................................... 998
Sulfacetamide sodium (sodium) ........................................... 999
Sulfacetamide sodium (sodium) ........................................... 1000
Sulfacetamide sodium (sodium) ........................................... 1001
Sulfacetamide sodium (sodium) ........................................... 1002
Sulfacetamide sodium (sodium) ........................................... 1003
Sulfacetamide sodium (sodium) ........................................... 1004
Sulfacetamide sodium (sodium) ........................................... 1005
Sulfacetamide sodium (sodium) ........................................... 1006
Abacavir

**Clinical use**

Nucleoside reverse transcriptase inhibitor:
- Used for HIV infection in combination with other antiretroviral drugs

**Dose in normal renal function**

600 mg daily in 1 or 2 divided doses

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>286.3 (670.7 as sulphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>49</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.8</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.5 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Abacavir is primarily metabolised by the liver with approximately 2% of the administered dose being renally excreted, as unchanged compound. The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5'-carboxylic acid and 5'-glucuronide which account for about 66% of the administered dose. The metabolites are excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antivirals: possibly reduces effects of ribavirin; concentration reduced by tipranavir.
- Orlistat: absorption possibly reduced by orlistat.

**Administration**

**Reconstitution**

- **Route**
  - Oral

- **Rate of administration**
  -
**Abatacept**

**Clinical use**
Treatment of moderate to severe rheumatoid arthritis and psoriatic arthritis in people who have not responded adequately to other treatment.

**Dose in normal renal function**

**IV:**
- Loading doses: <60 kg: 500 mg, 60–100 kg: 750 mg, >100 kg: 1000 mg repeated 2 and 4 weeks after initial infusion
- Then 125 mg weekly (SC)

Psoriatic arthritis:
- 125 mg weekly (SC)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>92 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.07</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>13.1 days / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Abatacept is cleared via Fc-mediated phagocytosis.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR = 10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Avoid with certolizumab, etanercept, golimumab and infliximab.
- Vaccines: avoid concomitant use with live vaccines.

**Administration**

**Reconstitution**
With 10 mL of water for injection per vial

**Route**
IV infusion, SC

**Rate of administration**
Over 30 minutes

**Comments**
- DO NOT SHAKE when reconstituting.
- Add dose to 100 mL of sodium chloride 0.9%.

**Other information**

- Stable for 24 hours at 2–8°C if made under aseptic conditions.
- Administer with an infusion set with a low protein binding filter (pore size 0.2–1.2 μm).
- Manufacturer does not have any information on its use in renal impairment. Main side effects are infections and malignancies, to which renal patients may be at increased risk, therefore use with caution.
Abciximab

Clinical use

Antiplatelet agent:
- Prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention
- Short-term prevention of myocardial infarction in patients with unstable angina not responding to treatment or awaiting percutaneous coronary intervention.

Dose in normal renal function

IV bolus: 250 mcg/kg then by infusion at 0.125 mcg/kg/minute for 12 hours after intervention (maximum 10 mcg/minute).

Pharmacokinetics

Molecular weight (daltons) 47,455.4
% Protein binding Binds to platelets.
% Excreted unchanged in urine Minimal (catabolised like other proteins)
Volume of distribution (L/kg) 0.118
Half-life — normal/ESRF (hrs) <10 minutes / Unchanged

Metabolism

Following IV administration, abciximab rapidly binds to the platelet GPIIb/IIIa receptors, and remains in the circulation for 15 days or more in a platelet-bound state. Metabolism is via proteolytic cleavage.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. Use with caution. See ‘Other information’.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Heparin, anticoagulants, antiplatelets and thrombolytics: increased risk of bleeding.

Administration

Reconstitution
—

Route
IV bolus, IV infusion

Rate of administration
Bolus: 1 minute; Infusion: 0.125 mcg/kg/minute (maximum 10 mcg/minute)

Comments
Dilute in sodium chloride 0.9% or glucose 5%. Give via a non-pyrogenic low-protein-binding 0.2, 0.22 or 5 micron filter.

Other information

- Increased risk of bleeding in CKD 5, benefits of abciximab treatment may be reduced.
- In the UK the licence says use with caution in severe renal disease due to increased risk of bleeding and benefits may be reduced. It also advises to avoid in haemodialysis patients due to increased risk of bleeding (as on heparin for dialysis) but it is used in normal doses in the USA.
- Antibodies to abciximab develop 2–4 weeks post dose in 5.8% of patients so monitor for hypersensitivity reactions if re-administered.
- Abciximab remains in the body for at least 15 days, bound to platelets.
- Once infusion is stopped, the concentration of abciximab falls rapidly for 6 hours then decreases at a slower rate.

Reference:
Abiraterone acetate

Clinical use
Hormone antagonist:
• Treatment of metastatic prostate cancer

Dose in normal renal function
1000 mg daily

Pharmacokinetics
Molecular weight (daltons) 391.6
% Protein binding 99.8
% Excreted unchanged in urine 5
Volume of distribution (L/kg) 5630 Litres
Half-life — normal/ESRF (hrs) 15 / Unchanged

Metabolism
Abiraterone acetate is hydrolysed to abiraterone, which then undergoes metabolism including sulphation, hydroxylation and oxidation mainly in the liver to form inactive metabolites. About 88% of a dose is excreted in the faeces, of which about 55% is unchanged abiraterone acetate and about 22% is abiraterone; about 5% of a dose is excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
APD/CAPD  Unlikely to be dialysed. Dose as in normal renal function.
HD  Not dialysed. Dose as in normal renal function.
HDF/High flux  Not dialysed. Dose as in normal renal function.
CAV/VVHD  Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Antibacterials: concentration possibly reduced by rifabutin and rifampicin – avoid.
• Antidepressants: concentration possibly reduced by St John’s wort – avoid.
• Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone – avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—
Comments
Should be taken on an empty stomach.

Other information
• The manufacturer suggests using normal doses in renal patients although no formal studies have been done so use with caution.
# Acamprosate calcium

## Clinical use
Maintenance of abstinence in alcohol dependence

## Dose in normal renal function
- >60 kg: 666 mg 3 times a day
- <60 kg: 666 mg at breakfast, 333 mg at midday and 333 mg at night

## Pharmacokinetics
- Molecular weight (daltons) 400.5
- % Protein binding 0
- % Excreted unchanged in urine Majority
- Volume of distribution (L/kg) Approximately 1
- Half-life — normal/ESRF (hrs) 33 / 85.8

## Metabolism
Acamprosate is excreted in the urine and is not metabolised significantly.

## Dose in renal impairment GFR (mL/min)
- 30–50: 333 mg 3 times daily.
- 10–30: 333 mg twice daily. See 'Other information'.
- <10: 333 mg once daily. See 'Other information'.

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–30 mL/min.

## Important drug interactions
- Potentially hazardous interactions with other drugs
  - None known

## Administration
### Reconstitution
- —

### Route
- Oral

### Rate of administration
- —

## Other information
- Recommended treatment period is a year.
- In USA manufacturer advises to avoid if GFR<30 mL/min, in the UK it is contraindicated if creatinine >120 micromol/L.
- Doses estimated from evaluation of pharmacokinetic data, use with caution in moderate to severe renal impairment.
- After a single dose of 666 mg in patients with severe renal impairment, the average maximum concentration was 4 times that in healthy individuals.
- Bioavailability is reduced if administered with food.
## Acarbose

### Clinical use

Antidiabetic agent

### Dose in normal renal function

50–200 mg 3 times a day

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>645.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>15</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>1.7 (35% including inactive metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.32</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–9 / Increased</td>
</tr>
</tbody>
</table>

### Metabolism

Oral bioavailability is 1–2%. After oral administration of the $^{14}$C-labelled substance, on average, 35% of the total radioactivity was excreted by the kidneys within 96 hours. The proportion of drug excreted in the urine was 1.7% of the administered dose. 50% of the activity was eliminated within 96 hours in the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>25–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–25</td>
<td>Avoid.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Important Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Avoid.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Avoid. See 'Other information.'</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Avoid. See 'Other information.'</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Avoid.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs

- Antibacterials: hypoglycaemic effect possibly enhanced and increased gastrointestinal side effects with neomycin.
- Lipid lowering agents: hypoglycaemic effect possibly enhanced by colestyramine.

### Administration

#### Reconstitution

—

#### Route

Oral

#### Rate of administration

—

### Other information

- Only 1–2% of active drug is absorbed.
- In renal impairment, peak concentrations are 5 times higher than in the general population and the AUC is 6 times higher.
- Manufacturer advises to avoid if GFR<25 mL/min due to lack of studies.
Acebutolol

Clinical use

Beta-adrenoceptor blocker:
- Hypertension
- Angina
- Arrhythmias

Dose in normal renal function

- Hypertension: 400 mg once a day or 200 mg twice daily, increased after 2 weeks to 400 mg twice daily if necessary
- Angina: 400 mg once a day, or 200 mg twice daily initially. Increase up to 300 mg 3 times daily; maximum 1200 mg
- Arrhythmias: 400–1200 mg/day (in 2–3 divided doses)

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>336.4 (372.9 as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>26</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>55</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–4 (8–13 for active metabolite) / Increased (32 for active metabolite)</td>
</tr>
</tbody>
</table>

Metabolism

After oral administration, there is rapid formation of a major equiactive metabolite, diacetolol, which possesses a similar pharmacological profile to acebutolol. Peak plasma concentrations of active material (i.e. acebutolol plus diacetolol) are achieved within 2–4 hours and the terminal plasma elimination half-life is around 8–10 hours. Because of biliary excretion and direct transfer across the gut wall from the systemic circulation to the gut lumen, more than 50% of an oral dose of acebutolol is recovered in the faeces with acebutolol and diacetolol in equal proportions; the rest of the dose is recovered in the urine, mainly as diacetolol.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>25–50</td>
<td>50% of normal dose, but frequency should not exceed once daily.</td>
<td></td>
</tr>
<tr>
<td>10–25</td>
<td>50% of normal dose, but frequency should not exceed once daily.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>25–50% of normal dose, but frequency should not exceed once daily.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR = 10–25 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

### Administration

**Reconstitution**

**Route**

Oral

### Rate of administration

### Other information

- Administration of high doses in severe renal failure cautioned due to accumulation.
- Doses from Sani M. Clinical pharmacology in the ICU. (1994); Section 1: p 64 and Drug Prescribing in Renal Failure, 5th edition by Aronoff *et al*.
- Dose frequency should not exceed once daily in renal impairment.
- Has an active metabolite – diacetolol.
**Aceclofenac**

### Clinical use

NSAID and analgesic

### Dose in normal renal function

100 mg twice daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>354.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>66 (mainly as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>25 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

About two-thirds of a dose is excreted in the urine, mainly as hydroxymetabolites, the principal one being 4-hydroxyaceclofenac. A small amount is converted to diclofenac.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function but use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function but avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function but only if on dialysis.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Not dialysed. Dose as in normal renal function. See 'Other information'.
- **HD**: Not dialysed. Dose as in normal renal function. See 'Other information'.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function. See 'Other information'.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs

- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.

- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possible increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect, hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

### Administration

**Reconstitution**

- **Route**: Oral

**Rate of administration**

- **Other information**
  - Use with caution in uraemic patients predisposed to gastrointestinal bleeding or uraemic coagulopathies.
  - Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID therapy – if raised, discontinue NSAID therapy.
  - Use normal doses in patients with ESRD on dialysis if they do not pass any urine.
  - Use with great caution in renal transplant recipients; it can reduce intrarenal autocoid synthesis.
Acenocoumarol (nicoumalone)

**Clinical use**
Anticoagulant

**Dose in normal renal function**
- Initially: 2–4 mg on 1st day without a loading dose;
- Loading dose: 6 mg on 1st day then 4 mg on 2nd day
- Maintenance dose usually 1–8 mg daily according to INR

**Pharmacokinetics**
- Molecular weight (daltons) 353.3
- % Protein binding >98
- % Excreted unchanged in urine <0.2
- Volume of distribution (L/kg) 0.16–0.18 R(+) enantiomer; 0.22–0.34 S(–) enantiomer
- Half-life — normal/ESRF (hrs) 8–11 / Probably unchanged

**Metabolism**
Acenocoumarol is extensively metabolised, although the metabolites appear to be pharmacologically inactive in man. 29% is excreted in the faeces and 60% in the urine, with less than 0.2% of the dose being renally excreted unchanged.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in normal renal function.
- HD Unknown dialysability. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs

There are many significant interactions with coumarins. Prescribe with care with regard to the following:
- Anticoagulant effect enhanced by: alcohol, amiodarone, anabolic steroids, aspirin, aztreonam, bicalutamide, cephalosporins, chloramphenicol, cimetidine, ciprofloxacin, fibrates, clopidogrel, cranberry juice, danazol, dipyriramole, disulfiram, dronedarone, esomeprazole, ezetimibe, fibrates, fluconazole, flutamide, fluvalastin, grapefruit juice, itraconazole, ketoconazole, levamisole, levofloxacin, macrolides, methylphenidate, metronidazole, miconazole, nalidixic acid, neomycin, norfloxacin, NSAIDs, ofloxacin, omeprazole, pantoprazole, paracetamol, penicillins, propafenone, ritonavir, rosuvastatin, SSRIs, simvastatin, sulfamprazine, sulphonamides, tamoxifen, testosterone, tetracyclines, thyroid hormones, tigecycline, toremifene, tramadol, trimethoprim, valproate, vitamin E, voriconazole.
- Anticoagulant effect decreased by: acitretin, azathioprine, carbamazepine, enteral feeds, enalapril, fosphenytoin, griseofulvin, oral contraceptives, phenobarbital, phenytoin, primidone, rifamycins, St John’s wort (avoid), sucralfat, vitamin K.
- Anticoagulant effects enhanced / reduced by: anion exchange resins, corticosteroids, dietary changes, efavirenz, fosamprazine, tricyclics.
- Analgesics: increased risk of bleeding with IV diclofenac and ketorolac – avoid concomitant use.
- Anticoagulants: increased risk of haemorrhage with apixaban, dabigatran, edoxaban and rivaroxaban – avoid.
- Antidiabetic agents: enhanced hypoglycaemic effect with sulphamylureas also possible changes to anticoagulant effect.
- Ciclosporin: there have been a few reports of altered anticoagulant effect; decreased ciclosporin levels have been seen rarely.
- Cytotoxics: increased risk of bleeding with erlotinib; enhanced anticoagulant effect with capecitabine, etoposide, fluorouracil, ifosfamide, sorafenib and tegafur; reduced effect with mercaptopurine and mitotane.

**Administration**
Reconstitution
- Route
  Oral
Rate of administration
—

Other information
- Acenocoumarol prolongs the thromboplastin time within approximately 36–72 hours.
- Decreased protein binding in uraemia.
- Titrate dose to INR.
- Company advises to avoid in severe renal disease due to increased risk of haemorrhage if risk is greater than benefit.
Acetazolamide

Clinical use
Carbonic anhydrase inhibitor:
• Glaucoma
• Diuretic
• Epilepsy

Dose in normal renal function
• Glaucoma / Epilepsy: 0.25–1 g daily in divided doses
• Diuretic: 250–375 mg daily

Pharmacokinetics
Molecular weight (daltons) 222.2
% Protein binding 70–90
% Excreted unchanged in urine 100
Volume of distribution (L/kg) 0.2
Half-life — normal/ESRF (hrs) 3–6 / 26

Metabolism
Acetazolamide is tightly bound to carbonic anhydrase and accumulates in tissues containing this enzyme, particularly red blood cells and the renal cortex. It is also bound to plasma proteins. It is excreted unchanged in the urine, renal clearance being enhanced in alkaline urine.

Dose in renal impairment GFR (mL/min)
20–50 250 mg up to twice a day.
10–20 250 mg up to twice a day.
<10 Avoid. See 'Other information'.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Unlikely dialysability. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Analgesics: high dose aspirin reduces excretion (risk of toxicity).

• Anti-arrhythmics: increased toxicity if hypokalaemia occurs.
• Antibacterials: effects of methenamine antagonised.
• Antiepileptics: increased risk of osteomalacia with phenytoin and phenobarbital; concentration of carbamazepine and possibly fosphenytoin and phenytoin increased.
• Antihypertensives: enhanced hypotensive effect.
• Antipsychotics: increased risk of ventricular arrhythmias due to hypokalaemia.
• Atomoxetine: increased risk of ventricular arrhythmias due to hypokalaemia.
• Beta-blockers: increased risk of ventricular arrhythmias due to hypokalaemia with sotalol.
• Cardiac glycosides: increased toxicity if hypokalaemia occurs.
• Ciclosporin: possibly increases ciclosporin concentration.
• Cytotoxics: alkaline urine increases methotrexate excretion; increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
• Lithium: lithium excretion increased.

Administration
Reconstitution
Add at least 5 mL of water for injection
Route
Oral, IM, IV
Rate of administration
Give slow IV
Comments
• Avoid IM due to alkaline pH.
• Monitor for signs of extravasation and skin necrosis during administration.

Other information
• Manufacturer advises to avoid in severe renal failure.
• Doses in renal impairment from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
• Acetazolamide sodium (Diamox) parenteral contains 2.36 millimoles of sodium per vial.
• Severe metabolic acidosis may occur in the elderly and in patients with reduced renal function.
• May cause neurological side effects in dialysis patients.
Acetylcysteine

**Clinical use**
- Treatment of paracetamol overdose
- Renal protection during radiological scans involving contrast media (unlicensed)
- Treatment of mucolytic in respiratory disorders

**Dose in normal renal function**
- IV infusion: Dose varies according to patient’s weight. See manufacturer’s information
- Renal protection – see ‘Other information’
- Mucolytic in respiratory disorders: 600 mg (orally) once daily

**Pharmacokinetics**
- Molecular weight (daltons) 163.2
- % Protein binding 50
- % Excreted unchanged in urine 20–30
- Volume of distribution (L/kg) 0.33–0.47
- Half-life — normal/ESRF (hrs) 2–6 / –

**Metabolism**
Acetylcysteine undergoes transformation in the liver, and may be present in plasma as the parent compound or as various oxidised metabolites such as N-acetylcystine, N,N-diacetylcystine, and cysteine either free or bound to plasma proteins. Oral bioavailability is low (4–10%). It has been suggested that acetylcysteine’s low oral bioavailability may be due to metabolism in the gut wall and first-pass metabolism in the liver.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Likely to be dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Likely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
Glucose 5%

**Route**
IV, oral

**Rate of administration**
See under Dose

**Comments**
- Acetylcysteine has been administered neat or in a 1 to 1 dilution using an infusion pump. These are unlicensed methods of administration.
- Minimum dilutions can range from 100–250 mL. It is advised to give strong solutions centrally. (UK Critical Care Group, *Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients*, 3rd edition, 2006).

**Other information**
- Bennett recommends administering 75% of dose for patients with severe renal impairment; however, the manufacturer does not recommend a dose reduction for paracetamol poisoning and, from its records, neither does the National Poisons Centre.
- There is some evidence that acetylcysteine may have a renoprotective effect during scans involving the use of contrast media, in patients with already impaired renal function.
- Dose = 600 mg PO BD the day before the scan, repeated the day of the scan, together with IV or PO fluids. Injection may be taken orally, or tablets are available from IDIS.
- Alternatively, give 1 g acetylcysteine IV in 500 mL sodium chloride 0.9% or dextrose 5%, the day before the scan, repeated the day of the scan.
Aciclovir IV

**Clinical use**

Antiviral agent:
- Herpes simplex and Herpes zoster infection

**Dose in normal renal function**

- Herpes simplex treatment: normal or immunocompromised 5 mg/kg every 8 hours
- Recurrent varicella zoster infection: normal immune status 5 mg/kg every 8 hours
- Primary and recurrent varicella zoster infection: immunocompromised 10 mg/kg every 8 hours
- Herpes simplex encephalitis: normal or immunocompromised 10 mg/kg every 8 hours

**Pharmacokinetics**

- Molecular weight (daltons) 225.2
- % Protein binding 9–33
- % Excreted unchanged in urine 40–70
- Volume of distribution (L/kg) 0.7
- Half-life — normal/ESRF (hrs) 2.9 / 19.5 (dialysis: 5.7)

**Metabolism**

Most of the drug is excreted unchanged by the kidney. Renal clearance of aciclovir is substantially greater than creatinine clearance, indicating that tubular secretion, in addition to glomerular filtration, contributes to the renal elimination of the drug. 9-carboxymethoxy-methylguanine is the only significant metabolite of aciclovir and accounts for 10–15% of the dose excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>25–50</td>
<td>5–10 mg/kg every 12 hours.</td>
</tr>
<tr>
<td>10–25</td>
<td>5–10 mg/kg every 24 hours (some units use 3.5–7 mg/kg every 24 hours).</td>
</tr>
<tr>
<td>&lt;10</td>
<td>2.5–5 mg/kg every 24 hours.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Not dialysed. Dose as in GFR<10 mL/min.
- **HD** Dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux** Dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD/HDF** Dialysed. Dose as in GFR=10–25 mL/min. See ‘Other information’.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Ciclosporin: reports of increased and decreased ciclosporin levels. Some editors report no experience of interaction locally; possibly increased risk of nephrotoxicity.
- Higher plasma levels of aciclovir and mycophenolate mofetil with concomitant administration.
- Tacrolimus: possibly increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

Sodium chloride 0.9% or water for injection; 10 mL to each 250 mg vial; 20 mL to 500 mg vial (Resulting solution contains 25 mg/mL.)

**Route**

IV

**Rate of administration**

1 hour; can worsen renal impairment if injected too rapidly!

**Comments**

- Reconstituted solution may be further diluted to concentrations not greater than 5 mg/mL.
- Use 100 mL infusion bags for doses of 250–500 mg; use 2 x 100 mL bags for 500–1000 mg.
- Compatible with sodium chloride 0.9% and glucose 5%.
- DO NOT REFRIGERATE.
- Do not use turbid or crystal-containing solutions.
- Reconstituted solution very alkaline (pH 11).

**Other information**

- Aciclovir clearance in CAVHD is approximately equivalent to urea clearance, i.e. lower clearance than in intermittent haemodialysis.
Monitor aciclovir levels in critically ill patients. Reports of neurological toxicity at maximum recommended doses.

Renal impairment developing during treatment with aciclovir usually responds rapidly to rehydration of the patient, and/or dosage reduction or withdrawal of the drug. Adequate hydration of the patient should be maintained.

Plasma aciclovir concentration is reduced by 60% during haemodialysis.

There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid 'flux' within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
Aciclovir oral

Clinical use

Antiviral agent:
- Herpes simplex and Herpes zoster infection

Dose in normal renal function

- Simplex treatment: 200–400 mg 5 times daily
- Prophylaxis (immunocompromised): 200–400 mg every 6 hours
- Suppression: 200 mg every 6 hours, or 400 mg every 12 hours
- Zoster: 800 mg 5 times a day for 7 days

Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>225.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>9–33</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40–70</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2.9 / 19.5 (dialysis: 5.7)</td>
</tr>
</tbody>
</table>

Metabolism

Most of the drug is excreted unchanged by the kidney. Renal clearance of aciclovir is substantially greater than creatinine clearance, indicating that tubular secretion, in addition to glomerular filtration, contributes to the renal elimination of the drug. 9-carboxymethoxy-methylguanine is the only significant metabolite of aciclovir and accounts for 10–15% of the dose excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>25–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–25</td>
<td>Simplex: 200 mg 3–4 times daily</td>
</tr>
<tr>
<td></td>
<td>Zoster: 800 mg every 8–12 hours</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Simplex: 200 mg every 12 hours</td>
</tr>
<tr>
<td></td>
<td>Zoster: 400–800 mg every 12 hours</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min. Give dose after dialysis.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min. Give dose after dialysis.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–25 mL/min. See 'Other information'.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Ciclosporin: reports of increase and decrease in ciclosporin levels; some editors report no experience of interaction locally; possibly increased risk of nephrotoxicity.
- Higher plasma levels of aciclovir and mycophenolate mofetil with concomitant administration.
- Tacrolimus: possibly increased risk of nephrotoxicity.

Administration

Reconstitution

Route
Oral

Rate of administration

Comments
Dispersible tablets may be dispersed in a minimum of 50 mL of water or swallowed whole with a little water.

Other information

- Consider IV therapy for zoster infection if patient severely immunocompromised.
- Plasma aciclovir concentration is reduced by 60% during haemodialysis.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
**Acipimox**

### Clinical use

Hyperlipidaemia

### Dose in normal renal function

250 mg 2 or 3 times daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>154.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>86–90</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.3–0.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2 / Increased</td>
</tr>
</tbody>
</table>

### Metabolism

Acipimox is not significantly metabolised and is eliminated almost completely intact by the urinary route.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–80</td>
<td>250 mg daily</td>
</tr>
<tr>
<td>20–40</td>
<td>250 mg alternate days. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;20</td>
<td>See 'Other information'.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy Type</th>
<th>Dose Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Likely dialysability. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=20–40 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- None known

### Administration

**Reconstitution**
- None

**Route**
- Oral

**Rate of administration**
- None

**Comments**
- Take with or after meals.

### Other information

- Females are twice as likely as males to suffer from side effects, e.g. flushing, pruritis and skin rashes.
- Manufacturer advises to avoid if GFR<30 mL/min.
- Doses up to 1200 mg have been given safely for long periods.
- After a 5 hour dialysis 70% of the drug had been removed.
- Dollery advises the doses given in the table, down to 20 mL/minute, but nothing after that.
- Micromedex gives the following recommendations:
  - GFR=30–60 mL/min: 150 mg twice daily
  - GFR=10–30 mL/min: 150 mg once daily
  - GFR<10 mL/min: 150 mg alternate days
Acitretin

Clinical use
- Severe extensive psoriasis, palmoplanar pustular psoriasis
- Severe congenital ichthyosis
- Severe Darier’s disease

Dose in normal renal function
- Initially: 25–30 mg daily (Darier’s disease 10 mg daily) for 2–4 weeks, adjusted according to response.
- Ongoing: usually 25–50 mg/day (maximum 75 mg) for further 6–8 weeks. (In Darier’s disease and ichthyosis not more than 50 mg daily for up to 6 months.)

Pharmacokinetics
- Molecular weight (daltons) 326.4
- % Protein binding >99 (< 0.1% present as unbound drug in pooled human plasma)
- % Excreted unchanged in urine Excreted as metabolites.
- Volume of distribution (L/kg) 9
- Half-life — normal/ESRF (hrs) 50 / –

Metabolism
Acitretin is metabolised by isomerisation into its 13-cis isomer (cis acitretin), which is also a teratogen, by glucuronidation and cleavage of the side chain. Acitretin is excreted entirely in the form of its metabolites, in approximately equal parts via the kidneys and the bile.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>No data available. Assume dose as in normal renal function. See ‘Other information’.</td>
</tr>
<tr>
<td>10–20</td>
<td>No data available. Assume dose as in normal renal function. See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>No data available. Assume dose as in normal renal function. See ‘Other information’.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR <10 mL/min.
- HD: Not dialysed. Dose as in GFR <10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR <10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR =10–20 mL/min.

Important drug interactions
- Potentially hazardous interactions with other drugs
  - Alcohol: increased risk of teratogenicity in women.
  - Antibacterials: possibly increased risk of benign intracranial hypertension with tetracyclines – avoid concomitant use.
  - Anticoagulants: possible antagonism of the anticoagulant effect of coumarins.
  - Cytotoxics: increased concentration of methotrexate (also increased risk of hepatotoxicity) – avoid concomitant use.
  - Vitamin A: risk of hypervitaminosis – avoid concomitant use.

Administration
- Reconstitution
  - Route
    - Oral
  - Rate of administration
  - Comments
    - Take once daily with meals or with milk.

Other information
- Manufacturer’s literature contraindicates the use of acitretin in severe renal failure.
- Patients with renal impairment are at risk of hypervitaminosis. Monitor liver function closely.
- Start with the lowest dose possible and increase cautiously.
Acrivastine

Clinical use

Antihistamine:
• Symptomatic relief of allergy such as hayfever, urticaria

Dose in normal renal function

8 mg 3 times a day

Pharmacokinetics

Molecular weight (daltons) 348.4
% Protein binding 50
% Excreted unchanged in urine 60
Volume of distribution (L/kg) 0.6–0.7
Half-life — normal/ESRF (hrs) 1.5 / –

Metabolism

Acrivastine undergoes metabolism in the liver, and along with an active metabolite, is excreted principally in the urine.

Dose in renal impairment GFR (mL/min)

20–50 8 mg twice a day.
10–20 8 mg 1–2 times a day.
<10 8 mg 1–2 times a day.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Unknown dialysability. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
• Antivirals: concentration possibly increased by ritonavir.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information

• Manufacturers do not recommend use in patients with significant renal impairment due to lack of data.
• Dose in severe renal impairment is from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
## Adalimumab

### Clinical use

Tumour necrosis factor alpha inhibitor:
- Treatment of moderate to severe rheumatoid arthritis with or without methotrexate
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease and ulcerative colitis
- Psoriasis

### Dose in normal renal function

- 40 mg on alternate weeks increased to weekly if monotherapy for rheumatoid arthritis
- Crohn's disease and ulcerative colitis: see product literature
- Psoriasis: 80 mg initially then 40 mg on alternate weeks
- Other conditions: 40 mg on alternate weeks

### Pharmacokinetics

- Molecular weight (daltons): 148 000
- % Protein binding: No data
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): 5–6 Litres
- Half-life — normal/ESRF (hrs): 14 days / –

### Metabolism

Most likely removed by opsonisation via the reticuloendothelial system.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose and Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose and Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Anakinra: avoid concomitant use.
- Live vaccines: avoid concomitant use.

### Administration

#### Reconstitution

- **Route:** SC

#### Rate of administration

- **Comments:** Suitable injection sites are the thigh and abdomen

### Other information

- Contraindicated in patients with severe infections and moderate to severe heart failure.
- Bioavailability is 64%.
- After subcutaneous injection peak concentrations are reached in about 3–8 days.
- Manufacturer is unable to provide a dose in renal impairment due to lack of studies.
- A case study has been reported where a haemodialysis patient was successfully treated with adalimumab for psoriatic arthritis – Initially at a dose of 80 mg followed by 40 mg on alternate weeks.¹
- Case reports of glomerulonephritis have been reported with adalimumab.²

### References:


Adefovir dipivoxil

Clinical use
Treatment of chronic hepatitis B infection

Dose in normal renal function
10 mg once daily

Pharmacokinetics
Molecular weight (daltons) 501.5
% Protein binding <4
% Excreted unchanged in urine 45
Volume of distribution (L/kg) 0.4
Half-life — normal/ESRF (hrs) 7 / 15

Metabolism
Following oral administration, the pro-drug adefovir dipivoxil is rapidly converted to adefovir, which in turn is excreted renally by a combination of glomerular filtration and active tubular secretion.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>10 mg every 48 hours.</td>
</tr>
<tr>
<td>10–30</td>
<td>10 mg every 72 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>10 mg every 72 hours. See 'Other information'</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. 10 mg weekly or after a cumulative total of 12 hours dialysis. See 'Other information'.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Use with caution in combination with other nephrotoxins.
- Antivirals: avoid concomitant administration with tenofovir
- Interferons: use with caution with peginterferon alfa.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information
- Nephrotoxic in higher IV doses, but risk is lower with oral doses; although cases of raised creatinine and AKI have been reported.
- Manufacturer has no data for GFR<10 mL/min and other forms of dialysis apart from haemodialysis therefore has no information on dosing.
- Dose in severe renal impairment is from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Discontinue treatment if any of the following occur: lactic acidosis, rapid increase in aminotransferase, progressive hepatomegaly or steatosis.
- 35% of dose is removed with a 4-hour dialysis session.
- There is a case report of it being used at a dose of 10mg 3 times a week post dialysis. (Tillmann HL, Bock CT, Bleck JS, et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl. 2003; 9(2): 191–6.)
## Clinical use
- Rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardias
- Diagnosis of broad or narrow complex supraventricular tachycardias

## Dose in normal renal function
Initially: 6 mg over 2 seconds with cardiac monitoring followed, if necessary, by 12 mg after 1–2 minutes and then by 12 mg after a further 1–2 minutes.

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>267.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>&lt;10 seconds /</td>
</tr>
<tr>
<td></td>
<td>Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
It is impossible to study adenosine in classical pharmacokinetic studies, since it is present in various forms in all the cells of the body. An efficient salvage and recycling system exists in the body, primarily in erythrocytes and blood vessel endothelial cells. The half-life in vitro is estimated to be less than 10 seconds, and may be even shorter in vivo.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased risk of myocardial depression.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval.
- Beta-blockers: increased risk of myocardial depression.
- Effect is enhanced and extended by dipyridamole; therefore if use of adenosine is essential, dosage should be reduced by a factor of 4 (i.e. initial dosage of 0.5–1 mg).
- Theophylline and other xanthines are potent inhibitors of adenosine.

## Administration
### Reconstitution
<table>
<thead>
<tr>
<th>Route</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td></td>
</tr>
</tbody>
</table>

### Rate of administration
Rapid IV bolus (see dose)

### Comments
- Do not refrigerate.
- Administer into central vein, large peripheral vein, or into an IV line. If IV line used, follow dose by rapid sodium chloride 0.9% flush.

## Other information
- Neither the kidney nor the liver are involved in the degradation of exogenous adenosine, so dose adjustments are not required in hepatic or renal insufficiency.
- Unlike verapamil, adenosine may be used in conjunction with a beta-blocker.
- Common side effects: facial flushing, chest pain, dyspnoea, bronchospasm, nausea and lightheadedness; the side effects are short-lived.
## Adrenaline (epinephrine)

### Clinical use
Sympathomimetic and inotropic agent

### Dose in normal renal function
0.01–1 mcg/kg/minute

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>183.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>50</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Phase 1: 3 minutes; Phase 2: 10 minutes</td>
</tr>
</tbody>
</table>

### Metabolism
Most adrenaline that is either injected into the body or released into the circulation from the adrenal medulla, is very rapidly inactivated by processes that include uptake into adrenergic neurones, diffusion, and enzymatic degradation in the liver and body tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). In general, adrenaline is methylated to metanephrine by COMT followed by oxidative deamination by MAO and eventual conversion to 4-hydroxy-3-methoxymandelic acid (formerly termed vanillylmandelic acid; VMA), or oxidatively deaminated by MAO and converted to 3,4-dihydroxymandelic acid which, in turn, is methylated by COMT, once again to 4-hydroxy-3-methoxymandelic acid. The metabolites are excreted in the urine mainly as their glucuronide and ethereal sulfate conjugates. Up to 90% of an IV dose is excreted in the urine as metabolites.

### Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Alpha-blockers: avoid with tolazoline.
- Anaesthetics: increased risk of arrhythmias if given with volatile anaesthetics.
- Antidepressants: increased risk of arrhythmias and hypertension if given with tricyclics; MAOIs and moclobemide may cause hypertensive crisis.
- Beta-blockers: increased risk of severe hypertension and bradycardia.
- Clonidine: possible increased risk of hypertension.
- Dopaminergics: effects possibly increased by entacapone; avoid concomitant use with rasagiline.
- Guanethidine: increased risk of hypertension.
- Sympathomimetics: effects possibly enhanced by dopexamine.

### Administration

#### Reconstitution
- 1 mg in 100 mL glucose 5%
- 6 mL/hour = 1 microgram/minute – according to local protocol

#### Route
- IV, IM, SC

#### Rate of administration
Monitor blood pressure and adjust dose according to response.

### Other information
- Catecholamines have a high non-renal systemic clearance; therefore the effect of any renal replacement therapy is unlikely to be relevant.
Afatinib

**Clinical use**
Protein kinase inhibitor:
- Treatment of non-small cell lung cancer

**Dose in normal renal function**
40–50 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 718.1 (as dimaleate)
- % Protein binding 95
- % Excreted unchanged in urine 4.3
- Volume of distribution (L/kg) 4500 Litres
- Half-life — normal/ESRF (hrs) 37 / Unchanged

**Metabolism**
Enzyme-catalysed metabolic reactions play a negligible role for afatinib in vivo. Covalent adducts to proteins were the major circulating metabolites of afatinib. Excreted mainly in the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 15–20: Dose as in normal renal function.
- <15: Use with caution. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in GFR<15 mL/min.
- HD: Unknown dialysability. Dose as in GFR<15 mL/min. See ‘Other information’.
- HDF/High flux: Unknown dialysability. Dose as in GFR<15 mL/min. See ‘Other information’.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=15–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.
- Ciclosporin: concentration of afatinib possibly increased, separate administration by 6–12 hours.
- Tacrolimus: concentration of afatinib possibly increased, separate administration by 6–12 hours.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Comments**
Food should not be consumed for at least 3 hours before and at least 1 hour after taking afatinib.

**Other information**
- Exposure to afatinib was found to be increased in patients with moderate or severe renal impairment. Adjustments to the starting dose are not necessary in patients with mild (eGFR=60–89 mL/min/1.73m²), moderate (eGFR=30–59 mL/min/1.73 m²) or severe (eGFR=15–29 mL/min/1.73 m²) renal impairment. Monitor patients with severe renal impairment (eGFR=15–29 mL/min/1.73 m²) and adjust dose if not tolerated. Treatment in patients with eGFR<15 mL/min/1.73 m² or on dialysis is not recommended by manufacturer due to lack of studies.
- A single dose study found minor alterations in the pharmacokinetics of patients with moderate (eGFR=30–59 mL/min/1.73 m²) and severe (eGFR=15–29 mL/min/1.73 m²) renal impairment and suggest that afatinib could be used in this population.
- A case report used afatinib in a haemodialysis patient initially at a dose of 30 mg for 2 months with good effect and tolerability. The dose was then increased to 40 mg and after a few days the patient experienced significant asthenia, vomiting and nausea. The patient stopped therapy.

References:
Aflibercept

**Clinical use**

Antineoplastic agent:
- Treatment of metastatic colorectal cancer

**Dose in normal renal function**

4 mg/kg every 2 weeks as part of a protocol

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>115 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>8 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6 days / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

No metabolism studies have been conducted with aflibercept since it is a protein. Aflibercept is expected to degrade to small peptides and individual amino acids. Free aflibercept is mainly cleared by binding to endogenous VEGF to form a stable, inactive complex. As with other large proteins, both free and bound aflibercept, are expected to be cleared, more slowly, by other biological mechanisms, such as proteolytic catabolism.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV infusion</td>
<td>Dose as normal renal function. See 'Other information'. Dilute with sodium chloride 0.9% or glucose 5% to provide a concentration of 0.6 mg/mL to 8 mg/mL. Administer via infusion sets containing a 0.2 micron polyethersulfone filter.</td>
</tr>
</tbody>
</table>

**Other information**

- The manufacturer has not done any formal studies in renal impairment. Clinical data suggest that no change in starting dose is required in patients with mild to moderate renal impairment. The manufacturer advises to use with caution in severe renal impairment due to lack of data. In the few patients with severe renal impairment, drug exposure was similar to that observed in patients with normal renal function.
- Severe hypertension, proteinuria, nephrotic syndrome, and thrombotic microangiopathy have been seen in patients treated with aflibercept.
# Agalsidase alfa (Replagal)

## Clinical use

Treatment of Fabry disease. Only to be prescribed by specialist centres.

## Dose in normal renal function

0.2 mg/kg, rounded to the nearer full vial every 2 weeks. Vials available as 3.5 mg.

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>51 200</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>0% as the drug is a protein</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.17</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>61–125 minutes / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism

Metabolic degradation pathway similar to other proteins.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in normal renal function.

## Important drug interactions

Potentially hazardous interactions with other drugs

- Replagal should not be administered with chloroquine, amiodarone, benoquin or gentamicin due to a theoretical risk of inhibition of intra-cellular α-galactosidase activity.

## Administration

### Reconstitution

**Route**

IV infusion

**Rate of administration**

Over 40 minutes, unless previous infusion reactions have resulted in a slower infusion rate.

### Comments

- Remove vials from fridge approximately 30 minutes before reconstitution.
- Dilute the total volume of Replagal required in 100 mL sodium chloride 0.9%.

### Other information

- Has been given safely and successfully on haemodialysis. If being administered on haemodialysis, give over the last 40 minutes unless known infusion reactions have resulted in an increased infusion time.
- Infusion reactions can occur at any time during treatment, and have been seen in patients who have been established on Replagal therapy for several years. Reactions should be managed according to local protocols for the management of anaphylactic reactions, in the form of antipyretics, antihistamines and occasionally steroids as needed. The infusion should also be stopped immediately. If clinically safe to do so the infusion can be restarted at a slower infusion rate, following discussion with a clinician at a specialised inherited metabolic diseases centre.
- Pre-treatment with an antihistamine and/or corticosteroid 1–24 hours pre-infusion may be required in some cases.
- Renal impairment may limit renal response to Replagal.
Agalsidase beta (Fabrazyme)

Clinical use
Treatment of Fabry disease. Only to be prescribed by specialist centres.

Dose in normal renal function
1 mg/kg, rounded to the nearest full vial every 2 weeks. Available as 5 mg and 35 mg vials.

Pharmacokinetics
Molecular weight (daltons) 100 000
% Protein binding 0% (Fabrazyme is a protein itself)
% Excreted unchanged in urine Negligible
Volume of distribution (L/kg) 8.3–40.8 Litres
Half-life — normal/ESRF (hrs) 45–100 minutes / No data

Metabolism
Metabolic degradation pathway similar to other proteins.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Renal Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

APD/CAPD          unlikely to be dialysed. Dose as in normal renal function.
HD                unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux     unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD          unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Fabrazyme should not be administered with chloroquine, amiodarone, benoquin or gentamicin due to a theoretical risk of inhibition of intra-cellular \(\alpha\)-galactosidase activity.

Administration

Reconstitution
- 5 mg vial with 1.1 mL of water for injection
- 35 mg vials with 7.2 mL of water for injection
- Add water for injection in a drop wise fashion. Do not shake or invert the vial as this will cause foaming. This produces a 5 mg/mL solution.

Route
IV infusion

Rate of administration
If initiating treatment, see table below for infusion rates:

<table>
<thead>
<tr>
<th>Visit number</th>
<th>Infusion rate</th>
<th>Infusion time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20 mL/hour for 1st hour, then 36 mL/hour for remainder</td>
<td>3 hours 15 mins</td>
</tr>
<tr>
<td>2</td>
<td>50 mL/hour</td>
<td>2 hours</td>
</tr>
<tr>
<td>3</td>
<td>66.6 mL/hour</td>
<td>90 mins</td>
</tr>
</tbody>
</table>

Once initiated on Fabrazyme, to be given at 66.6 mL/hour, to be administered over the last 90 minutes of haemodialysis, unless known infusion reactions have resulted in an increased infusion time.

Comments
- Remove vials from fridge approximately 30 minutes before reconstitution.
- If renal function is normal add to 500 mL sodium chloride 0.9%.
- Remove from 100 mL bag of sodium chloride 0.9% an equal volume of the Fabrazyme to be added, before adding the reconstituted Fabrazyme. Therefore the total volume of infusion should always be 100 mL.
- Administer through an in-line low protein binding 0.2 \(\mu\)m filter.

Other information
- Has been given safely and successfully on haemodialysis. If being administered on haemodialysis give over the last 90 minutes.
- Infusion reactions can occur at any time during treatment, and have been seen in patients who have been established on Fabrazyme therapy for several years. Reactions should be managed according to local protocols for the management of anaphylactic reactions, in the form of antipyretics, antihistamines and occasionally steroids as needed. The infusion should also be stopped immediately. If clinically safe to do so the infusion can be restarted at a slower
Agalsidase beta (Fabrazyme)

• infusion rate, following discussion with a clinician at a specialised inherited metabolic diseases centre.
• Pre-treatment with an antihistamine and/or corticosteroid 1–24 hours pre-infusion may be required in some cases.
• Renal impairment may limit renal response to Fabrazyme.
Agomelatine

Clinical use
Antidepressant

Dose in normal renal function
25–50 mg at bedtime

Pharmacokinetics
Molecular weight (daltons) 243.3
% Protein binding 95
% Excreted unchanged in urine Minimal (80% as inactive metabolites)
Volume of distribution (L/kg) 35 Litres
Half-life — normal/ESRF (hrs) 1–2

Metabolism
Agomelatine is rapidly metabolised, mainly by the hepatic cytochrome P450 isoenzyme CYP1A2; the isoenzymes CYP2C9 and CYP2C19 also make a minor contribution. The major metabolites, hydroxylated and demethylated agomelatine, are not active and are rapidly conjugated and eliminated in the urine.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function. Use with caution.
10–20 Dose as in normal renal function. Use with caution.
<10 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Method</th>
<th>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td></td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: avoid with ciprofloxacin.
- Antidepressants: metabolism inhibited by fluvoxamine.
- Antimalarials: avoid with artemether with lumefantrine and arteminol with piperaquine.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information
- Manufacturer advises to use with caution in moderate to severe renal impairment due to limited data but no pharmacokinetic changes were seen in severe renal impairment.
- Oral bioavailability <5%. The bioavailability is increased by intake of oral contraceptives and reduced by smoking and is higher in women compared to men.
- The effects of renal function on agomelatine pharmacokinetics were investigated in a study of healthy subjects and patients with severe impaired renal function. In the renal impairment patients, exposure to agomelatine increased more than 25% compared to healthy subjects. The available safety data from the clinical trials did not demonstrate any significant tolerability or safety issues with the use of agomelatine compared to placebo among patients with mildly to moderately impaired renal function. Although agomelatine can be used in patients with renal impairment, such patients should be monitored more closely. (Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat. 2009; 5: 563–76.)
# Albendazole (unlicensed product)

## Clinical use
- Treatment of *Echinococcus granulosus* (Hydatid disease), in combination with surgery
- Treatment of nematode infections

## Dose in normal renal function

### *Echinococcus granulosus:*
- >60 kg: 400 mg twice daily for 28 days
- <60 kg: 15 mg/kg in 2 divided doses to a maximum of 800 mg daily

Treatment of nematode infections: 400 mg as a single dose

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>265.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>70</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8–12 (metabolite) / Probably unchanged</td>
</tr>
</tbody>
</table>

## Metabolism

Albendazole rapidly undergoes extensive first-pass metabolism. Its principal metabolite albendazole sulfoxide has anthelmintic activity and a plasma half-life of about 8.5 hours. Albendazole sulfoxide is widely distributed throughout the body including into the bile and the CSF. It is about 70% bound to plasma protein. Albendazole sulfoxide is eliminated in the bile; only a small amount appears to be excreted in the urine.

## Important drug interactions

Potentially hazardous interactions with other drugs:
- Antiepileptics: metabolism increased by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antivirals: active metabolite of albendazole reduced by ritonavir.
- Dexamethasone: increased concentrations of metabolite of albendazole.

## Administration

### Reconstitution
- 

### Route
- Oral

### Rate of administration
- 

## Other information

- Available on a named patient basis from IDIS (Zentel).
Albiglutide

Clinical use
GLP-1 receptor agonist:
• Treatment of type 2 diabetes mellitus

Dose in normal renal function
30–50 mg once weekly

Pharmacokinetics
Molecular weight (daltons) 72 971.3
% Protein binding No data
% Excreted unchanged in urine Minimal
Volume of distribution (L/kg) 11 Litres
Half-life — normal/ESRF (hrs) 5 days / –

Metabolism
Albiglutide is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by ubiquitous proteolytic enzymes.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>15–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR &lt; 15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR &lt; 15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR &lt; 15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR = 15–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution
As supplied within pre-filled pen.

Route
SC

Rate of administration
—

Other information
• Not recommended in patients with GFR < 30 mL/min in UK SPC due to lack of studies. Data in severe renal impairment from US data sheet.
• Monitor closely when initiating and adjusting doses of albiglutide in patients with renal impairment.
• Patients with severe renal impairment receiving albiglutide experienced a higher frequency of diarrhoea, nausea and vomiting compared to patients with mild or moderate renal impairment. This in some cases may lead to acute kidney injury.
• Exposure was increased by approximately 30–40% in patients with severe renal impairment compared to those with normal renal function. In addition, a clinical pharmacology study showed a similar increased exposure for patients with moderate or severe renal impairment or those on haemodialysis relative to patients without renal impairment. These differences were not considered clinically relevant.
• A study investigated the pharmacokinetics and safety of albiglutide with varying degrees of renal impairment and haemodialysis. There was a trend for more glycaemic lowering as the eGFR decreased. The severe group had a higher frequency of gastrointestinal (e.g. diarrhoea, constipation, nausea and vomiting) and hypoglycaemic (with background sulfonylurea use) effects compared with patients with mild or moderate renal impairment. The advice from this study is that it should be used with caution in severe renal impairment. (Young MA, Wald JA, Matthews JE, et al. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide. Postgrad Med. 2014; 126(3): 35–46.)
Aldesleukin

Clinical use

Recombinant interleukin-2
• Treatment of metastatic renal cell carcinoma

Dose in normal renal function

• IV: 18 x 10^6 IU/m^2 for 5 days, followed by 2–6 days without treatment, then an additional 5 days with treatment and then 3 weeks without.
• SC: 18 x 10^6 IU every day for 5 days, followed by 2 days without treatment. For the following 3 weeks, 18 x 10^6 IU is administered on days 1 and 2 of each week followed by 9 x 10^6 IU on days 3–5. On days 6 and 7 no treatment is administered. After 1 week treatment this 4-week cycle should be repeated.
• Or as per local policy.

Pharmacokinetics

Molecular weight (daltons) 15 315
% Protein binding No data
% Excreted unchanged in urine 0 (mainly as amino acids)
Volume of distribution (L/kg) 0.18
Half-life — normal/ESRF (hrs) IV: 85 minutes; SC: 3–5

Metabolism

Greater than 80% of aldesleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolised to amino acids in the cells lining the proximal convoluted tubules. A secondary elimination pathway is IL-2 receptor- mediated uptake.

Dose in renal impairment GFR (mL/min)

20–50 Use with caution.
10–20 Use with caution.
<10 Use with caution.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Corticosteroids: avoid concomitant use.
• Cytotoxics: avoid concomitant use with cisplatin, dacarbazine and vinblastine.

Administration

Reconstitution
1.2 mL water for injection per 22 million IU vial

Route
IV, SC

Rate of administration
24 hours

Comments
Dilute in up to 500 mL with glucose 5% containing 1 mg/mL (0.1%) human albumin.

Other information

• No dosage from manufacturer due to lack of studies.
• Risk of toxicity may be greater in patients with renal impairment.
• Bioavailability is 31–47%.
• Can cause an increase in urea and creatinine.
• Clearance is preserved in patients with rising serum creatinine concentration.
Alemtuzumab (MabCampath)

Clinical use

- Treatment of chronic lymphocytic leukaemia (CLL) not totally responsive to other treatment
- Induction therapy in renal transplantation
- Treatment of relapsing remitting multiple sclerosis (MS)

Dose in normal renal function

- 3 mg increasing to 30 mg
- Maximum dose: 30 mg 3 times a week
- MS: 12 mg/day for 2 treatment courses – 1st course for 5 days 2nd course for 3 days

Pharmacokinetics

Molecular weight (daltons) 150 000
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 0.15
Half-life — normal/ESRF (hrs) 2–32 hours (single dose); 1–14 days (repeated dosing)

Metabolism

The metabolic pathway of alemtuzumab has not been elucidated. Clearance decreases with repeated administration due to decreased receptor mediated clearance (loss of CD52 receptors in the periphery).

Dose in renal impairment GFR (mL/min)

- 20–50 Use with extreme caution. See 'Other information'.
- 10–20 Use with extreme caution. See 'Other information'.
- <10 Use with extreme caution. See 'Other information'.

Dose in patients undergoing renal replacement therapies

- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Other chemotherapy: do not give within 3 weeks of each other.
- Live vaccines: avoid for at least 12 months after treatment.

Administration

Reconstitution
—

Route
IV infusion

Rate of administration
2 hours

Comments
- Add to 100 mL sodium chloride 0.9% or glucose 5%.
- Once diluted protect from light and use within 8 hours.
- Add dose through a low protein binding 5 micron filter.

Other information

- Patients should have a premedication of an antihistamine and paracetamol 30 minutes before treatment.
- Patients should also receive anti-herpes and anti-infective prophylaxis against PCP during, and up to 2 months after stopping treatment.
- More than 80% of patients will experience side effects, usually during the first week of therapy.
- There have been no studies using alemtuzumab for CLL in patients with renal failure and there is no information on excretion, therefore if it must be used it should be with great care at the consultant’s discretion.
- Doses of 20–30 mg given on the day of transplantation (and on day 1 according to local protocol), have been used for induction therapy in renal and combined kidney/pancreas transplantation.
Alendronic acid

Clinical use
Bisphosphonate:
- Treatment and prophylaxis of osteoporosis

Dose in normal renal function
10 mg daily or 70 mg once weekly

Pharmacokinetics
Molecular weight (daltons) 249.1 (325.1 as sodium salt)
% Protein binding 78
% Excreted unchanged in urine Approx 50
Volume of distribution (L/kg) 28 Litres
Half-life — normal/ESRF (hrs) >10 years / Increased

Metabolism
Alendronate transiently distributes to soft tissues but is then rapidly redistributed to bone or excreted in the urine. There is no evidence that alendronate is metabolised in animals or humans. Following a single intravenous dose of [14C]-alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces.

Dose in renal impairment GFR (mL/min)
35–50 Dose as in normal renal function.
<35 Avoid. See 'Other information'.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<35 mL/min.
HD Not dialysed. Dose as in GFR<35 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<35 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR<35 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Calcium salts: reduced absorption of alendronate.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Swallow whole with a glass of water on an empty stomach, at least 30 minutes before breakfast and any other oral medication.
- Patient should stand or sit upright for at least 30 minutes after taking tablets.
- Combination therapy with alendronate and intravenous calcitriol, for the treatment of secondary hyperparathyroidism in haemodialysis patients, has been used at a dose of 10 mg alendronate plus IV calcitriol 2 mcg post dialysis to reduce PTH levels. (McCarthy JT, Kao PC, Demick DS, et al. Combination therapy with alendronate and intravenous calcitriol for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Am Soc Nephrol. 1999; 10 Program, 81A–82A.)
- Manufacturers do not recommend use of alendronate in severe renal impairment due to lack of data.
- One paper reviewed all the information available and concluded that 50% of the recommended dose may be possible in ESRD, but more trials are required and osteomalacia and adynamic bone disease must first be excluded. (Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep. 2005; 3(1): 5–12.)
- Anecdotally, several renal units use either 70 mg weekly or standard doses of all preparations in patients with CKD 3, 4 and 5 to good effect.
- If used in patients with ESRD ensure the patient has an adequate PTH e.g. at least 3 times the upper limit of normal.
Alfacalcidol

Clinical use
Vitamin D analogue:
• Increase serum calcium levels
• Suppression of PTH production

Dose in normal renal function
0.25–1 micrograms daily according to response.
Alternatively, up to 4 micrograms 3 times a week.

Pharmacokinetics
Molecular weight (daltons) 400.6
% Protein binding Extensive plasma protein binding
% Excreted unchanged in urine 13
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) <3 / –

Metabolism
Alfacalcidol is hydroxylated in the liver by the enzyme vitamin D 25-hydroxylase to form the active 1,25-dihydroxycolecalciferol (calcitriol). Calcitriol is inactivated in both the kidney and the intestine, through the formation of a number of intermediates including the formation of the 1,24,25-trihydroxy derivatives. Vitamin D compounds and their metabolites are excreted mainly in the bile and faeces with only small amounts appearing in urine; there is some enterohepatic recycling but it is considered to have a negligible contribution to vitamin D status.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Carbamazepine, fosphenytoin, phenytoin, phenobarbital and primidone may increase metabolism of alfacalcidol, necessitating larger doses than normal to produce the desired effect.

Administration
Reconstitution
—
Route
Oral, IV
Rate of administration
Over 30 seconds

Other information
• Adjust dose according to response. Serum calcium ref range 2.1–2.6 mmol/L (total).
• An IV preparation (2 micrograms/mL) and an oral solution (2 micrograms/mL) are also available.
• Doses of 1 microgram daily for 5 days may need to be given immediately prior to parathyroidectomy. Alternatively, give 5 micrograms immediately prior to parathyroidectomy.
• Capsules of One-Alfa (Leo) contain sesame oil.
Alfentanil

Clinical use

Opioid analgesic:
• Short surgical procedures
• Intensive care sedation

Dose in normal renal function

• IV injection:
  – Spontaneous respiration: up to 500 micrograms over 30 seconds; supplemental dose: 250 micrograms
  – Assisted ventilation: 30–50 micrograms/kg; supplemental dose: 15 micrograms/kg
• By IV infusion with assisted ventilation: loading dose 50–100 micrograms/kg as bolus or fast infusion over 10 minutes, followed by 0.5–1 micrograms/kg/minute. Discontinue infusion 30 minutes before anticipated end of surgery.
• For analgesia and suppression of respiratory activity during intensive care with assisted ventilation: by IV infusion 2 mg/hour, adjusted according to response (usual range 0.5–10 mg/hour).
• For more rapid initial control give 5 mg IV in divided portions over 10 minutes (slower if hypotension or bradycardia develops); additional doses of 0.5–1 mg may be given by IV injection during short painful procedures.

Pharmacokinetics

Molecular weight (daltons) 453 (as hydrochloride)
% Protein binding 92
% Excreted unchanged in urine 0.4
Volume of distribution (L/kg) 0.4–1
Half-life — normal/ESRF (hrs) 1–2 (average 90 minutes) / Unchanged

Metabolism

Alfentanil is metabolised in the liver; oxidative N- and O-dealkylation by the cytochrome P450 isoenzyme CYP3A4 leads to inactive metabolites, which are excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Antibacterials: concentration increased by erythromycin; metabolism accelerated by rifampicin.
• Antidepressants: possible CNS excitation or depression (hypertension or hypotension) in patients also receiving MAOIs (including moclobemide) – avoid; possibly increased sedative effects with tricyclics.
• Antifungals: metabolism inhibited by fluconazole and ketoconazole (risk of prolonged or delayed respiratory depression); metabolism possibly inhibited by itraconazole; concentration increased by voriconazole, consider reducing alfentanil dose.
• Antihistamines: increased sedative effects with sedating antihistamines.
• Antipsychotics: enhanced hypotensive and sedative effects.
• Antivirals: concentration possibly increased by ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
• Cytotoxics: use crizotinib with caution.
• Dopaminergics: avoid with selegiline.
• Sodium oxybate: enhanced effect of sodium oxybate – avoid.

Administration

Reconstitution

Route
IV bolus, IV infusion

Rate of administration
See dose

Comments
• Alfentanil can be mixed with sodium chloride 0.9%, glucose 5%, or compound sodium lactate injection (Hartmann’s solution) at a concentration of 0.5 mg/
mL, but can be used at 2 mg/mL or even undiluted at 5 mg/mL. (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006).

**Other information**

- Free fraction of drug is increased in renal failure, hence dose requirements may be reduced.
- IV administration: 500 micrograms alfentanil has peak effect in 90 seconds, and provides analgesia for 5–10 minutes (in unpremedicated adults).
- Transient fall in BP and bradycardia may occur on administration.
- Analgesic potency = 1/4 that of fentanyl
- Duration of action = 1/3 that of an equi-analgesic dose of fentanyl.
- Onset of action = 4 times more rapid than an equi-analgesic dose of fentanyl.
Alfuzosin hydrochloride

Clinical use

Alpha-blocker:
- Treatment of benign prostatic hyperplasia
- Treatment of acute urinary retention

Dose in normal renal function

- 2.5 mg 2–3 times daily, maximum 10 mg daily
- XL: 10 mg once daily

Pharmacokinetics

Molecular weight (daltons) 425.9
% Protein binding 90
% Excreted unchanged in urine 11
Volume of distribution (L/kg) 3.2
Half-life — normal/ESRF (hrs) 3–5; XL: 8–9.1 / Unchanged

Metabolism

Extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP3A4, to inactive metabolites that are mainly excreted in faeces via the bile.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Initially 2.5 mg twice daily. See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initially 2.5 mg twice daily. See ‘Other information’.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

APD/CAPD  Not dialysed. Dose as in GFR<10 mL/min.
HD        Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux  Unlikely to be dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD  Not dialysed. Dose as in GFR=10–30 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antivirals: concentration possibly increased by ritonavir – avoid; avoid with telaprevir.
- Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect, separate administration by 4–6 hours.
- Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Cobicistat: concentration of alfuzosin possibly increased – avoid.
- Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Moxisylyte: possibly severe postural hypotension.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information

- Bioavailability is 64%.
- Bioavailability and C_{max} are increased by approximately 50% in moderate to severe renal impairment.
- Manufacturer advises to avoid XL in severe renal impairment due to lack of studies but a study by Marbury has found it to be safe (Marbury TC, Blum RA, Rauch C, et al. Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment. J Clin Pharmacol. 2002; 42(12): 1311–7).
# Alimemazine tartrate (trimeprazine)

## Clinical use
- Urticaria and pruritus
- Pre-med in children

## Dose in normal renal function
- 10 mg every 8–12 hours, maximum 100 mg/day
- Elderly: 10 mg once or twice daily

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>747</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&gt;70</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Large</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4.8 / –</td>
</tr>
</tbody>
</table>

## Metabolism
Undergoes biotransformation in the liver to hydroxy, N-dealkyl, S-oxide, and sulfone derivatives. The hydroxy compounds, which are the main metabolites (greater than 50%), are partly conjugated. 5–10% of metabolites are sulfones. Some of the metabolites were detected in the faeces, too. The relationship of the excretion products in urine and faeces is 75:25%.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Reduce frequency to every 12–24 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Reduce frequency to every 12–24 hours.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
- **APD/CAPD** Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HD** Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux** Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD** Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: sedative effects possibly increased with opioid analgesics.

## Administration
### Reconstitution
- **Route** Oral
- **Rate of administration** —

## Other information
- Significant amounts of alimemazine are excreted in urine. It is therefore contraindicated by the manufacturer in renal failure; reduced clearance and elevated serum levels will occur in patients with impaired renal function.
- However, it can be used at a dose of 10 mg at night to treat uraemic pruritis.
## Alirocumab

### Clinical use

Human IgG1 monoclonal antibody:
- Treatment of primary hypercholesterolaemia / mixed dyslipidaemia

### Dose in normal renal function

75–150 mg every 2 weeks

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>146 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.04–0.05</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>17–20 days / –</td>
</tr>
</tbody>
</table>

### Metabolism

As alirocumab is a protein it is expected to degrade to small peptides and individual amino acids. At low concentrations, the elimination is mainly through saturable binding to target (PCSK9), while at higher concentrations the elimination is largely through a non-saturable proteolytic pathway.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution. Start with lower dose.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Live vaccines: risk of generalised infections – avoid.

### Administration

**Reconstitution**
- —

**Route**
- SC

**Rate of administration**
- —

### Other information

- Manufacturer has limited data in severe renal impairment (eGFR<30 mL/min) therefore advises to use with caution.
- Since monoclonal antibodies are not known to be eliminated via renal pathways, renal function is not expected to impact the pharmacokinetics of alirocumab.
- Limited data are available in patients with severe renal impairment; in these patients the exposure to alirocumab was approximately 2-fold higher compared with subjects with normal renal function.
Aliskiren fumarate

**Clinical use**

Renin inhibitor:
- Hypertension

**Dose in normal renal function**

150–300 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1219.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>47–51</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0.6</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>135 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>34–41 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Approximately 1.4% of the total oral dose is metabolised by CYP3A4. Approximately 0.6% of the dose is recovered in urine following oral administration. Aliskiren is mainly eliminated as unchanged compound in the faeces (78%).

**Dose in renal impairment GFR (mL/min)**

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Other antihypertensive agents: enhanced antihypertensive effect; concentration possibly reduced by irbesartan; increased risk of hyperkalaemia and hypotension with ACE-Is and ARBs.
  - Antifungals: concentration increased by itraconazole and ketoconazole, avoid with itraconazole.
  - Ciclosporin: concentration of aliskiren increased – avoid.
  - Diuretics: may reduce concentration of furosemide; hyperkalaemia with potassium-sparing diuretics.
  - Grapefruit juice: concentration of aliskiren reduced – avoid.
  - Heparins: increased risk of hyperkalaemia.
  - Potassium salts: increased risk of hyperkalaemia.

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

**Other information**

- Potassium should be monitored in patients with renal impairment, diabetes or heart failure.
- Manufacturer advises to avoid if GFR<30 mL/min/1.73m² and should not be used in combination with ACE-I or ARBs if GFR<60 mL/min/1.73m² due to risk of hyperkalaemia.
- Oral bioavailability is only 2–3%.
Allopurinol

Clinical use

- Gout prophylaxis
- Hyperuricaemia

Dose in normal renal function

- 100–900 mg/day (usually 300 mg/day)
- Doses above 300 mg should be given in divided doses

Pharmacokinetics

Molecular weight (daltons) 136.1
% Protein binding <5
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 1.6
Half-life — normal/ESRF (hrs) 1–2 / Increased

Metabolism

Approximately 20% of ingested allopurinol is excreted in the faeces. Elimination of allopurinol is mainly by metabolic conversion to oxipurinol by xanthine oxidase and aldehyde oxidase, with less than 10% of the unchanged drug excreted in the urine.

Oxipurinol is a less potent inhibitor of xanthine oxidase than allopurinol, but the plasma half-life of oxipurinol is far more prolonged. Estimates range from 13–30 hours in man. Therefore effective inhibition of xanthine oxidase is maintained over a 24 hour period with a single daily dose. Oxipurinol is eliminated unchanged in the urine but has a long elimination half-life because it undergoes tubular reabsorption.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>200–300 mg daily</td>
</tr>
<tr>
<td>10–20</td>
<td>100–200 mg daily</td>
</tr>
<tr>
<td>&lt;10</td>
<td>100 mg daily or 100 mg on alternate days</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min or 300–400 mg post dialysis on dialysis days only.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR= 10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs

- ACE inhibitors: increased risk of toxicity with captopril.
- Antivirals: concentration of didanosine increased – avoid.
- Ciclosporin: isolated reports of raised ciclosporin levels (risk of nephrotoxicity).
- Cytotoxics: effects of azathioprine and mercaptopurine enhanced with increased toxicity; avoid with capecitabine and ideally azathioprine.

Administration

Reconstitution

- Route
  Oral

Rate of administration

- Comments
  - In all grades of renal impairment commence with 100 mg/day and increase if serum and/or urinary urate response is unsatisfactory. Doses less than 100 mg/day may be required in some patients.
  - Take as a single daily dose, preferably after food.

Other information

- A parenteral preparation is available from Glaxo Wellcome on a named patient basis.
- HD patients may be given 300 mg post dialysis, i.e. on alternate days.
- Increased incidence of skin rash in patients with renal impairment.
- Efficient dialysis usually controls serum uric acid levels.
- If a patient is prescribed azathioprine or 6-mercaptopurine concomitantly, reduce azathioprine or 6-mercaptopurine dose by 66–75%. Preferably avoid concomitant use.
- Main active metabolite: oxipurinol – renally excreted; plasma protein binding 17%; half-life: Normal / ESRF = 13–30 / >125 hours – 1 week.
# Almotriptan

## Clinical use

5HT₁ receptor agonist:
- Acute relief of migraine

## Dose in normal renal function

- 12.5 mg repeated after 2 hours if migraine recurs (do not take 2nd dose for the same attack)
- Maximum 25 mg in 24 hours

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>469.6 (as malate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>35</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40–50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>195 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3.5 / 7</td>
</tr>
</tbody>
</table>

## Metabolism

The major biotransformation route is via monoamine oxidase (MAO-A) mediated oxidative deamination to the indole acetic metabolite. Cytochrome P450 (3A4 and 2D6 isozymes) and flavin mono-oxygenase are other enzymes involved in the metabolism of almotriptan. None of the metabolites are significantly active pharmacologically.

More than 75% of a dose is eliminated in urine, and the remainder in faeces. Approximately, 50% of the urinary and faecal excretion is unchanged almotriptan.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>6.25 mg; maximum daily dose 12.5 mg. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>6.25 mg; maximum daily dose 12.5 mg. Use with caution.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs:
- Antidepressants: increased risk of CNS toxicity with citalopram – avoid; possibly increased serotonergic effects with duloxetine or venlafaxine; increased serotonergic effects with St John's wort – avoid.
- Antifungals: concentration increased by ketoconazole (increased risk of toxicity).
- Dapoxetine: possible increased risk of serotonergic effects – avoid for 2 weeks after stopping 5HT₁ agonists.
- Ergot alkaloids: increased risk of vasospasm – avoid.

## Administration

### Reconstitution

- 

### Route

- Oral

### Rate of administration

- 

---
# Alogliptin

## Clinical use

Dipeptidyl peptidase 4 inhibitor:
- Treatment of type 2 diabetes in combination with other therapies

## Dose in normal renal function

25 mg daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>461.5 (as benzoate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>20–30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>60–70</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>417 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>21 / –</td>
</tr>
</tbody>
</table>

### Metabolism

Alogliptin does not undergo extensive metabolism. Two minor metabolites were detected following administration of an oral dose of $^{14}$C-alogliptin, N-demethylated alogliptin, M-I (<1% of the parent compound), and N-acetylated alogliptin, M-II (<6% of the parent compound). M-I is an active metabolite and is a highly selective inhibitor of DPP-4 similar to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP-related enzymes. In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>12.5 mg daily.</td>
</tr>
<tr>
<td>10–30</td>
<td>6.25 mg daily.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>6.25 mg daily.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- None known

### Administration

#### Reconstitution

—

#### Route

Oral

#### Rate of administration

—

### Other information

- Bioavailability is 100%.
- The average renal clearance of alogliptin (170 mL/min) was greater than the average estimated glomerular filtration rate (approx. 120 mL/min), suggesting some active renal excretion.
- According to SPC alogliptin is only 7% removed by a 3-hour haemodialysis session. No dialysis information supplied. Monitor BMs.
- In patients with moderate or severe renal impairment, or ESRD on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively.
- There have been reports of fatal and non-fatal hepatic failure in patients taking alogliptin. It should be used with caution in patients with abnormal liver test results, and treatment interrupted in those who develop symptoms of liver injury and persistently elevated LFTs.
**Clinical use**

Fibrinolytic drug:
- Acute myocardial infarction
- Pulmonary embolism
- Acute ischaemic stroke
- To unblock dialysis lines

**Dose in normal renal function**

- Myocardial infarction: accelerated regimen (initiated within 6 hours) 15 mg IV bolus, 50 mg over 30 minutes, then 35 mg over 1 hour (total dose 100 mg); or (if initiated within 6–12 hours) 10 mg over 1–2 minutes followed by IV infusion of 50 mg over 1 hour, then 4 infusions each of 10 mg over 30 minutes (total dose – 100 mg over 3 hours).
- Reduce dose if patient <65 kg
- Pulmonary embolism: 10 mg by IV injection over 1–2 minutes, followed by an infusion of 90 mg over 2 hours. Total dose should not exceed 1.5 mg/kg in patients who weigh <65 kg.
- Acute ischaemic stroke: 0.9 mg/kg over 60 minutes, 10% of dose as initial bolus; maximum 90 mg. Must start within 4.5 hours of symptoms
- To unblock dialysis lines: 2 mg. See 'Other information'.

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>65 000 (non-glycosylated protein)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>α: 4–5 minutes; β: 40 minutes</td>
</tr>
</tbody>
</table>

**Metabolism**

Alteplase appears to be cleared principally by the liver, which subsequently releases degradation products into the blood. The excretion characteristics of alteplase and its degradation products have not been fully elucidated. There is limited evidence from healthy adults receiving radiolabeled human melanoma cell t-PA that exogenously administered t-PA is excreted mainly in urine, with about 80% of total radioactivity being excreted within 18 hours.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Risk of haemorrhage can be increased by the use of coumarin derivatives, platelet aggregation inhibitors, heparin, and other agents influencing coagulation.

**Administration**

**Reconstitution**
- 50 mg vial: dissolve in 50 mL water for injection.
- 20 mg vial: dissolve in 20 mL water for injection.
- The reconstituted solutions can be further diluted (minimum concentration 0.2 mg/mL) with sterile sodium chloride 0.9%.

**Route**
- IV

**Rate of administration**
- See under dose

**Comments**
- Water or glucose solution must NOT be used for dilution.
- 50 mg vial = 29 mega units/vial
- 20 mg vial = 11.6 mega units/vial

**Other information**
- Patients weighing less than 65 kg should receive a total dose of 1.5 mg/kg according to dose schedule.
- Allergic reactions are less likely with alteplase than streptokinase and repeated administration is possible.
- 1.7 g arginine in the 50 mg vial, 0.7 g arginine in 20 mg vial – may lead to hyperkalaemia in renal failure.
- Pay attention to potential bleeding sites during treatment.
- To unblock dialysis lines, use 2 mg in 2 mL down each lumen and leave in situ for at least 60 minutes or until the next dialysis session.
- Alternative regimens for unblocking dialysis lines: an infusion of 20 mg over 20 hours, or 50 mg over 12 hours, or 8 mg over 4 hours down each lumen.
Aluminium hydroxide

**Clinical use**
- Phosphate binding agent
- Antacid

**Dose in normal renal function**
- Phosphate binder: 4–20 capsules daily in divided doses
- Antacid: 1 capsule 4 times daily and at bedtime

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>78</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>70–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

**Metabolism**

Aluminium hydroxide or oxide is slowly solubilised in the stomach and reacts with hydrochloric acid to form aluminium chloride and water. In addition to forming aluminium chloride, dihydroxyaluminium sodium carbonate and aluminium carbonate form carbon dioxide, and aluminium phosphate forms phosphoric acid. About 17–30% of the aluminium chloride formed is absorbed and is rapidly excreted by the kidneys in patients with normal renal function. Aluminium-containing antacids also combine with dietary phosphate in the intestine forming insoluble, nonabsorbable aluminium phosphate which is excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Cytotoxics: concentration of dasatinib and erlotinib possibly reduced – give at least 4 hours before or 2 hours after erlotinib.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Comments**

- Take/administer with or immediately before meals.

**Other information**

- K/DOQI guidelines caution that CKD 5 patients on chronic therapy may develop aluminium toxicity; therefore best avoided in all but short-term therapy (calcium carbonate, calcium acetate, lanthanum or sevelamer are used in chronic therapy).
- In patients undergoing chronic therapy with aluminium hydroxide, serum aluminium levels should be monitored using the Desferrioxamine Test (5 mg/kg); see local protocol.
Amantadine hydrochloride

Clinical use
- Parkinson’s disease (but not drug-induced extrapyramidal symptoms)
- Post-herpetic neuralgia
- Prophylaxis and treatment of influenza A

Dose in normal renal function
- Parkinson’s disease: 100 mg once a day, increased after one week to 100–200 mg twice a day.
- Post-herpetic neuralgia: 100 mg twice a day for 14 days.
- Influenza A: treatment – 100 mg once a day for 4–5 days; prophylaxis – 100 mg once a day.

Dose in renal impairment GFR (mL/min)
- 35–50: 200 mg on first day then 100 mg every 24 hours.
- 15–35: 200 mg on first day then 100 mg every 48 hours.
- <15: 200 mg every 7 days. See ‘Other information’.

Pharmacokinetics
- Molecular weight (daltons): 187.7
- % Protein binding: 67
- % Excreted unchanged in urine: 90
- Volume of distribution (L/kg): 5–10
- Half-life — normal/ESRF (hrs): 15 / 500

Metabolism
Amantadine is metabolised in the liver to a minor extent, mainly by N-acetylation. The renal amantadine clearance is much higher than the creatinine clearance, suggesting renal tubular secretion in addition to glomerular filtration. After 4–5 days, 90% of the dose appears unchanged in urine. The rate is considerably influenced by urinary pH: a rise in pH brings about a fall in excretion.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in GFR<15 mL/min.
- HD: Not dialysed. Dose as in GFR<15 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<15 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=15–35 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Memantine: increased risk of CNS toxicity – avoid; effects of amantadine possibly enhanced.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Manufacturer in the UK advises to avoid if GFR<15 mL/min, doses in severe renal impairment are from US data sheet.
- Peripheral oedema may occur in some patients; should be used with caution when the drug is prescribed for those with congestive heart failure.
- Side effects are often mild and transient; usually appear within 2–4 days of treatment and disappear 24–48 hours after discontinuation of the drug.
- Due to extensive tissue binding, <5% of a dose is removed by a 4-hour haemodialysis session.
- A reduction in creatinine clearance to 40 mL/min may result in a 5-fold increase in elimination half-life.
Ambrisentan

**Clinical use**
Endothelin A (ETA) receptor antagonist:
- Treatment of pulmonary arterial hypertension

**Dose in normal renal function**
5–10 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 378.4
- % Protein binding 98.8
- % Excreted unchanged in urine 3.3
- Volume of distribution (L/kg) Low
- Half-life — normal/ESRF (hrs) 13.6–16.5

**Metabolism**
Ambrisentan is glucuronidated via several UGT isoenzymes (UGT1A9S, UGT2B7S and UGT1A3S) to form ambrisentan glucuronide (13%). Ambrisentan also undergoes oxidative metabolism mainly by CYP3A4 and to a lesser extent by CYP3A5 and CYP2C19 to form 4-hydroxymethyl ambrisentan (which has little activity) which is further glucuronidated to 4-hydroxymethyl ambrisentan glucuronide.

Ambrisentan is excreted mainly by the liver, although the contribution of hepatic metabolism and biliary excretion is unknown.

**Dose in renal impairment GFR (mL/min)**
- 30–50: Dose as in normal renal function.
- 10–30: Dose as in normal renal function. Use with care.
- <10: Dose as in normal renal function. Use with care.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Ciclosporin: concentration of ambrisentan doubled with an increased risk of side effects; maximum dose 5 mg daily.

**Administration**

Reconstitution
- 

Route
- Oral

Rate of administration
- 

**Other information**
- Renal clearance is reduced by 20–40% in moderate renal impairment.
- Manufacturer advises to use with care in severe renal impairment and to increase up to 10 mg cautiously due to lack of studies.
# Amikacin

## Clinical use
Antibacterial agent

## Dose in normal renal function
- 15 mg/kg/day in 1–2 divided doses
- In severe infections increased to 22.5 mg/kg/day in 3 divided doses
- (Maximum dose: 1.5 g/day; maximum cumulative dose: 15 g)

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>585.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;20</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>94–98</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.22–0.29</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–3 / 17–150</td>
</tr>
</tbody>
</table>

## Metabolism
Amikacin diffuses readily through extracellular fluids and has been found in cerebrospinal fluid, pleural fluid, amniotic fluid and in the peritoneal cavity following parenteral administration. It is excreted in the urine unchanged, primarily by glomerular filtration.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>5–6 mg/kg every 12 hours or as per local protocol.</td>
</tr>
<tr>
<td>10–20</td>
<td>3–4 mg/kg every 24 hours or as per local protocol.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>2 mg/kg every 24–48 hours or as per local protocol.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Dialysed. Dose as in GFR<10 mL/min.
- **HD**: Dialysed. Give 5 mg/kg after dialysis.
- **HDF/High flux**: Dialysed. Give 5 mg/kg after dialysis.
- **CAV/VVHD**: Dialysed. 7.5 mg/kg every 24 hours and monitor levels. See ‘Other information’.

## Important drug interactions
Potentially hazardous interactions with other drugs

- Antibacterials: increased risk of nephrotoxicity with colistimethate or polymyxins and possibly cephalosporins; increased risk of ototoxicity and nephrotoxicity with capreomycin or vancomycin.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxics: increased risk with platinum compounds of nephrotoxicity and possibly of ototoxicity
- Diuretics: increased risk of ototoxicity with loop diuretics.
- Muscle relaxants: enhanced effects of non-depolarising muscle relaxants and suxamethonium.
- Parasympathomimetics: antagonism of effect of neostigmine and pyridostigmine.
- Tacrolimus: increased risk of nephrotoxicity.

## Administration

### Reconstitution
- 

### Route
- IM / IV

### Rate of administration
- **IV bolus** – over 2–3 minutes
- **Infusion** – at concentration 2.5 mg/mL over 30 minutes (Diluents: sodium chloride 0.9%, glucose 5% and others)

### Comments
- May be used intraperitoneally.
- Do not mix physically with any other antibacterial agents.

## Other information
- Nephrotoxic and ototoxic; toxicity no worse when hyperbilirubinaemic.
- Serum levels must be measured for efficacy and toxicity.
- Peritoneal absorption increases in the presence of inflammation.
- Volume of distribution increases with oedema, obesity and ascites.
- Peak serum concentration should not exceed 30 mg/L.
- Trough serum concentration should be less than 5 mg/L.
- Amikacin affects auditory function to a greater extent than gentamicin.
• Doses in renal impairment from *Drug Dosing in Renal Insufficiency*, by Seyffart G.

• There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid 'flux' within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
1. CVVH Initial Drug Dosing Guidelines accessed 22/05/2006.
Amiloride hydrochloride

**Clinical use**
- Oedema
- Potassium conservation with thiazide and loop diuretics

**Dose in normal renal function**
5–10 mg daily; maximum 20 mg daily

**Pharmacokinetics**
- Molecular weight (daltons) 302.1
- % Protein binding 30–40
- % Excreted unchanged in urine 50
- Volume of distribution (L/kg) 5
- Half-life — normal/ESRF (hrs) 6–20 / 100

**Metabolism**
Amiloride is excreted unchanged in the urine. In two studies in which single doses of 14C-Amiloride were used, approximately 50% was recovered in urine and 40% in the faeces within 72 hours.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Use 50% of dose.
- 10–20: Use 50% of dose.
- <10: Avoid.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not applicable. Avoid
- HD: Not applicable. Avoid
- HDF/High flux: Not applicable. Avoid
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- ACE inhibitor and angiotensin-II antagonists: increased risk of hyperkalaemia and hypotension.
- Antibacterials: avoid concomitant use with lymecycline.
- Antidepressants: increased risk of postural hypotension with tricyclics; enhanced hypotensive effect with MAOIs.
- Antihypertensives: enhanced hypotensive effect.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium excretion reduced
- NSAIDS: increased risk of hyperkalaemia; increased risk of nephrotoxicity; antagonism of diuretic effect.
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Monitor for hyperkalaemia.
- Greatly increased risk of hyperkalaemia in patients with a GFR<30 mL/min, especially in diabetics.
- Increased risk of hyperchloraemic metabolic acidosis in patients with reduced GFR.
- Bioavailability is 50% and can be reduced by administering with food.
- Reduced natriuretic effect once the GFR<50 mL/min.
- Diuretic effect starts 2 hours after administration, peaks after 6–10 hours and can last up to 24 hours.
Aminophylline

Clinical use
- Reversible airways obstruction
- Acute severe asthma

Dose in normal renal function
- Modified release: 225–450 mg twice daily
- IV loading dose: 5 mg/kg (250–500 mg)
- Maintenance dose: 0.5–0.7 mg/kg/hour adjusted according to levels

Pharmacokinetics
Molecular weight (daltons) 420.4
% Protein binding 40–60 (theophylline)
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 0.4–0.7 (theophylline)
Half-life — normal/ESRF (hrs) 4–12 / Unchanged (theophylline)

Metabolism
Aminophylline is metabolised to theophylline in vivo. Theophylline is excreted in the urine as metabolites, mainly 1,3-dimethyluric acid and 3-methylxanthine, and about 10% is excreted unchanged.

Dose in patients undergoing renal replacement therapies
APD/CAPD  Not dialysed. Dose as in GFR<10 mL/min. Monitor blood levels. See 'Other information'.
HD  Not dialysed. Dose as in GFR<10 mL/min. Monitor blood levels. See 'Other information'.
HDF/High flux  Unknown dialysability. Dose as in GFR<10 mL/min. Monitor blood levels. See 'Other information'.
CAV/VVHD  Not dialysed. Dose as in GFR=10–20 mL/min. Monitor blood levels. See 'Other information'.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased concentration with azithromycin, clarithromycin, erythromycin, ciprofloxacin, norfloxacin and isoniazid; decreased erythromycin levels if erythromycin is given orally; increased risk of convulsions if given with quinolones; rifampicin accelerates metabolism of aminophylline.
- Antidepressants: concentration increased by fluvoxamine – avoid or halve theophylline dose and monitor levels; concentration reduced by St John’s wort – avoid.
- Antiepileptics: metabolism increased by carbamazepine, phenobarbital and primidone; concentration of both drugs increased with fosphenytoin and phenytoin.
- Antifungals: concentration increased by fluconazole and ketoconazole.
- Antivirals: metabolism of aminophylline increased by ritonavir; concentration possibly increased by aciclovir.
- Calcium-channel blockers: concentration increased by diltiazem and verapamil and possibly other calcium-channel blockers.
- Deferasirox: concentration of aminophylline increased.
- Feboxostat: use with caution.
- Interferons: reduced metabolism of aminophylline.
- Tacrolimus: may increase tacrolimus levels.
- Ulcer-healing drugs: metabolism inhibited by cimetidine; absorption possibly reduced by sucralfate.
Aminophylline

Administration

Reconstitution

Route
IV, oral

Rate of administration
Loading dose over 20 minutes by slow IV injection.

Comments
- Can be added to glucose 5%, sodium chloride 0.9% and compound sodium lactate.

Other information
- Aminophylline: 80% theophylline + 20% ethylenediamine.
- In bodily fluids, aminophylline rapidly dissociates from ethylenediamine and releases free theophylline in the body. It is therefore not present in the body long enough to be dialysed, whereas theophylline is dialysed, see theophylline monograph.
- Optimum response obtained at plasma theophylline levels of 10–20 mg/L (55–110 micromol/L).
- Increased incidence of GI and neurological side effects in renal impairment at plasma levels above optimum range.
Amiodarone hydrochloride

Clinical use
Cardiac arrhythmias

Dose in normal renal function
- Oral: 200 mg 3 times a day for 1 week, then twice a day for 1 week, then 200 mg daily maintenance dose or minimum required to control arrhythmia
- IV: via central catheter – 5 mg/kg (maximum 1.2 g in 24 hours)
- Ventricular arrhythmias or pulseless ventricular tachycardias: 300 mg over at least 3 minutes

Pharmacokinetics
Molecular weight (daltons) 681.8
% Protein binding 96
% Excreted unchanged in urine <5
Volume of distribution (L/kg) 60
Half-life — normal/ESRF (hrs) 20–100 days / Unchanged

Metabolism
Amiodarone is metabolised in the liver; the major metabolite, desethylamiodarone, also has antiarrhythmic properties. There is very little urinary excretion of amiodarone or its metabolites, the major route of excretion being in faeces via the bile; some enterohepatic recycling may occur.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: additive effect and increased risk of myocardial depression; increased risk of ventricular arrhythmias with disopyramide or dronedarone – avoid; increased flecainide concentration – halve flecainide dose; increased procainamide concentration – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with parenteral erythromycin, co-trimoxazole levofloxacin and moxifloxacin – avoid; increased risk of ventricular arrhythmias with delamanid; avoid with fidaxomicin; possibly increased risk of ventricular arrhythmias with telithromycin.
- Anticoagulants: metabolism inhibited (increased anti-coagulant effect); increased dabigatran concentration (reduce dabigatran dose).
- Antidepressants: increased risk of ventricular arrhythmias with citalopram and escitalopram, tricyclic antidepressants and venlafaxine – avoid.
- Antiepileptics: phenytoin and fosphenytoin metabolism inhibited (increased concentration).
- Antifungals: avoid with fluconazole due to risk of QT prolongation.
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antimalarials: increased risk of ventricular arrhythmias with chloroquine, hydroxychloroquine, mefloquine and quinine and possibly with piperaquine with artenimol and artemether/ lumeferantrine – avoid.
- Antimuscarinics: increased risk of ventricular arrhythmias with tolterodine.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval; increased risk of ventricular arrhythmias with amisulpride, benperidol, droperidol, haloperidol, phenothiazines, pimozide or zuclopenthixol – avoid; increased risk of ventricular arrhythmias with sulpiride.
- Antivirals: increased risk of ventricular arrhythmias with fosamprenavir ritonavir, saquinavir and telaprevir – avoid; concentration possibly increased by atazanavir; possible increased risk of bradycardia with daclatasvir, ledipasvir, sofosbuvir and simeprevir; avoid with indinavir, reduce the dose of the others.
- Atomoxetine: increased risk of ventricular arrhythmias.
Amiodarone hydrochloride

- Beta-blockers, diltiazem, and verapamil: increased risk of bradycardia, AV block and myocardial depression; increased risk of ventricular arrhythmias with sotalol – avoid.
- Ciclosporin: increased levels of ciclosporin possible.
- Cobicistat: concentration possibly increased by cobicistat – avoid.
- Colchicine: possibly increased colchicine toxicity.
- Cytotoxics: possibly increased afatinib concentration (separate administration by 6–12 hours); possibly increased risk of ventricular arrhythmias with panobinostat and vandetanib – avoid; concentration of ibrutinib possibly increased – reduce dose of ibrutinib; avoid with idelalisib; increased risk of ventricular arrhythmias with arsenic trioxide, bosutinib and ceritinib.
- Digoxin: increased concentration (halve digoxin maintenance dose).
- Fingolimod: possible increased risk of bradycardia.
- Grapefruit juice: may increase concentration of amiodarone – avoid.
- Ivabradine: increased risk of ventricular arrhythmias – avoid.
- Lipid-lowering drugs: give lomitapide 12 hours after amiodarone; increased risk of myopathy with simvastatin – do not exceed 20 mg of simvastatin.1
- Lithium: increased risk of ventricular arrhythmias – avoid.
- Pentamidine: increased risk of ventricular arrhythmias – avoid.

Administration

Reconstitution

Route
Oral, IV via central catheter or peripherally in veins with good blood flow.

Rate of administration
20–120 minutes (max 1.2 g in up to 500 mL glucose 5% in 24 hours)

Comments
- Add dose to 250 mL glucose 5%.
- Solutions containing less than 300 mg in 500 mL glucose 5% should not be used, as unstable.
- Minimum volumes for central use only are up to 900 mg in 48–50 mL. (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006).
- Volumetric pump should be used as amiodarone can reduce drop size.

Other information

- Amiodarone and desethylamiodarone levels can be monitored to assess compliance.
- In extreme clinical emergency, may be given by slow IV bolus using 150–300 mg in 10–20 mL glucose 5% over a minimum of 3 minutes with close monitoring. This should not be repeated for at least 15 minutes.
- Incompatible with sodium chloride 0.9%.
- Rapid IV administration has been associated with anaphylactic shock, hot flushes, sweating, and nausea.

Reference:
1. MHRA. Drug Safety Update. 2012 August; 1(6).
# Amisulpride

<table>
<thead>
<tr>
<th>Clinical use</th>
<th>Treatment of acute and chronic schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose in normal renal function</td>
<td>50–1200 mg daily (in divided doses if &gt;300 mg); varies according to indication</td>
</tr>
</tbody>
</table>
| Pharmacokinetics | Molecular weight (daltons) 369.5  
% Protein binding  16  
% Excreted unchanged in urine  50  
Volume of distribution (L/kg)  5.8  
Half-life — normal/ESRF (hrs) 12 / Unchanged |
| Metabolism | Amisulpride is weakly metabolised: two inactive metabolites, accounting for approximately 4% of the dose, have been identified. Amisulpride is eliminated unchanged in the urine. Fifty percent of an intravenous dose is excreted via the urine, of which 90% is eliminated in the first 24 hours. |
| Pharmacokinetics | Molecular weight (daltons) 369.5  
% Protein binding  16  
% Excreted unchanged in urine  50  
Volume of distribution (L/kg)  5.8  
Half-life — normal/ESRF (hrs) 12 / Unchanged |
| Metabolism | Amisulpride is weakly metabolised: two inactive metabolites, accounting for approximately 4% of the dose, have been identified. Amisulpride is eliminated unchanged in the urine. Fifty percent of an intravenous dose is excreted via the urine, of which 90% is eliminated in the first 24 hours. |
| Dose in renal impairment GFR (mL/min) | 30–60 Reduce dose by 50%.  
10–30 Use a third of the dose. See ‘Other information.’  
<10 Use with caution. Start with minimum dose and increase according to patient’s response. |
| Dose in patients undergoing renal replacement therapies | APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.  
HD Poorly dialysed. Dose as in GFR<10 mL/min.  
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.  
CAV/VVHD Poorly dialysed. Dose as in GFR=10–30 mL/min. |
| Important drug interactions | Potentially hazardous interactions with other drugs  
• Alcohol: may enhance CNS effects of alcohol.  
• Anaesthetics: enhanced hypotensive effect.  
• Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone – avoid.  
• Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; avoid with amiodarone, disopyramide and procainamide (risk of ventricular arrhythmias).  
• Antibacterials: avoid with erythromycin (increased risk of ventricular arrhythmias).  
• Antidepressants: increased level of tricyclics.  
• Antiepileptics: antagonises anticonvulsant effect.  
• Antihypertensives: increased risk of hypotension.  
• Antimalarials: avoid with artemether/lumefantrine.  
• Antipsychotics: increased risk of ventricular arrhythmias with droperidol, sertindole – avoid.  
• Antivirals: concentration possibly increased by ritonavir.  
• Anxiolytics and hypnotics: increased sedative effects.  
• Atomoxetine: increased risk of ventricular arrhythmias.  
• Beta-blockers: increased risk of ventricular arrhythmias with sotalol.  
• Cytotoxics: increased risk of ventricular arrhythmias with vandetanib – avoid; increased risk of ventricular arrhythmias with arsenic trioxide.  
• Diuretics: increased risk of ventricular arrhythmias due to hypokalaemia.  
• Pentamidine: increased risk of ventricular arrhythmias – avoid. |
| Administration | Reconstitution  
Route Oral  
Rate of administration  
Other information | Elimination half-life is unchanged in patients with renal insufficiency, while systemic clearance is reduced by a factor of 2.5–3. The AUC of amisulpride in mild renal failure (GFR=30–60 mL/min) is increased 2-fold, and almost 10-fold in moderate renal failure (GFR=10–30 mL/min). Experience is limited and there is no data with doses >50 mg. Manufacturer advises to avoid if GFR<10 mL/min due to lack of data. |
Amitriptyline hydrochloride

### Clinical use

Tricyclic antidepressant:
- Depression, used especially where sedation is required
- Neuropathic pain (unlicensed)
- Migraine prophylaxis (unlicensed)

### Dose in normal renal function

10–200 mg daily depending on indication

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>313.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>96</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>6–36</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>9–25 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Amitriptyline undergoes extensive first-pass metabolism and is demethylated in the liver by the cytochrome P450 isoenzymes CYP3A4, CYP2C9, and CYP2D6 to its primary active metabolite, nortriptyline. Other paths of metabolism of amitriptyline include hydroxylation (possibly to active metabolites) by CYP2D6 and N-oxidation; nortriptyline follows similar paths. Amitriptyline is excreted in the urine, mainly in the form of its metabolites, either free or in conjugated form.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Alcohol: increased sedative effect.
- Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; increased risk of ventricular arrhythmias with disopyramide, flecainide or propafenone; avoid with dronedarone.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and delamanid – avoid with moxifloxacin.
- Anticoagulants: may alter anticoagulant effect of coumarins.
- Antidepressants: possibly increased serotonergic effects with duloxetine; enhanced CNS excitation and hypertension with MAOIs and moclobemide; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram – avoid; possible increased risk of convulsions with vortioxetine; concentration reduced by St John's wort.
- Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, phenobarbital and possibly fosphenytoin, phenytoin and primidone.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
- Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, fluphenazine, haloperidol, pimozide, sulpiride and zuclopenthixol – avoid; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid; concentration possibly increased with ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Dapoxetine: possibly increased risk of serotonergic effects – avoid.
• Dopaminergics: avoid with entacapone; CNS toxicity reported with selegiline and rasagiline.
• Pentamidine: increased risk of ventricular arrhythmias.
• Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.

Administration

Reconstitution

Route
Oral

Rate of administration

Other information
• Introduce treatment gradually in renal impairment due to dizziness and postural hypotension.
• Withdraw treatment gradually.
• Anticholinergic side effects: causes urinary retention, drowsiness, dry mouth, blurred vision and constipation.
Amlodipine

**Clinical use**

Calcium-channel blocker:
- Hypertension
- Angina prophylaxis

**Dose in normal renal function**

5–10 mg daily

**Pharmacokinetics**

Molecular weight (daltons) 567.1 (as besilate)
% Protein binding >95
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 20
Half-life — normal/ESRF (hrs) 35–50 / 50

**Metabolism**

Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: possibly increased aminophylline and theophylline concentration.
- Anaesthetics: enhanced hypotensive effect.
- Antibacterials: metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin.
- Antidepressants: enhanced hypotensive effect with MAOIs, concentration possibly reduced by St John’s wort.
- Antiepileptics: effects probably reduced by phenobarbital and primidone.
- Antifungals: negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antivirals: concentration increased by telaprevir and possibly by ritonavir – reduce dose of amlodipine.
- Ciclosporin: ciclosporin concentration may be increased by up to 40%.
- Lipid lowering agents: possibly increased risk of myopathy – do not exceed 20 mg of simvastatin.¹
- Tacrolimus: possibly increased tacrolimus levels.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

Reference:

Amoxicillin

### Clinical use
Antibacterial agent

### Dose in normal renal function
250 mg – 1 g every 8 hours (maximum 6 g per day, up to 12 g in endocarditis)

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>365.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>20</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–1.5 / 7–20</td>
</tr>
</tbody>
</table>

### Metabolism
Amoxicillin is metabolised to a limited extent to penicilloic acid which is excreted in the urine. About 60% of an oral dose of amoxicillin is excreted unchanged in the urine by glomerular filtration and tubular secretion. Probenecid reduces renal excretion. High concentrations have been reported in bile; some may be excreted in the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>250 mg – 1 g every 8 hours (Maximum 6 g per day in endocarditis.)</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapeutic Modality</th>
<th>Dose Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Amoxicillin can reduce the excretion of methotrexate (increased risk of toxicity).

### Administration

#### Reconstitution
IV: Dissolve each 250 mg in 5 mL water for injection
IM: Dissolve 250 mg in 1.5 mL water for injection; 500 mg in 2.5 mL water for injection; 1 g in 2.5 mL water for injection or 1% sterile lidocaine hydrochloride

#### Route
Oral, IV, IM

#### Rate of administration
Slow bolus IV over 3–4 minutes
Infusion over 30–60 minutes

#### Comments
IV Infusion: Dilute in 100 mL glucose 5% or sodium chloride 0.9%
Stability in infusion depends upon diluent

### Other information
- Sodium – 3.3 mmol/g vial of Amoxil.
- Do not mix with aminoglycosides.
## Amphotericin IV – Abelcet (lipid complex)

### Clinical use

Antifungal agent:
- Systemic fungal infections (yeasts and yeast-like fungi including *Candida albicans*)

### Dose in normal renal function

5 mg/kg/day for at least 14 days (see individual product data sheet)

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>924.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2286</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>173.4 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

The metabolic fate of amphotericin B in humans has not been fully elucidated. Conventional amphotericin B is eliminated very slowly (over weeks to months) by the kidneys; slow release of the drug from the peripheral compartment may account for the long elimination half-life. Over a 7-day period, the cumulative urinary excretion of a single dose of conventional amphotericin B is about 40% of the administered drug. It has been estimated that only about 2–5% of a total dose of amphotericin B is excreted in urine unchanged. When conventional IV amphotericin B therapy is discontinued, the drug can be detected in blood for up to 4 weeks and in urine for up to 4–8 weeks.

Abelcet is Amphotericin B complexed to phospholipids; the pharmacokinetic properties of Abelcet and conventional amphotericin B are different. Pharmacokinetic studies showed that, after administration of Abelcet, amphotericin B levels were highest in the liver, spleen and lung.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs:
- **Antibacterials**: possible increased risk of arrhythmias with sodium stibogluconate – give 14 days apart.
- **Cardiac glycosides**: increased toxicity if hypokalaemia occurs.
- **Ciclosporin**: increased nephrotoxicity.
- **Corticosteroids**: increased risk of hypokalaemia (avoid concomitant use unless corticosteroids are required to control reactions).
- **Cytotoxics**: increased risk of ventricular arrhythmias with arsenic trioxide.
- **Flucytosine**: enhanced toxicity in combination with amphotericin.
- **Increased risk of nephrotoxicity with aminoglycosides and other nephrotoxic agents and cytotoxics.**
- **Tacrolimus**: increased nephrotoxicity.

### Administration

**Reconstitution**

See individual data sheet. Prepare intermittent infusion in glucose 5% (incompatible with sodium chloride 0.9%, electrolytes or other drugs). Dilute to a concentration of 1–2 mg/mL.

**Route**

IV infusion

**Rate of administration**

2.5 mg/kg/hour

**Comments**

- Paracetamol and parenteral pethidine may alleviate rigors associated with amphotericin administration. Can also use antihistamines to control reactions.
• Flush existing IV line with glucose 5% before and after infusion administration.
• For patients on CAV/VVHD, amphotericin should be given into the venous return of the dialysis circuit.
• Should be given post dialysis.

Other information

*** AMPHOTERICIN IS HIGHLY NEPHROTOXIC ***
• Can cause distal tubular acidosis.

• May cause polyurea, hypovolaemia, hypokalaemia and acidosis.
• Amphotericin and flucytosine act synergistically when co-administered enabling lower doses to be used effectively.
• A test dose of amphotericin is recommended at the beginning of a new course (1 mg over 15 minutes).
• Monitor renal function, full blood count, potassium, magnesium and calcium levels.
• Liposomal amphotericin is considerably less nephrotoxic compared with conventional amphotericin B, but is considerably more expensive.
Amphotericin IV – AmBisome (liposomal)

Clinical use
Antifungal agent:
- Systemic fungal infections (yeasts and yeast-like fungi including *Candida albicans*)
- Treatment of visceral leishmaniasis

Dose in normal renal function
1–3 mg/kg/day, maximum 5 mg/kg (unlicensed dose)
Visceral leishmaniasis: total dose of 21–30 mg/kg given over 10–21 days

Pharmacokinetics
- Molecular weight (daltons): 924.1
- % Protein binding: 90
- % Excreted unchanged in urine: 2–5
- Volume of distribution (L/kg): 0.1–0.44

Metabolism
The metabolic fate of amphotericin B in humans has not been fully elucidated. Conventional amphotericin B is eliminated very slowly (over weeks to months) by the kidneys; slow release of the drug from the peripheral compartment may account for the long elimination half-life. Over a 7-day period, the cumulative urinary excretion of a single dose of conventional amphotericin B is about 40% of the administered drug. It has been estimated that only about 2–5% of a total dose of amphotericin B is excreted in urine unchanged. When conventional IV amphotericin B therapy is discontinued, the drug can be detected in blood for up to 4 weeks and in urine for up to 4–8 weeks.

AmBisome has a significantly different pharmacokinetic profile from that reported in the literature for conventional presentations of amphotericin B, with higher amphotericin B plasma concentrations (*C*$_{max}$) and increased exposure (*AUC*$_{0-24}$). Due to the size of the liposomes, there is no glomerular filtration and renal elimination of AmBisome, thus avoiding interaction of amphotericin B with the cells of the distal tubuli and reducing the potential for nephrotoxicity seen with conventional amphotericin B presentations.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: possible increased risk of arrhythmias with sodium stibogluconate – give 14 days apart.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Ciclosporin: increased nephrotoxicity.
- Corticosteroids: increased risk of hypokalaemia (avoid concomitant use unless corticosteroids are required to control reactions).
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Flucytosine: enhanced toxicity in combination with amphotericin.
- Increased risk of nephrotoxicity with aminoglycosides and other nephrotoxic agents and cytotoxics.
- Tacrolimus: increased nephrotoxicity.

Administration
Reconstitution
See SPC. Prepare intermittent infusion in glucose 5% (incompatible with sodium chloride 0.9%, electrolytes or other drugs). Reconstitute vial contents with water for injection.
Dilute to a concentration of 0.2–2 mg/mL.
Route
IV infusion

Rate of administration
30–60 minutes (doses >5mg/kg over 2 hours)

Comments
- Paracetamol and parenteral pethidine may alleviate rigors associated with amphotericin administration. Antihistamines can also be administered to control reactions.
- Flush existing IV line with glucose 5% before and after infusion administration.
- For patients on CAV/VVHD, amphotericin should be given into the venous return of the dialysis circuit.
- Should be given post dialysis.

Other information

*** AMPHOTERICIN IS HIGHLY NEPHROTOXIC ***

- Can cause distal tubular acidosis.
- May cause polyurea, hypovolaemia, hypokalaemia and acidosis.
- Amphotericin and flucytosine act synergistically when co-administered enabling lower doses to be used effectively.
- A test dose of amphotericin is recommended at the beginning of a new course (1 mg over 10 minutes then stop and observe for next 30 minutes).
- Monitor renal function, full blood count, potassium, magnesium and calcium levels.
- Liposomal amphotericin is considerably less nephrotoxic compared with amphotericin, but is considerably more expensive.
Amphotericin IV – Fungizone

Clinical use

Antifungal agent:
- Systemic fungal infections (yeasts and yeast-like fungi including *Candida albicans*)

Dose in normal renal function

250 micrograms – 1.5 mg/kg/day
Can be given on alternate days if using a higher dose.

Pharmacokinetics

- Molecular weight (daltons) 924.1
- % Protein binding >90
- % Excreted unchanged in urine 2–5
- Volume of distribution (L/kg) 4
- Half-life — normal/ESRF (hrs) 24–48 (up to 15 days with long term use) / Unchanged

Metabolism

The metabolic fate of amphotericin B in humans has not been fully elucidated. Conventional amphotericin B is eliminated very slowly (over weeks to months) by the kidneys; slow release of the drug from the peripheral compartment may account for the long elimination half-life. Over a 7-day period, the cumulative urinary excretion of a single dose of conventional amphotericin B is about 40% of the administered drug. It has been estimated that only about 2–5% of a total dose of amphotericin B is excreted in urine unchanged. When conventional IV amphotericin B therapy is discontinued, the drug can be detected in blood for up to 4 weeks and in urine for up to 4–8 weeks.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Not dialysed. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: possible increased risk of arrhythmias with sodium stibogluconate – give 14 days apart.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Ciclosporin: increased nephrotoxicity.
- Corticosteroids: increased risk of hypokalaemia – avoid concomitant use unless corticosteroids are required to control reactions.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Flucytosine: enhanced toxicity in combination with amphotericin.
- Increased risk of nephrotoxicity with aminoglycosides and other nephrotoxic agents and cytotoxics.
- Tacrolimus: increased nephrotoxicity.

Administration

Reconstitution
See SPC. Prepare intermittent infusion in glucose 5% (incompatible with sodium chloride 0.9%, electrolytes or other drugs). Reconstitute vial contents with water for injection. pH should be adjusted to >4.2. Dilute to a concentration of 10 mg in 100 mL.

Route
IV infusion

Rate of administration
2–6 hours
If given over 12–24 hours there is a reduced incidence of side effects.

Comments
- Minimum volume peripherally 0.2 mg/mL, centrally 0.5mg/mL. (UK Critical Care Group, *Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients*, 3rd edition, 2006).
• Higher rates of infusion are associated with greater risk of adverse reactions. Administration over less than 1 hour, particularly in renal failure, has been associated with hyperkalaemia and arrhythmias.
• Paracetamol and parenteral pethidine may alleviate rigors associated with amphotericin administration. Can also give antihistamines and corticosteroids to control reactions.
• Flush existing IV line with glucose 5% before and after infusion administration.
• For patients on CAV/VVHD, amphotericin should be given into the venous return of the dialysis circuit.

Other information

*** AMPHOTERICIN IS HIGHLY NEPHROTOXIC ***
• Permanent renal impairment may occur, particularly in patients receiving conventional amphotericin B at doses >1 mg/kg/day, or with pre-existing renal impairment, prolonged therapy, sodium depletion or concurrent nephrotoxic drugs.
• Nephrotoxicity may be reduced by giving an IV infusion of sodium chloride 0.9% 250–500 mL over 30–45 minutes immediately before administering amphotericin B.
• Can cause distal tubular acidosis.
• May cause polyurea, hypovolaemia, hypokalaemia and acidosis.
• Amphotericin and flucytosine act synergistically when co-administered enabling lower doses to be used effectively.
• A test dose of amphotericin is recommended at the beginning of a new course (1 mg over 20–30 minutes then stop and observe for 30 minutes).
• Monitor renal function, full blood count, potassium, magnesium and calcium levels.
• Liposomal amphotericin is considerably less nephrotoxic compared with conventional amphotericin B, but is considerably more expensive.
• There are reports of the use of amphotericin in 20% lipid solution being as well tolerated as liposomal amphotericin.
Ampicillin

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
- Oral: 250 mg – 1 g every 6 hours
- IM / IV: 500 mg – 2 g every 4–6 hours

**Pharmacokinetics**
- Molecular weight (daltons): 349.4
- % Protein binding: 20
- % Excreted unchanged in urine:
  - Oral: 20–60;
  - Parenteral: 60–80
- Volume of distribution (L/kg): 0.17–0.31
- Half-life — normal/ESRF (hrs): 1–1.5 / 7–20

**Metabolism**
Ampicillin is metabolised to some extent to penicilloic acid which is excreted in the urine.
Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion; it is reduced by probenecid. About 20–40% of an oral dose and 60–80% of an IV dose may be excreted unchanged in the urine in 6 hours. High concentrations are reached in bile; it undergoes enterohepatic recycling and some is excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: 250 mg – 2 g every 6 hours.
- <10: 250 mg – 1 g every 6 hours.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min. See ‘Other information’.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Ciclosporin: may increase ciclosporin levels.
- Reduces excretion of methotrexate (increased risk of toxicity).

**Administration**

**Reconstitution**
Use water for injection: 5 mL for each 250 mg (1.5 mL for 250 mg or 500 mg for IM administration).

**Route**
Oral, IV, IM

**Rate of administration**
Slow IV bolus over 3–4 minutes. Doses greater than 500 mg should be given by infusion.
Infusion: 30–60 minutes.

**Comments**
Can be diluted in 100 mL glucose 5% or sodium chloride 0.9%.

**Other information**
- Rashes more common in patients with renal impairment.
- Can cause nephrotoxicity if dose not reduced in renal impairment.
- Sodium content of injection 1.47 mmol/500 mg vial.
- Ampicillin may be used in peritoneal dialysis fluids for treatment of peritonitis.
- Do not mix with aminoglycosides.
- Doses in renal impairment estimated from evaluation of pharmacokinetics.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Anagrelide

**Clinical use**

Platelet-reducing agent

**Dose in normal renal function**

1–10 mg daily in divided doses; maximum single dose 2.5 mg; normal range 1–3 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>292.5 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>12</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.3 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Anagrelide is primarily metabolised by CYP1A2; less than 1% is recovered in the urine as anagrelide. Two major urinary metabolites, 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline and 3-hydroxy anagrelide (pharmacologically active) have been identified. The mean recovery of 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline in urine is approximately 18–35% of the administered dose.

**Dose in renal impairment GFR (mL/min)**

- **30–50** Dose as in normal renal function.
- **10–30** Dose as in normal renal function, but use with caution and keep to lowest dose possible.
- **<10** Dose as in normal renal function, but use with caution and keep to lowest dose possible.

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD** Unknown dialysability. Dose as in GFR<10 mL/min.
- **HDF/High flux** Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD** Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Aspirin: potential risks and benefits must first be assessed, additive antiplatelet effect.
- Cilostazol: avoid concomitant use.
- Grapefruit juice: may reduce clearance of anagrelide.
- Phosphodiesterase inhibitors: avoid with milrinone and enoximone.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Manufacturer has no data in renal impairment so use with caution.
- May cause fluid retention, tachycardia and various cardiac complications.
- Rarely can increase creatinine levels.
- High doses can cause a drop in blood pressure.
Anakinra

<table>
<thead>
<tr>
<th><strong>Clinical use</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Interleukin-1 inhibitor</td>
<td></td>
</tr>
<tr>
<td>• Treatment of rheumatoid arthritis with methotrexate</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dose in normal renal function</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mg once daily</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Pharmacokinetics</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>17 300</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Majority</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4–6 / 9.7¹</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Metabolism</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Renally metabolised and excreted.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Important drug interactions</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Potentially hazardous interactions with other drugs</td>
<td></td>
</tr>
<tr>
<td>• Adalimumab, certolizumab, etanercept, golimumab and infliximab: avoid concomitant use.</td>
<td></td>
</tr>
<tr>
<td>• Live vaccines: avoid concomitant use.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Administration</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reconstitution</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Route</strong></td>
<td>SC</td>
</tr>
<tr>
<td><strong>Rate of administration</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Other information</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Bioavailability is 95%.</td>
<td></td>
</tr>
<tr>
<td>• UK SPC advises to avoid in severe renal impairment (GFR&lt;30 mL/min) but American data sheet advises to administer on alternate days.</td>
<td></td>
</tr>
<tr>
<td>• In severe renal insufficiency and ESRD (CRCL&lt;30 mL/min), mean plasma clearance declined by 70% and 75%, respectively.</td>
<td></td>
</tr>
<tr>
<td>• Less than 2.5% of the administered dose was removed by haemodialysis or continuous ambulatory peritoneal dialysis.</td>
<td></td>
</tr>
</tbody>
</table>

Reference:
# Anastrozole

## Clinical use
Treatment of breast cancer in post menopausal women

## Dose in normal renal function
1 mg daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>293.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>40</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>40–50 / Probably unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
Anastrozole is extensively metabolised by postmenopausal women with less than 10% of the dose excreted in the urine unchanged within 72 hours of dosing. Metabolism of anastrozole occurs by N-dealkylation, hydroxylation and glucuronidation via CYP 3A4 and 3A5, and UGT1A4. The metabolites are excreted primarily via the urine. Triazole, the major metabolite in plasma, does not inhibit aromatase.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Oestrogen-containing therapies: avoid concomitant administration as would negate pharmacological action.
- Tamoxifen: avoid concomitant administration.

## Administration

### Reconstitution
—

### Route
Oral

### Rate of administration
—

## Other information
- Although renal clearance of anastrozole decreases proportionally with creatinine clearance, the reduction in renal clearance does not affect total body clearance of anastrozole.
- According to the US data sheet a dose reduction is not required in renal impairment.
- In the UK, the SPC recommends avoiding the use of anastrozole in patients with GFR<20 mL/min.
Anidulafungin

Clinical use

Antifungal agent:
- Invasive candidiasis

Dose in normal renal function

200 mg loading dose then 100 mg daily

Pharmacokinetics

- Molecular weight (daltons): 1140.2
- % Protein binding: >99
- % Excreted unchanged in urine: <1
- Volume of distribution (L/kg): 30–50 Litres
- Half-life — normal/ESRF (hrs): 40–50 / Unchanged

Metabolism

Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes.

Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. The ring-opened product is subsequently converted to peptidic degradants and eliminated mainly through biliary excretion.

In a single-dose clinical study, radiolabelled $^{14}$C-anidulafungin (~88 mg) was administered to healthy subjects. Approximately 30% of the administered radioactive dose was eliminated in the faeces over 9 days, of which less than 10% was intact drug. Less than 1% of the administered radioactive dose was excreted in the urine, indicating negligible renal clearance.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- None known

Administration

Reconstitution
With diluent provided

Route
IV infusion

Rate of administration
1.1 mg/minute (3 mL/minute)

Comments
Can be further diluted in sodium chloride 0.9% or glucose 5%.
Add 100 mg to 250 mL or 200 mg to 500 mL of fluid.
Apixaban

Clinical use

Factor Xa inhibitor:
- Prevention of venous thromboembolism in adults undergoing elective hip or knee replacement surgery
- Prophylaxis of stroke and systemic embolism in AF
- Treatment and prevention of DVTs and PEs

Dose in normal renal function

- Surgery: 2.5 mg twice daily
- AF: 2.5–5 mg twice daily (depending on weight and age)
- Treatment of DVTs and PEs: 10 mg twice daily for 7 days then 5 mg twice daily
- Prevention of DVTs and PEs: 2.5 mg twice daily

Pharmacokinetics

Molecular weight (daltons) 459.5
% Protein binding 87
% Excreted unchanged in urine 27
Volume of distribution (L/kg) 21 Litres
Half-life — normal/ESRF (hrs) 12 / –

Metabolism

Apixaban is metabolised in the liver mainly via the P450 cytochromes CYP3A4 and CYP3A5.
Apixaban has multiple routes of elimination. Of the administered apixaban dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces. Renal excretion of apixaban accounts for approximately 27% of total clearance. There are also additional contributions from biliary and direct intestinal excretion.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>15–30</td>
<td>Dose as in normal renal function. Use with caution. AF: 2.5 mg twice daily.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Use with caution. AF: 2.5 mg twice daily. See 'Other information'.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=15–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Analgesics: increased risk of haemorrhage with IV diclofenac and ketorolac – avoid.
- Antibacterials: avoid with clarithromycin and telithromycin; concentration possibly reduced by rifampicin – avoid if treating DVT/PE.
- Anticoagulants: increased risk of haemorrhage with other anticoagulants – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid if treating DVT/PE.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone – avoid if treating DVT/PE with carbamazepine.
- Antifungals: concentration increased by ketoconazole – avoid; avoid withitraconazole, posaconazole and voriconazole.
- Antivirals: avoid with atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir, telaprevir and tipranavir.
- Cobicistat: avoid concomitant use.

Administration

Reconstitution

Route
Oral

Rate of administration

Comments
- Can be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally. Can also be crushed and suspended in 60 mL of water or D5W and immediately delivered through a nasogastric.
- Stable in water, D5W, apple juice, and apple puree for up to 4 hours.

**Other information**

- Oral bioavailability is 50%.
- Manufacturer does not recommend use in severe renal impairment due to lack of data and the potential of an increased risk of bleeding.
- The American Heart Association/American Stroke Association do not recommend its use in severe renal impairment for stroke/embolism prevention.
- Haemodialysis reduces the AUC by 14%.

- There was no impact of impaired renal function on peak concentration of apixaban. There was an increase in apixaban exposure correlated to a decrease in renal function, as assessed via measured CRCL. In individuals with mild (CRCL=51–80 mL/min), moderate (CRCL=30–50 mL/min) and severe (CRCL=15–29 mL/min) renal impairment, apixaban plasma concentrations (AUC) were increased by 16, 29, and 44% respectively, compared to individuals with normal creatinine clearance. Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-Xa activity.
Apomorphine hydrochloride

**Clinical use**

Treatment of refractory motor fluctuations in Parkinson’s disease

**Dose in normal renal function**

- 3–30 mg daily in divided doses (maximum single dose 10 mg); infusion: 1–4 mg/hour during waking hours
- Maximum dose 100 mg daily

**Pharmacokinetics**

- Molecular weight (daltons) 312.8
- % Protein binding 90
- % Excreted unchanged in urine <2
- Volume of distribution (L/kg) 2–19
- Half-life — normal/ESRF (hrs) 29.1–36.9 minutes

**Metabolism**

After subcutaneous injection its fate can be described by a two-compartment model, with a distribution half-life of 5 (±1.1) minutes and an elimination half-life of 33 (±3.9) minutes. Clinical response correlates well with levels of apomorphine in the cerebrospinal fluid.

Apomorphine is extensively metabolised in the liver, mainly by conjugation with glucuronic acid or sulfate; the major metabolite is apomorphine sulfate. It is also demethylated to produce norapomorphine.

Most of a dose is excreted in urine, mainly as metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR range</th>
<th>Dose details</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Start with 1 mg.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Start with 1 mg.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with 1 mg.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antihypertensives: enhanced hypotensive effect.
- Domperidone: possible increased risk of ventricular arrhythmias.
- 5HT₃-receptor antagonists: possibly increased hypotensive effects with ondansetron.
- Nitrates: enhanced hypotensive effect.

**Administration**

**Reconstitution**

- **Route**
  - SC
- **Rate of administration**
  - 1–4 mg/hour
- **Comments**
  - Change site every 4 hours for SC administration

**Other information**

- Pre-treatment with domperidone is required for at least 2 days before and at least 3 days after treatment.
- Bioavailability by subcutaneous administration is 17–18%.
Apremilast

Clinical use
Treatment of active psoriatic arthritis (PsA) and moderate to severe chronic plaque psoriasis (PSOR)

Dose in normal renal function
30 mg twice daily after dose titration

Pharmacokinetics
Molecular weight (daltons) 460.5
% Protein binding 68
% Excreted unchanged in urine 3
Volume of distribution (L/kg) 87 Litres
Half-life — normal/ESRF (hrs) 9 / 12

Metabolism
Apremilast is extensively metabolised by both CYP and non-CYP mediated pathways including oxidation, hydrolysis, and conjugation, suggesting inhibition of a single clearance pathway. After oral administration of radiolabelled apremilast, about 3% and 7% of the radioactive dose is recovered as apremilast in urine and faeces, respectively.

Dose in renal impairment GFR (mL/min)
30–50 Dose as in normal renal function.
10–30 30 mg once daily.
<10 30 mg once daily.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Unknown dialysability. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin — avoid.
- Antidepressants: concentration possibly reduced by St John’s wort — avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone — avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- The safety profile observed in patients with mild renal impairment was comparable to patients with normal renal function. The safety of apremilast was not evaluated in PsA or PSOR patients with moderate or severe renal impairment in the clinical studies.
- Bioavailability is 73%.
- In 8 subjects with severe renal impairment given a single dose of 30 mg apremilast, the AUC and C_{max} of apremilast increased by approximately 89% and 42%, respectively.

Reference:
Aprepitant

**Clinical use**
Prevention of acute and delayed nausea and vomiting associated with moderate and highly emetogenic cancer chemotherapy

**Dose in normal renal function**
125 mg once daily on day 1 followed by 80 mg once daily on days 2 and 3

**Pharmacokinetics**
- Molecular weight (daltons) 534.4
- % Protein binding >95
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) 66 Litres
- Half-life — normal/ESRF (hrs) 9–13 / Unchanged

**Metabolism**
Aprepitant undergoes extensive metabolism. Following a single IV 100mg dose of [14C]fosaprepitant, a prodrug for aprepitant, aprepitant accounts for approximately 19% of the radioactivity in plasma over 72 hours. 12 metabolites of aprepitant have been identified in human plasma. The metabolism of aprepitant, primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19, occurs largely via oxidation at the morpholine ring and its side chains and the resultant metabolites were only weakly active.

Aprepitant is not excreted unchanged in urine.
Metabolites are excreted in urine (57%) and via biliary excretion in faeces (45%).

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antidepressants: avoid with St John’s wort.
- Antipsychotics: avoid with pimozide.
- Avanafil: possibly increases avanafil concentration.
- Cytotoxics: possibly increases bosutinib concentration – avoid or reduce bosutinib dose; possibly increases ibrutinib concentration – reduce ibrutinib dose.
- Oestrogens and progestogens: may cause contraceptive failure.
- Ulipristal: possibly reduces contraceptive effect – avoid.

**Administration**
**Reconstitution**
—
**Route**
Oral
**Rate of administration**
—

**Other information**
- Less than 0.2% of a dose is recovered in dialysate after haemodialysis.
Argatroban

Clinical use

Anticoagulant:
• Prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT)
• Adjunct in patients at risk of HIT undergoing percutaneous coronary intervention

Dose in normal renal function

• Anticoagulant for prophylaxis or treatment of thrombosis: Infusion of 2 mcg/kg/min; adjust according to response (APTT); maximum 10 mcg/kg/min.
• Anticoagulant for patients undergoing percutaneous coronary intervention: Initially a bolus of 350 mcg/kg administered via a large bore IV line over 3–5 minutes, followed by an infusion of 25 mcg/kg/min. Additional IV bolus doses of 150 mcg/kg may be given if required and the infusion rate changed to 15–40 mcg/kg/min.
• Haemodialysis anticoagulation: initial bolus (250 microgram/kg) followed by continuous infusion of 2 microgram/kg/min. The infusion is stopped 1 hour before the end of dialysis. The target ACT range is 170–230 seconds.

Pharmacokinetics

Molecular weight (daltons) 508.6
% Protein binding 54
% Excreted unchanged in urine 16
Volume of distribution (L/kg) 0.17
Half-life — normal/ESRF (hrs) 39–51 minutes/Unchanged

Metabolism

The metabolism of argatroban has not yet been fully characterised. The metabolites identified (M-1, M-2, and M-3) are formed by hydroxylation and aromatisation of the 3-methyltetrahydroquinoline ring in the liver. The main metabolite (M1) exerts 40-fold weaker antithrombin effect than argatroban. Metabolites M-1, M-2 and M-3 were detected in the urine, and M-1 was detected in plasma and faeces. Aratroban is excreted mainly in the faeces, presumably through biliary secretion. Following intravenous infusion of [14C]-argatroban 21.8±5.8% of the dose was excreted in urine and 65.4±7.1% in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Analgesics: increased risk of haemorrhage with IV diclofenac and ketorolac – avoid.
• Antiplatelets and anticoagulants: increased risk of bleeding complications.
• Heparin: avoid concomitant administration.
• Urokinase: may increase the risk of bleeding.
• Thrombolytics: may increase risk of bleeding complications; enhance effect of argatroban.

Administration

Reconstitution

Route

IV

Rate of administration

• Bolus: over 3–5 minutes
• Infusion: 2–25 mcg/kg/min

Comments

• Physically and chemically stable for up to 96 hours if refrigerated or at controlled room temperature and protected from light.
• Dilute to 1 mg/mL with sodium chloride 0.9%, glucose 5% or Lactated Ringer’s solution, i.e. 250 mg (2.5 mL) into 250 mL of diluent. The solution must be mixed by inversion for 1 minute.
Other information

- Can also be used for haemodialysis anticoagulation: 0.1 mg/kg bolus, followed by a continuous infusion of 0.1-0.2 mg/kg/hour, dosing being adjusted to maintain an APTT 1.5-3 times normal.
- For CVVHD a dose of 0.5–1 mcg/kg/min was suggested, dosing being adjusted to maintain an APTT 1.5–2 times normal. (O’Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Seminars in Dialysis. 2003; 16(1): 61–7).
- 20% of argatroban is removed during a 4 hour dialysis session.
- There is no specific antidote.
- Contraindicated in patients with overt major bleeding.
Aripiprazole

Clinical use
Atypical antipsychotic:
• Treatment of schizophrenia
• Depression in bipolar disorder

Dose in normal renal function
• Oral: 10–30 mg daily
• IM: 5.25–15 mg daily after 2 hours, max 3 injections daily
• Deep IM: 400 mg monthly
• Combined route daily dose: 30 mg

Pharmacokinetics
Molecular weight (daltons) 448.4
% Protein binding >99
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 4.9
Half-life — normal/ESRF (hrs) 75 (146 in poor metabolisers) / Unchanged

Metabolism
Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the main active moiety in systemic circulation. At steady state, dehydroaripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.

Following a single oral dose of [14C]-aripiprazole, approximately 27% of the administered radioactivity was recovered in the urine and approximately 60% in the faeces. Less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% was recovered unchanged in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Anaesthetics: enhanced hypotensive effect.
• Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
• Antihypertensives: may enhance antihypertensive effect.
• Alcohol and other CNS drugs: increased sedation and other related side effects.
• Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval.
• Antibacterials: concentration possibly reduced by rifabutin and rifampicin – increase dose of aripiprazole.
• Antidepressants: fluoxetine and paroxetine possibly inhibit metabolism — reduce dose of aripiprazole; concentration possibly reduced by St John’s wort — increase aripiprazole dose; increased concentration of tricyclics.
• Antiepileptics: antagonise anticonvulsant effect; concentration reduced by carbamazepine and possibly reduced by fosphenytoin, phenytoin, phenobarbital and primidone – increase dose of aripiprazole.
• Antifungals: metabolism inhibited by ketoconazole and possibly by itraconazole – reduce dose of aripiprazole.
• Antimalarials: avoid with artemether/lumefantrine.
• Antipsychotics: possible increased risk of ventricular arrhythmias with risperidone.
• Antivirals: metabolism possibly inhibited by atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir and tipranavir – reduce dose of aripiprazole; concentration possibly reduced.
reduced by efavirenz and nevirapine – increase dose of aripiprazole.

- Anxiolytics and hypnotics: increased sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.

### Administration

**Reconstitution**

- **Route**
  - Oral, IM

**Rate of administration**

- **Other information**
  - Can cause QT prolongation.
Arsenic trioxide

**Clinical use**

Antineoplastic agent:
- Acute promyelocytic leukaemia (APL)

**Dose in normal renal function**

- 150 mcg/kg daily until remission occurs
- Consolidation: 150 mcg/kg daily for 5 days per week for 25 doses spread over up to 5 weeks (to start 3–4 weeks after completion of induction)

**Pharmacokinetics**

- Molecular weight (daltons) 197.8
- % Protein binding 96% bound to haemoglobin
- % Excreted unchanged in urine 1–8
- Volume of distribution (L/kg) 4 Litres
- Half-life — normal/ESRF (hrs) 92 / Increased

**Metabolism**

When placed into solution, arsenic trioxide immediately forms the hydrolysis product arsenious acid (As\(^{III}\)), which is the pharmacologically active species of arsenic trioxide.

The metabolism of arsenic trioxide involves oxidation of As\(^{III}\) to arsenic acid (As\(^{V}\)), as well as oxidative methylation to monomethylarsonic acid (MMA\(^{V}\)) and dimethylarsinic acid (DMA\(^{V}\)) by methyltransferases, primarily in the liver.

Approximately 15% of the administered arsenic trioxide dose is excreted in the urine as unchanged As\(^{III}\). The methylated metabolites of As\(^{III}\) (MMA\(^{V}\), DMA\(^{V}\)) are primarily excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Reduce dose. Use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>Reduce dose. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Reduce dose. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Use with care in combination with other drugs known to cause QT interval prolongation.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone and disopyramide.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid, erythromycin, levofloxacin and moxifloxacin.
- Antidepressants: increased risk of ventricular arrhythmias with amitriptyline or clomipramine.
- Antifungals: increased risk of ventricular arrhythmias with amphotericin.
- Antimalarials: increased risk of ventricular arrhythmias with piperaquine with artenimol – avoid.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval and haloperidol; avoid with clozapine, increased risk of agranulocytosis.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Cytotoxics: increased risk of ventricular arrhythmias with vandetanib – avoid.
- Diuretics: increased risk of ventricular arrhythmias if hypokalaemia occurs due to acetazolamide, loop diuretics or thiazide diuretics.
- Lithium: increased risk of ventricular arrhythmias.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>IV</th>
</tr>
</thead>
</table>

**Rate of administration**

Over 1–4 hours
Comments
Dilute with 100–250 mL glucose 5% or sodium chloride 0.9%.

Other information
- Manufacturer advises to use with caution in renal impairment due to lack of data.
- Renal excretion is the main route of elimination; can accumulate in renal impairment.
- Plasma clearance of As\textsuperscript{III} was not altered in patients with mild renal impairment (CRCL=50–80 mL/min) or moderate renal impairment (CRCL=30–49 mL/min). The plasma clearance of As\textsuperscript{III} in patients with severe renal impairment (CRCL<30 mL/min) was 40% lower when compared with patients with normal renal function. Systemic exposure to MMA\textsuperscript{V} and DMA\textsuperscript{V} tended to be larger in patients with renal impairment; the clinical consequence of this is unknown but no increased toxicity was noted.
- Can cause QT interval prolongation and hypokalaemia.
- Arsenic trioxide is under investigation for other conditions, e.g. multiple myeloma, acute myeloid leukaemias and myelodysplastic syndromes.
- Intensive monitoring is required.
- Arsenic is stored mainly in liver, kidney, heart, lung, hair and nails. Trivalent forms of arsenic are methylated in humans and mostly excreted in urine. In APL patients, daily administration of 0.15 mg/kg/day of arsenic trioxide resulted in an approximate 4-fold increase in the urinary excretion of arsenic after 2–4 weeks of continuous dosing, when compared to baseline values.
Artemether with lumefantrine

**Clinical use**
Treatment of malaria

**Dose in normal renal function**
- ≥35 kg: 6 doses of 4 tablets, i.e. 24 tablets given over 60 hours
- Give 4 tablets at 0, 8, 24, 36, 48 and 60 hours

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Artemether</th>
<th>Lumefantrine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>298.4</td>
<td>528.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95.4</td>
<td>99.9</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Artemether: 5.4–8.6; Lumefantrine: 3.8</td>
<td></td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Artemether 0.8–7; Lumefantrine 48–72 (4–6 days in people with falciparum malaria)</td>
<td></td>
</tr>
</tbody>
</table>

**Metabolism**

Human liver microsomes metabolise artemether to the biologically active main metabolite dihydroartemisinin (demethylation), predominantly through the isoenzyme CYP3A4/5. Dihydroartemisinin is further converted to inactive metabolites.

Lumefantrine is N-debutylated, mainly by CYP3A4, in human liver microsomes, and is excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>As in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>As in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>As in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs:
- Anti-arrhythmics: avoid with amiodarone, disopyramide, flecainide and procainamide – risk of ventricular arrhythmias.
- Antibacterials: avoid with macrolides and quinolones.
- Antidepressants: avoid concomitant use.
- Antifungals: avoid with imidazoles and triazoles.
- Antimalarials: avoid with antimalarials; increased risk of ventricular arrhythmias with quinine – avoid.
- Antipsychotics: avoid concomitant use.
- Antivirals: use atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir and tipranavir with caution; avoid with boceprevir; concentration of lumefantrine increased by darunavir; concentration reduced by efavirenz and etravirine.
- Beta-blockers: avoid with metoprolol and sotalol.
- Cytotoxics: possible increased risk of ventricular arrhythmias with vandetanib – avoid.
- Grapefruit juice: may increase bioavailability and inhibit metabolism – avoid.
- Ulcer-healing drugs: avoid cimetidine.

**Administration**

**Reconstitution**
- **Route**
  - Oral

**Rate of administration**
- **Comments**
  - Take with food to increase absorption.
  - If patient vomits within 1 hour of taking the tablet the dose should be repeated.

**Other information**
- In renal impairment monitor ECG and potassium levels.
- Manufacturer advises to use with caution in severe renal impairment due to lack of studies.
Ascorbic acid

Clinical use

- Acidification of urine
- Vitamin C deficiency

Dose in normal renal function

- Up to 4 g daily in divided doses
- Prophylaxis: 25–75 mg daily
- Therapeutic: 250 mg daily in divided doses
- IV: 0.5–1 g daily
- Preventative therapy: 200–500 mg daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>176.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>25</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal¹</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–4 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism

Ascorbic acid is reversibly oxidised to dehydroascorbic acid; some is metabolised to ascorbate-2-sulfate, which is inactive, and oxalic acid which are excreted in the urine. Ascorbic acid in excess of the body’s needs is also rapidly eliminated unchanged in the urine; this generally occurs with intakes exceeding 100 mg daily.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- None known

Administration

Reconstitution

Route
Oral, IV

Rate of administration

Other information

- No scientific evidence from clinical trial of efficacy in reducing UTI via acidification of urine.
- In CKD 5 on dialysis, requirements are usually about 75–90 mg per day. (Kalanter-Zadeh K, Kopple JD. Trace elements and vitamins in maintenance dialysis patients. Adv Ren Replace Ther. 2003; 10(3): 170–82.)
- Try to use lower doses in CKD 5 patients due to risk of oxalate formation.

Reference:
Asenapine

Clinical use
Atypical antipsychotic
  - Treatment of schizophrenia and bipolar disease

Dose in normal renal function
5–10 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 401.8 (as maleate)
% Protein binding 95
% Excreted unchanged in urine 50 (small amount unchanged)
Volume of distribution (L/kg) 20–25
Half-life — normal/ESRF (hrs) 24 / –

Metabolism
Metabolism is by direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2) are the primary metabolic pathways for asenapine. Excretion is 50% renal and 50% via the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
15–20 Dose as in normal renal function.
<15 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<15 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<15 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in GFR<15 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
  - Anaesthetics: enhanced hypotensive effect.
  - Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids.
  - Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; avoid with amiodarone, disopyramide and procainamide (risk of ventricular arrhythmias).
  - Antidepressants: concentration possibly increased by fluvoxamine; possibly increased paroxetine concentration; concentration of tricyclics possibly increased.
  - Antiepileptics: antagonises anticonvulsant effect.
  - Antimalarials: avoid with artemether/lumefantrine.
  - Antivirals: concentration possibly increased by ritonavir.
  - Anxiolytics and hypnotics: increased sedative effects.

Administration
Reconstitution
—
Route Sublingual
Rate of administration
—
Comments
Avoid eating and drinking for 10 minutes after taking tablet as affects bioavailability.

Other information
  - Manufacturer has no information in GFR<15 mL/min but does not advise a dose reduction.
**Aspirin**

**Clinical use**

NSAID:
- Analgesic and antipyretic
- Prophylaxis of cerebrovascular disease or myocardial infarction

**Dose in normal renal function**

- Analgesia: Oral: 300–900 mg every 4 hours
- Maximum 4 g daily in acute conditions
- PR: 450–900 mg every 4 hours
- Prophylaxis of cerebrovascular disease or myocardial infarction: 75–300 mg daily

**Pharmacokinetics**

- Molecular weight (daltons): 180.2
- % Protein binding: 80–90
- % Excreted unchanged in urine: 2 (acidic urine); 30 (alkaline urine)
- Volume of distribution (L/kg): 0.1–0.2

**Metabolism**

After oral doses, absorption of non-ionised aspirin occurs in the stomach and intestine. Some aspirin is hydrolysed to salicylate in the gut wall. Once absorbed, aspirin is rapidly converted to salicylate, but during the first 20 minutes after an oral dose aspirin is the main form of the drug in the plasma. Both aspirin and salicylate have pharmacological activity although only aspirin has an anti-platelet effect. Salicylate is extensively bound to plasma proteins and is rapidly distributed to all body parts.

Salicylate is mainly eliminated by hepatic metabolism; the metabolites include salicyluric acid, salicyl phenolic glucuronide, salicylyc acyl glucuronide, gentisic acid, and gentisuric acid. The formation of the major metabolites, salicyluric acid and salicyl phenolic glucuronide, is easily saturated and follows Michaelis-Menten kinetics. As a result, steady-state plasma-salicylate concentrations increase disproportionately with dose. Salicylate is also excreted unchanged in the urine; the amount excreted by this route increases with increasing dose and also depends on urinary pH, about 30% of a dose being excreted in alkaline urine compared with 2% of a dose in acidic urine.

Renal excretion involves glomerular filtration, active renal tubular secretion, and passive tubular reabsorption.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal function</th>
<th>See 'Other information'</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect, increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs – increased side effects; avoid with ketorolac – increased risk of side effects and haemorrhage.
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins enhanced; possibly increased risk of bleeding with edoxaban, heparins and coumarins.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
• Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect, hyperkalaemia with potassium-sparing diuretics; increased risk of toxicity of acetazolamide with high dose aspirin.
• Lithium: excretion decreased.
• Pentoxifylline: increased risk of bleeding.
• Tacrolimus: increased risk of nephrotoxicity.

Administration
Reconstitution

Route
Oral

Rate of administration

Other information
• Aspirin at analgesic/antipyretic dose is best avoided in patients with renal impairment, especially if severe.
• Antiplatelet effect may add to uraemic gastrointestinal and haematologic symptoms.
• Degree of protein binding reduced in ESRD.
Atazanavir

Clinical use

Protease inhibitor:
- HIV infection, in combination with other antiretroviral drugs

Dose in normal renal function

300 mg once daily with ritonavir 100 mg once daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>802.9 (as sulphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>86</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>7</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7 / No data</td>
</tr>
</tbody>
</table>

Metabolism

Atazanavir is principally metabolised by CYP3A4 isozyme to oxygenated metabolites. Metabolites are then excreted in the bile as either free or glucuronidated metabolites. Additional minor metabolic pathways consist of N-dealkylation and hydrolysis. Two minor metabolites of atazanavir in plasma have been characterised. Neither metabolite demonstrated in vitro antiviral activity.

Following a single 400 mg dose of \(^{14}\text{C}\)-atazanavir, 79% and 13% of the total radioactivity was recovered in the faeces and urine, respectively. Unchanged drug accounted for approximately 20% and 7% of the administered dose in the faeces and urine, respectively.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Anti-arrhythmics: possibly increased levels of amiodarone and lidocaine.
- Antibacterials: concentration of both drugs increased when given with clarithromycin; rifabutin concentration increased – reduce dose of rifabutin; rifampicin reduces atazanavir concentration – avoid; avoid with telithromycin in severe renal and hepatic impairment.
- Anticoagulants: avoid with apixaban and rivaroxaban.
- Antidepressants: concentration reduced by St John's wort – avoid.
- Antifungals: concentration increased by posaconazole; concentration of voriconazole increased or decreased, concentration of atazanavir also reduced.
- Antimalarials: avoid with artemether/lumefantrine; may increase quinine concentration.
- Antipsychotics: possibly inhibits metabolism of aripiprazole – reduce dose of aripiprazole; possibly increased concentration of pimozide and quetiapine – avoid.
- Antivirals: concentration reduced by boceprevir; increased by daclatasvir; absorption reduced by didanosine tablets; concentration reduced by efavirenz – avoid; concentration of elvitegravir increased when atazanavir boosted with ritonavir – reduce elvitegravir dose; concentration possibly reduced by nevirapine – avoid; concentration of maraviroc increased, consider reducing dose of maraviroc; possibly reduces telaprevir concentration, also concentration of atazanavir increased; concentration of tipranavir increased, also concentration of atazanavir reduced; avoid with elbasvir/grazoprevir, increased grazoprevir concentration.
- Anxiolytics and hypnotics: possibly increases concentration of midazolam – avoid with oral midazolam.
- Calcium-channel blockers: concentration of diltiazem increased – reduce dose of diltiazem; possibly increased verapamil concentration.
- Ciclosporin: possibly increased concentration of ciclosporin.
• Colchicine: possibly increases risk of colchicine toxicity, avoid in hepatic or renal impairment.
• Cytotoxics: possibly increases concentration of axitinib, reduce dose of axitinib; possibly increases concentration of bosutinib, avoid or reduce dose; possibly increases concentration of crizotinib and everolimus – avoid; avoid with cabazitaxel and pazopanib; concentration of ibrutinib possibly increased, reduce dose of ibrutinib; possibly inhibits metabolism of irinotecan – increased risk of toxicity.
• Dapoxetine: avoid concomitant use, increased risk of toxicity.
• Ergot alkaloids: possibly increased concentration of ergot alkaloids – avoid.
• Orlistat: absorption possibly reduced by orlistat.
• Ranolazine: possibly increases ranolazine concentration – avoid.
• Sildenafil: possibly increased side effects of sildenafil.
• Sirolimus: possibly increased concentration of sirolimus.
• Statins: avoid with simvastatin – increased risk of myopathy; possibly increased risk of myopathy with atorvastatin, pravastatin and rosuvastatin – reduce rosuvastatin dose.
• Tacrolimus: possibly increased concentration of tacrolimus.
• Ticagrelor: possibly increases concentration of ticagrelor – avoid.
• Ulcer-healing drugs: concentration significantly reduced by omeprazole and esomeprazole and possibly other proton pump inhibitors – avoid; concentration possibly reduced by histamine H₂ antagonists.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**
Take with food.

**Comments**
Take didanosine 2 hours after atazanavir if used in combination.
Atenolol

**Clinical use**
Beta-adrenoceptor blocker:
- Hypertension
- Angina
- Arrhythmias

**Dose in normal renal function**

**Oral:**
- Hypertension: 25–50 mg daily
- Angina: 100 mg daily in 1 or 2 divided doses
- Arrhythmias: 50–100 mg daily
- Migraine prophylaxis (unlicensed): 50–200 mg daily in divided doses.

**IV:**
- Arrhythmias: 2.5 mg at a rate of 1 mg/min repeated at 5 minute intervals to a maximum of 10 mg

**Infusion:**
- 150 mcg/kg, repeated every 12 hours if required

**Pharmacokinetics**
- Molecular weight (daltons) 266.3
- % Protein binding 3
- % Excreted unchanged in urine >90
- Volume of distribution (L/kg) 1.1
- Half-life — normal/ESRF (hrs) 6–7 / 15–35

**Metabolism**
Atenolol has low lipid solubility. It crosses the placenta and is distributed into breast milk where concentrations higher than those in maternal plasma have been achieved. Only small amounts are reported to cross the blood-brain barrier. Atenolol undergoes little or no hepatic metabolism and more than 90% of that absorbed reaches the systemic circulation unaltered; it is excreted mainly in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

**Administration**

**Reconstitution**
Atenolol

Route
Oral, IV

Rate of administration
Infusion: 20 minutes
IV injection: 1 mg/minute

Comments
Dilute with glucose 5% or sodium chloride 0.9%

Other information
- CSM advise that beta-blockers are contraindicated in patients with asthma or history of obstructive airway disease.
ATG (rabbit) (thymoglobuline)

### Clinical use
Prophylaxis and treatment of acute or steroid resistant transplant rejection

### Dose in normal renal function
Prophylaxis:
- Kidney 1–1.5 mg/kg/day for 3–9 days
- Heart 1–2.5 mg/kg/day for 3–5 days

Treatment of steroid resistant graft rejection: 1.5 mg/kg/day for 7–14 days

NB: In obese patients use ideal body-weight to avoid overdosage.

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>No data</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.12</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>48–72 / –</td>
</tr>
</tbody>
</table>

### Metabolism
Total rabbit IgG remains detectable in 81% of patients at 2 months. Active ATG (that is IgG which is available to bind to human lymphocytes and which causes the desired immunological effects) disappears from the circulation faster, with only 12% of patients having detectable active ATG levels at day 90.

Significant immunisation against rabbit IgG is observed in about 40% of patients. In most cases, immunisation develops within the first 15 days of treatment initiation. Patients presenting with immunisation show a faster decline in total but not active rabbit IgG levels.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Risk of over-immunosuppression with concomitant prescribing of standard maintenance immunosuppressive regimens.
- Safety of immunisation with attenuated live vaccines following Thymoglobuline therapy has not been studied; therefore, immunisation with attenuated live vaccines is not recommended for patients who have recently received ATG.

### Administration

#### Reconstitution
—

#### Route
IV via central line or via peripheral vein with good blood flow rates.

#### Rate of administration
4–16 hours

#### Comments
- Dilute dose in 250 mL sodium chloride 0.9%, maximum concentration 5 mg/mL for peripheral administration.
- To minimise risk of adverse effects, chlorphenamine (10 mg IV) and hydrocortisone (100 mg IV) may be given 15–60 minutes before administration of full dose ATG.
- Chlorphenamine, hydrocortisone and adrenaline should be immediately available in case of severe anaphylaxis.

### Other information
- Aim to keep total lymphocyte count below 3% of total white cell count or 50 cells/μL. Alternatively, keep absolute T cell count below 50 cells/μL, and only dose when above this.
• The manufacturers advise that overdosage of Thymoglobulin may result in leucopenia (including lymphopenia and neutropenia) and/or thrombocytopenia.

• The dose of ATG should be reduced by one-half if the WBC count is between 2000 and 3000 cells/mm$^3$ or if the platelet count is between 50 000 and 75 000 cells/mm$^3$.

• Stopping ATG treatment should be considered if the WBC count falls below 2000 cells/mm$^3$ or platelets below 50 000 cells/mm$^3$.

• Avoid simultaneous transfusions of blood or blood derivatives and infusions of other solutions, particularly lipids.

• The recommended route of administration for ATG is IV infusion using a high-flow vein; however, it may be administered through a peripheral vein. In this instance, concomitant use of heparin and hydrocortisone in an infusion solution of 0.9% sodium chloride may minimise the potential for superficial thrombophlebitis and deep vein thrombosis.

• The combination of ATG, heparin and hydrocortisone in a dextrose infusion solution has been noted to precipitate and is not recommended.

• ATG should not be administered in presence of: fluid overload, allergy to rabbit protein, pregnancy or acute viral illness.
Atorvastatin

**Clinical use**
Hyperlipidaemia and hypercholesterolaemia

**Dose in normal renal function**
10–80 mg daily

**Pharmacokinetics**
- Molecular weight (daltons): 558.6 (1209.4 as calcium salt)
- % Protein binding: >98
- % Excreted unchanged in urine: Negligible
- Volume of distribution (L/kg): 381 Litres
- Half-life — normal/ESRF (hrs): 14 (active metabolite 20–30) / Unchanged

**Metabolism**
Atorvastatin undergoes extensive presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Atorvastatin is metabolised by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. These products are further metabolised via glucuronidation. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. Atorvastatin is eliminated primarily in bile as active metabolites following hepatic and/or extrahepatic metabolism, but does not appear to undergo significant enterohepatic recirculation.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: concentration possibly increased by dronedarone.
- Antibacterials: azithromycin, erythromycin, clarithromycin or fusidic acid possibly increased risk of myopathy — avoid atorvastatin for at least 7 days after fusidic acid stopped; concentration increased by clarithromycin — do not exceed 20 mg of atorvastatin; avoid with telithromycin; increased risk of myopathy with daptomycin; concentration possibly reduced by rifampicin.
- Anticoagulants: may transiently reduce anticoagulant effect of warfarin.
- Antifungals: increased risk of myopathy with itraconazole — do not exceed 40 mg of atorvastatin; increased risk of myopathy with fluconazole, ketoconazole, posaconazole, voriconazole and possibly other imidazoles and triazoles — avoid.
- Antivirals: increased risk of myopathy with atazanavir, boceprevir (reduce atorvastatin dose), and possibly darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir or tipranavir (max dose of atorvastatin 10 mg); concentration reduced by efavirenz and possibly etravirine; avoid with dasabuvir, ombitasvir, paritaprevir and telaprevir; possible increased risk of myopathy with ledipasvir — reduce atorvastatin dose; concentration increased by simeprevir — consider reducing atorvastatin dose.
- Calcium channel blockers: concentration increased by diltiazem — increased risk of myopathy; concentration of verapamil increased also possible increased risk of myopathy — consider reducing atorvastatin dose.
- Ciclosporin: increased risk of myopathy — do not exceed 10 mg of atorvastatin.
- Cobicistat: reduce atorvastatin dose.
- Colchicine: possible increased risk of myopathy.
- Grapefruit juice: concentration possibly increased.
- Lipid lowering agents: increased risk of myopathy with fibrates, gemfibrozil (avoid) and nicotinic acid.

**Administration**

**Reconstitution**
—

**Route**
Oral
Rate of administration

Other information

- Rhabdomyolysis with renal dysfunction secondary to myoglobinemia has been reported with other statins.

Reference:
Atovaquone

Clinical use
Treatment of PCP if intolerant to co-trimoxazole

Dose in normal renal function
750 mg twice daily for 21 days

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>366.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99.9</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.62 ± 0.19</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–3 days / No data</td>
</tr>
</tbody>
</table>

Metabolism
There is indirect evidence that atovaquone may undergo limited metabolism, although no specific metabolites have been identified. It has a long plasma half-life, thought to be due to enterohepatic recycling. It is excreted almost exclusively in faeces as unchanged drug.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: avoid with rifabutin, concentration of both drugs reduced; avoid with rifampicin, concentration reduced and rifampicin concentration increased; concentration reduced by tetracycline.
- Antivirals: concentration reduced by efavirenz – avoid; concentration of indinavir possibly reduced; concentration of zidovudine increased.
- Metoclopramide: significant reduction in plasma atovaquone levels.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Manufacturer advises to use with caution due to lack of data.
- Administer with food. The presence of food, particularly high fat food, increases bioavailability 2 or 3-fold.
- The most commonly reported abnormalities in laboratory parameters are increased liver function tests and amylase levels, and hyponatraemia.
Atracurium besilate

**Clinical use**

Non-depolarising muscle relaxant of short to medium duration

**Dose in normal renal function**

- Initially: 300–600 mcg/kg, depending on duration of full block required.
- Maintenance: 100–200 mcg/kg as required or IV infusion: 300–600 mcg/kg/hour

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1243.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>82</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.16</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Approx 20 minutes / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Atracurium besilate undergoes spontaneous degradation via Hofmann elimination (a non-enzymatic breakdown process occurring at physiological pH and temperature) to produce laudanosine and other metabolites. There is also ester hydrolysis by non-specific plasma esterases. The metabolites have no neuromuscular blocking activity. Excretion of atracurium is in urine and bile, mostly as metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anaesthetics: effects enhanced by ketamine; enhanced effect with volatile liquid general anaesthetics.
- Anti-arrhythmics: procainamide enhances muscle relaxant effect.
- Antibacterials: aminoglycosides, clindamycin, polymyxin and piperacillin enhance effect of atracurium.
- Antiepileptics: muscle relaxant effects antagonised by carbamazepine; effects reduced by long-term use of phenytoin but might be increased by acute use.
- Atracurium enhances the neuromuscular block produced by botulinum toxin (risk of toxicity).

**Administration**

**Reconstitution**

- **Route**
  - IV bolus, IV infusion

**Rate of administration**

- IV infusion: Initial bolus dose of 0.3–0.6 mg/kg over 60 seconds, then administer as a continuous infusion at rates of 0.3–0.6 mg/kg/hour.

**Comments**

Stable in sodium chloride 0.9% for 24 hours, and glucose 5% for 8 hours when diluted to concentrations of 0.5 mg/mL or above.
Avanafil

Clinical use
Phosphodiesterase type 5 inhibitor:
- Treatment of erectile dysfunction

Dose in normal renal function
- 50–200 mg, 30 minutes before sexual activity
- Maximum 100 mg every 48 hours with concomitant CYP450 inhibitors

Pharmacokinetics
Molecular weight (daltons) 484
% Protein binding 99
% Excreted unchanged in urine 21 (as metabolites)
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 5 (6–17 with CYP450 inhibitors)

Metabolism
Avanafil is metabolised in the liver mainly by the cytochrome P450 isoenzyme CYP3A4 and to a minor extent by the CYP2C isoform. Two major metabolites are produced, one of which is active.
Avanafil is excreted as metabolites mainly in the faeces (approximately 63%) in the urine (approximately 21%).

Dose in renal impairment GFR (mL/min)
30–50 Dose as in normal renal function.
10–30 Use with caution. See 'Other information'.
<10 Use with caution. See 'Other information'.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Alpha-blockers: enhanced hypotensive effect – maximum dose 50 mg.
- Antibacterials: concentration possibly increased by clarithromycin and telithromycin – avoid; concentration increased by erythromycin – reduce avanafil dose; concentration reduced by rifampicin – avoid.
- Antifungals: concentration increased by ketoconazole – avoid and fluconazole – reduce avanafil dose; concentration possibly increased by itraconazole and voriconazole – avoid.
- Antivirals: concentration possibly increased by atazanavir, indinavir and saquinavir – avoid; concentration possibly reduced by efavirenz – avoid; concentration possibly increased by fosamprenavir – reduce avanafil dose; concentration significantly increased by ritonavir – avoid.
- Aprepitant: concentration possibly increased by aprepitant – reduce avanafil dose.
- Calcium channel blockers: concentration possibly increased by diltiazem and verapamil – reduce avanafil dose.
- Cobicistat: concentration of avanafil possibly increased – avoid.
- Nicorandil: possibly enhanced hypotensive effect – avoid.
- Nitrates: enhanced hypotensive effect – avoid.
- Riociguat: possibly enhanced hypotensive effect – avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Manufacturer advises to avoid in severe renal impairment due to lack of studies.
- Reduced efficacy has been reported in patients with mild to moderate renal impairment (CRCL≥30 mL/min but <80 mL/min).
Axitinib

Clinical use
Tyrosine kinase inhibitor
- Treatment of advanced renal cell carcinoma

Dose in normal renal function
2–10 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 368.5
% Protein binding >99
% Excreted unchanged in urine 23 (as metabolites)
Volume of distribution (L/kg) 160 Litres
Half-life — normal/ESRF (hrs) 2.5–6.1 / Unchanged

Metabolism
Axitinib is metabolised primarily in the liver by CYP3A4/5 and to a lesser extent by CYP1A2, CYP2C19, and UGT1A1.
Most of the drug is excreted via the faeces and urine as metabolites.

Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>15–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely dialysability. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely dialysability. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely dialysability. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis); avoid with pimozide.
- Concomitant use with strong CYP3A4/5 inhibitors: avoid; however, if concomitant use cannot be avoided then reduce the dose of axitinib by approximately half; subsequent doses can be increased or decreased based on individual safety and tolerability; if CYP3A4/5 inhibitor is discontinued, then increase the axitinib dose used prior to initiation of the strong inhibitor after 3–5 half-lives of the inhibitor (strong CYP3A4/5 inhibitors include ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, ritonavir, saquinavir, and voriconazole).

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- No experience in GFR<15 mL/min hence use with caution.
- Bioavailability of 58%.
# Azacitidine

## Clinical use

Antineoplastic agent:
- Treatment of people not eligible for stem cell transplants with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia

## Dose in normal renal function

- 75 mg/m² daily for 7 days followed by a rest period of 21 days
- Following doses may be altered depending on bone marrow toxicity

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>244.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50–85</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>50–102</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>33–49 minutes / No data</td>
</tr>
</tbody>
</table>

## Metabolism

Azacitidine undergoes spontaneous hydrolysis and deamination mediated by cytidine deaminase. Following IV administration of radioactive azacitidine to 5 cancer patients, the cumulative urinary excretion was 85% of the radioactive dose. Faecal excretion accounted for <1% of administered radioactivity over three days. Mean excretion of radioactivity in urine following SC administration of [¹⁴C]-azacitidine was 50%.

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dialysability</th>
<th>Dose in renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown</td>
<td>Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown</td>
<td>Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown</td>
<td>Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown</td>
<td>Dose as in GFR 10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- None known

## Administration

### Reconstitution

4 mL water for injection

### Route

SC

### Rate of administration

—

### Comments

- The reconstituted suspension must be administered within 45 minutes. If made up in advance it can be in a refrigerator (2–8°C) immediately after reconstitution, and kept for a maximum of 8 hours. The syringe with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20–25°C.

## Other information

- Clearance was 147 ± 47 L/hour.
- If unexplained reductions in serum bicarbonate levels <20 mmol/L occur, the dose should be reduced by 50% on the next cycle. If unexplained elevations in serum creatinine or BUN to ≥2-fold above baseline values occur, the next cycle should be delayed until values return to normal or baseline and the dose should be reduced by 50% on the next treatment cycle.
- Patients with renal impairment should be closely monitored for toxicity since azacitidine and/or its metabolites are primarily excreted by the kidney.
Azathioprine

**Clinical use**

Immunosuppressive:
- Prophylaxis of transplant rejection
- Treatment of various auto-immune conditions

**Dose in normal renal function**

1–5 mg/kg/day

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>277.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.55–0.8</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–5 / Increased</td>
</tr>
</tbody>
</table>

**Metabolism**

Azathioprine is extensively metabolised to its active moiety mercaptopurine, which in turn is activated intracellularly by conversion to nucleotide derivatives. Mercaptopurine is rapidly and extensively metabolised in the liver, by methylation, oxidation and by the formation of inorganic sulfates. Thiol methylation is catalysed by the enzyme thiopurine methyltransferase (TPMT). TPMT activity is highly variable in patients because of a genetic polymorphism in the TPMT gene. About 10% of a dose of azathioprine is reported to be split between the sulfur and the purine ring to give 1-methyl-4-nitro-5-thioimidazole. The proportion of different metabolites is reported to vary between patients. Metabolites and small amounts of unchanged azathioprine and mercaptopurine are eliminated in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR range (mL/min)</th>
<th>Dose classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>75–100%</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50–100%</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Allopurinol: enhances effect with increased toxicity. Reduce azathioprine dose by 50–75% if administered concomitantly – ideally avoid.
- Antibacterials: increased risk of haematological toxicity with co-trimoxazole.
- Anticoagulants: possibly reduced anticoagulant effect of coumarins.
- Antipsychotics: avoid with clozapine.
- Antivirals: myelosuppressive effects enhanced by ribavirin.
- Ciclosporin: decreased ciclosporin absorption and bioavailability.
- Cytotoxics may be additive or synergistic in producing toxicity, particularly on the bone marrow.
- Febuxostat: avoid concomitant use.
- Vaccines: risk of generalised infections with live vaccines – avoid.

**Administration**

**Reconstitution**

Add 5 mL water for injection to each vial (50 mg).

**Route**

Oral, IV

**Rate of administration**

Over not less than 1 minute.

**Comments**

- Some units dilute to 100 mL sodium chloride or glucose 5% and infuse over 1 hour. (UK Critical Care Group, *Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients*, 3rd edition, 2006.)
- IV bolus peripherally, preferably in the side arm of a fast-running infusion.
- VERY IRRITANT TO VEINS. Flush with 50 mL sodium chloride 0.9% after administration.
- Take tablets with or after food.

**Other information**

- 1 mg by IV injection is equivalent to 1 mg by oral route.
- 6-mercaptopurine levels can be monitored in patients with low urate clearance.
- Monitor white cell and platelet counts.
- Cytotoxic Drug – DO NOT HANDLE.
- Can be given as an intermittent infusion (up to 250 mg in 100 mL).
- About 40–60% is removed by haemodialysis.
Azilsartan medoxomil

Clinical use

Angiotensin-II antagonist:
• Hypertension

Dose in normal renal function

20–80 mg once daily

Pharmacokinetics

Molecular weight (daltons) 568.5
% Protein binding >99
% Excreted unchanged in urine 15
Volume of distribution (L/kg) 16 Litres
Half-life — normal/ESRF (hrs) 11 / –

Metabolism

Azilsartan is metabolised in the liver by CYP2C9 to two inactive metabolites. The major metabolite is formed by O-dealkylation (M-II), and the minor metabolite is formed by decarboxylation, (M-I).
Approximately 55% of radioactivity was recovered in faeces and approximately 42% in urine.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function.
10–20 Initial dose 20 mg and increase according to response.
<10 Initial dose 20 mg and increase according to response.

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
• Anaesthetics: enhanced hypotensive effect.
• Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
• Antihypertensives: increased risk of hyperkalaemia and hypotension with ACE-Is and aliskiren.
• Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
• Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
• ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
• Lithium: reduced excretion, possibility of enhanced lithium toxicity.
• Potassium salts: increased risk of hyperkalaemia.
• Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information

• Oral bioavailability is 60%.
• In patients with mild, moderate, and severe renal impairment azilsartan total exposure (AUC) was 30%, 25% and 95% increased.
• Adverse reactions, especially hyperkalaemia are more common in patients with renal impairment.
• Renal failure has been reported in association with angiotensin-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with congestive heart failure.
• Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
Azithromycin

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

- Genital chlamydia/uncomplicated gonorrhoea infections: 1 g as single dose
- All other indications: 500 mg daily for 3 days or 500 mg on day 1 followed by 250 mg daily for 4 days
- Typhoid (unlicensed)/Lyme disease: 500 mg daily for 7–10 days (7 days for typhoid)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>785</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>12–52</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>6–12</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>31.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>48–96 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

In pharmacokinetic studies it has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably higher (as much as 50 times) than those measured in plasma, which indicates that the agent strongly binds to tissues. Azithromycin is excreted in bile mainly as unchanged drug. Ten metabolites have also been detected in bile, which are formed through N- and O- demethylation in the liver, hydroxylation of desosamine – and aglycone rings and cleavage of cladinose conjugate. The metabolites of azithromycin are not microbiologically active.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anti-arrhythmics: increased toxicity with disopyramide; increased risk of ventricular arrhythmias with dronedarone – avoid.
- Antibacterials: possibly increased rifabutin concentration (increased risk of uveitis and neutropenia) – reduce dose of rifabutin.
- Anticoagulants: effect of coumarins may be enhanced.
- Antidepressants: the manufacturer of reboxetine advises to avoid concomitant use.
- Antihistamines: may inhibit the metabolism of mizolastine (risk of hazardous arrhythmias) – avoid.
- Antimalarials: avoid with artemether/lumefantrine; increased risk of ventricular arrhythmias with piperaquine with artenimol – avoid.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol – avoid.
- Antivirals: concentration possibly increased by ritonavir.
- Ciclosporin: may inhibit the metabolism of ciclosporin (increased ciclosporin levels).
- Colchicine: treatment with both agents has been shown in a study to increase the risk of fatal colchicine toxicity, especially in patients with renal impairment – avoid.
- Ergot alkaloids: increased risk of ergotism – avoid.
- Statins: possible increased risk of myopathy with atorvastatin and simvastatin.

**Administration**

**Reconstitution**

Powder for oral suspension to be reconstituted with water (200 mg/5 mL strength)

**Route**

Oral

**Rate of administration**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Comments**

- Administer as a once daily dose one hour before food or 2 hours after food.

**Other information**

- In patients with a GFR<10 mL/min a 33% increase in systemic exposure to azithromycin was seen therefore the manufacturer advises to use with caution.
- Dose in severe renal impairment is from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- May be used safely in patients on tacrolimus who require treatment with a macrolide.
Aztreonam

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

- 1 g every 8 hours or 2 g every 12 hours
- Severe infections: 2 g every 6–8 hours
- UTI: 0.5–1 g every 8–12 hours
- Nebulised: 75 mg three times per day for 28 days

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>435.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>60–70</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.5–1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.7 / 6–8</td>
</tr>
</tbody>
</table>

**Metabolism**

Aztreonam is not extensively metabolised. The principal metabolite, SQ-26992, is inactive and is formed by opening of the beta-lactam ring; it has a much longer half-life than the parent compound.

Aztreonam is excreted as unchanged drug with only small quantities of metabolites, mainly in the urine, by renal tubular secretion and glomerular filtration. Only small amounts of unchanged drug and metabolites are excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>IV: 1–2 g loading dose; then maintenance of 50% of appropriate normal dose. Nebulised: Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>IV: 1–2 g loading dose; then maintenance of 25% of appropriate normal dose. Nebulised: Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Loading dose of 2 g then 1–2 g every 12 hours.¹
- CVVHD/HDF: Dialysed. 2 g every 12 hours.¹ See 'Other information.'

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Possibly enhanced anticoagulant effect of coumarins.

**Administration**

**Reconstitution**

3 mL of water for injection per 1 g vial

**Route**

IM, IV bolus, IV infusion, nebulised

**Rate of administration**

IM injection: Give by deep injection into a large muscle mass.

IV: Slowly inject directly into the vein over a period of 3–5 minutes.

IV infusion: Give over 20–60 minutes.

**Comments**

- Suitable infusion solutions: glucose 5%, sodium chloride 0.9%, compound sodium lactate.
- Dilute to a concentration of not less than 20 mg/mL.
- Once reconstituted aztreonam can be stored in a refrigerator for 24 hours.
- IV route recommended for single doses >1 g.

**Other information**

- Manufacturers recommend that patients with renal impairment be given the usual initial dose followed by a maintenance dose adjusted according to creatinine clearance. The normal dose interval should not be altered.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid 'flux' within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate,
dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

References:

# Baclofen

## Clinical use
Chronic severe spasticity of voluntary muscles

## Dose in normal renal function

### Oral:
- 5 mg, 3 times a day; increase dose gradually up to 100 mg/day

### Intrathecal:
- 12 micrograms – 2 mg daily for spasticity of spinal origin
- 22 micrograms – 1.4 mg for spasticity of cerebral origin.

See SPC

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>213.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>70</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–4 / –</td>
</tr>
</tbody>
</table>

## Metabolism
After oral doses some baclofen crosses the blood-brain barrier, with concentrations in CSF about 12% of those in the plasma. Baclofen is metabolised to only a minor extent. Deamination yields the main metabolite, \( \beta \)-\((p\text{-chlorophenyl})\)-4-hydroxybutyric acid, which is pharmacologically inactive.

Approximately 70–80% of a dose is excreted in the urine mainly as unchanged drug; about 15% is metabolised in the liver.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose and titration advice</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>5 mg 3 times a day and titrate according to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>5 mg twice a day and titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5 mg once a day and titrate according to response.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: enhanced muscle relaxant effect with procainamide.
- Antidepressants: enhanced muscle relaxant effect with tricyclics.
- Antihypertensives: enhanced hypotensive effect.
- Lithium: use with caution.

## Administration

### Reconstitution

- **Route**: Oral, intrathecal injection

### Rate of administration

- **Comments**
  - Take with or after food.
  - Baclofen can be given intrathecally (at doses greatly reduced compared with oral dose), by bolus injection, or continuous infusion. Individual titration of dosage is essential due to variability in response. Test doses must be given. Maintenance dose: 300–800 micrograms/day but doses up to 2000 mcg have been used but experience is limited in doses >1000 mcg.

### Other information
- Doses in US data sheet in renal impairment are CRCL=50–80 mL/min give a third of the dose, 30–50 mL/min give half of dose, <30 mL/min – give a third of the dose.
- Withdraw treatment gradually over 1–2 weeks to avoid anxiety and confusional state, etc.
- Drowsiness and nausea frequent at the start of therapy.

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapies</th>
<th>Advice</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>
• Signs of overdose have been seen in renal patients given doses >5 mg.

• Another report has seen reduced conscious levels in a haemodialysis patient who was receiving baclofen 5 mg three times a day, within 12 hours she became disorientated and by 36 hours had a GCS of 8. (Su W, Yegappan C, Carlisle EJ, et al. Reduced level of consciousness from baclofen in people with low kidney function. BMJ. 2009; 339: 4559.)
Balsalazide sodium

Clinical use
Treatment and maintenance of remission, in mild to moderate ulcerative colitis

Dose in normal renal function
- Acute treatment: 2.25 g, 3 times a day
- Maintenance: 1.5 g twice daily, maximum 6 g/day

Pharmacokinetics
Molecular weight (daltons) 437.3
% Protein binding 40 (similar to mesalazine), (NASA – 80%)
% Excreted unchanged in urine 25 (as metabolites)
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) No data (T_1/2 NASA = 6–9)

Metabolism
Very little of an oral dose of balsalazide is absorbed via the upper gastrointestinal tract, and almost the entire dose reaches its site of action in the colon intact. It is broken down by the colonic bacterial flora into 5-aminosalicylic acid (mesalazine), which is active, and 4-aminobenzoylalanine, which is considered to be an inert carrier. Most of a dose is eliminated via the faeces, but about 25% of the released mesalazine is absorbed and acetylated. A small proportion of 4-aminobenzoylalanine is absorbed and acetylated by first-pass metabolism through the liver. The acetylated metabolites are excreted in the urine.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Use with caution and only if necessary.
- <10 Start with low doses and monitor closely.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Balsalazide is a prodrug of mesalazine (5-aminosalicylic acid).
- Manufacturer advises to avoid in moderate to severe renal impairment.
- Mesalazine is best avoided in patients with established renal impairment, but if necessary should be used with caution and the patient carefully monitored.
- Serious blood dyscrasias have been reported with mesalazine – monitor full blood count closely.
Baricitinib

**Clinical use**

Janus kinase inhibitor:
- Treatment of moderate to severe active rheumatoid arthritis

**Dose in normal renal function**

2–4 mg once daily

**Pharmacokinetics**

- Molecular weight (daltons) 371.4
- % Protein binding 50
- % Excreted unchanged in urine 69
- Volume of distribution (L/kg) 76 Litres
- Half-life — normal/ESRF (hrs) 12.5

**Metabolism**

Baricitinib is hepatically metabolism by CYP3A4, <10% of the dose identified as undergoing biotransformation. No metabolites were detected in plasma.

In a clinical pharmacology study, baricitinib was excreted mainly as the unchanged active substance in urine (69%) and faeces (15%) and only 4 minor oxidative metabolites were identified (3 in urine; 1 in faeces) constituting approximately 5% and 1% of the dose, respectively.

**Dose in renal impairment GFR (mL/min)**

- 30–60 2 mg once daily.
- <30 Avoid.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Likely to be dialysed. Avoid.
- HD Likely to be dialysed. Avoid.
- HDF/High flux Likely to be dialysed. Avoid.
- CAV/VVHD Likely to be dialysed. Dose as in GFR=30–60 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Avoid with other DMARDs due to increased immunosuppression.
- Use with care with other immunosuppressants.
- Antipsychotics: increased risk of agranulocytosis with clozapine – avoid.
- Live vaccines: avoid concomitant use.

**Administration**

**Reconstitution**

- Route Oral
- Rate of administration —

**Other information**

- Oral bioavailability is 79%.
- Renal function was found to significantly affect baricitinib exposure. The mean ratios of AUC in patients with mild and moderate renal impairment to patients with normal renal function are 1.41 (90 % CI: 1.15-1.74) and 2.22 (90 % CI: 1.81-2.73), respectively. The mean ratios of $C_{\text{max}}$ in patients with mild and moderate renal impairment to patients with normal renal function are 1.16 (90 % CI: 0.92-1.45) and 1.46 (90 % CI: 1.17-1.83), respectively.
- Phase 2 multicentre, randomised, double-blind, multi-dose, placebo-controlled study in participants with type 2 diabetic nephropathy with reduced kidney function (eGFR = 25–75 mL min/1.73m$^2$) and substantial persistent albuminuria (>300 mg/day) who were already treated with RAAS-inhibiting agents. Participants received placebo or baricitinib at low-to-high daily doses (0.75 mg, 1.5 mg in single or divided dose, 4 mg) for 24 weeks, followed by a 4-week wash-out period. Baricitinib treatment resulted in a reduction in albuminuria at both 3 and 6 months. At 6 months, there was a statistically significant decrease in haemoglobin compared to placebo in the high-dose baricitinib group. This reduction was not unexpected in the higher dose range since erythropoietin signalling is dependent on JAK2 activation. More trials are being done looking at this response. (Brosius FC, Tuttle KR, Kretzler M. JAK inhibition in the treatment of diabetic kidney disease. *Diabetologia*, 2016; 59(8): 1624–7.)
**Basiliximab**

### Clinical use
Chimeric murine/human monoclonal anti CD25 antibody:
- Prophylaxis of acute allograft rejection in combination with maintenance immunosuppression

### Dose in normal renal function
20 mg 2 hours before transplant and 20 mg 4 days after transplant

### Pharmacokinetics
- Molecular weight (daltons): Approx 144 000
- % Protein binding: See 'Other information'.
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): 4.5–12.7 Litres
- Half-life — normal/ESRF (hrs): 4–10.4 days / Unchanged

### Metabolism
*In vitro* studies using human tissues indicate that basiliximab binds only to activated lymphocytes and macrophages/monocytes. It is most likely removed by opsonisation via the reticuloendothelial system when bound to lymphocytes, or by human antimurine antibody production.

### Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Ciclosporin: may alter ciclosporin requirements.
- Tacrolimus: may alter tacrolimus requirements.
- Vaccines: risk of generalised infections with live vaccines – avoid.

### Administration
**Reconstitution**
Reconstitute each vial with 5 mL water for injection then dilute to 50 mL or greater with sodium chloride 0.9% or glucose 5%.

**Route**
IV infusion

**Rate of administration**
20–30 minutes

### Other information
- Basiliximab is detectable in serum for up to 3 months after 15–25 mg doses.
- Use with caution in patients who have previously had basiliximab due to increased risk of developing hypersensitivity reactions.
# Bedaquiline fumarate

## Clinical use
Antimycobacterial agent (diarylquinoline):
- Treatment of multi-drug resistant tuberculosis in combination with other treatment

## Dose in normal renal function
400 mg once daily for 2 weeks then 200 mg 3 times a week

## Pharmacokinetics
- Molecular weight (daltons) 671.6
- % Protein binding >99.9
- % Excreted unchanged in urine <0.001
- Volume of distribution (L/kg) 164 Litres
- Half-life — normal/ESRF (hrs) 2–8 months /

## Metabolism
Bedaquiline is metabolised mainly by the hepatic CYP3A4 isoenzyme to the N-monodesmethyl metabolite (M2), which is 4–6 times less active than the parent compound.
Bedaquiline is excreted mainly in the faeces.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose suggestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose建议</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- **Antibacterials**: concentration possibly increased by ciprofloxacin, clarithromycin and erythromycin – avoid concomitant use if for more than 14 days; avoid with moxifloxacin; concentration possibly reduced by rifampicin – avoid; possibly increased risk of ventricular arrhythmias with clofazimine.
- **Antiepileptics**: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin – avoid.
- **Antivirals**: AUC increased by ritonavir, use with caution, avoid in combination with lopinavir.

## Administration
### Reconstitution
- 
### Route
- Oral
### Rate of administration
- 
### Comments
- Take with food to increase oral bioavailability.

## Other information
- Manufacturer advises to use with caution and monitor for side effects as absorption may be altered in renal impairment.
- QT prolongation can occur. Use with caution in combination with other drugs which can prolong QT interval.
Belatacept

**Clinical use**

Prevents T-cell activation
- Prophylaxis of renal transplant rejection

**Dose in normal renal function**

- 10 mg/kg
- Reduces to 5 mg/kg once in maintenance phase

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>90 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.11–0.12</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8.2–9.8 days</td>
</tr>
<tr>
<td>(depends on dose)</td>
<td></td>
</tr>
</tbody>
</table>

**Metabolism**

Because the drug is a protein, belatacept is degraded into smaller peptides and amino acids by proteolytic enzymes.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Vaccines: avoid concomitant use with live vaccines.

**Administration**

**Reconstitution**

10.5 mL of sodium chloride 0.9%, glucose 5% or water for injection

**Route**

IV infusion

**Rate of administration**

30 minutes

Use an infusion set and a sterile, non-pyrogenic, low protein binding filter (pore size of 0.2–1.2 μm)

**Comments**

Make up to 100 mL with sodium chloride 0.9% or glucose 5% (volumes may vary between 50–250 mL depending on dose).

Use the silicone free syringes supplied and do not shake to minimise foaming.

**Other information**

- MPA exposure is approximately 40% higher with belatacept co-administration than with ciclosporin co-administration.
- There was a trend toward higher clearance of belatacept with increasing body weight.
## Belimumab

### Clinical use

Anti-lymphocyte monoclonal antibody:
- Treatment of systemic lupus erythematosus

### Dose in normal renal function

10 mg/kg repeated 2 and 4 weeks after initial infusion then every 4 weeks

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>147 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Negligible</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>5.29 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>19.4 days / Slightly increased</td>
</tr>
</tbody>
</table>

### Metabolism

Belimumab is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by widely distributed proteolytic enzymes. Classical biotransformation studies have not been conducted.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Live vaccines: avoid concomitant use.

### Administration

**Reconstitution**

120 mg vial with 1.5 mL water for injection; 400 mg vial with 4.8 mL water for injection. To provide 80 mg/mL dilution

**Route**

IV infusion

**Rate of administration**

Over 1 hour

**Comments**

Further dilute to 250 mL with sodium chloride 0.9%.

### Other information

- Use with caution in severe renal impairment due to lack of studies.
- During clinical development belimumab was studied in patients with SLE and renal impairment (261 subjects with moderate renal impairment, creatinine clearance ≥30 and <60 mL/min; 14 subjects with severe renal impairment, creatinine clearance ≥15 and <30 mL/min). The reduction in systemic clearances were 1.4% for mild (75 mL/min), 11.7% for moderate (45 mL/min) and 24% for severe (22.5 mL/min) renal impairment. Although proteinuria (≥2 g/day) increased belimumab clearance and decreases in creatinine clearance decreased belimumab clearance, these effects were within the expected range of variability. Therefore, no dose adjustment is recommended for patients with renal impairment.
# Bendamustine hydrochloride

## Clinical use
Alkylating agent:
- CLL, NHL and multiple myeloma

## Dose in normal renal function
- CLL: 100 mg/m² on days 1 and 2 every 4 weeks
- NHL: 120 mg/m² on days 1 and 2 every 3 weeks
- Multiple myeloma: 120–150 mg/m² on days 1 and 2 every 4 weeks
- Or according to local protocol

## Pharmacokinetics
- Molecular weight (daltons) 394.7
- % Protein binding >95
- % Excreted unchanged in urine 3 (20% as unchanged drug and metabolites)
- Volume of distribution (L/kg) 15.8–20.5 Litres
- Half-life — normal/ESRF (hrs) 28.2 minutes / –

## Metabolism
A major route of clearance of bendamustine is the hydrolysis to monohydroxy- and dihydroxy-bendamustine. Formation of N-desmethyl-bendamustine and gamma-hydroxy-bendamustine by hepatic metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme. Another major route of bendamustine metabolism involves conjugation with glutathione. Excreted in the urine and faeces as unchanged drug and metabolites.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).

## Administration
### Reconstitution
- 10 mL water for injection per 25 mg
- 40 mL water for injection per 100 mg

### Route
- IV infusion

### Rate of administration
- 30–60 minutes

### Comments
- Add to 500 mL sodium chloride 0.9%

## Other information
- Manufacturer advises to use with caution in severe renal impairment due to lack of studies although there is little renal clearance.
**Clinical use**

Thiazide diuretic:
- Hypertension
- Oedema

**Dose in normal renal function**

- Oedema: 5–10 mg in the morning or alternate days
- Maintenance: 5–10 mg, 1–3 times weekly
- Hypertension: 2.5 mg daily

**Pharmacokinetics**

- Molecular weight (daltons): 421.4
- % Protein binding: 94
- % Excreted unchanged in urine: 30
- Volume of distribution (L/kg): 1.2–1.5

**Metabolism**

There are indications that bendroflumethiazide is fairly extensively metabolised. About 30% is excreted unchanged in the urine with the remainder excreted as uncharacterised metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Unlikely to work.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Unlikely to work.
- HD: Not dialysed. Unlikely to work.
- HDF/High flux: Unknown dialysability. Unlikely to work.
- CAV/VVHD: Probably not dialysed. Unlikely to work.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect.
- Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised.
- Antibacterials: avoid administration with lymecycline.
- Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hyponatraemia with carbamazepine.
- Antifungals: increased risk of hypokalaemia with amphotericin.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with post-synaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol.
- Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide – avoid.
- Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Ciclosporin: increased risk of nephrotoxicity and hypomagnesaemia.
- Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium excretion reduced, increased toxicity.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Monitor for hypokalaemia.
  - Manufacturer advises to avoid in severe renal impairment.
  - Thiazide diuretics are unlikely to be of use once GFR < 30 mL/min.
  - There are anecdotal reports of bendroflumethiazide being used in combination with loop diuretics for a synergistic effect in resistant oedema.
Benzbromarone (unlicensed product)

**Clinical use**

Treatment of hyperuricaemia, chronic gout and tophaceous gout

**Dose in normal renal function**

- 50–200 mg daily
- (Usual dose 50–100 mg daily)

**Pharmacokinetics**

Molecular weight (daltons) 424.1
% Protein binding >99
% Excreted unchanged in urine 6–18 (as metabolites)
Volume of distribution (L/kg) 19 Litres
Half-life — normal/ESRF (hrs) 2–4 / –

**Metabolism**

Benzbromarone is metabolised to 1’-hydroxy BBR and 6-hydroxy BBR in the liver. 6-Hydroxy BBR is further metabolized to 5,6-dihydroxy BBR. Benzbromarone and its metabolites are excreted mainly in the faeces; a small amount appears in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose (mg daily)</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–60</td>
<td>50–200</td>
</tr>
<tr>
<td>20–40</td>
<td>50–100</td>
</tr>
<tr>
<td>&lt;20</td>
<td>Avoid. Ineffective.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Avoid. Ineffective.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Avoid. Ineffective.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Avoid. Ineffective.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Use with caution. Dose as in GFR=20–40 mL/min.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Aspirin and salicylates: antagonise uricosuric effects of benzbromarone.
- Anticoagulants: may enhance effect of warfarin.
- Hepatotoxic agents: enhanced hepatotoxicity
- Pyrazinamide, sulfinpyrazone and thiazide diuretics: antagonise uricosuric effects of benzbromarone.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Monitor LFTs while on benzbromarone as can cause fulminant liver failure.
- Benzbromarone has been withdrawn in a number of countries due to hepatotoxicity.
- As with other uricosurics, treatment with benzbromarone should not be started during an acute attack of gout.
- Maintain an adequate fluid intake to reduce the risk of uric acid renal calculi.
- Biological effect of 100 mg benzbromarone is equivalent to 1.5 g probenecid or greater than 300 mg of allopurinol. (Masbernard A. Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. *SAMJ*. 1981; 59(20): 701–6.)
- Benzbromarone is considered unsafe in patients with acute porphyria.

Reference:

Benzylpenicillin

Clinical use
Antibacterial agent

Dose in normal renal function
2.4–14.4 g daily in 4–6 divided doses

Pharmacokinetics
Molecular weight (daltons) 334.4
% Protein binding 60
% Excreted unchanged in urine 60–90
Volume of distribution (L/kg) 0.3–0.42
Half-life — normal/ESRF (hrs) 0.5 / 10

Metabolism
Benzylpenicillin is metabolised to a limited extent and the penicilloic acid derivative has been recovered in the urine. Benzylpenicillin is rapidly excreted in the urine; about 20% of an oral dose appears unchanged in the urine; about 60–90% of an IM dose of benzylpenicillin undergoes renal elimination, 10% by glomerular filtration and 90% by tubular secretion, mainly within the first hour. Significant concentrations occur in bile, but in patients with normal renal function only small amounts are excreted via the bile.
Renal tubular secretion is inhibited by probenecid, which can be given to increase plasma-penicillin concentrations and prolong half-life.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>600 mg – 2.4 g every 6 hours depending on severity of infection.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>600 mg – 1.2 g every 6 hours depending on severity of infection.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–20 mL/min. See 'Other information'.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Reduced excretion of methotrexate.

Administration
Reconstitution
IV bolus: 600 mg in 5 mL water for injection
IV infusion: 600 mg in at least 10 mL sodium chloride 0.9%
IM: 600 mg in 1.6 mL water for injection
600 mg displaces 0.4 mL

Route
IV bolus, IV infusion, IM

Rate of administration
IV bolus: over 3–4 minutes
IV infusion: over 30–60 minutes

Comments
IV doses in excess of 1.2 g must be given slowly at minimum rate of 300 mg/minute.

Other information
• Maximum dose in severe renal impairment: 4.8 g per day.
• 600 mg of benzylpenicillin sodium (1 mega unit) contains 1.68 mmol of sodium.
• 600 mg of benzylpenicillin potassium contains 1.7 mmol potassium.
• Increased incidence of neurotoxicity in renal impairment (seizures).
• False positive urinary protein reactions may be caused by benzylpenicillin therapy.
• There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
**Clinical use**

Treatment of vertigo, tinnitus and hearing loss associated with Ménière’s syndrome

**Dose in normal renal function**

8–16 mg 3 times a day

**Pharmacokinetics**

Molecular weight (daltons) 209.1  
% Protein binding 0–5  
% Excreted unchanged in urine 85–90  
Volume of distribution (L/kg) No data  
Half-life — normal/ESRF (hrs) 3.4 / –

**Metabolism**

Betahistine is excreted almost exclusively in the urine as 2-pyridylacetic acid within 24 hours of administration. No unchanged betahistine has been detected.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>8–16 mg 2–3 times a day.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Likely dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- None known

**Administration**

**Reconstitution**  
—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Betahistine is rapidly and completely absorbed after oral administration.
- Manufacturer has no data in renal impairment.
Betamethasone

**Clinical use**

Corticosteroid:
- Suppression of inflammatory and allergic disorders
- Congenital adrenal hyperplasia

**Dose in normal renal function**

Oral: 0.5–5 mg daily
Injection: 4–20 mg repeated up to 4 times in 24 hours

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>392.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>65</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5.5 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Corticosteroids are metabolised mainly in the liver but also in other tissues, and are excreted in the urine. The slower metabolism of the synthetic corticosteroids with their lower protein-binding affinity may account for their increased potency compared with the natural corticosteroids.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced.
- Anticoagulants: efficacy of coumarins and phenindione may be altered.
- Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited by itraconazole and ketoconazole.
- Antivirals: concentration possibly increased by ritonavir.
- Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids.
- Cobicistat: concentration of betamethasone possibly increased.
- Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
- Vaccines: high dose corticosteroids can impair immune response to vaccines; avoid with live vaccines.

**Administration**

**Reconstitution**
- Unknown

**Route**
- Oral, IV, IM, topical

**Rate of administration**
- IV bolus: over half to one minute.

**Comments**
- Can be added to glucose 5% or sodium chloride 0.9%

**Other information**

- 750 micrograms betamethasone is equivalent to approximately 5 mg prednisolone.
- Even when applied topically, sufficient corticosteroid may be absorbed to give a systemic effect.
- Effects of betamethasone on sodium and water retention are less than those of prednisolone and approximately equal to those of dexamethasone.
Betaxolol hydrochloride

**Clinical use**
Beta-adrenoceptor blocker:
- Topical use in glaucoma

**Dose in normal renal function**
Apply twice daily

**Pharmacokinetics**
- Molecular weight (daltons) 343.9
- % Protein binding 50
- % Excreted unchanged in urine 15
- Volume of distribution (L/kg) 5–10
- Half-life — normal/ESRF (hrs) 16–22 / 30–35

**Metabolism**
Betaxolol is highly lipophilic which results in good permeation of the cornea, allowing high intraocular levels of the drug. The elimination of betaxolol is primarily by the renal rather than faecal route. The major metabolic pathways yield two carboxylic acid forms plus unchanged betaxolol in the urine (approximately 16% of the administered dose).

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics: enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline, and possibly with dobutamine.

**Administration**

**Reconstitution**
—

**Route**
Topical

**Rate of administration**
—

**Other information**
- Use with caution in patients with asthma, or a history of obstructive airways disease or diabetes.
- Systemic absorption may follow topical administration to the eye.
Bevacizumab

**Clinical use**

Monoclonal antibody:
- Treatment of colorectal cancer
- Treatment of breast cancer
- Treatment of renal cell carcinoma
- Treatment of lung cancer
- Treatment of ovarian, fallopian tube or peritoneal cancer

**Dose in normal renal function**

- 5–10 mg/kg every 14 days
- Or 7.5–15 mg/kg every 3 weeks
- Dose varies according to indication
- Consult local protocol

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>149 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.046</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>11–50 days (average 20 days)</td>
</tr>
</tbody>
</table>

**Metabolism**

Assessment of bevacizumab metabolism in rabbits following a single IV dose of $^{125}$I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF. The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver. Binding of the IgG to the FcRn receptor results in protection from cellular metabolism and the long terminal half-life.

**Dose in renin impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Bisphosphonates: increased risk of osteonecrosis of the jaw.
- Cytotoxics: avoid with panitumumab.
- Vaccines: risk of generalised infections with live vaccines – avoid.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IV infusion</td>
<td></td>
</tr>
</tbody>
</table>

**Rate of administration**

30–90 minutes depending on how the patient tolerates it

**Comments**

Dilute in 100 mL of sodium chloride 0.9%.  DO NOT mix with glucose solutions.

**Other information**

- Increased incidence of hypertension has been seen with treatment.
- Manufacturer advises to use with caution due to lack of data.
- MHRA/CHM advice: may increase risk of developing osteonecrosis of the jaw.
- Necrotising fasciitis has also been reported, discontinue if suspected.
- People with a history of hypertension may be at an increased risk of proteinuria. Discontinue therapy in patients with Grade 4 proteinuria (nephrotic syndrome).
- Can delay wound healing.
- Bevacizumab has been used in a haemodialysis patient at a dose of 5 mg/kg every 14 days. (Garnier-Viogeat N, Rixe O, Paintaud G, et al. Pharmacokinetics of bevacizumab in haemodialysis. *Nephrol Dial Transplant.* 2007; 22: 975.)
Bexarotene

**Clinical use**

Antineoplastic agent:
- Treatment of skin manifestations of cutaneous T-cell lymphoma

**Dose in normal renal function**

300mg/m² daily as a single dose

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>348.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–3 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Hepatic metabolism. Studies suggest glucuronidation as a metabolic pathway, and that cytochrome P450 3A4 is the major cytochrome P450 isozyme responsible for formation of the oxidative metabolites. Bexarotene metabolites have little pharmacological activity.

No studies have been done in renal failure although the pharmacokinetic data indicates that renal elimination is a minor excretory pathway.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis)
- Lipid-regulating drugs: concentration increased by gemfibrozil – avoid.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- No formal studies have been conducted in patients with renal insufficiency. Clinical pharmacokinetic data indicate that urinary elimination of bexarotene and its metabolites is a minor excretory pathway for bexarotene. In all evaluated patients, the estimated renal clearance of bexarotene was less than 1 mL/minute. In view of the limited data, patients with renal insufficiency should be monitored carefully while on Targretin capsule therapy.¹

Reference:
Bezafibrate

Clinical use

Hyperlipidaemia

Dose in normal renal function

- 200 mg, 3 times a day
- Modified release: 400 mg daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>361.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.24–0.35</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–2 (MR: 3.4) / 7.8–20</td>
</tr>
</tbody>
</table>

Metabolism

50% of the administered bezafibrate dose is recovered in the urine as unchanged drug and 20% in the form of glucuronides. Elimination is rapid, with excretion almost exclusively renal. 95% of the activity of the [14C]-labelled drug is recovered in the urine and 3% in the faeces within 48 hours.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–60</td>
<td>400 mg daily</td>
</tr>
<tr>
<td>15–40</td>
<td>200 mg every 24–48 hours</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Avoid</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapies</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. 200 mg every 72 hours.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. 200 mg every 72 hours.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. 200 mg every 72 hours.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=15–40 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant use.
- Anticoagulants: enhances effect of coumarins and phenindione; dose of anticoagulant should be reduced by up to 50% and adjusted by monitoring INR.
- Antidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureas.
- Ciclosporin: may increase nephrotoxicity and reduce ciclosporin levels.
- Colchicine: possible increased risk of myopathy.
- Lipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe – avoid with ezetimibe; do not exceed 10 mg of simvastatin and 20 mg of rosvastatin.1

Administration

Reconstitution

—

Route

Oral

Rate of administration

—

Other information

- Take dose with or after food.
- Contraindicated in nephrotic syndrome.
- There should be an interval of 2 hours between intake of ion exchange resin and bezafibrate.
- Modified-release preparation is not appropriate in renal impairment.

Reference:
1. MHRA. Drug Safety Update. 2012 August; 6(1).
Bezlotoxumab

**Clinical use**

Human monoclonal antitoxin antibody:
- Prevention of recurrence of *Clostridium difficile* infection

**Dose in normal renal function**

Single dose of 10 mg/kg

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>148 200</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>7.33 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>19 days / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Bezlotoxumab is catabolized through protein degradation processes; metabolism does not contribute to its clearance. It is eliminated from the body primarily by protein degradation.

**Dose in renal impairment GFR (mL/min)**

- **20–50** Dose as in normal renal function.
- **10–20** Dose as in normal renal function.
- **<10** Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Unlikely to be dialysed. Dose as in normal renal function.
- **HD** Unlikely to be dialysed. Dose as in normal renal function.
- **HDF/High flux** Unlikely to be dialysed. Dose as in normal renal function.
- **CAV/VVHD** Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

- **Route** IV infusion

**Rate of administration**

Over 60 minutes

**Comments**

Add dose to sodium chloride 0.9% or glucose 5% to give a concentration of 1–10 mg/mL. Use a non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or add-on filter.

**Other information**

- Administer during the course of antimicrobial treatment.
- The effect of renal impairment on the pharmacokinetics of bezlotoxumab was evaluated in patients with mild (eGFR 60 to <90 mL/min/1.73 m²), moderate (eGFR 30 to <60 mL/min/1.73 m²), or severe (eGFR 15 to <30 mL/min/1.73 m²) renal impairment, or with ESRD (eGFR <15 mL/min/1.73 m²) compared to patients with normal renal function. No clinically meaningful differences in the exposure of bezlotoxumab were found between patients with renal impairment and patients with normal renal function.
**Bicalutamide**

**Clinical use**
Treatment of prostate cancer

**Dose in normal renal function**
50–150 mg daily
(with orchidectomy or gonadorelin therapy)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>430.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>96</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Approx 50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–7 days / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**
The (S)-enantiomer is rapidly cleared relative to (R)-enantiomer, the latter having a plasma elimination half-life of about 1 week.

On daily administration of bicalutamide 150 mg, the (R)-enantiomer accumulates about 10-fold in plasma as a consequence of its long half-life.

At steady state, the predominantly active (R)-enantiomer accounts for 99% of the total circulating enantiomers. Bicalutamide is highly protein bound (racemate 96%, (R)-enantiomer >99%) and extensively metabolised (oxidation and glucuronidation); its metabolites are eliminated via the kidneys and bile in approximately equal proportions.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhances anticoagulant effect of coumarins.
- Lipid lowering agents: separate lomitapide and bicalutamide administration by 12 hours.
- See ‘Other information’.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**

- *In vitro* studies have shown that bicalutamide is an inhibitor of CYP3A4. For drugs eliminated by this route, e.g. ciclosporin, tacrolimus, sirolimus, it is recommended that plasma concentrations and clinical condition be monitored following initiation or cessation of bicalutamide therapy.
# Bilastine

## Clinical use
Non-sedating antihistamine:
- Symptomatic relief of allergy such as hay fever, urticaria

## Dose in normal renal function
20 mg once daily

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>463.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>84–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>28.3</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.29</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>14.5 / –</td>
</tr>
</tbody>
</table>

## Metabolism
Not significantly metabolised. Almost 95% of the administered dose was recovered in urine (28.3%) and faeces (66.5%) as unchanged bilastine.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antivirals: concentration possibly increased by ritonavir.
- Grapefruit juice: concentration of bilastine reduced.

## Administration

### Reconstitution
—

### Route
Oral

### Rate of administration
—

## Other information
- Oral bioavailability is 61%.
Bisacodyl

Clinical use

Laxative

Dose in normal renal function

- Oral: 5–10 mg at night, increasing to 20 mg at night if required
- Rectal: 10 mg in the morning
- Bowel evacuation: 10 mg orally in the morning and 10 mg at night the day before the procedure followed by 10 mg as suppositories the next morning

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>361.4</td>
</tr>
<tr>
<td>Protein binding %</td>
<td>Negligible</td>
</tr>
<tr>
<td>Excreted unchanged in urine %</td>
<td>30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>See 'Other information.'</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>See 'Other information.'</td>
</tr>
</tbody>
</table>

Metabolism

Bisacodyl is rapidly hydrolysed to the active principle bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), mainly by esterases of the enteric mucosa. After oral and rectal administration, only small amounts of the drug are absorbed and are almost completely conjugated in the intestinal wall and the liver to form the inactive BHPM glucuronide. Following the administration of bisacodyl coated tablets, an average of 51.8% of the dose was recovered in the faeces as free BHPM and an average of 10.5% of the dose was recovered in the urine as BHPM glucuronide. Following the administration as a suppository, an average of 3.1% of the dose was recovered as BHPM glucuronide in the urine. Stool contained large amounts of BHPM (90% of the total excretion) in addition to small amounts of unchanged bisacodyl.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- None known

Administration

Reconstitution

<table>
<thead>
<tr>
<th>Route</th>
<th>Rate of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral, rectal</td>
<td></td>
</tr>
</tbody>
</table>

Other information

- Absorption is <5% orally or rectally.
**Bisoprolol fumarate**

**Clinical use**

Beta-1 adrenoceptor blocker:
- Hypertension
- Angina
- Adjunctive treatment for heart failure

**Dose in normal renal function**

- 5–20 mg daily
- Heart failure: 1.25 mg daily increasing to 10 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>767</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>9–12 / 18–24</td>
</tr>
</tbody>
</table>

**Metabolism**

Bisoprolol is excreted from the body by two routes. 50% is metabolised by the liver to inactive metabolites which are then excreted by the kidneys. The remaining 50% is excreted by the kidneys in an unmetabolised form.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antibacterials: concentration reduced by rifampicin.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline, and possibly with dobutamine.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Use with caution in patients with chronic obstructive airways disease, asthma or diabetes.
# Bivalirudin

## Clinical use

**Anticoagulant:**
- Percutaneous coronary intervention (PCI)
- Unstable angina or non-ST elevation MI

## Dose in normal renal function

- **PCI:** Initially bolus of 750 mcg/kg then an infusion of 1.75 mg/kg/hour
- **Unstable angina or non-ST elevation MI:** 100 mcg/kg bolus then 250 mcg/kg/hour – see product literature

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>2180.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>13–37 minutes / 57 minutes (310 minutes in dialysis patients on non-HD days)</td>
</tr>
</tbody>
</table>

## Metabolism

As a peptide, bivalirudin is expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acid in the body pool. Bivalirudin is metabolised by proteases, including thrombin. The primary metabolite resulting from the cleavage of Arg-Pro bond of the N-terminal sequence by thrombin is not active because of the loss of affinity to the catalytic active site of thrombin.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–59</td>
<td>Normal bolus dose. Reduce infusion to 1.4 mg/kg/hour.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Normal bolus dose then reduce infusion to 1 mg/kg/hour. See 'Other information'.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

- **APD/CAPD:** Unknown dialysability. Use with caution.
- **HD:** Dialysed. Normal bolus dose then reduce infusion to 0.25 mg/kg/hour.
- **HDF/High flux:** Dialysed. Normal bolus dose then reduce infusion to 0.25 mg/kg/hour.
- **CAV/VVHD:** Unknown dialysability. Dose as in GFR<30 mL/min.

## Important drug interactions

Potentially hazardous interactions with other drugs:
- **Analgesics:** increased risk of haemorrhage with IV diclofenac and ketorolac.
- **Antiplatelets and anticoagulants:** increased risk of bleeding.
- **Thrombolytics:** may increase risk of bleeding complications; enhance effect of bivalirudin.

## Administration

### Reconstitution

Reconstitute each 250 mg vial with 5 mL water for injection

### Route

**IV**

### Rate of administration

1.75 mg/kg/hour

### Comments

- Further dilute with 50 mL sodium chloride 0.9% or glucose 5% if for infusion.
- Stable for 24 hours at room temperature.

## Other information

- Monitor ACT in renal impairment.
- Can start bivalirudin 30 minutes after stopping unfractionated heparin and 8 hours after stopping LMWH.
- No known antidote.
- Contraindicated in UK SPC if GFR<30 mL/min.
- Dose in severe renal impairment and dialysis is from US data sheet.
  - GFR=30–50 mL/min: 1.75 mg/kg/hour
  - GFR<30 mL/min: 1 mg/kg/hour
  - On haemodialysis: 0.25 mg/kg/hour
**Bleomycin**

### Clinical use
Antineoplastic agent

### Dose in normal renal function

Squamous cell carcinoma and testicular teratoma:
- range 45–60 x 10⁴ IU per week IM/IV (total cumulative dose up to 500 x 10⁴ IU)
- OR, continuous IV infusion 15 x 10³ IU/24 hours for up to 10 days
- OR, 30 x 10³ IU/24 hours for up to 5 days

Malignant lymphomas:
- 15–30 x 10³ IU/week IM to total dose of 225 x 10³ IU Lower doses required in combination chemotherapy.

Malignant effusions:
- 60 x 10⁴ IU in 100 mL sodium chloride 0.9% intrapleurally (total cumulative dose of 500 x 10³ IU)

### Pharmacokinetics

- **Molecular weight (daltons)**: Approximately 1500
- **% Protein binding**: <1
- **% Excreted unchanged in urine**: 60–70
- **Volume of distribution (L/kg)**: 0.3
- **Half-life — normal/ESRF (hrs)**:
  - (bolus): 4, (continuous infusion): 9 / 20

### Metabolism

The mechanism for bio-transformation is not yet fully known. Inactivation takes place during enzymatic breakdown by bleomycin hydrolase, primarily in plasma, liver and other organs and, to a much lesser degree, in skin and lungs.

About 60-70% of the administered drug is excreted unchanged in the urine, probably by glomerular filtration. Approximately 50% is recovered in the urine in the 24 hours following an IV or IM injection. The rate of excretion, therefore, is highly influenced by renal function; concentrations in plasma are greatly elevated if usual doses are given to patients with renal impairment with only up to 20% excreted in 24 hours.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>75% of normal dose (100% for malignant effusions).</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of normal dose (100% for malignant effusions).</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs:
- **Antipsychotics**: avoid clozapine, increased risk of agranulocytosis.
- **Cytotoxics**: increased pulmonary toxicity with cisplatin and brentuximab, avoid with brentuximab; in combination with vinca alkaloids can lead to Raynaud’s syndrome and peripheral ischaemia.
- **Live vaccines**: avoid concomitant use.

### Administration

#### Reconstitution

- **IM**: dissolve required dose in up to 5 mL sodium chloride 0.9% (or 1% solution of lidocaine if pain on injection)
- **IV**: dissolve dose in 5–200 mL sodium chloride 0.9%.
- **Intracavitary**: 60 x 10³ IU in 100 mL sodium chloride 0.9%.
- **Locally**: dissolve in sodium chloride 0.9% to make a 1–3 x10³ IU/mL solution.

#### Route

IM, IV, also intra-arterially, intrapleurally, intraperitoneally, locally into tumour.

#### Rate of administration

Give by slow IV injection, or add to reservoir of a running IV infusion.

#### Comments

Avoid direct contact with the skin.
**Other information**

- Lesions of skin and oral mucosa common after full course of bleomycin.
- Pulmonary toxicity: interstitial pneumonia and fibrosis – most serious delayed effect.

- Dose in severe renal impairment is from *Drug Prescribing in Renal Failure, 5th edition* by Aronoff *et al*.
- Rapid distribution to body tissues (highest concentration is in skin, lungs, peritoneum and lymph).
Boceprevir

Clinical use

HCV-protease inhibitor:
- Treatment of chronic Hepatitis C (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin

Dose in normal renal function

800 mg three times a day with food

Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>519.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>75</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>9</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>772 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3.4 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism

Boceprevir mainly undergoes metabolism through the aldo-ketoreductase mediated pathway to ketone-reduced metabolites that are inactive against HCV. After a single 800 mg oral dose of ^14^C-boceprevir, the most abundant circulating metabolites were a diasteriomeric mixture of ketone-reduced metabolites with a mean exposure approximately 4-fold greater than that of boceprevir. Boceprevir also undergoes, to a lesser extent, oxidative metabolism mediated by CYP3A4/5. Mainly excreted by the liver – approximately 79% and 9% of the dose was excreted in faeces and urine, respectively, with approximately 8% and 3% eliminated as boceprevir in faeces and urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly reduced by rifampicin – avoid.
- Anticoagulants: avoid with apixaban.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone – avoid.
- Antifungals: concentration increased by ketoconazole.
- Antimalarials: avoid with artemether and lumefantrine.
- Antipsychotics: avoid pimozide; possibly increases lurasidone and quetiapine concentration – avoid.
- Antivirals: reduces concentration of atazanavir; avoid with daclatasvir, darunavir, fosamprenavir and lopinavir; concentration of both drugs reduced with ritonavir.
- Anxiolytics and hypnotics: increased oral midazolam concentration – avoid.
- Ciclosporin: concentration of ciclosporin increased.
- Cilostazol: possibly increases cilostazol concentration.
- Cytotoxics: possibly increases bosutinib concentration – avoid or reduce bosutinib dose; avoid with dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, olaparib, pazopanib, sorafenib and sunitinib; reduce dose of ruxolitinib.
- Domperidone: possible increased risk of ventricular arrhythmias – avoid.
- Ergot alkaloids: avoid concomitant use.
- Guanfacine: concentration possibly increased, halve guanfacine dose.
- Lipid-regulating drugs: enhances effects and toxicity of atorvastatin, reduce atorvastatin dose; increases pravastatin concentration; avoid with simvastatin.
- Oestrogens: possibly causes contraception failure.
- Sirolimus: possibly increases sirolimus concentration.
- Tacrolimus: concentration of tacrolimus increased, reduce tacrolimus dose.

Administration

Reconstitution

Route
Oral
Rate of administration

—
Other information

- Absorption is increased by 60% when given with food.
- Boceprevir is administered as an approximately equal mixture of two diastereomers which rapidly interconvert in plasma. At steady-state, the exposure ratio for the two diastereomers is approximately 2:1, with the predominant diastereomer being pharmacologically active.
# Bortezomib

## Clinical use

Proteasome inhibitor:  
- Treatment of multiple myeloma for people who have already tried at least 1 prior therapy and have disease progression

## Dose in normal renal function

1.3 mg/m\(^2\) twice weekly for 2 weeks (days 1, 4, 8 and 11) followed by a 10 day rest period

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>384.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>82.9</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Small amount</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>498–1,884 Litres/m(^2)</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>40–193 / Unknown</td>
</tr>
</tbody>
</table>

## Metabolism

*In vitro* studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolised via cytochrome P450 enzymes, 3A4, 2C19, and 1A2. The major metabolic pathway is deboronation to form two deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Monitor carefully. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>A reduced dose may be required. Monitor carefully.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs:
- Antibacterials: potential reduced efficacy with rifampicin resulting in increased monoclonal IgG \(\lambda\) – avoid.\(^1\)
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

## Administration

### Reconstitution

3.5 mL sodium chloride 0.9%

### Route

SC, IV bolus

### Rate of bolus

3–5 seconds

### Comments

Administer within 8 hours of reconstitution

## Other information

- Consecutive doses should be at least 72 hours apart.
- Normal doses have been used in patients with a GFR of 10–30 mL/min but there is an increased risk of adverse effects.\(^2\)
- Some trials have used doses of 1 mg/m\(^2\) in patients with a GFR of 10–30 mL/min, with similar efficacy and incidence of side effects.
- Both hypo– and hyperkalaemia have been reported with bortezomib as has hypophosphataemia and hypomagnesaemia.
- There have been incidences of renal impairment, renal colic, proteinuria, dysuria, urinary frequency, urinary hesitation and haematuria.
- Anecdotally, has been used at normal doses in a few haemodialysis patients; in some of the patients platelet infusions have been required.
- In patients with peripheral neuropathy then bortezomib has a high probability of exacerbating it.

## References:

Bosentan

**Clinical use**

Treatment of primary arterial pulmonary hypertension (PAH), and PAH secondary to scleroderma without significant interstitial pulmonary disease.

Treatment of systemic sclerosis with ongoing digital ulcer disease.

**Dose in normal renal function**

- PAH: 62.5–250 mg twice daily
- Systemic sclerosis: 62.5–125 mg twice daily

**Pharmacokinetics**

Molecular weight (daltons) 551.6
% Protein binding >98
% Excreted unchanged in urine <3
Volume of distribution (L/kg) 18 Litres
Half-life — normal/ESRF (hrs) 5–8 / Unchanged

**Metabolism**

Upon multiple dosing, plasma concentrations of bosentan decrease gradually to 50%–65% of those seen after single dose administration. This decrease is probably due to auto-induction of metabolising liver enzymes. Steady-state conditions are reached within 3–5 days.

Bosentan is eliminated by biliary excretion following metabolism in the liver by the cytochrome P450 isoenzymes, CYP2C9 and CYP3A4. Bosentan forms three metabolites and only one of these is pharmacologically active. This metabolite is mainly excreted unchanged via the bile. In adult patients, the exposure to the active metabolite is greater than in healthy subjects. In patients with evidence of the presence of cholestasis, the exposure to the active metabolite may be increased.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antibacterials: concentration reduced by rifampicin – avoid.
- Antidiabetics: increased risk of hepatotoxicity with glibenclamide – avoid.
- Antifungals: fluconazole, ketoconazole and itraconazole cause large increases in concentration of bosentan – avoid.
- Antivirals: concentration of bosentan increased by lopinavir and ritonavir – consider reducing bosentan dose; telaprevir concentration reduced and bosentan concentration possibly increased; avoid with tipranavir.
- Ciclosporin: When ciclosporin and bosentan are co-administered, initial trough concentrations of bosentan are 30 times higher than normal. At steady state, trough levels are 3–4 times higher than normal. Blood concentrations of ciclosporin decreased by 50% – avoid.
- Cytotoxics: concentration of bosutinib possibly reduced – avoid.
- Guanfacine: concentration of guanfacine possibly reduced – increase guanfacine dose.
- Lipid lowering agents: concentration of simvastatin reduced by 45% – monitor cholesterol levels and adjust dose of statin.
- Oestrogens, progestogens and ulipristal: may be failure of contraception – use alternative method.

**Administration**

Reconstitution

Route
Oral
Rate of administration
Other information

- In patients with severe renal impairment (CRCL=15–30 mL/min), plasma concentrations of bosentan decreased by approximately 10%. Plasma concentrations of bosentan metabolites increased about 2-fold in these patients as compared to subjects with normal renal function.
- Bosentan should only be used if the systemic systolic blood pressure is >85 mm/Hg.
- Treatment with bosentan is associated with a dose-related, modest decrease in haemoglobin concentration.
- Bosentan is an inducer of CYP 3A4 and CYP 2C9.
- Bosentan has been associated with dose-related elevations in liver aminotransferases.
- Side effects include leg oedema and hypotension.
**Bosutinib**

**Clinical use**

Protein kinase inhibitor:
- Treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia resistant or intolerant to prior therapy

**Dose in normal renal function**

500–600 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>530.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>94–96</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>6530–12 590 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>34 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Mainly hepatically metabolised. The major circulating metabolites identified in plasma are oxydechlorinated (M2) bosutinib (19% of parent exposure) and N-desmethylated (M5) bosutinib (25% of parent exposure), with bosutinib N-oxide (M6) as a minor circulating metabolite. All the metabolites are inactive. Excretion is mainly via the faeces.

**Dose in renal impairment GFR (mL/min)**

- 30–50: 400–500 mg once daily.
- <30: 300–400 mg once daily.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>APD/CAPD</th>
<th>Not dialysed. Dose as in GFR&lt;30 mL/min.</th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: possibly increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: possibly increased risk of ventricular arrhythmias with amiodarone and disopyramide; concentration possibly increased by dronedarone – avoid or consider reducing dose of bosutinib.
- Antibacterials: concentration possibly increased by ciprofloxacin, clarithromycin, erythromycin and telithromycin – avoid or consider reducing dose of bosutinib; possibly increased risk of ventricular arrhythmias with moxifloxacin; concentration reduced by rifampicin and possibly rifabutin – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone – avoid.
- Antifungals: concentration increased by ketoconazole and possibly by fluconazole, itraconazole, posaconazole and voriconazole – avoid or consider reducing dose of bosutinib.
- Antimalarials: possibly increased risk of ventricular arrhythmias with chloroquine and hydroxychloroquine.
- Antipsychotics: possibly increased risk of ventricular arrhythmias with haloperidol; avoid with clozapine, increased risk of agranulocytosis.
- Antivirals: concentration possibly increased by atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, ritonavir, saquinavir and telaprevir – avoid or consider reducing dose of bosutinib; concentration possibly reduced by efavirenz and etravirine – avoid.
- Aprepitant: concentration possibly increased – avoid or consider reducing dose of bosutinib.
- Beta-blockers: possibly increased risk of ventricular arrhythmias with sotalol.
- Bosentan: concentration of bosutinib possibly reduced – avoid.
- Calcium channel blockers: concentration possibly increased by diltiazem or verapamil – avoid or consider reducing dose of bosutinib.
- Cytotoxics: concentration possibly increased by imatinib – avoid or consider reducing dose of bosutinib.
- Domperidone: avoid concomitant use, risk of ventricular arrhythmias.
- Fosaprepitant: concentration possibly increased by fosaprepitant – avoid or consider reducing dose of bosutinib.
- Grapefruit juice: concentration possibly increased by grapefruit juice – avoid or consider reducing dose of bosutinib.
- Modafinil: concentration of bosutinib possibly reduced – avoid.
<table>
<thead>
<tr>
<th>Administration</th>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reconstitution</td>
<td>• Treatment with bosutinib may result in a clinically significant decline in renal function in CML patients.</td>
</tr>
<tr>
<td>Route Oral</td>
<td>• People with moderate and severe renal impairment had an increase in AUC over healthy volunteers of 35% and 60%, respectively. Maximal exposure $C_{\text{max}}$ increased by 28% and 34% in the moderate and severe groups, respectively.</td>
</tr>
<tr>
<td>Rate of administration</td>
<td>—</td>
</tr>
</tbody>
</table>
Brentuximab vedotin

**Clinical use**

Monoclonal antibody:
- Hodgkin's lymphoma
- Systemic anaplastic large cell lymphoma

**Dose in normal renal function**

- 1.8 mg/kg every 3 weeks
- Maximum weight calculation 100 kg

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>1.2 mg/kg</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>1.2 mg/kg</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>1.2 mg/kg</td>
<td>Use with caution.</td>
</tr>
</tbody>
</table>

**Pharmacokinetics**

Molecular weight (daltons) 153 000
% Protein binding 68–82 (MMAE)
% Excreted unchanged in urine 24 (MMAE) – in urine and faeces
Volume of distribution (L/kg) 6–10 Litres
Half-life — normal/ESRF (hrs) 4–6 days / Increased

**Metabolism**

Brentuximab vedotin consists of a monoclonal antibody conjugated with monomethyl auristatin E (MMAE). Only a small fraction of MMAE released from brentuximab vedotin is metabolised; this metabolism is mainly via oxidation by cytochrome P450 isoenzyme CYP3A4/5.

MMAE is eliminated in the faeces (72% unchanged) and urine.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antifungals: possible increased risk of neutropenia with ketoconazole.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Cytotoxics: increased risk of pulmonary toxicity with bleomycin – avoid.
- Live vaccines: avoid concomitant use.

**Administration**

Reconstitution
10.5 mL water for injection

Route
IV infusion

Rate of administration
Over 30 minutes

Comments
Add to 150 mL sodium chloride 0.9%, glucose 5% or Lactated Ringer’s solution to achieve a concentration of 0.4–1.2 mg/mL.

**Other information**

- A study by the manufacturer found that MMAE exposure increased approximately 1.9-fold in patients with severe renal impairment (CRCL<30 mL/min). No effect was observed in patients with mild or moderate renal impairment.
- A premedication of paracetamol and an antihistamine before infusion may be required.
Brivaracetam

Clinical use
Antiepileptic agent

Dose in normal renal function
25–100 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 212.3
% Protein binding <20
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 0.5
Half-life — normal/ESRF (hrs) 9 / 9.8

Metabolism
Brivaracetam is mainly metabolised by hydrolysis of the amide moiety to form the corresponding carboxylic acid (approximately 60% the elimination), and secondarily by hydroxylation on the propyl side chain (approximately 30% the elimination). The hydrolysis of the amide moiety leading to the carboxylic acid metabolite (34% of the dose in urine) is supported by hepatic and extra-hepatic amidase. The metabolites are inactive. Greater than 95% of the dose is excreted in the urine as brivaracetam and its metabolites.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin.
- Antidepressants: antagonism of anticonvulsant effect (convulsive threshold lowered).
- Antimalarials: mefloquine antagonises anticonvulsant effect.
- Antipsychotics: antagonism of anticonvulsant effect (convulsive threshold lowered).
- Orlistat: possibly increased risk of convulsions.

Administration
Reconstitution
Route Oral, IV bolus, infusion
Rate of administration 15 minutes

Other information
- Not recommended by manufacturer in end-stage renal disease in patients on dialysis due to lack of data.
- A study in subjects with severe renal impairment (creatinine clearance <30 mL/min/1.73 m² and not requiring dialysis) revealed that the plasma AUC of brivaracetam was moderately increased (+21%) relative to healthy controls, while the AUC of the acid, hydroxy and hydroxyacid metabolites were increased 3-, 4-, and 21-fold, respectively. The renal clearance of these non-active metabolites was decreased 10-fold. The hydroxyacid metabolite did not reveal any safety concerns in non-clinical studies.
- Oral bioavailability is approximately 100%.

Reference:
### Clinical use
Human monoclonal immunoglobulin IgG2 antibody:
- Treatment of moderate to severe plaque psoriasis

### Dose in normal renal function
210 mg at weeks 0, 1 and 2 and then 210 mg every 2 weeks

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>144 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>7.24 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10.9 days</td>
</tr>
</tbody>
</table>

### Metabolism
Brodalumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.
Brodalumab is expected to be mainly eliminated via catabolism and hepatic impairment is not expected to influence clearance.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Caution</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- **HD**: Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in normal renal function. Use with caution.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Avoid with live vaccines.

### Administration

#### Reconstitution
—

#### Route
SC

#### Rate of administration
—

### Other information
- Manufacturer has no data in renal impairment.
- Renal elimination of intact brodalumab is expected to be low and of minor consequence.
Bromocriptine

Clinical use
- Parkinsonism (but not drug-induced extrapyramidal symptoms)
- Endocrine disorders

Dose in normal renal function
- Parkinson's disease:
  - Week 1: 1–1.25 mg at night
  - Week 2: 2–2.5 mg at night
  - Week 3: 2.5 mg twice daily
  - Week 4: 2.5 mg, 3 times daily
  - then increasing by 2.5 mg every 3–14 days according to response – usual range 10–30 mg daily
- Hypogonadism / galactorrhoea, infertility: 1–1.25 mg at night, increased gradually; usual dose 7.5 mg daily in divided doses (maximum 30 mg daily);
- Infertility without hyperprolactinaemia: 2.5 mg twice daily
- Cyclical benign breast disease and cyclical menstrual disorders: 1–1.25 mg at night increased gradually; usual dose 2.5 mg twice daily
- Acromegaly: 1–1.25 mg at night increased gradually to 5 mg every 6 hours
- Prolactinoma: 1–1.25 mg at night increased gradually to 5 mg every 6 hours (maximum 30 mg daily)

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
- Potentially hazardous interactions with other drugs
  - Increased risk of toxicity with bromocriptine and isomethptene.

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>750.7 (as mesilate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90–96</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>2.5–5.5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1–3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8–20 / –</td>
</tr>
</tbody>
</table>

Metabolism
Bromocriptine is extensively metabolised. It undergoes extensive first-pass biotransformation in the liver, reflected by complex metabolite profiles and by almost complete absence of parent drug in urine and faeces. In plasma the elimination half life is 3–4 hours for the parent drug and 50 hours for the inactive metabolites.

The parent drug and its metabolites are also completely excreted via the liver with only 6% being eliminated via the kidney.

Other information
- Hypotensive reactions may occur during the first few days of treatment. Tolerance may be reduced by alcohol.
- Digital vasospasm can occur.
- Concomitant administration of macrolide antibiotics may elevate bromocriptine levels.
Budesonide

Clinical use
- Asthma
- Allergic and vasomotor rhinitis
- Inflammatory skin disorders
- Crohn’s disease
- Autoimmune hepatitis

Dose in normal renal function
- Inhaler / Turbohaler: 200–1600 micrograms daily in divided doses
- Respules: 1–2 mg twice daily; half doses for maintenance
- Nasal spray: depends on preparation.
- Topical preparations: apply 1–2 times daily

Crohn’s disease:
- Capsules: 3 mg, 3 times a day, CR: 9 mg once daily
- Enema: 2 mg/100 mL at bedtime
- Autoimmune hepatitis (oral): 3 mg three times daily, maintenance 3 mg twice daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>430.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>85–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.8–2.2 (inhaled), 3–4 (oral) / –</td>
</tr>
</tbody>
</table>

Metabolism
Budesonide is rapidly and almost completely absorbed after oral administration, but has poor systemic availability (about 10%) due to extensive first-pass metabolism in the liver, mainly by the cytochrome P450 isoenzyme CYP3A4. The major metabolites, 6-β-hydroxybudesonide and 16-α-hydroxyprednisolone have less than 1% of the glucocorticoid activity of unchanged budesonide.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antibacterials: metabolism accelerated by rifamycins.
- Anticoagulants: efficacy of coumarins and phenindione may be altered.
- Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: concentration of inhaled and oral budesonide increased by itraconazole and ketoconazole.
- Antivirals: concentration of inhaled, intranasal and rectal budesonide increased by ritonavir.
- Cobicistat: concentration possibly increased by cobicistat — increased risk of adrenal suppression.
- Grapefruit juice: concentration of oral budesonide increased — avoid.
- Vaccines: high dose corticosteroids can impair immune response to vaccines — avoid with live vaccines.

Administration
Reconstitution
Respules: may be diluted up to 50% with sterile sodium chloride 0.9%
Route
Inhalation, topical, oral
Rate of administration
-

Other information
- Special care is needed in patients with quiescent lung tuberculosis, fungal and viral infections in the airways.
**Bumetanide**

**Clinical use**
Loop diuretic

**Dose in normal renal function**
- Oral: 1–10 mg daily, may be given in 2 divided doses.
- Injection: IV 1–2 mg repeated after 20 minutes; IM if necessary, 1 mg then adjust according to response.
- IV infusion: 2–5 mg over 30–60 minutes

**Pharmacokinetics**
- Molecular weight (daltons) 364.4
- % Protein binding 95
- % Excreted unchanged in urine 50
- Volume of distribution (L/kg) 0.2–0.5
- Half-life — normal/ESRF (hrs) 0.75–2.6 / 1.5

**Metabolism**
About 80% of a dose of bumetanide is excreted in the urine, about 50% as unchanged drug, and 10–20% in the faeces. No active metabolites are known. In patients with chronic renal failure the liver takes more importance as an excretory pathway although the duration of action is not markedly prolonged.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect with NSAIDs.
- Anti-arrhythmics: risk of cardiac toxicity with anti-arrhythmics if hypokalaemia occurs; effects of lidocaine and mexiletine antagonised.
- Antibacterials: increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid with lymecycline.
- Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hyponatraemia with carbamazepine.
- Antifungals: increased risk of hypokalaemia with amphotericin.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalaemia occurs.
- Antipsychotics: increased risk of ventricular arrhythmias with amisulpride or pimozide if hypokalaemia occurs – avoid with pimozide; enhanced hypotensive effect with phenothiazines.
- Atomoxetine: increased risk of ventricular arrhythmias if hypokalaemia occurs.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium: risk of toxicity.

**Administration**

**Reconstitution**

**Route**
Oral, IV, IM

**Rate of administration**
- IV infusion: 2–5 mg in 500 mL of infusion fluid over 30–60 minutes
- IV bolus: 1–2 mg over 3–4 minutes

**Comments**
Compatible with glucose 5% or sodium chloride 0.9%

**Other information**
- 1 mg bumetanide ≡ 40 mg furosemide at low doses, but avoid direct substitution at high doses.
- In patients with severe chronic renal failure given high doses of bumetanide there are reports of musculoskeletal pain and muscle spasm.
- Orally: diuresis begins within 30 minutes, peaks after 1–2 hours, lasts 3 hours.
- IV: diuresis begins within few minutes and ceases in about 2 hours.
- Use with caution in patients receiving nephrotoxic or ototoxic drugs.
- Smaller doses may be sufficient in the elderly and cirrhotics (500 micrograms).
- Use twice daily for higher doses.
Buprenorphine

**Clinical use**

Opioid analgesic

**Dose in normal renal function**

Sublingual: 200–400 mcg every 6–8 hours
IM, Slow IV: 300–600 mcg every 6–8 hours
Transdermal:
- Transtec: 35–140 mcg/hour every 96 hours
- Butrans: 5–40 mcg/hour, change patch every 7 days
- Hapocasin: 35–70 mcg/hour, change patch every 72 hours

Opioid dependence (SL): 12–24 mg daily, maximum 32 mg daily

**Pharmacokinetics**

Molecular weight (daltons) 467.6
% Protein binding 96
% Excreted unchanged in urine Minimal
Volume of distribution (L/kg) 2.5
Half-life — normal/ESRF (hrs) 20–25 (Transdermal 30 hours) / Unchanged

**Metabolism**

Elimination of buprenorphine is bi- or triphasic; metabolism takes place in the liver by oxidation via the cytochrome P450 isoenzyme CYP3A4 to the pharmacologically active metabolite N-dealkylbuprenorphine (norbuprenorphine), and by conjugation to glucuronide metabolites. Buprenorphine is subject to considerable first-pass metabolism after oral doses. However, when given by the usual routes buprenorphine is excreted mainly unchanged in the faeces; there is some evidence for enterohepatic recirculation. Metabolites are excreted in the urine, but very little unchanged drug is excreted in this way.

**Dose in patients undergoing renal replacement therapies**

| Procedure     | Dose
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: possible opiate withdrawal with other opioids.
- Antidepressants: possible CNS excitation or depression (hypotension or hypertension) if administered with MAOIs or moclobemide – avoid; sedative effects possibly increased when given with tricyclics.
- Antifungals: metabolism inhibited by ketoconazole – reduce buprenorphine dose.
- Antihistamines: sedative effects possibly increased with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Antivirals: concentration possibly increased by ritonavir; possibly reduced tipranavir concentration.
- Dopaminergics: avoid with selegiline.
- Sodium oxybate: avoid concomitant use.

**Administration**

**Reconstitution**

—

**Route**

Sublingual, IM, IV, transdermal

**Rate of administration**

—

**Other information**

- It may take up to 30 hours for plasma buprenorphine concentration to decrease by 50% after transdermal patches have been removed.
- Do not give another opiate for 24 hours after transdermal patches have been removed.
- Naloxone 5–12 mg may reverse the effects of transdermal patches but the effect may be delayed by 30 minutes.
- Patches are not suitable for acute pain.
Bupropion hydrochloride (amfebutamone HCL)

Clinical use
Adjunct to smoking cessation

Dose in normal renal function
150 mg once daily for 6 days, then twice daily

Pharmacokinetics
Molecular weight (daltons) 276.2
% Protein binding 84
% Excreted unchanged in urine 0.5
Volume of distribution (L/kg) 2000 Litres
Half-life — normal/ESRF (hrs) 14–20 / –

Metabolism
Several metabolites of bupropion are pharmacologically active and have longer half-lives, and achieve higher plasma concentrations, than the parent compound. Hydroxybupropion is the major metabolite, produced by the metabolism of bupropion by the cytochrome P450 isoenzyme CYP2B6; in animal studies hydroxybupropion was one-half as potent as bupropion. Threohydrobupropion and erythrohydrobupropion are produced by reduction and are about one-fifth the potency of the parent compound. The metabolites of bupropion are excreted mainly in the urine; less than 1% of the parent drug is excreted unchanged.

Dose in renal impairment GFR (mL/min)
20–50 150 mg daily.
10–20 150 mg daily.
<10 150 mg daily.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Antidepressants: avoid MAOIs and linezolid with and for 2 weeks before starting treatment; avoid with moclobemide; possibly increased citalopram concentration; possibly increased tricyclics concentration, increased risk of convulsions.
• Ciclosporin: may reduce ciclosporin levels.
• Hormone antagonists: possibly inhibits metabolism of tamoxifen to active metabolites – avoid.
• Methylthioninium: possible increased risk of CNS toxicity – avoid if possible.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Bupropion and metabolites may accumulate in renal failure.
**Clinical use**
- Treatment of advanced prostate cancer and endometriosis
- Pituitary desensitisation in preparation for ovulation induction regimens using gonadotrophins

**Dose in normal renal function**
- Prostate cancer: 500 mcg every 8 hours for 7 days SC then intranasally 1 spray into each nostril 6 times daily
- Endometriosis: 150 mcg is sprayed into each nostril three times daily
- Pituitary desensitisation in preparation for ovulation induction regimens using gonadotrophins: Intranasally: 600 mcg daily in 4 divided doses
- SC: 200–500 mcg daily as a single injection

**Pharmacokinetics**
- Molecular weight (daltons) 1239.4 (1299.5 as acetate)
- % Protein binding 15<sup>1</sup>
- % Excreted unchanged in urine 30 (SC), <1 (intranasal)<sup>2</sup>
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 80 minutes / –

**Metabolism**
Metabolic inactivation by peptides occurs in the liver and kidney. The drug is also inactivated by pituitary membrane enzymes.
Excreted in the urine and bile as unchanged drug and metabolites.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.
  Monitor closely.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
Intranasal, SC

**Rate of administration**
—

**Other information**
- Buserelin accumulates in the liver and kidneys as well as in the anterior pituitary.

**References:**
## Clinical use

Anxiolytic

## Dose in normal renal function

Initially 5 mg 2–3 times daily. Usual range 15–30 mg daily in divided doses (maximum 45 mg daily).

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>422</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2.69–7.91</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–11 / 4–13</td>
</tr>
</tbody>
</table>

## Metabolism

Systemic bioavailability of buspirone is low because of extensive first-pass metabolism. Metabolism in the liver is extensive via the cytochrome P450 isoenzyme CYP3A4; hydroxylation yields several inactive metabolites and oxidative dealkylation produces 1-(2-pyrimidinyl)piperazine, which is reported to be about 25% as potent as the parent drug in one model of anxiolytic activity. Buspirone is excreted mainly as metabolites in the urine, and also the faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Start at a low dose and give twice daily.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Start at a low dose and give twice daily.</td>
<td>Reduce by 25–50% if patient is anuric.</td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
<td>Reduce by 25–50% if patient is anuric.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
<td></td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs

- **Antibacterials**: concentration increased by erythromycin – reduce dose; concentration reduced by rifampicin.
- **Antidepressants**: avoid with tranylcypromine; risk of severe hypertension with MAOIs – avoid.
- **Antifungals**: concentration increased by itraconazole – reduce dose.
- **Antipsychotics**: enhanced sedative effects; haloperidol concentration increased.
- **Antivirals**: concentration increased by ritonavir, increased risk of toxicity.
- **Calcium-channel blockers**: concentration increased by diltiazem and verapamil – reduce dose.
- **Grapefruit juice**: concentration increased by grapefruit juice – reduce dose.
- **Methylthioninium**: possible risk of CNS toxicity – avoid if possible.

## Administration

### Reconstitution

- **Route**: Oral

### Rate of administration

- **Other information**

- **Drug Prescribing in Renal Failure, 5th edition** by Aronoff et al. advises no reduction in renal impairment.

- **Peak plasma levels** occur 60–90 minutes after dosing.

- **Steady state plasma concentrations** achieved within 2 days, although response to treatment may take 2 weeks.

- **Non-sedative.**

- **Do not use in patients with severe hepatic disease.**

- **Use in severe renal impairment not recommended; risk of accumulation of active metabolites.**

## References:

Busulfan

Clinical use
- Chronic myeloid leukaemia
- Remission of polycythaemia vera
- Essential thrombocythaemia and myelofibrosis
- Conditioning before bone marrow transplantation

Dose in normal renal function
Oral:
- Chronic myeloid leukaemia: 60 mcg/kg daily (maximum 4 mg daily); maintenance: 0.5–2 mg daily
- Polycythaemia vera: 4–6 mg daily; maintenance: 2–3 mg daily
- Essential thrombocythaemia and myelofibrosis: 2–4 mg daily

IV infusion:
- Conditioning before bone marrow transplantation: 0.8 mg/kg every 6 hours over 4 days for 16 doses

Pharmacokinetics
Molecular weight (daltons) 246.3
% Protein binding 7–32
% Excreted unchanged in urine 1–2
Volume of distribution (L/kg) 0.62–0.85
Half-life — normal/ESRF (hrs) 3 / –

Metabolism
Busulfan is extensively metabolised in the liver, mainly by conjugation with glutathione, either spontaneously or mediated by the enzyme glutathione-S-transferase. About 12 inactive metabolites have been identified, which are excreted in the urine. About 1% of busulfan is excreted unchanged. Elimination in the faeces is considered to be negligible.

Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in normal renal function.
- HD Dialysed. Dose as in normal renal function.
- HDF/High flux Dialysed. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration increased by metronidazole.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Antifungals: metabolism inhibited by itraconazole, monitor for signs of busulfan toxicity.

Administration
Reconstitution
Route
Oral, IV infusion
Rate of administration
Over 2 hours
Comments
- Dilute the solution to 500 mcg/mL with sodium chloride or glucose 5%.
- Give via a central venous catheter.

Other information
- Can cause haemorrhagic cystitis.
- Can cause an increase in creatinine and haematuria.
**Cabazitaxel**

**Clinical use**

Mitotic inhibitor

- Used in combination with prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen

**Dose in normal renal function**

25 mg/m² every 3 weeks

**Pharmacokinetics**

- Molecular weight (daltons) 835.9
- % Protein binding 89–92
- % Excreted unchanged in urine 2.3
- Volume of distribution (L/kg) 4870 Litres
- Half-life — normal/ESRF (hrs) \( \alpha, \beta, \) and \( \gamma \) half-lives of 4 minutes, 2 hours, and 95 hours, respectively.

**Metabolism**

Extensively metabolised in the liver (>95%), mainly by the CYP3A4 isoenzyme (80–90%). Cabazitaxel is the main circulating compound in human plasma. Seven metabolites were detected in plasma (including 3 active metabolites issued from O-demethylations), with the main one accounting for 5% of parent exposure. Excreted as metabolites into the urine (4%) and faeces (76%).

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>15–30</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- HD: Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function. Use with caution.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antibacterials: Avoid with clarithromycin, rifabutin, rifampicin and telithromycin.
- Antidepressants: Avoid with St John’s wort.
- Antiepileptics: Avoid with carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: Avoid with itraconazole, ketoconazole and voriconazole.
- Antipsychotics: Avoid with clozapine (increased risk of agranulocytosis).
- Antivirals: Avoid with atazanavir, indinavir, ritonavir and saquinavir.

**Administration**

**Reconstitution**

Dilute with solvent provided

**Route**

IV infusion

**Rate of administration**

60 minutes

**Comments**

- Dilute in sodium chloride 0.9% or glucose 5% to give a final concentration of 0.1–0.26 mg/mL
- Administer via a 0.22 micron in-line filter.
- PVC containers and polyurethane infusion sets should not be used.

**Other information**

- Premedication should be administered at least 30 minutes prior to each administration.
- Throughout the treatment, adequate hydration of the patient needs to be ensured, in order to prevent renal failure. Serum creatinine should be measured at baseline, with each blood count and whenever the patient reports a change in urine output. Cabazitaxel treatment should be discontinued in case of any reduction in renal function.
- No studies have been done in haemodialysis patients so the company advises to monitor closely and use with caution.
**Clinical use**
- Endocrine disorders
- Adjunct to levodopa (with a decarboxylase inhibitor) in Parkinson's disease
- Inhibition / suppression of lactation

**Dose in normal renal function**
- Parkinson's disease: 1–3 mg daily
- Hyperprolactinaemic disorders: 0.25–2 mg weekly
- Inhibition of lactation: single 1 mg dose during first day post partum
- Suppression of lactation: 0.25 mg twice a day for 2 days

**Pharmacokinetics**
- Molecular weight (daltons) 451.6
- % Protein binding 41–42
- % Excreted unchanged in urine 2–3
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 63–68 (healthy individuals), 79–115 (hyperprolactinaemic individuals) / Unchanged

**Metabolism**
Cabergoline is subject to first-pass metabolism and is extensively metabolised to several metabolites that do not appear to contribute to its pharmacological activity.

Cabergoline is mainly eliminated via the faeces (72%); a small proportion is excreted in the urine (18%).

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Dialysed. Dose as in normal renal function.
- HD Dialysed. Dose as in normal renal function.
- HDF/High flux Dialysed. Dose as in normal renal function.
- CAV/VVHD Dialysed. Dose as in normal renal function.

**Important drug interactions**
- Potentially hazardous interactions with other drugs
  - None known

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
-
**Cabozantinib**

**Clinical use**

Protein kinase inhibitor:
- Treatment of renal cell carcinoma (Cabometyx®)
- Treatment of metastatic medullary thyroid carcinoma (Cometriq®)

**Dose in normal renal function**

- Cabometyx®: 60 mg once daily
- Cometriq®: 140 mg once daily

**Pharmacokinetics**

Molecular weight (daltons) 635.6 (as S-malate)
% Protein binding >99.7
% Excreted unchanged in urine 27
Volume of distribution (L/kg) 319 Litres
Half-life — normal/ESRF (hrs) 99 / Increased

**Metabolism**

Cabozantinib is metabolised mostly by CYP3A4 and, to a minor extent, by CYP2C9. Both enzymes produce an N-oxide metabolite.

Cabozantinib is eliminated mainly by the faeces (54%) and also by the urine (27%).

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function. Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Dose as in normal renal function. Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose as in normal renal function. Use with caution. See 'Other information'.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly increased by clarithromycin and erythromycin; concentration reduced by rifampicin – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone – avoid.
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Not recommended by manufacturer due to lack of data for safety and efficacy in severe renal impairment (eGFR<29 mL/min/1.73 m²).
- Results from a study in patients with renal impairment indicate that the \( C_{\text{max}} \) and \( AUC_{0-\infty} \) were 19% and 30% higher for people with mild renal impairment and 2% and 6–7% for people with moderate renal impairment. Patients with severe renal impairment have not been studied.
- Can cause QT prolongation.
- Can cause proteinuria.
- Tablets (Cabometyx®) and capsules (Cometriq®) are not interchangeable.
- Fatal haemorrhages have been reported.
Calcitonin (salmon) / salcatonin

**Clinical use**
- Hypercalcaemia of malignancy
- Paget’s disease of bone
- Postmenopausal osteoporosis
- Prevention of acute bone loss due to sudden immobility

**Dose in normal renal function**
- Hypercalcaemia of malignancy: 100–400 units every 6–8 hours (SC/IM); in severe or emergency situation, up to 10 units/kg by IV infusion.
- Paget’s disease of bone: 50 units 3 times a week to 100 units daily (SC/IM).
- Prevention of acute bone loss due to sudden immobility: 100 units daily in 1–2 divided doses for 2–4 weeks then reduce to 50 units daily until fully mobile (SC/IM).

**Pharmacokinetics**
- Molecular weight (daltons) 3431.9
- % Protein binding 30–40
- % Excreted unchanged in urine Minimal
- Volume of distribution (L/kg) 9.9 Litres
- Half-life — normal/ESRF (hrs) 50–90 minutes (parenteral); 16–43 minutes (intranasal) / Increased

**Metabolism**
Animal studies have shown that calcitonin is primarily metabolised via proteolysis in the kidney following parenteral administration. The metabolites lack the specific biological activity of calcitonin. Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. Therefore, the metabolic clearance is much lower in patients with ESRD than in healthy subjects. However, the clinical relevance of this finding is not known.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

**Route**
IM, IV, SC

**Rate of administration**
Over at least 6 hours

**Comments**
Dilute in 500 mL sodium chloride 0.9% and administer immediately; dilution may result in a loss of potency.

**Other information**
- Peak plasma concentration occurs 15–25 minutes after parenteral administration.
- Mainly GI side effects.
Calcitriol

Clinical use
Vitamin D analogue:
• Promotes intestinal calcium absorption
• Suppresses PTH production and release

Dose in normal renal function
Orally: 250 nanograms daily or on alternate days, increased if necessary in steps of 250 nanograms at intervals of 2–4 weeks. Usual dose 0.5–1 micrograms daily.

Pharmacokinetics
Molecular weight (daltons) 416.6
% Protein binding 99.9
% Excreted unchanged in urine 7–10
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 9–10 / 18–20

Metabolism
During transport in the blood at physiological concentrations, calcitriol is mostly bound to a specific vitamin D binding protein (DBP), but also, to a lesser degree, to lipoproteins and albumin. At higher blood calcitriol concentrations, DBP appears to become saturated, and increased binding to lipoproteins and albumin occurs.
Calcitriol is inactivated in both the kidney and the intestine, through the formation of a number of intermediates including the formation of the 1,24,25-trihydroxy derivatives. It is excreted in the bile and faeces and is subject to enterohepatic circulation.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Titrate to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Titrate to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Titrate to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Antiepileptics: the effects of vitamin D may be reduced in patients taking barbiturates or anticonvulsants.
• Diuretics: increased risk of hypercalcaemia with thiazides.
• Sevelamer: absorption may be impaired by sevelamer

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• IV preparation available from IDIS.
• Check plasma calcium concentrations at regular intervals (initially weekly).
• Dose of phosphate-binding agent may need to be modified as phosphate transport in the gut and bone may be affected.
• Hypercalcaemia and hypercalciuria are the major side effects, and indicate excessive dosage.
## Calcium acetate

### Clinical use
Phosphate binding agent

### Dose in normal renal function
1–4 tablets, 3 times daily

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>158.2</td>
</tr>
<tr>
<td>Protein binding</td>
<td>—</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>—</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>—</td>
</tr>
<tr>
<td>Half-life — normal ESRF (hrs)</td>
<td>—</td>
</tr>
</tbody>
</table>

### Metabolism
The residual acetate will be metabolised through bicarbonate, which will be further excreted via normal metabolic routes.

Any unbound calcium not involved in the binding of phosphate will be variable and may be absorbed.

Calcium is absorbed mainly from the small intestine by active transport and passive diffusion. About one-third of ingested calcium is absorbed although this can vary depending upon dietary factors and the state of the small intestine. 1,25-Dihydroxycholecalciferol (calcitriol), a metabolite of vitamin D, enhances the active phase of absorption.

Excess calcium is mainly excreted renally. Unabsorbed calcium is eliminated in the faeces, together with that secreted in the bile and pancreatic juice. Minor amounts are lost in the sweat, skin, hair, and nails.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Titrate to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Titrate to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Titrate to response.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Can impair absorption of some drugs, e.g. iron, ciprofloxacin.

### Administration

#### Reconstitution
—

#### Route
Oral

#### Rate of administration
—

#### Comments
Take tablets with meals.

### Other information
- Phosex: calcium content per tablet = 250 mg (6.2 mmol).
- PhosLo: calcium content per tablet = 169 mg (4.2 mmol).
- Renacet: calcium content per tablet = 120.25 mg (3 mmol) and 240.5 (6 mmol).
Calcium carbonate

Clinical use
- Phosphate binding agent
- Calcium supplement

Dose in normal renal function
Dose adjusted according to serum phosphate and calcium levels.

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>100.1</td>
</tr>
<tr>
<td>Protein binding %</td>
<td>40</td>
</tr>
<tr>
<td>Excreted unchanged in urine %</td>
<td>—</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>—</td>
</tr>
<tr>
<td>Half-life — normal ESRF (hrs)</td>
<td>—</td>
</tr>
</tbody>
</table>

Metabolism
Under the influence of gastric acid, any residual carbonate will be converted to carbon dioxide and water.
Any unbound calcium not involved in the binding of phosphate will be variable and may be absorbed.
Calcium is absorbed mainly from the small intestine by active transport and passive diffusion. About one-third of ingested calcium is absorbed although this can vary depending upon dietary factors and the state of the small intestine. 1,25-Dihydroxycholecalciferol (calcitriol), a metabolite of vitamin D, enhances the active phase of absorption.
Excess calcium is mainly excreted renally. Unabsorbed calcium is eliminated in the faeces, together with that secreted in the bile and pancreatic juice. Minor amounts are lost in the sweat, skin, hair, and nails.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Titrated to response.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Titrated to response.</td>
<td></td>
</tr>
<tr>
<td>&lt; 10</td>
<td>Dose as in normal renal function. Titrated to response.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Can impair absorption of some drugs, e.g. iron, ciprofloxacin.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Comments
Take with or immediately before meals.

Other information

- Monitor for hypercalcaemia particularly if patient is also taking alfacalcidol.
- Calcichew contains 1250 mg calcium carbonate (500 mg elemental calcium).
- Calcium 500 contains 1250 mg calcium carbonate (500 mg elemental calcium).
- Cacit contains 1250 mg calcium carbonate (500 mg elemental calcium).
- Adcal contains 1500 mg calcium carbonate (600 mg elemental calcium).
Calcium gluconate

Clinical use

Hypocalcaemia

Dose in normal renal function

- Depending on indication
- Acute hypocalcaemia: 10–20 mL calcium gluconate 10% (2.25–4.5 mmol calcium) slow IV injection over 3–10 minutes.
- Oral: Dose varies depending on requirements.

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>448.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>—</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>—</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>—</td>
</tr>
<tr>
<td>Half-life — normal ESRF (hrs)</td>
<td>—</td>
</tr>
</tbody>
</table>

Metabolism

Calcium is absorbed mainly from the small intestine by active transport and passive diffusion. About one-third of ingested calcium is absorbed although this can vary depending upon dietary factors and the state of the small intestine. 1,25-Dihydroxycholecalciferol (calcitriol), a metabolite of vitamin D, enhances the active phase of absorption.

Excess calcium is mainly excreted renally. Unabsorbed calcium is eliminated in the faeces, together with that secreted in the bile and pancreatic juice. Minor amounts are lost in the sweat, skin, hair, and nails.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Titrate to response</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Titrate to response.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Titrate to response.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Titrate to response.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Can impair absorption of some drugs, e.g. iron, ciprofloxacin.

Administration

Reconstitution

Route
Oral, IV, IM

Rate of administration
IV: slow 3–4 minutes for each 10 mL (2.25 mmol calcium); not greater than 20 mmol/hour for continuous infusions

Comments
- Can be added to glucose 5% or sodium chloride 0.9%
- IV: Can be used undiluted for continuous and intermittent infusions (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006).

Other information

- Check patient’s magnesium levels.
- Monitor calcium and PO₄ serum levels.
- Sandocal 1000: 25 mmol calcium per tablet
- Calcium Sandoz syrup: 2.7 mmol/5 mL.
- Calcium levels cannot be corrected until magnesium levels are normal.
Calcium resonium

**Clinical use**
Hyperkalaemia (not for emergency treatment)

**Dose in normal renal function**
- Oral: 15 g 3–4 times daily in water
- PR: 30 g in methylcellulose solution retained for 9 hours

**Pharmacokinetics**
- Molecular weight (daltons) —
- % Protein binding —
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) —
- Half-life — normal ESRF (hrs) —

**Metabolism**
Not applicable as calcium resonium is not systemically absorbed.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Titrade to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Titrade to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Titrade to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known.

**Administration**

**Reconstitution**
PR: Mix with methylcellulose solution 2%.
Oral: Mix with a little water, sweetened if preferred.

**Route**
Oral, PR

**Rate of administration**
—

**Other information**
- Ensure a regular laxative is prescribed – can mix calcium resonium powder with lactulose to be taken orally.
- Some units mix dose with a little water and give PR 4 times/day. Not retained for so long, but still effective.
Canagliflozin

**Clinical use**
Sodium-glucose co-transporter 2 inhibitor:
- Treatment of type 2 diabetes

**Dose in normal renal function**
100–300 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons): 453.5 (as hemihydrate)
- % Protein binding: 99
- % Excreted unchanged in urine: <1
- Volume of distribution (L/kg): 85 Litres
- Half-life — normal/ESRF (hrs): 8.5–12.7 (100 mg), 9.8–16.3 (300 mg)

**Metabolism**
O-glucuronidation is the major metabolic elimination pathway mainly by UGT1A9 and UGT2B4 to two inactive metabolites. CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans.

**Dose in renal impairment GFR (mL/min)**
- >60: Dose as in normal renal function.
- 45–60: See 'Other information'.
- <45: Avoid.

**Dose in patients undergoing renal replacement therapies**

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin.
- Lipid-regulating drugs: avoid canagliflozin for 1 hour before or 4–6 hours after bile acid sequestrants.

**Administration**

**Reconstitution**
- Route
  - Oral

**Rate of administration**
- 

**Other information**
- Do not initiate therapy if eGFR<60 mL/min/1.73 m² but if already on it and tolerating it then reduce dose to 100 mg daily. Avoid if eGFR<45 mL/min/1.73 m². Manufacturer does not expect it to be effective in ESRD.
- Oral bioavailability is 65%.
- A single-dose, open-label study evaluated the pharmacokinetics of canagliflozin 200 mg in subjects with varying degrees of renal impairment (classified using CRCL based on the Cockroft-Gault equation) compared to healthy subjects. The study included 8 subjects with CRCL≥80 mL/min, 8 subjects with CRCL=50–80 mL/min (mild), 8 subjects with CRCL=30–50 mL/min (moderate), and 8 subjects with CRCL<30 mL/min (severe) as well as 8 subjects on haemodialysis. The C_max of canagliflozin was increased by 13%, 29%, and 29% in subjects with mild, moderate, and severe renal failure, respectively, but not in subjects on haemodialysis. Compared to healthy subjects, plasma AUC of canagliflozin was increased by approximately 17%, 63%, and 50% in subjects with mild, moderate, and severe renal impairment, respectively, but was similar for ESRD subjects and healthy subjects.
Candesartan cilexetil

**Clinical use**

Angiotensin-II antagonist:
- Hypertension
- Heart failure

**Dose in normal renal function**

2–32 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>610.7</td>
</tr>
<tr>
<td>% Protein binding &lt;=99</td>
<td></td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>26</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>9 / 18</td>
</tr>
</tbody>
</table>

**Metabolism**

Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9).

The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. Following an oral dose of 14C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Initial dose 2 mg and increase according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initial dose 2 mg and increase according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia hypotension and renal impairment with ACE-Is and aliskiren.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Lithium: reduced excretion, possibility of enhanced lithium toxicity.
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - In patients with mild–moderate renal impairment $C_{\text{max}}$ and AUC are increased by 50% and 70% respectively. Corresponding changes in patients with severe renal impairment are 50% and 110% respectively.
  - Adverse reactions, especially hyperkalaemia are more common in patients with renal impairment.
  - Renal failure has been reported in association with angiotensin-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with congestive heart failure.
  - Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
**Cangrelor**

**Clinical use**

Direct P2Y₁₂ platelet receptor antagonist:  
- Antiplatelet for patients undergoing a PCI

**Dose in normal renal function**

30 mcg/kg bolus followed by 4 mcg/kg/min IV infusion

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>776.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97–98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>58</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3.9 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–6 minutes / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Cangrelor is deactivated rapidly in the plasma by dephosphorylation to form its main metabolite, a nucleoside. Following a 2 micrograms/kg/min infusion of [³H] cangrelor, 58% was found in urine and the remaining 35% was found in faeces, presumably following biliary excretion.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:  
- None known

**Administration**

**Reconstitution**  
5 mL water for injection per 50 mg vial

**Route**  
IV bolus and infusion

**Rate of administration**  
Bolus: <1 minute, Infusion: 4 mcg/kg/min

**Comments**  
After reconstitution add to 250 mL sodium chloride 0.9% or glucose 5%

**Other information**

- Platelet function is restored within 60 minutes of stopping infusion.
- In pivotal studies conducted in patients undergoing PCI, events of acute renal failure (0.1%), renal failure (0.1%) and increased serum creatinine (0.2%) were reported to occur after administration of cangrelor in clinical trials. In patients with severe renal impairment (creatinine clearance 15–30 mL/min) a higher rate of worsening in renal function (3.2%) was reported in the cangrelor group compared to clopidogrel (1.4%). In addition, a higher rate of GUSTO moderate bleeding was reported in the cangrelor group (6.7%) compared to clopidogrel (1.4%). Cangrelor should be used with caution in these patients.
Capecitabine

Clinical use
Antineoplastic agent (antimetabolite):
- Colorectal, colon, advanced gastric and breast cancer

Dose in normal renal function
- Monotherapy, also combination therapy in breast cancer: 1.25 g/m² twice daily for 14 days, repeated after 7 days
- Combination therapy for colon, rectal or gastric cancer: 800–1000 mg/m² twice daily for 14 days, repeated after 7 days
- Or 625 mg/m² twice daily continuously

Pharmacokinetics
Molecular weight (daltons) 359.4
% Protein binding 54
% Excreted unchanged in urine 3
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 0.85 / Increased

Metabolism
Capecitabine is a prodrug. It is hydrolysed in the liver to 5′-deoxy-5-fluorocytidine (5′-DFCR), which is then converted to 5′-deoxy-5-fluorouridine (5′-DFUR) and subsequently to the active 5-fluorouracil in body tissues, via the enzyme thymidine phosphorylase. 5-Fluorouracil is further metabolised to 5-fluorouridine monophosphate and 5-fluorodeoxyuridine monophosphate. About 15% of 5-fluorouracil is excreted unchanged in the urine within 6 hours. The remainder is inactivated mainly in the liver and is catabolised via dihydropyrimidine dehydrogenase. A large amount is excreted as respiratory carbon dioxide; urea and other metabolites are also produced. About 3% of a dose of capecitabine is excreted in the urine unchanged.

Dose in renal impairment GFR (mL/min)
30–50 75% of 1.2g/m² dose (950 mg/m² twice daily). Use with care.
10–30 Avoid.
<10 Avoid.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Allopurinol: avoid concomitant use.
- Anticoagulants: possibly enhances effect of coumarins.
- Antiepileptics: reported toxicity with fosphenytoin and phenytoin, due to increased phenytoin levels.
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.
- Folic acid: toxicity of capecitabine increased – avoid.

Administration
Reconstitution —
Route Oral
Rate of administration —
Comments Give after food.

Other information
- Contraindicated in severe renal impairment due to increased incidence of grade 3 or 4 adverse reactions in patients with a GFR of 30–50 mL/min.
Capreomycin

Clinical use
Antibacterial agent in combination with other drugs:
• Tuberculosis that is resistant to first-line drugs

Dose in normal renal function
Deep IM injection: 1 g daily (not more than 20 mg/kg) for 2–4 months, then 1 g 2–3 times each week

Pharmacokinetics
Molecular weight (daltons) 668.7
% Protein binding No data
% Excreted unchanged in urine 50
Volume of distribution (L/kg) 0.37–0.42
Half-life — normal/ESRF (hrs) 2 / 55.5

Metabolism
Approximately 50% of a dose is excreted unchanged in the urine by glomerular filtration within 12 hours.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>1 g every 48 hours.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs

• Increased risk of nephrotoxicity and ototoxicity with aminoglycosides and vancomycin.

Administration

Reconstitution
Dissolve in 2 mL of sodium chloride 0.9% or water for injection. 2–3 minutes should be allowed for complete dissolution.

Route
Deep IM injection

Rate of administration
—

Other information

• Nephrotoxic.
• Check potassium levels as hypokalaemia may occur.
• Desired steady state serum capreomycin level is 10 micrograms/mL.
• Dose should not exceed 1 g/day in renal failure.
• Doses in renal impairment from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
• Capreomycin sulphate 1 000 000 Units is approximately equivalent to capreomycin base 1 g.

Manufacturer has a table based on mg/kg:

<table>
<thead>
<tr>
<th>Creatinine Clearance (mL/min)</th>
<th>Dose for these dosing intervals (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24h</td>
</tr>
<tr>
<td>24h</td>
<td>1.29</td>
</tr>
<tr>
<td>72h</td>
<td>2.43</td>
</tr>
<tr>
<td>10</td>
<td>3.58</td>
</tr>
<tr>
<td>14</td>
<td>4.72</td>
</tr>
<tr>
<td>20</td>
<td>5.87</td>
</tr>
<tr>
<td>30</td>
<td>7.01</td>
</tr>
<tr>
<td>40</td>
<td>8.16</td>
</tr>
<tr>
<td>50</td>
<td>10.40</td>
</tr>
<tr>
<td>60</td>
<td>12.70</td>
</tr>
<tr>
<td>80</td>
<td>13.90</td>
</tr>
<tr>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>
Captopril

Clinical use

Angiotensin-converting enzyme inhibitor:
- Hypertension
- Heart failure
- Post myocardial infarction
- Diabetic nephropathy

Dose in normal renal function

6.25–50 mg 2–3 times daily
Diabetic nephropathy: 75–100 mg daily in divided doses

Pharmacokinetics

Molecular weight (daltons) 217.3
% Protein binding 25–30
% Excreted unchanged in urine 40–50
Volume of distribution (L/kg) 2
Half-life — normal/ESRF (hrs) 2–3 / 21–32

Metabolism

About half the absorbed dose of captopril is rapidly metabolised, mainly to captopril-cysteine disulfide and the disulfide dimer of captopril. In vitro studies suggest that captopril and its metabolites may undergo reversible interconversions. It has been suggested that the drug may be more extensively metabolised in patients with renal impairment than in patients with normal renal function. Captopril and its metabolites are excreted in urine. Renal excretion of unchanged captopril occurs principally via tubular secretion. In patients with normal renal function, more than 95% of an absorbed dose is excreted in urine in 24 hours; about 40–50% of the drug excreted in urine is unchanged captopril and the remainder is mainly the disulfide dimer of captopril and captopril-cysteine disulfide. In one study in healthy individuals, about 20% of a single dose of captopril was recovered in faeces in 5 days, apparently representing unabsorbed drug.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Start low – adjust according to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Start low – adjust according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start low – adjust according to response.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
- Bee venom extract: possible severe anaphylactoid reactions when used together.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of angioedema with everolimus.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Gold: flushing and hypotension with sodium aurothiomalate.
- Lithium: reduced excretion, possibility of enhanced lithium toxicity.
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Administration

Reconstitution
- Route
  Oral
  Rate of administration
  - Comments
    Tablets may be dispersed in water.
**Other information**

- Adverse reactions, especially hyperkalaemia, are more common in patients with renal impairment.
- Effective sub-lingually in emergencies.
- As renal function declines a hepatic elimination route for captopril becomes increasingly more significant.
- Renal failure has been reported in association with ACE inhibitors in patients with renal artery stenosis, post renal transplant, or in those with congestive heart failure.
- A high incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor – this combination should therefore be avoided.
- Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
Carbamazepine

Clinical use

- All forms of epilepsy except absence seizures
- Trigeminal neuralgia
- Prophylaxis in manic depressive illness
- Unlicensed: alcohol withdrawal and diabetic neuropathy

Dose in normal renal function

- Epilepsy: initially 100–200 mg 1–2 times daily, increased to maintenance of 0.4–1.2 g daily in divided doses; maximum 1.6–2 g daily.
- Rectal: maximum 1 g daily in 4 divided doses for up to 7 days use.
- Trigeminal neuralgia: Initially 100 mg 1–2 times daily; usual dose 200 mg 3–4 times daily; maximum 1.6 g/day; reduce dose gradually as pain goes into remission.
- Prophylaxis in manic-depressive illness: 400–600 mg daily in divided doses, maximum 1.6 g/day.
- Alcohol withdrawal: 800 mg daily in divided doses reducing to 200 mg daily over 5 days.
- Diabetic neuropathy: 100 mg 1-2 times daily increasing according to response, usual dose 200 mg 3-4 times daily, max 1.6 g daily.

Pharmacokinetics

Molecular weight (daltons) 236.3
% Protein binding 70–80
% Excreted unchanged in urine 2
Volume of distribution (L/kg) 0.8–1.9
Half-life — normal/ESRF (hrs) 5–26 / Unchanged

Metabolism

Carbamazepine is metabolised in the liver by cytochrome P450 3A4, where the epoxide pathway of biotransformation yields the 10, 11-transdiall derivative and its glucuronide as the main metabolites. 9-Hydroxy-methyl-10-carbamoyl acridan is a minor metabolite related to this pathway. Other important biotransformation pathways for carbamazepine lead to various monohydroxylated compounds, as well as to the N-glucuronide of carbamazepine produced by UGT2B7. After administration of a single oral dose of 400 mg carbamazepine, 72% is excreted in the urine and 28% in the faeces. In the urine, about 2% of the dose is recovered as unchanged drug and about 1% as the pharmacologically active 10,11-epoxide metabolite.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs

- Analgesics: effect enhanced by dextropropoxyphene; decreased effect of fentanyl, tramadol and methadone; possibly increases paracetamol metabolism, also reports of hepatotoxicity.
- Anthelmintics: concentration of albendazole and praziquantel reduced – consider increasing dose for systemic infections.
- Anti-arrhythmics: possibly reduces dronedarone concentration – avoid.
- Antibacterials: reduced effect of doxycycline; concentration increased by clarithromycin, erythromycin and isoniazid; increased risk of isoniazid hepatotoxicity; possibly reduces bedaquiline concentration – avoid; avoid with delamanid; concentration reduced by rifabutin; concentration of telithromycin reduced – avoid.
- Anti-coagulants: metabolism of coumarins accelerated (reduced anticoagulant effect); concentration of apixaban and dabigatran possibly reduced – avoid; concentration of edoxaban possibly reduced; concentration of rivaroxaban possibly reduced – monitor for signs of thrombosis.
- Antidepressants: antagonism of anticonvulsant effect; concentration increased by fluoxetine and fluvoxamine; concentration of mianserin, mirtazapine, paroxetine, reboxetine, trazodone, tricyclics and vortioxetine reduced; avoid with MAOIs; concentration reduced by St John’s wort – avoid.
- Antiepileptics: concentration of eslicarbazepine possibly reduced but risk of side effects increased; concentration of ethosuximide, retigabine, topiramate
Carbamazepine

and valproate possibly reduced, concentration of active carbamazepine metabolite increased by valproate; concentration of lamotrigine, perampanel, tiagabine and zonisamide reduced; concentration of phenobarbital and primidone increased; increased risk of carbamazepine toxicity with levetiracetam; concentration sometimes reduced by oxcarbazepine but active metabolite of carbamazepine may be increased and oxcarbazepine metabolite reduced; concentration of both drugs reduced with fosphenytoin, phenytoin and rufinamide, fosphenytoin and phenytoin concentration may also be increased; concentration increased by stripentol.

• Antifungals: concentration possibly increased by fluconazole, ketoconazole and miconazole; concentration of itraconazole, isavuconazole, caspofungin, ketoconazole, posaconazole and voriconazole possibly reduced, avoid with isavuconazole and voriconazole; consider increasing caspofungin dose.

• Antimarialars: avoid with piperaquine with arteminol; chloroquine, hydroxychloroquine and mefloquine antagonise anticonvulsant effect.

• Antipsychotics: antagonism of anticonvulsant effect; reduced concentration of aripiprazole (avoid or increase aripiprazole dose), haloperidol, clozapine, lurasidone (avoid), olanzapine, paliperidone, quetiapine and risperidone; avoid concomitant use with other drugs that can cause agranulocytosis.

• Antivirals: concentration of boceprevir, daclatasvir, dasabuvir, ombitasvir, paritaprevir, rilpivirine and simeprevir reduced – avoid; possibly reduced concentration of darunavir, dolutegravir, fosamprenavir, indinavir, lopinavir, nevirapine, saquinavir and tipranavir; concentration possibly increased by indinavir and ritonavir; concentration of both drugs reduced in combination with efavirenz; avoid with elvitegravir, etravirine, ledipasvir, sofosbuvir and telaprevir.

• Apremilast: possibly reduces apremilast concentration – avoid.

• Calcium-channel blockers: effects enhanced by diltiazem and verapamil; reduced effect of felodipine, isradipine and probably dihydropyridines, nicardipine, nifedipine and nimodipine – avoid with nimodipine.

• Cannabis extract: possibly reduces cannabis extract concentration – avoid.

• Ciclosporin: metabolism accelerated (reduced ciclosporin concentration).

• Clopidogrel: possibly reduced antiplatelet effect.

• Cobicistat: possibly reduces cobicistat concentration – avoid.

• Corticosteroids: reduced effect of corticosteroids.

• Cytotoxics: possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of bortezomib, bosutinib, ceritinib, crizotinib, dasatinib, ibrutinib, idelalisib, imatinib, lapatinib, ponatinib, vandetanib and vismodegib and possibly cabozantinib – avoid; avoid with cabazitaxel, dabrafenib, gefitinib, olaparib, panobinostat and vemurafenib; concentration of irinotecan and its active metabolite and possibly eribulin reduced; increased risk of sensitivity reactions with procarbazine.

• Diuretics: increased risk of hyponatraemia; concentration increased by acetazolamide; reduced eplerenone concentration – avoid.

• Fesoterodine: concentration of active metabolite of fesoterodine reduced – avoid.

• Guanfacine: possibly reduces guanfacine concentration – increase guanfacine dose.

• Hormone antagonists: possibly reduces abiraterone concentration – avoid; metabolism inhibited by danazol; possibly accelerated metabolism of toremifene.

• Ivacaftor: possibly reduces ivacaftor concentration – avoid.

• Lipid-regulating drugs: concentration of simvastatin reduced.

• Naloxegol: possibly reduces naloxegol concentration – avoid.

• Oestrogens and progestogens: reduced contraceptive effect.

• Orlistat: possibly increased risk of convulsions.

• Ulcer-healing drugs: concentration increased by cimetidine.

• Ulipristal: contraceptive effect possibly reduced – avoid.

Administration

Reconstitution

Route

Oral, rectal

Rate of administration

Comments

• When switching a patient from tablets to liquid the same total dose may be used, but given in smaller more frequent doses.

• 125 mg suppository is equivalent 100 mg of tablets.

Other information

• Important to initiate carbamazepine therapy at a low dose and build this up over 1–2 weeks, as it autoinduces its metabolism.

• May cause inappropriate antidiuretic hormone secretion.

• Therapeutic plasma concentration range: 4–12 micrograms/mL (20–50 micromol/L at steady state).
Carbimazole

Clinical use
Treatment of hyperthyroidism

Dose in normal renal function
5–60 mg daily

Pharmacokinetics
Molecular weight (daltons) 186.2
% Protein binding Unbound (methimazole is 5%)
% Excreted unchanged in urine <12 (methimazole)
Volume of distribution (L/kg) 0.5 (methimazole)
Half-life — normal/ESRF (hrs) 3–6.4 (methimazole) / Increased

Metabolism
Carbimazole is rapidly metabolised to thiamazole, which is concentrated in the thyroid gland. Over 90% of orally administered carbimazole is excreted in the urine as thiamazole or its metabolites. The remainder appears in faeces. There is 10% enterohepatic circulation. Thiamazole is metabolised, probably by the liver, and excreted in the urine. Less than 12% of a dose of thiamazole may be excreted as unchanged drug.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution —
Route Oral
Rate of administration —

Other information
• There have been reports of glomerulonephritis associated with the development of antineutrophil cytoplasmic antibodies in patients receiving thiourea anti-thyroid drugs.
Carboplatin

Clinical use
Antineoplastic platinum agent:
- Ovarian carcinoma of epithelial origin
- Small cell carcinoma of the lung

Dose in normal renal function
400 mg/m²
Or dose = Target AUC x \([GFR \text{ (mL/min) } + 25]\) where AUC is commonly 5 or 7 depending on protocol used (Calvert equation)

Pharmacokinetics
- Molecular weight (daltons): 371.2
- % Protein binding: 29–89
- % Excreted unchanged in urine: 32–70
- Volume of distribution (L/kg): 0.23–0.28
- Half-life — normal/ESRF (hrs): 1.5–6 / Increased

Metabolism
There is little, if any, true metabolism of carboplatin. Excretion is primarily by glomerular filtration in the urine, with 70% of the drug excreted within 24 hours, most of it in the first 6 hours. Approximately 32% of the dose is excreted unchanged. Platinum from carboplatin slowly becomes protein bound, and is subsequently excreted with a terminal half-life of 5 days or more.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function. See 'Other information'.
- 10–20: Dose as in normal renal function. See 'Other information'.
- <10: Dose as in normal renal function. See 'Other information'.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of nephrotoxicity and possibly ototoxicity with aminoglycosides, capreomycin, polymyxins or vancomycin.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

Administration
Reconstitution
- Route: IV
- Rate of administration: IV infusion over 15–60 minutes.

Comments
- Therapy should not be repeated until 4 weeks after the previous carboplatin course.
- May be diluted with glucose 5%, or sodium chloride 0.9% to concentrations as low as 0.5 mg/mL.

Other information
- Patients with abnormal kidney function or receiving concomitant therapy with nephrotoxic drugs are likely to experience more severe and prolonged myelotoxicity.
- Blood counts and renal function should be monitored closely.
- Contraindicated by manufacturer if GFR<20 mL/min.
- Drug Prescribing in Renal Failure, 5th edition by Aronoff et al. recommend 50% of dose if GFR=10–50 mL/min and 25% of dose if GFR<10 mL/min.
- Some units still use a dose in normal renal function of 400 mg/m². In this instance, the dose should be reduced to 50% of normal dose for a GFR of 10–20 mL/min, and to 25% of normal dose for a GFR<10 mL/min.
Carfilzomib

**Clinical use**

Tetrapeptide epoxyketone proteasome inhibitor:
- Treatment of multiple myeloma

**Dose in normal renal function**

20–56 mg/m² as per product literature or local guidelines

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>719.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>25 (as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>28 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>&lt;1 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Carfilzomib was rapidly and extensively metabolised by mainly peptidase cleavage and epoxide hydrolysis. Cytochrome P450 mediated mechanisms played a minor role in overall carfilzomib metabolism. The metabolites have no known biologic activity.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.

**Administration**

**Reconstitution**

29 mL water for injection per vial

**Route**

IV infusion

**Rate of administration**

20–27 mg/m²: over 10 minutes; 20–56 mg/m²: over 30 minutes

**Comments**

Can be further added to 50–100ml glucose 5% if required

**Other information**

- No studies have been done in moderate to severe renal impairment.
- In phase 3 clinical studies the incidence of adverse events of AKI was higher in subjects with lower baseline creatinine clearance than that among subjects with higher baseline creatinine clearance.
- Renal function should be monitored at least monthly or in accordance with accepted clinical practice guidelines, particularly in patients with lower baseline creatinine clearance.
- Antiviral prophylaxis should be considered in patients being treated with carfilzomib to decrease the risk of herpes zoster reactivation.
- Thromboprophylaxis is also recommended.
- Contains 0.3 mmols (7 mg) of sodium.
Carmustine

Clinical use
Alkylation agent:
• Myeloma, lymphoma and brain tumours

Dose in normal renal function
• 150–200 mg/m² as a single dose or 75–100 mg/m² on 2 consecutive days every 6 weeks
• Implants: 7.7 mg, maximum 8 implants

Pharmacokinetics
Molecular weight (daltons) 214.1
% Protein binding 77
% Excreted unchanged in urine 60–70
Volume of distribution (L/kg) 3.25
Half-life — normal/ESRF (hrs) 22 minutes / –

Metabolism
Intravenous carmustine is rapidly metabolised, and no intact drug is detectable after 15 minutes. It is partially metabolised to active metabolites by liver microsomal enzymes, which have a long half-life. It is thought that the antineoplastic activity may be due to metabolites.
Approximately 30% of a dose is excreted in the urine after 24 hours, and 60–70% of the total dose after 96 hours.
About 10% is excreted as respiratory CO₂. Terminal half-life of the metabolites is about 1 hour.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Implant: Dose as in normal renal function. IV: 80% of dose.</th>
<th>Implant: Dose as in normal renal function. IV: 75% of dose.</th>
<th>Implant: Dose as in normal renal function. IV: Avoid.</th>
</tr>
</thead>
<tbody>
<tr>
<td>45–60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR &lt; 30 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR &lt; 30 mL/min. See 'Other information'.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR &lt; 30 mL/min. See 'Other information'.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR = 30–45 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).

Administration
Reconstitution
3 mL of the supplied diluent (absolute ethanol) then add 27 mL of sterile water for injection.

Route
IV

Rate of administration
Administer by IV drip over a period of 1–2 hours.

Comments
• Therapy should not be repeated before 6 weeks.
• Can further dilute the reconstituted solution with 500 mL of sodium chloride 0.9% or glucose 5%.

Other information
• Renal abnormalities, e.g. a decrease in kidney size: progressive azotaemia and renal failure have been reported in patients receiving large cumulative doses after prolonged therapy.
• Carmustine has been used at normal dose in a haemodialysis patient without any problems.

References:
Carvedilol

**Clinical use**

Beta-adrenoceptor blocker with alpha<sub>1</sub>-blocking action:
- Hypertension
- Angina
- Heart failure

**Dose in normal renal function**

- Hypertension: 12.5–50 mg daily in single or divided doses
- Angina: 12.5–25 mg twice daily
- Heart failure: 3.125–25 mg twice daily (50 mg twice daily if wt>85 kg)

**Pharmacokinetics**

Molecular weight (daltons) 406.5
% Protein binding > 98
% Excreted unchanged in urine < 2
Volume of distribution (L/kg) 2
Half-life — normal/ESRF (hrs) 6–10 / Unchanged

**Metabolism**

Carvedilol is subject to considerable first-pass metabolism in the liver; the absolute bioavailability is about 25%. It is extensively metabolised in the liver, primarily by the cytochrome P450 isoenzymes CYP2D6 and CYP2C9, and the metabolites are excreted mainly in the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely dialysability. Dose as in normal renal function. Start with low doses and titrate according to response.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function. Start with low doses and titrate according to response.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function. Start with low doses and titrate according to response.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely dialysability. Dose as in normal renal function. Start with low doses and titrate according to response.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antibacterials: concentration reduced by rifampicin.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Ciclosporin: increased trough concentration, reduce dose by 20% in affected patients.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

**Administration**

**Reconstitution**

---

**Route**

Oral

**Rate of administration**

---
**Clinical use**

- Invasive aspergillosis in adult patients who are refractory to or intolerant of amphotericin B and/or itraconazole
- Invasive candidiasis

**Dose in normal renal function**

- 70 mg loading dose on day 1 followed by 50 mg daily, thereafter
- If patient weighs >80 kg use 70 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1213.4 (as acetate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>1.4</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12–15 days / Increased but not significantly. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Metabolism**

Plasma concentrations of caspofungin decline in a polyphasic manner after intravenous infusion. The initial short $\alpha$-phase occurs immediately post-infusion and is followed by a $\beta$-phase with a half-life of 9–11 hours; an additional longer $\gamma$-phase also occurs with a half-life of 40–50 hours. Plasma clearance is dependent on distribution rather than on biotransformation or excretion. Caspofungin undergoes spontaneous degradation to an open ring compound. There is further slow metabolism of caspofungin by hydrolysis and $N$-acetylation and excretion in faeces and urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Ciclosporin: monitor liver enzymes as transient increases in ALT and AST have been reported with concomitant administration. Avoid co-administration if possible. Increases AUC of caspofungin by 35%.
- Tacrolimus: reduces tacrolimus trough concentration by 26%.

**Administration**

**Reconstitution**

10.5 mL water for injection

**Route**

IV infusion

**Rate of administration**

Approximately 1 hour

**Comments**

- Caspofungin is unstable in fluids containing glucose; add to 250 mL sodium chloride 0.9% or lactated Ringer’s solution.
- If patient is fluid restricted, doses of 35 or 50 mg may be added to 100 mL infusion fluid.

**Other information**

- In established renal failure the AUC is increased by 30–49% but a change in dosage schedule is not required.
- Caspofungin has been used at a dose of 50 mg daily in combination with IV amphotericin B to successfully treat fungal peritonitis in 1 case study; the catheter was removed. (Fourtounas C, Marangos M, Kalliakmanis P, et al. Treatment of peritoneal dialysis related fungal peritonitis with caspofungin plus amphotericin B combination therapy. *Nephrol Dial Transplant.* 2006; 21(1): 236–7.)
**Cefaclor**

### Clinical use
Antibacterial agent

### Dose in normal renal function
250 mg every 8 hours (dose may be doubled for more severe infections – maximum 4 g daily)

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>385.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>25</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>60–85</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.24–0.35</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.5–0.9 / 2.3–2.8</td>
</tr>
</tbody>
</table>

### Metabolism
Cefaclor is rapidly excreted by the kidneys; up to 85% of a dose appears unchanged in the urine within 8 hours, the greater part within 2 hours. Probenecid delays excretion.

### Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD** Dialysed. 250–500 mg every 8 hours.
- **HD** Dialysed. 250–500 mg every 6–8 hours.
- **HDF/High flux** Dialysed. 250–500 mg every 6–8 hours.
- **CAV/VVHD** Dialysed. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

### Administration
Reconstitution
- Route
- Oral
- Rate of administration
- 

### Other information
- Cefaclor is associated with protracted skin reactions.
Cefadroxil

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

500 mg – 1 g every 12–24 hours

**Pharmacokinetics**

Molecular weight (daltons) 381.4

% Protein binding 20

% Excreted unchanged in urine >90

Volume of distribution (L/kg) 0.31

Half-life — normal/ESRF (hrs) 1.3–2 / 22

**Metabolism**

More than 90% of a dose of cefadroxil may be excreted unchanged in the urine within 24 hours by glomerular filtration and tubular secretion.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>25–50</td>
<td>1 g stat then 500–1000 mg every 12 hours.</td>
</tr>
<tr>
<td>10–25</td>
<td>1 g stat then 500–1000 mg every 24 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>1 g stat then 500–1000 mg every 36 hours.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–25 mL/min. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anticoagulants: effects of coumarins may be enhanced.

**Administration**

Reconstitution

Route

Oral

Rate of administration

—

**Other information**

- 63% of a 1 g dose is removed after 6–8 hours of haemodialysis.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid 'flux' within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Cefalexin

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

- 250 mg every 6 hours or 500 mg every 8–12 hours; maximum 6 g daily
- Recurrent UTI prophylaxis: 125 mg at night

**Pharmacokinetics**

- Molecular weight (daltons): 365.4
- % Protein binding: 15
- % Excreted unchanged in urine: 80–90
- Volume of distribution (L/kg): 0.35
- Half-life — normal/ESRF (hrs): 1 / 16

**Metabolism**

Cefalexin is not metabolised. About 80% or more of a dose is excreted unchanged in the urine in the first 6 hours by glomerular filtration and tubular secretion. Probenecid delays urinary excretion. Therapeutically effective concentrations may be found in the bile and some may be excreted by this route.

**Dose in renal impairment GFR (mL/min)**

- 40–50: Dose as in normal renal function.
- 10–40: 250–500 mg every 8–12 hours.¹²
- <10: 500 mg every 12–24 hours.²

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–40 mL/min. See 'Other information'.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Use dose for normal renal function to treat urinary tract infection in ERF.
- High doses, together with the use of nephrotoxic drugs such as aminoglycosides or potent diuretics, may adversely affect renal function.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

**References:**

1. Vaziri S. *Guidelines for Prescribing Drugs in Adults with Impaired Renal Function*. Renal dosing protocols. Detroit VA Medical Centre.
Cefixime

Clinical use
Antibacterial agent

Dose in normal renal function
200–400 mg/day (given as a single dose or in 2 divided doses).

Pharmacokinetics
- Molecular weight (daltons) 507.5
- % Protein binding 65
- % Excreted unchanged in urine 20 (50% of absorbed dose)
- Volume of distribution (L/kg) 0.11–0.6
- Half-life — normal/ESRF (hrs) 3–4 / 11.5

Metabolism
About 20% of an oral dose (or 50% of an absorbed dose) is excreted unchanged in the urine via glomerular filtration within 24 hours. Up to 60% may be eliminated by non-renal mechanisms; there is no evidence of metabolism but some drug is probably excreted into the faeces from bile.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.¹
- <10 200 mg/day.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Manufacturer recommends that patients with a GFR<20 mL/min or having regular APD or HD should not have a dose greater than 200 mg/day.

Reference:
Cefotaxime

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
- Mild infection: 1 g every 12 hours
- Moderate infection: 1 g every 8 hours
- Severe infection: 2 g every 6 hours
- Life-threatening infection: up to 12 g daily in 3–4 divided doses

**Pharmacokinetics**
- Molecular weight (daltons) 477.4 (as sodium salt)
- % Protein binding 40
- % Excreted unchanged in urine 40–60
- Volume of distribution (L/kg) 0.15–0.55
- Half-life — normal/ESRF (hrs) 0.9–1.14 / 2.5
  (10 hours for the metabolite)

**Metabolism**
After partial metabolism in the liver to desacetylccefotaxime and inactive metabolites, elimination is mainly by the kidneys and about 40–60% of a dose has been recovered unchanged in the urine within 24 hours; a further 20% is excreted as the desacetyl metabolite. Relatively high concentrations of cefotaxime and desacetylccefotaxime occur in bile and about 20% of a dose has been recovered in the faeces. Probenecid competes for renal tubular secretion with cefotaxime resulting in higher and prolonged plasma concentrations of cefotaxime and its desacetyl metabolite.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 5–20: Dose as in normal renal function.
- <5: Reduce dose by 50% and keep frequency the same.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<5 mL/min.
- HD: Dialysed. Dose as in GFR<5 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<5 mL/min.
- CAV/VVHD: Dialysed. 1–2 g every 12 hours.¹
- CVVHD/HDF: Dialysed. 2 g every 12 hours.¹ See 'Other information'.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

**Administration**

**Reconstitution**
- IV bolus / IM: 4 mL water for injection to 1 g
- IV infusion: 1 g in 50 mL sodium chloride 0.9%

**Route**
- IV, IM

**Rate of administration**
- Bolus over 3–4 minutes; infusion over 20–60 minutes

**Other information**
- 1 g contains 2.09 mmol sodium.
- Reduce dose further if concurrent hepatic and renal failure.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
Cefradine

Clinical use
Antibacterial agent

Dose in normal renal function
- Oral: 250–500 mg every 6 hours (or 500 mg – 1 g every 12 hours)
- Severe infections: 1 g every 6 hours

Pharmacokinetics
Molecular weight (daltons) 349.4
% Protein binding 8–12
% Excreted unchanged in urine >90
Volume of distribution (L/kg) 0.25–0.46
Half-life — normal/ESRF (hrs) 1 / 6–15

Metabolism
Cefradine is excreted unchanged in the urine by glomerular filtration and tubular secretion, over 90% of an oral dose or 60–80% of an intramuscular dose being recovered within 6 hours. Probenecid delays excretion.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 250–500 mg every 6 hours.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Dialysed. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

Administration
Reconstitution —
Route Oral
Rate of administration —

Other information
- Dose in severe renal impairment estimated from evaluation of pharmacokinetics.
Ceftaroline fosamil

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
600 mg every 12 hours

**Pharmacokinetics**
- Molecular weight (daltons) 762.75
- % Protein binding 20
- % Excreted unchanged in urine 88
- Volume of distribution (L/kg) 20.3 Litres
- Half-life — normal/ESRF (hrs) 2.5 / Increased

**Metabolism**
Ceftaroline fosamil (prodrug) is converted into the active ceftaroline in plasma by phosphatase enzymes. Hydrolysis of the beta-lactam ring of ceftaroline occurs to form the microbiologically inactive, open-ring metabolite, ceftaroline M-1.

Ceftaroline is mainly eliminated by the kidneys. Renal clearance is approximately equal, or slightly lower than the glomerular filtration rate in the kidney, and in vitro transporter studies indicate that active secretion does not contribute to the renal elimination of ceftaroline.

**Dose in renal impairment GFR (mL/min)**
- 30–50 400 mg every 12 hours.
- 15–30 300 mg every 12 hours.
- <15 200 mg every 12 hours.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Dialysed. Dose as in GFR<15 mL/min.
- HD Dialysed. Dose as in GFR<15 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<15 mL/min.
- CAV/VVHD Dialysed. Dose as in GFR=15–30 mL/min. See 'Other information'.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

**Administration**

Reconstitution
20 mL water for injection

Route
IV infusion

Rate of administration
Over 60 minutes

Comments
- Normally added to 250 mL of infusion fluid but in cases of fluid restriction can be added to 50–100 mL.
- Can be added to sodium chloride 0.9%, glucose 5% or Lactated Ringer's solution.

**Other information**
- Administer within 6 hours of preparation.
- Side effects are more likely in patients with renal impairment.
- 74% is removed by a 4-hour haemodialysis session.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid 'flux' within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Ceftazidime

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

- 1–2 g every 8–12 hours
- Severe infections: 3 g every 12 hours
- Pseudomonal lung infections in cystic fibrosis: 100–150 mg/kg in 3 divided doses
- Surgical prophylaxis: 1 g at induction

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>637.7</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>&lt;10</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>80–90</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.28–0.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2 / 13–25</td>
</tr>
</tbody>
</table>

**Metabolism**

Ceftazidime is passively excreted in bile, although only a small proportion (1%) is eliminated by this route. It is mainly excreted by the kidneys, almost exclusively by glomerular filtration; probenecid has little effect on the excretion. About 80–90% of a dose appears unchanged in the urine within 24 hours.

**Dose in renal impairment GFR (mL/min)**

- 31–50: 1–2 g every 12 hours.
- 16–30: 1–2 g every 24 hours.
- 6–15: 500 mg – 1 g every 24 hours.
- <5: 500 mg – 1 g every 48 hours.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>APD/CAPD</th>
<th>Dialysed. 500 mg – 1 g every 24 hours.</th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>Dialysed. 500 mg – 1 g every 48 hours or post dialysis.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. 500 mg – 2 g every 48 hours or post dialysis.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. 2 g every 8 hours¹ or 1–2 g every 12 hours.¹²</td>
</tr>
<tr>
<td>CVVHD/HDF</td>
<td>Dialysed. 2 g every 12 hours.² See 'Other information.'</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anticoagulants: effects of coumarins may be enhanced.
- Ciclosporin: may cause increased ciclosporin levels.

**Administration**

**Reconstitution**

Water for injection:
- 1.5 mL to 500 mg vial for IM administration
- 5 mL to 500 mg vial for IV injection
- 3 mL to 1 g vial for IM administration
- 10 mL to 1 g vial for IV injection

**Route**

IV / IM rarely

**Rate of administration**

Bolus: 3–4 minutes
Infusion: over 30 minutes

**Comments**

- May be given IP in CAPD fluid 125–250 mg/2 L.
- Reconstituted solutions vary in colour, but this is quite normal.
- Compatible with most IV fluids, e.g. sodium chloride 0.9%, glucose-saline, glucose 5%.

**Other information**

- Volume of distribution increases with infection.
- In exceptional circumstances, patients on haemodialysis may be given a dose of 2 g, 3 times a week post HD.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ’flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

**References:**

1. Ceftazidime

(Assumes that polysulphone membranes are used.)

## Ceftobiprole medocaril sodium

### Clinical use
Antibacterial agent

### Dose in normal renal function
500 mg every 8 hours

### Pharmacokinetics
- Molecular weight (daltons): 534.5
- % Protein binding: 16
- % Excreted unchanged in urine: 89 (as ceftobiprole)
- Volume of distribution (L/kg): 18 Litres

### Metabolism
Ceftobiprole medocaril sodium is the pro-drug of the active moiety ceftobiprole. Conversion from the prodrug ceftobiprole medocaril sodium, to the active moiety ceftobiprole, occurs rapidly and is mediated by non-specific plasma esterases. Ceftobiprole undergoes minimal metabolism to the open-ring metabolite, which is microbiologically inactive.

### Dose in renal impairment GFR (mL/min)
- 30–50: 500 mg every 12 hours.
- 10–30: 250 mg every 12 hours.
- <10: 250 mg every 12 hours.

### Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. 250 mg every 24 hours.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. 250 mg every 24 hours.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. 250 mg every 24 hours.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–30 mL/min. See ‘Other information.’</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

### Administration
**Reconstitution**
10 mL water for injection or glucose 5%

**Route**
IV infusion

**Rate of administration**
Over 2 hours

**Comments**
Dilute 250 mg dose in 125 mL and 500 mg dose in 250 mL sodium chloride 0.9%, glucose 5% or Lactated Ringer’s solution

### Other information
- Manufacturer advises to use with caution in severe renal impairment due to lack of data.
- Ceftobiprole AUC was 2.5- and 3.3-fold higher in subjects with moderate (CRCL=30–50 mL/min) and severe (CRCL<30 mL/min) renal impairment, respectively, than in healthy subjects with normal renal function.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Ceftriaxone

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
- 1 g daily (severe infections: 2–4 g daily)
- Gonorrhoea: single dose 250 mg IM

**Pharmacokinetics**
- Molecular weight (daltons): 661.6 (as sodium salt)
- % Protein binding: 85–95
- % Excreted unchanged in urine: 40–60
- Volume of distribution (L/kg): 0.12–0.18
- Half-life — normal/ESRF (hrs): 6–9 / 14.7

**Metabolism**
About 40–65% of a dose of ceftriaxone is excreted unchanged in the urine, principally by glomerular filtration; the remainder is excreted in the bile and is ultimately found in the faeces as unchanged drug and microbiologically inactive compounds.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. Maximum 2 g daily.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. 2 g every 12–24 hours.1
- CVVHD/HDF: Likely dialysability. 2 g every 12–24 hours.1

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.
- Ciclosporin: may cause increased ciclosporin levels.

**Administration**

**Reconstitution**
- 250 mg: IV – 5 mL water for injection; IM – 1 mL 1% lidocaine hydrochloride.
- 1 g: IV – 10 mL water for injection; IM – 3.5 mL 1% lidocaine hydrochloride.
- Infusion: 2 g in 40 mL of calcium-free solution, e.g. sodium chloride 0.9%, glucose 5%.
- Incompatible with calcium containing solutions, e.g. Hartmann’s, Ringer’s.

**Route**
- IV, IM, SC

**Rate of administration**
- Bolus: over 2–4 minutes.
- Infusion: over at least 30 minutes.

**Comments**
- For IM injection: doses greater than 1 g should be divided and injected at more than one site.

**Other information**
- Calcium ceftriaxone has appeared as a precipitate in urine, or been mistaken as gallstones in patients receiving higher than recommended doses.
- Contains 3.6 mmol sodium per gram of ceftriaxone.
- Information from the company shows that the bioavailability of SC administration is equivalent to IV. The maximum amount able to be given in a single SC injection is 500 mg dissolved in 2 mL lidocaine 1%. Administration was said to be tolerable.

**Reference:**
Cefuroxime (oral)

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
125–500 mg every 12 hours

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>510.5 (as axetil)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>50</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>85–90</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.13–1.8</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.2 / 17</td>
</tr>
</tbody>
</table>

**Metabolism**

After oral administration cefuroxime axetil is rapidly hydrolysed in the intestinal mucosa and blood to release active cefuroxime. Cefuroxime is excreted unchanged in the urine, 50% by glomerular filtration and 50% by renal tubular secretion. Probenecid competes for renal tubular secretion with cefuroxime resulting in higher and more prolonged plasma concentrations of cefuroxime. Small amounts of cefuroxime are excreted in bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Dialysed. Dose as in normal renal function.
- **HD** Dialysed. Dose as in normal renal function.
- **HDF/High flux** Dialysed. Dose as in normal renal function.
- **CAV/VVHD** Dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Take with or after food.</td>
</tr>
</tbody>
</table>

**Other information**

- Doses in renal impairment are taken from *Drug Prescribing in Renal Failure, 5th edition* by Aronoff et al.
Cefuroxime (parenteral)

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
750 mg – 1.5 g every 6–8 hours

**Pharmacokinetics**
- Molecular weight (daltons) 446.4 (as sodium salt)
- % Protein binding 50
- % Excreted unchanged in urine 85–90
- Volume of distribution (L/kg) 0.13–1.8
- Half-life — normal/ESRF (hrs) 1.2 / 17

**Metabolism**
Cefuroxime is excreted unchanged in the urine, 50% by glomerular filtration and 50% by renal tubular secretion. On injection, most of a dose of cefuroxime is excreted within 24 hours, the majority within 6 hours. Probenecid competes for renal tubular secretion with cefuroxime resulting in higher and more prolonged plasma concentrations of cefuroxime. Small amounts of cefuroxime are excreted in bile.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: 750 mg – 1.5 g every 12 hours
- <10: 750 mg – 1.5 g every 24 hours

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min. See ‘Other information’.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

**Administration**

**Reconstitution**
IM: 1 mL of water for injection to each 250 mg
IV bolus: 2 mL of water for injection to each 250 mg, but 15 mL of water for injection to 1.5 g
IV infusion: 1.5 g in 50 mL of water for injection

**Route**
IM, IV

**Rate of administration**
IV bolus: over 3–5 minutes
IV infusion: over 30 minutes

**Comments**
- Do not mix in syringe with aminoglycoside antibiotics.
- Injection may also be reconstituted with: sodium chloride 0.9%, glucose 5%, glucose saline, Hartmann’s solution.
- Cefuroxime and metronidazole can be mixed (see manufacturer’s guidelines).

**Other information**
- At high doses, take care in patients receiving concurrent treatment with potent diuretics such as furosemide, or aminoglycosides, as combination can adversely affect renal function.
- Each 750 mg vial contains approximately 1.8 mmol sodium.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Celecoxib

**Clinical use**

Cox 2 inhibitor and analgesic

**Dose in normal renal function**

100–200 mg once or twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>381.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;3</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>400 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8–12 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Celecoxib is metabolised in the liver mainly by the cytochrome P450 isoenzyme CYP2C9, which shows genetic polymorphism; the three identified metabolites are inactive as inhibitors of cyclo-oxygenase-1 (COX-1) or COX-2 enzymes. It is eliminated mainly as metabolites in the faeces and urine; less than 3% is recovered as unchanged drug.

**Dose in renal impairment GFR (mL/min)**

- **30–50** Dose as in normal renal function. Use with caution.
- **10–30** Dose as in normal renal function, but avoid if possible.
- **<10** Dose as in normal renal function, but only use if on dialysis.

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.
- **HD** Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.
- **HDF/High flux** Unknown dialysability. Dose as in normal renal function. See 'Other information'.
- **CAV/VVHD** Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones; concentration reduced by rifampicin.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antiepileptics: possibly increased phenytoin concentration.
- Antifungals: if used with fluconazole, halve the dose of celecoxib.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: possibly increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Clinical trials have shown renal effects similar to those observed with comparative NSAIDs. Monitor
patient for deterioration in renal function and fluid retention.

- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease. Avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID. If raised, discontinue NSAID therapy.
- Use normal doses in patients with ERF on dialysis if they do not pass any urine.

- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
- Celecoxib should be used with caution in uraemic patients predisposed to gastrointestinal bleeding or uraemic coagulopathies.
- Contraindicated in patients with ischaemic heart disease or cerebrovascular disease and class II–IV NYHA congestive heart failure.
Celiprolol hydrochloride

Clinical use
Beta-adrenoceptor blocker:
• Mild to moderate hypertension

Dose in normal renal function
200–400 mg daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>416</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>25</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>12–18</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>4.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–6 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism
Metabolism of celiprolol is minimal and it is mainly excreted unchanged in the urine (50%) and faeces (50%).

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start low – adjust according to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Anaesthetics: enhanced hypotensive effect.
• Analgesics: NSAIDs antagonise hypotensive effect.
• Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
• Antidepressants: enhanced hypotensive effect with MAOIs.
• Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
• Antimalarials: increased risk of bradycardia with mefloquine.
• Antipsychotics enhanced hypotensive effect with phenothiazines.
• Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
• Cytotoxics: possible increased risk of bradycardia with crizotinib.
• Diuretics: enhanced hypotensive effect.
• Fingolimod: possibly increased risk of bradycardia.
• Moxisylyte: possible severe postural hypotension.
• Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Comments
Take half to one hour before food.
Ceritinib

Clinical use
ALK-inhibitor:
• Treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib

Dose in normal renal function
750 mg once daily

Pharmacokinetics
Molecular weight (daltons) 558.1
% Protein binding 97
% Excreted unchanged in urine 1.3
Volume of distribution (L/kg) 4230 Litres
Half-life — normal/ESRF (hrs) 31–41 / –

Metabolism
In vitro studies demonstrated that CYP3A was the major enzyme involved in the metabolic clearance of ceritinib. The main route of excretion of ceritinib and its metabolites is via the faeces. Recovery of unchanged ceritinib in the faeces accounts for a mean of 68% of a dose.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Anti-arrhythmics: possibly increased risk of ventricular arrhythmias with amiodarone, disopyramide, dronedarone and flecainide.
• Antibacterials: possibly increased risk of ventricular arrhythmias with bedaquiline, clarithromycin, delamanid, IV erythromycin, moxifloxacin and telavancin; concentration reduced by rifampicin and possibly rifabutin – avoid.
• Antidepressants: risk of QT prolongation with citalopram, escitalopram, venlafaxine and tricyclics that prolong the QT interval – avoid; concentration possibly reduced by St John's wort – avoid.
• Anti-emetics: possibly increased risk of ventricular arrhythmias with domperidone and ondansetron.
• Antiepileptics: possibly increased concentration with carbamazepine – avoid; concentration possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone.
• Antifungals: concentration increased by ketoconazole and possibly itraconazole, posaconazole and voriconazole – avoid or reduce ceritinib dose.
• Antihistamines: avoid with hydralazine due to risk of QT prolongation.
• Antimalarials: possibly increased risk of ventricular arrhythmias with artemether and lumefantrine, piperazine with arteminol, chloroquine and quinine – avoid.
• Antipsychotics: possibly increased risk of ventricular arrhythmias with droperidol and haloperidol; avoid with other antipsychotics that prolong the QT interval; increased risk of agranulocytosis with clozapine – avoid.
• Antivirals: concentration possibly increased by atazanavir, fosamprenavir, lopinavir, ritonavir, saquinavir and tipranavir – avoid or reduce dose; risk of QT prolongation with dasatinib – avoid.
• Apomorphine: risk of QT prolongation – avoid.
• Ciclosporin: may increase ciclosporin concentration – avoid.
• Cobicistat: concentration of ceritinib increased – avoid or adjust ceritinib dose.
• Cytotoxics: risk of QT prolongation with arsenic trioxide, bosutinib, cabozantinib, crizotinib, eribulin, laptinib, nilotinib, osimertinib, panobinostat, pazopanib, sorafenib, sunitinib, vandetanib, vemurafenib, vinflunine – avoid; concentration
possibly increased by idelalisib – avoid or adjust ceritinib dose.
- Enzalutamide: increases ceritinib concentration – avoid.
- Methadone: possibly increased risk of ventricular arrhythmias.
- Pasireotide: possibly increased risk of ventricular arrhythmias – avoid.
- Ranolazine: possibly increased risk of ventricular arrhythmias – avoid.
- Sirolimus: avoid concomitant use.
- Tacrolimus: avoid concomitant use.
- Tetrabenazine: possibly increased risk of ventricular arrhythmias – avoid.
- Tizanidine: possibly increased risk of ventricular arrhythmias – avoid.
- Warfarin – avoid concomitant use.

### Administration

#### Reconstitution

- **Route**
  - Oral

#### Rate of administration

- **Other information**
  - Manufacturer advises to use with caution in severe renal impairment due to lack of studies.
  - QT prolongation has been reported.
Certolizumab pegol

Clinical use
Tumour necrosis factor alpha inhibitor:
- Treatment of moderate to severe rheumatoid arthritis in combination with methotrexate
- Treatment of ankylosing spondylitis
- Treatment of psoriatic arthritis

Dose in normal renal function
200 mg in 2 separate injections at weeks 0, 2, and 4 then maintenance of 200 mg every 2 weeks or 400 mg every 4 weeks

Pharmacokinetics
- Molecular weight (daltons) 91 000
- % Protein binding No data
- % Excreted unchanged in urine Mainly FAB
- Volume of distribution (L/kg) 8.01 Litres
- Half-life — normal/ESRF (hrs) 14 days /

Metabolism
The Fab fragment comprises protein compounds and is expected to be degraded to peptides and amino acids by proteolysis. The de-conjugated PEG component is rapidly eliminated from plasma and is to an unknown extent excreted renally.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Use with caution.
- <10 Use with caution.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anakinra and abatacept: avoid concomitant use.
- Live vaccines: avoid concomitant use.

Administration
Reconstitution
Route
SC
Rate of administration
—
Comments
Suitable injection sites are the thigh and abdomen.

Other information
- Manufacturer is unable to provide a dose in moderate to severe renal impairment due to lack of studies.
- Contraindicated in patients with severe infections and moderate to severe heart failure.
- Bioavailability is 76–88%.
- Clearance following subcutaneous dosing was estimated to be 21 mL/hour in a rheumatoid arthritis population pharmacokinetic analysis, with an inter-subject variability of 30.8% and an inter-occasion variability of 22%. The presence of antibodies to certolizumab pegol resulted in an approximately three-fold increase in clearance. Compared with a 70 kg person, clearance is 29% lower and 38% higher, respectively, in individual RA patients weighing 40 kg and 120 kg.
## Cetirizine hydrochloride

### Clinical use

**Antihistamine:**
- Symptomatic relief of allergy such as hay fever, urticaria

### Dose in normal renal function

10 mg daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>461.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>93</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50–60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.45</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8–10 / 20</td>
</tr>
</tbody>
</table>

### Metabolism

Cetirizine does not undergo extensive first pass metabolism. About two thirds of the dose is excreted unchanged in urine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5–10 mg daily</td>
</tr>
</tbody>
</table>

### Important drug interactions

**Potentially hazardous interactions with other drugs**
- Antivirals: concentration possibly increased by ritonavir.

### Administration

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

**Comments**
- Available as tablets and solution

### Other information

- Manufacturers recommend halving dose in renal impairment.
- Dose may be titrated up but may result in increased sedation.
- Less than 10% of a dose is removed by haemodialysis.
Cetuximab

Clinical use
Monoclonal antibody:
- Treatment of EGFR-expressing metastatic colorectal cancer in combination with irinotecan after failure of irinotecan-including cytotoxic therapy
- Treatment of head and neck cancer

Dose in normal renal function
Initial dose 400 mg/m² then 250 mg/m² weekly.

Pharmacokinetics
Molecular weight (daltons) 152 000
% Protein binding No data
% Excreted unchanged in urine Minimal
Volume of distribution (L/kg) 1.5–6.2 L/m²
Half-life — normal/ESRF (hrs) 70–100 / Unchanged

Metabolism
Several pathways have been described that may contribute to the metabolism of antibodies. All of these pathways involve the biodegradation of the antibody to smaller molecules, i.e. small peptides or amino acids.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Caution</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min. See 'Other information.'</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Avoid with live vaccines.

Administration

Reconstitution
—

Route
IV infusion

Rate of administration
- 1st dose: 120 minutes
- Further doses: 60 minutes
- Maximum infusion rate must not exceed 5 mL/min

Comments
- Administer via a 0.2 micrometer in-line filter
- The filter may clog and need to be replaced during the infusion

Other information
- Delayed hypersensitivity reactions may occur and patients should be warned to contact their doctor if this occurs.
- Premedication with an antihistamine is recommended.
- 2% of patients receiving cetuximab developed renal failure.
- Give irinotecan at least 1 hour after the end of cetuximab infusion.
- Manufacturer has no information in renal impairment.
Chloral hydrate

Clinical use
Insomnia (short-term use)

Dose in normal renal function
- Mixture: 5–20 mL at night
- Solution: 15–30 mL at night. Max 70 mL daily

Pharmacokinetics
- Molecular weight (daltons) 165.4
- % Protein binding 70–80
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 0.6
- Half-life — normal/ESRF (hrs) 7–11 / –

Metabolism
Chloral hydrate is rapidly metabolised to trichloroethanol (the active metabolite) and trichloroacetic acid in the erythrocytes, liver, and other tissues. It is excreted partly in the urine as trichloroethanol and its glucuronide (urochloralic acid) and as trichloroacetic acid. Some is also excreted in the bile.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 1 tablet at night.
- <10 Avoid.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Avoid.
- HD Dialysed. Avoid.
- HDF/High flux Dialysed. Avoid.
- CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: may transiently enhance effect of coumarins.
- Antipsychotics: enhanced sedative effects.
- Antivirals: concentration possibly increased by ritonavir.

Administration
Reconstitution
- Route
  Oral
Rate of administration
- Comments
  Take with water (or milk) 15–30 minutes before bedtime.

Other information
- Manufacturer advises to avoid in patients with marked hepatic or renal impairment, severe cardiac disease, marked gastritis and those susceptible to acute attacks of porphyria.
- Chloral hydrate followed by intravenous furosemide may result in sweating, hot flushes, and variable blood pressure including hypertension.
Chlorambucil

**Clinical use**

Alkylating agent:
- Hodgkin’s disease
- Non-Hodgkin’s lymphoma (NHL)
- Chronic lymphocytic leukaemia (CLL)
- Waldenström’s macroglobulinaemia (WM)

**Dose in normal renal function**

- Hodgkin’s disease: 200 mcg/kg/day (4–8 wks)
- NHL: 100–200 mcg/kg/day (4–8 wks) then reduce dose or give intermittently
- CLL: initially 150 mcg/kg/day, then 4 weeks after 1st course ended 100 mcg/kg/day
- WM: initially 6–12 mg daily, then reduce to 2–8 mg daily

**Pharmacokinetics**

- Molecular weight (daltons) 304.2
- % Protein binding 99
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 0.86
- Half-life — normal/ESRF (hrs) 1.5 / –

**Metabolism**

Chlorambucil is extensively metabolised in the liver via the hepatic microsomal enzyme oxidation system, principally to phenylacetic acid mustard, which is pharmacologically active, and which also undergoes some spontaneous degradation to further derivatives. Chlorambucil is excreted in the urine, almost exclusively as metabolites with less than 1% unchanged.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Ciclosporin: ciclosporin concentration possibly reduced.
- Patients who receive phenylbutazone may require reduced doses of chlorambucil.

**Administration**

**Reconstitution**

- Route
  - Oral

**Rate of administration**

- —

**Other information**

- Monitor patients with renal impairment closely as they are at increased risk of myelosuppression associated with azotaemia.
- Oral absorption slowed and decreased by 10–20% if ingested with food.
Chloramphenicol

Clinical use
Antibacterial agent

Dose in normal renal function
- Oral / IV: 12.5 mg/kg every 6 hours (maximum 100 mg/kg/day)
- Can be doubled for severe infections as long as dose is then reduced as soon as clinically indicated

Pharmacokinetics
- Molecular weight (daltons) 323.1
- % Protein binding 60
- % Excreted unchanged in urine 5–10
- Volume of distribution (L/kg) 0.5–1
- Half-life — normal/ESRF (hrs) 1.5–4 / Unchanged

Metabolism
Chloramphenicol is excreted mainly in the urine but only 5–10% of an oral dose appears unchanged; the remainder is inactivated in the liver, mostly by conjugation with glucuronic acid to inactive metabolites. About 3% is excreted in the bile. However, most is reabsorbed and only about 1%, mainly in the inactive form, is excreted in the faeces.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions
- Potentially hazardous interactions with other drugs
  - Anticoagulants: effect of coumarins enhanced.
  - Antidiabetics: effect of sulphonylureas enhanced.
  - Antiepileptics: metabolism accelerated by phenobarbital and primidone (reduced concentration of chloramphenicol); increased concentration of fosphenytoin and phenytoin (risk of toxicity).
  - Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
  - Ciclosporin: possibly increases ciclosporin concentration.
  - Clopidogrel: possibly reduces antiplatelet effect.
  - Tacrolimus: possibly increases tacrolimus concentration.

Administration
Reconstitution
- Kemicetine: 1 g vial – reconstitute with water for injection, sodium chloride 0.9% or glucose 5%.
- 1.7 mL = 400 mg/mL solution
- 3.2 mL = 250 mg/mL solution
- 4.2 mL = 200 mg/mL solution

Route
- Oral, IV, IM (Kemicetine only).

Rate of administration
- Over at least 1 minute

Other information
- Manufacturers recommend monitoring serum levels in patients with renal impairment – Micromedex therapeutic range 10–25 micrograms/mL.
- Levels should be taken 1 hour after IV administration, aim for 15–25 mg/L, trough <15 mg/L.
- Kemicetine 1 g vial = 3.14 mmol sodium.
Chlordiazepoxide hydrochloride

Clinical use
- Anxiety (short-term use)
- Alcohol withdrawal

Dose in normal renal function
- Anxiety: 30–100 mg daily in divided doses
- Alcohol withdrawal: 10–50 mg 4 times a day, reducing gradually

Pharmacokinetics
Molecular weight (daltons) 336.2
% Protein binding 96
% Excreted unchanged in urine 1–2
Volume of distribution (L/kg) 0.3–0.5
Half-life — normal/ESRF (hrs) 6–30 / Unchanged

Metabolism
Chlordiazepoxide is extensively metabolised in the liver. The elimination half-life of chlordiazepoxide ranges from about 6–30 hours, but its main active metabolite desmethyldiazepam (nordazepam) has a half-life of several days. Other pharmacologically active metabolites of chlordiazepoxide include desmethylchlordiazepoxide, demoxepam, and oxazepam.

Unchanged drug and metabolites are excreted in the urine, mainly as conjugated metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of normal dose.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
APD/CAPD   Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD         Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD   Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism possibly increased by rifampicin.
- Antipsychotics: enhanced sedative effects; serious adverse events reported with clozapine and benzodiazepines.
- Antivirals: concentration possibly increased by ritonavir.
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.
- Ulcer-healing drugs: metabolism inhibited by cimetidine.

Administration
Reconstitution
- Route Oral
- Rate of administration
Chloroquine

**Clinical use**
- Treatment and prophylaxis of malaria
- Discoid and systemic lupus erythematosus
- Rheumatoid arthritis

**Dose in normal renal function**
- Orally.
- Malaria treatment: 600 mg, followed by 300 mg 6–8 hours later, then 300 mg/day for 2 days.
- Malaria prophylaxis: 300 mg once a week on the same day each week (start 1 week before exposure to risk and continue until 4 weeks after leaving the malarial area).
- SLE: 150 mg daily.
- Rheumatoid arthritis: 150 mg daily; maximum 2.5 mg/kg

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>319.9 (515.9 as phosphate), (436 as sulphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>50–70</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>42–47</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–60 days / 5–50 days</td>
</tr>
</tbody>
</table>

**Metabolism**

Chloroquine is extensively metabolised in the liver, mainly to monodesethylchloroquine with smaller amounts of bisdesethylchloroquine (didesethylchloroquinine) and other metabolites being formed. Monodesethylchloroquine has been reported to have some activity against *Plasmodium falciparum*. Chloroquine and its metabolites are excreted in the urine, with about half of a dose appearing as unchanged drug and about 10% as the monodesethyl metabolite. Chloroquine may be detected in urine for several months.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of normal dose.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- **APD/CAPD**: Not dialysed. Dose as in GFR < 10 mL/min.
- **HD**: Not dialysed. Dose as in GFR < 10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR < 10 mL/min.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin – avoid; concentration of praziquantel reduced – consider increasing praziquantel dose.
- Anti-depressants: possible increased risk of ventricular arrhythmias with citalopram and escitalopram.
- Antiepileptics: antagonism of anticonvulsant effect.
- Antimalarials: increased risk of convulsions with mefloquine; avoid with artemether/lumefantrine.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol – avoid.
- Ciclosporin: increases ciclosporin concentration – increased risk of toxicity.
- Cytotoxics: possible increased risk of ventricular arrhythmias with bosutinib, ceritinib and panobinostat.
- Digoxin: possibly increased concentration of digoxin.
- Lanthanum: absorption possibly reduced by lanthanum, give at least 2 hours apart.

**Administration**

**Reconstitution**
- **Route**
  - Oral, IV, IM/SC in rare cases

**Rate of administration**
- **IV infusion**: Administer dose of 10 mg/kg of chloroquine base in sodium chloride 0.9% by slow IV infusion over 8 hours followed by 3 further 8 hour infusions containing 5 mg base/kg (total dose 25 mg base/kg over 32 hours)
Comments
- Oral: Do not take indigestion remedies at the same time of day as this medicine.
- Chloroquine sulphate inj. is available: 5.45% w/v (equivalent to 40 mg chloroquine base per mL).

Other information
- Excretion is increased in alkaline urine.
- Manufacturer advises to use with caution in patients with renal or hepatic disease.
- Dose in severe renal impairment is from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Bone marrow suppression may occur with extended treatment.
- 150 mg chloroquine base is equivalent to 200 mg of sulphate and 250 mg of phosphate.
Chlorphenamine maleate (chlorpheniramine)

**Clinical use**

Antihistamine:
- Relief of allergy, pruritus
- Treatment / prophylaxis of anaphylaxis

**Dose in normal renal function**

Oral: 4 mg 4–6 times a day (maximum 24 mg/day)
IV/IM/SC: 10–20mg (maximum 40 mg/day)

**Pharmacokinetics**

- Molecular weight (daltons) 390.9
- % Protein binding Approx 70
- % Excreted unchanged in urine Approx 22
- Volume of distribution (L/kg) 3
- Half-life — normal/ESRF (hrs) 12–43 / –

**Metabolism**

Chlorphenamine appears to undergo extensive first-pass metabolism. Chlorphenamine maleate is extensively metabolised in the liver. Metabolites include desmethyl- and didesmethylchlorphenamine.

Unchanged drug and metabolites are excreted mainly in the urine; excretion is dependent on urinary pH and flow rate. Only trace amounts have been found in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: sedative effects possibly increased with opioid analgesics.
- Anticonvulsant: inhibits phenytoin metabolism and can lead to phenytoin toxicity.
- Antivirals: concentration possibly increased by lopinavir.

**Administration**

**Reconstitution**

---

**Route**

Oral, IV

**Rate of administration**

Bolus over 1 minute

**Comments**

Injection reported to cause stinging or burning sensation at site of injection.

**Other information**

- Increased cerebral sensitivity in patients with renal impairment.
Chlorpromazine hydrochloride

**Clinical use**
- Anti-emetic
- Anxiolytic
- Antipsychotic
- Hiccups

**Dose in normal renal function**
- Anti-emetic:
  - Oral: 10–25 mg every 4–6 hours
  - IM: 25–50 mg every 3–4 hours
- Antipsychotic, anxiolytic:
  - Oral: 25 mg every 8 hours (or 75 mg at night) initially; increase as necessary; usual maintenance dose 75–300 mg daily (up to 1 g daily)
  - IM: 25–50 mg every 6–8 hours
- Induction of hypothermia: 25–50 mg every 6–8 hours
- Hiccups: Oral: 25–50 mg every 6–8 hours
- PR (unlicensed): 100 mg every 6–8 hours

**Pharmacokinetics**
- Molecular weight (daltons) 355.3
- % Protein binding 95–98
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 7–20
- Half-life — normal/ESRF (hrs) 23–37 / Unchanged

**Metabolism**
Chlorpromazine is subject to considerable first-pass metabolism in the gut wall and is also extensively metabolised in the liver. Paths of metabolism of chlorpromazine include hydroxylation and conjugation with glucuronic acid, N-oxidation, oxidation of a sulfur atom, and dealkylation.

Chlorpromazine is excreted in the urine and bile in the form of both active and inactive metabolites; there is some evidence of enterohepatic recycling.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Start with small dose and increase according to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval and disopyramide; avoid with amiodarone and dronedarone.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid, moxifloxacin and telithromycin – avoid with moxifloxacin.
- Antidepressants: increased level of tricyclics, possibly increased risk of ventricular arrhythmias and antimuscarinic side effects; increased risk of ventricular arrhythmias with citalopram and escitalopram – avoid; increased risk of convulsions with vortioxetine.
- Anticonvulsants: antagonises anticonvulsant effect; concentration of fosphenytoin and phenytoin possibly increased or decreased; concentration of both drugs reduced with phenobarbital.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with artemisinol.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol and pimozide – avoid; concentration of haloperidol possibly increased; possible increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration possibly increased with ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
- Anxiolytics and hypnotics: increased sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias.
• Beta-blockers: enhanced hypotensive effect; concentration of both drugs may increase with propranolol; increased risk of ventricular arrhythmias with sotalol.
• Cytotoxics: increased risk of ventricular arrhythmias with vandetanib – avoid; increased risk of ventricular arrhythmias with arsenic trioxide.
• Diuretics: enhanced hypotensive effect.
• Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
• Pentamidine: increased risk of ventricular arrhythmias.
• Ulcer-healing drugs: effects enhanced by cimetidine.

Administration

Reconstitution

Route
Oral, deep IM, PR (unlicensed)

Rate of administration

Other information
• Start with small doses in severe renal impairment due to increased cerebral sensitivity.
• Manufacturer advises to use with caution due to risk of accumulation.

Reference:
Chlortalidone (chlorthalidone)

**Clinical use**

Thiazide-like diuretic:
- Hypertension
- Ascites
- Oedema
- Diabetes insipidus
- Mild to moderate heart failure

**Dose in normal renal function**

- Hypertension: 25–50 mg daily
- Oedema: up to 50 mg daily
- Diabetes insipidus: 100 mg every 12 hours initially, reducing to 50 mg daily where possible
- Heart failure: 25–50 mg daily increasing to 100–200 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>338.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>76</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3.9</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>40–60 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Chlortalidone is highly bound to red blood cells; the receptor to which it is bound has been identified as carbonic anhydrase. It is much less strongly bound to plasma proteins. Chlortalidone is mainly excreted unchanged in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Avoid. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapies</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Avoid.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Avoid.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Avoid.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect.
- Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised.
- Antibacterials: avoid administration with lymecycline.
- Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hyponatraemia with carbamazepine.
- Antifungals: increased risk of hypokalaemia with amphotericin.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with post-synaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol.
- Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide – avoid.
- Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Ciclosporin: increased risk of nephrotoxicity and hypomagnesaemia.
- Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium excretion reduced, increased toxicity.

**Administration**

**Reconstitution**

**Route**

Oral

**Rate of administration**

**Comments**

A single dose at breakfast time is preferable.

**Other information**

- Can precipitate diabetes mellitus and gout, and cause severe electrolyte disturbances and an increase in serum lipids.
- Thiazide diuretics are unlikely to be of use once GFR < 30 mL/min.
Ciclosporin

**Clinical use**

Immunosuppressant:
- Prophylaxis of solid organ transplant rejection
- Nephrotic syndrome
- Atopic dermatitis
- Psoriasis
- Rheumatoid arthritis
- Ulcerative colitis

**Dose in normal renal function**

- Organ transplantation:
  - Oral: 2–15 mg/kg/day based on levels. (See local protocol.)
  - IV: One-third to one-half of oral dose. (See local protocol.)
- Bone marrow transplantation:
  - Oral: 12.5–15 mg/kg daily
  - IV: 3–5 mg/kg daily
- Nephrotic syndrome: 5 mg/kg orally in 2 divided doses
- Atopic dermatitis / psoriasis: 2.5–5 mg/kg orally in 2 divided doses
- Rheumatoid arthritis: Oral: 2.5–5 mg/kg in 2 divided doses
- Ulcerative colitis: IV infusion: 2 mg/kg daily over 24 hours

**Pharmacokinetics**

- Molecular weight (daltons) 1202.6
- % Protein binding Approx 90
- % Excreted unchanged in urine 0.1
- Volume of distribution (L/kg) 3–5
- Half-life — normal/ESRF (hrs) 5–20 / Unchanged

**Metabolism**

Ciclosporin is widely distributed throughout the body. Distribution in the blood is concentration-dependent, with between 41–58% in erythrocytes and 10–20% in leucocytes; the remainder is found in plasma, about 90% protein-bound, mostly to lipoprotein.

Clearance from the blood is biphasic. Ciclosporin is extensively metabolised in the liver and mainly excreted in faeces via the bile. About 6% of a dose is reported to be excreted in the urine, less than 0.1% unchanged.

**Dose in renal impairment GFR (mL/min)**

- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Not dialysed. Dose as in normal renal function; adjust according to levels.
- HD Not dialysed. Dose as in normal renal function; adjust according to levels.
- HDF/High flux Unknown dialysability. Dose as in normal renal function; adjust according to levels.
- CAV/VVHD Not dialysed. Dose as in normal renal function; adjust according to levels.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Increased risk of hyperkalaemia with ACE inhibitors, angiotensin-II antagonists, potassium-sparing diuretics, potassium salts.
- Increased risk of nephrotoxicity with aminoglycosides, amphotericin, co-trimoxazole, disopyramide, foscarnet, melphalan, NSAIDs, polymyxins, quinolones, sulphonamides, thiazide diuretics, trimethoprim and vancomycin.
- Increased ciclosporin levels with acetazolamide, aciclovir, amiodarone, atazanavir, boceprevir, carvedilol, chloramphenicol, chloroquine, cimetidine, danazol, diltiazem, doxycline, famotidine, fluconazole, fluoxetine, fosamprenavir, glibenclamide, glipizide, grapefruit juice, hydroxychloroquine, imatinib, indinavir, iraconazole, ketoconazole, lercanidipine (concentration of both drugs increased – avoid), macrolides, miconafungin, miconazole, high-dose methylprednisolone, metoclopramide, metronidazole, muromonab-CD3, nicardipine, posaconazole, progestogens, propafenone, ritonavir, saquinavir and telaprevir (concentration of both drugs increased), tacrolimus, verapamil and voriconazole.
- Decreased ciclosporin levels with barbiturates, bupropion, carbamazepine, efavirenz, fosphenytoin, griseofulvin, lanreotide, modafinil, octreotide, pasireotide, phenytoin, primidone, quinine, red wine, rifampicin, St John’s wort, sulfadiazine, IV sulfadimidine, sulfasalazine, sulfisoxazole,
terbinafine, ticlopidine and IV trimethoprim and possibly by oxcarbazepine.
- Aliskiren: concentration of aliskiren increased – avoid.
- Ambrisentan: concentration of ambrisentan increased.
- Antibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant use.
- Anticoagulants: concentration of dabigatran and edoxaban increased – avoid with dabigatran and reduce dose of edoxaban.
- Antidiabetics: may increase repaglinide concentration, risk of hypoglycaemia.
- Antimuscarinics: avoid with darifenacin.
- Antivirals: avoid with simeprevir, increased simeprevir concentration; when starting co-administration with dasabuvir and ombitasvir/paritaprevir/ritonavir, give one fifth of the total daily dose of ciclosporin once daily. Monitor ciclosporin levels and adjust dose and/or dosing frequency as needed.
- Basiliximab: may alter ciclosporin levels.
- Bosentan: co-administration of ciclosporin and bosentan is contraindicated. When ciclosporin and bosentan are co-administered, initial trough concentrations of bosentan are 30 times higher than normal. At steady state, trough levels are 3–4 times higher than normal. Blood concentrations of ciclosporin decreased by 50%
- Calcium-channel blockers: increased nifedipine concentration and toxicity; amlodipine may increase ciclosporin concentration by up to 40%.
- Cardiac glycosides: increased digoxin concentration and toxicity.
- Caspofungin: caspofungin concentration increased – monitor LFTs.
- Colchicine: risk of myopathy or rhabdomyolysis; also increased blood-ciclosporin concentrations and nephrotoxicity – avoid.
- Cytotoxics: increased risk of neurotoxicity with doxorubicin; concentration of epirubicin, everolimus and idarubicin increased; reduced excretion of mitoxantrone; increased toxicity with methotrexate; seizures have been reported in bone marrow transplant patients taking busulfan and cyclophosphamide; use crizotinib with caution; concentration of etoposide possibly increased (increased risk of toxicity); possible interaction with docetaxel.
- Eltrombopag: exposure reduced by ciclosporin.
- Fidaxomicin: avoid concomitant use.
- Lenalidomide: concentration of lenalidomide increased.
- Lipid-lowering agents: absorption reduced by colesevelam, increased risk of myopathy with statins (avoid with simvastatin, max dose of atorvastatin should be 10 mg1); avoid with rosuvastatin; increased risk of nephrotoxicity with fenofibrate; bezafibrate may increase creatinine and reduce ciclosporin levels; concentration of both drugs may be increased with ezetimibe.
- Mycophenolate mofetil: some studies show that ciclosporin decreases plasma MPA AUC levels – no dose change required.
- NSAIDs: diclofenac concentration increased – reduce diclofenac dose.
- Omeprazole: may alter ciclosporin concentration.
- Orlistat: absorption of ciclosporin possibly reduced.
- Prednisolone: increased prednisolone concentration.
- Rifaximin: concentration of rifaximin increased.
- Sirolimus: increased absorption of sirolimus – give sirolimus 4 hours after ciclosporin; sirolimus concentration increased; long term concomitant administration may be associated with deterioration in renal function.
- Tacrolimus: increased ciclosporin concentration and toxicity – avoid.
- Ursodeoxycholic acid: unpredictably increased absorption and raised ciclosporin levels in some patients.

Administration

Reconstitution
—
Route
Oral, IV peripherally or centrally
Rate of administration
Over 2–6 hours peripherally or 1 hour centrally.
Comments
Dilute 50 mg in 20–100 mL with sodium chloride 0.9% or glucose 5%.

Other information
- To convert from IV to oral multiply by 2–3 (usually 2.5).
- Dose and monitor blood levels in accordance with local protocol.

Reference:
Cidofovir

Clinical use
- Treatment of CMV retinitis in patients with AIDS, if other agents are unsuitable
- Treatment of BK polyoma virus in transplant patients (unlicensed)

Dose in normal renal function
- 5 mg/kg weekly for 2 weeks then once every 2 weeks.
- (See further information for BK polyoma virus treatment)

Pharmacokinetics
- Molecular weight (daltons): 279.2
- Protein binding: <6%
- % Excreted unchanged in urine: 80–100%
- Volume of distribution (L/kg): 0.3–0.8
- Half-life — normal/ESRF (hrs): 1.7–2.7 / 16–25

Metabolism
After IV doses of cidofovir, serum concentrations decline with a reported terminal half-life of about 2.2 hours (the intracellular half-life of the active diphosphate may be up to 65 hours).
Cidofovir is eliminated mainly by renal excretion, both by glomerular filtration and tubular secretion. About 80–100% of a dose is recovered unchanged from the urine within 24 hours. Use with probenecid may reduce the excretion of cidofovir to some extent by blocking tubular secretion, although 70–85% has still been reported to be excreted unchanged in the urine within 24 hours.

Dose in renal impairment GFR (mL/min)
- >55: Dose as in normal renal function.
- <55: See 'Other information'.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. 0.5 mg/kg/dose.
- HD: Dialysed. 0.5 mg/kg/dose.
- HDF/High flux: Dialysed. 0.5 mg/kg/dose.
- CAV/VVHD: Unknown dialysability. 0.5 mg/kg/dose.

Important drug interactions
- Potentially hazardous interactions with other drugs
  - Antivirals: avoid concomitant use with tenofovir.

Administration
Reconstitution
-
Route
IV infusion
Rate of administration
Over 60 minutes
Comments
Dilute in 100 mL sodium chloride 0.9%.

Other information
- Always administer with oral probenecid and intravenous sodium chloride 0.9%.
- Administer 2 hours before dialysis session to benefit from peak concentration without having delayed clearance.
- 52–75% of dose dialysed out with high-flux haemodialysis.
- Information for the treatment of BK polyoma virus in transplant patients is from Pittsburgh. Starting dose was 0.25 mg/kg (if GFR<30 mL/min) in 100 mL sodium chloride 0.9% administered over 1 hour, given every 10–14 days. Hydration pre- and post-dose with 1 Litre of sodium chloride 0.9% if tolerated. If no change within 10–14 days increase to 0.3–0.5 mg/kg; dose can be increased up to 1 mg/kg depending on response and side effects. Most patients would need a cumulative dose of 1–1.5 mg/kg. Initially use without probenecid. Monitor blood and urine samples for PCR measurement of viral load.
- The manufacturer advises to avoid in renal failure but theoretical doses, based on a 70 kg person, are suggested in the following paper:

Reference:

<table>
<thead>
<tr>
<th>CRCL (mL/min/kg)</th>
<th>Dose (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3–1.8</td>
<td>5</td>
</tr>
<tr>
<td>1–1.2</td>
<td>4</td>
</tr>
<tr>
<td>0.8–0.9</td>
<td>3</td>
</tr>
<tr>
<td>0.7</td>
<td>2.5</td>
</tr>
<tr>
<td>0.5–0.6</td>
<td>2</td>
</tr>
<tr>
<td>0.4</td>
<td>1.5</td>
</tr>
<tr>
<td>0.2–0.3</td>
<td>1</td>
</tr>
<tr>
<td>0.1</td>
<td>0.5</td>
</tr>
</tbody>
</table>
Cilostazol

**Clinical use**
Intermittent claudication

**Dose in normal renal function**
100 mg twice daily, 30 minutes before or 2 hours after food

**Pharmacokinetics**
- Molecular weight (daltons): 369.5
- % Protein binding: 95–98
- % Excreted unchanged in urine: <2 as dehydro-cilostazol (74% as metabolites)
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 10.5–13 / Unchanged

**Metabolism**
Cilostazol is extensively metabolised in the liver by cytochrome P450 isoenzymes, mainly CYP3A4 and to a lesser extent CYP2C19, to both active and inactive metabolites; these are mainly excreted in the urine (74%) with the remainder in the faeces (20%). The active metabolites have apparent elimination half-lives of 11–13 hours.

**Dose in renal impairment GFR (mL/min)**
- 25–50: Dose as in normal renal function.
- 10–25: Dose as in normal renal function. Use with caution. See 'Other information'.
- <10: Dose as in normal renal function. Use with caution. See 'Other information'.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–25 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anagrelide: avoid concomitant use.

- Antibacterials: concentration increased by clarithromycin and erythromycin – consider reducing cilostazol dose.
- Antifungals: concentration possibly increased by ketoconazole and itraconazole – consider reducing cilostazol dose.
- Antivirals: concentration possibly increased by boceprevir, ritonavir and telaprevir – reduce cilostazol dose to 50 mg twice daily.
- Calcium-channel blockers: concentration increased by diltiazem – consider reducing cilostazol dose.
- Ulcer-healing drugs: concentration increased by omeprazole – consider reducing cilostazol dose.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- There are two major metabolites, a dehydro-cilostazol and a 4'-trans-hydroxy cilostazol, both of which have similar apparent half-lives. The dehydro metabolite is 4–7 times as active a platelet anti-aggregant as the parent compound, and the 4'-trans-hydroxy metabolite is one fifth as active.
- In subjects with severe renal impairment, the free fraction of cilostazol was 27% higher and both C<sub>max</sub> and AUC were 29% and 39% lower respectively than in subjects with normal renal function. The C<sub>max</sub> and AUC of the dehydro metabolite were 41% and 47% lower respectively in the severely renally impaired subjects compared to subjects with normal renal function. The C<sub>max</sub> and AUC of 4'-trans-hydroxy cilostazol were 173% and 209% greater in subjects with severe renal impairment. The drug should be used with great caution if administered to patients with a creatinine clearance <25 mL/min.
- Contraindicated in patients with heart failure.
- Contraindicated by manufacturer if GFR<25 mL/min in the UK but only a use with caution in the US data sheet.
- Cilostazol is under investigation for its antiplatelet effect after coronary stent implantation.
- Dose can also be reduced to 50 mg twice daily if used with drugs which affect its clearance.
Cimetidine

Clinical use

H₂ antagonist:
- Conditions associated with hyperacidity
- Refractory uraemic pruritus (unlicensed use)

Dose in normal renal function

- Oral: duodenal and gastric ulceration treatment: 800 mg at night, or 400 mg twice daily; rarely, up to 1.6 g daily. Prophylaxis: 400 mg at night or 400 mg twice daily. Prophylaxis of stress ulceration: 200–400 mg every 4–6 hours.
- Reflux oesophagitis: 400 mg every 6 hours.
- Zollinger-Ellison syndrome: 400 mg every 6 hours.

Pharmacokinetics

Molecular weight (daltons) 252.3
% Protein binding 20
% Excreted unchanged in urine 50–75
Volume of distribution (L/kg) 1–1.3
Half-life — normal/ESRF (hrs) 2–3 / 5

Metabolism

The bioavailability of cimetidine after oral doses is about 60–70%, due to hepatic first-pass metabolism. Cimetidine is partially metabolised in the liver to the sulfoxide and to hydroxymethylcimetidine. About 50% of an oral dose, and 75% of an intravenous dose, is excreted unchanged in the urine in 24 hours. After an oral or parenteral dose of 300 mg, blood concentrations remain above that required to provide 80% inhibition of basal gastric acid secretion for 4–5 hours.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>200 mg four times daily.</td>
</tr>
<tr>
<td>15–30</td>
<td>200 mg three times daily.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>200 mg twice daily.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. 300 mg every 8 hours.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Alpha-blockers: effects of tolazoline antagonised.
- Aminophylline and theophylline: metabolism of aminophylline and theophylline inhibited.
- Anti-arrhythmics: increased concentration of amiodarone, flecainide, lidocaine, procainamide and propafenone.
- Anticoagulants: enhanced effect of coumarins.
- Antiepileptics: metabolism of carbamazepine, fosphenytoin, phenytoin and valproate inhibited.
- Antifungals: absorption of itraconazole and ketoconazole reduced; posaconazole concentration reduced – avoid; terbinafine concentration increased.
- Antimalarials: avoid with artemether/lumefantrine; metabolism of chloroquine, hydroxychloroquine and quinine inhibited.
- Antipsychotics: possibly enhanced effect of antipsychotics, chlorpromazine and clozapine.
- Antivirals: concentration of atazanavir reduced; concentration of raltegravir and saquinavir possibly increased – avoid; avoid for 12 hours before and 4 hours after rilpivirine.
- Ciclosporin: possibly increased ciclosporin levels.
- Clopidogrel: possibly reduces antiplatelet effect.
- Cytotoxics: possibly enhances myelosuppressive effects of carmustine and lomustine; concentration of epirubicin and fluorouracil increased; avoid with dasatinib and erlotinib; possibly reduced absorption of lapatinib; possibly reduced absorption of pazopanib – give at least 2 hours before or 10 hours after cimetidine.
- Ergot alkaloids: increased risk of ergotism – avoid.
- Fampridine: avoid concomitant use.
- Ulipristal: contraceptive effect possibly reduced – avoid with high dose ulipristal.
### Administration

<table>
<thead>
<tr>
<th>Reconstitution</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Route</th>
<th>Rate of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

### Other information

- Inhibits tubular secretion of creatinine.
- Uraemic patients susceptible to mental confusion.
# Cinacalcet

## Clinical use

Calcimimetic agent:
- Treatment of secondary hyperparathyroidism in patients with CKD 5 on dialysis
- Treatment of primary hyperparathyroidism
- Treatment of hypercalcaemia in patients with parathyroid carcinoma

## Dose in normal renal function

- Secondary hyperparathyroidism: 30–180 mg once daily
- Parathyroid carcinoma and primary hyperparathyroidism: 30 mg twice daily increasing to a maximum of 90 mg 4 times a day

## Pharmacokinetics

- Molecular weight (daltons): 393.9 as hydrochloride
- % Protein binding: 93–97
- % Excreted unchanged in urine: 80
- Volume of distribution (L/kg): 1000 Litres
- Half-life — normal/ESRF (hrs): 30–40 / Unchanged

## Metabolism

Cinacalcet is rapidly and extensively metabolised by cytochrome P450 isoenzymes CYP3A4 and CYP1A2, by oxidation followed by conjugation. The major circulating metabolites are inactive, and are renally excreted, with 80% of the dose recovered in the urine, and 15% in the faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs:
- Antifungals: metabolism inhibited by ketoconazole.
- Hormone antagonists: metabolism of tamoxifen to active metabolite inhibited – avoid.
- Tobacco: metabolism increased by tobacco.

## Administration

### Reconstitution
- **Route**: Oral

### Rate of administration
- **Comments**: Take with food or shortly after a meal

### Other information
- Adjust dose according to response.
- Monitor calcium levels to prevent hypocalcaemia.
- Can be used in combination with vitamin D analogues and phosphate binders.
- Steady state is achieved after 7 days.

## Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unlikely to be dialysed. Dose as normal renal function.
- **CAV/VVHD**: Not Dialysed. Dose as in normal renal function.
Cinnarizine

**Clinical use**

- Vestibular disorders
- Motion sickness

**Dose in normal renal function**

- Vestibular disorders: 30 mg 3 times a day
- Motion sickness: 30 mg 2 hours before travel then 15 mg every 8 hours when required

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>368.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>80</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–6 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Cinnarizine is extensively metabolised mainly via CYP2D6, but there is considerable inter-individual variation in the extent of metabolism. The elimination of metabolites occurs as follows: one third in the urine (unchanged as metabolites and glucuronide conjugates) and two thirds in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

- Potentially hazardous interactions with other drugs
  - Analgesics: possibly increased sedative effects with opioid analgesics.

**Administration**

- **Reconstitution**
  - **Route** Oral
  - **Rate of administration**
Ciprofibrate

Clinical use
Hyperlipidaemia

Dose in normal renal function
100 mg daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>289.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95–99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20–25</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>12 litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>38–86 / 171.9</td>
</tr>
</tbody>
</table>

Metabolism
Approximately 30–75% of a single dose administered to volunteers was excreted in the urine in 72 hours, either as unchanged ciprofibrate (20–25% of the total excreted) or as a glucuronide conjugate. Subjects with moderate renal impairment excreted on average 7% of a single dose as unchanged ciprofibrate over 96 hours, compared with 6.9% in normal subjects. In subjects with severe insufficiency this was reduced to 4.7%.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>100 mg every 48 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid. See ‘Other information.’</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Avoid.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Avoid.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Avoid.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant use.
- Anticoagulants: enhances effect of coumarins and phenindione. Dose of anticoagulant should be reduced by up to 50% and readjusted by monitoring INR.
- Antidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureas.
- Colchicine: possible increased risk of myopathy.
- Lipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe (Do not exceed 10 mg of simvastatin and 20 mg of rosuvastatin.) – avoid with ezetimibe.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Increased risk of rhabdomyolysis in doses of 200 mg or greater.

Reference:
## Ciprofloxacin

### Clinical use
Antibacterial agent

### Dose in normal renal function
- Oral: 250–750 mg every 12 hours
- IV: 100–400 mg every 8–12 hours

### Pharmacokinetics
- Molecular weight (daltons): 331.3
- % Protein binding: 20–40
- % Excreted unchanged in urine: 40–70
- Volume of distribution (L/kg): 2.5

### Metabolism
Ciprofloxacin is eliminated principally by urinary excretion, but non-renal clearance may account for about one-third of elimination and includes hepatic metabolism, biliary excretion, and possibly transmural secretion across the intestinal mucosa. At least 4 active metabolites have been identified. Oxociprofloxacin appears to be the major urinary metabolite and sulfociprofloxacin the primary faecal metabolite. Urinary excretion is by active tubular secretion as well as glomerular filtration and is reduced by probenecid; it is virtually complete within 24 hours. About 40–50% of an oral dose is excreted unchanged in the urine and about 15% as metabolites. Up to 70% of a parenteral dose may be excreted unchanged within 24 hours and 10% as metabolites. Faecal excretion over 5 days has accounted for 20–35% of an oral dose and 15% of an intravenous dose.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>50–100% of normal dose.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of normal dose. (100% dose may be given for short periods under exceptional circumstances.)</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Not dialysed. Oral: 250 mg every 8–12 hours. IV: 200 mg every 12 hours.
- **HD**: Not dialysed. Oral: 250–500 mg every 12 hours. IV: 200 mg every 12 hours.
- **HDF/High flux**: Unknown dialysability. Oral: 250–500 mg every 12 hours. IV: 200 mg every 12 hours.
- **CAV/VVHD**: Dialysed. Oral: 500–750 mg every 12 hours. IV: 200–400 mg every 12 hours. 'See 'Other information.'

### Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: possibly increased risk of convulsions; increased levels of aminophylline and theophylline.
- Analgesics: increased risk of convulsions with NSAIDs.
- Anticoagulants: anticoagulant effect of coumarins enhanced.
- Antidepressants: metabolism of duloxetine inhibited – avoid; avoid with agomelatine.
- Antimalarials: manufacturer of artemether with lumefantrine advises avoid concomitant use.
- Antipsychotics: possibly increased concentration of olanzapine and clozapine.
- Ciclosporin: variable response; no interaction seen locally; some reports of increased nephrotoxicity.
- Clopidogrel: possibly reduced antiplatelet effect.
- Cytotoxics: possibly increased concentration of bosutinib, ibrutinib and olaparib – avoid or consider reducing dose of bosutinib; possibly reduced excretion of methotrexate; concentration of erlotinib increased.
- Muscle relaxants: tizanidine concentration increased – avoid.
- Pirfenidone: concentration of pirfenidone increased – reduce dose of pirfenidone.
- Tacrolimus: increased levels (anecdotally).

### Administration

#### Reconstitution

- **Route**: Oral, IV
Rate of administration
Infusion: over 30–60 minutes

Comments
- Swallow tablets whole, do not chew.
- Do not take milk, iron preparations, indigestion remedies or phosphate binders at the same time as ciprofloxacin orally.

Other information
- Intraperitoneal ciprofloxacin in CAPD, dose range from 25 mg/L to 100 mg/L.
- In CAPD peritonitis ORAL ciprofloxacin up to 500 mg twice daily may be administered.
- Long-term use in severe renal impairment can lead to the patients becoming nauseous.
- Oral bioavailability is 70–80%.
- Only very small amounts removed by dialysis.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
### Clinical use

Antineoplastic platinum agent:
- Testicular and metastatic ovarian tumours
- Cervical tumours
- Lung carcinoma
- Bladder cancer
- Squamous cell cancer of head and neck

### Dose in normal renal function

- **Single agent therapy:** 50–120 mg/m² as a single dose every 3–4 weeks or 15–20 mg/m² daily for 5 days every 3–4 weeks
- **Combination therapy:** 20 mg/m² and upward, every 3–4 weeks
- **Cervical cancer in combination with radiotherapy:** 40 mg/m² weekly for 6 weeks

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>See ‘Other information’.</td>
</tr>
<tr>
<td>10–20</td>
<td>See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>See ‘Other information’.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- **Aldesleukin:** avoid concomitant use.
- **Antibacterials:** increased risk of nephrotoxicity and possibly ototoxicity with aminoglycosides, capreomycin, polymyxins or vancomycin.
- **Antipsychotics:** avoid with clozapine, increased risk of agranulocytosis.
- **Cytotoxics:** increased risk of ototoxicity with ifosfamide; increased pulmonary toxicity with bleomycin and methotrexate.

### Metabolism

Cisplatin is non-enzymatically transformed into multiple metabolites. More than 90% of the platinum from a dose is protein bound within 2–4 hours; only the unbound fraction has significant antineoplastic activity. There is good uptake of cisplatin in the kidneys, liver and intestine. It also distributes into third spaces such as ascites and pleural fluid.

Excretion of intact drug and metabolites is mainly in the urine but is incomplete and prolonged: up to about 50% of a dose has been reported to be excreted in urine over 5 days, and platinum may be detected in tissue for several months afterwards. The unbound fraction, which is more rapidly cleared (20–80% within 24 hours), may be actively secreted by the renal tubules.

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>300</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>27–45</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.3–1 (terminal half-life 2–5 days)</td>
</tr>
</tbody>
</table>

### Administration

#### Reconstitution
Water for injection to form a 1 mg/mL solution

#### Route
IV infusion

#### Rate of administration
Over 6–8 hours

#### Comments
- Pre-treatment hydration, with 1–2 litres of fluid infused for 8–12 hours prior to cisplatin dose, is recommended in order to initiate diuresis. The drug is then well diluted in 2 Litres sodium chloride 0.9% or glucose-saline solutions to ensure hydration and maintain urine output. Adequate hydration MUST be maintained during the following 24 hours, with potassium and magnesium supplementation given as necessary.
- Cisplatin solutions react with aluminium – do not use equipment containing aluminium.
Other information

- Contraindicated by manufacturer.
- Dose modification depends not only on the degree of renal dysfunction, but also on the intended dose and the therapeutic end-point. In general, any patient with a GFR<70 mL/min should be highlighted as 'at risk' from cisplatin renal toxicity.

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
<td>100%</td>
</tr>
<tr>
<td>50–60</td>
<td>75%</td>
</tr>
<tr>
<td>40–50</td>
<td>50%</td>
</tr>
<tr>
<td>&lt;40</td>
<td>Avoid</td>
</tr>
</tbody>
</table>

- Bennett

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;50</td>
<td>100%</td>
</tr>
<tr>
<td>10–50</td>
<td>75%</td>
</tr>
<tr>
<td>&lt;10 and HD</td>
<td>50%</td>
</tr>
</tbody>
</table>

- An alternative approach is to consider changing to carboplatin, which can be dosed specifically according to GFR.
- Ototoxicity, nephrotoxicity and myelosuppression reported. Check hearing, renal function and haematology before treatment and before each subsequent course.
- Toxicity is also associated with cumulative doses of cisplatin.
- Hypomagnesaemia, hypocalcaemia and hyperuricaemia observed.
- The addition of mannitol to the infusion may aid diuresis and protect the kidneys.
Citalopram

Clinical use

SSRI antidepressant:
- Depressive illness
- Panic disorder

Dose in normal renal function

10–40 mg daily
Oral drops: 8–32 mg (4 drops = 8 mg liquid = 10 mg tablet)

Pharmacokinetics

Molecular weight (daltons) 324.4
% Protein binding <80
% Excreted unchanged in urine 12
Volume of distribution (L/kg) 12.3
Half-life — normal/ESRF (hrs) 36 / 49.5

Metabolism

Citalopram is metabolised by demethylation, deamination, and oxidation to active and inactive metabolites. The demethylation of citalopram to one of its active metabolites, demethylcitalopram, involves the cytochrome P450 isoenzymes CYP3A4 and CYP2C19; the metabolism of citalopram is also partly dependent on CYP2D6. Didemethylcitalopram has also been identified as a metabolite of citalopram.

It is excreted mainly via the liver (85%) with the remainder via the kidneys. About 12% is excreted in the urine as unchanged drug.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Analgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone, disopyramide and dronedarone – avoid.
- Antibacterials: possibly increased risk of ventricular arrhythmias with IV erythromycin, moxifloxacin, pentamidine and telithromycin.
- Anticoagulants: effect of coumarins possibly enhanced; possibly increased risk of bleeding with dabigatran.
- Antidepressants: avoid with MAOIs and moclobemide, increased risk of toxicity; avoid with St John’s wort; possibly enhanced serotonergic effects with dapoxetine and duloxetine; can increase tricyclics antidepressant concentration; increased agitation and nausea with tryptophan; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered.
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol; possible increased risk of ventricular arrhythmias with chloroquine and quinine.
- Antipsychotics: possibly increased clozapine concentration; increased risk of ventricular arrhythmias with haloperidol and pimozide – avoid.
- Antivirals: concentration possibly increased by ritonavir.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol – avoid.
- Dopaminergics: avoid with selegiline; increased risk of CNS toxicity with rasagiline.
- 5 HT₁ agonist: increased risk of CNS toxicity – avoid; possibly increased risk of serotonergic effects with naratriptan.
- Lithium: increased risk of CNS effects.
- Methylthioninium: risk of CNS toxicity – avoid if possible.

Administration

Reconstitution
Route
Oral
Rate of administration
—

Other information
- Only 1% of drug is removed by haemodialysis.
- There is reduced clearance of citalopram in severe renal failure.
- Use with caution due to lack of information from manufacturer.
- Risk of QT prolongation and ventricular arrhythmias. Maximum dose in elderly, poor metabolisers of CYP2C19 and patients with hepatic failure is 20 mg.
Cladribine

**Clinical use**
Antineoplastic agent:
- Hairy cell leukaemia (HCL)
- Chronic lymphocytic leukaemia (CLL) in patients who have failed to respond to standard regimens.

**Dose in normal renal function**

**Leustat:**
- HCL: 0.09 mg/kg (3.6 mg/m²) daily for 7 days
- CLL: 0.12 mg/kg (4.8 mg/m²) daily for 2 hours on days 1–5 of a 28-day cycle

**Litak:**
- HCL: 0.14 mg/kg/day for 5 days by subcutaneous injection
- Or according to local protocol

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>285.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>20</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>18</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>9</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–22 / No data</td>
</tr>
</tbody>
</table>

**Metabolism**
Cladribine is extensively distributed and penetrates into the CNS. Cladribine is phosphorylated within cells by deoxycytidine kinase to form 2-chlorodeoxyadenosine-5'-monophosphate which is further phosphorylated to the diphosphate by nucleoside monophosphate kinase and to the active metabolite 2-chlorodeoxyadenosine-5'-triphosphate (CdATP) by nucleoside diphosphate kinase. CdATP inhibits DNA synthesis and repair, particularly in lymphocytes and monocytes.

There is little information available on the route of excretion of cladribine in man. An average of 18% of the administered dose has been reported to be excreted in urine of patients with solid tumours during a 5-day continuous intravenous infusion.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>75% of dose</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>75% of dose</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of dose</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR = 10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.
- Antivirals: avoid with lamivudine.
- Caution when administering with any other immunosuppressive or myelosuppressive therapy.

**Administration**

**Reconstitution**
—

**Route**
SC, IV infusion

**Rate of administration**
24 hours or 2 hours depending on condition being treated.

**Comments**
Add to 100–500 mL of sodium chloride 0.9%

**Other information**

- Prodrug – activated by intracellular phosphorylation. The nucleotide that is formed accumulates in the cell and is incorporated into the DNA.
- Regular monitoring is recommended in renal failure.
- Acute renal insufficiency has developed in some patients receiving high-dose cladribine.
- Use with caution advised by manufacturer due to inadequate data on dosing of patients with renal insufficiency therefore use according to clinical need.
- Dosing in renal impairment is from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- A study showed that <10% of dose is excreted in urine as metabolites and <20% as parent drug.
Clarithromycin

**Clinical use**
Antibacterial agent:
- Also adjunct in treatment of duodenal ulcers by eradication of *H pylori*

**Dose in normal renal function**
- Oral: 250–500 mg every 12 hours
- XL: 500–1000 mg once daily
- IV: 500 mg every 12 hours

**Pharmacokinetics**
- Molecular weight (daltons): 748
- % Protein binding: 80
- % Excreted unchanged in urine: 15–40
- Volume of distribution (L/kg): 2–4
- Half-life — normal/ESRF (hrs): 3–7 / Prolonged

**Metabolism**
The microbiologically active metabolite 14-hydroxyclarithromycin is formed by first pass metabolism. The pharmacokinetics of clarithromycin are non-linear. At 250 mg bd, 15–20% of unchanged drug is excreted in the urine. With 500 mg bd dosing urinary excretion is approximately 36%. The 14-hydroxyclarithromycin is the major urinary metabolite and accounts for 10–15% of the dose. Most of the remainder of the dose is eliminated in the faeces, primarily via the bile. 5–10% of the parent drug is recovered from the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Oral: 250–500 mg every 12 hours. IV: 250–500 mg every 12 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Oral: 250–500 mg every 12 hours. IV: 250–500 mg every 12 hours. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–30 mL/min. See ‘Other information’.

**Important drug interactions**
Potentially hazardous interactions with other drugs:
- Anti-arrhythmics: possibly increased disopyramide concentration; increased risk of ventricular arrhythmias with dronedarone – avoid.
- Antibacterials: increased rifabutin concentration – reduce rifabutin dose; concentration of bedaquiline possibly increased – avoid if for more than 14 days; possibly increased risk of ventricular arrhythmias with delamanid; avoid with fidaxomicin; clarithromycin concentration reduced by rifamycins.
- Anticoagulants: avoid with apixaban; effect of coumarins enhanced; increased risk of bleeding with dabigatran.
- Antidepressants: avoid with reboxetine; concentration of trazodone possibly enhanced.
- Antiepileptics: increased carbamazepine, phenytoin and fosphenytoin concentration.
- Antifungals: avoid combination with ketoconazole in severe renal impairment; concentration of itraconazole increased.
- Antihistamines: metabolism of mizolastine inhibited – avoid.
- Antimalarials: avoid concomitant administration with artemether/lumefantrine; increased risk of ventricular arrhythmias with piperaquine with arteminol – avoid.
- Antimuscarnics: reduce dose of fosoterodine; avoid with tolterodine.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol and pimozide – avoid; possibly increased lurasidone and quetiapine concentration – avoid.
- Antivirals: concentration of both drugs increased with atazanavir and telaprevir; concentration of daclatasvir increased – reduce dose of daclatasvir; avoid with dasabuvir and paritaprevir; concentration of clarithromycin reduced by efavirenz and active metabolites of clarithromycin increased; concentration of etravirine increased and clarithromycin concentration reduced; concentration of maraviroc possibly increased – consider reducing maraviroc dose; concentration reduced by nevirapine but active metabolite increased also nevirapine concentration increased; concentration of tipranavir possibly increased – avoid; increased risk of ventricular arrhythmias with saquinavir – avoid; avoid with simeprevir; oral clarithromycin reduces absorption of zidovudine; concentration increased by ritonavir and tipranavir, also concentration of...


**Administration**

**Reconstitution**
Add 10 mL water for injection to vial (500 mg). Add reconstituted product to 250 mL glucose 5% or sodium chloride 0.9%. (Stable in 100 mL, but more likely to cause phlebitis, pain and inflammation at the injection site.)

**Route**
IV infusion into one of the larger proximal veins. Not to be administered by bolus or IM injection.

**Rate of administration**
Over 60 minutes.

**Other information**

- Use with caution in renal or hepatic failure.
- Oral bioavailability is 55%.
- Patients with GFR<10 mL/min, vomiting may be a problem with high doses.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid flux within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

**References:**

Clemastine

Clinical use

Antihistamine:
- Symptomatic relief of allergy such as hay fever, urticaria

Dose in normal renal function

1–3 mg twice daily

Pharmacokinetics

Molecular weight (daltons) 460 (as fumarate)
% Protein binding 95–98%
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 7–15
Half-life — normal/ESRF (hrs) 21 / –

Metabolism

Extensively metabolised in the liver mainly by mono- and didemethylation and glucuronide conjugation. The metabolites are mainly excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Probably dialysed. Dose as in normal renal function.
- CAV/VVHD: Probably dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Analgesics: sedative properties increased with opioid analgesics.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

Reference:
Clindamycin

Clinical use
Antibacterial agent

Dose in normal renal function
- Oral: 150–450 mg every 6 hours
- Endocarditis prophylaxis: 600 mg 1 hour before procedure
- IV/IM: 0.6–4.8 g daily in 2–4 divided doses
- Prophylaxis: 300 mg 15 minutes before procedure then 150 mg 6 hours later.

Pharmacokinetics
Molecular weight (daltons) 461.4 (as hydrochloride); 505 (as phosphate)
% Protein binding >90
% Excreted unchanged in urine 10
Volume of distribution (L/kg) 0.6–1.2
Half-life — normal/ESRF (hrs) 2–3 / 3–5

Metabolism
Clindamycin undergoes metabolism, presumably in the liver, to the active N-demethyl and sulfoxide metabolites, and also to some inactive metabolites. About 10% of a dose is excreted in the urine as active drug or metabolites and about 4% in the faeces; the remainder is excreted as inactive metabolites. Excretion is slow, and takes place over several days.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
<td></td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Ciclosporin: may cause reduced ciclosporin levels.
- Erythromycin: antagonism demonstrated in vitro; manufacturers recommend that the two drugs should not be administered concurrently.
- Muscle relaxants: enhanced neuromuscular blockade.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Administration
Reconstitution
- Route Oral, IV, IM
- Rate of administration 10–60 minutes.

Comments
- Dilute prior to IV administration: up to 900 mg, in at least 50 mL of diluent; over 900 mg, in 100 mL of diluent. Compatible with sodium chloride 0.9% or glucose 5%.
- Administration of more than 1200 mg in a single 1 hour infusion is not recommended.
- Doses greater than 600 mg should be given as IV infusions.

Other information
- Capsules should be swallowed whole with a glass of water.
- Pseudomembranous colitis may occur.
- Periodic kidney and liver function tests should be carried out during prolonged therapy.
- Dosage may require reduction in patients with severe renal impairment due to prolonged half-life.
**Clobazam**

**Clinical use**
Benzodiazepine:
- Anticonvulsant
- Anxiolytic

**Dose in normal renal function**
20–30 mg daily; maximum 60 mg daily

**Pharmacokinetics**
- Molecular weight (daltons): 300.7
- % Protein binding: 85
- % Excreted unchanged in urine: 87 (unchanged drug and metabolite)
- Volume of distribution (L/kg): 0.87–1.83
- Half-life — normal/ESRF (hrs): 11–77 (42 hours for metabolite) / –

**Metabolism**
Clobazam is metabolised in the liver by demethylation and hydroxylation; the cytochrome P450 isoenzyme CYP2C19 plays a role in its metabolism. Unlike the 1,4-benzodiazepines such as diazepam, clobazam, a 1,5-benzodiazepine, is hydroxylated at the 4-position rather than the 3-position.

Clobazam is excreted unchanged and as its main active metabolite, N-desmethylclobazam, mainly in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. Start with low doses.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism possibly increased by rifampicin.
- Antipsychotics: increased sedative effects; serious adverse events reported with clozapine and benzodiazepines.
- Antivirals: concentration possibly increased by ritonavir.
- Disulfiram: metabolism of clobazam inhibited; increased sedative effects.
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Syrup is available.
- Causes less sedation than clonazepam.
- There is a case report of clobazam being used to treat phantom limb pain at a dose of 10 mg 3 times a day. (Rice-Oxley CP. The limited list: clobazam for phantom limb pain. BMJ. 1986; 293(6557): 1309.)
Clofazimine

Clinical use
Treatment of leprosy

Dose in normal renal function
- Multibacillary leprosy: 300 mg once monthly (supervised) and 50 mg daily or 100 mg alternate days (unsupervised)
- Lepromatous lepra reactions: 300 mg daily

Pharmacokinetics
Molecular weight (daltons) 473.4
% Protein binding Low
% Excreted unchanged in urine <1
Volume of distribution (L/kg) High
Half-life — normal/ESRF (hrs) 10–70 days / Unchanged

Metabolism
Because of its lipophilic nature, clofazimine is mainly distributed to fatty tissue and reticuloendothelial cells, including macrophages. Clofazimine accumulates in the body and is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. About 1% of the dose is excreted in 24 hours in the urine as unchanged clofazimine and metabolites. A small amount of clofazimine is also excreted through sebaceous and sweat glands, and in sputum.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of ventricular arrhythmias with bedaquiline.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- In the sunlight a red/brown discolouration may appear on the skin.
- Secretions may also become a red/brown colour.
- Available on a named patient basis.

Reference:
Clomethiazole (chlormethiazole)

Clinical use
- Alcohol withdrawal
- Insomnia
- Restlessness and agitation

Dose in normal renal function
- Alcohol withdrawal: 2–4 capsules stat, then:
  - Day 1: 3 capsules 3 or 4 times daily
  - Day 2: 2 capsules 3 or 4 times daily
  - Day 3: 1 capsule 4 times daily
  - Reduce over a further 4–6 days; give a total treatment of not more than 9 days
- Insomnia: 1–2 capsules at night. Or 5–10 mL at night.
- Restlessness and agitation: 1 capsule 3 times daily. Or 5 mL three times day

Pharmacokinetics
- Molecular weight (daltons) 161.7
- % Protein binding 65
- % Excreted unchanged in urine 0.1–5
- Volume of distribution (L/kg) 4–16
- Half-life — normal/ESRF (hrs) 4 / Unchanged

Metabolism
Clomethiazole is extensively metabolised, probably by first-pass metabolism in the liver with only small amounts appearing unchanged in the urine. The rate of elimination is decreased by about 30% in liver cirrhosis.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. See 'Other information'.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: enhanced sedative effects.
- Antivirals: concentration possibly increased by ritonavir.
- Cimetidine: inhibits metabolism of clomethiazole.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—
Comments
Syrup should be stored in a fridge.

Other information
- Clomethiazole has a high hepatic extraction ratio.
- Increased cerebral sensitivity in renal impairment.
- Manufacturers recommend caution should be observed in patients with chronic renal disease.
Clomipramine hydrochloride

Clinical use
- Depressive illness
- Phobic and obsessional states
- Adjunctive treatment of cataplexy associated with narcolepsy

Dose in normal renal function
- 10–250 mg daily
- Cataplexy: 10–75 mg daily

Pharmacokinetics
Molecular weight (daltons) 351.3
% Protein binding 97.6
% Excreted unchanged in urine 2
Volume of distribution (L/kg) 12–17
Half-life — normal/ESRF (hrs) 12–36 /

Metabolism
Clomipramine is extensively demethylated during first-pass metabolism in the liver to its primary active metabolite, desmethylclomipramine. Clomipramine has been estimated to have a plasma elimination half-life of about 21 hours; that of desmethylclomipramine is longer (about 36 hours).

Paths of metabolism of both clomipramine and desmethylclomipramine include hydroxylation and N-oxidation. About two-thirds of a single dose of clomipramine is excreted in the urine, mainly in the form of its metabolites, either free or in conjugated form; the remainder of the dose appears in the faeces.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Alcohol: increased sedative effect.
- Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; increased risk of ventricular arrhythmias with disopyramide, flecainide or propafenone; avoid with droxidone.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin and possibly telithromycin – avoid with delamanid and moxifloxacin.
- Anticoagulants: may alter anticoagulant effect of coumarins.
- Antidepressants: possibly increased serotonergic effects with duloxetine; enhanced CNS excitation and hypertension with MAOIs and moclobemide; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram – avoid; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, phenobarbital and possibly fosphenytoin, phenytoin and primidone.
- Antimalarials: avoid with artemether/lumefantrine and piperquine with artemether.
- Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, fluphenazine, haloperidol, pimozide, sulpiride and zuclopenthixol – avoid; increased risk of ventricular arrhythmias with risperidone; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid; concentration possibly increased with ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Dapoxetine: possibly increased risk of serotonergic effects – avoid.
- Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline.
- Methylthioninium: risk of CNS toxicity – avoid if possible.
- Pentamidine: increased risk of ventricular arrhythmias.
- Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Normal doses have been used in dialysis patients long term, but caution as parent drug and active metabolites may accumulate.
**Clonazepam**

**Clinical use**
Benzodiazepine:
- Anticonvulsant
- Anxiolytic
- Restless leg syndrome

**Dose in normal renal function**
- Oral: 0.5–20 mg daily in 3–4 divided doses or as a single dose at night once on maintenance therapy; normal maintenance dose: 4–8 mg daily.
- IV: 1 mg, repeated if necessary.
- Restless legs syndrome: 0.5–4 mg at night.

**Pharmacokinetics**
- Molecular weight (daltons) 315.7
- % Protein binding 86
- % Excreted unchanged in urine <0.5
- Volume of distribution (L/kg) 3
- Half-life — normal/ESRF (hrs) 20–60 / –

**Metabolism**
Clonazepam is extensively metabolised in the liver, its principal metabolite being 7-aminoclonazepam, which has no antiepileptic activity; minor metabolites are the 7-acetamido- and 3-hydroxy-derivatives.
It is excreted mainly in the urine almost entirely as its metabolites in free or conjugated form.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Start at low dose and increase according to response.
- 10–20: Start at low dose and increase according to response.
- <10: Start at low dose and increase according to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR <10 mL/min.
- HD: Not dialysed. Dose as in GFR <10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as GFR <10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in GFR = 10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism possibly increased by rifampicin.
- Antipsychotics: increased sedative effects; increased risk of hypotension, bradycardia and respiratory depression with parenteral clonazepam and IM olanzapine; risk of serious adverse effects in combination with clozapine.
- Antivirals: concentration possibly increased by ritonavir.
- Disulfiram: metabolism inhibited, increased sedative effects.
- Sodium oxybate: enhanced effects of sodium oxybate — avoid.

**Administration**

**Reconstitution**
- IV bolus: Reconstitute with 1 mL diluent (water for injection) to give 1 mg in 1 mL solution.
- IV infusion: up to 3 mg (3 amps) added to 250 mL sodium chloride 0.9% or glucose 5%.

**Route**
- Oral, IV bolus or infusion.

**Rate of administration**
- IV bolus: 0.25–0.5 mg over 1 minute.

**Comments**
IV infusion of clonazepam is potentially hazardous (especially if prolonged), calling for close and constant observation; best carried out in specialist centres with ICU facilities. Risks include apnoea, hypotension and deep unconsciousness.

**Other information**
- In long term administration, active metabolites may accumulate and lower doses should be used.
- Clonazepam is one of several agents that are used in restless leg syndrome, and has also been tried in the management of intractable hiccup where chlorpromazine has failed.
Clonidine hydrochloride

Clinical use
- Hypertension
- Migraine
- Gilles de la Tourette syndrome
- Menopausal flushing

Dose in normal renal function
- Hypertension: 50–100 mcg 3 times a day, increasing gradually to 1.2 mg daily
- Slow IV: 150–300 micrograms; maximum 750 mcg in 24 hours
- Migraine, menopausal flushing, Gilles de la Tourette syndrome: 50–75 mcg twice daily

Pharmacokinetics
Molecular weight (daltons) 266.6
% Protein binding 30–40
% Excreted unchanged in urine 40–60
Volume of distribution (L/kg) 3–6
Half-life — normal/ESRF (hrs) 10–20 / 41

Metabolism
About 50% of a of clonidine dose is metabolised in the liver.
It is excreted in the urine as unchanged drug and metabolites, 40–60% of an oral dose being excreted in 24 hours as unchanged drug; about 20% of a dose is excreted in the faeces, probably via enterohepatic circulation.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: tricyclics antagonise hypotensive effect and also increase risk of hypertension on clonidine withdrawal; increased hypotensive effect with MAOIs; hypotensive effect possibly antagonised by mirtazapine.
- Beta-adrenoreceptor antagonists: increased risk of hypertension on withdrawal.
- Cyclosporin: may increase ciclosporin levels.
- Sympathomimetics: possibly increased risk of hypertension with adrenaline and noradrenaline; serious adverse effects reported with methylphenidate.

Administration
Reconstitution
—
Route
Oral, IV
Rate of administration
Slow IV injection
Comments
Minimum volume for infusion 6–50 mcg/mL in sodium chloride 0.9% or glucose 5%, (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006)

Other information
- Use in renal impairment: clonidine plasma concentrations for a given dose are 2–3 times higher in patients with severe renal impairment; however, blood pressure control appears satisfactory and adverse effects are not increased.
- Clonidine withdrawal: rebound hypertension if drug is abruptly withdrawn.
Clopidogrel

Clinical use

Antiplatelet agent

Dose in normal renal function

75 mg daily
Acute coronary syndrome and post-MI: 300 mg loading dose then 75 mg daily (with aspirin 75–325 mg daily)
Prevention of atherothrombotic events in PCI (adjunct with aspirin) if patient not already on clopidogrel:
Loading dose 300–600 mg before procedure

Pharmacokinetics

Molecular weight (daltons) 419.9 (as hydrogen sulphate)
% Protein binding 98
% Excreted unchanged in urine 50
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 8 (active metabolite)

Metabolism

Clopidogrel is a prodrug and is extensively metabolised in the liver, mainly to the inactive carboxylic acid derivative; metabolism is mediated by cytochrome P450 isoenzymes including CYP3A4 and CYP2B6, CYP1A2, CYP1A1, and CYP2C19. The active metabolite appears to be a thiol derivative.
Clopidogrel and its metabolites are excreted in urine and in faeces; about 50% of an oral dose is recovered from the urine and about 46% from the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type of therapy</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

- Antibacterials: antiplatelet effect possibly reduced by erythromycin.
- Anticoagulants: enhanced anticoagulant effect with coumarins and phenindione; manufacturer advises to avoid with warfarin.
- Heparin: increased risk of bleeding.
- Antidepressants: antiplatelet effect possibly reduced by fluoxetine, fluvoxamine and moclobemide.
- Anti-diabetics: avoid with repaglinide if possible due to increased repaglinide exposure.
- Antiepileptics: antiplatelet effect possibly reduced by carbamazepine and oxcarbazepine.
- Antifungals: antiplatelet effect possibly reduced by fluconazole, itraconazole, ketoconazole and voriconazole.
- Antivirals: antiplatelet effect possibly reduced by etravirine.
- Statins: concentration of rosuvastatin increased, maximum rosuvastatin dose is 20 mg.
- Ulcer healing drugs: antiplatelet effect possibly reduced by cimetidine, Lansoprazole, pantoprazole and rabeprazole; antiplatelet effect reduced by omeprazole and esomeprazole – avoid concomitant use if possible.

Administration

Reconstitution

- Route
  - Oral
- Rate of administration


## Clozapine

### Clinical use

**Atypical antipsychotic:**
- Schizophrenia
- Psychosis in Parkinson's disease

### Dose in normal renal function

- Schizophrenia: 200–450 mg daily in divided doses, maximum 900 mg daily
- Psychosis in Parkinson's disease: 25–37.5 mg daily at night, maximum 100 mg daily in 1–2 divided doses

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>326.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95–97</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal (50% as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.6–6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–26 / –</td>
</tr>
</tbody>
</table>

### Metabolism

Clozapine undergoes extensive first-pass metabolism. The systemic drug is almost completely metabolised and routes of metabolism include N-demethylation, hydroxylation, and N-oxidation; the desmethyl metabolite (norclozapine) has limited activity. The metabolism of clozapine is mediated mainly by the cytochrome P450 isoenzyme CYP1A2.

Metabolites and trace amounts of unchanged drug are excreted mainly in the urine and also in the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with a low dose and titrate slowly.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- **HD**: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR < 10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR = 10–20 mL/min.

### Important drug interactions

Potentially hazardous interactions with other drugs:
- **Anaesthetics**: enhanced hypotensive effect.
- **Analgesics**: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
- **Anti-arrhythmics**: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; increased risk of arrhythmias with flecainide.
- **Antibacterials**: concentration possibly increased by erythromycin (possible increased risk of convulsions); concentration increased by ciprofloxacin; concentration possibly reduced by rifampicin; avoid with chloramphenicol and sulphonamides (increased risk agranulocytosis).
- **Antidepressants**: concentration possibly increased by citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline and venlafaxine (increased risk of toxicity); possibly increased CNS effects of MAOIs; possibly increased antimuscarinic effects with tricyclics; increased concentration of tricyclics.
- **Antiepileptics**: antagonises anticonvulsant effect; metabolism accelerated by carbamazepine, phenytoin and possibly phenobarbital; avoid with drugs known to cause agranulocytosis; concentration possibly increased or decreased by valproate.
- **Antimalarials**: avoid with artemether/lumefantrine.
- **Antipsychotics**: avoid with depot formulations (cannot be withdrawn quickly if neutropenia occurs); possible increased risk of ventricular arrhythmias with risperidone – avoid.
- **Antivirals**: concentration increased by ritonavir – avoid; increased risk of ventricular arrhythmias with saquinavir – avoid.
- **Anxiolytics and hypnotics**: increased sedative effects; adverse reports with clozapine and benzodiazepines.
• Atomoxetine: increased risk of ventricular arrhythmias.
• Cytotoxics: increased risk of agranulocytosis – avoid; increased risk of ventricular arrhythmias with arsenic trioxide.
• Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
• Penicillamine: increased risk of agranulocytosis – avoid.
• Ulcer-healing drugs: effects possibly enhanced by cimetidine; concentration possibly reduced by omeprazole.

**Other information**

• Contraindicated by manufacturer in severe renal impairment.
• Patient must be registered with appropriate company monitoring scheme.
• Associated with myocarditis (increased risk in the first 2 months) and cardiomyopathy.
• Potentially fatal agranulocytosis and neutropenia have been reported. WCC has to be monitored at least weekly for the first 18 weeks then 2 weekly for weeks 18–52 and then at least 4 weekly.
• Increased risk of side effects especially seizures in doses above 450 mg daily.
• Rarely interstitial nephritis has been reported with clozapine.
• Dose in severe renal impairment taken from personal experience.
• Clozapine can cause severe constipation so patients must be monitored closely especially PD patients.

**Administration**

Reconstitution

Route
Oral

Rate of administration

—
Co-amoxiclav
(amoxicillin / clavulanic acid)

Clinical use
Antibacterial agent

Dose in normal renal function
- IV: 1.2 g every 8 hours (increasing to every 6 hours in severe infections)
- Oral: 375–625 mg 3 times daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>Amoxicillin: 365.4; Clavulanic acid: 199.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Amoxicillin: 20; Clavulanic acid: 25</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Amoxicillin: 60; Clavulanic acid: 40</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Amoxicillin: 0.3; Clavulanic acid: 0.3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Amoxicillin: 1–1.5 / 7–20; Clavulanic acid: 1 / 3–4</td>
</tr>
</tbody>
</table>

Metabolism
Amoxicillin is metabolised to a limited extent to penicilloic acid which is excreted in the urine. About 60% of an oral dose of amoxicillin is excreted unchanged in the urine by glomerular filtration and tubular secretion. High concentrations have been reported in bile; some may be excreted in the faeces.
Clavulanic acid is mainly excreted in the urine (73%). Elimination also occurs via expired air (17%) and in the faeces (8%).

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>IV: 1.2 g every 12 hours.</td>
</tr>
<tr>
<td></td>
<td>Oral: Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>IV: 1.2 g stat followed by 600 mg every 8 hours or 1.2 g every 12 hours.</td>
</tr>
<tr>
<td></td>
<td>Oral: Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins are potentially enhanced.
- Oral contraceptives: potentially reduced efficacy.
- Methotrexate: reduced excretion thereby increasing risk of toxicity.
- See 'Other information'.

Administration

Reconstitution
600 mg with 10 mL water for injection; 1.2 g with 20 mL water for injection

Route
Oral, IV

Rate of administration
- IV bolus: over 3–4 minutes.
- Infusion: infuse over 30–40 minutes in 50–100 mL sodium chloride 0.9%.

Comments
- IV preparation is less stable in infusion solutions containing glucose, dextran or bicarbonate. May be injected into drip tubing over period of 3–4 minutes.
- Do not mix with aminoglycosides.

Other information
- CSM has advised that cholestatic jaundice may occur if treatment exceeds a period of 14 days or up to 6 weeks after treatment has been stopped. The incidence of cholestatic jaundice occurring with co-amoxiclav is higher in males than in females, and prevalent particularly in men over the age of 65 years.
The probability of co-amoxiclav associated cholestatic jaundice is 6 times more common than with amoxicillin, and with higher doses of clavulanic acid.

- Doses in renal impairment are taken from personal experience.
- Each 1.2 g vial contains: sodium 2.7 mmol, potassium 1 mmol.
- In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) of approximately 50% has been reported after starting oral co-amoxiclav. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.

There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Co-beneldopa (Madopar)

**Clinical use**
Treatment of Parkinsonism

**Dose in normal renal function**
- 150–800 mg daily in divided doses after meals (expressed as levodopa)
- MR: Initially 1–2 capsules 3 times daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Benserazide</th>
<th>Levodopa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons) HCl</td>
<td>293.7</td>
<td>197.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
<td>10–30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0 (64 as metab)</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
<td>0.36–1.6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.5 / Increased</td>
<td>1.5 / Increased by 25%</td>
</tr>
</tbody>
</table>

**Metabolism**

Levodopa is rapidly decarboxylated by the enzyme aromatic L-amino acid decarboxylase, mostly in the gut, liver, and kidney, to dopamine, which is metabolised in turn, principally to dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Other routes of metabolism include O-methylation, transamination, and oxidation, producing a variety of minor metabolites including noradrenaline and 3-O-methyldopa; the latter may accumulate in the CNS due to its relatively long half-life.

About 80% of an oral dose of levodopa is excreted in the urine within 24 hours, mainly as dihydroxyphenylacetic and homovanillic acids. Only small amounts of levodopa are excreted unchanged in the faeces.

Benserazide is rapidly excreted in the urine in the form of metabolites, mostly within the first 6 hours; 85% of urinary excretion occurs within 12 hours. It is mainly metabolised in the gut and appears to protect levodopa against decarboxylation primarily in the gut, but also in the rest of the body, mainly by way of its metabolite trihydroxybenzylhydrazine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: risk of arrhythmias with volatile liquid anaesthetics such as halothane.
- Antidepressants: hypertensive crisis with MAOIs and linezolid (including moclobemide) – avoid for at least 2 weeks after stopping MAOI.
- Bupropion: increased risk of side effects of levodopa
- Ferrous sulphate: reduces AUC of levodopa by 30–50%, clinically significant in some but not all patients.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Other information**

- Can be used to treat restless legs syndrome at a dose of 62.5–125 mg.
- Urine may be red-tinged and turn dark on standing, due to metabolites.
- Serum uric acid and blood urea nitrogen levels are occasionally elevated.
Co-careldopa (Sinemet)

Clinical use
Treatment of Parkinsonism

Dose in normal renal function
- 150–800 mg carbidopa daily in divided doses after meals
- MR: initially 1 tablet twice daily

Pharmacokinetics
Molecular weight (daltons)  
Carbidopa: 244.2,  
Levodopa: 197.2
% Protein binding  
Carbidopa: 36,  
Levodopa: 10–30
% Excreted unchanged in urine  
Carbidopa: 30,  
Levodopa: <1
Volume of distribution (L/kg)  
Carbidopa: No data,  
Levodopa: 0.36–1.6
Half-life — normal/ESRF (hrs)  
Carbidopa: 2–3,  
Levodopa: 0.6–1.3 / Unknown

Metabolism
Levodopa is rapidly decarboxylated by the enzyme aromatic l-amino acid decarboxylase, mostly in the gut, liver, and kidney, to dopamine, which is metabolised in turn, principally to dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Other routes of metabolism include O-methylation, transamination, and oxidation, producing a variety of minor metabolites including noradrenaline and 3-O-methyldopa; the latter may accumulate in the CNS due to its relatively long half-life.
About 80% of an oral dose of levodopa is excreted in the urine within 24 hours, mainly as dihydroxyphenylacetic and homovanillic acids. Only small amounts of levodopa are excreted unchanged in the faeces.
Carbidopa inhibits the peripheral decarboxylation of levodopa to dopamine. It is rapidly excreted in the urine both unchanged and in the form of metabolites.

Dose in renal impairment GFR (mL/min)
20–50  Dose as in normal renal function.
10–20  Dose as in normal renal function.
<10   Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD  Unlikely to be dialysed. Dose as in normal renal function.
HD  Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux  Dialysed. Dose as in normal renal function.
CA V/VVHD  Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: risk of arrhythmias with volatile liquid anaesthetics such as halothane.
- Antidepressants: hypertensive crisis with MAOIs and linezolid (including moclobemide) – avoid for at least 2 weeks after stopping MAOI.
- Bupropion: increased risk of side effects of levodopa
- Ferrous sulphate: reduces AUC of levodopa by 30–50%, clinically significant in some but not all patients.

Administration
Reconstitution  —
Route  Oral
Rate of administration  —

Other information
- Can be used to treat restless legs syndrome.
- May cause dark urine.
Co-codamol (paracetamol and codeine phosphate)

Clinical use
Analgesic

Dose in normal renal function
1–2 tablets up to 4 times a day

Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>Paracetamol: 151.2; Codeine: 317.4 (Codeine phosphate 406.4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>Paracetamol: 20–30; Codeine: 7</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Paracetamol: &lt;5; Codeine: 0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Paracetamol: 1–1.2; Codeine: 3–4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Paracetamol: 1–4 / Unchanged; Codeine: 2.5–4 / 13</td>
</tr>
</tbody>
</table>

Metabolism
Paracetamol is metabolised mainly in the liver and excreted in the urine mainly as the glucuronide and sulfate conjugates. A minor hydroxylated metabolite (N-acetyl-p-benzoquinoneimine), is usually produced in very small amounts by cytochrome P450 isoenzymes (mainly CYP2E1 and CYP3A4) in the liver and kidney. It is usually detoxified by conjugation with glutathione but may accumulate after paracetamol overdosage and cause tissue damage.

Codeine is metabolised by O- and N-demethylation in the liver to morphine, norcodeine, and other metabolites including normorphine and hydrocodone. Metabolism to morphine is mediated by the cytochrome P450 isoenzyme CYP2D6, which shows genetic polymorphism. Codeine and its metabolites are excreted almost entirely by the kidney, mainly as conjugates with glucuronic acid.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism increased by rifampicin.
- Antidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use, and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Dopaminergics: avoid with selegiline.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

Administration

Reconstitution

Route
Oral

Rate of administration

Other information
- Available in 3 strengths: (1) 8/500; 8 mg codeine phosphate / 500 mg paracetamol; (2) 15/500; 15 mg codeine phosphate / 500 mg paracetamol; (3) 30/500; 30 mg codeine phosphate / 500 mg paracetamol.
- 30/500 formulation: may cause drowsiness, due to increased cerebral sensitivity in patients with renal failure and put patients at risk of constipation.
- Effervescent formulations of Solpadol and Tylex (30/500) should be avoided in renal impairment. They contain 16.9 mmol and 13.6 mmol sodium per tablet respectively.
Co-dydramol (paracetamol and dihydrocodeine)

Clinical use
Analgésic

Dose in normal renal function
1–2 tablets up to 4 times a day.

Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>Paracetamol: 151.2; Dihydrocodeine: 451.5 (as tartrate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>Paracetamol: 20–30; Dihydrocodeine: –</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Paracetamol: &lt;5; Dihydrocodeine: 13–22</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Paracetamol: 1–2; Dihydrocodeine: 1.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Paracetamol: 1–4 / Unchanged; Dihydrocodeine: 3.5–5 / 6+</td>
</tr>
</tbody>
</table>

Metabolism
Paracetamol is metabolised mainly in the liver and excreted in the urine mainly as the glucuronide and sulfate conjugates. A minor hydroxylated metabolite (N-acetyl-p-benzoquinoneimine), is usually produced in very small amounts by cytochrome P450 isoenzymes (mainly CYP2E1 and CYP3A4) in the liver and kidney. It is usually detoxified by conjugation with glutathione but may accumulate after paracetamol overdose and cause tissue damage.

Dihydrocodeine is metabolised in the liver via the cytochrome P450 isoenzyme CYP2D6, to dihydromorphine, which has potent analgesic activity, although the analgesic effect of dihydrocodeine appears to be mainly due to the parent compound; some is also converted via CYP3A4 to nordihydrocodeine. Dihydrocodeine is excreted in urine as unchanged drug and metabolites, including glucuronide conjugates.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>50–100% of dose every 6 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50–100% of dose every 6–8 hours.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use, and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information
Co-trimoxazole (trimethoprim + sulfamethoxazole)

Clinical use

Antibacterial agent:
- Treatment and prophylaxis of Pneumocystis jiroveci pneumonia (PCP)
- Acute exacerbations of chronic bronchitis
- Urinary tract infections, on microbiological advice

Dose in normal renal function

PCP: 120 mg/kg/day in 2–4 divided doses.
Oral prophylaxis: 480–960 mg daily or 960 mg on alternate days.
Acute exacerbations of chronic bronchitis and urinary tract infections on microbiological advice:
- IV: 960 mg – 1.44 g twice a day.
- Oral: 960 mg twice a day.

Pharmacokinetics

Molecular weight (daltons)
- Sulfamethoxazole: 253.3
- Trimethoprim: 290.3

% Protein binding
- Sulfamethoxazole: 70
- Trimethoprim: 45

% Excreted unchanged in urine
- Sulfamethoxazole: 15–30
- Trimethoprim: 40–60

Volume of distribution (L/kg)
- Sulfamethoxazole: 0.28–0.38
- Trimethoprim: 1–2.2

Half-life — normal/ESRF (hrs)
- Sulfamethoxazole: 6–12 / 20–50
- Trimethoprim: 8–10 / 20–49

Metabolism

Sulfamethoxazole undergoes conjugation mainly in the liver, chiefly to the inactive N4-acetyl derivative; this metabolite represents about 15% of the total amount of sulfamethoxazole in the blood. Metabolism is increased in patients with renal impairment and decreased in those with hepatic impairment. Elimination in the urine is dependent on pH. About 80–100% of a dose is excreted in the urine, of which about 60% is in the form of the acetyl derivative, with the remainder as unchanged drug and glucuronide.

Trimethoprim is excreted mainly by the kidneys through glomerular filtration and tubular secretion. About 10–20% of trimethoprim is metabolised in the liver and small amounts are excreted in the faeces via the bile, but most, about 40–60% of a dose, is excreted in urine, mainly as unchanged drug, within 24 hours.

Dose in renal impairment GFR (mL/min)

30–50 Dose as in normal renal function.
15–30 PCP: 60 mg/kg twice daily for 3 days then 30 mg/kg twice daily; Other indications: 50% of dose.
<15 PCP: 30 mg/kg twice daily; Other indications: 50% of dose. (This should only be given if haemodialysis facilities are available.)

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Dose as in GFR<15 mL/min.
HD Dialysed. Dose as in GFR<15 mL/min.
HDF/High flux Dialysed. Dose as in GFR<15 mL/min.
CAV/VVHD Dialysed. Dose as in GFR=15–30 mL/min. See ‘Other information’.

Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: possibly inhibits effects of sulphonamides – avoid.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; concentration of procainamide increased.
- Antibacterials: increased risk of crystalluria with methenamine.
- Anticoagulants: effect of coumarins enhanced; metabolism of phenindione possibly inhibited.
- Antiepileptics: antifolate effect and concentration of phenytoin increased.
Co-trimoxazole (trimethoprim + sulfamethoxazole)

- Antimalarials: increased risk of antifolate effect with pyrimethamine.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Ciclosporin: increased risk of nephrotoxicity; possibly reduced ciclosporin levels.
- Cytotoxics: increased risk of haematological toxicity with azathioprine, methotrexate and mercaptopurine. Antifolate effect of methotrexate increased.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

Reconstitution

**Route**
- IV, oral

**Rate of administration**
- Over 60–90 minutes
- Alternatively: 2–3 hours for high doses as undiluted solution via central line (unlicensed)

**Comments**
- For an IV infusion dilute each 5 mL co-trimoxazole strong solution with 125 mL sodium chloride 0.9% or glucose 5%.
- GlaxoSmithKline: dilute 5 mL to 75 mL glucose 5% and administer over 1 hour if fluid restricted.

**Other information**

- Alternative dosing (for acute exacerbations of chronic bronchitis and urinary tract infections) on microbiological advice only.
- After 2–3 days, plasma samples collected 12 hours post dose should have levels of sulfamethoxazole not higher than 150 micrograms/mL. If higher, stop treatment until levels fall below 120 micrograms/mL.
- Plasma levels of trimethoprim should be 5 micrograms/mL or higher, for optimum efficacy for PCP.
- Folic acid supplementation may be necessary during chronic therapy.
- Monthly blood counts advisable.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid flux within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Cobicistat

**Clinical use**
Pharmacokinetic enhancer used to increase the effect of atazanavir and darunavir

**Dose in normal renal function**
150 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 776
- % Protein binding 97–98
- % Excreted unchanged in urine 8.2
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 3–4

**Metabolism**
Cobicistat is metabolised via CYP3A (major)- and CYP2D6 (minor)-mediated oxidation. Following oral administration of $^{14}$C-cobicistat, 99% of circulating radioactivity in plasma was unchanged cobicistat. Low levels of metabolites are observed in urine and faeces and do not contribute to the CYP3A inhibitory activity of cobicistat. Following oral administration of $^{14}$C-cobicistat, 86% and 8.2% of the dose were recovered in faeces and urine, respectively.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alpha-blockers: concentration of alfuzosin possibly increased – avoid.
- Anti-arrhythmics: concentration of amiodarone possibly increased – avoid.
- Antibacterials: concentration reduced by rifabutin and rifampicin – adjust cobicistat dose, avoid with rifampicin.
- Anticoagulants: avoid with apixaban; anticoagulant effect of rivaroxaban possibly enhanced – avoid.
- Antidepressants: concentration possibly reduced by St John's wort – avoid.
- Antiepileptics: concentration of cobicistat possibly reduced by carbamazepine, fosphenytoin phenobarbital, phenytoin and primidone – avoid.
- Antifungals: concentration of itraconazole and ketoconazole possibly increased – reduce antifungal dose.
- Antipsychotics: concentration of lurasidone and pimozide possibly increased – avoid.
- Antivirals: concentration of daclatasvir and maraviroc possibly increased – reduce daclatasvir and maraviroc dose; avoid with dasabuvir, nevirapine, ombitasvir, paritaprevir, ritonavir and simeprevir; concentration of elbasvir and grazoprevir increased – avoid; concentration of olaparib possibly increased – avoid or reduce olaparib dose; concentration of both drugs reduced with tipranavir – avoid.
- Anxiolytics: avoid with oral midazolam.
- Avanafil: concentration of avanafil possibly increased – avoid.
- Bosentan: avoid concomitant use.
- Cardiac glycosides: concentration of digoxin possibly increased – reduce initial dose of digoxin.
- Corticosteroids: concentration of corticosteroids possibly increased avoid or use with caution.
- Cytotoxics: concentration of ibrutinib possibly increased – reduce ibrutinib dose; concentration of olaparib possibly increased – avoid or reduce olaparib dose; concentration of both drugs reduced with tipranavir – avoid.
- Domperidone: possible increased risk of ventricular arrhythmias – avoid.
- Ergot alkaloids: concentration of ergot alkaloids possibly increased – avoid.
- Immunosuppression: concentration of ciclosporin, sirolimus and tacrolimus possibly increased.
- Lipid-lowering drugs: concentration of atorvastatin possibly increased – reduce atorvastatin dose; avoid with simvastatin.
- Oestrogens: metabolism of oestrogens accelerated, reduced contraceptive effect – avoid or use with caution.
• Salmeterol: avoid concomitant use.
• Sildenafil: concentration of sildenafil possibly increased – avoid sildenafil for pulmonary arterial hypertension, reduce dose for erectile dysfunction.
• Tadalafil: concentration of tadalafil possibly increased – reduce dose of tadalafil.
• Vardenafil: concentration of vardenafil possibly increased – reduce dose of vardenafil.

Administration

Reconstitution

Route
Oral

Rate of administration

Other information
• Manufacturer advises to use with caution in dialysis patients due to lack of data.
• Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Cobimetinib

**Clinical use**

Protein kinase inhibitor:
- Treatment of unresectable or metastatic melanoma with a BRAF V600 mutation in combination with vemurafenib

**Dose in normal renal function**

60 mg daily for 21 days in a 28-day cycle

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1178.7 (as fumarate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>94.8</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>1.6</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>806 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>23.1–69.6 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolised by oxidation by CYP3A and glucuronidation by UGT2B7. Extensively metabolised and eliminated in faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antifungals: concentration increased by itraconazole.
- Antipsychotics: increased risk of agranulocytosis — avoid.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Manufacturer advises to use with caution in severe renal impairment due to lack of data.
- Oral bioavailability is 45.9%.
# Codeine phosphate

## Clinical use
- Analgesic
- Antidiarrhoeal
- Cough suppressant

## Dose in normal renal function
30–60 mg up to every 4 hours

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>406.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>7</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3–4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2.5–4 / 13</td>
</tr>
</tbody>
</table>

## Metabolism
Codeine is metabolised by O- and N-demethylation in the liver to morphine, norcodeine, and other metabolites including normorphine and hydrocodone. Metabolism to morphine is mediated by the cytochrome P450 isoenzyme CYP2D6, which shows genetic polymorphism. Codeine and its metabolites are excreted almost entirely by the kidney, mainly as conjugates with glucuronic acid.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>30 mg up to every 4 hours. Increase if tolerated.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>30 mg up to every 6 hours. Increase if tolerated.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism increased by rifampicin.
- Antidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use, and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

## Administration
### Reconstitution
- Route
  - Oral, IV, IM, SC

### Rate of administration
- IV bolus

## Other information
- Increased risk of drowsiness due to increased cerebral sensitivity in patients with renal failure.
- Increased risk of constipation – caution in patients on peritoneal dialysis.
Colchicine

**Clinical use**

- Acute gout
- Short-term prophylaxis during initial therapy with allopurinol and uricosuric drugs
- Prophylaxis of familial Mediterranean fever (unlicensed)

**Dose in normal renal function**

- Acute: 500 micrograms 2–4 times daily until pain relieved or vomiting/diarrhoea occurs. Maximum of 6 mg per course. Do not repeat course within 3 days.
- Short-term prophylaxis: 500 micrograms 2 times per day
- Prophylaxis of familial Mediterranean fever: 0.5–2 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>399.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>30–50</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5–20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1–2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4.4 / 18.8</td>
</tr>
</tbody>
</table>

**Metabolism**

The absorption of colchicine from the gastrointestinal tract is thought to be limited by its expulsion by P-glycoprotein, for which colchicine is a substrate. It is demethylated in the liver via the cytochrome P450 isoenzyme CYP3A4 to 2 primary metabolites, 2-O-demethylcolchicine and 3-O-demethylcolchicine (2-DMC and 3-DMC, respectively), and 1 minor metabolite, 10-O-demethylcolchicine (also known as colchiceine). Enterohepatic recycling occurs. The main route of elimination is hepatobiliary excretion in the faeces. Renal excretion accounts for 10–20% of colchicine elimination in patients with normal renal function.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Reduce dose or increase dosage interval by 50%.</td>
</tr>
<tr>
<td>10–20</td>
<td>Reduce dose or increase dosage interval by 50%.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>500 mcg 3–4 times a day; maximum total dose of 3 mg.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anti-arrhythmics: possible increased risk of toxicity with amiodarone.
- Antibacterials: possible increased risk of toxicity with azithromycin, clarithromycin, erythromycin and telithromycin – suspend or reduce dose of colchicine, avoid concomitant use in renal or hepatic failure.
- Antifungals: possible increased risk of toxicity with itraconazole and ketoconazole – suspend or reduce dose of colchicine, avoid concomitant use in renal or hepatic failure.
- Antivirals: possible increased risk of toxicity with atazanavir, indinavir, ritonavir and telaprevir - suspend or reduce dose of colchicine, avoid concomitant use in renal or hepatic failure.
- Calcium-channel blockers: possible increased risk of toxicity with diltiazem and verapamil - suspend or reduce dose of colchicine, avoid concomitant use in renal or hepatic failure.
- Cardiac glycosides: possible increased risk of myopathy with digoxin.
- Ciclosporin: risk of myopathy or rhabdomyolysis, also increased blood-ciclosporin concentrations and nephrotoxicity - suspend or reduce dose of colchicine, avoid concomitant use in renal or hepatic failure.
- Grapefruit juice: possible increased risk of toxicity.
- Lipid-regulating drugs: possible increased risk of myopathy with fibrates and statins.

**Administration**

**Reconstitution**

- **Route**
  - Oral
Rate of administration

---

**Other information**

- Colchicine has a narrow therapeutic window and is extremely toxic and may be fatal in overdose. Patients at particular risk of toxicity are those with renal or hepatic impairment, gastrointestinal or cardiac disease, and patients at extremes of age.
- The signs of overdose may be delayed.
- If nausea, vomiting or diarrhoea occurs, stop therapy.
- Manufacturer contraindicates colchicine in GFR<10 mL/min but in practice is used routinely at low doses to treat gout in patients with severe renal impairment.
- Dose in renal impairment is from *Drug Prescribing in Renal Failure, 5th* edition by Aronoff *et al.* and *Drug Dosage in Renal Insufficiency* by Seyffart G.
- In CKD 5, colchicine can be administered concurrently with allopurinol, but seek specialist advice.
### Colecalciferol

#### Clinical use
Vitamin D3:
- Prevention, treatment and maintenance of vitamin D deficiency

#### Dose in normal renal function
**High dose:**
- Treatment: 40 000 units weekly for 7 weeks
- Maintenance: 1–3 x 20 000 units monthly
- Prevention: 20 000 units monthly
- Some high risk groups may need higher doses

**Low dose:**
- Treatment: 800–4000 units daily for 10 weeks
- Maintenance: 400–1600 units daily

#### Pharmacokinetics
- Molecular weight (daltons) 384.6
- % Protein binding 50–80
- % Excreted unchanged in urine Minimal
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 50 days

#### Metabolism
Within the liver, cholecalciferol is hydroxylated to calcidiol (25-hydroxycholecalciferol) by the enzyme 25-hydroxylase. Within the kidney, calcidiol serves as a substrate for 1-alpha-hydroxylase, yielding calcitriol (1,25-dihydroxycholecalciferol), the biologically active form of vitamin D3. Cholecalciferol and its metabolites are excreted mainly in the bile and faeces.

#### Dose in renal impairment GFR (mL/min)
- **30–50** Dose as in normal renal function.
- **10–30** Dose as in normal renal function. See 'Other information'.
- **<10** Dose as in normal renal function. See 'Other information'.

#### Dose in patients undergoing renal replacement therapies
- **APD/CAPD** Probably dialysed. Dose as in GFR<10 mL/min.
- **HD** Probably dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux** Probably dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD** Probably dialysed. Dose as in GFR=10–30 mL/min.

#### Important drug interactions
Potentially hazardous interactions with other drugs
- **Antiepileptics:** the effects of vitamin D may be reduced in patients taking barbiturates or anticonvulsants.
- **Diuretics:** increased risk of hypercalcaemia with thiazides.
- **Sevelamer:** absorption may be impaired by sevelamer.

#### Administration

##### Reconstitution
---
**Route**
Oral

**Rate of administration**
---

##### Other information
- Contraindicated by manufacturers in severe renal impairment due to risk of soft tissue calcification and impairment of metabolism.
- Higher doses should only be prescribed in moderate to severe renal impairment under the advice of a senior renal physician.
- Colecalciferol should not be taken by patients with a tendency to form calcium-containing renal calculi.
Colesevelam hydrochloride

Clinical use
Hyperlipidaemias

Dose in normal renal function
- Monotherapy: 3.75 g daily (in 1–2 divided doses). Maximum 4.375 g daily
- Combination therapy: 2.5–3.75 g daily in 1–2 divided doses

Pharmacokinetics
Molecular weight (daltons) Small
% Protein binding 0
% Excreted unchanged in urine 0.05
Volume of distribution (L/kg) Not absorbed.
Half-life — normal/ESRF (hrs) Not absorbed.

Metabolism
Not absorbed.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidiabetic agents: absorption of glipizide, glibenclamide and glimepiride reduced, administer at least 4 hours before colesevelam; metformin extended release exposure increased, monitor carefully.
- Ciclosporin: may reduce absorption of ciclosporin.
- Olmesartan: absorption of olmesartan reduced, administer at least 4 hours before colesevelam.

Administration
Reconstitution

<table>
<thead>
<tr>
<th>Route</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Administer other drugs at least 4 hours before or after colesevelam.</td>
</tr>
</tbody>
</table>
# Colestipol hydrochloride

## Clinical use

Hyperlipidaemias, particularly type IIa

## Dose in normal renal function

5 g once or twice daily, increased if necessary at intervals of 1–2 months, to a maximum of 30 g daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>—</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Not absorbed.</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Not absorbed.</td>
</tr>
</tbody>
</table>

## Metabolism

Not applicable as colestipol is not systemically absorbed.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapies</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Anticoagulants: may enhance or reduce effects of coumarins and phenindione.
- Ciclosporin: no reports of an interaction; however, ciclosporin levels should be carefully monitored if colestipol and ciclosporin are prescribed concurrently, as colestipol may interfere with ciclosporin absorption.

## Administration

### Reconstitution
- —

### Route
- Oral

### Rate of administration
- —

### Comments
- Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption.
- Colestipol granules may be administered as a suspension in water or a flavoured vehicle.
- Colestipol orange contains 32.5 mg aspartame (18.2 mg phenylalanine) per sachet.

## Other information

- Colestipol may interfere with the absorption of fat soluble vitamins.
**Colestyramine (cholestyramine)**

### Clinical use
- Hyperlipidaemias
- Pruritus associated with partial biliary obstruction and primary biliary cirrhosis
- Diarrhoeal disorders

### Dose in normal renal function
- Lipid reduction: 12–24 g daily (in single or up to 4 divided doses). Maximum 36 g daily
- Pruritis: 4–8 g daily
- Diarrhoeal disorders: 12–24 g daily. Maximum 36 g daily

### Pharmacokinetics
- Molecular weight (daltons) —
- % Protein binding 0
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) Not absorbed.
- Half-life — normal/ESRF (hrs) Not absorbed.

### Metabolism
Not applicable as colestyramine resin is not absorbed from the digestive tract.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: effect of coumarins and phenindione may be enhanced or reduced.
- Ciclosporin: may interact unpredictably with ciclosporin. Take ciclosporin at least 1 hour before or 4–6 hours after to prevent problems with absorption.
- Leflunomide: avoid concomitant use.
- Raloxifene, thyroid hormones, bile acids, valproate, cardiac glycosides and mycophenolate mofetil: absorption reduced.

### Administration

#### Reconstitution
- Mix with water, or a suitable liquid such as fruit juice, and stir to a uniform consistency.
- May also be mixed with skimmed milk, thin soups, apple sauce, etc.

#### Route
- Oral

#### Rate of administration
- —

#### Comments
- Do not take in dry form.
- Administer other drugs at least one hour before or 4–6 hours after colestyramine.
- Prepare powder immediately prior to administration.

### Other information
- Hyperchloraemic acidosis occasionally reported on prolonged use of colestyramine.
- On chronic use, an increased bleeding tendency may occur associated with vitamin K deficiency.
Colistimethate sodium (Colistin)

Clinical use

Polymyxins:
- Antibacterial agent, gastrointestinal infections (oral)

Dose in normal renal function

IV:
- 9 million units/day in 2–3 divided doses
- In critically ill patients a loading dose of 9–12 million units should be given
- Intrathecal, intra-ventricular: 125,000 units/day

Nebulised solutions:
- Promixin: 1–2 million units every 8–12 hours
- Colobreathe: 1 capsule (1,662,500 IU) twice daily
- Oral: 1.5–3 million units every 8 hours

Pharmacokinetics

Molecular weight (daltons)  Approximately 1748
% Protein binding  55\(^1\)
% Excreted unchanged in urine  80 (<3 nebulised)
Volume of distribution (L/kg)  0.09–0.34\(^1\)

Metabolism

Studies on the gastrointestinal absorption of colistin have shown no significant systemic absorption following oral administration.

Colistimethate sodium is converted to the colistin base by hydrolysis in-vivo. As 80% of the dose can be recovered unchanged in the urine, and there is no biliary excretion, it can be assumed that the remaining drug is inactivated in the tissues. The mechanism is unknown.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>IV: Normal loading dose in critically ill patients then 5.5–7.5 million units per day in 2 divided doses. Other routes: Dose as in normal renal function.</th>
<th>10–30</th>
<th>IV: Normal loading dose in critically ill patients then 4.5–5.5 million units per day in 2 divided doses. Other routes: Dose as in normal renal function.</th>
<th>&lt;10</th>
<th>IV: Normal loading dose in critically ill patients then 3.5 million units per day in 2 divided doses. Other routes: Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

APD/CAPD  Dialysed. Normal loading dose in critically ill patients then 2.25 million units/day in 2 divided doses.

HD  Dialysed. Normal loading dose in critically ill patients then Non-HD days: 2.25 million units/day in 2 divided doses; HD days: 3 million units/day after dialysis.

HDF/High flux  Dialysed. Normal loading dose in critically ill patients then Non-HDF days: 2.25 million units/day in 2 divided doses; HDF days: 3 million units/day after dialysis.

CAV/VVHD  Dialysed. Dose as in normal renal function in 3 divided doses. (Also in CVVHDF.)

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of nephrotoxicity with aminoglycosides and capreomycin; increased risk of nephrotoxicity and ototoxicity with vancomycin.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxics: increased risk of nephrotoxicity and possibly otoxicity with platinum agents.
- Diuretics: increased risk of ototoxicity with loop diuretics.
- Muscle relaxants: polymyxins enhance the effect of non-depolarising muscle relaxants and suxamethonium.
- Parasympathomimetics: polymyxins antagonise the effect of neostigmine and pyridostigmine.
**Administration**

**Reconstitution**
Sodium chloride 0.9% or water for injection

**Route**
IV, nebulised, inhaled, topical, intrathecal, intraventricular, oral

**Rate of administration**
Infusion: over 30–60 minutes
Bolus: over 5 minutes (only if patient has a totally implantable venous access device, TIVAD)

**Comments**
IV: Give in 10–50 mL sodium chloride 0.9% or water for injection.
Inhalation: Dissolve in 2–4 mL sodium chloride 0.9% or water for injection.

**Other information**
- Less than 0.5 mmol/L sodium per 0.5–2 million unit vial (before reconstitution).
- Can cause renal failure, muscle weakness and apnoea in overdose. Risk factors are usually the IV route, high doses, concomitant use with other nephrotoxic agents, and if the dose is not reduced appropriately in renal failure.
- In renal impairment, neonates, and cystic fibrosis patients, plasma concentrations of 10–15 mg/L (125–200 units/mL) are usually adequate.
- Dosage schedules vary according to which preparation is being used. Doses in this monograph are from the Colomycin SPC.

Reference:
# Crisantasaspase

## Clinical use

Antineoplastic agent:
- Treatment of acute lymphoblastic leukaemia and other neoplastic conditions

## Dose in normal renal function

- 6000 units/m² (200 units/kg), three times a week for 3 weeks.
- Or according to local protocol

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>31 732</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>5 L/m²</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7–13 / –</td>
</tr>
</tbody>
</table>

## Metabolism

No data

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Cytotoxics: effects of methotrexate antagonised, give crisantasaspase 24 hours after methotrexate; possibly increases toxicity of vincristine – give at least 3–24 hours before crisantasaspase.
- Avoid with live vaccines.

## Administration

### Reconstitution

1–2 mL sodium chloride 0.9%

### Route

IM, IV, SC

### Rate of administration

—

### Comments

Use within 15 minutes of preparation.
**Clinical use**

Antineoplastic tyrosine kinase inhibitor:
- Treatment of ALK-positive non-small cell lung cancer

**Dose in normal renal function**

250 mg twice daily (reduce dose if side effects occur)

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>450.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>91</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>2.3</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1772 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>42 / —</td>
</tr>
</tbody>
</table>

**Pharmacokinetics**

Mainly metabolised in the liver by CYP3A4/5. The main metabolic pathways are oxidation (to crizotinib lactam) and O-dealkylation.

Excreted 53% via faeces (53% unchanged) and 22% via urine (2% unchanged).

<table>
<thead>
<tr>
<th>Dose in renal impairment GFR (mL/min)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Start with a dose of 250 mg once daily, increasing to 200 mg twice daily if tolerated. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with a dose of 250 mg once daily, increasing to 200 mg twice daily if tolerated. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

| APD/CAPD | Unlikely dialysability. Dose as in GFR<10 mL/min. |
| HD       | Unlikely dialysability. Dose as in GFR<10 mL/min. |
| HDF/High flux | Unlikely dialysability. Dose as in GFR<10 mL/min. |
| CAV/VVHD | Unlikely dialysability Dose as in GFR=10–30 mL/min. |

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: use alfentanil and fentanyl with caution.
- Antibacterials: concentration reduced by rifabutin and rifampicin – avoid; concentration increased by clarithromycin and telithromycin – avoid.
- Antidepressants: St John’s wort may reduce concentration of crizotinib – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital and phenytoin – avoid.
- Antifungals: concentration increased by ketoconazole and possibly with itraconazole and voriconazole – avoid.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis); avoid with pimozide.
- Antivirals: concentration possibly increased by atazanavir, indinavir, ritonavir and saquinavir – avoid.
- Anxiolytics and hypnotics: increases concentration of midazolam.
- Ciclosporin: use with caution.
- Cytotoxics: possibly increases ibrutinib concentration – reduce dose of ibrutinib.
- Ergot alkaloids: use with caution.
- Grapefruit juice: may increase concentration of crizotinib, avoid.
- Oestrogens and progestogens: contraceptive effect possibly reduced – avoid.
- Sirolimus: use with caution.
- Tacrolimus: use with caution.
- Tacrolimus: use with caution.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Clearances were similar in studies down to 30 mL/min.
  - The mean AUC for crizotinib increased by 79% and mean Cmax increased by 34% in patients with severe renal impairment compared to those with normal renal function.
  - May cause QT prolongation.
  - Crizotinib has also been associated with fatal hepatotoxicity.
  - Bioavailability is 43%.
Cyclizine

Clinical use

- Nausea and vomiting
- Vertigo
- Motion sickness
- Labyrinthine disorders

Dose in normal renal function

50 mg up to 3 times daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>266.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>20 / –</td>
</tr>
</tbody>
</table>

Metabolism

Cyclizine is metabolised in the liver to the relatively inactive N-demethylated metabolite, norcyclizine. Both cyclizine and norcyclizine have plasma elimination half-lives of 20 hours.

Less than 1% of the total oral dose is eliminated in the urine in 24 hours.

Dose in renal impairment GFR (mL/min)

- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- None known

Administration

Reconstitution

- Route
  - IV, IM, oral
- Rate of administration
  - Slow IV
- Comments
  - Increased cerebral sensitivity in patients with renal failure.
# Cyclopenthiazide

## Clinical use
Thiazide diuretic:
- Hypertension
- Heart failure
- Oedema

## Dose in normal renal function
- Hypertension: 250–500 mcg once daily
- Heart failure: 250 mcg – 1 mg once daily
- Oedema: up to 500 mcg once daily

## Pharmacokinetics
- Molecular weight (daltons): 379.9
- % Protein binding: No data
- % Excreted unchanged in urine: 100
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 12 / Increased

## Metabolism
Cyclopenthiazide appears to be entirely excreted unchanged in the urine.

## Dose in renal impairment GFR (mL/min)
- 30–50: Dose as in normal renal function.
- 10–30: Unlikely to work.
- <10: Unlikely to work.

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Unlikely to work.
- HD: Unknown dialysability. Unlikely to work.
- HDF/High flux: Unknown dialysability. Unlikely to work.
- CAV/VVHD: Unknown dialysability. Unlikely to work.

## Important drug interactions
Potentially hazardous interactions with other drugs:
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect.
- Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised.
- Antibacterials: avoid administration with lymecycline.
- Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hyponatraemia with carbamazepine.
- Antifungals: increased risk of hypokalaemia with amphotericin.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with post-synaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol.
- Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide – avoid.
- Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia.
- Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium: excretion reduced, increased toxicity.

## Administration

### Reconstitution
—

### Route
Oral

### Rate of administration
—

## Other information
- Monitor for hypokalaemia.
- Acts within 1–3 hours, peaks in 4–8 hours and lasts up to 12 hours.
Cyclophosphamide

Clinical use
Alkylating agent:
- Immunosuppression of autoimmune diseases including rheumatoid arthritis
- Treatment of malignant disease

Dose in normal renal function
- Autoimmune disease:
  - Oral: 1–2.5 mg/kg/day
  - IV: Usually 0.5–1 g/m² or 10–15 mg/kg repeated at intervals, e.g. monthly (pulse therapy)
- Malignant disease:
  - Oral: 50–250 mg/m² daily or according to local protocol.

Pharmacokinetics
- Molecular weight (daltons): 279.1
- % Protein binding:
  - Parent drug: 0–10
  - Alkylating metabolites: >60
- % Excreted unchanged in urine: 5–25
- Volume of distribution (L/kg): 0.78
- Half-life — normal/ESRF (hrs): 3–12 / 10

Metabolism
Cyclophosphamide is a pro-drug and undergoes activation by various cytochrome P450 isoenzymes (notably CYP2B6) in the liver (great inter-patient variability in metabolism). The initial metabolites are 4-hydroxycyclophosphamide and its acyclic tautomer, aldophosphamide, which both undergo further metabolism; aldophosphamide may undergo non-enzymatic conversion to active phosphoramid mustard. Acrolein is also produced and may be responsible for bladder toxicity.

Cyclophosphamide is excreted principally in urine, as metabolites and some unchanged drug.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: 75–100% of normal dose depending on clinical indication and local protocol.
- <10: 50–100% of normal dose depending on clinical indication and local protocol.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min. Following dose, do not perform CAPD exchange for 12 hours.
- HD: Dialysed. Dose as in GFR<10 mL/min. Dose at minimum of 12 hours before HD session.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min. Dose at minimum of 12 hours before HDF session.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Cytotoxics: increased toxicity with high-dose cyclophosphamide and pentostatin – avoid.

Administration
Reconstitution
Add 5 mL water for injection to each 100 mg (Sodium chloride 0.9% for Endoxana)
Route
Oral, IV
Rate of administration
Directly into vein over 2–3 minutes, OR directly into tubing of fast running IV infusion with patient supine.
Comments
IV route occasionally used for pulse therapy. Can be administered as an IV infusion.
Injection can be administered orally down a NG tube.

Other information
- Reduce IV dose to 75% of oral dose, bioavailability is 75%.
Cyclophosphamide and its alkylating metabolites can be eliminated by dialysis.

Patients receiving chronic indefinite therapy may be at increased risk of developing urothelial carcinoma.

If patient is anuric and on dialysis, neither cyclophosphamide or its metabolites, nor Mesna should appear in the urinary tract. The use of Mesna may therefore be unnecessary, although this would be a clinical decision.

If the patient is still passing urine, Mesna should be given to prevent urothelial toxicity.

Reference:
Cycloserine

**Clinical use**

Antibacterial agent:
- Tuberculosis

**Dose in normal renal function**

Initially 250 mg every 12 hours for 2 weeks; then increased according to blood concentration and response to maximum 500 mg every 12 hours

**Pharmacokinetics**

- Molecular weight (daltons) 102.1
- % Protein binding <20
- % Excreted unchanged in urine 50–70
- Volume of distribution (L/kg) 0.11–0.26
- Half-life — normal/ESRF (hrs) 8–12 / Increased

**Metabolism**

Cycloserine is excreted largely unchanged by glomerular filtration. About 50% of a single 250 mg dose is excreted unchanged in the urine within 12 hours and about 70% is excreted within 72 hours. As negligible amounts of cycloserine appear in the faeces, it is assumed that the remainder of a dose is metabolised to unidentified metabolites.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Likely dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Alcohol: Increased risk of seizures.

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

**Other information**

- May cause drowsiness – increased cerebral sensitivity in patients with renal impairment.
- Blood concentration monitoring is required, especially in renal impairment, if dose exceeds 500 mg daily, or if signs of toxicity. Blood concentration should not exceed 30 mg/L.
- Contraindicated by manufacturer in severe renal insufficiency.
- Doses in renal impairment from *Drug Prescribing in Renal Failure, 5th* edition by Aronoff et al.
- Can cause CNS toxicity.
- Pyridoxine has been used in an attempt to treat or prevent neurological reactions, but its value is unproven.
Cyproheptadine hydrochloride

### Clinical use

Antihistamine:
- Symptomatic relief of allergy such as hay fever, urticaria

### Dose in normal renal function

4–20mg daily in divided doses. Maximum dose 32 mg daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>350.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>96–99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Large</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–4 / Increased</td>
</tr>
</tbody>
</table>

### Metabolism

Undergoes almost complete metabolism in the liver. The main metabolite found in humans is a quaternary ammonium glucuronide conjugate of cyproheptadine. 40% is excreted in the urine mainly as metabolites and 2–20% via the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Analgesics: sedative properties increased with opioid analgesics.

### Administration

**Reconstitution**
- 
**Route**
- Oral
**Rate of administration**
- 

### Other information

- May cause excessive drowsiness in renal patients. Start with a low dose and gradually increase.
Cyproterone acetate

Clinical use
- Control of libido in severe hypersexuality and sexual deviation in adult male
- Management of patients with prostatic cancer (LHRH ‘flare’, palliative treatment)
- Hot flushes post orchidectomy

Dose in normal renal function
- Control of hypersexuality: 50 mg twice daily
- Prostatic cancer: 200–300 mg/day in 2–3 divided doses
- Hot flushes: 50–150 mg daily in 1–3 divided doses

Pharmacokinetics
Molecular weight (daltons) 416.9
% Protein binding Approx 96
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 10–30
Half-life — normal/ESRF (hrs) 32.1–56.7 /

Metabolism
Cyproterone is metabolised by various pathways including hydroxylation and conjugation; about 35% of a dose is excreted in urine, the remainder being excreted in the bile. The principal metabolite, 15β-hydroxycyproterone, has anti-androgenic activity.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in normal renal function.
HD Unknown dialysability. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- May cause drowsiness – increased CNS sensitivity in patients with renal impairment.
- CSM has advised that in view of the hepatotoxicity associated with long-term doses of 300 mg daily, the use of cyproterone acetate in prostatic cancer should be restricted to short courses, to cover testosterone ‘flare’ associated with gonadorelin analogues, treatment of hot flushes after orchidectomy or gonadorelin analogues, and for patients who have not responded to (or are intolerant of) other treatments.
- Direct hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported. Liver function tests should be performed before treatment and whenever symptoms suggestive of hepatotoxicity occur.
**Cytarabine**

### Clinical use

Antineoplastic agent:
- Acute leukaemias and lymphomas
- Meningeal neoplasms

### Dose in normal renal function

- Continuous: 0.5–2 mg/kg/day
- Intermittent: 3–5 mg/kg/day
- Single agent in acute leukaemia: up to 200 mg/m²
- Maintenance: 1 mg/kg once or twice a week
- Leukaemic meningitis: 10–30 mg/m² (Intrathecal) three times a week. See SPC for more information, depends on place in treatment
- Or according to local policy

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>243.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>13</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5.8–10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2.6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–3 (Intrathecal liposomal: 100–263) / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Cytarabine is converted by phosphorylation to an active form, which is rapidly deaminated, mainly in the liver and the kidneys, by cytidine deaminase to inactive 1-β-d-arabinofuranosyluracil (uracil arabinoside, ara-U). Approximately 80% of an intravenous dose is excreted in the urine within 24 hours, mostly as the inactive metabolite with about 10% as unchanged cytarabine. A small amount is excreted in the bile.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>100% of conventional low dose regime. For high dose, see ’Other information’.</td>
</tr>
<tr>
<td>10–20</td>
<td>100% of conventional low dose regime. For high dose, see ’Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>100% of conventional low dose regime. For high dose, see ’Other information’.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

### Administration

**Reconstitution**

**Route**

IV infusion, IV injection, SC, intrathecal

**Rate of administration**

- IV injection: rapid
- IV infusion: 1–24 hours

**Comments**

- Patients generally tolerate higher doses when medication given by rapid IV injection (compared with slow infusion), due to the rapid metabolism of cytarabine and the consequent short duration of action of the high dose.

### Other information

- Elevated baseline serum creatinine (>1.2 mg/dl) is an independent risk factor for the development of neurotoxicity during treatment with high-dose cytarabine.
- Retrospective analysis implicates impaired renal function as an independent risk factor for high-dose cytarabine-induced cerebral and cerebellar toxicity.
- The incidence of neurotoxicity was 86–100% following administration of high-dose cytarabine to patients with CRCL<40 mL/min and 60–76% following administration to patients with CRCL<60 mL/min. In contrast, when patients with CRCL>60 mL/min received high-dose cytarabine, the incidence of neurotoxicity was found to be 8%, which correlates with the overall incidence of this adverse effect.
Accordingly, it has been suggested that high-dose cytarabine should be used with caution in patients with impaired renal function: Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995; 21(1): 33–64.

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>45–60</td>
<td>60%</td>
</tr>
<tr>
<td>30–45</td>
<td>50%</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Avoid</td>
</tr>
</tbody>
</table>

Anecdotally, an initial dose of 25% of the normal dose has been given to patients with a GFR < 20 mL/min, with subsequent doses escalated according to tolerance.
Cytomegalovirus (CMV) human immunoglobulin (unlicensed product)

Clinical use
- Prophylaxis for renal transplant recipients at risk of primary cytomegalovirus (CMV) disease
- Treatment of CMV disease (usually with ganciclovir)

Dose in normal renal function
See local protocols

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>150</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>N/A</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>50</td>
</tr>
</tbody>
</table>

Metabolism
The metabolism and elimination of CMV human immunoglobulin is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Ciclosporin: no effect on efficacy of CMV immunoglobulin.

Administration

Reconstitution
- 
Route
- IV peripherally or centrally
Rate of administration
- 
Comments
Follow guidelines supplied by company.

Other information

- Can give 10 mg IV chlorphenamine 1 hour before administration.
- Monitor for anaphylaxis, have epinephrine available.
- Do not mix with any other drugs or infusion fluids.
Dabigatran etexilate

Clinical use
Direct thrombin inhibitor:
- Prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery (VTE)
- Prevention of stroke and systemic embolism in AF (AF)
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults

Dose in normal renal function
- VTE: 110 mg within 1–4 hours of completed surgery and thereafter 220 mg once daily (length of course depends on type of surgery)
- Elderly or on CYP 450 inhibitors e.g. amiodarone or verapamil: 75 mg once daily then 150 mg daily
- AF: 150 mg twice daily
- Elderly, concomitant verapamil or high risk of bleeding: 110 mg twice daily
- Treatment and prevention of recurrent DVT and PEs: 150 mg twice daily
- Elderly, concomitant verapamil or high risk of bleeding: 110 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 627.7
% Protein binding 34–35
% Excreted unchanged in urine 85
Volume of distribution (L/kg) 60–70 Litres
Half-life — normal/ESRF (hrs) 12–14 (14-17 after major orthopaedic surgery) / 24–28

Metabolism
Dabigatran etexilate is a prodrug which does not exhibit any pharmacological activity. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalysed hydrolysis in plasma and in the liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma.
Mainly excreted in the urine (85%) and 6% via the faeces.

Dose in renal impairment GFR (mL/min)
30–50 VTE: 75 mg within 1–4 hours of completed surgery and thereafter 150 mg once daily; 75 mg if also on CYP450 inhibitor.
AF/DVT/PE: 110–150 mg twice daily.
10–30 Avoid. See ‘Other information’. 
<10 Avoid. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
APD/CAPD Dialysed. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Dialysed. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: possible increased risk of bleeding with NSAID’s; increased risk of haemorrhage with ketorolac or IV diclofenac – avoid.
- Anti-arrhythmics: concentration increased by amiodarone, reduce dose of dabigatran; concentration increased by dronedarone – avoid.
- Antibacterials: concentration reduced by rifampicin – avoid; possibly increased risk of bleeding with clarithromycin.
- Anticoagulants: increased risk of haemorrhage with other anticoagulants – avoid.
- Antidepressants: possible increased risk of bleeding with SSRIs; concentration possibly reduced by St John’s wort – avoid.
- Antifungals: concentration increased by ketoconazole and possibly itraconazole – avoid.
- Ciclosporin: concentration possibly increased by ciclosporin – avoid.
- Sulfipyrirazone: possible increased risk of bleeding.
- Tacrolimus: concentration possibly increased by tacrolimus – avoid.
- Ticagrelor: concentration of dabigatran increased.
- Verapamil: reduce dose of dabigatran to 150 mg daily, 75 mg in GFR=30–50mL/min.
**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Other information**

- Oral bioavailability is 6.5%.
- Haemodialysis removes approximately 50–60% of dabigatran over 4 hours with a 700 mL/min dialysate flow rate and a blood flow rate of 200 mL/min or 350–390 mL/min respectively.
- Contraindicated by manufacturer in renal failure due to increased risk of bleeding.
- Information from US data sheet for AF:

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;30</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>15–30</td>
<td>75 mg twice daily. Avoid if also on a CYP450 inhibitor.</td>
<td></td>
</tr>
</tbody>
</table>

- In people with GFR = 30–50 mL/min and 10–30 mL/min, the AUC was approximately 2.7 and 6 times higher respectively compared to people with normal renal function.
- It is recommended to wait 12 hours after the last dose before switching from dabigatran to a parenteral anticoagulant.
Dabrafenib

**Clinical use**
Selective inhibitor of BRAF-kinase:
- Treatment of metastatic melanoma and advanced non-small cell lung cancer with a BRAF V600 mutation

**Dose in normal renal function**
150 mg twice daily

**Pharmacokinetics**
- **Molecular weight (daltons)**: 519.6 (615.7 as mesilate)
- **% Protein binding**: 99.7
- **% Excreted unchanged in urine**: 23 (as metabolites)
- **Volume of distribution (L/kg)**: 46 Litres
- **Half-life — normal/ESRF (hrs)**: 8 / Unchanged

**Metabolism**
Metabolism is mainly by CYP2C8 and CYP3A4 isoenzymes to form hydroxy-dabrafenib, which is further oxidised via CYP3A4 to form carboxy-dabrafenib. Carboxy-dabrafenib can be decarboxylated via a non-enzymatic process to form desmethyl-dabrafenib. Carboxy-dabrafenib is excreted in bile and urine. Desmethyl-dabrafenib may also be formed in the gut and reabsorbed. Desmethyl-dabrafenib is metabolised by CYP3A4 to oxidative metabolites. Both hydroxy- and desmethyl-dabrafenib are likely to contribute to the clinical activity of dabrafenib while the activity of carboxy-darafenib is not likely to be significant.

**Dose in renal impairment GFR (mL/min)**
- **30–50**: Dose as in normal renal function.
- **10–30**: Dose as in normal renal function. Use with caution.
- **<10**: Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- **APD/CAPD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HD**: Not dialysed. Dose as in GFR<10 mL/min. See ‘Other information’.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Oestrogens and progestogens: possibly reduced contraceptive effect.

**Administration**

**Reconstitution** — 
**Route** Oral
**Rate of administration** — 

**Other information**
- Manufacturer advises to use with caution in severe renal impairment due to lack of studies. There was no difference in the pharmacokinetics of dabrafenib down to a GFR<30 mL/min.
- Oral bioavailability of 95%.
- There is a case report of a haemodialysis patient being treated with dabrafenib 75 mg twice daily and trametinib 1 mg once daily. The patient developed diarrhoea so treatment was stopped. Once resolved the dabrafenib was restarted at 50 mg once daily. After 2 months there was some tumour response. The patient developed skin toxicities so trametinib was restarted at a dose of 0.5 mg once daily with anti-diarrhoeal treatment to control the side effects.¹

Reference:
### Dacarbazine

#### Clinical use

Antineoplastic agent:
- Metastatic melanoma
- Hodgkin’s disease
- Soft tissue sarcomas

#### Dose in normal renal function

- Single agent: 200–250 mg/m\(^2\) daily for 5 days, repeated every 3 weeks or 850 mg/m\(^2\) on day 1 then once every 3 weeks
- Hodgkin’s disease: 375 mg/m\(^2\) every 15 days in combination

#### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Likely dialysability</th>
<th>Dose in GFR &lt; 30 mL/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>182.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0–5</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20–50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.49</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.5–5 / Increased</td>
</tr>
</tbody>
</table>

#### Metabolism

Dacarbazine (DTIC) is assumed to be inactive. Dacarbazine is extensively metabolised in the liver by the cytochrome P450 isoenzymes CYP1A2 and CYP2E1 (and possibly in the tissues by CYP1A1) to its active metabolite 5-(3-methyl-triazen-1-yl)-imidazole-4-carboxamide (MTIC), which spontaneously decomposes to the major metabolite 5-amino-imidazole-4-carboxamide (AIC). About half of a dose is excreted in the urine by tubular secretion; 50% as unchanged DTIC and approximately 50% as AIC.

#### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>% of dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>45–60</td>
<td>80%</td>
</tr>
<tr>
<td>30–45</td>
<td>75%</td>
</tr>
<tr>
<td>&lt;30</td>
<td>70%</td>
</tr>
</tbody>
</table>

#### Important drug interactions

Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

#### Administration

**Reconstitution**
10 mL water for injection per 100 mg vial (50 mL for 1 g vial)

**Route**
IV

**Rate of administration**
- Bolus: 1–2 minutes
- Infusion: 15–30 minutes

**Comments**
- For infusion can be diluted with up to 125–300 mL glucose 5% or sodium chloride 0.9%.
- Avoid contact with skin and mucous membranes.
- Protect from light.
- Doses above 200 mg/m\(^2\) should be given as infusions.

#### Other information

- Nadir for white cell count usually occurs 21–25 days after a dose.
- Contraindicated by manufacturer in severe renal impairment due to lack of data.
Daclatasvir

Clinical use

Inhibitor of nonstructural protein 5A (NS5A):
- Treatment of chronic hepatitis C infection in combination with other medication

Dose in normal renal function

60 mg once daily

Pharmacokinetics

Molecular weight (daltons) 738.9
% Protein binding 99
% Excreted unchanged in urine 6.6
Volume of distribution (L/kg) 47 Litres
Half-life — normal/ESRF (hrs) 12–15 / –

Metabolism

Daclatasvir is a substrate of CYP3A with CYP3A4 being the major CYP isoform responsible for the metabolism. No metabolites circulate at levels more than 5% of the parent concentration.

Following single-dose oral administration of [14C]-daclatasvir in healthy subjects, 88% of the total radioactivity was recovered in faeces (53% as unchanged drug) and 6.6% was excreted in the urine (mainly as unchanged drug).

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Anti-arrhythmics: possible increased risk of bradycardia with amiodarone.
- Antibacterials: concentration possibly increased by clarithromycin and telithromycin – reduce daclatasvir dose to 30 mg; concentration reduced by rifampicin and possibly rifabutin – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin and primidone – avoid.
- Antifungals: concentration possibly increased by itraconazole, ketoconazole, posaconazole and voriconazole – reduce daclatasvir dose to 30 mg.
- Antivirals: concentration increased by atazanavir and telaprevir and possibly boceprevir, reduce daclatasvir dose to 30 mg; concentration possibly increased by darunavir and lopinavir – avoid; concentration reduced by efavirenz, increase daclatasvir dose to 90 mg; concentration possibly reduced by etravirine and nevirapine – avoid.
- Cardiac glycosides: concentration of digoxin increased.
- Cobicistat: concentration possibly increased by cobicistat – reduce daclatasvir dose to 30 mg.

Administration

Reconstitution

—

Route
Oral

Rate of administration

—

Other information

- Oral bioavailability is 67%.
- Daclatasvir unbound AUC was estimated to be 18%, 39% and 51% higher for subjects with creatinine clearance of 60, 30 and 15 mL/min, respectively, relative to subjects with normal renal function.
- Subjects with end-stage renal disease requiring hemodialysis had a 27% increase in daclatasvir AUC and a 20% increase in unbound AUC compared to subjects with normal renal function.
Daclizumab

Clinical use
IgG1 monoclonal antibody (IL-2 receptor antagonist):
  • Treatment of multiple sclerosis

Dose in normal renal function
150 mg once a month

Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>142 612</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>6.34 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>21 days / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism
As an IgG1 monoclonal antibody, daclizumab is expected to undergo catabolism to peptides and amino acids in the same manner as endogenous IgG. Daclizumab is not expected to undergo metabolism by hepatic enzymes such as CYP isoenzymes.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Replacement Therapy</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
  • Avoid live vaccines.

Administration

Reconstitution
—

Route
SC

Rate of administration
—

Other information

• Daclizumab has not been studied in renal impairment but as there is little renal excretion the manufacturer does not recommend a dose reduction.
• LFTs should be measured before and during treatment due to risk of hepatic injury.
Dactinomycin

**Clinical use**

Antineoplastic antibiotic

**Dose in normal renal function**

- Dose varies according to patient tolerance, size and location of neoplasm
- Maximum dose: 15 mcg/kg or 400–600 mcg/m² daily for 5 days per 2 week cycle

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1255.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>5</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>&gt;12.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>36 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Intravenous doses of dactinomycin are rapidly distributed with high concentrations in bone marrow and nucleated cells. It undergoes only minimal metabolism and is slowly excreted in urine and bile. 15% is eliminated by hepatic metabolism. Approximately 30% of the dose was recovered in the urine and faeces in 1 week.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution. Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

- Antipsychotics: increased risk of agranulocytosis with clozapine – avoid.
- Cytotoxics: increased risk of hepatotoxicity with vincristine.
- Vaccines: risk of generalised infections with live vaccines – avoid.

**Administration**

**Reconstitution**

1.1 mL water for injection without preservative

**Route**

IV

**Rate of administration**

15 minutes

**Comments**

- Add to 50 mL glucose 5% or sodium chloride 0.9% (maximum concentration 10 mg/mL) or to a fast running IV infusion.
- Avoid direct contact with the skin.

**Other information**

- Nadir for platelet and white cell count usually occurs after 14–21 days, with recovery in 21–25 days.
- Can cause renal abnormalities.
Dalteparin sodium (LMWH)

**Clinical use**
1. Peri- and postoperative surgical and medical thromboprophylaxis
2. Prevention of clotting in extracorporeal circuits
3. Treatment of DVT
4. Acute coronary syndrome

**Dose in normal renal function**
1. Dose according to risk of thrombosis: Moderate risk: 2500 IU daily
   High risk and medical: 5000 IU daily
2. Dose for >4 hour session: IV bolus of 30–40 IU/kg, followed by infusion of 10–15 IU/kg/hour. Dose for <4 hour session: as above or single IV bolus injection of 5000 IU
If at increased risk of bleeding: IV bolus of 5–10 IU/kg, followed by infusion of 4–5 IU/kg/hour. See ‘Other information’
3. 200 IU/kg daily (maximum 18 000 units as a single dose) or 100 IU/kg twice daily
4. 120 IU/kg every 12 hours maximum 10 000 IU twice daily for 5–8 days

**Pharmacokinetics**
- Molecular weight (daltons): Average 6000
- % Protein binding: No data
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): 0.04–0.06
- Half-life — normal/ESRF (hrs): IV: 2; SC: 3.5–4 / Prolonged

**Metabolism**
Liver and the reticulo-endothelial system are the sites of biotransformation of dalteparin. It is partially metabolised by desulphatation and depolymerisation. The kidneys are the major site of dalteparin excretion (approximately 70% based on animal studies).

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function only for prophylaxis doses. See ‘Other information’.
- <10: Dose as in normal renal function only for prophylaxis doses. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of bleeding with NSAIDs, avoid concomitant use with IV diclofenac; increased risk of haemorrhage with ketorolac – avoid.
- Nitrates: anticoagulant effect reduced by infusions of glyceryl trinitrate.
- Use with care in patients receiving oral anticoagulants, platelet aggregation inhibitors, aspirin or dextran.

**Administration**
**Reconstitution**

**Route**
- SC injection into abdominal wall (pre-filled syringes)
- IV bolus/infusion (ampoules)

**Rate of administration**

**Comments**
Dalteparin solution for injection (ampoules) is compatible with sodium chloride 0.9% and glucose 5%.

**Other information**
- Anecdotally can be used at a dose reduced by 20% for treatment of DVT/PEs and ACS.
Low molecular weight heparins are renally excreted and hence accumulate in severe renal impairment. While the doses recommended for prophylaxis against DVT and prevention of thrombus formation in extracorporeal circuits are well tolerated in patients with ERF, the doses recommended for treatment of DVT and PE have been associated with severe, sometimes fatal, bleeding episodes in such patients. Hence the use of unfractionated heparin would be preferable in these instances.

In patients with GFR ≤30 mL/min, monitoring for anti-Xa levels is recommended to determine the appropriate dalteparin dose. Target anti-Xa range is 0.5–1.5 IU/mL. When monitoring anti-Xa in these patients, sampling should be performed 4–6 hrs after dosing and only after the patient has received 3–4 doses.

Antifactor-Xa levels should be regularly monitored in new patients on haemodialysis, during the first weeks; later, less frequent monitoring is generally required. Consult manufacturer’s literature.

Additional doses may be required if using LMWHs for anticoagulation in HDF.

Bleeding may occur especially at high doses corresponding with antifactor-Xa levels greater than 1.5 IU/mL.

The prolongation of the APTT induced by dalteparin is fully neutralised by protamine, but the anti-Xa activity is only neutralised to about 25–50%.

1 mg of protamine inhibits the effect of 100 IU (antifactor-Xa) of dalteparin.

Heparin can suppress adrenal secretion of aldosterone leading to hypercalcaemia, particularly in patients with chronic renal impairment and diabetes mellitus.

Alternative dosing for haemodialysis is 70 IU/kg as a single bolus into the arterial line at the start of dialysis; the dose may need to be greatly reduced in people on warfarin. An anti-Xa level >0.4 IU/ml after 4 hours of dialysis inhibits significant clotting during haemodialysis. (Sagedal S, Hartmann A, Sundstrom K, et al. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant. 1999; 14(8):1943–7.)
Danaparoid sodium

**Clinical use**
- Prophylaxis of DVT and PE
- Thromboembolic disease requiring parenteral anticoagulation in patients with heparin-induced thrombocytopenia (HIT)
- Anticoagulation for haemodialysis

**Dose in normal renal function**
- Prophylaxis, DVT and PE: 750 units twice daily for 7–10 days (SC)
- HIT: 2500 units IV bolus (Wt<55 kg: 1250 units; >90 kg: 3750 units) then an IV infusion of 400 units/hour for 2 hours, 300 units/hour for 2 hours, then 200 units/hour for 5 days
- Haemodialysis: See ‘Other information’

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>Approx 6500</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40–50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>8–9</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>25 / &gt;31</td>
</tr>
</tbody>
</table>

**Metabolism**

Danaparoid sodium is mainly eliminated by renal excretion and animal experiments indicate that the liver is not involved in its metabolism.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. Reduce second and subsequent doses for thromboembolism prophylaxis.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: increased risk of haemorrhage with IV diclofenac – avoid.
- Anticoagulants: enhances effects of oral anticoagulants.
- Interferes with laboratory monitoring of prothrombin time – monitor anticoagulation closely.

**Administration**

**Reconstitution**
Glucose 5% or sodium chloride 0.9%

**Route**
SC, IV

**Rate of administration**
See dose.

**Other information**

- Contraindicated by manufacturer in severe renal impairment unless patient has HIT and there is no other alternative.
- Monitor anti-Xa activity in patients >90 kg and with renal impairment.

Can also be used for haemodialysis anticoagulation:

2/3 times a week dialysis:
- 1st and 2nd dialysis: 3750 units IV bolus prior to dialysis. (If patient <55 kg then give 2500 unit IV bolus.)
- Subsequent dialysis: 3000 units by IV bolus prior to dialysis, provided there are no fibrin threads in the bubble chamber. (If patient <55 kg then give 2000 units.)

Daily dialysis:
- 1st dialysis: 3750 units IV bolus prior to dialysis; if patient <55 kg give 2500 units.
- 2nd dialysis: 2500 units IV bolus prior to dialysis; if patient <55 kg give 2000 units.
- Prior to the second and subsequent dialysis a specimen should be drawn for plasma anti-Xa levels (to be used for dosing a third and subsequent dialysis).

**Expected pre-dialysis ranges of anti-Xa levels**

- If plasma anti-Xa levels are <0.3 U/mL, then 3rd or subsequent dialysis dose should be 3000 units. For patients weighing <55 kg use 2000 units.
- If plasma anti-Xa levels are 0.3–0.35 U/mL, then 3rd or subsequent dialysis dose should be 2500 units. For patients weighing <55 kg use 1500 units.
• If plasma anti-Xa levels are 0.35–0.4 U/mL, then 3rd or subsequent dialysis dose should be 2000 units. For patients weighing <55 kg use 1500 units.
• If plasma anti-Xa levels are >0.4 U/mL, then do not give any danaparoid before dialysis. However, if fibrin threads form in the bubble chamber, then the patient may be given 1500 units IV bolus (irrespective of the patient’s weight).

---

• During dialysis the plasma anti-Xa level should be between 0.5–0.8 U/mL.
• If needed take a blood sample prior to every dialysis and during dialysis (at 30 minutes and at 4 hours).
• Protamine is no use as an antidote for bleeding complications. If no anti-Xa monitoring is available then the first 4 dialysis sessions should have pre-dialysis IV bolus of 3750, 3750, 3000 and 2500 units respectively, then 2500 units thereafter. Take blood sample prior to 4th and 7th dialysis to ensure there is no accumulation.
• Oozing from puncture sites has been noted 24–36 hours post dose.
• Haemofiltration: 55–90 kg: 2500 units bolus followed by 600 units/hr for 4 hours then 400 units/hr for 4 hours then 200–600 units/hr to maintain adequate anti-Xa levels. If patient <55 kg reduce bolus to 2000 units followed by 400 units/hr for 4 hours then 150–400 units/hr to maintain adequate anti-Xa levels. (Drug Information Handbook. 22nd edition. American Pharmacists Association. Lexicomp.)
• For CVVH, an initial bolus of 750 units followed by an infusion of 0.7–2 units/kg/hr can be given. (Wester JP. Guidelines for anticoagulation with danaparoid sodium and lepirudin in continuous venovenous hemofiltration. Neth J Crit Care. 2004; 8(4):293-301.) Although there are many different regimes this one uses the least amount of danaparoid.
Dantrolene sodium

**Clinical use**
- Oral: Treatment of chronic, severe spasticity of skeletal muscle
- IV: Treatment of malignant hyperthermia

**Dose in normal renal function**
- Oral: 25 mg once daily gradually increasing to 100 mg four times daily as tolerated
- Usual dose: 75 mg three times daily
- IV: 1 mg/kg, repeated up to a cumulative dose of 10 mg/kg

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>399.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>High (mainly to albumin)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>15 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–9 (IV: 12) / —</td>
</tr>
</tbody>
</table>

**Metabolism**

Dantrolene is inactivated by hepatic metabolism in the first instance. There are two alternative pathways. Most of the drug is hydroxylated to 5-hydroxydantrolene. The minor pathway involves nitro-reduction to amino-dantrolene, which is then acetylated (compound F-490). The 5-hydroxy metabolite is a muscle relaxant with nearly the same potency as the parent molecule, and may have a longer half-life than the parent compound. Compound F-490 is much less potent and is probably inactive at the concentrations achieved in clinical samples. Metabolites are subsequently excreted in the urine in the ratio of 79:5 hydroxy-dantrolene: 17 compound F-490: 4 unaltered dantrolene (salt or free acid). The proportion of drug excreted in the faeces depends upon dose size.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Avoid with other hepatotoxic medication.

**Administration**

**Reconstitution**
With 60 mL water for injection per vial

**Route**
Oral, IV

**Rate of administration**
Rapid IV bolus

**Comments**
Use reconstituted solution within 6 hours

**Other information**

- Crystalluria and haematuria have been noted in <1% of patients.
- Hepatic dysfunction, including hepatitis and fatal hepatic failure, has been reported with dantrolene sodium therapy.
- Oral bioavailability is 70%.
Dapagliflozin

Clinical use
Selective and reversible inhibitor of sodium-glucose co-transporter 2:
- Treatment of type 2 diabetes

Dose in normal renal function
10 mg once daily

Pharmacokinetics
Molecular weight (daltons) 408.9
% Protein binding 91
% Excreted unchanged in urine <2
Volume of distribution (L/kg) 118 Litres
Half-life — normal/ESRF (hrs) 12.9 / –

Metabolism
Dapagliflozin is extensively metabolised, primarily to dapagliflozin 3-O-glucuronide, which is an inactive metabolite. The formation of dapagliflozin 3-O-glucuronide is mediated by UGT1A9, an enzyme present in the liver and kidney, and CYP-mediated metabolism was a minor clearance pathway in humans. About 75% of the dose is excreted in the urine and 21% in the faeces.

Dose in renal impairment GFR (mL/min)
20–60 Avoid.
10–20 Avoid.
<10 Avoid.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Avoid.
- HD Avoid.
- HDF/High flux Avoid.
- CAV/VVHD Avoid.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Not recommended by manufacturer if GFR<60 mL/min due to increased side effects and lack of efficacy.
- In subjects with moderate renal impairment (patients with CRCL<60 mL/min or eGFR<60 mL/min/1.73 m²), a higher proportion of subjects treated with dapagliflozin had an increase in creatinine, phosphate, parathyroid hormone and hypotension, compared with placebo.
- Reports of acute kidney injury. FDA Report 14/06/2016.
- Oral bioavailability is 78%.
- Efficacy is reduced with reducing renal function.
## Dapsone

### Clinical use
- Treatment and prophylaxis of leprosy
- Dermatitis herpetiformis
- *Pneumocystis jiroveci* pneumonia (PCP)
- Malaria prophylaxis

### Dose in normal renal function
- Leprosy: 1–2 mg/kg or 100 mg daily
- PCP (with trimethoprim): 50–100 mg daily, 100 mg twice weekly or 200 mg once weekly
- Dermatitis herpetiformis: 50–300 mg daily
- Malaria prophylaxis: 100 mg weekly in combination with pyrimethamine 12.5 mg weekly

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>248.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>50–80</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1–1.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–80 / –</td>
</tr>
</tbody>
</table>

### Metabolism
Dapsone undergoes enterohepatic recycling. Dapsone is acetylated to monoacetyldapsone, the major metabolite, and other mono and diacetyl derivatives. Acetylation shows genetic polymorphism. Hydroxylation is the other major metabolic pathway resulting in hydroxylamine dapsone, which may be responsible for dapsone-associated methaemoglobinemia and haemolysis. Dapsone is mainly excreted in the urine, only 20% of a dose as unchanged drug.

### Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function. Use with caution.
- <10: 50–100 mg daily. Use with caution. No dose reduction is required for malaria prophylaxis. See ‘Other information’.

### Dose in patients undergoing renal replacement therapies
- APD/CAPD: Likely dialysability. Dose as in GFR < 10 mL/min.
- HD: Dialysed. Dose as in GFR < 10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR < 10 mL/min.
- CAV/VVHD: Likely dialysability. Dose as in GFR = 10–20 mL/min.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Antivirals: increased risk of ventricular arrhythmias with saquinavir — avoid.

### Administration
- **Reconstitution**
  - **Route**
  - Oral
- **Rate of administration**
  -

### Other information
- Greater risk of haemolytic side effects in patients with glucose-6-phosphate-dehydrogenase deficiency.
- Regular blood counts are recommended in patients with severe anaemia or renal impairment: weekly for the 1st month, then monthly for 6 months, then semi-annually.
- Almost all patients lose 1–2 g of haemoglobin.
- The dose for herpetiformis can be reduced if the patient is on a gluten free diet.
- One study used dapsone in a haemodialysis patient for bullous dermatosis: therapy was initiated at 100 mg but the dose had to be reduced to 50 mg due to haemolytic effects. (Serwin AB, Mysliwiec H, Laudanska H, *et al*. Linear IgA bullous dermatosis in a diabetic patient with chronic renal failure. *Int J Dermatol.* 2002; 41(11): 778–80.)
Daptomycin

Clinical use
Antibacterial agent

Dose in normal renal function
4–6 mg/kg once daily for 7–14 days depending on indication

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1620.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90–92</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Approximately 50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.092–0.104</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8.1–9 / 29.4</td>
</tr>
</tbody>
</table>

Metabolism

In-vitro studies indicate that daptomycin is not metabolised by, and does not affect, the cytochrome P450 isoenzyme system. Little or no metabolism is thought to take place although 4 minor metabolites have been detected in the urine. Daptomycin is excreted mainly via renal filtration with about 78% and 6% of a dose recovered in the urine and faeces, respectively.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>4–6 mg/kg every 48 hours.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD/VVHDF</td>
<td>Slightly dialysed. 4–6 mg/kg every 48 hours.² 'See Other information.'</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Warfarin: monitor INR when on daptomycin.
- Ciclosporin: increased risk of myopathy – try to avoid concomitant use.

- Lipid-regulating drugs: increased risk of myopathy with fibrates and statins – try to avoid concomitant use.

Administration

Reconstitution
Infusion: 7 mL sodium chloride 0.9% to give a solution of 50 mg/mL
Bolus: 10 mL sodium chloride 0.9%

Route
IV infusion, IV bolus

Rate of administration
Infusion: over 30 minutes
Bolus: over 2 minutes

Comments
- Once reconstituted, stable for 12 hours at room temperature and 48 hours refrigerated.
- Add to 50 mL sodium chloride 0.9% before administration. Stable for 12 hours at room temperature or 24 hours refrigerated.
- Incompatible with dextrose solutions.
- Compatible with solutions containing aztreonam, ceftazidime, ceftriaxone, gentamicin, fluconazole, levofloxacin, dopamine, heparin and lidocaine.

Other information
- May cause renal impairment.
- Vials do not contain any bacteriostatic or fungiostatic agents.
- Company advises to administer post dialysis.
- Monitor creatinine phosphokinase levels, muscle pain or weakness has been reported.
- Increased risk of myopathy in severe renal failure due to increased daptomycin levels.
- 15% of dose is removed by 4 hours of haemodialysis and 11% over 48 hours by peritoneal dialysis.
- Therapeutic concentrations of daptomycin are unlikely due to low PD clearance of drug therefore systemic use for peritonitis is unlikely to work.¹
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid 'flux'
within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

References:
Daratumumab

Clinical use
Human monoclonal IgG1κ antibody against CD38 antigen:
- Treatment of multiple myeloma

Dose in normal renal function
- 16 mg/kg weekly initially, then fortnightly then every 4 weeks
- Or as per local policy

Pharmacokinetics
Molecular weight (daltons) 148 000
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 0.06
Half-life — normal/ESRF (hrs) 9–18 days / Unchanged

Metabolism
No data

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Vaccines: avoid with live vaccines.

Administration
Reconstitution
—

Route
IV infusion

Rate of administration
50–200 mL/hour. See product information.

Comments
First infusion is diluted in 1000 mL sodium chloride 0.9%, future infusions in 500 mL

Other information
- No formal studies have been done by the manufacturer in renal impairment but the pharmacokinetic properties indicate that no dose adjustment is required.
- Pre-medication is essential with methylprednisolone, paracetamol and an oral or IV antihistamine.
- Daratumumab binds to CD38 found at low levels on RBCs and may result in a positive indirect Coombs test. This may persist for up to 6 months after the last daratumumab infusion. It should be recognised that daratumumab bound to RBCs may mask detection of antibodies to minor antigens in the patient’s serum. The determination of a patient’s ABO and Rh blood type are not impacted. Phenotyping may be considered prior to starting daratumumab treatment. Phenotyping may be performed at any time.
- Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.
Darbepoetin alfa

**Clinical use**
Treatment of anaemia associated with chronic renal failure, and with non-haematological malignancies in adult cancer patients receiving chemotherapy.

**Dose in normal renal function**
- Renal failure: 0.45 micrograms/kg once a week; dose is adjusted by 25% every 4 weeks according to response; maintenance every 1–2 weeks.
- Patients not on dialysis: 0.75 mcg/kg every 2 weeks; maintenance may be every 1–4 weeks.
- Chemotherapy related anaemia: 2.25 mcg/kg once a week, or 6.75 mcg/kg every 3 weeks; adjust doses by 50% every 4 weeks according to response.

**Pharmacokinetics**
- Molecular weight (daltons): 30 000–37 000
- % Protein binding: No data
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): 0.05
- Half-life — normal/ESRF (hrs): 21 (IV), 73 (SC) / Unchanged

**Metabolism**
The metabolic fate of both endogenous and recombinant erythropoietin is poorly understood. Current evidence from studies in animals suggests that hepatic metabolism contributes only minimally to elimination of the intact hormone, but desialylated epoetin (ie, terminal sialic acid groups removed) appears to undergo substantial hepatic clearance via metabolic pathways and/or binding. Desialylation and/or removal of the oligosaccharide side chains of erythropoietin appear to occur principally in the liver; bone marrow also may have a role in catabolism of the hormone.

Elimination of desialylated drug by the kidneys, bone marrow, and spleen also may occur; results of animal studies suggest that proximal renal tubular secretion may be involved in renal elimination. In preclinical studies it has been shown that renal clearance of darbepoetin is minimal (up to 2% of total clearance).

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs:
- Ciclosporin and tacrolimus: monitor ciclosporin and tacrolimus levels; since these drugs are bound to red blood cells there is a potential risk of a drug interaction as haemoglobin concentration increases.
- ACE inhibitors and angiotensin-II antagonists: increased risk of hyperkalaemia.

**Administration**

**Reconstitution**
—

**Route**
SC, IV

**Rate of administration**
—

**Other information**
- To convert to darbepoetin from epoetin, divide total weekly epoetin dose by 200 although that may slightly over estimate the darbepoetin dose.
- Same dose may be given either SC or IV – monitor response.
- Use with caution in patients with a history of epilepsy as convulsions have been reported in patients with CKD.
- Once a pre-filled pen has been removed from the fridge and brought to room temperature it must be used within 7 days.
- Pre-treatment checks and appropriate correction/treatment needed for iron, folate and B12 deficiency,
infection, inflammation or aluminium toxicity to produce optimum response to therapy.

- Concomitant iron therapy (200–300 mg elemental oral iron) needed daily. IV iron may be needed for patients with very low serum ferritin (<100 nanograms/mL).
- May increase heparin requirement during HD.

- Reported association of pure red cell aplasia (PRCA) with epoetin therapy. This is a very rare condition; due to failed production of red blood cell precursors in the bone marrow, resulting in profound anaemia. Possibly due to an immune response to the protein backbone of R-HuEPO. Resulting antibodies render the patient unresponsive to the therapeutic effects of all epoetins and darbepoetin.
Darifenacin

Clinical use
Symptomatic treatment of urinary incontinence, frequency or urgency

Dose in normal renal function
7.5–15 mg once daily

Pharmacokinetics
Molecular weight (daltons) 426.6 (507.5 as hydrobromide)
% Protein binding 98
% Excreted unchanged in urine 3
Volume of distribution (L/kg) 163 Litres
Half-life — normal/ESRF (hrs) 13–19 / Unchanged

Metabolism
After an oral dose, darifenacin is subject to extensive first-pass metabolism and has a bioavailability of about 15–19%. Darifenacin is metabolised in the liver by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4. Most of a dose is excreted as metabolites in the urine and faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.
- Antifungals: concentration increased by ketoconazole – avoid; avoid with itraconazole.
- Antivirals: avoid with fosamprenavir, atazanavir, indinavir, lopinavir, ritonavir, saquinavir and tipranavir.
- Calcium-channel blockers: avoid with verapamil.
- Ciclosporin: avoid concomitant use.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Administration
Reconstitution

Route
Oral

Rate of administration

—
Darunavir

**Clinical use**

Protease inhibitor:
- Treatment of HIV infection with 100 mg of ritonavir or 150 mg of cobicistat, in combination with other antiretroviral medication

**Dose in normal renal function**

- Previously treated with antiretrovirals: 600 mg twice daily
- Not previously treated with antiretrovirals: 800 mg once daily
- In combination with cobicistat or ritonavir: 800 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>593.7 (as ethanolate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>7.7</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>29.1–147.1 Litres (81.1–180.9 Litres with ritonavir)</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>15 (with ritonavir) / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Darunavir is metabolised by oxidation by the cytochrome P450 system (mainly the isoenzyme CYP3A4), with at least 3 metabolites showing some antiretroviral activity. About 80% of a dose is excreted in the faeces, with 41.2% of this as unchanged drug; 14% is excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: rifabutin concentration increased – reduce dose of rifabutin; darunavir concentration reduced by rifampicin – avoid.
- Anticoagulants: avoid with apixaban and rivaroxaban.
- Antidepressants: possibly reduced concentration of paroxetine and sertraline; darunavir concentration reduced by St John’s wort – avoid.
- Antimalarials: concentration of lumefantrine increased; possibly increases concentration of quinine.
- Antipsychotics: possibly increases concentration of aripiprazole (reduce dose of aripiprazole); possibly increases quetiapine concentration – avoid.
- Antivirals: avoid with boceprevir or telaprevir; take didanosine 1 hour before or 2 hours after darunavir administration; concentration reduced by efavirenz – adjust dose; concentration of both drugs increased with indinavir and simprevir – avoid with simprevir; concentration reduced by lopinavir, also concentration of lopinavir increased – avoid; concentration of maraviroc increased, consider reducing dose of maraviroc; concentration of paritaprevir and paritaprevir reduces darunavir concentration; concentration reduced by saquinavir; increased risk of rash with raltegravir; avoid with telaprevir.
- Cytotoxics: possibly increases bosutinib concentration, avoid or reduce dose of bosutinib; possibly increases everolimus concentration – avoid; possibly increases ibrutinib concentration – reduce ibrutinib dose.
- Ergot alkaloids: increased risk of ergotism – avoid.
- Lipid-lowering drugs: possibly increased risk of myopathy with atorvastatin and rosuvastatin, reduce dose of rosuvastatin; possibly increases pravastatin concentration; avoid with lomitapide; avoid with simvastatin.1
- Orlistat: absorption of darunavir possibly reduced.
- Ranolazine: possibly increases ranolazine concentration – avoid.

**Administration**

Reconstitution

**Route**

Oral

**Rate of administration**

**Other information**

Reference:
Dasabuvir

Clinical use
Treatment of chronic hepatitis C infection

Dose in normal renal function
250 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 533.6 (as sodium monohydrate)
% Protein binding 99.5
% Excreted unchanged in urine 0.03
Volume of distribution (L/kg) 396 Litres
Half-life — normal/ESRF (hrs) 6 / Unchanged

Metabolism
Dasabuvir is mainly metabolised by CYP2C8 and to a lesser extent by CYP3A. Seven metabolites were identified in plasma. The most abundant plasma metabolite was M1, which represented 21% of drug-related radioactivity (AUC) in circulation following single dose; it is formed via oxidative metabolism predominantly by CYP2C8.

Following a 400 mg 14C-dasabuvir dose, approximately 94% of the radioactivity was recovered in faeces with limited radioactivity (approximately 2%) in urine. Unchanged dasabuvir accounted for 26.2% and M1 for 31.5% of the total dose in faeces. M1 is mainly cleared through direct biliary excretion with the contribution of UGT-mediated glucuronidation and, to a small extent, oxidative metabolism.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Modification of dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Modality</th>
<th>Modification of dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: avoid concomitant use with clarithromycin and telithromycin; concentration possibly reduced by rifampicin – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antiepileptics: concentration reduced by carbamazepine – avoid; concentration possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone – avoid.
- Antifungals: concentration of both drugs increased with ketoconazole and possiblyitraconazole and posaconazole – avoid.
- Diuretics: concentration of furosemide increased (reduce furosemide dose).
- Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce dose and use only if benefit outweighs risk – see SPC).
- Lipid-regulating drugs: avoid with atorvastatin, gemfibrozil and simvastatin; concentration of rosvastatin increased (reduce dose of rosvastatin).
- Oestrogens: avoid concomitant use with ethinylestradiol.

Administration
Reconstitution
—

Route
Oral

Rate of administration
—

Other information
- In subjects with mild, moderate and severe renal impairment, dasabuvir mean AUC values were 21%, 37% and 50% higher, respectively. Dasabuvir M1 AUC values were 6%, 10% and 13% lower, respectively. The changes in dasabuvir exposures in subjects with mild, moderate and severe renal impairment are not considered to be clinically significant. It has not been studied in patients on dialysis.
- Bioavailability is 70%.
Dasatinib

Clinical use
- Chronic myeloid leukaemia (CML) in patients who have resistance or intolerance to previous therapy, including imatinib
- Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults who are resistant to or intolerant of prior therapy

Dose in normal renal function
- Chronic CML: 100 mg once daily
- All other indications: 140 mg daily
- Maximum: 180 mg once daily

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antacids: absorption possibly reduced by antacids, give at least 2 hours apart.
- Antibacterials: metabolism accelerated by rifampicin – avoid.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Antivirals: avoid with boceprevir.
- Ulcer healing drugs: avoid with histamine H₂ antagonists; concentration reduced by proton pump inhibitors.

Pharmacokinetics
Molecular weight (daltons) 488
% Protein binding 96
% Excreted unchanged in urine 0.1
Volume of distribution (L/kg) 2505 Litres
Half-life — normal/ESRF (hrs) 5–6 / –

Metabolism
Dasatinib is extensively metabolised, mainly via the cytochrome P450 isoenzyme CYP3A4, forming an active metabolite.
Elimination is predominantly in the faeces, mostly as metabolites. Following a single oral dose of [14C]-labelled dasatinib, approximately 89% of the dose was eliminated within 10 days, with 4% and 85% of the radioactivity recovered in the urine and faeces, respectively. Unchanged dasatinib accounted for 0.1% and 19% of the dose in urine and faeces, respectively, with the remainder of the dose as metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Administration
Reconstitution
- Route
Oral
Rate of administration
- 

Other information
- No studies have been done with dasatinib in renal impairment but due to the low renal excretion there is unlikely to be a reduction in clearance.
- Most common adverse effects of dasatinib include fluid retention, gastrointestinal disturbances, and bleeding. Fluid retention may be severe, and can result in pleural and pericardial effusion, pulmonary oedema and ascites.
### Clinical use

Antineoplastic agent:
- Acute leukaemias
- HIV-related Kaposi’s Sarcoma

### Dose in normal renal function

- 40–60 mg/m² dose and frequency varies according to indication and formulation
- Or as for local protocol

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>564 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>50–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5–18</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>39.2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>18.5; Liposomal: 4–5.2 / –</td>
</tr>
</tbody>
</table>

### Metabolism

Daunorubicin is rapidly taken up by the tissues, especially by the kidneys, liver, spleen and heart. Subsequent release of drug and metabolites is slow (half-life ~55 hours). It is rapidly metabolised in the liver and the major metabolite, daunorubicinol is also active.

It is excreted slowly in the urine, mainly as metabolites with 25% excreted within 5 days. Biliary excretion accounts for 40–50% elimination.

### Dose in renal impairment GFR (mL/min)

- 20–50: Dose as in normal renal function. See ‘Other information’.
- 10–20: Dose as in normal renal function. See ‘Other information’.
- <10: Dose as in normal renal function. See ‘Other information’.

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as GFR = 10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine due to risk of agranulocytosis.
- Cytotoxics: possible increased cardiotoxicity with trastuzumab – avoid for up to 28 weeks after stopping trastuzumab.
- Avoid with live vaccines.

### Administration

**Reconstitution**

Reconstitute 20 mg vial with 4 mL water for injection giving a concentration of 5 mg/mL. Dilute calculated dose of daunorubicin further in sodium chloride 0.9% to give a final concentration of 1 mg/mL.

**Route**

IV

**Rate of administration**

Acute leukaemia: 1 mg/mL solution should be infused over 20 minutes into the tubing or a side arm of a rapidly flowing IV infusion of sodium chloride 0.9%

HIV-related Kaposi’s sarcoma: 30–60 minutes

### Other information

- Potentially cardiotoxic.
- Monitor blood uric acid and urea levels.
- Manufacturer’s literature suggests that in patients with a serum creatinine of 105–265 μmol/L the dose should be reduced to 75% of normal; if the creatinine is >265 μmol/L, the dose should be 50% of normal.
- Dose in renal impairment is from *Drug Prescribing in Renal Failure*, 5th edition by Aronoff et al.
- A liposomal formulation of daunorubicin is now available (DaunoXome®). Dilute to 0.2–1 mg/mL with glucose 5% and administer over 30–60 minutes.
Decitabine

**Clinical use**
Antineoplastic antimetabolite agent:
- Treatment of acute myeloid leukaemia

**Dose in normal renal function**
20 mg/m² daily for 5 days repeated every 4 weeks

**Pharmacokinetics**
- Molecular weight (daltons) 228.2
- % Protein binding <1
- % Excreted unchanged in urine Approx 4
- Volume of distribution (L/kg) 69.1 Litres
- Half-life — normal/ESRF (hrs) 30–35 minutes / –

**Metabolism**
The exact route of metabolism and elimination is unknown but thought to be through deamination by cytidine deaminase in the liver, kidney, intestinal epithelium and blood to form inactive metabolites.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function. Use with caution.
- 10–20 Dose as in normal renal function. Use with caution.
- <10 Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Possibly dialysed. Dose as in GFR<10 mL/min.
- HD Probably dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

**Administration**

**Reconstitution**
10 mL water for injection

**Route**
IV infusion

**Rate of administration**
1 hour

**Comments**
After reconstitution dilute to 0.15–1 mg/mL with sodium chloride 0.9%, glucose 5%.

**Other information**
- Manufacturer has not done any studies in renal failure but because of low renal clearance use doses as for normal renal function.

Reference:
Deferasirox

**Clinical use**

Treatment of iron overload

**Dose in normal renal function**

Dispersible tablets: 10–30 mg/kg once daily rounded to the nearest whole tablet

Maximum: 40 mg/kg daily

Non-transfusion-dependent thalassaemia syndromes:

Initially 10 mg/kg once daily adjust dose by 5–10 mg/kg every 3–6 months according to ferritin concentration.

Maximum: 20 mg/kg daily

Film coated tablets: 7–21 mg/kg once daily

Maximum 28 mg/kg daily

Non-transfusion-dependent thalassaemia syndromes: Initially 7–14 mg/kg once daily according to ferritin concentration.

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>373.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>8</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>14 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8–16 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolism of deferasirox is mainly glucuronidation by uridine diphosphate glucuronosyltransferase (UGT) enzymes. Cytochrome P450 isoenzyme-mediated metabolism appears to be minor. Deconjugation of the glucuronidates in the intestine and subsequent enterohepatic recycling are likely to occur. It is excreted mainly in the faeces via bile, as metabolites and as unchanged drug. About 8% of a dose is excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–60</td>
<td>50% of dose. See ‘Other information.’</td>
<td></td>
</tr>
<tr>
<td>10–40</td>
<td>Avoid. See ‘Other information.’</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid. See ‘Other information.’</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Notes</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Avoid.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Avoid.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Avoid.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Avoid.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Aluminium-containing antacids: avoid concomitant use.
- Aminophylline and theophylline: concentration of aminophylline and theophylline increased, consider reducing aminophylline and theophylline dose.
- Other nephrotoxic agents: avoid concomitant therapy.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Comments**
  - Take on an empty stomach.
  - Disperse in a glass of water, orange or apple juice.

**Other information**

- The film coated tablets have a 36% greater bioavailability compared to the dispersible ones.
- UK manufacturer advises to avoid in moderate to severe renal impairment due to lack of data. Dose in renal impairment from US data sheet. New Zealand data sheet advises to use normal dose with caution if GFR=40–60 mL/min.
- During clinical trials, increases in serum creatinine of >33% on ≥2 consecutive occasions (sometimes above the upper limit of the normal range) occurred in about 36% of patients. These were dose-dependent. Cases of acute renal failure have been reported following post-marketing use of deferasirox.
• Patients with pre-existing renal conditions and patients who are receiving medicinal products that depress renal function may be more at risk of complications.

• Tests for proteinuria should be performed monthly. Other markers of renal tubular function may also be monitored (e.g. glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria).

• If, despite dose reduction and interruption, the serum creatinine remains significantly elevated and there is also persistent abnormality in another marker of renal function (e.g. proteinuria, Fanconi’s Syndrome), the patient should be referred to a renal specialist, and further specialised investigations (such as renal biopsy) may be considered.

• Closely monitor patients who are taking other agents which may cause ulceration e.g. NSAIDs.
# Deferiprone

## Clinical use
Orally administered chelator:
- Treatment of transfusional iron overload

## Dose in normal renal function
- 25 mg/kg 3 times daily
- Maximum 100 mg/kg daily

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>139.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>15 – See ‘Other information’</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.55–1.73</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–3 / Unknown</td>
</tr>
</tbody>
</table>

## Metabolism
Deferiprone is hepatically metabolised to an inactive glucuronide metabolite and is excreted mainly in the urine as the metabolite and the iron-deferiprone complex, with a small amount of unchanged drug.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>15–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Use with caution.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=15–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- None known.

## Administration

### Reconstitution
- —

### Route
- Oral

### Rate of administration
- —

## Other information
- Manufacturer advises to use with caution due to lack of studies. Since deferiprone is eliminated mainly via the kidneys, there may be an increased risk of complications in patients with impaired renal function.
- US data sheet advises to use as in normal renal function.
- A pharmacokinetic study found that although clearance was reduced in renal impairment there was no increase in overall exposure and suggested that the normal dose could safely be administered. (Fradette C, Pichette V, Sicard E, et al. Effects of renal impairment on the pharmacokinetics of orally administered deferiprone. *Br J Clin Pharmacol*. 2016; 82(4): 994–1001.)
- Side effects include reversible neutropenia, agranulocytosis, musculoskeletal and joint pain, subclinical ototoxicity, plus case reports of systemic vasculitis and fatal SLE.
- Can cause subnormal serum zinc levels.
- Reddish-brown discolouration of the urine reported in 40% of thalassaemia patients undergoing deferiprone therapy.
- Deferiprone removed aluminium *in vitro* from blood samples of 46 patients undergoing chronic haemodialysis. Only patients with serum aluminium concentrations >80 mcg/mL were included. Deferiprone removed the aluminium faster and more effectively from higher molecular weight proteins than desferrioxamine. (Canteros-Picotto MA, Fernández-Martín JL, Cannata-Ortiz MJ et al. Effectiveness of deferiprone (L1) releasing the aluminium bound to plasma proteins in chronic renal failure. *Nephrol Dial Transplant*. 1996; 11(7): 1488–9.)
### Deflazacort

**Clinical use**

Glucocorticoid:
- Suppression of inflammatory and allergic disorders

**Dose in normal renal function**

3–18 mg daily
(Acute disorders up to 120 mg daily initially)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>441.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>40</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>70</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.1–1.9 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Deflazacort is immediately converted by plasma esterases to the pharmacologically active metabolite (D 21-OH). It is 40% protein-bound and has no affinity for corticosteroid-binding-globulin (transcortin). Elimination takes place primarily through the kidneys; 70% of the administered dose is excreted in the urine. The remaining 30% is eliminated in the faeces. Metabolism of D 21-OH is extensive; only 18% of urinary excretion represents D 21-OH. The metabolite of D 21-OH, deflazacort 6-beta-OH, represents one third of the urinary elimination.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antibacterials: metabolism accelerated by rifamycins; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced.
- Anticoagulants: efficacy of coumarins and phenindione may be altered.
- Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited by itraconazole and ketoconazole.
- Antivirals: concentration possibly increased by ritonavir.
- Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids; increased half-life of deflazacort.
- Cobicistat: concentration increased by cobicistat – avoid.
- Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
- Vaccines: high dose corticosteroids can impair immune response to vaccines; avoid with live vaccines.

**Administration**

**Reconstitution**

—

**Route**
Oral

**Rate of administration**

—

**Other information**

- 6 mg of deflazacort is equivalent to 5 mg prednisolone.
Degarelix

**Clinical use**

Gonadotrophin releasing hormone antagonist:
- Treatment of advanced prostate cancer

**Dose in normal renal function**

240 mg starting dose (administered as 2 separate injections of 120 mg) followed by 80 mg every 28 days

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1632.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20–30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>43–53 days (28 after 80 mg maintenance dose) / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Undergoes peptide hydrolysis in the hepato-biliary system, and is mainly (70–80%) excreted as peptide fragments in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

3 mL solvent provided

**Route**

SC

**Rate of administration**

—

**Other information**

- Use with caution in severe renal impairment due to lack of experience.
- May prolong QT interval.
- Degarelix is injected to form a subcutaneous depot, and the pharmacokinetics of the drug is strongly influenced by the concentration of the injected solution.
- A phase III study has demonstrated that the clearance of degarelix in patients with mild to moderate renal impairment is reduced by approximately 23% so no dose adjustment is required.
Delamanid

Clinical use
Treatment of multi-drug resistant tuberculosis

Dose in normal renal function
100 mg twice daily

Pharmacokinetics
Molecular weight (daltons)  534.5
% Protein binding  >99.5
% Excreted unchanged in urine  <5
Volume of distribution (L/kg)  2100 Litres
Half-life — normal/ESRF (hrs)  30–38

Metabolism
Delamanid is mainly metabolised in plasma by albumin and to a lesser extent by CYP3A4. The complete metabolic profile of delamanid has not yet been elucidated. The identified metabolites do not show anti-mycobacterial activity but some contribute to QT prolongation, mainly DM-6705.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone and disopyramide.
- Antibacterials: possible increased risk of ventricular arrhythmias with clarithromycin, erythromycin and moxifloxacin; increased risk of ventricular arrhythmias with pentamidine; concentration reduced by rifampicin.
- Antidepressants: possible increased risk of ventricular arrhythmias with tricyclics.
- Antiepileptics: avoid with carbamazepine.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol, haloperidol, phenothiazines that prolong the QT interval and pimozide.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide and possibly vinblastine, vincristine, vindesine, vinflunine and vinorelbine.
- Domperidone: possible increased risk of ventricular arrhythmias.

Administration
Reconstitution
—

Route
Oral

Rate of administration
—

Other information
- Can cause QT prolongation.
- Manufacturer advises to avoid in severe renal impairment due to lack of data.
- Mild renal impairment (CRCL=50–80 mL/min) does not appear to affect delamanid exposure. Therefore no dose adjustment is needed for patients with mild or moderate renal impairment.
Demeclocycline hydrochloride

Clinical use

Antibacterial agent:
• Treatment of syndrome of inappropriate antidiuretic hormone secretion

Dose in normal renal function

• 150 mg 4 times a day or 300 mg twice daily
• Syndrome of inappropriate antidiuretic hormone: 900–1200 mg daily in divided doses
• Maintenance: 600–900 mg daily in divided doses

Pharmacokinetics

Molecular weight (daltons) 501.3
% Protein binding 41–90
% Excreted unchanged in urine 42
Volume of distribution (L/kg) 1.7
Half-life — normal/ESRF (hrs) 10–15 / 42–68

Metabolism

Demeclocycline hydrochloride, like other tetracyclines, is concentrated in the liver, where it is metabolised and excreted into the bile. It is found in much higher concentrations in the bile compared with the blood. Following a single 150 mg dose of demeclocycline hydrochloride in normal volunteers, 44% (n = 8) was excreted in urine and 13% and 46%, respectively, were excreted in faeces in two patients within 96 hours as active drug.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function.
10–20 600 mg every 24–48 hours.
<10 600 mg every 24–48 hours.

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. 600 mg every 48 hours.
HD Dialysed. 600 mg post dialysis.
HDF/High flux Dialysed. 600 mg post dialysis.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min. See ‘Other information’.

Important drug interactions

Potentially hazardous interactions with other drugs
• Anticoagulants: possibly enhanced anticoagulant effect of coumarins and phenindione.
• Oestrogens: possibly reduced contraceptive effects of oestrogens (risk probably small).
• Retinoids: possible increased risk of benign intracranial hypertension, avoid.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information

• Avoid if possible in renal impairment due to its potential nephrotoxicity.
• May be administered to anuric patients every 3–4 days.
• Dose in renal impairment is from Drug Dosage in Renal Insufficiency by Seyffart G.
• There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline:
  The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Denosumab

Clinical use

Human monoclonal antibody (IgG2):
• Osteoporosis in postmenopausal women and men with prostate cancer after hormone ablation at risk of fractures
• Reduction of bone damage in patients with bone metastases from solid tumours

Dose in normal renal function

• Osteoporosis: 60 mg every 6 months
• Reduction of bone damage: 120 mg every 4 weeks

Pharmacokinetics

Molecular weight (daltons) 144 700
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 14–55 days / Unchanged

Metabolism

Metabolism and elimination are expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• None known

Administration

Reconstitution
—

Route
SC

Rate of administration
—

Other information

• There is limited data from the manufacturer for monthly administration therefore use with caution.
• Hypocalcaemia is a major risk if GFR<30 mL/min.
• Calcium and vitamin D supplements must be taken.
• Osteonecrosis of the jaw has occurred although rarely.
Desferrioxamine mesilate

Clinical use

Chelating agent:
- Acute iron poisoning
- Chronic iron or aluminium overload

Dose in normal renal function

- SC/IV: Initially 500 mg then 20–60 mg/kg/day 3–7 times a week. Exact dosages should be determined for each individual
- IM: 0.5–2 g daily as stat, maintenance dose as per response
- Oral: acute iron poisoning: 5–10 g should be dissolved in 50–100 mL water
- Aluminium overload in HD: (IV) 5 mg/kg weekly over last hour of dialysis
- PD: (SC, IM, IV, IP) 5 mg/kg weekly before the final exchange of the day

Pharmacokinetics

Molecular weight (daltons) 656.8
% Protein binding <10
% Excreted unchanged in urine 22
Volume of distribution (L/kg) 2–2.5
Half-life — normal/ESRF (hrs) 6 / –

Metabolism

When given parenterally desferrioxamine forms chelates with iron and aluminium ions to form ferrioxamine and aluminoxamine, respectively. The chelates are excreted in the urine and faeces via the bile. Desferrioxamine is metabolised, mainly in the plasma. Four metabolites of desferrioxamine were isolated from urine of patients with iron overload. The following biotransformation reactions were found to occur with desferrioxamine: transamination and oxidation yielding an acid metabolite, beta-oxidation also yielding an acid metabolite, decarboxylation and N-hydroxylation yielding neutral metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dosage as in normal renal function. See 'Other information.'</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>See 'Other information.'</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>See 'Other information.'</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD Dialysed. Treatment of aluminium overload: 1 g once or twice each week prior to final exchange of the day by slow IV infusion, IM, SC or IP.
- HD Dialysed. Treatment of aluminium overload: 1 g once each week administered during the last hour of dialysis as a slow IV infusion.
- HDF/High flux Dialysed. Treatment of aluminium overload: 1 g once each week administered during the last hour of dialysis as a slow IV infusion.
- CAV/VVHD Dialysed. Dose schedule unknown. Metal chelates will be removed by dialysis.

Important drug interactions

Potentially hazardous interactions with other drugs
- Avoid prochlorperazine, levomepromazine and methotrimeprazine (prolonged unconsciousness).
- Do not administer with blood.

Administration

Reconstitution
Dissolve contents of one vial (500 mg) in 5 mL of water for injection =10% solution. If for IV administration, the 10% solution can be diluted with sodium chloride 0.9%, glucose 5% or glucose/sodium chloride.

Route
IV, SC (bolus or continuous infusion), IM, IP, oral

Rate of administration
- IV (acute overdose): Maximum 15 mg/kg/hour. Reduce after 4–6 hours so that total dose does not exceed 80 mg/kg/24 hours.
- SC: Infuse over 8–24 hours. Local irritation may occur.

Comments
- The urine may appear orange/red in patients treated with desferrioxamine for severe iron intoxication.
- SC infusion is about 90% as effective as IV administration, which is now the route of choice in transfusion-related iron overload.
- IM injection is less effective than SC.
Other information

- Studies suggest that during HD only a small amount of plasma desferrioxamine crosses the dialysis membrane.
- Manufacturer advises to use with caution in renal impairment except those on dialysis as the metal complexes are excreted via the kidney.
- Drug Prescribing in Renal Failure, 5th edition by Aronoff et al. advises to use 25–50% of dose if GFR=10–50 mL/min and to avoid if GFR<10 mL/min.
- 100 mg desferrioxamine mesilate can bind 4.1 mg Al³⁺.
- Desferrioxamine may predispose to development of infection with Yersinia species.
- In haemodialysis patients treated with desferrioxamine post dialysis, the half-life has been found to be extended to 19 hours between dialysis sessions.
- Anecdotally, escalating doses of up to 2 g, 3 times a week have been successfully used for iron overload in patients on haemodialysis.
- In treatment of acute iron poisoning, effectiveness of treatment is dependent on an adequate urine output. If oliguria or anuria develop, PD or HD may be necessary.
Desirudin (unlicensed product)

Clinical use
Prophylaxis of DVT in patients undergoing orthopaedic surgery

Dose in normal renal function
15 mg 5–15 minutes before surgery then 15 mg twice daily for 9–12 days or until mobile

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>6963.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40–50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.25</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–3 / –</td>
</tr>
</tbody>
</table>

Metabolism
Desirudin is metabolised and excreted by the kidney, and 40–50% of a dose is excreted unchanged in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose (mg)</th>
<th>APTT Aim</th>
</tr>
</thead>
<tbody>
<tr>
<td>31–60</td>
<td>Initially 5 mg twice daily. Aim for APTT &lt;0.85 seconds.</td>
<td></td>
</tr>
<tr>
<td>&lt;31</td>
<td>Initially 1.7 mg twice daily and monitor APTT.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;31 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;31 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;31 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR&lt;31 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants, antiplatelets, fondaparinux, NSAIDs, heparin and dextran – increased risk of bleeding.

Administration
Reconstitution
With diluent supplied
Route
SC
Rate of administration
—

Other information
- The effect is poorly reversible.
- APTT levels can be reduced by IV DDAVP.
- Available on a named patient basis from Aventis Pharma.
- 7% of dose is metabolised by the kidneys.
### Clinical use

Antihistamine:
- Symptomatic relief of allergy such as hay fever, urticaria

### Dose in normal renal function

5 mg daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>310.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>83–87</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40.6 (as active metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>27 / Increased</td>
</tr>
</tbody>
</table>

### Metabolism

Desloratadine is the primary active metabolite of loratadine. Approximately 40% of the dose is excreted in the urine and 42% in the faeces over a 10 day period and mainly in the form of conjugated metabolites. Approximately 27% of the dose is eliminated in the urine during the first 24 hours. Less than 1% of the active substance is excreted unchanged in the active form, as desloratadine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antivirals: concentration possibly increased by ritonavir.

### Administration

Reconstitution
- 

Route
Oral

Rate of administration
- 

### Other information

- Full dose may result in increased sedation in patients with GFR<10 mL/min.
Desmopressin (DDAVP)

Clinical use
- Diabetes insipidus
- Nocturnal enuresis
- Nocturia due to idiopathic nocturnal polyuria
- Post-biopsy bleeding (unlicensed indication)
- Pre-biopsy prophylaxis (unlicensed indication)

Dose in normal renal function
- Diabetes insipidus: Oral: 0.2–1.2 mg daily in 3 divided doses. IV/SC/IM: 1–4 mcg daily. Inhaled: 10–40 mcg in 1 or 2 divided doses. Sub-lingual: 120–720 mcg daily
- Nocturnal enuresis: Oral: 200–400 mcg at bedtime. Sub-lingual: 120–240 mcg at bedtime
- Nocturia due to multiple sclerosis: (Intranasal) 10–20 mcg at bedtime
- Nocturia due to idiopathic nocturnal polyuria (Sublingual): 25 mcg (women), 50 mcg (men) taken 1 hour before bedtime
- Biopsy: Males – 16 mcg; Females – 12 mcg or 300–400 nanograms/kg
- Pre-biopsy prophylaxis in uraemic patients: 20 mcg (IV) over 30 minutes

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Apart from Noqdirna – contraindicated.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Apart from Noqdirna – contraindicated.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration

Reconstitution
-

Route
IV, intranasally, oral, SC, IM, SL

Rate of administration
Over 20–60 minutes

Comments
- Dilute dose to 50 mL with sodium chloride 0.9%
- Do not inject at a faster rate – greater risk of tachyphylaxis.
- In patients with ischaemic heart disease, infuse more slowly – increased risk of acute ischaemic event.

Other information
- Emergency treatment of more generalised bleeding unresponsive to normal treatments: 0.1–0.5 micrograms/kg 4 times a day + IV conjugated oestrogens (premarin) 0.6 mg/kg/day for up to 5 days.
- DDAVP works as a haemostatic by stimulating factor VIII production.
- Onset of action less than 1 hour. Duration of effect 4–8 hours.
## Clinical use

**Corticosteroid:**
- Cerebral oedema
- Bacterial meningitis (unlicensed indication)
- Suppression of inflammatory and allergic disorders
- Rheumatic disease
- Congenital adrenal hyperplasia
- Anti-emetic (unlicensed indication)

## Dose in normal renal function

Cerebral oedema, bacterial meningitis: depends on preparation.

Rheumatic disease:
- intra-articular, intrasynovial: according to preparation and size of joint
- soft tissue infiltration: 1.7–5 mg

Oral: 0.5–10 mg daily, IV/IM: 0.4–20 mg

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>392.5 (472.4 as phosphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>77</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>65</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.8–1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3.5–4.5 / –</td>
</tr>
</tbody>
</table>

## Metabolism

Corticosteroids are metabolised mainly in the liver but also in other tissues, and are excreted in the urine. The slower metabolism of the synthetic corticosteroids with their lower protein-binding affinity may account for their increased potency compared with the natural corticosteroids. Up to 65% of a dose of dexamethasone is excreted in urine within 24 hours.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs:
- Aldesleukin: avoid concomitant use.
- Antibacterials: metabolism accelerated by rifamycins; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced.
- Anticoagulants: efficacy of coumarins and phenindione may be altered.
- Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited by itraconazole and ketoconazole; caspofungin concentration possibly reduced (may need to increase dose).
- Antivirals: concentration of indinavir, lopinavir, saquinavir and telaprevir possibly reduced; avoid with rilpivirine; concentration possibly increased by ritonavir.
- Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids.
- Cobicistat: concentration possibly increased by cobicistat.
- Cytotoxics: possibly decreases axitinib concentration, increase dose of axitinib.
- Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
- Netupitant: concentration of dexamethasone increased – halve dexamethasone dose.
- Vaccines: high dose corticosteroids can impair immune response to vaccines; avoid concomitant use with live vaccines.

## Administration

Reconstitution

---
Route
Oral, IV, IM, intra-articular, intrasynovial

Rate of administration
IV slowly over not less than 5 minutes. If underlying cardiac pathology, infusion over 20–30 minutes advised

Comments
- Dexamethasone sodium phosphate 1.3 mg = dexamethasone 1 mg.
- 750 mcg of dexamethasone is equivalent to 5 mg prednisolone.
- Injection solution can be administered orally or via naso-gastric tube.
- Tablets will disperse in water.
Dexibuprofen

Clinical use

NSAID and analgesic

Dose in normal renal function

- Initially: 600–900 mg daily in up to 3 divided doses, after food; Maximum 1.2 g daily (900 mg daily for dysmenorrhoea);
- Maximum single dose: 400 mg (300 mg for dysmenorrhoea).

Pharmacokinetics

Molecular weight (daltons) 206.3
% Protein binding >99
% Excreted unchanged in urine 82 (mainly as inactive metabolites)
Volume of distribution (L/kg) 10–11 Litres
Half-life — normal/ESRF (hrs) 1.6–1.9 / Unchanged

Metabolism

Dexibuprofen is the S(+)-enantiomer of ibuprofen. After metabolic transformation in the liver (hydroxylation and carboxylation), the pharmacologically inactive metabolites are completely excreted, mainly by the kidneys (90%), but also in the bile.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but only use if on dialysis.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect, increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

Administration

Reconstitution
- Route
  Oral

Rate of administration
- Other information
  - Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine
48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.

- Use normal doses in patients with CKD 5 on dialysis.

- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
Dexketoprofen

Clinical use
NSAID and analgesic

Dose in normal renal function
- 12.5 mg every 4–6 hours
- Or 25 mg every 8 hours

Pharmacokinetics
Molecular weight (daltons) 254.3
% Protein binding 99
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 0.24
Half-life — normal/ESRF (hrs) 1.65 / Increased

Metabolism
Dexketoprofen is the S-enantiomer of ketoprofen. The main elimination route for dexketoprofen is glucuronide conjugation in the liver followed by renal excretion.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function but use with caution.
10–20 Dose as in normal renal function but avoid if possible.
<10 Dose as in normal renal function but only if on dialysis.

Dose in patients undergoing renal replacement therapies
APD/CAPD Dialysed. Dose as in normal renal function. See 'Other information'.
HD Dialysed. Dose as in normal renal function. See 'Other information'.
HDF/High flux Dialysed. Dose as in normal renal function. See 'Other information'.
CAV/VVHD Dialysed. Dose as for GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects);
- avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect, hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Probenecid: excretion reduced by probenecid.
- Tacrolimus: increased risk of nephrotoxicity.

Administration
Reconstitution
- Route Oral
- Rate of administration

Other information
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48-72 hours after starting NSAID – if raised, discontinue NSAID therapy.
- Use normal doses in patients with ERF on dialysis if they do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autacoid synthesis.
- Dexketoprofen should be used with caution in uraemic patients predisposed to gastrointestinal bleeding or uraemic coagulopathies.
**Dexrazoxane**

**Clinical use**
Cardioxane*: Prevention of cardiotoxicity in patients receiving doxorubicin or epirubicin for breast cancer
Savene*: Treatment of extravasation caused by anthracyclines

**Dose in normal renal function**
Cardioxane*: 10 times the dose of doxorubicin or epirubicin
Savene*: days 1 and 2: 1000 mg/m² (maximum daily dose 2000 mg), day 3: 500 mg/m² (maximum daily dose 1000 mg)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Cardioxane*</th>
<th>Savene*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>268.3</td>
<td></td>
</tr>
<tr>
<td>% Protein binding</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Cardioxane*: 40; Savene*: 34–60</td>
<td></td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.13–1.3</td>
<td></td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Cardioxane*: 1–3.4; Savene*: 1.9–9.1 / Increased</td>
<td></td>
</tr>
</tbody>
</table>

**Metabolism**
Dexrazoxane is hydrolysed by the enzyme dihydropyrimidine amidohydrolase in the liver and kidney to active metabolites that are capable of binding to metal ions.
It is excreted unchanged via the kidney.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Cardioxane*</th>
<th>Savene*</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–50</td>
<td>Dose as in normal renal function. Give 50% of dose. See ‘Other information’.</td>
<td></td>
</tr>
<tr>
<td>&lt;40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Probably dialysed. Dose as in GFR&lt;40 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Probably dialysed. Dose as in GFR&lt;40 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Probably dialysed. Dose as in GFR&lt;40 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably dialysed. Dose as in GFR&lt;40 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antiepileptics: may reduce absorption of fosphenytoin and phenytoin.
- Ciclosporin: increased risk of immunosuppression with risk of lymphoproliferative disease.
- Tacrolimus: increased risk of immunosuppression with risk of lymphoproliferative disease.
- Vaccines: risk of generalised infections with live vaccines – avoid.

**Administration**

**Reconstitution**
25 mL water for injection (Cardioxane*); 25 mL of diluent (Savene*) / vial

**Route**
IV infusion

**Rate of administration**
Cardioxane*: Over 15 minutes; Savene*: over 1–2 hours

**Comments**
Cardioxane*: Then further dilute to 25–100 mL / vial with Ringer/sodium lactate

**Other information**
- Monitor for haematological toxicity in renal impairment.
- Compared with normal subjects, exposure was 2-fold greater in subjects with moderate (CRCL=30–50 mL/min) to severe (CRCL<30 mL/min) renal impairment.
- Clearance of dexrazoxane and its active metabolites may be reduced in patients with decreased creatinine clearance.
Diamorphine hydrochloride

**Clinical use**

Opiate analgesic:
- Control of severe pain
- Pain relief in myocardial infarction (MI)
- Acute pulmonary oedema

**Dose in normal renal function**

- Severe pain: Oral/SC/IM: 5–10 mg 4 hourly, increasing dose as necessary.
- MI, acute pulmonary oedema: IV: 2.5–5 mg. Elderly patients – reduce dose by half.

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>423.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>35</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0.1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>40–50 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.7–5.3 minutes / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Diamorphine is rapidly hydrolysed to the active metabolite 6-O-monoacetylmorphine (6-acetylmorphine) in the blood and then to morphine. Oral doses are subject to extensive first-pass metabolism to morphine; neither diamorphine nor 6-acetylmorphine has been detected in the blood after giving diamorphine by this route. The majority of the drug is excreted via the kidney as glucuronides and to a much lesser extent as morphine. About 7–10% is eliminated via the biliary system into the faeces.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: possible opioid withdrawal with buprenorphine and pentazocine.
- Anti-arrhythmics: delayed absorption of mexiletine.
- Antidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced sedative and hypotensive effect.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

**Administration**

**Reconstitution**
1 mL water for injection or sodium chloride 0.9% (less may be used, e.g. for SC injection use 0.1 mL for 10 mg)

**Route**
IV, IM, SC, oral

**Rate of administration**
IV: 1 mg/minute

**Comments**
Monitor BP and respiratory rates.

**Other information**

- Increased cerebral sensitivity in renal impairment which can result in excessive sedation and serious respiratory depression necessitating ventilation.
- More rapid onset and shorter duration of action than morphine.
- EXTREME CAUTION with regular dosing – accumulation of active metabolites may occur.
- Naloxone must be readily available for reversal if required.
Diazepam

Clinical use

Benzodiazepine:
- Perioperative sedation (IV)
- Anxiolytic
- Muscle relaxant
- Status epilepticus

Dose in normal renal function

- Pre-med: Oral: 5–10 mg, IV: 10–20 mg or 100–200 mcg/kg; PR: 500 mcg/kg repeated after 12 hours as rectal solution
- Anxiety: Oral: 2 mg 3 times a day, increasing if necessary to 15–30 mg daily in divided doses; PR: 10–30 mg daily in divided doses
- Insomnia: 5–15 mg at night
- Muscle spasms: 2–15 mg daily in divided doses, maximum 60 mg daily
- Status epilepticus: IV: 10 mg, repeated after 10 minutes if required
- PR: 10–20 mg

Pharmacokinetics

Molecular weight (daltons) 284.7
% Protein binding 95–99
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 0.95–2
Half-life — normal/ESRF (hrs) 24–48 / Increased

Metabolism

Diazepam has a biphasic half-life with an initial rapid distribution phase and a prolonged terminal elimination phase of 1 or 2 days; its action is further prolonged by the even longer half-life of 2–5 days of its principal active metabolite, desmethyldiazepam. Diazepam is extensively metabolised in the liver, notably via the cytochrome P450 isoenzymes CYP2C19 and CYP3A4; in addition to desmethyldiazepam, its active metabolites include oxazepam and temazepam. It is excreted in the urine, mainly in the form of free or conjugated metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use small doses and titrate to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use small doses and titrate to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: metabolism enhanced by rifampicin; metabolism inhibited by isoniazid.
- Antifungals: concentration increased by fluconazole and voriconazole – risk of prolonged sedation.
- Antipsychotics: increased sedative effects; increased risk of hypotension, bradycardia and respiratory depression with parenteral diazepam and IM olanzapine; risk of serious adverse effects in combination with clozapine.
- Antivirals: concentration possibly increased by ritonavir.
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.

Administration

Reconstitution

Route
- IV injection, infusion, IM, oral, PR

Rate of administration
- 5 mg (1 mL)/minute

Comments
- Injection can be mixed with sodium chloride 0.9% or glucose 5% to 40 mg in 500 mL.

Other information
- Increased cerebral sensitivity in renal impairment which may result in excessive sedation and encephalopathy.
- Always have flumazenil available to reverse effect.
- Protein binding decreased in ERF.
- Volume of distribution increased in ERF.
- IV emulsion formulation (Diazemuls) less likely to cause thrombophlebitis.
Diazoxide

**Clinical use**
- Treatment of hypertensive emergencies including severe hypertension associated with renal disease
- Hypoglycaemia

**Dose in normal renal function**
- Hypertension: IV: 1–3 mg/kg; maximum single dose: 150 mg, repeat after 5–15 minutes.
- Hypoglycaemia: Oral: 3–5 mg/kg in 2–3 divided doses; adjust according to response, usually 3–8 mg/kg; total doses up to 1 g have been used

**Pharmacokinetics**
- Molecular weight (daltons) 230.7
- % Protein binding >90
- % Excreted unchanged in urine 50
- Volume of distribution (L/kg) 0.2–0.3
- Half-life — normal/ESRF (hrs) 20–45 / 30–60

**Metabolism**
Diazoxide is partly metabolised in the liver and is excreted in the urine both unchanged and in the form of metabolites; only small amounts are recovered from the faeces. The plasma half-life of diazoxide greatly exceeds the duration of vascular activity.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Start with a lower dose and increase gradually according to response. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antihypertensives and vasodilators: enhanced hypotensive effect.
- MAOIs: withdraw at least 14 days before starting diazoxide.
- Phenytoin: may reduce phenytoin levels.

**Administration**

**Reconstitution**

**Route**
- IV bolus, oral

**Rate of administration**
- <30 seconds

**Other information**
- Single doses above 300 mg have been associated with angina and myocardial and cerebral infarction.
- Can cause sodium and water retention.
Diclofenac sodium

**Clinical use**

NSAID and analgesic

**Dose in normal renal function**

75–150 mg daily in divided doses.

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>318.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99.7</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.12–0.17</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–2 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Diclofenac undergoes first-pass metabolism and is then extensively metabolised to 4'-hydroxydiclofenac, 5-hydroxydiclofenac, 3'-hydroxydiclofenac, and 4',5-dihydroxydiclofenac by glucuronidation of the intact molecule or more commonly by single and multiple hydroxylation followed by glucuronidation.

It is then excreted in the form of glucuronide and sulfate conjugates, mainly in the urine (about 60%) but also in the bile (about 35%).

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but only use if on dialysis.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.

- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).

- Antibacterials: possibly increased risk of convulsions with quinolones; concentration reduced by rifampicin.

- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban; increased risk of haemorrhage with IV diclofenac – avoid.

- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.

- Antidiabetic agents: effects of sulphonylureas enhanced.

- Antiepileptics: possibly increased phenytoin concentration.

- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.

- Ciclosporin: may potentiate nephrotoxicity; concentration increased by ciclosporin.

- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.

- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.

- Lithium: excretion decreased.

- Pentoxifylline: increased risk of bleeding.

- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

---

**Route**

Oral, IV, IM, PR

**Rate of administration**

25–50 mg over 15–60 minutes; 75 mg over 30–120 minutes.

Continuous infusion of 5 mg/hour.
Comments
Dilute 75 mg in 100–500 mL of sodium chloride 0.9% or glucose 5% buffered with 0.5 mL sodium bicarbonate 8.4%

Other information
- Diclofenac should be used with caution in uraemic patients predisposed to gastrointestinal bleeding or uraemic coagulopathies.
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.
- Use normal doses in patients with ERF on dialysis if they do not pass any urine.
- Use with great caution in renal transplant recipients – can reduce intrarenal autacoid synthesis.
Didanosine

**Clinical use**
Nucleoside reverse transcriptase inhibitor:
- Treatment of HIV in combination with other antiretroviral drugs

**Dose in normal renal function**
>60 kg: 400 mg daily in 1–2 divided doses
<60 kg: 250 mg daily in 1–2 divided doses

**Pharmacokinetics**
Molecular weight (daltons) 236.2
% Protein binding <5
% Excreted unchanged in urine 20
Volume of distribution (L/kg) 1
Half-life — normal/ESRF (hrs) 1.4 / 4.1

**Metabolism**
Didanosine is metabolised intracellularly to the active antiviral metabolite dideoxyadenosine triphosphate.
The terminal metabolism of didanosine in man has not been evaluated. However, based on animal studies, it is presumed that it follows the same pathways responsible for the elimination of endogenous purines. Renal clearance is by glomerular filtration and active tubular secretion; about 20% of an oral dose is recovered in the urine.

**Dose in renal impairment GFR (mL/min)**
30–59
<60 kg: 150 mg daily in 1 or 2 divided doses; >60 kg: 200 mg daily in 1 or 2 divided doses.
10–29
<60 kg: 100 mg daily; >60 kg: 150 mg daily.
<10
<60 kg: 75 mg daily; >60 kg: 100 mg daily.

**Dose in patients undergoing renal replacement therapies**
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Dialysed. Dose as in GFR=10–29 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Allopurinol: concentration of didanosine increased – avoid.
- Antibacterials: ciprofloxacin, tetracyclines, and other antibiotics affected by indigestion remedies – do not administer within 2 hours of didanosine.
- Antivirals: absorption of atazanavir reduced (give at least 2 hours before or 1 hour after didanosine tablets); manufacturer of darunavir advises to take didanosine 1 hour before or 2 hours after darunavir; didanosine tablets reduce absorption of indinavir (give at least 1 hour apart); concentration possibly increased by ganciclovir, valganciclovir and tenofovir – avoid with tenofovir; give didanosine and ritonavir at least 2.5 hours apart; increased risk of side effects with ribavirin and stavudine – avoid; concentration reduced by tipranavir (give tipranavir and didanosine capsules at least 2 hours apart); give didanosine 2 hours before or 4 hours after ritipivirine.
- Cytotoxics: increased risk of toxicity with hydroxycarbamide – avoid.
- Orlistat: absorption of didanosine possibly reduced.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Comments**
Give dose after dialysis on dialysis days, AND at the same time on non-dialysis days.

**Other information**
- Haemodialysis removes 20–35% of the dose.
- Administer 30 minutes to 2 hours before meals (depends on formulation).
- Magnesium content of tablets 8.6 mEq.
- Chew, crush tablet or disperse in at least 30 mL of water.
- Can be diluted in apple juice.
- Ingestion with food decreases absorption by 55%. 
Digoxin

**Clinical use**
- Supraventricular arrhythmias
- Heart failure

**Dose in normal renal function**
- Digitalisation: 0.75–1.5 mg in divided doses over 24 hours, followed by 62.5–500 mcg daily, adjusted according to response.
- Heart failure: 62.5-125 mcg once daily
- Emergency loading (IV): 0.75–1 mg over at least 2 hours

**Pharmacokinetics**
- Molecular weight (daltons) 780.9
- Protein binding 25%
- Excreted unchanged in urine 50–75%
- Volume of distribution (L/kg) 5–8
- Half-life — normal/ESRF (hrs) 30–40 / 100

**Metabolism**
Digoxin is mainly excreted unchanged in the urine by glomerular filtration and tubular secretion; reabsorption also occurs. Extensive metabolism has been reported in a minority of patients. Metabolites that have been detected in the urine include digoxigenin, dihydrodigoxigenin, the mono- and bisdigitoxosides of digoxigenin, and dihydrodigoxin. Digoxigenin mono- and bisdigitoxosides are known to be cardioactive whereas dihydrodigoxin is probably much less active than digoxin.

In about 10% of patients there is considerable reduction to cardio-inactive metabolites, chiefly dihydrodigoxin, and 40% or more of a dose may be excreted in the urine as dihydrodigoxin. Bacterial flora in the gastrointestinal tract appear to be responsible for this metabolism and antibacterials can reduce the process.

Excretion of digoxin is proportional to the glomerular filtration rate. After intravenous injection 50–70% of the dose is excreted unchanged.

**Dose in renal impairment GFR (mL/min)**
- Digitalisation using 750 micrograms – 1 mg.
- Interval between normal or reduced doses may need to be lengthened.
  - 20–50 125–250 micrograms per day.
  - 10–20 125–250 micrograms per day. Monitor levels.
  - <10 Dose commonly 62.5 micrograms alternate days, or 62.5 micrograms daily. Monitor levels.

**Pharmacokinetics**
- Molecular weight (daltons) 780.9
- Protein binding 25%
- Excreted unchanged in urine 50–75%
- Volume of distribution (L/kg) 5–8
- Half-life — normal/ESRF (hrs) 30–40 / 100

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Angiotensin-II antagonists: concentration increased by telmisartan.
- Anti-arrhythmics: concentration increased by amiodarone, dronedarone and propafenone (half maintenance dose of digoxin).
- Antidepressants: concentration reduced by St John’s wort – avoid.
- Antifungals: increased toxicity if hypokalaemia occurs with amphotericin; concentration increased by itraconazole.
- Antimalarials: concentration possibly increased by quinine, hydroxychloroquine and chloroquine; increased risk of bradycardia with mefloquine.
- Antivirals: concentration increased by daclatasvir.
- Calcium-channel blockers: concentration increased by diltiazem, lercanidipine, nicardipine, verapamil and possibly nifedipine; increased risk of AV block and bradycardia with verapamil.
- Ciclosporin: concentration increased by ciclosporin.
- Colchicine: possibly increased risk of myopathy.
- Diuretics: increased toxicity if hypokalaemia occurs; concentration increased by spironolactone and possibly potassium canrenoate.
- Ticagrelor: concentration of digoxin increased.
### Administration

<table>
<thead>
<tr>
<th>Reconstitution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route</td>
</tr>
<tr>
<td>Oral, IV</td>
</tr>
</tbody>
</table>

#### Rate of administration
Loading dose: infuse over 10–20 minutes.

#### Comments
- IV administration: dilute dose to 4 times volume with sodium chloride 0.9% or glucose 5%.
- IV dosing may be used for very rapid control.

### Other information
- Complex kinetics in renal impairment: Volume of distribution and total body clearance reduced in CKD 5.
- Steady-state plasma monitoring advisable: normal range 0.8–2 nanograms/mL; take at least 8 hours post-dose, ideally before dose in the morning.
- If changing from oral to IV reduce dose by a third.
- Hypokalaemia, hypomagnesaemia, marked hypercalcaemia and hypothyroidism increase toxicity.
- Increases uraemic gastrointestinal symptoms.
- Only 3% of dose is removed after a 5 hour HD session.
- Concomitant administration of phosphate binders reduces GI absorption by up to 25%.
Dihydrocodeine tartrate

**Clinical use**
Analgesia

**Dose in normal renal function**
- Oral: 30 mg every 4–6 hours
- SC/IM: up to 50 mg every 4–6 hours

**Pharmacokinetics**
- Molecular weight (daltons) 451.5
- % Protein binding No data
- % Excreted unchanged in urine 13–22
- Volume of distribution (L/kg) 1.1
- Half-life — normal/ESRF (hrs) 3.5–5 / >6

**Metabolism**
Dihydrocodeine is metabolised in the liver via the cytochrome P450 isoenzyme CYP2D6, to dihydromorphine, which has potent analgesic activity, although the analgesic effect of dihydrocodeine appears to be mainly due to the parent compound; some is also converted via CYP3A4 to nordihydrocodeine. Dihydrocodeine is excreted in urine as unchanged drug and metabolites, including glucuronide conjugates.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Use small doses and titrate to response.
- <10 Use small doses and titrate to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Unknown dialysability. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use, and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

**Adminstration**

**Reconstitution**

**Route**
Oral, IM, SC

**Rate of administration**

**Other information**
- Increased and prolonged effect in renal impairment, enhancing respiratory depression and constipation.
- Increased CNS sensitivity in renal impairment.
- Accumulation of active metabolites can occur – caution.
- Effects can be reversed by naloxone.
Diltiazem hydrochloride

**Clinical use**
Calcium-channel blocker:
- Prophylaxis and treatment of angina
- Hypertension

**Dose in normal renal function**
180–480 mg in up to 3 divided doses

**Pharmacokinetics**
- Molecular weight (daltons) 451
- % Protein binding 80–85
- % Excreted unchanged in urine 5
- Volume of distribution (L/kg) 3–8
- Half-life — normal/ESRF (hrs) 2–11; SR: 5–8 / Unchanged

**Metabolism**
Diltiazem is almost completely absorbed from the gastrointestinal tract after oral doses, but undergoes extensive first-pass hepatic metabolism resulting in a bioavailability of about 40%. It is extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP3A4; one of the metabolites, desacetyldiltiazem, has been reported to have 25–50% of the activity of the parent compound.
About 2–4% of a dose is excreted in urine as unchanged diltiazem with the remainder excreted as metabolites in bile and urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Start with a low dose and gradually increase as tolerated.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: enhanced effect of aminophylline and theophylline.
- Anaesthetics: enhanced hypotensive effect.
- Anti-arrhythmics: increased risk of bradycardia, AV block and myocardial depression with amiodarone; increased risk of bradycardia and myocardial depression with dronedarone.
- Antibacterials: metabolism increased by rifampicin; metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin.
- Antidepressants: enhanced hypotensive effect with MAOIs; concentration of imipramine and possibly other tricyclics increased.
- Antiepileptics: effect probably reduced by barbiturates, fosphenytoin, phenytoin, and primidone; enhanced effect of carbamazepine; increased levels of fosphenytoin and phenytoin.
- Antifungals: negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antipsychotics: concentration of lurasidone increased.
- Antivirals: concentration increased by atazanavir and ritonavir – reduce dose of diltiazem with atazanavir; concentration reduced by efavirenz; use telaprevir with caution.
- Avanafil: possibly increases avanafil concentration.
- Beta-blockers: risk of bradycardia and AV block if co-prescribed with beta-blockers.
- Cardiac glycosides: increased digoxin concentration.
- Ciclosporin: increased ciclosporin concentrations.
- Cilostazol: increased cilostazol concentration – avoid.
- Colchicine: possibly increased risk of colchicine toxicity – suspend or reduce colchicine, avoid concomitant use in renal or hepatic failure.
- Cytotoxics: concentration of bosutinib, ibrutinib and olaparib possibly increased – avoid or reduce dose; possibly increased risk of bradycardia with crizotinib.
- Fingolimod: increased risk of bradycardia.
- Ivabradine: concentration of ivabradine increased – avoid.
- Lipid lowering drugs: concentration of lomitapide possibly increased – avoid.
- Sirolimus: sirolimus concentration increased.
• Statins: increased atorvastatin concentration and possibly myopathy; increased myopathy with simvastatin. Do not exceed 20 mg of simvastatin with diltiazem.\(^1\)
• Tacrolimus: increased tacrolimus concentration.

**Administration**

**Reconstitution**

**Route**

Oral

**Rate of administration**

—

**Other information**

• Active metabolites.
• Monitor heart rate early on in therapy. If falls below 50 beats/minute, do not increase dose.
• Maintain patient on same brand.

Reference:

Dimethyl fumarate

Clinical use
- Treatment of relapsing-remitting multiple sclerosis
- Treatment of moderate to severe plaque psoriasis

Dose in normal renal function
- MS: 120 mg twice daily for 7 days then 240 mg twice daily
- Plaque psoriasis: initially 30 mg once daily increasing to 720 mg in 3 divided doses

Pharmacokinetics
Molecular weight (daltons) 144.1
% Protein binding 27–40
% Excreted unchanged in urine <0.1
Volume of distribution (L/kg) 60–90 Litres
Half-life — normal/ESRF (hrs) 1–2 / Unchanged

Metabolism
Dimethyl fumarate is rapidly hydrolysed to its active metabolite, monomethyl fumarate, by esterases in the gastrointestinal tract, blood and tissues. A single 240 mg [14C]-dimethyl fumarate dose study identified glucose as the predominant metabolite in human plasma. Other circulating metabolites included fumaric acid, citric acid and monomethyl fumarate. The downstream metabolism of fumaric acid occurs through the tricarboxylic acid cycle, with exhalation of CO2 serving as a primary route of elimination, accounting for 60% of the dose. Renal and faecal elimination are secondary routes of elimination, accounting for 15.5% and 0.9% of the dose respectively.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
- Route
- Oral
- Rate of administration
- Other information
- Manufacturer has limited data in severe renal impairment but unlikely to be any dose change required. Manufacturer advises to use with caution in severe renal impairment.
- Manufacturer of Skilarence advises to avoid in severe renal impairment due to lack of studies and reports of renal impairment during post marketing surveillance.
- There have been reports of acute renal failure, chronic renal tubular damage, and reversible proteinuria, associated with fumaric acid derivatives.

References:
Dipyridamole

Clinical use
Oral: Antiplatelet agent
IV: Myocardial imaging

Dose in normal renal function
- Oral: 100–200 mg 3 times daily
- Modified release: 200 mg twice daily
- IV: 0.142 mg/kg/minute (0.567 mg/kg total) infused over 4 minutes

Pharmacokinetics
Molecular weight (daltons) 504.6
% Protein binding 97–99
% Excreted unchanged in urine 1–5
Volume of distribution (L/kg) 1.33–3.53
Half-life — normal/ESRF (hrs) 9–12 / Unchanged

Metabolism
Dipyridamole is metabolised in the liver. Renal excretion of the parent compound is negligible (< 0.5%). Urinary excretion of the glucuronide metabolite is low (5%), the metabolites are mostly (about 95%) excreted via the bile into the faeces, with some evidence of entero-hepatic recirculation.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: effects of adenosine enhanced and extended.
- Anticoagulants: anticoagulant effect of coumarins, phenindione and heparin enhanced.

Administration
Reconstitution

Route
Oral, IV infusion
Rate of administration
Over 4 minutes
Disodium pamidronate

Clinical use

Bisphosphonate:
• Hypercalcaemia
• Bone pain
• Paget's disease

Dose in normal renal function

• Hypercalcaemia: depends on serum calcium – 15–90 mg in single or divided doses
• Bone pain: 90 mg every 4 weeks
• Paget's disease: 30 mg weekly for 6 weeks, or 30 mg first dose then 60 mg every other week

Pharmacokinetics

Molecular weight (daltons) 369.1
% Protein binding 54
% Excreted unchanged in urine 20–55
Volume of distribution (L/kg) 0.5–0.6
Half-life — normal/ESRF (hrs) 0.8–27 / Unchanged

Metabolism

Pamidronate is not metabolised, and about 20–55% of the dose is excreted in the urine unchanged within 72 hours; the remainder is mainly sequestered to bone and only very slowly eliminated.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Serum calcium &gt;4.0, give 60 mg. Serum calcium &lt;4.0, give 30 mg.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• None known

Administration

Reconstitution
• 15 mg in 5 mL water for injection
• 30 or 90 mg in 10 mL water for injection
• Final concentration should not exceed 30 mg per 125 mL sodium chloride 0.9%

Route
IV

Rate of administration
Maximum 20 mg/hour in patients with impaired renal function

Other information

• If pamidronate is not excreted adequately, kidney stones may be formed.
• In dialysis patients there is increased risk of asymptomatic hypocalcaemia with 90 mg doses (anecdotal).
Disopyramide

Clinical use
Ventricular and supraventricular arrhythmias

Dose in normal renal function
- Oral: 300–800 mg daily in divided doses
- IV: 2 mg/kg over 5 minutes to a maximum of 150 mg
- Infusion: 400 mcg/kg/hour, maximum 300 mg in 1st hour and 800 mg daily

Pharmacokinetics
- Molecular weight (daltons) 339.5
- % Protein binding 50–65
- % Excreted unchanged in urine 50–75
- Volume of distribution (L/kg) 0.8–2.6
- Half-life — normal/ESRF (hrs) 5–8 / 12–22

Metabolism
Disopyramide is partially metabolised in the liver by the cytochrome P450 isoenzyme CYP3A4. The major metabolite is mono-N-dealkylated disopyramide which retains some antiarrhythmic and antimuscarinic activity. The major route of excretion is through the kidney, about 50–60% as the unchanged drug, 20% as the N-dealkylated metabolite, and 10% as other metabolites. 64% of the N-dealkylated metabolite is excreted via the faeces.

Dose in renal impairment GFR (mL/min)
- 20–60 Oral: 100 mg every 8 hours or 150 mg every 12 hours. IV: Reduce dose.
- 8–20 Oral: 100 mg every 12 hours. IV: Reduce dose.
- <8 Oral: 150 mg every 24 hours (monitor levels). IV: Reduce dose.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in GFR<8 mL/min.
- HD Not dialysed. Dose as in GFR<8 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<8 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=8–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased myocardial depression with other anti-arrhythmics; amiodarone and dronedarone increase risk of ventricular arrhythmias – avoid.
- Antibacterials: concentration possibly increased by azithromycin, clarithromycin and erythromycin (risk of toxicity); increased risk of ventricular arrhythmias with moxifloxacin – avoid; possibly increased risk of ventricular arrhythmias with telithromycin and delamanid; concentration reduced by rifamycins.
- Antidepressants: increased risk of ventricular arrhythmias with tricyclics; increased risk of ventricular arrhythmias with citalopram and escitalopram – avoid.
- Antifungals: increased risk of ventricular arrhythmias with ketoconazole – avoid; avoid with itraconazole.
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine.
- Antihypertensives: increased myocardial depression and asystole with beta-blockers or verapamil; increased risk of ventricular arrhythmias with sotalol – avoid.
- Antimalarials: avoid with artemether/lumefantrine and piperazine with arteminol.
- Antimuscarinics: increased risk of antimuscarinic side effects; increased risk of ventricular arrhythmias with tolterodine.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval and phenothiazines and sulpiride; increased risk of ventricular arrhythmias with amisulpride, droperidol, pimozide and zuclopenthixol and possibly haloperidol – avoid.
- Antivirals: concentration possibly increased by ritonavir, increased risk of toxicity; increased risk
of ventricular arrhythmias with saquinavir and telaprevir – avoid.

- Atomoxetine: increased risk of ventricular arrhythmias.
- Beta blockers: increased myocardial depression; increased risk of ventricular arrhythmias with sotalol – avoid.
- Calcium channel blockers: increased risk of myocardial depression and asystole with verapamil.
- Ciclosporin: may increase risk of nephrotoxicity with ciclosporin.
- Cytotoxics: possibly increased risk of ventricular arrhythmias with panobinostat and vandetanib – avoid; increased risk of ventricular arrhythmias with arsenic trioxide and possibly bosutinib and ceritinib.
- Diuretics: increased cardiac toxicity if hypokalaemia occurs.
- Fingolimod: possible increased risk of bradycardia.
- Ivabradine: increased risk of ventricular arrhythmias.
- Pentamidine: possibly increased risk of ventricular arrhythmias.
- Ranolazine: avoid concomitant use.

### Administration

**Reconstitution**

---

**Route**

Oral, IV

**Rate of administration**

20–30 mg/hour (0.4 mg/kg/hour)

**Comments**

May be given by peripheral IV infusion in glucose 5%, sodium chloride 0.9% or compound sodium lactate.

### Other information

- Use with caution in patients with impaired renal function.
- Do not give renally impaired patients sustained release preparations.
- Optimum therapeutic plasma level 2–6 mg/L.
- Haemoperfusion can be used in cases of severe poisoning.
Disulfiram

**Clinical use**
Adjunct in the treatment of chronic alcohol dependence

**Dose in normal renal function**
800 mg on day 1 reducing over 5 days to 100–200 mg daily.

**Pharmacokinetics**
- Molecular weight (daltons): 296.5
- % Protein binding: 96
- % Excreted unchanged in urine: 70–76 (as metabolites)
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 12 / –

**Metabolism**
Disulfiram is rapidly reduced to diethyldithiocarbamate, mainly by the glutathione reductase system in erythrocytes; reduction may also occur in the liver. Diethyldithiocarbamate is metabolised in the liver to its glucuronide and methyl ester and to diethylamine, carbon disulfide, and sulfate ions. Metabolites are excreted mainly in the urine; carbon disulfide is exhaled in the breath.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Use with caution.
- <10: Avoid

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Avoid.
- HD: Unlikely to be dialysed. Avoid.
- HDF/High flux: Unlikely to be dialysed. Avoid.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alcohol: risk of severe disulfiram reaction.
- Anticoagulants: enhanced anticoagulant effect with coumarins.
- Antiepileptics: inhibition of metabolism of fosphenytoin and phenytoin (increased risk of toxicity).
- Paraldehyde: increased risk of toxicity with paraldehyde.

**Administration**
**Reconstitution**
—
**Route**
Oral
**Rate of administration**
—

**Other information**
- Review after 6 months.
- Patients should be warned about severe nature of alcohol and disulfiram reaction.
- Contraindicated in cardiovascular disease, psychoses or severe personality disorders.
- Disulfiram blocks the metabolism of alcohol and leads to an accumulation of acetaldehyde in the bloodstream. Use with caution in diabetics.
## Dobutamine

### Clinical use

Inotropic agent

### Dose in normal renal function

2.5–10 micrograms/kg/minute, increasing up to 40 micrograms/kg/minute according to response.

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>301.4; 337.8 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.12–0.28</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–4 minutes / –</td>
</tr>
</tbody>
</table>

### Metabolism

Dobutamine is metabolised in the liver and other tissues by catechol-o-methyltransferase to an inactive compound, 3-0-methydobutamine and by conjugation with glucuronic acid. Conjugates of dobutamine and 3-0-methyldobutamine are excreted mainly in urine and to a minor extent in faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: risk of ventricular arrhythmias with isoflurane – avoid.
- Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide.
- Beta-blockers: possibly severe hypertension and bradycardia with non-cardioselective beta-blockers.
- Dopaminergics: effects possibly enhanced by entacapone; avoid with rasagline.

### Administration

#### Reconstitution

- Route
  Continuous IV infusion centrally via CRIP (or peripherally via a large vein)

#### Rate of administration

Varies with dose

#### Comments

- Dilute to at least 50 mL with sodium chloride 0.9% or glucose 5% (less than 5 mg/mL, ideally 0.5–1 mg/mL).
- 250 mg may be diluted in as little as 50 mL diluent.
- Minimum volume 10 mg/mL or even undiluted; give strong solution via central line, (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006).

### Other information

- Cardiac and BP monitoring advised.
- Sodium bicarbonate rapidly inactivates dobutamine.
- Solution may turn pink, but potency is unaffected.
- Can cause hypokalaemia.
Docetaxel

Clinical use
Antineoplastic agent:
- Treatment of breast cancer, prostate cancer and non-small cell lung cancer unresponsive to alternative therapies, also gastric adenocarcinoma, squamous cell carcinoma of head and neck

Dose in normal renal function
75–100 mg/m² every 3 weeks depending on indication

Pharmacokinetics
Molecular weight (daltons) 807.9
% Protein binding >95
% Excreted unchanged in urine 6
Volume of distribution (L/kg) 113 Litres
Half-life — normal/ESRF (hrs) 4 min(α) / 36 min(β) / 11.1 hr(γ)

Metabolism
A study of [¹⁴C]-docetaxel has been conducted in three cancer patients. Docetaxel was eliminated in both the urine and faeces following cytochrome P450 3A4-mediated oxidative metabolism of the tert-butyl ester group, within seven days, the urinary and faecal excretion accounted for about 6% and 75% of the administered radioactivity, respectively. About 80% of the radioactivity recovered in faeces is excreted during the first 48 hours as one major inactive metabolite and 3 minor inactive metabolites and very low amounts of unchanged medicinal product.

Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly increased by clarithromycin – avoid or reduce docetaxel dose.
- Antifungals: concentration possibly increased by itraconazole and voriconazole – avoid or reduce docetaxel dose.
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.
- Antivirals: concentration possibly increased by indinavir, ritonavir and saquinavir avoid or reduce docetaxel dose.
- Ciclosporin: possibly inhibits metabolism of ciclosporin; bioavailability of docetaxel increased by ciclosporin.

Administration
Reconstitution
With diluent provided
Route
IV
Rate of administration
Over 1 hour
Comments
- Allow vials to come to room temperature for 5 minutes.
- Doses of up to 200 mg can be added to 250 mL infusion bags of glucose 5% or sodium chloride 0.9%.
- Doses greater than 200 mg should be diluted to a concentration of 0.74 mg/mL.
- Administer within 4 hours of dilution.

Other information
- Give premedication with oral dexamethasone 16 mg daily for 3 days, starting 1 day before commencing chemotherapy.
Dolutegravir

**Clinical use**

Integrase inhibitor:
- Treatment of HIV

**Dose in normal renal function**

50 mg once or twice daily (depending on concomitant medication)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>441.4 (as sodium)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>17–20 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>14 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Dolutegravir is primarily metabolised through glucuronidation via UGT1A1 with a minor CYP3A component.

53% of the total oral dose is excreted unchanged in the faeces. It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapeutic Modality</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin.
- Antidepressants: concentration reduced by St John's wort.
- Antiepileptics: concentration reduced by carbamazepine and possibly fosphenytoin, oxcarbazepine, phenobarbital, phenytoin and primidone.
- Antivirals: concentration reduced by efavirenz, tipranavir, etravirine and fosamprenavir; possibly reduced by nevirapine.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Manufacturer has no information in haemodialysis patients but the pharmacokinetics are unlikely to be altered.
# Domperidone

## Clinical use
- Acute nausea and vomiting (including that caused by levodopa and bromocriptine)
- Gastro-oesophageal reflux
- Dyspepsia

## Dose in normal renal function
- Nausea and vomiting: Adults 10–20 mg orally 3–4 times daily, maximum 80 mg daily.
- PR: 60 mg twice daily.

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>425.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>5.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7–9 / 20.8</td>
</tr>
</tbody>
</table>

## Metabolism
Domperidone undergoes extensive first-pass hepatic and intestinal metabolism. It undergoes rapid and extensive hepatic metabolism. The main metabolic pathways are N-dealkylation by cytochrome P450 isoenzyme CYP3A4, and aromatic hydroxylation by CYP3A4, CYP1A2, and CYP2E1. About 30% of an oral dose is excreted in urine within 24 hours, almost entirely as metabolites; the remainder of a dose is excreted in faeces over several days, about 10% as unchanged drug.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: possible increased risk of ventricular arrhythmias with clarithromycin, delamanid and erythromycin – avoid with clarithromycin and erythromycin.
- Antifungals: possibly increased risk of ventricular arrhythmias with itraconazole, ketoconazole and voriconazole – avoid.
- Antimalarials: possible increased risk of ventricular arrhythmias with piperaquine with artemimol – avoid.
- Antivirals: possible increased risk of ventricular arrhythmias with boceprevir; possible increased risk of ventricular arrhythmias with ritonavir, saquinavir and telaprevir – avoid.
- Apomorphine: possible increased risk of ventricular arrhythmias.
- Cobicistat: possible increased risk of ventricular arrhythmias.
- Cytotoxics: increased risk of ventricular arrhythmias with bosutinib and ceritinib – avoid with bosutinib.

## Administration

### Reconstitution
—

### Route
Oral, PR

### Rate of administration
—

### Comments
- Treatment of acute nausea and vomiting: maximum period of treatment is 12 weeks.
- Treatment of dyspepsia: administer before food; maximum period of treatment is 12 weeks.

## Other information
- Domperidone has the advantage over metoclopramide and phenothiazines of being less likely to cause central effects, such as sedation and dystonic reactions, as it does not readily cross the blood brain barrier.
- Due to minimal renal excretion no dose change is recommended although with prolonged administration the frequency in severe renal impairment may need to be reduced to once or twice daily.
The European Medicines Agency (07/03/2014) recommends that domperidone should only be used short-term for nausea and vomiting with a maximum dose of 30 mg daily for weight >35 kg. It also should not be used in patients with liver impairment or heart arrhythmias due to the risk of QT prolongation.
Donepezil hydrochloride

**Clinical use**

Treatment of dementia in mild to moderate Alzheimer’s disease

**Dose in normal renal function**

5–10 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>416</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>17</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>12</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>70 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Donepezil hydrochloride is both excreted in the urine intact and metabolised by the cytochrome P450 system to multiple metabolites, not all of which have been identified. Following administration of a single 5 mg dose of [14C]-labelled donepezil hydrochloride, plasma radioactivity, expressed as a percentage of the administered dose, was present primarily as intact donepezil hydrochloride (30%), 6-O-desmethyl donepezil (11% – only metabolite that exhibits activity similar to donepezil hydrochloride), donepezil-cis-N-oxide (9%), 5-O-desmethyl donepezil (7%) and the glucuronide conjugate of 5-O-desmethyl donepezil (3%). Approximately 57% of the total administered radioactivity was recovered from the urine, and 14.5% was recovered from the faeces, suggesting biotransformation and urinary excretion as the primary routes of elimination. There is no evidence to suggest enterohepatic recirculation of donepezil hydrochloride and/or any of its metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- None known

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Metabolised via CYP450 3A4 and 2D6 so may interact with other drugs metabolised by these pathways.
Dopamine hydrochloride

**Clinical use**
Cardiogenic shock in infarction or cardiac surgery

**Dose in normal renal function**
Initially 2–5 mcg/kg/min

**Pharmacokinetics**
- Molecular weight (daltons): 189.6
- % Protein binding: No data
- % Excreted unchanged in urine: Minimal
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 2 minutes / –

**Metabolism**
Dopamine is a metabolic precursor of noradrenaline and, whereas a proportion is excreted as the metabolic products of noradrenaline, the majority is mainly metabolised into 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxy-4-hydroxyphenylacetic (HVA) which are rapidly excreted in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alpha-blockers: avoid with tolazoline.
- Anaesthetics: risk of ventricular arrhythmias with isoflurane – avoid.
- Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide.
- Ciclosporin: may reduce risk of ciclosporin nephrotoxicity.
- Dopaminergics: effects possibly enhanced by entacapone; avoid with rasagiline; risk of hypertensive crisis with selegiline.

**Administration**

**Reconstitution**
—

**Route**
IV peripherally into large vein (centrally for inotropic dose). Central route always preferable.

**Rate of administration**
Via CRIP as indicated below.

**Comments**
- Minimum dilution 200 mg in 50 mL.
- Not compatible with sodium bicarbonate – rapid deactivation of dopamine.

**Other information**
- Renal dose is 2–5 mcg/kg/min but little evidence that it can improve renal function.
- Causes renal vasoconstriction at inotropic dose.
- Cardiac and BP monitoring advised.
- Very severe tissue damage caused by extravasation.
Dopexamine hydrochloride

Clinical use
Inotropic support in exacerbations of heart failure and heart failure associated with cardiac surgery

Dose in normal renal function
IV infusion: 0.5–1 mcg/kg/min and then in increments (0.5–1 mcg/kg/min) up to 6 mcg/kg/minute at not less than 15 minute intervals

Pharmacokinetics
Molecular weight (daltons) 429.4
% Protein binding No data
% Excreted unchanged in urine 10
Volume of distribution (L/kg) 0.45
Half-life — normal/ESRF (hrs) 6–11 minutes /

Metabolism
Dopexamine is rapidly eliminated from blood with a half-life of approximately 6–7 minutes in healthy volunteers and around 11 minutes in patients with cardiac failure. Subsequent elimination of the metabolites is by urinary and biliary excretion.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function and adjust to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function and adjust to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function and adjust to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: risk of ventricular arrhythmias with isoflurane – avoid.
- Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide.
- Beta-blockers: risk of severe hypertension.
- Dopaminergics: avoid with rasagiline.
- Sympathomimetics: effects of adrenaline and noradrenaline possibly enhanced.

Administration
Reconstitution
—
Route
By intravenous infusion into a central or large peripheral vein.
Rate of administration
See dosage instructions.
Comments
- IV infusion of 400 or 800 micrograms/mL in glucose 5% or sodium chloride 0.9%.
- Peripheral administration: concentration of infusion solution must not exceed 1 mg/mL.
- Central administration: concentration not >4 mg/mL.
- Rate of administration and duration of therapy should be adjusted according to the patient’s response as determined by heart rate and rhythm, blood pressure, urine flow and measurement of cardiac output.

Other information
- Avoid abrupt withdrawal.
Dornase alfa

**Clinical use**
To improve pulmonary function in cystic fibrosis

**Dose in normal renal function**
2.5 mg (2500 u) daily via nebuliser can be increased to twice daily if over 21 years of age.

**Pharmacokinetics**
- Molecular weight (daltons) 29 249.6
- % Protein binding No data
- % Excreted unchanged in urine No data
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 11 (from lungs in rats)

**Metabolism**
Dornase alfa acts as a mucolytic by hydrolysing DNA that has accumulated in sputum from decaying neutrophils. It is expected to be metabolised by proteases present in biological fluids.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**
**Reconstitution**
—
**Route**
Nebulised
**Rate of administration**
—
**Comments**
<15% of dose is systemically absorbed.

**Other information**
- No pharmacokinetic data available; little systemic absorption therefore little accumulation expected.
- Use undiluted, using recommended jet nebuliser / compressor system. Refer to data sheet.
Dosulepin hydrochloride (dothiepin)

Clinical use
Tricyclic antidepressant

Dose in normal renal function
50–225 mg daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>331.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>84</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>56 (mainly as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>45</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>14–24 / –</td>
</tr>
</tbody>
</table>

Metabolism
Dosulepin hydrochloride is readily absorbed from the gastrointestinal tract, and extensively demethylated by first-pass metabolism in the liver to its primary active metabolite, desmethyldothiepin (also termed northiaden). Paths of metabolism also include S-oxidation.

Dosulepin is excreted in the urine, mainly in the form of its metabolites; small amounts are also excreted in the faeces. Elimination half-lives of about 14–24 and 23–46 hours have been reported for dosulepin and its metabolites, respectively.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Start with small dose and titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with small dose and titrate according to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Alcohol: increased sedative effect.
- Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; increased risk of ventricular arrhythmias with disopyramide, dronedarone, flecainide or propafenone – avoid with dronedarone.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and possibly delamanid and telithromycin – avoid with moxifloxacin.
- Anticoagulants: may alter anticoagulant effect of coumarins.
- Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide – avoid; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram – avoid; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, phenobarbital and possibly fosphenytoin, phenytoin and primidone.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol.
- Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, fluphenazine, haloperidol, pimozide, risperidone, sulpiride and zuclopenthixol – avoid; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased with ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased with ritonavir.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.
- Dapoxetine: possible increased risk of serotonergic effects – avoid.
- Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline.
Dosulepin hydrochloride (dothiepin)

- Pentamidine: increased risk of ventricular arrhythmias.
- Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.

Administration

Reconstitution

- Metabolites are active and partly renally excreted.
- Metabolites accumulate and cause excessive sedation.
- 25–50 mg usually effective without too much sedation.

Route
Oral

Rate of administration

---

Other information

- Metabolites are active and partly renally excreted.
- Metabolites accumulate and cause excessive sedation.
- 25–50 mg usually effective without too much sedation.
Doxapram hydrochloride

Clinical use
- Postoperative respiratory depression
- Acute respiratory failure

Dose in normal renal function
- Postoperative respiratory depression: IV injection 1–1.5 mg/kg repeated at hourly intervals, or IV infusion 2–3 mg/minute, adjusted according to response
- Acute respiratory failure: 1.5–4 mg/minute as an IV infusion, adjusted according to response

Pharmacokinetics
Molecular weight (daltons) 433
% Protein binding No data
% Excreted unchanged in urine <5
Volume of distribution (L/kg) 0.58–2.74
Half-life — normal/ESRF (hrs) 2.4–4.1 / –

Metabolism
Doxapram is extensively metabolised in the liver, and the major route of excretion of metabolites and a small amount of unchanged drug is thought to be via bile to the faeces.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: increased risk of arrhythmias with volatile liquid general anaesthetics — avoid for at least 10 minutes after volatile liquid general anaesthetics.

Administration
Reconstitution
-
Route
IV bolus, IV infusion
Rate of administration
IV injection: over at least 30 seconds
IV infusion as indication
Comments
- Doxapram has a narrow margin of safety; the minimum effective dosage should be used and maximum recommended dosages should not be exceeded.

Other information
- Unlike naloxone, doxapram does not reverse the other effects of opioid analgesics (i.e. analgesia).
**Doxazosin**

**Clinical use**

Alpha-adrenoceptor blocker:
- Hypertension
- Benign prostatic hyperplasia (BPH)

**Dose in normal renal function**
- Hypertension: 1–16 mg daily
- XL preparation: 4–8 mg once daily
- BPH: 1–8 mg daily

**Pharmacokinetics**

- Molecular weight (daltons): 547.6 (as mesilate)
- % Protein binding: 98
- % Excreted unchanged in urine: <5
- Volume of distribution (L/kg): 1–1.7
- Half-life — normal/ESRF (hrs): 22 / Unchanged

**Metabolism**

Doxazosin is extensively metabolised in the liver, and excreted in faeces as inactive metabolites (6-hydroxydoxazosin) and a small amount of unchanged drug.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect, avoid with tadalafil, start the others at the lowest possible dose.
- Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Calcium-channel blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect.
- Diuretics: enhanced hypotensive effect, increased risk of first dose hypotensive effect.
- Moxisylyte: possibly severe postural hypotension when used in combination.

**Administration**

**Reconstitution**

- 

**Route**

- Oral

**Rate of administration**

- 

**Doxepin**

**Clinical use**

Tricyclic antidepressant

**Dose in normal renal function**

25–300 mg daily, doses above 100 mg given in 3 divided doses

**Pharmacokinetics**

Molecular weight (daltons) 315.8 (as hydrochloride)

% Protein binding 76

% Excreted unchanged in urine <3

Volume of distribution (L/kg) 20

Half-life — normal/ESRF (hrs) 8–24 / 10–30

**Metabolism**

Approximately 55–87% of doxepin undergoes first pass metabolism in the liver, forming the primary active metabolite desmethyldoxepin. Doxepin is excreted in the urine, mainly in the form of its metabolites, either free or in conjugated form.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Start with small dose and titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with small dose and titrate according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Alcohol: increased sedative effect.

- Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids.

- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; increased risk of ventricular arrhythmias with disopyramide, flecainide or propafenone; avoid with dronedarone.

- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and possibly delamanid and telithromycin – avoid with moxifloxacin.

- Anticoagulants: may alter anticoagulant effect of coumarins.

- Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide – avoid; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram – avoid; possible increased risk of convulsions with vortioxetine.

- Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, phenobarbital and possibly fosphenytoin, phenytoin and primidone.

- Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol.

- Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, fluphenazine, haloperidol, pimozide, risperidone, sulpiride and zuclopenthixol – avoid; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.

- Antivirals: increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased with ritonavir.

- Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions.

- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.

- Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.

- Dapoxetine: possible increased risk of serotonergic effects – avoid.

- Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegline and rasagiline.

- Pentamidine: increased risk of ventricular arrhythmias.

- Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.
**Administration**

Reconstitution

---

**Route**

Oral

---

**Rate of administration**

---

**Other information**

- The half-life of desmethyldoxepin (active metabolite) ranged from 33–80 hours (mean 51 hours).
Doxorubicin hydrochloride

Clinical use
Antineoplastic agent:
- Acute leukaemias
- Lymphomas
- Sarcomas
- Various solid tumours

Dose in normal renal function
Varies according to local protocol

Pharmacokinetics
Molecular weight (daltons) 580
% Protein binding 50–85
% Excreted unchanged in urine <15
Volume of distribution (L/kg) >20–30
Half-life — normal/ESRF (hrs) 30; (Liposomal:
55–75; Pegylated:
24–231) / Unchanged

Metabolism
The elimination of doxorubicin from the blood is triphasic with mean half-lives of 12 minutes (distribution), 3.3 hours and about 30 hours. Doxorubicin undergoes rapid metabolism in the liver. The main metabolite is the pharmacologically active doxorubicinol. Other metabolites are deoxyrubicin aglycone, glucuronide and sulphate conjugate.
About 40–50% of a dose is excreted in bile within 7 days, of which about half is excreted as unchanged drug and the rest as metabolites. Only 5–15% of the administered dose is eliminated in urine.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 75–100% of dose. Caelyx: No data.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Ciclosporin: increased risk of neurotoxicity.
- Cytotoxics: possible increased risk of cardiotoxicity with trastuzumab – avoid for 28 weeks after stopping trastuzumab.
- Avoid with live vaccines.

Administration
Reconstitution
Reconstitute with water for injection or sodium chloride 0.9%, 10 mg in 5 mL, 50 mg in 25 mL
Route
IV, intra-arterial, intravesical (bladder instillation)
Rate of administration
- Via the tubing of a fast running intravenous infusion of sodium chloride 0.9% or glucose 5%
- Injection: over 3–5 minutes
- Continuous infusion: over 24 hours
- Caelyx: initially 1 mg/min, if no reactions further doses over 60 minutes
- AIDS-related Kaposi's sarcoma: dilute in 250 mL glucose 5% over 30 minutes

Comments
For bladder instillation, concentration of doxorubicin in bladder should be 50 mg per 50 mL. To avoid undue dilution in urine, the patient should be instructed not to drink any fluid in the 12 hours prior to instillation. This should limit urine production to approximately 50 mL per hour.

Other information
- Manufacturer of Caelyx® has no information in GFR<30 mL/min.
- Drug Prescribing in Renal Failure, 5th edition by Aronoff et al. suggests using 100% of the dose for conventional doxorubicin.
- A cumulative dose of 450–550 mg/m² should only be exceeded with extreme caution. Above this level, the risk of irreversible congestive cardiac failure increases greatly.
- Patients with impaired hepatic function have prolonged and elevated plasma concentrations of both the drug and its metabolites. Dose reduction is required.
- Liposomal preparations available: up to 90 mg in 250 mL glucose 5%; if greater than 90 mg dilute in 500 mL glucose 5%.
Doxycycline

Clinical use
Antibacterial agent
- Also prophylaxis / treatment of malaria

Dose in normal renal function
- 200 mg on day 1, then 100 mg daily; severe infections 200 mg daily
- Syphilis: 100-200 mg twice daily
- Malaria: treatment: 200 mg once daily; prophylaxis: 100 mg daily

Pharmacokinetics
Molecular weight (daltons) 462.4
% Protein binding >90
% Excreted unchanged in urine 33–45
Volume of distribution (L/kg) 0.7
Half-life — normal/ESRF (hrs) 18 / Unchanged

Metabolism
Doxycycline is concentrated in the bile. About 40% of the administered dose is eliminated in 3 days in active form in the urine. However, the majority of a dose of doxycycline is excreted in the faeces after chelation in the intestines. Urinary concentrations are roughly 10 times higher than plasma concentrations at the same time.
In the presence of impaired renal function, urinary elimination decreases, faecal elimination increases and the half-life remains unchanged.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhanced anticoagulant effect of coumarins and phenindione.
- Ciclosporin: possibly increases plasma-ciclosporin concentration.
- Oestrogens: possibly reduced contraceptive effects of oestrogens (risk probably small).
- Retinoids: possible increased risk of benign intracranial hypertension – avoid.

Administration
Reconstitution
Route Oral
Rate of administration
Comments
Do not take iron preparations, indigestion remedies or phosphate binders at the same time of day as doxycycline.
**Dronedarone**

**Clinical use**

Anti-arrhythmic:

- Maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation

**Dose in normal renal function**

400 mg twice daily

**Pharmacokinetics**

- Molecular weight (daltons): 556.8 (593.2 as hydrochloride)
- % Protein binding: 99.7
- % Excreted unchanged in urine: 0 (6% as metabolites)
- Volume of distribution (L/kg): 1200–1400 Litres

**Metabolism**

Dronedarone is extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP3A4 to a less active N-debutyl metabolite, and several inactive metabolites.

About 6% of an oral dose is excreted in the urine (entirely metabolites) and 84% in the faeces (metabolites and unchanged drug).

**Dose in renal impairment GFR (mL/min)**

- 30–50: Dose as in normal renal function.
- 10–30: Dose as in normal renal function. See ‘Other information’.
- <10: Dose as in normal renal function. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as GFR<10 mL/min.
- HD: Not dialysed. Dose as GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as GFR<10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in GFR=10–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anti-arrhythmics: increased risk of myocardial depression with other anti-arrhythmics; increased risk of ventricular arrhythmias with amiodarone or disopyramide – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with clarithromycin, telithromycin and erythromycin; concentration reduced by reduced by amiodarone – avoid.
- Anticoagulants: increased anti-coagulant effect with coumarins and phenindione; increased dabigatran concentration – avoid; avoid with rivaroxaban; concentration of edoxaban increased – reduce dose of edoxaban.
- Antidepressants: increased risk of ventricular arrhythmias with tricyclic antidepressants, citalopram and escitalopram – avoid.
- Antiepileptics: concentration possibly reduced by fosphenytoin, phenytoin, carbamazepine, phenobarbital and primidone – avoid.
- Antifungals: concentration increased by ketoconazole – avoid; avoid with itraconazole, posaconazole and voriconazole.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval; increased risk of ventricular arrhythmias with phenothiazines – avoid.
- Antivirals: avoid with ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
- Beta-blockers: increased risk of myocardial depression; concentration of metoprolol and propranolol possibly increased; increased risk of ventricular arrhythmias with sotalol – avoid.
- Calcium channel blockers: concentration increased by nifedipine; increased risk of bradycardia and myocardial depression with diltiazem and verapamil.
- Cytotoxics: possibly increases bosutinib concentration – avoid or consider reducing bosutinib dose; possibly increases ibrutinib concentration – reduce ibrutinib dose.
- Digoxin: increased concentration (halve digoxin maintenance dose).
- Fingolimod: possibly increased risk of bradycardia.
- Grapefruit juice: concentration of dronedarone increased – avoid.
- Lipid-lowering drugs: concentration of atorvastatin and rosuvastatin possibly increased; increased risk
of myopathy with simvastatin; concentration of lomitapide possibly increased – avoid.
- Sirolimus: manufacturer advises use with caution.
- Tacrolimus: manufacturer advises use with caution.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Other information**

- Contraindicated by manufacturer in the UK but no dose alteration in the USA for severe renal impairment.
- Cases of life-threatening acute liver injury have been reported. Monitor LFTs before and during treatment.
- Cases of new-onset or worsening heart failure have been reported.
- An increase in plasma creatinine (mean increase 10 μmol/l) has been observed in healthy subjects and in patients. In most patients this increase occurs early after treatment initiation and reaches a plateau after 7 days. It is recommended to measure plasma creatinine values prior to and 7 days after initiation of dronedarone. If an increase in creatininemia is observed, serum creatinine should be re-measured after a further 7 days. If no further increase in creatinine is observed, this value should be used as the new reference baseline taking into account that this may be expected with dronedarone. If serum creatinine continues to rise then consideration should be given to further investigation and discontinuing treatment.
- Oral bioavailability is 4% (15% with food).
**Droperidol**

### Clinical use
- Treatment of postoperative nausea and vomiting (PONV)

### Dose in normal renal function
- PONV: 0.625–125 mg every 6 hours
- Prevention of PONV due to opioids in PCA: 15–50 mcg of droperidol for every 1 mg of morphine, maximum 5 mg

### Pharmacokinetics
- Molecular weight (daltons) 379.4
- % Protein binding 85–90
- % Excreted unchanged in urine 1
- Volume of distribution (L/kg) 1.5
- Half-life — normal/ESRF (hrs) 121–147 minutes / –

### Metabolism
Extensively metabolised in the liver, and undergoes oxidation, dealkylation, demethylation and hydroxylation by cytochrome P450 isoenzymes 1A2 and 3A4, and to a lesser extent by 2C19. The metabolites are inactive.

About 75% of a dose is excreted in the urine, with 1% being excreted unchanged; 11% appears in the faeces.

### Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: 625 mcg every 6 hours. Reduce dose of infusion.
- <10: 625 mcg every 6 hours. Reduce dose of infusion

### Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect; effects of thiopental enhanced.
- Analgesics: increased risk of ventricular arrhythmias with methadone; increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids.
- Anti-arrhythmics increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide, dronedarone and amiodarone – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and macrolides – avoid; increased risk of ventricular arrhythmias with delamanid.
- Antidepressants: increased risk of ventricular arrhythmias with fluoxetine, fluvoxamine, sertraline or tricyclics – avoid; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered.
- Antimalarials: avoid with arteether/lumefantrine and piperaquine with arteminol; increased risk of ventricular arrhythmias with chloroquine, hydroxychloroquine or quinine – avoid.
- Antipsychotics: increased risk of ventricular arrhythmias with amisulpride, pimozide, sulpiride, phenothiazines that prolong QT interval or haloperidol – avoid; possibly increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration possibly increased with ritonavir.
- Anxiolytics and hypnotics: increased sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol – avoid.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide and possibly ceritinib.
- Desferrioxamine: avoid concomitant use.
- Diuretics: enhanced hypotensive effect.
- Hormone antagonists: increased risk of ventricular arrhythmias with tamoxifen – avoid.
- Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
- Pentamidine: increased risk of ventricular arrhythmias – avoid.
- Tacrolimus: increased risk of ventricular arrhythmias – avoid.
**Administration**

<table>
<thead>
<tr>
<th>Reconstitution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route</td>
</tr>
<tr>
<td>Rate of administration</td>
</tr>
</tbody>
</table>

**Other information**

- Increased CNS sensitivity in severe renal impairment.
- Droperidol has been associated with QT prolongation, serious ventricular arrhythmias and sudden death. Withdrawn by Janssen-Cilag in 2001 but is still available in the UK and USA from other suppliers.
Dulaglutide

**Clinical use**
Long-acting glucagon-like peptide 1 (GLP-1) receptor agonist:
- Treatment of type 2 diabetes mellitus

**Dose in normal renal function**
Monotherapy: 0.75 mg once weekly
Combination therapy: 0.75–1.5 mg once weekly

**Pharmacokinetics**
- Molecular weight (daltons): 59 670
- Protein binding: No data
- % Excreted unchanged in urine: Minimal
- Volume of distribution (L/kg): 17.4–19.2 Litres
- Half-life — normal/ESRF (hrs): 4.5–4.7 days (depending on dose) / Unchanged

**Metabolism**
Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways.

**Dose in renal impairment GFR (mL/min)**
- 30–50: Dose as in normal renal function.
- 10–30: Dose as in normal renal function. Use with caution.
- <10: Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
- SC

**Rate of administration**
—

**Other information**
- Not recommended by manufacturer in the UK in patients with GFR<30 mL/min due to lack of data. Although in the US no dosage reduction is recommended.
- The pharmacokinetics of dulaglutide were found to be similar between healthy subjects and patients with mild to severe renal impairment (CRCL<30 mL/min), including end stage renal disease (requiring dialysis).
- Dulaglutide systemic exposure was increased by 20, 28, 14 and 12% for mild, moderate, severe, and ESRD renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in C$_{max}$ were 13, 23, 20 and 11%, respectively.
- In patients treated with GLP-1 receptor agonists, there have been post marketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require RRT. Some of these events were reported in patients without known underlying renal disease. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea or dehydration.
- The bioavailability of dulaglutide after a single 1.5 mg or 0.75 mg dose was 47 and 65%, respectively.
**Duloxetine**

**Clinical use**
- Moderate to severe stress urinary incontinence
- Depression
- Diabetic peripheral neuropathy
- Generalised anxiety disorder

**Dose in normal renal function**
- Incontinence: 20–40 mg twice daily
- Depression: 60 mg daily
- Diabetic neuropathy: 60–120 mg daily, 120 mg in divided doses
- Anxiety: 30–120 mg daily

**Pharmacokinetics**
- Molecular weight (daltons) 333.9 (as hydrochloride)
- % Protein binding 95–96
- % Excreted unchanged in urine <1 (77% as metabolites)
- Volume of distribution (L/kg) 1640 Litres
- Half-life — normal/ESRF (hrs) 8–17 / Unchanged

**Metabolism**
Duloxetine is extensively metabolised and the metabolites are excreted principally in urine. Both cytochromes P450-2D6 and 1A2 catalyse the formation of the two major metabolites, glucuronide conjugate of 4-hydroxy duloxetine and sulphate conjugate of 5-hydroxy, 6-methoxy duloxetine. Based upon in vitro studies, the circulating metabolites of duloxetine are considered pharmacologically inactive.

**Dose in renal impairment GFR (mL/min)**
- 30–50: Dose as in normal renal function; start with a low dose.
- 10–30: Start at very low dose and increase according to response. See ‘Other information’.
- <10: Start at very low dose and increase according to response. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism inhibited by ciprofloxacin – avoid.
- Anticoagulants: possibly increased risk of bleeding with dabigatran.
- Other CNS medication: enhanced effect.
- Antidepressants: avoid with MAOIs, moclobemide, St John’s wort, tryptophan, venlafaxine, amitriptyline, clomipramine and SSRIs due to increased risk of serotonin syndrome; increased risk of side effects with tricyclic antidepressants; fluvoxamine decreases the clearance of duloxetine by 77% – avoid; possible increased risk of convulsions with vortioxetine.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
- Dapoxetine: avoid concomitant use.
- Methylthioninium: risk of CNS toxicity – avoid if possible.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- In CKD 5 there is a 2-fold increase in C\text{max} and AUC. The renally excreted metabolites 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulphate were 7–9 times higher than in people with normal renal function.
- Contraindicated in uncontrolled hypertension due to potential risk of hypertensive crisis.
- Contraindicated by manufacturer if CRCL<30 mL/min due to increased plasma concentration and limited data.
- Anecdotally it has been used at a dose of 30 mg in ESRD patients.
# Dutasteride

## Clinical use
Testosterone-5-alpha-reductase inhibitor:
- Benign prostatic hyperplasia

## Dose in normal renal function
500 mcg daily

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>528.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99.5</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0.1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>300–500 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–5 weeks / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
Dutasteride is metabolised by the cytochrome P450 isoenzymes CYP3A4 and CYP3A5, and most of a dose is excreted as metabolites in the faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs
- None known

## Administration
### Reconstitution
- —
### Route
- Oral
### Rate of administration
- —

## Other information
- Oral bioavailability is approximately 60%.
Eculizumab

Clinical use
Recombinant monoclonal antibody:
- Paroxysmal nocturnal haemoglobinuria (PNH)
- Atypical haemolytic uraemic syndrome (aHUS)
- Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (MG)

Dose in normal renal function
- PNH: 600 mg once a week for 4 weeks then 900 mg every 12–16 days
- aHUS and MG: 900 mg once a week for 4 weeks then 1200 mg every 12–16 days

Pharmacokinetics
Molecular weight (daltons) 148 000
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 7.7 Litres
Half-life — normal/ESRF (hrs) 11–12 days / –

Metabolism
Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolised by lysosomal enzymes to small peptides and amino acids.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
- Route
  IV infusion
Rate of administration
25–45 minutes

Other information
- A 1 hour session of plasma exchange causes a 50% decline in concentration of eculizumab.
**Edoxaban tosilate**

### Clinical use

Selective factor Xa inhibitor:
- Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF)
- Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)

### Dose in normal renal function

- 60 mg once daily
- Dose reduced to 30 mg once daily if weight <60 kg or concomitant P-glycoprotein inhibitors

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>720.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Approx. 55</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>35</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>107 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–14 / –</td>
</tr>
</tbody>
</table>

### Metabolism

Unchanged edoxaban is main form in plasma. Edoxaban is metabolised via hydrolysis (mediated by carboxylesterase 1), conjugation or oxidation by CYP3A4/5 (<10%). Edoxaban has 3 active metabolites, the predominant metabolite (M-4), formed by hydrolysis, is active and reaches less than 10% of the exposure of the parent compound in healthy subjects. Exposure to the other metabolites is less than 5%. Edoxaban is a substrate for the efflux transporter P-glycoprotein (P-gp), but not a substrate for uptake transporters such as organic anion transporter polypeptide OATP1B1, organic anion transporters OAT1 or OAT3 or organic cation transporter OCT2. Its active metabolite is a substrate for OATP1B1.

Renal clearance accounts for approximately 35% of the administered dose. Metabolism and biliary/intestinal excretion account for the remaining clearance.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>15–50</td>
<td>30 mg once daily.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>15 mg once daily.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Analgesics: increased risk of bleeding with NSAIDs and high dose aspirin; increased risk of haemorrhage with IV diclofenac and ketorolac – avoid.
- Anti-arrhythmics: concentration increased by dronedarone (reduce edoxaban dose).
- Antibacterials: concentration increased by erythromycin (reduce edoxaban dose); concentration reduced by rifampicin.
- Anticoagulants: increased risk of haemorrhage with other anticoagulants – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: concentration increased by ketoconazole (reduce edoxaban dose).
- Ciclosporin: concentration of edoxaban increased (reduce edoxaban dose).

### Administration

**Reconstitution**

- **Route**
  - Oral
- **Rate of administration**

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**
  - Not dialysed. Dose as in GFR<15 mL/min.
- **HD**
  - 9% dialysed. Dose as in GFR<15 mL/min.
- **HDF/High flux**
  - Unknown dialysability. Dose as in GFR<15 mL/min.
- **CAV/VVHD**
  - Unknown dialysability. Dose as in GFR=15–50 mL/min.
The plasma AUC for subjects with mild (CRCL >50–80 mL/min), moderate (CRCL 30–50 mL/min) and severe (CRCL <30 mL/min but not undergoing dialysis) renal impairment was increased by 32%, 74%, and 72%, respectively, relative to subjects with normal renal function.

Bioavailability is 62%.

9% of edoxaban is removed after a 4-hour haemodialysis session.

Reference:
Efavirenz

**Clinical use**
Non-nucleoside reverse transcriptase inhibitor:
- HIV infection in combination with other antiretroviral drugs

**Dose in normal renal function**
600 mg once daily (tablets and capsules should be taken on an empty stomach to minimise side effects)
Oral solution: 720 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>315.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99.5–99.75</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2–4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>40–55 (multiple dosing); 52–76 (single dosing) / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**
Studies in humans and in vitro studies using human liver microsomes have demonstrated that efavirenz is principally metabolised by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1. The in vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism and that it inhibited P450 isozymes 2C9, 2C19, and 3A4. In in vitro studies efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 only at concentrations well above those achieved clinically.
Approximately 14–34% of a radiolabelled dose of efavirenz was recovered in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: concentration of rifabutin reduced.
- Anticoagulants: possibly affects concentration of coumarins.
- Antidepressants: concentration reduced by St John’s wort – avoid.
- Antifungals: itraconazole, posaconazole and voriconazole concentration reduced; voriconazole increases efavirenz concentration – reduce dose of efavirenz by 50% and increase dose of voriconazole to 400 mg twice daily; possibly reduces caspofungin concentration – may possibly need to increase caspofungin dose.
- Antimalarials: concentration of artemether with lumefantrine reduced.
- Antipsychotics: possibly increased risk of ventricular arrhythmias with pimozide – avoid; possibly reduces aripiprazole concentration – increase aripiprazole dose.
- Antivirals: concentration of atazanavir and boceprevir reduced – avoid; saquinavir concentration significantly reduced; concentration of daclatasvir, darunavir, dolutegravir, indinavir, lopinavir, telaprevir and possibly etravirine and maraviroc reduced – adjust daclatasvir, darunavir, dolutegravir, lopinavir, maraviroc and telaprevir dose, avoid with etravirine; concentration reduced by nevirapine; monitor LFTs when used in combination with ritonavir.
- Anxiolytics and hypnotics: risk of prolonged sedation with midazolam – avoid.
- Atovaquone: concentration of atovaquone reduced – avoid.
- Ciclosporin: concentration of ciclosporin possibly reduced.
- Cytotoxics: concentration of bosutinib possibly reduced – avoid.
- Ergot alkaloids: risk of ergotism – avoid.
• Grapefruit juice: concentration possibly increased.
• Guanfacine: concentration of guanfacine possibly reduced, increase dose of guanfacine.
• Oestrogens and progestogens: possibly reduced contraceptive effect.
• Orlistat: absorption possibly reduced by orlistat.
• Tacrolimus: possibly affects tacrolimus concentration.
• Ulipristal: possibly reduced contraceptive effect.

**Administration**

**Reconstitution**

**Route**

Oral

**Rate of administration**

—

**Other information**

• Induces its own metabolism.
• Monitor cholesterol levels as increases of 10–20% in total cholesterol have been reported.
• Half-life of 10 hours in haemodialysis patients has been reported.
• Bioavailability of oral solution is less than that for capsules or tablets – therefore not interchangeable.
Eletriptan

Clinical use

5HT₁ receptor agonist:
- Acute relief of migraine

Dose in normal renal function

- 40–80 mg repeated after 2 hours if migraine recurs (do not take 2⁰ dose for the same attack).
- Maximum 80 mg in 24 hours.

Pharmacokinetics

Molecular weight (daltons) 463.4 (as hydrobromide)
% Protein binding 85
% Excreted unchanged in urine 9
Volume of distribution (L/kg) 2–2.5
Half-life — normal/ESRF (hrs) 4 / Unchanged

Metabolism

In vitro studies indicate that eletriptan is primarily metabolised by hepatic cytochrome P-450 enzyme CYP3A4. This finding is substantiated by increased plasma concentrations of eletriptan following co-administration with erythromycin and ketoconazole, known selective and potent CYP3A4 inhibitors. In vitro studies also indicate a small involvement of CYP2D6 although clinical studies do not indicate any evidence of polymorphism with this enzyme.

There are two major circulating metabolites identified that significantly contribute to plasma radioactivity following administration of ¹⁴C-labelled eletriptan. The metabolite formed by N-oxidation, has demonstrated no activity in animal in vitro models. The metabolite formed by N-demethylation, has been demonstrated to have similar activity to eletriptan in animal in vitro models.

A third area of radioactivity in plasma has not been formally identified, but is most likely to be a mixture of hydroxylated metabolites which have also been observed excreted in urine and faeces.

The plasma concentrations of the N-demethylated active metabolite are only 10–20% of those of parent, so would not be expected to significantly contribute to the therapeutic action of eletriptan. Non-renal clearance accounts for approximately 90% of the total clearance indicating that eletriptan is eliminated primarily by metabolism.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Maximum daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>20 mg</td>
<td>40 mg. Use with caution.</td>
</tr>
<tr>
<td>10–30</td>
<td>20 mg</td>
<td>40 mg. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>20 mg</td>
<td>40 mg. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: concentration increased by clarithromycin and erythromycin – avoid.
- Antidepressants: increased risk of CNS toxicity with citalopram – avoid; possibly increased serotonergic effects with duloxetine and venlafaxine; increased serotonergic effects with St John’s wort – avoid.
- Antifungals: concentration increased by itraconazole and ketoconazole – avoid.
- Antivirals: concentration increased by indinavir and ritonavir – avoid.
- Dapoxetine: possible increased risk of serotonergic effects – avoid for 2 weeks after stopping 5HT₁ agonists.
- Ergot alkaloids: increased risk of vasospasm – avoid.

Administration

Reconstitution

Route
Oral
Rate of administration

Other information

- Manufacturer in UK SPC advises to avoid in severe renal impairment due to enhanced hypertensive effect but no contraindication in US data sheet.
- Contraindicated in uncontrolled hypertension.
Eltrombopag

Clinical use

Thrombopoetin receptor agonist:
- Treatment of chronic immune idiopathic thrombocytopenic purpura (ITP)
- Chronic hepatitis C associated thrombocytopenia (HCV)
- Severe aplastic anaemia

Dose in normal renal function

- ITP: 25–75 mg daily
- HCV: 25–100 mg daily
- Aplastic anaemia: 25–150 mg daily

Pharmacokinetics

Molecular weight (daltons) 442.5 (564.6 as olamine)
% Protein binding >99.9
% Excreted unchanged in urine 0 (31% as metabolites)
Volume of distribution (L/kg) 8.72 Litres
Half-life — normal/ESRF (hrs) 21–32 / –

Metabolism

Mainly hepatically metabolised through cleavage, oxidation by cytochrome P450 isoenzymes CYP1A2 and CYP 2C8 and conjugation with glucuronic acid, glutathione, or cysteine.
Approximately 31% of a dose is eliminated in the urine as metabolites, and about 59% in the faeces (20% unchanged).

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Ciclosporin: concentration of eltrombopag reduced.
- Statins: increased rosuvastatin concentration, may need to reduce rosuvastatin dose.

Administration

Reconstitution

Route
Oral

Rate of administration

Comments
Take at least 4 hours before or after antacids, dairy products (or other calcium containing food products), or mineral supplements containing polyvalent cations (e.g. iron, calcium, magnesium, aluminium, selenium and zinc).

Other information

- Patients with impaired renal function should use eltrombopag with caution and close monitoring, for example by measuring creatinine and/or urine analysis.
- LFTs should be measured before treatment and then every 2 weeks while the dose is established; once the dose is established, monthly monitoring is recommended. Tests should be repeated within 3–5 days if found to be abnormal, liver function should be monitored every week. If alanine aminotransferase levels increase to 3 times the upper limit of normal or above, and these are progressive or persist for 4 weeks or longer or are accompanied by increased bilirubin or by signs of hepatic injury or decompensation, eltrombopag should be stopped.
- The most common serious adverse effect of eltrombopag is haemorrhage.
- Following administration of a single 50 mg dose, the AUC_{0-\infty} of eltrombopag was 32–36% lower in patients with mild to moderate renal impairment, and 60% lower in severe renal impairment compared with healthy volunteers.
- Plasma-eltrombopag exposure is about 70% higher in some patients of East Asian origin (e.g. Japanese, Chinese, Taiwanese, and Korean), compared with Caucasian patients so a lower starting dose is recommended.

Reference:
Eluxadoline

Clinical use
Mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist:
- Treatment of irritable bowel syndrome with diarrhoea

Dose in normal renal function
75–100 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 569.7
% Protein binding 81
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 27 100 Litres
Half-life — normal/ESRF (hrs) 3.7–6 / Unchanged

Metabolism
Eluxadoline is mainly excreted in the faeces, either as unabsorbed active substance or via the biliary system with the kidney playing a minimal role in elimination.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly increased by rifampicin — avoid.
- Antivirals: concentration possibly increased by atazanavir, lopinavir, ritonavir, saquinavir and tipranavir — avoid.
- Ciclosporin: concentration of eluxadoline increased — avoid.
- Lipid-lowering agents: concentration possibly increased by gemfibrozil — avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- No safety and pharmacokinetic studies have been done but manufacturer advises that due to low renal excretion then normal doses could be used.
- Low systemic absorption and therefore bioavailability.
Empagliflozin

**Clinical use**
Selective and reversible inhibitor of sodium-glucose co-transporter 2:
- Treatment of type 2 diabetes

<table>
<thead>
<tr>
<th><strong>Dose in normal renal function</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>10–25 mg once daily</td>
</tr>
</tbody>
</table>

**Pharmacokinetics**
- Molecular weight (daltons): 450.9
- % Protein binding: 86
- % Excreted unchanged in urine: 54.4
- Volume of distribution (L/kg): 73.8 Litres
- Half-life — normal/ESRF (hrs): 12.4 / 27.9

**Metabolism**
*In vitro* studies suggested that the main route of metabolism is glucuronidation by the uridine 5’-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Following administration of oral [14C]-empagliflozin solution to healthy volunteers, approximately 96% of the drug-related radioactivity was eliminated in faeces (41%) or urine (54%). The majority of drug-related radioactivity recovered in faeces was unchanged parent drug and approximately half of drug-related radioactivity excreted in urine was unchanged parent drug.

**Dose in renal impairment GFR (mL/min)**
- 45–60: 10 mg once daily. See 'Other information'.
- <45: Avoid. See 'Other information'.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Avoid.
- HD: Unlikely to be dialysed. Avoid.
- HDF/High flux: Unlikely to be dialysed. Avoid.
- CAV/VVHD: Unlikely to be dialysed. Avoid.

**Important drug interactions**
- Potentially hazardous interactions with other drugs
  - None known

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Empagliflozin should not be initiated in patients with an eGFR<60 mL/min/1.73 m². In patients tolerating empagliflozin whose eGFR falls persistently below 60 mL/min/1.73 m², the dose of empagliflozin should be adjusted to or maintained at 10 mg once daily. Empagliflozin should be discontinued when eGFR is persistently <45 mL/min/1.73 m².
- Peak plasma levels of empagliflozin were roughly 20% higher in subjects with mild and severe renal impairment as compared to subjects with normal renal function.
- Unlikely to work if GFR<45mL/min/1.73 m².
- Two single dose studies from Japan looked at the safety and pharmacokinetics and concluded that empagliflozin could safely be used in Japanese ESRD patients at normal doses. The first study comprised 8 subjects with ESRD but without type 2 diabetes. The study showed no increase in side effects despite an increase in exposure in the ESRD patients. The second study looked at patients with CKD 4 with type 2 diabetes (n=8). In contrast to the other study they did not find such a big increase in half-life in the patients with CKD 4 compared to patients with normal renal function.1,2

References:
**Emtricitabine**

### Clinical use

Nucleoside reverse transcriptase inhibitor:
- Treatment of HIV-1 in combination with other antiretroviral agents

### Dose in normal renal function

- 200 mg once daily (if weight >33 kg)
- Oral solution: 240 mg once daily, (6 mg/kg if weight <33 kg)

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>247.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;4</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>86</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.1–1.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10 / Increased</td>
</tr>
</tbody>
</table>

### Metabolism

There is limited metabolism of emtricitabine. The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulphoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose). Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). 13% of the emtricitabine dose was recovered in urine as three metabolites.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Tablets: 200 mg daily. Oral solution: 240 mg daily.</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td></td>
</tr>
<tr>
<td>15–30</td>
<td></td>
</tr>
<tr>
<td>&lt;15</td>
<td></td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=15–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antivirals: avoid concomitant use with lamivudine.
- Orlistat: absorption of emtricitabine possibly reduced.

### Administration

#### Reconstitution

- **Route**
  - Oral

- **Rate of administration**

### Other information

- Haemodialysis should be started at least 12 hours after the last dose of emtricitabine.
- In patients with ESRD on haemodialysis, approximately 30% of the emtricitabine dose was recovered in dialysate over a 3 hour dialysis period which had been started within 1.5 hours of emtricitabine dosing (blood flow rate of 400 mL/min and dialysate flow rate of approximately 600 mL/min).
- Pharmacokinetic parameters were determined following administration of a single dose of 200 mg emtricitabine hard capsules to 30 non-HIV infected subjects with varying degrees of renal insufficiency. Subjects were grouped according to baseline creatinine clearance (>80 mL/min as normal function; 50–80 mL/min as mild impairment; 30–49 mL/min as moderate impairment; <30 mL/min as severe impairment; <15 mL/min as functionally anephric requiring haemodialysis). The systemic emtricitabine exposure (mean ± standard deviation) increased from 11.8±2.9 μg·h/mL in subjects with normal renal function to 19.9±1.1, 25±5.7 and 34±2.1 μg·h/mL in patients with mild, moderate and severe renal impairment, respectively.
- 200 mg of the hard capsules is equivalent to 240 mg of the oral solution.
- Dose may be reduced instead of increasing dosage interval.
Enalapril maleate

**Clinical use**

Angiotensin converting enzyme inhibitor:
- Hypertension
- Heart failure

**Dose in normal renal function**

2.5–40 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>492.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>50–60</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.17</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>11 / 34–60</td>
</tr>
</tbody>
</table>

**Metabolism**

Following absorption, oral enalapril is rapidly and extensively hydrolysed to enalaprilat, a potent angiotensin converting enzyme inhibitor. Peak serum concentrations of enalaprilat occur about 4 hours after an oral dose of enalapril tablet, and the effective half-life is 11 hours. Excretion of enalaprilat is primarily renal. The principal components in urine are enalaprilat, accounting for about 40% of the dose, and intact enalapril.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Start with 2.5 mg per day and increase according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with 2.5 mg per day and increase according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
- Bee venom extract: possible severe anaphylactoid reactions when used together.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of angioedema with everolimus.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Gold: flushing and hypotension with sodium aurothiomalate.
- Lithium: reduced excretion, possibility of enhanced lithium toxicity.
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

**Administration**

**Reconstitution**

- Route Oral

**Rate of administration**

- 

**Other information**

- Side effects (e.g. hyperkalaemia, metabolic acidosis) are more common in patients with impaired renal function.
- Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
- Renal failure has been reported in association with ACE inhibitors in patients with renal artery stenosis, post renal transplant, and in those with severe congestive heart failure.
- High incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated
concomitantly with an ACE inhibitor – this combination should therefore be avoided.

- ACE inhibitor cough may be helped by sodium cromoglycate inhalers.
- Enalaprilat injection available on a named patient basis.

Reference:
# Enfuvirtide

## Clinical use
Treatment of HIV-1 in combination with other antiretroviral agents

## Dose in normal renal function
90 mg twice daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>4491.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>92</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>4.4–6.6 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3.2–4.4 / Probably unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
As a peptide, enfuvirtide is expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool. *In vitro* human microsomal studies and *in vivo* studies indicate that enfuvirtide is not an inhibitor of CYP450 enzymes. In *in vitro* human microsomal and hepatocyte studies, hydrolysis of the amide group of the C-terminus amino acid, phenylalanine results in a deamidated metabolite. Mass balance studies to determine elimination pathway(s) of enfuvirtide have not been performed in humans.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>35–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–35</td>
<td>Dose as in normal renal function.¹</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.¹</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>13% dialysed.¹ Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–35 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Orlistat: absorption possibly reduced by orlistat.

## Administration

### Reconstitution
1.1 mL water for injection

### Route
SC

### Rate of administration
—

### Comments
- Do not shake vial or turn it upside down as this causes foaming.
- The powder may take up to 45 minutes to dissolve.
- Use within 24 hours if kept in refrigerator. Allow to reach room temperature before injecting.

## Other information
- Renal calculi have been reported with enfuvirtide therapy.
- In a renal impairment study AUC of enfuvirtide was increased on average by 43–62% in patients with severe or end stage renal disease compared to patients with normal renal function.

Reference:
Enoxaparin sodium (LMWH)

**Clinical use**
- Prophylaxis of thromboembolic disorders of venous origin
- Treatment of deep vein thrombosis and pulmonary embolism
- Anticoagulation of the extracorporeal circulation during haemodialysis
- Acute coronary syndrome

**Dose in normal renal function**
- Prophylaxis DVT:
  - Moderate risk surgery: 20 mg once daily
  - High risk surgery / medical prophylaxis: 40 mg once daily
- Treatment DVT and PE: 1.5 mg/kg every 24 hours
- Anticoagulation of extracorporeal circuits – see ’Other information’
- Acute coronary syndrome: 1 mg/kg every 12 hours

**Pharmacokinetics**
- Molecular weight (daltons) Mean = 4500
- % Protein binding No data
- % Excreted unchanged in urine 10
- Volume of distribution (L/kg) 5 Litres
- Half-life — normal/ESRF (hrs) 4–5 / Increased

**Metabolism**
Hepatic metabolism by desulphation and depolymerisation contributes to elimination.

**Dose in renal impairment GFR (mL/min)**
- 30–80 Dose as in normal renal function.
  - Prophylaxis: 20 mg daily. Treatment: 1 mg/kg daily. Initial stat dose of 30 mg for patients who have had a STEMI and are <75 years.
- 15–30 Treatment: 1 mg/kg daily. Initial stat dose of 30 mg for patients who have had a STEMI and are <75 years. Prophylaxis: 20 mg daily. See ’Other information’.
- <15 Not dialysed. Dose as in GFR<15 mL/min.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in GFR<15 mL/min.
- HD Not dialysed. Dose as in GFR<15 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<15 mL/min.
- CAV/VVHD Not dialysed. Dose as in GFR=15–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of bleeding with NSAIDs — avoid with IV diclofenac; increased risk of haemorrhage with ketorolac – avoid.
- Nitrates: anticoagulant effect reduced by infusions of glyceryl trinitrate.
- Use with care in patients receiving oral anticoagulants, platelet aggregation inhibitors, aspirin or dextran.

**Administration**

**Reconstitution**
-

**Route**
SC

**Rate of administration**
-

**Other information**
- From December 2016, the manufacturer has changed the dosing in severe renal impairment in line with European guidelines. It is now contraindicated for all indications in severe renal impairment apart from its use for dialysis anti-coagulation.
- A linear relationship between anti-Xa plasma clearance and creatinine clearance at steady-state has been observed, which indicates decreased clearance of enoxaparin sodium in patients with reduced renal function. In patients with severe renal impairment (CRCL< 30 mL/min), the AUC at steady state is significantly increased by an average of 65% after repeated, once daily subcutaneous doses of 40 mg.
- In extracorporeal circulation during haemodialysis, 1 mg/kg enoxaparin is introduced into the arterial line of the circuit at the beginning of the session. The effect of this dose is usually sufficient for a 4-hour
session. If fibrin rings are found, a further dose of 0.5–1 mg/kg may be given.

- For patients with a high risk of haemorrhage, the dose should be reduced to 0.5 mg/kg for double vascular access or 0.75 mg/kg for single vascular access.

- The dose of protamine to neutralise the effect of enoxaparin should equal the dose of enoxaparin: 50 anti-heparin units of protamine should neutralise the anti-factor-Xa activity generated by 1 mg of enoxaparin. If prothrombin time is still raised 2–4 hours later give 0.5 mg/kg infusion of protamine. (Hovanessian H. Letter. Ann Emerg Med. 2006; 36(3): 278.)

- Manufacturer advises monitoring of the anti-factor-Xa activity, whatever the severity of the renal impairment, when treatment doses are being employed. They also advise monitoring patients if given prolonged treatment with prophylactic doses.

- Low molecular weight heparins are renally excreted and hence accumulate in severe renal impairment. While the doses recommended for prophylaxis against DVT and prevention of thrombus formation in extracorporeal circuits are well tolerated in patients with ESRF, the doses recommended for treatment of DVT and PE have been associated with severe, sometimes fatal, bleeding episodes in such patients. Hence the use of unfractionated heparin would be preferable in these instances.

- Additional doses may be required if using LMWHs for anticoagulation in HDF.
Entacapone

Clinical use

Catechol-O-methyltransferase inhibitor:
• Treatment of Parkinson's disease

Dose in normal renal function

• 200 mg with each dose of levodopa with dopadecarboxylase inhibitor
• Max 2 g daily

Pharmacokinetics

Molecular weight (daltons) 305.3
% Protein binding 98 (mainly albumin)
% Excreted unchanged in urine Traces (10–20% as unchanged drug and metabolites)
Volume of distribution (L/kg) 20 Litres
Half-life — normal/ESRF (hrs) 1.6–3.4 / Unchanged

Metabolism

Entacapone undergoes extensive first-pass metabolism to form glucuronide metabolites.
It is eliminated mainly in the faeces with about 10–20% being excreted in the urine, mainly as glucuronide conjugates.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Anticoagulants: enhances anticoagulant effect of warfarin.
• Antidepressants: use with caution in combination with moclobemide, tricyclics and venlafaxine; avoid with MAOIs.
• Dopaminergics: possibly enhances effects of apomorphine; possibly reduces concentration of rasagiline; max dose of selegiline is 10 mg in combination.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information

• Manufacturer suggests that a longer dosing interval may be required in dialysis patients.
• Bioavailability is 35%.
# Entecavir

## Clinical use

Treatment of chronic hepatitis B infection

## Dose in normal renal function

| Dose | 500 mcg daily; 1000 mcg daily in lamivudine-refractory patients. |

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>295.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>13</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>75</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Large</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>128–149 / –</td>
</tr>
</tbody>
</table>

## Metabolism

Entecavir is not a substrate, inhibitor or inducer of the CYP450 enzyme system. Following administration of \(^{14}\)C-entecavir, no oxidative or acetylated metabolites and minor amounts of the phase II metabolites, glucuronide and sulfate conjugates, were observed. Entecavir is predominantly eliminated by the kidney: renal clearance is independent of dose and ranges between 360-471 mL/min suggesting that entecavir undergoes both glomerular filtration and net tubular secretion.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>250 mcg daily or 500 mcg every 48 hours; 500 mcg daily in lamivudine-refractory patients.</td>
</tr>
<tr>
<td>10–30</td>
<td>150 mcg daily or 500 mcg every 72 hours; 300 mcg daily or 500 mcg every 48 hours in lamivudine-refractory patients.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50 mcg daily or 500 mcg every 5–7 days; 100 mcg daily or 500 mcg every 72 hours in lamivudine-refractory patients.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>0.3% dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>13% dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Likely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- None known

## Administration

### Reconstitution

- 

### Route

Oral

### Rate of administration

- 

## Other information

- Entecavir clearance decreases with decreasing creatinine clearance. A 4-hour period of haemodialysis removed \(\approx 13\)% of the dose, and 0.3% was removed by CAPD.
Enzalutamide

Clinical use
Androgen receptor signalling inhibitor:
  • Treatment of prostate cancer

Dose in normal renal function
160 mg once daily

Pharmacokinetics
Molecular weight (daltons) 464.4
% Protein binding 97–98
% Excreted unchanged in urine 71 (unchanged drug + metabolite)
Volume of distribution (L/kg) 110 Litres
Half-life — normal/ESRF (hrs) 2.8–10.2 days / Unchanged

Metabolism
Clearance of enzalutamide is mainly via hepatic metabolism, producing an active metabolite that is equally as active as enzalutamide and circulates at approximately the same plasma concentration as enzalutamide. Under conditions of clinical use, enzalutamide is a strong inducer of CYP3A4, a moderate inducer of CYP2C9 and CYP2C19, and has no clinically relevant effect on CYP2C8.
Excreted mainly as metabolites 71% in urine and 14% via faeces.

Dose in renal impairment GFR (mL/min)
20–50  Dose as in normal renal function.
10–20  Dose as in normal renal function.
<10   Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD  Unlikely to be dialysed. Dose as in normal renal function.
HD  Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.
HDF/High flux  Unknown dialysability. Dose as in normal renal function.
CAV/VVHD  Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
  • Anticoagulants: possibly reduces concentration effect of coumarins.
  • Anxiolytics: concentration of midazolam reduced.
  • Cytotoxics: concentration of palbociclib possibly reduced – avoid.
  • Lipid-regulating drugs: concentration increased by gemfibrozil – avoid or halve enzalutamide dose.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
  • Manufacturer advises to use with caution in patients with severe renal impairment as enzalutamide has not been studied in this patient population.
  • A case study has been reported of a 66-year old haemodialysis patient being given 80 mg once daily of enzalutamide for 3 months with good effect. The only side effect reported was a possible rise in BP, the patient was usually hypotensive. The editors conclude that this was suggestive that enzalutamide may have been accumulating. (Tsang ES, de Haan M, Eigl BJ. A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer. J Oncol Pharm Pract. 2017 Jan: doi: 10.1177/1078155216689381.)
Epirubicin hydrochloride

Clinical use
Antineoplastic agent:
- Leukaemias
- Malignant lymphomas
- Multiple myeloma
- Various solid tumours

Dose in normal renal function
60–90 mg/m² every 3 weeks.
High dose: 60–135 mg/m² every 3–4 weeks, or 45 mg/m² on days 1, 2, and 3, every 3 weeks.
Dose and frequency depend on condition and whether monotherapy or combination therapy
Or according to local protocol.

Pharmacokinetics
Molecular weight (daltons) 580
% Protein binding 77
% Excreted unchanged in urine 9–10
Volume of distribution (L/kg) 14–38
Half-life — normal/ESRF (hrs) 30–40 / Unchanged

Metabolism
Epirubicin is extensively and rapidly metabolised in the liver; 27–40% eliminated by biliary excretion. Slow elimination through the liver is due to extensive tissue distribution. Also is metabolised in other organs and cells, including red blood cells. Four main metabolic pathways have been identified. Only the metabolite epirubicinol (13-OH epirubicin) appears to have cytotoxic activity; however, epirubicinol is unlikely to reach in vivo concentrations sufficient to produce cytotoxic effects. Epirubicin and its major metabolites are eliminated in faeces via biliary excretion (40% of the administered dose being recovered in the bile in 72 hours) and to a lesser extent in urine (10% of a dose in 48 hours).

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function but use lower dose.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.
- Ciclosporin: increased risk of neurotoxicity.
- Cytotoxics: possible increased risk of cardiotoxicity with trastuzumab – avoid for up to 28 weeks after stopping trastuzumab.
- Ulcer-healing drugs: concentration increased by cimetidine.
- Vaccines: avoid with live vaccines.

Administration
Reconstitution
Reconstitute with water for injection or sodium chloride 0.9% (rapid dissolution only)
Route
IV, intravesical (bladder instillation), intrathecal
Rate of administration
IV: give via the tubing of a fast running intravenous infusion of sodium chloride 0.9% or glucose 5%, taking 3–5 minutes over the injection
IV infusion: 30 minutes
Comments
- For bladder instillation: concentration of epirubicin in bladder should be 50–80 mg per 50 mL once a week. To avoid undue dilution in urine, the patient should be instructed not to drink any fluid in the 12 hours prior to instillation.
- In the case of local toxicity dose is reduced to 30 mg per 50 mL.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
</tbody>
</table>
Other information

- A cumulative dose of 900–1000 mg/m² should only be exceeded with extreme caution. Above this level, the risk of irreversible congestive cardiac failure increases greatly.

- Patients with impaired hepatic function have prolonged and elevated plasma concentrations of epirubicin – dose reduction is required.

- Epirubicin may make the urine red for 1–2 days after administration.
Eplerenone

Clinical use
Aldosterone antagonist:
• Left ventricular dysfunction and heart failure

Dose in normal renal function
25–50 mg daily

Pharmacokinetics
Molecular weight (daltons) 414.5
% Protein binding 50
% Excreted unchanged in urine <5
Volume of distribution (L/kg) 43–57 Litres
Half-life — normal/ESRF (hrs) 3–6 / –

Metabolism
Eplerenone metabolism is primarily mediated via CYP3A4. No active metabolites of eplerenone have been identified in human plasma. Less than 5% of an eplerenone dose is recovered as unchanged drug in the urine and faeces. Following a single oral dose of radiolabelled drug, approximately 32% of the dose was excreted in the faeces and approximately 67% was excreted in the urine.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.¹
10–20 Dose as in normal renal function.¹
<10 Dose as in normal renal function.¹

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD 10% dialysed.¹ Dose as in GFR<10 mL/min.²
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.²
CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• ACE inhibitors or AT-II antagonists: enhanced hypotensive effect; risk of severe hyperkalaemia.
• Anti-arrhythmics: concentration increased by amiodarone – reduce eplerenone dose.
• Antibacterials: concentration increased by clarithromycin and telithromycin – avoid; concentration increased by erythromycin – reduce eplerenone dose; concentration reduced by rifampicin – avoid; against with lymecycline; increased risk of hyperkalaemia with trimethoprim.
• Antidepressants: concentration reduced by St John’s wort – avoid; increased risk of postural hypotension with tricyclics; enhanced hypotensive effect with MAOIs.
• Antiepileptics: concentration reduced by carbamazepine, fosphenytoin, phenytoin, phenobarbital and primidone – avoid.
• Antifungals: concentration increased by itraconazole and ketoconazole – avoid; concentration increased by fluconazole – reduce eplerenone dose.
• Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect with post-synaptic alpha-blockers.
• Antivirals: concentration increased by ritonavir – avoid; concentration increased by saquinavir – reduce eplerenone dose.
• Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
• Cytotoxics: increased risk of nephrotoxicity and ototoxicity with platinum compounds.
• NSAIDs: increased risk of hyperkalaemia (especially with indometacin); increased risk of nephrotoxicity; antagonism of diuretic effect.
• Potassium salts: increased risk of hyperkalaemia.
• Lithium: reduced lithium excretion – avoid.
• Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.
• CYP3A4 inhibitors: Do not exceed a dose of 25 mg daily for eplerenone.
• CYP3A4 inducers: reduced eplerenone concentration – avoid.
Administration

Reconstitution

—

Route
Oral

Rate of administration
—

Other information

• Monitor potassium levels regularly in people with renal impairment.
• Contraindicated by manufacturer due to risk of hyperkalaemia in severe renal impairment.
• From personal experience can be used safely in severe renal impairment with close monitoring.

References:
Epoetin alfa (Eprex)

Clinical use
- Anaemia associated with renal impairment in predialysis and dialysis patients, and in patients receiving cancer chemotherapy
- Increased yield of autologous blood

Dose in normal renal function
- Renal:
  - CORRECTION PHASE: (To raise haemoglobin to target level) 50 u/kg 2–3 times weekly; increase, according to response, by 25 u/kg 3 times weekly at intervals of 4 weeks. Rise in haemoglobin should not exceed 2 g/100 mL/month (optimum rise in haemoglobin up to 1 g/100 mL/month to avoid hypertension). Target haemoglobin usually 10–12 g/100 mL.
  - MAINTENANCE PHASE: Adjust dose to maintain required haemoglobin level; usual dose needed is 75–300 u/kg weekly in 1–3 divided doses.
- Cancer: Initially 150 u/kg 3 times a week and adjust according to response.
- Autologous blood harvest: 600 u/kg IV once or twice a week for 3 weeks prior to surgery.

Pharmacokinetics
- Molecular weight (daltons) 30 400
- % Protein binding No data
- % Excreted unchanged in urine No data
- Volume of distribution (L/kg) 0.03–0.05
- Half-life — normal/ESRF (hrs) IV: 4 / 5; SC: ≈24 / Unchanged

Metabolism
The metabolic fate of both endogenous and recombinant erythropoietin is poorly understood. Current evidence from studies in animals suggests that hepatic metabolism contributes only minimally to elimination of the intact hormone, but desialylated epoetin (i.e. terminal sialic acid groups removed) appears to undergo substantial hepatic clearance via metabolic pathways and/or binding. Desialylation and/or removal of the oligosaccharide side chains of erythropoietin appear to occur principally in the liver; bone marrow also may have a role in catabolism of the hormone. Elimination of desialylated drug by the kidneys, bone marrow, and spleen also may occur; results of animal studies suggest that proximal renal tubular secretion may be involved in renal elimination.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Hyperkalaemia with ACE inhibitors and angiotensin-II antagonists.

Administration
Reconstitution
- Route
  - IV / SC (maximum 1 mL per injection site)
Rate of administration
- 1–5 minutes
Comments
- When given IV, higher doses normally needed to produce required response

Other information
- Reported association of pure red cell aplasia (PRCA) with epoetin therapy. This is a very rare condition; due to failed production of red blood cell precursors in the bone marrow, resulting in profound anaemia. Possibly due to an immune response to the protein backbone of R-HuEPO. Resulting antibodies render the patient unresponsive to the therapeutic effects of all epoetins and darbepoetin.
- Pre-treatment checks and appropriate correction/treatment needed for iron, folate and B12 deficiency, infection, inflammation or aluminium toxicity, to produce optimum response to therapy.
- Concomitant iron therapy (200–300 mg elemental oral iron) needed daily. IV iron may be needed for patients with very low serum ferritin (<100 nanograms/mL).
- May increase heparin requirement during HD.
Epoetin beta (Neorecormon)

Clinical use
Anaemia associated with renal impairment in pre-dialysis and dialysis patients, and in patients receiving cancer chemotherapy

Dose in normal renal function
- Renal:
  - CORRECTION PHASE: (To raise haemoglobin to target level) 20 u/kg SC or 40 u/kg IV 3 times weekly for 4 weeks; increase, according to response, in steps of 20 u/kg 3 times weekly at monthly intervals. Maximum dose 720 u/kg weekly. Target haemoglobin usually 10–12 g/100mL.
  - MAINTENANCE DOSE: (To maintain haemoglobin at target level) Half correction phase dose, then adjust according to response at intervals of 1–2 weeks.
- Cancer: Initially 450 u/kg weekly in 3–7 divided doses and adjust according to response.

Pharmacokinetics
- Molecular weight (daltons): 30 400
- % Protein binding: No data
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): 0.03–0.05

Metabolism
The metabolic fate of both endogenous and recombinant erythropoietin is poorly understood. Current evidence from studies in animals suggests that hepatic metabolism contributes only minimally to elimination of the intact hormone, but desialylated epoetin (i.e. terminal sialic acid groups removed) appears to undergo substantial hepatic clearance via metabolic pathways and/or binding. Desialylation and/or removal of the oligosaccharide side chains of erythropoietin appear to occur principally in the liver; bone marrow also may have a role in catabolism of the hormone. Elimination of desialylated drug by the kidneys, bone marrow, and spleen also may occur; results of animal studies suggest that proximal renal tubular secretion may be involved in renal elimination.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Risk of hyperkalaemia with ACE inhibitors and angiotensin-II antagonists.

Administration
Reconstitution

Route
- SC, IV

Rate of administration
- 2 minutes

Comments
May also be given IV, but higher doses are needed to produce required response.

Other information
- Pre-treatment checks and appropriate correction/treatment needed for iron, folate and B12 deficiencies, infection, inflammation or aluminium toxicity to produce optimum response to therapy.
- Concomitant iron therapy (200–300 mg elemental oral iron) needed daily. IV iron may be needed for patients with very low serum ferritin (<100 nanograms/mL).
- May increase heparin requirement during HD.
- Reported association of pure red cell aplasia (PRCA) with epoetin therapy. This is a very rare condition; due to failed production of red blood cell precursors in the bone marrow, resulting in profound anaemia. Possibly due to an immune response to the protein backbone of R-HuEPO. Resulting antibodies render the patient unresponsive to the therapeutic effects of all epoetins and darbepoetin.
Epoprostenol (prostacyclin)

**Clinical use**
- Vasodilation and inhibition of platelet aggregation without prolonging bleeding time
- Alternative to heparin in haemodialysis
- Treatment of peripheral vascular disease and pulmonary hypertension

**Dose in normal renal function**
- 2–50 ng/kg/minute, adjusted according to response.
- Dialysis anticoagulation: 4 ng/kg/minute starting 10–15 minutes before and continuing during dialysis via the arterial line, adjusted according to response (range: 0.5–12 ng/kg/minute).

**Pharmacokinetics**
- Molecular weight (daltons) 352.5
- % Protein binding No data
- % Excreted unchanged in urine < 5 (40–90 as drug + metabolites)
- Volume of distribution (L/kg) 0.357–1.015
- Half-life — normal/ESRF (hrs) 2–6 minutes / –

**Metabolism**
On intravenous infusion epoprostenol is hydrolysed rapidly to the more stable but much less active 6-keto-prostaglandin F$_1$α (6-oxo-prostaglandin F$_1$α). A second metabolite, 6,15-diketo-13,14-dihydro-prostaglandin F$_1$α, is formed by enzymatic degradation. Following the administration of radiolabelled epoprostenol to humans, at least 16 metabolites were found, 10 of which were structurally identified. Unlike many other prostaglandins, epoprostenol is not metabolised during passage through the pulmonary circulation. The urinary and faecal recoveries of radioactivity were 82% and 4%, respectively.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in normal renal function.
- HD Unknown dialysability. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Increased hypotensive effect with ‘acetate’ dialysis.

**Administration**

**Reconstitution**
500 microgram vial with diluent provided gives solution of 10 micrograms/mL. Can be diluted further.

**Route**
IV or into blood supplying dialyser.

**Rate of administration**
Via CRIP

**Comments**
- Complicated dosing schedule – check calculations carefully.
- There are now 2 different formulations available and care must be taken to ensure the correct dilution and rate is used. Always check the product literature when making it up.

**Other information**
- Monitor BP and heart rate. Reduce dose if patient becomes hypotensive. Cardiovascular effects cease 30 minutes after stopping the infusion.
- Some patients may exhibit allergic reaction to buffer solution used to reconstitute epoprostenol.
- Solution retains 90% potency for 12 hours after dilution.
- The concentrated solution should be filtered using the filter provided in the pack.
Eprosartan

Clinical use
Angiotensin-II antagonist:
• Hypertension

Dose in normal renal function
600 mg daily

Pharmacokinetics
Molecular weight (daltons) 520.6 (as mesilate)
% Protein binding 98
% Excreted unchanged in urine <2 (as metabolites)
Volume of distribution (L/kg) 13 Litres
Half-life — normal/ESRF (hrs) 5–9 / Unchanged

Metabolism
Following oral and intravenous dosing with $^{14}$C eprosartan in human subjects, eprosartan was the only drug-related compound found in the plasma and faeces. In the urine, approximately 20% of the radioactivity excreted was an acyl glucuronide of eprosartan with the remaining 80% being unchanged eprosartan. Eprosartan is eliminated by both biliary and renal excretion. Following intravenous $^{14}$C eprosartan, about 61% of radioactivity is recovered in the faeces and about 37% in the urine. Following an oral dose of $^{14}$C eprosartan, about 90% of radioactivity is recovered in the faeces and about 7% in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initially 300 mg daily and increase according to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Anaesthetics: enhanced hypotensive effect.
• Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
• Antihypertensives: increased risk of hyperkalaemia hypotension and renal impairment with ACE inhibitors and aliskiren.
• Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
• Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
• Epoetin: increased risk of hyperkalaemia; antagonism of hypotensive effect.
• Lithium: reduced excretion, possibility of enhanced lithium toxicity.
• Potassium salts: increased risk of hyperkalaemia.
• Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Side effects (e.g. hyperkalaemia, metabolic acidosis) are more common in patients with impaired renal function.
• Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
• Renal failure has been reported in association with AT-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with severe congestive heart failure.
Eptifibatide

**Clinical use**

Antiplatelet agent:
- Prevention of early myocardial infarction in patients with unstable angina or non-ST segment-elevation myocardial infarction and with last episode of chest pain within 24 hours

**Dose in normal renal function**

IV bolus of 180 mcg/kg then by IV infusion at a rate of 2 mcg/kg/minute for up to 72–96 hours

**Pharmacokinetics**

- Molecular weight (daltons) 832
- % Protein binding 25
- % Excreted unchanged in urine 50
- Volume of distribution (L/kg) 0.185–0.26
- Half-life — normal/ESRF (hrs) 2.5 / Increased

**Metabolism**

Renal excretion accounts for approximately 50% of total body clearance of eptifibatide; approximately 50% of the amount cleared is excreted unchanged in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Normal bolus dose. Reduce infusion to 1 mcg/kg/minute and use with caution due to limited experience.</td>
</tr>
<tr>
<td>10–30</td>
<td>Normal bolus dose. Reduce infusion to 1 mcg/kg/minute and use with caution due to limited experience.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Normal bolus dose. Reduce infusion to 1 mcg/kg/minute and use with caution due to limited experience.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Iloprost: increased risk of bleeding.

**Administration**

**Reconstitution**

Route
- IV bolus, IV infusion

**Rate of administration**
- 1–2 mcg/kg/minute depending on renal function.

**Other information**

- Antiplatelet effect lasts for about 4 hours after stopping infusion.
- Main side effect is bleeding.
- In patients with a GFR<50 mL/min, clearance is halved and plasma concentration doubled.
- Contraindicated by UK SPC if GFR<30 mL/min but not in US data sheet. Although contraindicated in dialysis-dependent patients in US data sheet.
## Eribulin

### Clinical use

Antineoplastic agent:
- Treatment of metastatic breast cancer

### Dose in normal renal function

- **1.23 mg/m² (as base) on days 1 and 8 of every 21-day cycle**
- Consult relevant local protocol

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>729.9 (826 as mesilate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>49–65</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>9</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>43–114 Litres/m²</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>40 / –</td>
</tr>
</tbody>
</table>

### Metabolism

Minimal metabolism. Eribulin is eliminated primarily by biliary excretion. The transport protein involved in the excretion is presently unknown. Preclinical studies indicate that eribulin is transported by Pgp. However, it is unknown whether Pgp is contributing to the biliary excretion of eribulin.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>1.1 mg/m²/dose.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Reduce dose.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD** Not dialysed. Dose as in GFR<30 mL/min.
- **HD** Not dialysed. Dose as in GFR<30 mL/min.
- **HDF/High flux** Not dialysed. Dose as in GFR<30 mL/min.
- **CAV/VVHD** Not dialysed. Dose as in GFR=30–50 mL/min.

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).

### Administration

#### Reconstitution

- **Route** IV

#### Rate of administration

- **Over 2–5 minutes**

#### Comments

- May be diluted in 100 mL of sodium chloride 0.9%

### Other information

- Due to lack of data the manufacturer cannot recommend a dose if GFR<50 mL/min.
- Information in GFR=30–50 mL/min from US data sheet.
- A 1.5-fold higher dose-normalised AUC_{(0-inf)} was observed in patients with moderate and severe renal impairment (CRCL=15–50 mL/min).
Erlotinib

Clinical use
Tyrosine kinase inhibitor, antineoplastic agent:
- Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least 1 other regime
- Pancreatic cancer

Dose in normal renal function
- Non-small cell lung cancer: 150 mg once daily at least 1 hour before or 2 hours after food.
- Pancreatic cancer: 100 mg once daily
Or see local protocol

Pharmacokinetics
Molecular weight (daltons) 429.9 (as hydrochloride)
% Protein binding 93–95
% Excreted unchanged in urine 9 (<2% as unchanged drug)
Volume of distribution (L/kg) 232 Litres
Half-life — normal/ESRF (hrs) 36 / –

Metabolism
Erlotinib is metabolised mainly by the cytochrome P450 isoenzyme CYP3A4, and to a lesser extent by CYP1A2. Extrahepatic metabolism by CYP3A4 in intestine, CYP1A1 in lung, and 1B1 in tumour tissue potentially contribute to the metabolic clearance of erlotinib. Metabolic pathways include demethylation, to metabolites OSI-420 and OSI-413, oxidation, and aromatic hydroxylation. The metabolites OSI-420 and OSI-413 have comparable potency to erlotinib in non-clinical in vitro assays and in vivo tumour models. They are present in plasma at levels that are <10 % of erlotinib and display similar pharmacokinetics as erlotinib. Erlotinib is excreted predominantly as metabolites via the faeces (>90%) with renal elimination accounting for only a small amount (approximately 9%) of an oral dose. Less than 2% of the orally administered dose is excreted as parent substance.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
15–20 Dose as in normal renal function.
<15 Use with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<15 mL/min
HD Unlikely to be dialysed. Dose as in GFR<15 mL/min
HDF/High flux Unlikely to be dialysed. Dose as in GFR<15 mL/min
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of bleeding with NSAIDs.
- Antacids: concentration possibly reduced by antacids, give at least 4 hours before or 2 hours after erlotinib.
- Anticoagulants: increased risk of bleeding with coumarins.
- Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis.
- Antivirals: avoid with boceprevir.
- Ulcer-healing drugs: avoid with cimetidine, esomeprazole, famotidine, lansoprazole, nizatidine, pantoprazole and rabeprazole; concentration reduced by ranitidine, give at least 2 hours before or 10 hours after ranitidine; concentration reduced by omeprazole – avoid.

Administration
Reconstitution —
Route Oral
Rate of administration —

Other information
- Has not been studied in patients with a GFR<15 mL/min; therefore use with caution, but drug has limited renal excretion.
- Major side effects are rash and diarrhoea.
- Can cause interstitial lung disease and abnormal liver function tests.
- Smoking may reduce erlotinib concentration by increasing clearance.
Ertapenem

Clinical use
Antibacterial agent

Dose in normal renal function
1 g daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>497.5 (as sodium)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>85–95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>38</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4 / 14</td>
</tr>
</tbody>
</table>

Metabolism

After intravenous infusion of radiolabelled 1 g ertapenem, the plasma radioactivity consists predominantly (94%) of ertapenem. The major metabolite of ertapenem is the ring-opened derivative formed by dehydropeptidase-I-mediated hydrolysis of the beta-lactam ring. Approximately 80% of a dose is recovered in urine and 10% in faeces. Of the 80% recovered in urine, approximately 38% is excreted as unchanged ertapenem and approximately 37% as the ring-opened metabolite.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Use 50–100% of dose.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use 50% of dose, or 1 g 3 times a week.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antiepileptics: concentration of valproate reduced – avoid concomitant use.

Administration

Reconstitution
10 mL water for injection or sodium chloride 0.9%.

Route
IV, (IM – not licensed)

Rate of administration
IV Infusion: 30 minutes.

Comments
- Dilute in sodium chloride 0.9% only.
- Incompatible with glucose.
- Dilute solutions are stable for 6 hours at room temperature or 24 hours in a refrigerator. Use within 4 hours of removal from refrigerator.

Other information
- Not recommended by UK manufacturer due to lack of data in GFR<30 mL/min but a dose of 50% is recommended in US data sheet.
- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Approximately 30% of dose is dialysed after a 4-hour haemodialysis session.
- Anecdotally ertapenem has been used at a dose of 1 g 3 times a week in haemodialysis patients.
- Give at least 6 hours before haemodialysis session if unable to give post dialysis.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
**Clinical use**

Antibacterial agent

**Dose in normal renal function**

- IV: 6.25–12.5 mg/kg every 6 hours
- Oral: 250–500 mg every 6 hours or 0.5–1 g every 12 hours
- Maximum 4 g daily

**Pharmacokinetics**

- Molecular weight (daltons) 733.9
- % Protein binding 70–95
- % Excreted unchanged in urine 2–15
- Volume of distribution (L/kg) 0.6–1.2 (increased in CKD 5)
- Half-life — normal/ESRF (hrs) 1.5–2 / 4–7

**Metabolism**

Erythromycin is partly metabolised in the liver by the cytochrome P450 isoenzyme CYP3A4 via N-demethylation to inactive, unidentified metabolites. It is excreted in high concentrations in the bile and undergoes intestinal reabsorption. About 2–5% of an oral dose is excreted unchanged in the urine and as much as 12–15% of an intravenous dose may be excreted unchanged by the urinary route.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. See 'Other information'.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Aminophylline and theophylline: inhibits aminophylline and theophylline metabolism; if erythromycin given orally decreased erythromycin concentration.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with IV erythromycin and amiodarone – avoid; increased toxicity with disopyramide; increased risk of ventricular arrhythmias with dronedarone – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and IV erythromycin – avoid; possibly increased rifabutin concentration – reduce rifabutin dose; concentration of bedaquiline possibly increased – avoid if for more than 14 days; possibly increased risk of ventricular arrhythmias with delamanid; avoid with fidaxomicin.
- Anticoagulants: enhanced effect of coumarins; concentration of edoxaban increased – reduce edoxaban dose.
- Antidepressants: avoid concomitant use with reboxetine; avoid IV erythromycin with citalopram and escitalopram, risk of ventricular arrhythmias; risk of ventricular arrhythmias with venlafaxine – avoid.
- Antiepileptics: increased carbamazepine concentration and possibly valproate.
- Antifungals: avoid with fluconazole.
- Antihistamines: possibly increases loratadine concentration; inhibits mizolastine metabolism – avoid concomitant use; concentration of rupatadine increased.
- Antimalarials: avoid with artemether/lumefantrine; increased risk of ventricular arrhythmias with piperaquine with artemisinol – avoid.
- Antimuscarinics: avoid concomitant use with tolerodine.
- Antipsychotics: increased risk of ventricular arrhythmias with sulpiride and zuclopenthixol and IV erythromycin avoid; possibly increases clozapine concentration leading to increased risk of convulsions; possibly increased lurasidone concentration; possibly increased risk of ventricular arrhythmias with amisulpride, droperidol and pimozide – avoid; possibly increased quetiapine concentration.
- Antivirals: concentration of both drugs increased with telaprevir and simeprevir, avoid with simeprevir; concentration increased by ritonavir; avoid with...
rilpivirine, concentration increased; increased risk of ventricular arrhythmias with saquinavir – avoid.

- Anxiolytics and hypnotics: inhibits midazolam and zopiclone metabolism; increases buspirone concentration.
- Atomoxetine: increased risk of ventricular arrhythmias with parenteral erythromycin.
- Avanafil: concentration of avanafil increased, max dose 100 mg every 48 hours.
- Calcium-channel blockers: possibly inhibit metabolism of calcium channel blockers; avoid with lercanidipine.
- Ciclosporin: markedly elevated ciclosporin blood levels – decreased levels on withdrawing drug. Monitor blood levels of ciclosporin carefully and adjust dose promptly as necessary.
- Cilostazol: concentration of cilostazol increased, reduce cilostazol to 50 mg twice daily.
- Clopidogrel: possibly reduced antiplatelet effect.
- Colchicine: increased risk of colchicine toxicity – suspend or reduce dose of colchicine, avoid in hepatic or renal impairment.
- Cytotoxics: possibly increased afatinib concentration, separate administration by 6–12 hours; concentration of axitinib increased – reduce axitinib dose; concentration of bosutinib possibly increased – avoid or reduce dose of bosutinib; concentration of cabozantinib, dasatinib and ibrutinib and possibly olaparib increased – avoid with dasatinib, reduce dose of ibrutinib, avoid or reduce dose of olaparib; concentration of everolimus possibly increased; increased risk of ventricular arrhythmias with IV erythromycin and vandetanib – avoid; possible interaction with docetaxel; increased risk of ventricular arrhythmias with arsenic trioxide; increases vinblastine toxicity – avoid.
- Diuretics: increased eplerenone concentration – reduce eplerenone dose.
- Domperidone: possible increased risk of ventricular arrhythmias – avoid.
- Ergot alkaloids: increase risk of ergotism – avoid concomitant use.
- 5HT1 agonists: increased eletriptan concentration – avoid concomitant use.
- Ibrutinibe: increased risk of ventricular arrhythmias – avoid concomitant use.
- Ivacaftor: concentration of ivacaftor possibly increased.

- Lipid-lowering drugs: possibly increased myopathy with atorvastatin; concentration of pravastatin increased; concentration of rosvustatin reduced; avoid concomitant use with simvastatin.¹; concentration of lomitapide possibly increased – avoid.
- Pentamidine: increased risk of ventricular arrhythmias with IV erythromycin.
- Sildenafil: concentration of sildenafil increased – reduce initial dose for ED or reduce frequency to twice daily for PAH.
- Sirolimus: concentration of both drugs increased.
- Tacrolimus: markedly elevated tacrolimus blood levels – decreased levels on withdrawing drug. Monitor blood levels of tacrolimus carefully and adjust dose promptly as necessary.
- Ticagrelor: concentration of ticagrelor possibly increased.

### Administration

#### Reconstitution
1 g with 20 mL water for injection, then dilute resultant solution further to 1–5 mg/mL.

#### Route
IV, oral

#### Rate of administration
20–60 minutes using constant rate infusion pump

#### Comments
Use central line if concentration greater than 5 mg/mL; if >10 mg/mL monitor carefully (some units use 1 g in 100 mL of sodium chloride 0.9%). (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006.)

#### Other information
- May also give one third of daily dose by infusion over 8 hours peripherally at concentration of 1 g/250 mL (4 mg/mL). Repeat 8 hourly, i.e. continuously.
- Increased risk of ototoxicity in renal impairment especially at high doses.
- Avoid peaks produced by oral twice-daily dosing, i.e. dose 4 times daily.
- Monitor closely for thrombophlebitic reactions at site of infusion.

#### Reference
Escitalopram

**Clinical use**

SSRI antidepressant:
- Depressive illness
- Panic and social anxiety disorder

**Dose in normal renal function**

- Antidepressant: 10–20 mg daily
- Panic and social anxiety disorder: 5–20 mg
- Patients >65 years: maximum 10 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>414.4 (as oxalate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;80</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>8</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>12–26</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>22–32 / Slightly increased</td>
</tr>
</tbody>
</table>

**Metabolism**

Escitalopram is metabolised in the liver to the demethylated and didemethylated metabolites. Both of these are pharmacologically active. Alternatively, the nitrogen may be oxidised to form the N-oxide metabolite. Both parent substance and metabolites are partly excreted as glucuronides. After multiple dosing the mean concentrations of the demethyl and didemethyl metabolites are usually 28–31% and <5%, respectively, of the escitalopram concentration. Biotransformation of escitalopram to the demethylated metabolite is mediated primarily by CYP2C19. Some contribution by the enzymes CYP3A4 and CYP2D6 is possible. The major metabolites have a significantly longer half-life than the parent drug.

Escitalopram and major metabolites are assumed to be eliminated by both hepatic and renal routes, with the major part of the dose excreted as metabolites in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Start with a low dose and titrate slowly.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with a low dose and titrate slowly.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone, disopyramide and dronedarone – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with IV erythromycin, moxifloxacin, pentamidine and telithromycin.
- Anticoagulants: effect of coumarins possibly enhanced; possibly increased risk of bleeding with dabigatran.
- Antidepressants: avoid concomitant use with MAOI, increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with moclobemide – avoid concomitant use; avoid concomitant use with St John’s wort; possibly enhanced serotonergic effects with dapoxetine and duloxetine; can increase concentration of tricyclics; increased agitation and nausea with tryptophan; increased risk of ventricular arrhythmias with rasagiline; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered.
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antimalarials: avoid concomitant use with artemether/lumefantrine and piperaquine with artemisinol; possible increased risk of ventricular arrhythmias with chloroquine and quinine.
- Antipsychotics: possibly increased risk of ventricular arrhythmias with haloperidol, phenothiazines and pimozide – avoid.
- Antivirals: concentration possibly increased by ritonavir.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol – avoid.
- Dopaminergics: avoid with selegiline; increased risk of CNS toxicity with rasagiline.
- 5HT₁ agonist: increased risk of CNS toxicity with sumatriptan; possibly increased risk of serotonergic effects with naratriptan.
- Linezolid: use with care, possibly increased risk of side effects.
- Lithium: increased risk of CNS effects.
- Methylthioninium: risk of CNS toxicity – avoid if possible.

### Administration

**Reconstitution**
- **Route**
  - Oral

**Rate of administration**
- **Comments**
  - Oral drops: 20 drops = 10 mg

### Other information
- Escitalopram is an isomer of citalopram.
- Risk of QT prolongation and ventricular arrhythmias.
Eslicarbazepine acetate

**Clinical use**
Antiepileptic

**Dose in normal renal function**
400–1200 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>296.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;40</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1 (90 plus metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2.71</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–20 / Increased</td>
</tr>
</tbody>
</table>

**Metabolism**
Eslicarbazepine acetate is rapidly and extensively biotransformed to its major active metabolite eslicarbazepine by hydrolytic first-pass metabolism. Minor metabolites in plasma are R-licarbazepine and oxcarbazepine, which were shown to be active, and the glucuronic acid conjugates of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine. Eslicarbazepine acetate and its metabolites are mainly excreted in the urine unchanged.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>Initially 400 mg every 48 hours or 200 mg once daily increased to 400 mg daily. Dose may be increased as required.</td>
</tr>
<tr>
<td>10–30</td>
<td>400 mg alternate days for 2 weeks, increasing to 400 mg once daily, max dose 600 mg daily.²</td>
</tr>
<tr>
<td>&lt;10</td>
<td>400 mg alternate days for 2 weeks, increasing to 400 mg once daily, max dose 600 mg daily.²</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Probably dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. 400–600 mg post dialysis.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. 400–600 mg post dialysis.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antidepressants: anticonvulsant effect possibly antagonised by MAOIs, SSRIs and TADs; avoid with St John’s wort.
- Antiepileptics: avoid concomitant use with carbamazepine, oxcarbazepine; concentration reduced by phenytoin and concentration of phenytoin increased.
- Antimalarials: anticonvulsant effect antagonised by mefloquine.
- Antipsychotics: antagonism of anticonvulsant effect.
- Oestrogens and progestogens: reduced contraceptive effect.
- Orlistat: possibly increased risk of convulsions.
- Ulipristal: possibly reduces contraceptive effect — avoid.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Not recommended by manufacturer in GFR<30 mL/min due to lack of data.
- May prolong PR interval.
- High bioavailability.
- Metabolites are effectively cleared by haemodialysis.

References:
**Esmolol hydrochloride**

### Clinical use

Beta-adrenoceptor blocker:
- Short-term treatment of supraventricular arrhythmias (including AF, atrial flutter, sinus tachycardia)
- Tachycardia and hypertension in the perioperative period

### Dose in normal renal function

50–200 micrograms/kg/minute; see product literature for titration schedule.

### Pharmacokinetics

- **Molecular weight (daltons)**: 331.8
- **% Protein binding**: 55
- **% Excreted unchanged in urine**: <2
- **Volume of distribution (L/kg)**: 1.9
- **Half-life — normal/ESRF (hrs)**: 9 minutes / Unchanged

### Metabolism

Esmolol hydrochloride is metabolised by esterases into an acid metabolite (ASL-8123) and methanol. This occurs through hydrolysis of the ester group by esterases in the red blood cells. Esmolol hydrochloride is excreted by the kidneys, partly unchanged (less than 2% of the administered amount), partly as acid metabolite that has a weak (less than 0.1% of esmolol) beta-blocking activity. The acid metabolite is also excreted in the urine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Dialysed. Dose as in normal renal function.
- **HD**: Dialysed. Dose as in normal renal function.
- **HDF/High flux**: Dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs:
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; with amiodarone, increased risk of bradycardia and AV block and myocardial depression; increased risk of myocardial depression and bradycardia with flecaïnide.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics: enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; severe hypotension and heart failure occasionally with nifedipine and possibly other dihydropyridines; asystole, severe hypotension and heart failure with verapamil – avoid concomitant verapamil use.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly dobutamine.

### Administration

#### Reconstitution

- **Route**: IV infusion
- **Rate of administration**: 50–200 mcg/kg/minute
- **Comments**:
  - Incompatible with sodium bicarbonate solutions.
  - Dilute to a concentration of 10 mg/mL with sodium chloride 0.9% or glucose 5%.
  - Local irritation has occurred with infusions of 20 mg/mL.

### Other information

- Hyperkalaemia can occur in CKD 5.
- Titrate dose according to blood pressure response.
Esomeprazole

**Clinical use**

Gastric acid suppression

**Dose in normal renal function**

- Oral: 20–40 mg daily
- Zollinger-Ellison syndrome: 80–160 mg daily (doses >80 mg given in divided doses)
- IV: 20–40 mg daily
- Severe peptic ulcer bleeding: 80 mg over 30 minutes then 8 mg/hour for 72 hours

**Pharmacokinetics**

- Molecular weight (daltons) 345.4
- % Protein binding 97
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 0.22
- Half-life — normal/ESRF (hrs) 1.3 / Unchanged

**Metabolism**

Esomeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma. The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces. Less than 1% of the parent drug is found in urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anticoagulants: effect of coumarins possibly enhanced.
- Antiepileptics: effects of fosphenytoin and phenytoin enhanced.
- Antifungals: absorption of itraconazole and ketoconazole reduced; avoid with posaconazole; concentration possibly increased by voriconazole.
- Antivirals: concentration of atazanavir and rilpivirine reduced – avoid concomitant use; concentration of raltegravir and saquinavir possibly increased – avoid; concentration of esomeprazole reduced by tipranavir.
- Clopidogrel: reduced antiplatelet effect.
- Cytotoxics: possibly reduced excretion of methotrexate; avoid with dasatinib, erlotinib and vandetanib; possibly reduced lapatinib absorption; possibly reduced absorption of pazopanib.
- Ulipristal: reduced contraceptive effect, avoid with high dose ulipristal.

**Administration**

**Reconstitution**

5 mL sodium chloride 0.9%

**Route**

Oral, IV

**Rate of administration**

- Bolus: over 3 minutes
- Infusion: 10–30 minutes

**Comments**

Dilute with up to 100 mL sodium chloride 0.9%.

**Other information**

- Can be dispersed in half a glass of non-carbonated water. Stir well until it disintegrates; the liquid with pellets should be drunk immediately or within 30 minutes of preparation. The glass should then be rinsed with water which should also be drunk.
- Do not crush or chew.
- Manufacturer advises to use with caution due to lack of data.
Estramustine phosphate

Clinical use
Alkylating agent:
  • Prostate cancer

Dose in normal renal function
0.14–1.4 g daily in divided doses (usual initial dose 560–840 mg daily)

Pharmacokinetics
Molecular weight (daltons) 564.3 (as sodium phosphate)
% Protein binding No data
% Excreted unchanged in urine 22–36
Volume of distribution (L/kg) 0.43
Half-life — normal/ESRF (hrs) 10 (estromustine: 20) / –

Metabolism
Estramustine sodium phosphate is absorbed from the gastrointestinal tract and rapidly dephosphorylated in the intestine and prostate to estramustine and its oxidised isomer estromustine. Some hydrolysis of the carbamate linkage occurs in the liver, releasing estradiol, estrone, and the normustine group. Estramustine and estromustine are excreted with their metabolites mainly in the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in normal renal function.
HD Unknown dialysability. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
  • Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).
  • Bisphosphonates: concentration increased by sodium clodronate.

Administration
Reconstitution —
Route Oral
Rate of administration —
Comments Do not give less than 1 hour before or 2 hours after meals.

Other information
  • Can cause fluid retention so use with caution in renal impairment.

Reference:
Etamsylate

**Clinical use**
- Short-term treatment of blood loss in menorrhagia
- Prophylaxis of surgical bleeding (unlicensed)

**Dose in normal renal function**
- Menorrhagia: 500 mg 4 times a day during menstruation
- Surgical bleeding: 1–1.5 g daily or 250–500 mg every 4–6 hours

**Pharmacokinetics**
- Molecular weight (daltons): 263.3
- % Protein binding: >90
- % Excreted unchanged in urine: 72–80
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 3.7–8 / –

**Metabolism**
Etamsylate is excreted unchanged, mainly in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—
**Etanercept**

### Clinical use

Tumour necrosis factor alpha inhibitor:
- Treatment of moderate to severe rheumatoid arthritis in combination with methotrexate
- Psoriatic arthritis
- Ankylosing spondylitis
- Severe non-radiographic axial spondyloarthritis
- Plaque psoriasis

### Dose in normal renal function

- 25 mg twice weekly or 50 mg weekly
- Plaque psoriasis: can go up to 50 mg twice weekly for up to 12 weeks

### Pharmacokinetics

- Molecular weight (daltons) 150 000
- % Protein binding No data
- % Excreted unchanged in urine No data
- Volume of distribution (L/kg) 10.4 Litres
- Half-life — normal/ESRF (hrs) 72–132 / Unchanged

### Metabolism

Since etanercept is a fusion glycoprotein, consisting entirely of human protein components, it is expected to undergo proteolysis.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs
- Anakinra and abatacept: avoid concomitant use.
- Live vaccines: avoid concomitant use.

### Administration

**Reconstitution**

1 mL water for injection (solvent provided)

**Route**

SC

**Rate of administration**

—

### Other information

- Contraindicated in patients with severe infections and moderate to severe heart failure.
- Bioavailability is 76%.
- Case reports of glomerulonephritis have been reported with etanercept.

Reference:
Etelcalcetide

Clinical use

Synthetic peptide calcimimetic agent:
• Treatment of secondary hyperparathyroidism in patients on haemodialysis

Dose in normal renal function

N/A – Only used in haemodialysis patients

Pharmacokinetics

Molecular weight (daltons) 1048.3
% Protein binding Low (mainly bound to albumin)
% Excreted unchanged in urine 7
Volume of distribution (L/kg) 796 Litres
Half-life — normal/ESRF (hrs) 3–5 days

Metabolism

Etelcalcetide is biotransformed in blood by reversible disulphide exchange with endogenous thiols to predominantly form conjugate with serum albumin.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>N/A. Only used in haemodialysis patients.</td>
</tr>
<tr>
<td>10–20</td>
<td>N/A. Only used in haemodialysis patients.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>N/A. Only used in haemodialysis patients.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>N/A.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. 2.5–15 mg three times a week post dialysis.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. 2.5–15 mg three times a week post dialysis.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>N/A.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Avoid with cinacalcet.

Administration

Reconstitution
—

Route
IV bolus

Rate of administration
—

Comments

Administer into the venous line of the dialysis circuit at the end of the haemodialysis treatment during rinse-back or intravenously after rinse-back. When given during rinse-back at least 150 mL of rinse-back volume should be administered after injection. If rinse-back is completed and etelcalcetide was not administered, then it may be administered intravenously followed by at least 10 mL saline flush volume.

Other information

• Etelcalcetide should not be started in patients until 7 days after the last dose of cinacalcet and the corrected serum calcium is at or above the lower limit of the normal range.
• 60% removed by haemodialysis.
• In trials the incidence of nausea in the first 8 weeks of treatment was not significantly different for patients randomised to etelcalcetide and cinacalcet.
• Can cause QT prolongation, muscle spasms and worsening of heart failure may also occur secondary to hypocalcaemia.
Ethambutol hydrochloride

Clinical use
Antibacterial agent:
• Tuberculosis

Dose in normal renal function
15 mg/kg/day or 30 mg/kg 3 times a week (supervised dosing)

Pharmacokinetics
Molecular weight (daltons) 277.2
% Protein binding 20–30
% Excreted unchanged in urine 50
Volume of distribution (L/kg) 1.6–3.2
Half-life — normal/ESRF (hrs) 3–4 / 5–15

Metabolism
Ethambutol is partially metabolised in the liver to the aldehyde and dicarboxylic acid derivatives, which are inactive.
Up to 80% of a dose appears in the urine within 24 hours, 50% as unchanged drug and 8–15% as the inactive metabolites. About 20% of the dose is excreted unchanged in the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 15 mg/kg every 24–36 hours, or 7.5–15 mg/kg/day.
<10 15 mg/kg every 48 hours, or 5–7.5 mg/kg/day.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min, or on dialysis days only give 25 mg/kg 4–6 hours before dialysis.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min, or on dialysis days only give 25 mg/kg 4–6 hours before dialysis.
CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min. See 'Other information'.

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Monitor plasma levels. Dosages should be individually determined and adjusted according to measured levels and renal replacement therapy.
• Peak levels are taken 2–2.5 hours post dose (2–6 mg/L or 7–22 micromol/L); trough is taken pre dose (<1 mg/L or <4 micromol/L).
• Baseline visual acuity tests should be performed prior to initiating ethambutol.
• Daily dosing is preferred by some specialists to aid compliance and ensure maximum therapeutic effect.
• Dose in renal impairment is from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
• There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid 'flux' within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
## Ethosuximide

### Clinical use
Epilepsy

### Dose in normal renal function
500 mg – 2 g daily in 2 divided doses

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>141.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>12–20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.6–0.9</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>40–60 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism
Ethosuximide is extensively hydroxylated in the liver to its principal metabolite which is reported to be inactive. Ethosuximide is excreted in the urine mainly in the form of its metabolites, either free or conjugated, but about 12–20% is also excreted unchanged.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: concentration increased by isoniazid.
- Antidepressants: lower convulsive threshold; avoid with St John’s wort.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenytoin and phenobarbital; concentration of fosphenytoin and phenytoin possibly increased; concentration increased by valproate.
- Antimalarials: anticonvulsant effect antagonised by mefloquine.
- Antipsychotics: lower convulsive threshold.
- Orlistat: possible increased risk of convulsions.

### Administration

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

### Other information

Reference:
Etodolac

**Clinical use**
NSAID and analgesic

**Dose in normal renal function**
- 300–600 mg daily in 1–2 divided doses
- XL: 600 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 287.4
- % Protein binding >99
- % Excreted unchanged in urine 1
- Volume of distribution (L/kg) 0.4
- Half-life — normal/ESRF (hrs) 6–7.4 / Unchanged

**Metabolism**
Excretion of etodolac is mainly in the urine as hydroxylated metabolites and glucuronide conjugates; some may be excreted in the bile.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function, but avoid if possible.
- 10–20: Dose as in normal renal function, but avoid if possible.
- <10: Dose as in normal renal function, but only use if on dialysis.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function. See 'Other information'.
- HD: Not dialysed. Dose as in normal renal function. See 'Other information'.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function. See 'Other information'.
- CAV/VVHD: Unlikely to be dialysed. Use lowest possible dose.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect, increased risk of nephrotoxicity and hyperkalaemia.

- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac, increased risk of side effects and haemorrhage.
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity
- Cytoxic agents: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Comments**
Take with or after food.

**Other information**
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if increased, discontinue therapy.
- In patients with renal, cardiac or hepatic impairment, especially those taking diuretics, caution is required since the use of NSAIDs may result in deterioration
of renal function. The dose should be kept as low as possible and renal function should be monitored.

- Use normal doses in patients with ERF on dialysis if they do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
- Accumulation of etodolac is unlikely in AKI, CKD or dialysis patients as it is metabolised in the liver.
## Etomidate

### Clinical use
Induction of anaesthesia

### Dose in normal renal function
150–300 mcg/kg, maximum total dose 60 mg with Hypnomidate®

### Pharmacokinetics
- Molecular weight (daltons): 244.3
- % Protein binding: 76
- % Excreted unchanged in urine: 2
- Volume of distribution (L/kg): 2–4.5

### Metabolism
Etomidate is rapidly redistributed from the CNS to other body tissues, and undergoes rapid metabolism in the liver and plasma. Pharmacokinetics are complex and have been described by both 2- and 3-compartment models. Etomidate is about 76% bound to plasma proteins. Etomidate is metabolised in the liver. After 24 hours, 75% of the administered dose of etomidate has been eliminated in the urine primarily as metabolites, although some is excreted in the bile. Only 2% of etomidate is excreted unchanged via the urine.

### Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Adrenergic neurone blockers: enhanced hypotensive effect.
- Antihypertensives: enhanced hypotensive effect.
- Antidepressants: avoid MAOIs for 2 weeks before surgery; increased risk of arrhythmias and hypotension with tricyclics.
- Antipsychotics: enhanced hypotensive effect.

### Administration

#### Reconstitution
- **Route**: Intravenous injection only

#### Rate of administration
- 30–60 seconds

### Other information
- In cases of adrenocortical gland dysfunction and during very long surgical procedures, a prophylactic cortisol supplement may be required (e.g. 50–100 mg hydrocortisone).
## Etoposide

### Clinical use
Antineoplastic agent

### Dose in normal renal function
- IV: 50–120 mg/m² daily according to local protocol.
- Oral: 120–240 mg/m² daily for 5 consecutive days
- Or according to local protocol

### Pharmacokinetics
- **Molecular weight (daltons)**: 588.6
- **% Protein binding**: 74–94
- **% Excreted unchanged in urine**: 29
- **Volume of distribution (L/kg)**: 0.17–0.5
- **Half-life — normal/ESRF (hrs)**: 4–11 / 19

### Metabolism
Etoposide is metabolised by the cytochrome P450 isoenzyme CYP3A4, yielding inactive metabolites.

### Dose in renal impairment GFR (mL/min)
- **30–50**: IV: 75% of dose and see 'Other information'. Oral: Dose as in normal renal function.
- **15–30**: IV: 75% of dose and see 'Other information'. Oral: Dose as in normal renal function.
- **<15**: IV: 50% of dose, based on clinical response and see 'Other information'. Oral: Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Not dialysed. Dose as in GFR<15 mL/min.
- **HD**: Not dialysed. Dose as in GFR<15 mL/min.
- **HDF/High flux**: Not dialysed. Dose as in GFR<15 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=15–30 mL/min.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhanced anticoagulant effect with coumarins.
- Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis.
- Ciclosporin: 50% reduction in etoposide clearance.

### Administration
- **Reconstituted**: 5–10 mL of infusion fluid or water for injection
- **Route**: Oral, IV
- **Rate of administration**: IV infusion: 5 minutes – 3.5 hours
- **Comments**: Dilute with sodium chloride 0.9% or glucose 5% to give a solution concentration as low as 100 mcg/mL of etoposide.

### Other information
- Avoid skin contact.
- One study suggested that patients with serum creatinine >130 μmol/L require a 30% dose reduction. ([Joel S, Clark P, Slevin M. Renal function and etoposide pharmacokinetics: is dose modification necessary? Am Soc Clin Oncol. 1991; 10: 103](https://www.ncbi.nlm.nih.gov/pubmed/1923397)). This dose adjustment was calculated to result in equivalent total dose exposure in patients with reduced renal function.
- Patients with a raised bilirubin and/or decreased albumin may have an increase in free etoposide and hence greater myelosuppression.
- Reaches high concentration in kidney: possible accumulation in renal impairment.
- Plasma clearance is reduced and volume of distribution increased in renal impairment.
- Dose in severe renal impairment is from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Has been used without any problems in a haemodialysis patient, using a dose that increased gradually to 250 mg per treatment. (Holthuis JJ, Van [Unspec](https://www.ncbi.nlm.nih.gov/pubmed/1136197)).

- Bristol-Myers Squibb advise giving 75% of dose if GFR=15–50 mL/min.
Clinical use
Cox-2 inhibitor and analgesic

Dose in normal renal function
- 30–60 mg once daily. May be increased temporarily to 90 mg daily in RA and ankylosing spondylitis if required
- Acute gouty arthritis: 120 mg once daily

Pharmacokinetics
Molecular weight (daltons) 358.8
% Protein binding 92
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 120 Litres
Half-life — normal/ESRF (hrs) 22 / Unchanged

Metabolism
Etoricoxib is extensively metabolised with <1% of a dose recovered in urine as the parent drug. The major route of metabolism to form the 6'-hydroxymethyl derivative is catalysed by CYP enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib in vivo. Five metabolites have been identified in man. The principal metabolite is the 6'-carboxylic acid derivative of etoricoxib formed by further oxidation of the 6'-hydroxymethyl derivative. These principal metabolites either demonstrate no measurable activity or are only weakly active as COX-2 inhibitors. None of these metabolites inhibit COX-1. Elimination of etoricoxib occurs almost exclusively through metabolism followed by renal excretion. Following administration of a single 25-mg radiolabeled intravenous dose of etoricoxib to healthy subjects, 70% of radioactivity was recovered in urine and 20% in faeces, mostly as metabolites. Less than 2% was recovered as unchanged drug.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function, but avoid if possible.
10–20 Dose as in normal renal function, but avoid if possible.
<10 Dose as in normal renal function, but only use if on dialysis.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Unknown dialysability. Use lowest possible dose.

Important drug interactions
Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac, increased risk of side effects and haemorrhage.
- Antibacterials: possibly increased risk of convulsions with quinolones; concentration reduced by rifampicin.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity
- Cytotoxics: reduced excretion of methotrexate; possibly reduced excretion of pemetrexed; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.
**Administration**

Reconstitution

---

**Route**

Oral

**Rate of administration**

---

**Comments**

- Take with or without food but onset of action is faster without food.

**Other information**

- Clinical trials have shown renal effects similar to those observed with comparative NSAIDs. Monitor patient for deterioration in renal function and fluid retention.
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.
- Use normal doses in patients with ERF on dialysis if they do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
- Etoricoxib should be used with caution in uraemic patients predisposed to gastrointestinal bleeding or uraemic coagulopathies.
Etravirine

**Clinical use**
Non-nucleoside reverse transcriptase inhibitor:
- Treatment of HIV infection in combination with other antiretrovirals

**Dose in normal renal function**
200 mg twice daily

**Pharmacokinetics**
Molecular weight (daltons) 435.3
% Protein binding 99.9
% Excreted unchanged in urine 0 (1.2% as metabolites)
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 30–40 / Probably unchanged

**Metabolism**
Etravirine is extensively metabolised by hepatic microsomal enzymes, mainly by the cytochrome P450 isoenzymes CYP3A4, CYP2C9, and CYP2C19, to substantially less active metabolites. Unchanged etravirine accounted for 81.2–86.4% of the administered dose in faeces. Unchanged etravirine was not detected in urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: concentration increased by clarithromycin, also concentration of clarithromycin reduced; concentration of both drugs reduced with rifabutin; avoid concomitant use with rifampicin.
- Antivirals: concentration possibly reduced by efavirenz and nevirapine – avoid concomitant use; concentration of fosamprenavir increased, consider reducing fosamprenavir dose; possibly reduces bosutinib and indinavir concentration – avoid concomitant use; concentration of dolutegravir reduced; possibly reduces concentration of maraviroc; concentration reduced by tipranavir and tipranavir concentration increased – avoid concomitant use.
- Clopidogrel: possibly reduced antiplatelet effect.
- Guanfacine: possibly reduces concentration of guanfacine – increase guanfacine dose.
- Orlistat: absorption possibly reduced by orlistat.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Comments**
Give after food

**Other information**
- Etravirine is readily absorbed after oral doses and peak plasma concentrations occur after about 2.5–4 hours; absorption is increased by food.
**Clinical use**

Protein kinase inhibitor:
1. Treatment of advanced renal cell carcinoma, breast cancer and neuroendocrine tumours (Afinitor®)
2. Renal angiomyolipoma and subependymal giant cell astrocystoma associated with tuberous sclerosis complex (Votubia®)
3. Prophylaxis of acute rejection in allogenic renal and cardiac transplants, in combination with ciclosporin; liver transplants with tacrolimus (Certican®)

**Dose in normal renal function**

1. Treatment of advanced renal cell carcinoma, breast cancer and neuroendocrine tumours (Afinitor®): 10 mg daily
2. Renal angiomyolipoma and subependymal giant cell astrocystoma associated with tuberous sclerosis complex (Oral – Votubia®): 10 mg daily
3. Transplantation (Oral – Certican®):
   Renal and cardiac: 0.75 mg twice daily
   Liver: 1 mg twice daily
   Titrate according to levels and tolerability
   Intravenous: 0.75 mg twice daily
   (Titrate according to levels – see ‘Other information’.)

**Pharmacokinetics**

Molecular weight (daltons) 958.2
% Protein binding 74
% Excreted unchanged in urine <5
Volume of distribution (L/kg) 235–449 Litres
Half-life — normal/ESRF (hrs) 18–35 / Unchanged

**Metabolism**

Everolimus is metabolised in the liver and to some extent in the gastrointestinal wall, and is a substrate of P-glycoprotein and the cytochrome P450 isoenzyme CYP3A4. Six main metabolites of everolimus have been detected in human blood, including three monohydroxylated metabolites, two hydrolytic ring-opened products, and a phosphatidylcholine conjugate of everolimus. These metabolites were shown to have approximately 100 times less activity than everolimus itself. Following the administration of a single dose of radiolabelled everolimus, 80% of the radioactivity was recovered from the faeces, while 5% was excreted in the urine. The parent substance was not detected in urine or faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapies</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- ACE-Is: increased risk of angioedema.
- Antibacterials: erythromycin, clarithromycin and telithromycin increase everolimus levels – avoid with clarithromycin and telithromycin; rifampicin decreases everolimus levels by factor of 3.
- Antidepressants: St John’s wort decreases everolimus levels.
- Antifungals: concentration increased by ketoconazole and possiblyitraconazole, posaconazole and voriconazole – avoid.
- Antipsychotics: increased risk of agranulocytosis with clozapine – avoid.
- Antivirals: concentration possibly increased by atazanavir, darunavir, indinavir, ritonavir and saquinavir – avoid; concentration significantly increased by dasabuvir and ombitasvir/paritaprevir/ritonavir – avoid concomitant use.
- Calcium channel blockers: concentration of both drugs increased with verapamil.
- Ciclosporin: increases everolimus AUC by 168% and C<sub>max</sub> by 82%.
- Cytotoxics: concentration increased by imatinib – consider reducing everolimus dose.
- Grapefruit juice: increases everolimus levels.
Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

• $C_{\text{max}}$ and AUC are reduced by 60% and 16% respectively when everolimus is taken with a high fat meal. Take doses consistently either with or without food to achieve consistent blood levels.

• Patients achieving whole-blood trough levels of $\geq 3$ ng/mL have been found to have a lower incidence of biopsy-proven acute rejection; the upper limit which has been assessed is 8 ng/mL. Measure levels 4–5 days after a dose change.
Evolocumab

Clinical use
IgG2 monoclonal antibody:
• Treatment of hypercholesterolaemia, mixed dyslipidaemia and homozygous familial hypercholesterolaemia

Dose in normal renal function
• Hypercholesterolaemia and mixed dyslipidaemia: 140 mg every 2 weeks or 420 mg once monthly
• Homozygous familial hypercholesterolaemia: 420 mg every month titrating up to 420 mg every 2 weeks

Pharmacokinetics
Molecular weight (daltons) 141 800
% Protein binding No data
% Excreted unchanged in urine Minimal
Volume of distribution (L/kg) 0.5 Litres
Half-life — normal/ESRF (hrs) 11–17 days / Unchanged

Metabolism
Evolocumab is composed of amino acids and carbohydrates as native immunoglobulin and is unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.
• Vaccines: avoid concomitant use with live vaccines.

Administration
Reconstitution
—
Route
SC
Rate of administration
—

Other information
• Manufacturer advises to use with caution in severe renal impairment due to lack of studies.
# Exemestane

## Clinical use
Irreversible, steroidal aromatase inhibitor:
- Treatment of breast cancer

## Dose in normal renal function
25 mg daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>296.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>20 000 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>24 / –</td>
</tr>
</tbody>
</table>

## Metabolism
Metabolised via oxidation by the cytochrome P450 isoenzyme CYP3A4, and via reduction by aldoketoreductase. Metabolites are excreted in the urine (39–45%) and faeces (36–48%).

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs:
- None known

## Administration

### Reconstitution
—

### Route
Oral

### Rate of administration
—

## Other information
- In patients with severe renal impairment (CRCL < 30 mL/min) the systemic exposure to exemestane was 2 times higher compared with healthy volunteers but due to the safety profile no dose alteration is required.
Exenatide

Clinical use
Adjunctive therapy in type 2 diabetes mellitus

Dose in normal renal function
- 5–10 mcg twice daily within 60 minutes before the morning and evening meal
- MR: 2 mg once weekly

Pharmacokinetics
Molecular weight (daltons) 4186.6
% Protein binding No data
% Excreted unchanged in urine Majority
Volume of distribution (L/kg) 28 Litres
Half-life — normal/ESRF (hrs) 2.4 / 6

Metabolism
Exenatide is eliminated through the kidneys by glomerular filtration followed by proteolytic degradation.

Dose in renal impairment GFR (mL/min)
30–50 Increase dose to 10 mcg with caution. Avoid MR.
10–30 Avoid. See ‘Other information’.
<10 Avoid. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Unknown dialysability. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhances anticoagulant effect of warfarin.
- Other nephrotoxins: avoid concomitant use.

Administration

Reconstitution
—
Route
SC
Rate of administration
—

Other information
- Clearance is reduced by 84% in patients with established renal failure.
- US data sheet: increased gastrointestinal side effects in patients with severe renal impairment and on dialysis.
- May cause renal failure including proteinuria. Avoid in patients with pre-existing renal impairment.

Reference:
Ezetimibe

Clinical use
Hypercholesterolaemia either in combination with a statin or as monotherapy

Dose in normal renal function
10 mg daily

Pharmacokinetics
Molecular weight (daltons) 409.4
% Protein binding 99.7
% Excreted unchanged in urine 11
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 22 / –

Metabolism
Ezetimibe is rapidly absorbed and extensively conjugated to a pharmacologically-active phenolic glucuronide (ezetimibe-glucuronide). Ezetimibe is metabolised primarily in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary excretion. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10–20% and 80–90% of the total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are slowly eliminated from plasma with evidence of significant enterohepatic recycling. Following oral administration of 14C-ezetimibe (20 mg) to human subjects, total ezetimibe accounted for approximately 93% of the total radioactivity in plasma. Approximately 78% and 11% of the administered radioactivity were recovered in the faeces and urine, respectively, over a 10-day collection period. After 48 hours, there were no detectable levels of radioactivity in the plasma.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Ciclosporin: concentration of both drugs possibly increased.
• Lipid lowering agents: avoid with fibrates; concentration of rosuvastatin increased – reduce rosuvastatin dose.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information
• When used with a statin LFTs should be monitored before initiation of therapy and then at regular intervals.
• If GFR < 30 mL/min there is a 1.5 increase in the AUC of ezetimibe but no dose adjustment is required.
• Very rarely, cases of rhabdomyolysis have occurred – discontinue if myopathy is suspected.
Famciclovir

Clinical use
Antiviral agent

Dose in normal renal function
- Varicella zoster virus (VZV) infections: 500 mg 3 times a day or 750 mg once or twice daily.
  (Immunocompromised: 500 mg 3 times a day.)
- Herpes simplex virus (HSV) infections (genital herpes):
  - First HSV episode: 250 mg 3 times a day.
  - Recurrent HSV: 125 mg twice a day.
    (Immunocompromised: 500 mg twice a day.)
- Suppression of recurrent HSV: 250 mg twice daily.
  (Immunocompromised: 500 mg twice daily.)

Pharmacokinetics
- Molecular weight (daltons) 321.3
- % Protein binding <20 as penciclovir
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) 0.91–1.25
- Half-life — normal/ESRF (hrs) 2 (penciclovir) / 3.2–23.6 (3.8–25 penciclovir)

Metabolism
Famciclovir is a pro-drug; it is rapidly converted to penciclovir; virtually no famciclovir is detectable in the plasma or urine. Bioavailability of penciclovir is reported to be 77%.
Famciclovir is mainly excreted in the urine (partly by renal tubular secretion) as penciclovir and its 6-deoxy precursor. No unchanged famciclovir has been detected in urine.

Dose in renal impairment GFR (mL/min)
In immunocompromised patients the duration of treatment is different from immunocompetent patients. See SPC.

40–59 VZV (incl immunocompromised): 500 mg twice daily.
HSV: Dose as in normal renal function.

20–39 VZV (incl immunocompromised): 500 mg once daily.
HSV first episode: 250 mg twice daily;
Recurrent: Dose as in normal renal function. (Immunocompromised: 500 mg once daily.)
Suppression of recurrent HSV: 125 mg twice daily. (Immunocompromised: 250 mg once daily.)

<20 VZV (incl immunocompromised): 250 mg once daily.
HSV first episode: 250 mg once daily.
Recurrent HSV: 125 mg once daily.
(Immunocompromised: 250 mg once daily.)
Suppression of recurrent HSV: 125 mg once daily. (Immunocompromised: 250 mg once daily.)

Dose in patients undergoing renal replacement therapies

APD/CAPD Moderate dialysability likely. Dose as in GFR<20 mL/min.

HD Dialysed. Dose as in GFR<20 mL/min but only give post dialysis.

HDF/High flux Dialysed. Dose as in GFR<20 mL/min but only give post dialysis.

CAV/VVHD Likely dialysability. Dose as in GFR=20–39 mL/min. See 'Other information'.

Important drug interactions
Potentially hazardous interactions with other drugs
- Probenecid: decreased excretion of famciclovir.
- Increased famciclovir levels reported with mycophenolate mofetil.
Famciclovir

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Four hours haemodialysis results in approximately 75% reduction in plasma concentration of penciclovir.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Famotidine

Clinical use

H₂-blocker:
• Conditions associated with hyperacidity

Dose in normal renal function

• 20–80 mg daily
• Zollinger-Ellison syndrome: 80–800 mg daily in divided doses

Pharmacokinetics

Molecular weight (daltons) 337.4
% Protein binding 15–20
% Excreted unchanged in urine 25–30
Volume of distribution (L/kg) 1.1–1.4
Half-life — normal/ESRF (hrs) 3 / >20

Metabolism

Metabolism of famotidine occurs in the liver, with formation of an inactive metabolite, the sulfoxide. Following oral administration, the mean urinary excretion of famotidine is 65–70% of the absorbed dose, 25–30% as unchanged compound. Renal clearance is 250–450 mL/min, indicating some tubular excretion. A small amount may be excreted as the sulfoxide.

Dose in renal impairment GFR (mL/min)

20–50 50% of normal dose or increase dose to every 36–48 hours.
10–20 50% of normal dose or increase dose to every 36–48 hours.
<10 20 mg at night (maximum or increase dose to every 36–48 hours.

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
• Antifungals: absorption of itraconazole and ketoconazole reduced; concentration of posaconazole possibly reduced – avoid with suspension.
• Antivirals: concentration of atazanavir reduced – adjust doses of both drugs; concentration of raltegravir possibly increased – avoid; for 12 hours before and 4 hours after rilpivirine.
• Ciclosporin: possibly increased ciclosporin levels.
• Cytotoxics: possibly reduced dasatinib concentration – avoid if possible; avoid with erlotinib; possibly reduced absorption of pazopanib – give at least 2 hours before or 10 hours after famotidine; possibly reduced absorption of lapatinib.
• Ulipristal: contraceptive effect possibly reduced – avoid with high dose ulipristal.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

• CNS effects have been seen in patients with moderate to severe renal impairment.
• Contraindicated in UK SPC in moderate to severe renal impairment but doses in monograph are from US data sheet.
# Febuxostat

## Clinical use

Xanthine oxidase inhibitor:
- Treatment of chronic gout
- Prevention and treatment of acute hyperuricaemia with chemotherapy

## Dose in normal renal function

80–120 mg daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>316.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99.2</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>3 (49% as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>29–75 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–8 / Increased</td>
</tr>
</tbody>
</table>

## Metabolism

Extensively metabolised by conjugation via the uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system, and by oxidation via the cytochrome P450 isoenzyme system to form active metabolites. About 49% of a dose is excreted via the urine, and 45% via the faeces (12% as unchanged drug).

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Start with 40 mg and monitor closely.</td>
</tr>
<tr>
<td></td>
<td>See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with 40 mg and monitor closely.</td>
</tr>
<tr>
<td></td>
<td>See 'Other information'.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Azathioprine: avoid concomitant use, increased risk of neutropenia.
- Cytotoxics: avoid concomitant use with mercaptopurine.
- Theophylline: use with caution.

## Administration

### Reconstitution

—

### Route

Oral

### Rate of administration

—

## Other information

- Not recommended in UK SPC in severe renal impairment due to lack of data.
- Advise to use with caution in severe renal impairment in US data sheet, starting with a dose of 40 mg in moderate renal impairment.
- In patients with severe renal impairment (GFR=10–29), peak plasma concentrations of febuxostat did not alter compared to those with normal renal function; although the mean AUC was increased by 1.8.
- A study found that although exposure to febuxostat and its metabolites was generally higher in subjects with increasing degrees of renal impairment, decreases in uric acid were comparable regardless of renal function.1
- Treatment in patients with ischaemic heart disease or congestive heart failure is not recommended.
- There have been 2 case reports of febuxostat causing neutropenia in 2 haemodialysis patients.2
- There is a series of cases from Japan using febuxostat in haemodialysis patients at a dose of 10–20 mg daily with good effect.3
- There has also been a case report of a patient with ESRD developing agranulocytosis with febuxostat at a dose of 40 mg daily.4

## References


## Felodipine

### Clinical use
Calcium-channel blocker:
- Hypertension
- Angina

### Dose in normal renal function
- Hypertension: 2.5–20 mg once daily
- Angina: 2.5–10 mg daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>384.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;0.5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>10</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>24 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Felodipine is metabolised in the liver and all identified metabolites are devoid of vasodilating properties. Approximately 70% of a given dose is excreted as metabolites in the urine and about 10% with the faeces. Less than 0.5% of the dose is excreted unchanged in the urine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: possibly increased aminophylline and theophylline concentration.
- Anaesthetics: enhanced hypotensive effect.
- Antibacterials metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone.
- Antifungals: metabolism inhibited by itraconazole and ketoconazole; negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antivirals: concentration possibly increased by ritonavir; use with caution with telaprevir.
- Grapefruit juice: concentration increased – avoid concomitant use.
- Tacrolimus: possibly increased tacrolimus concentration.

### Administration

#### Reconstitution

- **Route**: Oral

#### Rate of administration

- **Rate of administration**:
Fenofibrate

**Clinical use**

Treatment of hyperlipidaemias types IIa, IIb, III, IV and V

**Dose in normal renal function**

Depends on preparation

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>360.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.89</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>20 / 140–360</td>
</tr>
</tbody>
</table>

**Metabolism**

After oral administration, fenofibrate is rapidly hydrolysed by esterases to the active metabolite fenofibric acid.

No unchanged fenofibrate can be detected in the plasma. Fenofibric acid is excreted mainly in the urine, mainly as the glucuronide conjugate, but also as a reduced form of fenofibric acid and its glucuronide; practically all the drug is eliminated from the body within 6 days.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–60</td>
<td>134 mg daily.</td>
</tr>
<tr>
<td>15–20</td>
<td>67 mg daily.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Avoid.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dosage Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Avoid.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Avoid.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Avoid.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=15–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant use.
- Anticoagulants: enhances effect of coumarins and phenindione; dose of anticoagulant should be reduced by up to 50% and readjusted by monitoring INR.
- Antidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureas.
- Ciclosporin: ciclosporin levels appear to be unaffected; however, it is recommended that concomitant therapy should be avoided because of the possibility of elevated serum creatinine levels.
- Colchicine: possible increased risk of myopathy.
- Lipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe (maximum 20 mg of rosvuastatin); increased risk of cholelithiasis and gallbladder disease with ezetimibe – avoid with ezetimibe.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- A few studies have noted that use of second-generation fibrates in transplant recipients is hampered by frequent rises in serum creatinine.
- Avoid use in patients with GFR<10 mL/min due to increased risk of rhabdomyolysis.
- Contraindicated by some manufacturers if eGFR<30 mL/min/1.73m² and advise a dose of 67 mg once daily if eGFR= 30–59 mL/min/1.73m².
Fenoprofen

Clinical use
NSAID and analgesic

Dose in normal renal function
300–600 mg 3–4 times a day; maximum 3 g daily.

Pharmacokinetics
Molecular weight (daltons) 558.6 (as calcium salt)
% Protein binding >99
% Excreted unchanged in urine 2–5
Volume of distribution (L/kg) 0.10
Half-life — normal/ESRF (hrs) 3 / Unchanged

Metabolism
Approximately 90% of a dose is excreted in the urine in 24 hours, chiefly as the glucuronide and the glucuronide of hydroxylated fenoprofen.

Dose in renal impairment GFR (mL/min)
20–50 Start with low dose, but avoid if possible.
10–20 Start with low dose, but avoid if possible.
<10 Start with low dose, but only use if on dialysis.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Start with low doses and increase according to response. See ‘Other information’.
HD Not dialysed. Start with low doses and increase according to response. See ‘Other information’.
HDF/High flux Not dialysed. Start with low doses and increase according to response. See ‘Other information’.
CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min. See ‘Other information’.

Important drug interactions
Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: increased risk of hyperkalaemia and nephrotoxicity; reduced hypotensive effect.
- Analgesics: avoid concomitant use with other NSAIDs or aspirin; avoid concomitant use with ketorolac (increased side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs or venlafaxine.
- Antidiabetics: effects of sulphonylureas enhanced.
- Antiepileptics: possibly enhanced effect of phenytoin.
- Antivirals: concentration possibly increased by ritonavir; increased risk of haematological toxicity with zidovudine.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion reduced.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Contraindicated in patients with history of significantly impaired renal function.
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid use if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if it has increased, discontinue therapy.
- Possibility of decreased platelet aggregation.
- Can use normal doses in patients with ERF on dialysis.
- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
- Associated with nephrotic syndrome, interstitial nephritis, hyperkalaemia, sodium retention.
Fentanyl

**Clinical use**

Opioid analgesic:
- Short surgical procedures
- Ventilated patients
- Chronic intractable pain

**Dose in normal renal function**

- IV injection:
  - with spontaneous respiration: 50–200 mcg, then 25–50 mcg as required.
  - with assisted ventilation: 0.3–3.5 mg, then 100–200 mcg as required.
- IV infusion:
  - with spontaneous respiration: 3–4.8 micrograms/kg/hour adjusted according to response.
  - with assisted ventilation: 10 mcg/kg over 10 minutes, then 6 mcg/kg/hour, may require up to 180 mcg/kg/hr during cardiac surgery.
- Topical (chronic pain): Initially 12–25 mcg/hour, patches changed every 72 hours according to response.
- Oral: varies according to preparation see SPC for more information.
- Nasal spray: varies according to preparation see SPC for more information.

**Pharmacokinetics**

- Molecular weight (daltons): 336.5
- % Protein binding: 80–85
- % Excreted unchanged in urine: <7
- Volume of distribution (L/kg): 4
- Half-life — normal/ESRF (hrs): 2–7 / Possibly increased

**Metabolism**

Fentanyl is metabolised in the liver by N-dealkylation and hydroxylation via the cytochrome P450 isoenzyme CYP3A4. Metabolites and some unchanged drug are excreted mainly in the urine. The short duration of action is probably due to rapid redistribution into the tissues rather than metabolism and excretion. The relatively longer elimination half-life reflects slower release from tissue depots. The main metabolites of fentanyl, which are excreted in the urine, have been identified as 4-N-(N-propionylanilino) piperidine and 4-N-(N-hydroxypropionylanilino) piperidine; 1-(2-phenethyl)-4-N-(N-hydroxypropionylanilino) piperidine is a minor metabolite. Fentanyl has no active or toxic metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as a % of Normal Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>75% of normal dose. Titrate according to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>75% of normal dose. Titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of normal dose. Titrate according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose as per GFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: metabolism increased by rifampicin.
- Antidepressants: possible CNS excitation or depression (hypertension or hypotension) in patients also receiving MAOIs (including moclobemide) – avoid concomitant use; possibly increased sedative effects with tricyclics.
- Antifungals: concentration increased by triazoles.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Antivirals: concentration increased by ritonavir; increased risk of ventricular arrhythmias with saquinavir - avoid.
- Cytotoxics: use crizotinib with caution.
- Dopaminergics: avoid with selegiline.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid concomitant use.
<table>
<thead>
<tr>
<th>Administration</th>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reconstitution</strong></td>
<td>• For short surgical procedures the degree of renal impairment is irrelevant.</td>
</tr>
<tr>
<td></td>
<td>• For other indications, renal impairment may have a moderate effect on the elimination of the drug; however, as fentanyl is titrated to response the usual dose and method of administration remains valid.</td>
</tr>
<tr>
<td><strong>Route</strong></td>
<td>• Doses in renal impairment are from <em>Drug Prescribing in Renal Failure</em>, 5th edition by Aronoff et al.</td>
</tr>
<tr>
<td>IV, IM, topically buccal, sublingual, intranasal</td>
<td>• Like other opiates, start with a low dose and titrate as tolerated.</td>
</tr>
<tr>
<td><strong>Rate of administration</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comments</td>
</tr>
<tr>
<td></td>
<td>Compatible with sodium chloride 0.9% and glucose 5%.</td>
</tr>
</tbody>
</table>
Ferric carboxymaltose

Clinical use

Ferric carboxymaltose complex:
- Treatment of iron deficiency anaemia (when oral treatment is ineffective or contraindicated)

Dose in normal renal function

Dose calculated according to weight

Pharmacokinetics

Molecular weight (daltons) Approx 150 000
% Protein binding No data
% Excreted unchanged in urine 0.0005
Volume of distribution (L/kg) 3 Litres
Half-life — normal/ESRF (hrs) 7–12 / –

Metabolism

Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Dimercaprol: avoid concomitant use.
- Oral iron: reduced absorption.

Administration

Reconstitution

Route
IV

Rate of administration

Bolus (undiluted): 200–500 mg at a rate of 100 mg/min
Doses >500 mg over 15 minutes

Comments

- Doses 100–200 mg can be added to a maximum of 50 mL sodium chloride 0.9%
- Doses 200–500 mg can be added to a maximum of 100 mL sodium chloride 0.9%
- Doses >500 mg can be added to a maximum of 250 mL sodium chloride 0.9%
- Patients should be monitored during and for 30 minutes after administration.

Other information

- After a single 100 mg IV iron dose of ferric carboxymaltose (n=6) injected over 1 min, serum iron concentration peaked at a mean of 15 min. After 500, 800 or 1000 mg iron in 250 mL normal saline infused over 15 min (n=6 for each dose), serum iron concentration peaked at means of 20 min, 1 hour and 1.2 hours, respectively. (http://www.medsafe.govt.nz/profs/datasheet/f/ferinjectinj.pdf).

Reference:
### Ferrous fumarate

#### Clinical use
Iron deficiency anaemia

#### Dose in normal renal function
Dose varies according to preparation

#### Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>169.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>—</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>—</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>—</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>—</td>
</tr>
</tbody>
</table>

#### Metabolism
Following absorption, the majority of iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin. The remainder is stored within ferritin or haemosiderin or is incorporated into myoglobin with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts are excreted as the body reabsorbs the iron after the haemoglobin has broken down.

#### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose details</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

#### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Not dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function.

#### Important drug interactions
Potentially hazardous interactions with other drugs
- **Antibacterials**: reduced absorption of 4-quinolones and tetracyclines.
- **Dimercaprol**: avoid concomitant use.
- **Mycophenolate**: may significantly reduce absorption of mycophenolate.

#### Administration

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Absorption of iron may be enhanced with concurrent administration of ascorbic acid.
  - Phosphate binding agents, e.g. calcium carbonate or magnesium carbonate, reduce absorption of iron from the gut.
  - Absorption may be impaired in patients with CKD due to upregulation of hepcidin – consider using IV iron.
  - Monitor: serum iron, transferrin saturation and ferritin levels (in line with local policy).
Ferrous gluconate

Clinical use
Iron deficiency anaemia

Dose in normal renal function
Prophylaxis: 2 tablets daily
Therapeutic: 4–6 tablets daily in divided doses

Pharmacokinetics
Molecular weight (daltons) 482.2
% Protein binding —
% Excreted unchanged in urine —
Volume of distribution (L/kg) —
Half-life — normal/ESRF (hrs) —

Metabolism
Following absorption, the majority of iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin. The remainder is stored within ferritin or haemosiderin or is incorporated into myoglobin with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts are excreted as the body reabsorbs the iron after the haemoglobin has broken down.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: reduced absorption of 4-quinolones and tetracyclines.
- Dimercaprol: avoid concomitant use.
- Mycophenolate: may significantly reduce absorption of mycophenolate.

Administration
Reconstitution

<table>
<thead>
<tr>
<th>Route</th>
<th>Rate of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

Other information
- One 300 mg ferrous gluconate tablet contains 35 mg elemental iron.
- Best taken before food to aid absorption.
- Phosphate binding agents, e.g. calcium carbonate or magnesium carbonate, reduce absorption of iron from the gut.
- Absorption may be impaired in patients with CKD due to upregulation of hepcidin – consider using IV iron.
- Monitor serum iron, transferrin saturation and ferritin levels (in line with local policy).
**Ferrous sulphate**

### Clinical use
Iron deficiency anaemia

### Dose in normal renal function
- **Prophylaxis:** 200 mg daily  
- **Therapeutic:** 200 mg 2–3 times daily  
- **M/R:** 1–2 tablets/capsules daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>278</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>—</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>—</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>—</td>
</tr>
<tr>
<td>Half-life normal/ESRF (hrs)</td>
<td>—</td>
</tr>
</tbody>
</table>

### Metabolism
Following absorption, the majority of iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin. The remainder is stored within ferritin or haemosiderin or is incorporated into myoglobin with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts are excreted as the body reabsorbs the iron after the haemoglobin has broken down.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD:** Not dialysed. Dose as in normal renal function.  
- **HD:** Not dialysed. Dose as in normal renal function.  
- **HDF/High flux:** Not dialysed. Dose as in normal renal function.  
- **CAV/VVHD:** Not dialysed. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs:
- **Antibacterials:** reduced absorption of 4-quinolones and tetracyclines.  
- **Dimercaprol:** avoid concomitant use.  
- **Mycophenolate:** may significantly reduce absorption of mycophenolate.

### Administration

#### Reconstitution
—

#### Route
Oral

#### Rate of administration
—

### Other information
- One 200 mg ferrous sulphate tablet contains 65 mg elemental iron.  
- Absorption of iron may be enhanced with concurrent administration of ascorbic acid.  
- Phosphate binding agents, e.g. calcium carbonate or magnesium carbonate, reduce absorption of iron from the gut.  
- Absorption may be impaired in patients with CKD due to upregulation of hepcidin – consider using IV iron.  
- Monitor: serum iron, transferrin saturation and ferritin levels (in line with local policy).
Fesoterodine fumarate

Clinical use
Antimuscarinic:
• Symptomatic treatment of urinary incontinence, frequency or urgency

Dose in normal renal function
4–8 mg once daily

Pharmacokinetics
Molecular weight (daltons) 527.7
% Protein binding 50 (metabolite)
% Excreted unchanged in urine 70 (as metabolites)
Volume of distribution (L/kg) 169 Litres
Half-life — normal/ESRF (hrs) 7 / –

Metabolism
Rapidly and extensively hydrolysed to its active metabolite. The active metabolite is further metabolised in the liver to its carboxy, carboxy-N-desisopropyl, and N-desisopropyl metabolites via two major pathways involving CYP2D6 and CYP3A4. None of these metabolites contribute significantly to the antimuscarinic activity of fesoterodine. Approximately 70% of an oral dose of fesoterodine is recovered in the urine as metabolites, and a smaller amount in the faeces.

Dose in renal impairment GFR (mL/min)
50–80 Dose as in normal renal function.
30–50 Dose as in normal renal function. See 'Other information'.
<30 4 mg daily. See 'Other information'.

Dose in patients undergoing renal replacement therapies
APD/CAPD Probably dialysed. Dose as in GFR<30 mL/min.
HD Probably dialysed. Dose as in GFR<30 mL/min.
HDF/High flux Probably dialysed. Dose as in GFR<30 mL/min.
CAV/VVHD Probably dialysed. Dose as in GFR=30–50 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.
• Antifungals: dose reduction advised with itraconazole and ketoconazole.
• Antivirals: dose reduction advised with atazanavir, indinavir, ritonavir and saquinavir.
• Induction of CYP3A4 may lead to subtherapeutic plasma levels. Concomitant use with CYP3A4 inducers (e.g. carbamazepine, rifampicin, phenobarbital, phenytoin, St John’s Wort) is not recommended.
• Co-administration of a potent CYP2D6 inhibitor may result in increased exposure and adverse events. A dose reduction to 4 mg may be needed’
• See ‘Other information’.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Bioavailability of active metabolite is 52%.
• UK licensed product information for fesoterodine fumarate states that patients with GFR=30–80 mL/min, should increase their dose with caution; those also receiving moderate CYP3A4 inhibitors should not exceed an oral dose of fesoterodine fumarate of 4 mg once daily, and concomitant potent CYP3A4 inhibitors are not recommended. Patients with GFR<30 mL/min and concomitant moderate or potent CYP3A4 inhibitors are advised not to take fesoterodine.
• In patients with GFR=30–80 mL/min, C\textsubscript{max} and AUC of the active metabolite increased up to 1.5- and 1.8-fold, respectively, as compared to healthy subjects. In patients with GFR<30 mL/min, C\textsubscript{max} and AUC are increased 2- and 2.3-fold, respectively.
Fexofenadine hydrochloride

**Clinical use**

Antihistamine:
- Symptomatic relief of rhinitis and urticaria

**Dose in normal renal function**

120–180 mg daily depending on condition

**Pharmacokinetics**

- Molecular weight (daltons) 538.1
- % Protein binding 60–70
- % Excreted unchanged in urine 10
- Volume of distribution (L/kg) 5–6
- Half-life — normal/ESRF (hrs) 11–15 / 19–25

**Metabolism**

Fexofenadine undergoes negligible metabolism (hepatic or non-hepatic); about 5% of the total dose is metabolised, mostly by the intestinal mucosa, with 0.5–1.5% of the dose undergoing hepatic biotransformation by the cytochrome P450 system. The major route of elimination is believed to be via biliary excretion while up to 10% of ingested dose is excreted unchanged through the urine.

**Dose in renal impairment GFR (mL/min)**

- 20–50 Dose as in normal renal function. Use with care.
- 10–20 Dose as in normal renal function. Use with care. See ‘Other information.’
- <10 Dose as in normal renal function. Use with care. See ‘Other information.’

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: effects possibly reduced by rifampicin.
- Antivirals: concentration possibly increased by ritonavir.
- Aluminium/magnesium containing antacids: reduced absorption – avoid for 2 hours.

**Administration**

Reconstitution
- Route
- Oral
- Rate of administration
- Comments
- Take before food.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Unlikely dialysability. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Other information**

- Start with lowest dose and increase carefully as higher doses may result in increased sedation in severe renal impairment.
Fidaxomicin

Clinical use

Macrolide antibacterial agent:
• Treatment of Clostridium Difficile infection

Dose in normal renal function

200 mg twice daily for 10 days

Pharmacokinetics

Molecular weight (daltons) 1058
% Protein binding No data
% Excreted unchanged in urine <1
Volume of distribution (L/kg) Unknown
Half-life — normal/ESRF (hrs) 8–10 / Unchanged

Metabolism

Mainly metabolised by hydrolysis in the gut at the isobutyryl ester to form its main and microbiologically active metabolite, OP-1118. Over 92% of a dose is excreted in the faeces as either fidaxomicin or OP-1118, although very small amounts of OP-1118 have been recovered in the urine.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
• Anti-arrythmics: avoid concomitant use with amiodarone and dronedarone.
• Antibacterials: avoid concomitant use with clarithromycin and erythromycin.
• Antifungals: avoid concomitant use with ketoconazole.
• Calcium channel blockers: avoid concomitant use with verapamil.
• Ciclosporin: increased fidaxomicin levels, avoid concomitant use.

Administration

Reconstitution —
Route Oral
Rate of administration —

Other information

• UK SPC advises to use with caution if GFR<30 mL/min due to lack of data.
• Dose in renal impairment is taken from the US data sheet.
• Volume of distribution is unknown due to minimal systemic absorption.
• Limited data suggest that there is no major difference in plasma concentration of fidaxomicin or its metabolite OP-1118 between patients with reduced renal function (CRCL< 50 mL/min) and patients with normal renal function (CRCL≥50 mL/min).
Filgrastim

Clinical use
Recombinant human granulocyte-colony stimulating factor (rhG-CSF):
• Treatment of neutropenia

Dose in normal renal function
0.1–1.2 MU/kg/day according to indication and patient response

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>18 800</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Very high</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.15</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3.5 / –</td>
</tr>
</tbody>
</table>

Metabolism
Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalisation of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function and titrate dose to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function and titrate dose to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function and titrate dose to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Cytotoxics: neutropenia possibly exacerbated with capecitabine, fluorouracil and tegafur.

Administration

Reconstitution
—

Route
IV, SC

Rate of administration
• IV: Over 30 minutes or continuous IV infusion over 24 hours.
• SC: Can give as continuous SC infusion over 24 hours.

Comments
• IV: Dilute with glucose 5% ONLY; minimum concentration 0.2 MU per mL – add Human Serum Albumin if concentration is less than 1.5 MU per mL.
• SC: Continuous infusion – dilute with 20 mL of glucose 5%.
• Dilute Neupogen may be adsorbed to glass and plastic materials – follow recommendations for dilution.

Other information
• One very small study (2–3 patients) concluded that body clearance of filgrastim was not affected by any degree of renal impairment.
**Clinical use**

- Benign prostatic hypertrophy (BPH)
- Male pattern baldness

**Dose in normal renal function**

- BPH: 5 mg daily
- Male pattern baldness: 1 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>372.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>≈93</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.07</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–8 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Finasteride is metabolised primarily via the cytochrome P450 3A4 enzyme subfamily. Following an oral dose of 14C-finasteride in man, two metabolites of the drug were identified that possess only a small fraction of the 5α-reductase inhibitory activity of finasteride. 39% of the dose was excreted in the urine in the form of metabolites (virtually no unchanged drug was excreted in the urine) and 57% of total dose was excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- None known

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Data sheet states that no dosage adjustment is required in renally impaired patients whose creatinine clearance is as low as 9 mL/min. No studies have been done in patients with creatinine clearance of less than 9 mL/min.
Fingolimod

Clinical use
Sphingosine 1-phosphate receptor modulator:
• Treatment of highly active relapsing-remitting multiple sclerosis

Dose in normal renal function
500 micrograms once daily

Pharmacokinetics
Molecular weight (daltons) 307.5 (343.9 as hydrochloride)
% Protein binding >99
% Excreted unchanged in urine 0
Volume of distribution (L/kg) 940–1460 litres
Half-life — normal/ESRF (hrs) 6–9 days / Unchanged

Metabolism
Transformed by reversible stereoselective phosphorylation to the pharmacologically active (S)-enantiomer of fingolimod phosphate. It is eliminated by oxidative biotransformation mainly via the cytochrome P450 4F2 isoenzyme and subsequent fatty acid-like degradation to inactive metabolites, and by formation of pharmacologically inactive non-polar ceramide analogues of fingolimod. The main enzyme involved in the metabolism of fingolimod is partially identified and may be either CYP4F2 or CYP3A4. 81% excreted as inactive metabolites in the urine and <2.5% in the faeces as metabolites and unchanged drug.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Anti-arrhythmics: possible increased risk of bradycardia with amiodarone, disopyramide and dronedarone.
• Antifungals: concentration increased by ketoconazole.
• Beta-blockers: possibly increased risk of bradycardia.
• Calcium channel blockers: possible increased risk of bradycardia with diltiazem and verapamil.

Administration
Reconstitution —
Route Oral
Rate of administration —

Other information
• Oral bioavailability is 93%.
• In patients with severe renal impairment, fingolimod C\text{max} and AUC are increased by 32% and 43%, respectively, and fingolimod-phosphate C\text{max} and AUC are increased by 25% and 14%, respectively, with no change in apparent elimination half-life. Based on these findings, no dose change is required in patients with renal impairment. The systemic exposure of two metabolites (M2 and M3) is increased by 3- and 13-fold, respectively. The toxicity of these metabolites is not known.
Flecainide acetate

Clinical use

Class Ic anti-arrhythmic agent:
- Ventricular arrhythmias and tachycardias

Dose in normal renal function

- Oral: Supraventricular arrhythmias: 100–300 mg daily in 2 divided doses.
- IV bolus: 2 mg/kg over 10–30 minutes (maximum 150 mg), then IV infusion of 1.5 mg/kg/hour for 1 hour, subsequently 0.1–0.25 mg/kg/hour; maximum 600 mg in 24 hours.

Pharmacokinetics

Molecular weight (daltons) 474.4
% Protein binding 32–58
% Excreted unchanged in urine 42
Volume of distribution (L/kg) 8.31
Half-life — normal/ESRF (hrs) 12–27 / 19–26

Metabolism

Flecainide is extensively metabolised (subject to genetic polymorphism), the 2 major metabolites being m-O-dealkylated flecainide and m-O-dealkylated lactam of flecainide, both of which may have some activity. Its metabolism appears to involve the cytochrome P450 isoenzyme CYP2D6, which shows genetic polymorphism. Flecainide is excreted mainly in the urine, approximately 30% as unchanged drug and the remainder as metabolites. About 5% is excreted in the faeces. Haemodialysis removes only about 1% of unchanged flecainide.

Dose in patients undergoing renal replacement therapies

APD/CAPD ≈1% dialysed.1 Dose as in GFR<10 mL/min.
HD ≈1% dialysed.1 Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Minimal removal. Dose as in GFR=10–35 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Anti-arrhythmics: concentration increased by amiodarone – halve dose of flecainide; increased myocardial depression with other anti-arrhythmics.
- Antidepressants: concentration increased by fluoxetine; increased risk of ventricular arrhythmias with tricyclics.
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antihypertensives: increased myocardial depression and bradycardia with beta-blockers; increased myocardial depression and asystole with verapamil.
- Antimalarials: concentration increased by quinine; avoid with artemether/lumefantrine.
- Antimuscarinics: increased risk of ventricular arrhythmias with tolterodine.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval and phenothiazines; increased risk of arrhythmias with clozapine.
- Antivirals: concentration possibly increased by fosamprenavir, indinavir, lopinavir, ritonavir and saquinavir; increased risk of ventricular arrhythmias – avoid; use telaprevir with caution.
- Diuretics: increased cardiac toxicity if hypokalaemia occurs.

Dose in renal impairment GFR (mL/min)

35–50 Dose as in normal renal function.
10–35 Oral: Initially 100 mg daily (or 50 mg twice daily). IV: Reduce dose by 50%. See ‘Other information’.
<10 Oral: Initially 100 mg daily (or 50 mg twice daily). IV: Reduce dose by 50%. See ‘Other information’.

Administration

Reconstitution
-

Route
Oral, IV bolus, IV infusion

Rate of administration
See ‘Other information’.
Comments

- Infusion: Dilute with 5% glucose infusion; if chloride containing solutions are used the injection should be added to a volume of not less than 500 mL, otherwise a precipitate will form.
- Trough plasma levels of 200–1000 nanograms/mL may be needed to obtain the maximum therapeutic effect. Plasma levels above 700–1000 nanograms/mL are associated with increased likelihood of adverse events.

Other information

- Manufacturer recommends frequent plasma level monitoring in severe renal impairment.
- Electrolyte disturbances should be corrected before using flecainide.

Reference:

Flucloxacillin

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

- Oral: 250–500 mg every 6 hours
- IV: 250 mg – 2 g every 6 hours
- IM: 250–500 mg every 6 hours
- Endocarditis: maximum 2 g every 4 hours if >85 kg
- Osteomyelitis: maximum 8 g daily in divided doses

**Pharmacokinetics**

- Molecular weight (daltons) 453.9
- % Protein binding 95
- % Excreted unchanged in urine 66–76
- Volume of distribution (L/kg) 0.13
- Half-life — normal/ESRF (hrs) 53–60 minutes / 135–173 minutes

**Metabolism**

In normal subjects approximately 10% of the flucloxacillin administered is metabolised to penicilloic acid. Excretion occurs mainly through the kidney. Between 65.5% (oral route) and 76.1% (parenteral route) of the dose administered is recovered in unaltered active form in the urine within 8 hours. A small portion of the dose administered is excreted in the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function up to a total daily dose of 4 g.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Reduces excretion of methotrexate.

**Administration**

**Reconstitution**

- IV: 250 mg and 500 mg in 5–10 mL water for injection; 1 g in 15–20 mL water for injection.
- IM: 250 mg in 1.5 mL water for injection; 500 mg in 2 mL water for injection.

**Route**

- IV, IM, oral

**Rate of administration**

- Bolus: 3–4 minutes
- Infusion: 30–60 minutes

**Comments**

Compatible with various infusion fluids.

**Other information**

- Monitor urine for protein at high doses.
- Sodium content of injection: 2.26 mmol/g.
- Monitor liver function tests in hypoalbuminaemic patients receiving high doses of flucloxacillin (e.g. CAPD patients).
Fluconazole

**Clinical use**

Antifungal agent

**Dose in normal renal function**

50–400 mg daily, maximum 800 mg daily (unlicensed dose)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>306.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>11–12</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>80</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.65–0.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>30 / 98</td>
</tr>
</tbody>
</table>

**Metabolism**

Fluconazole is metabolised only to a minor extent. Of a radioactive dose, only 11% is excreted as metabolites in the urine. The major route of excretion is renal, with approximately 80% of the administered dose appearing in the urine as unchanged medicinal product. Fluconazole clearance is proportional to creatinine clearance. There is no evidence of circulating metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>50–100% of normal dose</td>
<td>See ‘Other information’.</td>
</tr>
<tr>
<td>10–20</td>
<td>50–100% of normal dose</td>
<td>See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of normal dose</td>
<td>See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. 50% of normal dose daily, or 100% of normal dose 3 times a week after dialysis.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. 50% of normal dose daily, or 100% of normal dose 3 times a week after dialysis.</td>
</tr>
<tr>
<td>CAV/VVH</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CVVHD/HDF</td>
<td>Dialysed. 400–800 mg every 24 hours.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Aminophylline: concentration of aminophylline possibly increased.
- Analgesics: increases concentration of celecoxib – halve celecoxib dose; concentration of flurbiprofen, ibuprofen and methadone increased; increases concentration of parecoxib – reduce parecoxib dose; inhibits metabolism of alfentanil; concentration of fentanyl possibly increased.
- Anti-arrhythmics: avoid concomitant use with amiodarone due to risk of QT prolongation.
- Antibacterials: avoid with erythromycin; increases rifabutin levels – reduce dose; metabolism accelerated by rifampicin; concentration of bedaquiline possibly increased – avoid if fluconazole for >14 days.
- Anticoagulants: potentiate effect of coumarins.
- Antidepressants: avoid concomitant use with reboxetine; concentration of amitriptyline and nortriptiline increased.
- Antidiabetics: possibly enhances hypoglycaemic effect of nateglinide; increases concentration of sulphonylureas.
- Antiepileptics: increases fosphenytoin and phenytoin levels; possibly increased carbamazepine concentration.
- Antimalarials: avoid concomitant administration with artemether/lumefantrine and piperaquine with arteminol.
- Antipsychotics: increased risk of ventricular arrhythmias with pimozide – avoid concomitant use; possibly increases lurasidone concentration; possibly increased quetiapine levels – reduce dose of quetiapine.
- Antivirals: increases nevirapine, ritonavir, tipranavir and zidovudine levels, and possibly saquinavir: concentration of simeprevir possibly increased – avoid.
- Anxiolytics and hypnotics: increases diazepam and midazolam levels.
- Avanafil: concentration of avanafil possibly increased.
- Bosentan: increased bosentan levels – avoid concomitant use.
- Ciclosporin: increases blood/serum ciclosporin levels.
- Clopidogrel: possibly reduced antiplatelet effect.
- Cytotoxics: possibly increased side effects of cyclophosphamide; concentration of bosutinib and possibly olaparib increased – avoid or reduce dose of
bosutinib; possibly increases ibrutinib concentration – reduce ibrutinib dose; reduce dose of ruxolitinib.

- Dapoxetine: reduce dose of dapoxetine.
- Diuretics: increased eplerenone levels – avoid concomitant use; concentration of fluconazole increased by hydrochlorothiazide.
- Ergot alkaloids: increased risk of ergotism – avoid concomitant use.
- Guanfacine: possibly increased guanfacine dose – halve dose of guanfacine.
- Ivabradine: increased ivabradine levels – reduce initial dose.
- Ivacaftor: increased concentration of ivacaftor.
- Lipid-lowering drugs: possibly increased risk of myopathy with atorvastatin or simvastatin; concentration of fluvastatin increased possibly increased risk of myopathy; avoid with lomitapide.
- Retinoids: possibly increased risk of tretinoin toxicity.
- Sirolimus: may increase sirolimus concentration.
- Tacrolimus: increases blood/serum tacrolimus levels.
- Theophylline: possibly increases theophylline levels.

**Rate of administration**

IV: 5–10 mL/minute peripherally

**Comments**

Oral ≡ IV dose. Very high bioavailability.

**Other information**

- Oral bioavailability is 90%.
- Approximately 50% is removed during a 3-hour haemodialysis session.
- Has been used as adjunct to IV amphotericin and IP flucytosine in CAPD peritonitis.
- No dose adjustment is required for single dose therapy.
- Recurrent yeast peritonitis: Flucytosine 2000 mg orally stat, then 1000 mg daily in addition to fluconazole 150 mg IP or 200 mg orally on alternate days. Remove Tenckhoff if no response.
- Dose of 800 mg is appropriate in CRRT as long as dialysate flow rate is 2 L/hour and treating a relatively resistant organism.²

References:

Flucytosine

**Clinical use**
Antifungal agent

**Dose in normal renal function**
100–200 mg/kg per day in 4 divided doses

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>129.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>2–4</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>90</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.65–0.91</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–6 / 75–200</td>
</tr>
</tbody>
</table>

**Metabolism**
About 90% of a dose of flucytosine is excreted unchanged in the urine. A small amount of flucytosine may be metabolised to 5-fluorouracil.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–40</td>
<td>50 mg/kg 12 hourly</td>
</tr>
<tr>
<td>10–20</td>
<td>50 mg/kg 24 hourly</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50 mg/kg then dose according to levels. Dose of 0.5–1 g daily is usually adequate.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Dialysed. Give 50 mg/kg daily in 4 divided doses. Monitor levels.
- **HD** Dialysed. Dose as in GFR<10 mL/min, given post dialysis. Monitor trough level pre-dialysis, and reduce post-dialysis dose accordingly.
- **HDF/High flux** Dialysed. Dose as in GFR<10 mL/min, given post-dialysis. Monitor trough level pre-dialysis, and reduce post-dialysis dose accordingly.
- **CAV/VVHD** Dialysed. Give dose as in GFR=10–20 mL/min and monitor blood levels, predose. See ‘Other information’.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Cytarabine: concentration of flucytosine possibly reduced.

**Administration**

**Reconstitution**

**Route** Oral, IV peripherally through a blood filter

**Rate of administration** 20–40 minutes

**Other information**
- Monitor blood levels 24 hours after therapy commences. Pre-dose level 25–50 mg/L is usually adequate. Do not exceed 80 mg/L.
- 250 mL intravenous flucytosine infusion contains 34.5 mmol sodium.
- Bone marrow suppression more common in patients with renal impairment.
- Tablets available on named patient basis only.
- Can be given IP at a dose of 50 mg/L.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
## Fludarabine phosphate

### Clinical use

B-cell chronic lymphocytic leukaemia

### Dose in normal renal function

- **IV:** 25 mg/m\(^2\) daily for 5 days, repeated every 28 days
- **Oral:** 40 mg/m\(^2\) for 5 days every 28 days

### Pharmacokinetics

- **Molecular weight (daltons):** 365.2
- **% Protein binding:** 19–29
- **% Excreted unchanged in urine:** 40–60
- **Volume of distribution (L/kg):** 0.8–4
- **Half-life — normal/ESRF (hrs):** 20 / 24

### Metabolism

Intravenous fludarabine phosphate is rapidly dephosphorylated to fludarabine which is taken up by lymphocytes and rephosphorylated via the enzyme deoxycytidine kinase to the active triphosphate nucleotide. Clearance of fludarabine from the plasma is triphasic; elimination is mostly via renal excretion: 40–60% of an intravenous dose is excreted in the urine. The pharmacokinetics of fludarabine show considerable inter-individual variation.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–70</td>
<td>50–75% of normal dose.</td>
</tr>
<tr>
<td>10–30</td>
<td>50–75% of normal dose. Use with care.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of normal dose. Use with care.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD:** Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD:** Unknown dialysability. Dose as in GFR<10 mL/min.
- **HDF/High flux:** Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD:** Unknown dialysability. Dose as in GFR=10–30 mL/min.

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis.
- Cytotoxics: increased pulmonary toxicity with pentostatin (unacceptably high incidence of fatalities); increases intracellular concentration of cytarabine.

### Administration

**Reconstitution**

Reconstitute each vial with 2 mL of water to give a concentration of 25 mg/mL.

**Route**

IV, oral

**Rate of administration**

Infusion should be administered over 30 minutes.

**Comments**

- IV bolus in 10 mL of sodium chloride 0.9%.
- IV infusion in 100 mL of sodium chloride 0.9%.

### Other information

- Rapidly dephosphorylated in plasma to (2-F-9-ß-D-arabinofuranosyladenine) 2-F-ara-ATP, which is necessary for cellular uptake.
- Approximately 60% of an administered dose is excreted in the urine within 24 hours.
- Administer up to achievement of clinical response (usually 6 cycles) then discontinue.
- In a study, patients with a GFR=17–41 mL/min/m\(^2\) received 20 mg/m\(^2\) and those with a GFR<17 mL/min/m\(^2\) received 15 mg/m\(^2\). The patients with a GFR=17–41 mL/min/m\(^2\) had a similar AUC as patients with normal renal function receiving the full dose but the AUC was increased in those with a GFR<17 mL/min/m\(^2\). (Lichtman S, Etcubanas E, Budman DR. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. *Cancer Investigation* 2002; 20(7&8): 904–13.)
- Dose in severe renal impairment is from *Drug Prescribing in Renal Failure*, 5th edition by Aronoff et al.
Fludrocortisone acetate

Clinical use
Replacement therapy in adrenal insufficiency

Dose in normal renal function
50–300 micrograms daily

Pharmacokinetics
Molecular weight (daltons) 422.5
% Protein binding 70–80
% Excreted unchanged in urine 80% (as metabolites)
Volume of distribution (L/kg) Widely distributed
Half-life — normal/ESRF (hrs) 3.5 (Biological half-life 18–36 hours) / –

Metabolism
Fludrocortisone is hydrolysed to produce the non-esterified alcohol. In human volunteers, excretion through urine was about 80%, and it was concluded that about 20% were excreted by a different route. It is likely that, as for the metabolism of other steroids, excretion into the bile is balanced by re-absorption in the intestine and some part is excreted with the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antibacterials: metabolism accelerated by rifamycins; metabolism possibly inhibited by erythromycin; possibly reduce isoniazid concentration.
- Anticoagulants: efficacy of coumarins and phenindione may be altered.
- Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited by itraconazole and ketoconazole.
- Antivirals: concentration possibly increased by ritonavir.
- Cobicistat: concentration of fludrocortisone increased.
- Vaccines: high dose corticosteroids can impair immune response to vaccines – avoid concomitant use with live vaccines.

Administration

Reconstitution

Route
Oral

Rate of administration

Comments
Use for as short a time and as low a dose as possible.
Flumazenil

**Clinical use**
Reversal of sedative effects of benzodiazepines in anaesthetic, intensive care, and diagnostic procedures

**Dose in normal renal function**
- Initially 200 micrograms over 15 seconds, then 100 micrograms at 60 second intervals if required; usual dose range 300–600 micrograms; maximum dose 1 mg, or 2 mg in intensive care situations
- If drowsiness recurs, an IV infusion of 100–400 micrograms per hour may be given

**Pharmacokinetics**
- Molecular weight (daltons) 303.3
- % Protein binding 50
- % Excreted unchanged in urine <0.1
- Volume of distribution (L/kg) 0.6–1.1
- Half-life — normal/ESRF (hrs) 0.7–1.3 / Unchanged

**Metabolism**
Flumazenil is extensively metabolised in the liver. The carboxylic acid metabolite is the main metabolite in plasma (free form) and urine (free form and its glucuronide). This main metabolite showed no benzodiazepine agonist or antagonist activity in pharmacological tests.

Flumazenil is almost completely (99%) eliminated by non-renal routes. Practically no unchanged flumazenil is excreted in the urine, suggesting complete metabolic degradation of the drug. Elimination of radiolabelled drug is essentially complete within 72 hours, with 90–95% of the radioactivity appearing in urine and 5–10% in the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
IV injection, IV infusion

**Rate of administration**
See ‘Dose in normal renal function’.

**Comments**
Infusion: suitable diluents include sodium chloride 0.9%, sodium chloride 0.45% and glucose 5%.

**Other information**
- The half-life of flumazenil is shorter than those of diazepam and midazolam – patients should be closely monitored to avoid the risk of them becoming re-sedated.
Fluorouracil

Clinical use
Antineoplastic agent

Dose in normal renal function
- IV infusion: 15 mg/kg/day to a total dose of 12–15 g
- IV bolus: 12 mg/kg/day for 3 days, then 6 mg/kg on alternate days or 15 mg/kg once a week
- Maintenance: 5–15 mg/kg once a week
- Intra-arterial infusion: 5–7.5 mg/kg by continuous 24-hour infusion
- Or consult relevant local chemotherapy protocol

Pharmacokinetics
Molecular weight (daltons) 130.1
% Protein binding 10
% Excreted unchanged in urine 15
Volume of distribution (L/kg) 0.25–0.5
Half-life — normal/ESRF (hrs) 16 minutes / Unchanged

Metabolism
After intravenous injection fluorouracil is cleared rapidly from plasma. It is distributed throughout body tissues and fluids, and disappears from the plasma within about 3 hours. Within the target cell fluorouracil is converted to 5-fluorouridine monophosphate and floxuridine monophosphate (5-fluorodeoxyuridine monophosphate), the former undergoing conversion to the triphosphate which can be incorporated into RNA while the latter inhibits thymidylate synthetase. About 15% of an intravenous dose is excreted unchanged in the urine within 6 hours. Approximately 80% is inactivated mainly in the liver and is catabolised via dihydropyrimidine dehydrogenase (DPD) similarly to endogenous uracil, 60–80% is excreted as respiratory carbon dioxide; urea and other metabolites are also produced, and 2–3% by the biliary system.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Some removal likely. Dose as in normal renal function.
- HD Dialysed. Dose as in normal renal function.
- HDF/High flux Dialysed. Dose as in normal renal function.
- CAV/VVHD Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhances effect of coumarins.
- Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis.
- Cytotoxics: avoid with panitumumab.
- Folic acid: toxicity of fluorouracil increased – avoid.
- Metronidazole and cimetidine inhibit metabolism (increased toxicity).
- Temoporfin: increased skin photosensitivity with topical fluorouracil.

Administration
Reconstitution
Consult relevant local protocol.

Route
IV infusion: intermittent or continuous, IV injection, intra-arterial, topical

Rate of administration
- 30–60 minutes, 4 hours
- Or as a continuous infusion over 24 hours
- Or consult relevant local protocol.

Other information
- Use ideal body weight in patients showing obesity, ascites, and oedema.
Fluoxetine

Clinical use

SSRI antidepressant:
• Depressive illness
• Bulimia nervosa
• Obsessive compulsive disorder

Dose in normal renal function

20–60 mg daily depending on indication

Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>345.8 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>94.5</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>20–40</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td></td>
</tr>
<tr>
<td>Acute dosing</td>
<td>24–72</td>
</tr>
<tr>
<td>Unchanged</td>
<td>4–6</td>
</tr>
</tbody>
</table>

Half-life — normal/ESRF (hrs)

Chronic dosing: 4–6 days / Increased

Metabolism

Fluoxetine is extensively metabolised by the enzyme CYP2D6 in the liver to its primary active metabolite norfluoxetine (desmethylfluoxetine), by desmethylation. The elimination half-life of fluoxetine is 4–6 days and for norfluoxetine 4–6 days. Excretion is mainly (about 60%) via the kidney.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use low dose, or on alternate days and increase according to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

• Analgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol; concentration of methadone possibly increased.
• Anti-arrhythmics: increased flecainide concentration.
• Anticoagulants: effect of coumarins possibly enhanced; possibly increased risk of bleeding with dabigatran.

• Antidepressants: avoid concomitant use with MAOIs and moclobemide, increased risk of toxicity; avoid with St John’s wort; possibly enhanced serotonergic effects with duloxetine and mirtazapine; can increase concentration of tricyclics; increased agitation and nausea with tryptophan; possible increased risk of convulsions with vortioxetine.

• Antiepileptics: antagonism (lowered convulsive threshold); concentration of carbamazepine, fosphenytoin and phenytoin increased.
• Antimalarials: avoid with artemether/lumefantrine and piperazine with artemisin.

• Antipsychotics: concentration of haloperidol, clozapine and risperidone increased; possibly inhibits aripiprazole metabolism – reduce aripiprazole dose; increased risk of ventricular arrhythmias with droperidol and pimozide – avoid.

• Antivirals: concentration possibly increased by ritonavir.

• Anxiolytics and hypnotics: concentration of alprazolam increased.

• Ciclosporin: may increase ciclosporin concentration.
• Clopidogrel: possibly reduced antiplatelet effect.
• Dapoxetine: possible increased risk of serotonergic effects – avoid.
• Dopaminergics: increased risk of hypertension and CNS excitation with selegiline – avoid; increased risk of CNS toxicity with rasagiline – avoid.
• Hormone antagonists: metabolism of tamoxifen to active metabolite possibly reduced – avoid.
• 5HT,

• 5HT,

• Agonist: increased risk of CNS toxicity with sumatriptan; possibly increased risk of serotonergic effects with naratriptan.
• Lithium: increased risk of CNS effects (lithium toxicity reported).
• Methylphenidate: risk of CNS toxicity – avoid if possible.
**Administration**

Reconstitution
---

Route
Oral

Rate of administration
---

**Other information**

- Accumulation may occur in patients with severe renal failure during chronic treatment (metabolites are excreted renally).

- Choong-Ki L, Var T, Blaine TW. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. *Gen Hosp. Psychiat.* 1996; **18**(1): 8–13, studied 7 patients undergoing haemodialysis and concluded that the process of HD does not alter the pharmacokinetics of fluoxetine or its major metabolite. All patients received fluoxetine 20 mg per day for 8 weeks.

- *Drug Prescribing in Renal Failure, 5th* edition by Aronoff et al. advises to use 100% of dose.
Flupentixol

Clinical use

Antipsychotic:
- Schizophrenia and other psychoses
- Depression

Dose in normal renal function

- Psychosis:
  - Oral: 3–9 mg twice daily, max 18 mg daily
  - Deep IM: 50 mg 4 weekly to 300 mg 2 weekly; maximum dose 400 mg weekly; 20–40 mg every 2–4 weeks may be adequate in some patients
- Depression: 0.5–3 mg daily (doses above 2 mg should be in 2 divided doses, and 2nd dose should not be after 4 pm)

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>434.5 (588.8 as decanoate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Negligible</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>12–14</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>22–36 (IM: 3–8 days) / Increased</td>
</tr>
</tbody>
</table>

Metabolism

Flupentixol is readily absorbed from the gastrointestinal tract after oral use and is probably subject to first-pass metabolism in the gut wall. It is also extensively metabolised in the liver and is excreted in the urine and faeces in the form of numerous metabolites; there is evidence of enterohepatic recycling. Paths of metabolism of flupentixol include sulfoxidation, side-chain N-dealkylation, and glucuronic acid conjugation.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with quarter to half of the dose and titrate slowly.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs:
- Alcohol: enhanced effects.
- Anaesthetics: enhanced hypotensive effects.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of arrhythmias with anti-arrhythmics that prolong the QT interval.
- Antidepressants: increased concentration of tricyclics; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: anticonvulsant effect antagonised.
- Antimalarials: avoid with artemether/lumefantrine.
- Antipsychotics: avoid clozapine with depot preparations in case of neutropenia; increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration possibly increased with ritonavir.
- Anxiolytics and hypnotics: increased sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.

Administration

Reconstitution

Route
Oral, IM

Rate of administration

—
### Other information

- May cause hypotension and sedation in renal impairment.
- Increased CNS sensitivity in renally impaired patients – start with small doses as can accumulate.

- For IM injection a 20 mg test dose should first be given.
- Oral bioavailability is 40–55%.
- Peak levels occur 7 days after IM injection and 4 hours after oral administration.
# Fluphenazine decanoate

## Clinical use

**Antipsychotic:**
- Schizophrenia and other psychoses

## Dose in normal renal function

<table>
<thead>
<tr>
<th>Dose (mg)</th>
<th>Interval (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.5–100</td>
<td>14–35</td>
</tr>
</tbody>
</table>

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>591.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>10</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–9 days / 14–26 days</td>
</tr>
</tbody>
</table>

## Metabolism

The cytochrome P450 isoenzyme CYP2D6 is involved in fluphenazine metabolism.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>As in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>As in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with a low dose and titrate slowly.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

- Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; increased risk of ventricular arrhythmias with amiodarone and dronedarone — avoid; increased risk of ventricular arrhythmias with disopyramide.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin — avoid.
- Antidepressants: increased risk of ventricular arrhythmias with tricyclics, citalopram, escitalopram; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: antagonises anticonvulsant effect.
- Antimalarials: increased risk of ventricular arrhythmias with arteether/lumefantrine — avoid.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol, pimozide and risperidone — avoid; avoid use of depot formulations with clozapine (cannot be withdrawn quickly if neutropenia occurs).
- Antituberculosis: increased risk of ventricular arrhythmias with saquinavir — avoid; concentration possibly increased with ritonavir.
- Anxiolytics and hypnotics: increased sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Diuretics: enhanced hypotensive effect.
- Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
- Pentamidine: increased risk of ventricular arrhythmias — avoid.
- Avoid with drugs that prolong the QT interval.

## Administration

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Rate of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM</td>
<td>—</td>
</tr>
</tbody>
</table>
Flurbiprofen

**Clinical use**
NSAID and analgesic

**Dose in normal renal function**
- 150–200 mg daily in divided doses, increased in acute conditions to 300 mg daily
- Dysmenorrhoea: 50–100 mg every 4–6 hours; maximum 300 mg daily

**Pharmacokinetics**
- Molecular weight (daltons) 244.3
- % Protein binding 99
- % Excreted unchanged in urine <3
- Volume of distribution (L/kg) 0.1–0.2
- Half-life — normal/ESRF (hrs) 3–6 / Unchanged

**Metabolism**
Flurbiprofen is metabolised mainly by hydroxylation (via the cytochrome P450 isoenzyme CYP2C9) and conjugation in the liver and excreted in the urine. The rate of urinary excretion of flurbiprofen and its two major metabolites ([2-(2-fluoro-4′-hydroxy-4-biphenylyl) propionic acid] and [2-(2-fluoro-3′-hydroxy-4′-methoxy-4-biphenylyl) propionic acid]) in both free and conjugated states is similar for both the oral and rectal routes of administration.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function, but avoid if possible.
- 10–20: Dose as in normal renal function, but avoid if possible.
- <10: Dose as in normal renal function, but only if on dialysis.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Removal very unlikely. Dose as in GFR<10 mL/min. See ‘Other information’.
- HD: Removal very unlikely. Dose as in GFR<10 mL/min. See ‘Other information’.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min. See ‘Other information’.
- CAV/VVHD: Removal very unlikely. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use with other NSAIDs or aspirin; avoid concomitant use with ketorolac (increased side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs or venlafaxine.
- Antidiabetics: effects of sulphonylureas enhanced.
- Antiepileptics: possibly enhanced effect of phenytoin.
- Antivirals: concentration possibly increased by ritonavir; increased risk of haematological toxicity with zidovudine.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion reduced (risk of lithium toxicity).
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- NSAIDs have been reported to cause nephrotoxicity in various forms; interstitial nephritis, nephrotic syndrome and renal failure. In patients with renal, cardiac or hepatic impairment, caution is required since the use of NSAIDs may result in deterioration of renal function.
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function,
especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if creatinine has increased, discontinue therapy.

- Use normal doses in patients with ERF on dialysis if they do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
**Flutamide**

**Clinical use**

Treatment of advanced prostate cancer

**Dose in normal renal function**

250 mg every 8 hours; start 3 days before LHRH agonist

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>276.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>45</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6 / Slightly increased</td>
</tr>
</tbody>
</table>

( active metabolite)

**Metabolism**

It is rapidly and extensively metabolised; the major metabolite (2-hydroxyflutamide) possesses anti-androgenic properties. Both flutamide and 2-hydroxyflutamide are more than 90% bound to plasma proteins. Excretion is mainly in the urine with only minor amounts appearing in the faeces.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anticoagulants: effects of coumarins enhanced

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Administration**

**Reconstitution**

[Blank]

**Route**

Oral

**Rate of administration**

[Blank]
Fluvastatin

Clinical use

HMG CoA reductase inhibitor:
- Primary hypercholesterolaemia
- Slowing progression of atherosclerosis
- Secondary prevention of coronary events after percutaneous coronary intervention

Dose in normal renal function

- 20–80 mg daily in the evening
- XL: 80 mg daily

Pharmacokinetics

Molecular weight (daltons) 433.4 (as sodium salt)
% Protein binding >98
% Excreted unchanged in urine 6
Volume of distribution (L/kg) 0.35
Half-life — normal/ESRF (hrs) 1.4–3.2 / Unchanged

Metabolism

Fluvastatin is rapidly and completely absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism in the liver. Metabolism is mainly by the cytochrome P450 isoenzyme CYP2C9, with only a small amount metabolised by CYP3A4. The major components circulating in the blood are fluvastatin and the pharmacologically inactive N-desisopropyl-propionic acid metabolite. The hydroxylated metabolites have pharmacological activity but do not circulate systemically. About 93% is excreted in the faeces, mainly as metabolites, with only about 6% being excreted in the urine.

Dose in renal impairment GFR (mL/min)

30–50 Dose as in normal renal function.
10–30 Dose as in normal renal function. See 'Other information'.
<10 Dose as in normal renal function. See 'Other information'.

Dose in patients undergoing renal replacement therapies

APD/CAPD Removal unlikely. Dose as in GFR<10 mL/min.
HD Removal unlikely. Dose as in GFR<10 mL/min.
HDF/High flux Removal unlikely. Dose as in GFR<10 mL/min.
CAV/VVHD Removal unlikely. Dose as in GFR=10–30 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: rifampicin increases metabolism; increased risk of myopathy with daptomycin; avoid for 7 days after last dose of fusidic acid.
- Anticoagulants: anticoagulant effect enhanced.
- Antiepileptics: concentration of either or both drugs may be increased with fosphenytoin and phenytoin.
- Antifungals: concentration increased by fluconazole — increased risk of myopathy.
- Antivirals: possible increased risk of myopathy with ledipasvir — reduce fluvastatin dose; avoid with paritaprevir.
- Ciclosporin: concomitant treatment with ciclosporin may lead to risk of muscle toxicity.
- Colchicine: isolated cases of myopathy have been reported.
- Lipid-lowering drugs: increased risk of myopathy with gemfibrozil, fibrates and nicotinic acid — avoid with gemfibrozil.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information

- The Committee on Safety of Medicines has advised that rhabdomyolysis associated with lipid-lowering drugs, such as the fibrates and statins, appears to be rare (approx. 1 case in every 100 000 treatment years), but may be increased in those with renal impairment and possibly in those with hypothyroidism.
- Manufacturer advises to use doses above 40 mg in patients with GFR<30 mL/min with caution due to lack of data.
- Drug Prescribing in Renal Failure, 5th edition by Aronoff et al. advises to use 100% of dose.
**Clinical use**

SSRI antidepressant:
- Depression
- Obsessive compulsive disorder

**Dose in normal renal function**

- 50–300 mg daily (doses over 150 mg in divided doses)
- Depression: usual maintenance dose 100 mg daily
- Obsessive compulsive disorder: usual maintenance dose 100–300 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>434.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>80</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>25</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>13–15 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Fluvoxamine undergoes extensive hepatic transformation by CYP2D6, mainly via oxidative demethylation, into at least 9 metabolites. The 2 major metabolites showed negligible pharmacological activity. The other metabolites are not expected to be pharmacologically active. Excretion is mainly in the urine; about 2% of a dose is excreted as unchanged drug.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dosage as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dosage as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dosage as in normal renal function but titrate slowly.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Aminophylline and theophylline: increased aminophylline and theophylline concentrations – avoid; if not possible, halve aminophylline or theophylline dose and monitor levels.
- Analgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol; concentration of methadone possibly increased.
- Anti-arrhythmics: increased risk of toxicity with mexiletine.
- Anticoagulants: effect of coumarins possibly enhanced; possibly increased risk of bleeding with dabigatran.
- Antidepressants: avoid with reboxetine, MAOIs, moclobemide and St John’s wort; possibly enhanced serotonergic effects with mirtazapine; fluvoxamine inhibits metabolism of duloxetine – avoid; can increase tricyclics concentration; metabolism of agomelatine reduced; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: antagonise anticonvulsant threshold; concentration of carbamazepine, fosphenytoin and phenytoin increased.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with artemirol.
- Antipsychotics: concentration of asenapine, haloperidol, clozapine and olanzapine increased; increased risk of ventricular arrhythmias with droperidol and possibly pimozide – avoid.
- Antivirals: concentration possibly increased by ritonavir.
- Ciclosporin: may increase ciclosporin concentration.
- Clopidogrel: possibly reduced antiplatelet effect.
- Cytotoxics: concentration of pomalidomide increased.
- Dapoxetine: possible increased risk of serotonergic effects – avoid.
- Dopaminergics: increased risk of CNS toxicity with rasagiline – avoid; hypertension and CNS excitation with selegiline – avoid.
- 5HT, agonists: risk of CNS toxicity increased with sumatriptan; possibly increased risk of serotonergic effects with naratriptan; inhibits metabolism of frovatriptan; possibly inhibits metabolism of zolmitriptan – reduce zolmitriptan dose.
- Linezolid: use with care, possibly increased risk of side effects.
- Lithium: increased risk of CNS effects – monitor levels.
- Melatonin: concentration of melatonin increased – avoid.
- Methylthioninium: risk of CNS toxicity – avoid if possible.
- Muscle relaxants: increased risk of toxicity with tizanidine – avoid.
- Pirfenidone: concentration of pirfenidone increased – avoid.
Folic acid

**Clinical use**
- Folate-deficient megaloblastic anaemia
- Supplement in HD patients

**Dose in normal renal function**
5 mg daily for 4 months, then weekly according to response
Maintenance: 5 mg every 1–7 days

**Pharmacokinetics**
- Molecular weight (daltons) 441.4
- % Protein binding 70
- % Excreted unchanged in urine Varies with daily dose
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 2.5 / –

**Metabolism**
Folic acid given therapeutically enters the portal circulation largely unchanged, since it is a poor substrate for reduction by dihydrofolate reductase. It is converted to the metabolically active form 5-methyltetrahydrofolate in the plasma and liver. Folate undergoes enterohepatic circulation. Folate metabolites are eliminated in the urine and folate in excess of body requirements is excreted unchanged in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50  Dose as in normal renal function.
- 10–20  Dose as in normal renal function.
- <10  Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Dialysed. Dose as in normal renal function.
- HD Dialysed. Dose as in normal renal function.
- HDF/High flux Dialysed. Dose as in normal renal function.
- CAV/VVHD Dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antiepileptics: reduces phenytoin, primidone and phenobarbital levels.
- Cytotoxics: avoid with raltitrexed.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- If seriously folate deficient, give 10 mg/day for 1 month, then 5 mg/day.
- Doses up to 15 mg daily have been used in cases of malabsorption.
- Most nutritionists recommend 0.5–1 mg folic acid daily for patients on HD or CAPD; may accumulate in uraemic patients.
- Dosage used by dialysis units varies from 5 mg daily to 5 mg once weekly.
Folinic acid (calcium folinate)

**Clinical use**
- Folinic acid rescue
- Enhancement of 5-fluorouracil cytotoxicity in advanced colorectal cancer
- Folate deficiency

**Dose in normal renal function**
Varies according to indication

**Pharmacokinetics**
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>511.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>54</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>80–90 (as inactive metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>17.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>32–35 minutes / –</td>
</tr>
</tbody>
</table>

**Metabolism**
Folinic acid is a racemate where the L-form (L-5-formyl-tetrahydrofolate, L-5-formyl-THF), is the active enantiomer. The major metabolic product of folinic acid is 5-methyl-tetrahydrofolic acid (5-methyl-THF) which is predominantly produced in the liver and intestinal mucosa.

80–90% with the urine (5- and 10-formyl-tetrahydrofolic acid inactive metabolites), 5–8% with the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Some removal likely. Dose as in normal renal function.
- HD Some removal likely. Dose as in normal renal function.
- HDF/High flux Dialysed. Dose as in normal renal function.
- CAV/VVHD Some removal likely. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Should not be administered simultaneously with a folic acid antagonist as this may nullify the effect of the antagonist.
- Cytotoxics: avoid with panitumumab and raltitrexed.

**Administration**

**Reconstitution**

**Route**
IM, IV injection, IV infusion, oral

**Rate of administration**
Because of the calcium content of leucovorin solutions, no more than 160 mg/minute should be injected IV.

**Comments**
For IV infusion, compatible with: sodium chloride 0.9%, glucose 5%, sodium lactate injection.
Fondaparinux sodium

Clinical use
- Prophylaxis of deep vein thrombosis
- Treatment of deep vein thrombosis, pulmonary embolism, unstable angina and after a myocardial infarction

Dose in normal renal function
Prophylaxis DVT:
- Surgical: 2.5 mg 6 hours after surgery, then 2.5 mg daily
- Medical: 2.5 mg daily
- Treatment of superficial-vein thrombosis: 2.5 mg daily (if weight >50 kg)
- Unstable angina and MI: 2.5 mg daily

Treatment DVT and PE:
- <50 kg: 5 mg daily
- 50–100 kg: 7.5 mg daily
- >100 kg: 10 mg daily

Dose in renal impairment GFR (mL/min)
- 20–50: 1.5 mg daily. See ‘Other information’.
- 10–20: Reduce dose. See ‘Other information’.
- <10: Reduce dose. See ‘Other information’.

Pharmacokinetics
- Molecular weight (daltons) 1728
- % Protein binding 97–98.6 (to anti-thrombin)
- % Excreted unchanged in urine 64–77
- Volume of distribution (L/kg) 0.1–0.12
- Half-life — normal/ESRF (hrs) 17–21 / 72

Metabolism
Although not fully evaluated, there is no evidence of fondaparinux metabolism and in particular no evidence for the formation of active metabolites.
Fondaparinux is excreted to 64–77% by the kidney as unchanged compound.

Important drug interactions
Potentially hazardous interactions with other drugs
- Increased risk of bleeding in combination with any other drugs that affect coagulation.

Administration
Reconstitution
Route
SC
Rate of administration

Other information
- In patients with a GFR of 30–50 mL/min and weight >100 kg, give an initial dose of 10 mg then reduce to 7.5 mg daily for treatment of a DVT; use with caution.
- Manufacturer advises to avoid in severe renal impairment due to increased risk of bleeding.
- Clearance of fondaparinux increases by up to 20% during haemodialysis.
- Has been used successfully at a dose of 2.5 mg for concomitant treatment of a DVT and dialysis anticoagulation every 48 hours for 10 weeks without any problems. (Haase M, Bellomo R, Rocktaeschel J, et al. Use of fondaparinux (arixtra) in a dialysis patient with symptomatic heparin-induced thrombocytopenia type II. Nephrol Dial Transplant. 2005 Feb; 20(2): 444–6.)
- It has also been used for dialysis anticoagulation at a dose of 2.5 mg daily for 4 hours of dialysis using low flux dialysers. Although anti-Xa levels were still increased before the next dialysis session, increasing the bleeding risk. (Sombolos KI, Fragia TK, Gionanlis LC, et al. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. Int J Clin Pharmacol Ther. 2008; 46(4):198–203.)
- Some units have used fondaparinux for haemodiafiltration in doses ranging from 2.5–5 mg pre dialysis.
- The following study recommends an initial dose of 0.03 mg/kg pre dialysis for dialysis anticoagulation. (Mahieu E, Claes K, Jacquemin M, et al. Anticoagulation with fondaparinux during hemodialysis: a preliminary study. Artif Organs. 2013; 37(5):482–7.)

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.
# Formoterol fumarate (eformoterol)

## Clinical use
Long acting selective beta-2 agonist

## Dose in normal renal function
- 1–2 puffs twice daily
- Turbohaler: 6–24 mcg 1–2 times daily as a single dose, up to 72 mcg daily may be needed

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>804.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>61–64</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>6.4–8</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8 / –</td>
</tr>
</tbody>
</table>

## Metabolism
Formoterol is eliminated primarily by metabolism, direct glucuronidation being the major pathway of biotransformation, with O-demethylation followed by further glucuronidation being another pathway. Minor pathways involve sulphate conjugation of formoterol and deformylation followed by sulphate conjugation.

After a single oral dose of $^3$H-formoterol, 59–62% of the dose was recovered in the urine and 32–34% in the faeces. Approximately 6.4–8% of the dose was recovered in the urine as unchanged formoterol, with the (R,R) and (S,S)-enantiomers contributing 40% and 60% respectively.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs
- None known

## Administration
### Reconstitution
—

### Route
Inhaled

### Rate of administration
—
Fosamprenavir

Clinical use
Protease inhibitor:
• For HIV infection, in combination with other antiretroviral drugs

Dose in normal renal function
700 mg twice daily with ritonavir 100 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 625.7 (as calcium salt)
% Protein binding 90 (amprenavir)
% Excreted unchanged in urine <1 (amprenavir)
Volume of distribution (L/kg) 6 (amprenavir)
Half-life — normal/ESRF (hrs) 7.7 / Unchanged (amprenavir)

Metabolism
Fosamprenavir is rapidly and almost completely hydrolysed to amprenavir and inorganic phosphate as it is absorbed through the gut epithelium, following oral administration. The primary route of metabolism of amprenavir is via the cytochrome P450 3A4 enzyme. The primary route of elimination of amprenavir is via hepatic metabolism with less than 1% excreted unchanged in the urine and no detectable amprenavir in faeces. Metabolites account for approximately 14% of the administered amprenavir dose in the urine, and approximately 75% in the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Anti-arrhythmics: possibly increased concentration of amiodarone, flecainide, lidocaine and propafenone (increased risk of ventricular arrhythmias) – avoid.
• Antibacterials: increases concentration of rifabutin – reduce rifabutin dose; concentration significantly reduced by rifampicin – avoid; avoid with telithromycin in severe renal and hepatic impairment.
• Anticoagulants: avoid with apixaban and rivaroxaban.
• Antidepressants: concentration reduced by St John’s wort – avoid.
• Antimalarials: use artemether/lumefantrine with caution; possibly increases quinine concentration.
• Antipsychotics: possibly inhibits aripiprazole metabolism – reduce aripiprazole dose; possibly increases quetiapine concentration – avoid; possibly increases pimozide concentration (increased risk of ventricular arrhythmias) – avoid.
• Antivirals: avoid with boceprevir, raltegravir and telaprevir; concentration of dolutegravir reduced; concentration increased by etravirine, consider reducing fosamprenavir dose; concentration reduced by lopinavir, maraviroc and tipranavir, effect on lopinavir unpredictable – avoid, avoid with maraviroc; concentration possibly reduced by nevirapine; avoid with raltegravir.
• Anxiolytics and hypnotics: increased risk of prolonged sedation and respiratory depression with midazolam – avoid with oral midazolam.
• Avanafil: concentration of avanafil possibly increased.
• Cytotoxics: possibly increases concentration of bosutinib and ibrutinib, avoid or consider reducing bosutinib and ibrutinib dose.
• Ergot alkaloids: increased risk of ergotism – avoid.
• Immunosuppressants: monitor ciclosporin, tacrolimus and sirolimus levels.
• Lomitapide: avoid concomitant use.
• Orlistat: absorption possibly reduced by orlistat.
• Ranolazine: possibly increases ranolazine concentration – avoid.
• Statins: possibly increased risk of myopathy with atorvastatin; possibly increased myopathy with simvastatin and rosuvastatin – avoid.

Administration
Reconstitution
Route
Oral
Rate of administration
—

Other information

Prodrug of amprenavir, 700 mg of fosamprenavir is equivalent to 600 mg amprenavir.
Fosaprepitant

**Clinical use**

Prevention of acute and delayed nausea and vomiting associated with moderate and highly emetogenic cancer chemotherapy

**Dose in normal renal function**

150 mg 30 minutes before chemotherapy on day 1 of cycle

**Pharmacokinetics**

Molecular weight (daltons) 614.4
% Protein binding 97
% Excreted unchanged in urine 0
Volume of distribution (L/kg) 82 Litres
Half-life — normal/ESRF (hrs) 11 / Unchanged

**Metabolism**

Fosaprepitant is a prodrug and is rapidly metabolised to aprepitant. Aprepitant undergoes extensive hepatic metabolism, mainly via oxidation by the cytochrome P450 isoenzyme CYP3A4; the isoenzymes CYP1A2 and CYP2C19 mediate minor metabolic pathways. The resultant metabolites have weak activity and are excreted in the urine and in the faeces.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antidepressants: avoid with St John’s wort.
- Antipsychotics: avoid with pimozide.
- Cytotoxics: possibly increases bosutinib concentration – avoid or reduce bosutinib dose.
- Oestrogens and progestogens: may cause contraceptive failure.

**Administration**

**Reconstitution**
5 mL of sodium chloride 0.9%

**Route**
IV infusion

**Rate of administration**
20–30 minutes

**Comments**
Add to 145 mL of sodium chloride 0.9%

**Other information**

- Less than 0.2% of the dose is dialysed.
Foscanet sodium

Clinical use

Antiviral agent:
- Treatment and maintenance therapy of cytomegalovirus retinitis (CMV)
- Mucocutaneous herpes simplex infection (HSI)

Dose in normal renal function

- CMV: 60 mg/kg every 8 hours induction dose for 2–3 weeks, then 60 mg/kg daily, increase to 90–120 mg/kg if tolerated
- HSI: 40 mg/kg every 8 hours

Pharmacokinetics

- Molecular weight (daltons) 300
- % Protein binding 14–17
- % Excreted unchanged in urine 85
- Volume of distribution (L/kg) 0.4–0.6
- Half-life — normal/ESRF (hrs) 2–4 / >100

Metabolism

There is no metabolic conversion of foscarnet and it is eliminated by the kidneys as unchanged drug mainly through glomerular filtration, with some active tubular secretion.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose for CMV: mg/kg 8 hourly</th>
<th>Dose for HSV: mg/kg 8 hourly</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>28</td>
<td>35</td>
</tr>
<tr>
<td>10–20</td>
<td>15</td>
<td>33</td>
</tr>
<tr>
<td>&lt;10</td>
<td>6</td>
<td>28</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min. See ‘Other information.’
- HD: Dialysed. Dose as in GFR<10 mL/min. See ‘Other information.’
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min. See ‘Other information.’
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min. See ‘Other information.’

Important drug interactions

- Pentamidine: increased risk of hypocalcaemia with parenteral pentamidine.

Administration

Reconstitution

Route
Centrally (undiluted); peripherally (diluted).

Rate of administration
Continuous infusion over 24 hours,
OR intermittent infusion over at least 60 minutes

Comments
- If given peripherally dilute with glucose 5% or sodium chloride 0.9% to a concentration of 12 mg/mL or less.
- Alternatively, piggy-back the undiluted foscarnet dose to 1 Litre of a glucose 5% or sodium chloride 0.9% infusion.
- If given centrally, can be administered undiluted but additional fluids should be given to reduce the risk of nephrotoxicity.

Other information

- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Some renal units dose by creatinine clearance/weight as follows (Based on SPC):

Treatment doses for CMV and HSV

<table>
<thead>
<tr>
<th>Clearance mL/min/kg</th>
<th>Dose for CMV: mg/kg 8 hourly</th>
<th>Dose for HSV: mg/kg 8 hourly</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.6–1.4</td>
<td>55</td>
<td>37</td>
</tr>
<tr>
<td>1.4–1.2</td>
<td>49</td>
<td>33</td>
</tr>
<tr>
<td>1.2–1</td>
<td>42</td>
<td>28</td>
</tr>
<tr>
<td>1–0.8</td>
<td>35</td>
<td>24</td>
</tr>
<tr>
<td>0.8–0.6</td>
<td>28</td>
<td>19</td>
</tr>
<tr>
<td>0.6–0.4</td>
<td>21</td>
<td>14</td>
</tr>
<tr>
<td>0.4–0.2</td>
<td>14</td>
<td>9</td>
</tr>
<tr>
<td>0.2–0.1</td>
<td>10</td>
<td>5</td>
</tr>
</tbody>
</table>

Maintenance therapy doses for CMV

<table>
<thead>
<tr>
<th>Clearance mL/min/kg</th>
<th>Dose: mg/kg daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.6–1.4</td>
<td>55</td>
</tr>
<tr>
<td>1.4–1.2</td>
<td>49</td>
</tr>
<tr>
<td>1.2–1</td>
<td>42</td>
</tr>
<tr>
<td>1–0.8</td>
<td>35</td>
</tr>
<tr>
<td>0.8–0.6</td>
<td>28</td>
</tr>
<tr>
<td>0.6–0.4</td>
<td>21</td>
</tr>
</tbody>
</table>
Foscarnet sodium

<table>
<thead>
<tr>
<th>Clearance mL/min/kg</th>
<th>Dose: mg/kg daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4–0.2</td>
<td>14</td>
</tr>
<tr>
<td>0.2–0.1</td>
<td>10</td>
</tr>
</tbody>
</table>

- Maintain adequate hydration to prevent renal toxicity.
- Monitor serum calcium and magnesium.
- Some units use full-dose ganciclovir and half-dose foscarnet concomitantly for treatment of resistant CMV disease.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline:

  The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Fosfomycin

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
- Oral: 3 g sachet as a stat dose
- IV: 12–24 g in 2–3 divided doses depending on indication
- Bacterial meningitis: 16–24 g in 3–4 divided doses
- Maximum single dose is 8 g

**Pharmacokinetics**
- Molecular weight (daltons) 138.1 (259.2 as tromethamine)
- % Protein binding 0
- % Excreted unchanged in urine 80–90
- Volume of distribution (L/kg) 0.3
- Half-life — normal/ESRF (hrs) 2.9–8.5 / 40

**Metabolism**
Fosfomycin undergoes no biotransformation and is excreted mainly unchanged through the kidneys. This results in very high urinary concentrations (up to 3 mg/mL) within 2–4 hours of a dose. Therapeutic concentrations of 200–300 mcg/mL in urine are usually maintained for at least 36 hours, and can last from 48–72 hours.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Oral</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>31–40</td>
<td>Dose as in normal renal function.</td>
<td>Normal loading dose for 1st dose. 70% of dose in 2–3 divided doses.</td>
</tr>
<tr>
<td>21–30</td>
<td>Dose as in normal renal function.</td>
<td>Normal loading dose for 1st dose. 60% of dose in 2–3 divided doses.</td>
</tr>
<tr>
<td>11–20</td>
<td>Dose as in normal renal function.</td>
<td>Normal loading dose for 1st dose. 40% of dose in 2–3 divided doses.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Contraindicated due to prolonged half-life. See ‘Other information’.</td>
<td>Normal loading dose for 1st dose. 20% of dose in 1–2 divided doses.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
- Potentially hazardous interactions with other drugs
  - Metoclopramide: increases gastrointestinal motility and therefore lowers the serum concentration and urinary excretion of fosfomycin.

**Administration**

**Reconstitution**
2 g with 50 mL; 4 g with 100 mL; 8 g with 200 mL water for injection or glucose 5–10%.

**Route**
- IV, Oral

**Rate of administration**
- 2 g over at least 15 minutes
- 4 g over at least 30 minutes
- 8 g over at least 60 minutes

**Comments**
The displacement values for the reconstituted solutions are 1 mL for 2 g, 2 mL for 4 g and 4 mL for 8 g vials.

**Other information**
- Oral bioavailability is 34–41%.
- There is limited data in doses >16 g. Manufacturer advises to use with caution.
- Dose in CVVHF is using post-dilution, no information on pre-dilution.
- In 5 anuric patients undergoing haemodialysis, the half-life of fosfomycin during haemodialysis was 40 hours. In patients with varying degrees of renal impairment (creatinine clearances varying from 54 mL/min to 7 mL/min), the half-life of fosfomycin increased from 11 hours to 50 hours. The percentage of fosfomycin recovered in urine decreased from 32–11% indicating that renal impairment significantly decreases the excretion of fosfomycin.
• Development of bacterial resistance under therapy is a frequent occurrence and makes fosfomycin unsuitable for sustained therapy of severe infections.

• In severe renal impairment a 3 g dose can maintain therapeutic plasma levels for 7–10 days.
Fosinopril sodium

Clinical use

Angiotensin-converting enzyme inhibitor:
- Hypertension
- Heart failure

Dose in normal renal function

10–40 mg once daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>585.6</td>
</tr>
<tr>
<td>Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.15</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>11.5–14 / 14–32</td>
</tr>
</tbody>
</table>

Metabolism

Fosinopril acts as a prodrug of the diacid fosinoprilat, its active metabolite. Fosinopril is rapidly and completely hydrolysed to fosinoprilat in both gastrointestinal mucosa and liver. Fosinoprilat is excreted both in urine and in the faeces via the bile.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Start with low dose.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with low dose.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
- Bee venom extract: possible severe anaphylactoid reactions when used together.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of angioedema with everolimus.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Gold: flushing and hypotension with sodium aurothiomalate.
- Lithium: reduced excretion, possibility of enhanced lithium toxicity.
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

- Hepatobiliary elimination compensates for diminished renal excretion.
- Hyperkalaemia and other side effects more common in patients with impaired renal function.
- Close monitoring of renal function during therapy necessary in those with renal insufficiency.
- Renal failure has been reported in association with ACE inhibitors in patients with renal artery stenosis, post renal transplant, and those with congestive heart failure.
- High incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor – this combination should therefore be avoided.
Fosphenytoin sodium

**Clinical use**
- Control of status epilepticus
- Seizures associated with neurosurgery or head injury when oral phenytoin is not possible

**Dose in normal renal function**
- Status epilepticus:
  - Treatment: 20 mg PE/kg (loading dose) by IV infusion
  - Maintenance: 4–5 mg PE/kg daily in 1–2 divided doses
- Prophylaxis or treatment of seizures: 10–15 mg PE/kg by IV infusion; then convert to phenytoin or 4–5 mg PE/kg daily in 1–2 divided doses

**Pharmacokinetics**
- Molecular weight (daltons) 406.2
- % Protein binding 95–99
- % Excreted unchanged in urine 1–5
- Volume of distribution (L/kg) 4.3–10.8 Litres
- Half-life — normal/ESRF (hrs) 18.9 (IV), 41.2 (IM)

**Metabolism**
Fosphenytoin is rapidly and completely hydrolysed to phenytoin with a conversion half-life of about 15 minutes; one mmol of fosphenytoin yields one mmol of phenytoin. Phenytoin is hydroxylated in the liver to inactive metabolites chiefly 5-(4-hydroxyphenyl)-5-phenylhydantoin by an enzyme system which is saturable. Phenytoin undergoes enterohepatic recycling and is excreted in the urine, mainly as its hydroxylated metabolite, in either free or conjugated form.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus).
- 10–20: Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus).
- <10: Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus).

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: concentration of both drugs reduced with aminophylline and theophylline.
- Analgesics: enhanced effect with NSAIDs; metabolism of methadone accelerated; possibly increases pethidine toxicity.
- Anthelmintics: concentration of albendazole and praziquantel reduced; concentration of fosphenytoin possibly increased by levamisole.
- Anti-arrhythmics: increased concentration with amiodarone; concentration of disopyramide and possibly dronedarone reduced – avoid with dronedarone.
- Antibacterials: level increased by clarithromycin, chloramphenicol, isoniazid, metronidazole, sulphonamides and trimethoprim (+ antifolate effect); concentration increased or decreased by ciprofloxacin; concentration of bedaquiline, doxycline and telithromycin reduced – avoid with telithromycin; concentration of rifampicins.
- Anticoagulants: increased metabolism of coumarins (reduced effect but also reports of enhancement); possibly reduced apixaban, dabigatran, edoxaban and rivaroxaban concentration – avoid with dabigatran.
- Antidepressants: antagonise anticonvulsant effect; concentration increased by fluoxetine and fluvoxamine and possibly sertraline; concentration of mianserin, mirtazapine and paroxetine and possibly tricyclics reduced; concentration reduced by St John’s wort – avoid.
- Antiepileptics: concentration of both drugs reduced with carbamazepine, concentration may also be increased by carbamazepine, eslicarbazepine, ethosuximide, oxcarbazepine, stripentol and topiramate; concentration of ethosuximide, active oxcarbazepine metabolite, reitigabine, rufinamide (concentration of phenytoin possibly increased), topiramate and valproate possibly reduced; concentration of eslicarbazepine, ethosuximide, lamotrigine, perampanel, tiagabine and zonisamide reduced; concentration of phenobarbital often
increased; phenobarbital and valproate may alter concentration; concentration reduced by vigabatrin.

- **Antifungals:** concentration of ketoconazole, itraconazole, posaconazole, voriconazole and possibly isavuconazole and caspofungin reduced – avoid with isavuconazole and itraconazole, increase voriconazole dose and possibly caspofungin; levels increased by fluconazole, miconazole and voriconazole – consider reducing fosphenytoin dose.

- **Antimalarials:** avoid with piperaquine with artemimol, mefloquine and pyrimethamine – antagonise anticonvulsant effect; increased antifolate effect with pyrimethamine.

- **Antipsychotics:** antagonise anticonvulsant effect; possibly reduced aripiprazole concentration – increase aripiprazole dose; metabolism of clozapine, haloperidol, quetiapine and sertindole increased; concentration increased or decreased with chlorpromazine; possibly reduces lurasidone concentration – avoid.

- **Antivirals:** possibly reduced concentration of abacavir, boceprevir, daclatasvir, darunavir, dasabuvir, dolutegravir, indinavir, lopinavir, ombitasvir, paritaprevir, ritonavir, saquinavir and simeprevir – avoid with boceprevir, daclatasvir, dasabuvir, ombitasvir, paritaprevir and simeprevir; rilpivirine reduced – avoid; concentration possibly increased by indinavir and ritonavir; concentration possibly reduced by zidovudine; avoid with elvitegravir, etravirine and telaprevir.

- **Apremilast:** concentration of apremilast reduced – avoid.

- **Calcium-channel blockers:** levels increased by diltiazem; concentration of diltiazem, felodipine, isradipine, nimodipine and verapamil reduced; avoid with isradipine and nimodipine.

- **Cannabis extract:** concentration possibly reduced by phenytoin – avoid.

- **Ciclosporin:** reduced ciclosporin levels.

- **Cobicistat:** concentration of cobicistat possibly reduced.

- **Corticosteroids:** metabolism accelerated (effect reduced).

- **Cytotoxics:** metabolism possibly inhibited by fluorouracil; increased antifolate effect with methotrexate; reduced fosphenytoin absorption; concentration of busulfan, cabozantinib, ceritinib, eribulin, etoposide and imatinib reduced – avoid with cabozantinib, ceritinib and imatinib; concentration possibly reduced by bosutinib, cisplatin iibrutinib and idelalisib – avoid with iibrutinib and idelalisib; possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of crizotinib – avoid; avoid with cabazitaxel, gefitinib, lapatinib, olaparib, panobinostat, vemurafenib and vismodegib; concentration of irinotecan and its active metabolite reduced.

- **Dexrazoxane:** absorption of fosphenytoin possibly reduced.

- **Disulfiram:** metabolism of fosphenytoin inhibited.

- **Diuretics:** concentration increased by acetazolamide; concentration of eplerenone reduced – avoid; increased risk of osteomalacia with carbonic anhydrase inhibitors; antagonises effect of furosemide.

- **Guanfacine:** concentration of guanfacine possibly reduced – increase dose of guanfacine.

- **Hormone antagonists:** possibly reduced concentration of abiraterone – avoid; metabolism of toremifene accelerated.

- **Ivacaftor:** concentration of ivacaftor possibly reduced – avoid.

- **Muscle relaxants:** long-term use of phenytoin reduces effects of non-depolarising muscle relaxants, but acute use may enhance effects.

- **Oestrogens and progestogens:** metabolism increased (reduced contraceptive effect).

- **Orlistat:** possibly increased risk of convulsions.

- **Sulfinpyrazone:** concentration increased by sulfinpyrazone.

- **Ulcer-healing drugs:** metabolism inhibited by cimetidine; absorption reduced by sucralfate; enhanced effect with esomeprazole and omeprazole.

- **Ulipristal:** contraceptive effect possibly reduced – avoid.

### Administration

#### Reconstitution

**Route**

IV, IM

**Rate of administration**

- Status epilepticus: 100–150 mg PE/min
- Treatment and prophylaxis of seizures: 50–100 mg PE/min

**Comments**

Dilute further when using for IV infusion with sodium chloride 0.9% or glucose 5% to 1.5–25 mg PE/mL.

### Other information

- 75 mg of fosphenytoin sodium is equivalent to 50 mg of phenytoin.
- 0.037 mmol of phosphate/mg of fosphenytoin.
- Decreased protein binding in renal failure.
- Monitor ECG, BP and respiratory function during infusion.
- When substituting IV, IM use same dose and frequency as for oral phenytoin, administer at a rate of 50–100 mg PE/min.
- May increase blood glucose in diabetic patients.
- Some is dialysed out, as not all PE is protein-bound.
- Half-life of fosphenytoin to phenytoin is 15 minutes; more rapid in renal failure due to reduced protein binding.
Frovatriptan

Clinical use
5HT₁ receptor agonist:
- Acute relief of migraine

Dose in normal renal function
- 2.5 mg; a second dose can be taken if required after at least 2 hours
- Maximum daily dose is 5 mg

Pharmacokinetics
Molecular weight (daltons) 243.3
% Protein binding 15
% Excreted unchanged in urine 10–32
Volume of distribution (L/kg) 3–4.2
Half-life — normal/ESRF (hrs) 26 / Unchanged

Metabolism
Following oral administration of radiolabelled frovatriptan, 32% of the dose was recovered in urine and 62% in faeces. Radiolabelled compounds excreted in urine were unchanged frovatriptan, hydroxy frovatriptan, N-acetyl desmethyl frovatriptan, hydroxy N-acetyl desmethyl frovatriptan, and desmethyl frovatriptan, together with several other minor metabolites formed under the action of CYP1A2. Desmethyl frovatriptan had about 3-fold lower affinity at 5-HT₁ receptors than the parent compound. N-acetyl desmethyl frovatriptan had negligible affinity at 5-HT₁ receptors. The activity of other metabolites has not been studied. Renal clearance accounted for 38% (82 mL/min) and 49% (65 mL/min) of total clearance in males and females, respectively.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Likely dialysability. Dose as in normal renal function.
HD Likely dialysability. Dose as in normal renal function.
HDF/High flux Likely dialysability. Dose as in normal renal function.
CAV/VVHD Likely dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: increased CNS toxicity with citalopram – avoid; blood levels of frovatriptan increased 27–49% by fluvoxamine – avoid; possibly increased serotonergic effects with duloxetine, venlafaxine and SSRIs; increased serotonergic effects with St John’s wort – avoid.
- Dapoxetine: possible increased risk of serotonergic effects – avoid for 2 weeks after stopping 5HT₁ agonists.
- Ergot alkaloids: increased risk of vasospasm – avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—
Fulvestrant

Clinical use
Treatment of postmenopausal women with oestrogen-receptor-positive, locally advanced or metastatic breast cancer

Dose in normal renal function
500 mg every 2 weeks for the first 3 doses then 500 mg every month

Pharmacokinetics
Molecular weight (daltons) 606.8
% Protein binding 99
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 3–5
Half-life — normal/ESRF (hrs) 40 days / Unchanged

Metabolism
The metabolism of fulvestrant has not been fully evaluated, but involves combinations of a number of possible biotransformation pathways analogous to those of endogenous steroids. Identified metabolites (includes 17-ketone, sulphone, 3-sulphate, 3- and 17-glucuronide metabolites) are either less active or exhibit similar activity to fulvestrant in anti-oestrogen models.
Fulvestrant is eliminated mainly in metabolised form. The major route of excretion is via the faeces.

Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
—
Route
IM
Rate of administration
1–2 minutes
Comments
Administer as 2 separate injections, one in each buttock.

Other information
- As it is an intramuscular injection, use with caution in patients who are heparinised.
- Manufacturer in UK SPC advises to use with caution due to lack of data if GFR<30 mL/min but US data sheet has no restrictions as minimal renal excretion.
Fumaric acid esters (fumaderm)

**Clinical use**

Fumaric acid esters:
- Treatment of severe forms of psoriasis vulgaris, if topical therapy is not indicated
- Treatment of relapsing remitting multiple sclerosis (MS)

**Dose in normal renal function**

- Psoriasis: Initially one tablet daily increasing up to 2 tablets three times daily if required
- MS: 120–240 mg twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>144.1 (as dimethyl fumarate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>27–45 (methyl hydrogen fumarate: approx. 50%; ethyl hydrogen fumarate: approx. 60%)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0.9</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>60–90 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1</td>
</tr>
</tbody>
</table>

**Metabolism**

Dimethyl fumarate appears to be hydrolysed very rapidly in the intestine to monomethyl fumarate. Exhalation of CO₂ is the main route of dimethyl fumarate elimination accounting for 60% of the dose. Renal and faecal elimination are secondary routes of elimination, accounting for 15.5% and 0.9% of the dose respectively.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Psoriasis: Avoid. MS: Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Psoriasis: Avoid. MS: Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal Replacement Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Avoid with other nephrotoxins e.g. methotrexate, ciclosporin, retinoids, psoralene, cytotoxics, immunosuppressants.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Comments**
1.5–2 Litres of fluid should be taken throughout the day while on fumaderm therapy

**Other information**

- Manufacturer advises to use with caution in severe renal impairment for MS due to lack of studies.
- For psoriasis, manufacturer advises to avoid use due to lack of studies.
- There have been reports of acute kidney injury, chronic renal tubular damage, and reversible proteinuria associated with fumaric acid derivatives.
Furosemide (frusemide)

**Clinical use**
Loop diuretic

**Dose in normal renal function**
- Oral: 20 mg – 1 g daily
- IV: 20 mg – 1.5 g daily
- Doses titrated to response

**Pharmacokinetics**
Molecular weight (daltons) 330.7
% Protein binding 91–99
% Excreted unchanged in urine 80–90
Volume of distribution (L/kg) 0.07–0.2
Half-life — normal/ESRF (hrs) 0.5–2 / 9.7

**Metabolism**
Little biotransformation of furosemide takes place. It is mainly eliminated via the kidneys (80–90%); a small fraction of the dose undergoes biliary elimination and 10–15% of the activity can be recovered from the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function; increased doses may be required.
- <10 Dose as in normal renal function; increased doses may be required.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect with NSAIDs.
- Antibacterials: increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid with lymecycline.
- Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypertensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hyponatraemia with carbamazepine; effects antagonised by phenytoin.
- Antifungals: increased risk of hypokalaemia with amphotericin.
- Antihypertensives: enhanced hypertensive effect; increased risk of first dose hypertensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalaemia occurs.
- Antipsychotics: increased risk of ventricular arrhythmias with amisulpride or pimozide (avoid with pimozide) if hypokalaemia occurs; enhanced hypertensive effect with phenothiazines.
- Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
- Ciclosporin: variable reports of increased nephrotoxicity, ototoxicity and hepatotoxicity.
- Cytotoxics: concentration of furosemide increased by dasabuvir, ombitasvir and paritaprevir – reduce furosemide dose; increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium: risk of toxicity.

**Administration**

**Reconstitution**

---

**Route**
IV peripherally or centrally, IM, oral

**Rate of administration**
1 hour; not greater than 4 mg/minute

**Comments**
- 250 mg to 50 mL sodium chloride 0.9% or undiluted via CRIP.
- Increased danger of ototoxicity and nephrotoxicity if infused at faster rate than approximately 4 mg/minute.
- Protect from light.
Other information

- 500 mg orally = 250 mg IV.
- Excreted by tubular secretion, therefore in severe renal impairment (GFR=5–10 mL/min) higher doses may be required due to a reduction in the number of functioning nephrons.
- Furosemide acts within 1 hour of oral administration, (after IV peak effect within 30 minutes) diuresis complete within 6 hours.
Gabapentin

**Clinical use**

Antiepileptic:
- Adjunctive treatment of partial seizures with or without secondary generalisation
- Neuropathic pain
- Migraine prophylaxis (unlicensed)

**Dose in normal renal function**

- Epilepsy: 300 mg on day 1; 300 mg twice daily on day 2; 300 mg 3 times daily on day 3.
- Usual range 0.9–3.6 g daily in 3 divided doses, max 4.8 g daily in divided doses.
- Neuropathic pain: Maximum 3.6 g in 3 divided doses.
- Migraine prophylaxis: Initially 300 mg daily increasing up to 2.4 g daily in divided doses.

**Pharmacokinetics**

- Molecular weight (daltons) 171.2
- % Protein binding <3
- % Excreted unchanged in urine ≈100
- Volume of distribution (L/kg) 0.7
- Half-life — normal/ESRF (hrs) 5–7 / 52

**Metabolism**

There is no evidence of gabapentin metabolism in humans. Gabapentin is eliminated unchanged solely by renal excretion.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>Start at low dose and increase dose according to response.</td>
</tr>
<tr>
<td>15–30</td>
<td>Start at low dose and increase dose according to response.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>300 mg on alternate days or 100 mg at night initially increase according to tolerability.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Probably dialysed. Dose as in GFR<15 mL/min. See ‘Other information’.
- **HD**: Dialysed. Loading dose of 300–400 mg in patients who have never received gabapentin. Maintenance dose of 200–300 mg after each HD session and increase according to tolerability. See ‘Other information’.

**Important drug interactions**

- **Potentially hazardous interactions with other drugs**
  - Antacids: reduce absorption.
  - Antidepressants: antagonism of anticonvulsive effect (convulsive threshold lowered); avoid with St John’s wort.
  - Antimalarials: anticonvulsant effect antagonised by mefloquine.
  - Antipsychotics: antagonism of anticonvulsive effect (convulsive threshold lowered).
  - Orlistat: possible increased risk of convulsions.

**Administration**

**Reconstitution**

- **Route**
  - Oral
- **Rate of administration**

**Other information**

- For neuropathic pain in renal patients do not give loading dose.
- Can cause false positive readings with some urinary protein tests.
- For neuropathic pain or restless legs in patients with moderate to severe renal impairment, start with 100 mg daily and increase according to response.
## Clinical use
Mild to moderate dementia in Alzheimer’s disease

## Dose in normal renal function
4–12 mg twice daily  
XL: 8–24 mg once daily

## Pharmacokinetics
- Molecular weight (daltons): 368.3 (as hydrobromide)  
- % Protein binding: 18%  
- % Excreted unchanged in urine: 18–22  
- Volume of distribution (L/kg): 175 Litres  
- Half-life — normal/ESRF (hrs): 7–8 (XL: 8–10) / Increased

## Metabolism
Galantamine is partially (up to 75%) metabolised by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4; a number of active metabolites are formed.  
After 7 days, 90–97% of a single oral dose is recovered in the urine with up to about 6% detected in the faeces; about 20–30% of the dose is excreted in the urine as unchanged galantamine. Clearance is reported to be 20% lower in females than in males and 25% lower in poor metabolisers than in extensive metabolisers.

## Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.  
- 10–20: Dose as in normal renal function.  
- <10: Dose as in normal renal function but start with lower doses.

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.  
- HD: Dialysed. Dose as in GFR<10 mL/min.  
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.  
- CAV/VVHD: Dialysed. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs  
- Antibacterials: erythromycin increases concentration of galantamine.

## Administration
### Reconstitution
- —

### Route
- Oral

### Rate of administration
- —

## Other information
- Manufacturer advises to avoid use if GFR<9 mL/min due to lack of studies.
Ganciclovir

**Clinical use**
Antiviral agent:
- Treatment of life- or sight-threatening cytomegalovirus (CMV) in immunocompromised people
- CMV prophylaxis in immunosuppressed patients secondary to organ transplantation

**Dose in normal renal function**
- Induction / treatment of active CMV disease: 5 mg/kg 12 hourly for 14–21 days.
- Maintenance for CMV retinitis: 6 mg/kg per day for 5 days per week or 5 mg/kg daily until recovery of adequate immunity.

**Pharmacokinetics**
- Molecular weight (daltons) 255.2
- % Protein binding <2
- % Excreted unchanged in urine 84.6–94.6
- Volume of distribution (L/kg) 0.54–0.87
- Half-life — normal/ESRF (hrs) 2.9 / 28.5

**Metabolism**
Renal excretion of unchanged drug by glomerular filtration and active tubular secretion is the major route of elimination of ganciclovir. In patients with normal renal function, 89.6 ± 5.0% of IV administered ganciclovir was recovered unmetabolised in the urine.

**Dose in renal impairment GFR (mL/min)**
- 50–69 Induction: 2.5 mg/kg 12 hourly. Maintenance: 2.5 mg/kg/day. See 'Other information'.
- 25–49 Induction: 2.5 mg/kg/day. Maintenance: 1.25 mg/kg/day. See 'Other information'.
- 10–24 Induction: 1.25 mg/kg/day. Maintenance: 0.625 mg/kg/day. See 'Other information'.
- <10 Induction: 1.25 mg/kg 3 times a week. Maintenance: 0.625 mg/kg three times a week. See 'Other information'.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Dialysed. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Dialysed. Dose as in GFR=10–24 mL/min. See 'Other information'.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of convulsions with imipenem/cilastatin.
- Antivirals: possibly increased didanosine concentration; profound myelosuppression with zidovudine – avoid if possible.
- Increased risk of myelosuppression with other myelosuppressive drugs.
- Mycophenolate: concomitant treatment with ganciclovir and mycophenolate causes increased concentration of ganciclovir and inactive mycophenolate metabolite.

**Administration**

**Reconstitution**
Reconstitute 1 vial (500 mg) with 10 mL water for injection (50 mg/mL), then transfer dose to 100 mL sodium chloride 0.9%.

**Route**
IV peripherally in fast-flowing vein or centrally – see below.

**Rate of administration**
Over 1 hour

**Comments**
May give 50% dose over 15 minutes after HD in washback (unlicensed).

**Other information**
Alternative regimen used by some units:

<table>
<thead>
<tr>
<th>Creatinine Clearance (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;50</td>
<td>5 mg/kg 12 hourly</td>
</tr>
<tr>
<td>25–50</td>
<td>2.5 mg/kg 12 hourly</td>
</tr>
<tr>
<td>10–25</td>
<td>2.5 mg/kg 24 hourly</td>
</tr>
<tr>
<td>&lt;10</td>
<td>1.25 mg/kg 24 hourly</td>
</tr>
</tbody>
</table>
- Some units use 2.5 mg/kg twice daily in CAV/VVHD.
- Monitor patient for myelosuppression, particularly in patients receiving prophylactic co-trimoxazole therapy.
- Pre-dialysis therapeutic blood levels in range 5–12 mg/L.
- For intermittent haemodialysis, the fraction of ganciclovir removed in a single dialysis session varied from 50–63%.
- Not to be infused in concentrations over 10 mg/mL peripherally.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Gefitinib

Clinical use
Tyrosine kinase inhibitors:
- Treatment of non-small cell lung cancer

Dose in normal renal function
250 mg once daily
Consult relevant local protocol

Pharmacokinetics
Molecular weight (daltons) 446.9
% Protein binding 90
% Excreted unchanged in urine <4
Volume of distribution (L/kg) 1400 Litres
Half-life — normal/ESRF (hrs) 41–48 / Unchanged

Metabolism
Extensively metabolised in the liver, mainly by the cytochrome P450 isoenzymes CYP3A4 and CYP2D6; the major metabolite is O-desmethylgefitinib, which is much less potent than gefitinib, and unlikely to contribute to its clinical activity. 
Gefitinib is excreted mainly as metabolites via the faeces (86%); renal elimination of gefitinib and its metabolites accounts for <4% of the dose.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Replacement Therapy</th>
<th>Dose Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: Avoid with rifampicin (reduced gefitinib concentration).
- Anticoagulants: possibly enhanced anticoagulant effect with warfarin
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Antivirals: avoid with boceprevir.
- Ulcer-healing drugs: concentration reduced by ranitidine.
- Avoid concomitant use with other inhibitors or inducers of CYP3A4. Dose alterations may be required.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Manufacturer advises to use gefitinib with caution if GFR<20 mL/min due to lack of studies but clearance is unlikely to be affected due to low renal excretion.
- Bioavailability is 59%.
- Adverse effects are related to dose and exposure.
Gemcitabine

Clinical use
Antineoplastic agent:
- Palliative treatment, or first-line treatment with cisplatin, of locally advanced or metastatic non-small cell lung cancer
- Pancreatic, ovarian and breast cancer
- Bladder cancer in combination with cisplatin

Dose in normal renal function
1–1.25 mg/m², frequency dependent on chemotherapy regimen; dose reduced according to toxicity.

Pharmacokinetics
Molecular weight (daltons) 299.7 (as hydrochloride)
% Protein binding Negligible
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 12.4 Litres/m² (women); 17.5 Litres/m² (men)
Half-life — normal/ESRF (hrs) 42–94 minutes / –

Metabolism
After intravenous doses gemcitabine is rapidly cleared from the blood and metabolised by cytidine deaminase in the liver, kidney, blood, and other tissues. Clearance is about 25% lower in women than in men.
Almost all (99%) of the dose is excreted in urine as 2′-deoxy-2′,2′-difluorouridine (dFdU), only about 1% being found in the faeces. Intracellular metabolism produces mono-, di-, and triphosphate metabolites, the latter two active. The active intracellular metabolites have not been detected in plasma or urine.

Dose in patients undergoing renal replacement therapies

Dose in normal renal function

<table>
<thead>
<tr>
<th>Dose in renal impairment GFR (mL/min)</th>
<th>Dose in patients undergoing renal replacement therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>APD/CAPD Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>10–20</td>
<td>HD Dialysed. Dose as in GFR&lt;10 mL/min. Dose after dialysis, and give next dialysis after 48 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>HDF/High flux Dialysed. Dose as in GFR&lt;10 mL/min. Dose after dialysis, and give next dialysis after 48 hours.</td>
</tr>
<tr>
<td></td>
<td>CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

Administration
Reconstitution
Reconstitute with sodium chloride 0.9%, 5 mL to 200 mg vial and 25 mL to 1 g vial.
Can be further diluted in sodium chloride 0.9% if required.
Route
IV
Rate of administration
30 minutes

Other information
- Manufacturer advises to use with caution due to lack of studies.
- Causes reversible haematuria with or without proteinuria in about 50% of patients; no evidence for cumulative renal toxicity with repeated dosing of gemcitabine.
- Haemolytic uraemic syndrome (HUS) has been reported with a crude incidence rate of 0.015%.
- A study looking at the use of gemcitabine 500–1000 mg/m² administered IV on days 1, 8, and 15 every 28 days in patients with renal dysfunction, concluded that this regimen was well tolerated in patients with a GFR as low as 30 mL/min. (Data on file from Eli Lilly.)
- Another study in patients with serum creatinine in the range 130–420 μmol/L, at doses of 650–800 mg/m² weekly for 3 weeks out of a 4 week cycle, found dose limiting toxicities, including neutropenia,
fever, raised transaminases and increased serum creatinine. It was concluded that a reduced dose of gemcitabine might be appropriate in patients with established renal impairment. (Egorin MJ, Venook MP, Rosner G, et al. Phase 1 study of gemcitabine (G) in patients with organ dysfunction. Proc Annual Meet Am Soc Clin Oncol. 1998; 17: A719.)

- The following series of 5 cases showed that gemcitabine can be used safely at doses of 800–1000 mg as long as the patients are on haemodialysis. (Matsuda M. Gemcitabine for patients with chronic renal failure on hemodialysis. J Clin Oncol. 2007; 25(18S) (June 20 Supplement): 15189. 2007 ASCO Annual Meeting Proceedings.)
Gemfibrozil

Clinical use
Hyperlipidaemias of types IIa, IIb, III, IV and V

Dose in normal renal function
1.2 g daily, usually in 2 divided doses; range 0.9–1.2 g daily.

Pharmacokinetics
Molecular weight (daltons) 250.3
% Protein binding >97
% Excreted unchanged in urine <6
Volume of distribution (L/kg) 9–13 Litres
Half-life — normal/ESRF (hrs) 1.3–1.5 / Unchanged

Metabolism
Gemfibrozil undergoes oxidation of a ring methyl group to form successively a hydroxymethyl and a carboxyl metabolite (the main metabolite). This metabolite has a low activity compared to the mother compound gemfibrozil and an elimination half-life of approximately 20 hours.

Gemfibrozil is eliminated mainly by metabolism. Approximately 70% of the administered human dose is excreted in the urine, mainly as conjugates of gemfibrozil and its metabolites. Less than 6% of the dose is excreted unchanged in the urine; 6% of the dose is found in faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Initially 900 mg daily.</td>
</tr>
<tr>
<td>10–20</td>
<td>Initially 900 mg daily. Monitor carefully.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initially 900 mg daily. Monitor carefully.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of myopathy with daptomycin — try to avoid concomitant use.
- Anticoagulants: enhances effect of coumarins and phenindione; dose of anticoagulant should be reduced by up to 50% and adjusted by monitoring INR.
- Antidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureas; possibly enhanced effect with nateglinide; increased risk of severe hypoglycaemia with repaglinide — avoid.
- Antivirals concentration of paritaprevir increased — avoid.
- Ciclosporin: Parke-Davis have one report on file of an interaction with ciclosporin where serum ciclosporin levels were decreased. No effects on muscle were noted.
- Colchicine: possible increased risk of myopathy.
- Cytotoxics: bexarotene concentration increased — avoid; concentration of enzalutamide increased — avoid or halve enzalutamide dose.
- Lipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe — avoid (maximum 20 mg of rosvastatin).

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Contraindicated by manufacturer in severe renal impairment.
- Dose in severe renal impairment is from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Adverse effects have not been reported in patients with renal disease, but such patients should start treatment at 900 mg daily, which may be increased after careful assessment of response and renal function.
- Cases of rhabdomyolysis may be increased in those with renal impairment.
- Gemfibrozil alone has caused myalgia and myositis, but the effects appear to occur much more frequently and are more severe when a statin is also used. The combination is therefore not recommended.
Gentamicin

Clinical use
Antibacterial agent

Dose in normal renal function
- Once daily dose: 3–7 mg/kg, dose is then adjusted according to levels
- Endocarditis: 1 mg/kg every 12 hours
- Intrathecal: 1–5 mg daily
- PD peritonitis: see local policy

Pharmacokinetics
- Molecular weight (daltons): 477.6
- % Protein binding: 0–30
- % Excreted unchanged in urine: 90
- Volume of distribution (L/kg): 0.3

Metabolism
Gentamicin is not metabolised in the body but is excreted unchanged in microbiologically active form predominantly via the kidneys.

Dose in renal impairment GFR (mL/min)
- Or as local policy
  - 30–70: 3–5 mg/kg daily and monitor levels.
  - 10–30: 2–3 mg/kg daily and monitor levels.
  - 5–10: 2 mg/kg every 48–72 hours according to levels.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. CAPD clearance is about 3 mL/min. Dose as in GFR=5–10 mL/min. Monitor levels.
- HD: Dialysed. Dose as in GFR=5–10 mL/min. Give after dialysis.
- HDF/High flux: Dialysed. Dose as in GFR=5–10 mL/min. Give after dialysis.
- CAV/VVHD: Dialysed. Dose in GFR= 10–30 mL/min according to severity of infection, and measure levels.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of nephrotoxicity with colistimethate or polymyxins and possibly cephalosporins; increased risk of ototoxicity and nephrotoxicity with capreomycin or vancomycin.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxics: increased risk of nephrotoxicity and possibly of ototoxicity with platinum compounds.
- Diuretics: increased risk of ototoxicity with loop diuretics.
- Muscle relaxants: effects of non-depolarising muscle relaxants and suxamethonium enhanced.
- Parasympathomimetics: antagonism of effect of neostigmine and pyridostigmine.
- Tacrolimus: increased risk of nephrotoxicity.

Administration
Reconstitution

Route
IV, IM, IP, intrathecal

Rate of administration
Bolus IV: over not less than 3 minutes
Short infusion: 20–30 minutes
Once daily large infusions over 30–60 minutes

Comments
Can be added to sodium chloride or glucose 5%.

Other information
- Concurrent penicillins may result in sub-therapeutic blood levels.
- Monitor blood levels. 1 hour post-dose peak levels must not exceed 10 mg/L. Pre-dose trough levels should be less than 2 mg/L.
- IP therapy commonly used for PD peritonitis. Dose varies according to local protocol and whether CAPD or APD dialysis. Monitoring of blood levels is advisable, as absorption is increased by inflamed peritoneum.
- Potential nephrotoxicity of the drug may worsen residual renal function.
- Long-term concurrent use of gentamicin with teicoplanin causes additive ototoxicity.
Glatiramer acetate

**Clinical use**

Immunomodulating drug:
- Treatment for patients at a high risk of developing multiple sclerosis and for reduction in relapses in ambulatory patients

**Dose in normal renal function**

20 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>5000–9000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Large</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

**Metabolism**

A substantial fraction of a subcutaneous dose of glatiramer is believed to be hydrolysed locally. Some of the injected dose is also presumed to enter the lymphatic system, either intact or partially hydrolysed.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

Reconstitution
- 

Route
- SC

Rate of administration
- 

**Other information**

- Manufacturer advises use with caution in renal impairment due to lack of studies.
Glibenclamide

Clinical use
Non-insulin dependent diabetes mellitus

Dose in normal renal function
Initially 5 mg daily (elderly patients – avoid) adjusted according to response; maximum 15 mg daily.

Pharmacokinetics
Molecular weight (daltons) 494
% Protein binding 97
% Excreted unchanged in urine <5
Volume of distribution (L/kg) 0.125
Half-life — normal/ESRF (hrs) 2.1–10 / –

Metabolism
Glibenclamide is metabolised, almost completely, in the liver, the principal metabolite being only very weakly active.
About 50% of a dose is excreted in the urine and 50% via the bile into the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Initial dose (mg)</th>
<th>Monitor</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>1.25–2.5</td>
<td>closely</td>
<td>Use cautiously with continuous monitoring.</td>
</tr>
<tr>
<td>10–20</td>
<td>1.25–2.5</td>
<td>closely</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>1.25–2.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Metabolites</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Metabolites</td>
<td>as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Low dialysability</td>
<td>as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability</td>
<td>as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability</td>
<td>as in GFR&lt;10 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: effects enhanced by NSAIDs.
- Antibacterials: effects enhanced by chloramphenicol, sulphonamides, tetracyclines and trimethoprim; effects possibly enhanced by ciprofloxacin and norfloxacin; effect reduced by rifamycins.
- Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR.
- Antifungals: concentration increased by fluconazole and miconazole and possibly voriconazole.
- Bosentan: increased risk of hepatic toxicity – avoid.
- Ciclosporin: may increase ciclosporin levels.
- Lipid-regulating drugs: absorption reduced by colesevelam; concentration possibly increased by fluvastatin; possibly additive hypoglycaemic effect with fibrates.
- Sulfinpyrazone: enhanced effect of sulphonylureas.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—
Comments
Take with breakfast.

Other information
- Metabolites of glibenclamide are only weakly hypoglycaemic; this is not clinically relevant where renal and hepatic functions are normal. If CRCL<10 mL/min, accumulation of metabolite and unchanged drug in plasma may cause prolonged hypoglycaemia.
- Company information states that use is contraindicated in severe renal impairment.
- Dose in renal impairment is from Drug Dosage in Renal Insufficiency by Seyffart G.
- Compensatory excretion via bile in faeces occurs in renal impairment.
**Gliclazide**

### Clinical use
Non-insulin dependent diabetes mellitus

### Dose in normal renal function
Initially: 40–80 mg daily, with breakfast, adjusted according to response up to 160 mg as a single dose; higher doses should be divided; maximum 320 mg daily.

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>323.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Approx 95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.24</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–12 (MR: 12–20) / Prolonged</td>
</tr>
</tbody>
</table>

### Metabolism
Gliclazide is extensively metabolised in the liver to metabolites that have no significant hypoglycaemic activity.
Metabolites and a small amount of unchanged drug are excreted in the urine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Initially 20–40 mg daily. Use with caution and monitor closely. See ‘Other information’.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Initially 20–40 mg daily. Use with caution and monitor closely. See ‘Other information’.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initially 20–40 mg daily. Use with caution and monitor closely. See ‘Other information’.</td>
<td></td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: effects enhanced by NSAIDs.
- Antibacterials: effects enhanced by chloramphenicol, sulphonamides, tetracyclines and trimethoprim; effect reduced by rifamycins.
- Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR.
- Antifungals: concentration increased by fluconazole and miconazole and possibly voriconazole – avoid with miconazole.
- Lipid-regulating drugs: possibly additive hypoglycaemic effect with fibrates.
- Sulfinpyrazone: enhanced effect of sulphonylureas.

### Administration

#### Reconstitution
- __—__

#### Route
- Oral

#### Rate of administration
- __—__

### Other information
- Care should be exercised in patients with hepatic and/or renal impairment, and a small starting dose should be used with careful patient monitoring.
- Company contraindicates prescribing of Diamicron in severe renal impairment, which they define as creatinine clearance below 40 mL/min.
- Doses estimated from evaluation of pharmacokinetic data, use with caution in moderate to severe renal impairment.
Glimepiride

**Clinical use**
Non-insulin dependent diabetes mellitus

**Dose in normal renal function**
1–4 mg daily; maximum 6 mg daily taken shortly before or with first main meal

**Pharmacokinetics**
- Molecular weight (daltons) 490.6
- % Protein binding >99
- % Excreted unchanged in urine 0 (58–60% as metabolites)
- Volume of distribution (L/kg) 0.113
- Half-life — normal/ESRF (hrs) 5–9 / Unchanged

**Metabolism**
The drug is extensively metabolised in the liver to two main metabolites. The cytochrome P450 isoenzyme CYP2C9 is involved in the formation of a hydroxy derivative, which is further metabolised to a carboxy derivative by cytosolic enzymes. About 60% of a dose is eliminated in the urine and 40% in the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Initially 1 mg and monitor closely.
- <10 Initially 1 mg and monitor closely.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Analgesics: effects enhanced by NSAIDs.
- Antibacterials: effects enhanced by chloramphenicol, sulphonamides, tetracyclines and trimethoprim; effect reduced by rifamycins.
- Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR.
- Antifungals: concentration increased by fluconazole and miconazole and possibly voriconazole.
- Lipid-regulating drugs: possibly additive hypoglycaemic effect with fibrates.
- Sulfinpyrazone: enhanced effect of sulphonylureas.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Contraindicated by manufacturer in UK, dosage in severe renal impairment is from US data sheet.
Glipizide

Clinical use
Non-insulin dependent diabetes mellitus

Dose in normal renal function
Initially 2.5–5 mg daily, adjusted according to response; maximum 20 mg daily; up to 15 mg may be given as a single dose before breakfast; higher doses divided.

Pharmacokinetics
Molecular weight (daltons) 445.5
% Protein binding 98–99
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 0.13–0.16
Half-life — normal/ESRF (hrs) 2–4

Metabolism
The metabolism of glipizide is extensive and occurs mainly in the liver. The primary metabolites are inactive hydroxylation products and polar conjugates and are excreted mainly in the urine.

Dose in renal impairment GFR (mL/min)

| GFR (mL/min) | Initial dose | Titration
|-------------|-------------|----------
| 20–50       | 2.5 mg daily | according to response.
| 10–20       | 2.5 mg daily | according to response.
| <10         | 2.5 mg daily | according to response.

Dose in patients undergoing renal replacement therapies

| Therapy       | Initial dose | Titration
|---------------|-------------|----------
| APD/CAPD      | Initially 2.5 mg daily. Titrate according to response. | Dose as in GFR<10 mL/min.
| HD            | Initially 2.5 mg daily. Titrate according to response. | Dose as in GFR<10 mL/min.
| HDF/High flux | Initially 2.5 mg daily. Titrate according to response. | Dose as in GFR<10 mL/min.
| CAV/VVHD      | Initially 2.5 mg daily. Titrate according to response. | Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: effects enhanced by NSAIDs.
- Antibacterials: effects enhanced by chloramphenicol, sulphonamides, tetracyclines and trimethoprim; effect reduced by rifamycins.
- Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR.
- Antifungals: concentration increased by fluconazole, posaconazole and miconazole and possibly voriconazole – avoid with miconazole.
- Ciclosporin: may increase ciclosporin levels.
- Lipid-regulating drugs: possibly additive hypoglycaemic effect with fibrates.
- Sulfinpyrazone: enhanced effect of sulphonylureas.

Administration
Reconstitution
—

Route
Oral

Rate of administration
—

Other information
- UK SPC does not recommend the use of glipizide in patients with severe renal insufficiency.
- Doses taken from US data sheet and Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Renal or hepatic insufficiency may cause elevated blood levels of glipizide (increased risk of serious hypoglycaemic reactions).
Glyceryl trinitrate

Clinical use
Vasodilator:
- Treatment and prophylaxis of angina, left ventricular failure, hypertension during surgery
- Anal fissures
- Maintenance of venous patency

Dose in normal renal function
- S/L tablets: 0.3–1 mg as required.
- S/L spray: 1–2 sprays as required.
- Patches: 5–20 mg every 24 hours.
- Maintenance of venous patency: 5 mg patch.
- IV infusion: 10–200 mcg/minute; up to 400 mcg/minute may be required during surgery.
- Anal fissures: 0.2–0.8% ointment every 12 hours.

Pharmacokinetics
Molecular weight (daltons) 227.1
% Protein binding 30–60
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 2–3
Half-life — normal/ESRF (hrs) 1–4 minutes / Unchanged

Metabolism
GTN undergoes extensive first-pass metabolism in the liver. It is taken up by smooth muscle cells of blood vessels and the nitrate group is cleaved to inorganic nitrite and then to nitric oxide. This reaction requires the presence of cysteine or another thiol. Glyceryl trinitrate also undergoes hydrolysis in plasma and is rapidly metabolised in the liver by glutathione-organic nitrate reductase to dinitrates and mononitrates.

Dose in normal renal function GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: infusion of GTN reduces anticoagulant effect of heparins.
- Antidepressants: tricyclics may reduce effect of sublingual tablets due to dry mouth.
- Antimuscarinics: may reduce effect of sublingual tablets due to dry mouth.
- Avanafil, sildenafil, tadalafil, vardenafil: hypotensive effect significantly enhanced – avoid concomitant use.
- Riociguat: avoid concomitant use due to risk of hypotension.

Administration
Reconstitution
Route
IV, S/L, topical
Rate of administration
10–400 mcg/minute (depends on response)
Comments
Compatible with sodium chloride 0.9% and glucose 5%. Incompatible with polyvinylchloride bags.

Other information
- Tolerance may develop; may be minimised by having nitrate-‘free’ periods.
- IV infusions contain propylene glycol which can cause lactic acidosis – restrict to using for no more than 3 consecutive days.
### Clinical use

Synthetic decapeptide analogue of LHRH:
- Treatment of advanced prostate cancer, breast cancer, endometriosis and endometrial thinning and uterine fibroids

### Dose in normal renal function

3.6 mg every 28 days or 10.8 mg every 12 weeks. Duration of treatment varies according to condition being treated.

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1269.4 (1329.5 as acetate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>27</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20¹ (90% as unchanged drug and metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>30.5–57.8 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–4 / 12¹</td>
</tr>
</tbody>
</table>

### Metabolism

Metabolised by tissue peptidases and is excreted in urine and bile as unchanged drug and metabolites.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Monitor closely.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- None known

### Administration

**Reconstitution**
-  |  
**Route**
- SC  
**Rate of administration**
-  

### Other information

Reference:
Granisetron

Clinical use
Prevention or treatment of nausea and vomiting induced by cytotoxic chemotherapy, radiotherapy, or postoperative nausea and vomiting (PONV)

Dose in normal renal function
- Cytotoxic chemotherapy or radiotherapy:
  - PO: 1–2 mg within 1 hour before start of treatment, then 2 mg daily in 1–2 divided doses during treatment
  - IV: 1–3 mg before start of cytotoxic therapy; up to 2 additional 3 mg doses can be given within 24 hours no less than 10 minutes apart
  - IV Infusion: 10–40 mcg/kg (max 3 mg) before treatment; repeated once more if required
  - Transdermal: Apply 3.1 mg patch 24–48 hours before chemotherapy
- PONV: 1 mg IV before induction of anaesthesia; then 1 mg as required (maximum 3 mg in one day)

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Pharmacokinetics
Molecular weight (daltons) 312.4 (348.9 as hydrochloride)
% Protein binding ≈65
% Excreted unchanged in urine <20
Volume of distribution (L/kg) 3
Half-life — normal/ESRF (hrs) 4–5 / Unchanged

Metabolism
Granisetron is metabolised primarily in the liver by oxidation followed by conjugation. The major compounds are 7-OH-granisetron and its sulphate and glucuronide conjugates. Although antiemetic properties have been observed for 7-OH-granisetron and indazoline N-desmethyl granisetron, it is unlikely that these contribute significantly to the pharmacological activity of granisetron in man. Clearance is predominantly by hepatic metabolism. Urinary excretion of unchanged granisetron averages 12% of dose whilst that of metabolites amounts to about 47% of dose. The remainder is excreted in faeces as metabolites.

Important drug interactions
Potentially hazardous interactions with other drugs
- Cytotoxics: possible increased risk of ventricular arrhythmias with panobinostat.

Administration
Reconstitution

Route
Oral, IV bolus, IV infusion, transdermal

Rate of administration
IV bolus: diluted in 5 or 15 mL sodium chloride 0.9% over not less than 30 seconds.
IV infusion: 20–50 mL over 5 minutes.

Comments
- Compatible with sodium chloride 0.9%, sodium chloride 0.18% and glucose 4% solution, glucose 5%, Hartmann’s solution, sodium lactate injection, 10% Mannitol.
- Maximum administered dose over 24 hours should not exceed 9 mg.

Other information
- No special dosing adjustments necessary in patients with renal or hepatic failure.
## Griseofulvin

### Clinical use

Antifungal agent:
- Dermatophyte infections of the skin, scalp, hair and nails

### Dose in normal renal function

500 mg daily, in divided doses or as a single dose, in severe infection dose may be doubled.

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>352.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>84</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.2–1.41</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>9–24 / 20</td>
</tr>
</tbody>
</table>

### Metabolism

Griseofulvin is metabolised by the liver mainly to 6-demethylgriseofulvin and its glucuronide conjugate which are excreted in the urine. A large amount of a dose of griseofulvin of reduced particle size appears unchanged in the faeces; less than 1% is excreted unchanged in the urine; some is excreted in the sweat.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Anticoagulants: metabolism of coumarins accelerated (reduced anticoagulant effect).
- Ciclosporin: griseofulvin possibly reduces ciclosporin concentration (two reports of such an interaction in literature).
- Oestrogens and progestogens: metabolism of oral contraceptives accelerated (reduced contraceptive effect).
- Ulipristal: possibly reduced contraceptive effect – avoid.

### Administration

Reconstitution
- **Route**
  - Oral

Rate of administration
- **Other information**
  - Use with extreme caution in patients with SLE.
  - Griseofulvin is deposited in keratin precursor cells and is concentrated in the stratum corneum of the skin and in the nails and hair, thus preventing fungal invasion of newly formed cells.
Guanethidine monosulphate

**Clinical use**
Treatment of hypertensive crisis

**Dose in normal renal function**
10–20 mg, repeated after 3 hours if required

**Pharmacokinetics**
- Molecular weight (daltons) 296.4
- % Protein binding <5
- % Excreted unchanged in urine 25–60
- Volume of distribution (L/kg) Large
- Half-life — normal/ESRF (hrs) 120–240 / Increased

**Metabolism**
Guanethidine is partially metabolised in the liver, and is excreted in the urine as metabolites and unchanged guanethidine.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Give every 24 hours.
- 10–20 Give every 24 hours.
- <10 Give every 24–36 hours; use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Likely dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Sympathomimetics: hypotensive effect antagonised by dexamfetamine, ephedrine, isomethptene, lisdexamfetamine, metaraminol, methylphenidate, noradrenaline, oxymetazoline, phenylephrine, phenylpropanolamine, pseudoephedrine and xylometazoline.

**Administration**

**Reconstitution**
—

**Route**
IM

**Rate of administration**
—

**Other information**
- Blood pressure should fall within 30 minutes of dose.
- Contraindicated by manufacturer.
- Doses in renal impairment from *Drug Prescribing in Renal Failure*, 5th edition by Aronoff et al.
Haloperidol

Clinical use
- Sedative in severe anxiety
- Intractable hiccup
- Motor tics
- Nausea and vomiting
- Schizophrenia and other psychoses

Dose in normal renal function
- Anxiety: 0.5 mg twice daily
- Agitation and restlessness in the elderly: 0.75–1.5 mg 2–3 times daily.
- Hiccup: 1.5 mg 2–3 times daily
- Nausea and vomiting: maximum 10 mg/day in divided doses; SC infusion: 2.5–10 mg daily
- Schizophrenia: oral: 2–20 mg daily in single or divided doses, IM: 2–5 mg initially then every 4–8 hours; maximum 12 mg daily.
- Deep IM: 50–300 mg every 4 weeks; higher doses may sometimes be required.
- Motor tics: 1.55–3 mg 2–3 times daily, increased according to response.

Pharmacokinetics
- Molecular weight (daltons) 375.9
- % Protein binding 92
- % Excreted unchanged in urine 1
- Volume of distribution (L/kg) 14–21
- Half-life — normal/ESRF (hrs) 12–38 / –

Metabolism
Haloperidol is metabolised in the liver and is excreted in the urine and, via the bile in the faeces; there is evidence of enterohepatic recycling. Routes of metabolism of haloperidol include oxidative N-dealkylation, particularly via the cytochrome P450 isoenzymes CYP3A4 and CYP2D6, glucuronidation, and reduction of the ketone group to form an alcohol known as reduced haloperidol. Metabolites are ultimately conjugated with glycine and excreted in the urine. There is debate over the pharmacological activity of the metabolites.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Start with lower doses. For single doses use 100% of normal dose. Accumulation with repeated dosage.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effects.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; possibly severe drowsiness with indomethacin or acemetacin; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; increased risk of ventricular arrhythmias with amiodarone or disopyramide — avoid.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and delamanid — avoid with moxifloxacin; concentration reduced by rifampicin.
- Antidepressants: increased risk of ventricular arrhythmias with citalopram, escitalopram and tricyclics — avoid; concentration increased by fluoxetine and venlafaxine and possibly fluvoxamine; possible increased risk of convulsions with vortioxetine; concentration of tricyclics increased.
- Antiepileptics: metabolism increased by carbamazepine, phenobarbital and primidone; lowered seizure threshold; concentration reduced by fosphenytoin and phenytoin.
- Antifungals: concentration possibly increased byitraconazole.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol; possible increased
risk of ventricular arrhythmias with mefloquine or quinine – avoid.
- Antipsychotics: avoid concomitant use of depot formulations with clozapine (cannot be withdrawn quickly if neutropenia occurs); increased risk of ventricular arrhythmias with sulpiride and droperidol and possibly risperidone – avoid with droperidol; concentration possibly increased by chlorpromazine.
- Antivirals: concentration possibly increased with ritonavir; increased risk of ventricular arrhythmias with saquinavir - avoid.
- Anxiolytics and hypnotics: increased sedative effects; concentration increased by alprazolam and buspirone.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Cytotoxics: increased risk of ventricular arrhythmias with bosutinib, ceritinib and vandetanib – avoid with vandetanib; increased risk of ventricular arrhythmias with arsenic trioxide.
- Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.

**Administration**

**Reconstitution**

—

**Route**

Oral, IM or IV (slow bolus)

**Rate of administration**

—

**Other information**

- May cause hypotension and excessive sedation.
- Increased CNS sensitivity in renally impaired patients – start with small doses; metabolites may accumulate.
- Equivalent IV/IM dose = 40% of oral dose.
Heparin

Clinical use

Anticoagulant

Dose in normal renal function

- Treatment of deep vein thrombosis and pulmonary embolism:
  - IV: Loading dose: 5000–10 000 units then a continuous intravenous infusion of 18 units/kg/hour.
- Treatment of deep vein thrombosis:
  - SC: 15 000 units every 12 hours, dose is adjusted according to laboratory monitoring.
- Prophylaxis: 5000 units every 8–12 hours or according to local protocols

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>3000–40 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0 (up to 50% after large doses)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.06–0.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–6 / Slightly prolonged (half-life increases with dose)</td>
</tr>
</tbody>
</table>

Metabolism

Heparin is taken up by the reticuloendothelial system. It is excreted in the urine, mainly as metabolites, although after large doses up to 50% may be excreted unchanged.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

- Analgesics: increased risk of bleeding with NSAIDs – avoid concomitant use with IV diclofenac; increased risk of haemorrhage with ketorolac – avoid.
- Nitrates: anticoagulant effect reduced by infusions of glyceryl trinitrate.
- Use with care in patients receiving oral anticoagulants, platelet aggregation inhibitors, aspirin or dextran.

Administration

Reconstitution

Route

IV infusion or bolus, SC

Rate of administration

18 units/kg/hour, or according to local protocol

Other information

- Half-life is slightly prolonged in haemodialysis patients after intravenous administration.
- Also used for the maintenance of extracorporeal circuits in cardiopulmonary bypass and haemodialysis.
- 1 mg protamine is required to neutralise 100 IU heparin; give slowly over 10 minutes, and do not exceed a total dose of 50 mg.
- To reduce or prevent fibrin formation in patients on PD, heparin may be added to PD fluid at a concentration of 1000 IU/L.
Hydralazine hydrochloride

Clinical use
Vasodilator antihypertensive agent

Dose in normal renal function
- Oral:
  - Hypertension: 25–50 mg twice daily; maximum daily dose 100 mg in women and slow acetylators, 200 mg in fast acetylators.
  - Heart failure: 25–75 mg 3–4 times daily.
- IV: slow IV injection: 5–10 mg over 20 minutes; repeat after 20–30 minutes if necessary.
- Infusion: 200–300 micrograms/minute initially, reducing to 50–150 micrograms/minute.

Pharmacokinetics
- Molecular weight (daltons) 196.6
- % Protein binding 87
- % Excreted unchanged in urine 2–14
- Volume of distribution (L/kg) 0.5–0.9
- Half-life — normal/ESRF (hrs) 2–4 / 16

Metabolism
Hydralazine undergoes considerable first-pass metabolism by acetylation in the gastrointestinal mucosa and liver. The rate of metabolism is genetically determined and depends upon the acetylator status of the individual. Systemic metabolism in the liver is by hydroxylation of the ring system and conjugation with glucuronic acid; most sources suggest that N-acetylation is not of major importance in systemic clearance and that therefore acetylator status does not affect elimination. Hydralazine is excreted mainly in urine as metabolites.

Dose in renal impairment GFR (mL/min)
- 20–50 Start at low dose and adjust in accordance with response.
- 10–20 Start at low dose and adjust in accordance with response.
- <10 Start at low dose and adjust in accordance with response.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
- Potentially hazardous interactions with other drugs
  - Anaesthetics: increased hypotensive effects.

Administration
Reconstitution
20 mg with 1 mL water for injection then dilute with 10 mL sodium chloride 0.9% for IV injection or 500 mL sodium chloride 0.9% for IV infusion.

Route
Oral, IV peripherally

Rate of administration
As above

Comments
Minimum volume of 60 mg in 60 mL. (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill patients, 3rd edition, 2006.)

Other information
- Avoid long-term use in severe renal insufficiency and dialysis patients, due to accumulation of metabolites.
Hydrocortisone acetate

Clinical use
Corticosteroid:
• Local inflammation of joints and soft tissue

Dose in normal renal function
5–50 mg according to joint size

Pharmacokinetics
Molecular weight (daltons) 404.5
% Protein binding >90
% Excreted unchanged in urine Minimal
Volume of distribution (L/kg) 0.4–0.7
Half-life — normal/ESRF (hrs) Approx 100 minutes / Unchanged

Metabolism
Hydrocortisone is metabolised in the liver and most body tissues to hydrogenated and degraded forms such as tetrahydrocortisone and tetrahydrocortisol. These are excreted in the urine, mainly conjugated as glucuronides, with a very small proportion of unchanged hydrocortisone.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Aldesleukin: avoid concomitant use.
• Antibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced.
• Anticoagulants: efficacy of coumarins and phenindione may be altered.
• Antiepileptics: metabolism accelerated by carbamazepine, phenobarbital, fosphenytoin, phenytoin and primidone.
• Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited by itraconazole and ketoconazole.
• Antivirals: concentration possibly increased by ritonavir.
• Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids.
• Cobicistat: concentration of hydrocortisone possibly increased – increased risk of adrenal suppression.
• Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
• Vaccines: high dose corticosteroids can impair immune response to vaccines – avoid concomitant use with live vaccines.

Administration
Reconstitution
—
Route
Intra-articular, periarticular
Rate of administration
—

Other information
• Used for its local effects. Systemic absorption occurs slowly.
# Hydrocortisone sodium succinate

## Clinical use
Corticosteroid:
- Anti-inflammatory agent in respiratory, GI, endocrine disorders, and allergic states
- Shock

## Dose in normal renal function
- Oral: 20–30 mg in divided doses for replacement
- MR: 20–30 mg once daily in the morning
- IV/IM: 100–500 mg, 3–4 times in 24 hours, or as required

## Pharmacokinetics
- Molecular weight (daltons) 484.5 (486.4 as sodium phosphate)
- % Protein binding >90
- % Excreted unchanged in urine Minimal
- Volume of distribution (L/kg) 0.4–0.7
- Half-life — normal/ESRF (hrs) Approx 100 minutes / Unchanged

## Metabolism
Hydrocortisone is metabolised in the liver and most body tissues to hydrogenated and degraded forms such as tetrahydrocortisone and tetrahydrocortisol. These are excreted in the urine, mainly conjugated as glucuronides, with a very small proportion of unchanged hydrocortisone.

## Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced.
- Anticoagulants: efficacy of coumarins and phenindione may be altered.
- Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited by itraconazole and ketoconazole.
- Antivirals: concentration possibly increased by ritonavir.
- Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids.
- Cobicistat: concentration of hydrocortisone possibly increased – increased risk of adrenal suppression.
- Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
- Vaccines: high dose corticosteroids can impair immune response to vaccines – avoid concomitant use with live vaccines.

## Administration
### Reconstitution
IV injection, IM injection: add 2 mL of sterile water for injection.
IV infusion: add not more than 2 mL water for injection, then add to 100–1000 mL (not less than 100 mL) glucose 5% or sodium chloride 0.9%.

### Route
IV injection, IV infusion, IM

### Rate of administration
IV bolus: 2–3 minutes

### Comments
Minimum volume 100 mg in 50 mL. (UK Critical Care Group, *Minimum Infusion Volumes for FluidRestricted Critically Ill Patients*, 3rd edition, 2006).

## Other information
- Non-plasma protein bound hydrocortisone is removed by HD.
- One study has shown that plasma clearance rates of hydrocortisone during haemodialysis were 30–63% higher than after dialysis. No recommendations exist to indicate dosing should be altered to take account of this.
Hydromorphone hydrochloride

Clinical use
Relief of severe cancer pain

Dose in normal renal function
1.3 mg 4 hourly, increasing dose as required.
SR: 4 mg 12 hourly, increasing dose as required.
SC: Bolus: 1–2mg every 3–4 hours, Infusion: 0.15–0.45 mg/hr (0.004 mg/kg/hr).
IV: Bolus: 1–1.5mg every 3–4 hours, Infusion: 0.15–0.45 mg/hr (0.004 mg/kg/hr).

Pharmacokinetics
Molecular weight (daltons) 321.8
% Protein binding 7.1
% Excreted unchanged in urine 6
Volume of distribution (L/kg) 0.99–1.45
Half-life — normal/ESRF (hrs) 2.5 / –

Metabolism
Hydromorphone undergoes extensive first-pass metabolism. It is extensively metabolised by glucuronidation in the liver and excreted in the urine mainly as conjugated hydromorphone, dihydroisomorphine, and dihydromorphine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Reduce dose — start with lowest dose and titrate according to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Reduce dose — start with lowest dose and titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Reduce dose — start with lowest dose and titrate according to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Delivery</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Alcohol: can cause dose dumping with sustained release preparations.
- Analgesics: possible opioid withdrawal effects with buprenorphine and pentazocine.
- Antidepressants: possible CNS excitation or depression with MAOIs — avoid concomitant use and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate — avoid.

Administration
Reconstitution
Route
Oral, IV bolus and infusion, SC
Rate of administration
Bolus: over 3–4 mins, Infusion: 0.15–0.45 mg/hr
Comments
If being administered with cyclizine in a pump it must be sufficiently diluted with water for injection rather than sodium chloride 0.9% to prevent precipitation.

Other information
- 1.3 mg of hydromorphone is equivalent to 10 mg oral morphine.
- An approximate conversion is 3 mg of oral hydromorphone is equivalent to 1 mg of intravenous hydromorphone.
- Metabolites may cause neuroexcitation and cognitive impairment.
Hydroxycarbamide (hydroxyurea)

**Clinical use**
Antineoplastic agent

**Dose in normal renal function**
CML: 20–30 mg/kg daily or 80 mg/kg every 3 days
Consult local protocol

**Pharmacokinetics**
- Molecular weight (daltons) 76.05
- % Protein binding 75–80
- % Excreted unchanged in urine 9–95
- Volume of distribution (L/kg) 0.5
- Half-life — normal/ESRF (hrs) 2–6 / –

**Metabolism**
Up to 50% of a dose is metabolised by the liver; 50% of a dose of hydroxyurea is excreted in urine as metabolites and unchanged drug. Some is excreted as carbon dioxide via the lungs or via the urine as urea. About 80% of a dose is reported to be excreted in the urine within 12 hours.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Antivirals: increased toxicity with didanosine and stavudine – avoid.
- Vaccines: risk of generalised infections – avoid.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
<td>85% of normal dose and titrate to response.¹</td>
</tr>
<tr>
<td>45–60</td>
<td>80% of normal dose and titrate to response.¹</td>
</tr>
<tr>
<td>30–45</td>
<td>75% of normal dose and titrate to response.¹</td>
</tr>
<tr>
<td>10–30</td>
<td>50% of normal dose and titrate to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>20% of normal dose and titrate to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Likely dialysability. Dose as in GFR<10 mL/min.
- HD Likely dialysability. Dose as in GFR<10 mL/min.
- HDF/High flux Likely dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Likely dialysability. Dose as in GFR=10–30 mL/min.

**Other information**
- Full blood count, renal and hepatic function should be monitored repeatedly during treatment.
- Dosage should be based on the patient’s actual or ideal weight, whichever is less.
- Hydroxyurea has been associated with impairment of renal tubular function and accompanied by elevation in serum uric acid, BUN, and creatinine levels.
- The following formula can be used to determine the fraction of normal dose used for renally impaired patients: Fraction of normal dose = (normal dose) × [(f (k, − 1)) + 1]. f = fraction of the original dose excreted as active or toxic moiety (f = 0.35 for hydroxyurea); k, = patient’s creatinine clearance (mL/min) divided by 120 mL/minute.
- Administer with caution to patients with marked renal dysfunction; such patients may rapidly develop visual and auditory hallucinations and significant haematological toxicity.
- Doses in severe renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.

**Reference:**
Hydroxychloroquine sulphate

Clinical use

- Rheumatoid arthritis
- Systemic lupus erythematosus
- Dermatological conditions caused or aggravated by sunlight
- Malaria (unlicensed in UK)

Dose in normal renal function

200–400 mg daily in divided doses; maximum of 6.5 mg/kg/day
Prophylaxis of malaria: 400 mg weekly

Pharmacokinetics

Molecular weight (daltons) 434
% Protein binding 30–40
% Excreted unchanged in urine 3
Volume of distribution (L/kg) Large
Half-life — normal/ESRF (hrs) 5.9–504 / –

Metabolism

Hydroxychloroquine is metabolised to chloroquine, which in turn is extensively metabolised in the liver, mainly to monodesethylchloroquine with smaller amounts of bisdesethylchloroquine (didesethylchloroquinine) and other metabolites being formed. Monodesethylchloroquine has been reported to have some activity against Plasmodium falciparum. Chloroquine and its metabolites are excreted in the urine, with about half of a dose appearing as unchanged drug and about 10% as the monodesethyl metabolite.

Dose in renal impairment GFR (mL/min)

See 'Other information'.
30–50 150 mg daily.
10–30 50–100 mg daily. Use with caution.
<10 50–100 mg daily. Use with caution.

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs

- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin – avoid.
- Antiepileptics: antagonism of anticonvulsant effect.
- Antimalarials: increased risk of convulsions with mefloquine; avoid with artemether/lumefantrine.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol – avoid.
- Ciclosporin: increased ciclosporin concentration (increased risk of toxicity).
- Cytotoxics: possibly increased risk of ventricular arrhythmias with bosutinib.
- Digoxin: possibly increased concentration of digoxin.
- Lanthanum: absorption possibly reduced by lanthanum – give at least 2 hours apart.

Administration

Reconstitution

Route
Oral
Rate of administration

Other information

- Take with a meal or a glass of milk.
- Excretory patterns are not well characterised, but hydroxychloroquine and its metabolites are slowly excreted via the kidneys.
- Attempt to avoid prolonged use in renal failure.
- In renal insufficiency, need more than annual eye examinations.
- Doses in renal impairment are from Seyffart, but probably not actually practical to give reduced dose so try giving longer dose intervals.
Hydroxyzine hydrochloride

### Clinical use
Antihistamine:
- Pruritus
- Anxiety (short-term)

### Dose in normal renal function
- Pruritus: 25 mg at night increasing as necessary to 3–4 times a day
- Anxiety: 50–100 mg 4 times daily
- Maximum daily dose: 100 mg daily, 50 mg in elderly

### Pharmacokinetics
- Molecular weight (daltons) 447.8
- % Protein binding No data
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) 19.5
- Half-life — normal/ESRF (hrs) 20 / –

### Metabolism
Hydroxyzine is extensively metabolised. The formation of the major metabolite cetirizine, a carboxylic acid metabolite (approximately 45% of the oral dose), is mediated by alcohol dehydrogenase. This metabolite has significant peripheral H1-antagonist properties. The other metabolites identified include a N-dealkylated metabolite, and an O-dealkylated metabolite with a plasma half-life of 59 hours. These pathways are mediated principally by CYP3A4/5. Only 0.8% of the dose is excreted unchanged in urine. The major metabolite cetirizine is excreted mainly unchanged in urine (25% and 16 % of the hydroxyzine oral and IM dose, respectively).

### Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: sedative effects possibly increased with opioid analgesics.

### Administration
- Reconstitution —
- Route Oral
- Rate of administration —

### Other information
- Increased possibility of side effects, particularly drowsiness.
- Can cause QT prolongation. Avoid in patients at risk of QT prolongation.

### Reference:
Hyoscine butylbromide

Clinical use
Symptomatic relief of gastrointestinal or genitourinary disorders due to smooth muscle spasm
- Bowel colic
- Excessive respiratory secretions

Dose in normal renal function
- Oral: 20 mg 4 times a day
- Irritable bowel syndrome: 10 mg 3 times a day, increasing to 20 mg 4 times a day if required
- IV/IM: 20 mg repeated after 30 minutes if required; maximum 100 mg daily
- Bowel colic: 60–300 mg/24 hours by subcutaneous infusion
- Excessive respiratory secretions: 20–120 mg/24 hours by subcutaneous infusion

Pharmacokinetics
Molecular weight (daltons) 440.4
% Protein binding 10
% Excreted unchanged in urine 1–2
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 8 / –

Metabolism
The main metabolic pathway is the hydrolytic cleavage of the ester bond. Orally administered hyoscine butylbromide is excreted in the faeces and in the urine. Studies in man show that 2–5% of radioactive doses is eliminated renally after oral, and 0.7–1.6% after rectal administration. Approximately 90% of recovered radioactivity can be found in the faeces after oral administration. The urinary excretion of hyoscine butylbromide is less than 0.1% of the dose. The metabolites excreted via the renal route bind poorly to muscarinic receptors and are therefore not considered to contribute to the effect of the hyoscine butylbromide.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution

Route
Oral, IV, IM, SC

Rate of administration

Other information
- Only 2–8% of oral dose is absorbed.
- Risk of adverse effects (including tachycardia, hypotension and anaphylaxis) in patients with underlying cardiac disease. MHRA February 2017.
Hyoscine hydrobromide

**Clinical use**
- Motion sickness
- Premedication
- Palliative care
- Hypersalivation with clozapine therapy (unlicensed)

**Dose in normal renal function**
- Motion sickness:
  - Oral: 150–300 mcg 30 minutes before start of journey then repeat every 6 hours if required; maximum 900 mcg in 24 hours.
  - Topical: 1 patch 5–6 hours before journey replace after 72 hours.
- Hypersalivation: 300 mcg up to 3 times daily.
- Premedication (SC/IM): 200–600 mcg 30–60 minutes before anaesthesia.
- SC Infusions: Excessive secretions and bowel colic (patch can also be used for excessive secretions): 1.2–2 mg over 24 hours.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Pharmacokinetics**
- Molecular weight (daltons) 438.3
- % Protein binding 10
- % Excreted unchanged in urine 2 (1 – oral, 34 – transdermal)
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 8 / –

**Metabolism**
Hyoscine hydrobromide is almost entirely metabolised, probably in the liver; only a small proportion of an oral dose is excreted unchanged in the urine. In one study in man, 3.4% of a single dose, administered by subcutaneous injection was excreted unchanged in urine within 72 hours.

**Administration**

**Reconstitution**
—

**Route**
Oral, topical, SC, IM

**Rate of administration**
—

**Other information**
- Only 2–8% of oral dose is absorbed.
- Manufacturer advises to use with caution in renal impairment.
Ibandronic acid

Clinical use
Bisphosphonate:
- Reduction of bone damage in bone metastases in breast cancer
- Hypercalcaemia of malignancy
- Postmenopausal osteoporosis

Dose in normal renal function
- Oral: 50 mg daily
- IV: 6 mg every 3–4 weeks
- Hypercalcaemia of malignancy: 2–4 mg as a single dose, repeated according to serum calcium level
- Postmenopausal osteoporosis: 150 mg monthly (oral), 3 mg every 3 months (IV bolus)

Pharmacokinetics
Molecular weight (daltons) 319.2 (Ibandronate Na 359.2)
% Protein binding 87
% Excreted unchanged in urine 50–60
Volume of distribution (L/kg) 90 Litres
Half-life — normal/ESRF (hrs) 10–72
Insignificantly increased¹

Metabolism
After initial systemic exposure, ibandronic acid rapidly binds to bone or is excreted into urine. There is no evidence that ibandronic acid is metabolised in animals or humans. The absorbed fraction of ibandronic acid is removed from the circulation via bone absorption (estimated to be 40–50% in postmenopausal women) and the remainder is eliminated unchanged by the kidney. The unabsorbed fraction of ibandronic acid is eliminated unchanged in the faeces. Renal clearance accounts for 50–60% of total clearance and is related to creatinine clearance. The difference between the apparent total and renal clearances is considered to reflect the uptake by bone.

Dose in renal impairment GFR (mL/min)
- 30–50 Oral: 50 mg every 48 hours. IV: 4 mg every 3–4 weeks. See ‘Other information’.
- 10–30 Oral: 50 mg weekly, IV infusion: 2 mg every 3–4 weeks. See ‘Other information’.
- <10 Oral: 50 mg weekly. IV infusion: 2 mg every 3–4 weeks. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Dialysed.² Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed.² Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
- Route Oral, IV infusion, IV bolus
Rate of administration
- Infusion: over 15 minutes – 2 hours (depends on indication and renal function)
- IV bolus: over 15–30 seconds
Comments
- Add dose to 100–500 mL glucose 5% or sodium chloride 0.9% (depends on indication and renal function).

Other information
- Oral bioavailability <1%.
- Swallow tablets whole with a glass of water on an empty stomach, at least 30 minutes before breakfast and any other oral medication.
• The patient should stand or sit upright for at least 60 minutes after taking tablets.
• Do not give infusion over 15 minutes if CRCL<50 mL/min; give in 500 mL over 1 hour.
• Bolus dose is contraindicated if GFR<30 mL/min due to lack of studies.
• One study used a dose of 6 mg over 30 minutes in various degrees of renal impairment with no deterioration in renal function.¹
• Clearance is reduced in severe renal impairment.
• Due to the high bone-binding effect with ibandronic acid a dose of 2 mg monthly in haemodialysis patients is equivalent to a dose of 4–5 mg in patients with normal renal function.³
• May cause osteonecrosis of the jaw similar to other bisphosphonates.

References:
Ibrutinib

Clinical use
Tyrosine kinase inhibitor:
• Treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL)
• Treatment of Waldenström’s macroglobulinaemia (WM)

Dose in normal renal function
• MCL: 560 mg once daily
• CLL/WM: 420 mg once daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>440.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97.3</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0 (&lt;10 as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>10 000 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4–13 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism
Ibrutinib is metabolised primarily by CYP3A4 to produce a dihydrodiol metabolite with an inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib. Involvement of CYP2D6 in the metabolism of ibrutinib appears to be minimal.

After a single oral administration of radiolabeled [14C]-ibrutinib in healthy subjects, approximately 90% of radioactivity was excreted within 168 hours, with the majority (80%) excreted in the faeces and <10% in the urine. Unchanged ibrutinib accounted for approximately 1% of the radiolabeled excretion product in faeces and none in urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Anti-arrhythmics: concentration possibly increased by amiodarone and dronedarone – avoid or reduce dose of ibrutinib.
• Antibacterials: concentration possibly increased by ciprofloxacin, clarithromycin, erythromycin and telithromycin – avoid or reduce dose of ibrutinib; concentration reduced by rifampicin – avoid.
• Antidepressants: concentration possibly reduced by St. John’s wort – avoid.
• Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital and phenytoin – avoid.
• Antifungals: concentration possibly increased by fluconazole, itraconazole, ketoconazole and voriconazole – avoid or reduce dose of ibrutinib.
• Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
• Antivirals: concentration possibly increased by atazanavir, darunavir, fosamprenavir, indinavir, ritonavir and saquinavir – avoid or reduce dose of ibrutinib.
• Aprepitant: concentration possibly increased – avoid or reduce dose of ibrutinib.
• Calcium channel blockers: concentration possibly increased by diltiazem or verapamil – avoid or reduce dose of ibrutinib.
• Cobicistat: concentration possibly increased, avoid or reduce dose of ibrutinib.
• Cytotoxics: concentration possibly increased by crizotinib – avoid or reduce dose of ibrutinib; concentration possibly increased by imatinib – reduce dose of ibrutinib.
• Grapefruit juice and Seville oranges: avoid.
<table>
<thead>
<tr>
<th>Administration</th>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reconstitution</td>
<td>• Oral bioavailability in fasted state is 2.9%. Doubled if taken with a meal.</td>
</tr>
<tr>
<td>Route</td>
<td>• A case study has been reported in a patient who started with CKD and was temporarily on haemodialysis who was given ibrutinib at normal dose for CLL. His renal function improved on the ibrutinib as well as disease control of his CLL. (Aw A, Hellman JM, Birner A, et al. A complex case of ibrutinib treatment for a CLL patient on haemodialysis. Br J Haematol. May 2017; doi: 10.1111/bjh.14718.)</td>
</tr>
<tr>
<td>Rate of administration</td>
<td>• Manufacturer has no data in creatinine clearance &lt;30 mL/min and advises to use only if benefit outweighs the risks.</td>
</tr>
</tbody>
</table>
Ibuprofen

**Clinical use**
NSAID and analgesic

**Dose in normal renal function**
Initially: 200–400 mg 3–4 times daily, after food.
Maximum 2.4 g daily

**Pharmacokinetics**
- Molecular weight (daltons) 206.3
- % Protein binding 90–99
- % Excreted unchanged in urine 1
- Volume of distribution (L/kg) 0.14
- Half-life — normal/ESRF (hrs) 2 / Unchanged

**Metabolism**
Ibuprofen is rapidly excreted in the urine mainly as metabolites and their conjugates. About 1% is excreted in the urine as unchanged ibuprofen and about 14% as conjugated ibuprofen.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function, but avoid if possible.
- 10–20: Dose as in normal renal function, but avoid if possible.
- <10: Dose as in normal renal function, but only use if on dialysis.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function. See ‘Other information’.
- HD: Not dialysed. Dose as in normal renal function. See ‘Other information’.
- HDF/High flux: Not dialysed. Dose as in normal renal function. See ‘Other information’.
- CAV/VVHD: Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage); possibly reduced antiplatelet effect with aspirin.
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

**Other information**
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.
- Use normal doses in patients with ERF on dialysis if they do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autacoid synthesis.
Idarubicin is extensively metabolised, both in the liver and extrahepatically; the principal metabolite, idarubicinol (13-dihydroidarubicin) has equal antineoplastic activity. Peak concentrations of idarubicin and idarubicinol in bone marrow and nucleated blood cells are 400 (idarubicin) and 200 (idarubicinol) times greater than those in plasma; cellular concentrations of drug and metabolite decline with apparent terminal half-lives of 15 and 72 hours respectively, whereas plasma half-lives are reported to be 20–22 hours and about 45 hours respectively. Idarubicin is excreted in bile, and to a lesser extent in urine, as unchanged drug and metabolites. 17% (IV) / 8% (oral) is recovered in the faeces over 5 days and 16% (IV) / 5% (oral) is recovered in the urine over 4 days.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Use 75% of dose.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use 75% of dose with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use 50% of dose with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

### Important drug interactions

Potentially hazardous interactions with other drugs:
- Other myelosuppressant medication and radiotherapy: increased risk of myelosuppression.
- Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis.
- Ciclosporin: concentration increased by ciclosporin.
- Cytotoxics: possible increased cardiotoxicity with trastuzumab.
- Live vaccines: risk of generalised infections – avoid.

### Administration

#### Reconstitution

5 mL water for injection per 5 mg

#### Route

IV, oral, intravesical

#### Rate of administration

Give via the tubing of a fast running intravenous infusion of sodium chloride 0.9% or glucose 5%, over 5–10 minutes

#### Comments

- Incompatible with alkaline solutions and heparin.
- Reconstituted solution is physically and chemically stable for 7 days at 2–8°C and 72 hours at room temperature.
- Does not contain any antibacterial preservative so maximum recommended stability is 24 hours.
Other information

- Contraindicated by manufacturer in severe renal impairment.
- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- May cause the urine to become red for 1–2 days after administration.
- Oral bioavailability is between 18–39%, 29–58% for idarubicinol.

- A phase II study instilled 6.25–12.5 mg of idarubicin diluted in 45 mL of sodium chloride 0.9% (0.125–0.25 mg/mL) into the bladder of patients with resected recurrent bladder cancer although it may not be any more effective than doxorubicin or epirubicin and toxicity may limit its use. (Boccardo F, Cannata D, Cussotto M, et al. Intravesical idarubicin: a dose-finding study. Cancer Chemother Pharmacol. 1996; 38(1): 102-5.)
Idarucizumab

Clinical use
Humanised monoclonal antibody fragment:
• Rapid reversal of dabigatran

Dose in normal renal function
• 5 g stat
• A 2nd dose can be given in certain circumstances

Pharmacokinetics
Molecular weight (daltons) 47 766
% Protein binding No data
% Excreted unchanged in urine 32.1
Volume of distribution (L/kg) 8.9 Litres
Half-life — normal/ESRF (hrs) 10.3 / –

Metabolism
Several pathways have been described that may contribute to the metabolism of antibodies. All of these pathways involve biodegradation of the antibody to smaller molecules, i.e. small peptides or amino acids, which are then reabsorbed and incorporated in the general protein synthesis.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Vaccines: avoid concomitant use with live vaccines.

Administration
Reconstitution
Route
IV infusion, IV bolus
Rate of administration
5–10 minutes per 2.5 g infusion

Other information
• Idarucizumab causes transient proteinuria that usually peaks about 4 hours after a dose and normalises within 12–24 hours. It is due to renal protein overflow and is not a sign of renal damage.

Idarucizumab causes transient proteinuria that usually peaks about 4 hours after a dose and normalises within 12–24 hours. It is due to renal protein overflow and is not a sign of renal damage.
**Idelalisib**

**Clinical use**
Phosphatidylinositol 3-kinase p110δ (PI3Kδ) inhibitor:
- Treatment of chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL)

**Dose in normal renal function**
150 mg twice daily

**Pharmacokinetics**
- Molecular weight (daltons) 415.4
- % Protein binding 93–94%
- % Excreted unchanged in urine 23
- Volume of distribution (L/kg) 96 Litres
- Half-life — normal/ESRF (hrs) 8.2 / Unchanged

**Metabolism**
Idelalisib is metabolised mainly via aldehyde oxidase, and to a lesser extent via CYP3A and UGT1A4. The primary and only circulating metabolite, GS-563117, is inactive against PI3Kδ.

Following a single 150 mg oral dose of [14C]-labelled idelalisib, approximately 78% and 15% was excreted in faeces and urine, respectively. Unchanged idelalisib accounted for 23% of total radioactivity recovered in urine over 48 hours and 12% of total radioactivity recovered in faeces over 144 hours.

**Dose in renal impairment GFR (mL/min)**
- 30–50: Dose as in normal renal function.
- 10–30: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin – avoid.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis; avoid with pimozi and quetiapine.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- A study of pharmacokinetics and safety of idelalisib was performed in healthy subjects and subjects with severe renal impairment (estimated CRCL=15–29 mL/min). Following a single 150 mg dose, no clinically relevant changes in exposures to idelalisib or GS-563117 were observed in subjects with severe renal impairment compared to healthy subjects.
Ifosfamide

**Clinical use**

Antineoplastic agent:
- Treatment of solid tumours, lymphomas and soft tissue sarcoma

**Dose in normal renal function**

- Usual total dose for each course is either 8–12 g/m², equally divided as single daily doses over 3–5 days, or 5–6 g/m² (maximum 10 g) given as a 24 hour infusion
- **OR** according to local protocol

**Pharmacokinetics**

- Molecular weight (daltons) 261.1
- % Protein binding 0
- % Excreted unchanged in urine 12–18
- Volume of distribution (L/kg) 0.4–0.64
- Half-life — normal/ESRF (hrs) 4–8 / –

**Metabolism**

The pharmacokinetics of ifosfamide are reported to exhibit considerable inter-individual variation. It is a prodrug that is extensively metabolised, chiefly by cytochrome P450 isoenzymes CYP3A4 and CYP2B6 in the liver, to both active and inactive alkylating metabolites; there is some evidence that metabolism is saturated at very high doses. After repeated doses (fractionated therapy) there is a decrease in the elimination half-life, apparently due to auto-induction of metabolism. It is excreted largely in urine, as unchanged drug (80%) and metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
<td>80% of normal dose.</td>
</tr>
<tr>
<td>30–60</td>
<td>80% of normal dose.</td>
</tr>
<tr>
<td>15–30</td>
<td>80% of normal dose.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>60% of normal dose.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Dialysed. Dose as in GFR<15 mL/min. Following dose, do not perform CAPD exchange for 12 hours.
- HD: Dialysed. Dose as in GFR<15 mL/min. Dose at minimum of 12 hours before next HD session.
- HDF/High flux: Dialysed. Dose as in GFR<15 mL/min. Dose at minimum of 12 hours before next HD session.
- CAV/VVHD: Dialysed. Dose as in GFR=15–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhanced effect of coumarins.
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).

**Administration**

**Reconstitution**

Reconstitute 1 g vial with 12.5 mL water for injection. Reconstitute 2 g vial with 25 mL water for injection. The resultant solution of 8% ifosfamide should NOT be injected directly into the vein.

**Route**

IV injection: dilute to less than a 4% solution.
IV infusion: dilute as detailed below.

**Rate of administration**

IV infusion:
- Infuse in glucose 5% or sodium chloride 0.9% over 30–120 minutes, or
- Inject directly into a fast running infusion, or
- Made up in 3 L of glucose 5% or sodium chloride 0.9%; each Litre should be given over 8 hours.

**Other information**

- Nephrotoxicity may occur with oliguria, raised uric acid, increased BUN and serum creatinine, and decreased creatinine clearance.
- Ifosfamide is known to be more nephrotoxic than cyclophosphamide; hence greater caution is advised.
- SPC contraindicates the use of ifosfamide if serum creatinine >120 μmol/L.
- If patient is anuric and on dialysis, neither the ifosfamide nor its metabolites nor Mesna should
Ifosfamide

appear in the urinary tract. The use of Mesna may therefore be unnecessary, although this would be a clinical decision.

- If the patient is passing urine, Mesna should be given to prevent urothelial toxicity.

| GFR > 60 mL/min | 80% of dose |
| GFR = 45–60 mL/min | 75% of dose |
| GFR = 30–45 mL/min | 70% of dose |

- There are 3 case reports of ifosfamide being used in doses of 1.5-4 g/m² in patients on haemodialysis, the main side effect was myelosuppression.

Reference:
# Iloprost

## Clinical use
Prostacyclin analogue:
- Treatment of pulmonary arterial hypertension
- Relief of pain, promotion of ulcer-healing and limb salvage in patients with severe peripheral arterial ischaemia (unlicensed product)

## Dose in normal renal function
- Pulmonary hypertension:
  - Nebulised: 2.5–5 mcg per inhalation session 6–9 times per day
  - IV: Usually 1–8 ng/kg/min, but can use higher doses (up to 25 ng/kg/min) according to response.
- Severe peripheral arterial ischaemia:
  - Dose is adjusted according to individual tolerability within the range of 0.5–2 nanograms/kg/minute over 6 hours daily.

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>360.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>≈60</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.6–0.8</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.3–0.5 / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
On intravenous infusion iloprost is rapidly cleared from the plasma by oxidation. About 80% of the metabolites are excreted in urine and 20% in the bile.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: enhanced anticoagulant effect and increased risk of bleeding with heparin, coumarins and phenindione, as iloprost inhibits platelet aggregation.
- Increased risk of bleeding with NSAIDs, aspirin, clopidogrel, eptifibatide and tirofiban.

## Administration
### Reconstitution
Dilute 0.1 mg with 500 mL sodium chloride 0.9% or glucose 5%. Final concentration = 0.2 micrograms iloprost/mL.

### Route
Nebulised, IV infusion via peripheral vein or central venous catheter.

### Rate of administration
Infuse 0.1mg over 6 hours daily (see below).

### Comments
- Treatment should be started at an infusion rate of 10 mL/hour for 30 minutes, which corresponds to a dose of 0.5 nanograms/kg/minute for a patient of 65 kg.
- Then increase dose in steps of 10 mL/hour every 30 minutes up to a rate of 40 mL/hour (50 mL/hour if patient's body weight is more than 75 kg).
- If side effects occur (e.g. headache, nausea, or an undesired drop in BP), infusion rate should be reduced until the tolerable dose is found; if side effects are severe, infusion should be interrupted.
- For rest of the treatment period, continue with dose found to be tolerated in the first 2–3 days.

## Other information
- BP and heart rate must be measured at the start of the infusion and after every increase in dose.
- Duration of treatment is up to 4 weeks. Shorter treatment periods (3–5 days) are often sufficient in Raynaud’s phenomenon.
- Iloprost infusions can also be used to control blood pressure during a scleroderma hypertensive crisis.
- For fluid-restricted patients, dilute 0.1 mg iloprost with 50 mL sodium chloride 0.9%, and run at a rate of 1–4 mL/hour.
- Toxic by inhalation, contact with skin, and if swallowed.
- Manufacturer advises to use with caution if GFR<30 mL/min due to lack of data.
Imatinib

**Clinical use**

Tyrosine kinase inhibitor, antineoplastic agent:
- Treatment of chronic myeloid leukaemia
- Treatment of metastatic malignant gastrointestinal stromal tumours
- Treatment of acute lymphoblastic leukaemia

**Dose in normal renal function**

- 400–600 mg daily, increasing to a maximum of 400 mg twice daily
- Dose depends on indication

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>589.7 (as mesilate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>18 / Unknown</td>
</tr>
</tbody>
</table>

**Metabolism**

The main circulating metabolite in humans is the N-demethylated piperazine derivative, which shows similar *in vitro* potency to the parent. Imatinib and the N-demethyl metabolite together accounted for about 65% of the circulating radioactivity (AUC\(_{0-48h}\)). The remaining circulating radioactivity consisted of a number of minor metabolites. *In vitro* results showed that CYP3A4 was the major human P450 enzyme catalysing the biotransformation of imatinib. Based on the recovery of compound(s) after an oral \[^{14}\text{C}\]-labelled dose of imatinib, approximately 81% of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% faeces), the remainder being metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR range (mL/min)</th>
<th>Dose prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin – avoid.
- Anticoagulants: enhanced anticoagulant effect of warfarin, replace with heparin.
- Antiepileptics: concentration reduced by carbamazepine, fosphenytoin, oxcarbazepine and phenytoin – avoid; absorption of phenytoin possibly reduced.
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).
- Antivirals: avoid with boceprevir.
- Ciclosporin: may increase ciclosporin levels.
- Cytotoxics: possibly increases bosutinib concentration – avoid or reduce bosutinib dose; concentration of everolimus and possibly ibrutinib increased – reduce dose of everolimus and ibrutinib.
- Tacrolimus: may increase tacrolimus levels.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—
Other information

- Manufacturer recommends a starting dose of 400 mg daily if CRCL < 60 mL/min.
- Associated with oedema and superficial fluid retention in 50–70% of cases. Probability is increased in patients receiving higher doses, age > 65 years, and those with a prior history of cardiac disease. Severe fluid retention (e.g. pleural effusion, pericardial effusion, pulmonary oedema and ascites) has been reported in up to 16% of patients. Can be managed by diuretic therapy, and dose reduction or interruption of imatinib therapy.
- Severe elevation of serum creatinine has been observed in approximately 1% of patients.
- Oral bioavailability is 98%.
Imidapril hydrochloride

Clinical use
Angiotensin-converting enzyme inhibitor:
• Hypertension

Dose in normal renal function
2.5–20 mg once daily

Pharmacokinetics
Molecular weight (daltons) 441.9
% Protein binding 85
% Excreted unchanged in urine 9 (as imidaprilat)
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 2 / Increased (>24 hours as imidaprilat)

Metabolism
Imidapril is a prodrug, and is metabolised in the liver to the diacid imidaprilat, its active metabolite. The bioavailability of imidaprilat is about 42% after oral doses of imidapril.
About 40% of an oral dose is excreted in the urine, the rest in the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Initially 2.5 mg daily and adjust according to response.
10–20 Initially 2.5 mg daily and adjust according to response.
<10 Initially 2.5 mg daily and adjust according to response.

Dose in patients undergoing renal replacement therapies
APD/CAPD Probably dialysed. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Probably dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Anaesthetics: enhanced hypotensive effect.
• Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
• Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
• Bee venom extract: possible severe anaphylactoid reactions when used together.
• Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
• Cytotoxics: increased risk of angioedema with everolimus.
• Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
• ESAs: increased risk of hyperkalaemia and hypotensive effect.
• Gold: flushing and hypotension with sodium aurothiomalate.
• Lithium: reduced excretion, possibility of enhanced lithium toxicity.
• Potassium salts: increased risk of hyperkalaemia.
• Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Hyperkalaemia and other side effects are more common in patients with impaired renal function.
• Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
• Renal failure has been reported in association with ACE inhibitors with renal artery stenosis, post renal transplant or congestive heart failure.
• High incidence of anaphylactoid reactions have been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor – combination should therefore be avoided.
Imipramine hydrochloride

**Clinical use**
Tricyclic antidepressant

**Dose in normal renal function**
25 mg up to 3 times daily increasing up to 150–200 mg daily; maximum 300 mg in hospital patients

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>316.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>31</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>9–28 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Imipramine is extensively demethylated by first-pass metabolism in the liver, to its primary active metabolite, desipramine (desmethylimipramine). Paths of metabolism of both imipramine and desipramine include hydroxylation and N-oxidation.

About 80% is excreted in the urine and about 20% in the faeces, mainly in the form of inactive metabolites. Urinary excretion of unchanged imipramine and of the active metabolite desipramine is about 5% and 6% respectively. Only small quantities of these are excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Alcohol: increased sedative effect.
- Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; increased risk of ventricular arrhythmias with disopyramide, flecainide or propafenone; avoid with dronedarone.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid, moxifloxacin and possibly telithromycin – avoid with delamanid and moxifloxacin.
- Anticoagulants: may alter anticoagulant effect of coumarins.
- Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide – avoid; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram – avoid; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, phenobarbital and possibly fosphenytoin, phenytoin and primidone.
- Antimalarials: avoid with arteether/lumefantrine and piperaquine with arteminol.
- Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, fluphenazine, haloperidol, pimozide, sulpiride and zuclopenthixol – avoid; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased with ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol; concentration increased by labetalol and propranolol.
- Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.
- Dapoxetine: possibly increased risk of serotonergic effects – avoid.
- Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline.
• Pentamidine: increased risk of ventricular arrhythmias.
• Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.
**Indapamide**

**Clinical use**
Thiazide-like diuretic:
- Essential hypertension

**Dose in normal renal function**
- 2.5 daily in the morning
- Modified release: 1.5 mg daily in the morning

**Pharmacokinetics**
- Molecular weight (daltons) 365.8
- % Protein binding 79
- % Excreted unchanged in urine 5–7
- Volume of distribution (L/kg) 0.3–1.3
- Half-life — normal/ESRF (hrs) 14–24 / Unchanged

**Metabolism**
Indapamide is strongly bound to red blood cells, and is taken up by the vascular wall in smooth vascular muscle according to its high lipid solubility. 60–70% of a single oral dose is eliminated by the kidneys and 23% by the gastrointestinal tract. Indapamide is extensively metabolised with 5–7% of unchanged drug found in the urine during the 48 hours following administration. About 16–23% of dose is excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect.
- Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised.
- Antibacterials: avoid administration with lymecycline.
- Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hypokalaemia with carbamazepine.
- Antifungals: increased risk of hypokalaemia with amphotericin.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol.
- Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide – avoid.
- Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia.
- Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium excretion reduced (increased toxicity).

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—
Other information

- If pre-existing renal insufficiency is aggravated – stop indapamide.
- Doses greater than 2.5 mg daily are not recommended.
- Caution if hypokalaemia develops.
- Ineffective in ERF.
- One-month studies of functionally anephric patients undergoing chronic haemodialysis have not shown evidence of drug accumulation, despite the fact that indapamide is not dialysable.
- Contraindicated by manufacturer in severe renal impairment in UK SPC but not US data sheet.
Indinavir

Clinical use

Protease inhibitor:
- Treatment of HIV infection, in combination with a nucleoside reverse transcriptase inhibitor

Dose in normal renal function

800 mg every 8 hours

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>711.9 (as sulphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>10.4</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>14</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.8 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism

Seven major metabolites have been identified and the metabolic pathways were identified as glucuronidation at the pyridine nitrogen, pyridine–N–oxidation with and without 3’–hydroxylation on the indane ring, 3’–hydroxylation of indane, p–hydroxylation of phenylmethyl moiety, and N–depyridomethylation with and without the 3’–hydroxylation. In vitro studies with human liver microsomes indicated that CYP3A4 is the only P450 isozyme that plays a major role in the oxidative metabolism of indinavir. Analysis of plasma and urine samples from subjects who received indinavir indicated that indinavir metabolites had little proteinase inhibitory activity. Less than 20 % of indinavir is excreted renally, about half of this as unchanged drug. The remainder is excreted in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Monitor closely.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Monitor closely.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Dialysis Method</th>
<th>Dose and Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min. Monitor closely.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min. Monitor closely.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min. Monitor closely.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

- Anti-arrhythmics: possibly increased amiodarone and flecainide concentration – avoid.
- Antibacterials: rifampicin increases metabolism – avoid concomitant use; increased rifabutin concentration – avoid; avoid with telithromycin in severe renal and hepatic failure.
- Anticoagulants: avoid with apixaban and rivaroxaban.
- Antidepressants: concentration reduced by St John’s wort – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenytoin, primidone and phenobarbital, also concentration of carbamazepine, fosphenytoin and phenytoin increased.
- Antifungals: itraconazole and ketoconazole inhibits metabolism – reduce dose of indinavir to 600 mg every 8 hours.
- Antimalarials: use artemether/lumefantrine with caution; possibly increased quinine concentration.
- Antipsychotics: possibly increased risk of ventricular arrhythmias with pimozide – avoid; possibly inhibits aripiprazole metabolism – reduce aripiprazole dose; possibly increases lurasidone and quetiapine concentration – avoid.
- Antivirals: avoid with atazanavir; concentration reduced by efavirenz, nevirapine and possibly etravirine, avoid with etravirine; concentration of both drugs increased with darunavir; concentration of maraviroc increased, consider reducing maraviroc dose; concentration increased by ritonavir; saquinavir concentration increased.
- Anxiolytics and hypnotics: increased risk of prolonged sedation with alprazolam and midazolam – avoid.
• Avanafil: concentration of avanafil possibly increased – avoid.
• Ciclosporin: concentration of ciclosporin increased.
• Colchicine: possibly increases risk of colchicine toxicity, avoid in hepatic or renal impairment.
• Cytotoxics: possibly increases concentration of axitinib, reduce dose of axitinib; possibly increases bosutinib, cabazitaxel and docetaxel concentration – avoid or reduce dose of bosutinib, cabazitaxel and docetaxel; possibly increases concentration of crizotinib and everolimus – avoid; possibly increases ibrutinib concentration, reduce dose of ibrutinib; avoid with olaparib and pazopanib; reduce dose of ruxolitinib.
• Ergot alkaloids: risk of ergotism – avoid.
• Guanfacine: possibly increases guanfacine concentration, halve dose of guanfacine.
• 5HT\textsubscript{1} agonists: concentration of eletriptan increased – avoid.
• Lipid-regulating drugs: avoid with lomitapide increased risk of myopathy with rosvustatin and simvastatin – avoid; and possibly with atorvastatin.
• Naloxegol: possibly increases naloxegol concentration – avoid.
• Orlistat: absorption possibly reduced by orlistat.
• Ranolazine: possibly increases ranolazine concentration – avoid.
• Sildenafil: concentration of sildenafil increased – reduce initial sildenafil dose.
• Vardenafil: concentration of vardenafil increased – avoid.

**Administration**

**Reconstitution**

**Route**

Oral

**Rate of administration**

**Comments**

• Drink 1.5 litres of water in 24 hours.
• Give one hour before, or 2 hours after food, or with a low fat meal with water.

**Other information**

• If giving with didanosine, leave 1 hour between each drug.
• Mild renal insufficiency is usually due to crystalluria, but a case of interstitial nephritis has been reported.
• If nephrolithiasis with flank pain occurs (with or without haematuria), temporarily stop therapy (e.g. for 1–3 days).
## Indometacin

### Clinical use

**NSAID:**
- Pain and inflammation in rheumatic disease and other musculoskeletal disorders
- Acute gout
- Dysmenorrhea
- Closure of ductus arteriosus

### Dose in normal renal function

- Oral: 50–200 mg daily in divided doses, after food
- PR: 100 mg twice daily if required
- Gout: 150–200 mg daily in divided doses
- Dysmenorrhea: up to 75 mg daily
- Maximum combined oral and PR: 150–200 mg daily
- MR: 75 mg 1–2 times daily, once daily in dysmenorrhea

### Pharmacokinetics

- Molecular weight (daltons): 357.8
- % Protein binding: 90–99
- % Excreted unchanged in urine: 5–20 (60% as metabolites)
- Volume of distribution (L/kg): 0.34–1.57
- Half-life — normal/ESRF (hrs): 1–16 / Unchanged

### Metabolism

Indometacin is metabolised in the liver primarily by demethylation and deacetylation; it also undergoes glucuronidation and enterohepatic circulation.

Indometacin is mainly excreted in the urine, approximately 60%, the pH of the urine can affect this amount. Lesser amounts are excreted in the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but only use if CKD 5 and on dialysis.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs:
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: effects of phenytoin enhanced.
- Antipsychotics: possible severe drowsiness with haloperidol.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxic: reduced excretion of methotrexate.
- Diuretics: increased risk of nephrotoxicity, hyperkalaemia with potassium-sparing diuretics; antagonism of diuretic effect.
- Lithium: lithium excretion reduced.
- Pentoxifylline: possibly increased risk of bleeding.
- Probencid: excretion of indometacin reduced.
- Tacrolimus: increased risk of nephrotoxicity.

### Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in normal renal function. See ‘Other information.’
- HD: Not dialysed. Dose as in normal renal function. See ‘Other information.’
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function. See ‘Other information.’
- CAV/VVHD: Not dialysed. Dose as in GFR=10–20 mL/min.
Administration

Reconstitution
—

Route
Oral, PR, IV

Rate of administration
20–30 minutes

Other information

- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.
- Use normal doses in patients with ERF on dialysis if they do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autacoid synthesis.
# Indoramin

## Clinical use

**Alpha-adrenoceptor blocker:**
- Hypertension
- Benign prostatic hyperplasia (BPH)

## Dose in normal renal function

- **Hypertension:** 25 mg twice daily initially, increasing to a maximum of 200 mg daily in 2–3 divided doses.
- **BPH:** 20 mg twice daily increasing to a maximum of 100 mg daily in divided doses.

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>383.9 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>7.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5 / Increased by 50% (reduced by 40% in HD patients)</td>
</tr>
</tbody>
</table>

## Metabolism

In studies with radiolabelled indoramin at doses of 40–60 mg daily for up to three days, after two or three days 35% of the radioactivity was excreted in the urine and 46% in the faeces. Extensive first pass metabolism was suggested. There is evidence to suggest that some metabolites may have some alpha-adrenoceptor blocking activity.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function.

## Important drug interactions

Potentially hazardous interactions with other drugs:
- **Anaesthetics:** enhanced hypotensive effect.
- **Analgesics:** antagonism of hypotensive effect with NSAIDs.
- **Avanafil, vardenafil, sildenafil and tadalafil:** enhanced hypotensive effect—avoid.
- **Antidepressants:** enhanced hypotensive effect, especially with MAOIs and linezolid—avoid.
- **Beta-blockers:** enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- **Calcium-channel blockers:** enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- **Diuretics:** enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- **Moxisylyte:** possibly severe postural hypotension when used in combination.

## Administration

### Reconstitution
- **—**

### Route
- **Oral**

### Rate of administration
- **—**

## Other information

- For BPH, 20 mg at night may be adequate in the elderly.
- In the elderly the half-life can be prolonged to 6.6–32.8 hours with a mean of 14.7 hours due to reduced clearance.
- Seyffart recommends a maximum dose of 50 mg daily for patients with severe renal impairment if not on dialysis. Dialysis patients should receive a maximum of 100 mg daily on dialysis days, but 50 mg on non-dialysis days.
Infliximab

Clinical use

Tumour necrosis factor alpha (TNFα) inhibitor:
- Treatment of Crohn's disease, psoriasis, rheumatic diseases and ulcerative colitis

Dose in normal renal function

3–7.5 mg/kg depending on indication

Pharmacokinetics

Molecular weight (daltons) 144 190
% Protein binding No data
% Excreted unchanged in urine 0
Volume of distribution (L/kg) 3–4.1 Litres
Half-life — normal/ESRF (hrs) 8–9.5 days / Unknown

Metabolism

Most likely removed by opsonisation via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function. Use with caution.
10–20 Dose as in normal renal function. Use with caution.
<10 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Anakinra and abatacept: avoid concomitant use.
- Live vaccines: avoid concomitant use.

Administration

Reconstitution
10 mL water for injection

Route
IV

Rate of administration
2 hours

Comments
Dilute total volume to 250 mL with sodium chloride 0.9%.
Use an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 1.2 micrometer or less).

Other information

- Acute infusion reactions during or within 1–2 hours of infusion are common especially with the first or second dose. Symptoms include fever, chills, pruritus, urticaria, dyspnoea, chest pain, and hypertension or hypotension. Mild reactions may respond to a reduced rate of infusion or a temporary interruption. If reactions are more severe, therapy should be stopped. Pretreatment with paracetamol, corticosteroids, and antihistamines may be considered.
- Infections are common and most often affect the upper respiratory tract and the urinary tract.
- After repeated doses has been detected in serum for at least 8 weeks.
- A case study has been reported where a patient was successfully treated with infliximab at a dose of 5 mg/kg for psoriatic arthritis.¹
- Case reports of glomerulonephritis have been reported with infliximab.²

References:
# Inosine pranobex

## Clinical use

Treatment of mucocutaneous herpes simplex, genital warts, subacute sclerosing panencephalitis

## Dose in normal renal function

- **Mucocutaneous herpes simplex**: 1 g four times a day for 7–14 days
- **Genital warts**: 1 g three times a day for 14–28 days
- **Subacute sclerosing panencephalitis**: 50–100 mg/kg daily in 6 divided doses

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1115.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Majority (as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>50 minutes</td>
</tr>
</tbody>
</table>

## Metabolism

Hepatically metabolised. The major excretion product of the inosine moiety is uric acid, while the p-acetamidobenzoic acid and N,N-dimethylamino-2-propanol components are excreted in the urine as glucuronidated and oxidised products, respectively, as well as being excreted unchanged.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution. See 'Other information'.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution. See 'Other information'.</td>
<td></td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=10–20 mL/min.

## Important drug interactions

Potentially hazardous interactions with other drugs

- None known

## Administration

**Reconstitution**

- **Route**: Oral

**Rate of administration**

- **—**

## Other information

- As the inosine component of Imunovir is metabolised to uric acid, it should be used with caution in patients with renal impairment, a history of gout or hyperuricaemia.
- In the US data sheet, dose reductions are recommended in moderate to severe renal impairment.
Inositol nicotinate

Clinical use
- Peripheral vascular disease
- Hyperlipidaemia

Dose in normal renal function
3 g daily in 2–3 divided doses, maximum 4 g daily

Pharmacokinetics
- Molecular weight (daltons) 810.7
- % Protein binding High
- % Excreted unchanged in urine No data
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 24 / –

Metabolism
Inositol nicotinate is believed to be slowly hydrolysed to nicotinic acid. The main route of metabolism is then conversion to N-methylnicotinamide and the 2-pyridone and 4-pyridone derivatives; nicotinuric acid is also formed. Small amounts of nicotinic acid are excreted unchanged in urine.

Dose in renal impairment GFR (mL/min)
- 30–50 Dose as in normal renal function.
- 10–30 Dose as in normal renal function.
- <10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in normal renal function.
- HD Unknown dialysability. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Statins: increased risk of myopathy.

Administration
Reconstitution
- Route Oral
- Rate of administration —
# Insulin – soluble
## (Actrapid or Humulin S)

### Clinical use
- Hyperglycaemia, control of diabetes mellitus
- Emergency management of hyperkalaemia

### Dose in normal renal function
Variable

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>5808</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>5</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.15</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–5 / 13</td>
</tr>
</tbody>
</table>

### Metabolism
Insulin is rapidly metabolised, mainly in the liver but also in the kidneys and muscle tissue. In the kidneys it is reabsorbed in the proximal tubule and either returned to venous blood or metabolised, with only a small amount excreted unchanged in the urine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Variable.</td>
</tr>
<tr>
<td>10–20</td>
<td>Variable.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Variable.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose according to clinical response.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose according to clinical response.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose according to clinical response.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose according to clinical response.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Fibrates: may improve glucose tolerance; additive effect with insulin.

### Administration

#### Reconstitution

- **Route**
  - SC, IV via CRIP

- **Rate of administration**
  - Over 30 minutes or as required

- **Comments**
  - Add 15–25 IU insulin to 50 mL 50% glucose for treatment of hyperkalaemia.
  - For maintenance infusion or sliding scale infusion, add 50 IU insulin to 500 mL 10% glucose and adjust rate according to blood glucose levels.
  - Continue infusing insulin/glucose solution at rate of 10 mL/hour according to serum potassium.

### Other information

- Monitor blood glucose.
- Prior to insulin / glucose infusion for hyperkalaemia, give IV 20 mL 10% calcium gluconate to protect myocardium and 50–100 mL 8.4% sodium bicarbonate to correct acidosis.
- Commence calcium resonium 15 g 4 times per day orally.
- Insulin is metabolised renally; therefore, requirements may be reduced in ERF.
### Interferon alfa-2A (Roferon A)

#### Clinical use
1. Hairy cell leukaemia
2. Chronic myelogenous leukaemia
3. Cutaneous T-cell lymphoma
4. Chronic hepatitis B
5. Chronic hepatitis C
6. Follicular non-Hodgkin’s lymphoma
7. Advanced renal cell carcinoma
8. Malignant melanoma

#### Dose in normal renal function
1. Hairy cell leukaemia: 1.5–3 million IU daily or 3 times per week
2. Chronic myelogenous leukaemia: 3–9 million IU daily or 3 times per week
3. Cutaneous T-cell lymphoma: 3–18 million IU daily or 3 times per week
4. Chronic hepatitis B: 2.5–5 million IU/m² 3 times per week
5. Chronic hepatitis C: 3–6 million IU 3 times per week
6. Follicular non-Hodgkin’s lymphoma: 6 million IU/m² on days 22–26 of each 28 day cycle
7. Advanced renal cell carcinoma: 9–18 million IU 3 times per week
8. Malignant melanoma: 1.5–3 million IU 3 times a week

#### Pharmacokinetics
- Molecular weight (daltons): 19 000
- % Protein binding: 0
- % Excreted unchanged in urine: Negligible
- Volume of distribution (L/kg): 0.4
- Half-life — normal/ESRF (hrs): 3.7–8.5 / –

#### Metabolism
Alpha-interferons are totally filtered through the glomeruli and undergo rapid proteolytic degradation during tubular reabsorption, rendering a negligible reappearance of intact alfa interferon in the systemic circulation.

#### Dose in renal impairment GFR (mL/min)
- <10: Use with great caution. See ‘Other information’.

#### Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: metabolism of aminophylline and theophylline reduced, consider reducing dose of aminophylline and theophylline.
- Antivirals: increased risk of peripheral neuropathy with telbivudine.
- Immunosuppressants, e.g. ciclosporin, tacrolimus, sirolimus may have an antagonistic effect.

#### Administration

**Reconstitution**
- **Route**
  - SC, IM

**Rate of administration**
- 

#### Other information
- Interferon up-regulates the cell surface presentation of class II histocompatibility antigens, which raises the possibility of drug-induced allograft rejection. There are numerous clinical reports of allograft rejection, acute renal failure and graft loss after interferon therapy. Hence extreme care should be exercised in the use of interferon after renal transplantation.
- In patients undergoing haemodialysis, the interferon molecule may accumulate as it is too large to be dialysed and will not undergo renal degradation. Hence, the dose may need to be adjusted.
- Contraindicated by manufacturer in severe renal impairment.
Interferon alfa-2B

Clinical use
1. Chronic hepatitis B
2. Chronic hepatitis C
3. Hairy cell leukaemia
4. Multiple myeloma
5. Carcinoid tumour
6. Chronic myelogenous leukaemia
7. Follicular lymphoma
8. Malignant melanoma

Dose in normal renal function
1. Chronic hepatitis B: 5–10 million IU 3 times a week
2. Chronic hepatitis C: 3 million IU 3 times a week
3. Hairy cell leukaemia: 2 million IU/m² 3 times a week
4. Multiple myeloma: 3 million IU/m² 3 times a week
5. Carcinoid tumour: 3–9 million IU/m² 3 times a week
6. Chronic myelogenous leukaemia: 4–5 million IU/m² daily
7. Follicular lymphoma: 5 million IU 3 times a week
8. Malignant melanoma: 20 million IU/m² (IV infusion) daily for 5 days, decreasing to 10 million IU/m² (SC) 3 times a week

Pharmacokinetics
Molecular weight (daltons) 15 000–21 000
% Protein binding 0
% Excreted unchanged in urine Negligible
Volume of distribution (L/kg) 0.4
Half-life — normal/ESRF (hrs) 2.7 / –

Metabolism
Alpha-interferons are totally filtered through the glomeruli and undergo rapid proteolytic degradation during tubular reabsorption, rendering a negligible reappearance of intact alfa interferon in the systemic circulation.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function. Monitor renal function closely.
<10 Use with great caution. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Aminophylline and theophylline: metabolism of aminophylline and theophylline reduced, consider reducing dose of aminophylline and theophylline.
• Antivirals: increased risk of peripheral neuropathy with telbivudine.
• Immunosuppressants, e.g. ciclosporin, tacrolimus, sirolimus may have an antagonistic effect.
• Administration of interferon in combination with other chemotherapeutic agents, e.g. cytarabine, cyclophosphamide, doxorubicin may lead to increased risk of severe toxicity.

Administration
Reconstitution
—
Route
IM, SC, IV
Rate of administration
20 minutes
Comments
Add to sodium chloride 0.9%

Other information
• Interferon up-regulates the cell surface presentation of class II histocompatibility antigens, which raises the possibility of drug-induced allograft rejection. There are numerous clinical reports of allograft rejection, acute renal failure and graft loss after interferon therapy. Hence extreme care should be exercised in the use of interferon after renal transplantation.
• In patients undergoing haemodialysis, the interferon molecule may accumulate as it is too large to be dialysed and will not undergo renal degradation. Hence, the dose may need to be adjusted.
• Several small controlled trials have examined the efficacy of low-dose interferon therapy (3 MU 3 times a week given after dialysis) for chronic hepatitis C in patients on haemodialysis. Treatment appears to have been remarkably effective, possibly because reduced renal clearance of interferon results in higher and more sustained levels of the drug. (Huraib S, Tanimu D, Romeh SA, et al. Interferon-α in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis. 1999; 34(1): 55–60.)

• Contraindicated by manufacturer in severe renal impairment.
# Interferon beta

## Clinical use

Treatment of relapsing, remitting multiple sclerosis

## Dose in normal renal function

Interferon beta-1 a:
- Avonex: 6 million IU (30 micrograms) once a week
- Rebif: 8.8–44 micrograms 3 times a week

Interferon beta-1 b:
- Betaferon/Extavia: 8 million IU (250 mcg) every second day

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>18 500–22 500</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Negligible. See ‘Other information’</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–10/–</td>
</tr>
</tbody>
</table>

## Metabolism

Interferon beta is mainly metabolised and excreted by the liver and the kidneys.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Monitor renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution due to risk of accumulation, and monitor renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Ciclosporin and tacrolimus: interferon reported to reduce the activity of hepatic cytochrome P450 enzymes.

## Administration

### Reconstitution

With diluent provided

### Route

- IM (Avonex), SC (Rebif, Betaferon, Extavia)

### Rate of administration

---

### Comments

Stable for 6 hours at 2–8°C once reconstituted

## Other information

- Pre-treatment with paracetamol is recommended to reduce incidence of flu-like symptoms.
- Vary the site of injection each week.
- Rare cases of lupus erythematosus syndrome have occurred.
- Transient increases in creatinine, potassium, urea, nitrogen and urinary calcium may occur.
- Interferon up-regulates the cell surface presentation of class II histocompatibility antigens, which raises the possibility of drug-induced allograft rejection. There are numerous clinical reports of allograft rejection, acute renal failure and graft loss after interferon therapy. Hence extreme care should be exercised in the use of interferon after renal transplantation.
- In patients undergoing haemodialysis, the interferon molecule may accumulate as it is too large to be dialysed and will not undergo renal degradation. Hence, the dose may need to be adjusted.
Interferon gamma-1B (Immukin)

**Clinical use**
Adjunct to antibiotics to reduce the frequency of serious infections in patients with chronic granulomatous disease.

**Dose in normal renal function**
50 mcg/m$^2$ 3 times a week
or 1.5 mcg/kg 3 times a week if surface area<0.5 m$^2$

**Pharmacokinetics**
- Molecular weight (daltons) 15 000–21 000
- % Protein binding No data
- % Excreted unchanged in urine Negligible
- Volume of distribution (L/kg) 0.2–0.6
- Half-life — normal/ESRF (hrs) 5.9 / –

**Metabolism**
The metabolism of cloned interferons falls within the natural handling of proteins. Interferon gamma-1b was not detected in the urine of healthy male subjects following administration via IV, IM or SC routes. *In vitro* hepatic and renal perfusion studies demonstrate that the liver and kidneys are capable of clearing interferon gamma-1b from perfusate.

Interferon is metabolised primarily in the kidney. It is excreted in the urine, but is reabsorbed by the tubules where it undergoes lysosomal degradation.

**Dose in renal impairment GFR (mL/min)**
- 20–50 No data on use in renal impairment. Dose as for normal renal function and monitor renal function closely.
- 10–20 No data on use in renal impairment. Dose as for normal renal function and monitor renal function closely.
- <10 Use with caution due to risk of accumulation. Monitor renal function closely.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Avoid with vaccines.

**Administration**

**Reconstitution** —

**Route**
SC

**Rate of administration** —

**Other information**
- Pre-treatment with paracetamol is recommended to reduce incidence of flu-like symptoms.
- Interferon up-regulates the cell surface presentation of class II histocompatibility antigens, which raises the possibility of drug-induced allograft rejection. There are numerous clinical reports of allograft rejection, acute renal failure and graft loss after interferon therapy. Hence extreme care should be exercised in the use of interferon after renal transplantation.
- In patients undergoing haemodialysis, the interferon molecule may accumulate as it is too large to be dialysed and will not undergo renal degradation. Hence, the dose may need to be adjusted.
- Manufacturer advises to use with caution due to risk of accumulation.
**Ipilimumab**

**Clinical use**
Antineoplastic agent:
- Treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy

**Dose in normal renal function**
3 mg/kg every 3 weeks for 4 doses

**Pharmacokinetics**
- Molecular weight (daltons) 148,000
- % Protein binding No data
- % Excreted unchanged in urine No data
- Volume of distribution (L/kg) 7.22 Litres
- Half-life — normal/ESRF (hrs) 15 days / Unchanged

**Metabolism**
Most likely removed by opsonisation via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function. Use with caution.
- <10 Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Live vaccines: risk of generalised infections – avoid.

**Administration**

**Reconstitution**
-

**Route**
IV

**Rate of administration**
Over 90 minutes

**Comments**
- May be administered undiluted or may be added to sodium chloride 0.9% or glucose 5% to give a concentration of 1–4 mg/mL.
- Give via a low-protein binding in-line filter (pore size of 0.2 μm to 1.2 μm).

**Other information**
- No studies have been done in patients with a GFR<22 mL/min but the pharmacokinetic parameters indicate that it should not accumulate.
- US data sheet does not advise a dose reduction in severe renal impairment.
- Some cases of rejection occurred in association with ipilimumab due to interference with immunosuppressive treatment. MHRA 20 July 2017.
### Ipratropium bromide

#### Clinical use

Anticholinergic bronchodilator:
- Reversible airways obstruction, particularly in COPD

#### Dose in normal renal function

- Nebuliser solution: 250–500 micrograms 3–4 times daily
- Inhaler: 20–80 micrograms 3–4 times daily

#### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>430.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;20</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>4.6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.6 / –</td>
</tr>
</tbody>
</table>

#### Metabolism

After inhalation, around 10–30% of a dose is deposited in the lungs where it exerts its therapeutic effect. Only a small amount of ipratropium reaches the systemic circulation. The majority of a dose is swallowed but is poorly absorbed from the gastrointestinal tract. Ipratropium and its metabolites are eliminated in the urine and faeces.

#### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

#### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

#### Important drug interactions

Potentially hazardous interactions with other drugs
- None known

#### Administration

**Reconstitution**
—

**Route**
Inhaled

**Rate of administration**
Nebuliser: according to nebuliser.

**Comments**
- The dose of nebuliser solution may need to be diluted in order to obtain a final volume suitable for the nebuliser.
- Sterile sodium chloride 0.9% should be used if dilution is required.
**Irbesartan**

### Clinical use

Angiotensin-II receptor antagonist:
- Hypertension
- Diabetic nephropathy

### Dose in normal renal function

75–300 mg daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>428.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>96</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>53–93 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>11–15 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Following oral or intravenous administration of $^{14}$C irbesartan, 80–85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). *In vitro* studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of $[^{14}$C]-irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.

### Dose in renal impairment GFR (mL/min)

- **20–50**: Dose as in normal renal function.
- **10–20**: Dose as in normal renal function.
- **<10**: Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose and Titration Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Initial dose 75 mg daily and gradually increase.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Initial dose 75 mg daily and gradually increase.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Initial dose 75 mg daily and gradually increase.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Initial dose 75 mg daily and gradually increase.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia hypotension and renal impairment with ACE-Is and aliskiren.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

### Administration

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

### Other information

- Hyperkalaemia and other side effects are more common in patients with impaired renal function.
- Renal failure has been reported in association with angiotensin-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with congestive heart failure.
- Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
Irinotecan hydrochloride

Clinical use

Treatment of metastatic colorectal cancer resistant to fluorouracil, or in conjunction with fluorouracil

Dose in normal renal function

- Without 5-FU: 350 mg/m\(^2\) every 3 weeks
- With 5-FU: 180 mg/m\(^2\) every 2 weeks

Pharmacokinetics

Molecular weight (daltons) 677.2
% Protein binding 65
% Excreted unchanged in urine 20
Volume of distribution (L/kg) 110–234 Litres/m\(^2\)
Half-life — normal/ESRF (hrs) 14 / –

Metabolism

After intravenous doses it is hydrolysed by carboxylesterase in body tissues to active SN-38 (7-ethyl-10-hydroxycamptothecin). Plasma protein binding for SN-38 is about 95%. SN-38 is mainly eliminated by glucuronidation, predominantly by the enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). Irinotecan is also partly metabolised by cytochrome P450 isoenzymes CYP3A4 and perhaps CYP3A5. The majority of an intravenous dose of irinotecan is excreted as unchanged drug, with about 64% in the faeces via the bile. The mean 24 hour urinary excretion of irinotecan and SN-38 (its active metabolite) was 19.9% and 0.25% respectively.

Dose in renal impairment GFR (mL/min)

| GFR (mL/min) | Dose
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function and monitor closely.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function and monitor closely.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Reduce dose (50–80 mg/m(^2)) and monitor closely. Increase as tolerated.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

| Type         | Dose
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antidepressants: concentration reduced by St John’s wort – avoid.
- Antifungals: increased toxicity with itraconazole – avoid; concentration reduced by ketoconazole, but active metabolite of irinotecan increased – avoid.
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).
- Antivirals: metabolism possibly inhibited by atazanavir (increased risk of toxicity).
- Cytotoxics: concentration of active metabolite of irinotecan increased by lapatinib, consider reducing dose of irinotecan; avoid with panitumumab; concentration possibly increased by sorafenib.
- Live vaccines: risk of generalised infections – avoid.

Administration

Reconstitution

Route
IV infusion
Rate of administration
Over 30–90 minutes
Comments
Dilute in 250 mL sodium chloride 0.9% or glucose 5%

Other information

- Manufacturer advises avoiding use in renal impairment due to lack of data.
- There is a case study from Korea using irinotecan at a dose of 100 mg/m\(^2\) in a haemodialysis patient without any complications. (Kim DM, Kim HL, Chung CH, et al. Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease. Korean J Intern Med. 2009; 24(1): 73–5.)
- Infrequent reports of renal insufficiency due to inadequate hydration.
- Transient, mild to moderate increase in serum creatinine reported in 7.3% of patients.
Iron dextran 5% solution

Clinical use

- Prophylaxis of iron deficiency anaemia (when oral treatment is ineffective or contraindicated)
- Treatment of iron deficiency during ESA therapy especially if serum ferritin is very low (<50 nanograms/mL)

Dose in normal renal function

- Total iron infusion: Dose of iron dextran (mg) = weight (kg) × \[\text{Target Hb (g/L)} − \text{Actual Hb (g/L)}\] × 0.24 + 500 mg iron for iron stores (if body weight >35 kg), 20 mg/kg in a single dose.
- Target haemoglobin level (110 g/L for renal patients as a guide) or 100–200 mg 2 or 3 times a week depending on haemoglobin.
- A test dose is essential. Give 0.5 mL or 25 mg iron over 15 minutes and observe for 60 minutes (15 minutes if using low dose bolus) for anaphylaxis. Have resuscitative equipment and drugs at hand (adrenaline, chlorphenamine and hydrocortisone).

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>165 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.031–0.055</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–20 / –</td>
</tr>
</tbody>
</table>

Metabolism

After intravenous infusion, iron dextran is taken up by the cells of the reticuloendothelial cells, particularly in the liver and spleen. The reticuloendothelial cells gradually separate iron from the iron-dextran complex. Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin.

Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Dimercaprol: avoid concomitant use.
- Oral iron: reduced absorption of oral iron

Administration

Reconstitution

- Route
  - IV, IM

Rate of administration

- Infusion: 100 mL over 30 minutes
- Bolus: 10 mg/minute
- Total dose infusion: over 4–6 hours; increase rate of infusion to 45–60 drops per minute

Comments

- Infusion: 100–200 mg in 100 mL sodium chloride or glucose 5%.
- Bolus: add to 10–20 mL sodium chloride or glucose 5%.
- Total dose infusion: add to 500 mL sodium chloride 0.9% or glucose 5%.
- Keep under strict supervision during and for 1 hour after infusion.

Other information

- Do not give to patients with history of asthma.
- If patients with a history of allergy are prescribed iron dextran, give adequate antihistamine cover prior to administration.
- The dose of iron dextran varies widely from 100 mg per dialysis session for 6–10 sessions, to single doses of 500 mg to 1 g.
- The incidence of anaphylaxis with the Cosmofer brand of iron dextran is significantly lower than with the old Imferon brand, since the iron is complexed to a much shorter dextran chain than was used previously.
Iron isomaltoside 1000

Clinical use
Complex of ferric iron and isomaltosides:
• Treatment of iron deficiency anaemia (when oral treatment is ineffective or contraindicated)

Dose in normal renal function
Dose according to weight

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5 / –</td>
</tr>
</tbody>
</table>

Metabolism
Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Dimercaprol: avoid concomitant use.
• Do not administer with oral iron.

Administration

Reconstitution
—

Route
IV

Rate of administration
• IV bolus (up to 500 mg): 50 mg/min
• IV infusion: up to 1000 mg over 30 minutes
• Doses >20 mg/kg in 2 doses with an interval of at least 1 week

Comments
• Patients should be monitored during and for 30 minutes after administration
Iron sucrose

**Clinical use**
- Prophylaxis of iron deficiency anaemia (when oral treatment is ineffective or contraindicated)
- Treatment of iron deficiency during ESA therapy especially if serum ferritin is very low (<50 nanograms/mL)

**Dose in normal renal function**
According to local protocol. See ‘Other information.’

**Pharmacokinetics**
- Molecular weight (daltons): 34 000–60 000
- % Protein binding: No data
- % Excreted unchanged in urine: <5
- Volume of distribution (L/kg): 8 Litres
- Half-life — normal/ESRF (hrs): 6 / –

**Metabolism**
After intravenous infusion, iron sucrose is taken up by the cells of the reticuloendothelial cells, particularly in the liver and spleen. The reticuloendothelial cells gradually separate iron from the iron-sucrose complex. Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Dimercaprol: avoid concomitant use.
- Do not administer with oral iron.

**Administration**

**Reconstitution**
—

**Route**
IV

**Rate of administration**
- Bolus: 1 mL/minute
- Infusion: in sodium chloride 0.9% at a concentration of 1 mg/mL over 20–30 minutes per 100 mg

**Comments**
- Doses can be administered via the venous limb of the dialysis machine.
- Patients should be monitored during and for 30 minutes after administration.
- Stable for 24 hours at room temperature.

**Other information**
- Some regimes are:
  - 50–300 mg weekly
  - 100 mg once or twice monthly
  - 20–40 mg with each dialysis
- Oral iron can be restarted 5 days after completion of the course of IV iron.
Isavuconazole

**Clinical use**

Triazole antifungal agent:
- Invasive aspergillosis
- Mucormycosis in patients for whom amphotericin B is inappropriate

**Dose in normal renal function**

200 mg every 8 hours for 6 doses then 200 mg once daily starting 12–24 hours after last loading dose

**Pharmacokinetics**

- Molecular weight (daltons) 814.8 (as isavuconazonium sulphate)
- % Protein binding >99
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 450 Litres
- Half-life — normal/ESRF (hrs) 2–4 (as isavuconazole); 80–130 (as isavuconazonium) / Unchanged

**Metabolism**

Following administration, isavuconazonium sulfate is rapidly hydrolysed by plasma esterases to the active moiety isavuconazole; plasma concentrations of the prodrug are very low and detectable only for a short time after intravenous dosing. Following oral administration of radio-labelled isavuconazonium sulfate to healthy subjects, a mean of 46.1% of the radioactive dose was recovered in faeces, and 45.5% was recovered in urine.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: possibly increases fentanyl concentration.
- Antibacterials: concentration reduced by rifampicin and possibly rifabutin – avoid; possibly increased concentration of rifabutin – increased risk of uveitis.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid; avoid with reboxetine.
- Antiepileptics: concentration reduced by carbamazepine and possibly fosphenytoin, phenobarbital, phenytoin and primidone – avoid.
- Antifungals: concentration increased by ketoconazole – avoid.
- Antimalariais: avoid with artemether and lumefantrine; avoid with artenimol with piperaquine – possible risk of ventricular arrhythmias.
- Antipsychotics: increased risk of ventricular arrhythmias with pimozide – avoid; possibly increased quetiapine concentration – avoid.
- Endothelin antagonists: possibly increased risk of ergotism – avoid.
- Ergotamine: increased risk of ergotism – avoid.
- Lomitapide: concentration of lomitapide possibly increased – avoid.

**Administration**

**Reconstitution**

5 mL water for injection

**Route**

Oral, IV infusion

**Rate of administration**

Over a minimum of 1 hour

**Comments**

- The reconstituted solution should then be added to at least 250 mL sodium chloride 0.9% or glucose 5%
- The infusion solution contains approximately 1.5 mg/mL isavuconazonium sulfate (corresponding to approximately 0.8 mg isavuconazole per mL)
- The infusion must be administered via an infusion set with an in-line filter with a microporous membrane made of polyethersulfone (PES) and with a pore size of 0.2 μm to 1.2 μm

**Other information**

- Oral bioavailability is 98%.
**Isoniazid**

### Clinical use

Antibacterial agent:
- Treatment and prophylaxis of tuberculosis in ‘at risk’ immunocompromised patients

### Dose in normal renal function

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM/IV</td>
<td>200–300 mg daily</td>
</tr>
<tr>
<td>Oral</td>
<td>300 mg daily</td>
</tr>
<tr>
<td>Intermittent</td>
<td>15 mg/kg 3 times weekly</td>
</tr>
<tr>
<td>Prophylaxis</td>
<td>100–200 mg daily</td>
</tr>
<tr>
<td>Intrapleural</td>
<td>50–250 mg</td>
</tr>
<tr>
<td>Intrathecal</td>
<td>25–50 mg daily</td>
</tr>
</tbody>
</table>

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>137.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>4–32</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.75</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.2–3.5 / 1–17 (depends on acetylator status)</td>
</tr>
</tbody>
</table>

### Metabolism

The primary metabolic route is the acetylation of isoniazid to acetyl-isoniazid by N-acetyltransferase found in the liver and small intestine. Acetyl-isoniazid is then hydrolysed to isonicotinic acid and monoacetylhydrazine; isonicotinic acid is conjugated with glycine to isonicotinyl glycine (isonicotinuric acid) and monoacetylhydrazine is further acetylated to diacetylhydrazine. Some unmetabolised isoniazid is conjugated to hydrazones. The metabolites of isoniazid have no tuberculostatic activity and, apart from possibly monoacetylhydrazine, they are also less toxic. The rate of acetylation of isoniazid and monoacetylhydrazine is genetically determined and there is a bimodal distribution of persons who acetylate them either slowly or rapidly. In patients with normal renal function, over 75% of a dose appears in the urine in 24 hours, mainly as metabolites. Small amounts of drug are also excreted in the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>200–300 mg daily</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of hepatotoxicity with rifampicin.
- Antiepileptics: metabolism of carbamazepine, ethosuximide and phenytoin inhibited (enhanced effect); also with carbamazepine, isoniazid hepatotoxicity possibly increased.

### Administration

**Reconstitution**
Dilute with water for injection if required.

**Route**
Oral, IM, IV, intrapleural, intrathecal

**Rate of administration**
Not critical. Give by slow IV bolus.

### Other information

- Adjust dose accordingly if hepatic illness, slow/fast acetylator status identified.
- Pyridoxine 10 mg daily has been recommended for prophylaxis of peripheral neuritis.
Isosorbide dinitrate

**Clinical use**

Vasodilator:
- Prophylaxis and treatment of angina
- Left ventricular failure

**Dose in normal renal function**

- Oral:
  - Angina: 30–120 mg daily in divided doses;
  - LVF: 40–240 mg daily
- IV: 2–20 mg/hour depending on response

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>236.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;1</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>10–20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2–4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.5–1 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Isosorbide dinitrate undergoes extensive first-pass metabolism in the liver. It is taken up by smooth muscle cells of blood vessels and the nitrate group is cleaved to inorganic nitrite and then to nitric oxide. It is also rapidly metabolised in the liver to the major active metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate. Isosorbide mononitrate is metabolised to inactive metabolites, including isosorbide and isosorbide glucuronide. Only about 2% of isosorbide mononitrate is excreted unchanged in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as normal</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as normal</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as normal</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Avanfil, sildenafil, tadalafil, vardenafil: hypotensive effect significantly enhanced – avoid concomitant use.
- Riociguat: avoid concomitant use due to risk of hypotension.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral, IV infusion</td>
<td>1 mg/10 mL; 60 mL/hour ≡ 6 mg/hour</td>
</tr>
<tr>
<td></td>
<td>2 mg/10 mL; 30 mL/hour ≡ 6 mg/hour</td>
</tr>
</tbody>
</table>

**Comments**

- Dilute using sodium chloride 0.9% or glucose 5% to 1 mg/10 mL or 2 mg/10 mL; final volume 500 mL.
- Use of PVC giving sets and containers should be avoided since significant losses of the active ingredient by absorption can occur.

**Other information**

- Both metabolites have longer half-lives than the parent compound.
Isosorbide mononitrate

Clinical use
Vasodilator:
- Treatment and prophylaxis of angina
- Adjunct in congestive heart failure

Dose in normal renal function
20–120 mg/day in divided doses

Pharmacokinetics
Molecular weight (daltons) 191.1
% Protein binding <4
% Excreted unchanged in urine 2
Volume of distribution (L/kg) 0.6
Half-life — normal/ESRF (hrs) 1.5–5 / Unchanged

Metabolism
Unlike isosorbide dinitrate, isosorbide mononitrate does not undergo first-pass hepatic metabolism. Isosorbide mononitrate is taken up by smooth muscle cells of blood vessels and the nitrate group is cleaved to inorganic nitrite and then to nitric oxide. Isosorbide mononitrate is metabolised to inactive metabolites, including isosorbide and isosorbide glucuronide.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Dialysed. Dose as in normal renal function.
HDF/High flux Dialysed. Dose as in normal renal function.
CAV/VVHD Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Avanafil: hypotensive effect significantly enhanced – avoid.
- Levosimendan: possible severe hypotension.
- Riociguat: avoid concomitant use due to risk of hypotension.
- Sildenafil: hypotensive effect significantly enhanced – avoid.
- Tadalafil: hypotensive effect significantly enhanced – avoid.
- Vardenafil: hypotensive effect significantly enhanced – avoid.

Administration
Reconstitution
—
Route Oral
Rate of administration
—

Other information
- Tolerance may develop. This may be minimised by having nitrate-‘free’ periods.
Isotretinoin

Clinical use
Treatment of nodulo-cystic and conglobate acne, and severe acne which has failed to respond to an adequate course of systemic antibiotics

Dose in normal renal function
- 0.5–1 mg/kg daily in 1–2 divided doses initially.
- Maximum cumulative dose: 150 mg/kg per course.
- Topically: 1–2 times daily.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initial dose 10 mg daily and slowly increase as tolerated up to 1 mg/kg daily. See ‘Other information.’</td>
</tr>
</tbody>
</table>

Pharmacokinetics
Molecular weight (daltons) 300.4
% Protein binding 99.9
% Excreted unchanged in urine As metabolites
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 10–20 / Unchanged

Metabolism
Isotretinoin undergoes metabolism in the gut wall and first-pass metabolism in the liver. It is metabolised in the liver by CYP2C8, CYP2C9, CYP3A4, and CYP2B6 to its major metabolite 4-oxo-isotretinoin; there is also some isomerisation of isotretinoin to tretinoin. Isotretinoin, tretinoin, and their metabolites undergo enterohepatic recycling. Return to physiological levels of retinoids takes about 2 weeks after stopping therapy. Equal amounts of a dose appear in the faeces, mainly as unchanged drug, and in the urine as metabolites.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: possible increased risk of benign intracranial hypertension with tetracyclines – avoid.
- Antifungals: possible increased risk of toxicity with fluconazole, ketoconazole and voriconazole.
- Vitamins: increased risk of hypervitaminosis with vitamin A.

Administration
Reconstitution
- Route
Oral, topical (0.05% gel)

Other information
- Since the drug is highly protein bound, it is not expected to be significantly removed by dialysis.
- Monitor for signs of vitamin A toxicity.
# Ispaghula husk

## Clinical use

Bulk-forming laxative

## Dose in normal renal function

- Fibrelief: 1–6 sachets daily in water in 1–3 divided doses
- Fybogel: One sachet (3.5 g) in water twice daily
- Isogel: 2 teaspoonfuls in water 1–2 times daily (constipation), 3 times daily (diarrhoea)
- Regulan: 1 sachet in water 1–3 times daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>% Protein binding</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Not absorbed.</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Not absorbed.</td>
</tr>
</tbody>
</table>

## Metabolism

The mode of action of Fybogel is physical and does not depend on absorption into the systemic circulation.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- None known

## Administration

### Reconstitution

<table>
<thead>
<tr>
<th>Route</th>
<th>Oral</th>
</tr>
</thead>
</table>

### Rate of administration

<table>
<thead>
<tr>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fybogel and regulan should be stirred into 150 mL water and taken as quickly as possible, preferably after meals.</td>
</tr>
<tr>
<td>Additional fluid intake should be maintained.</td>
</tr>
</tbody>
</table>

## Other information

- Fibrelief contains aspartame.
- Fluid restrictions in dialysis patients can render these treatments inappropriate.
- Fybogel is low in sodium and potassium, containing approximately 0.4 mmol sodium and 0.7 mmol potassium per sachet. It is sugar and gluten free and contains aspartame (contributes to the phenylalanine intake and may affect control of phenylketonuria).
- Orange and lemon/lime flavours of regulan contain: 3.4 g ispaghula husk BP, 0.23 mmol sodium, <1 mmol potassium per sachet and are gluten and sugar free. They also contain aspartame.
- Fibrelief contains aspartame.
Isradipine

Clinical use
Calcium-channel blocker:
- Essential hypertension

Dose in normal renal function
Initially 2.5 mg twice daily, increased if necessary to 10 mg twice daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>371.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3–4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4–8 / 10–11</td>
</tr>
</tbody>
</table>

Metabolism
Isradipine undergoes extensive first pass metabolism resulting in a bioavailability of 15–24%. Isradipine is extensively metabolised in the liver, at least partly by the cytochrome P450 isoenzyme CYP3A4.

About 70% of an oral dose is reported to be excreted as metabolites in urine, the remainder in faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: possibly increased aminophylline and theophylline concentration.
- Anaesthetics: enhanced hypotensive effect.
- Antibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone.
- Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole; negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antivirals: concentration possibly increased by ritonavir.
- Grapefruit juice: concentration increased – avoid concomitant use.

Administration
Reconstitution
- 
Route
Oral
Rate of administration
- 

Other information
- In elderly patients, or where hepatic or renal function is impaired, initial dose should be 1.25 mg twice daily. Dose should be increased according to the requirements of the individual patient.
Itraconazole

Clinical use
Antifungal agent

Dose in normal renal function

- **Oral**: 100–200 mg every 8–24 hours according to indication
- **IV**: 200 mg every 12–24 hours

Pharmacokinetics

- **Molecular weight (daltons)**: 705.6
- **% Protein binding**: 99.8
- **% Excreted unchanged in urine**: <0.03
- **Volume of distribution (L/kg)**: 10
- **Half-life — normal/ESRF (hrs)**: 20–40 / Unchanged

Metabolism

Itraconazole is metabolised in the liver mainly by cytochrome P450 isoenzyme CYP3A4. The major metabolite, hydroxyitraconazole, has antifungal activity comparable with that of itraconazole.

Itraconazole is excreted mainly as inactive metabolites in urine (35%) and faeces (54%) within one week of an oral solution dose. Renal excretion of itraconazole and the active metabolite hydroxy-itraconazole account for less than 1% of an intravenous dose. Based on an oral radiolabelled dose, faecal excretion of unchanged drug varies between 3–18% of the dose. Small amounts are eliminated in the stratum corneum and hair.

Dose in renal impairment GFR (mL/min)

- 10–30: Oral: Dose as in normal renal function. IV: Avoid. See ‘Other information’.
- <10: Oral: Dose as in normal renal function. IV: Avoid. See ‘Other information’.

Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Not dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Not dialysed. Dose as in GFR=10–30 mL/min. See ‘Other information’.

Important drug interactions

Potentially hazardous interactions with other drugs

- **Aliskiren**: concentration of aliskiren increased – avoid
- **Analgesics**: possibly inhibits alfentanil metabolism; concentration of fentanyl possibly increased; possibly increases methadone concentration – increased risk of ventricular arrhythmias.
- **Anti-arrhythmics**: avoid concomitant use with disopyramide and dronedarone.
- **Antibacterials**: metabolism accelerated by rifabutin and rifampicin – avoid; possibly increased rifabutin concentration – reduce rifabutin dose; clarithromycin can increase itraconazole concentration.
- **Anticoagulants**: avoid with apixaban and rivaroxaban; effect of coumarins enhanced; concentration of dabigatran possibly increased – avoid.
- **Antidepressants**: avoid concomitant use with reboxetine.
- **Antidiabetics**: can enhance effects of repaglinide.
- **Antiepileptics**: concentration reduced by carbamazepine, fosphenytoin, phenobarbital and phenytoin – avoid with phenytoin.
- **Antihistamines**: inhibits mizolastine metabolism – avoid.
- **Antimalarials**: avoid with piperaquine with artemimol and artemether/lumefantrine.
- **Antimuscarinics**: possibly increases solifenacin concentration.
- **Antipsychotics**: possibly increases haloperidol concentration; possibly inhibits metabolism of aripiprazole – reduce aripiprazole dose; increased risk of ventricular arrhythmias with pimozide – avoid; possibly increased quetiapine concentration – reduce quetiapine dose; possibly increases lurasidone concentration – avoid.
- **Antivirals**: concentration of daclatasvir increased – reduce daclatasvir dose; concentration of both drugs increased with dasabuvir, paritaprevir and simeprevir – avoid; concentration reduced by efavirenz and nevirapine; concentration of both drugs possibly increased by fosamprenavir; concentration of indinavir increased – may need to reduce indinavir dose; with ritonavir concentration of both drugs may be increased; concentration of saquinavir possibly increased; concentration possibly increased by telaprevir; concentration reduced by efavirenz.
- **Anxiolytics and hypnotics**: concentration of buspirone, midazolam and alprazolam increased – reduce buspironode.
• Itraconazole and avanafil: possibly increased avanafil and vardenafil concentration – avoid.
• Bosentan: possibly increased bosentan concentration.
• Calcium-channel blockers: negative inotropic effect possibly increased; metabolism of felodipine and possibly dihydropyridines inhibited; avoid with lercanidipine.
• Cardiac glycosides: concentration of digoxin increased.
• Ciclosporin: metabolism of ciclosporin inhibited (increased ciclosporin levels).
• Cilostazol: possibly increases cilostazol concentration.
• Clopidogrel: possibly reduced antiplatelet effect.
• Colchicine: possibly increased risk of colchicine toxicity – avoid in hepatic and renal impairment.
• Corticosteroids: increases budesonide concentration – all formulations.
• Cytotoxics: possibly increases bosutinib, cabazitaxel, ceritinib, docetaxel and olaparib concentration – avoid or reduce bosutinib, cabazitaxel, ceritinib, docetaxel and olaparib dose; metabolism of busulfan inhibited, increased risk of toxicity; concentration of cobimetanib increased; possibly increases axitinib, everolimus, gefitinib and crizotinib concentration – reduce dose of axitinib, avoid with crizotinib and everolimus; possibly increases ibrutinib and panobinostat concentration – reduce ibrutinib and panobinostat dose; increased risk of toxicity with irinotecan, vinblastine, vincristine, vinodesine, vinflunine and vinorelbine – avoid; possibly increased side effects with cyclophosphamide; avoid with laptinib, nilotinib, pazopanib and temsirolimus; reduce dose of ruxolitinib.
• Dapoxetine: increased risk of toxicity – avoid.
• Domperidone: possible increased risk of ventricular arrhythmias – avoid.
• Diuretics: increased eplerenone levels – avoid concomitant use.
• Ergot alkaloids: increased risk of ergotism – avoid.
• Guanfacine: possibly increases guanfacine concentration.
• 5HT1 agonists: increased eletriptan concentration – avoid.
• Ivabradine: possibly increased ivabradine levels – reduce initial dose.
• Ivacaftor and lumacaftor: possibly increases ivacaftor concentration – reduce dose of ivacaftor and ivacaftor with lumacaftor.
• Lenalidomide: possibly increases lenalidomide concentration – increased risk of toxicity.
• Lipid-lowering drugs: increased risk of myopathy with atorvastatin, rosuvastatin and simvastatin – avoid with simvastatin, reduce dose of rosuvastatin and maximum atorvastatin dose 40 mg; avoid with lomitapide.
• Naloxegol: possibly increases naloxegol concentration – avoid.
• Ranolazine: possibly increased ranolazine concentration – avoid.
• Sirolimus: concentration increased by itraconazole.
• Tacrolimus: possibly increased tacrolimus levels.
• Ulcer-healing drugs: absorption reduced by histamine H2 antagonists and proton pump inhibitors.

### Administration

#### Reconstitution

—

#### Route

Oral, IV infusion

#### Rate of administration

Over 60 minutes

#### Comments

Add 250 mg vial to 50 mL sodium chloride 0.9%, administer 60 mL (increased volume due to large displacement value)

### Other information

• Preparations absorbed at different rates: liquid is absorbed within 2.5 hours, capsules within 2–5 hours.
• Oral bioavailability of itraconazole may be lower in some patients with renal insufficiency, e.g. those receiving CAPD.
• Janssen-Cilag advise no dose alterations for the oral preparation are required in renal impairment as drug is extensively metabolised in the liver, and pharmacokinetics are unchanged in patients with ERF compared to normal.
• Hydroxypropyl-β-cyclodextrin, a required component of Sporanox intravenous formulation, is eliminated through glomerular filtration. Therefore, in patients with CRCL<30 mL/min the use of itraconazole IV is contraindicated in the UK SPC.
• There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid flux within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
Ivabradine hydrochloride

Clinical use
Symptomatic treatment of chronic stable angina pectoris in patients with sinus rhythm
Treatment of mild to severe chronic heart failure

Dose in normal renal function
2.5–7.5 mg twice daily (dose is reduced if heart rate is consistently below 50 beats per minute)

Pharmacokinetics
Molecular weight (daltons) 504.5
% Protein binding 70
% Excreted unchanged in urine 4
Volume of distribution (L/kg) 100 Litres
Half-life — normal/ESRF (hrs) 2 / Unchanged

Metabolism
Ivabradine is extensively metabolised by the liver and the gut by oxidation through cytochrome P450 3A4 (CYP3A4) only. The major active metabolite is N-desmethyl-ivabradine (S 18982) with an exposure about 40% of that of the parent compound. This active metabolite undergoes further metabolism by CYP3A4. Excretion of metabolites occurs to a similar extent via faeces and urine.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
15–20 Dose as in normal renal function.
<15 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<15 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<15 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<15 mL/min.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone and disopyramide.
- Antibacterials: concentration possibly increased by clarithromycin and telithromycin — avoid; increased risk of ventricular arrhythmias with erythromycin — avoid.
- Antifungals: concentration increased by ketoconazole — avoid; concentration increased by fluconazole — reduce initial ivabradine dose; concentration possibly increased by itraconazole — avoid.
- Antimalarials: increased risk of ventricular arrhythmias with mefloquine.
- Antipsychotics: increased risk of ventricular arrhythmias with pimozide.
- Antivirals: concentration possibly increased by ritonavir — avoid.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Calcium-channel blockers: concentration increased by diltiazem and verapamil — avoid.
- Grapefruit juice: ivabradine concentration increased.
- Pentamidine: increased risk of ventricular arrhythmias.
- St John’s wort: ivabradine concentration reduced — avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Manufacturer advises to use with caution due to lack of data but in practice has been used in end-stage renal disease at normal doses without any problems.
Ixazomib citrate

Clinical use
Highly selective and reversible proteasome inhibitor:
• Treatment of multiple myeloma in combination with lenalidomide and dexamethasone

Dose in normal renal function
4 mg once weekly on days 1, 8 and 15 of a 28-day cycle

Pharmacokinetics
Molecular weight (daltons) 361 (517.1 as citrate)
% Protein binding 99
% Excreted unchanged in urine <3.5
Volume of distribution (L/kg) 543 Litres
Half-life — normal/ESRF (hrs) 9.5 days

Metabolism
Ixazomib citrate is a prodrug that rapidly hydrolyses under physiological conditions to its biologically active form, ixazomib. Metabolism is by multiple CYP enzymes and non-CYP proteins. At clinically relevant ixazomib concentrations, in vitro studies using human cDNA-expressed cytochrome P450 isozymes indicate that no specific CYP isozyme predominantly contributes to ixazomib metabolism and non-CYP proteins contribute to overall metabolism.
62% of the administered dose is excreted in urine and 22% in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>3 mg weekly.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>3 mg weekly.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Antibacterials: concentration reduced by rifampicin — avoid.
• Antidepressants: concentration possibly reduced by St John’s wort — avoid.
• Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin — avoid.
• Antipsychotics: increased risk of agranulocytosis with clozapine — avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Oral bioavailability is 58%.
• Unbound AUC of ixazomib was 38% higher in patients with severe renal impairment or ESRD requiring dialysis as compared to patients with normal renal function.
Ketamine

Clinical use
Anaesthetic agent, analgesic

Dose in normal renal function
All doses are expressed as the base: 1.15 mg ketamine hydrochloride ≡ 1 mg of base
- Anaesthesia: IM
  - Short procedures: initially 6.5–13 mg/kg (10 mg/kg usually gives 12–25 minutes of surgical anaesthesia)
  - Painful diagnostic manoeuvres: initially 4 mg/kg
- IV Injection:
  - Initially 1–4.5 mg/kg over at least 60 seconds (2 mg/kg usually gives 5–10 minutes of surgical anaesthesia)
- IV Infusion:
  - Induction total dose of 0.5–2 mg/kg; maintenance 10–45 mcg/kg/min; adjust rate according to response if infusion required
- Analgesia:
  - IM: 1.5–2 mg/kg
  - IV Infusion: 2–3 mg/kg or infusion rate 5–10 mg/hour of a solution of 5 mg/mL

Pharmacokinetics
Molecular weight (daltons) 274.2 (as hydrochloride)
% Protein binding 20–50
% Excreted unchanged in urine 2 (88% as metabolites)
Volume of distribution (L/kg) 4
Half-life — normal/ESRF (hrs) 2–4 / Unchanged

Metabolism
After intravenous boluses, ketamine shows a bi- or triexponential pattern of elimination. The alpha phase which lasts about 45 minutes, represents ketamine’s anaesthetic action, and is terminated by redistribution from the CNS to peripheral tissues and hepatic biotransformation to an active metabolite norketamine. Other metabolic pathways include hydroxylation of the cyclohexone ring and conjugation with glucuronic acid. Ketamine is excreted mainly in the urine as metabolites.

Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely dialysability. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Adrenergic-neurone blockers: enhanced hypotensive effect.
- Antihypertensives: enhanced hypotensive effect.
- Antidepressants: stop MAOIs 2 weeks before surgery; increased risk of arrhythmias and hypotension with tricyclics.
- Antipsychotics: enhanced hypotensive effect.
- Memantine: increased risk of CNS toxicity, avoid concomitant use.
- Muscle relaxants: enhances effects of atracurium.

Administration
Reconstitution
Route
IV bolus, IV Infusion, IM
Rate of administration
Injection: over at least 60 seconds
Infusion: depends on clinical indication
Comments
- For infusion add to glucose 5% or sodium chloride 0.9%, dilute to 1 mg/mL. In the USA can dilute to 2 mg/mL in fluid restricted patients (Dollery).
- Incompatible with diazepam and barbiturates.
- Use infusion solutions within 24 hours.
- 100 mg/mL strength must be diluted with an equal volume of water for injection, sodium chloride 0.9% or glucose 5% before use.
• Minimum volume 50 mg/mL (undiluted). (UK Critical Care Group, *Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition*, 2006.)

**Other information**

• Contraindicated in patients with severe hypertension; 1–2 mg/kg can increase arterial systolic blood pressure by approximately 20–40 mmHg.

• Avoid in those prone to hallucinations or psychotic disorders.

• 4–10% can be removed by haemodialysis.
Ketoconazole

Clinical use

Antifungal agent:
- Treatment of endogenous Cushing’s syndrome

Dose in normal renal function

400–1200 mg daily in 2–3 divided doses
See ‘Other information’

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>531.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>13</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.36</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2 / 3.3</td>
</tr>
</tbody>
</table>

Metabolism

Following absorption from the gastrointestinal tract, ketoconazole is converted into several inactive metabolites. The major identified metabolic pathways are oxidation and degradation of the imidazole and piperazine rings, oxidative O-dealkylation and aromatic hydroxylation. Plasma elimination is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter. About 13% of the dose is excreted in the urine, of which 2–4% is unchanged drug. The major route of excretion is through the bile into the intestinal tract.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Aminophylline and theophylline; possibly increased concentration of aminophylline and theophylline.
- Analgesics: inhibits buprenorphine metabolism – reduce buprenorphine dose; possible increased risk of ventricular arrhythmias with methadone – avoid; increases oxycodone and sufentanil concentration; avoid with paracetamol.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with disopyramide – avoid; concentration of dronedarone increased – avoid.
- Antibacterials: metabolism increased by rifampicin; may reduce rifampicin concentration; concentration of bedaquiline increased – avoid; avoid with fidaxomicin; concentration possibly reduced by isoniazid; avoid with clarithromycin and telithromycin in severe renal (both) and hepatic impairment (telithromycin only).
- Anticoagulants: anticoagulant effect of coumarins enhanced; concentration of apixaban, dabigatran and rivaroxaban increased – avoid; concentration of edoxaban increased – reduce edoxaban dose.
- Antidepressants: avoid concomitant use with reboxetine; ketoconazole increases concentration of mirtazapine.
- Antidiabetics: concentration of pioglitazone, saxagliptin and tolbutamide increased.
- Antiepileptics: concentration of ketoconazole reduced by fosphenytoin and phenytoin and possibly carbamazepine; concentration of perampanel and possibly carbamazepine increased.
- Antifungals: concentration of isavuconazole increased – avoid.
- Antihistamines: concentration of loratidine possibly increased – avoid; avoid with mizolastine; concentration of rupatadine increased.
- Antimalarials: avoid with piperazine with artenimol and artemether and lumefantrine; concentration of mefloquine increased.
- Antimuscarinics: absorption of ketoconazole reduced; concentration of darifenacin increased – avoid; reduce dose of fesoterodine; concentration of oxybutynin and solifenacin increased; avoid with tolterodine.
- Antipsychotics: increased risk of ventricular arrhythmias with pimozide – avoid; possibly increased concentration of quetiapine – reduce quetiapine dose; inhibits aripiprazole metabolism – reduce aripiprazole dose; concentration of lurasidone increased – avoid.
• **Antivirals:** concentration of both drugs increased with darunavir, dasabuvir and paritaprevir — avoid with dasabuvir and paritaprevir; concentration of daclatasvir increased — reduce daclatasvir dose; concentration reduced by nevirapine and efavirenz — avoid with nevirapine; ketoconazole and ritonavir can increase concentration of each other; concentration of boceprevir, indinavir, maraviroc and saquinavir increased reduce dose of indinavir and maraviroc, avoid with saquinavir; concentration increased by fosamprenavir and possibly concentration of fosamprenavir increased; avoid with ombitasvir and simeprevir; concentration of both drugs increased with telaprevir.

• **Anxiolytics and hypnotics:** concentration of alprazolam and midazolam increased (risk of prolonged sedation).

• **Avanafil, tadalafil and vardenafil:** increased concentration of avanafil, tadalafil and vardenafil, avoid.

• **Calcium-channel blockers:** increased concentration of felodipine; avoid with lercanidipine; possibly inhibits metabolism of dihydropyridines.

• **Ciclosporin:** increased ciclosporin concentration.

• **Cilostazol:** possibly increased concentration of cilostazol, consider reducing dose.

• **Cinacalcet:** increased cinacalcet concentration.

• **Clopidogrel:** possibly reduces antiplatelet effect.

• **Colchicine:** possibly increases risk of colchicine toxicity, avoid concomitant use in hepatic or renal failure.

• **Corticosteroids:** possibly inhibits metabolism of corticosteroids including inhaled and rectal formulations.

• **Cytotoxics:** concentration of axitinib increased (reduce dose of axitinib); concentration of bosutinib, ceritinib and ibritinib increased — avoid or reduce bosutinib, ceritinib and ibritinib dose; concentration of crizotinib, everolimus, lapatinib, nilotinib and regorafenib increased — avoid; possibly increases concentration of dasatinib; inhibits metabolism of erlotinib and sunitinib; concentration of bortezomib, imatinib, nintedanib and panobinostat increased — reduce panobinostat dose; avoid with cabazitaxel, everolimus and pazopanib, reduce dose with ruxolitinib; inhibits active metabolite of temsirolimus — avoid; docetaxel possibly interacts with ketoconazole; possible increased risk of neutropenia with brentuximab; concentration of irinotecan, but active metabolite of irinotecan reduced — avoid; concentration of active metabolite of temsirolimus increased — avoid; concentration of vinflunine increased — avoid.

• **Dapoxetine:** concentration of dapoxetine increased — avoid.

• **Diuretics:** increased eplerenone concentration — avoid.

• **Domperidone:** possibly increased risk of arrhythmias - avoid.

• **Ergot alkaloids:** increased risk of ergotism with ergotamine and methysergide — avoid.

• **Fingolimod:** concentration of fingolimod increased.

• **Guanfacine:** concentration of guanfacine increased — halve guanfacine dose.

• **5HT1 agonists:** increased concentration of eletriptan — avoid; increased almotriptan concentration (increased toxicity).

• **Ivabradine:** concentration of ivabradine increased — avoid.

• **Ivacaftor and lumacaftor:** concentration of ivacaftor increased — reduce dose of lumacaftor with ivacaftor.

• **Lanthanum:** reduces absorption of ketoconazole — give at least 2 hours apart.

• **Lenalidomide:** possibly increases lenalidomide concentration — increased risk of toxicity.

• **Lomitapide:** concentration of lomitapide increased — avoid.

• **Naloxegol:** concentration of naloxegol increased — avoid.

• **Ranolazine:** concentration of ranolazine increased — avoid.

• **Retinoids:** concentration of altretinoin increased; possibly increased risk of tretinoin toxicity.

• **Sirolimus:** concentration increased by ketoconazole — avoid.

• **Statins:** possibly increased risk of myopathy with atorvastatin and simvastatin — avoid.1

• **Sympathomimetics:** concentration of olodaterol and salmeterol increased.

• **Tacrolimus:** increased tacrolimus concentration.

• **Tamulosin:** concentration of tamsulosin increased.

• **Ticagrelor:** concentration of ticagrelor increased — avoid.

---

**Administration**

**Reconstitution**

---

**Route**

Oral, topical

**Rate of administration**

---

**Other information**

- The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) advise that oral ketoconazole is no longer recommended for fungal infections due to the increased risk of liver damage. 26 July 2013.

- Monitor LFTs especially if on long-term treatment.

Reference:

Ketoprofen

Clinical use
NSAID and analgesic

Dose in normal renal function
- Oral: 100–200 mg daily in 2–4 divided doses
- Dysmenorrhea: 50 mg every 8 hours

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>254.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.5–8 / 5–9</td>
</tr>
</tbody>
</table>

Metabolism

Two processes are involved in the biotransformation of ketoprofen: one very minor (hydroxylation), and the other largely predominant (conjugation with glucuronic acid). Less than 1% of the dose of ketoprofen administered is recovered in unchanged form in the urine, whereas the glucuronide metabolite accounts for about 65–75%. The drug is excreted as metabolites essentially by the urinary route. The rate of excretion is rapid, since 50% of the dose administered is eliminated in the first 6 hours.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose advice</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but only use if on dialysis.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose advice</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect, increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with edoxaban, heparin and dabigatran – avoid long term NSAID use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetics: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxic agents: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect, hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Probencid: excretion reduced by probencid.
- Tacrolimus: increased risk of nephrotoxicity.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

- Combined oral and rectal treatment, maximum total daily dose 200 mg.
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease.
Ketoprofen

– avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.

• Use normal doses in patients with ERF on dialysis if they do not pass any urine.

• Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.

• NSAIDs decrease platelet aggregation.

• Associated with nephrotic syndrome, interstitial nephritis, hyperkalaemia and sodium retention.
Ketorolac trometamol

Clinical use
Short-term management of moderate to severe acute postoperative pain

Dose in normal renal function
- Oral: 10 mg every 4–6 hours (elderly every 6–8 hours); maximum 40 mg daily; maximum duration 7 days.
- IM/IV: initially 10 mg, then 10–30 mg when required every 4–6 hours (every 2 hours in initial postoperative period); maximum 90 mg daily (elderly and patients less than 50 kg: maximum 60 mg daily); maximum duration 2 days.

Pharmacokinetics
- Molecular weight (daltons) 376.4
- % Protein binding >99
- % Excreted unchanged in urine Approx 60
- Volume of distribution (L/kg) 0.15
- Half-life — normal/ESRF (hrs) IM dose: 3.5–9.2 / 5.9–19.2

Metabolism
The major metabolic pathway is glucuronic acid conjugation; there is some para-hydroxylation. About 91.4% of a dose is excreted in urine as unchanged drug and conjugated and hydroxylated metabolites, with a further 6.1% being excreted in the faeces.

Dose in renal impairment GFR (mL/min)
- 20–50 Maximum 60 mg daily
- 10–20 Avoid if possible. Use small doses and monitor closely.
- <10 Avoid if possible. Use small doses and monitor closely.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: increased risk of bleeding with heparin, dabigatran, phenindione and coumarins — avoid concomitant use; increased risk of haemorrhage with parenteral ketorolac and heparin — avoid.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetics: effects of sulphonylureas possibly enhanced.
- Antiepileptics: effect of phenytoin possibly enhanced.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxics: excretion of methotrexate reduced; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion of lithium reduced — avoid.
- Pentoxifylline: risk of ketorolac associated bleeding increased — avoid.
- Tacrolimus: increased risk of nephrotoxicity.

Administration
Reconstitution

Route
IM, IV, oral

Rate of administration
IV bolus over no less than 15 seconds.

Comments
Compatible with sodium chloride 0.9%, glucose 5%, Ringers, lactated Ringers or plasmalyte solutions.
Other information

- Drugs that inhibit prostaglandin biosynthesis (including NSAIDs) have been reported to cause nephrotoxicity, including, but not limited to, glomerular nephritis, interstitial nephritis, renal papillary necrosis, nephrotic syndrome and acute renal failure. In patients with renal, cardiac or hepatic impairment, caution is required since the use of NSAIDs may result in deterioration of renal function.
- Ketorolac and its metabolites are excreted primarily by the kidney.
- Reported renal side effects include increased urinary frequency, oliguria, acute renal failure, hyponatraemia, hyperkalaemia, haemolytic uraemic syndrome, flank pain (with or without haematuria), raised serum urea and creatinine.
Ketotifen

**Clinical use**

Antihistamine:
- Allergic conditions

**Dose in normal renal function**

- 1-2 mg twice daily
- Initial dose in readily sedated patients: 0.5–1 mg at night

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>425.5 (as fumarate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>75</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>8.8 (^1)</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>21</td>
</tr>
</tbody>
</table>

**Metabolism**

Undergoes hepatic first-pass metabolism to form inactive metabolites which are mainly excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: sedative effects possibly increased with opioid analgesics.

**Administration**

**Reconstitution**
- 

**Route**
- Oral, topical

**Rate of administration**
- 

**Other information**

- Increased possibility of side effects, particularly drowsiness.
- Bioavailability is 50%.

Reference:
Klean-prep

**Clinical use**
Colonic lavage prior to diagnostic examination or surgical procedures requiring a clean colon.

**Dose in normal renal function**
4 sachets, each reconstituted in 1 Litre of water, at a rate of 250 mL every 10–15 minutes.

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>3350 (Macrogol)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>N/A</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>N/A</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>N/A</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Metabolism**

Macrogol 3350 is unchanged along the gut. It is virtually unabsorbed from the gastrointestinal tract.
Any macrogl 3350 that is absorbed is excreted via the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Not absorbed. Dose as in normal renal function.
- **HD**: Not absorbed. Dose as in normal renal function.
- **HDF/High flux**: Not absorbed. Dose as in normal renal function.
- **CAV/VVHD**: Not absorbed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
Each sachet in 1 Litre of water.

**Route**
Oral

**Rate of administration**
250 mL every 15–30 minutes.
If given via NG tube, rate is 20–30 mL/minute.

**Comments**
Klean-Prep is formulated to be hyper-osmotic and draw water into the bowel. None is absorbed systemically.

**Other information**
Each sachet of Klean-Prep contains:
- Polyethylene glycol 3350 – 59 g
- Anhydrous sodium sulphate – 5.685 g
- Sodium bicarbonate – 1.685 g
- Sodium chloride – 1.465 g
- Potassium chloride – 0.7425 g

The electrolyte content of 1 sachet when made up in 1 Litre of water is:
- Sodium – 125 mmol
- Sulphate – 40 mmol
- Chloride – 35 mmol
- Bicarbonate – 20 mmol
- Potassium – 10 mmol
Labetalol hydrochloride

**Clinical use**

Beta-adrenoceptor blocker:
- Hypertensive crisis, hypertension

**Dose in normal renal function**

- Oral: 50–400 mg twice daily (in 3–4 divided doses if >800 mg daily); maximum 2.4 g daily
- IV infusion: 2 mg/minute until satisfactory response; usual total dose 50–200 mg
- IV bolus: 50 mg over 1 minute, repeated at 5 minute intervals to a total dose of 200 mg
- Pregnancy: 20–160 mg/hour
- Hypertension after an MI: 15–120 mg/hour

**Pharmacokinetics**

- Molecular weight (daltons): 364.9
- % Protein binding: 50
- % Excreted unchanged in urine: 5
- Volume of distribution (L/kg): 5.6
- Half-life — normal/ESRF (hrs): 4–8 / Unchanged

**Metabolism**

Labetalol is subject to considerable first-pass metabolism. It is metabolised mainly in the liver, the metabolites being excreted in the urine with only small amounts of unchanged labetalol; its major metabolite has not been found to have significant alpha- or beta-blocking effects. Excretion also occurs in the faeces via the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antidepressants: enhanced hypotensive effect with MAOIs; concentration of imipramine increased.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

**Administration**

**Reconstitution**

—

**Route**

Oral, IV

**Rate of administration**

2 mg/minute initially then titrate according to response or to indication

**Comments**

- 200 mg labetalol (40 mL) to 200 mL glucose 5%.
- Can be used undiluted. (UK Critical Care Group, *Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006.*)
Other information

- No adverse effects on renal function.
- No accumulation in renal impairment.
- Hypoglycaemia can occur in dialysis patients.
- Tachyphylaxis can occur with prolonged use.
Lacidipine

**Clinical use**
Calcium-channel blocker:
- Hypertension

**Dose in normal renal function**
2–6 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 455.5
- % Protein binding 95
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) 0.9–2.3
- Half-life — normal/ESRF (hrs) 13–19 / —

**Metabolism**
Lacidipine undergoes extensive first-pass metabolism in the liver. The drug is eliminated primarily by hepatic metabolism (involving cytochrome P450 CYP3A4). The principal metabolites possess little, if any, pharmacodynamic activity.
Approximately 70% of the administered dose is eliminated as metabolites in the faeces and the remainder as metabolites in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in normal renal function.
- HD Unknown dialysability. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: possibly increased aminophylline and theophylline concentration.
- Anaesthetics: enhanced hypotensive effect.
- Antibacterials: metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antiepileptics: effect possibly reduced by carbamazepine, barbiturates, phenytoin and primidone.
- Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole; negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antivirals: concentration possibly increased by ritonavir.
- Ciclosporin: 10 kidney transplant patients on ciclosporin, prednisone and azathioprine were given 4 mg lacidipine daily. A very small increase in the trough serum levels (+6%) and AUC (+14%) of the ciclosporin occurred.
- Grapefruit juice: concentration increased – avoid concomitant use.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—
Lacosamide

**Clinical use**

Antiepileptic

**Dose in normal renal function**

50–200 mg twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>250.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>&lt;15</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>13 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

The metabolism of lacosamide has not been completely characterised. Lacosamide is a CYP2C19 substrate. Metabolites are inactive. About 95% of a dose is excreted in the urine, about 40% as unchanged drug and less than 30% as the inactive O-desmethyl metabolite. Less than 0.5% of a dose is excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

| 30–50 | Dose as in normal renal function |
| 10–30 | Maximum dose 250 mg daily.       |
| <10   | Titrate slowly. Maximum dose 250 mg daily. |

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antidepressants: anticonvulsant effect antagonised; avoid with St John’s wort.
- Antimalarials: mefloquine antagonises anticonvulsant effect.
- Antipsychotics: anticonvulsant effect antagonised.
- Orlistat: possibly increased risk of convulsions.

**Administration**

**Reconstitution**

- **Route**
  - Oral, IV infusion

  **Rate of administration**
  - 15–60 minutes

**Other information**

- Metabolite with no known pharmacological activity accumulates in ERF, therefore use with caution.
- Prolongations in PR interval with lacosamide have been observed in clinical studies.
- Infusion contains 2.6 mmol (or 59.8 mg) sodium per vial.
- Tablets have 100% bioavailability.
- The AUC of lacosamide was increased by approximately 30% in mildly and moderately and 60% in severely renal impaired patients and patients with ERF requiring haemodialysis compared to healthy subjects, whereas $C_{\text{max}}$ was unaffected.
- Approximately 50% of lacosamide is removed following a 4-hour haemodialysis session.
**Lactulose**

**Clinical use**
- Constipation
- Hepatic encephalopathy

**Dose in normal renal function**
- Constipation: initially 15 mL twice daily; adjust according to requirements
- Hepatic encephalopathy: 30–50 mL 3 times daily, adjusted to produce 2–3 soft stools daily

**Pharmacokinetics**
- Molecular weight (daltons): 342.3
- % Protein binding: No data
- % Excreted unchanged in urine: <3
- Volume of distribution (L/kg): N/A – not absorbed
- Half-life — normal/ESRF (hrs): No data

**Metabolism**
Lactulose passes essentially unchanged into the large intestine where it is metabolised by saccharolytic bacteria with the formation of simple organic acids, mainly lactic acid and small amounts of acetic and formic acids. A small amount of absorbed lactulose is subsequently excreted unchanged in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function
- 10–20: Dose as in normal renal function
- <10: Dose as in normal renal function

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function
- HD: Not dialysed. Dose as in normal renal function
- HDF/High flux: Not dialysed. Dose as in normal renal function
- CAV/VVHD: Not dialysed. Dose as in normal renal function

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**
Reconstitution
- Route
- Oral

**Rate of administration**
- 

**Other information**
- May take up to 72 hours to work.
- Not significantly absorbed from GI tract.
- Safe for diabetics (lactulose is converted to lactic, formic and acetic acid in the bowel).
- Osmotic and bulking effect.
Lamivudine

Clinical use
Nucleoside reverse transcriptase inhibitor:
• Treatment of HIV in combination with other antiretroviral drugs
• Treatment of chronic hepatitis B in adults

Dose in normal renal function
• HIV: 150 mg twice daily or 300 mg daily.
• Hepatitis B: 100 mg daily.

Pharmacokinetics
Molecular weight (daltons) 229.3
% Protein binding <36
% Excreted unchanged in urine 70
Volume of distribution (L/kg) 1.3
Half-life — normal/ESRF (hrs) 5–7 / 20

Metabolism
Lamivudine is metabolised intracellularly to the active antiviral triphosphate. Hepatic metabolism is low (5–10%) and the majority of lamivudine is excreted unchanged in the urine via glomerular filtration and active secretion (organic cationic transport system).

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>HIV Dosing</th>
<th>Hepatitis B Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>See ‘Other information’: HIV: 150 mg daily. Hepatitis B: 100 mg stat then 50 mg daily.</td>
<td></td>
</tr>
<tr>
<td>15–30</td>
<td>See ‘Other information’: HIV: 150 mg stat then 100 mg daily. Hepatitis B: 100 mg stat then 25 mg daily.</td>
<td></td>
</tr>
<tr>
<td>5–15</td>
<td>See ‘Other information’: HIV: 150 mg stat then 50 mg daily. Hepatitis B: 35 mg stat then 15 mg daily.</td>
<td></td>
</tr>
<tr>
<td>&lt;5</td>
<td>See ‘Other information’: HIV: 50 mg stat then 25–50 mg daily. Hepatitis B: 35 mg stat then 10 mg daily.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;5 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;5 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;5 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=5–15 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Antibacterials: trimethoprim inhibits excretion of lamivudine – avoid concomitant use of high dose co-trimoxazole.
• Antivirals: avoid concomitant use with foscarnet, emtricitabine and IV ganciclovir.
• Cytotoxics: avoid with cladribine.
• Orlistat: absorption possibly reduced by orlistat.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—
Comments
Administer with or without food.

Other information
• 15 mL of oral suspension contains 3 g of sucrose.
• Dosage from Bennett (5th edition):
  GFR>50 mL/min: 100% of dose
  GFR=10–50 mL/min: 150 mg loading dose then 50–150 mg daily
  GFR<10 mL/min: 50 mg loading dose then 25–50 mg daily

References:
Lamotrigine

Clinical use

- Monotherapy and adjunctive treatment of partial seizures, and primary and secondary generalised tonic-clonic seizures
- Prevention of depressive episodes in bipolar disease
- Trigeminal neuralgia (unlicensed)

Dose in normal renal function

25–200 mg daily in 1–2 divided doses, according to clinical indication. Maximum 500 mg daily; 700 mg with enzyme-inducing drugs

Pharmacokinetics

Molecular weight (daltons) 256.1
% Protein binding 55
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 0.92–1.22
Half-life — normal/ESRF (hrs) 24–35 / Unchanged

Metabolism

Lamotrigine is extensively metabolised in the liver by UDP-glucuronyl transferases and excreted almost entirely in urine, principally as an inactive glucuronide conjugate. It slightly induces its own metabolism. Only about 2% of lamotrigine-related material is excreted in faeces.

Dose in renal impairment GFR (mL/min)

20–50 Caution. Start with 75% of dose and monitor closely.
10–20 Caution. Start with 75% of dose and monitor closely.
<10 Caution. Start with low doses and monitor closely.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unlikely dialysability. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs

- Antibacterials: concentration reduced by rifampicin.
- Antidepressants: antagonism of anticonvulsant effect; avoid with St John’s wort.
- Antiepileptics: concentration reduced by carbamazepine, phenobarbital and phenytoin, also possibility of increased concentration of active carbamazepine metabolite; concentration increased by valproate – reduce lamotrigine dose.
- Antimalarials: mefloquine antagonises anticonvulsant effect
- Antipsychotics: anticonvulsant effect antagonised.
- Oestrogens and progestogens: concentration of lamotrigine reduced and the dose may need to be increased by as much as 2-fold; may affect contraceptive effect.
- Orlistat: possibly increased risk of convulsions.

Administration

Reconstitution

Route
Oral
Rate of administration

Other information

- Pharmacokinetic studies using single doses in subjects with renal failure indicate that lamotrigine pharmacokinetics are little affected, but plasma concentrations of the major glucuronide metabolite increase almost 8-fold due to reduced renal clearance.
- The 2-N-glucuronide is inactive and accounts for 75–90% of the metabolised drug present in the urine. Although the metabolite is inactive the consequences of accumulation are unknown; hence the company advise caution with the use of lamotrigine in renal impairment.
- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- The half-life of lamotrigine is affected by other drugs; reduced to 14 hours when given with enzyme-inducing drugs, e.g. carbamazepine and phenytoin, and is increased to approximately 70 hours when co-administered with sodium valproate alone.
Lanreotide

Clinical use
Treatment of neuroendocrine and thyroid tumours and acromegaly

Dose in normal renal function
LA: Neuroendocrine tumours and acromegaly: 30 mg every 14 days, increased to every 7–10 days according to response
Thyroid tumours: 30 mg every 14 days, increased to every 10 days according to response
Autogel: Acromegaly: 60 mg every 28 days, adjusted according to response
Neuroendocrine tumours: 60–120 mg every 28 days, adjusted according to response

Pharmacokinetics
Molecular weight (daltons) 1096.3
% Protein binding Unknown
% Excreted unchanged in urine <5
Volume of distribution (L/kg) 16.1 Litres
Half-life — normal/ESRF (hrs) 2.5 (Depot 5–30 days) / 5 (Depot 10–60 days)

Metabolism
No data.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in normal renal function.
HD Dialysed. Dose as in normal renal function.
HDF/High flux Dialysed. Dose as in normal renal function.
CAV/VVHD Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Ciclosporin: ciclosporin concentration reduced.

Administration
Reconstitution
Route
LA: IM; Autogel: SC
Rate of administration

Other information
- Due to a wide therapeutic window, lanreotide may be given at the normal starting dose and then adjusted according to response despite reduced clearance in renal impairment.
- Bioavailability is 55–80% depending on product.
# Lansoprazole

## Clinical use
Gastric acid suppression

## Dose in normal renal function
- 5–30 mg daily in the morning; duration dependent on indication
- Zollinger-Ellison syndrome: initially 60 mg daily; adjust according to response (if >120 mg, give in 2 divided doses)

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>369.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0 (15–30 as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>25–33 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–2 / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
Lansoprazole is extensively metabolised in the liver, primarily by cytochrome P450 isoenzyme CYP2C19 to form 5-hydroxyl-lansoprazole and by CYP3A4 to form lansoprazole sulfone.

The metabolites are excreted by both the renal and biliary route. A study with $^{14}$C-labelled lansoprazole indicated that approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability, probably not removed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antifungals: absorption of itraconazole and ketoconazole reduced; avoid with posaconazole.
- Antivirals: concentration of atazanavir and rilpivirine reduced – avoid; concentration of raltegravir and saquinavir possibly increased – avoid.
- Ciclosporin: theoretical, interaction unlikely – little information available.
- Clopidogrel: possibly reduced antiplatelet effect.
- Cytotoxics: possibly reduced excretion of methotrexate; avoid with dasatinib, erlotinib and vandetanib; possibly reduced lapatinib absorption; possibly reduced absorption of pazopanib.
- Tacrolimus: may increase tacrolimus concentration.
- Ulipristal: reduced contraceptive effect, avoid with high dose ulipristal.

## Administration

### Reconstitution
- 

### Route
- Oral

### Rate of administration
- 

---

Lansoprazole 571
Lanthanum carbonate

Clinical use
Phosphate binder in patients with CKD 5

Dose in normal renal function
- Usually 500 mg – 1 g 3 times a day with meals
- Maximum 3750 mg daily

Pharmacokinetics
- Molecular weight (daltons) 457.8
- % Protein binding >99.7
- % Excreted unchanged in urine Negligible
- Volume of distribution (L/kg) Not absorbed
- Half-life — normal/ESRF (hrs) 36 / –

Metabolism
Lanthanum carbonate is poorly absorbed from the gastrointestinal tract, with an absolute oral bioavailability of less than 1%. The small fraction that is absorbed is more than 99% bound to plasma proteins and is widely distributed in the tissues, particularly the bones, the liver, and the gastrointestinal tract. Lanthanum is not metabolised.

It is excreted mainly in the faeces with only around 0.000031% of an oral dose excreted via the urine in healthy subjects (renal clearance approximately 1 mL/min, representing <2% of total plasma clearance).

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: possibly reduces absorption of quinolones – give at least 2 hours before or 4 hours after lanthanum.
- Antifungals: absorption of ketoconazole reduced – give at least 2 hours apart.
- Antimalarials: absorption of chloroquine and hydroxychloroquine possibly reduced – give at least 2 hours apart.
- Thyroid hormones: reduces absorption of levothyroxine – give at least 2 hours apart.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—
Comments
Must be chewed WITH food; do not take before meals.

Other information
- Following ingestion, lanthanum carbonate is converted in the GI tract to the insoluble lanthanum phosphate, which is not readily absorbed into the blood.
- Sachets should be mixed with soft food and consumed within 15 minutes.
- Bioavailability of drugs administered concomitantly may be reduced due to binding by lanthanum carbonate.
- Very little is absorbed.
- If not taken with meals, may result in vomiting.
Lapatinib

**Clinical use**
Tyrosine kinase inhibitor:
- Treatment of advanced or metastatic breast cancer in combination with capecitabine

**Dose in normal renal function**
- In combination with capecitabine: 1.25 g once daily
- In combination with an aromatase inhibitor: 1.5 g once daily
- In combination with trastuzumab: 1 g once daily

**Pharmacokinetics**
- Molecular weight (daltons): 943.5 (as tosylate)
- % Protein binding: >99
- % Excreted unchanged in urine: <2
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 24 / –

**Metabolism**
Extensive hepatic metabolism, mainly by cytochrome P450 isoenzymes CYP3A4 and CYP3A5; CYP2C19 and CYP2C8 account for some minor metabolism.
About 27% and 14% of an oral dose is recovered in the faeces, as parent lapatinib and metabolites, respectively; renal excretion is negligible.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: avoid with rifabutin, rifampicin and telithromycin.
- Antidepressants: avoid with St John's wort.
- Antidiabetics: avoid with repaglinide.
- Antiepileptics: concentration reduced by carbamazepine - avoid; possibly reduced fosphenytoin and phenytoin concentration - avoid.
- Antifungals: concentration increased by ketoconazole - avoid; avoid with itraconazole, posaconazole and voriconazole.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis); avoid with pimozide.
- Antivirals: avoid with boceprevir, ritonavir and saquinavir.
- Cytotoxics: concentration of pazopanib increased; possible increased risk of neutropenia with docetaxel and paclitaxel; concentration of active metabolite of irinotecan increased, consider reducing irinotecan dose.
- Grapefruit juice: avoid concomitant use.

**Administration**
**Reconstitution**

**Route**
Oral

**Rate of administration**

**Comments**
Take either at least one hour before, or at least one hour after food, food increases absorption.

**Other information**
- No experience in severe renal impairment hence use with caution.
**Clinical use**

Disease modifying agent:
- Active rheumatoid arthritis
- Psoriatic arthritis

**Dose in normal renal function**

- Rheumatoid arthritis: 100 mg daily for 3 days then 10–20 mg daily
- Psoriatic arthritis: 100 mg daily for 3 days then 20 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>270.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>11 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2 weeks (metabolite) / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

After oral doses leflunomide undergoes rapid first-pass metabolism in the liver and gut wall to teriflunomide (A-771726), which is responsible for the majority of the *in vivo* activity. Teriflunomide is mostly eliminated as unchanged drug in the bile and as metabolites in the urine. It is thought to undergo enterohepatic recycling and has an elimination half-life of about 18–19 days after repeated oral doses.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution. See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Hepatotoxic or haemotoxic drugs: increased risk of toxicity.
- Cytotoxics: risk of toxicity with methotrexate.
- Lipid-lowering agents: effect significantly reduced by colestyramine — avoid.
- Live vaccines: avoid concomitant use.

**Administration**

**Reconstitution**

- **Route** Oral

**Rate of administration**

- **Comments** Administer with food.

**Other information**

- Contraindicated in moderate to severe renal impairment by UK manufacturer due to insufficient evidence.
- US data sheet says it can be used in renal impairment with caution.
- Protein binding is variable in CKD.
- In haemodialysis and PD the free fraction of the active metabolite in plasma is doubled.
- A case study from Beaman used leflunomide in a haemodialysis patient at a dose of 100 mg loading dose followed by 10 mg daily which was later increased to 20 mg daily but then reduced to 15 mg daily due to altered hepatic function. He concluded that it could be safely used in haemodialysis patients. (Beaman JM, Hackett LP, Lyoutu G, et al. Effect of haemodialysis on leflunomide plasma concentrations. *Ann Pharmacother.* 2002 Jan; 36(1): 75-7.)
Lenalidomide

Clinical use
Treatment of multiple myeloma, mantle cell lymphoma and myelodysplastic syndrome

Dose in normal renal function
- Myeloma: 25 mg daily on days 1–21 of a 28 day cycle; with melphelan: 10 mg daily
- Mantle cell lymphoma: 25 mg daily on days 1–21 of a 28 day cycle
- Myelodysplastic syndrome: 10 mg once daily initially, reduce dose if patient has neutropenia or thrombocytopenia; see data sheet

Pharmacokinetics
Molecular weight (daltons) 259.3
% Protein binding 22.7–29.2
% Excreted unchanged in urine 65–85
Volume of distribution (L/kg) 86 Litres
Half-life — normal/ESRF (hrs) 3.5 / >9

Metabolism
Lenalidomide is poorly metabolised as 82% of the dose is excreted unchanged in urine. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively. The renal clearance of lenalidomide exceeds the glomerular filtration rate and therefore is at least actively secreted to some extent. Approximately 4% of lenalidomide is eliminated in faeces.

Dose in renal impairment GFR (mL/min)
30–50 Myeloma and mantle cell lymphoma: 10 mg daily, increasing to 15 mg after 2 cycles if patient is not responding. Myelodysplastic syndrome: initially 5 mg once daily.
<30 Myeloma and mantle cell lymphoma: 15 mg every 48 hours, can be increased to 10 mg daily if patient is not responding. Myelodysplastic syndrome: initially 2.5 mg once daily.

Dose in patients undergoing renal replacement therapies
APD/CAPD Probably dialysed. Myeloma and mantle cell lymphoma: 15 mg 2–3 times a week or 5 mg daily; Myelodysplastic syndrome: Dose as in GFR<30 mL/min.
HD Probably dialysed. 15 mg 3 times a week post dialysis or 5 mg daily; Myelodysplastic syndrome: dose as in GFR<30 mL/min.
HDF/High flux Probably dialysed. 15 mg 3 times a week post dialysis or 5 mg daily. Myelodysplastic syndrome: dose as in GFR<30 mL/min.
CA V/VVHD Probably dialysed. Dose as in GFR=30–50 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly increased by clarithromycin.
- Antifungals: concentration possibly increased by itraconazole and ketoconazole.
- Calcium channel blockers: concentration possibly increased by verapamil.
- Cardiac glycosides: possibly increases concentration of digoxin.
- Ciclosporin: concentration possibly increased by ciclosporin.

Administration
Reconstitution
—
Route Oral
Rate of administration
—

Other information
- Patients with renal impairment are more likely to develop side effects.
Lenograstim

**Clinical use**
Recombinant human granulocyte-colony stimulating factor (rHuG-CSF):
- Reduction of duration of neutropenia

**Dose in normal renal function**
- Cytotoxic neutropenia: 150 mcg/m² (19.2 MIU/m²) daily SC
- Mobilisation of peripheral blood progenitor cells: 10 mcg/kg (1.28 MIU/kg) daily
- Bone marrow transplant: 150 mcg/m² (19.2 MIU/m²) daily as an IV infusion or SC injection

**Pharmacokinetics**
- Molecular weight (daltons) 20 000
- % Protein binding No data
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 1
- Half-life — normal/ESRF (hrs) 3–4

**Metabolism**
Lenograstim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalisation of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells. During chemotherapy-induced neutropenia, the clearance of lenograstim is significantly reduced and the concentration of lenograstim is sustained until onset of neutrophil recovery.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**
- **Reconstitution**
  Water for injection (1 mL)
- **Route**
  SC, IV
- **Rate of administration**
  30 minutes
- **Comments**
  Dilute lenograstim-13.4 in up to 50 mL sodium chloride 0.9%.
  Dilute lenograstim-33.6 in up to 100 mL sodium chloride 0.9%.
Lenvatinib mesilate

**Clinical use**
Protein kinase inhibitor:
- Treatment of renal cell carcinoma (RCC) - Kisplyx®
- Treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC) - Lenvima®

**Dose in normal renal function**
- RCC: 18 mg once daily
- DTC: 24 mg once daily

**Pharmacokinetics**
Molecular weight (daltons) 523
% Protein binding 98–99
% Excreted unchanged in urine 25
Volume of distribution (L/kg) 43.2–121 Litres
Half-life — normal/ESRF (hrs) 28

**Metabolism**
Lenvatinib is metabolised by CYP3A and aldehyde oxidase.
Following administration of radiolabelled lenvatinib to 6 patients with solid tumours, approximately two-thirds and one-fourth of the radiolabel were eliminated in the faeces and urine, respectively.

**Dose in renal impairment GFR (mL/min)**
- 30–50 Dose as in normal renal function.
- <30 RCC: 10 mg once daily, DTC: starting dose 14 mg once daily. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<30 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<30 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<30 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=30–50mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**
**Reconstitution**
- **Route**
  Oral
- **Rate of administration**
  —

**Other information**
- Manufacturer does not recommend in ESRD due to lack of data.
- In the RCC study, 8.1% of patients in the lenvatinib plus everolimus treated group developed renal failure and 3.2% developed renal impairment, (9.7% of patients had a grade 3 event of renal failure or impairment). In the everolimus monotherapy group 2% of patients developed renal failure (2% were grade 3).
- In the DTC study, 5% of patients developed renal failure and 1.9% developed renal impairment, (3.1% of patients had a grade ≥3 event of renal failure or impairment). In the placebo group 0.8% of patients developed renal failure or impairment (0.8% were grade ≥3). Main cause of renal impairment was due to dehydration/hypovolaemia due to diarrhoea and vomiting.
- Lenvatinib exposure, based on AUC_{0–inf} data, was 101%, 90%, and 122% of normal for subjects with mild, moderate, and severe renal impairment, respectively.
- Can cause QT prolongation.
# Lercanidipine hydrochloride

## Clinical use
Calcium-channel antagonist:
- Mild to moderate hypertension

## Dose in normal renal function
10–20 mg daily

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>648.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50 (as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8–10 / Increased</td>
</tr>
</tbody>
</table>

## Metabolism
Lercanidipine undergoes extensive first-pass metabolism. Lercanidipine is extensively metabolised by CYP3A4; no parent drug is found in the urine or the faeces. It is predominantly converted to inactive metabolites and about 50% of the dose is excreted in the urine, and 50% via the faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Use small doses and titrate to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use small doses and titrate to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use small doses and titrate to response.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: possibly increased aminophylline and theophylline concentration.
- Anaesthetics: enhanced hypotensive effect.
- Antibacterials: metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin – avoid with erythromycin.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone.
- Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole – avoid; negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antivirals: concentration increased by ritonavir – avoid.
- Cardiac glycosides: digoxin concentration increased.
- Ciclosporin: concentration of both drugs may be increased – avoid.
- Grapefruit juice: concentration increased – avoid.

## Administration

### Reconstitution
- 

### Route
- Oral

### Rate of administration
- 

### Comments
- Take before food.

## Other information
- Causes less peripheral oedema than other calcium-channel blockers.
Letrozole

**Clinical use**
Treatment of breast cancer

**Dose in normal renal function**
2.5 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>285.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>6</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.87</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>48 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolic clearance via the cytochrome P450 isoenzymes 3A4 and 2A6 to a pharmacologically inactive carbinol metabolite is the major elimination pathway of letrozole. Formation of minor unidentified metabolites and direct renal and faecal excretion play only a minor role in the overall elimination of letrozole. Within 2 weeks after administration of 2.5 mg [¹⁴C]-labelled letrozole to healthy postmenopausal volunteers, 88.2 ± 7.6% of the radioactivity was recovered in urine and 3.8 ± 0.9% in faeces. At least 75% of the radioactivity recovered in urine up to 216 hours (84.7 ± 7.8% of the dose) was attributed to the glucuronide of the carbinol metabolite, about 9% to two unidentified metabolites, and 6% to unchanged letrozole.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Probably dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**

- Manufacturer advises to use with caution if GFR<10 mL/min due to lack of data. In studies down to a GFR of 9 mL/min there were no differences in the pharmacokinetics of letrozole.
- From personal experience, letrozole can be used in patients with end-stage renal impairment and those on renal replacement therapies in normal doses.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information.</td>
</tr>
</tbody>
</table>
Leuprolin acetate

Clinical use
Treatment of advanced prostate cancer and endometriosis

Dose in normal renal function
- 11.25 mg every 3 months (SC depot injection, prostate cancer only)
- Or 3.75 mg every 4 weeks
- Endometriosis: 3.75 mg every month or 11.25 mg every 3 months for maximum 6 months (not to be repeated)

Pharmacokinetics
Molecular weight (daltons) 1269.5
% Protein binding 43–49
% Excreted unchanged in urine <5 (+ metabolites)
Volume of distribution (L/kg) 27 Litres
Half-life — normal/ESRF (hrs) 3 / increased

Metabolism
Leuprolin binds to the LHRH receptors and is rapidly degraded by peptidases, then excreted in the urine.

Dose in normal renal function
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
With diluent provided

Route
IM, SC depot

Rate of administration
—

Other information
- Women on dialysis may be at greater risk of ovarian hyperstimulation, possibly because dialysis affects circulating leuprolin concentration so endogenous gonadotrophins were still excreted. Alternatively, haemodialysis patients may have increased responsiveness to endogenous gonadotrophins.
Levamisole (unlicensed product)

Clinical use

Treatment of roundworm (Ascaris lumbricoides)

Dose in normal renal function

2.5 mg/kg as a single dose

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>204.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>19–26</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>100–120 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–4 (16 for metabolites) / –</td>
</tr>
</tbody>
</table>

Metabolism

Levamisole is extensively metabolised in the liver. It is excreted mainly in the urine as metabolites and a small proportion in the faeces. About 70% of a dose is excreted in the urine over 3 days.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Alcohol: may produce a disulfiram-like reaction.
- Phenytoin: increased levels of phenytoin have been reported.
- Warfarin: enhanced INR.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

- Available on a named patient basis from IDIS.
- Avoid in patients with pre-existing blood disorders.
- Has been successfully used to treat relapsing nephrotic syndrome in children at a dose of 2.5 mg/kg/alternate day. (Al-Saran K, Mirza K, Al-Ghanam G, et al. Experience with levamisole in frequently relapsing, steroid-dependent nephritic syndrome. Pediatr Nephrol. 2006 Feb; 21(2): 201–5.)
- Has also been used in haemodialysis patients to enhance response to Hepatitis B vaccine at a dose of 80 mg after each dialysis session for 4 months. (Kayatas M. Levamisole treatment enhances protective antibody response to hepatitis B vaccine in hemodialysis patients. Artif Organs. 2002 Jun; 26(6): 492–6.)
Levetiracetam

Clinical use
Antiepileptic

Dose in normal renal function
250 mg – 1.5 g twice daily

Pharmacokinetics
Molecular weight (daltons) 170.2
% Protein binding <10
% Excreted unchanged in urine 66 (95% drug + metabolite)
Volume of distribution (L/kg) 0.5–0.7
Half-life — normal/ESRF (hrs) 6–8 / 25

Metabolism
Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24% of the dose) is an enzymatic hydrolysis of the acetamide group, to form the primary metabolite, ucb L057, which is pharmacologically inactive.

Two minor metabolites have also been identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose).

The major route of excretion was via urine, accounting for a mean 95% of the dose (approximately 93% of the dose was excreted within 48 hours). The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66% and 24% of the dose, respectively during the first 48 hours. Excretion via faeces accounted for only 0.3% of the dose. Levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>50–79</td>
<td>500–1000 mg twice daily</td>
</tr>
<tr>
<td>30–49</td>
<td>250–750 mg twice daily</td>
</tr>
<tr>
<td>&lt;30</td>
<td>250–500 mg twice daily</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Likely to be dialysed. 750 mg loading dose then 500–1000 mg daily.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. 750 mg loading dose then 500–1000 mg once daily.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. 750 mg loading dose then 500–1000 mg once daily.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Likely to be dialysed. Dose as in GFR=30–49 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: antagonism of anticonvulsant effect (convulsive threshold lowered); avoid with St John’s wort.
- Antimalarials: mefloquine antagonises anticonvulsant effect.
- Antipsychotics: convulsant effect antagonised.
- Cytotoxics: possibly increases methotrexate concentration.
- Orlistat: possibly increased risk of convulsions.

Administration
Reconstitution
—
Route
Oral, IV
Rate of administration
15 minutes
Comments
Dilute in 100 mL sodium chloride or glucose 5%.

Other information
- 51% of the dose is removed with 4 hours of haemodialysis.
- The inactive metabolite (ucb L057) accumulates in renal failure.
Levocetirizine hydrochloride

Clinical use

Antihistamine:
- Symptomatic relief of allergy such as hay fever, urticaria

Dose in normal renal function

5 mg daily

Pharmacokinetics

Molecular weight (daltons) 461.8
% Protein binding 90
% Excreted unchanged in urine 85.4 (includes metabolites)
Volume of distribution (L/kg) 0.4
Half-life — normal/ESRF (hrs) 6–9.8 / Increased

Metabolism

The extent of metabolism of levocetirizine in humans is less than 14% of the dose. Metabolic pathways include aromatic oxidation, N- and O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. The major route of excretion of levocetirizine and metabolites is via urine. Excretion via faeces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>5 mg every 48 hours. See ‘Other information.’</td>
</tr>
<tr>
<td>10–30</td>
<td>5 mg every 72 hours. See ‘Other information.’</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5 mg every 72 hours. See ‘Other information.’</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Dose Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antivirals: concentration possibly increased by ritonavir.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information
- Manufacturer recommends to avoid in GFR<10 mL/min, but anecdotally it has been used at normal dose in haemodialysis patients.
- Less than 10% is removed during a 4-hour haemodialysis session.
Levofloxacín

### Clinical use
Antibacterial agent

### Dose in normal renal function
- Oral/IV: 250–500 mg once or twice a day (varies depending on indication)
- Nebulised: 240 mg twice daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>361.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>30–40</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&gt;85</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.1–1.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–8 (5–7 nebulised) / 35</td>
</tr>
</tbody>
</table>

### Metabolism
Levofloxacín is metabolised to a very small extent, the metabolites being desmethyl-levofloxacín and levofloxacín N-oxide.

These metabolites account for <5% of the dose and are excreted in urine. Excretion is primarily by the renal route.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Schedules</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Initial dose 250–500 mg then 125 mg daily to 250 mg 12–24 hourly. See 'Other information.' Nebulised: dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Initial dose 250–500 mg then 125 mg 12–48 hourly. See 'Other information.' Nebulised: dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initial dose 250–500 mg then 125 mg 24–48 hourly. See 'Other information.' Nebulised: dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

APD/CAPD | Not dialysed. Dose as in GFR<10 mL/min.
HD        | Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux | Not dialysed. Dose as in GFR<10 mL/min.
CAV/VH/HD/HDF | Not dialysed. Loading dose: 500 mg then 250 mg every 24 hours. See 'Other information.'

### Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: possibly increased risk of convulsions.
- Analgesics: possibly increased risk of convulsions with NSAIDs.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid.
- Anticoagulants: anticoagulant effect of coumarins and phenindione enhanced.
- Antimalarials: manufacturer advises avoid concomitant use with arteether and lumefantrine.
- Ciclosporin: half-life of ciclosporin increased by 33%; increased risk of nephrotoxicity.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Tacrolimus: may increase tacrolimus concentration.

### Administration

#### Reconstitution

- **Route** Oral, IV, nebulised

#### Rate of administration

30 minutes per 250 mg

#### Other information

- Nebulised solution is not recommended by manufacturer if CRCL<20 mL/min due to lack of data.
- Absorption after inhalation is approximately 50% lower than systemic administration, although in some cases may be similar due to variable absorption.
- Dose and frequency depend on indication.
- Drug Prescribing in Renal Failure, 5th edition by Aronoff et al. suggests:
  - GFR=10–50 mL/min: 500–750 mg stat followed by 250–750 mg every 24–48 hours.
  - GFR<10 mL/min: 500 mg stat followed by 250–500 mg every 48 hours.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to
a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
Levofolinic acid

Clinical use
- Prevention of methotrexate-induced adverse effects
- Enhancement of 5-fluorouracil cytotoxicity in advanced colorectal cancer

Dose in normal renal function
- Prevention of methotrexate-induced adverse effects: 7.5 mg every 6 hours for 10 doses
- Methotrexate overdose: Initial dose at least 50% of methotrexate dose; see SPC
- Colorectal cancer: depends on regimen; see SPC

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Some removal likely. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Some removal likely. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antiepileptics: possibly reduces fosphenytoin, phenytoin, primidone and phenobarbital levels.
- Cytotoxics: avoid with raltitrexed.
- Should not be administered simultaneously with a folic acid antagonist as this may nullify the effect of the antagonist.

Pharmacokinetics
- Molecular weight (daltons): 473.4
- % Protein binding: 27
- % Excreted unchanged in urine: 20
- Volume of distribution (L/kg): 17.5 Litres
- Half-life — normal/ESRF (hrs): 30 minutes / –

Metabolism
The active isomeric form levofolinic acid (L-5-formyltetrahydrofolic acid) is quickly metabolised to 5-methyltetrahydrofolic acid in the liver.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Other information
- Disodium levofolinate is bioequivalent with calcium levofolinate as well as with the racemate disodium foltinate with respect to plasma concentrations of levofolinic acid and the main, active metabolite, 5-methyltetrahydrofolic acid after intravenous administration of the same molar dose of the active isomer.
Levomepromazine (methotrimeprazine)

**Clinical use**
- Treatment of schizophrenia
- Adjunctive treatment in palliative care
- Nausea and vomiting

**Dose in normal renal function**

Schizophrenia: Oral, initially 25–50 mg daily, increasing to 100–200 mg in 3 divided doses; maximum dose 1 g daily

Palliative care:
- Oral/SC: 12.5–50 mg every 4–8 hours
- IM/IV: 12.5–50 mg every 6–8 hours
- SC infusion: 5–200 mg/24 hours

**Pharmacokinetics**

Molecular weight (daltons) 328.5
% Protein binding No data
% Excreted unchanged in urine 1
Volume of distribution (L/kg) 23–42
Half-life — normal/ESRF (hrs) 30 / –

**Metabolism**

Levomepromazine is metabolised in the liver and degraded to a sulfoxide, a glucuronide and a demethyl-moiety.
It is eliminated via urine and faeces.

**Dose in renal impairment GFR (mL/min)**

20–50  Dose as in normal renal function.
10–20  Dose as in normal renal function.
<10  Start with small dose and increase as necessary.

**Dose in patients undergoing renal replacement therapies**

APD/CAPD  Unknown dialysability. Dose as in GFR<10 mL/min.
HD  Unknown dialysability. Dose as in GFR<10 mL/min.
HDF/High flux  Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD  Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: increased risk of convulsions with tramadol; increased hypotension and sedation with opioid analgesics; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of ventricular arrhythmias due to prolongation of QT interval; increased risk of ventricular arrhythmias with amiodarone, disopyramide and dronedarone – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin – avoid.
- Antidepressants: possibly increased concentration of tricyclics, increased antimuscarinic effects and ventricular arrhythmias; avoid with MAOIs (2 fatalities have been reported); risk of ventricular arrhythmias with citalopram and escitalopram – avoid; possible increased risk of convulsions with vortioxetine.
- Anticonvulsant: lowers anticonvulsant threshold.
- Antihypertensives: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol, pimozide and risperidone – avoid.
- Antivirals: concentration possibly increased by ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
- Anxiolytics and hypnotics: increased sedation.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Diuretics: enhanced hypotensive effect.
- Lithium: increased risk of extrapyramidal effects and neurotoxicity.
- Pentamidine: increased risk of ventricular arrhythmias – avoid.

**Administration**

Reconstitution
—

**Route**
Oral, IV, IM, SC
Levomepromazine (methotrimeprazine)

Rate of administration

- 

Comments
- For a subcutaneous infusion dilute in sodium chloride 0.9% and give via a syringe driver.
- Compatible with diamorphine.
- For IV injection, dilute with an equal volume of sodium chloride 0.9%.

Other information
- In renal disease there is an increased risk of cerebral sensitivity.
Levothyroxine sodium (thyroxine)

**Clinical use**
Hypothyroidism

**Dose in normal renal function**
25–300 micrograms daily depending on thyroid hormone levels

**Pharmacokinetics**
- Molecular weight (daltons) 798.9
- % Protein binding 99.97
- % Excreted unchanged in urine 30–55
- Volume of distribution (L/kg) 8.7–9.7
- Half-life — normal/ESRF (hrs) 6–7 days/ Unchanged

**Metabolism**
Levothyroxine is mainly metabolised in the liver and kidney to tri-iodothyronine (liothyronine) and, about 40%, to inactive reverse tri-iodothyronine (reverse T₃) both of which undergo further deiodination to inactive metabolites. Further metabolites result from conjugation and decarboxylation; tetra-iodothyroacetic acid (tetrac) is one such metabolite. Further hydrolysis of the conjugates releases free hormone, which can be reabsorbed in the intestine to undergo enterohepatic recycling. Some conjugates reach the colon unchanged, then undergo hydrolysis, and are eliminated in the faeces as free hormone. Levothyroxine is mainly eliminated by the kidneys as free drug, deiodinated metabolites, or conjugates.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Not dialysed. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: effect of coumarins and phenindione enhanced.
- Lanthanum: absorption reduced by lanthanum, give at least 2 hours apart.
- Sevelamer: absorption reduced by sevelamer.

**Administration**

**Reconstitution**
- **Route** Oral
- **Rate of administration**

**Other information**
- Uraemic toxins may result in inhibition of the enzyme associated with conversion of L-thyroxine to liothyronine.
Lidocaine hydrochloride (Lignocaine)

Clinical use

- Local anaesthetic
- Ventricular arrhythmias

Dose in normal renal function

- Local anaesthetic: usually 1 or 2% solutions used, according to patient’s weight and procedure
- Ventricular arrhythmias: 100 mg as a bolus in patients without gross circulatory impairment (50 mg in lighter patients or in severely impaired circulation), followed by an infusion of 4 mg/min for 30 minutes, 2 mg/min for 2 hours, then 1 mg/min or according to local policy

Pharmacokinetics

Molecular weight (daltons) 288.8
% Protein binding 66
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 1.3
Half-life — normal/ESRF (hrs) 1–2 / 1.3–3

Metabolism

Lidocaine is largely metabolised in the liver. First-pass metabolism is extensive and bioavailability is about 35% after oral doses. Metabolism in the liver is rapid and about 90% of a given dose is dealkylated to form monoethylglycinexylidide and glycinexylidide. Both of these metabolites may contribute to the therapeutic and toxic effects of lidocaine and since their half-lives are longer than that of lidocaine, accumulation, particularly of glycinexylidide, may occur during prolonged infusions. Further metabolism occurs and metabolites are excreted in the urine with less than 10% of unchanged lidocaine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

- Anti-arrhythmics: increased risk of myocardial depression.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval.
- Antivirals: concentration possibly increased by atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir and tipranavir – avoid; increased risk of ventricular arrhythmias with saquinavir – avoid.
- Beta-blockers: increased risk of myocardial depression; increased risk of lidocaine toxicity with propranolol.
- Diuretics: effects antagonised by hypokalaemia.
- Ulcer-healing drugs: concentration increased by cimetidine, increased toxicity.

Administration

Reconstitution

Route

- IV, SC, topical

Rate of administration

According to dose

Comments

- Usually 1–2 mg/mL in glucose 5%.
- Minimum volume 8–20 mg/mL but watch for extravasation. (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006.)

Other information

- IV injection only lasts for 15–20 minutes.
# Linagliptin

## Clinical use
Type 2 diabetes mellitus

## Dose in normal renal function
5 mg once daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>472.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>75–99 (concentration dependent)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1110 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12 / –</td>
</tr>
</tbody>
</table>

## Metabolism
Minimal metabolism to inactive metabolites. Approximately 80% is eliminated in the faeces and 5% in the urine.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: effects possibly reduced by rifampicin.

## Administration

### Reconstitution
—

### Route
Oral

### Rate of administration
—

## Other information
- Bioavailability is 30%.
- In moderate renal failure, a moderate increase in exposure of about 1.7 fold was observed compared with control. Exposure in T2DM patients with severe renal failure was increased by about 1.4-fold compared to T2DM patients with normal renal function. Steady-state predictions for AUC of linagliptin in patients with ESRD indicated comparable exposure to that of patients with moderate or severe renal impairment.
**Linezolid**

### Clinical use
Antibacterial agent

### Dose in normal renal function
600 mg twice daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>337.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>31</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–7 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism
Linezolid is primarily metabolised by oxidation of the morpholine ring resulting mainly in the formation of two inactive open-ring carboxylic acid derivatives: the aminoethoxyacetic acid metabolite (PNU-142300) and the hydroxyethyl glycine metabolite (PNU-142586). The hydroxyethyl glycine metabolite (PNU-142586) is the predominant human metabolite and is believed to be formed by a non-enzymatic process. The aminoethoxyacetic acid metabolite (PNU-142300) is less abundant. Other minor, inactive metabolites have been characterised.

In patients with normal renal function or mild to moderate renal insufficiency, linezolid is primarily excreted under steady-state conditions in the urine as PNU-142586 (40%), parent drug (30%) and PNU-142300 (10%). Virtually no parent drug is found in the faeces whilst approximately 6% and 3% of each dose appears as PNU-142586 and PNU-142300, respectively. Non-renal clearance accounts for approximately 65% of the total clearance of linezolid.

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose in Normal Renal Function</th>
<th>Detailed Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Likely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>CVVHDF</td>
<td>Dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Alcohol: enhanced hypotensive effect with tyramine containing products.
- Analgesics: avoid with nefopam; possible CNS excitation or depression with opioid analgesics.
- Antidepressants: increased risk of serotonergic syndrome with SSRIs and tricyclics; avoid concomitant use with duloxetine, MAOIs, moclobemide, reboxetine, venlafaxine and vortioxetine.
- Antiepileptics: antagonism of anticonvulsant effect, avoid with carbamazepine.
- Antimalarials: avoid with artemether with lumefantrine and artenimol with piperaquine
- Antipsychotics: CNS effects possibly increased by clozapine.
- Atomoxetine: avoid concomitant use.
- Bupropion: avoid concomitant use.
- Dopaminergics: risk of hypertensive crisis with co-beneldopa, co-careldopa, entacapone, levodopa, rasagiline and selegiline — avoid.
- Dapoxetine: increased serotonergic effects – avoid.
- 5HT₂ receptor agonists: risk of CNS toxicity – avoid with rizatriptan, sumatriptan and zolmitriptan.
- Indoramin: avoid concomitant use.
- Opicapone: avoid concomitant use.
- Sympathomimetics: risk of hypertensive crisis – avoid.

### Administration

#### Reconstitution
—

#### Route
Oral, IV
Rate of administration
Over 30–120 minutes

Other information

- 30% of dose is removed by a 3 hour haemodialysis session.
- After single doses of 600 mg, there was a 7–8-fold increase in exposure to the two primary metabolites of linezolid in the plasma of patients with severe renal insufficiency (i.e. CRCL < 30 mL/min). However, there was no increase in AUC of parent drug. Although there is some removal of the major metabolites of linezolid by haemodialysis, metabolite plasma levels after single 600 mg doses were still considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.
- In 24 patients with severe renal insufficiency, 21 of whom were on regular haemodialysis, peak plasma concentrations of the two major metabolites after several days dosing were about 10-fold those seen in patients with normal renal function. Peak plasma levels of linezolid were not affected.
- In patients with GFR < 10 mL/min, if platelet count drops on a dose of 600 mg twice daily, consider reducing dose to 600 mg once daily.
- Two metabolites accumulate in renal failure which have MAOI activity but no antibacterial activity – monitor patients closely.
- There is 5 mmol sodium per 300 mL infusion.
- Linezolid is a weak, reversible non-selective inhibitor of MAO therefore can be used with drugs not normally given with MAOIs (e.g. SSRIs) but monitor closely.
- In patients who have been on linezolid for longer than 28 days, there have been reports of peripheral neuropathy and/or optic neuropathy occasionally leading to loss of vision, anaemia requiring transfusions, and lactic acidosis – visual function should be monitored in these patients.
- After oral or IV administration, adequate drug concentrations can be found in PF fluid to treat VRE peritonitis. (Salzer W. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int. 2005; 25(4): 313–9.)
- A pharmacokinetic study found an increased incidence of thrombocytopenia in patients with renal impairment due to reduced clearance and suggest reducing the dose in this population.²

References:
Liothyronine sodium (tri-iodothyronine)

**Clinical use**
Hypothyroidism

**Dose in normal renal function**
- Oral: 10–20 micrograms daily, increased to 60 micrograms in 2–3 divided doses.
- IV: 5–20 micrograms every 4–12 hours, or 50 micrograms initially then 25 micrograms every 8 hours, reducing to 25 micrograms twice a day.

**Pharmacokinetics**
- Molecular weight (daltons) 673
- % Protein binding <99
- % Excreted unchanged in urine 2.5
- Volume of distribution (L/kg) 0.1–0.2
- Half-life — normal/ESRF (hrs) 24–48 / –

**Metabolism**
Liothyronine is metabolised by deiodination to inactive di-iodothyronine and mono-iodothyronine. Iodine released by deiodination is largely reused within the thyroid cells. Further metabolites result from conjugation and decarboxylation; tiratricol (triac) is one such metabolite.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Not dialysed. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: effect of coumarins and phenindione enhanced.

**Administration**
Reconstitution
1–2 mL water for injection.
Route
IV, oral
Rate of administration
Slow bolus
Comments
Alkaline solution – may cause irritation if given IM.

**Other information**
- 20 mcg of liothyronine is equivalent to 100 mcg of levothyroxine.
- Protein-losing states, such as nephrotic syndrome, will result in a decrease in total T3 and T4.
- Thyroxine (T4) is the drug of choice in hypothyroidism, but T3 can be useful due to its rapid onset of action.
- Elderly patients should receive smaller initial doses.
**Lipegfilgrastim**

**Clinical use**
Glycopegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF):
- Treatment of neutropenia

**Dose in normal renal function**
6 mg for each chemotherapy cycle, given approximately 24 hours after chemotherapy

**Pharmacokinetics**
- Molecular weight (daltons) 18 800
- % Protein binding Very high
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) 0.15
- Half-life — normal/ESRF (hrs) 28–62/ Unchanged

**Metabolism**
Lipegfilgrastim is metabolised via intra- or extracellular degradation by proteolytic enzymes. It is internalised by neutrophils (non-linear process), then degraded within the cell by endogenous proteolytic enzymes. The linear pathway is likely due to extracellular protein degradation by neutrophil elastase and other plasma proteases.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Not dialysed. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Cytotoxics: neutropenia possibly exacerbated with capecitabine, fluorouracil or tegafur.

**Administration**
**Reconstitution** —
**Route** SC
**Rate of administration** —

**Other information**
- Capillary leak syndrome has been reported after administration of G-CSF or derivatives and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.
- Hypokalaemia has been reported.
Liraglutide

Clinical use
Glucagon-like peptide-1 analogue:
• Treatment of type 2 diabetes mellitus in combination with other antidiabetic therapy

Dose in normal renal function
0.6–1.8 mg daily

Pharmacokinetics
Molecular weight (daltons) 3751.3
% Protein binding >98
% Excreted unchanged in urine Minimal (6% as metabolites)
Volume of distribution (L/kg) 0.07
Half-life — normal/ESRF (hrs) 13

Metabolism
Liraglutide is metabolised in a similar manner to large proteins without a specific organ having been identified as major route of elimination. Only 2 minor metabolites have been identified.

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution —
Route SC
Rate of administration —
Comments
Can be given at any time of day independent of meals. Dose of concomitant sulphonylurea may need to be reduced.

Other information
• Not recommended in GFR<30 mL/min by UK manufacturer due to lack of experience.
• Maximum concentration is reached 8–12 hours post dose.
• Bioavailability is 55%.
• Liraglutide exposure was lowered by 33%, 14%, 27% and 28%, respectively, in subjects with mild (GFR=50–80 mL/min), moderate (GFR=30–50 mL/min), and severe (GFR<30 mL/min) renal impairment and in people on dialysis.
• Can cause acute kidney injury requiring haemodialysis, therefore use with caution.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–60</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

References:
2. Thong KY, Walton C, Ryder REJ. Liraglutide is safe and effective in mild or moderate renal impairment: the Association of British Clinical Diabetologists (ABCD) Nationwide Liraglutide Audit. Presented at the American Diabetes Association, 8–12 June 2012, Philadelphia, PA, USA.
Lisinopril

Clinical use
Angiotensin-converting enzyme inhibitor:
- Hypertension, heart failure, following myocardial infarction in haemodynamically stable patients
- Diabetic nephropathy

Dose in normal renal function
- Hypertension: 2.5–80 mg daily
- Heart failure: 2.5–35 mg daily
- After a myocardial infarction: 2.5–10 mg daily

Pharmacokinetics
Molecular weight (daltons) 441.5
% Protein binding 0
% Excreted unchanged in urine 80–90
Volume of distribution (L/kg) 0.44–0.51
Half-life — normal/ESRF (hrs) 12 / 40–50

Metabolism
Lisinopril does not undergo significant metabolism and is excreted unchanged predominantly in the urine.

Dose in renal impairment GFR (mL/min)
- 20–50 Initial dose 2.5 mg daily and titrate according to response.
- 10–20 Initial dose 2.5 mg daily and titrate according to response.
- <10 Initial dose 2.5 mg daily and titrate according to response.

Dose in patients undergoing renal replacement therapies
ApD/CapD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
Cav/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Anti hypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
- Bee venom extract: possible severe anaphylactoid reactions when used together.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of angioedema with everolimus.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Gold: flushing and hypotension with sodium aurothiomalate.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Administration
Reconstitution
-
Route
Oral
Rate of administration
-

Other information
- Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
- Renal failure has been reported in association with ACE inhibitors and has been mainly in patients with severe congestive heart failure, renal artery stenosis, and post renal transplant.
- High incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polycrylonitrile membranes and treated concomitantly with an ACE inhibitor – this combination should therefore be avoided.
- Hyperkalaemia and other side effects are more common in patients with impaired renal function.
Lithium carbonate

**Clinical use**
- Treatment and prophylaxis of mania, manic depressive illness, and recurrent depression
- Aggressive or self-mutilating behaviour

**Dose in normal renal function**
See individual preparations. Adjust according to lithium plasma concentration.

**Pharmacokinetics**
- Molecular weight (daltons) 73.9
- % Protein binding 0
- % Excreted unchanged in urine 95
- Volume of distribution (L/kg) 0.5–0.9
- Half-life — normal/ESRF (hrs) 12–24 / 40–50

**Metabolism**
Lithium is excreted mainly unchanged in the urine; only a small amount can be detected in the faeces, saliva, and sweat.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Avoid if possible, or reduce dose to 50–75% and monitor plasma concentration carefully.
- 10–20 Avoid if possible, or reduce dose to 50–75% and monitor plasma concentration carefully.
- <10 Avoid if possible, or reduce dose to 25–50% and monitor plasma concentration carefully.

**Dosage in patients undergoing renal replacement therapies**
- APD/CAPD Dialysed in lithium intoxication. Dose as in GFR<10 mL/min.
- HD Dialysed in lithium intoxication. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed in lithium intoxication. Dose as in GFR<10 mL/min.
- CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: lithium excretion reduced – avoid.
- Analgesics: NSAIDs and ketorolac reduce excretion of lithium.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid.
- Antidepressants: increased risk of CNS effects with SSRIs; risk of toxicity with tricyclics; possible increased serotonergic effects with venlafaxine.
- Antipsychotics: increased risk of extrapyramidal side effects and possibly neurotoxicity with clozapine, flupentixol, haloperidol, phenothiazines, risperidone or zuclopenthixol; increased risk of extrapyramidal side effects with sulpiride; possible risk of toxicity with olanzapine.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Dapoxetine: increased risk of serotonergic effects – avoid.
- Diuretics: lithium excretion reduced by loop diuretics, potassium-sparing diuretics, aldosterone antagonists and thiazides; lithium excretion increased by acetazolamide.
- Methyldopa: neurotoxicity may occur without increased lithium levels.

**Administration**

**Reconstitution**

—

**Route**
Oral

**Rate of administration**

—

**Comments**
Different preparations vary widely in bioavailability; a change in the preparation used requires the same precautions as initiation of treatment.

**Other information**
- Contraindicated by manufacturer in severe renal impairment and use with caution in mild to moderate renal impairment.
- Doses are adjusted to achieve lithium plasma concentrations of 0.4–1 mmol/L (lower end of range for maintenance therapy in elderly patients)
samples taken 12 hours after the preceding dose. It takes 4–7 days to reach steady state.
• Doses in renal impairment are from *Drug Prescribing in Renal Failure, 5th* edition by Aronoff *et al.*
• Long-term treatment may result in permanent changes in kidney histology and impairment of renal function. High serum concentration of lithium, including episodes of acute lithium toxicity, may aggravate these changes. The minimum clinically effective dose of lithium should always be used.
• Manufacturer advises that cases of microcysts, oncocytomas and collecting duct renal carcinoma have been reported in patients with severe renal impairment who received lithium for more than 10 years.
• Lithium generally should not be used in patients with severe renal disease because of increased risk of toxicity.
• Dialysability: serum lithium concentrations rebound within 5–8 hours post haemodialysis because of redistribution of the drug, often necessitating repeated courses of haemodialysis. Peritoneal dialysis is less effective at removing lithium and is only used if haemodialysis is not possible.
• Up to one-third of patients on lithium may develop polyuria, usually due to lithium blocking the effect of ADH. This reaction is reversible on withdrawal of lithium therapy.
Lixisenatide

Clinical use
Glucagon-like peptide 1 analogue:
• Treatment of type 2 diabetes mellitus

Dose in normal renal function
10–20 mcg once daily

Pharmacokinetics
Molecular weight (daltons) 4858.6
% Protein binding 55
% Excreted unchanged in urine 0
Volume of distribution (L/kg) 100 Litres
Half-life — normal/ESRF (hrs) 3 / –

Metabolism
As a peptide, lixisenatide is eliminated through glomerular filtration, followed by tubular reabsorption and subsequent metabolic degradation, resulting in smaller peptides and amino acids, which are reintroduced in the protein metabolism.

Dose in renal impairment GFR (mL/min)
30–50 Dose as in normal renal function. Use with caution.
10–30 Use lower dose with caution.¹
<10 Use lower dose with caution.¹

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Analgesics: possibly reduces paracetamol absorption if given 1–4 hours before paracetamol.

Administration
Reconstitution —
Route SC
Rate of administration —

Other information
• In subjects with moderate renal impairment (CRCL=30–50 mL/min) AUC was increased by 24% and in subjects with severe renal impairment (CRCL=15–30 mL/min) AUC was increased by 46%.
• Manufacturer advises to avoid if CRCL<30 mL/min due to lack of studies.
• In severe renal impairment (CRCL<30 mL/min) drug exposure was increased so dosage adjustment may be needed.¹

Reference:
Lofepramine

**Clinical use**
Tricyclic antidepressant

**Dose in normal renal function**
140–210 mg daily in 2–3 divided doses

**Pharmacokinetics**
- Molecular weight (daltons) 455.4 (as hydrochloride)
- % Protein binding 99
- % Excreted unchanged in urine Mainly as metabolites
- Volume of distribution (L/kg) Large
- Half-life — normal/ESRF (hrs) 1.7–5 / –

**Metabolism**
Lofepramine is metabolised in the liver by cleavage of the p-chlorophenacyl group from the lofepramine molecule leaving desmethylimipramine (DMI). The latter is pharmacologically active. The p-chlorobenzoyl portion is mainly metabolised to p-chlorobenzoic acid which is then conjugated with glycine. The conjugate is excreted mostly in the urine. DMI has been found excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Start with a small dose and titrate slowly.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Unknown dialysability. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alcohol: increased sedative effect.
- Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; increased risk of ventricular arrhythmias with disopyramide, flecainide or propafenone; avoid with dronedarone.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and possibly telithromycin – avoid with moxifloxacin.
- Anticoagulants: may enhance or reduce anticoagulant effect of coumarins.
- Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide; concentration possibly increased with SSRIs; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, fosphenytoin, phenobarbital, primidone and possibly phenytoin.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol.
- Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, haloperidol, pimozide and sulphiride – avoid; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased with ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased with ritonavir.
- Beta-blockers: increased risk of ventricular arrhythmias; possibly increased risk of convulsions.
- Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.
- Dapoxetine: possible increased risk of serotonergic effects – avoid.
- Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline.
- Pentamidine: increased risk of ventricular arrhythmias.
- Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.
Administration
Reconstitution
—
Route
Oral

Rate of administration
—

Other information
• Contraindicated by manufacturer in severe renal impairment due to lack of data.
Lomitapide

Clinical use
Adjunctive treatment of homozygous familial hypercholesterolemia

Dose in normal renal function
5–60 mg once daily

Pharmacokinetics
Molecular weight (daltons) 693.7 (789.8 as mesilate)
% Protein binding 99.8
% Excreted unchanged in urine 52.9–59.5
Volume of distribution (L/kg) 985–1292 Litres
Half-life — normal/ESRF (hrs) 39.7 / 79.4

Metabolism
Lomitapide is metabolised extensively by the liver via oxidation, oxidative N-dealkylation, glucuronide conjugation, and piperidine ring opening. Cytochrome P450 (CYP) 3A4 metabolizes lomitapide to its major metabolites, M1 and M3, as detected in plasma. The oxidative N-dealkylation pathway breaks the lomitapide molecule into M1 and M3. M1 is the moiety that retains the piperidine ring, whereas M3 retains the rest of the lomitapide molecule in vitro. CYPs 1A2, 2B6, 2C8, and 2C19 may metabolise lomitapide to a small extent to M1. M1 and M3 do not inhibit activity of microsomal triglyceride transfer protein in vitro. Just over half of a dose is excreted in the urine and about a third in the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function. Use with caution.
10–20 Dose as in normal renal function. Use with caution.
<10 Maximum dose 40 mg daily.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: concentration of lomitapide possibly increased by dronedarone – avoid.
- Antibacterials: concentration of lomitapide possible increased by clarithromycin and erythromycin – avoid.
- Anticoagulants: increases warfarin concentration.
- Antifungals: concentration of lomitapide possibly increased by ketoconazole and triazoles – avoid.
- Antivirals: concentration of lomitapide possibly increased by darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir, telaprevir and tipranavir – avoid.
- Bicalutamide: separate lomitapide and bicalutamide administration by 12 hours.
- Calcium channel blockers: concentration of lomitapide possibly increased by diltiazem and verapamil – avoid.
- Lipid lowering agents: reduce simvastatin dose by 50% if used together.

Administration
Reconstitution
—
Route Oral
Rate of administration —
Comments
Administer at least 2 hours after evening meal as food can increase GI side effects.

Other information
- Use with caution in renal impairment due to lack of studies.
- Can cause deranged LFTs.
- Exposure is increased by 50% in renal impairment.
- Oral bioavailability is approximately 7%.
Lomustine

**Clinical use**
Treatment of Hodgkin’s disease and certain solid tumours

**Dose in normal renal function**
120–130 mg/m² every 6–8 weeks if used alone; lower dose is used in combination treatment and compromised bone marrow function

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>233.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50 (as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>16–48 (metabolites)</td>
</tr>
</tbody>
</table>

**Metabolism**
After oral application of radioactive marked lomustine approximately 15–30% of the measured radioactivity in the plasma can be detected in the cerebrospinal fluid. Lomustine is rapidly metabolised through hepatic microsomal enzymes and the metabolites are excreted mainly via the kidneys. About half a dose is excreted as metabolites in the urine within 24 hours and about 75% is excreted within 4 days. In addition, 10% is excreted as CO₂ and <5% excreted in the faeces. Lomustine cannot be detected in its active form in the urine at any time.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>45–60</td>
<td>75% of dose.</td>
</tr>
<tr>
<td>30–45</td>
<td>50–70% of dose.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Not recommended. See ‘Other information’</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Avoid.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Avoid. See ‘Other information’.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Avoid. See ‘Other information’.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Avoid. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Bone marrow toxicity is delayed.
- Contraindicated by manufacturer in severe renal impairment in the UK but not in the US.
- Dosage from BC Cancer Agency: Accessed 17/09/2013 GFR=10–50 mL/min, give 75% of previous dose. GFR<10 mL/min, give 50% of previous dose.
# Loperamide hydrochloride

## Clinical use
Antidiarrhoeal agent

## Dose in normal renal function
4 mg stat, then 2 mg after each loose stool; maximum 16 mg daily

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>513.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>80</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>9–14 / –</td>
</tr>
</tbody>
</table>

## Metabolism
Loperamide undergoes extensive first pass metabolism in the liver, where it is predominantly metabolised to inactive metabolites, conjugated and excreted via the bile. Oxidative N-demethylation is the main metabolic pathway for loperamide, and is mediated mainly through CYP3A4 and CYP2C8. Excretion of the unchanged loperamide and the metabolites mainly occurs through the faeces.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- None known

## Administration

### Reconstitution
—

### Route
Oral

### Rate of administration
—

## Other information
- In normal doses loperamide may cause excessive drowsiness in CKD 5.
Lopinavir

**Clinical use**
Protease inhibitor:
- Treatment of HIV infected patients, in combination with other antiretroviral agents

**Dose in normal renal function**
2 tablets twice daily or 4 tablets once daily (in combination with ritonavir, Kaletra®), or 5 mL twice daily

**Pharmacokinetics**
- Molecular weight (daltons) 628.8
- % Protein binding 98–99
- % Excreted unchanged in urine 2.2
- Volume of distribution (L/kg) 0.5
- Half-life — normal/ESRF (hrs) 5–6 / 12–17

**Metabolism**
Lopinavir is extensively metabolised, mainly by oxidation by cytochrome P450 isoenzyme CYP3A4; 13 metabolites have been identified with some, such as 4-oxolopinavir and 4-hydroxylopinavir, having antiviral activity. Lopinavir is mainly excreted in faeces and to a smaller extent in the urine; unchanged lopinavir accounts for about 2.2% of a dose excreted in the urine and 19.8% in the faeces. After multiple dosing, less than 3% of the absorbed lopinavir dose is excreted unchanged in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
In combination with ritonavir – see ritonavir interactions.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with flecainide – avoid; possibly increased lidocaine concentration.
- Antibacterials: concentration reduced by rifampicin – avoid; concentration of delamanid increased; avoid with telithromycin in severe renal and hepatic impairment; AUC of bedaquiline increased by 22%, avoid.
- Anticoagulants: avoid with apixaban and rivaroxaban.
- Antidepressants: concentration reduced by St John’s wort – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenytoin, primidone and phenobarbital.
- Antimalarial: use artemether/lumefantrine with caution.
- Antipsychotics: possibly inhibits metabolism of aripiprazole – reduce dose of aripiprazole; possibly increases quetiapine concentration – avoid.
- Antivirals: avoid with boceprevir, daclatasvir and telaprevir; concentration of darunavir and fosamprenavir reduced – avoid; in combination with ritonavir concentration of elvitegravir increased – reduce dose of elvitegravir; concentration reduced by efavirenz, tipranavir and possibly nevirapine, consider increasing lopinavir dose; concentration of paritaprevir increased – avoid; increased risk of ventricular arrhythmias with saquinavir – avoid; concentration of tadalafil reduced; concentration of maraviroc increased, consider reducing maraviroc dose.
- Bosentan: concentration of bosentan increased, consider reducing bosentan dose.
- Ciclosporin: increase concentration of ciclosporin.
- Cytotoxics: reduce dose of ruxolitinib.
- Lipid lowering agents: increased risk of myopathy with atorvastatin; possibly increased risk of myopathy with rosuvastatin (reduce rosuvastatin dose) and simvastatin – avoid; avoid with lomitapide.
- Orlistat: absorption of lopinavir possibly reduced.
- Ranolazine: possibly increases ranolazine concentration – avoid.
- Sirolimus: may increase concentration of sirolimus.
- Tacrolimus: may increase concentration of tacrolimus.
### Administration

<table>
<thead>
<tr>
<th>Reconstitution</th>
<th>Rate of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Route**

<table>
<thead>
<tr>
<th>Oral</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Take with food.</td>
</tr>
</tbody>
</table>
## Loratadine

### Clinical use

Antihistamine:
- Symptomatic relief of allergy such as hay fever, urticaria

### Dose in normal renal function

10 mg daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>382.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>97–99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12–15 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Loratadine undergoes an extensive first pass metabolism, mainly by CYP3A4 and CYP2D6. The major metabolite—desloratadine—is pharmacologically active and responsible for a large part of the clinical effect.

Approximately 40% of the dose is excreted in the urine and 42% in the faeces over a 10 day period and mainly in the form of conjugated metabolites. Approximately 27% of the dose is eliminated in the urine during the first 24 hours. Less than 1% of the active substance is excreted unchanged in the active form, as loratadine or desloratadine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs
- **Antibacterials**: concentration possibly increased by erythromycin.
- **Antifungals**: concentration of loratadine possibly increased by ketoconazole—avoid concomitant use.
- **Antivirals**: concentration possibly increased by ritonavir.

### Administration

**Reconstitution**

---

**Route**

Oral

**Rate of administration**

---

### Other information

- Patients with renal impairment are at increased risk of sedation.
Lorazepam

**Clinical use**

Benzodiazepine:
- Short-term use in anxiety or insomnia
- Status epilepticus
- Perioperative

**Dose in normal renal function**

- Anxiety: 1–4 mg daily in divided doses
- Insomnia associated with anxiety: 1–2 mg at bedtime
- Acute panic attacks: (IV/IM): 25–30 mcg/kg; repeat 6 hourly if required; usual range 1.5–2.5 mg
- Status epilepticus: 4 mg IV repeated once after 10 minutes

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>321.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>85</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.9–1.3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–20 / 32–70</td>
</tr>
</tbody>
</table>

**Metabolism**

Lorazepam is metabolised in the liver to the inactive glucuronide, and excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. Start with small doses.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialyzed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: metabolism possibly increased by rifampicin.
- Antipsychotics: increased sedative effects; increased risk of hypotension, bradycardia and respiratory depression when parenteral benzodiazepines are given with IM olanzapine; risk of serious adverse effects in combination with clozapine.
- Antivirals: concentration possibly increased by ritonavir.
- Disulfiram: metabolism inhibited, increased sedative effects.
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.
- Ulcer-healing drugs: metabolism inhibited by cimetidine.

**Administration**

**Reconstitution**

- **Route**: Oral, IV, IM, sublingual
- **Rate of administration**: Slow IV bolus
- **Comments**: Onset of effect after IM injection is similar to oral administration. IV route preferred over IM route. Dilute 1:1 with sodium chloride 0.9% or water for injection. Can be used undiluted. (UK Critical Care Group, *Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients*, 3rd edition, 2006.)

**Other information**

- Patients with impaired renal or hepatic function should be monitored frequently and have their dosage adjusted carefully according to response. Lower doses may be sufficient in these patients.
- Lorazepam as intact drug is not removed by dialysis. The glucuronide metabolite is highly dialysable, but is pharmacologically inactive.
- Increased CNS sensitivity in patients with renal impairment.
Lormetazepam

**Clinical use**
Benzodiazepine:
- Insomnia (short-term use)

**Dose in normal renal function**
0.5–1.5 mg at night

**Pharmacokinetics**
- Molecular weight (daltons): 335.2
- % Protein binding: 85
- % Excreted unchanged in urine: <6 (86 as metabolites)
- Volume of distribution (L/kg): 4.6
- Half-life — normal/ESRF (hrs): 11–16 / Unchanged

**Metabolism**
Lormetazepam is metabolised in the liver to the inactive glucuronide, and excreted in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function. Start with small doses.
- <10: Dose as in normal renal function. Start with small doses.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism possibly increased by rifampicin.
- Antipsychotics: increased sedative effects; risk of serious adverse effects in combination with clozapine.
- Antivirals: concentration possibly increased by ritonavir.
- Disulfiram: metabolism inhibited, increased sedative effects.
- Sodium oxybate: enhanced effect – avoid.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Increased CNS sensitivity in renal impairment.
- Long-term use may lead to dependence and withdrawal symptoms in certain patients.
- The half-life of the glucuronide metabolite is increased in renal impairment.
Losartan potassium

**Clinical use**

Angiotensin-II receptor antagonist:
- Hypertension
- Type 2 diabetic nephropathy
- Heart failure

**Dose in normal renal function**

- 25–100 mg daily
- Heart failure: 12.5–150 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>461</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>4</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.5–2.5 (active metabolite 3–9) / 4–6</td>
</tr>
</tbody>
</table>

**Metabolism**

Losartan undergoes substantial first-pass metabolism resulting in a systemic bioavailability of about 33%. It is metabolised to an active carboxylic acid metabolite E-3174 (EXP-3174), which has greater pharmacological activity than losartan; some inactive metabolites are also formed. Metabolism is mainly by cytochrome P450 isoenzymes CYP2C9 and CYP3A4.

Losartan is excreted in the urine, and in the faeces via bile, as unchanged drug and metabolites. About 4% of an oral dose is excreted unchanged in urine and about 6% is excreted in urine as the active metabolite.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Initial dose 25 mg and titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initial dose 25 mg and titrate according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Not dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal impairment with ACE-Is and aliskiren.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

**Administration**

**Reconstitution**

- **Route**: Oral

**Rate of administration**

**Other information**

- Adverse reactions, especially hyperkalaemia are more common in patients with renal impairment.
- Renal failure has been reported in association with angiotensin-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with congestive heart failure.
- Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
Loxapine

Clinical use

Typical antipsychotic:
- Treatment of mild to moderate agitation in schizophrenia or bipolar disease

Dose in normal renal function

4.5–9.1mg as a single dose, a second dose can be given after 2 hours if required

Pharmacokinetics

Molecular weight (daltons) 327.8
% Protein binding 96.6
% Excreted unchanged in urine Mainly as metabolites
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 6–8 / –

Metabolism

Extensively metabolised.
Metabolites are excreted in the urine in the form of conjugates and in the faeces unconjugated.

Dose in renal impairment GFR (mL/min)

20–50 Start with a low dose and gradually increase.
10–20 Start with a low dose and gradually increase.
<10 Start with a low dose and gradually increase.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR = 10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- None known

Administration

Reconstitution
—

Route
Inhaled

Rate of administration
—

Other information

- Renal failure after overdosage has been reported.
- Manufacturer cannot recommend in renal impairment as it was not tested.
## Lurasidone hydrochloride

### Clinical use

Atypical antipsychotic:
- Treatment of schizophrenia

### Dose in normal renal function

37–148 mg once daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>529.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>19 (+metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>6000 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>20–40 / –</td>
</tr>
</tbody>
</table>

### Metabolism

Lurasidone is metabolised mainly via CYP3A4. The major biotransformation pathways are oxidative N-dealkylation, hydroxylation of norbornane ring, and S-oxidation. Lurasidone is metabolised into two active metabolites (ID-14283 and ID-14326) and two non-active metabolites (ID-20219 and ID-20220).

Following oral administration of a radiolabelled dose, approximately 67% dose was recovered in faeces and 19% in urine. Urine comprised mostly of a number of metabolites with minimal renal excretion of parent compound.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>18.5–74 mg once daily.</td>
</tr>
<tr>
<td>15–30</td>
<td>18.5–74 mg once daily.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>18.5–74 mg once daily. Use with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Unlikely to be dialysed. Dose as in GFR<15 mL/min.
- **HD**: Unlikely to be dialysed. Dose as in GFR<15 mL/min.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in GFR<15 mL/min.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in GFR=15–30 mL/min.

### Important drug interactions

Potentially hazardous interactions with other drugs
- **Anaesthetics**: enhanced hypotensive effect with general anaesthetics.
- **Antibacterials**: concentration possibly increased by clarithromycin and telithromycin – avoid; concentration possibly increased by erythromycin, max dose 74 mg daily; concentration reduced by rifampicin – avoid.
- **Antidepressants**: concentration possibly reduced by St John’s wort – avoid.
- **Antiepileptics**: antagonises anticonvulsant effect; concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone – avoid.
- **Antifungals**: concentration possibly increased by fluconazole, max dose 74 mg daily; concentration possibly increased by itraconazole, ketoconazole, posaconazole and voriconazole – avoid.
- **Antipsychotics**: possibly increases pimozide concentration, increased risk of toxicity.
- **Antivirals**: concentration possibly increased by boceprevir, indinavir, ritonavir, saquinavir and telaprevir – avoid.
- **Anxiolytics and hypnotics**: increased sedative effects; concentration of midazolam increased.
- **Calcium channel blockers**: enhanced hypotensive effect; concentration increased by diltiazem and possibly verapamil, max dose 74 mg daily.
- **Cobicistat**: concentration possibly increased by cobicistat – avoid.
- **Grapefruit juice**: avoid concomitant use.

### Administration

**Reconstitution**
- **Route**: Oral

**Rate of administration**
- **Comments**: Take with a meal.

### Other information

- Manufacturer advises to use only if benefit exceeds risk in end-stage renal disease.
- May increase creatinine levels and cause dysuria.
- The serum concentration of lurasidone is increased in healthy subjects with mild, moderate and severe renal impairment with an increased exposure of 1.5, 1.9 and 2.0-fold respectively.
Lymecycline

Clinical use
Antibacterial agent:
- Also used for treatment of acne

Dose in normal renal function
- 408 mg (1 capsule) twice daily, increasing to 3–4 capsules daily in severe infections
- Acne: 408 mg daily for at least 8 weeks

Pharmacokinetics
Molecular weight (daltons) 602.6
% Protein binding Approx 25–60
% Excreted unchanged in urine 25
Volume of distribution (L/kg) Approx 1.3–1.7
Half-life — normal/ESRF (hrs) 10 / Increased

Metabolism
The tetracyclines are excreted in the urine and in the faeces. Renal clearance is by glomerular filtration. Up to 60% of an intravenous dose, and up to 55% of an oral dose, is eliminated unchanged in the urine. Usually between 40% and 70% of a dose is excreted in the urine; urinary excretion is increased if urine is alkalised.

Dose in renal impairment GFR (mL/min)
20–50  Dose as in normal renal function.
10–20  Dose as in normal renal function.
<10   Avoid. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
APD/CAPD  Not dialysed. Dose as in GFR<10 mL/min.
HD       Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD  Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhanced anticoagulant effect of coumarins and phenindione.
- Oestrogens: possibly reduce contraceptive effects of oestrogens (risk probably small).
- Retinoids: possible increased risk of benign intracranial hypertension – avoid.

Administration
Reconstitution
Route
Oral
Rate of administration
Comments
Do not take iron preparations, indigestion remedies or phosphate binders at the same time of day as lymecycline.

Other information
- Lymecycline is a tetracycline derivative.
- 408 mg lymecycline ≡ 300 mg tetracycline.
- Contraindicated by manufacturer in severe renal impairment as lymecycline is mainly excreted by the kidneys.
- Irish medicines board advises to use a lower dose in moderate renal impairment and to avoid in severe renal impairment.
Macitentan

**Clinical use**

Endothelin receptor antagonist:
- Treatment of pulmonary arterial hypertension

**Dose in normal renal function**

10 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>588.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50 (as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>50 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>16 (48 for active metabolite) / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Formation of the active metabolite is mainly mediated by the isoenzyme CYP3A4, with minor contribution from CYP2C8, CYP2C9, and CYP2C19. All of these isoenzymes are also involved in the formation of several other inactive metabolites via different metabolic pathways.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.
- **HD** Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.
- **HDF/High flux** Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.
- **CAV/VVHD** Unlikely to be dialysed. Dose as in normal renal function. See 'Other information'.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin – avoid.
- Antidepressants: avoid with St John's wort.
- Antiepileptics: avoid with carbamazepine, fosphenytoin and phenytoin.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Oral</th>
</tr>
</thead>
</table>

**Rate of administration**

| — |

**Other information**

- Manufacturer does not recommend a dosage reduction in severe renal impairment due to pharmacokinetics. Not recommended in dialysis patients due to lack of data.
- Patients with renal impairment are more likely to experience hypotension and anaemia.
- Exposure to macitentan and its active metabolite was increased by 1.3- and 1.6-fold, respectively, in patients with severe renal impairment. This increase is not considered clinically relevant.
Maraviroc

Clinical use

CCR5 antagonist:
- Treatment of HIV infection in combination with other antiretrovirals

Dose in normal renal function

150–600 mg twice daily depending on other antiretroviral agents

Pharmacokinetics

Molecular weight (daltons) 513.7
% Protein binding 76
% Excreted unchanged in urine 8 (20% as unchanged drug and metabolites)
Volume of distribution (L/kg) 194 Litres
Half-life — normal/ESRF (hrs) 13.2

Metabolism

Metabolised in the liver by cytochrome P450 3A4 to metabolites which are inactive against HIV.
It is excreted in both urine (20%) and faeces (76%) as unchanged drug and metabolites.

Dose in renal impairment GFR (mL/min)

20–80 If administered without potent CYP3A4 inhibitors dose as in normal renal function.
If administered with potent CYP3A4 inhibitors: 150 mg daily.

10–20 If administered without potent CYP3A4 inhibitors dose as in normal renal function.
If administered with potent CYP3A4 inhibitors: 150 mg daily.

<10 If administered without potent CYP3A4 inhibitors dose as in normal renal function.
If administered with potent CYP3A4 inhibitors: 150 mg daily.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Some dialysability. Dose as in GFR<10 mL/min.
HDF/High flux Probably dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Some dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly increased by clarithromycin and telithromycin, consider reducing dose of maraviroc; concentration reduced by rifampicin, consider increasing dose of maraviroc.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antifungals: concentration increased by ketoconazole.
- Antivirals: concentration increased by atazanavir, cobicistat, darunavir, indinavir, lopinavir and saquinavir – consider reducing maraviroc dose; concentration reduced by efavirenz – consider increasing dose of maraviroc; concentration of fosamprenavir reduced – avoid.
- Orlistat: absorption possibly reduced by orlistat.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

- Increased risk of postural hypotension in renal impairment especially if co-administered with potent CYP3A4 inhibitors.
- Bioavailability is 23–33%.
Mebendazole

Clinical use
Treatment of threadworm, roundworm, whipworm, hookworm infections and echinococcosis

Dose in normal renal function
- Threadworm: 100 mg as a single dose; if re-infection occurs repeat after 2 weeks
- Whipworm, roundworm, hookworm: 100 mg twice daily for 3 days
- Echinococcosis: 40–50 mg/kg daily for at least 3–6 months

Pharmacokinetics
- Molecular weight (daltons) 295.3
- % Protein binding 95
- % Excreted unchanged in urine 2
- Volume of distribution (L/kg) 1–1.2
- Half-life — normal/ESRF (hrs) 0.93 / –

Metabolism
Mebendazole undergoes extensive first-pass metabolism in the liver. Mebendazole, the conjugated forms of mebendazole, and its metabolites are excreted in the urine and bile.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Cimetidine: possibly inhibits metabolism of mebendazole.
- Antiepileptics: phenytoin, carbamazepine and phenobarbital: lower mebendazole concentrations, only relevant when being used in high doses for echinococcosis.

Administration
Reconstitution —
Route Oral
Rate of administration —

Other information
- Contraindicated in pregnancy.
- Poorly absorbed from the gastrointestinal tract (5–10%).
Medroxyprogesterone acetate

Clinical use
Progestogen:
• Cachexia (unlicensed), contraception, epilepsy, male hypersexuality, malignant neoplasms, respiratory disorders, sickle-cell disease, dysfunctional uterine bleeding, endometriosis

Dose in normal renal function
• Cachexia (unlicensed): 500 mg twice daily\(^1\)
• Contraception: 150 mg (deep IM) or 104 mg (SC) within first 5 days of cycle or within first 5 days after parturition
• Breast cancer: Oral: 400–1500 mg daily
• Other hormone sensitive malignancies: Oral: 100–600 mg daily
• Endometrial and renal cell cancer: 200–600 mg daily
• Dysfunctional uterine bleeding: 2.5–10 mg daily for 5–10 days beginning on day 16–21 of cycle, repeated for 2–3 cycles
• Endometriosis: 10 mg 3 times a day for 90 consecutive days, beginning on day 1 of cycle
• Progestogenic opposition of oestrogen HRT: 10 mg daily for the last 14 days of each 28 day oestrogen HRT cycle
• See product literature for more specific information

Pharmacokinetics
Molecular weight (daltons) 386.5
% Protein binding 94
% Excreted unchanged in urine <5
Volume of distribution (L/kg) >20 Litres
Half-life — normal/ESRF (hrs) 24–48 (up to 50 days after IM administration) / –

Metabolism
Medroxyprogesterone is mainly metabolised in the liver and excreted mainly as glucuronide conjugates in the urine and faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. Monitor carefully.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Antibacterials: metabolism of progestogens accelerated by griseofulvin and rifamycins (reduced contraceptive effect).
• Anticoagulants: progestogens antagonise anticoagulant effect of phenindione and may enhance or reduce effect of coumarins.
• Antidepressants: contraceptive effect reduced by St John’s Wort – avoid.
• Antiepileptics: metabolism accelerated by carbamazepine, eslicarbazepine, fosphenytoin, lamotrigine, oxcarbazepine, perampanel, phenytoin, phenobarbital, primidone, rufinamide and topiramate (reduced contraceptive effect); concentration of lamotrigine reduced.
• Antivirals: contraceptive effect possibly reduced by efavirenz; metabolism accelerated by nevirapine (reduced contraceptive effect).
• Aprepitant: possible contraceptive failure.
• Bosentan: possible contraceptive failure.
• Ciclosporin: progestogens inhibit metabolism of ciclosporin (increased plasma concentration).
• Cytotoxics: possibly reduced contraceptive effect with crizotinib dabrafenib, olaparib and vemurafenib.
• Dopaminergics: concentration of selegiline increased – avoid.
• Fosaprepitant: possible contraceptive failure.
• Lumacaftor: possible contraceptive failure.
• Ulipristal: contraceptive effect possibly reduced.

Administration
Reconstitution
—
Route Oral, IM
Rate of administration
—

Other information
• Do not use in patients with porphyria.

Reference:
Mefenamic acid

Clinical use

NSAID:
• Mild to moderate rheumatic pain
• Dysmenorrhoea and menorrhagia

Dose in normal renal function

500 mg 3 times a day

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>241.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>6</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.06</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–4 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism

Metabolised in the liver by the cytochrome P450 isoenzyme CYP2C9 to 3-hydroxymethyl mefenamic acid, which may then be oxidised to 3-carboxyfmefamnic acid. Over 50% of a dose may be recovered in the urine, as unchanged drug or, mainly, as conjugates of mefenamic acid and its metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but only use if on dialysis.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function. See ‘Other information’.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function. See ‘Other information’.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function. See ‘Other information’.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
• Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
• Antibacterials: possibly increased risk of convulsions with quinolones.
• Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
• Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
• Antidiabetics: effects of sulphonylureas enhanced.
• Antiepileptics: possibly increased phenytoin concentration.
• Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
• Ciclosporin: may potentiate nephrotoxicity.
• Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
• Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
• Lithium: excretion decreased.
• Pentoxifylline: increased risk of bleeding.
• Tacrolimus: increased risk of nephrotoxicity.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

• As with other prostaglandin inhibitors, allergic glomerulonephritis has occurred occasionally. There have also been reports of acute interstitial nephritis with haematuria and proteinuria and occasionally nephrotic syndrome.
Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid use if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.

Use with caution in renal transplant recipients (can reduce intrarenal autacoid synthesis).

Use normal doses in patients with CKD 5 on dialysis if they do not pass any urine.
**Mefloquine**

### Clinical use
Malaria prophylaxis and treatment

### Dose in normal renal function
- **Prophylaxis**: 250 mg weekly, if < 45 Kg see SPC
- **Treatment**: 20–25 mg/kg in 2–3 divided doses; maximum 1.5 g

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>414.8 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>9 (+4% metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>20</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>21 days / –</td>
</tr>
</tbody>
</table>

### Metabolism
Mefloquine is extensively metabolised in the liver by the cytochrome P450 isoenzyme CYP3A4. There is evidence that mefloquine is excreted mainly in the bile and faeces.

### Dose in renal impairment GFR (mL/min)
- **20–50**: Dose as in normal renal function.
- **10–20**: Dose as in normal renal function.
- **<10**: Use with caution. Prophylaxis: Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- **Anti-arrhythmics**: increased risk of ventricular arrhythmias with amiodarone – avoid.
- **Antibacterials**: increased risk of ventricular arrhythmias with moxifloxacin – avoid; concentration reduced by rifampicin – avoid.
- **Antiepileptics**: antagonism of anticonvulsant effect.
- **Antidepressants**: possibly increased risk of convulsions with vortioxetine.
- **Antimalarials**: increased risk of convulsions with chloroquine, hydroxychloroquine and quinine; avoid with artemether and lumefantrine.
- **Antipsychotics**: increased risk of ventricular arrhythmias with haloperidol and pimozide and possibly with risperidone – avoid with haloperidol and pimozide.
- **Atomoxetine**: increased risk of ventricular arrhythmias.
- **Ivabradine**: increased risk of ventricular arrhythmias.

### Administration
#### Reconstitution
- **Route**: Oral
#### Rate of administration
- **Other information**
  - Start prophylaxis 1–3 weeks before arriving in malarial area and continue for 4 weeks after leaving the malarial area.
  - Increased risk of convulsions in patients with epilepsy.
  - Use with caution advised by manufacturer due to lack of experience in severe renal impairment.
  - Doses in renal impairment are from *Drug Prescribing in Renal Failure, 5th* edition by Aronoff *et al.*
Megestrol acetate

Clinical use

Progestogen:
• Treatment of breast cancer, cachexia (unlicensed)

Dose in normal renal function

160 mg daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>384.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Highly</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>56.5–78.4 (5–8% as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>34 / –</td>
</tr>
</tbody>
</table>

Metabolism

It undergoes hepatic metabolism, with 57–78% of a dose being excreted in the urine and 8–30% in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td></td>
<td>Monitor carefully.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Antibacterials: metabolism of progestogens accelerated by griseofulvin and rifamycins.
• Anticoagulants: progestogens antagonise anticoagulant effect of phenindione; may enhance or reduce anticoagulant effect of coumarins.
• Antiepileptics: metabolism accelerated by carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone, rufinamide and topiramate; concentration of lamotrigine reduced; concentration reduced by high dose perampanel.
• Antivirals: metabolism accelerated by nevirapine.
• Ciclosporin: progestogens inhibit metabolism of ciclosporin (increased plasma concentration).
• Dopaminergics: concentration of selegiline increased — avoid.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Increased risk of toxic reactions in renal impairment.
Melatonin

**Clinical use**

Melatonin receptor agonist:
- Short-term use for insomnia

**Dose in normal renal function**

2 mg once daily 1–2 hours before bedtime

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>232.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60%</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>2%</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>65–88 Litres (as metabolites)</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3.5–4 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolised in the liver to form inactive metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
<th>Dose in renal impairment GFR (mL/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antidepressants: increased sedative effects with mirtazapine or tricyclics.
- Antipsychotics: enhanced sedative effects.
- Antivirals: concentration possibly increased by ritonavir.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Manufacturer advises to use with caution in severe renal impairment due to lack of studies.
- Oral bioavailability is 15%.
Meloxicam

**Clinical use**

Cox II inhibitor and analgesic

**Dose in normal renal function**

7.5–15 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>351.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>3</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>11 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>20 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Extensively metabolised by cytochrome P450 isoenzyme CYP2C9 and to a lesser degree by CYP3A4, mainly by oxidation to its major metabolite, 5'-carboxymeloxicam. Meloxicam, in the form of metabolites, is excreted in similar amounts in the urine and in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td>Dose as in normal renal function. See 'Other information.'</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
<td>Dose as in normal renal function, but avoid if possible. Only use if on dialysis.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
<td>Only use if on dialysis.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function. See 'Other information.'
- HD: Not dialysed. Dose as in normal renal function. See 'Other information.'
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function. See 'Other information.'
- CAV/VVHD: Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetics: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: decreased excretion leading to increased lithium levels.
- Pentoxifylline: possibly increased risk of bleeding.
- Tacrolimus: possibly increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Clinical trials have shown renal effects similar to those observed with comparative NSAIDs. Monitor patient for deterioration in renal function and fluid retention.
  - Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.
Meloxicam

- Use with caution in renal transplant recipients (can reduce intrarenal autocoid synthesis).
- Meloxicam should be used with caution in uraemic patients predisposed to gastrointestinal bleeding or uraemic coagulopathies.

- Use normal doses in patients with CKD 5 on dialysis if they do not pass any urine.
## Melphalan

### Clinical use

Alkylating agent:
- Myelomas
- Solid tumours
- Polycythaemia vera

### Dose in normal renal function

- Orally: 150–200 micrograms/kg daily
- Polycythaemia vera: 6–10 mg daily, reduced after 5–7 days to 2–4 mg daily, then further reduced to 2–6 mg per week
- IV administration: 16–240 mg/m² according to indication and local protocol

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>305.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>11</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.5–2.5 / 4–6</td>
</tr>
</tbody>
</table>

### Metabolism

Spontaneous hydrolysis degradation rather than enzymatic metabolism. Percentage of dose excreted in the urine as active or toxic moiety ranges from 11–93%; 20–50% excreted in the faeces within 6 days.

### Administration

**Reconstitution**
10 mL of provided diluent

**Route**
IV, oral

**Rate of administration**
Inject slowly into a fast running infusion solution or via an infusion bag.

**Comments**
Further dilution with sodium chloride 0.9%.

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Ciclosporin: increased risk of nephrotoxicity.

### Other information

- Melphalan clearance, though variable, is decreased in renal impairment.
- Incomplete and variable oral absorption – 25–89% post oral dose; AUC decreased by 39% when taken with food.
- Manufacturer states that currently available pharmacokinetic data do not justify an absolute recommendation on dosage reduction when administering melphalan tablets to patients with moderate to severe renal impairment, but it may be prudent to use a reduced dosage initially until tolerance is established.
- When melphalan injection is used at conventional IV dosage (8–40 mg/m²BSA) in patients with moderate to severe renal impairment, it is recommended that the initial dose should be reduced by 50% and subsequent dosage be determined by the degree of haematological suppression.
- For high IV doses of melphalan (100–240 mg/m²BSA), the need for dose reduction depends upon the degree of renal impairment, whether autologous bone marrow stem cells are re-infused, and therapeutic need. High dose melphalan is not recommended in patients with more severe renal impairment (EDTA clearance less than 30 mL/minute).
- It should be borne in mind that dose reduction of melphalan in renal impairment is somewhat arbitrary. At moderate doses, where melphalan
is used as part of a combined regimen, dosage reductions of up to 50% may be appropriate. However, at high doses, e.g. conditioning for bone marrow transplant, there is a risk of under-dosing the patient and not achieving the desired therapeutic effect, so the dose should be reduced with caution in these instances.

- Adequate hydration and forced diuresis may be necessary in patients with poor renal function.
- In myeloma patients with renal damage, temporary but significant increases in blood urea levels have been observed during melphalan therapy.
Memantine

Clinical use
NMDA-receptor antagonist:
  • Treatment of moderate to severe dementia in Alzheimer’s disease

Dose in normal renal function
5–20 mg daily

Pharmacokinetics
Molecular weight (daltons) 215.8
% Protein binding 45
% Excreted unchanged in urine 48 (74% plus metabolites)
Volume of distribution (L/kg) 10
Half-life — normal/ESRF (hrs) 60–100 / 117–156

Metabolism
Memantine undergoes partial hepatic metabolism to form mainly three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine. Renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption.

Dose in patients undergoing renal replacement therapies
APD/CAPD Dialysed. Dose as in GFR<5 mL/min.
HD Dialysed. Dose as in GFR<5 mL/min.
HDF/High flux Dialysed. Dose as in GFR<5 mL/min.
CAV/VVHD Dialysed. Dose as in GFR=5–29 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
  • Anaesthetics: increased risk of CNS toxicity with ketamine – avoid.
  • Analgesics: increased risk of CNS toxicity with dextromethorphan – avoid.
  • Dopaminergics: possibly enhances effects of dopaminergics and selegiline; increased risk of CNS toxicity with amantadine – avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Bioavailability is 100%.
• Mean AUC\(0-\infty\) increased by 4%, 60%, and 115% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. The terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects.

Reference:
Mepacrine hydrochloride (unlicensed product)

Clinical use
- Giardiasis
- Discoid lupus erythematosus

Dose in normal renal function
100 mg every 8 hours for 5–7 days

Pharmacokinetics
Molecular weight (daltons) 508.9
% Protein binding 80–90
% Excreted unchanged in urine <11
Volume of distribution (L/kg) Large
Half-life — normal/ESRF (hrs) 5–14 days / –

Metabolism
Mepacrine is excreted slowly mainly in the urine, with an elimination half-life of 5 days, and is still detectable in the urine after 2 months.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Alcohol: can cause a mild disulfiram reaction.
- Antimalarials: increased concentration of primaquine (increased risk of toxicity).

Administration
Reconstitution
Route Oral
Rate of administration —
Mepolizumab

**Clinical use**

Humanised IL-5 antagonist monoclonal antibody:
- Treatment of severe refractory eosinophilic asthma

**Dose in normal renal function**

100 mg every 4 weeks

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>149 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0 (binds to IL-5)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.055–0.085</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>16–22 days / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Mepolizumab is a humanised IgG1 monoclonal antibody degraded by proteolytic enzymes which are widely distributed in the body and not restricted to hepatic tissue.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Vaccines: avoid concomitant use with live vaccines.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Administration**

**Reconstitution**
1.2 mL water for injection

**Route**
SC

**Rate of administration**
—
Meptazinol

Clinical use
Opioid analgesic used for moderate to severe pain

Dose in normal renal function
- Oral: 200 mg every 3–6 hours
- IM: 75–100 mg every 2–4 hours; obstetric analgesia: 100–150 mg depending on patient’s weight (2 mg/kg)
- Slow IV: 50–100 mg every 2–4 hours

Pharmacokinetics
Molecular weight (daltons) 269.8 (as hydrochloride)
% Protein binding 27
% Excreted unchanged in urine <5
Volume of distribution (L/kg) 3.1
Half-life — normal/ESRF (hrs) 1.4–4 /

Metabolism
Meptazinol is extensively metabolised in the liver and is excreted mainly in the urine as the glucuronide conjugate. Less than 10% of a dose has been recovered from the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with low doses.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Likely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Likely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: possible CNS excitation or depression with MAOIs – avoid; possible CNS excitation or depression with moclobemide; possibly increased sedative effects with tricyclics.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

Administration
Reconstitution
-
Route
Oral, IV, IM
Rate of administration
-

Other information
- Oral and IM peak analgesic effect occurs within 30–60 minutes and last for 3–4 hours.
- IV works immediately and lasts for at least 1 hour.
Mercaptopurine

Clinical use

Antineoplastic agent:
- Acute leukaemias
- Inflammatory bowel disease (unlicensed)

Dose in normal renal function

- Initially 2.5 mg/kg/day, but the dose and duration of administration depend on the nature and dosage of other cytotoxic agents given in conjunction
- Crohn’s disease or ulcerative colitis: 1–1.5 mg/kg daily, some patients may respond to a lower dose

Pharmacokinetics

Molecular weight (daltons) 170.2
% Protein binding 20
% Excreted unchanged in urine 7
Volume of distribution (L/kg) 0.1–1.7
Half-life — normal/ESRF (hrs) 1–1.5 / –

Metabolism

Extensively metabolised by first-pass metabolism in the liver via intracellular activation to an active metabolite. At conventional doses clearance is primarily hepatic. Renal clearance may become important at high doses. The active metabolites have a longer half-life than the parent drug. The main method of elimination for 6-mercaptopurine is by metabolic alteration. The kidneys eliminate approximately 7% of 6-mercaptopurine unaltered within 12 hours of the drug being administered. Xanthine oxidase is the main catabolic enzyme of 6-mercaptopurine and it converts the drug into the inactive metabolite, 6-thiouric acid. This is excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose/reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Caution – reduce dose. See ‘Other information’.</td>
</tr>
<tr>
<td>10–20</td>
<td>Caution – reduce dose. See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Caution – reduce dose. See ‘Other information’.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Allopurinol: decreased rate of metabolism of mercaptopurine – reduce dose of mercaptopurine to a quarter of normal dose.
- Antibacterials: increased risk of haematological toxicity with co-trimoxazole and trimethoprim.
- Anticoagulants: possibly reduced anticoagulant effect of coumarins.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Febuxostat: avoid concomitant use.

Administration

Reconstitution

Route
Oral
Rate of administration

Other information

- Absorption of an oral dose is incomplete, averaging ~50%. This is largely due to first-pass metabolism (less when given with food). There is enormous inter-individual variability in absorption, which can result in a 5-fold variation in AUC.
- Manufacturer recommends reducing the dose in patients with impaired hepatic or renal function, although no specific dosing guidelines are available due to lack of data.
- The following dosing intervals have been suggested in renal impairment: 24–36 hrs for CRCL of 50–80 mL/min, and 48 hours for CRCL of 10–50 mL/min. (Summerhayes M, Daniels S (ed). Practical Chemotherapy – A Multidisciplinary Guide. Oxford: Radcliffe Medical Press Ltd. 2003. p. 384.)
Mercaptopurine

- A recent study on anti-cancer drug renal toxicity and elimination concluded that the dose of 6-mercaptopurine does not require modification in patients with decreased renal function (except in conjunction with allopurinol). This study also gives percentage excreted unchanged in urine as 21%. (Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995; 21(1): 33–64.)
**Clinical use**
Antibacterial agent

**Dose in normal renal function**
- 500 mg – 1 g every 8 hours
- Higher doses used in cystic fibrosis and meningitis (up to 2 g every 8 hours)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>437.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>2</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>70</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.35¹</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1 / 6–13.7²</td>
</tr>
</tbody>
</table>

**Metabolism**

Meropenem is more stable to renal dehydropeptidase I than imipenem but undergoes some renal metabolism, and is mainly excreted in the urine by tubular secretion and glomerular filtration. About 70% of a dose is recovered unchanged in the urine over a 12-hour period. Meropenem is reported to have one metabolite (ICI-213689), which is inactive and is excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>26–50</td>
<td>500 mg – 2 g every 12 hours.</td>
</tr>
<tr>
<td>10–25</td>
<td>500 mg – 1 g every 12 hours or 500 mg every 8 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>500 mg – 1 g every 24 hours.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Dialysed. Dose as in GFR<10 mL/min.
- **HD**: Dialysed. Dose as in GFR<10 mL/min or 1–2 g post dialysis.²
- **HDF/High flux**: Dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVH/HD**: Dialysed. 0.5–1 g every 8 hours²³ or 1 g every 12 hours.¹
- **CVVHDF**: 1 g every 12 hours.¹ See 'Other information'.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antiepileptics: concentration of valproate reduced – avoid.
- Probenecid: avoid concomitant use.

**Administration**

**Reconstitution**
Add 5 mL water for injection to each 250 mg of meropenem.

**Route**
IV

**Rate of administration**
- Bolus: 5 minutes
- IV Infusion: 15–30 minutes

**Comments**
- Further dilute in 50–200 mL sodium chloride 0.9%, glucose 5% or glucose 10% if for infusion.
- Stable for 24 hours once reconstituted.
- Minimum volume 1 g in 10 mL. (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006.)
- Each 1 g vial contains 3.9 mmol of sodium.
- Has less potential to induce seizures than imipenem.
- Has been used intraperitoneally for peritoneal dialysis Pseudomonas peritonitis at a concentration of 100 mg/L.
- 50% is removed by CVVHF, 13–53% by CVVHDF, 50% by intermittent HD.²
- Differences in renal replacement doses are due to the different flow rates used in the studies.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be
according to the GFR rather than using the dialysis recommendations.

References:
**Mesalazine**

**Clinical use**
Induction and maintenance of remission in ulcerative colitis

**Dose in normal renal function**
Dose depends on preparation

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>153.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>40–50</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.6 / –</td>
</tr>
</tbody>
</table>

**Metabolism**
The absorbed part of mesalazine is almost completely acetylated in the gut wall and in the liver to acetyl-5-aminosalicylic acid. The acetylated metabolite is excreted mainly in urine by tubular secretion, with traces of the parent compound.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Caution – use only if necessary. Start with low dose and increase according to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Caution – use only if necessary. Start with low dose and monitor closely.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Caution – use only if necessary. Start with low dose and monitor closely.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
Oral, PR

**Rate of administration**
—

**Other information**
- Contraindicated by manufacturer if GFR<20 mL/min.
- Nephrotoxicity has been reported.
- Mesalazine is best avoided in patients with established renal impairment, but if necessary should be used with caution, and the patient carefully monitored.
### Mesna

#### Clinical use
Prophylaxis of urothelial toxicity in patients treated with ifosfamide or cyclophosphamide

#### Dose in normal renal function
Dose and timing depends on cytotoxic agent and on route of administration of mesna

<table>
<thead>
<tr>
<th>Pharmacokinetics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>164.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>70</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>32</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.65</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.3 / –</td>
</tr>
</tbody>
</table>

#### Metabolism
Rapidly metabolised in the liver to the disulfide, dimesna, and is excreted in the urine as both metabolite and unchanged drug; dimesna is reduced back to mesna, which is the active form, in the kidney.

#### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>As in normal renal function. See 'Other information'.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>As in normal renal function. See 'Other information'.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>As in normal renal function. See 'Other information'.</td>
<td></td>
</tr>
</tbody>
</table>

#### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown</td>
</tr>
<tr>
<td>HD</td>
<td>Probably</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Probably</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably</td>
</tr>
</tbody>
</table>

#### Important drug interactions
Potentially hazardous interactions with other drugs
- None known

#### Administration

##### Reconstitution
—

##### Route
Oral, IV bolus, IV infusion

##### Rate of administration
- IV bolus: over 15–30 minutes
- IV infusion: over 12–24 hours

##### Comments
- Compatible with sodium chloride 0.9% and glucose 5%.
- Mesna injection can be administered orally in orange juice or cola to improve palatability.

#### Other information
- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Urinary output should be maintained at 100 mL/hour (as required for oxazaphosphorine treatment).
- The dose of mesna is dependent on the dose of oxazaphosphorine, e.g. reduce dose of cyclophosphamide to 50% of normal if GFR<10 mL/min; hence, dose of mesna will consequently be reduced.
- From what is known about the pharmacokinetics and mechanism of action of mesna, its availability in the urinary tract depends on renal function.
- In the case of completely anuric patients (extremely rare) neither cyclophosphamide nor its metabolites should appear in the urinary tract: the use of mesna concomitantly may therefore be unnecessary in anuric patients. If there is any risk of cyclophosphamide or its metabolites entering the urinary tract, mesna should probably be given to prevent urothelial toxicity.
- Limited kinetic information would suggest mesna would be eliminated by haemodialysis.
Metaraminol

**Clinical use**
Treatment of acute hypotension

**Dose in normal renal function**
- 15–100 mg, adjusted according to response
- Emergency treatment: 0.5–5 mg then 15–100 mg by IV infusion

**Pharmacokinetics**
- Molecular weight (daltons): 167.2 (317.3 as tartrate)
- % Protein binding: 45
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): No data

**Metabolism**
Hepatically metabolised.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Adrenergic neurone blockers: hypotensive effect antagonised.
- Anaesthetics: risk of ventricular arrhythmias with isoflurane – avoid.
- Antibacterials: risk of hypertensive crisis with linezolid and tedizolid – avoid for at least 2 weeks after stopping linezolid and tedizolid.
- Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide – avoid for at least 2 weeks after stopping MAOIs.
- Dopaminergics: avoid with rasagiline and selegiline.

**Administration**

**Reconstitution**
- Route: IV bolus, IV infusion

**Rate of administration**
- According to response

**Comments**
- Add to 500 mL sodium chloride 0.9% or glucose 5% for infusion.

**Other information**
- The pressor effect of a single dose of metaraminol lasts from about 20 minutes up to one hour. The vasopressor effects taper off when therapy is stopped.
Metformin hydrochloride

Clinical use

- Non-insulin dependent diabetes mellitus
- Polycystic ovary syndrome

Dose in normal renal function

- 500 mg 3 times a day; maximum 3 g daily in divided doses
- Polycystic ovary syndrome: 1.5–1.7 g daily in 2–3 divided doses
- MR: 500 mg – 2 g daily in 1–2 divided doses

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>165.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Negligible</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>100</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1–4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–6 / Prolonged</td>
</tr>
</tbody>
</table>

Metabolism

Metformin is not metabolised to any great extent, and is entirely excreted unchanged in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>10–45</td>
<td>25% of dose. See ‘Other information.’</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid. See ‘Other information.’</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

- Alcohol: increased risk of lactic acidosis.
- Cimetidine: inhibits renal excretion of metformin.

Administration

Reconstitution

—

Route

Oral

Rate of administration

—

Other information

- Doses in renal impairment are from *Drug Prescribing in Renal Failure, 5th edition* by Aronoff et al.
- Lactic acidosis is a rare but serious metabolic complication that can occur due to metformin accumulation. Reported cases have occurred primarily in diabetic patients with significant renal impairment.
- Contraindicated by manufacturer if GFR<30 mL/min. In GFR=30–44 mL/min, maximum daily dose is 1000 mg.
- A recent paper debates how safe metformin is in renal disease and suggests it can be used in patients with GFR>30 mL/min with careful monitoring and query the data which says it commonly causes lactic acidosis. (Herrington WG, Levy JB. Metformin: effective and safe in renal disease? *Int Urol Nephrol*. 2008; 40(2): 411–7.)
- As metformin is renally excreted eGFR values should be determined before initiating treatment and regularly thereafter:
  - at least annually in patients with normal renal function
  - at least 2–4 times a year in patients with an eGFR at the lower limit of normal and in elderly subjects.
- Special caution should be exercised in the elderly in situations where renal function may become impaired, e.g. initiating therapy with antihypertensives, diuretics or NSAIDs.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Avoid.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Avoid.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Avoid.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably dialysed. Avoid.</td>
</tr>
</tbody>
</table>
# Methadone hydrochloride

## Clinical use
- Treatment of opioid drug addiction
- Analgesic for moderate to severe pain

## Dose in normal renal function
- Opioid addiction: 10–60 mg per day, increasing by 10 mg per day until there are no signs of withdrawal or intoxication; reduce gradually
- Analgesia: 5–10 mg every 6–8 hours

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>346.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>15–60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3–6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>13–47 / –</td>
</tr>
</tbody>
</table>

## Metabolism
Metabolised in the liver to the major metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine and the minor metabolite 2-ethyl-3,3-diphenyl-5-methylypyrrolidine, both of them inactive. Two other metabolites have also been identified. These metabolites are excreted in the faeces and urine with unchanged methadone.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50–75% of normal dose, and titrate according to response.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: possible opioid withdrawal with buprenorphine and pentazocine.
- Antibacterials: metabolism increased by rifampicin; increased risk of ventricular arrhythmias with delamanid and telithromycin.
- Antidepressants: concentration possibly increased by fluoxetine, fluvoxamine, paroxetine and sertraline; possible CNS excitation or depression with MAOIs and moclobemide – avoid; possibly increased sedative effects with tricyclics; concentration possibly reduced by St John’s wort.
- Antiepileptics: concentration reduced by carbamazepine, phenobarbital and phenytoin.
- Antifungals: concentration increased by fluconazole, ketoconazole, voriconazole and possibly itraconazole – may need to reduce methadone dose with voriconazole, avoid with ketoconazole.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antimalarials: increased risk of ventricular arrhythmias with piperaquine with arteminol – avoid.
- Antipsychotics: enhanced hypotensive and sedative effects; increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval – avoid with amisulpiride.
- Antivirals: methadone possibly increases concentration of zidovudine; concentration reduced by efavirenz, fosamprenavir and ritonavir; concentration possibly reduced by abacavir, nevirapine and rilpivirine; concentration possibly affected by boceprevir; concentration of didanosine possibly reduced; increased risk of ventricular arrhythmias with saquinavir and telaprevir – avoid with saquinavir and use with caution with telaprevir.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Cytotoxics: possible increased risk of ventricular arrhythmias with bosutinib, ceritinib, panobinostat and vandetanib.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.
Methadone hydrochloride

**Administration**

<table>
<thead>
<tr>
<th>Reconstitution</th>
</tr>
</thead>
<tbody>
<tr>
<td>—</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM, SC, oral</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rate of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>—</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone is probably not suitable to be used as an analgesic for patients with severe renal impairment.</td>
</tr>
</tbody>
</table>

**Other information**

- Dose in severe renal impairment is from *Drug Prescribing in Renal Failure, 5th edition* by Aronoff *et al*.
- Overdosage with methadone can be reversed using naloxone.
- Risk of QT interval prolongation especially with high doses and concomitant risk factors.
Methenamine hippurate

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
1 g every 8–12 hours

**Pharmacokinetics**
- Molecular weight (daltons): 319.4
- % Protein binding: No data
- % Excreted unchanged in urine: 80–90
- Volume of distribution (L/kg): No data

**Metabolism**
Under acid conditions methenamine is slowly hydrolysed to formaldehyde and ammonia. Almost no hydrolysis of methenamine takes place at physiological pH, and it is therefore virtually inactive in the body. Methenamine is rapidly and almost completely eliminated in the urine, and provided this is acidic (preferably below pH 5.5) bactericidal concentrations of formaldehyde occur. Because of the time taken for hydrolysis, however, these do not occur until the urine reaches the bladder.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Avoid. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Avoid. See ‘Other information’.
- HD: Unknown dialysability. Avoid. See ‘Other information’.
- HDF/High flux: Unknown dialysability. Avoid. See ‘Other information’.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of crystalluria with sulphonamides.
- Diuretics: effects antagonised by acetazolamide.

**Administration**
**Reconstitution**
- Route: Oral
- Rate of administration

**Other information**
- Avoid hippurate salt in renal impairment due to the risk of hippurate crystalluria.
- Methenamine is not recommended in severe renal impairment as urinary concentrations are too low for it to be effective.
- Contraindicated in metabolic acidosis, severe dehydration, renal parenchymal infections and hepatic failure.
Methotrexate

Clinical use

Antineoplastic agent:
- Severe rheumatoid arthritis
- Severe uncontrolled psoriasis
- Crohn's disease (unlicensed)
- Neoplastic disease

Dose in normal renal function

- Rheumatoid arthritis:
  - Oral: 7.5–20 mg once weekly
  - IM, IV, SC: 7.5–25 mg once weekly
- Psoriasis: (Oral, IM, IV, SC) 10–25 mg once weekly, adjusted to response
- Crohn's disease (unlicensed): Oral: 10–25 mg once weekly; IM: Induction: 25 mg once weekly; Maintenance: 15 mg once weekly
- Neoplastic disease: Dose by weight or surface area according to specific indication

Pharmacokinetics

Molecular weight (daltons) 454.4
% Protein binding 45–60
% Excreted unchanged in urine 80–90
Volume of distribution (L/kg) 0.4–0.8
Half-life — normal/ESRF (hrs) 2–17 / Increased

Metabolism

Metabolism is via liver and intracellular metabolism to polyglutamated products. Methotrexate does not appear to undergo significant metabolism at low doses; after high-dose therapy the 7-hydroxy metabolite has been detected. Methotrexate may be partly metabolised by the intestinal flora after oral doses. It is excreted mainly in the urine by glomerular filtration and active tubular secretion. Small amounts are excreted in bile and found in faeces; there is some evidence for enterohepatic recirculation.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>50% of normal dose. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>50% of normal dose. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Contraindicated. See 'Other information'.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: antifolate effect increased by nitrous oxide – avoid.
- Analgesics: increased risk of toxicity with NSAIDs – avoid.
- Antibacterials: absorption possibly reduced by neomycin; antifolate effect increased with co-trimoxazole and trimethoprim; penicillins and possibly ciprofloxacin reduce excretion of methotrexate (increased risk of toxicity); increased haematological toxicity with doxycycline, sulphonamides and tetracycline.
- Antiepileptics: concentration possibly increased by levetiracetam.
- Antimalarials: antifolate effect enhanced by pyrimethamine.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Ciclosporin: methotrexate may inhibit the clearance of ciclosporin or its metabolites; ciclosporin may inhibit methotrexate elimination.
- Corticosteroids: increased risk of haematological toxicity.
- Cytotoxics: effects of methotrexate antagonised by asparaginase, crisantaspase and pegaspargase – give asparaginase, crisantaspase and pegaspargase 24 hours after methotrexate; increased pulmonary toxicity with cisplatin.
- Leflunomide: risk of toxicity.
- Probencid: excretion of methotrexate reduced.
- Retinoids: concentration increased by acitretin, also increased hepatotoxicity – avoid.
- Ulcer-healing drugs: PPIs may reduce high dose methotrexate elimination; consider temporarily stopping PPI.
**Administration**

**Reconstitution**
Compatible with glucose 5%, sodium chloride 0.9%, compound sodium lactate, or Ringers solution.

**Route**
Oral, IM, SC, IV (bolus injection or infusion), intrathecal, intra-arterial, intraventricular

**Rate of administration**
Slow IV injection

**Comments**
High-dose methotrexate may cause precipitation of methotrexate or its metabolites in renal tubules. A high fluid throughput and alkalinisation of urine, using sodium bicarbonate if necessary, is recommended.

**Other information**
- Renal function should be closely monitored throughout treatment. If there is any deterioration in renal function methotrexate must be discontinued and discussed with the consultant who started treatment.
- Doses in renal impairment are from *Drug Prescribing in Renal Failure, 5th* edition by Aronoff et al.
- The dose is well absorbed at doses <30 mg/m² – bioavailability is decreased by food and milk.
- Calcium folinate (calcium leucovorin) is a potent agent for neutralising the immediate toxic effects of methotrexate on the haematopoietic system.
- Calcium folinate rescue may begin 24/32/36 hours post start of methotrexate therapy, according to local protocol. Doses of up to 120 mg may be given over 12–24 hours by IM or IV injection or infusion, followed by 12–15 mg IM, or 15 mg orally every 6 hours for the next 48 hours.
- An approximate correction for renal function may be made by reducing the dose in proportion to the reduction in creatinine clearance based on a normal creatinine clearance of 60 mL/min/m².
- Alternative dosing regimen:

<table>
<thead>
<tr>
<th>CRCL (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;80</td>
<td>100%</td>
</tr>
<tr>
<td>60</td>
<td>65%</td>
</tr>
<tr>
<td>45</td>
<td>50%</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Avoid</td>
</tr>
</tbody>
</table>

Doses in renal failure from Kintzel PE, Dorr RT.

BC Cancer agency suggest: (accessed 31/05/2017)

| GFR=61–80 | 75% of dose |
| GFR=51–60 | 70% of dose |
| GFR=10–50 | 30–50% of dose |
| GFR<10   | Avoid        |
Methyldopa

**Clinical use**
Hypertension

**Dose in normal renal function**
- 250 mg 2–3 times a day, increasing to a maximum dose of 3 g daily
- Elderly: 125 mg twice daily to a maximum of 2 g daily

**Pharmacokinetics**
- Molecular weight (daltons) 238.2
- % Protein binding <15
- % Excreted unchanged in urine 25–40
- Volume of distribution (L/kg) 0.5
- Half-life — normal/ESRF (hrs) 1.6–2 / 6–16

**Metabolism**
Methyldopa is extensively metabolised in the liver to form active metabolites with a long half-life.
It is excreted in urine mainly as unchanged drug and the O-sulfate conjugate.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function and adjust according to response.
- 10–20 Dose as in normal renal function and adjust according to response.
- <10 Dose as in normal renal function and adjust according to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Dialysed. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Probably dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Antidepressants: avoid concomitant use with MAOIs.
- Lithium: neurotoxicity (without increased plasma-lithium concentrations).
- Salbutamol: acute hypotension reported with salbutamol infusions.

**Administration**
Reconstitution
- Route
  - Oral
Rate of administration
- 

**Other information**
- Interferes with serum creatinine measurement.
- Orthostatic hypotension more common in renally impaired patients.
Methylprednisolone

Clinical use

Corticosteroid:
• Suppression of inflammatory and allergic disorder
• Immunosuppressant
• Rheumatic disease
• Cerebral oedema

Dose in normal renal function

• Oral: 2–360 mg daily
• IM/IV: 10–500 mg
• Graft rejection: up to 1 g daily for up to 3 days. See 'Other information'
• IM depot: 40–120 mg into gluteal muscle, repeated after 2–3 weeks if required

Pharmacokinetics

Molecular weight (daltons) 375
% Protein binding 40–60
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 1.2–1.5
Half-life — normal/ESRF (hrs) 2.4–3.5 / Unchanged

Metabolism

Metabolism in the liver occurs primarily via the CYP3A4 enzyme to inactive metabolites, which are excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

APD/CAPD  Dialysed. Dose as in normal renal function.
HD        Dialysed. Dose as in normal renal function.
HDF/High flux Dialysed. Dose as in normal renal function.
CAV/VVHD  Dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs

• Aldesleukin: avoid concomitant use.
• Antibacterials: metabolism accelerated by rifampicin; metabolism inhibited by erythromycin and possibly clarithromycin; concentration of isoniazid possibly reduced.
• Anticoagulants: efficacy of coumarins and phenindione may be altered.
• Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
• Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism inhibited by ketoconazole and possibly itraconazole.
• Antivirals: concentration possibly increased by ritonavir.
• Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids; levels of ciclosporin increased with high dose methylprednisolone.
• Cobicistat: concentration possibly increased by cobicistat.
• Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
• Vaccines: high dose corticosteroids can impair immune response to vaccines; avoid with live vaccines.

Administration

Reconstitution
Use solvent supplied (Solu-medrone) or see manufacturer’s recommendations.

Route
Oral, IM, IV peripherally or centrally

Rate of administration
30 minutes

Comments
NB: Rapid bolus injection may be associated with arrhythmias or cardiovascular collapse.

Other information

• A single dose of 500 mg –1 g is often given at transplantation.
• Three 500 mg –1 g doses at 24 hour intervals are often used as first line for reversal of acute rejection episodes. (Some units use 300–500 mg daily for 3 days.)
• Anecdotally, possesses less mineralocorticoid activity than equipotent doses of prednisolone.
Metoclopramide hydrochloride

**Clinical use**
Nausea and vomiting

**Dose in normal renal function**
- 10 mg 3 times a day
- Use in patients under 20 years should be restricted

**Pharmacokinetics**
- Molecular weight (daltons) 354.3
- % Protein binding 13–22
- % Excreted unchanged in urine 20–30
- Volume of distribution (L/kg) 3.5
- Half-life — normal/ESRF (hrs) 4–6 / 15

**Metabolism**
Metoclopramide undergoes first-pass hepatic metabolism. It is excreted in the urine, about 85% of a dose being eliminated in 72 hours, 20% as unchanged metoclopramide and the remainder as sulfate or glucuronide conjugates, or as metabolites. About 5% of a dose is excreted in faeces via the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Dialysed. Dose as in normal renal function.
- HDF/High flux Dialysed. Dose as in normal renal function.
- CAV/VVHD Dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Ciclosporin: increased ciclosporin blood levels.

**Administration**

**Reconstitution**
- **Route**
  - Oral, IV, IM
- **Rate of administration**
  - 1–2 minutes

**Other information**
- Increased risk of extrapyramidal reactions in severe renal impairment.
- Can be used for hiccups at a dose of 10 mg 3 times a day.
Metolazone (unlicensed)

**Clinical use**

Thiazide diuretic, acts synergistically with loop diuretics:
- Oedema
- Hypertension

**Dose in normal renal function**

- Oedema: 5–10 mg, increased to 20 mg daily; maximum 80 mg daily
- Hypertension: 5 mg initially; maintenance: 5 mg on alternate days

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>365.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>80–95</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8–10 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Minimal metabolism in the kidney. About 70–80% of the amount of metolazone absorbed is excreted in the urine. The remainder is excreted in the bile and some enterohepatic circulation has been reported.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect.
- Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised.
- Antibacterials: avoid administration with lymecycline.
- Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hyponatraemia with carbamazepine.
- Antifungals: increased risk of hypokalaemia with amphotericin.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with post-synaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol.
- Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide — avoid.
- Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia.
- Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium excretion reduced, increased toxicity.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- May result in profound diuresis. Monitor patient’s fluid balance carefully.
- Monitor for hypokalaemia.
- In patients with creatinine clearance less than 50 mL/min there is no clinical evidence of accumulation.
Metoprolol tartrate

Clinical use
Beta-adrenoceptor blocker:
- Hypertension
- Angina
- Cardiac arrhythmias
- Migraine prophylaxis
- Hyperthyroidism

Dose in normal renal function
Oral:
- Hypertension: 100–400 mg daily in divided doses
- MR: 200 mg once daily
- Angina: 50–100 mg 2–3 times daily
- MR: 200–400 mg daily
- Arrhythmias: 100–300 mg in 2–3 divided doses
- Migraine: 100–200 mg daily in divided doses
- MR: 200 mg daily
- Hyperthyroidism: 50 mg 4 times daily
IV: 5 mg repeated after 5 minutes to a total dose of 10–15 mg
In surgery: 2–4 mg by slow IV injection then 2 mg as required to a maximum of 10 mg

Pharmacokinetics
Molecular weight (daltons) 684.8
% Protein binding 10–12
% Excreted unchanged in urine 5–10
Volume of distribution (L/kg) 5.6
Half-life — normal/ESRF (hrs) 1–9 (av: 3.5) / Unchanged

Metabolism
Extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP2D6, and undergoes oxidative deamination, O-dealkylation followed by oxidation, and aliphatic hydroxylation.
The metabolites are excreted in the urine with only small amounts of unchanged metoprolol.

Dose in renal impairment GFR (mL/min)
20–50  Dose as in normal renal function.
10–20  Start with small doses and titrate in accordance with response.
<10   Start with small doses and titrate in accordance with response.

Dose in patients undergoing renal replacement therapies
APD/CAPD  Not dialysed. Dose as in GFR<10 mL/min.
HD  Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux  Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD  Dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide; concentration increased by propafenone and dronedarone.
- Antibacterials: concentration reduced by rifampicin.
- Antidepressants: enhanced hypotensive effect with MAOIs; concentration increased by citalopram and escitalopram and possibly by paroxetine – avoid.
- Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquin; avoid with arteether/lumefantrine.
- Antipsychotics enhanced hypotensive effect with phenothiazines.
- Antivirals: avoid concomitant use with tipranavir in heart failure.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

### Administration

<table>
<thead>
<tr>
<th>Reconstitution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Route</strong></td>
</tr>
<tr>
<td>Oral, IV</td>
</tr>
</tbody>
</table>

#### Rate of administration
For bolus injection, 1–2 mg/minute or by continuous infusion via CRIP

#### Comments
A total dose of 10–15 mg IV is usually sufficient.

#### Other information
- Can cause hypoglycaemia in dialysis patients.
- Accumulation of the metabolites will occur in renal failure, but does not seem to cause any side effects.
Metronidazole

Clinical use

Antibiotic:
- Anaerobic and protozoal infections

Dose in normal renal function

- Oral: 200–500 mg every 8–12 hours
- IV: 500 mg every 8 hours
- PR: 1 g every 8–12 hours

Pharmacokinetics

Molecular weight (daltons) 171.2
% Protein binding 10–20
% Excreted unchanged in urine 20
Volume of distribution (L/kg) 0.7–1.5
Half-life — normal/ESRF (hrs) 5.6–11.4 / 7–21

Metabolism

Metabolised in the liver by side-chain oxidation and glucuronide formation. The main hydroxy metabolite has antibacterial activity and is detected in plasma and urine, the acid metabolite has virtually no antibacterial activity and is often not detected in plasma, but is excreted in urine. Small amounts of reduced metabolites, acetamide and N-(2-hydroxyethyl)oxamic acid (HOA), have also been detected in urine and are probably formed by the intestinal flora. Active metabolites have long half-life in renal impairment.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Alcohol: disulfiram-like reaction.
- Anticoagulants: effects of coumarins enhanced.
- Antiepileptics: metabolism of phenytoin inhibited; concentration reduced by phenobarbital.
- Busulfan: concentration of busulfan increased – risk of toxicity.
- Ciclosporin: raised blood level of ciclosporin.
- Cytotoxics: busulfan concentration increased; metabolism of fluorouracil inhibited.

Administration

Reconstitution
—

Route
IV, oral, PR

Rate of administration
IV: 5 mL/minute, i.e. 500 mg over 20 minutes.

Other information

- Increased incidence of GI reactions and vestibular toxicity in renal failure.
- Drug induced lupus is a rare adverse drug reaction.
- Rectally: dose frequency reduced to 12 hours after 3 days.
- 500 mg /100 mL infusion provides 14 mmol sodium.
Mexiletine hydrochloride (unlicensed)

**Clinical use**
Life-threatening ventricular arrhythmias, especially after a myocardial infarction

**Dose in normal renal function**
- **Oral:** 400 mg loading dose, followed by 200–300 mg 3 times daily commencing 2 hours after the loading dose. Maximum 1.2 g daily
- **IV injection:** 100–250 mg at a rate of 25 mg/minute with ECG monitoring, followed by an infusion of 250 mg as a 0.1% solution over 1 hour, 125 mg/hour for 2 hours then 500 micrograms/minute thereafter

**Pharmacokinetics**
<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>215.7</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>50–70</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>5–7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–17 / 16</td>
</tr>
</tbody>
</table>

**Metabolism**
Mexiletine is metabolised in the liver to several metabolites; metabolism may involve cytochrome P450 isoenzymes CYP1A2, CYP2D6, and CYP3A4, and genetic polymorphism in relation to CYP2D6 has been identified.
Mexiletine is excreted in the urine, mainly in the form of its metabolites; clearance is increased in acid urine.

**Dose in renal impairment GFR (mL/min)**
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50–100% of normal dose and titrate according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- **APD/CAPD:** Not dialysed. Dose as in GFR<10 mL/min.
- **HD:** Not dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux:** Dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD:** Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Analgesics: opioids delay absorption.
- Anti-arrhythmics: increased myocardial depression with any combination of anti-arrhythmics.
- Antidepressants: metabolism inhibited by fluvoxamine (increased toxicity).
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval.
- Antivirals: possibly increased risk of arrhythmias with ritonavir and tipranavir.
- Beta-blockers: increased myocardial depression.
- Diuretics: action of mexiletine antagonised by hypokalaemia.

**Administration**

**Reconstitution**
---
**Route**
IV infusion, oral.

**Rate of administration**
Variable

**Comments**
Add 250–500 mg mexiletine to 500 mL of infusion solution, e.g. sodium chloride 0.9%, glucose 5%, sodium bicarbonate 8.4%, sodium lactate, sodium chloride 0.9% with potassium chloride 0.3% or 0.6%.

**Other information**
- Drug Prescribing in Renal Failure, 5th edition by Aronoff et al. suggest using 100% of dose in renal impairment.
- Mexiletine has a narrow therapeutic index. Its therapeutic effect has been correlated with plasma concentrations of 0.5–2 micrograms per mL.
- Rate of elimination increased with acidic urine.
- Injection can be given orally; however due to local anaesthetic effect, care needed with hot foods.
- Available from “special order” manufacturers.
Mianserin hydrochloride

**Clinical use**
Antidepressant

**Dose in normal renal function**
30–90 mg daily either at bedtime or in divided doses

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>300.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>4–7</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>17.9–37.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–39</td>
</tr>
</tbody>
</table>

**Metabolism**
Mianserin is hepatically metabolised via aromatic hydroxylation, N-oxidation and N-demethylation. There are 3 urinary metabolites, (N-desmethyl, 8-hydroxy, and N-oxide derivative) which have been identified. The desmethyl metabolite, which is also active, has similar pharmacokinetic behaviour as the parent compound. Mianserin is excreted in the urine, almost entirely as its metabolites, either free or in conjugated form; 14–28% in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Start with a low dose and gradually increase.</td>
</tr>
<tr>
<td>10–20</td>
<td>Start with a low dose and gradually increase.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with a low dose and gradually increase.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Not dialysed. Dose as in GFR<10 mL/min.
- **HD** Not dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux** Not dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD** Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Alcohol: increased sedative effect.
- Antibacterials: avoid with linezolid and tedizolid.
- Antidepressants: avoid with MAOIs and moclobemide.
- Antiepileptics: convulsive threshold possibly lowered; concentration reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with artemimol.
- Safinamide: increased risk of hypertension and CNS excitation.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—
Micafungin

Clinical use

Antimycotic:
• Treatment of invasive candidiasis
• Treatment of oesophageal candidiasis
• Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia

Dose in normal renal function

• Weight >40 kg: 50–200 mg once daily
• Weight <40 kg: 1–4 mg/kg
• (Dose depends on indication)

Pharmacokinetics

Molecular weight (daltons) 1292.3 (as sodium salt)
% Protein binding >99
% Excreted unchanged in urine 11.6
Volume of distribution (L/kg) 0.28–0.5
Half-life — normal/ESRF (hrs) 10–17 / Unchanged

Metabolism

Metabolised in the liver by arylsulfatase to its catechol form and further metabolised to the methoxy form by catechol-O-methyltransferase. Some hydroxylation to micafungin via cytochrome P450 isoenzymes also occurs. Exposure to these metabolites is low and metabolites do not contribute to the overall efficacy of micafungin. After 28 days about 71% of a dose is recovered in the faeces and 12% in the urine.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
• Ciclosporin: possibly increases ciclosporin concentration.
• Sirolimus: increases sirolimus concentration.

Administration

Reconstitution
5 mL sodium chloride 0.9% or glucose 5%.
Route
IV
Rate of administration
Over 60 minutes.
Comments
Add dose to 100 mL sodium chloride 0.9% or glucose 5%.

Other information

• Isolated cases of renal dysfunction or acute kidney injury have occurred in patients taking micafungin.
**Miconazole**

### Clinical use

Antifungal agent

### Dose in normal renal function

- Oral gel: 2.5–10 mL in mouth, after food, 4 times daily
- Buccal: 50 mg daily

### Pharmacokinetics

- Molecular weight (daltons): 416.1
- % Protein binding: 90
- % Excreted unchanged in urine: 1
- Volume of distribution (L/kg): 20
- Half-life — normal/ESRF (hrs): 24 / Unchanged

### Metabolism

Miconazole is metabolised in the liver to inactive metabolites; 10–20% of an oral dose is excreted in the urine as metabolites. About 50% of an oral dose may be excreted mainly unchanged in the faeces.

### Dose in renal impairment GFR (mL/min)

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be significantly dialysed. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs
- Anticoagulants: effect of coumarins enhanced.
- Antidepressants: avoid concomitant use with reboxetine.
- Antidiabetics: enhances hypoglycaemic effect of gliclazide and glipizide; concentration of sulphonylureas increased.
- Antiepileptics: effect of fosphenytoin and phenytoin enhanced; possibly increased carbamazepine concentration.
- Antihistamines: avoid with mizolastine, risk of ventricular arrhythmias.
- Antimalarials: avoid with piperaquine with artemimol and artemether with lumefantrine.
- Antipsychotics: increased risk of ventricular arrhythmias with pimozone – avoid; possibly increased concentration of quetiapine – avoid.
- Antivirals: concentration of saquinavir possibly increased.
- Ciclosporin: possibly increased ciclosporin concentration.
- Ergot alkaloids: increased risk of ergotism with ergotamine and methysergide – avoid.
- Sirolimus: concentration increased by miconazole.
- Statins: possibly increased risk of myopathy with atorvastatin and simvastatin – avoid with simvastatin.
- Tacrolimus: possibly increased tacrolimus concentration.

### Administration

**Reconstitution**

---

**Route**

Oral gel, buccal, topical

**Rate of administration**

---

### Other information

- There is little absorption through skin or mucous membranes when miconazole nitrate is applied topically.
- 50% removed during haemodialysis.
Midazolam

Clinical use
Benzodiazepine:
• Sedation with amnesia in conjunction with local anaesthesia, premedication, induction
• Status epilepticus (unlicensed)

Dose in normal renal function
• See SPC for dosing guidelines.
• Status epilepticus: Buccal: 10 mg repeated once after 10 minutes if required

Pharmacokinetics
Molecular weight (daltons) 325.8 (362.2 as hydrochloride)
% Protein binding 96–98
% Excreted unchanged in urine < 1
Volume of distribution (L/kg) 0.7–1.2
Half-life — normal/ESRF (hrs) 2–7 / Unchanged

Metabolism
Metabolised in the liver via the cytochrome P450 isoenzyme CYP3A4. The major metabolite, alpha-hydroxymidazolam has some activity; its half-life is less than 1 hour.
Midazolam metabolites are excreted in the urine, mainly as glucuronide conjugates.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Use sparingly and titrate according to response. Only bolus doses, not continuous infusion.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Antibacterials: concentration increased by erythromycin, clarithromycin and telithromycin (profound sedation); metabolism possibly accelerated by rifampicin.
• Antidepressants: concentration of oral midazolam possibly reduced by St John’s wort.
• Antifungals: concentration increased by itraconazole, fluconazole, ketoconazole, posaconazole and voriconazole (prolonged sedative effect).
• Antipsychotics: increased sedative effects; increased risk of hypotension, bradycardia and respiratory depression when parenteral benzodiazepines are given with IM olanzapine.
• Antivirals: concentration increased by atazanavir, boceprevir, efavirenz, indinavir, fosamprenavir, ritonavir, saquinavir and telaprevir increase risk of prolonged sedation; avoid with oral midazolam.
• Ciclosporin: in vitro studies suggested that ciclosporin could inhibit the metabolism of midazolam. However, blood ciclosporin concentrations in patients given ciclosporin to prevent graft rejection were considered too low to result in an interaction.
• Cobicistat: avoid with oral midazolam.
• Cytotoxics: concentration increased by crizotinib and nilotinib; concentration reduced by enzalutamide.
• Sodium oxybate: enhanced effects of sodium oxybate – avoid.

Administration
Reconstitution
—
Route
IV, IM, buccal
Rate of administration
1–10 mL/hour according to response
Comments
Can be used undiluted.
Compatible with glucose 5%, sodium chloride 0.9%.

Other information
• Protein binding of midazolam is decreased in ERF; hence more unbound drug is available to produce CNS effects, so a decrease in dose is recommended.
• CSM has received reports of respiratory depression, sometimes associated with severe hypotension, following intravenous administration.
• Caution when used for sedation in severe renal impairment especially when used with opiates and/or neuromuscular blocking agents – monitor sedation and titrate to response.

• Increased CNS sensitivity in patients with renal impairment.
• One study reports midazolam as having a sieving coefficient = 0.06 and unlikely to be removed by haemofiltration.
• Midazolam injection can be administered by the buccal route (unlicensed).
Midodrine hydrochloride

Clinical use
Treatment of orthostatic hypotension, including dialysis related hypotension

Dose in normal renal function
2.5 mg twice daily up to 10 mg 3 times a day

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>290.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Negligible</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>25 minutes (3 hours for active metabolite) / increased (9 for active metabolite)</td>
</tr>
</tbody>
</table>

Metabolism
Undergoes enzymatic hydrolysis in the systemic circulation to an active metabolite (desglymidodrine).

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Start with a lower dose and titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with a lower dose and titrate according to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Initial dose, 2.5 mg if &lt;70 kg, 5 mg if &gt;70 kg. See ‘Other information’.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Initial dose, 2.5 mg if &lt;70 kg, 5 mg if &gt;70 kg. See ‘Other information’.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Adrenergic neurone blockers: midodrine antagonises hypotensive effect.
- Anaesthetics: risk of arrhythmias if given with volatile anaesthetics.
- Antidepressants: risk of arrhythmias and hypertension if given with tricyclic antidepressants, MAOIs and moclobemide.
- Antihypertensives: antagonise hypertensive effect of midodrine; risk of severe hypertension if given with beta-blockers.
- Dopaminergics: avoid with rasagiline and selegiline.
- Other drugs which increase blood pressure: enhanced hypertensive effect.

Administration

Reconstitution
- Route
  Oral
- Rate of administration
  - Comments
    Take last dose at least 4 hours before bed.

Other information
- After dialysis only 15% of drug remaining, so effectively removed by dialysis.
- Hypertension post dialysis is not a problem because drug is dialysed out.
- Peak levels occur 30 minutes after administration (60 minutes for active metabolite) so give 30 minutes before dialysis — avoid in patients with active coronary ischaemia.
- 93% bioavailability.
- For haemodialysis patients, start at a low dose and increase to a maximum of 30 mg; a second dose can be given midway through dialysis (maximum dose 10 mg).
- Contraindicated in severe organic heart disease, urinary retention, phaeochromocytoma and thyrotoxicosis.
# Mifamurtide

## Clinical use

Antineoplastic agent:
- Treatment of metastatic osteosarcoma

## Dose in normal renal function

2 mg/m² initially twice weekly, reduced to once weekly after 12 weeks

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1237.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>25.9 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.65–2.45 / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism

The cells of the reticuloendothelial system clear mifamurtide liposomes by phagocytosis.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs:
- Analgesics: avoid with high dose NSAIDs.
- Ciclosporin: avoid concomitant use.
- Corticosteroids: avoid concomitant use.
- Tacrolimus: avoid concomitant use.

## Administration

**Reconstitution**
50 mL sodium chloride 0.9%

**Route**
IV infusion

**Rate of administration**
1 hour

**Comments**
Use filter provided.
Appropriate dose is further diluted in 50 mL sodium chloride 0.9%.

## Other information

- Manufacturer advises to use with caution in severe renal impairment due to lack of studies.
- There was no difference in pharmacokinetics in GFR down to 30 mL/min compared to healthy volunteers.

Reference:
Minocycline

Clinical use
Antibacterial agent

Dose in normal renal function
- 100 mg twice daily
- Acne: 100 mg daily in 1 or 2 divided doses

Pharmacokinetics
- Molecular weight (daltons): 457.5
- % Protein binding: 75
- % Excreted unchanged in urine: 5–10
- Volume of distribution (L/kg): 1–1.5
- Half-life — normal/ESRF (hrs): 11–26 / 12–18

Metabolism
Undergoes some metabolism in the liver, mainly to 9-hydroxyminocycline.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhanced anticoagulant effect of coumarins and phenindione.
- Oestrogens: possibly reduced contraceptive effect of oestrogens (risk probably small).
- Retinoids: possibly increased risk of benign intracranial hypertension – avoid.

Administration
Reconstitution
-
Route
Oral
Rate of administration
-
Comments
Do not take iron preparations, indigestion remedies or phosphate binders at the same time of day as minocycline.
Minoxidil

**Clinical use**
- Severe hypertension (in addition to a diuretic and a beta-blocker)
- Male pattern baldness

**Dose in normal renal function**
- Initially 5 mg (elderly 2.5 mg) daily in 1–2 doses increased by 5–10 mg every 3 or more days; maximum 100 mg daily
- Male pattern baldness: 1 mL twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>209.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>15–20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2–3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4.2 / 8.9</td>
</tr>
</tbody>
</table>

**Metabolism**
Extensively metabolised by the liver. It requires sulphation to become active, but the major metabolite is a glucuronide conjugate.

Excreted mainly in the urine in the form of metabolites. Minoxidil and its metabolites are dialysable, although the pharmacological effect is not reversed.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Start with small doses and titrate according to response. See ‘Other information’.</td>
</tr>
<tr>
<td>10–20</td>
<td>Start with small doses and titrate according to response. See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with small doses and titrate according to response. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

**Other information**
- A study of the pharmacokinetics of minoxidil in patients with varying degrees of renal impairment found that the non-renal clearance was also impaired as renal function worsened. Substantial accumulation of minoxidil might occur in these patients during multiple-dose therapy. Recommended that minoxidil therapy be initiated with smaller doses or a longer dose interval in patients with significant renal impairment.
- Minoxidil is a peripheral vasodilator and should be given in conjunction with a diuretic to control salt and water retention, and a beta-blocker to control reflex tachycardia. Patients on dialysis do not need to be given minoxidil in conjunction with a diuretic.
- Following topical application, between 0.3% and 4.5% of the total applied dose of minoxidil is absorbed from intact scalp.
Mirabegron

**Clinical use**

Potent and selective beta 3-adrenoceptor agonist:
- Urinary frequency, urgency and incontinence

**Dose in normal renal function**

50 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>396.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>71</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>25</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1670 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>50 / Increased</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolised via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis. Renal elimination of mirabegron is primarily through active tubular secretion along with glomerular filtration.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>Dose as in normal renal function. 25 mg with CYP 3A inhibitors.</td>
</tr>
<tr>
<td>15–29</td>
<td>25 mg daily. Avoid with CYP 3A inhibitors.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>25 mg daily. Avoid with CYP 3A inhibitors. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dosing recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=15–29 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

**Other information**

- Not recommended by manufacturer in severe renal impairment due to lack of information.
- Oral bioavailability is 29–35% depending on dose.
- In patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m²), mean $C_{max}$ and AUC values were 92% and 118% higher compared to healthy subjects with normal renal function.
Mircera

Clinical use
Management of anaemia associated with renal impairment in pre-dialysis and dialysis patients

Dose in normal renal function
- ESA-naive patients: 0.6 mcg/kg every 2 weeks or 1.2 mcg/kg every 4 weeks, changing by 25% according to response; once stable change to monthly dosing
- Target haemoglobin usually 10–12 g/dL
- If previously on an ESA: 120–360 mcg monthly depending on previous ESA dose, and adjust according to response

Pharmacokinetics
Molecular weight (daltons) 60 000
% Protein binding No data
% Excreted unchanged in urine Unlikely
Volume of distribution (L/kg) 3–5.4 Litres
Half-life — normal/ESRF (hrs) IV: 134 / Unchanged;
SC: 139 (142 if not on dialysis) / Unchanged

Metabolism
The metabolic fate of both endogenous and recombinant erythropoietin is poorly understood. Current evidence from studies in animals suggests that hepatic metabolism contributes only minimally to elimination of the intact hormone, but desialylated epoetin (i.e. terminal sialic acid groups removed) appears to undergo substantial hepatic clearance via metabolic pathways and/or binding. Desialylation and/or removal of the oligosaccharide side chains of erythropoietin appear to occur principally in the liver; bone marrow also may have a role in catabolism of the hormone. Elimination of desialylated drug by the kidneys, bone marrow, and spleen also may occur; results of animal studies suggest that proximal renal tubular secretion may be involved in renal elimination.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Not dialysed. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Risk of hyperkalaemia with ACE inhibitors and angiotensin-II antagonists.

Administration
Reconstitution —
Route SC, IV
Rate of administration —

Other information
- Pre-treatment checks and appropriate correction/treatment needed for iron, folate and B12 deficiencies, infection, inflammation or aluminium toxicity to produce optimum response to therapy.
- Concomitant iron therapy (200–300 mg elemental oral iron) needed daily. IV iron may be needed for patients with very low serum ferritin (<100 nanograms/mL).
- May increase heparin requirement during HD.
- Reported association of pure red cell aplasia (PRCA) with epoetin therapy – very rare; due to failed production of red blood cell precursors in the bone marrow, resulting in profound anaemia. Possibly due to an immune response to the protein backbone of R-HuEPO. Resulting antibodies render the patient unresponsive to the therapeutic effects of all epoetins and darbepoetin.
Mirtazapine

**Clinical use**
Antidepressant

**Dose in normal renal function**
15–45 mg daily in 1 or 2 divided doses

**Pharmacokinetics**
Molecular weight (daltons) 265.4
% Protein binding 85
% Excreted unchanged in urine 75
Volume of distribution (L/kg) 107 Litres
Half-life — normal/ESRF (hrs) 20–40 / Increased

**Metabolism**
Extensively metabolised in the liver via CYP2D6, CYP1A2, and CYP3A4. The major biotransformation pathways are demethylation and oxidation followed by glucuronide conjugation. The N-desmethyl metabolite is pharmacologically active. Elimination is via urine and faeces (15%).

**Dose in renal impairment GFR (mL/min)**
- 20–40: Dose as in normal renal function.
- 10–20: Start at low dose and monitor closely.
- <10: Start at low dose and monitor closely.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR < 10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR = 10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alcohol: increased sedative effect.
- Antidepressants: possibly increased risk of serotonergic effects with fluoxetine, fluvoxamine or venlafaxine; CNS excitation and hypertension with MAOI and moclobemide — avoid.
- Antimalarials: avoid with artemether and lumefantrine and piperaquine with artenimol.
- Methylthioninium: risk of CNS toxicity — avoid if possible.

**Administration**

**Reconstitution**
-

**Route**
Oral

**Rate of administration**
—
**Clinical use**
- Benign gastric and duodenal ulceration and NSAID associated ulceration
- Prophylaxis of NSAID induced ulceration

**Dose in normal renal function**
- Treatment: 800 mcg daily in 2 or 4 divided doses
- Prophylaxis: 200 mcg 2–4 times daily

**Pharmacokinetics**
- Molecular weight (daltons) 382.5
- % Protein binding <90 (as misoprostol acid)
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 858 Litres
- Half-life — normal/ESRF (hrs) 20–40 minutes / 40–80 minutes (as misoprostol acid)

**Metabolism**
Rapidly metabolised to its active form (misoprostol acid) after oral doses. Misoprostol acid is further metabolised by oxidation in several body organs and is excreted mainly in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

**Other information**
- Plasma concentrations of misoprostol are generally undetectable due to its rapid metabolic conversion to misoprostol acid.
- Dosage adjustment is not usually necessary in patients with varying degrees of renal impairment, even though there is an approximate doubling of half-life, maximum plasma concentration and AUC. If renal patients are unable to tolerate it, the dose can be reduced.
# Mitomycin

## Clinical use
Cytotoxic antibiotic used in a range of neoplastic conditions

## Dose in normal renal function
- **IV**: Some regimens use an initial dose of 10–20 mg/m² others use 4–10 mg or 0.06–0.15 mg/kg given every 1–6 weeks, depending on concurrent therapy and bone marrow recovery
- For instillation into bladder: 20–40 mg

## Pharmacokinetics
- Molecular weight (daltons): 334.3
- % Protein binding: No data
- % Excreted unchanged in urine: 10
- Volume of distribution (L/kg): 0.5
- Half-life — normal/ESRF (hrs): 50 minutes / –

## Metabolism
Mitomycin is a pro-drug, and is activated *in vivo* by metabolism mainly in the liver to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Rate of clearance is inversely proportional to the maximum serum concentration, due to saturation of the degradative pathways. Approximately 10% is excreted unchanged in the urine. Since metabolic pathways are saturated at low doses, the percentage dose excreted in the urine increases with increasing dose.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>75% of normal dose.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unknown dialysability. Dose as in GFR < 10 mL/min.
- **HD**: Unknown dialysability. Dose as in GFR < 10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR < 10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Live vaccines: risk of generalised infections – avoid.

## Administration
**Reconstitution**
With water for injection or sodium chloride 0.9%; 5 mL for the 2 mg vial, at least 10 mL for the 10 mg vial and at least 20 mL for the 20 mg vial.

**Route**
- IV injection, intra-arterial, bladder instillation

**Rate of administration**
- Bolus injection over 3–5 minutes (1 mL/min)
- Infusion over 15–30 minutes

## Other information
- Dose in severe renal impairment is from *Drug Prescribing in Renal Failure, 5th edition* by Aronoff et al.
- A syndrome of thrombotic microangiopathy resembling haemolytic uraemic syndrome has been seen in patients receiving mitomycin, either alone or, more frequently, combined with other agents. Symptoms of haemolysis and renal failure may be accompanied by ATN and cardiovascular problems, pulmonary oedema and neurological symptoms.
- Principal toxicity of mitomycin-C is bone marrow suppression. The nadir is usually around 4 weeks after treatment and toxicity is cumulative, with increasing risk after each course of treatment.
Mitotane

Clinical use
Antineoplastic agent
- Treatment of advanced or inoperable adrenocortical carcinoma

Dose in normal renal function
- 2–3 g daily (up to 6 g daily in severe illness) in 2–3 divided doses adjusted according to plasma mitotane concentration
- Consult relevant local protocol

Pharmacokinetics
Molecular weight (daltons) 320
% Protein binding 6
% Excreted unchanged in urine 0 (10–25% as metabolites)
Volume of distribution (L/kg) Large
Half-life — normal/ESRF (hrs) 18–159 days /

Metabolism
Metabolised in the liver and other tissues and excreted as metabolites in urine and bile. From 10–25% of a dose has been recovered in the urine as a water-soluble metabolite and 1–17% in the faeces as metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Use with caution and monitor levels.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution and monitor levels.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid. See 'Other information'.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: possibly reduced anticoagulant effect of coumarins.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Diuretics: avoid with spironolactone.

Administration
Reconstitution

Route
Oral

Rate of administration

Other information
- Aim for plasma mitotane levels of 14–20 mg/L.
- There is no experience of mitotane in patients with renal failure so manufacturer is unable to advise on dosing.
- No reduction for renal failure in US data sheet.
**Mitoxantrone**

**Clinical use**

Antineoplastic agent:
- Metastatic breast cancer
- Non-Hodgkin’s lymphoma
- Adult acute non-lymphocytic leukaemia

**Dose in normal renal function**

- Metastatic breast cancer, non-Hodgkin’s lymphoma and hepatoma: 14 mg/m² every 21 days (12 mg/m² or less if inadequate bone marrow reserves)
- Adult acute non-lymphocytic leukaemia: 12 mg/m² for 5 consecutive days
- For untreated patients in combination with cytarabine: 10–12 mg/m² daily for 3 days
- Or according to local protocol

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>517.4 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>78</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>7</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1000 L/m²</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–18 days / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Extensive metabolism in the liver. Excretion is predominantly via the bile and faeces. 5–10% of a dose is excreted in the urine and 13–25% in the faeces, within 5 days.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Other antineoplastic agents: enhanced myelosuppression – when used in combination reduce mitoxantrone dose by 2–4 mg/m²
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Cardiotoxic drugs: increased risk of cardiac toxicity.
- Ciclosporin: excretion of mitoxantrone reduced.
- Live vaccines: risk of generalised infections – avoid.

**Administration**

**Reconstitution**

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Route</td>
</tr>
<tr>
<td>IV infusion</td>
</tr>
</tbody>
</table>

**Rate of administration**

At least 3 minutes

**Comments**

Dilute to at least 50 mL in sodium chloride 0.9%, glucose 5% or sodium chloride 0.18% and glucose 4%.

**Other information**

- Has been administered intraperitoneally at a dose of 28–38 mg/m² every 3–4 weeks although some people advise a maximum dose of only 30 mg/m² per month with a dwell time of 1–4 hours. (Alberts DS, Surwit EA, Peng YM, et al. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. *Cancer Res*. 1988; 48(20): 5874–7.)
Mivacurium

Clinical use
Non-depolarising muscle relaxant of short duration

Dose in normal renal function
- IV injection: 70–250 micrograms/kg; maintenance 100 micrograms/kg every 15 minutes
- IV infusion: maintenance of block 8–10 micrograms/kg/minute, adjusted to maintenance dose of 6–7 micrograms/kg/minute according to response

Pharmacokinetics
Molecular weight (daltons) 1029 (1100.2 as chloride)
% Protein binding No data
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 0.1–0.3
Half-life — normal/ESRF (hrs) 2–10 minutes / –

Metabolism
Mivacurium is a mixture of 3 stereoisomers, 2 of which (cis-trans and trans-trans) are considered to account for most of the neuromuscular blocking effect. All 3 isomers are inactivated by plasma cholinesterase. Renal and hepatic mechanisms are involved in their elimination with excretion in urine and bile.

Dose in renal impairment GFR (mL/min)
- 20–50 Initially 50% and adjust to response. Slower infusion rate may be required.
- 10–20 Initially 50% and adjust to response. Slower infusion rate may be required.
- <10 Initially 50% and adjust to response. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Adjust infusion to response.
- HD Unknown dialysability. Adjust infusion to response.
- HDF/High flux Unknown dialysability. Adjust infusion to response.
- CAV/VVHD Unknown dialysability. Adjust infusion to response.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced muscle relaxant effect.
- Anti-arrhythmics: procainamide enhances muscle relaxant effect.
- Antibacterials: effect enhanced by aminoglycosides, clindamycin, polymyxins and piperacillin.
- Antiepileptics: muscle relaxant effects antagonised by carbamazepine; effects reduced by long-term use of fosphenytoin and phenytoin but might be increased by acute use.
- Botulinum toxin: neuromuscular blockade enhanced, (risk of toxicity).

Administration
Reconstitution
—
Route
IV bolus, IV infusion
Rate of administration
IV bolus: doses of up to 0.15 mg/kg may be administered over 5–15 seconds. Higher doses should be administered over 30 seconds.
Comments
Compatible with sodium chloride 0.9%; glucose 5%; dilute to 500 micrograms/mL.
Compatible with fentanyl, alfentanil, droperidol and midazolam.

Other information
- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Spontaneous recovery is complete in approximately 15 minutes and is independent of dose administered.
- In patients with CKD 5 the clinically effective duration of block produced by 0.15 mg/kg is approximately 1.5 times longer than in patients with normal renal function; hence, dosage should be adjusted according to individual clinical response.
- Results from a study comparing 20 anephric patients with 20 healthy patients highlight the need for reduced dosages of Mivacron in patients with renal failure: patients with renal failure had a slightly shorter time to maximum depression of T1/T0, a slower recovery of T1/T0 to 5% (15.3 vs 9.8 min), required a slower infusion rate (6.5 vs 10.4 micrograms/kg/min) and experienced slower spontaneous recovery (12.2 vs 7.7 min). The drug company has no specific guidelines as to the extent of dose reduction required.
Mizolastine

Clinical use
Antihistamine:
• Symptomatic relief of allergy, e.g. hayfever, urticaria

Dose in normal renal function
10 mg daily

Pharmacokinetics
Molecular weight (daltons) 432.5
% Protein binding 98.4
% Excreted unchanged in urine <0.5
Volume of distribution (L/kg) 1.4
Half-life — normal/ESRF (hrs) 13 / –

Metabolism
Mainly metabolised by glucuronidation although other metabolic pathways are involved, including metabolism by the cytochrome P450 isoenzyme CYP3A4, with the formation of inactive hydroxylated metabolites.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Anti-arrhythmics: increased risk of ventricular arrhythmias – avoid with amiodarone, disopyramide, flecainide, mexiletine, procainamide and propafenone.
• Antibacterials: metabolism possibly inhibited by macrolides – avoid; increased risk of ventricular arrhythmias with moxifloxacin – avoid.
• Antidepressants: risk of ventricular arrhythmias with citalopram and escitalopram – avoid.
• Antifungals: metabolism inhibited by itraconazole and ketoconazole and possibly imidazoles – avoid.
• Antimalarials: avoid with piperaquine with arteminol.
• Antivirals: concentration possibly increased by ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
• Beta-blockers: increased risk of ventricular arrhythmias with sotalol – avoid.
• Ciclosporin: use with caution due to inhibition of ciclosporin metabolism.
• Cytotoxics: possible increased risk of ventricular arrhythmias with vandetanib.
• Avoid concomitant treatment with any drug that could prolong QT interval.
• Caution with drugs that inhibit cytochrome P450 enzymes (may elevate mizolastine levels).

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Contraindicated in patients with electrolyte imbalances, particularly hypokalaemia.
Moclobemide

**Clinical use**
Reversible MAOI:
- Depression
- Social phobia

**Dose in normal renal function**
- Depression: 150–600 mg daily in divided doses
- Social phobia: 300 mg twice daily

**Pharmacokinetics**
- Molecular weight (daltons) 268.7
- % Protein binding 50
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 1
- Half-life — normal/ESRF (hrs) 2–4 / Unchanged

**Metabolism**
Moclobemide is extensively metabolised in the liver, partly by the cytochrome P450 isoenzymes CYP2C19 and CYP2D6.
Metabolites of moclobemide and a small amount of unchanged drug are excreted in the urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Likely dialysability. Dose as in normal renal function.
- HD: Likely dialysability. Dose as in normal renal function.
- HDF/High flux: Likely dialysability. Dose as in normal renal function.
- CAV/VVHD: Likely dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Analgesics: possible CNS excitation or depression with dextromethorphan or pethidine – avoid; possible CNS excitation or depression with opioid analgesics.
- Antidepressants: avoid concomitant use; possible increased serotonergic effects with duloxetine.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
- Bupropion: avoid concomitant use.
- Clopidogrel: antiplatelet effect possibly reduced.
- Dopaminergics: use with caution with entacapone; increased side effects with levodopa; avoid with selegiline.
- 5HT₃ agonists: increased CNS toxicity with rizatriptan and sumatriptan – avoid; increased CNS toxicity with zolmitriptan – reduce zolmitriptan dose.
- Opicapone: avoid concomitant use.
- Sympathomimetics: risk of hypertensive crisis.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Comments**
Take after food.

**Other information**
- Hyponatraemia has been reported (especially in elderly patients) due to inappropriate secretion of antidiuretic hormone.
Modafinil

**Clinical use**
Excessive daytime drowsiness associated with narcolepsy and obstructive sleep apnoea

**Dose in normal renal function**
200–400 mg daily in 1 or 2 divided doses

**Pharmacokinetics**
- Molecular weight (daltons) 273.4
- % Protein binding 60
- % Excreted unchanged in urine <10
- Volume of distribution (L/kg) 0.9
- Half-life — normal/ESRF (hrs) 15 / –

**Metabolism**
Metabolised in the liver, partly by the cytochrome P450 isoenzymes CYP3A4 and CYP3A5; two major metabolites have been identified: acid modafinil and modafinil sulfone, both of which are inactive. Excretion is mainly through the kidneys.

**Dose in renal impairment GFR (mL/min)**
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start at 50% normal dose and increase according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Ciclosporin: reduced ciclosporin concentration.
- Cytotoxics: concentration of bosutinib possibly reduced – avoid.
- Guanfacine: concentration of guanfacine possibly reduced – avoid.
- Oestrogens: metabolism accelerated (reduced contraceptive effect).
- Ulipristal: possibly reduces contraceptive effect of ulipristal – avoid.

**Administration**
Reconstitution
Route
Oral
Rate of administration

**Other information**
- Recommended that modafinil not be used in patients with left ventricular hypertrophy or ischaemic ECG changes.
- Modafinil is not recommended in severe renal impairment by the manufacturer due to lack of data. In single dose studies with 200 mg modafinil, at a GFR<20 mL/min there was no difference in the pharmacokinetics although there was a 9-fold increase in exposure to the inactive metabolite.
Moexipril hydrochloride

Clinical use
Angiotensin-converting enzyme inhibitor:
• Hypertension

Dose in normal renal function
3.75–30 mg daily

Pharmacokinetics
Molecular weight (daltons) 535
% Protein binding 50
% Excreted unchanged in urine 1
Volume of distribution (L/kg) 183 Litres
Half-life — normal/ESRF (hrs) 12 (of active metabolite) / Increased

Metabolism
Moexipril is a prodrug that is converted to an active metabolite, moexiprilat, in the gastrointestinal mucosa and liver.
Moexipril is excreted mainly in the urine as moexiprilat, unchanged drug, and other metabolites; some moexiprilat may also be excreted in the faeces.

Dose in renal impairment GFR (mL/min)
20–40 Start with low dose and adjust according to response.
10–20 Start with low dose and adjust according to response.
<10 Start with low dose and adjust according to response.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Unknown dialysability. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Anaesthetics: enhanced hypotensive effect.
• Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
• Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARB’S and aliskiren.
• Bee venom extract: possible severe anaphylactoid reactions when used together.
• Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
• Cytotoxics: increased risk of angioedema with everolimus.
• Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
• ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
• Gold: flushing and hypotension with sodium aurothiomalate.
• Lithium: reduced excretion (possibility of enhanced lithium toxicity).
• Potassium salts: increased risk of hyperkalaemia.
• Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
• Renal failure has been reported in association with ACE inhibitors, mainly in patients with severe congestive heart failure, renal artery stenosis, or post renal transplant.
• High incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor. This combination should therefore be avoided.
• Hyperkalaemia and other side effects are more common in patients with impaired renal function.
Montelukast

Clinical use
Leukotriene receptor antagonist:
• Prophylaxis of asthma
• Seasonal allergic rhinitis

Dose in normal renal function
10 mg at night

Pharmacokinetics
Molecular weight (daltons) 608.2 (as sodium salt)
% Protein binding >99
% Excreted unchanged in urine <0.2
Volume of distribution (L/kg) 8–11 Litres
Half-life — normal/ESRF (hrs) 2.7–5.5 / –

Metabolism
Extensively metabolised in the liver by cytochrome P450 isoenzymes CYP3A4, CYP2A6, and CYP2C9. Excreted principally in the faeces via the bile. Metabolites have minimal therapeutic activity.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—
Morphine

**Clinical use**

Opiate analgesic

**Dose in normal renal function**

- 5–20 mg every 4 hours (higher in very severe pain or terminal illness)
- PR: 15–30 mg every 4 hours
- SR/XL: according to preparation every 12 or 24 hours

**Pharmacokinetics**

Molecular weight (daltons) 285.3 (758.8 as sulphate); (774.8 as tartrate)

% Protein binding 20–35

% Excreted unchanged in urine 10

Volume of distribution (L/kg) 3–5

Half-life — normal/ESRF (hrs) 2–3 / Unchanged

**Metabolism**

Extensive first-pass metabolism in the liver and gut. The majority of a dose of morphine is conjugated with glucuronic acid in the liver and gut to produce morphine-3-glucuronide and morphine-6-glucuronide (active). Other active metabolites include normorphine, codeine, and morphine ethereal sulphate. After an oral dose, about 60% is excreted in the urine in 24 hours, with about 3% excreted as free morphine in 48 hours. After a parental dose, about 90% is excreted in 24 hours, with about 10% as free morphine, 65–70% as conjugated morphine, 1% as normorphine and 3% as normorphine glucuronide. Up to 10% of a dose may be excreted in the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>75% of normal dose</td>
</tr>
<tr>
<td>10–20</td>
<td>Use small doses (50% of dose), e.g. 2.5–5 mg and extended dosing intervals. Titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use small doses (25% of dose), e.g. 1.25–2.5 mg and extended dosing intervals. Titrate according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed – active metabolite removed significantly. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed – active metabolite removed significantly. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Analgesics: possible opioid withdrawal with buprenorphine and pentazocine.
- Antibacterials: metabolism increased by rifampicin.
- Antidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use, and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- Antiepileptics: increases bioavailability of gabapentin.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Antivirals: concentration possibly reduced by ritonavir.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

**Administration**

**Reconstitution**

- **Route**
  Oral, SC, IM, IV, PR

**Rate of administration**

2 mg/min (titrate according to response).

**Other information**

- Doses in renal impairment are from *Drug Prescribing in Renal Failure, 5th* edition by Aronoff et al.
• Extreme caution with all opiates in patients with impaired renal function.
• Potential accumulation of morphine-6-glucuronide (a renally excreted active metabolite, more potent than morphine) and morphine-3-glucuronide. Half-life of morphine-6-glucuronide is increased from 3–5 hours in normal renal function to about 50 hours in ERF.
• ENSURE NALOXONE READILY AVAILABLE.
• Some units avoid slow release oral preparations as any side effects may be prolonged.
Movicol (active ingredient is the osmotic laxative polyethylene glycol)

### Clinical use
Laxative

### Dose in normal renal function
- 1–3 sachets daily in divided doses in 125 mL of water
- Maintenance: 1–2 sachets daily
- Faecal impaction: 4 sachets on 1st day increasing up to 8 sachets daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>3350</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Not absorbed</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Not absorbed</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Not absorbed</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Not absorbed</td>
</tr>
</tbody>
</table>

### Metabolism
Not absorbed systemically.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- None known

### Administration

#### Reconstitution
—

#### Route
Oral

#### Rate of administration
—

### Other information

- Movicol contains polyethylene glycol, sodium chloride, sodium bicarbonate and potassium chloride.
- Electrolyte content of a sachet when made up with 125 mL water is:
  - Sodium 65 mmol/L
  - Chloride 53 mmol/L
  - Potassium 5.4 mmol/L
  - Bicarbonate 17 mmol/L
- Sachets are formulated to ensure that there is virtually no net gain or loss of sodium, potassium or water.
Moxifloxacan

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
400 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 437.9 (as hydrochloride)
- % Protein binding 30–50
- % Excreted unchanged in urine 19
- Volume of distribution (L/kg) 2
- Half-life — normal/ESRF (hrs) 12 / Unchanged

**Metabolism**
Metabolised mainly via sulphate and glucuronide conjugation, and is excreted in the urine and the faeces as unchanged drug and as metabolites, the sulphate conjugate mainly in the faeces and the glucuronide exclusively in the urine.

**Dose in renal impairment GFR (mL/min)**
<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
- Antibacterials: increased risk of ventricular arrhythmias with parenteral erythromycin – avoid; increased risk of ventricular arrhythmias with delamanid and telithromycin.
- Anticoagulants: anticoagulant effect enhanced.
- Antidepressants: increased risk of ventricular arrhythmias with tricyclics, citalopram, escitalopram and venlafaxine – avoid.
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antimalarials: increased risk of ventricular arrhythmias with chloroquine, hydroxychloroquine, mefloquine or quinine – avoid; avoid with artemether with lumefantrine and piperaquine with arteminol.
- Antipsychotics: increased risk of ventricular arrhythmias with benperidol, droperidol, haloperidol, phenothiazines, pimozide or zuclopenthixol – avoid.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir – avoid.
- Atomoxetine: increased risk of ventricular arrhythmias – avoid.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol – avoid.
- Ciclosporin: some reports of increased nephrotoxicity.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide, bosutinib, ceritinib, panobinostat and vandetanib, avoid with panobinostat and vandetanib.
- Pentamidine: increased risk of ventricular arrhythmias – avoid.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Comments**
Do not take milk, iron preparations, indigestion remedies or phosphate binders at the same time as moxifloxacin.

**Other information**
Oral bioavailability is 90%.
Moxisylyte (thymoxamine)

**Clinical use**
Primary Raynaud’s syndrome

**Dose in normal renal function**
40–80 mg 4 times daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>315.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Low</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–2 /</td>
</tr>
</tbody>
</table>

**Metabolism**
Rapidly converted to desacetylmoxisylyte (metabolite I) and desmethyldesacetylmoxisylyte (metabolite II) which are pharmacologically active. These are then further metabolised to the sulphate and glucuronide conjugates of metabolites I and II. Excretion is almost exclusively via the kidneys.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alpha-blockers: possibly severe postural hypotension when given in combination.
- Beta-blockers: possibly severe postural hypotension when given in combination.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Other information**
- Theoretically may decrease insulin requirements in diabetics.

**Reference:**
# Moxonidine

## Clinical use
Antihypertensive agent (centrally acting agonist at I₁ receptor, imidazoline and alpha₂ adrenoceptors)

## Dose in normal renal function
200–600 mcg daily
(Doses >400 mcg should be in 2 divided doses)

## Pharmacokinetics
- Molecular weight (daltons): 241.7
- % Protein binding: 7
- % Excreted unchanged in urine: 50–75
- Volume of distribution (L/kg): 1.8
- Half-life — normal/ESRF (hrs): 2–3 / 6.9 +/- 3.7

## Metabolism
10–20% metabolised, predominantly to 4,5-dehydromoxonidine and to an aminomethanamidine derivative both of which are much less active than moxonidine.

Moxonidine and its metabolites are almost entirely eliminated via the kidney. More than 90% of the dose is eliminated in the first 24 hours via the kidney, while approximately 1% is eliminated in the faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- None known

## Administration
### Reconstitution
—

### Route
Oral

### Rate of administration
—

## Other information
- In moderately impaired renal function (GFR=30–60 mL/min) AUC is increased by 85% and clearance decreased by 52%; therefore, monitor patient closely.
- Anecdotal evidence suggests that moxonidine can be used safely at standard doses in patients with all degrees of renal impairment.
Muromonab CD3 (OKT3) (unlicensed)

**Clinical use**
- Steroid resistant acute transplant rejection
- Prophylaxis of rejection in sensitised patients

**Dose in normal renal function**
5 mg daily for 10–14 days (10 days most common)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>50 000 (Heavy chain) + 25 000 (Light chain)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.093</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>18–36 / –</td>
</tr>
</tbody>
</table>

**Metabolism**
Most likely removed by opsonisation via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Ciclosporin: increases ciclosporin plasma levels.
- Indometacin: may increase risk of encephalopathy.
- Volatile anaesthetics / drugs that decrease cardiac contractility: increase risk of developing cardiovascular problems.

**Administration**

**Reconstitution**

**Route**
IV

**Rate of administration**
FAST over less than 1 minute

**Comments**
NB Doctor administration recommended

**Other information**

*** ENSURE PATIENT IS NOT FLUID OVERLOADED PRIOR TO ADMINISTRATION ***

- Possible future scope for dose titration according to CD3 or absolute T-cell count.
- Reduce or stop other immunosuppressant therapy during treatment, and resume 3 days prior to cessation of OKT3.
- IV methylprednisolone sodium succinate (8 mg/kg given 1–4 hours prior to the first dose of OKT3) is strongly recommended to decrease the incidence and severity of reactions to the first dose. Paracetamol and antihistamines given concomitantly with OKT3 may also help to reduce some early reactions.
- Side effects pronounced: WARN PATIENT.

- Reduce or stop other immunosuppressant therapy during treatment, and resume 3 days prior to cessation of OKT3.
Mycophenolate

Clinical use
- Mycophenolate sodium: for renal transplantation
- Mycophenolate mofetil: prophylaxis against acute transplant rejection; autoimmune renal diseases

Dose in normal renal function
- Mycophenolate sodium: 720 mg twice daily
- Mycophenolate mofetil: 1–1.5 g twice a day

Pharmacokinetics
Molecular weight (daltons) 320.3 (mycophenolic acid) 433.5 (as mofetil) 342.3 (as sodium)
% Protein binding 97
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 3.6–4
Half-life — normal/ESRF (hrs) 12–17.9

Metabolism
Mycophenolate undergoes presystemic metabolism in the liver to active mycophenolic acid (MPA). MPA undergoes enterohepatic recirculation and secondary increases in plasma MPA concentrations are seen; these have been reported at between 6–12 hours after a dose of mycophenolate mofetil, and at between 6–8 hours after a dose of mycophenolate sodium. MPA is metabolised by glucuronidation to the inactive mycophenolic acid glucuronide.
The majority of a dose of mycophenolate is excreted in the urine as this glucuronide, with negligible amounts of MPA; about 6% of a dose is recovered in faeces.

Dose in renal impairment GFR (mL/min)
25–50 Dose as in normal renal function.
10–25 Mycophenolate mofetil: 1 g twice a day, starting immediately post transplant.
Mycophenolate sodium: Maximum 1440 mg daily, starting immediately post transplant.
<10 Mycophenolate mofetil: 1 g twice a day, starting immediately post transplant.
Mycophenolate sodium: Maximum 1440 mg daily, starting immediately post transplant.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Antivirals: higher concentrations of both mycophenolate and aciclovir or ganciclovir when the two are prescribed concomitantly.
- Antacids: absorption of mycophenolate decreased in presence of magnesium and aluminium salts.
- Antibacterials: bioavailability of mycophenolate possibly reduced by metronidazole and norfloxacin; concentration of active metabolite reduced by rifampicin.
- Colestyramine: 40% reduction in oral bioavailability of mycophenolate.
- Ciclosporin: some studies show that ciclosporin decreases plasma MPA AUC levels; other studies show increases – no dose change required.
- Iron preparations: may significantly reduce absorption of mycophenolate.
- Sevelamer: reduced levels of mycophenolate.
- Tacrolimus: increases MPA concentrations– no dose change required but monitor closely.
- See ‘Other information’.

Administration
Reconstitution
Add 14 mL of glucose 5% per 500 mg vial
Route Oral, IV
Rate of administration Over 2 hours
Comments Dilute reconstituted solution further with glucose 5% to achieve a concentration of 6 mg/mL.
Other information

- If neutrophil count drops below $1.3 \times 10^3/\mu L$, consider suspending MMF therapy.
- No dosage reduction is required in the event of a transplant rejection episode.
- Mycophenolate sodium 720 mg is approximately equivalent to 1 g mycophenolate mofetil.
- In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) of approximately 50% has been reported after starting oral co-amoxiclav. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.
Nabilone

Clinical use

Synthetic cannabinoid:
- Treatment of nausea and vomiting due to chemotherapy

Dose in normal renal function

- 1–2 mg twice daily
- Maximum dose: 6 mg daily in 3 divided doses

Pharmacokinetics

Molecular weight (daltons) 372.5
% Protein binding Highly
% Excreted unchanged in urine 25
Volume of distribution (L/kg) 12.5
Half-life — normal/ESRF (hrs) 2 (metabolites: 35 hours)

Metabolism

Nabilone is hepatically metabolised. The major pathway probably involves direct oxidation of nabilone to produce hydroxylic and carboxylic analogues. One or more of the metabolites may be active. These compounds are thought to account for the remaining plasma radioactivity when carbinol metabolites have been extracted. Excreted mainly by the biliary route, >60% of the total is eliminated in the faeces and about 25% in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD Unknown dialysability. Dose as in normal renal function.
- HD Unknown dialysability. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Use with caution with other psychoactive medication or CNS depressants.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—
# Nabumetone

## Clinical use

NSAID and analgesic

## Dose in normal renal function

1 g at night; in severe conditions 0.5–1 g in the morning as well; elderly 0.5–1 g daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>228.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.11</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>24 / 39†</td>
</tr>
</tbody>
</table>

## Metabolism

Nabumetone is rapidly metabolised in the liver to the main active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA). The metabolite is a potent inhibitor of prostaglandin synthesis. Excretion of the metabolite is predominantly in the urine.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function, but avoid if possible</td>
</tr>
<tr>
<td>10–20</td>
<td>0.5–1 g daily, but avoid if possible</td>
</tr>
<tr>
<td>&lt;10</td>
<td>0.5–1 g daily, but only use if on dialysis. See ‘Other information.’</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparring diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

## Administration

### Reconstitution

- **Route**
  - Oral

### Rate of administration

- **—**

## Other information

- The SPC recommends a dose reduction if CRCL<30 mL/min; however, an article by Brier et al. concluded that dosage adjustments may not be necessary with decreased renal function. The authors found an increase in the elimination half-life of 6-MNA, but stated that the increased half-life in patients with renal failure is offset by changes in the apparent volume of distribution that prevent the accumulation of 6-MNA. (Brier ME, Sloan RS, Aronoff GR. Population pharmacokinetics of the active metabolite of nabumetone in renal

- **Drug Prescribing in Renal Failure, 5th edition** by Aronoff et al. recommends 50–100% of dose.
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if increased, discontinue NSAID therapy.

- Use normal doses in patients with CKD 5 on dialysis if they do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.

Reference:

Nadolol

**Clinical use**

Beta-adrenoceptor blocker:
- Hypertension
- Angina
- Arrhythmias
- Migraine
- Thyrotoxicosis

**Dose in normal renal function**

- Hypertension: 80–240 mg per day
- Angina, arrhythmias, migraine: 40–160 mg daily
- Thyrotoxicosis: 80–160 mg daily

**Pharmacokinetics**

- Molecular weight (daltons): 309.4
- % Protein binding: 30
- % Excreted unchanged in urine: 73
- Volume of distribution (L/kg): 1.9
- Half-life — normal/ESRF (hrs): 12–24 / 45

**Metabolism**

Unlike most other beta-blockers, nadolol is not metabolised and is excreted unchanged mainly by the kidneys.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Start with low dose and increase according to response.
- 10–20: Start with low dose and increase according to response.
- <10: Start with low dose and increase according to response.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalariais: increased risk of bradycardia with mefloquine.
- Antipsychotics enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

**Administration**

**Reconstitution**

- Route: Oral

**Rate of administration**

- Other information

- SPC guidelines for increasing dosing interval for patients with renal impairment may be impractical with respect to patient compliance.
- UK SPC provides no guidance in renal impairment.
- US data sheet advises:
  - GFR=31–50: every 24–36 hours.
  - GFR<10: 40–60 hours.
Naftidrofuryl oxalate

Clinical use
Vasodilator:
• Peripheral and cerebral vascular disease

Dose in normal renal function
• Peripheral vascular disease: 100–200 mg 3 times daily
• Cerebral vascular disease: 100 mg 3 times daily

Pharmacokinetics
Molecular weight (daltons) 473.6
% Protein binding 60–65
% Excreted unchanged in urine <1 (mainly as metabolites)
Volume of distribution (L/kg) 61.5 Litres
Half-life — normal/ESRF (hrs) 1–2 / 3.5

Metabolism
Metabolised by plasma pseudo-cholinesterases to 3 active metabolites.1

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function. Start with low doses.
<10 Dose as in normal renal function. Start with low doses.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• IV preparation was withdrawn due to increased risk of cardiac and neurological toxicity. It has also been associated with acute renal failure secondary to oxalate crystallisation in the renal tubules.

Reference:
Nalidixic acid

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
600–900 mg every 6 hours

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>232.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>93–97</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>11–33 (80–90% as inactive metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.47–0.55</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–8 / 21</td>
</tr>
</tbody>
</table>

**Metabolism**
Nalidixic acid is partially metabolised in the liver to hydroxynalidixic acid, which has antibacterial activity similar to that of nalidixic acid and accounts for about 30% of active drug in the blood. Both nalidixic acid and hydroxynalidixic acid are rapidly metabolised to inactive glucuronide and dicarboxylic acid derivatives; the major inactive metabolite 7-carboxynalidixic acid is usually only detected in urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy Type</th>
<th>Dose Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: possibly increased risk of convulsions.
- Analgesics: increased risk of convulsions with NSAIDs.
- Antibacterials: possibly antagonised by nitrofurantoin.
- Anticoagulants: anticoagulant effect of coumarins enhanced.
- Antimalarials: manufacturer of artemether with lumefantrine advises avoid.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxics: increases risk of melphalan toxicity.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Avoid in severe renal impairment because the concentration in the urine is inadequate, and risk of monoglucuronide metabolite toxicity.
Nalmefene hydrochloride dihydrate

Clinical use

Opioid system modulator:
• Reduction of alcohol consumption

Dose in normal renal function

ONE tablet daily if at risk of drinking

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>375.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;3</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3200 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10 / 26</td>
</tr>
</tbody>
</table>

Metabolism

It is metabolised in the liver, mainly to the inactive glucuronide, and is excreted in the urine (54%). Some of the dose is excreted in the faeces and it may undergo enterohepatic recycling.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Avoid.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Likely to be dialysed. Avoid.</td>
</tr>
<tr>
<td>HD</td>
<td>Likely to be dialysed. Avoid.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Likely to be dialysed. Avoid.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Likely to be dialysed. Avoid.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Analgesics: avoid with opioid analgesics.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

• Contraindicated by manufacturer if GFR<30 mL/min as no studies have been done.
• Oral bioavailability is 41%.
Naloxone hydrochloride

Clinical use
Reversal of opioid induced respiratory depression

Dose in normal renal function
See 'Other information'.

Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>363.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>54</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–1.5 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism
Naloxone hydrochloride is rapidly metabolised in the liver, mainly by conjugation with glucuronic acid to naloxone-3-glucuronide, which is excreted in the urine.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
Route
- IV, IM, SC. IV more rapid response
Rate of administration
- Rapid if bolus injection

Other information
- IV postoperative use: Give 1.5–3 micrograms/kg; if response inadequate, increments of 100 micrograms every 2 minutes. Further dose by IM injection if needed.
- OR Dilute 400 micrograms in 100 mL sodium chloride 0.9% or glucose 5% (4 micrograms/mL) and give by continuous infusion. Titrate dose according to response.
- Opioid overdosage: initial dose of 400–2000 micrograms IV; may be repeated at 2–3 minute intervals if the desired degree of counteraction and improvement in respiratory function is not obtained. (If no response after 10 mg then question the diagnosis of opioid induced toxicity.) OR give as an infusion: 4 mg in 20 mL (200 mcg/mL solution) (unlicensed).
Naltrexone hydrochloride

### Clinical use

Opioid antagonist:
- Adjunctive prophylactic treatment in patient’s previously opioid dependant
- Treatment of alcohol dependence

### Dose in normal renal function

- Opioid dependence: Initially 25 mg daily then 50 mg once daily
- Alcohol dependence: 50 mg once daily
- There is an option for a 3 times a week regimen if compliance may be an issue

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>377.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>21</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1350 Litres (IV)</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4 (13 for active metabolite)</td>
</tr>
</tbody>
</table>

### Metabolism

Naltrexone is well absorbed from the gastrointestinal tract but is subject to considerable first-pass metabolism and may undergo enterohepatic recycling. It is extensively metabolised in the liver and the major metabolite, 6-β-naltrexol, may also possess weak opioid antagonist activity.

It is excreted mainly in the urine, <5% is excreted in the faeces.

The renal clearance for naltrexone ranges from 30–127 mL/min and suggests that renal elimination is primarily by glomerular filtration.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Likely dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Opioids: Avoid concomitant use.

### Administration

**Reconstitution**
- **Route**
  - Oral

**Rate of administration**
- **Other information**
  - Contraindicated in UK SPC in severe renal impairment due to lack of studies. Use with caution advised in New Zealand and US data sheets as naltrexone and its metabolites are renally excreted.
  - A naloxone test must first be done to ensure patients do not have any opioids in their system.
  - Oral bioavailability varies from 5–40%.
Naproxen

**Clinical use**

NSAID and analgesic

**Dose in normal renal function**

- Rheumatic disease: 0.5–1 g in 1–2 divided doses
- Musculoskeletal disorders and dysmenorrhoea: 500 mg initially then 250 mg every 6–8 hours; maximum 1.25 g daily
- Gout: 750 mg initially then 250 mg every 8 hours

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>230.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.16</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12–15 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Naproxen is extensively metabolised in the liver to 6-O-desmethyl naproxen. Both naproxen and 6-O-desmethyl naproxen are further metabolised to their respective acylglucuronide conjugated metabolites. About 95% of a dose is excreted in urine as naproxen and 6-O-desmethylnaproxen and their conjugates. Less than 5% of a dose appears in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but only use if on dialysis. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Slightly dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Slightly dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparring diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Probenecid: excretion reduced by probenecid.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

-
Other information

- Associated with an intermediate risk of side effects.
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy. Use normal doses in patients with CKD 5 on dialysis and who do not pass any urine.
- Use with caution in renal transplant recipients (can reduce intrarenal autocoid synthesis).
Naratriptan

Clinical use
5HT\textsubscript{1} receptor agonist:
- Acute treatment of migraine

Dose in normal renal function
2.5 mg. Dose may be repeated after 4 hours; maximum 5 mg / 24 hours

Pharmacokinetics
Molecular weight (daltons) 371.9 (as hydrochloride)
% Protein binding 29
% Excreted unchanged in urine 50
Volume of distribution (L/kg) 170 Litres
Half-life — normal/ESRF (hrs) 6 / 11

Metabolism
Naratriptan undergoes some hepatic metabolism via a wide range of cytochrome P450 isoenzymes to form inactive metabolites.
Naratriptan is excreted by glomerular filtration and active secretion into the renal tubules. It is mainly excreted in the urine with 50% of a dose being recovered as unchanged drug and 30% as inactive metabolites.

Dose in renal impairment GFR (mL/min)
20–50 Maximum 2.5 mg daily.
15–20 Maximum 2.5 mg daily.
<15 Use with caution – maximum 2.5 mg daily.

Dose in patients undergoing renal replacement therapies
APD/CAPD Likely dialysability. Dose as for GFR<15 mL/min.
HD Likely dialysability. Dose as for GFR<15 mL/min.
HDF/High flux Likely dialysability. Dose as for GFR<15 mL/min.
CAV/VVHD Unknown dialysability. Dose as for GFR=15–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: increased CNS toxicity with citalopram – avoid; possibly increased serotonergic effects with duloxetine, SSRIs and venlafaxine; increased serotonergic effects with St John’s wort – avoid.
- Dapoxetine: possible increased risk of serotonergic effects – avoid for 2 weeks after stopping 5HT\textsubscript{1} agonists.
- Ergot alkaloids: increased risk of vasospasm – avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Do not take second dose at 4 hours during an attack if the first dose was ineffectual.
- Contraindicated by manufacturer if GFR<15 mL/min due to reduced clearance therefore use with caution.
- Studies in patients with impaired renal function (GFR=18–115 mL/min) showed an 80% increase in half-life and a 50% decrease in clearance compared with matched individuals with normal renal function.
# Natalizumab

## Clinical use
Monoclonal antibody:
- Treatment of relapsing-remitting multiple sclerosis

## Dose in normal renal function
300 mg every 4 weeks

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>149 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3.8–7.6 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7–15 days</td>
</tr>
</tbody>
</table>

## Metabolism
Most likely removed by opsonisation via the reticuloendothelial system when bound to leukocytes.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Avoid concomitant administration with beta-interferons or glatiramer acetate.
- Live vaccines: risk of generalised infections – avoid.

## Administration

### Reconstitution
- **Route**: IV infusion

### Rate of administration
- **60 minutes (2 mL/min)**

### Comments
Dilute in 100 ml sodium chloride 0.9%. Use within 8 hours of preparation.

## Other information
- No studies have been conducted in renal impairment but the mechanism for elimination and pharmacokinetics suggest that dose adjustment would not be necessary in patients with renal impairment.
- The effect of plasma exchange on natalizumab clearance and pharmacodynamics was evaluated in a study of 12 MS patients. Estimates of the total natalizumab removal after 3 plasma exchanges (over a 5–8 day interval) was approximately 70–80%. The impact of plasma exchange on the restitution of lymphocyte migration and ultimately its clinical usefulness is unknown.
## Nateglinide

### Clinical use

Treatment of type 2 diabetes in combination with metformin

### Dose in normal renal function

60–180 mg 3 times daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>317.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97–99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>6–16</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.17–0.2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.5 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Nateglinide is mainly metabolised in the liver by cytochrome P450 isoenzyme CYP2C9, and to a lesser extent by CYP3A4. The major metabolites are less potent than nateglinide. The parent drug and metabolites are mainly excreted in the urine but about 10% is eliminated in the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>15–30</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;15</td>
<td>Start at a low dose and increase according to response.</td>
<td></td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin.
- Antifungals: hypoglycaemic effect possibly enhanced by fluconazole.
- Lipid-lowering agents: hypoglycaemic effect possibly enhanced by gemfibrozil.

### Administration

#### Reconstitution

- Route
  - Oral

#### Rate of administration

- 

### Other information

- Although there is a 49% decrease in $C_{\text{max}}$ of nateglinide in dialysis patients, the systemic availability and half-life in diabetic subjects with moderate to severe renal insufficiency (CRCL=15–50 mL/min) was comparable between renal subjects requiring haemodialysis and healthy subjects. Although safety was not compromised in this population, dose adjustment may be required in view of low $C_{\text{max}}$.
- Metabolite removed by dialysis.
Nebivolol

**Clinical use**
Beta-adrenoceptor blocker:
- Essential hypertension
- Adjunct in heart failure

**Dose in normal renal function**
- Hypertension: 2.5–5 mg once daily.
- Adjunct in heart failure: 1.25–10 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 405.4 (441.9 as hydrochloride)
- % Protein binding 98
- % Excreted unchanged in urine <0.5
- Volume of distribution (L/kg) 11.2
- Half-life — normal/ESRF (hrs) 10 (32–34 in poor hydroxylators) / –

**Metabolism**
Nebivolol is extensively metabolised in the liver by acyclic and aromatic hydroxylation, N-dealkylation, and glucuronidation. Hydroxylation is by cytochrome P450 isoenzyme CYP2D6, partly to active hydroxy-metabolites. It is excreted in the urine and faeces, almost entirely as metabolites.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Initial dose 2.5 mg and adjust according to response.
- 10–20 Initial dose 2.5 mg and adjust according to response.
- <10 Initial dose 2.5 mg and adjust according to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarial: increased risk of bradycardia with mefloquine.
- Antipsychotics enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

**Administration**

**Reconstitution**
-

**Route**
Oral

**Rate of administration**
-

**Other information**
- 38% of the dose is excreted in the urine as active metabolites.
- In a trial of 10 patients with renal artery stenosis given nebivolol 5 mg daily, plasma renin activity significantly decreased, although serum aldosterone levels did not change to any great extent. In addition, there was no change in effective renal plasma flow, GFR, renal blood flow, or renal vascular resistance. Renal function remained well-preserved.
Necitumumab

Clinical use

IgG1 monoclonal antibody:
- Treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer

Dose in normal renal function

800 mg on days 1 and 8 of a 3-week cycle

Pharmacokinetics

Molecular weight (daltons) 144 800
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 6.97 Litres
Half-life — normal/ESRF (hrs) 14 days / Unchanged

Metabolism

The elimination routes of necitumumab are only partially documented, and involve degradation to peptides after being internalised into its target cells, proteolysis within the liver or the reticuloendothelial system, as well as nonspecific endocytosis.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Live vaccines: avoid concomitant use.

Administration

Reconstitution

Route
IV infusion
Rate of administration
Over 60 minutes
Comments
Dilute in 250 mL sodium chloride 0.9%

Other information

- Treatment for severe infusion reactions should be available during necitumumab infusions including availability of resuscitation equipment.
- Manufacturer has no information in severe renal impairment but does not recommend any dosage reductions.
- There was no change in pharmacokinetics of necitumumab down to a creatinine clearance of 11 mL/min.
- Progressively decreasing serum magnesium levels occur frequently (81.3%) and may lead to severe hypomagnesaemia (18.7%).
- Contains 76 mg sodium per dose.
**Nefopam hydrochloride**

### Clinical use
Analgesic for moderate pain

### Dose in normal renal function
Oral: 30–90 mg 3 times a day

### Pharmacokinetics
- Molecular weight (daltons): 289.8
- % Protein binding: 73
- % Excreted unchanged in urine: <5
- Volume of distribution (L/kg): No data

### Metabolism
Extensively metabolised in the liver to produce active metabolites.
It is mainly excreted in the urine. About 8% of a dose is excreted via the faeces.

### Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. See 'Other information'.

### Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: avoid MAOIs; tricyclics possibly increased risk of side effects.

### Administration

#### Reconstitution
—

#### Route
Oral

#### Rate of administration
—

### Other information
- Avoid repeated or chronic administration in end-stage renal disease and dialysis patients.
- In the elderly a dose of 30 mg 8 hourly is recommended due to reduced metabolism and increased susceptibility to side effects. Renal patients may also have reduced metabolism and excretion so may also have the same problems – always start with the lower dose.
- Avoid in convulsive disorders.
Nelarabine

**Clinical use**
Antineoplastic agent:
- T-cell acute lymphoblastic leukaemia (T-ALL)
- T-cell lymphoblastic lymphoma (T-LBL)

**Dose in normal renal function**
- IV: 1.5 g/m² on days 1, 3 and 5; repeated every 21 days
- Consult relevant local protocol

**Pharmacokinetics**
- Molecular weight (daltons) 297.3
- % Protein binding <25
- % Excreted unchanged in urine 5.3 (23.2 as metabolite)
- Volume of distribution (L/kg) 115 L/m²
- Half-life — normal/ESRF (hrs) 30 minutes / —

**Metabolism**
Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G.
Extensive metabolism by O-demethylation by adenosine deaminase to form ara-G, which undergoes hydrolysis to form guanine. In addition, some nelarabine is hydrolysed to form methylguanine, which is O-demethylated to form guanine. Guanine is N-deaminated to form xanthine, which is further oxidised to yield uric acid. Nelarabine and ara-G are partially eliminated by the kidneys.

**Dose in renal impairment GFR (mL/min)**
- 30–50: Dose as in normal renal function. Monitor closely
- 10–30: Dose as in normal renal function. Monitor closely
- <10: Dose as in normal renal function. Monitor closely. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**
**Reconstitution**
- —

**Route**
- IV infusion

**Rate of administration**
- 2 hours

**Comments**
Nelarabine must NOT be diluted prior to administration. The appropriate dose must be transferred into polyvinylchloride or ethyl vinyl acetate infusion bags or glass containers.

**Other information**
- No studies have been done in renal impairment (GFR<50 mL/min). Patients with renal impairment are more at risk of toxicities. So monitor closely.
- Contains 1.725 mg/ml (75 micromols) of sodium.
- Severe neurotoxicity is a dose limiting side effect.
- The mean apparent clearance of ara-G was about 15% and 40% lower in patients with mild and moderate renal impairment, respectively, than in patients with normal renal function.
## Neomycin sulphate

### Clinical use

Antibacterial agent:
- Bowel sterilisation before surgery
- Hepatic coma

### Dose in normal renal function

- Bowel sterilisation: 1 g every hour for 4 hours, then 1 g every 4 hours for 2–3 days
- Hepatic coma: up to 4 g daily in divided doses usually for 5–7 days

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>711.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0–30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>30–50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.25</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–3 / 12–24</td>
</tr>
</tbody>
</table>

### Metabolism

Only 3% of dose is absorbed. Approximately 97% of an oral dose is excreted unchanged in the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution and monitor renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution and monitor renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution and monitor renal function.</td>
<td></td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: absorption of phenoxymethylpenicillin reduced; increased risk of nephrotoxicity with colistimethate or polymyxins and possibly cephalosporins; increased risk of ototoxicity and nephrotoxicity with capreomycin or vancomycin.
- Anticoagulants: altered INR with coumarins or phenindione.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxics: possibly reduced methotrexate absorption; bioavailability of sorafenib reduced; increased risk of nephrotoxicity and possibly of ototoxicity with platinum compounds.
- Diuretics: increased risk of ototoxicity with loop diuretics.
- Muscle relaxants: enhanced effects of suxamethonium and non-depolarising muscle relaxants.
- Parasympathomimetics: antagonism of effect of neostigmine and pyridostigmine.
- Tacrolimus: increased risk of nephrotoxicity.

### Administration

#### Reconstitution

-  

#### Route

Oral, topical

#### Rate of administration

-  

### Other information

- Impaired GI motility may increase absorption of the drug; therefore, possible that prolonged therapy could result in ototoxicity and nephrotoxicity, particularly in patients with a degree of renal failure.
- If renal impairment occurs the dose should be reduced or treatment discontinued.
- High doses associated with nephrotoxicity and ototoxicity.
- In mild renal failure, i.e. a GFR>50 mL/min, the frequency should be reduced to every 6 hours.
Neostigmine

Clinical use

- Myasthenia gravis
- Antagonist to non-depolarising neuromuscular blockade

Dose in normal renal function

- Myasthenia gravis: Oral: neostigmine bromide 15–30 mg at suitable intervals throughout day – total daily dose 75–300 mg
- Neostigmine metilsulfate, IM, SC, 1–2.5 mg – usual total daily dose 5–20 mg
- Antagonist to non-depolarising neuromuscular blockade: 50–70 mcg/kg over 1 minute; maximum dose 5 mg

Pharmacokinetics

Molecular weight (daltons) 223.3 (303.2 as bromide); (334.4 as metilsulphate)
% Protein binding 15–25
% Excreted unchanged in urine 50
Volume of distribution (L/kg) 0.5–1
Half-life — normal/ESRF (hrs) 0.8–1.5 / 3

Metabolism

Poorly absorbed orally. Neostigmine undergoes hydrolysis by cholinesterases and is also metabolised in the liver. Neostigmine is rapidly eliminated and is excreted in the urine both as unchanged drug and metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as % of normal dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>50–100%</td>
</tr>
<tr>
<td>10–20</td>
<td>50–100%</td>
</tr>
<tr>
<td>&lt;10</td>
<td>25–100%</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Aminoglycosides, clindamycin and polymyxins antagonise effects of neostigmine.

Administration

Reconstitution

- Route
  - Neostigmine bromide: Oral
  - Neostigmine metilsulfate: SC, IM, IV

Rate of administration

IV: Very slowly

Other information

- Neostigmine 0.5 mg IV = 1–1.5 mg IM/SC =15 mg orally.
- When used for reversal of non-depolarising neuromuscular blockade, atropine (0.6–1.2 mg IV) or glycopyrronium should be given before or with neostigmine in order to prevent bradycardia, excessive salivation and other muscarinic actions of neostigmine.
- The physicochemical nature of neostigmine may tend to encourage its removal by various renal replacement therapies.
- No dose reduction is advised in SPC but a dose reduction is suggested in Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
Nevirapine

Clinical use

Non-nucleoside reverse transcriptase inhibitor:
- Treatment of progressive or advanced HIV infection in combination with at least two other antivirals

Dose

Dose in normal renal function
- 200 mg daily, increasing to twice daily after 14 days if tolerated
- MR: 400 mg once daily

Dose in renal impairment

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

Pharmacokinetics

- Molecular weight (daltons): 266.3
- % Protein binding: 60
- % Excreted unchanged in urine: <3
- Volume of distribution (L/kg): 1.12–1.3
- Half-life — normal/ESRF (hrs): 45 (single dose), 25–30 (multiple dosing) / Unchanged

Metabolism

Nevirapine is extensively metabolised by hepatic microsomal enzymes, mainly by the cytochrome P450 isoenzymes CYP3A4 and CYP2B6, to several inactive hydroxylated metabolites. Auto-induction of these enzymes results in a 1.5- to 2-fold increase in apparent oral clearance after 2–4 weeks at usual dosage, and a decrease in terminal half-life.

Nevirapine is mainly excreted in the urine as glucuronide conjugates of the hydroxylated metabolites.

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: reduces concentration of clarithromycin, but concentration of active metabolite increased, also concentration of nevirapine increased; concentration decreased by rifampicin – avoid; possibly increased rifabutin concentration.
- Anticoagulants: may increase or reduce effect of warfarin.
- Antidepressants: concentration reduced by St John's wort – avoid.
- Antifungals: concentration of ketoconazole reduced – avoid; concentration increased by fluconazole; possibly reduced caspofungin and itraconazole concentration – may need to increase caspofungin and itraconazole dose.
- Antipsychotics: possibly reduced aripiprazole concentration – increase aripiprazole dose.
- Antivirals: concentration of dolutegravir, indinavir and efavirenz reduced and possibly etravirine, fosamprenavir, lopinavir, simeprevir and atazanavir – avoid with atazanavir, etravirine and simeprevir consider increasing lopinavir dose; increased risk of granulocytopenia with zidovudine.
- Cytotoxics: avoid with olaparib.
- Guanfacine: concentration possibly reduced – increase guanfacine dose.
- Oestrogens and progestogens: accelerated metabolism (reduced contraceptive effect).
- Orlistat: absorption possibly reduced by orlistat.
- Ulipristal: possibly reduces contraceptive effect.
Reconstitution

Route
Oral

Rate of administration

Other information

- Little data available on the use of nevirapine in renal failure, but need for dose adjustment is unlikely due to the pharmacokinetics of nevirapine. Use with caution.

- There was a preliminary study of haemodialysis patients which showed that a normal dose was not associated with increased side effects. (Izzedine H, Launay-Vacher V, Aymard G, et al. Pharmacokinetic of nevirapine in haemodialysis. Nephrol Dial Transplant. 2001; 16(1): 192–3.)
**Nicardipine hydrochloride**

**Clinical use**

Calcium-channel blocker:
- Prophylaxis and treatment of angina
- Mild to moderate hypertension
- Acute life-threatening hypertension and post-operative hypertension (IV)

**Dose in normal renal function**

- Oral: 20–40 mg 3 times daily
- SR: 30–60 mg twice daily
- IV: Initial dose: 3–5 mg/hour for 15 minutes. Increase by 0.5–1 mg every 15 minutes. Maximum rate: 15 mg/hour
- Maintenance dose: Once target BP attained reduce dose gradually to 2–4 mg/hour

**Pharmacokinetics**

Molecular weight (daltons) 516
% Protein binding >99
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 0.8
Half-life — normal/ESRF (hrs) 8.6 / Unchanged

**Metabolism**

Nicardipine is subject to saturable first-pass metabolism. It is extensively metabolised in the liver and excreted in the urine and faeces, mainly as inactive metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Oral: Dose as in normal renal function. IV: Initially 1–5 mg/hr, increasing every 30 minutes by 0.5 mg/hr as tolerated. Max rate: 15 mg/hr.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal Replacement</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Aminophylline: possibly increases aminophylline concentration.
- Anaesthetics: enhanced hypotensive effect.
- Antibacterials: metabolism possibly accelerated by rifampicin; metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone.
- Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole; negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antivirals: concentration possibly increased by ritonavir; use telaprevir with caution.
- Cardiac glycosides: digoxin concentration increased.
- Ciclosporin: concentration of ciclosporin increased
- Grapefruit juice: concentration increased – avoid.
- Tacrolimus: may increase tacrolimus levels.
- Theophylline: possibly increased theophylline concentration.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Oral, IV infusion</th>
</tr>
</thead>
</table>

**Rate of administration**

Continuous infusion
Comments

- Administration of nicardipine with food appears to reduce the bioavailability and delay the achievement of peak plasma concentrations.
- Unless given by a central line, dilute to a concentration of 0.1–0.2 mg/mL with glucose 5%.

Other information

- Nicardipine blood levels may be elevated in some renally impaired patients. Therefore, start with a low dose and titrate to BP and response. The dose interval may also need to be extended to 12 hourly.
- IV infusion should only be used under specialist supervision.
## Nicorandil

### Clinical use
Prevention and treatment of chronic stable angina

### Dose in normal renal function
5–40 mg twice daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>211.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Slightly</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism
Metabolism of nicorandil is mainly by denitration of the molecule into the nicotinamide pathway. About 20% of a dose is excreted in the urine mainly as metabolites.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Avanafil, sildenafil, tadalafil and vardenafil: enhanced hypotensive effect – avoid.
- Riociguat: possible enhanced hypotensive effect – avoid.

### Administration

**Reconstitution**

**Route**

- Oral

**Rate of administration**

---
Nicotinic acid (unlicensed)

Clinical use

Hyperlipidaemia

Dose in normal renal function

375 mg – 2 g daily at night
(Only available from specials manufacturer)

Pharmacokinetics

Molecular weight (daltons) 123.1
% Protein binding High
% Excreted unchanged in urine 12
Volume of distribution (L/kg) Very high
Half-life — normal/ESRF (hrs) 1–5 / –

Metabolism

The main route of metabolism is its conversion to
N-methylnicotinamide and the 2-pyridone and
4-pyridone derivatives; nicotinuric acid is also formed.
Small amounts of nicotinic acid are excreted unchanged
in urine.

Dose in renal impairment GFR (mL/min)

30–50 50% of dose and increase according to
response.
15–30 50% of dose and increase according to
response.
<15 25% of dose and increase according to
response.

Dose in patients undergoing renal replacement therapies

APD/CAPD Dialysed. Dose as in GFR<15 mL/min.
HD Dialysed. Dose as in GFR<15 mL/min.
HDF/High flux Dialysed. Dose as in GFR<15 mL/min.
CAV/VVHD Dialysed. Dose as in GFR=15–30
mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
• Aspirin: increased flushing.
• Lipid-regulating drugs: increased risk of myopathy
  when used in combination with statins.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—

Other information

• Doses from National Kidney Foundation Inc.
  American Journal of Kidney Disease. 2003; 41(4)
  Suppl. 3: S1:S91 K/DOQI guidelines.
• Use with caution in renal failure due to increased risk
  of rhabdomyolysis.
• Toxic reactions are frequent in CKD 5.
• Nicotinic acid and its metabolites are renally excreted
  and the metabolites account for some of the side
  effects of nicotinic acid.
• One study showed that once daily nicotinic acid
  used in patients with a GFR<60 mL/min (average
  61 mL/min) was safe and effective. (McGovern
  ME, Stanek E, Malott C, et al. Once-daily niacin
  extended-release is effective and safe for treatment of
dyslipidaemia associated with chronic kidney disease.
# Nifedipine

## Clinical use

Calcium-channel blocker:
- Prophylaxis and treatment of angina
- Hypertension
- Raynaud’s phenomenon

## Dose in normal renal function

- Capsules: 5–20 mg 3 times daily
- Tablets: 10–40 mg twice daily
- MR: 20–90 mg daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>346.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>92–98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.4–11 (depends on preparation) / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism

Nifedipine is metabolised in the gut wall and oxidised in the liver via the cytochrome P450 isoenzyme CYP3A4, to inactive metabolites. Excreted mainly as metabolites via the kidney.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Start with small doses.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with small doses.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs

- Aminophylline: possibly increases aminophylline concentration.
- Anaesthetics: enhanced hypotensive effect.
- Anti-arrhythmics: concentration of dronedarone increased.
- Antibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin.
- Antidepressants: metabolism possibly inhibited by fluoxetine; concentration reduced by St John’s wort; enhanced hypotensive effect with MAOIs.
- Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone.
- Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole; concentration increased by micafungin; negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers; occasionally severe hypotension and heart failure with beta-blockers.
- Antivirals: concentration possibly increased by ritonavir; use telaprevir with caution.
- Cardiac glycosides: digoxin concentration possibly increased.
- Ciclosporin: may increase ciclosporin level, but not a problem in practice; nifedipine concentration may be increased.
- Cytotoxics: metabolism of vincristine possibly reduced.
- Grapefruit juice: concentration increased – avoid.
- Magnesium salts: profound hypotension with IV magnesium.
- Tacrolimus: increased tacrolimus levels.
- Theophylline: possibly increased theophylline concentration.

## Administration

### Reconstitution

- **Route**: Oral

### Rate of administration

- **Route**: Oral
Other information

- Protein binding decreased in severe renal impairment.
- Acute renal dysfunction reported.
- Increased incidence of side effects (headache, flushing, dizziness and peripheral oedema) in patients with ERF.
- For acute use, bite capsule then swallow contents with 10–50 mL water.
Nilotinib

Clinical use
Tyrosine kinase inhibitor:
• Treatment of chronic myelogenous leukaemia (CML)

Dose in normal renal function
• Newly diagnosed CML: 300 mg twice daily
• Chronic and accelerated phase CML: 400 mg twice daily
• Consult relevant local protocol

Pharmacokinetics
Molecular weight (daltons) 529.5 (584 as hydrochloride)
% Protein binding 98
% Excreted unchanged in urine 0
Volume of distribution (L/kg) 0.55–3.9
Half-life — normal/ESRF (hrs) 17 / Unchanged

Metabolism
Nilotinib is metabolised in the liver via oxidation and hydroxylation, in which cytochrome P450 isoenzyme CYP3A4 plays an important role.
Most of an oral dose is eliminated unchanged in the faeces within 7 days.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Antibacterials: avoid with clarithromycin, rifampicin (concentration reduced) and telithromycin.
• Antifungals: avoid with itraconazole, ketoconazole (concentration increased) and voriconazole.
• Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
• Antivirals: avoid with boceprevir and ritonavir (concentration possibly increased).
• Grapefruit juice: avoid concomitant administration.
• Avoid concomitant use with other inhibitors or inducers of CYP3A4. Dose alterations may be required.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Bioavailability is 30%.
• Clinical studies have not been performed in patients with impaired renal function but since nilotinib and its metabolites are not renally excreted, a decrease in total body clearance is not anticipated in patients with renal impairment.
• Prolongs QT interval.

Reference:
Nimodipine

Clinical use
Calcium-channel blocker:
- Prevention and treatment of ischaemic neurological deficits following subarachnoid haemorrhage

Dose in normal renal function
- Prevention: 60 mg orally every 4 hours
- Treatment via central catheter: 1 mg/hour initially, increased after 2 hours to 2 mg/hour. If BP unstable, weight <70 kg, start with 0.5 mg/hour or less if necessary.

Pharmacokinetics
Molecular weight (daltons) 418.4
% Protein binding 98
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 0.9–1.6
Half-life — normal/ESRF (hrs) 1.1–1.7 / 22

Metabolism
Nimodipine is extensively metabolised in the liver via the cytochrome P450 isoenzyme CYP3A4. It is eliminated as metabolites, mainly by dehydrogenation of the dihydropyridine ring and oxidative O-demethylation. Oxidative ester cleavage, hydroxylation of the 2- and 6-methyl groups, and glucuronidation as a conjugation reaction are other important metabolic steps. The three primary metabolites occurring in plasma show no or only therapeutically negligible residual activity. The metabolites are excreted about 50% renally and 30% in faeces via the bile.

Dose in renal impairment GFR (mL/min)

| GFR (mL/min) | Dose
|-------------|-----------------
| 20–50       | Dose as in normal renal function.
| 10–20       | Dose as in normal renal function.
| <10         | Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies

| Renal replacement therapy | Details
|---------------------------|-----------------
| APD/CAPD                 | Not dialysed. Dose as in normal renal function.
| HD                       | Not dialysed. Dose as in normal renal function.
| HDF/High flux            | Unknown dialysability. Dose as in normal renal function.
| CAV/VVHD                 | Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline: possibly increases aminophylline concentration.
- Anaesthetics: enhanced hypotensive effect.
- Antibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone.
- Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole; negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antivirals: concentration possibly increased by ritonavir; use telaprevir with caution.
- Grapefruit juice: concentration increased – avoid.
- Theophylline: possibly increased theophylline concentration.

Administration
Reconstitution
- Route
  Oral, IV
Rate of administration
IV – First 2 hours: 1 mg (5 mL) nimodipine per hour. After 2 hours: Infuse 2 mg (10 mL) nimodipine per hour.
Comments
- Nimodipine solution must not be added to an infusion bag or bottle and must not be mixed with other drugs.
- Nimodipine solution should be administered only via a bypass into a running drip (40 mL/hour) of either sodium chloride 0.9% or glucose 5%.
- In the event of nimodipine tablets and solution being administered sequentially, the total duration of treatment should not exceed 21 days.

Other information
- Nimodipine solution reacts with PVC. Polyethylene tubes are supplied.
- Patients with known renal disease and/or receiving nephrotoxic drugs should have renal function monitored closely during IV treatment.
## Nintedanib

### Clinical use
Tyrosine kinase inhibitor:
- Treatment of locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology in combination with docetaxel
- Treatment of Idiopathic Pulmonary Fibrosis (IPF)

### Dose in normal renal function
- NSCLC: 200 mg twice daily on days 2–21 of a 21 day cycle; or according to local protocol
- IPF: 100–150 mg twice daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>539.6 (649.8 as esilate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97.8</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1050 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>9–15</td>
</tr>
</tbody>
</table>

### Metabolism
Nintedanib is metabolised in the liver, initially by hydrolytic cleavage by esterases and then by glucuronidation by uridine diphosphate glucuronosyltransferase enzymes. Only a minor portion is metabolised by cytochrome P450 isoenzymes, mainly CYP3A4.

More than 90% of a dose is eliminated by faecal/biliary excretion.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR = 10–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin – avoid.
- Antifungals: concentration increased by ketoconazole.
- Antipsychotics: increased risk of agranulocytosis with clozapine – avoid.

### Administration

#### Reconstitution
- Route
  - Oral
- Rate of administration
  - 

### Other information
- The safety, efficacy and pharmacokinetics of nintedanib have not been studied in patients with severe renal impairment (CRCL < 30 mL/min).
- Oral bioavailability is 4.69%.
Nitrazepam

### Clinical use
Benzodiazepine:
- Hypnotic

### Dose in normal renal function
5–10 mg at bedtime; elderly (or debilitated) 2.5–5 mg

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>281.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>87</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>24–30 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism
Metabolised in the liver, mainly by nitroreduction followed by acetylation; none of the metabolites possess significant activity. Excreted in the urine mainly as metabolites.

### Dose in renal impairment GFR (mL/min)
- **20–50** Dose as in normal renal function.
- **10–20** Dose as in normal renal function.
- **<10** Dose as in normal renal function. Start with small doses.

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD** Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HD** Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux** Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD** Unlikely to be dialysed. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs:
- Antibacterials: metabolism possibly increased by rifampicin.
- Antipsychotics: increased sedative effects; risk of serious adverse effects in combination with clozapine.
- Antivirals: concentration possibly increased by ritonavir.
- Disulfiram: metabolism of nitrazepam inhibited, increased sedative effects.
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.

### Administration

#### Reconstitution
—

#### Route
Oral

#### Rate of administration
—

### Other information
- Mild to moderate renal insufficiency does not alter the kinetics of nitrazepam.
- CKD 5 patients will be more susceptible to adverse effects (drowsiness, sedation, unsteadiness).
Nitrofurantoin

Clinical use

Antibacterial agent

Dose in normal renal function

- Treatment: 50–100 mg every 6 hours
- Prophylaxis: 50–100 mg at night
- MR: 100 mg twice daily

Pharmacokinetics

Molecular weight (daltons) 238.2
% Protein binding 60–90
% Excreted unchanged in urine 30–40
Volume of distribution (L/kg) 0.3–0.7
Half-life — normal/ESRF (hrs) 0.3–1 / 1

Metabolism

Nitrofurantoin is metabolised in the liver and most body tissues, while about 30–40% of a dose is excreted rapidly in the urine as unchanged nitrofurantoin. Some tubular reabsorption may occur in acid urine.

Dose in renal impairment GFR (mL/min)

45–60 Dose as in normal renal function. Use with caution. See ‘Other information’.
<45 Contraindicated. See ‘Other information’.

Dose in patients undergoing renal replacement therapies

APD/CAPD Dialysed. Avoid – contraindicated.
HDF/High flux Dialysed. Avoid – contraindicated.
CAV/VVHD Dialysed. Avoid – contraindicated.

Important drug interactions

Potentially hazardous interactions with other drugs
- None known

Administration

Reconstitution

—

Route

Oral

Rate of administration

—

Comments

- Urine may be coloured a dark yellow or brown.
- Macrourricular form has slower dissolution and absorption rates, produces lower serum concentration and takes longer to achieve peak concentration in the urine.

Other information

- Anecdotally, nitrofurantoin may be used at GFR=40–60 mL/min but with increased risk of treatment failure and side effects.
- Toxic plasma concentrations can occur in moderate to severe renal impairment causing adverse effects, e.g. neuropathy, blood dyscrasias.
- Advice from MHRA advises to avoid nitrofurantoin if GFR<60 mL/min due to risk of treatment failure as the drug is ineffective due to inadequate urine concentration. (MHRA. Drug Safety Update. Nitrofurantoin: reminder on precautions for use, especially renal impairment in (elderly) patients. August 2013; 7(1).)
- An expert group from the MHRA has reconsidered nitrofurantoin. Their advice is for an amendment to the contraindication against use from CRCL<60 mL/min to eGFR<45 mL/min, with additional advice that nitrofurantoin may be used with caution in individual cases as short-course therapy only for the treatment of lower UTI with an eGFR between 30–44 mL/min to treat resistant pathogens, when the benefits may outweigh the risks of undesirable effects.
- Nitrofurantoin gives false positive urinary glucose (if testing for reducing substances).
Nivolumab

Clinical use
Monoclonal antibody:
- Treatment of advanced (unresectable or metastatic) melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell cancer of the head and neck and urothelial carcinoma

Dose in normal renal function
- Monotherapy: 3 mg/kg every 2 weeks
  - With ipilimumab: 1 mg/kg every 3 weeks for the first 4 doses then 3 mg/kg every 2 weeks

Pharmacokinetics
- Molecular weight (daltons): 143 597
- % Protein binding: No data
- % Excreted unchanged in urine: Minimal
- Volume of distribution (L/kg): 8 Litres
- Half-life — normal/ESRF (hrs): 26.7 days

Metabolism
The metabolic pathway of nivolumab has not been investigated. It is expected to be degraded into small peptides and amino acids via catabolic pathways in the same way as endogenous IgG.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Use with caution. See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. See ‘Other information’.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs:
- Live vaccines: avoid concomitant use.

Administration
Reconstitution
- Route
  - IV infusion
Rate of administration
  - Over 60 minutes
Comments
Administer through a sterile, non-pyrogenic, low protein binding in-line filter with a pore size of 0.2–1.2 μm.

Other information
- Manufacturer advises to use with caution in severe renal impairment due to lack of data.
- The effect of renal impairment on the clearance of nivolumab was evaluated in patients with mild (GFR<90 and ≥60 mL/min/1.73 m²), moderate (GFR<60 and ≥30 mL/min/1.73 m²) or severe (GFR<30 and ≥15 mL/min/1.73 m²) renal impairment compared to patients with normal renal function. No clinically important differences in the clearance of nivolumab were found between patients with mild or moderate renal impairment and patients with normal renal function. Data from patients with severe renal impairment are too limited to draw conclusions on this population.
- Severe immune-related nephritis and renal dysfunction have been reported with monotherapy treatment or in combination with ipilimumab. Patients should be monitored for signs and symptoms of nephritis or renal dysfunction. Most patients present with asymptomatic increases in serum creatinine.
- There is a case report of nivolumab being used in a patient on dialysis with good response. The patient did experience hypercarbic respiratory failure requiring intubation but the author did not relate this to be due to the drug. (Carlo MI, Feldman DR. Response to nivolumab in a patient with metastatic clear cell renal cell carcinoma and end-stage renal disease on dialysis. *Eur Urol.* 2016; 70(6): 1082–3.)
- There is a case report with a transplant patient who developed melanoma and received nivolumab. She developed AKI and loss of her transplant after receiving the first dose of nivolumab. All her immunosuppression had been stopped except her prednisolone before receiving her nivolumab. After commencing haemodialysis her melanoma progressed and she was commenced on nivolumab again at the normal dose with an adequate effect.

## Nizatidine

### Clinical use

H₂-receptor antagonist

### Dose in normal renal function

Oral: 150–600 mg daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>331.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>35</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.8–1.3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–2 / 3.5–11</td>
</tr>
</tbody>
</table>

### Metabolism

A small amount of nizatidine is metabolised in the liver: nizatidine N-2-oxide, nizatidine S-oxide, and N-2-monodesmethylnizatidine have been identified, the latter having about 60% of the activity of nizatidine. More than 90% of a dose of nizatidine is excreted in the urine, in part by active tubular secretion, within 12 hours, about 60% as unchanged drug. Less than 6% is excreted in the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>150 mg every 12–48 hours.</td>
</tr>
<tr>
<td>&lt;20</td>
<td>150 mg every 24–72 hours.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=20–50 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs

- Antifungals: absorption of itraconazole, ketoconazole and possibly posaconazole reduced, avoid with posaconazole suspension.
- Antivirals: concentration of atazanavir reduced; concentration of raltegravir possibly increased – avoid; avoid for 12 hours before and 4 hours after rilpivirine.
- Cytotoxics: avoid with dasatinib and erlotinib; possibly reduced absorption of pazopanib – give at least 2 hours before or 10 hours after nizatidine; possibly reduced absorption of lapatinib.
- Ulipristal: contraceptive effect possibly reduced – avoid with high dose ulipristal.

### Administration

#### Reconstitution

- Route
  - Oral

#### Rate of administration

- Other information
  - Frequency in renal failure depends on indication.
  - The effect of haemodialysis is unproven. It is not expected to be efficient since nizatidine has a large volume of distribution.
  - Oral bioavailability >70%.
Noradrenaline acid tartrate (norepinephrine bitartrate)

Clinical use
- Hypotension
- Cardiac arrest (sympathomimetic)

Dose in normal renal function

(Doses expressed as noradrenaline base)
- Acute hypotension: 40 mcg/mL solution, initially 0.16–0.33 mL/minute; adjust according to response
- Cardiac arrest: 200 mcg/mL solution, 0.5–0.75 mL

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>337.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>~50</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>~16</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.09–0.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1 minute / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism

Extensively metabolised by catechol-O-methyltransferase (COMT), and monoamine oxidase (MAO). Up to 16% of an intravenous dose is excreted unchanged in the urine with methylated and deaminated metabolites in free and conjugated forms.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Adrenergic neurone blockers: antagonise hypotensive effect.
- Anaesthetics: increased risk of arrhythmias with volatile general anaesthetics.
- Antidepressants: tricyclics may cause hypertension and arrhythmias; MAOIs and moclobemide may cause hypertensive crisis.
- Beta-blockers: can cause severe hypertension.
- Clonidine: possibly increased risk of hypertension.
- Dopaminergics: effects possibly increased by entacapone; avoid with rasagiline.
- Sympathomimetics: effects possibly enhanced by dopexamine.

Administration

Reconstitution

Route
IV

Rate of administration
According to response

Comments
Preferably give centrally (low pH). Dilute 1–4 mg in 100 mL glucose 5%. Can be given undiluted.

Other information

- Do not mix with alkaline drugs/solutions.
- The pharmacokinetics of noradrenaline are not significantly affected by renal or hepatic disease.
- 1 mg of noradrenaline base is equivalent to 2 mg noradrenaline acid tartrate.
Norethisterone

**Clinical use**

Progestogen:

- Breast cancer, contraception, dysfunctional uterine bleeding, menorrhagia, dysmenorrhoea, endometriosis, premenstrual syndrome, postponement of menstruation

**Dose in normal renal function**

- Breast cancer: 40–60 mg daily
- Dysfunctional uterine bleeding, menorrhagia: 5 mg three times a day for 10 days to stop bleeding; to prevent bleeding 5 mg twice daily on days 19–26 of cycle
- Dysmenorrhoea: 5 mg three times daily from day 5–24 for 3–4 cycles
- Endometriosis: 10–15 mg daily beginning on day 5 of cycle, may be increased to 20–25 mg daily
- Premenstrual syndrome: 5 mg 2–3 times daily from day 19–26 of several cycles
- Postponement of menstruation: 5 mg three times daily starting 3 days before expected onset

See product literature for more specific information

**Pharmacokinetics**

- Molecular weight (daltons) 298.4
- % Protein binding 60
- % Excreted unchanged in urine 50–80 (as metabolites)
- Volume of distribution (L/kg) 3.1–5.7
- Half-life — normal/ESRF (hrs) 5 / –

**Metabolism**

It is metabolised in the liver with 50–80% of a dose being excreted in the urine and up to 40% appearing in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Monitor carefully.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antibacterials: metabolism of progestogens accelerated by rifamycins (reduced contraceptive effect).
- Anticoagulants: progestogens antagonise anticoagulant effect of phenindione; may enhance or reduce anticoagulant effect of coumarins.
- Antidepressants: contraceptive effect reduced by St John’s Wort – avoid.
- Antiepileptics: metabolism accelerated by carbamazepine, eslicarbazepine, fosphenytoin, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, rufinamide and topiramate (reduced contraceptive effect); concentration of lamotrigine reduced; concentration reduced by high dose perampanel.
- Antifungals: reduced contraceptive effect with griseofulvin.
- Antivirals: contraceptive effect reduced by efavirenz; metabolism accelerated by nevirapine (reduced contraceptive effect); atazanavir increases norethisterone concentration.
- Aprepitant: possible contraceptive failure.
- Bosentan: possible contraceptive failure.
- Ciclosporin: progestogens inhibit metabolism of ciclosporin (increased plasma concentration).
- Cytotoxics: possibly reduced contraceptive effect with crizotinib, dabrafenib, olaparib and vemurafenib.
- Dopaminergics: concentration of selegiline increased – avoid.
- Fosaprepitant: possible contraceptive failure.
- Lumacaftor: possible contraceptive failure.
- Tacrolimus: tacrolimus levels are greatly increased – avoid (anecdotal evidence).
- Ulipristal: contraceptive effect of progestogens possibly reduced.

**Administration**

**Reconstitution**

- —

**Route**

- Oral

**Rate of administration**

- —

**Other information**

- Do not use in patients with porphyria.
# Norfloxacin

## Clinical use
Antibacterial agent

## Dose in normal renal function
400 mg twice daily, duration of course depends on indication

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>319.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>14</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2.5–3.1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–4 / 6.5–8</td>
</tr>
</tbody>
</table>

## Metabolism
Some metabolism occurs, possibly in the liver. Norfloxacin is eliminated through metabolism, biliary excretion and renal excretion. Renal excretion occurs by both glomerular filtration and net tubular secretion. In the first 24 hours, 33–48% of the drug is recovered in the urine.

Norfloxacin exists in the urine as norfloxacin and six active metabolites of lesser antimicrobial potency. The parent compound accounts for over 70% of total excretion. About 30% of an oral dose appears in the faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>400 mg every 12–24 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>400 mg daily</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–30 mL/min. See ‘Other information.’</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline: possibly increased risk of convulsions, increased levels of aminophylline.
- Analgesics: increased risk of convulsions with NSAIDs.
- Anticoagulants: anticoagulant effect of coumarins enhanced.
- Antimalarials: manufacturer of artemether with lumefantrine advises avoid.
- Ciclosporin: increased risk of nephrotoxicity.
- Muscle relaxants: possibly increases tizanidine concentration.
- Theophylline: possibly increased risk of convulsions; increased levels of theophylline.

## Administration

### Reconstitution
—

### Route
Oral

### Rate of administration
—

## Other information
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Normal human immunoglobulin

Clinical use
- Replacement therapy in primary and secondary immunodeficiency
- Idiopathic Thrombocytopenic Purpura
- Guillain Barré syndrome
- Kawasaki disease
- Allogeneic bone marrow transplantation
- Treatment of infections and prophylaxis of graft versus host disease

Dose in normal renal function
- Variable according to preparation and indication
- See individual SPC

Pharmacokinetics
- Molecular weight (daltons) 150 000
- % Protein binding —
- % Excreted unchanged in urine —
- Volume of distribution (L/kg) —
- Half-life — normal/ESRF (hrs) 24–36 days / –

Metabolism
IgG and IgG-complexes are broken down in the cells of the reticuloendothelial system.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as normal renal function.
- 10–20 Dose as normal renal function.
- <10 Dose as normal renal function. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Probably not dialysed. Dose as in normal renal function.
- CAV/VVHD Probably not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Immunoglobulin administration may impair (for a period of at least 6 weeks and up to 3 months) the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella.

Administration
Reconstitution
—
Route
IV
Rate of administration
Variable – see individual SPC.

Other information
- Cases of acute kidney injury have been reported in patients receiving IVIg therapy. In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolaemia, overweight, concomitant nephrotoxic agents or, aged over 65. In all patients, IVIg administration requires:
  - adequate hydration prior to the initiation of the infusion of IVIg;
  - monitoring of urine output;
  - monitoring of serum creatinine levels;
  - avoidance of concomitant use of loop diuretics.
- In case of renal impairment, IVIg discontinuation should be considered. While reports of renal dysfunction and acute kidney injury have been associated with the use of many of the licensed IVIg products, those containing sucrose (compared to glycine, maltose or sorbitol) as a stabiliser accounted for a disproportionate share of the total number. In patients at risk, the use of IVIg products that do not contain sucrose may be considered. In addition, the product should be administered at the minimum concentration and infusion rate practicable.
- Overdose may lead to fluid overload and hyperviscosity, particularly in patients at risk, including elderly patients or patients with renal impairment.
- The MHRA has issued a Medical Device Alert relating to the following point of care and home-use blood glucose meters: Roche Accu-Chek and Glucotrend, Abbott Diabetes Care FreeStyle.
  - There is a risk of overestimation of blood glucose results when these meters are used for samples from patients on treatments that contain (or are metabolised to) maltose, xylose or galactose. The MHRA advises that the affected meters should not
be used to measure blood glucose in patients receiving such treatments. Treatments that are known to contain (or that are metabolised to) maltose, xylose or galactose include (Extraneal®) icodextrin (used in peritoneal dialysis, PD), and certain immunoglobulin preparations (including Octagam®).
Nortriptyline

**Clinical use**
Tricyclic antidepressant

**Dose in normal renal function**
10–150 mg daily in single or divided doses

**Pharmacokinetics**
- Molecular weight (daltons): 263.4 (299.8 as hydrochloride)
- % Protein binding: 95
- % Excreted unchanged in urine: <5
- Volume of distribution (L/kg): 15–23

**Metabolism**
Nortriptyline is the main active metabolite of amitriptyline. It has been reported to have a longer plasma half-life than amitriptyline.

Nortriptyline is subject to extensive first-pass metabolism in the liver to 10-hydroxynortriptyline, which is active.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function. Start with small dose.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**
- Antibacterials: increased risk of ventricular arrhythmias with delamanid, moxifloxacin and possibly telithromycin – avoid with moxifloxacin.
- Anticoagulants: may alter anticoagulant effect of coumarins.
- Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide – avoid; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram – avoid; increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, fosphenytoin, phenobarbital and possibly phenytoin.
- Antimalarials: avoid with arteether/lumefantrine and piperaquine with artenimol.
- Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, haloperidol, pimozide, risperidone and sulpiride – avoid; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased with ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.
- Dapoxetine: possible increased risk of serotonergic effects – avoid.
- Dopaminergics: avoid use with entacapone; CNS toxicity reported with seleligine and rasagiline.
- Pentamidine: increased risk of ventricular arrhythmias.
- Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- All metabolites are highly lipophilic.
Nystatin

Clinical use
Antifungal agent

Dose in normal renal function
- Oral: 100,000–1,000,000 units (1–10 mL) every 6 hours
- Topical: Apply 2–4 times daily (depends on formulation)

Pharmacokinetics
Molecular weight (daltons) 926.1
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) No data

Metabolism
No significant gastrointestinal absorption.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution

Route
Oral, topical

Rate of administration

Other information
- Not absorbed from intact skin or mucous membranes.
Obinutuzumab

Clinical use

Anti-CD20 monoclonal antibody:
- Treatment of chronic lymphocytic leukaemia (CLL)
- Treatment of follicular lymphoma (FL)

Dose in normal renal function

CLL:
- Cycle 1: 1: 100 mg, Day 2: 900 mg. Day 8 and 15: 1000 mg of a 28 day cycle
- Cycle 2–6: Day 1: 1000 mg

FL:
- Cycle 1: 1000 mg on days 1, 8 and 15 of a 28 day cycle
- Cycle 2–6: Day 1: 1000 mg

Or according to local protocol

Pharmacokinetics

Molecular weight (daltons) 146 100
% Protein binding 0
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 4.1 Litres
Half-life — normal/ESRF (hrs) 26.4–36.8 days / Unchanged

Metabolism

Not hepatically metabolised.
The elimination of obinutuzumab is comprised of a linear clearance pathway and a time dependent non-linear clearance pathway.

Dose in renal impairment GFR (mL/min)

30–50  Dose as in normal renal function. See 'Other information'.
<30  Dose as in normal renal function. Use with caution. See 'Other information'.

Dose in patients undergoing renal replacement therapies

APD/CAPD  Not dialysed. Dose as in GFR<30 mL/min.
HD  Not dialysed. Dose as in GFR<30 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<30 mL/min.
CAV/VVHD  Not dialysed. Dose as in GFR<30 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Cytotoxics: chlorambucil or bendamustine may increase neutropenia.
- Live vaccines: avoid concomitant use.

Administration

Reconstitution

Route  IV infusion

Rate of administration
25–400 mg/hour depending on day and cycle. See SPC.

Comments
Dilute 100 mg dose in 100 mL and 900–1000mg in 250 mL sodium chloride 0.9%.

Other information

- Manufacturer has no studies in GFR<30 mL/min, therefore cannot recommend a dose. Although there is no difference in the pharmacokinetics in moderate renal impairment.
- Patients with a high tumour burden and/or a high circulating lymphocyte count (>25 x 10^9/L) and/or renal impairment (CRCL<70 mL/min) are considered at risk of tumour lysis syndrome and should receive prophylaxis. Prophylaxis should consist of adequate hydration and administration of a uricosuric agent (e.g. allopurinol or rasburicase), starting 12–24 hours before starting treatment as per standard practice.
- Pre-medication is required before administration.
- Use with caution in patients with cardiac disease.
- Patients with CRCL<70 mL/min are more at risk of infections.
- Patients with CRCL<50 mL/min were more at risk of fatal adverse reactions.
**Octreotide**

**Clinical use**
Relief of symptoms of gastro-enteropancreatic endocrine tumours and acromegaly

**Dose in normal renal function**
- 50 micrograms – 1.5 mg daily
- Long-acting preparation: 10–30 mg every 4 weeks

**Pharmacokinetics**
- Molecular weight (daltons) 1019.2 (as acetate)
- % Protein binding 65
- % Excreted unchanged in urine 32
- Volume of distribution (L/kg) 0.27
- Half-life — normal/ESRF (hrs) 1.5 / Increased

**Metabolism**
Extensive hepatic metabolism.\(^1\)

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Ciclosporin: ciclosporin concentration reduced.

**Administration**

**Reconstitution**
- Route
  - SC, IV

**Rate of administration**
- IV bolus with ECG monitoring

**Comments**
- IV: sodium chloride 0.9% to a ratio of not less than 1:1 and not more than 1:9

**Other information**
- SC: to reduce local discomfort, warm to room temperature before injection.
- For multiple injections, use different sites.
- Patients with reduced renal function have been shown to have a reduced clearance of the drug (75 mL/min vs. 175 mL/min).

Reference:
Oestrogen, conjugated (unlicensed product)

Clinical use
Second line haemostatic agent for uraemic bleeding

Dose in normal renal function
0.6 mg/kg/day for 5 days

Metabolism
Conjugated oestrogens taken orally are hydrolysed by enzymes present in the intestine that remove the sulfate group and allow absorption of the unconjugated oestrogen. Metabolism occurs mainly in the liver; a variety of sulfate and glucuronide conjugates are formed, and these are excreted in the urine and the bile. Those excreted in the bile undergo enterohepatic recycling or are excreted in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Method</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs

• Antibacterials: metabolism possibly accelerated by rifamycins.
• Anticoagulants: antagonism of anticoagulant effect of coumarins and phenindione.
• Antiepileptics: accelerate metabolism of oestrogens.
• Antifungals: metabolism possibly accelerated by efavirenz and griseofulvin.
• Antivirals: metabolism possibly accelerated by nevirapine and ritonavir.
• Ciclosporin: concentration of ciclosporin increased.
• Cobicistat: accelerate metabolism of oestrogens.
• Dopaminergics: concentration of selegiline increased – avoid.

Administration
Reconstitution
To 50 mL with sodium chloride 0.9%
Route
IV
Rate of administration
Over a minimum of 30–40 minutes

Other information
• Duration of effect about 14 days.
• Used in association with desmopressin (DDAVP) in intractable cases.
• Orally 10–20 mg daily for 5–7 days.
• Conjugated oestrogens are a mixture of sodium oestrone sulphate and sodium equilin sulphate and other oestrogenic substances of the type excreted by pregnant mares.

Reference:
Ofatumumab

Clinical use
IgG1 monoclonal antibody:
• Treatment of chronic lymphocytic leukaemia

Dose in normal renal function
• 300 mg for the first infusion and 2000 mg for all subsequent infusions
• Consult relevant local protocol

Pharmacokinetics
Molecular weight (daltons) 149 000
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 1.7–5.1 Litres
Half-life — normal/ESRF (hrs) 1.3–14 days (depending on number of infusions)

Metabolism
Ofatumumab is eliminated by proteolytic enzymes and via binding to B-cells.

Dose in renal impairment GFR (mL/min)
30–50 Dose as in normal renal function.
10–30 Dose as in normal renal function. Use with caution.
<10 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Live vaccines: avoid concomitant use.

Administration
Reconstitution

Route
IV infusion

Rate of administration
1st and 2nd infusion: initial rate: 12 mL/hour. During infusion, the rate should be doubled every 30 minutes to a maximum of 200 mL/hour.
If the 2nd infusion has been completed without severe infusion-related adverse drug reactions, the remaining infusions can start at a rate of 25 mL/hour and doubled every 30 minutes up to a maximum of 400 mL/hour.

Comments
Further dilute to 1000 mL with sodium chloride 0.9% The in-line filter must be used during the entire infusion

Other information
• No studies have been done in patients with GFR<30 mL/min although the pharmacokinetics do not appear to be altered in renal impairment down to 33 mL/min.
• Contains 34.8 mg sodium per 300 mg dose and 232 mg sodium per 2000 mg dose.
• Pre-medication with paracetamol, and antihistamine and steroid should always be given pre-infusion.
Ofloxacin

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

Oral: 200–400 mg daily, increased if necessary to 400 mg twice daily

IV: 200–400 mg twice daily

**Pharmacokinetics**

Molecular weight (daltons) 361.4

% Protein binding 25

% Excreted unchanged in urine 65–80

Volume of distribution (L/kg) 1.5–2.5

Half-life — normal/ESRF (hrs) 4–6 / 15–60

**Metabolism**

Ofloxacin undergoes limited metabolism to desmethyl and N-oxide metabolites; desmethylofloxacin has moderate antibacterial activity.

Excretion is by tubular secretion and glomerular filtration, and 65–80% of a dose is excreted unchanged in the urine over 24–48 hours, resulting in high urinary concentrations.

Less than 5% is excreted in the urine as metabolites. From 4–8% of a dose may be excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>200–400 mg once daily.</td>
</tr>
<tr>
<td>10–20</td>
<td>200–400 mg once daily.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>100–200 mg once daily.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not significantly dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR = 10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Aminophylline: possibly increased risk of convulsions, increased levels of aminophylline.
- Analgesics: increased risk of convulsions with NSAIDs.
- Anticoagulants: anticoagulant effect of coumarins enhanced.
- Antimalarials: manufacturer of artemether with lumefantrine advises avoid.
- Ciclosporin: increased risk of nephrotoxicity.
- Theophylline: possibly increased risk of convulsions.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Oral, IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of administration</td>
<td>200 mg over 30 minutes</td>
</tr>
</tbody>
</table>

**Other information**

- Almost 100% oral bioavailability.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

**References:**

1. Mojgan S. Clinical Pharmacology in the ICU. Section 1; 1994. p. 58.
Olanzapine

**Clinical use**
- Schizophrenia
- Moderate to severe mania

**Dose in normal renal function**
- Oral: 5–20 mg daily
- IM: 5–10 mg repeated after 2 hours if required; maximum 3 doses daily for 3 days
- Depot injection: 150–300 mg every 2 weeks or 300–405 mg every 4 weeks
- Maximum dose of combined routes: 20 mg per day

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>312.4</td>
</tr>
<tr>
<td>Protein binding</td>
<td>93</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>7 (57% as metabolites and unchanged drug)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>10–20</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>30–38 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Olanzapine is extensively metabolised in the liver, mainly by direct glucuronidation and by oxidation mediated through the cytochrome P450 isoenzymes CYP1A2, and, to a lesser extent, CYP2D6. The 2 major metabolites, 10-N-glucuronide and 4’-N-desmethyl olanzapine, appear to be inactive.

About 57% of a dose is excreted in the urine, mainly as metabolites, and about 30% appears in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Initial dose</th>
<th>Depot dose</th>
<th>Titration note</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>5 mg daily</td>
<td>150 mg</td>
<td>every 4 weeks and titrate as necessary.</td>
</tr>
<tr>
<td>10–20</td>
<td>5 mg daily</td>
<td>150 mg</td>
<td>every 4 weeks and titrate as necessary.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5 mg daily</td>
<td>150 mg</td>
<td>every 4 weeks and titrate as necessary.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose note</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of ventricular arrhythmias.
- Antibacterials: concentration possibly increased by ciprofloxacin.
- Antidepressants: fluvoxamine increases concentration of olanzapine; increased concentration of tricyclics.
- Antiepileptics: antagonism (convulsive threshold lowered); carbamazepine increases metabolism of olanzapine; increased risk of neutropenia with valproate.
- Antimalariais: avoid with artemether/lumefantrine.
- Antipsychotics: increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration reduced by ritonavir – consider increasing olanzapine dose.
- Anxiolytics and hypnotics: increased sedative effects; increased risk of hypotension, bradycardia and respiratory depression with IM olanzapine and parenteral benzodiazepines.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.

**Administration**

**Reconstitution**
2.1 mL water for injection

**Route**
Oral, IM

**Rate of administration**

—
Olaparib

**Clinical use**

Human poly (ADP-ribose) polymerase enzymes inhibitor:
- Treatment of platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer

**Dose in normal renal function**

400 mg twice daily, dose can be reduced if not tolerated

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>434.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>82</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>15</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>167 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>11.9</td>
</tr>
</tbody>
</table>

**Metabolism**

*In vitro*, CYP3A4 was shown to be the main enzyme responsible for the metabolism of olaparib. The majority of the metabolism was due to oxidation reactions with a number of the components produced undergoing subsequent glucuronide or sulfate conjugation.

Following a single dose of $[^{14}C]$-olaparib, approximately 86% of the dose was recovered within a 7-day collection period, approximately 44% via the urine and 42% via the faeces. The majority of olaparib was excreted as metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>300 mg twice daily.</td>
</tr>
<tr>
<td>10–30</td>
<td>300 mg twice daily if benefit outweighs risks.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>300 mg twice daily if benefit outweighs risks.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly increased by ciprofloxacin, clarithromycin and erythromycin – avoid or reduce olaparib dose to 150 mg twice daily; avoid with rifabutin and rifampicin.
- Antidepressants: avoid with St John’s wort.
- Antiepileptics: avoid with carbamazepine, phenobarbital and phenytoin.
- Antifungals: concentration increased by itraconazole and possibly fluconazole – avoid or reduce olaparib dose to 150 mg twice daily.
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.
- Antivirals: concentration possibly increased by boceprevir, ritonavir and telaprevir – avoid or reduce olaparib dose to 150 mg twice daily; avoid with nevirapine.
- Calcium channel blockers: concentration possibly increased by diltiazem and verapamil – avoid or reduce olaparib dose to 150 mg twice daily.
- Cobicistat: concentration possibly increased – avoid or reduce olaparib dose to 150 mg twice daily.
- Grapefruit juice: avoid concomitant use.
- Oestrogens and progestogens: possibly reduced contraceptive effect.

**Administration**

**Reconstitution**

| Route | Oral |

**Rate of administration**

| — | — |

**Other information**

- Manufacturer has limited data in renal impairment but recommends it can be used if the benefit outweighs the risks.
- In patients with moderate renal impairment (GFR=31–50 mL/min), AUC increased by 44% and C<sub>max</sub> by 26% compared with patients with normal renal function. Olaparib dose adjustment is recommended for patients with moderate renal impairment.
Olaratumab

**Clinical use**

Monoclonal antibody:
- Treatment of advanced soft tissue sarcoma in combination with doxorubicin

**Dose in normal renal function**

15 mg/kg on days 1 and 8 of a 3-week cycle

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>154 600</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>7.7 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>11 days</td>
</tr>
</tbody>
</table>

**Metabolism**

Mainly degraded non-specifically by proteolytic enzymes.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Live vaccines: avoid with olaratumab in combination with doxorubicin.

**Administration**

**Reconstitution**

—

**Route**
IV infusion

**Rate of administration**
Over 60 minutes or no faster than 25 mg/minute for larger doses

**Comments**
Dilute further to 250 mL with sodium chloride 0.9%.

**Other information**

- Pre-medication is required before commencing treatment.
- Manufacturer has no information in severe renal impairment (CRCL<30 mL/min). Pharmacokinetic data suggest that no dose reduction is required in mild to moderate renal impairment.
- As olaratumab is not renally excreted, drug exposure is not likely to be different in severe renal impairment.¹
- Olaratumab contains 22 mg sodium per each 19 mL vial and 57 mg sodium per each 50 mL vial.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Dose as in normal renal function. Use with caution. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapeutic Modality</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=30–50 mL/min.</td>
</tr>
</tbody>
</table>

Reference:
# Olmesartan medoxomil

## Clinical use

Angiotensin-II receptor antagonist:
- Hypertension

## Dose in normal renal function

10–40 mg once daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>558.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99.7</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>35–50</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.24</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–15 / 36</td>
</tr>
</tbody>
</table>

## Metabolism

Olmesartan medoxomil is an ester prodrug that is hydrolysed during absorption from the gastrointestinal tract to the active form olmesartan. It is excreted in the urine and the bile as olmesartan; about 35–50% of the absorbed dose is excreted in the urine and the remainder in the bile.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Start with low doses.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Initial dose 10 mg daily and gradually increase.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia hypotension and renal impairment with ACE-Is and aliskiren.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

## Administration

### Reconstitution

- Route
  - Oral

### Rate of administration

### Other information

- Hyperkalaemia and other side effects are more common in patients with impaired renal function.
- Renal failure has been reported in association with angiotensin-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with congestive heart failure.
- Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
- In mild, moderate and severe renal failure, the AUC is increased by 62, 82 and 179% respectively.
Olsalazine sodium

Clinical use
诱导和维持溃疡性结肠炎的缓解

Dose in normal renal function
- 1–3 g daily
- Maintenance: 500 mg twice daily

Pharmacokinetics
- Molecular weight (daltons) 346.2
- % Protein binding >99
- % Excreted unchanged in urine 1–2
- Volume of distribution (L/kg) 6 Litres
- Half-life — normal/ESRF (hrs) 1 / Unchanged

Metabolism
Olsalazine is broken down by the colonic bacterial flora into 2 molecules of 5-aminosalicylic acid (mesalazine). The small amounts (1–2% of the dose or less) of intact olsalazine that are absorbed are excreted mainly in urine. Approximately 0.1% of an oral dose of olsalazine is hepatically metabolised to olsalazine-O-sulfate (olsalazine-S), which has a half-life of 7 days.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
- Potentially hazardous interactions with other drugs: None known

Administration

Reconstitution —
Route
Oral
Rate of administration —

Other information
- Potential to be nephrotoxic due to 5-aminosalicylic acid (5-ASA) component. Both 5-ASA and its acetylated metabolite are rapidly excreted in the urine.
- Less than 3% of an oral dose is absorbed before the drug reaches the colon.
- Unlikely that renal dysfunction will have any important effect on the kinetics of the drug.
- UK SPC contraindicates the use of olsalazine in patients with significant renal impairment due to lack of experience of its use in this patient population.
- US data sheet just advises close monitoring.
## Omalizumab

### Clinical use

Monoclonal antibody:
- Add-on therapy to improve asthma control
- Treatment of chronic spontaneous urticaria (CSU)

### Dose in normal renal function

- Usually 75–600 mg in 1–4 injections, dependent on baseline IgE levels and body weight every 2–4 weeks
- Maximum dose is 600 mg every 2 weeks
- CSU: 300 mg every 4 weeks

See SPC for more information

### Pharmacokinetics

- Molecular weight (daltons) 149 000
- % Protein binding 0
- % Excreted unchanged in urine No data
- Volume of distribution (L/kg) 0.046–0.11
- Half-life — normal/ESRF (hrs) 20–26 days / –

### Metabolism

Omalizumab is most likely metabolised by opsonisation via the reticuloendothelial system, and removed by IgG and IgE clearance processes in the liver. Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>As in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>As in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>As in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- **HD**: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in GFR < 10 mL/min.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in GFR = 10–20 mL/min.

### Important drug interactions

Potentially hazardous interactions with other drugs
- None known

### Administration

#### Reconstitution

- **Water for injection**

#### Route

- **SC**

#### Rate of administration

- **—**

#### Comments

- Preferably administer in the deltoid region of arm; alternatively in the thigh.
- Do not give more than 150 mg at one injection site.
- After reconstitution, chemically and physically stable for 8 hours at 2–8°C and 4 hours at 30°C

### Other information

- Has a bioavailability of 62%; peak concentrations occur after 7–8 days.
- UK SPC advises to use with caution in renal impairment due to lack of studies. Renal impairment does not appear to affect the pharmacokinetics, therefore suggest use with caution and monitor patients closely.
Ombitasvir / paritaprevir / ritonavir

Clinical use
Treatment of chronic hepatitis C infection

Dose in normal renal function
Two (12.5 mg / 75 mg / 50 mg) tablets once daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Ombitasvir</th>
<th>Paritaprevir</th>
<th>Ritonavir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>894.1</td>
<td>765.9</td>
<td>720.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99.9</td>
<td>97–98.6</td>
<td>98–99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0.03</td>
<td>0.05</td>
<td>3.5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>173 Litres</td>
<td>103 Litres</td>
<td>0.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>21–25</td>
<td>5.5</td>
<td>3–5 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism
Ombitasvir is metabolised via amide hydrolysis followed by oxidative metabolism. A total of 13 metabolites were identified in human plasma. These metabolites are not expected to have antiviral activity or off-target pharmacologic activity.

Paritaprevir is metabolised mainly by CYP3A4 and to a lesser extent CYP3A5. Following administration of a single 200 mg / 100 mg oral dose of $^{14}$C paritaprevir / ritonavir to humans, the parent drug was the major circulating component, accounting for approximately 90% of the plasma radioactivity. At least 5 minor metabolites of paritaprevir have been identified in circulation that accounted for approximately 10% of plasma radioactivity. These metabolites are not expected to have antiviral activity.

Ritonavir is extensively metabolised in the liver mainly by cytochrome P450 isoenzymes CYP3A4 and to a lesser extent by CYP2D6. Five metabolites have been identified and the major metabolite has antiviral activity, but concentrations in plasma are low.

About 86% of a dose is eliminated through the faeces (both as unchanged drug and as metabolites) and about 11% is excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs

Ombitasvir:
- Antibacterials: concentration possibly reduced by rifampicin – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antiepileptics: concentration reduced by carbamazepine – avoid, concentration possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone – avoid.
- Diuretics: concentration of furosemide reduced (reduce furosemide dose).
- Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce dose and use only if benefit outweighs risk – see SPC).
- Oestrogens: avoid with ethinyloestradiol.
- Statins: avoid with atorvastatin and simvastatin.

Paritaprevir:
- Antibacterials: avoid with clarithromycin; concentration possibly reduced by rifampicin – avoid.
• Antidepressants: concentration possibly reduced by St John's wort – avoid.
• Antiepileptics: concentration reduced by carbamazepine – avoid; possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone – avoid.
• Antifungals: concentration of both drugs increased with ketoconazole and possibly itraconazole and posaconazole – avoid.
• Antivirals: concentration increased by atazanavir; concentration increased by darunavir and concentration of darunavir decreased; avoid with efavirenz, etravirine, indinavir, nevirapine, saquinavir and tipranavir; concentration increased by lopinavir – avoid.
• Diuretics: concentration of furosemide increased (reduce furosemide dose).
• Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce dose and use only if benefit outweighs risk – see SPC).
• Lipid-regulating drugs: avoid with atorvastatin, fluvastatin and simvastatin; concentration of pravastatin and rosuvastatin increased (reduce pravastatin and rosuvastatin dose); concentration increased by gemfibrozil – avoid.
• Oestrogens: avoid with ethinyloestradiol.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

• Bioavailability is 50%.
# Omega-3-acid ethyl esters

<table>
<thead>
<tr>
<th>Clinical use</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Adjunct to diet and statin in hypertriglyceridaemia</td>
<td></td>
</tr>
<tr>
<td>• Adjunct to secondary prevention after a MI</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose in normal renal function</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Hypertriglyceridaemia: 2 capsules daily</td>
<td></td>
</tr>
<tr>
<td>• Post MI: 1 capsule daily</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pharmacokinetics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>Eicosapentaenoic acid (EPA): 330.5; Docosahexaenoic acid (DHA): 356.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>EPA: 82 Litres; DHA: 82</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>EPA: 39–67; DHA: 20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Metabolism</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DHA and EPA are metabolised and oxidised in the liver, which is the site of biosynthesis of n-3 fatty acid intermediates, synthesizing VLDL that transport fatty acids in the plasma to tissues.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose in patients undergoing renal replacement therapies</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR = 10–20 mL/min.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Important drug interactions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Potentially hazardous interactions with other drugs</td>
<td></td>
</tr>
<tr>
<td>• Anticoagulants: may increase bleeding time.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Administration</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reconstitution</td>
<td>—</td>
</tr>
<tr>
<td>Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Rate of administration</td>
<td>—</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• A literature review showed that fish oils may have benefits in CKD patients. Potential risks of supplementation include gastrointestinal distress, prolonged bleeding, and vitamin A toxicity, although the likelihood of serious side effects is probably low. (Vergili-Nelsen JM. Benefits of fish oil supplementation for hemodialysis patients. J Am Diet Assoc. 2003; 103(9): 1174–7.)</td>
<td></td>
</tr>
</tbody>
</table>
Omeprazole

Clinical use
Gastric acid suppression

Dose in normal renal function
- Oral: 10–120 mg daily
- IV: 40–60 mg once daily for up to 5 days
- Patients with recent bleeding on endoscopy: 80 mg stat followed by 8 mg/hour for 72 hours (British Society of Gastroenterology)

Pharmacokinetics
Molecular weight (daltons) 345.4
% Protein binding 95
% Excreted unchanged in urine Minimal
Volume of distribution (L/kg) 0.3
Half-life — normal/ESRF (hrs) 0.5–3 / Unchanged

Metabolism
Omeprazole is completely metabolised in the liver by the cytochrome P450 system to form inactive metabolites which are excreted mostly in the urine and to a lesser extent in bile. CYP2C19 produces hydroxyomeprazole, the major metabolite, CYP3A4 produces omeprazole sulphone.

Dose in renal impairment GFR (mL/min)
20–50  Dose as in normal renal function.
10–20  Dose as in normal renal function.
<10   Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD  Unlikely to be dialysed. Dose as in normal renal function.
HD    Not dialysed. Dose as in normal renal function.
HDF/High flux  Unknown dialysability. Dose as in normal renal function.
CAV/VVHD  Unknown dialysability. Dose as in normal renal function.

Important drug interactions
- Antiepileptics: effects of phenytoin possibly enhanced.
- Antifungals: absorption ofitraconazole and ketoconazole reduced; avoid with posaconazole; concentration increased by voriconazole.
- Antivirals: reduced atazanavir concentration – avoid; AUC of saquinavir increased by 82% (increased risk of toxicity) – avoid; concentration of raltegravir possibly increased – avoid; concentration of rilpivirine reduced – avoid; concentration of omeprazole reduced by tipranavir.
- Ciclosporin: variable response; mostly increase in ciclosporin level.
- Ciostazol: increased cilostazol concentration – reduce cilostazol dose.
- Clopidogrel: avoid due to reduced efficacy of clopidogrel.
- Cytotoxics: possibly reduced excretion of methotrexate; avoid with erlotinib and vandetanib; possibly reduced dasatinib and lapatinib absorption – avoid with dasatinib; possibly reduced absorption of pazopanib.
- Tacrolimus: may increase tacrolimus concentration.
- Ulipristal: reduced contraceptive effect, avoid with high dose ulipristal.

Administration
Reconstitution
5 mL solvent provided per 40 mg vial
Route
Oral, IV
Rate of administration
Bolus: over 5 minutes
Infusion: 40 mg over 20–30 minutes
Continuous infusion: 8 mg/hour
Comments
- Add to 100 mL sodium chloride 0.9% or glucose 5%.
- Once diluted stable for 12 hours in sodium chloride 0.9% and 3 hours in glucose 5%.
- Use oral as soon as possible.
- 200 mg in 50 mL for 8 mg/hour infusion (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006).

Other information
- Omeprazole clearance is not limited by renal disease.
Ondansetron

**Clinical use**

Anti-emetic

**Dose in normal renal function**

Oral: 4–32 mg daily in 2–3 divided doses
IV: 8–32 mg daily
PR: 16 mg pre-chemotherapy

**Pharmacokinetics**

- Molecular weight (daltons) 293.4
- % Protein binding 70–76
- % Excreted unchanged in urine <5
- Volume of distribution (L/kg) 2
- Half-life — normal/ESRF (hrs) 3–6 / 5.4

**Metabolism**

Ondansetron is metabolised in the liver through multiple enzymatic pathways; it is a substrate for cytochrome P450 isoenzymes, primarily CYP3A4, but also CYP1A2 and CYP2D6. The metabolites do not contribute to the pharmacological activity of ondansetron. Less than 5% of a dose is excreted unchanged in the urine.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Cytotoxics: possible increased risk of ventricular arrhythmias with panobinostat and vandetanib.
- Dopaminergics: possible increased risk of hypotension with apomorphine – avoid.

**Administration**

**Reconstitution**

—

**Route**

Oral, IV, IM, rectal

**Rate of administration**

- IV bolus over 3–5 minutes
- IV infusion: over 15 minutes
- Continuous infusion: 1 mg/hour

**Comments**

Dilute in 50–100 mL of sodium chloride 0.9% or glucose 5%.
Patients >65 years should always have the injection diluted for chemotherapy-induced nausea and vomiting.

**Other information**

- Can be used to treat uraemic pruritis.
- Renal clearance of ondansetron is low.
- Due to risk of QT prolongation the MHRA has advised, patients >75 years should have an maximum IV dose of 8 mg for chemotherapy-induced nausea and vomiting, if less than 75 years, maximum single dose is 16 mg. All adults should receive doses at least 4 hours apart.
- Can cause a dose dependent QT interval prolongation.
# Oritavancin

## Clinical use

Antibacterial agent

## Dose in normal renal function

1200 mg as a stat dose

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1793.1 (1989.1 as phosphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>85</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>87.6 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>245 / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism

*In vitro* human liver microsome studies indicated that oritavancin is not metabolised. It is excreted unchanged; less than 1% and 5% of a dose is recovered in the urine and the faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Anticoagulants: possibly increases warfarin concentration.

## Administration

### Reconstitution

40 mL water for injection

### Route

IV infusion

### Rate of administration

Over 3 hours

### Comments

Add reconstituted vial to a 1000 mL bag of glucose 5% with 120 mL removed.

## Other information

- Manufacturer has no data in severe renal impairment. Population pharmacokinetic analysis indicated that renal impairment had no clinically relevant effect on the exposure of oritavancin. No dedicated studies in dialysis patients have been conducted.
- Oritavancin has been shown to interfere with certain laboratory coagulation tests. Oritavancin concentrations that are found in the blood of patients following administration of a single dose have been shown to artificially prolong aPTT for up to 120 hours, PT and INR for up to 12 hours, Activated Clotting Time for up to 24 hours, Silica Clot Time for up to 18 hours, and dilute Russell’s Viper Venom Test for up to 72 hours.
Orlistat

**Clinical use**
Adjunct in obesity

**Dose in normal renal function**
120 mg taken immediately before, during or up to 1 hour after each meal; maximum 360 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>495.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0–4</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–2 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Orlistat is minimally absorbed and has no defined systemic pharmacokinetics. The metabolism of orlistat occurs mainly within the gastrointestinal wall to form 2 major inactive metabolites, M1 (4-member lactone ring hydrolysed) and M3 (M1 with N-formyl leucine moiety cleaved).

Faecal excretion of the unabsorbed drug is the major route of elimination. Approximately 97% of the administered dose is excreted in faeces and 83% of that as unchanged orlistat.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Acarbose: avoid concomitant administration.
- Amiodarone: possibly slightly reduces absorption.¹
- Anticoagulants: monitor INR more frequently (due to reduction in vitamin K absorption).¹
- Antiepileptics: possible increased risk of convulsions.
- Antivirals: absorption of abacavir, atazanavir, darunavir, didanosine, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, fosamprenavir, indinavir, lamivudine, lopinavir, maraviroc, nevirapine, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, tipranavir and zidovudine possibly reduced.
- Ciclosporin: possibly reduces absorption of ciclosporin.
- Tacrolimus: possibly reduces absorption of tacrolimus.¹
- Thyroid hormones: possible increased risk of hypothyroidism with levothyroxine.
- Vitamins: may reduce the absorption of fat soluble vitamins.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- If the meal doesn’t contain any fat, omit orlistat.
- Orlistat is poorly absorbed; bioavailability of less than 5%.
- Renal failure and fatal cases of hepatitis have been reported.

Reference:

Orphenadrine hydrochloride

Clinical use
Anti-muscarinic:
• Parkinsonism
• Drug induced extra-pyramidal symptoms

Dose in normal renal function
150–400 mg daily in divided doses

Pharmacokinetics
Molecular weight (daltons) 305.8
% Protein binding 95
% Excreted unchanged in urine 8
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 14 / –

Metabolism
Orphenadrine is almost completely metabolised to at least
8 metabolites in the liver.
It is mainly excreted in the urine as metabolites and small
amounts of unchanged drug.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in
normal renal function.
HD Unlikely to be dialysed. Dose as in
normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in
normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in
normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—
Oseltamivir

**Clinical use**
Treatment and post-exposure prevention of influenza

**Dose in normal renal function**
- Treatment: 75 mg twice daily for 5 days
- Post-exposure prevention: 75 mg once daily for at least 10 days; up to 6 weeks if epidemic in community

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>410.4 (as phosphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>42 (3 as carboxylate)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Negligible (99% excreted as carboxylate metabolite in urine)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.3–0.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–3, (6–10 as metabolite) / &gt;20</td>
</tr>
</tbody>
</table>

**Metabolism**
Oseltamivir is a prodrug; it is extensively metabolised by esterases in the liver to the active carboxylate metabolite. Oseltamivir carboxylate is not further metabolised and is eliminated entirely by renal excretion. Renal clearance exceeds glomerular filtration rate indicating that tubular secretion occurs in addition to glomerular filtration. Less than 20% of an oral radiolabelled dose is eliminated in faeces.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Dialysis Type</th>
<th>Treatment/Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Treatment and prophylaxis: 30 mg weekly (2 doses for prophylaxis).</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Treatment and prophylaxis: 30 mg three times a week post dialysis.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Treatment: 75 mg three times a week post dialysis. Prophylaxis: 30 mg three times a week post dialysis.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–30 mL/min. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**
Reconstitution
- Route
  - Oral
Rate of administration
-  

**Other information**

<table>
<thead>
<tr>
<th>CRCL (mL/min)</th>
<th>Treatment</th>
<th>Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>30 mg twice daily</td>
<td>30 mg once daily</td>
</tr>
<tr>
<td>10–30</td>
<td>30 mg once daily</td>
<td>30 mg once 48 hours</td>
</tr>
<tr>
<td>&lt;10</td>
<td>30 mg stat</td>
<td>30 mg once, repeat after 7 days</td>
</tr>
<tr>
<td>Haemodialysis</td>
<td>30 mg once then</td>
<td>30 mg once then</td>
</tr>
<tr>
<td></td>
<td>30 mg after each</td>
<td>30 mg after each</td>
</tr>
<tr>
<td></td>
<td>HD session</td>
<td>2nd HD session</td>
</tr>
<tr>
<td>Peritoneal</td>
<td>30 mg stat</td>
<td>30 mg once, repeat after 7 days</td>
</tr>
<tr>
<td>Dialysis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SEE OTHER INFORMATION**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Treatment</th>
<th>Prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>Dose as in normal renal function. Treatment: 75 mg once daily or 30 mg twice daily. Prophylaxis: 75 mg every 48 hours or 30 mg once daily.</td>
<td>30 mg once daily</td>
</tr>
<tr>
<td>10–30</td>
<td>Treatment: 75 mg as a single dose. Prophylaxis: 30 mg once a week (2 doses). See ‘Other information’.</td>
<td>30 mg once, repeat after 7 days</td>
</tr>
<tr>
<td>&lt;10</td>
<td>30 mg stat</td>
<td>30 mg once then</td>
</tr>
<tr>
<td>Haemodialysis</td>
<td>30 mg once then</td>
<td>30 mg once then</td>
</tr>
<tr>
<td>Peritoneal</td>
<td>30 mg stat</td>
<td>30 mg once, repeat after 7 days</td>
</tr>
<tr>
<td>Dialysis</td>
<td>30 mg stat</td>
<td>30 mg once, repeat after 7 days</td>
</tr>
</tbody>
</table>
Oseltamivir

Haemo(dia) filtration  
1–1.8 L/hr exchange rate  
Haemo(dia) filtration  
1.9–3.6 L/hr exchange rate  
Haemo(dia) filtration  
>3.6 L/hr exchange rate

30 mg once daily  
30 mg every 48 hours

30 mg twice daily  
30 mg once daily

75 mg twice daily  
75 mg once daily

• More oseltamivir is removed by APD than CAPD.

• A study looked at oseltamivir clearance in patients undergoing aggressive peritoneal dialysis treatments and found a single dose of 75 mg oseltamivir provided exposure at the upper end of the safety margin. It was well tolerated in all the patients. (Patel K, Rayner CR, Giraudon M, et al. Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. Br J Clin Pharmacol. 2015; 79(4): 624–35.)

• There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid flux within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Osimertinib mesilate

Clinical use
Protein kinase inhibitor:
- Treatment of non-small-cell lung cancer (NSCLC)

Dose in normal renal function
80 mg once daily

Pharmacokinetics
Molecular weight (daltons) 499.6
% Protein binding 94.7
% Excreted unchanged in urine 0.8
Volume of distribution (L/kg) 997 Litres
Half-life — normal/ESRF (hrs) 48 / Unchanged

Metabolism
Metabolised mainly by CYP3A4, and CYP3A5. The main metabolic pathway was oxidation and dealkylation. Based on in vitro studies, 2 pharmacologically active metabolites (AZ7550 and AZ5104) have been identified. Following a single oral dose of 20 mg, 67.8% of the dose was recovered in faeces and 14.2% in urine. Unchanged osimertinib accounted for approximately 2% of the elimination with 0.8% in urine and 1.2% in faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>15–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=15–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin – avoid.
- Antidepressants: avoid with St John’s wort.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin – avoid.
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.

Administration
Reconstitution
-
Route
Oral
Rate of administration
-

Other information
- Company has limited data in GFR<15 mL/min hence advises to use with caution.
- Can cause QT prolongation.
- Bioavailability is 70%.
- Based on a population pharmacokinetic analysis of 471 patients with mild renal impairment (CRCL=60–90 mL/min), 208 patients with moderate renal impairment (CRCL=30–60 mL/min) and 5 patients with severe renal impairment (CRCL=15–30 mL/min) and 402 patients with normal renal function, osimertinib exposures were similar.
## Oxaliplatin

### Clinical use
Antineoplastic platinum agent:
- Treatment of metastatic colorectal cancer in combination with fluorouracil and folinic acid and stage III colon cancer

### Dose in normal renal function
85 mg/m²; can be repeated at intervals of 2 weeks if toxicity permits

### Pharmacokinetics
- **Molecular weight (daltons)**: 397.3
- **% Protein binding**: 33
- **% Excreted unchanged in urine**: 54
- **Volume of distribution (L/kg)**: 330 ± 40.9 Litres
- **Half-life — normal/ESRF (hrs)**: 273 / Increased

### Metabolism
Oxaliplatin is extensively metabolised by non-enzymatic biotransformation to both inactive and active compounds. There is no *in vitro* evidence of cytochrome P450 metabolism of the diaminocyclohexane (DACH) ring. Several cytotoxic biotransformation products including the monochloro-, dichloro- and diaquo-DACH platinum species have been identified in the systemic circulation together with a number of inactive conjugates. Platinum removal is mainly by renal excretion and tissue distribution; platinum metabolites mainly by renal excretion. By day 5, approximately 54% of the total dose was recovered in the urine and <3% in the faeces.

### Dose in renal impairment GFR (mL/min)

| GFR (mL/min) | Dose
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>65 mg/m², use with caution and monitor closely.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>65 mg/m², use with caution and monitor closely.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs:
- Antibacterials: increased risk of nephrotoxicity and possibly ototoxicity with aminoglycosides, capreomycin, polymyxins or vancomycin.
- Cytotoxics: avoid with panitumumab.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).

### Administration

#### Reconstitution
Glucose 5% or water for injection to give a concentration of 5 mg/mL.

#### Route
IV infusion

#### Rate of administration
2–6 hours

#### Comments
Dilute with 250–500 mL glucose 5% to a concentration 0.2–0.7 mg/mL.

### Other information

- Contraindicated by manufacturer in UK SPC if GFR<30 mL/min due to lack of studies. Dose in severe renal impairment is from US data sheet.
- No *in vitro* evidence of cytochrome P450 metabolism.
- Binds irreversibly to red blood cells, which can prolong the half-life of the drug.
- Reduced renal clearance and volume of distribution in renal impairment.
- There is a 38–44% reduction of platinum clearance in mild-moderate renal impairment (GFR=20–39 mL/min) but no increased incidence of side effects has been reported.

### References:
# Oxazepam

## Clinical use
Benzodiazepine:
- Anxiolytic
- Insomnia

## Dose in normal renal function
- Anxiolytic: 15–30 mg 3 or 4 times a day
- Insomnia: 15–50 mg at night

## Pharmacokinetics
- Molecular weight (daltons): 286.7
- % Protein binding: 85–97
- % Excreted unchanged in urine: <1
- Volume of distribution (L/kg): 0.6–1.6

## Metabolism
Oxazepam is the ultimate pharmacologically active metabolite of diazepam and is itself largely metabolised to the inactive glucuronide which is excreted in the urine.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start at low dose and increase according to response.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs:
- Antibacterials: metabolism possibly increased by rifampicin.
- Antipsychotics: enhanced sedative effects; risk of serious adverse effects in combination with clozapine.
- Antivirals: possibly increased concentration with ritonavir.
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.
- Ulcer-healing drugs: metabolism inhibited by cimetidine.

## Administration
**Reconstitution**
- **Route**
  - Oral
- **Rate of administration**
  - 

## Other information
- Protein binding decreased and volume of distribution increased in ERF.
- Inactive glucuronide metabolite accumulates in CKD 5; significance of this unknown.
Oxcarbazepine

Clinical use

- Antiepileptic
- Trigeminal neuralgia (unlicensed indication)

Dose in normal renal function

- Epilepsy: 600 mg – 2.4 g daily in divided doses

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>252.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>40–60 (metabolite)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.7–0.8</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.3–2.3 (9 for metabolite) /</td>
</tr>
<tr>
<td>Unchanged (16–19 for metabolite)</td>
<td></td>
</tr>
</tbody>
</table>

Metabolism

Oxcarbazepine is rapidly reduced by cytosolic enzymes in the liver to the active monohydroxy metabolite (licarbezine, or MHD). MHD is metabolised further by conjugation with glucuronic acid. Minor amounts (4% of the dose) are oxidised to a pharmacologically inactive metabolite. Oxcarbazepine is excreted in the urine mainly as metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Start with 300 mg daily and titrate slowly.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with 300 mg daily and titrate slowly.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

- Antidepressants: antagonism of anticonvulsant effect; avoid with St John’s wort.
- Antiepileptics: concentration of perampanel reduced, also increased oxcarbazepine concentration.
- Antimalarials: anticonvulsant effect antagonised by mefloquine.
- Antipsychotics: antagonism of anticonvulsant effect.
- Antivirals: concentration of rilpivirine and possibly daclatasvir and simprevir reduced – avoid; possibly reduces dolutegravir concentration.
- Ciclosporin: metabolism accelerated (reduced ciclosporin concentration).
- Clopidogrel: possibly reduced antiplatelet effect.
- Cytotoxics: concentration of imatinib reduced – avoid.
- Guanfacine: possibly reduces guanfacine concentration – increase dose of guanfacine.
- Oestrogens and progestogens: metabolism accelerated (reduced contraceptive effect).
- Orlistat: possible increased risk of convulsions.
- Tacrolimus: metabolism accelerated (reduced tacrolimus concentration).
- Ulipristal: possibly reduces contraceptive effect.

Administration

Reconstitution

- Route
  Oral

Rate of administration

- Other information
  - Hyponatraemia is more common with oxcarbazepine than carbamazepine, monitoring is recommended.
  - Maximum plasma concentrations reached after about 1 hour.
  - In severe renal impairment increase in at least weekly intervals.
Oxprenolol hydrochloride

**Clinical use**

Beta-1 adrenoceptor blocker:
- Hypertension
- Angina
- Arrhythmias
- Anxiety

**Dose in normal renal function**

- Hypertension, angina: 80–160 mg daily in 2–3 divided doses; maximum 320 mg daily
- Arrhythmias: 40–240 mg daily in 2–3 divided doses
- Anxiety: 40–80 mg daily in 1–2 divided doses

**Pharmacokinetics**

Molecular weight (daltons) 301.8
% Protein binding 70–80
% Excreted unchanged in urine <3
Volume of distribution (L/kg) 1.2
Half-life — normal/ESRF (hrs) 1–2 / Unchanged

**Metabolism**

Oxprenolol is extensively metabolised in the liver, direct O-glucuronidation being the major metabolic pathway and oxidative reactions minor ones. Oxprenolol is excreted chiefly in the urine (almost exclusively in the form of inactive metabolites).

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin; increased risk of withdrawal hypertension with clonidine; increased risk of bradycardia and AV block with diltiazem; severe hypotension and heart failure occasionally with nifedipine; asystole, severe hypotension and heart failure with verapamil.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics: enhanced hypotensive effect with phenothiazines.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possibly severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline (especially with non-selective beta-blockers) and possibly with dopamine.

**Administration**

Reconstitution

- Route
  - Oral

Rate of administration

**Other information**

- Use with caution in patients with chronic obstructive airways disease, asthma or diabetes.
- Rhabdomyolysis with myoglobinuria has been reported in severe overdosage with oxprenolol.
Oxybutynin hydrochloride

**Clinical use**
- Urinary frequency, urgency and incontinence
- Neurogenic bladder instability and nocturnal enuresis

**Dose in normal renal function**
- 2.5–5 mg 2–3 times a day; maximum 5 mg 4 times a day
- XL: 5–20 mg once daily
- Patches: 1 patch (36 mg) twice weekly

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>393.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>83–85</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>193 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.1–3 (XL: 12–13)</td>
</tr>
</tbody>
</table>

**Half-life**

- Normal: 1–3 hrs
- ESRF: 12–13 hrs

**Metabolism**

Oxybutynin undergoes extensive first-pass metabolism, particularly by the cytochrome P450 isoenzyme CYP3A4. One of the metabolites, N-desethyloxybutynin is pharmacologically active. Oxybutynin and its metabolites are excreted in the urine and faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose specification</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.
- Other antimuscarinic agents: increased antimuscarinic effects.

**Administration**

**Reconstitution**
- 

**Route**
- Oral, topical

**Rate of administration**
- 

**Other information**
- Start with a low dose in elderly patients and those with renal impairment, and increase according to response.
Oxycodone hydrochloride

**Clinical use**

Opioid analgesic for moderate to severe pain

**Dose in normal renal function**

- **Oral:** 5 mg 4–6 hourly; usual maximum dose 400 mg daily
- **M/R:** 10 mg 12 hourly; usual maximum dose 200 mg 12 hourly
- **IV:** 1–10 mg every 4 hours
- **IV infusion:** 2 mg/hour adjusted according to response
- **SC:** Initially 5 mg every 4 hours
- **SC infusion:** Initially 7.5 mg over 24 hours

**Pharmacokinetics**

- **Molecular weight (daltons):** 351.8
- **% Protein binding:** 45
- **% Excreted unchanged in urine:** <10
- **Volume of distribution (L/kg):** 1.2–6.31
- **Half-life — normal/ESRF (hrs):** 2–4 (4.5 M/R) / 3–5 (5.5 M/R)

**Metabolism**

Oxycodone is metabolised in the liver to produce noroxycodone via the CYP3A system, oxymorphone via the CYP2D6 system and various conjugated glucuronides. The analgesic effects of the metabolites are clinically insignificant. Both metabolites undergo glucuronidation and are excreted with unchanged drug in urine.

**Dose in renal impairment GFR (mL/min)**

- **20–50:** Start with 75% of dose. Dose as in normal renal function.
- **10–20:** Start with 75% of dose. Dose as in normal renal function.
- **<10:** Start with small doses e.g 50% of dose. See 'Other information'.

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD:** Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD:** Unknown dialysability. Dose as in GFR<10 mL/min.
- **HDF/High flux:** Dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD:** Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- **Analgesics:** possible opioid withdrawal with buprenorphine and pentazocine.
- **Antibacterials:** metabolism possibly increased by rifampicin; metabolism inhibited by telithromycin.
- **Antidepressants:** CNS excitation or depression with MAOIs – avoid; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- **Antifungals:** concentration increased by voriconazole.
- **Antihistamines:** increased sedative effects with sedating antihistamines.
- **Antipsychotics:** enhanced hypotensive and sedative effects.
- **Antivirals:** concentration possibly increased by ritonavir.
- **Dopaminergics:** avoid with selegiline.
- **Nalmefene:** avoid concomitant use.
- **Sodium oxybate:** enhanced effect of sodium oxybate – avoid.

**Administration**

**Reconstitution**

---

**Route**

Oral, IV, IM, SC

**Rate of administration**

Infusion over 24 hours

**Comments**

Dilute to a concentration of 1 mg/mL with glucose 5% or sodium chloride 0.9%.

**Other information**

- Has been used in CKD 5 patients; start with lowest dose and gradually increase dose according to response.
- Limited accumulation of metabolites in renal failure compared with morphine.
- 2 mg of oral oxycodone is approximately equivalent to 1 mg of parenteral oxycodone.
- Doses in renal impairment are from *Drug Prescribing in Renal Failure, 5th* edition by Aronoff et al.
**Oxytetracycline**

### Clinical use

Antibacterial agent

### Dose in normal renal function

- 250–500 mg 4 times a day
- Acne: 500 mg twice daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>460.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>20–40</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>10–35</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>9 / 66</td>
</tr>
</tbody>
</table>

### Metabolism

Metabolism is negligible. The tetracyclines are excreted in the urine and in the faeces. Renal clearance is by glomerular filtration. Up to 60% of an intravenous dose of tetracycline, and up to 55% of an oral dose, is eliminated unchanged in the urine. The tetracyclines are excreted in the bile, where concentrations 5–25 times those in plasma can occur. There is some enterohepatic reabsorption and considerable quantities occur in the faeces after oral doses.

### Dose in renal impairment GFR (mL/min)

- **20–50** Dose as in normal renal function.
- **10–20** Dose as in normal renal function.
- **<10** 250 mg 4 times a day.

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs

- Anticoagulants: possibly enhanced anticoagulant effect of coumarins and phenindione.
- Oestrogens: possibly reduced contraceptive effects of oestrogens (risk probably small).
- Retinoids: possible increased risk of benign intracranial hypertension with tetracyclines and retinoids – avoid.

### Administration

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

### Other information

- Avoid if possible in renal impairment, due to potential nephrotoxicity and increased risk of azotaemia, hyperphosphataemia and acidosis.
- May cause an increase in blood urea which is dose related.
- Avoid in SLE.
Paclitaxel

**Clinical use**

Antineoplastic agent:
- Ovarian and breast cancer
- Non-small cell lung carcinoma
- AIDS-related Kaposi’s sarcoma

Abraxane (Paclitaxel albumin):
- Metastatic breast cancer
- Metastatic adenocarcinoma of pancreas

**Dose in normal renal function**

- 100–220 mg/m² every 3 weeks depending on condition being treated, local regime and duration of infusion

Abraxane:
- Breast cancer: 260 mg/m² over 30 minutes every 3 weeks
- Pancreatic adenocarcinoma: 125 mg/m² over 30 minutes on days 1, 8 and 15 of a 28-day cycle
  - Or according to local protocol

**Pharmacokinetics**

Molecular weight (daltons) 853.9
% Protein binding 89–98
% Excreted unchanged in urine 1.3–12.6
Volume of distribution (L/kg) 227–688 Litres/m²
Half-life — normal/ESRF (hrs) 3–52.7 (Abraxane: 13.27) / –

**Metabolism**

The distribution and metabolism of paclitaxel in humans has not been fully investigated. The cumulative excretion of unchanged paclitaxel in the urine has been between 1.3% and 12.6% of the dose on average, which is an indication of extensive non-renal clearance. Hepatic metabolism by the action of CYP450 enzyme and biliary clearance are possibly the principal mechanisms for elimination of paclitaxel. An average of 26% of the radioactively marked dose of paclitaxel was eliminated in the faeces as a 6α-hydroxypaclitaxel, 2% as 3’p-dihydroxypaclitaxel and 6% as 6α-3’p-dihydroxypaclitaxel.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Cytotoxics: increased risk of neutropenia with lapatinib.

**Administration**

**Reconstitution**

Abraxane: Add 20 mL sodium chloride 0.9% to a 100 mg vial and 50 mL to a 250 mg vial

**Route**

IV

**Rate of administration**

Paclitaxel: 3 hours depending on regime

Abraxane: 30 minutes

**Comments**

Paclitaxel:
- Dilute to a concentration of 0.3–1.2 mg/mL with sodium chloride 0.9% or glucose 5%.
- Administer through a 0.22 μm in line filter.
- Use non-PVC infusion bags.
- Stable for 27 hours at room temperature. Paclitaxel albumin (Abraxane®) should be administered via a 15 μm in line filter.

**Other information**

- Abraxane manufacturer unable to advise on a dose in renal impairment due to lack of studies.
Palbociclib

Clinical use

Protein kinase inhibitor:
- Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer

Dose in normal renal function

125 mg once daily for 21 days of a 28-day cycle

Pharmacokinetics

Molecular weight (daltons) 447.5
% Protein binding 85
% Excreted unchanged in urine 7
Volume of distribution (L/kg) 2583 Litres
Half-life — normal/ESRF (hrs) 28.8

Metabolism

Palbociclib undergoes extensive hepatic metabolism. The main metabolic pathways for palbociclib involved oxidation and sulphonation, with acylation and glucuronidation contributing as minor pathways. Unchanged drug accounts for 2.3% and 6.9% of radioactivity in faeces and urine, respectively. In faeces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 26% of the administered dose.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Use only if benefit outweighs risk.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<30 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<30 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<30 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR<30 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly increased by clarithromycin – avoid or reduce palbociclib dose; concentration reduced by rifampicin – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin – avoid.
- Antifungals: concentration possibly increased by itraconazole, ketoconazole, posaconazole and voriconazole – avoid or reduce palbociclib dose.
- Antipsychotics: increased risk of agranulocytosis with clozapine – avoid.
- Antivirals: concentration possibly increased by indinavir, lopinavir, ritonavir, saquinavir and telaprevir – avoid or reduce palbociclib dose.
- Cytotoxics: concentration possibly reduced by enzalutamide – avoid.
- Grapefruit juice: concentration possibly increased – avoid

Administration

Reconstitution

Route
Oral

Rate of administration

Other information

- Use with caution in severe renal impairment due to lack of data. Use only if benefit outweighs the risks and monitor closely for toxicity.
- Based on a population pharmacokinetic analysis that included 183 patients with cancer, where 73 patients had mild renal impairment (CRCL=60–90 mL/min) and 29 patients had moderate renal impairment (CRCL=30–60 mL/min), mild and moderate renal impairment had no effect on the exposure of palbociclib.
- Oral bioavailability is 46%.
### Paliperidone

#### Clinical use
Atypical antipsychotic for schizophrenia

#### Dose in normal renal function
- Oral: 3–12 mg once daily
- IM: 25–150 mg monthly

#### Pharmacokinetics
- Molecular weight (daltons): 426.5
- % Protein binding: 74
- % Excreted unchanged in urine: 59
- Volume of distribution (L/kg): 487 Litres
- Half-life — normal/ESRF (hrs): 23 / 51

#### Metabolism
Paliperidone is the active metabolite of risperidone. Four metabolic pathways have been identified in vivo, none of which accounted for more than 6.5% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. Following administration of $^{14}$C-paliperidone, 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolised in the liver. Approximately 80% of the administered radioactivity was recovered in urine and 11% in the faeces.

#### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Oral: 3 mg once daily and increase according to response. IM: Dose as in normal renal function for maintenance dose, reduce loading dose.</th>
<th>1.5 mg once daily, increasing to 3 mg daily according to response. IM: No experience.</th>
<th>1.5 mg daily, increasing to 3 mg daily according to response. IM: No experience.</th>
<th>3 mg alternate days, increasing to 3 mg daily according to response. Use with caution. IM: No experience.</th>
</tr>
</thead>
<tbody>
<tr>
<td>50–80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of ventricular arrhythmias when given with anti-arrhythmics that prolong the QT interval.
- Antidepressants: increases concentration of tricyclics (possibly increased risk of ventricular arrhythmias).
- Antiepileptics: antagonise anticonvulsant effect (convulsive threshold lowered); concentration reduced by carbamazepine.
- Antimalarials: avoidance of antipsychotics advised by manufacturer of artemether/lumefantrine.
- Antipsychotics: possible increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration possibly increased by ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias with atomoxetine.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.

#### Administration

##### Reconstitution
- 

##### Route
- Oral

##### Rate of administration
- 

##### Other information
- Clearance is reduced by 71% in ERF.
- Contraindicated (by manufacturer) in patients with GFR<10 mL/min, due to lack of experience.
**Palonosetron**

**Clinical use**

Anti-emetic:
- For use with cancer chemotherapy

**Dose in normal renal function**

- IV: 250 mcg as a single dose approximately 30 minutes before chemotherapy
- Oral: 500 mcg as a single dose approximately 60 minutes before chemotherapy

**Pharmacokinetics**

- Molecular weight (daltons) 332.9 (as hydrochloride)
- % Protein binding 62
- % Excreted unchanged in urine 40
- Volume of distribution (L/kg) 6.9–7.9
- Half-life — normal/ESRF (hrs) 40 / –

**Metabolism**

Palonosetron is eliminated by a dual route, about 40% eliminated through the kidney and approximately 50% metabolised by CYP2D6, and to a lesser extent, CYP3A4 and CYP1A2 isoenzymes in the liver to form two primary metabolites, which have less than 1% of the 5HT₃ receptor antagonist activity of palonosetron. After a single intravenous dose of [¹⁴C]-palonosetron, approximately 80% of the dose was recovered within 144 hours in the urine with unchanged palonosetron representing approximately 40% of the administered dose.

**Dose in renal impairment GFR (mL/min)**

- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

**Route**

IV bolus, oral

**Rate of administration**

30 seconds

**Other information**

- Use with caution in people at risk of QT prolongation.
## Pancreatin

### Clinical use
Pancreatic enzyme replacement

### Dose in normal renal function
1–10 capsules (depends on preparation) with meals, adjusted according to response
(1–2 capsules with meals if using the strong preparation)

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>No data</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

### Metabolism
Pharmacokinetic data are not available as the enzymes act locally in the gastrointestinal tract. After exerting their action, the enzymes are digested themselves in the intestine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- None known

### Administration

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

### Other information
- Not absorbed from GI tract.
## Pancuronium bromide

### Clinical use
Non-depolarising muscle relaxant of long duration

### Dose in normal renal function
Initial dose: 50–100 micrograms/kg then
Incremental dose: 10–20 micrograms/kg as required

Intensive care: Initially 100 mcg/kg (optional) then 60 mcg/g every 60–90 minutes

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>732.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>80–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40–60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.15–0.38</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2 / 4.3–8.2</td>
</tr>
</tbody>
</table>

### Metabolism
A small proportion of pancuronium is metabolised in the liver to metabolites with weak neuromuscular blocking activity.

It is largely excreted in urine as unchanged drug and metabolites; a small amount is excreted in bile.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td></td>
<td>Initial dose: 25–50 micrograms/kg.</td>
</tr>
<tr>
<td></td>
<td>Incremental dose: 5–10 micrograms/kg.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td></td>
<td>Initial dose: 10–25 micrograms/kg.</td>
</tr>
<tr>
<td></td>
<td>Incremental dose: 2.5–5 micrograms/kg.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td></td>
<td>Initial dose: 10–25 micrograms/kg.</td>
</tr>
<tr>
<td></td>
<td>Incremental dose: 2.5–5 micrograms/kg.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced muscle relaxant effect.
- Anti-arrhythmics: procainamide enhances muscle relaxant effect.
- Antibacterials: effect enhanced by aminoglycosides, clindamycin, polymyxins and piperacillin.
- Antiepileptics: muscle relaxant effects antagonised by carbamazepine; effects reduced by long-term use of fosphenytoin and phenytoin but might be increased by acute use.
- Botulinum toxin: neuromuscular block enhanced (risk of toxicity).

### Administration

<table>
<thead>
<tr>
<th>Reconstitution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route</td>
</tr>
<tr>
<td>IV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rate of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolus</td>
</tr>
</tbody>
</table>

### Other information
- Active metabolites accumulate in CKD 5; duration of action prolonged.
- Dose in severe renal impairment estimated from evaluation of pharmacokinetic data.
- Pancuronium distributes rapidly into extracellular fluid and the initial neuromuscular blockade produced will depend upon the peak drug concentration in this fluid. Since extracellular fluid volume is increased in chronic renal failure such patients may require a larger initial dose of pancuronium and a 45% increase in dose requirement has been reported in patients with end-stage renal failure. (Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Br J Anaesth. 1987; 59(8): 995–1003.)
Panitumumab

**Clinical use**
Monoclonal antibody:
- Treatment of metastatic colorectal cancer

**Dose in normal renal function**
- 6 mg/kg every 2 weeks
- Consult relevant local protocol

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>147 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.042 central; 0.026 peripheral¹</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3.6–10.9 days / –</td>
</tr>
</tbody>
</table>

**Metabolism**
Saturable elimination mediated via reticuloendothelial system, and internalisation and degradation of EGFR.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Cytotoxics: avoid with bevacizumab, fluorouracil, irinotecan and oxaliplatin.
- Folinic acid: avoid concomitant use.
- Live vaccines: avoid concomitant use.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Rate of administration</th>
<th>Comments</th>
</tr>
</thead>
</table>
| IV    | Over 30–90 minutes depending on dose and tolerability | Add to 100 mL of sodium chloride 0.9% to give a concentration no greater than 10 mg/mL. Doses >1000 mg should be added to 150 mL sodium chloride 0.9%.

**Other information**

- Manufacturer is unable to provide a dose in renal impairment due to lack of studies although renal impairment did not affect the pharmacokinetics.
- AKI has been seen in patients who develop severe diarrhoea and dehydration.

**Reference:**
Revised 01/11/2016.
Panobinostat

Clinical use
Histone deacetylase (HDAC) inhibitor:
• Treatment of relapsed and/or refractory multiple myeloma

Dose in normal renal function
20 mg once a day, on days 1, 3, 5, 8, 10 and 12 of a 21-day cycle

Pharmacokinetics
Molecular weight (daltons) 349.4
% Protein binding 90
% Excreted unchanged in urine <2.5
Volume of distribution (L/kg) 1000 Litres
Half-life — normal/ESRF (hrs) 37

Metabolism
Panobinostat is extensively metabolised, and a large fraction of the dose is metabolised before reaching the systemic circulation by reduction, hydrolysis, oxidation and glucuronidation. Oxidative metabolism of panobinostat played a less prominent role, with approximately 40% of the dose eliminated by this pathway. Cytochrome P450 3A4 (CYP3A4) is the main oxidation enzyme, with potential minor involvement of CYP2D6 and 2C19.
Panobinostat represented 6–9% of the drug-related exposure in plasma. The parent substance is deemed to be responsible for the overall pharmacological activity of panobinostat.
After a single oral dose of [14C]-panobinostat in patients, 29–51% of administered radioactivity is excreted in the urine and 44–77% in the faeces. Unchanged panobinostat accounted for <2.5% of the dose in urine and <3.5% of the dose in faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Analgesics: avoid with dextromethorphan possibly increased risk of ventricular arrhythmias with methadone – avoid.
• Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone and possibly disopyramide – avoid.
• Antibacterials: increased risk of ventricular arrhythmias with clarithromycin and moxifloxacin – avoid; avoid with rifampicin.
• Antidepressants: avoid with St John’s wort.
• Antiepileptics: avoid with carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
• Antifungals: concentration increased by ketoconazole and possibly posaconazole and voriconazole – reduce panobinostat dose; concentration possibly increased by itraconazole – avoid.
• Antimalarials: possibly increased risk of ventricular arrhythmias with chloroquine – avoid.
• Antipsychotics: avoid with pimozide.
• Antivirals: concentration possibly increased by ritonavir and saquinavir – reduce dose of panobinostat.
• Beta-blockers: possibly increased risk of ventricular arrhythmias with sotalol – avoid.
• Grapefruit juice: avoid concomitant use.
• 5HT3 antagonists: possibly increased risk of ventricular arrhythmias with granisetron and ondansetron – avoid with granisetron.
<table>
<thead>
<tr>
<th>Administration</th>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reconstitution</td>
<td>• The effect of renal impairment on the pharmacokinetics of panobinostat was assessed in a phase I study in 37 patients with advanced solid tumours with varying degrees of renal function. Mild, moderate and severe renal impairment based on baseline urinary creatinine clearance did not increase the panobinostat plasma exposure in mild, moderate and severe groups.</td>
</tr>
<tr>
<td>Route Oral</td>
<td></td>
</tr>
<tr>
<td>Rate of administration</td>
<td></td>
</tr>
</tbody>
</table>
Pantoprazole

**Clinical use**
Gastric acid suppression

**Dose in normal renal function**
Oral: 20–80 mg in the morning
IV: 40–160 mg daily; doses >80 mg in 2 divided doses

**Pharmacokinetics**
- Molecular weight (daltons): 383.4
- % Protein binding: 98
- % Excreted unchanged in urine: 80 (as metabolites)
- Volume of distribution (L/kg): 0.15
- Half-life — normal/ESRF (hrs): 1 / 2–3

**Metabolism**
Pantoprazole is extensively metabolised in the liver, primarily by the cytochrome P450 isoenzyme CYP2C19, to desmethylpantoprazole; small amounts are also metabolised by CYP3A4, CYP2D6, and CYP2C9. Metabolites are excreted mainly in the urine, with the remainder being excreted in faeces via the bile.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs:
- Anticoagulants: effect of coumarins possibly enhanced.
- Antifungals: absorption of itraconazole and ketoconazole reduced; avoid with posaconazole.
- Antivirals: concentration of atazanavir and rilpivirine reduced – avoid; concentration of raltegravir and saquinavir possibly increased – avoid.
- Clopidogrel: possibly reduced antiplatelet effect.
- Cytotoxics: possibly reduced excretion of methotrexate; avoid with dasatinib, erlotinib and vandetanib; possibly reduced lapatinib absorption; possibly reduced absorption of pazopanib.
- Ulipristal: reduced contraceptive effect, avoid with high dose ulipristal.

**Administration**
**Reconstitution**
10 mL sodium chloride 0.9%

**Route**
Oral, IV

**Rate of administration**
2–15 minutes

**Comments**
Use within 12 hours of reconstitution. Dilute to 100 mL with sodium chloride 0.9% or glucose 5%.
Clinical use

Opiate analgesia
(15.4 mg/mL) 1 mL contains 10 mg anhydrous morphine, 1.2 mg papaverine HCl, and 1.04 mg codeine HCl

Dose in normal renal function

SC/IM: 0.5–1 mL (7.7–15.4 mg) every 4 hours
IV: 25–50% of dose

Pharmacokinetics

<table>
<thead>
<tr>
<th></th>
<th>Papaverine HCl</th>
<th>Morphine HCl</th>
<th>Codeine HCl</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>375.8</td>
<td>375.8</td>
<td>371.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
<td>20–35</td>
<td>7</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>1</td>
<td>10</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Volume of distribution (L/Kg)</td>
<td>0.99–1.52</td>
<td>3–5</td>
<td>3–4</td>
</tr>
<tr>
<td>Half-life - normal/ESRF (hrs)</td>
<td>1.2–2.2</td>
<td>2–3</td>
<td>2.5–4</td>
</tr>
</tbody>
</table>

Metabolism

Papaverine: Mainly metabolised in the liver and excreted in the urine, almost entirely as glucuronide-conjugated phenolic metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>0.4–0.75 mL every 6–8 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>0.25–0.5 mL every 6–8 hours. Avoid if possible.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Analgesics: possible opioid withdrawal with buprenorphine and pentazocine.
- Anti-arrhythmics: delayed absorption of mexiletine.
- Antidepressants: possible CNS excitation or depression with MAOIs – avoid; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects.
- Dopaminergics: avoid with selegiline.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

Administration

Reconstitution
—

Route
SC, IM, IV

Rate of administration
IV bolus or continuous infusion (1 mg/mL)

Other information

- As with all opiates, use with extreme caution in patients with impaired renal function.
- May cause excessive sedation and respiratory depression.
# Paracetamol

## Clinical use

Analgesia and antipyretic

## Dose in normal renal function

500 mg – 1 g every 4–6 hours, maximum 4 g daily

(IV: if <50 kg, dose is 15 mg/kg)

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>500 mg – 1 g every 6–8 hours.</td>
</tr>
</tbody>
</table>

## Pharmacokinetics

- Molecular weight (daltons): 151.2
- % Protein binding: 20–30
- % Excreted unchanged in urine: <5
- Volume of distribution (L/kg): 1–2

## Metabolism

Paracetamol is metabolised mainly in the liver and excreted in the urine mainly as the glucuronide and sulfate conjugates. Less than 5% is excreted as unchanged paracetamol. A minor hydroxylated metabolite (N-acetyl-p-benzoquinoneimine), is usually produced in very small amounts by cytochrome P450 isoenzymes (mainly CYP2E1 and CYP3A4) in the liver and kidney. It is usually detoxified by conjugation with glutathione but may accumulate after paracetamol overdosage and cause tissue damage.

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

- Potentially hazardous interactions with other drugs: None known

## Administration

### Reconstitution

- **Route**: Oral, rectal, IV

### Rate of administration

- 15 minutes

## Other information

- Beware sodium content of soluble tablets (1 tablet ≡ 18.6 mmol sodium).
- Nephrotoxic in overdose due to a reactive alkylating metabolite.
- Metabolites may accumulate in CKD 5; normal doses are used in CKD 5.
- In smaller patients with CKD 5 a maximum oral dose of 3 g per day should be considered.
- IV preparation starts working within 5–10 minutes with peak activity after 60 minutes.
Parathyroid hormone

<table>
<thead>
<tr>
<th>Clinical use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of chronic hypoparathyroidism</td>
</tr>
</tbody>
</table>

**Dose in normal renal function**

- Initially 25–50 mcg daily, adjust dose according to calcium level
- Maximum dose: 100 mcg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>9420</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0 (all broken down into small fragments)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>5.4 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3</td>
</tr>
</tbody>
</table>

**Metabolism**

Parathyroid hormone is metabolised in the liver and to a lesser degree in the kidney. Parathyroid hormone is not excreted from the body in its intact form. Circulating carboxy-terminal fragments are filtered by the kidney, but are subsequently broken to even smaller fragments during tubular reuptake. Parathyroid hormone is efficiently removed from the blood by a receptor-mediated process in the liver and is broken down into smaller peptide fragments. The fragments derived from the amino-terminus are further degraded within the cell while the fragments derived from the carboxy-terminus are released back into the blood and cleared by the kidney. These carboxy-terminal fragments are thought to play a role in the regulation of parathyroid hormone activity.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function. Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR &lt;30 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=30–50 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Bisphosphonates: reduction of calcium-sparing effect with alendronate – avoid.

**Administration**

**Reconstitution**

- Route
  - SC

**Rate of administration**

- 1

**Other information**

- There is no data available in patients with severe renal impairment (CRCL<30 mL/min) therefore the manufacturer advises to use with caution in this group.
- Some of the mechanisms of action of parathyroid hormone (e.g. conversion of 25-OH vitamin D to 1,25-OH2 vitamin D) are dependent on renal function.
- Bioavailability is 53%.
- Pharmacokinetics following a single 100 micrograms SC dose of parathyroid hormone was evaluated in 16 subjects with normal renal function and 16 subjects with renal impairment. The mean maximum concentration (C\text{max}) of PTH following 100 micrograms parathyroid hormone in subjects with mild-to-moderate renal impairment (CRCL=30–80 mL/min) was approximately 23% higher than that observed in subjects with normal renal function. Exposure to PTH as measured by AUC\text{0-last} and baseline-corrected AUC\text{0-last} was approximately 3.9% and 2.5%, respectively, higher than that observed for subjects with normal renal function.
- Hypercalcaemia and hypercalciuria are very common with parathyroid hormone treatment, and persistent hypercalcaemia may necessitate dose reduction or withdrawal of therapy.
Parecoxib

**Clinical use**

Cox 2 inhibitor:
- Short-term treatment of postoperative pain

**Dose in normal renal function**

40 mg initially then 20–40 mg every 6–12 hours if required; maximum dose 80 mg daily
Elderly weighing <50 kg: 20–40 mg daily

**Pharmacokinetics**

Molecular weight (daltons) 392.4 (as sodium salt)
% Protein binding 98
% Excreted unchanged in urine <5 (as valdecoxib)
Volume of distribution (L/kg) 55 Litres
Half-life — normal/ESRF (hrs) 8 (as valdecoxib) / Unchanged

**Metabolism**

Parecoxib is rapidly and almost completely converted to valdecoxib and propionic acid. Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulphonamide moiety.
Excretion is mainly via the urine with about 70% of a dose appearing as inactive metabolites. No unchanged parecoxib is found in the urine with only trace amounts in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but only use if ERF on dialysis.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possible increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetics: possibly enhanced effect of sulphonylureas.
- Antiepileptics: possibly enhanced effect of phenytoin.
- Antifungals: if used with fluconazole reduce the dose of parecoxib.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: potential for increased risk of nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate, (possible increased risk of toxicity); increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; possible antagonism of diuretic effect; increased risk of hyperkalaemia with potassium-sparing diuretics.
- Lithium: reduced excretion of lithium (risk of toxicity).
- Pentoxifylline: possibly increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**
2 mL sodium chloride 0.9%

**Route**
IV, IM

**Rate of administration**
—

**Other information**

- Clinical trials have shown renal effects similar to those observed with comparative NSAIDs. Monitor
patient for deterioration in renal function and fluid retention.

- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if raised, discontinue NSAID therapy.
- Use normal doses in patients with ERF on dialysis.
- Use with caution in renal transplant recipients (can reduce intrarenal autocoid synthesis).
- Parecoxib should be used with caution in uraemic patients predisposed to gastrointestinal bleeding or uraemic coagulopathies.
- Works within 30 minutes.
- Contraindicated in patients with ischaemic heart disease or cerebrovascular disease and class II-IV NYHA congestive heart failure.
Paricalcitol

**Clinical use**

Vitamin D analogue:
- Treatment and prevention of secondary hyperparathyroidism associated with chronic renal failure

**Dose in normal renal function**

- IV: Give dose every other day or post dialysis; dose is dependent on PTH levels. See SPC for details
- Oral: 1–4 mcg either daily or 3 times a week according to PTH levels

**Pharmacokinetics**

- Molecular weight (daltons) 416.6
- % Protein binding >99
- % Excreted unchanged in urine 0 (16% as metabolites)
- Volume of distribution (L/kg) 17–25 Litres (6 Litres in haemodialysis patients)
- Half-life — normal/ESRF (hrs) 15 (oral 5–7) / Unchanged

**Metabolism**

Extensively metabolised via hepatic and non-hepatic pathways to form two relatively inactive metabolites. After oral administration of \(^3 \text{H}\)-paricalcitol, only about 2% of the dose was eliminated unchanged in the faeces, and no parent drug found in the urine. Approximately 70% of the radioactivity was eliminated in the faeces and 18% was recovered in the urine. Most of the systemic exposure was from the parent drug.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

- **Route:** IV, oral

**Rate of administration**

- Not less than 30 seconds

**Other information**

- Monitor calcium and phosphate levels at least monthly, more frequently during dose titration.
- Paricalcitol solution for injection contains 30% v/v of propylene glycol as an excipient. Isolated cases of central nervous system depression, haemolysis, and lactic acidosis have been reported as toxic effect associated with propylene glycol administration at high doses. Although they are not expected to be found with paricalcitol administration (as propylene glycol is eliminated during the dialysis process), the risk of toxic effects in overdosing situations has to be taken into account.
- Paricalcitol injection contains 20% v/v of ethanol (alcohol). Each dose may contain up to 1.3 g ethanol. Harmful for those suffering from alcoholism.
Paroxetine

Clinical use
Antidepressant:
• Panic disorders
• Obsessive compulsive disorder
• Social anxiety
• Post traumatic stress disorder

Dose in normal renal function
10–60 mg daily depending on indication

Pharmacokinetics
Molecular weight (daltons) 329.4
% Protein binding 95
% Excreted unchanged in urine <2
Volume of distribution (L/kg) 13
Half-life — normal/ESRF (hrs) 24 / 30

Metabolism
Paroxetine is extensively metabolised in the liver to pharmacologically inactive metabolites. Urinary excretion of unchanged paroxetine is generally less than 2% of dose whilst that of metabolites is about 64% of dose. About 36% of the dose is excreted in faeces, probably via the bile, of which unchanged paroxetine represents less than 1% of the dose. Thus paroxetine is eliminated almost entirely by metabolism.

Dose in renal impairment GFR (mL/min)
30–50 Dose as in normal renal function.
10–30 20 mg daily and titrate slowly.
<10 20 mg daily and titrate slowly.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as for GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Analgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol; concentration of methadone possibly increased.
• Anti-arrhythmics: possibly inhibits propafenone metabolism (increased risk of toxicity).
• Anticoagulants: effect of coumarins possibly enhanced; possibly increased risk of bleeding with dabigatran.
• Antidepressants: avoid concomitant use with MAOIs and moclobemide (increased risk of toxicity); avoid with St John’s wort; possibly enhanced serotonergic effects with duloxetine; can increase concentration of tricyclics; possible increased risk of convulsions with vortioxetine.
• Antiepileptics: antagonism (lowered convulsive threshold); concentration reduced by phenytoin and phenobarbital.
• Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
• Antipsychotics: concentration of clozapine and possibly risperidone increased; metabolism of perphenazine inhibited, reduce dose of perphenazine; possibly inhibits aripiprazole metabolism, reduce aripiprazole dose; concentration possibly increased by asenapine; increased risk of ventricular arrhythmias with pimozide – avoid.
• Antivirals: concentration possibly reduced by darunavir and ritonavir.
• Beta blockers: concentration of metoprolol possibly increased – increased risk of AV block – avoid in cardiac insufficiency.
• Dapoxetine: possible increased risk of serotonergic effects – avoid.
• Dopaminergics: increased risk of hypertension and CNS excitation with selegiline – avoid; increased risk of CNS toxicity with rasagiline – avoid.
• Hormone antagonists: metabolism of tamoxifen to active metabolite possibly reduced – avoid.
• 5HT, agonists: risk of CNS toxicity increased by sumatriptan – avoid; possibly increased risk of serotonergic effects with naratriptan.
• Lithium: increased risk of CNS effects – monitor levels.
• Methylthioninium: risk of CNS toxicity – avoid if possible.
<table>
<thead>
<tr>
<th>Administration</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reconstitution</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td>Rate of administration</td>
</tr>
</tbody>
</table>
Pasireotide

Clinical use
- Treatment of Cushing’s disease when surgery has failed or is inappropriate (pasireotide diaspartate)
- Acromegaly (pasireotide pamoate)

Dose in normal renal function
- Cushing’s disease: 600–900 mcg twice daily
- Acromegaly: 20–60 mg every 4 weeks

Pharmacokinetics
Molecular weight (daltons) 1047.2 (diaspartate: 1313.4, pamoate: 1435.6)
% Protein binding 88
% Excreted unchanged in urine 8
Volume of distribution (L/kg) >100 Litres
Half-life — normal/ESRF (hrs) 9–12

Metabolism
Pasireotide is metabolically highly stable and in vitro data show that pasireotide is not a substrate, inhibitor or inducer of any major enzymes of CYP450. In healthy volunteers, pasireotide is mainly found in the unchanged form in plasma, urine and faeces.
Pasireotide is eliminated mainly by hepatic clearance and is mostly found, unchanged, in the faeces (48%) and urine.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Unlikely to be dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antifungals: avoid with ketoconazole.
- Ciclosporin: possibly reduces ciclosporin concentration.

Administration
Reconstitution
Pasireotide pamoate – with 2 mL solvent provided
Route
SC (pasireotide diaspartate), IM (pasireotide pamoate)
Rate of administration
-

Other information
- Renal clearance has a minor contribution to the elimination of pasireotide. In a clinical study with single SC dose administration of 900 mcg pasireotide in subjects with mild, moderate or severe renal impairment or ESRD there was not a significant impact on total pasireotide plasma exposure. The unbound plasma pasireotide exposure (AUCinf,u) was increased in subjects with renal impairment (mild: 33%; moderate: 25%, severe: 99%, ESRD: 143%) compared to control subjects.
- Due to the increase in unbound drug exposure, pasireotide should be used with caution in patients with severe renal impairment or ESRD. Although manufacturer does not recommend a dose reduction in renal disease.
Patiromer sorbitex calcium

**Clinical use**

Treatment of hyperkalaemia

**Dose in normal renal function**

- 8.4 g once daily
- Maximum 25.2 g once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>344.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>—</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>—</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>—</td>
</tr>
</tbody>
</table>

**Metabolism**

N/A as not systemically absorbed.
Patiromer is excreted approximately 24–48 hours after intake, based on average gastrointestinal transit time. Excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Give 3 hours after oral medication.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Comments**

Mix with water or apple or cranberry juice.

**Other information**

- Onset of action is 4–7 hours.
- Manufacturer has limited data in dialysis patients.
- The sorbitol content is approximately 4 g (10.4 kcal) per 8.4 g of patiromer.
## Clinical use

Tyrosine kinase inhibitor:
- Treatment of metastatic renal cell carcinoma and soft tissue sarcoma

## Dose in normal renal function

- 800 mg once daily
- Consult relevant local protocol

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>474 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Large</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>30.9 / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism

Metabolism primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8. The four principle pazopanib metabolites account for only 6% of the exposure in plasma. One of these metabolites inhibits the proliferation of VEGF-stimulated human umbilical vein endothelial cells with a similar potency to that of pazopanib, the others are 10- to 20-fold less active. Therefore, activity of pazopanib is mainly dependent on parent pazopanib exposure. Elimination is mostly via the faeces.

## Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: avoid with clarithromycin, rifampicin and telithromycin.
- Antifungals: avoid with itraconazole, ketoconazole and voriconazole.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Antivirals: avoid with atazanavir, boceprevir, indinavir, ritonavir and saquinavir.
- Grapefruit juice: avoid concomitant administration.
- Avoid concomitant use with other inhibitors or inducers of CYP3A4. Dose alterations may be required.

## Administration

### Reconstitution

- **Route**: Oral

### Rate of administration

- —

## Other information

- Manufacturer advises to use pazopanib with caution if GFR<30 mL/min due to lack of studies but clearance is unlikely to be affected due to low renal excretion.
- LFTs should be measured before and regularly during treatment.
Pegfilgrastim

**Clinical use**

Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF):
- Reduction of duration of neutropenia (except in chronic myeloid leukaemia and myelodysplastic syndromes)

**Dose in normal renal function**

6 mg given approximately 24 hours post chemotherapy

**Pharmacokinetics**

- Molecular weight (daltons) 39 000
- % Protein binding Very high (filgrastim)
- % Excreted unchanged in urine Minimal
- Volume of distribution (L/kg) 0.15 (filgrastim)
- Half-life — normal/ESRF (hrs) 15–80 / Unchanged

**Metabolism**

Eliminated by neutrophil-mediated clearance.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD Not dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Cytotoxics: neutropenia possibly exacerbated if administered with capecitabine, fluorouracil and tegafur.

**Administration**

**Reconstitution**

- **Route**
  - SC

**Rate of administration**

- **Comments**
  Incompatible with sodium chloride solutions. Discard after 72 hours if left at room temperature.

**Other information**

- Pegfilgrastim is a sustained-release form of filgrastim.
Peginterferon alfa

Clinical use
Treatment of chronic hepatitis B and C infection with or without ribavirin

Dose in normal renal function
- ViraferonPeg: 1.5 mcg/kg once weekly in combination with ribavirin
- Monotherapy: 0.5–1 mcg/kg once weekly
- Pegasys: 180 mcg weekly

Pharmacokinetics
- Molecular weight (daltons): 40 000
- Protein binding: No data
- % Excreted unchanged in urine: 30
- Volume of distribution (L/kg): 0.99
- Half-life — normal/ESRF (hrs): 40–80 / Increased by about 25–45%

Metabolism
The metabolism is not known. Clearance is via the kidneys.

Dose in renal impairment GFR (mL/min)
- 30–50
  - Pegasys: Dose as in normal renal function.
  - ViraferonPeg: Reduce starting dose by 25%. See ‘Other information’.
- 15–30
  - Pegasys: 135 mcg once weekly.
  - ViraferonPeg: Reduce dose by 50%. See ‘Other information’.
- <15
  - Pegasys: 135 mcg once weekly.
  - ViraferonPeg: Reduce dose and use with caution. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<15 mL/min.
- HD: Dialysed. Dose as in GFR<15 mL/min. See ‘Other information’.
- HDF/High flux: Dialysed. Dose as in GFR<15 mL/min. See ‘Other information’.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=15–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: inhibits metabolism of aminophylline and theophylline (enhanced effect).
- Antivirals: use adefovir with caution; increased risk of peripheral neuropathy with telbivudine.
- Immunosuppressants: (e.g. ciclosporin, tacrolimus, sirolimus) may have an antagonistic effect.

Administration
Reconstitution
0.7 mL water for injection or pre-filled syringes
Route
SC
Rate of administration
—
Comments
Stable for 24 hours at 2–8°C after reconstitution.

Other information
- Administer 12 hours after haemodialysis.
- ViraferonPeg should be used with caution if GFR<15 mL/min due to lack of studies.
- If renal function deteriorates discontinue ViraferonPeg.
- US data sheet suggests using 50% of the dose in haemodialysis patients and monitor carefully.
- In haemodialysis patients, 135 mcg Pegasys is equivalent to a 180 mcg dose in the general population. Reduce to 90 mcg if required due to adverse effects.
- In patients with CKD 5 undergoing haemodialysis there is a 25–45% reduction in clearance compared with patients with normal renal function.
Pembrolizumab

**Clinical use**
Humanised monoclonal antibody:
- Treatment of advanced melanoma
- Treatment of non-small cell lung carcinoma (NSCLC)
- Treatment of relapsed or refractory classical Hodgkin lymphoma (cHL)
- Treatment of urothelial carcinoma

**Dose in normal renal function**
- NSCLC not previously treated, cHL, urothelial carcinoma: 200 mg every 3 weeks
- NSCLC previously treated or melanoma: 2 mg/kg every 3 weeks

**Pharmacokinetics**
- Molecular weight (daltons) 149 000
- % Protein binding 0
- % Excreted unchanged in urine No data
- Volume of distribution (L/kg) 7.5 Litres
- Half-life — normal/ESRF (hrs) 25 days

**Metabolism**
Pembrolizumab undergoes catabolism to small peptides and single amino acids via general protein degradation routes and does not rely on metabolism for clearance.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>15–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Dose as in normal renal function. Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=15–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Vaccines: risk of generalised infections with live vaccines – avoid.

**Administration**

**Reconstitution**
- **Route**
  - IV infusion

**Rate of administration**
- Over 30 minutes

**Comments**
Withdraw the required volume up to 4 mL (100 mg) of concentrate and transfer into a bag containing sodium chloride 0.9% or glucose 5% to prepare a diluted solution with a final concentration ranging from 1–10 mg/mL.
Each vial contains an excess fill of 0.25 mL (total content per vial 4.25 mL) to ensure the recovery of 4 mL of concentrate. Mix diluted solution by gentle inversion.
Use a sterile, non-pyrogenic, low-protein binding 0.2–5 μm in-line or add-on filter.

**Other information**
- Manufacturer has no information in severe renal impairment.
- No clinically important differences in the clearance of pembrolizumab were found between patients with mild or moderate renal impairment and patients with normal renal function.
- There is a case report of a patient on haemodialysis being treated successfully for melanoma at normal doses. (Chang R, Shirai K. Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Rep. 2016 Sep 22; Epub doi: 10.1136/bcr-2016-216426.)
**Pemetrexed**

**Clinical use**
- Treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma in combination with cisplatin
- Monotherapy for non-small cell lung cancer

**Dose in normal renal function**
500 mg/m² on the first day of each 21-day cycle

**Pharmacokinetics**
- Molecular weight (daltons): 471.4 (as disodium)
- % Protein binding: 81
- % Excreted unchanged in urine: 70–90
- Volume of distribution (L/kg): 6–9 Litres/m²
- Half-life — normal/ESRF (hrs): 2–4 / Increased

**Metabolism**
Pemetrexed undergoes minimal hepatic metabolism, and about 70–90% of a dose is eliminated unchanged in the urine within 24 hours. In vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter).

**Dose in renal impairment GFR (mL/min)**
- 45–50: Dose as in normal renal function.
- 20–45: Use with caution, at a lower dose. See ‘Other information’.
- <20: Use with caution, at a lower dose. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<20 mL/min.
- HD: Not dialysed.¹ Dose as in GFR<20 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<20 mL/min.
- CAV/VVHD: Not dialysed.¹ Dose as in GFR=20–45 mL/min.

**Important drug interactions**
- Potentially hazardous interactions with other drugs:
  - Antimalarials: antifolate effect increased by pyrimethamine.
  - Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
  - Nephrotoxic agents: may reduce clearance of pemetrexed – use with caution.
  - Live vaccines: avoid use; YELLOW FEVER VACCINE ABSOLUTELY CONTRAINDIQUED.

**Administration**

**Reconstitution**
20 mL sodium chloride 0.9% per 500 mg vial

**Route**
IV infusion

**Rate of administration**
Over 10 minutes

**Comments**
Dilute in 100 mL preservative-free sodium chloride 0.9%. Incompatible with calcium containing fluids.

**Other information**
- Not recommended by manufacturer if GFR<45 mL/min due to lack of data.
- To reduce the incidence and severity of skin reactions, a steroid (equivalent to 4 mg of dexamethasone) should be given the day before, the day of, and the day after pemetrexed therapy. Patients should also take a vitamin preparation containing folic acid and IM vitamin B₁₂.
- 25% of patients get reversible mild renal dysfunction.
- In one study, pemetrexed was discontinued in patients with a GFR<30 mL/min after a patient with a GFR=19 mL/min died due to drug related toxicities. (Mita C, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. *J Clin Oncol*. 2006; 24(4): 552–62.)

**Reference:**
Penicillamine

Clinical use
Rheumatoid arthritis, Wilson’s disease, cystinuria, lead poisoning, chronic active hepatitis

Dose in normal renal function
- Rheumatoid arthritis: 125–250 mg daily for first month; increase by same amount every 4–12 weeks until remission occurs. Maintenance dose: usually 500–750 mg daily in divided doses. Maximum 1.5 g daily
- Wilson’s disease: 750–2000 mg daily in divided doses
- Cystinuria: Dissolution: 1–3 g daily in divided doses. Prevention: 500–1000 mg on retiring
- Lead poisoning: 1–1.5 g daily in divided doses
- Chronic active hepatitis: 500–1250 mg daily in divided doses

Pharmacokinetics
- Molecular weight (daltons) 149.2
- % Protein binding 80
- % Excreted unchanged in urine 10–40
- Volume of distribution (L/kg) 0.8
- Half-life — normal/ESRF (hrs) 1–3 / Increased

Metabolism
Penicillamine undergoes limited metabolism in the liver, to S-methyl penicillamine.
It is mainly excreted in the urine as disulfides, along with some S-methyl penicillamine and unchanged drug; a small amount may be excreted in the faeces

Dose in renal impairment GFR (mL/min)
- 20–50 Avoid if possible or reduce dose. 125 mg for first 12 weeks. Increase by same amount every 12 weeks.
- 10–20 Avoid – nephrotoxic.
- <10 Avoid – nephrotoxic.

Dose in patients undergoing renal replacement therapies
- HD Dialysed. 125–250 mg 3 times a week after HD.
- HDF/High flux Dialysed. 125–250 mg 3 times a week after HD.
- CAV/VVHD Dialysed. Avoid – nephrotoxic.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Sodium aurothiomalate: increased risk of haematological toxicity.

Administration
Reconstitution
- Route
Oral
Rate of administration
- Other information
- Proteinuria occurs frequently and is partially dose-related. In some patients it may progress to glomerulonephritis or nephrotic syndrome.
- Dose in haemodialysis is from Drug Dosage in Renal Insufficiency by Seyffart G and Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
- Urinalysis should be carried out weekly for the first two months of treatment, after any change in dosage, and monthly thereafter. Increasing proteinuria may necessitate withdrawal of treatment.
## Pentamidine isetionate

### Clinical use

**Antibacterial agent:**
- Pneumocystis treatment and prophylaxis
- Visceral leishmaniasis
- Cutaneous leishmaniasis
- Trypanosomiasis

### Dose in normal renal function

- **Pneumocystis:**
  - Treatment (unlicensed): Nebuliser: 600 mg daily for 3 weeks;
  - IV: 4 mg/kg/day for at least 14 days
  - Prophylaxis: 300 mg monthly or 150 mg every 2 weeks
- **Visceral leishmaniasis:** 3–4 mg/kg on alternate days to a maximum of 10 doses (deep IM)
- **Cutaneous leishmaniasis:** 3–4 mg/kg once or twice weekly (deep IM)
- **Trypanosomiasis:** 4 mg/kg daily, or alternate days to a total of 7–10 doses (deep IM or IV)

### Pharmacokinetics

- **Molecular weight (daltons)**: 592.7
- **% Protein binding**: 69
- **% Excreted unchanged in urine**: <5
- **Volume of distribution (L/kg)**: 3–4
- **Half-life — normal/ESRF (hrs)**: 6–9 / 9

### Metabolism

Extensively hepatically metabolised. Renal clearance accounts for <5% of the plasma clearance of pentamidine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Depending on severity of infection: 4 mg/kg/day IV for 7–10 days, then on alternate days to complete minimum 14 doses. OR 4 mg/kg on alternate days to complete minimum 14 doses.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy Type</th>
<th>Dose Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- **Anti-arrhythmics:** increased risk of ventricular arrhythmias with amiodarone – avoid; possible increased risk of ventricular arrhythmias with disopyramide.
- **Antibacterials:** increased risk of ventricular arrhythmias with delamanid, moxifloxacin and parenteral erythromycin – avoid with moxifloxacin; increased risk of ventricular arrhythmias with parenteral pentamidine and telithromycin.
- **Antidepressants:** increased risk of ventricular arrhythmias with tricyclics; increased risk of ventricular arrhythmias with citalopram and escitalopram – avoid.
- **Antimalarials:** increased risk of ventricular arrhythmias with piperaquine with arteminol – avoid.
- **Antipsychotics:** increased risk of ventricular arrhythmias with amisulpride, droperidol and phenothiazines – avoid with amisulpride and droperidol.
- **Antivirals:** increased risk of hypocalcaemia with parenteral pentamidine and foscarnet; increased risk of ventricular arrhythmias with saquinavir – avoid.
- **Cytotoxics:** increased risk of ventricular arrhythmias with vandetanib – avoid.
- **Ivabradine:** increased risk of ventricular arrhythmias.

### Administration

**Reconstitution**
- IV: 300 mg with 3–5 mL water for injection.
- IM: 300 mg with 3 mL water for injection
- Inhalation: 600 mg with 6 mL water for injection

**Route**
- IV, IM, nebulised
Rate of administration
Over at least 1 hour

Comments
Dilute calculated dose in 50–250 mL sodium chloride 0.9% or glucose 5%.

Other information
- Monitor patients closely.
- Patient must be lying down when drug is administered intravenously.
- If given by IV infusion, patient should be monitored closely: heart rate, blood pressure, blood glucose.
- IV prophylaxis (unlicensed): 4–5 mg/kg over a minimum of 1 hour every 4 weeks.
- Nebulise over 20 minutes using Respigard II or other suitable nebuliser, oxygen flow rate 6–10 L/minute.
- 5 mg nebulised salbutamol may be given prior to pentamidine nebulisation to reduce risk of bronchospasm. Do not mix together in nebuliser.
- May produce reversible impairment of renal function.
Pentostatin

Clinical use
Antineoplastic agent:
• Treatment of hairy cell leukaemia

Dose in normal renal function
4 mg/m² every other week

Pharmacokinetics
Molecular weight (daltons) 268.3
% Protein binding 4
% Excreted unchanged in urine 50–96
Volume of distribution (L/kg) 36.1 Litres
Half-life — normal/ESRF (hrs) 2.6–10 / 18

Metabolism
Only a small amount is metabolised via the liver.
It is primarily excreted unchanged by the kidneys
(30–90% excreted by kidneys within 24 hours).

Dose in renal impairment GFR (mL/min)
50–60 50% of dose. See ‘Other information’.
10–50 See ‘Other information’
<10 See ‘Other information’

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Unknown dialysability. Dose as in GFR<10 mL/min.
HDF/High flux Likely dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–50 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
• Cytotoxics: increased risk of toxicity with high-dose cyclophosphamide – avoid; increased pulmonary toxicity with fludarabine (unacceptably high incidence of fatalities).

Administration
Reconstitution
5 mL water for injections
Route
IV bolus or infusion
Rate of administration
20–30 minutes
Comments
Add to 25–50 mL glucose 5% or sodium chloride 0.9%
(final concentration 180–330 mcg/mL).

Other information
• Patients with CKD are at a greater risk of toxicity with pentostatin.
• Contraindicated by manufacturer if GFR<60 mL/min due to lack of studies.
• One study used 3 mg/m² in patients with a GFR=41–60 mL/min and 2 mg/m² in patients with a GFR=21–40 mL/min without any problems. (Lathia C, Fleming GF, Meyer M, et al. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002; 50(2): 121–6.)
• Another study used it in a haemodialysis patient at increasing doses of 1, 2, then 3 mg/m². Treatment was then continued at a dose of 2 mg/m². The patient was dialysed for 4 hours 1–2 hours after receiving the pentostatin to remove any remaining drug. The main complication was anorexia. Tumour lysis syndrome also occurred 4 days after the 3 mg/m² dose. (Arima N, Sugiyama T. Pentostatin treatment for a patient with chronic type adult T-cell leukaemia undergoing haemodialysis. Rinsho Ketsueki. 2005; 46(11): 1191–5.)
• Hydration with 500–1000 mL of fluid is recommended before treatment and another 500 mL after treatment.
  – GFR=60 mL/min, give 70% of dose.
  – GFR=45 mL/min, give 60% of dose.
  – GFR<30 mL/min, avoid.
Pentoxifylline (oxpentifylline)

Clinical use
- Peripheral vascular disease
- Venous leg ulcers (unlicensed indication)

Dose in normal renal function
400 mg 2–3 times daily

Pharmacokinetics
- Molecular weight (daltons): 278.3
- % Protein binding: 0
- % Excreted unchanged in urine: 0 (95% as active metabolites)
- Volume of distribution (L/kg): 2.4–4.2
- Half-life — normal/ESRF (hrs): 0.4–1 / Unchanged (see ‘Other information’)

Metabolism
Pentoxifylline is hepatically metabolised to form active metabolites. In 24 hours most of a dose is excreted in the urine, mainly as metabolites, and less than 4% is recovered in the faeces.

Dose in renal impairment GFR (mL/min)
- 30–50: Dose as in normal renal function.
- 10–30: Reduce dose by 30–50% depending on individual tolerance (400 mg once or twice daily).
- <10: Reduce dose by 30–50% depending on individual tolerance (400 mg once or twice daily).

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. 400 mg daily, slowly increasing if necessary.
- HD: Dialysed. 400 mg daily, slowly increasing if necessary.
- HDF/High flux: Dialysed. 400 mg daily, slowly increasing if necessary.
- CAV/VVHD: Dialysed. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: possibly increased risk of bleeding when administered in combination with NSAIDs; increased risk of bleeding with ketorolac – avoid concomitant use.

Administration
Reconstitution
Route
Oral
Rate of administration

Other information
- May enhance hypoglycaemia.
- Avoid in porphyria.
- Active metabolites are renally excreted and have an extended half-life in renal impairment.
- A case study has shown that pentoxyfylline at a dose of 400 mg twice daily can accumulate in ESRD in a patient on dialysis. The patient showed signs of toxicity after 6 days treatment at the increased dose of twice daily. The patient improved after the dose was reduced to once daily.

Reference:
Perampanel

Clinical use
Selective AMPA-type glutamate receptor antagonist:
• Antiepileptic

Dose in normal renal function
2–12mg daily before bedtime

Pharmacokinetics
Molecular weight (daltons) 349.4
% Protein binding 95
% Excreted unchanged in urine 22 (mainly as metabolites)
Volume of distribution (L/kg) 51–105 Litres
Half-life — normal/ESRF (hrs) 105 / Increased

Metabolism
Extensively metabolised via primary oxidation via the cytochrome P450 isoenzyme CYP3A sub family and sequential glucuronidation.
Perampanel is excreted in the urine and faeces mainly as oxidative and conjugated metabolites.

Dose in renal impairment GFR (mL/min)
30–50 Start with a low dose and titrate gradually.¹
10–30 Start with a low dose and titrate gradually.
<10 Start with a low dose and titrate gradually.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Antidepressants: anticonvulsant effect antagonised; avoid with St John’s wort.
• Antiepileptics: concentration reduced by carbamazepine, fosphenytoin, oxcarbazepine and phenytoin.
• Antimalarials: anticonvulsant effect antagonised by mefloquine.
• Antipsychotics: anticonvulsant effect antagonised.
• Orlistat: possibly increased risk of convulsions.
• Progestogens: high-dose perampanel reduces plasma concentration of progestogens (possibly reduced contraceptive effect).

Administration
Reconstitution
Route Oral
Rate of administration

Other information
• Manufacturer advises to avoid in moderate to severe renal impairment due to lack of studies.
• Bioavailability is almost 100%.
• Results showed that perampanel apparent clearance was decreased by 27% in patients with mild renal impairment (CRCL=50–80 mL/min) compared to patients with normal renal function (CRCL>80 mL/min), with a corresponding 37% increase in AUC.¹

Reference:
Pergolide

**Clinical use**
Treatment of Parkinson’s disease

**Dose in normal renal function**
Initially 50 mcg once daily, increasing to 2.1–3 mg daily in 3 divided doses

**Pharmacokinetics**
- Molecular weight (daltons): 314.5 (410.6 as mesilate)
- % Protein binding: 90
- % Excreted unchanged in urine: 55 (as metabolites)
- Volume of distribution (L/kg): 0.47–1.11
- Half-life — normal/ESRF (hrs): 27

**Metabolism**
Extensively hepatically metabolised. At least 10 metabolites have been detected in the urine and faeces. Following oral administration of [14C]-radiolabelled pergolide mesilate to healthy subjects, approximately 55% of the administered radioactivity can be recovered as pergolide metabolites from the urine, 40% from the faeces and 5% from expired CO₂, suggesting that a significant fraction is absorbed.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Importantly Drug Interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other Information**
- Fibrotic and serosal inflammatory disorders, such as pleuritis, pleural effusion, pleural fibrosis, pulmonary fibrosis, pericarditis, pericardial effusion, cardiac valvulopathy involving one or more valves (aortic, mitral and tricuspid), or retroperitoneal fibrosis have occurred with pergolide treatment.
- Before initiating treatment all patients must undergo a cardiovascular evaluation, including ECHO, to assess the potential presence of asymptomatic valvular disease.
- Has been trialled in restless legs syndrome. In a randomised placebo-controlled study, therapeutic effects were seen with mean daily doses of 400 mcg pergolide after 6 weeks and maintained after 12 months with doses of up to 720 micrograms daily. (Trenkwalder C, Hundemer HP, Lledo A, et al. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS study. Neurology 2004; 62(8): 1391–7.)

Reference:
**Perindopril**

**Clinical use**
Angiotensin-converting enzyme inhibitor:
- Hypertension
- Heart failure
- Following myocardial infarction or revascularisation

**Dose in normal renal function**
- Erbumine: 2–8 mg daily
- Arginine: 2.5–10 mg daily

**Pharmacokinetics**
- Molecular weight (daltons) 441.6 (as erbumine); 542.7 (as arginine)
- % Protein binding 60 (10–20 as perindoprilat)
- % Excreted unchanged in urine 4–12
- Volume of distribution (L/kg) 0.2
- Half-life — normal/ESRF (hrs) 1 / 27

**Metabolism**
Perindopril is a pro-drug. It is extensively metabolised, mainly in the liver, to the active perindoprilat and inactive metabolites including glucuronides. Perindopril is excreted mainly in the urine, as unchanged drug, as perindoprilat, and as other metabolites.

**Dose in renal impairment GFR (mL/min)**
- 30–60 Initially 2 mg (erbume); 2.5 mg (arginine) daily, adjust according to response.
- 15–30 Initially 2 mg (erbume); 2.5 mg (arginine) daily, adjust according to response.
- <15 Initially 2 mg daily (erbume); 2.5 mg (arginine) alternate days, adjust according to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in GFR<15 mL/min.
- HD Dialysed. Dose as in GFR<15 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<15 mL/min.
- CAV/VVHD Dialysed. Dose as in GFR=15–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
- Bee venom extract: possible severe anaphylactoid reactions when used together.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of angioedema with everolimus.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Gold: flushing and hypotension with sodium aurothiomalate.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

**Administration**
Reconstitution
- Route Oral
- Rate of administration

**Other information**
- Active metabolite perindoprilat has a half-life of 25–30 hours.
- Titrate dose according to response; normal doses have been used in CKD 5.
- Small volume of distribution due to low lipophilicity.
- Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
- Renal failure has been reported in association with ACE inhibitors in patients with renal artery stenosis, post renal transplant and those with severe congestive heart failure.
• High incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor – this combination should therefore be avoided.

• Hyperkalaemia and other side-effects are more common in patients with renal impairment.
Pertuzumab

Clinical use
Monoclonal antibody:
- Treatment of HER2 receptor +ve breast cancer

Dose in normal renal function
Loading dose: 840 mg then 420 mg every 3 weeks

Pharmacokinetics
Molecular weight (daltons) 148 000
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 5.12 Litres
Half-life — normal/ESRF (hrs) 18 days / Unchanged

Metabolism
Antibodies are cleared mainly by catabolism.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>Dose as in normal renal function. Use with caution. See 'Other information'.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Dose as in GFR<30 mL/min.
HD Not dialysed. Dose as in GFR<30 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<30 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR<30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
Route
IV infusion
Rate of administration
30–60 minutes (depends on dose)

Other information
- Manufacturer is unable to advise on a dose in severe renal impairment (CRCL<30 mL/min) due to lack of studies.
- No relationship between creatinine clearance and pertuzumab exposure was observed over the range of 27–244 mL/min.
# Pethidine hydrochloride

## Clinical use

Opiate analgesia

## Dose in normal renal function

- **IV**: 25–50 mg every 4 hours
- **Oral**: 50–150 mg every 4 hours
- **S/C, IM**: 25–100 mg every 4 hours

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>283.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60–80</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>4.17</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–6 / 7–32</td>
</tr>
</tbody>
</table>

## Metabolism

Pethidine is metabolised in the liver by hydrolysis to pethidinic acid or by demethylation to norpethidine (active metabolite) and hydrolysis to norpethidinic acid, followed by conjugation with glucuronic acid. Norpethidine is pharmacologically active and its accumulation may result in toxicity. Pethidine has a half-life of about 3–6 hours; norpethidine is eliminated more slowly, with a half-life reported to be up to about 20 hours.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dosage as in normal renal function. Use small doses – increase dosing interval to 6 hours and decrease dose by 25%.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>DOSAGE as in GFR&lt;10 mL/min. Use small doses – increase dosing interval to 8 hours and decrease dose by 50%.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid if possible. If not, use small doses: increase dosing interval to 8 hours and decrease dose by 50%.</td>
<td></td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

## Important drug interactions

Potential hazardous interactions with other drugs
- Analgesics: possible opioid withdrawal with buprenorphine and pentazocine.
- Anti-arrhythmics: delayed absorption of mexiletine.
- Antidepressants: possible CNS excitation or depression with MAOIs and moclobemide – avoid; possibly increased serotonergic effects with duloxetine; increased sedative effects with tricyclics.
- Antiepileptics: possible increased risk of pethidine toxicity with fosphenytoin and phenytoin.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced sedative and hypotensive effect.
- Antivirals: concentration reduced by ritonavir but concentration of toxic pethidine metabolite increased – avoid.
- Dopaminergics: risk of CNS toxicity with rasagiline – avoid; hyperpyrexia and CNS toxicity reported with selegiline – avoid.
- Nalmefene: avoid concomitant use.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid.

## Administration

### Reconstitution

- **—**

### Route

IV, oral, SC, IM

### Rate of administration

IV: Bolus 3–4 minutes

## Other information

- Risk of CNS and respiratory depression or convulsions, particularly in ERF patients receiving regular doses, due to accumulation of active metabolite, norpethidine. Norpethidine levels can be measured.
**Phenelzine**

### Clinical use

MAOI antidepressant

### Dose in normal renal function

15 mg 3 times daily; maximum: 30 mg 3 times daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>136 (234.3 as sulphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0.25–1.1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.2 / –</td>
</tr>
</tbody>
</table>

### Metabolism

Phenelzine is metabolised in the liver by oxidation via monoamine oxidase, and is excreted in the urine almost entirely in the form of metabolites.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy Type</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Possibly dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Possibly dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Possibly dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs

- Alpha-blockers: avoid with indoramin; enhanced hypotensive effect.
- Analgesics: CNS excitation or depression with pethidine, other opioids and nefopam – avoid; increased risk of serotonergic effects and convulsions with tramadol - avoid.
- Antidepressants: enhancement of CNS effects and toxicity. Care with all antidepressants including drug free periods when changing therapies.
- Antiepileptics: antagonism of anticonvulsant effect; avoid carbamazepine with or within 2 weeks of MAOIs.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
- Antipsychotics: effects enhanced by clozapine.
- Atomoxetine: avoid concomitant use and for 2 weeks after use.
- Bupropion: avoid with or for 2 weeks after MAOIs.
- Dapoxetine: risk of hypertensive crisis – avoid.
- Diuretics: avoid with indoramin.
- Dopaminergics: avoid with entacapone and tolcapone; hypertensive crisis with levodopa and rasagiline – avoid for at least 2 weeks after stopping MAOI; hypotension with selegiline.
- 5HT<sub>1</sub> agonist: risk of CNS toxicity with sumatriptan, rizatriptan and zolmitriptan – avoid sumatriptan and rizatriptan for 2 weeks after MAOI.
- Methyldopa: avoid concomitant use.
- Opicapone: avoid concomitant use.
- Sympathomimetics: hypertensive crisis with sympathomimetics – avoid with methylphenidate.
- Tetrabenazine: risk of CNS excitation and hypertension avoid.

### Administration

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—
Clinic Use

Anticoagulant

Dose in normal renal function

Day 1: 200 mg
Day 2: 100 mg
Maintenance dose: 50–150 mg daily according to INR

Pharmacokinetics

Molecular weight (daltons) 222.2
% Protein binding >97
% Excreted unchanged in urine No data
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 5–6 /

Metabolism

Hepatically metabolised. Metabolites of phenindione often colour the urine pink or orange.

Dose in renal impairment GFR (mL/min)

20–50: Dose as in normal renal function.
10–20: Dose as in normal renal function.
<10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies

APD/CAPD: Unknown dialysability. Dose as in normal renal function.
HD: Unknown dialysability. Dose as in normal renal function.
HDF/High flux: Unknown dialysability. Dose as in normal renal function.
CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs

There are many significant interactions with coumarins. Prescribe with care with regard to the following:

- Anticoagulant effect enhanced by: alcohol, amiodarone, anabolic steroids, aspirin, aztreonam, bicalutamide, cephalosporins, chloramphenicol, cimetidine, ciprofloxacin, dronedarone, fibrates, clopidogrel, cranberry juice, danazol, dipyriramole, disulfiram, fibrates, grapefruit juice, levoflaxacin, macrolides, metronidazole, nalidixic acid, neomycin, norfloxacin, NSAIDs, ofloxacin, paracetamol, penicillins, ritonavir, rosuvastatin, sulphonamides, thyroid hormones, testosterone, tetracyclines, tigecycline, tramadol, trimethoprim.
- Anticoagulant effect decreased by: oral contraceptives, rifamycins, vitamin K.
- Anticoagulant effects enhanced/reduced by: anion exchange resins, corticosteroids, dietary changes, enteral feeds.
- Analgesics: increased risk of bleeding with IV diclofenac and ketorolac – avoid.
- Anticoagulants: increased risk of haemorrhage with apixaban, dabigatran, edoxaban and rivaroxaban – avoid.
- Ciclosporin: there have been a few reports of altered anticoagulant effect; decreased ciclosporin levels have been seen rarely.

Administration

Reconstitution

Route
Oral
Rate of administration

Other information

- Contraindicated by manufacturer in severe renal impairment.
- Titrate dose to INR.
- Enhanced anticoagulant effect in renal impairment, due to reduced protein binding.
Phenobarbital (phenobarbitone)

**Clinical use**
Antiepileptic

**Dose in normal renal function**
Oral: 60–180 mg at night
Status epilepticus: 10 mg/kg, max 1 g IV

**Pharmacokinetics**
Molecular weight (daltons) 232.2 (254.2 as sodium salt)
% Protein binding 45–60
% Excreted unchanged in urine 25
Volume of distribution (L/kg) 1
Half-life — normal/ESRF (hrs) 75–120 / Unchanged

**Metabolism**
Partly metabolised in the liver.
25% of a dose is excreted in the urine unchanged at normal urinary pH.

**Dose in renal impairment GFR (mL/min)**
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function, but avoid very large doses.
<10 Reduce dose by 25–50% and avoid very large single doses.

**Dose in patients undergoing renal replacement therapies**
APD/CAPD Dialysed. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: reduced concentration of disopyramide; possibly reduced concentration of dronedarone – avoid; possibly increases metabolism of propafenone.
- Antibacterials: reduced concentration of chloramphenicol, doxycycline, metronidazole, telithromycin and rifampicin – avoid with telithromycin.
- Anticoagulants: increased metabolism of coumarins (reduced effect); concentration of apixaban, edoxaban and rivaroxaban reduced.
- Antidepressants: antagonise anticonvulsant effect; reduces concentration of paroxetine, reboxetine, mianserin and tricyclics; concentration reduced by St John’s wort – avoid.
- Antiepileptics: concentration increased by oxcarbazepine, phenytoin, stripentol and valproate and possibly carbamazepine, also active metabolite of oxcarbazepine reduced and valproate concentration reduced, concentration of fosphenytoin and phenytoin usually reduced but can also be increased; concentration of ethosuximide, rufinamide and topiramate possibly reduced; concentration of lamotrigine, tiagabine and zonisamide reduced.
- Antifungals: possibly reduced concentration of itraconazole, isavuconazole, posaconazole and voriconazole – avoid with voriconazole; reduced absorption of griseofulvin (reduced effect).
- Antimalarials: avoid with piperidine with artemisin; anticonvulsant effect antagonised by mefloquine.
- Antimuscarinics: possibly reduces active metabolite of fosoterodine – avoid.
- Antipsychotics: antagonise anticonvulsant effect; metabolism of haloperidol increased; possibly reduces aripiprazole concentration – increase aripiprazole dose; concentration of both drugs reduced with chlorpromazine; possibly reduces clozapine concentration; possibly reduces lurasidone concentration – avoid.
- Antivirals: concentration of abacavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, rilpivirine and saquinavir possibly reduced; avoid with boceprevir and rilpivirine; possibly reduces daclatasvir, dasabuvir, omibitasvir, paritaprevir and simeprevir concentration – avoid; avoid with elvitegravir, etravirine, ledipasvir, sofosbuvir and telaprevir; possibly reduces concentration of dolutegravir.
- Apremilast: possibly reduces concentration of apremilast – avoid.
Phenobarbital (phenobarbitone)

- Bile acids: avoid with cholic acid.
- Calcium-channel blockers: effects of calcium-channel blockers probably reduced – avoid with isradipine and nimodipine.
- Cannabis extract: possibly reduces concentration of cannabis extract – avoid.
- Ciclosporin: reduced ciclosporin levels.
- Cobicitidat: possibly reduces concentration of cobicitidat – avoid.
- Corticosteroids: metabolism of corticosteroids accelerated, reduced effect.
- Cytotoxics: possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of bortezomib, bosutinib, cabozantinib, ceritinib, crizotinib, dasatinib, ponatinib and vandetanib – avoid; avoid with cabazitaxel, ceritinib, dabrafenib, gefitinib, olaparib and panobinostat; concentration of irinotecan and its active metabolite and possibly etoposide reduced; possible increased hypersensitivity reactions with procarbazine.
- Diuretics: concentration of eplerenone reduced – avoid; increased risk of osteomalacia with carbonic anhydrase inhibitors.
- Guanfacine: concentration of guanfacine possibly reduced – increase dose of guanfacine.
- Hormone antagonists: possibly reduced concentration of abiraterone – avoid; metabolism of toremifene accelerated.
- Ivacaftor: possibly reduced concentration of ivacaftor – avoid.
- Oestrogens and progestogens: metabolism accelerated, reduced contraceptive effect.
- Orlistat: possibly increased risk of convulsions.
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.
- Tacrolimus: concentration of tacrolimus reduced.
- Ulipristal: contraceptive effect reduced – avoid.

Administration

Reconstitution

Route
IV, oral

Rate of administration
Not more than 100 mg/minute

Comments
For IV administration, dilute 1 in 10 with water for injection.

Other information

- Aim for plasma concentration of 15–40 mg/L (65–170 μmol/L) for optimum response.
- Contraindicated by manufacturer in severe renal impairment in UK. The US data sheet just advises to reduce dose in renal impairment.
- Dose in renal impairment is from Drug Dosage in Renal Insufficiency by Seyffart G.
- May cause excessive sedation and increased osteomalacia in ERF.
- Charcoal haemoperfusion and haemodialysis more effective than peritoneal dialysis for poisoning.
- Up to 50% unchanged drug excreted in urine with alkaline diuresis.
Phenoxybenzamine hydrochloride

Clinical use
Non-competitive long acting-adrenergic receptor antagonist:
  • Hypertensive episodes in phaeochromocytoma

Dose in normal renal function
• IV: 1 mg/kg daily, do not repeat within 24 hours
• Oral: 10 mg daily, increased by 10 mg daily to usual dose of 1–2 mg/kg in 2 divided doses

Pharmacokinetics
Molecular weight (daltons) 340.3
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 24 (IV) / –

Metabolism
Metabolised in the liver and excreted in the urine and bile, but small amounts remain in the body for several days.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
  • Anaesthetics: enhanced hypotensive effect.
  • Antidepressants: enhanced hypotensive effect with MAOIs, avoid.
  • Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect, avoid concomitant use.
  • Beta-blockers: enhanced hypotensive effect.
  • Calcium-channel blockers: enhanced hypotensive effect.
  • Diuretics: enhanced hypotensive effect.
  • Moxisylyte: possibly severe postural hypotension when used in combination.

Administration

Reconstitution
—

Route
IV, oral

Rate of administration
At least 2 hours

Comments
Dilute in 200–500 mL of sodium chloride 0.9%

Other information
  • Phenoxybenzamine is incompletely and variably absorbed from the gastrointestinal tract.
Phenoxymethylpenicillin (penicillin V)

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
500–1000 mg every 6 hours

**Pharmacokinetics**
- Molecular weight (daltons): 350.4
- % Protein binding: 80
- % Excreted unchanged in urine: 60–90
- Volume of distribution (L/kg): 0.5
- Half-life — normal/ESRF (hrs): 0.5–1 / 4

**Metabolism**
Penicillin V is metabolised in the liver to form several metabolites, including penicilloic acid. The unchanged drug and metabolites are excreted rapidly in the urine. Only small amounts are excreted in the bile.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Reduces excretion of methotrexate.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Renal failure prolongs half-life of phenoxymethylpenicillin, but as it has a wide therapeutic index no dose adjustment is necessary.
- UK SPC advises to reduce dose in severe renal impairment but not the US version.
- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
Phentolamine mesilate (unlicensed)

**Clinical use**

Alpha-adrenoceptor blocker:
- Hypertensive crisis

**Dose in normal renal function**

2–5 mg repeated if necessary

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>377.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>54</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>13</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>19 minutes / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Phentolamine is extensively metabolised. Only about 10–13% of an intravenous dose is excreted unchanged in the urine, and the fate of the remainder of the drug is unknown.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Other Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Titrate dose to end point, i.e. lower BP.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Other Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- Anaesthetics: enhanced hypotensive effect.
- Antidepressants: additive hypotensive effect with MAOIs – avoid.
- Antihypertensives: enhanced hypotensive effect.
- Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use.
- Diuretics: enhanced hypotensive effect.
- Linezolid: additive hypotensive effect.
- Moxisylyte: possibly severe postural hypotension.

**Administration**

**Reconstitution**

—

**Route**

IV

**Rate of administration**

—

**Other information**

- Titrate according to response.
- Manufacturer advises to use with caution due to lack of studies in UK SPC only. No dose reduction recommended in US data sheet.
Phenytoin

### Clinical use
- Antiepileptic
- Diabetic neuropathy
- Trigeminal neuralgia

### Dose in normal renal function
- Oral: 150–500 mg/day or 3–4 mg/kg/day in 1–2 divided doses; higher doses can be used in exceptional cases.
- Status epilepticus (IV): 10–20 mg/kg (max 2 g, at a rate of no more than 1 mg/kg/minute) (with BP and ECG monitoring) then 100 mg every 6–8 hours according to levels

### Pharmacokinetics
- Molecular weight (daltons) 252.3 (274.2 as sodium salt)
- % Protein binding 90
- % Excreted unchanged in urine Up to 5
- Volume of distribution (L/kg) 0.52–1.19
- Half-life — normal/ESRF (hrs) 7–42 / Unchanged

### Metabolism
Phenytoin is hydroxylated in the liver to inactive metabolites chiefly 5-(4-hydroxyphenyl)-5-phenylhydantoin by an enzyme system which is saturable. Phenytoin undergoes enterohepatic recycling and is excreted in the urine, mainly as its hydroxylated metabolite, in either free or conjugated form.

### Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies
- APD/CAPD Not dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Dialysed. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: concentration of both drugs reduced with aminophylline and theophylline.
- Analgesics: enhanced effect with NSAIDs; metabolism of methadone accelerated; possibly increases risk of phenytoin toxicity.
- Anthelmintics: concentration of albendazole and praziquantel reduced; concentration of phenytoin possibly increased by levamisole.
- Anti-arrhythmics: increased concentration with amiodarone; concentration of disopyramide and mexiletine and possibly dronedarone reduced – avoid with dronedarone.
- Antibacterials: level increased by clarithromycin, chloramphenicol, isoniazid, metronidazole, sulphonamides and trimethoprim (+ antifolate effect); concentration increased or decreased by ciprofloxacin; concentration of bedaquiline, doxycycline and telithromycin reduced – avoid with bedaquiline and telithromycin; concentration reduced by rifamycins.
- Anticoagulants: increased metabolism of coumarins (reduced effect but also reports of enhancement); possibly reduced apixaban, dabigatran, edoxaban and rivaroxaban concentration – avoid with dabigatran.
- Antidepressants: antagonise anticonvulsant effect, concentration increased by fluoxetine and fluvoxamine and possibly sertraline; concentration of mianserin, mirtazapine and paroxetine and possibly tricyclics reduced; concentration reduced by St John's wort – avoid; possibly reduces concentration of vortioxetine.
- Antiepileptics: concentration of both drugs reduced with carbamazepine, concentration may also be increased by carbamazepine, eslicarbazepine, ethosuximide, oxcarbazepine, stiripentol and topiramate; concentration of ethosuximide, active oxcarbazepine metabolite, retigabine, rufinamide (concentration of phenytoin possibly increased), topiramate and valproate possibly reduced; concentration of eslicarbazepine, ethosuximide, lamotrigine, perampanel, tiagabine and zonisamide reduced; concentration of phenobarbital often increased; phenobarbital and valproate may alter concentration; concentration reduced by vigabatrin.
- Antifungals: concentration of ketoconazole, itraconazole, posaconazole, voriconazole and possibly isavuconazole and caspofungin reduced – avoid with itraconazole and isavuconazole, increase voriconazole
dose and possibly caspofungin; levels increased by fluconazole, miconazole and voriconazole.

- Antimalarials: avoid with piperaquine with artemimol; mefloquine and pyrimethamine antagonise anticonvulsant effect; increased antifolate effect with pyrimethamine.

- Antimuscarinics: concentration of active metabolite of fesoterodine possibly reduced – avoid.

- Antipsychotics: antagonise anticonvulsant effect; possibly reduced aripiprazole concentration – avoid or increase aripiprazole dose; metabolism of clozapine, haloperidol, quetiapine and sertindole increased; concentration increased or decreased with chlorpromazine; possibly reduces lurasidone concentration – avoid.

- Antivirals: possibly reduced concentration of abacavir, boceprevir, daclatasvir, darunavir, dasabuvir, dolutegravir, indinavir, lopinavir, ombitasvir, paritaprevir, ritonavir, simeprevir and saquinavir – avoid with daclatasvir, dasabuvir, ombitasvir, paritaprevir and simeprevir; concentration of boceprevir and rilpivirine reduced – avoid; concentration possibly increased by indinavir and ritonavir; concentration increased or decreased with zidovudine; avoid with elvitegravir, etravirine and telaprevir.

- Apremilast: concentration of apremilast reduced – avoid.

- Calcium-channel blockers: levels increased by diltiazem; concentration of diltiazem, felodipine, isradipine, nimodipine and verapamil reduced; avoid with isradipine and nimodipine.

- Cannabis extract: concentration possibly reduced by phenytoin – avoid.

- Ciclosporin: reduced ciclosporin levels.

- Cobisstat: concentration of cobisicstat possibly reduced.

- Corticosteroids: metabolism accelerated (effect reduced).

- Cytotoxics: metabolism possibly inhibited by fluorouracil; increased antifolate effect with methotrexate; concentration of busulfan, cabozantinib, ceritinib, eribulin, etoposide and imatinib reduced – avoid with imatinib; concentration possibly reduced by cisplatin, ibrutinib, idelalisib – avoid with ibrutinib, idelalisib; possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of crizotinib – avoid; avoid with cabazitaxel, gefitinib, lapatinib, olaparib, panobinostat, vemurafenib and vismodegib; concentration of irinotecan and its active metabolite reduced.

- Diuretics: concentration increased by acetazolamide; concentration of eplerenone reduced – avoid concomitant use; increased risk of osteomalacia with carbonic anhydrase inhibitors; antagonises effect of furosemide.

- Guanfacine: concentration of guanfacine possibly reduced – increase dose of guanfacine.

- Hormone antagonists: possibly reduced concentration of abiraterone – avoid; metabolism of toremifene accelerated.

- Ivacaftor: concentration of ivacaftor possibly reduced – avoid.

- Muscle relaxants: long-term use of phenytoin reduces effects of non-depolarising muscle relaxants, but acute use may enhance effects.

- Oestrogens and progestogens: metabolism increased (reduced contraceptive effect).

- Orlistat: possibly increased risk of convulsions.

- Sulfapyrazone: concentration increased by sulfapyrazone.

- Ulcer-healing drugs: metabolism inhibited by cimetidine; absorption reduced by sucralfate; enhanced effect with esomeprazole and omeprazole.

- Ulipristal: contraceptive effect possibly reduced – avoid.

### Administration

#### Reconstitution

---

**Route**

IV, oral

**Rate of administration**

IV infusion and bolus: not greater than 50 mg/minute

#### Comments

- Infusion: dilute in 50–100 mL sodium chloride 0.9%; final concentration not exceeding 10 mg/mL.

- An in-line filter (0.22–0.50 microns) should be used due to high risk of precipitation e.g. via a separate filter attached to giving set or giving sets like those used for taxol.

- Give by slow IV injection into large vein followed by sodium chloride 0.9% flush, to avoid irritation. Cardiac monitoring recommended.

#### Other information

- Aim for phenytoin levels of 10–20 mg/L (40–80 micromol/L).

- Total phenytoin levels must be adjusted for hypoalbuminaemia and uraemia (levels of 5–12 mcg/mL may be enough).

- Decreased protein binding and volume of distribution in renal failure.
- Free fraction of phenytoin is increased in uraemia to approximately 0.2.
- Request free phenytoin serum levels, if possible.
- Loading dose 15 mg/kg IV or oral, then 5 mg/kg/day. Steady state reached in 3–5 days if loading dose given.
- Increase dose gradually (25–50 mg/day at weekly intervals); demonstrates saturation kinetics.
- Phenytoin absorption is markedly reduced by concurrent nasogastric enteral nutrition administration. Avoid concomitant administration with divalent cations.

- May cause folate deficiency.
- To correct a phenytoin level for low albumin:

\[
C_{\text{corrected}} = \frac{C_{\text{measured}}}{[0.9 \times \text{albumin}(\text{g/L})/42^*] + 0.1}
\]

*Midpoint of reference range for serum albumin

This only gives a rough estimate and the clinical condition of the patient should always be taken into consideration.
# Phosphate supplements

## Clinical use

**Hypophosphataemia**

## Dose in normal renal function

- **Oral:** 4–6 tablets daily
- **IV:** 9–50 mmol/day (maximum 500 micromols/kg in critically ill patients)
- See ‘Other information’

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>94–97 (phosphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>High</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

## Metabolism

Approximately two thirds of ingested phosphate is absorbed from the gastrointestinal tract; most of the absorbed phosphate is then filtered by the glomeruli and subsequently undergoes reabsorption.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

- **APD/CAPD:** Dialysed. Dose as in normal renal function.
- **HD:** Dialysed. Dose as in normal renal function.
- **HDF/High flux:** Dialysed. Dose as in normal renal function.
- **CAV/VVHD:** Dialysed. Dose as in normal renal function.

## Important drug interactions

Potentially hazardous interactions with other drugs
- Avoid insoluble incompatibilities, e.g. calcium salts.

## Administration

### Reconstitution

**—**

### Route

**IV, oral**

### Rate of administration

Usually over 6–12 hours

### Comments

- Phosphate polyfusor: give undiluted over 24 hours, peripherally.
- Addiphos: peripherally – give each vial (20 mL) diluted to 250–500 mL with glucose 5% over 6–12 hours; centrally – 20 mL vial made up to 60 mL with glucose 5% over 6–8 hours via syringe driver.
- Glycophos: peripherally – give each vial (20 mL) diluted to 500 mL with glucose 5% over 12 hours.

### Other information

- Oral dosing: Phosphate Sandoz – 16.1 mmol phosphate, 20.4 mmol sodium, 3.1 mmol potassium per tablet.
- IV dosing: (i) Phosphate Polyfusor (500 mL) containing: 50 mmol phosphate, 81 mmol sodium, 9.5 mmol potassium. (ii) Addiphos (20 mL) containing: 40 mmol phosphate, 30 mmol sodium, 30 mmol potassium. (iii) Glycophos (20 mL) containing: 20 mmol phosphate, 40 mmol sodium.
- Some units use a phosphate polyfusor before and after dialysis for low phosphate.
- HD patients usually need 15–20 mmol/day in TPN.
- CAV/VVHD patients usually need 30–40 mmol/day.
- During IV phosphate replacement, serum calcium, potassium and phosphate should be monitored 6–12 hourly. Repeat the dose within 24 hours if an adequate level has not been achieved. Urinary output should also be monitored.
- There is experience giving 15 mmol over 2 hours up to 3 times a day.
- Excessive doses of phosphate may cause hypocalcaemia and metastatic calcification.
Phytomenadione (vitamin K)

Clinical use
- Vitamin K deficiency
- Antidote to oral anticoagulants

Dose in normal renal function
5–40 mg daily in divided doses

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>450.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.05–0.13</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.5–3 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism
Phytomenadione is rapidly metabolised to more polar metabolites and is excreted in bile and urine as glucuronide and sulphate conjugates.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antagonises effect of coumarins and phenindione.

Administration
Reconstitution
- Route
  - IV, IM, oral

Rate of administration
Konakion* – very slow injection (1 mg/min)
Konakion MM® – dilute each 10 mg with 55 mL of glucose 5% and give by slow infusion over 15–30 minutes.

Comments
- Risk of anaphylaxis if IV injected too rapidly.
- Protect infusion from light.
- Konakion® should not be diluted (non-micellar).
- Only Konakion MM Paediatric® can be given IM or orally.

Other information
- Konakion MM® recommended for severe haemorrhage.
- Anticoagulation antidote: re-test prothrombin time 8–12 hours after Konakion*, 3 hours after Konakion MM® – repeat dose if inadequate.
- Patients with obstructive jaundice requiring oral vitamin K should be prescribed the water-soluble preparation menadiol sodium diphosphate – dosage range is similar.
Pimozide

Clinical use
Antipsychotic

Dose in normal renal function
2–20 mg daily

Pharmacokinetics
Molecular weight (daltons) 461.5
% Protein binding 99
% Excreted unchanged in urine <1
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 55–150 / –

Metabolism
Pimozide is metabolised in the liver via the cytochrome P450 isoenzyme CYP3A4 and to a lesser extent by CYP2D6 mainly by N-dealkylation and excreted in the urine and faeces in the form of metabolites and unchanged drug.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with low dose and increase according to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dialysability</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Antibacterials: avoid with macrolides and moxifloxacin (increased risk of ventricular arrhythmias).
• Antidepressants: concentration increased by SSRIs – avoid; increased risk of ventricular arrhythmias with SSRIs and tricyclics – avoid; increased risk of ventricular arrhythmias with delamanid.
• Antiepileptics: antagonises anticonvulsant effect.
• Antifungals: avoid with imidazoles and triazoles – risk of ventricular arrhythmias.
• Antimalarials: avoid with imidazoles and triazoles; increased risk of ventricular arrhythmias with mefloquine and quinine – avoid.
• Antipsychotics: increased risk of ventricular arrhythmias with droperidol, phenothiazines, risperidone or sulpiride – avoid; concentration possibly increased by lurasidone.
• Antivirals: concentration increased by atazanavir, boceprevir, efavirenz, fosamprenavir, indinavir, ritonavir, saquinavir and telaprevir, increased risk of ventricular arrhythmias – avoid.
• Anxiolytics and hypnotics: increased sedative effects.
• Aprepitant: avoid concomitant use.
• Atomoxetine: increased risk of ventricular arrhythmias.
• Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
• Cobicistat: concentration possibly increased by cobicistat – avoid.
• Cytotoxics: use crizotinib with caution; avoid with lapatinib and idelalisib; increased risk of ventricular arrhythmias with panobinostat and vandetanib – avoid; increased risk of ventricular arrhythmias with arsenic trioxide.
• Diuretics: increased risk of ventricular arrhythmias due to hypokalaemia.
• Fosaprepitant: avoid concomitant use.
• Grapefruit juice: avoid concomitant use.
• Ivabradine: increased risk of ventricular arrhythmias.

Administration
Reconstitution
Route
Oral
Rate of administration

Other information
• ECG required before treatment. To be repeated annually.
Pindolol

Clinical use

Beta-blocker:
- Hypertension
- Angina

Dose in normal renal function

- Hypertension: 15–45 mg daily in divided doses (15 mg can be given as a single dose)
- Angina: 2.5–5 mg up to 3 times daily

Pharmacokinetics

Molecular weight (daltons) 248.3
% Protein binding 40–60
% Excreted unchanged in urine 30–40
Volume of distribution (L/kg) 2–3
Half-life — normal/ESRF (hrs) 3–4 / Increased

Metabolism

Pindolol undergoes minimal hepatic metabolism to form inactive metabolites, and is excreted in the urine both unchanged and in the form of metabolites.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics: enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

Administration

Reconstitution
—
Route
Oral
Rate of administration
—
Pioglitazone

**Clinical use**
Treatment of type 2 diabetes mellitus

**Dose in normal renal function**
15–45 mg once daily

**Pharmacokinetics**
Molecular weight (daltons) 392.9 (as hydrochloride)
% Protein binding >99
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 0.25
Half-life — normal/ESRF (hrs) 5–6 (active metabolites: 16–23) / Unchanged

**Metabolism**
Pioglitazone undergoes extensive hepatic metabolism by hydroxylation mainly via cytochrome P450 2C8 to form active and inactive metabolites. Three of the six identified metabolites are active (M-II, M-III, and M-IV). Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%).

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose in normal renal function and monitor carefully.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function and monitor carefully.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function and monitor carefully.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function and monitor carefully.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function and monitor carefully.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Manufacturer does not advise using in dialysis patients due to lack of studies.
- Liver function tests should be measured prior to initiation of therapy and then every 2 months for the first 12 months, and thereafter at regular intervals.
- Pioglitazone should not be used in patients with heart failure or history of heart failure; incidence of heart failure is increased when pioglitazone is combined with insulin. Patients should be closely monitored for signs of heart failure.
Piperazine

Clinical use
Treatment of threadworm and roundworm infections

Dose in normal renal function
- Threadworm: 4 g sachet stirred into a glass of milk or water and drunk immediately; repeat after 14 days
- Roundworms: 4 g sachet stirred into a glass of milk or water and drunk immediately; repeat at monthly intervals for up to 3 months if re-infection risk

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>86.14 (202.1 as phosphate); (642.7 as citrate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5–30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

Metabolism
About 25% is metabolised in the liver. Piperazine is nitrosated to form N-mononitrosopiperazine (MNPz) in gastric juice, which is then metabolised to N-nitroso-3-hydroxypyrrolidine (NHPYR).
It is excreted in the urine mainly as metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function but avoid repeated administration.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Pyrantel: antagonises effect of piperazine.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- May accumulate in severe renal impairment causing neurotoxicity.
- Acts within the lumen of the gastrointestinal tract which is independent of any systemic absorption.
Piracetam

Clinical use

Myoclonus

Dose in normal renal function

7.2 g daily in 2–3 divided doses titrated to a maximum of 24 g daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>142.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>15</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&gt;90</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5 / Increased</td>
</tr>
</tbody>
</table>

Metabolism

Up to now, no metabolite of piracetam has been found. Piracetam is excreted almost completely in urine and the fraction of the dose excreted in urine is independent of the dose given.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>50–80</td>
<td>4.8 g in 2–3 divided doses.</td>
</tr>
<tr>
<td>30–50</td>
<td>1.2 g twice daily.</td>
</tr>
<tr>
<td>20–30</td>
<td>1.2 g daily as a single dose.</td>
</tr>
<tr>
<td>&lt;20</td>
<td>Contraindicated.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Likely dialysability. Avoid.</td>
</tr>
<tr>
<td></td>
<td>Contraindicated.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=20–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• None known

Administration

Reconstitution
—

Route
Oral

Rate of administration
—
**Piroxicam**

**Clinical use**

NSAID and analgesic

**Dose in normal renal function**

20 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>331.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99%</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.14</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>50 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Piroxicam metabolism is mainly via cytochrome P450 CYP 2C9 in the liver by hydroxylation of the pyridyl ring of the piroxicam side-chain, followed by conjugation with glucuronic acid. It is excreted mainly in the urine with smaller amounts in the faeces. Enterohepatic recycling occurs. Less than 5% of the dose is excreted unchanged in the urine and faeces.

**Dose in renal impairment GFR (mL/min)**

- **20–50** Dose as in normal renal function, but avoid if possible.
- **10–20** Dose as in normal renal function, but avoid if possible.
- **<10** Dose as in normal renal function, but only use if on dialysis.

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Not dialysed. Dose as in GFR<10 mL/min. See ’Other information’.
- **HD** Not dialysed. Dose as in GFR<10 mL/min. See ’Other information’.
- **HDF/High flux** Unknown dialysability. Dose as in GFR<10 mL/min. See ’Other information’.
- **CAV/VVHD** Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

- **Route** Oral, topical

**Rate of administration**

**Other information**

- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if serum creatinine is increased, stop NSAID.
- Use normal doses in patients with CKD 5 if on dialysis and do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
- Water soluble inactive metabolites may be removed by HD and CAPD.
# Pivmecillinam hydrochloride

## Clinical use
Antibacterial agent

## Dose in normal renal function
- Acute uncomplicated cystitis: 400 mg initially, then 200 mg 3 times a day
- Chronic or recurrent bacteriuria: 400 mg every 6–8 hours
- Enteric fever (Typhoid): 1.2–2.4 g daily for 14 days

## Pharmacokinetics
- Molecular weight (daltons): 476
- % Protein binding: 5–10
- % Excreted unchanged in urine: 45–50 (as mecinillam)
- Volume of distribution (L/kg): 0.2–0.4 (as mecinillam)
- Half-life — normal/ESRF (hrs): 1.2 / Increased

## Metabolism
Pivmecillinam is rapidly hydrolysed to mecinillam which is the active drug, plus pivalic acid and formaldehyde. About 45% of a dose may be excreted in the urine as mecinillam, mainly within the first 6 hours. Meclinillam is partly excreted with bile, giving rise to biliary concentrations about 3 times the serum levels.

## Dose in patients undergoing renal replacement therapies
- **APD/CAPD** Likely dialysability. Dose as in GFR<10 mL/min.
- **HD** Dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux** Dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD** Dialysed. Dose as in normal renal function.

## Important drug interactions
- Potentially hazardous interactions with other drugs
  - Antiepileptics: avoid concomitant use with valproate.
  - Methotrexate: penicillins can reduce the excretion of methotrexate (increased risk of toxicity).
  - Probenecid: reduces excretion of penicillins.

## Administration
### Reconstitution
- **Route** Oral
- **Rate of administration** —
- **Comments** Take with food

## Other information
- Contraindicated in carnitine deficiency as it can cause carnitine deficiency.
- Can cause oesophageal injury, take with water and food while standing up.
- Can cause porphyria.
- Can be crushed and administered with water down a PEG tube.
- Accumulation may occur in patients with severe renal impairment, so use the lower dose if using for extended periods of time.
- Unlikely to work in people with little residual kidney function as works by renal excretion into the bladder, where its site of action is.
# Pixantrone

## Clinical use

**Anthracycline:**
- Treatment of non-Hodgkin B-cell lymphomas

## Dose in normal renal function

50 mg/m² on days 1, 8 and 15 of a 28-day cycle

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>325.4 (557.5 as maleate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>50</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>9.7–29.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>14.5–44.8</td>
</tr>
</tbody>
</table>

## Metabolism

Pixantrone may be metabolised in the liver and/or excreted in the bile. As metabolism appears to be limited, biliary excretion of unchanged pixantrone may be the major elimination pathway. Acetylated metabolites were pharmacologically inactive and metabolically stable. In human urine, the compound was mainly excreted unchanged, and very small amounts of phase I and phase II acetylated metabolites were found.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Likely to be dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Likely to be dialysed. Dose as in GFR = 10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Live vaccines: risk of generalised infections – avoid.

## Administration

**Reconstitution**
5 mL sodium chloride 0.9% per vial

**Route**
IV infusion

**Rate of administration**
Over at least 60 minutes

**Comments**
- Add to 250 mL sodium chloride 0.9%
- Administer via a 0.2 micron in-line filter

## Other information

- Manufacturer advises to use with caution in impaired renal function due to lack of data.
- Due to the limited contribution of renal clearance, plasma clearance is mainly non-renal.
- Contains approximately 1000 mg (43 mmol) sodium per dose after dilution.
- Can cause proteinuria and haematuria.
Pizotifen

Clinical use
Prophylactic treatment of vascular headaches including migraine

Dose in normal renal function
- 1.5 mg at night or 500 mcg 3 times a day adjusted according to response
- Maximum single dose: 3 mg
- Maximum daily dose: 4.5 mg

Pharmacokinetics
- Molecular weight (daltons) 429.5 (as malate)
- % Protein binding >90
- % Excreted unchanged in urine <1 (55% as metabolites)
- Volume of distribution (L/kg) 6–8
- Half-life — normal/ESRF (hrs) 1 (metabolite 23 hours) / –

Metabolism
Pizotifen undergoes extensive metabolism. Over half of a dose is excreted in the urine, chiefly as metabolites; a significant proportion is excreted in the faeces.

Administration
Reconstitution
- Route
Oral
- Rate of administration
- Other information
- Use with caution in people with a predisposition for urinary retention or closed angle glaucoma.
- Pizotifen has appetite stimulating properties.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
- Potentially hazardous interactions with other drugs
  - Adrenergic neurone blockers: pizotifen antagonises hypotensive effect.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose reduction may be required. Monitor for drowsiness.
## Plerixafor

### Clinical use

Chemokine receptor antagonist:
- To enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly

### Dose in normal renal function

- Weight <83 kg: 20 mg fixed dose or 240 mcg/kg/day
- Weight >83 kg: 240 mcg/kg/day
- Maximum dose 40 mg daily
- In combination with G-CSF

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose (mg/kg/day)</th>
<th>Maximum (mg daily)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>0.16</td>
<td>27</td>
</tr>
<tr>
<td>10–20</td>
<td>0.16</td>
<td>27</td>
</tr>
<tr>
<td>&lt;10</td>
<td>0.16</td>
<td>27</td>
</tr>
</tbody>
</table>

### Pharmacokinetics

- Molecular weight (daltons) 502.8
- % Protein binding 58
- % Excreted unchanged in urine 70
- Volume of distribution (L/kg) 0.3
- Half-life — normal/ESRF (hrs) 3–5 / Increased

### Metabolism

Not metabolised. About 70% of a dose is eliminated in the urine within 24 hours.

### Important drug interactions

Potentially hazardous interactions with other drugs
- None known

### Administration

#### Reconstitution

- **Route**: SC

#### Rate of administration

- **Other information**

- In UK SPC manufacturer has no dose for GFR<20 mL/ min due to lack of experience but in the data sheet for the USA they advise dose as in GFR<50 mL/ min.
- Following a single dose of 0.24 mg/kg, clearance was reduced in people with varying degrees of renal impairment and was positively correlated with creatinine clearance (CRCL). The mean AUC$_{0-24h}$ in people with mild (CRCL=51–80 mL/min), moderate (CRCL=31–50 mL/min), and severe (CRCL<31 mL/min) renal impairment was 7%, 32%, and 39% higher than healthy subjects with normal renal function. Renal impairment had no effect on $C_{max}$.

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Dialysed. Dose as in GFR<10 mL/min.
- **HD**: Dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Dialysed. Dose as in GFR=10–20 mL/min.
Pomalidomide

Clinical use

Treatment of multiple myeloma

Dose in normal renal function

4 mg once daily on days 1–21 of a 28-day cycle

Pharmacokinetics

Molecular weight (daltons) 273.2
% Protein binding 12–44
% Excreted unchanged in urine 2 (73% plus metabolites)
Volume of distribution (L/kg) 62–138 Litres
Half-life — normal/ESRF (hrs) 9.5 (healthy), 7.5 (myeloma) / Not significantly changed

Metabolism

Mainly metabolised in the liver by the cytochrome P450 isoenzymes CYP1A2 and CYP3A4, with CYP2C19 and CYP2D6 playing a minor role.

Following a single oral administration of [14C]-pomalidomide (2 mg) to healthy subjects, approximately 73% and 15% of the radioactive dose was eliminated in urine and faeces, respectively, with approximately 2% and 8% of the dosed radiocarbon eliminated as pomalidomide in urine and faeces.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Probably dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antidepressants: concentration increased by fluvoxamine.

Administration

Reconstitution —
Route Oral
Rate of administration —

Other information

- On dialysis days patients should take their pomalidomide after their dialysis session.

Reference:
**Ponatinib**

### Clinical use
Protein kinase inhibitor:
- Treatment of chronic myeloid leukaemia (CML)
- Treatment of Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)

### Dose in normal renal function
- 45 mg once daily, adjust dose according to toxicity
- Consult relevant local protocol

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>532.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1101–1223 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>22–24 / –</td>
</tr>
</tbody>
</table>

### Metabolism
Ponatinib is metabolised to an inactive carboxylic acid by esterases and/or amidases, and metabolised by CYP3A4 to an N-desmethyl metabolite that is 4 times less active than ponatinib.

Ponatinib is mainly eliminated via faeces. Following a single oral dose of [14C]-labelled ponatinib, approximately 87% of the radioactive dose is recovered in the faeces and approximately 5% in the urine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin — avoid.
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).

### Administration

**Reconstitution**

**Route**
Oral

**Rate of administration**

### Other information
- Manufacturer advises to use with caution due to lack of studies but ponatinib has minimal renal excretion.
**Clinical use**

Triazole antifungal agent

**Dose in normal renal function**

- **Suspension:** 400 mg twice daily with food or 240 mL of a nutritional supplement
- **Or:** 200 mg 4 times a day without food
- **Tablets:** 300 mg twice daily on day 1 then 300 mg once daily

**Oropharyngeal candidiasis severe infection or in immunocompromised patients:**
- **Suspension:** Loading dose of 200 mg once a day on day 1, then 100 mg once a day for 13 days

**Prophylaxis of invasive fungal infections:**
- **Suspension:** 200 mg 3 times a day
- **Tablets:** 300 mg twice daily on day 1 then 300 mg once daily
- **IV:** 300 mg twice daily on day 1 then 300 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>700.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;98%</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;0.2%</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1774 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>20–66 (average 35) / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Limited metabolism, most circulating metabolites are glucuronide conjugates with only small amounts of oxidative metabolites. The main elimination route of posaconazole is via the faeces (77%) where 66% of a dose is excreted unchanged. About 14% of a dose is excreted in the urine with only trace amounts excreted unchanged.

**Dose in renal impairment GFR (mL/min)**

- **20–50** Oral: Dose as in normal renal function. IV: See 'Other information'.
- **10–20** Oral: Dose as in normal renal function. IV: See 'Other information'.
- **<10** Oral: Dose as in normal renal function. IV: See 'Other information'.

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Not dialysed. Dose as in GFR<10 mL/min.
- **HD** Not dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux** Not dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD** Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

**Potentially hazardous interactions with other drugs**

- **Analgesics:** concentration of fentanyl possibly increased.
- **Anti-arrhythmics:** avoid concomitant use with dronedarone.
- **Antibacterials:** rifamycins may reduce posaconazole concentration; avoid unless benefit outweighs risk; rifabutin concentration increased.
- **Anticoagulants:** avoid with apixiban and rivaroxaban.
- **Antidepressants:** avoid concomitant use with reboxetine.
- **Antidiabetics:** posaconazole can decrease glucose concentrations, monitor glucose levels in diabetic patients; possibly enhances hypoglycaemic effect of glipizide.
- **Antiepileptics:** phenytoin, fosphenytoin, carbamazepine, phenobarbital and primidone may reduce posaconazole concentration – avoid unless benefit outweighs risks.
- **Antimalarials:** avoid with artemether/lumefantrine and piperaquine with artenimol.
- **Antipsychotics:** increased risk of ventricular arrhythmias with pimozide – avoid; possibly increase quetiapine levels – reduce dose of quetiapine; possibly increases lurasidone concentration – avoid.
- **Antivirals:** concentration of atazanavir increased and possibly daclatasvir and simeprevir (reduce dose of daclatasvir, avoid with simeprevir); concentration reduced by efavirenz and possibly fosamprenavir; possibly increases saquinavir levels; increased risk of ventricular arrhythmias with telaprevir; concentration of both drugs increased with dasabuvir and paritaprevir – avoid.
- **Anxiolytics and hypnotics:** increases midazolam levels.

**Other information**

- **IV:** See 'Other information'.

**Important drug interactions**

<table>
<thead>
<tr>
<th>Interaction Type</th>
<th>Interaction Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>Concentration of fentanyl possibly increased.</td>
</tr>
<tr>
<td>Anti-arrhythmics</td>
<td>Avoid concomitant use with dronedarone.</td>
</tr>
<tr>
<td>Antibacterials</td>
<td>Rifamycins may reduce posaconazole concentration; avoid unless benefit outweighs risk; rifabutin concentration increased.</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>Avoid with apixiban and rivaroxaban.</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Avoid concomitant use with reboxetine.</td>
</tr>
<tr>
<td>Antidiabetics</td>
<td>Posaconazole can decrease glucose concentrations, monitor glucose levels in diabetic patients; possibly enhances hypoglycaemic effect of glipizide.</td>
</tr>
<tr>
<td>Antiepileptics</td>
<td>Phenytoin, fosphenytoin, carbamazepine, phenobarbital and primidone may reduce posaconazole concentration – avoid unless benefit outweighs risk.</td>
</tr>
<tr>
<td>Antimalarials</td>
<td>Avoid with artemether/lumefantrine and piperaquine with artenimol.</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>Increased risk of ventricular arrhythmias with pimozide – avoid; possibly increase quetiapine levels – reduce dose of quetiapine; possibly increases lurasidone concentration – avoid.</td>
</tr>
<tr>
<td>Antivirals</td>
<td>Concentration of atazanavir increased and possibly daclatasvir and simeprevir (reduce dose of daclatasvir, avoid with simeprevir); concentration reduced by efavirenz and possibly fosamprenavir; possibly increases saquinavir levels; increased risk of ventricular arrhythmias with telaprevir; concentration of both drugs increased with dasabuvir and paritaprevir – avoid.</td>
</tr>
<tr>
<td>Anxiolytics and hypnotics</td>
<td>Increases midazolam levels.</td>
</tr>
</tbody>
</table>
• Ciclosporin: increases posaconazole concentration; posaconazole can increase ciclosporin concentration – dose reduction may be required.
• Cytotoxics: concentration of bosutinib increased – avoid or reduce dose of bosutinib; possibly increased everolimus concentration – avoid; avoid with lapatinib; reduce dose of panobinostat and ruxolitinib; possibly inhibits metabolism of vinblastine and vincristine, increased risk of neurotoxicity.
• Ergot alkaloids: may increase ergot alkaloid concentration leading to ergotism – avoid.
• Guanfacine: possibly increases guanfacine concentration – halve guanfacine dose.
• Ivacaftor: possibly increased concentration of ivacaftor.
• Lipid-lowering drugs: avoid with lomitapide; possibly increased risk of myopathy with atorvastatin or simvastatin – avoid.¹
• Lumacaftor: posaconazole concentration possibly reduced – reduce dose of lumacaftor with ivacaftor.
• Ranolazine: possibly increased ranolazine concentration – avoid.
• Sirolimus: may increase concentration of sirolimus – adjust sirolimus dose as required according to levels.
• Sulphonylureas: posaconazole can decrease glucose concentrations, monitor glucose levels in diabetic patients.
• Tacrolimus: increases $C_{\text{max}}$ and AUC of tacrolimus by 121% and 358% respectively – reduce tacrolimus dose to about a third of current dose and adjust as required.
• Ulcer-healing drugs: cimetidine may reduce posaconazole concentration by 39% – avoid unless benefit outweighs risk; avoid with histamine $H_2$-antagonists and proton pump inhibitors.

### Administration

#### Reconstitution

<table>
<thead>
<tr>
<th>Route</th>
<th>Oral, IV infusion</th>
</tr>
</thead>
</table>

| Rate of administration | Over 90 minutes centrally | Over 30 minutes peripherally |

| Comments | • Transfer 16.7 mL into a suitable diluent to achieve a concentration of 1–2 mg/mL for central administration and 2 mg/mL for peripheral administration. | • Suitable diluents are sodium chloride 0.9%, 0.45% or glucose 5%. |

| Other information | • Use with caution in people with arrhythmias, electrolyte disturbances, QT prolongation, sinus bradycardia and cardiomyopathy. | • Contains 7 g of glucose per 800 mg daily dose. |

| | • Measure liver function tests as moderate increases have been noted. | • In patients with moderate or severe renal impairment (CRCL<50 mL/min), accumulation of the intravenous vehicle, Betadex Sulfobutyl Ether Sodium (SBECD), is expected to occur. Avoid unless benefit outweighs the risk. |

Reference:

**Potassium chloride**

**Clinical use**

Hypokalaemia

**Dose in normal renal function**

2–4 g (25–50 mmol) daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>74.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>N/A</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>N/A</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>N/A</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Metabolism**

Potassium is excreted mainly by the kidneys; it is secreted in the distal tubules in exchange for sodium or hydrogen ions. Some potassium is excreted in the faeces and small amounts may also be excreted in sweat.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>According to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>According to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>According to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose according to response.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose according to response.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose according to response.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose according to response.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: increased risk of hyperkalaemia.
- Ciclosporin: increased risk of hyperkalaemia.
- Potassium-sparing diuretics: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia.

**Administration**

**Reconstitution**

—

**Route**

Oral, IV

**Rate of administration**

Infusion up to 20 mmol potassium per hour except in extreme hypokalaemic emergency where some units give up to 40 mmol/hour with cardiac monitoring.

**Comments**

- Give IV solution well diluted (not exceeding 40 mmol/500 mL) for peripheral administration.
- Mix IV solutions thoroughly to avoid layering effect.
- Some units give more concentrated solution centrally: 100–200 mmol/100 mL sodium chloride 0.9% or glucose 5%, but at a rate not more than 20 mmol/hour.
- Cardiac monitoring mandatory.

**Other information**

- Potassium chloride injection MUST NOT be injected undiluted.
- Monitor serum potassium levels.
- Sando K: 12 mmol potassium per tablet.
- Kay-Cee-L Syrup: 1 mmol potassium per mL.
- Potassium chloride strong 15% injection: 20 mmol potassium /10 mL.
- Potassium levels cannot be corrected until magnesium levels are normal.
Pramipexole

**Clinical use**
- Parkinson's disease
- Symptomatic treatment of restless legs

**Dose in normal renal function**
- Parkinson's disease: 88–1100 mcg 3 times a day
- Prolonged release: 0.26–3.15 mg daily
- Restless legs: 88–540 mcg taken 2–3 hours before bedtime
(Doses expressed as base)

**Pharmacokinetics**
- Molecular weight (daltons) 302.3 (as hydrochloride)
- % Protein binding <20
- % Excreted unchanged in urine <90
- Volume of distribution (L/kg) 400–500 Litres
- Half-life — normal/ESRF (hrs) 8–14 / 36

**Metabolism**
- Pramipexole undergoes <10% metabolism to inactive metabolites.
- More than 90% of a dose is excreted via renal tubular secretion unchanged into the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Initially 88 mcg twice daily and titrate slowly. Maximum 1.57 mg daily.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Initially 88 mcg once daily and titrate slowly. Maximum 1.1 mg daily.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initially 88 mcg once daily and titrate slowly. Maximum 1.1 mg daily.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Avoid concomitant use with antipsychotics.

**Administration**

**Reconstitution**
- **Route** Oral
- **Rate of administration**
- **Other information**
- 88 mcg of base ≡ 125 mcg of salt, 180 mcg ≡ 250 mcg, 350 mcg ≡ 500 mcg, 700 mcg ≡ 1 mg, 1.1 mg ≡ 1.5 mg.
- Less than 9% of dose is removed by haemodialysis.
- Drowsiness is a common side effect especially at higher doses.
- For restless legs, dose as in normal renal function.
**Clinical use**
Antiplatelet agent

**Dose in normal renal function**
60 mg loading dose followed by 10 mg daily (5 mg daily if weight <60kg or aged >75 years)

**Pharmacokinetics**
- Molecular weight (daltons) 409.9 (as hydrochloride)
- % Protein binding 98 (active metabolite)
- % Excreted unchanged in urine 0 (68% as active metabolite)
- Volume of distribution (L/kg) 44–68 Litres
- Half-life — normal/ESRF (hrs) 2–15 (active metabolite) / Unchanged

**Metabolism**
Prasugrel is a prodrug and is rapidly metabolised in the liver by various cytochrome P450 enzymes to an active metabolite and inactive metabolites. The active metabolite is further metabolised to 2 inactive compounds which are excreted in the urine and faeces; about 68% of a dose is excreted in urine and about 27% in faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function. Use with caution.
- 10–20 Dose as in normal renal function. Use with caution.
- <10 Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: enhanced anticoagulant effect with coumarins and phenindione.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Use with caution in renal impairment due to limited use and increased risk of bleeding complications.
- $C_{max}$ and AUC of the active metabolite decreased by 51% and 42%, respectively, in CKD 5 patients.
Pravastatin sodium

Clinical use
HMG CoA reductase inhibitor:
- Hypercholesterolaemia

Dose in normal renal function
10–40 mg daily at night

Pharmacokinetics
Molecular weight (daltons) 446.5
% Protein binding Approx 50
% Excreted unchanged in urine 20
Volume of distribution (L/kg) 0.5
Half-life — normal/ESRF (hrs) 1.5–2 / Unchanged

Metabolism
Pravastatin undergoes extensive hepatic metabolism to a relatively inactive metabolite. About 70% of an oral dose of pravastatin is excreted in the faeces, as unabsorbed drug and via the bile.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of myopathy with daptomycin, fusidic acid (avoid) and telithromycin; concentration increased by clarithromycin and erythromycin.
- Antivirals: increased risk of myopathy with atazanavir and boceprevir; concentration possibly increased by darunavir; concentration reduced by efavirenz.
- Ciclosporin: increased risk of myopathy.
- Colchicine: possible increased risk of myopathy.
- Lipid lowering agents: increased risk of myopathy with fibrates, gemfibrozil (avoid) and nicotinic acid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Rhabdomyolysis with acute renal failure, secondary to statin-induced myoglobinemia, has been reported.
- Inactive polar metabolite accumulates but is readily removed by haemodialysis.
Praziquantel (unlicensed product)

Clinical use
- Treatment of tapeworm
- *Hymenolepis nana*
- *Schistosoma haematobium* worms
- *S. Japonicum* infections

Dose in normal renal function
- Tapeworm: 5–10 mg/kg after a light breakfast
- *Hymenolepis nana*: 15–25 mg/kg
- *Schistosomiasis*: 20 mg/kg repeated after 4–6 hours
- *S. Japonicum*: 60 mg/kg in 3 divided doses on 1 day

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Pharmacokinetics
- Molecular weight (daltons): 312.4
- % Protein binding: 80
- % Excreted unchanged in urine: 80% as metabolites
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 1–1.5 (metabolites 4 hours) / Slightly increased

Metabolism
Praziquantel undergoes rapid and extensive metabolism in the liver, mainly via the cytochrome P450 isoenzymes CYP2B1 and CYP3A4, being hydroxylated to metabolites that are thought to be inactive.
It is excreted in the urine, mainly as metabolites, about 80% of the dose being eliminated within 4 days and more than 90% of this in the first 24 hours.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin — avoid.
- Antiepileptics: concentration reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antimalarials: concentration reduced by chloroquine.
- Ulcer-healing drugs: concentration reduced by cimetidine.

Administration
Reconstitution
- Route
- Oral
Rate of administration
- Other information
- Available on a named patient basis from Merck (Cysticide).
- One study did not show any adverse effects in a haemodialysis patient.
Prazosin

**Clinical use**

Alpha-adrenoceptor blocker:
- Hypertension
- Congestive heart failure
- Raynaud’s syndrome
- Benign prostatic hyperplasia (BPH)

**Dose in normal renal function**

- 0.5–20 mg daily in 2–3 divided doses
- Raynaud’s syndrome, BPH: 0.5–2 mg twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>419.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>97</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.2–1.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–4 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Prazosin is extensively metabolised in the liver, mainly by demethylation and conjugation; some of the metabolites have antihypertensive activity.

It is excreted as metabolites and 5–11% as unchanged prazosin mainly in the faeces via the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anaesthetics: enhanced hypotensive effect.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid.
- Beta-blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect.
- Calcium-channel blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect.
- Diuretics: enhanced hypotensive effect, increased risk of first dose hypotensive effect.
- Moxisylyte: possibly severe postural hypotension when used in combination.

**Administration**

**Reconstitution**

**Route**

Oral

**Rate of administration**

—
Prednisolone

Clinical use

Corticosteroid:
- Immunosuppression
- Anti-inflammatory

Dose in normal renal function

- Oral: variable
- IM: 25–100 mg once or twice weekly (as prednisolone acetate)

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>360.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>70–95 (saturable)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>11–30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.3–1.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–4 / Increased</td>
</tr>
</tbody>
</table>

Metabolism

Prednisolone is hepatically metabolised and excreted in the urine as sulphate and glucuronide conjugates, with an appreciable proportion of unchanged prednisolone.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antibacterials: metabolism accelerated by rifamycins and rifampicin; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced.
- Anticoagulants: efficacy of coumarins and phenindione may be altered.
- Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited by itraconazole and ketoconazole.
- Antivirals: concentration possibly increased by ritonavir.
- Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids; increased levels of prednisolone; increased ciclosporin levels reported with prednisolone.
- Cobicistat: concentration possibly increased by cobicistat – increased risk of adrenal suppression.
- Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
- Vaccines: high-dose corticosteroids can impair immune response to vaccines – avoid with live vaccines.

Administration

Reconstitution

- Route
  Oral, IM, rectal

Rate of administration

- Other information
  - Evidence of unpredictable bioavailability from enteric coated tablets – avoid if possible.
# Pregabalin

## Clinical use
- Antiepileptic
- Neuropathic pain
- Generalised anxiety disorder

## Dose in normal renal function
150–600 mg daily in 2 or 3 divided doses

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>159.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>92–99</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.56</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–6.5 / Increased</td>
</tr>
</tbody>
</table>

## Metabolism
Pregabalin undergoes negligible metabolism, and about 98% of a dose is excreted in the urine as unchanged drug.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose and Titration</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>Initial dose 75 mg daily and titrate according to tolerability and response.</td>
</tr>
<tr>
<td>15–30</td>
<td>Initial dose 25–50 mg daily and titrate according to tolerability and response.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Initial dose 25 mg daily and titrate according to tolerability and response.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: anticonvulsant effect antagonised.
- Antimalarials: anticonvulsant effect antagonised by mefloquine.
- Antipsychotics: anticonvulsant effect antagonised.
- Orlistat: possible increased risk of convulsions.

## Administration
### Reconstitution
- 

### Route
- Oral

### Rate of administration
- 

## Other information
- Oral bioavailability >90%.
- 50% of dose is removed after a 4-hour haemodialysis session.
- Use with caution in people with severe congestive heart failure.
- May cause reversible deterioration in renal function.
Primaquine phosphate

Clinical use
- Treatment of malaria (*Plasmodium vivax* and *Plasmodium ovale*), in combination with chloroquine
- Treatment of *Pneumocystis jiroveci* pneumonia (PCP), in combination with clindamycin

Dose in normal renal function
- Malaria: 15–30 mg once daily for 14 days
- PCP: 30 mg once daily

Pharmacokinetics
- Molecular weight (daltons) 455.3
- % Protein binding No data
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 3–4
- Half-life — normal/ESRF (hrs) 3–6 / Unknown

Metabolism
Rapidly metabolised in the liver. Its major metabolite carboxyprimaquine accumulates in the plasma on repeated dosage but possesses less antimalarial activity than the parent compound.
Little unchanged drug is excreted in the urine.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antimalarials: avoid concomitant use with artemether/lumefantrine.

Administration
Reconstitution
- Route Oral
- Rate of administration

Other information
- Primaquine base 7.5 mg is approximately equivalent to 13.2 mg primaquine phosphate.
- Contraindicated in acutely ill patients with rheumatoid arthritis or SLE – increased risk of developing granulocytopenia.
- Risk of haemolytic anaemia in patients with G-6-PD deficiency; haemolysis generally appears 2–3 days after primaquine administration.
- Risk of methaemoglobinaemia at high doses.
Primaxin (imipenem / cilastatin)

Clinical use
Antibacterial agent

Dose in normal renal function
IV: 500 mg every 6 hours or 1 g every 6–8 hours (as imipenem)

Pharmacokinetics
- Molecular weight (daltons): Imipenem: 317.4; Cilastatin: 380.4
- % Protein binding: Imipenem: 20; Cilastatin: 40
- % Excreted unchanged in urine: Imipenem: 20–70; Cilastatin: 75
- Volume of distribution (L/kg): Imipenem: 0.23; Cilastatin: 0.22
- Half-life — normal/ESRF (hrs): Imipenem: 1 / 4; Cilastatin: 1 / 12

Metabolism
When administered alone, imipenem is metabolised in the kidneys by dehydropeptidase-I, an enzyme in the brush border of the renal tubules, to inactive, nephrotoxic metabolites, with only about 5 to 40 or 45% of a dose excreted in the urine as unchanged active drug. Cilastatin inhibits the metabolism of imipenem. When given with cilastatin about 70% of an intravenous dose of imipenem is recovered unchanged in the urine within 10 hours. Cilastatin is also excreted mainly in the urine, the majority as unchanged drug and about 12% as N-acetyl cilastatin. Less than 1% of imipenem is excreted via the bile in the faeces.

Dose in renal impairment GFR (mL/min)
- 60–90: 400–500 mg every 6 hours or 750 mg every 8 hours.
- 30–60: 300 mg every 6 hours or 500 mg every 6–8 hours.
- 15–30: 200 mg every 6 hours or 500 mg every 12 hours.
- <15: 200 mg every 6 hours or 500 mg every 12 hours. As long as haemodialysis will be started within 48 hours.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. Dose as in GFR<15 mL/min.
- HD: Dialysed. Dose as in GFR<15 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<15 mL/min.
- CAV/VVH: Dialysed. 250 mg every 6 hours or 500 mg every 8 hours.
- CVVHD/HDF: Dialysed. 250 mg every 6 hours or 500 mg every 6–8 hours. See ‘Other information’.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antiepileptics: reduced valproate concentration – avoid.
- Antivirals: convulsions reported with concomitant administration of ganciclovir and valganciclovir.
- Ciclosporin: variable reports of increase / no change in ciclosporin levels, and of neurotoxicity.

Administration
Reconstitution
10 mL sodium chloride 0.9% per 500 mg vial
Route
IV peripherally or centrally (500 mg/50 mL – given centrally)
Rate of administration
250 or 500 mg dose over 20–30 minutes
>500 mg over 40–60 minutes
Comments
250 mg with 50 mL, 500 mg with 100 mL sodium chloride 0.9% (in some units 500 mg with 50 mL)

Other information
- Risk of adverse neurological effects, e.g. convulsions. Extreme caution required in patients with history of CNS disease.
- Cilastatin can accumulate in patients with impaired renal function.
- Sodium content 1.72 mmol/500 mg vial.
- Imipenem is administered with cilastatin to prevent metabolism of imipenem within the kidney.
- Non-renal clearance in acute renal failure is less than in chronic renal failure.
• Patients with GFR < 5 mL/min should not receive drug unless HD is started within 48 hours.
• There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g., blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
Primidone

**Clinical use**
- Antiepileptic
- Also used for essential tremor

**Dose in normal renal function**
- Epilepsy: 500 mg–1.5 g daily in 2 divided doses
- Essential tremor: 50–750 mg daily

**Pharmacokinetics**
- Molecular weight (daltons) 218.3
- % Protein binding 20
- % Excreted unchanged in urine 40
- Volume of distribution (L/kg) 0.4–1
- Half-life — normal/ESRF (hrs) 10–15 / Unchanged

**Metabolism**
Partially metabolised to phenobarbital and phenylethylmalonamide in the liver, both of which are active and have longer half-lives compared to primidone (metabolites may accumulate in renal impairment).
It is excreted in urine as unchanged drug and metabolites.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function, but avoid very large doses.
- <10: Reduce dose by 25–50% initially, and avoid very large single doses.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: metabolism of aminophylline and theophylline increased, reduced effect.
- Anthelmintics: concentration of albendazole and praziquantel reduced.
- Anti-arrhythmics: reduced concentration of disopyramide and possibly propafenone; possibly reduced concentration of dronedarone – avoid.
- Antibacterials: reduced concentration of chloramphenicol, doxycycline, metronidazole, telithromycin and rifampicin – avoid with telithromycin.
- Anticoagulants: increased metabolism of coumarins (reduced effect); possibly reduced concentration of apixaban and edoxaban and possibly rivaroxaban.
- Antidepressants: antagonise anticonvulsant effect; reduces concentration of paroxetine, reboxetine, mianserin and tricyclics; concentration reduced by St John’s wort – avoid.
- Antiepileptics: concentration increased by fosphenytoin, oxcarbazepine, phenytoin, stripentol and valproate and possibly carbamazepine, also active metabolite of oxcarbazepine reduced and valproate concentration reduced, concentration of fosphenytoin and phenytoin usually reduced but can also be increased; concentration of ethosuximide, rufinamide and topiramate possibly reduced; concentration of lamotrigine, tiagabine and zonisamide reduced.
- Antifungals: possibly reduced concentration of isavuconazole, itraconazole, posaconazole and voriconazole – avoid concomitant use with voriconazole; reduced absorption of griseofulvin (reduced effect).
- Antimalarials: avoid with piperaquine with artenimol; anticonvulsant effect antagonised by mefloquine
- Antipsychotics: antagonise anticonvulsant effect; metabolism of haloperidol increased; possibly reduces aripiprazole concentration – increase aripiprazole dose; concentration of both drugs reduced with chlorpromazine; possibly reduces clozapine concentration; possibly reduces lurasidone concentration – avoid.
- Antivirals: concentration of abacavir, boceprevir, darunavir, dolutegravir, fosamprenavir, indinavir, lopinavir, rilpivirine and saquinavir possibly reduced; avoid with boceprevir and rilpivirine; concentration of daclatasvir, dasabuvir, ombitasvir, paritaprevir and simeprevir possibly reduced – avoid; avoid with elvitegravir, etravirine, ledipasvir, sofosbuvir and telaprevir.
- Calcium-channel blockers: effects of calcium-channel blockers probably reduced – avoid with isradipine and nimodipine.
- Cannabis extract: concentration possibly reduced by primidone – avoid.
- Ciclosporin: reduced ciclosporin levels.
- Cobicistat: concentration of cobicistat possibly reduced.
- Corticosteroids: metabolism of corticosteroids accelerated, reduced effect.
- Cytotoxics: possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of bortezomib, bosutinib, cabozantinib, ceritinib, crizotinib, dasatinib, ponatinib and vandetanib – avoid; avoid with cabazitaxel, dabrafenib, gefitinib and panobinostat; concentration of irinotecan and its active metabolite and possibly etoposide reduced; possible increased hypersensitivity reactions with procarbazine.
- Diuretics: concentration of eplerenone reduced – avoid; increased risk of osteomalacia with carbonic anhydrase inhibitors.
- Guanfacine: concentration of guanfacine possibly reduced – increase dose of guanfacine.
- Hormone antagonists: possibly reduced concentration of abiraterone – avoid; metabolism of toremifene accelerated.
- Ivacaftor: concentration of ivacaftor possibly reduced – avoid.
- Oestrogens and progestogens: metabolism accelerated, reduced contraceptive effect.
- Orlistat: possibly increased risk of convulsions.
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.
- Tacrolimus: concentration of tacrolimus reduced.
- Ulipristal: contraceptive effect reduced – avoid.

### Administration

**Reconstitution**
- **Route**
  - Oral

**Rate of administration**
- {}

**Other information**
- Plasma concentrations of 5–12 mcg/L (23–55 μmol/L) have been loosely correlated with optimum response.
- May cause excessive sedation and osteomalacia.
Procarbazine

**Clinical use**
Antineoplastic agent:
- Main indication is Hodgkin’s disease

**Dose in normal renal function**
- 250–300 mg daily in divided doses; begin with small doses
- Maintenance: 50–150 mg daily

**Pharmacokinetics**
- Molecular weight (daltons) 257.8 (as hydrochloride)
- % Protein binding No data
- % Excreted unchanged in urine 5
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) 10 minutes / Increased

**Metabolism**
Procarbazine is metabolised to an active alkylating agent by microsomal enzymes in the liver and kidneys and only about 5% is excreted unchanged in the urine. The remainder is oxidised to N-isopropylterephthalamic acid and excreted in the urine, with up to 70% of a dose recovered in the urine after 24 hours.

**Dose in renal impairment GFR (mL/min)**
- 20–50 50–100% of dose.
- 10–20 50–100% of dose. Use with caution.
- <10 50–100% of dose. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alcohol: may produce a disulfiram reaction.
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).

**Administration**
**Reconstitution**
- **Route** Oral

**Rate of administration**
- **Other information**
  - Contraindicated by manufacturer in severe renal impairment in UK SPC only.
  - After oral absorption, the drug appears to be rapidly and completely absorbed.
  - Nadir for bone-marrow depression is 4 weeks with recovery within 6 weeks.
  - For 48 hours after dose, wear protective clothing to handle urine.
  - Increased toxicity reported in patients with renal impairment.
**Prochlorperazine**

**Clinical use**
- Nausea and vomiting
- Labyrinthine disorders
- Psychoses
- Severe anxiety

**Dose in normal renal function**
- Oral: 5–10 mg 2–3 times daily
- Buccal: 1–2 tablets twice daily
- IM/IV: 12.5 mg (unlicensed IV)
- Psychoses: Oral: 75–100 mg daily, IM: 12.5–25 mg 2–3 times daily
- Severe anxiety: 15–20 mg daily by mouth, in divided doses; maximum 40 mg daily
- Deep IM: 12.5–25 mg 2–3 times daily

**Pharmacokinetics**
- Molecular weight (daltons) 373.9
- % Protein binding 96
- % Excreted unchanged in urine Minimal
- Volume of distribution (L/kg) 23
- Half-life — normal/ESRF (hrs) 6–9 / –

**Metabolism**
Prochlorperazine undergoes extensive first pass metabolism in the gut wall. It is also extensively metabolised in the liver and is excreted in the urine and bile. The metabolites are inactive.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

**Potentially hazardous interactions with other drugs**
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide, dronedarone and amiodarone – avoid with amiodarone and dronedarone.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin – avoid.
- Antidepressants: increase concentrations and additive antimuscarinic effects, notably with tricyclics; increased risk of ventricular arrhythmias with citalopram and escitalopram – avoid; increased risk of convulsions with vortioxetine.
- Antiepileptics: antagonised (convulsive threshold lowered).
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol and pimozide – avoid; increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration possibly increased with ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
- Anxiolytics and hypnotics: increased sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Desferrioxamine: avoid concomitant use.
- Diuretics: enhanced hypotensive effect.
- Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
- Pentamidine: increased risk of ventricular arrhythmias.

**Administration**

**Reconstitution** —
Prochlorperazine

Route
IM, IV (unlicensed), oral, buccal

Rate of administration
IM or IV over 3–4 minutes

Comments
Unlicensed IV administration methods:
• Either: dilute with water for injection to 5 times its own volume, and administer slowly over not less than 5 minutes,
• Or dilute to 1 mg/mL and administer at rate not greater than 1 mg/minute.

Other information
• Increased CNS sensitivity in severe renal impairment.
• Doses estimated from evaluation of pharmacokinetic data.
Procyclidine hydrochloride

Clinical use

- Control of extrapyramidal symptoms
- Acute dystonias

Dose in normal renal function

- Oral: 2.5–10 mg 3 times a day; maximum 60 mg daily
- Acute dystonias: IM/IV: 5–10 mg

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>323.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12 / –</td>
</tr>
</tbody>
</table>

Metabolism

When given orally about one fifth of the dose is known to be metabolised in the liver, principally by cytochrome P450 and then conjugated with glucuronic acid. Metabolites have been found in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- None known

Administration

Reconstitution

Route
IV, IM, oral
Rate of administration
Bolus over 3–5 minutes

Other information
- Oral bioavailability is 75%.
Proguanil hydrochloride

**Clinical use**
Malaria chemoprophylaxis

**Dose in normal renal function**
200 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>290.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>75</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>20 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Proguanil is metabolised in the liver to the active metabolite, cycloguanil, and to \( p \)-chlorophenylbiguanide which is inactive, mainly by cytochrome P450, CYP 2C19 and slightly by CYP 3A4. Unlike proguanil and \( p \)-chlorophenylbiguanide, cycloguanil is not concentrated in erythrocytes so concentrations of cycloguanil in plasma and whole blood are similar. About 40–60% of a dose of proguanil is excreted in the urine, 60% of this as the unchanged drug, 30% as cycloguanil, and 8% as \( p \)-chlorophenylbiguanide. About 10% of a dose is excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–60</td>
<td>100 mg daily.</td>
</tr>
<tr>
<td>10–20</td>
<td>50 mg every 48 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50 mg weekly.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anticoagulants: effect of warfarin possibly enhanced.
- Antimalarials: avoid concomitant use with artemether/lumefantrine; increased antifolate effect with pyrimethamine.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Other information**
- Rare reports of haematological changes (e.g. megaloblastic anaemia and pancytopenia) in patients with severe renal impairment.
Promazine hydrochloride

Clinical use
Antipsychotic for agitation and restlessness

Dose in normal renal function
- Psychomotor agitation: 100–200 mg 4 times a day
- Agitation and restlessness in elderly: 25–50 mg 4 times a day

Pharmacokinetics
- Molecular weight (daltons): 320.9
- % Protein binding: 95–98
- % Excreted unchanged in urine: <1
- Volume of distribution (L/kg): 7–20

Pharmacokinetic data as for chlorpromazine¹

Metabolism
Promazine undergoes considerable first-pass metabolism in the gut wall. It is also extensively metabolised in the liver and is excreted in the urine and faeces in the form of numerous active and inactive metabolites.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Start with low doses and titrate slowly.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions
- Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval – avoid with amiodarone, disopyramide and dronedarone.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin – avoid.
- Antidepressants: increased level of tricyclics (possibly increased risk of ventricular arrhythmias and antimuscarinic side effects); increased risk of ventricular arrhythmias with citalopram and escitalopram – avoid; increased risk of convulsions with vortioxetine.
- Anticonvulsants: antagonises anticonvulsant effect.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol and pimozide – avoid; increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration possibly increased with ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
- Anxiolytics and hypnotics: increased sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Diuretics: enhanced hypotensive effect.
- Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
- Pentamidine: increased risk of ventricular arrhythmias.

Administration
Reconstitution
- Route
Oral
Rate of administration
- Other information

Reference:
# Promethazine hydrochloride

## Clinical use
Antihistamine

## Dose in normal renal function
Oral: 25 mg at night increased to twice daily, or 10–20 mg 2–3 times a day
Slow IV/IM: 25–100 mg

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>320.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>76–93</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>13.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–14 / –</td>
</tr>
</tbody>
</table>

## Metabolism
Extensively hepatically metabolised, mainly to promethazine sulfoxide, and also to N-desmethylpromethazine.
It is excreted slowly via the urine and bile, mainly as metabolites.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose (mL/min)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs:
- Analgesics: possibly increased sedative effects.

## Administration
Reconstitution
- **Route**
  - IV, IM, oral
- **Rate of administration**
  - Bolus over 3–5 minutes
- **Comments**
  - Administer in 10 mL water for injection for slow IV injection (2.5 mg/mL).

## Other information
- Excessive sedation may occur in CKD 5.
Propafenone hydrochloride

Clinical use

Anti-arrhythmic agent:
- Ventricular arrhythmias
- Paroxysmal supraventricular tachyarrhythmias, (including paroxysmal atrial flutter or fibrillation, and paroxysmal re-entrant tachycardias involving the AV node or accessory pathway) where standard therapy has failed or is unsuitable

Dose in normal renal function
- >70 kg: 150–300 mg 3 times daily
- If <70 kg start with a lower dose

Pharmacokinetics

Molecular weight (daltons) 377.9
% Protein binding >95
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 1.9–3
Half-life — normal/ESRF (hrs) 2–10 (10–32 hours in slow metabolisers) / Unchanged

Metabolism

Propafenone is hepatically metabolised mainly by CYP2D6 isoenzyme but also to a small extent by CYP1A2 and CYP3A4. This forms 2 active metabolites, 5-hydroxypropafenone and N-depropylpropafenone and some inactive ones. Propafenone and its metabolites also undergo glucuronidation. The extent of metabolism is genetically determined. Propafenone is excreted in the urine and faeces mainly in the form of conjugated metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased myocardial depression with other anti-arrhythmics.
- Antibacterials: increased metabolism with rifampicin (reduced effect).
- Anticoagulants: enhanced anticoagulant effect of coumarins.
- Antidepressants: increased risk of arrhythmias with tricyclics; metabolism of propafenone possibly inhibited by paroxetine (increased risk of toxicity).
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval.
- Antivirals: concentration of propafenone increased by saquinavir and ritonavir and possibly by fosamprenavir, increased risk of ventricular arrhythmias – avoid; use with caution with telaprevir.
- Beta-blockers: increased myocardial depression; increased concentration of metoprolol and propranolol.
- Cardiac glycosides: increased digoxin concentration – halve digoxin dose.
- Ciclosporin: possibly increased ciclosporin concentration.
- Ulcer-healing drugs: levels increased by cimetidine.

Administration

Reconstitution

—

Route
Oral

Rate of administration

—

Other information

- Half-life depends on acetylator status of patient.
- Ensure that electrolyte disturbances are corrected before commencing treatment.
- Therapeutic plasma concentrations are between 150–1500 ng/mL.
**Propiverine hydrochloride**

**Clinical use**
- Treatment of urinary frequency, urgency and incontinence
- Neurogenic bladder instability

**Dose in normal renal function**
- 15 mg 1–3 times a day
- XL: 30 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 403.9
- % Protein binding 90–95
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 125–473 Litres (average: 279 Litres)
- Half-life — normal/ESRF (hrs) 20 / –

**Metabolism**
Propiverine is extensively metabolised by intestinal and hepatic enzymes. Four metabolites were identified in urine; two of them are pharmacologically active and may contribute to the therapeutic efficacy. Propiverine and its metabolites are excreted in the urine, bile and faeces.

**Dose in renal impairment GFR (mL/min)**
- 30–50 Dose as in normal renal function.
- 10–30 Dose as in normal renal function. Maximum 30 mg daily.
- <10 Dose as in normal renal function. Maximum 30 mg daily.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Unknown dialysability. Dose as in GFR<10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**
—
Propofol

Clinical use

- Induction and maintenance of general anaesthesia
- Sedation of ventilated patients for up to 3 days

Dose in normal renal function

- Induction: 1.5–2.5 mg/kg at a rate of 20–40 mg every 10 seconds
- If > 55 years or debilitated: 1-1.5 mg/kg at a rate of 20 mg every 10 seconds
- Maintenance: 25–50 mg repeated according to response or 4–12 mg/kg/hour (3–6 mg/kg/hour in elderly or debilitated)
- Sedation: 0.3–4 mg/kg/hour
- Sedation for surgical and diagnostic procedures: 0.5–1 mg/kg over 1–5 minutes then maintenance: 1.5–4.5 mg/kg/hour or 10–20 mg/kg

Pharmacokinetics

Molecular weight (daltons) 178.3
% Protein binding >95
% Excreted unchanged in urine <0.3
Volume of distribution (L/kg) 8–19
Half-life — normal/ESRF (hrs) 3–12 / Unchanged

Metabolism

Clearance of propofol occurs by metabolic processes, mainly in the liver where it is blood flow dependent, to form inactive conjugates of propofol and its corresponding quinol, which are excreted in urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Adrenergic-neurone blockers: enhanced hypotensive effect.
- Antihypertensives: enhanced hypotensive effect.
- Antidepressants: avoid MAOIs for 2 weeks before surgery; increased risk of arrhythmias and hypotension with tricyclics.
- Antipsychotics: enhanced hypotensive effect.
- Muscle relaxants: increased risk of myocardial depression and bradycardia with suxamethonium.

Administration

Reconstitution

Route
IV

Rate of administration
See local protocols.
Propranolol hydrochloride

### Clinical use

Beta-adrenoceptor blocker:
- Hypertension
- Phaeochromocytoma
- Angina
- Arrhythmias
- Anxiety
- Migraine prophylaxis

### Dose in normal renal function

- Hypertension: 40–160 mg twice daily
- Prophylaxis of variceal bleeding in portal hypertension: 40–160 mg twice daily
- Phaeochromocytoma: 60 mg daily for 3 days before surgery, or 30 mg daily if unsuitable for surgery
- Angina: 120–240 mg daily in divided doses
- Arrhythmias, anxiety, hypertrophic cardiomyopathy, thyrotoxicosis: 10–40 mg 3–4 times daily
- Anxiety with symptoms e.g. palpitations: 40 mg 1–3 times daily
- Prophylaxis after an MI: 40 mg 4 times daily then 80 mg twice daily
- Essential tremor: 80–160 mg daily
- Migraine: 80–240 mg daily in divided doses
- IV: 1 mg over 1 minute repeated after 2 minutes to a maximum of 10 mg (5 mg with anaesthesia)

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>295.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>80–95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–6 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Propranolol is subject to considerable hepatic-tissue binding and first-pass metabolism. It is metabolised in the liver to an active metabolite (4-hydroxypropranolol) and several inactive ones. The metabolites and small amounts of unchanged drug are excreted in the urine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Start with small doses and increase according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with small doses and increase according to response.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs:
- Anaesthetics: enhanced hypotensive effect; risk of bupivacaine toxicity increased.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; concentration increased by propafenone and possibly dronedarone; increased risk of myocardial depression and bradycardia with flecainide; increased risk of lidocaine toxicity.
- Antibacterials: metabolism increased by rifampicin.
- Antidepressants: enhanced hypotensive effect with MAOIs; concentration increased by fluvoxamine; concentration of imipramine increased.
- Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics enhanced hypotensive effect with phenothiazines; concentration of both drugs increased with chlorpromazine.
• Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
• Cytotoxics: possible increased risk of bradycardia with crizotinib.
• Diuretics: enhanced hypotensive effect.
• Fingolimod: possibly increased risk of bradycardia.
• Moxisylyte: possible severe postural hypotension.
• Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

### Administration

#### Reconstitution

—

#### Route

Oral, IV

#### Rate of administration

—

### Other information

- Non-selective active metabolites accumulate in renal impairment. Consider metoprolol or atenolol.
- May reduce renal blood flow in severe renal impairment.
Propylthiouracil

**Clinical use**

Hyperthyroidism

**Dose in normal renal function**

- Initially: 200–400 mg daily
- Maintenance dose: 50–150 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>170.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>80</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.3–0.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1–2 / 8.5</td>
</tr>
</tbody>
</table>

**Metabolism**

Propylthiouracil undergoes rapid first-pass metabolism in the liver, and is mainly excreted in the urine as the glucuronic acid conjugate, with very little excreted as unchanged drug.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>75% of normal dose and titrate to response. See 'Other information.'</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50% of normal dose and titrate to response. See 'Other information.'</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Unknown dialysability. Dose as in GFR < 10 mL/min.
- **HD**: Not dialysed. Dose as in GFR < 10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR < 10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR = 10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution** —

**Route** Oral

**Rate of administration** —

**Other information**

- Renally impaired patients are at a greater risk of cardiotoxicity and leucopenia.
- UK manufacturer advises a dose reduction if GFR < 50 mL/min but not in the US data sheet.
- Drug Prescribing in Renal Failure, 5th edition by Aronoff et al. advises to use 100% of dose.
Protamine sulphate

**Clinical use**
Counteract anticoagulant effect of heparin

**Dose in normal renal function**
Depends on time since stopping IV / subcutaneous heparin and dose of heparin given

**Pharmacokinetics**
- Molecular weight (daltons): Approx 4500
- % Protein binding: 1
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): 12.3 Litres
- Half-life — normal/ESRF (hrs): 7.4 minutes / –

**Metabolism**
The metabolism of the heparin-protamine complex has not been elucidated, it has been postulated that it may be partially metabolised or may be attacked by fibrinolysin, thus freeing heparin.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
—

**Route**
—

**Rate of administration**
5 mg / minute

**Other information**
- Counteracting the anticoagulant effect of heparin during extra-corporeal treatments requires approximately 1.5 mg protamine per 100 IU heparin.
- Most clinicians recommend a dose of 1–1.5 mg protamine sulphate for each 100 units heparin given depending on the length of time since heparin administration.
- May be used topically to stop bleeding fistulae.
Pseudoephedrine hydrochloride

**Clinical use**

Nasal decongestant

**Dose in normal renal function**

60 mg 4 times a day

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>201.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>90–98</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2–3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5.5 (depends on pH of urine)</td>
</tr>
</tbody>
</table>

**Metabolism**

A small amount of pseudoephedrine is hepatically metabolised by N-demethylation.

It is excreted largely unchanged in the urine with small amounts of its hepatic metabolite.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Unlikely dialysability. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anaesthetics: increased risk of ventricular arrhythmias with isoflurane.
- Antibacterials: risk of hypertensive crisis with linezolid.
- Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide.
- Dopaminergics: avoid concomitant use with selegiline and rasagiline.

**Administration**

**Reconstitution**

- **Route**: Oral

**Rate of administration**

- **Other information**

  - Between 5–20% is removed by haemodialysis.
  - Increased risk of developing hypertension in patients with GFR<20 mL/min.
  - Not recommended in severe renal impairment in UK SPC.
## Pyrazinamide (unlicensed product)

### Clinical use
Antimicrobial agent for tuberculosis

### Dose in normal renal function
- **<50 kg**: 1.5 g per day or 2 g three times a week
- **>50 kg**: 2 g per day or 2.5 g three times a week

### Pharmacokinetics
- **Molecular weight (daltons)**: 123.1
- **% Protein binding**: 10
- **% Excreted unchanged in urine**: 4
- **Volume of distribution (L/kg)**: 0.75–1.3
- **Half-life — normal/ESRF (hrs)**: 9–10 / 26

### Metabolism
Pyrazinamide is metabolised mainly in the liver by hydrolysis to the major active metabolite pyrazinoic acid, which is subsequently hydroxylated to the major excretory product 5-hydroxypyrazinoic acid. It is excreted via the kidneys mainly by glomerular filtration. About 70% of a dose appears in the urine within 24 hours mainly as metabolites.

### Dose in renal impairment GFR (mL/min)
- **20–50**: Dose as in normal renal function.
- **10–20**: Dose as in normal renal function. See 'Other information'.
- **<10**: Use 50–100% of dose. See 'Other information'.

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Not dialysed. Dose as in GFR < 10 mL/min.
- **HD**: 50–100% dialysed. Dose as in GFR < 10 mL/min or 25–30 mg/kg post dialysis.
- **HDF/High flux**: Dialysed. Dose as in GFR < 10 mL/min or 25–30 mg/kg post dialysis.
- **CAV/VVHD**: Dialysed. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Ciclosporin: on limited evidence, pyrazinamide appears to reduce ciclosporin levels.

### Administration

#### Reconstitution
—

#### Route
Oral

#### Rate of administration
—

### Other information
- Available from IDIS on a named patient basis.
- Can precipitate gout as impairs urate excretion.
- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.

**Reference:**
Pyridostigmine bromide

**Clinical use**
Myasthenia gravis

**Dose in normal renal function**
0.3–1.2 g per day in divided doses

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>261.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>80–90</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.8–1.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–4 / 6</td>
</tr>
</tbody>
</table>

**Metabolism**
Pyridostigmine undergoes hydrolysis by cholinesterases and is also metabolised in the liver. It appears that 75% of the plasma clearance of pyridostigmine depends on renal function. 3-Hydroxy-N-methylpyridinium has been identified as one of the 3 metabolites isolated from the urine. Pyridostigmine is excreted mainly in the urine as unchanged drug and metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>35% of daily dose.</td>
</tr>
<tr>
<td>10–20</td>
<td>35% of daily dose.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>20% of daily dose.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Aminoglycosides, clindamycin and polymyxins antagonise effects of pyridostigmine.

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

**Other information**
- Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
Pyridoxine hydrochloride

Clinical use
Vitamin B₆

Dose in normal renal function
- Deficiency: 20–50 mg up to 3 times daily
- Prophylaxis against isoniazid neuropathy: 10–20 mg daily; 50 mg 3 times daily for treatment
- Idiopathic sideroblastic anaemia: 100–400 mg daily in divided doses
- Penicillamine induced nephropathy, prophylaxis in Wilson’s disease (unlicensed): 20 mg daily
- Premenstrual syndrome: 50–100 mg daily

Pharmacokinetics
- Molecular weight (daltons): 205.6
- % Protein binding: High (as pyridoxal and pyridoxal phosphate)
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 15–20 days / –

Metabolism
Pyridoxine is metabolised to its active form pyridoxamine phosphate. It is stored mainly in the liver where there is oxidation to 4-pyridoxic acid and other inactive metabolites which are excreted in the urine.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution —
Route Oral
Rate of administration —

Other information
- Long-term use of pyridoxine in doses greater than 200 mg daily has been associated with neuropathy.
Pyrimethamine

**Clinical use**

Antiprotozoal agent:
- Malaria
- Toxoplasmosis

**Dose in normal renal function**

- Malaria: used in dual drug combinations
- Malaria prophylaxis: 25 mg weekly
- Toxoplasmosis: 100 mg daily for 1–2 days then 2550 mg daily for 2–6 weeks (in combination with sulfadiazine)

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>248.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>80–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>15–30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>35–175 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Pyrimethamine is metabolised in the liver and slowly excreted via the kidney, with up to 30% recovered in the urine as parent compound over a period of several weeks. Several metabolites have also been detected in the urine, although data are lacking on the nature of these metabolites, their route, rate of formation and elimination, and any pharmacological activity, particularly after prolonged daily dosing.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Increased antifolate effect with sulphonamides, trimethoprim, methotrexate and pemetrexed.
- Antiepileptics: anticonvulsant effect of fosphenytoin and phenytoin antagonised, also increased antifolate effect.
- Antimalarials: avoid concomitant use with artemether/lumefantrine; increased antifolate effect with proguanil.

**Administration**

Reconstitution
- 

Route
- Oral

Rate of administration
- 

**Other information**

- Pyrimethamine should always be administered with a folate supplement to reduce the risk of bone marrow depression.
# Quetiapine

## Clinical use
- Schizophrenia
- Mania in bipolar disorder
- Depression in bipolar disorder

## Dose in normal renal function
- Schizophrenia: 50–750 mg daily in 2 divided doses
- Mania / mania and depression in bipolar disorder: 50–400 mg twice daily
- Depression in bipolar disorder: 50–600 mg once daily
- XL: Schizophrenia / mania / mania and depression: 300–800 mg once daily

## Pharmacokinetics
- Molecular weight (daltons) 883.1 (as fumarate)
- % Protein binding 83
- % Excreted unchanged in urine <5
- Volume of distribution (L/kg) 6–14
- Half-life — normal/ESRF (hrs) 6–7 / Unchanged

## Metabolism
Quetiapine is extensively metabolised in the liver by sulfoxidation mediated mainly by the cytochrome P450 isoenzyme CYP3A4 and by oxidation. The primary metabolite is norquetiapine, which is also eliminated by CYP3A4. Following the administration of radiolabelled quetiapine, the parent compound accounted for less than 5% of unchanged drug-related material in the urine or faeces. Approximately 73% of the radioactivity is excreted in the urine and 21% in the faeces, mainly as inactive metabolites.

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of ventricular arrhythmias.
- Antibacterials: concentration possibly increased by macrolides – avoid.
- Antidepressants: concentration of tricyclics possibly increased.
- Antiepileptics: antagonism of convulsive threshold; metabolism accelerated by carbamazepine and phenytoin; concentration possibly increased by valproate.
- Antifungals: concentration possibly increased by imidazoles and triazoles – avoid.
- Antimalarials: manufacturer advises avoid use with artemether and lumefantrine.
- Antipsychotics: possible increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration possibly increased by atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir, telaprevir and tipranavir – avoid.
- Anxiolytics and hypnotics: enhanced sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias with arsenic trioxide.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Grapefruit juice: concentration of quetiapine possibly increased – avoid.
<table>
<thead>
<tr>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reconstitution</td>
</tr>
<tr>
<td>Route Oral</td>
</tr>
<tr>
<td>Rate of administration</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Plasma clearance is reduced by 25% in severe renal impairment.</td>
</tr>
<tr>
<td>• Absorption is increased by food so it should be taken consistently either with or without food.</td>
</tr>
</tbody>
</table>
Quinagolide

**Clinical use**

Hyperprolactinaemia

**Dose in normal renal function**

75–150 micrograms daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>432 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Very little</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>100 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>17</td>
</tr>
</tbody>
</table>

**Metabolism**

Quinagolide is extensively metabolised. Quinagolide and its N-desethyl analogue are the biologically active but minor components. Their inactive sulphate or glucuronide conjugates represent the major circulating metabolites. Studies performed with \(^3\)H-labelled quinagolide revealed that more than 95% of the drug is excreted as metabolites. About equal amounts of total radioactivity are found in faeces and urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Use with caution. Start with low dose and titrate according to response.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution. Start with low dose and titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. Start with low dose and titrate according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- None known

**Administration**

Reconstitution —

Route

Oral

Rate of administration —

**Other information**

- Manufacturer advises to avoid use in renal impairment due to lack of data.
**Quinapril**

**Clinical use**
Angiotensin converting enzyme inhibitor:
- Hypertension
- Congestive heart failure

**Dose in normal renal function**
- Hypertension: 2.5–80 mg daily in 1–2 divided doses
- Congestive heart failure: 2.5–40 mg daily in 1–2 divided doses

**Pharmacokinetics**
- Molecular weight (daltons): 475 (as hydrochloride)
- % Protein binding: 97
- % Excreted unchanged in urine: 30
- Volume of distribution (L/kg): 1.5
- Half-life — normal/ESRF (hrs): 1 / 12–14

**Metabolism**
Quinapril is a prodrug which is metabolised in the liver to its active form, quinaprilat, and to minor inactive metabolites.
Quinaprilat is eliminated primarily by renal excretion.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Start with low dose, adjust according to response.
- 10–20: Start with low dose, adjust according to response.
- <10: Start with low dose, adjust according to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: 25% dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
- Bee venom extract: possible severe anaphylactoid reactions when used together.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of angioedema with everolimus.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Gold: flushing and hypotension with sodium aurothiomalate.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Renal failure has been reported with ACE inhibitors: mainly in patients with renal artery stenosis, post renal transplant and those with severe congestive heart failure.
- A high incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor – this combination should be avoided.
- Hyperkalaemia and other side effects more common in patients with renal impairment.
- Close monitoring of renal function during therapy is necessary in those patients with known renal insufficiency.
**Quinine**

### Clinical use
- Severe and complicated falciparum malaria
- Nocturnal cramp

### Dose in normal renal function
- **IV:** Quinine dihydrochloride: Loading dose 20 mg/kg to maximum 1.4 g, then after 8 hours, maintenance 10 mg/kg (up to maximum 700 mg) 8 hourly, reduced to 5–7 mg/kg if parenteral treatment required for more than 48 hours.
- **Oral:** Quinine sulphate 600 mg every 8 hours for 5–7 days
- **Nocturnal cramp:** Quinine sulphate 200–300 mg at night

### Pharmacokinetics
- Molecular weight (daltons) 324.4 (397.3 as dihydrochloride); (782.9 as sulphate)
- % Protein binding 70–90
- % Excreted unchanged in urine 5–20
- Volume of distribution (L/kg) 2.5–7.1
- Half-life — normal/ESRF (hrs) 11 (healthy), 18 (malaria) / 26

### Metabolism
Quinine is extensively metabolised in the liver and rapidly excreted mainly in the urine. Excretion is increased in acid urine.

### Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Malaria</th>
<th>Cramp</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>5–7 mg/kg every 8 hours.</td>
<td>dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>5–7 mg/kg every 8–12 hours.</td>
<td>dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5–7 mg/kg every 24 hours.</td>
<td>dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD** Dialysed. Dose as in GFR<10 mL/min.
- **HD** Dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux** Dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD** Not dialysed. Dose as in GFR=10–20 mL/min.

### Important drug interactions
Potentially hazardous interactions with other drugs
- **Anti-arrhythmics:** flecainide levels increased; increased risk of ventricular arrhythmias with amiodarone – avoid.
- **Antibacterials:** increased risk of ventricular arrhythmias with moxifloxacin – avoid; concentration reduced by rifampicin.
- **Antidepressants:** possible increased risk of ventricular arrhythmias with citalopram and escitalopram.
- **Antimalarials:** increased risk of convulsions with mefloquine; avoid concomitant use with artemether/lumefantrine.
- **Antipsychotics:** increased risk of ventricular arrhythmias with droperidol, pimozide, risperidone and possibly haloperidol – avoid.
- **Antivirals:** concentration possibly increased by atazanavir, darunavir, fosamprenavir, indinavir and tipranavir; concentration increased by ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
- **Cardiac glycosides:** levels of digoxin increased (half maintenance dose).
- **Ciclosporin:** decreased ciclosporin levels reported.
- **Cimetidine:** may increase plasma levels of quinine.

### Administration

#### Reconstitution
- **Route**
  - IV infusion, oral, IM (quinine dihydrochloride)
- **Rate of administration**
  - 4 hours
- **Comments**
  - Add to sodium chloride 0.9% or glucose 5% for infusion.
- Loading dose of 20 mg/kg may be required in some cases (refer to specialist treatment). Not to be given if patient has had quinine or mefloquine in previous 12–24 hours.

**Other information**

- Quinine dihydrochloride injection is available as a special order.

- Monitor for signs of cardiotoxicity.
- Give doses after haemodialysis on dialysis days.
- Monitor quinine levels if patient exhibits any symptoms of toxicity.
- Doses in renal impairment are from *Drug Prescribing in Renal Failure, 5th edition* by Aronoff et al.
Rabeprazole sodium

<table>
<thead>
<tr>
<th>Clinical use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric acid suppression</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose in normal renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>10–120 mg daily, doses &gt;100 mg in 2 divided doses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pharmacokinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
</tr>
<tr>
<td>% Protein binding</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Metabolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabeprazole is mainly metabolised via nonenzymatic reduction and, to a lesser extent, via the cytochrome P450 isoenzymes CYP2C19 and CYP3A4. Metabolites are excreted principally in the urine (about 90%) with the remainder in the faeces.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Importantly hazardous interactions with other drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Antifungals: absorption of itraconazole and ketoconazole reduced; avoid with posaconazole.</td>
</tr>
<tr>
<td>• Antivirals: concentration of atazanavir and rilpivirine reduced – avoid; concentration of raltegravir and saquinavir possibly increased – avoid.</td>
</tr>
<tr>
<td>• Clopidogrel: possibly reduced antiplatelet effect.</td>
</tr>
<tr>
<td>• Cytotoxics: possibly reduced excretion of methotrexate; avoid with dasatinib, erlotinib and vandetanib; possibly reduced lapatinib absorption; possibly reduced absorption of pazopanib.</td>
</tr>
<tr>
<td>• Ulipristal: reduced contraceptive effect, avoid with high dose ulipristal.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reconstitution —</td>
</tr>
<tr>
<td>Route Oral</td>
</tr>
<tr>
<td>Rate of administration —</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Interstitial nephritis has been reported with rabeprazole.</td>
</tr>
<tr>
<td>• Oral bioavailability is 52%.</td>
</tr>
</tbody>
</table>
**Clinical use**

Treatment of acute diarrhoea

**Dose in normal renal function**

100 mg followed by 100 mg three times a day preferably before main meals

**Pharmacokinetics**

- Molecular weight (daltons) 385.5
- % Protein binding 90 (active metabolite—mainly to albumin)
- % Excreted unchanged in urine 81.4 (as active and inactive metabolites)
- Volume of distribution (L/kg) 66.4
- Half-life — normal/ESRF (hrs) 3 / Increased

**Metabolism**

Quickly metabolised by hydrolysis to active metabolite, thiorphan. Racecadotril is eliminated as active and inactive metabolites. Elimination is mainly via the renal route, and to a much lesser extent via the faecal route (around 8%). The pulmonary route is not significant (less than 1% of the dose).

**Dose in renal impairment GFR (mL/min)**

- **20–50**: Dose as in normal renal function. Use with caution.
- **10–20**: Dose as in normal renal function. Use with caution.
- **<10**: Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

- **Route**: Oral

**Rate of administration**

- 

**Other information**

- In patients with severe renal failure (CRCL=11–39 mL/min), the kinetic profile of the active metabolite of racecadotril showed smaller C\text{max} (–49%) and greater AUC (+16%) and half-life as compared to healthy volunteers (CRCL>70 mL/min).
**Raloxifene hydrochloride**

### Clinical use
Treatment and prevention of osteoporosis in post menopausal women

### Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: antagonism of anticoagulant effect of coumarins.
- Colestyramine: reduced absorption of raloxifene – avoid.

### Dose in normal renal function
60 mg daily

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>510</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>98–99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2348</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>27.7 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism
Raloxifene undergoes extensive first pass metabolism to the glucuronide conjugates: raloxifene-4'-glucuronide, raloxifene-6-glucuronide, and raloxifene-6, 4'-diglucuronide.

Rafoxifene undergoes enterohepatic recycling, and is excreted almost entirely in the faeces. Less than 6% of dose is excreted in the urine.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapies</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Other information
- This study showed that raloxifene could reduce vertebral fractures although they were more likely to suffer from side effects. ([Ishani A, Blackwell T, Jamal SA, et al.](https://www.jasn.org/article/S1046-6673(08)01681-0/fulltext) *The effect of raloxifene treatment in postmenopausal women with CKD.* *J Am Soc Nephrol.* 2008; 19(7):1430–8.)
- UK SPC advises use is contraindicated in severe renal impairment due to lack of data rather than known toxicity. The US data sheet advises to use with caution.
Raltegravir

Clinical use
Integrase inhibitor:
- Treatment of HIV infection, in combination with other antiretroviral medication

Dose in normal renal function
- Tablets: 400 mg twice daily
- Chewable tablet: 300 mg twice daily
- Oral suspension: 100 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 444.4 (482.5 as potassium)
% Protein binding 83
% Excreted unchanged in urine 7–14
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 9 / Unchanged

Metabolism
Metabolised via glucuronidation, catalysed by the enzyme uridine diphosphate glucuronosyltransferase. Raltegravir is excreted in both urine and faeces as unchanged drug and metabolites.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Minimal dialysability. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin, consider increasing raltegravir dose.
- Antivirals: avoid with fosamprenavir.
- Orlistat: absorption of raltegravir possibly reduced.
- Ulcer-healing drugs: concentration increased by omeprazole and famotidine.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- The tablets and oral suspension are not bioequivalent.

References:
Raltitrexed

Clinical use
Treatment of colorectal cancer when fluorouracil and folinic acid cannot be used

Dose in normal renal function
3 mg/m² every 3 weeks

Pharmacokinetics
Molecular weight (daltons) 458.5
% Protein binding 93
% Excreted unchanged in urine 40–50
Volume of distribution (L/kg) 548 Litres
Half-life — normal/ESRF (hrs) 198 / Increased

Metabolism
Raltitrexed is actively transported into cells and metabolised to active polyglutamate forms. The remainder of a dose is not metabolised and is excreted unchanged, about 50% of a dose appearing in the urine, and about 15% in the faeces.

Dose in renal impairment GFR (mL/min)
55–65 Use 75% of the dose (2.25 mg/m²) every 4 weeks.
25–54 Use 50% of the dose (1.5 mg/m²) every 4 weeks.
<25 Avoid. See ‘Other information’.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<25 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<25 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<25 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=25–54 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Folic and folinic acid: impairs cytotoxic action — avoid.

Administration
Reconstitution
4 mL water for injection
Route
IV infusion
Rate of administration
Over 15 minutes
Comments
- Dilute in 50–250 mL sodium chloride 0.9% or glucose 5%.
- Stable for 24 hours at 2–8°C.

Other information
- Doses above 3 mg/m² have an increased incidence of life-threatening / fatal toxicity.
- Increased risk of treatment-related toxicity if CRCL<65 mL/min.
- Anecdotal reports of using 30–40% of the dose every 4 weeks in patients with severe renal impairment and closely monitoring haematological parameters. Risk of severe and prolonged side effects – use if risk of not treating the patient outweighs the risk of adverse effects.
**Ramipril**

### Clinical use

Angiotensin-converting enzyme inhibitor:
- Hypertension
- Secondary prevention of myocardial infarction (MI), stroke or cardiovascular death
- Heart failure
- Diabetic nephropathy

### Dose in normal renal function

- 1.25–10 mg once a day
- Prophylaxis after a MI: 2.5–5 mg twice daily
- Diabetic nephropathy: 1.25–5 mg once daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>416.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>56 (as ramiprilat)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>13–17 / Increased (as ramiprilat)</td>
</tr>
</tbody>
</table>

### Metabolism

Ramipril is metabolised in the liver to its active metabolite, ramiprilat, and other inactive metabolites. It is excreted mainly in the urine, as ramiprilat, other metabolites, and some unchanged drug. About 40% of an oral dose appears in the faeces; this may represent both biliary excretion and unabsorbed drug.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Initial dose 1.25 mg daily and increase according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initial dose 1.25 mg daily and increase according to response.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARB’S and aliskiren.
- Bee venom extract: possible severe anaphylactoid reactions when used together.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of angioedema with everolimus.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Gold: flushing and hypotension with sodium aurothiomalate.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

### Administration

**Reconstitution**

**Route**

Oral

**Rate of administration**

**Other information**

- Renal failure has been reported in association with ACE inhibitors in patients with renal artery stenosis, post renal transplant, and those with congestive heart failure.
- A high incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor – this combination should therefore be avoided.
- Hyperkalaemia and other side effects more common in patients with impaired renal function.
- Close monitoring of renal function during therapy is necessary in those patients with known renal insufficiency.
- Normal doses have been used in CKD 5.
Ramucirumab

Clinical use

Human monoclonal antibody:
- Treatment of advanced gastric cancer or gastro-oesophageal junction adenocarcinoma, colorectal cancer and non-small cell lung cancer (NSLC)

Dose in normal renal function

- Gastric cancer or gastro-oesophageal junction adenocarcinoma: 8 mg/kg on days 1 and 15 of a 28-day cycle (with paclitaxel)
- Gastric cancer or gastro-oesophageal junction adenocarcinoma (monotherapy) and colorectal cancer: 8 mg/kg every 2 weeks
- NSLC: 10 mg/kg on day 1 of a 21-day cycle

Pharmacokinetics

Molecular weight (daltons) 143 600
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 5.4 Litres
Half-life — normal/ESRF (hrs) 15 days

Metabolism

The metabolism of ramucirumab has not been studied. Monoclonal antibodies are mainly cleared by catabolism.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>29–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>15–29</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<15 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<15 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<15 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=15–29 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Vaccines: risk of generalised infections with live vaccines – avoid.

Administration

Reconstitution
- Route
  IV infusion
Rate of administration
  Over 60 minutes
Comments
  Make up to 250 mL with sodium chloride 0.9%. Use with a 0.22 micron in-line filter.

Other information

- No formal studies have been done in patients with renal impairment and there is limited data in patients with a CRCL=15–29 mL/min.
- From pharmacokinetic studies down to a CRCL of 15 mL/min there is unlikely to be any difference in exposure compared with normal renal function.
- Pre-medication with an antihistamine is recommended.
- An increase in proteinuria has been reported.
Ranitidine

Clinical use
H₂ antagonist:
- Conditions associated with hyperacidity

Dose in normal renal function
- Oral: 150–300 mg once or twice daily
- Zollinger Ellison: 150 mg 3 times daily up to 6 g/day
- IM / Slow IV injection: 50 mg every 6–8 hours
- IV infusion: 25 mg/hour for 2 hours, 6–8 hourly; or for stress ulceration prophylaxis 125–250 mcg/kg/hour

Pharmacokinetics
Molecular weight (daltons) 314.4
% Protein binding 15
% Excreted unchanged in urine Oral: 30–35; IV: 80
Volume of distribution (L/kg) 1.4
Half-life — normal/ESRF (hrs) 2–3 / 6–9

Metabolism
Ranitidine is not extensively metabolised. A small proportion of ranitidine is metabolised in the liver to the N-oxide, the S-oxide, and desmethylranitidine; the N-oxide is the major metabolite but accounts for only about 4–6% of a dose.
The fraction of the dose recovered as metabolites is similar after both oral and IV dosing; and includes 6% of the dose in urine as the N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and 1–2% as the furoic acid analogue. There is also some excretion in the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Oral: 50–100% of normal dose. IV: 50 mg 12 hourly.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Dialysed. IV: 50 mg every 8–12 hours. Oral: Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Alpha-blockers: effects of tolazoline antagonised.
- Antifungals: absorption of itraconazole and ketoconazole reduced; concentration of posaconazole possibly reduced – avoid.
- Antivirals: concentration of atazanavir reduced; concentration of raltegravir possibly increased – avoid; avoid for 12 hours before and 4 hours after rilpivirine.
- Ciclosporin: may increase or not change ciclosporin levels; nephrotoxicity, additive hepatotoxicity and thrombocytopenia reported.
- Cytotoxics: reduced gefitinib concentration; reduces concentration of erlotinib and possibly pazopanib, give at least 2 hours before or 10 hours after ranitidine; absorption of dasatinib reduced – avoid; possibly reduced absorption of lapatinib.
- Ulipristal: contraceptive effect possibly reduced – avoid with high dose ulipristal.

Administration
Reconstitution

Route
Oral, IV, IM (undiluted)

Rate of administration
- Bolus: 50 mg made up to 20 mL, over at least 2 minutes
- Intermittent infusion: 50 mg to 100 mL of appropriate intravenous solution run over 2 hours
- Continuous infusion: required dose in 250 mL of intravenous fluid over 24 hours

Comments
- Compatible with sodium chloride 0.9%, glucose 5% and other fluids.
- Admixtures stable for 24 hours.
- Minimum volume: can be used undiluted as a bolus over at least 2 minutes. (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd ed. 2006)

Other information
- In CKD 5 usually twice daily for IV preparation and normal dose for oral.

References:
Ranolazine

**Clinical use**
Add on therapy for angina

**Dose in normal renal function**
375–750 mg twice daily

**Pharmacokinetics**
- Molecular weight (daltons): 427.5
- % Protein binding: 62
- % Excreted unchanged in urine: <5 (75% as metabolites)
- Volume of distribution (L/kg): 180 Litres
- Half-life — normal/ESRF (hrs): 7 / Increased

**Metabolism**
Extensively metabolised in the gastrointestinal tract and liver. Four main metabolites have been identified.
Approximately 75% of a dose is excreted in the urine with the remainder in the faeces.

**Dose in renal impairment GFR (mL/min)**
- 30–50: Dose as in normal renal function. Titrate slowly.
- 10–30: Use lower dose with caution. See ‘Other information’.
- <10: Use lower dose with caution. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: avoid with disopyramide.
- Antibacterials: concentration possibly increased by clarithromycin and telithromycin — avoid concomitant use; concentration reduced by rifampicin — avoid.
- Antifungals: concentration increased by ketoconazole and possibly itraconazole, posaconazole and voriconazole — avoid.
- Antivirals: concentration possibly increased by atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir and tipranavir — avoid.
- Beta-blockers: avoid with sotalol.
- Ciclosporin: concentration of both drugs possibly increased.
- Grapefruit juice: concentration of ranolazine possibly increased — avoid.
- Statins: concentration of simvastatin increased — maximum dose of simvastatin is 20 mg.
- Tacrolimus: concentration of tacrolimus increased.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Contraindicated by manufacturer in UK SPC in severe renal impairment (CRCL<30 mL/min).
- Bioavailability is 35–50%.
- AKI has been reported in patients taking ranolazine.
- May cause an increase in QT interval.
- May increase blood pressure in patients with severe renal impairment.
- Steady state occurs within 3 days.
- In patients with renal impairment there may be an increased incidence of side effects. In patients with mild or moderate renal impairment (CRCL≥30–80 mL/min) compared to those with normal renal function, the most commonly reported events included: constipation (8% versus 4%), dizziness (7% versus 5%), and nausea (4% versus 2%).
- The AUC of ranolazine was on average 1.7 to 2-fold higher in subjects with mild, moderate, and severe renal impairment compared with subjects with normal renal function. The AUC of metabolites increased with decreased renal function. The AUC of one pharmacologically active ranolazine metabolite was 5-fold increased in patients with severe renal impairment.
- Case report of use in a HDF patient who did not tolerate 375 mg twice daily due to intolerable side effects but tolerated once daily.
Rasagiline

Clinical use

Treatment of Parkinson’s disease

Dose in normal renal function

1 mg daily

Pharmacokinetics

Molecular weight (daltons) 267.3 (as mesilate)
% Protein binding 60–70
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 243 Litres
Half-life — normal/ESRF (hrs) 0.6–2 / Unchanged

Metabolism

Rasagiline is extensively metabolised in the liver by N-dealkylation and hydroxylation, via the cytochrome P450 isoenzyme CYP1A2, and conjugation. 1-Aminoindan is a major metabolite and is stated to be active although it is not a monoamine oxidase B inhibitor. The metabolites are excreted mainly in the urine and partly in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Likely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

- Analgesics: avoid with dextromethorphan; avoid with pethidine (risk of serious adverse reactions) – allow at least 14 days before starting pethidine.
- Antidepressants: avoid with other MAOIs (can lead to hypertensive crisis) – allow at least 14 days before starting a MAOI; avoid with fluoxetine and fluvoxamine; allow 5 weeks between stopping fluoxetine and starting rasagiline; allow 14 days between stopping rasagiline and starting fluoxetine or fluvoxamine; increased CNS toxicity with SSRIs, tricyclics and vortioxetine.
- Sympathomimetics: concomitant use is not recommended.

Administration

Reconstitution

—

Route

Oral

Rate of administration

—

Other information

- Rasagiline is an irreversible selective inhibitor of monoamine oxidase type B.
- Bioavailability is 36%.
**Rasburicase**

**Clinical use**
Prophylaxis and treatment of acute hyperuricaemia with initial chemotherapy for haematological malignancy

**Dose in normal renal function**
200 mcg/kg once daily for up to 7 days

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>34 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.11–0.127</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>19 / –</td>
</tr>
</tbody>
</table>

**Metabolism**
Rasburicase is a protein; it is expected that metabolic degradation will follow the pathways of other proteins, i.e. peptide hydrolysis.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
With solvent provided

**Route**
IV

**Rate of administration**
Over 30 minutes

**Comments**
Add appropriate volume to 50 mL sodium chloride 0.9%

**Other information**

- Renal elimination of rasburicase is considered to be a minor pathway for rasburicase clearance.
- After infusion of rasburicase at a dose of 0.2 mg/kg/day, steady state is achieved at day 2–3.
Reboxetine

**Clinical use**
Antidepressant

**Dose in normal renal function**
4–5 mg twice daily; maximum 12 mg daily

**Pharmacokinetics**
- Molecular weight (daltons) 409.5 (as mesilate)
- % Protein binding 97 (92% in elderly)
- % Excreted unchanged in urine 10
- Volume of distribution (L/kg) 26–63 Litres
- Half-life — normal/ESRF (hrs) 13 / 26

**Metabolism**
Reboxetine is predominantly metabolised in vitro via cytochrome P4503A (CYP3A4); the main metabolic pathways identified are dealkylation, hydroxylation, and oxidation followed by glucuronide or sulfate conjugation. Elimination is mainly via urine (78%) with 10% excreted as unchanged drug.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: 2 mg twice daily and adjust according to response.
- <10: 2 mg twice daily and adjust according to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: avoid with macrolides and linezolid.
- Antidepressants: risk of increased toxicity with MAOIs – avoid; avoid with fluvoxamine.
- Antifungals: avoid with imidazoles and triazoles
- Antimalarials: avoid with artemether with lumefantrine and piperaquine with artenimol.
- Ciclosporin: use with caution as high concentrations of reboxetine inhibit CYP3A4 and CYP2D6.

**Administration**
Reconstitution
- Route
  - Oral
Rate of administration
-
Regorafenib

Clinical use
- Treatment of colorectal cancer and gastrointestinal stromal tumours
- Treatment of hepatocellular carcinoma

Dose in normal renal function
160 mg once daily for 21 days of every 28-day cycle

Pharmacokinetics
Molecular weight (daltons) 482.8
% Protein binding 99.5
% Excreted unchanged in urine 19
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 20–30 / Unchanged

Metabolism
Regorafenib is metabolised by CYP3A4 and UGT1A9. The main circulating metabolites of regorafenib measured at steady-state in human plasma are M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl), both of them having similar in vitro pharmacological activity and steady-state concentrations as regorafenib. M-2 and M-5 are highly protein bound (99.8% and 99.95%, respectively). Approximately 90% of the radioactive dose was recovered within 12 days after administration, with about 71% of the dose excreted in faeces (47% as parent compound, 24% as metabolites), and about 19% of the dose excreted in urine as glucuronides. Urinary excretion of glucuronides decreased below 10% under steady-state conditions. Parent compound found in faeces could be derived from intestinal degradation of glucuronides or reduction of metabolite M-2 (N-oxide), as well as unabsorbed regorafenib.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–59</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- HD Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- HDF/High flux Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function. Use with caution.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: avoid with mefenamic acid.
- Antibacterials: concentration reduced by rifampicin – avoid.
- Anticoagulants: increased risk of bleeding with warfarin.
- Antifungals: concentration increased by ketoconazole – avoid.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Available clinical data from SPC indicate similar exposure of regorafenib and its metabolites M-2 and M-5 in patients with mild, moderate or severe renal impairment compared to patients with normal renal function.
- The pharmacokinetics of regorafenib has not been studied in patients with severe renal impairment or end-stage renal disease. However, physiology-based pharmacokinetic modelling does not predict any relevant change in exposure in these patients.
- Use with caution due to lack of data although no changes to pharmacokinetics were seen in mild renal impairment.
- Severe and sometimes fatal hepatotoxicity has been reported.
- Oral bioavailability of tablets is 69% and the oral solution is 83%.
Remifentanil

Clinical use
- Analgesic
- Induction of anaesthesia

Dose in normal renal function
- Induction: 0.5–1 microgram/kg/min
- Maintenance:
  - Ventilated patients: 0.05–2 mcg/kg/min
  - Spontaneous respiration: 25–100 nanograms/kg/min
- Analgesia and sedation in ventilated, intensive care patients: 6–740 nanograms/kg/minute
- Additional analgesia during painful procedures in ventilated, intensive care patients: 100–750 nanograms/kg/minute
- Or as per SPC or local guidelines

Pharmacokinetics
- Molecular weight (daltons) 412.9 (as hydrochloride)
- % Protein binding 70
- % Excreted unchanged in urine 95 (as metabolites)
- Volume of distribution (L/kg) 0.35
- Half-life — normal/ESRF (hrs) 3–10 minutes
  - (biological activity) / Unchanged
- Terminal elimination 10–20 minutes

Metabolism
Remifentanil is an esterase metabolised opioid that is susceptible to metabolism by non-specific blood and tissue esterases. The metabolism of remifentanil results in the formation of an essentially inactive carboxylic acid metabolite (1/4600th as potent as remifentanil). About 95% of a dose of remifentanil is excreted in the urine as the metabolite.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

Important drug interactions
- Potentially hazardous interactions with other drugs
  - Anti-arrhythmics: delayed absorption of mexiletine.
  - Antidepressants: possible CNS excitation or depression (hypertension or hypotension) in patients also receiving MAOIs (including moclobemide) – avoid; possibly increased sedative effects with tricyclics.
  - Antihistamines: sedative effects possibly increased with sedating antihistamines.
  - Antipsychotics: enhanced sedative and hypotensive effect.
  - Antivirals: concentration possibly increased by ritonavir (risk of toxicity) – avoid.
  - Dopaminergics: avoid with selegiline.
  - Nalmefene: avoid concomitant use.
  - Sodium oxybate: enhanced effect of sodium oxybate – avoid.

Administration
- **Reconstitution**
  To 1 mg/mL with infusion fluid
- **Route**
  IV
- **Rate of administration**
  Dependent on indication
- **Comments**
  Dilute to 20–250 mcg/mL with glucose 5%, sodium chloride 0.9% or water for injection; usually 50 micrograms/mL for general anaesthesia.

Other information
- Half-life of metabolite is increased to 30 hours in renal failure compared with 90 minutes in patients with normal renal function.
- Remifentanil would be expected to be metabolised before patient needs to be dialysed.
- 25–35% of metabolites are removed by dialysis.
Repaglinide

**Clinical use**

Type 2 Diabetes mellitus

**Dose in normal renal function**

- 0.5–16 mg daily, doses given 15–30 minutes before a meal; doses up to 4 mg can be given as a single dose
- Not recommended if >75 years

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>452.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;8 (mainly as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>30 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1 / 2</td>
</tr>
</tbody>
</table>

**Metabolism**

Repaglinide appears to be a substrate for active hepatic uptake by the organic anion transporting protein OATP1B1, and undergoes almost complete hepatic metabolism involving the cytochrome P450 isoenzymes CYP2C8 and CYP3A4. The glucuronidation of repaglinide is thought to involve uridine diphosphate glucuronosyltransferase (UGT) enzymes, particularly UGT1A1.

The metabolites, which are inactive, are excreted in the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Start at a low dose and gradually increase according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start at a low dose and gradually increase according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HD/F High flux: Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antibacterials: effects enhanced by clarithromycin and possibly trimethoprim – avoid with trimethoprim; hypoglycaemic effect antagonised by rifampicin.
- Antifungals: effect possibly enhanced by itraconazole.
- Ciclosporin: may increase repaglinide concentration, possibly enhanced hypoglycaemic effect.
- Clopidogrel: avoid concomitant use if possible due to increased repaglinide exposure.
- Cytotoxics: avoid with lapatinib.
- Lipid-lowering agents: increased risk of severe hypoglycaemia with gemfibrozil – avoid.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- —
# Reslizumab

## Clinical use

Treatment of severe eosinophilic asthma

## Dose in normal renal function

3 mg/kg every 4 weeks

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>147 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>5 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>24 days / –</td>
</tr>
</tbody>
</table>

## Metabolism

Reslizumab is believed to be degraded by enzymatic proteolysis into small peptides and amino acids. As reslizumab binds to a soluble target, linear non-target-mediated clearance is expected.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Vaccines: risk of generalised infections with live vaccines – avoid.

## Administration

### Reconstitution

<table>
<thead>
<tr>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV infusion</td>
</tr>
</tbody>
</table>

### Rate of administration

Over 20–50 minutes

### Comments

- Administer through a sterile, non-pyrogenic infusion, single-use, low protein binding filter (0.2 μm).
- Add to 50 mL of sodium chloride 0.9%.

## Other information

- Reslizumab is not expected to be excreted in urine. No major differences in the pharmacokinetics of reslizumab were seen across various degrees of renal function down to eGFR=30–59 mL/min/1.73 m². Reslizumab has not been studied in patients with severe renal impairment or end-stage renal disease.
# Reteplase

## Clinical use
Thrombolytic, used for acute myocardial infarction

## Dose in normal renal function
10 units over 2 minutes; second dose of 10 units given 30 minutes later

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>39,571.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Negligible</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>6–6.5 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Fibrinolytic half-life is 1.6 hours / Increased Dominant ($\alpha$) half-life is $14.6 \pm 6.7$ minutes Terminal ($\beta$) half-life is $1.6 \text{ hrs} \pm 39$ minutes</td>
</tr>
</tbody>
</table>

## Metabolism
Cleared primarily by liver and kidneys.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Prescription Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antiplatelets, heparin, vitamin K antagonists: increased risk of bleeding.

## Administration

### Reconstitution
With diluent provided

### Route
Slow IV

### Rate of administration
Over not more than 2 minutes

### Comments
- Use immediately once reconstituted.
- Do not mix with heparin in the same line.

## Other information
- Heparin and aspirin should be given before and after reteplase therapy to reduce the risk of re-thrombosis but may increase the risk of bleeding.
- Half-life is increased in severe renal failure in animal models.
- Possible increased risk of bleeding complications in severe renal impairment.
- Contraindicated in severe renal impairment in UK SPC but only use with caution in US data sheet due to increased risk of bleeding.
Ribavirin (tribavirin)

**Clinical use**

Antiviral agent:
Chronic Hepatitis C in combination with Interferon α or Peginterferon α

**Dose in normal renal function**

Copegus (PegIFN alfa-2b with or without direct acting antivirals):
- <65 kg: 400 mg twice daily
- 65–80 kg: 400 mg in the morning and 600 mg at 6 pm
- 81–105 kg: 600 mg twice daily
- >105 kg: 600 mg in the morning and 800 mg at 6 pm

Rebetol and Copegus:
- <75 kg: 400 mg in the morning and 600 mg at 6 pm
- >75 kg: 600 mg twice daily
- Dose depends on genotype see SPC

**Pharmacokinetics**

- Molecular weight (daltons) 244.2
- % Protein binding 0
- % Excreted unchanged in urine 10–40
- Volume of distribution (L/kg) 5000 Litres
- Half-life — normal/ESRF (hrs) Oral: 79 / Increased

**Metabolism**

Ribavirin is metabolised by reversible phosphorylation and a degradative pathway involving deribosylation and amide hydrolysis to produce an active triazole carboxyacid metabolite.

Ribavirin is mainly excreted in the urine as unchanged drug and metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>200 mg and 400 mg alternate days. See 'Other information'.</td>
</tr>
<tr>
<td>10–30</td>
<td>200 mg daily. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>200 mg daily. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antivirals: effects possibly reduced by abacavir; increased risk of toxicity with stavudine; increased side effects with didanosine – avoid; increased risk of anaemia with zidovudine – avoid.
- Azathioprine: possibly enhances myelosuppressive effects of azathioprine.

**Administration**

**Reconstitution**

Dissolve contents of one vial in water for injection

**Route**

Oral, IV

**Rate of administration**

IV: over 10–15 minutes

**Other information**

- Oral: Administer ribavirin with interferon α 3 MIU 3 times a week or peginterferon α 1.5 mcg/kg/week.
- There are two studies using ribavirin (200–400 mg daily) in combination with interferon in haemodialysis and peritoneal dialysis patients. Anaemia was one of the main problems, resulting in either increased doses of erythropoietin or discontinuation of ribavirin therapy. Most patients were stabilised on a dose of 200 mg daily or 200 mg 3 times a week. A dose of 200 mg daily gave troughs comparable to those in patients with normal renal function taking 1200 mg daily. (Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection – a pilot study. J Viral Hepat. 2001; 8(4): 287–92 and Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant. 2001; 16(1):193–5.)
• After stopping therapy the half-life was approximately 298 hours, due to slow elimination from non-plasma compartments.
• Ribavirin is also available (on named patient basis) as an intravenous infusion, from ICN Pharmaceuticals.
• Recommended IV dosing schedule in patients with normal renal function is:
  – Initial loading dose: 33 mg/kg
  – Six hours after the initial dose: 16 mg/kg every 6 hours for 4 days (16 doses)
  – Eight hours following the last of these doses: 8 mg/kg every 8 hours for 3 days (9 doses).
• Patients with impaired renal function should be carefully monitored during therapy with ribavirin for signs and symptoms of toxicity, such as haemolytic anaemia.
  – Available clinical experience suggests that patients with renal insufficiency and CRCL=50–80 mL/min tolerate the usual dosage regimen of ribavirin.
  – Individuals with moderate to severe renal insufficiency (CRCL=30–50 mL/min) have tolerated, without reports of complications, a dose regimen with an initial loading dose of 20–25 mg/kg, followed by single daily doses of 10 mg/kg for 9–10 consecutive days.
  – There is no experience in patients with end-stage renal disease.
• See SPC for further information.
Ribociclib

Clinical use

Protein kinase inhibitor:
• Treatment of breast cancer

Dose in normal renal function

600 mg daily for 21 days every 28 days

Pharmacokinetics

Molecular weight (daltons) 434.5 (552.6 as succinate)
% Protein binding 70
% Excreted unchanged in urine 12.1
Volume of distribution (L/kg) 1090 Litres
Half-life — normal/ESRF (hrs) 32

Metabolism

Ribociclib is hepatically metabolised via CYP3A4 by oxidation. Ribociclib was the main circulating drug in plasma (44%). The major circulating metabolites included metabolite M13 (CCI284, N-hydroxylation), M4 (LEQ803, N-demethylation), and M1 (secondary glucuronide). Clinical activity of ribociclib was due mainly to parent drug, with negligible contribution from circulating metabolites. Unchanged drug accounted for 17.3% and 12.1% of the dose in faeces and urine, respectively. Metabolite LEQ803 represented approximately 13.9% and 3.74% of the administered dose in faeces and urine, respectively. Numerous other metabolites were detected in both faeces and urine in minor amounts (≤2.78%). Ribociclib and its metabolites are eliminated mainly via faeces (69.1%), with a small contribution from the renal route (22.6%).

Dose in renal impairment GFR (mL/min)

30–50 Dose as in normal renal function.
<30 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unknown dialysability. Dose as in GFR<30 mL/min.
HD Unknown dialysability. Dose as in GFR<30 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<30 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR<30 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
• The concomitant use of strong CYP3A4 inhibitors including, but not limited to, the following must be avoided: clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir, ritonavir, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, verapamil and voriconazole.
• The concomitant use of strong CYP3A4 inducers may therefore lead to decreased exposure and consequently a risk for lack of efficacy. The concomitant use of strong CYP3A4 inducers should be avoided, including, but not limited to, phenytoin, rifampicin, carbamazepine and St John’s wort.
• Caution and monitoring for toxicity are advised during concomitant treatment with sensitive substrates of drug transporters P-gp, BCRP, OATP1B1/1B3, OCT1, OCT2, MATE1 and BSEP which exhibit a narrow therapeutic index, including but not limited to digoxin, pravastatin, rosuvastatin and metformin.
• Co-administration of Kisqali with medicinal products with a known potential to prolong the QT interval such as anti-arrhythmic medicinal products (including, but not limited to, amiodarone, disopyramide, procainamide, quinidine and sotalol), and other medicinal products that are known to prolong the QT interval (including, but not limited to, chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, pimozide and intravenous ondansetron) should be avoided.

Administration

Reconstitution

Route
Oral
Rate of administration

Other information

• Can cause QT prolongation.
• Manufacturer advises to use with caution in severe renal impairment due to lack of studies and to monitor closely for toxicity.
• Contains soya lecithin therefore should be avoided in people who are hypersensitive to peanut or soya.
• There was no change in the pharmacokinetics in mild to moderate renal impairment.
Rifabutin

Clinical use
Antibacterial agent:
• Tuberculosis
• Mycobacterial infection

Dose in normal renal function
• Prophylaxis of \textit{Mycobacterium avium} in patients with low CD4 count: 300 mg daily
• Treatment of non-tuberculous mycobacterial disease, in combination with other drugs: 450–600 mg daily
• Treatment of pulmonary tuberculosis, in combination with other drugs: 150–450 mg daily

Pharmacokinetics
Molecular weight (daltons) 847
% Protein binding 70
% Excreted unchanged in urine 5
Volume of distribution (L/kg) 8–9
Half-life — normal/ESRF (hrs) 35–40 / Unchanged

Metabolism
Rifabutin is rapidly metabolised in the liver by the cytochrome P450 isoenzyme CYP3A4 mainly to active 25-O-deacetyl and 31-hydroxy metabolites. Rifabutin induces its own metabolism resulting in a lower AUC after 4 weeks of continuous treatment than after the first few doses.
About 53% of a dose is found in the urine, mainly as metabolites and about 30% of a dose is excreted in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Maximum 300 mg daily. (Dose reduction of 50%).</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Maximum 300 mg daily. (Dose reduction of 50%).</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR &lt; 10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR = 10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Anti-arrhythmics: metabolism of disopyramide, and propafenone accelerated; concentration of dronedarone reduced.
• Antibacterials: increased risk of side effects with azithromycin; clarithromycin and other macrolides increase concentration of rifabutin, resulting in increased risk of uveitis – reduce rifabutin dose; reduced concentration of dapsone and clarithromycin.
• Anticoagulants: reduced anticoagulant effect of coumarins.
• Antidiabetics: reduced antidiabetic effect of tolbutamide; possibly reduced antidiabetic effect with sulphonylureas.
• Antiepileptics: reduced concentration of fosphenytoin, phenytoin and carbamazepine.
• Antifungals: fluconazole, triazoles, posaconazole and voriconazole increase the concentration of rifabutin resulting in increased risk of uveitis – reduce rifabutin dose; rifabutin reduces concentration of posaconazole, voriconazole and itraconazole – increase voriconazole dose, avoid with isavuconazole and itraconazole.
• Antipsychotics: possibly reduced aripiprazole concentration – increase dose of aripiprazole.
• Antivirals: atazanavir darunavir, fosamprenavir, saquinavir and tipranavir and possibly nevirapine increase concentration of rifabutin – halve or reduce dose of rifabutin; efavirenz reduces the concentration of rifabutin – increase dose of rifabutin; concentration of both drugs reduced with etravirine; indinavir increases rifabutin concentration – avoid; concentration of indinavir reduced – increase indinavir dose; concentration of elvitegravir reduced and active metabolite of rifabutin increased – reduce dose of rifabutin; concentration of rilpivirine reduced – increase rilpivirine dose to 50
mg once daily; ritonavir increases the concentration of rifabutin resulting in increased risk of uveitis – reduce rifabutin dose; concentration of saquinavir reduced and concentration of rifabutin increased – reduce rifabutin dose; concentration of daclatasvir and simeprevir possibly reduced – avoid; avoid with ledipasvir, sofosbuvir and telaprevir.

- Atovaquone: concentration of atovaquone reduced (possible therapeutic failure of atovaquone).
- Ciclosporin: possibly reduced ciclosporin levels.
- Cobicistat: concentration of cobicistat reduced – adjust cobicistat dose.
- Corticosteroids: reduced level of corticosteroids – double steroid dose. Give as twice daily dosage.
- Cytotoxics: possibly reduced concentration of axitinib (increase axitinib dose), bosutinib, cabazitaxel, ceritinib, crizotinib, lapatinib, olaparib, panobinostat, ponatinib and vemurafenib – avoid.
- Guanfacine: concentration of guanfacine possibly reduced – increase dose of guanfacine.
- Hormone antagonists: concentration of abiraterone possibly reduced – avoid.
- Ivacaftror: concentration of ivacaftor possibly reduced – avoid.
- Oestrogens and progestogens: reduced contraceptive effect due to increased metabolism.
- Sirolimus: reduced sirolimus concentration – avoid.

- Tacrolimus: possibly reduced tacrolimus trough concentration.
- Ulipristal: possibly reduced contraceptive effect – avoid.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Can cause an orange-tan skin pigmentation as well as discoloured urine.
  - Can cause abnormal LFTs and hepatitis.
  - Can cause uveitis especially in combination with clarithromycin and fluconazole.
  - Rifabutin is a less potent CYP4503A enzyme inducer than rifampicin but similar interactions may occur.
  - *Drug Prescribing in Renal Failure, 5th edition* by Aronoff et al. recommends a dose of 300 mg daily in renal impairment.
**Clinical use**

Antibacterial agent:
- Tuberculosis
- Staphylococcal infection

**Dose in normal renal function**

600–1200 mg daily in 2–4 divided doses

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>822.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>80</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>15–30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.64–0.66</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–5 / 1.8–11</td>
</tr>
</tbody>
</table>

**Metabolism**

Rifampicin is rapidly metabolised in the liver mainly to active 25-O-deacetylrifampicin and excreted in the bile. Deacetylation diminishes intestinal reabsorption and increases faecal excretion, although significant enterohepatic circulation still takes place. About 60% of a dose eventually appears in the faeces. The amount excreted in the urine increases with increasing doses and up to 30% of a dose may be excreted in the urine, about half of it being unchanged drug. The metabolite formylrifampicin is also excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50–100% of normal dose.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anthelmintics: concentration of praziquantel reduced – avoid.
- Anti-arrhythmics: metabolism of disopyramide, and propafenone accelerated; concentration of dronedarone reduced – avoid.
- Antibacterials: reduced concentration of bedaquiline, chloramphenicol, delamanid, clarithromycin, dapsone, doxycycline, linezolid and trimethoprim and possibly tinidazole – avoid with bedaquiline; concentration increased by clarithromycin and other macrolides; increased risk of hepatotoxicity with isoniazid.
- Anticoagulants: reduced anticoagulant effect of warfarin; reduced concentration of apixaban, edoxaban and rivaroxaban; avoid with dabigatran.
- Antidepressants: concentration of vortioxetine reduced – consider increasing vortioxetine dose.
- Antidiabetics: reduced antidiabetic effect of linagliptin and tolvaptan; concentration of canagliflozin, nateglinide and repaglinide reduced; possibly reduced antidiabetic effect with sulphonylureas.
- Antiepileptics: reduced concentration of brivaracetam, fosphenytoin, phenytoin and lamotrigine; concentration possibly reduced by phenobarbital.
- Antifungals: concentration of both drugs may be reduced with ketoconazole; reduced concentration of fluconazole, itraconazole, posaconazole and terbinafine – avoid with itraconazole; concentration of isavuconazole and voriconazole reduced – avoid; initially increases then reduces caspofungin concentration.
- Antimalarials: avoid with piperaquine with artesimol; concentration of mefloquine reduced – avoid, concentration of quinine reduced.
- Antimuscarinics: concentration of active metabolite of fesoterodine reduced – avoid.
- Antipsychotics: reduced concentration of haloperidol, aripiprazole and clozapine – increase dose of aripiprazole; concentration of lurasidone reduced – avoid.
- Antivirals: concentration of abacavir, dasabuvir, ombitasvir, paritaprevir, ritonavir and tipranavir possibly reduced – avoid with dasabuvir, ombitasvir, paritaprevir and tipranavir; concentration of atazanavir, boceprevir, daclatasvir, darunavir, etravirine, fosamprenavir, indinavir, lopinavir, nevirapine, ombitasvir, rilpivirine, saquinavir,
simeprevir and telaprevir reduced also risk of hepatotoxicity with saquinavir – avoid; concentration of efavirenz, maraviroc and raltegravir reduced – increase dose of efavirenz and possibly maraviroc and raltegravir; avoid with elvitegravir, ledipasvir, sofosbuvir and zidovudine; concentration of dolutegravir reduced.

- Apremilast: concentration of apremilast reduced – avoid.
- Atovaquone: concentration of atovaquone reduced (possible therapeutic failure of atovaquone); concentration of rifampicin increased – avoid.
- Bosentan: reduced bosentan concentration – avoid.
- Calcium-channel blockers: metabolism of diltiazem, verapamil, isradipine, nicardipine, nifedipine and nimodipine accelerated.
- Cannabis extract: concentration of cannabis extract reduced – avoid.
- Ciclosporin: markedly reduced levels (danger of transplant rejection); ciclosporin dose may need increasing 5-fold or more.
- Cobicistat: concentration of cobicistat possibly reduced – adjust cobicistat dose.
- Corticosteroids: reduced level of corticosteroids – double steroid dose. Give as twice daily dosage.
- Cytotoxics: reduced concentration of axitinib, brentuximab, bortezomib, bosutinib, cabazitaxel, cabozantinib, ceritinib, crizotinib, dabrafenib, dasatinib, everolimus, gefitinib, ibrutinib, idelalisib, imatinib, lapatinib, nilotinib, nintedanib, olaparib, osimertinib, panobinostat, ponatinib, regorafenib, vandetanib, vemurafenib, vinflunine and vismodegib – avoid; concentration of afatinib, erlotinib, ruxolitinib, sorafenib, sunitinib and trabectedin and possibly erubulin and pazopanib reduced; concentration of everolimus reduced – avoid or increase everolimus dose; active metabolite of temsirolimus reduced – avoid.
- Diuretics: concentration of eplerenone reduced – avoid.
- Guanfacine: concentration of guanfacine reduced – increase dose of guanfacine.
- Hormone antagonists: concentration of abiraterone reduced – avoid; concentration of tamoxifen and possibly exemestane reduced.
- Ivacaftor: concentration of ivacaftor reduced – avoid.
- Macitentan: concentration of macitentan reduced – avoid.
- Mycophenolate: concentration of active mycophenolate metabolite reduced.
- Naloxegol: concentration of naloxegol reduced – avoid.
- Netupitant: concentration of netupitant reduced – avoid.
- Oestrogens and progestogens: reduced contraceptive effect due to increased metabolism.
- Ranolazine: concentration of ranolazine reduced – avoid.
- Roflumilast: effects of roflumilast inhibited – avoid.
- Sirolimus: reduced sirolimus concentration.
- Tacrolimus: reduced tacrolimus concentration.
- Tadalafil: concentration of tadalafil reduced – avoid.
- Ticagrelor: concentration of ticagrelor reduced.
- Ulipristal: contraceptive effect possibly reduced – avoid.

### Administration

**Reconstitution**
Use solvent provided.

**Route**
Oral, IV

**Rate of administration**
2–3 hours

**Comments**
- Dilute in 500 mL glucose 5% or sodium chloride 0.9%.
- For central administration, 600 mg in 100 mL glucose 5% over 0.5–2 hours has been used (unlicensed).
- Stable for up to 24 hours at room temperature.

### Other information

- Some units give dose in concentrations up to 60 mg/mL (in its own solvent) over 10 minutes, on prescriber’s responsibility.
- May cause acute interstitial nephritis, potassium wasting or renal tubular defects.
- Reduce dose if LFTs are abnormal or patient <45 kg.
- Absorption from gastrointestinal tract can be reduced by up to 80% by the presence of food in the gastrointestinal tract.
- CAPD exit site infections: 300 mg twice daily for 4 weeks has been used.
- Rifampicin is excreted into CAPD fluid causing an orange/yellow colour.
- Monitor rifampicin levels if necessary.
- In severe renal impairment there is no increase in half-life at doses less than 600 mg daily.
**Rifaximin**

**Clinical use**

Antibacterial agent:
- Treatment of traveller’s diarrhoea
- Reduction of recurrence of hepatic encephalopathy

**Dose in normal renal function**

- Traveller’s diarrhoea: 200 mg every 8 hours for 3 days
- Hepatic encephalopathy: 550 mg twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>785.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>67.5</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0.03</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5.85</td>
</tr>
</tbody>
</table>

**Metabolism**

Not greatly absorbed. Systemically available rifaximin is believed to be metabolised in the liver, similarly to other rifamycin derivatives.
Excreted mainly in faeces (97%) as unchanged drug.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- Ciclosporin: concentration increased by ciclosporin.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Oral</th>
</tr>
</thead>
</table>

**Rate of administration**

| — |

**Other information**

- Not effective for diarrhoea caused by invasive enteric pathogens e.g. Shighella, Campylobacter.
- Bioavailability <0.4%.
- Use higher dose for encephalopathy with caution in renal impairment.
Rilpivirine

Clinical use
Non-nucleoside reverse transcriptase inhibitor:
- Treatment of progressive or advanced HIV infection in combination with at least two other antivirals

Dose in normal renal function
25 mg once daily
(50 mg daily in combination with rifabutin)

Pharmacokinetics
Molecular weight (daltons) 366.4 (402.9 as hydrochloride)
% Protein binding 99.7
% Excreted unchanged in urine <1
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 45

Metabolism
Primarily undergoes oxidative metabolism mediated by the cytochrome P450 (CYP) 3A system.
85% excreted via the faeces (25% as unchanged drug) and 6% via the urine.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: avoid with clarithromycin and erythromycin – concentration possibly increased; concentration decreased by rifampicin and rifabutin – avoid with rifampicin, increase dose of rilpivirine to 50 mg daily.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, primidone and phenytoin – avoid.
- Corticosteroids: avoid with dexamethasone (except as a single dose).
- Orlistat: absorption possibly reduced by orlistat.
- Ulcer-healing drugs: concentration possibly reduced by esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole – avoid; avoid histamine H₂-antagonists for 12 hours before and 4 hours after rilpivirine.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Use with caution in severe renal impairment and ESRD due to lack of studies.
Riociguat

**Clinical use**
Guanylate cyclase stimulator:
- Treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)

**Dose in normal renal function**
1–2.5 mg three times daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>422.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40 (mainly as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>30 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7–12 / –</td>
</tr>
</tbody>
</table>

**Metabolism**
N-demethylation, catalysed by CYP1A1, CYP3A4, CYP2C8 and CYP2J2 is the major biotransformation pathway leading to its major circulating active metabolite M-1 (pharmacological activity: 1/10th to 1/3rd of riociguat) which is further metabolised to the pharmacologically inactive N-glucuronide.
Riociguat and metabolites are excreted via both renal (33–45%) and biliary/faecal routes (48–59%). Approximately 9–44% of the administered dose was found as unchanged riociguat in faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>15–30</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Avanafil, sildenafil, tadalafil, vardenafil: enhanced hypotensive effect – avoid.
- Nicorandil: possibly enhanced hypotensive effect – avoid.
- Nitrates: possibly enhanced hypotensive effect – avoid.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=15–30 mL/min.</td>
</tr>
</tbody>
</table>

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose as in normal renal function. See 'Other information'.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

**Other information**

- If treatment is interrupted for more than 3 days then dose re-titration is required.
- UK manufacturer does not recommend use in patients with CRCL<30 mL/min due to lack of studies. US data sheet use with caution due to lack of data with a CRCL<15 mL/min.
- Patients with renal impairment are more at risk of hypotension due to increased exposure so dose should be titrated carefully.
- In non-smoking individuals with CRCL= 80–50 mL/min, 50–30 mL/min or <30 mL/min, riociguat plasma concentrations (AUC) were increased by 53%, 139% or 54%, respectively.
- Oral bioavailability is 94%.
Risedronate sodium

Clinical use
Bisphosphonate:
- Treatment and prevention of osteoporosis (including corticosteroid induced)
- Paget's disease

Dose in normal renal function
- Osteoporosis: 5 mg daily or 35 mg weekly
- Paget's disease: 30 mg daily for 2 months

Pharmacokinetics
Molecular weight (daltons) 305.1
% Protein binding 24
% Excreted unchanged in urine 50
Volume of distribution (L/kg) 6.3
Half-life — normal/ESRF (hrs) 480 / Increased

Metabolism
The mean bioavailability of risedronate is 0.63% in the fasting state, and there is no evidence of systemic metabolism of risedronate sodium. About half of the absorbed portion is excreted in the urine within 24 hours; the remainder is sequestered to bone for a prolonged period. Unabsorbed drug is eliminated unchanged in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose details</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>See ‘Other information.’</td>
</tr>
<tr>
<td>&lt;10</td>
<td>See ‘Other information.’</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Calcium-containing substances: avoid for 2 hours before and after administration.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Swallow whole with a glass of water 30 minutes before food. Sit or stand upright for 30 minutes after administration.
- Renal clearance is decreased by 70% in patients with CRCL<30 mL/min.
- One paper reviewed all the information available and concluded that 50% of the recommended dose may be possible in ESRF, but more trials are required, and osteomalacia and adynamic bone disease must first be excluded. (Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep. 2005; 3(1): 5–12.)
- Examples of use in other units in HD patients: Normal doses; 5 mg once weekly.
- If used in patients with ESRD ensure the patient has an adequate PTH e.g. at least 3 times the upper limit of normal.
Risperidone

**Clinical use**
- Schizophrenia
- Psychoses
- Mania
- Persistent aggression in Alzheimer’s dementia

**Dose in normal renal function**
- Oral: 2–16 mg daily in divided doses
- IM: 25–50 mg every 2 weeks
- Mania: 1–6 mg daily
- Persistent aggression in Alzheimer’s dementia: 0.25–1 mg twice daily

**Pharmacokinetics**
- Molecular weight (daltons): 410.5
- % Protein binding: 90
- % Excreted unchanged in urine: 70
- Volume of distribution (L/kg): 1–2
- Half-life — normal/ESRF (hrs): 19.5 / Increased

**Metabolism**
Risperidone is metabolised in the liver by CYP 2D6 to its main active metabolite, 9-hydroxy-risperidone (paliperidone), which has a similar pharmacological activity as risperidone. This hydroxylation is subject to genetic polymorphism. Oxidative N-dealkylation is a minor metabolic pathway. Excretion is mainly in the urine and, to a lesser extent, in the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Initially 50% of dose, increases should also be 50% less and at a slower rate. Use with caution. See ‘Other information’ for IM dosing.
- 10–20: Initially 50% of dose, increases should also be 50% less and at a slower rate. Use with caution. See ‘Other information’ for IM dosing.
- <10: Initially 50% of dose, increases should also be 50% less and at a slower rate. Use with caution. See ‘Other information’ for IM dosing.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone – avoid.
- Antidepressants: concentration increased by fluoxetine and possibly paroxetine; concentration of tricyclics possibly increased.
- Antiepileptics: antagonism, convulsive threshold may be lowered; metabolism accelerated by carbamazepine.
- Antimalarials: avoid with artemether with lumefantrine; possible increased risk of ventricular arrhythmias with mefloquine and quinine.
- Antipsychotics: possible increased risk of ventricular arrhythmias with other antipsychotics that prolong the QT interval; avoid concomitant use of depot formulations with clozapine (cannot be withdrawn quickly if neutropenia occurs).
- Antivirals: ritonavir may increase concentration of risperidone.
- Anxiolytics and hypnotics: enhanced sedative effects.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Beta blockers: possible increased risk of ventricular arrhythmias with sotalol.
- Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
- Lithium: increased risk of extra-pyramidal side effects and possible neurotoxicity.

**Administration**
**Reconstitution**
With solvent provided
Risperidone

Route
Oral, deep IM

Rate of administration
—

Other information
- At a dose of 3 mg twice daily, 1.5 mg (i.e. 25%) of risperidone is removed after a 5-hour dialysis session with a dialysate flow of 500 mL/min.
- In overdose, rare cases of QT prolongation have been reported.
- Clearance of risperidone and active metabolites decreased by 60% in severe renal impairment.
- If a dose of 2 mg daily orally is tolerated then a dose of 25 mg (IM) every 2 weeks can be used initially in renal impairment.
Ritonavir

Clinical use
Protease inhibitor:
• Treatment of HIV-1 infection in combination with other antiretrovirals

Dose in normal renal function
• 600 mg twice daily
• As low dose booster with other protease inhibitors: 100–200 mg once or twice daily

Pharmacokinetics
Molecular weight (daltons) 720.9
% Protein binding 98–99
% Excreted unchanged in urine 3.5
Volume of distribution (L/kg) 0.4
Half-life — normal/ESRF (hrs) 3–5 / Unchanged

Metabolism
Ritonavir is extensively metabolised in the liver mainly by cytochrome P450 isoenzymes CYP3A4 and to a lesser extent by CYP2D6. Five metabolites have been identified and the major metabolite has antiviral activity, but concentrations in plasma are low.
About 86% of a dose is eliminated through the faeces (both as unchanged drug and as metabolites) and about 11% is excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Alpha-blockers: concentration of alfuzosin increased – avoid.
• Aminophylline: concentration of aminophylline reduced.
• Analgesics: buprenorphine and NSAID levels may be increased (risk of toxicity) – avoid dextropropoxyphene and piroxicam; methadone, pethidine and possibly morphine concentration reduced; increased alfentanil, fentanyl and toxic pethidine metabolite concentration – avoid with pethidine.
• Anthelmintics: possibly reduces active metabolite of albendazole, consider increasing albendazole dose.
• Anti-arrhythmics: increased concentration of amiodarone, flecainide and propafenone (increased risk of ventricular arrhythmias) – avoid; possible increased risk of arrhythmias with disopyramide; avoid with dronedarone.
• Antibacterials: rifabutin concentration increased (risk of uveitis) – reduce rifabutin dose; concentration of clarithromycin and other macrolides increased – reduce dose of clarithromycin in renal impairment; concentration reduced by rifampicin; concentration of both drugs may be increased in combination with fusidic acid – avoid; AUC of bedaquiline increased by 22%, avoid if ritonavir given for >14 days; concentration of delamanid increased.
• Anticoagulants: anticoagulant effect of coumarins and phenindione possibly increased; effect of warfarin may be enhanced or reduced; avoid with apixaban; concentration of rivaroxaban increased – avoid.
• Antidepressants: SSRIs and tricyclic concentrations possibly increased; concentration reduced by St John’s wort - avoid; possibly reduced paroxetine concentration; increased side effects with trazodone.
• Antiepileptics: carbamazepine fosphenytoin and phenytoin concentration may be increased; concentration reduced by fosphenytoin, phenytoin; concentration of lamotrigine and valproate reduced.
• Antifungals: in combination with itraconazole or ketoconazole concentration of both drugs may be increased; concentration increased by fluconazole; voriconazole concentration reduced – avoid.
• Antimalarials: use artemether/lumefantrine with caution; concentration possibly reduced by mefloquine; concentration of quinine increased.
- Antimuscarinics: avoid with darifenacin and tolterodine; reduce dose of fesoterodine; concentration of solifenacin possibly increased.
- Antipsychotics: concentration of lurasidone, pimozide, quetiapine, clozapine and possibly other antipsychotics may be increased (risk of toxicity) – avoid; possibly inhibits metabolism of aripiprazole – reduce aripiprazole dose; olanzapine concentration reduced.
- Antivirals: concentration of both drugs reduced with boceprevir; didanosine and ritonavir should be taken 2.5 hours apart; indinavir, maraviroc and saquinavir levels increased; increased risk of toxicity with efavirenz – monitor LFTs, avoid high dose ritonavir with atripil; concentration of simeprevir increased – avoid; possibly reduces telaprevir concentration.
- Anxiolytics and hypnotics: levels of many of them increased (risk of extreme sedation and respiratory depression) – avoid alprazolam, diazepam, flurazepam, midazolam, zolpidem; concentration of buspirone increased.
- Avanafil: concentration of avanafil significantly increased – avoid.
- Bosentan: increases bosentan concentration.
- Calcium-channel blockers: levels of calcium-channel blockers possibly increased – avoid with lercanidipine.
- Ciclosporin: levels possibly increased by ritonavir.
- Cilostazol: possibly increases cilostazol concentration.
- Colchicine: possibly increases risk of colchicine toxicity, avoid in hepatic or renal impairment.
- Corticosteroids: possibly increased corticosteroid concentration; increased concentration of inhaled/intranasal budesonide and fluticasone.
- Cytotoxics: increases concentration of afatinib (separate ritonavir by 6–12 hours); possibly increases concentration of axitinib, panobinostat and pazopanib, reduce dose of axitinib, panobinostat and pazopanib; possibly increases concentration of bosutinib, cabazitaxel, ceritinib and olaparib – avoid or reduce dose of bosutinib, cabazitaxel, ceritinib and olaparib; possibly increases concentration of cabozantinib and vinblastine; possibly increases concentration of crizotinib, everolimus, nilotinib, simeprevir and vinflunine – avoid; avoid with dasatinib and lapatinib; concentration of ibrutinib possibly increased – reduce dose of ibrutinib; concentration of docetaxel possibly increased – avoid or reduce docetaxel dose; reduce dose of ruxolitinib; possibly increases concentration of ponatinib – consider reducing initial dose of ponatinib; concentration of paclitaxel increased.
- Dapoxetine: avoid concomitant use.
- Diuretics: eplerenone concentration increased – avoid.
- Domperidone: possible increased risk of ventricular arrhythmias – avoid.
- Ergot alkaloids: risk of ergotism – avoid.
- Guanfacine: possibly increases guanfacine dose – half guanfacine dose.
- 5HT1 agonists: concentration of eletriptan increased – avoid.
- Ivabradine: ivabradine concentration possibly increased – avoid.
- Lipid-lowering drugs: increased risk of myopathy with rosuvastatin and simvastatin – avoid; possibly increased risk of myopathy with atorvastatin; avoid with lomitapide.
- Naloxegol: possibly increases naloxegol concentration – avoid.
- Oestrogens and progestogens: metabolism accelerated (contraceptive effect reduced).
- Orlistat: absorption of ritonavir possibly reduced.
- Ranolazine: possibly increases ranolazine concentration – avoid.
- Sildenafil: concentrations of sildenafil significantly increased – avoid.
- Tacrolimus: levels possibly increased by ritonavir.
- Tadalafil: concentrations of tadalafil increased – avoid.
- Theophylline: metabolism accelerated, theophylline levels reduced.
- Ticagrelor: possibly increases concentration of ticagrelor – avoid.
- Ulipristal: contraceptive effect reduced – avoid.
- Vardenafil: possibly increased vardenafil concentration – avoid.

### Administration

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Administer with food.
## Clinical use

Monoclonal antibody:
- Lymphomas
- Diffuse large B-cell non-Hodgkin's lymphoma (NHL) in combination with other chemotherapy
- Chronic lymphocytic leukaemia (CLL)
- Rheumatoid arthritis
- Severe, active Granulomatosis with polyangiitis (Wegener's) (GPA) and Microscopic polyangiitis (MPA)
- Lupus nephritis (unlicensed)

## Dose in normal renal function

### IV dosing:
- 375 mg/m² weekly for 4 weeks
- Follicular lymphoma (FL): 375 mg/m² once every 2–3 months for up to 2 years
- CLL: 375 mg/m² on day 0 of first cycle followed by 500 mg/m² on day 1 of subsequent cycles
- Rheumatoid arthritis: two 1 g doses 2 weeks apart
- GPA/MPA: 375 mg/m² once weekly for 4 weeks
- Lupus nephritis: 375 mg/m² for 1–2 doses, two weeks apart

### SC dosing:
- NHL and FL: 1400 mg frequency depends on indication. 1st cycle should always be with the IV dosing and formulation
- Or as per local protocol

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>144 000</td>
</tr>
<tr>
<td>Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>76.3 (after 1st infusion) / –</td>
</tr>
<tr>
<td></td>
<td>205.8 (after 4th infusion) / –</td>
</tr>
</tbody>
</table>

## Metabolism

The mechanisms involved in the metabolism and elimination of rituximab are not fully understood, it is postulated that rituximab is most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production. It is then degraded nonspecifically in the liver and excreted in the urine.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Use with caution.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Use with caution.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Use with caution.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Use with caution.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Vaccines: risk of generalised infections with live vaccines – avoid.

## Administration

### Reconstitution

- **Route**
  - IV infusion, SC

### Rate of administration

- 1st dose: 50 mg/hour then increase the rate every 30 minutes by 50 mg/hour to achieve a maximum rate of 400 mg/hour.
- Further doses: 100 mg/hour, increasing by 100 mg/hour every 30 minutes to achieve a maximum rate of 400 mg/hour.

### Comments

- Add to sodium chloride 0.9% or glucose 5% to achieve a concentration of 1–4 mg/mL, and gently invert to prevent foaming.
- Use immediately after dilution. Infusion solution is stable for 12 hours at room temperature.
- Prepared solution has 24 hours chemical stability at 2–8°C.
**Other information**

- Always give a premedication of methylprednisolone 125 mg, paracetamol and an antihistamine before infusion.
- Mean serum half-life increases with dose and repeated dosing (76.3 hours after 1st infusion and 205.8 hours after 4th infusion). Detectable in body for 3–6 months.
- Alternative regime for vasculitis (anecdotal): 1 g/m² on days 1 and 14, repeated at relapse or after 6 months.
- Patients with high tumour burden or malignant cells > 50 000 mm³ may be at risk of severe cytokine release syndrome which may be associated with acute renal failure – treat with caution.

- Rituximab has been used to reduce alloreactive antibodies pre-transplant, to treat focal segmental glomerulosclerosis, mixed essential cryoglobulinaemia, SLE, primary systemic vasculitis, PRCA, HUS, and PTLD. (Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. *Nat Clin Pract Nephrol*. 2006; 2(4): 221–30.)
- There is a case report of it being used in a haemodialysis patient at 375 mg/m² the main problem was life-threatening hyperkalaemia due to probable tumour lysis syndrome. (Jillella AP, Dainer PM, Kallab AM, *et al.* Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. *Am J Hematol*. 2002; 71(3): 219–22.)
Rivaroxaban

Clinical use
Factor Xa inhibitor:
• Prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery
• Treatment of DVT or PE
• Prophylaxis of stroke in AF
• Prophylaxis of atherothrombotic events in ACS

Dose in normal renal function
• Surgery: 10 mg daily
• Treatment of DVT or PE: 15 mg twice daily for 21 days then 20 mg once daily
• AF: 20 mg once daily
• ACS: 2.5 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 435.9
% Protein binding 92–95
% Excreted unchanged in urine 36
Volume of distribution (L/kg) 50 Litres
Half-life — normal/ESRF (hrs) 7–11 / Increased

Metabolism
Metabolised by the cytochrome P450 isoenzymes CYP3A4 and CYP2J2 and by other mechanisms. About two-thirds of an oral dose is metabolised, with the metabolites excreted equally in the urine and faeces; the remaining third is excreted unchanged in the urine, mainly by active renal secretion.

Dose in renal impairment GFR (mL/min)
30–50 AF: 15 mg once daily. DVT/PE: 15 mg twice daily for 3 weeks then 15–20 mg once daily.
15–29 Use with caution. AF: 15 mg once daily. DVT/PE: 15 mg twice daily for 3 weeks then 15–20 mg once daily.
<15 Avoid.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Avoid.
HD Not dialysed. Avoid.
HDF/High flux Not dialysed. Avoid.
CAV/VVHD Not dialysed. Dose as in GFR=15–29 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• Analgesics: increased risk of haemorrhage with IV diclofenac and ketorolac – avoid.
• Antibacterials: concentration reduced by rifampicin.
• Anticoagulants: increased risk of haemorrhage with other anticoagulants – avoid.
• Antidepressants: concentration possibly reduced by St John’s wort.
• Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
• Antifungals: concentration increased by ketoconazole – avoid; avoid with itraconazole, posaconazole and voriconazole.
• Antivirals: avoid with atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, saquinavir and tipranavir; avoid with lopinavir; concentration increased by ritonavir – avoid.
• Cobicistat: possibly enhanced effect with cobicistat – avoid.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Bioavailability is 80–100%.
• AUC increased 1.5- and 1.6-fold in GFR=30–49 and 15–29 mL/min respectively leading to an increased risk of bleeding.
• Protamine and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban.
Rivastigmine

**Clinical use**
- Mild–moderate dementia in Alzheimer’s disease
- Idiopathic Parkinson’s disease

**Dose in normal renal function**
- 3–6 mg twice daily (initially 1.5 mg twice daily)
- Transdermal: 4.6–13.3 mg/24 hour patch daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>250.3 (400.4 as hydrogen tartrate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>40</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0 (&gt;90 as pharmacologically inactive metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.8–2.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1 / –</td>
</tr>
</tbody>
</table>

**Metabolism**
Rivastigmine is rapidly and extensively metabolised, primarily via cholinesterase-mediated hydrolysis to the weakly active decarbamylated metabolite. After oral use, more than 90% of a dose is excreted in the urine within 24 hours. Less than 1% of a dose appears in the faeces.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose in renal impairment GFR (mL/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Likely dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Likely dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Muscle relaxants: enhances effect of suxamethonium; antagonises effect of non-depolarising muscle relaxants.

**Administration**

**Reconstitution**
- 

**Route**
- Oral, transdermal

**Rate of administration**
- 

**Other information**
- Administer with food. Swallow whole.
Rizatriptan

Clinical use

5HT₁ receptor agonist:
- Acute treatment of migraine

Dose in normal renal function

10 mg, repeated after 2 hours if required; maximum of 2 doses in 24 hours

Pharmacokinetics

Molecular weight (daltons) 391.5 (as benzoate)
% Protein binding 14
% Excreted unchanged in urine 14
Volume of distribution (L/kg) 110 Litres (females), 140 Litres (males)
Half-life — normal/ESRF (hrs) 2–3 / Unchanged

Metabolism

The main route of rizatriptan metabolism is via oxidative deamination by monoamine oxidase-A (MAO-A) to the indole acetic acid metabolite, which is not pharmacologically active. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound, is formed to a minor degree, but does not contribute significantly to the pharmacodynamic activity of rizatriptan.
Less than 1% is excreted in the urine as active N-monodesmethyl metabolite.

Dose in renal impairment GFR (mL/min)

| GFR (mL/min) | Dose
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. 5 mg, repeated after 2 hours; maximum 15 mg daily.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
- Antidepressants: increased risk of CNS excitation with citalopram – avoid; risk of CNS toxicity with MAOIs, moclobemide and linezolid – avoid for 2 weeks after discontinuation of MAOI and moclobemide; possibly increased serotonergic effects with duloxetine and venlafaxine; increased serotonergic effects with St John’s wort – avoid.
- Dapoxetine: possible increased risk of serotonergic effects – avoid for 2 weeks after stopping 5HT₁ agonists.
- Ergot alkaloids: increased risk of vasospasm – avoid.
- Propranolol: rizatriptan levels increased, reduce dose of rizatriptan to 5 mg (max 10 mg in 24 hours).

Administration

Reconstitution

—

Route
Oral

Rate of administration

—

Other information

- Contraindicated in severe renal impairment by manufacturer in UK SPC only.
- Bioavailability is 40–45%.
- Administration with food delays absorption by approximately 1 hour.
- AUC increases by 44% in haemodialysis patients.
Rocuronium bromide

Clinical use
Muscle relaxant in general anaesthesia, medium duration

Dose in normal renal function
- IV injection: intubation dose: 0.6 mg/kg; maintenance: 0.075–0.15 mg/kg
- IV infusion: 0.6 mg/kg loading dose, followed by 0.3–0.6 mg/kg/hour

Pharmacokinetics
Molecular weight (daltons) 609.7
% Protein binding 25–30
% Excreted unchanged in urine 40
Volume of distribution (L/kg) 0.2
Half-life — normal/ESRF (hrs) 1.2–1.4 / Unchanged

Metabolism
Rocuronium is metabolised by the liver to a less active metabolite, 17-desacetylrocuronium which is reported to have weak neuromuscular blocking effect.
Up to 40% of a dose may be excreted in the urine within 24 hours; rocuronium is also excreted in the bile. After injection of a radiolabelled dose of rocuronium bromide, excretion of the radiolabel is on average 47% in urine and 43% in faeces after 9 days. Approximately 50% is recovered as the parent compound. No metabolites are detected in plasma.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Normal loading dose; maintenance to 0.075–0.1 mg/kg; infusion: 0.3–0.4 mg/kg/hr. See ‘Other information’.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Normal loading dose; maintenance to 0.075–0.1 mg/kg; infusion: 0.3–0.4 mg/kg/hr. See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Normal loading dose; maintenance to 0.075–0.1 mg/kg; infusion: 0.3–0.4 mg/kg/hr. See ‘Other information’.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in GFR < 10 mL/min.
- HD Unknown dialysability. Dose as in GFR < 10 mL/min.
- HDF/High flux Unknown dialysability. Dose as in GFR < 10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR = 10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced muscle relaxant effect.
- Anti-arrhythmics: procainamide enhances muscle relaxant effect.
- Antibacterials: effect enhanced by aminoglycosides, clindamycin, polymyxins and piperacillin.
- Antiepileptics: muscle relaxant effects antagonised by carbamazepine; effects reduced by long-term use of fosphenytoin and phenytoin but might be increased by acute use.
- Botulinum toxin: neuromuscular block enhanced (risk of toxicity).

Administration
Reconstitution
Route
IV
Rate of administration
Slow bolus or continuous infusion
Comments
Compatible with sodium chloride 0.9% and glucose 5%

Other information
- Use with caution in renal failure: variable duration of action (range: 22–90 minutes).
- Use the lowest possible dose in patients with GFR < 20 mL/min, as at risk of prolonged paralysis.
Romiplostim

Clinical use
Fc-peptide fusion protein:
• Treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Dose in normal renal function
Initial dose: 1 mcg/kg weekly, titrate dose as required to a maximum of 10 mcg/kg

Pharmacokinetics
Molecular weight (daltons) 59 000
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 0.048–0.122
Half-life — normal/ESRF (hrs) 1–34 days (median 3.5 days) / –

Metabolism
Mainly renal clearance.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution
With diluents supplied
Route
SC
Rate of administration
—

Other information
• Manufacturer advises to use with caution in renal impairment due to lack of studies.
• Anecdotally has been used in haemodialysis patients with good effect at normal doses.
Ropinirole

Clinical use
- Anti-Parkinson agent
- Restless legs syndrome (RLS)

Dose in normal renal function
- Parkinson's disease (PD): 9–24 mg daily in divided doses
- MR: 8–24 mg once daily
- RLS: 0.25 mg daily initially, increasing to a maximum of 4 mg daily

Pharmacokinetics
Molecular weight (daltons) 260.4 (296.8 as hydrochloride)
% Protein binding 10–40
% Excreted unchanged in urine <10
Volume of distribution (L/kg) 8
Half-life — normal/ESRF (hrs) 6 / –

Metabolism
Ropinirole is hepatically metabolised by the cytochrome P450 enzyme, CYP1A2, and excreted in the urine as inactive metabolites.

Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. RLS: 0.25–2 mg daily; PD: 0.75–18 mg daily in divided doses; MR: 2–18 mg daily.
- HDF/High flux Unlikely to be dialysed. RLS: 0.25–2 mg daily; PD: 0.75–18 mg daily in divided doses; MR: 2–18 mg daily.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–30 mL/min

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: antagonism of anti-Parkinsonian effect – avoid.
- Metoclopramide: antagonism of anti-Parkinsonian effect – avoid.
- Oestrogens: concentration increased.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information
- If administered with L-dopa, decrease the dose of L-dopa by 20%.
- Take with meals to improve GI tolerance, but $T_{\text{max}}$ increases by 2.6 hours.
- Manufacturer has not studied patients with a CRCL<30 mL/min who are not on haemodialysis so does not supply dosage information for this group.
- For use in restless legs syndrome in CKD 5, start with a low dose and increase according to tolerability.
Rosuvastatin

**Clinical use**

HMG CoA reductase inhibitor:
- Hyperlipidaemia

**Dose in normal renal function**

- 5–40 mg daily
- Asians, elderly, people at increased risk of myopathy, and in combination with fibrates: 5–20 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>1001.1 (as calcium salt)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>134 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>19 / Increased</td>
</tr>
</tbody>
</table>

**Metabolism**

Rosuvastatin undergoes limited metabolism in the liver mainly by the cytochrome P450 isoenzyme CYP2C9 (approximately 10%). Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>5–20 mg daily</td>
</tr>
<tr>
<td>10–30</td>
<td>5–10 mg daily Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5–10 mg daily Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

- Antibacterials: erythromycin reduces concentration of rosuvastatin; increased risk of myopathy with daptomycin and fusidic acid – avoid.
- Anticoagulants: effect of coumarins and phenindione enhanced.
- Antifungals: concentration increased by itraconazole – reduce dose of rosuvastatin.
- Antivirals: increased risk of myopathy with atazanavir, darunavir, dasabuvir, fosamprenavir, indinavir, ledipasvir, lopinavir, paritaprevir, ritonavir, saquinavir and tipranavir – reduce dose of rosuvastatin, avoid with fosamprenavir, indinavir, ledipasvir, ritonavir and saquinavir.
- Ciclosporin: increased risk of myopathy – avoid.
- Clopidogrel: concentration of rosuvastatin increased, maximum rosuvastatin dose is 20 mg in normal renal function.
- Colchicine: possible increased risk of myopathy.
- Cytotoxics: concentration increased by eltrombopag – reduce dose of rosuvastatin.
- Lipid-lowering agents: increased risk of myopathy with ezetimibe, fibrates, gemfibrozil (avoid) and nicotinic acid – reduce dose of rosuvastatin.
- Teriflunomide: concentration increased by teriflunomide – reduce dose of rosuvastatin.

**Administration**

**Reconstitution**

| Route | Oral |

**Rate of administration**

**Other information**

- Contraindicated in UK SPC in severe renal impairment due to a 3-fold increase in plasma concentration and 9-fold increase in metabolite concentration. Dose recommendations taken from US data sheet.
- In renal impairment, doses above 20 mg should not be used due to risk of myopathy.
- Always start at a dose of 5 mg.
- The 40 mg dose should only be used under specialist supervision.
- Increased risk of proteinuria with doses above 40 mg.
- Case studies from Glasgow have shown that statins in combination with fusidic acid have an increased risk of causing myopathy in diabetic patients.
# Rotigotine

## Clinical use
- Treatment of Parkinson’s disease
- Restless legs syndrome (RLS)

## Dose in normal renal function
- 2–8 mg every 24 hours
- With levodopa: max 16 mg every 24 hours
- RLS: 1–3 mg every 24 hours

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>315.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>92</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>71</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>84</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–7 / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
Rotigotine is metabolised in the gut wall and liver by N-dealkylation as well as direct and secondary conjugation. Main metabolites are sulfates and glucuronide conjugates of the parent compound as well as N-desalkyl-metabolites, which are biologically inactive. Approximately 71% of the rotigotine dose is excreted in urine and a smaller part of about 23% is excreted in faeces.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid concomitant use (antagonism of effect).
- Metoclopramide: avoid concomitant use (antagonism of effect).

## Administration

### Reconstitution

- **Route**
  - Topical

### Rate of administration

- **Other information**
  - Discontinue gradually at a rate of 2 mg / 24 hours, every other day.
  - Apply to intact skin on the abdomen, thigh, hip, flank, shoulder or upper arm.
  - If a patch falls off replace with a new one.
  - Backing layer contains aluminium and should be removed prior to MRIs or cardioversion.

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>
Rufinamide

Clinical use
Adjunctive treatment of seizures in Lennox-Gastaut syndrome

Dose in normal renal function
200 mg twice daily increasing to a maximum dose of:
• Weight 30–50 kg: 900 mg twice daily
• Weight 50–70 kg: 1.2 g twice daily
• Weight >70 kg: 1.6 g twice daily

Pharmacokinetics
Molecular weight (daltons) 238.2
% Protein binding 34
% Excreted unchanged in urine <2
Volume of distribution (L/kg) 50 Litres (dose dependant)
Half-life — normal/ESRF (hrs) 6–10 / Unchanged

Metabolism
Almost exclusively eliminated by metabolism via hydrolysis of the carboxylamide group to the pharmacologically inactive acid derivative CGP 47292. Cytochrome P450-mediated metabolism is very minor. The formation of small amounts of glutathione conjugates cannot be completely excluded. 84.7% was excreted by the renal route.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Antidepressants: antagonism of anticonvulsant effect (convulsive threshold lowered); avoid with St John’s wort.
• Antimalarials: mefloquine antagonises anticonvulsant effect.
• Antipsychotics: antagonism of anticonvulsant effect (convulsive threshold lowered).
• Oestrogens and progestogens: metabolism accelerated by rufinamide – reduced contraceptive effect.
• Orlistat: possibly increased risk of convulsions with orlistat.
• Ulipristal: possibly reduces contraceptive effect.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• 30% is removed by haemodialysis.
Rupatadine

**Clinical use**

Antihistamine

**Dose in normal renal function**

10 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>416</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>98.5–99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Insignificant</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3-7¹</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5.9 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Mainly metabolised by the cytochrome P450 (CYP 3A4) enzyme pathway. The amounts of unaltered active substance found in urine and faeces were insignificant. This means that rupatadine is almost completely metabolised.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antibacterials: concentration increased by clarithromycin and erythromycin – use with caution.
- Antifungals: concentration increased by itraconazole, ketoconazole, posaconazole and voriconazole – avoid; use fluconazole with caution.
- Antivirals: concentration possibly increased by ritonavir and other protease inhibitors – avoid.
- Grapefruit juice: concentration increased – avoid.
- Lipid-lowering agents: use in combination with statins with caution.
- Ciclosporin, sirolimus, tacrolimus – concentration possibly increased by rupatadine.

**Administration**

Reconstitution

- Route
  - Oral

**Other information**

- Manufacturer contraindicates use due to lack of experience in renal impairment.

Reference:

Ruxolitinib

**Clinical use**

Tyrosine kinase inhibitor:
- Treatment of disease related splenomegaly or symptoms in patients with primary myelofibrosis (MF), post polycythaemia vera (PV) myelofibrosis or post-essential thrombocythemia myelofibrosis

**Dose in normal renal function**

5–25 mg twice daily
Dose depends on platelet count

**Pharmacokinetics**

Molecular weight (daltons) 404.4 (as phosphate)
% Protein binding 97 (mostly to albumin)
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 53–65 Litres
Half-life — normal/ESRF (hrs) 3 (metabolites 5.8 hours) / –

**Metabolism**

Ruxolitinib is mainly metabolised by CYP3A4 (>50%), with additional contribution from CYP2C9 to produce 2 major and active metabolites. About 74% of a dose is excreted in the urine and about 22% via the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>15–30</td>
<td>MF: reduce dose by approximately 50% and give twice daily; PV: starting dose of 5 mg twice daily.</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Avoid.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

**APD/CAPD**

Not dialysed. Use with caution.

**HD**

Not dialysed. MF: 15–20 mg post dialysis or 10 mg 12 hourly on dialysis days only, given after dialysis, platelet count between 100 000/mm³ and 200 000/mm³: 15 mg stat, platelet count >200 000/mm³: 20 mg post dialysis or 10 mg 12 hourly on dialysis days only, given after dialysis. PV: 10mg as a single dose or 2 doses of 5 mg 12 hours apart on dialysis day only. See ‘Other information’.

**HDF/High flux**

Not dialysed. MF: 15–20 mg post dialysis or 10 mg 12 hourly on dialysis days only, given after dialysis, platelet count between 100 000/mm³ and 200 000/mm³: 15 mg stat, platelet count >200 000/mm³: 20 mg post dialysis or 10 mg 12 hourly on dialysis days only, given after dialysis. PV: 10mg as a single dose or 2 doses of 5 mg 12 hours apart on dialysis day only. See ‘Other information’.

**CAV/VVHD**

Not dialysed. Dose as in GFR=15–30 mL/min. Use with caution.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: concentration increased by clarithromycin and telithromycin, reduced dose of ruxolitinib; concentration reduced by rifampicin.
- Antifungals: reduce dose of ruxolitinib with fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole.
- Antipsychotics: avoid with clozapine, risk of agranulocytosis.
- Antivirals: reduce dose of ruxolitinib with boceprevir, indinavir, lopinavir, ritonavir, saquinavir and telaprevir.

**Administration**

**Reconstitution**

—

**Route**

Oral
Rate of administration

Other information

- Treatment of patients on dialysis: The dosing recommended is from limited data. Other dosing regimens may be more suitable from an efficacy perspective. However, due to increased metabolite exposure and lack of knowledge on the potential safety consequences of these exposures, dose modification should be followed by careful monitoring of safety and efficacy in individual patients.
- No data is available for dosing patients who are undergoing peritoneal dialysis or continuous venovenous haemofiltration.
- Following a single ruxolitinib dose of 25 mg, the exposure of ruxolitinib was similar in subjects with various degrees of renal impairment and in those with normal renal function. However, plasma AUC values of ruxolitinib metabolites tended to increase with increasing severity of renal impairment, and were most markedly increased in the subjects with severe renal impairment. It is unknown whether the increased metabolite exposure is of safety concern. A dose modification is recommended in patients with severe renal impairment and end-stage renal disease. Dosing only on dialysis days reduces the metabolite exposure, but also the pharmacodynamic effect, especially on the days between dialysis.
Safinamide

### Clinical use
Highly selective and reversible MAO-B inhibitor:
- Treatment of Parkinson's disease

### Dose in normal renal function
50–100 mg daily

### Pharmacokinetics
- Molecular weight (daltons): 302.3 (398.4 as mesilate)
- % Protein binding: 88–90
- % Excreted unchanged in urine: <10
- Volume of distribution (L/kg): 1.8
- Half-life — normal/ESRF (hrs): 20–30

### Metabolism
There are three routes of hepatic metabolism. The main route involves hydrolytic oxidation of the amide moiety leading to the main metabolite safinamide acid (NW-1153). Another pathway involves oxidative cleavage of the ether bond forming 'O-debenzyalted safinamide' (NW-1199). Finally the 'N-dealkylated acid' (NW-1689) is formed by oxidative cleavage of the amine bond of either safinamide (minor) or the primary safinamide acid metabolite (NW-1153) (major). The 'N-dealkylated acid' (NW-1689) undergoes conjugation with glucuronic acid yielding its acyl glucuronide. None of these metabolites are pharmacologically active.

In humans, safinamide is almost exclusively eliminated via metabolism of which 76% is renal and 1.5% via the faeces.

### Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs:
- Analgesics: avoid with pethidine.
- Antibacterials: possible enhanced hypotensive effect with linezolid and tedizolid.
- Antidepressants: increased risk of hypertension and CNS excitation with SSRIs and tricyclics – adjust SSRI or tricyclic doses, avoid or adjust dose of fluoxetine and fluvoxamine; possible enhanced hypotensive effect with MAOIs and moclobemide – avoid.
- Sympathomimetics: use with caution.

### Administration
**Reconstitution**
- **Route**
  - Oral

### Other information
- Oral bioavailability is 95%.
Salbutamol

Clinical use

Beta₂-adrenoceptor agonist:
- Reversible airways disease

Dose in normal renal function

- Oral: 2–4 mg 3–4 times daily
- SC/IM: 500 micrograms, repeated 4 hourly if necessary
- IV: 250 micrograms slow bolus, repeated if required. Infusion: start with 5 micrograms/minute, adjust according to response, usually 3–20 micrograms/minute
- Aerosol: 100–200 micrograms (1–2 puffs) 4 times daily
- Powder: 200–400 micrograms 4 times daily
- Nebulisation: 2.5–5 mg 4 times daily, or more frequently

Pharmacokinetics

Molecular weight (daltons) 239.3
% Protein binding 10
% Excreted unchanged in urine 51–64
Volume of distribution (L/kg) 2–2.5
Half-life — normal/ESRF (hrs) 4–6 / Unchanged

Metabolism

Salbutamol is subject to first-pass metabolism in the liver and possibly in the gut wall but does not appear to be metabolised in the lung; the main metabolite is the inactive sulphate conjugate.
Salbutamol is rapidly excreted, mainly in the urine, as metabolites and unchanged drug; a smaller proportion is excreted in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs
- Increased risk of hypokalaemia when diuretics, theophylline or large doses of corticosteroids are given with high doses of salbutamol.
- Antihypertensives: acute hypotension with IV infusion of salbutamol and methyldopa.

Administration

Reconstitution

- Route
  - IV, SC, IM, oral, inhaled, nebulised
- Rate of administration
  - IV slow bolus; IV infusion 3–20 micrograms/minute
- Comments
  - Infusion: dilute 10 mL (10 mg) to 500 mL with sodium chloride 0.9% or glucose 5% (20 micrograms/mL).
  - Via syringe pump: dilute 10 mL (10 mg) to 50 mL with sodium chloride 0.9% or glucose 5% (200 micrograms/mL).

Other information

- Monitor ECG/BP/pulse.
- Nebulised salbutamol may be prescribed for hypokalaemic effect in acute hyperkalaemia (unlicensed).
**Clinical use**

Protease inhibitor:
- Treatment of HIV infection in combination with other antiviral drugs

**Dose in normal renal function**

- Previously treated with antiretrovirals, with low dose ritonavir: 1 g twice daily
- Previously not treated with antiretrovirals, with low dose ritonavir: initially 500 mg twice daily for 7 days then 1 g twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>670.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>10</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>13.2 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Saquinavir is absorbed to a limited extent (about 30%) after oral doses of the mesilate and undergoes extensive first-pass hepatic metabolism via cytochrome P450 isoenzyme, CYP3A4 to form a range of mono- and di-hydroxylated inactive compounds. It is excreted mainly in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR Range</th>
<th>Dose Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy Type</th>
<th>Dose Instruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Analgesics: increased risk of ventricular arrhythmias with alfentanil, fentanyl and methadone – avoid.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone, disopyramide, dronedarone, flecainide, lidocaine or propafenone – avoid.
- Antibacterials: increased risk of ventricular arrhythmias with clarithromycin, dapsone, erythromycin or moxifloxacin – avoid; increased risk of ventricular arrhythmias with delamanid; concentration of rifabutin increased; rifampicin and rifabutin can reduce saquinavir levels by 80% and 40% respectively (metabolism accelerated); increased hepatotoxicity with rifabutin – avoid; concentration of both drugs increased with fusidic acid.
- Anticoagulants: avoid with apixaban and rivaroxaban.
- Antidepressants: increased risk of ventricular arrhythmias with trazodone or tricyclics – avoid; concentration reduced by St John’s wort – avoid.
- Antiepileptics: carbamazepine, phenobarbital, and phenytoin and possibly primidone can reduce saquinavir levels.
- Antifungals: concentration increased by ketoconazole – avoid.
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antimalarials: avoid with piperaquine with arteminol; use artether/lumefantrine with caution; increased risk of ventricular arrhythmias with quinine – avoid.
- Antipsychotics: increased risk of ventricular arrhythmias with clozapine, haloperidol or phenothiazines – avoid; possibly increased risk of ventricular arrhythmias with pimozone and quetiapine – avoid; possibly inhibits aripiprazole metabolism – reduce aripiprazole dose; possibly increases lurasidone concentration – avoid.
- Antivirals: tipranavir and efavirenz can reduce saquinavir levels; increased risk of ventricular arrhythmias with atazanavir or lopinavir – avoid; concentration increased by indinavir and ritonavir; reduced darunavir concentration; concentration of maraviroc increased, consider reducing dose of maraviroc.
- Anxiolytics and hypnotics: midazolam concentration possibly increased (prolonged sedation) – avoid with oral midazolam.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol – avoid.
- Ciclosporin: concentration of both drugs increased.
- Cytotoxics: possibly increases concentration of axitinib, ibrutinib and panobinostat, reduce dose of axitinib, ibrutinib and panobinostat; possibly increases bosutinib, cabazitaxel, ceritinib and docetaxel concentration – avoid or consider reducing dose; possibly increases concentration of crizotinib and everolimus – avoid; avoid with lapatinib, olaparib and pazopanib; reduce dose of ruxolitinib.
- Dapoxetine: increased risk of toxicity – avoid.
- Domperidone: possibly increases risk of ventricular arrhythmias – avoid.
- Ergot alkaloids: risk of ergotism – avoid.
- Guanfacine: concentration possibly increased – halve guanfacine dose.
- Lipid-lowering drugs: increased risk of myopathy with rosuvastatin and simvastatin – avoid; possibly increased myopathy with atorvastatin; avoid with lomitapide.
- Naloxegol: possibly increases naloxegol concentration – avoid.
- Orlistat: absorption possibly reduced by orlistat.
- Pentamidine: increased risk of ventricular arrhythmias – avoid.
- Ranolazine: possibly increases ranolazine concentration – avoid.
- Sildenafil, tadalafil, vardenafil and avanafil: increased risk of ventricular arrhythmias – avoid.
- Tacrolimus: possibly increased tacrolimus concentration – may need to reduce dose.
- Ulcer-healing drugs: concentration increased by cimetidine; possibly increased by esomeprazole, lansoprazole, pantoprazole and rabeprazole – avoid; omeprazole increases AUC of saquinavir by 82%, (increased risk of toxicity) – avoid.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Comments
Administer within 2 hours after meal.

Other information

- Therapeutic drug monitoring is available from HIV Focus Roche Products UK and the University of Liverpool, but this service is not available to all patients.
- Manufacturer advises to use with caution in severe renal impairment due to lack of studies but saquinavir has minimal renal clearance.
Saxagliptin

Clinical use
Dipeptidyl peptidase 4 inhibitor:
  • Treatment of type 2 diabetes

Dose in normal renal function
5 mg daily

Pharmacokinetics
Molecular weight (daltons) 315.4 (351.9 as hydrochloride)
% Protein binding Negligible
% Excreted unchanged in urine 24
Volume of distribution (L/kg) 1.3–5.2
Half-life — normal/ESRF (hrs) 2.5 (3.1 for metabolite) / –

Metabolism
Metabolism is mainly by cytochrome P450 3A4/5.
The major metabolite of saxagliptin is also a selective, reversible, competitive DPP 4 inhibitor, half as potent as saxagliptin.
Saxagliptin and 5-hydroxy saxagliptin are excreted in the urine; there may be some active renal excretion of unchanged saxagliptin. There is also some elimination via the faeces.

Dose in patients undergoing renal replacement therapies
APD/CAPD Dialysed. Dose as in GFR<10mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
  • None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
  • UK manufacturer advises to use with caution in moderate to severe renal impairment due to lack of studies.
  • Dose in severe and ESRD from US data sheet.
  • Saxagliptin and its major metabolite can be removed by haemodialysis (23% of dose over 4 hours).
  • In subjects with moderate or severe renal impairment, the AUC values of saxagliptin and its active metabolite were up to 2.1- and 4.5-fold higher, respectively, than AUC values in subjects with normal renal function.

Reference:
Secukinumab

Clinical use

Human IgG1/κ monoclonal antibody:
- Treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis

Dose in normal renal function

- Plaque psoriasis alone or plus psoriatic arthritis: 300 mg at weeks 0, 1, 2 and 3 then maintenance of 300 mg monthly starting at week 4
- Ankylosing spondylitis and psoriatic arthritis: 150 mg at weeks 0, 1, 2 and 3 then maintenance of 150 mg monthly starting at week 4

Pharmacokinetics

Molecular weight (daltons) 147 940
% Protein binding Minimal
% Excreted unchanged in urine Low
Volume of distribution (L/kg) 7.1–8.6 Litres
Half-life — normal/ESRF (hrs) 18–46 days

Metabolism

The majority of IgG elimination occurs via intracellular catabolism, following fluid-phase or receptor mediated endocytosis.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Vaccines: risk of generalised infections with live vaccines – avoid.

Administration

Reconstitution
- Route SC
- Rate of administration —

Other information

- Manufacturer has no information in renal impairment.
- The renal elimination of intact secukinumab is expected to be low and of minor importance.
Selegiline hydrochloride

**Clinical use**

Monoamine-oxidase-B inhibitor:
- Treatment of Parkinson's disease

**Dose in normal renal function**

- Oral: 5–10 mg daily in the morning
- Oral lyophilisate: 1.25 mg daily before breakfast

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>223.7</td>
</tr>
<tr>
<td>Protein binding percentage</td>
<td>75–85</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Mainly as metabolites</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>500 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.5–3.5 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Extensive first-pass metabolism in the liver to produce at least 5 metabolites, including desmethylselegiline (norselegiline), N-methylamfetamine, and amfetamine. Plasma concentrations of selegiline metabolites are greatly reduced after doses of the oral lyophilisate preparation, the majority of which undergoes absorption through the buccal mucosa.

Selegiline is excreted as metabolites mainly in the urine and about 15% appears in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Likely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: hyperpyrexia and CNS toxicity reported with pethidine – avoid; avoid with opioid analgesics.
- Antidepressants: avoid with citalopram and escitalopram; increased risk of hypertension and CNS excitation with fluvoxamine, sertraline or venlafaxine, do not start selegiline until 1 week after stopping them, avoid for 2 weeks after stopping selegiline; increased risk of hypertension and CNS excitation with paroxetine, do not start selegiline until 2 weeks after stopping paroxetine, avoid for 2 weeks after stopping selegiline avoid concomitant use with other MAOIs and moclobemide (can lead to hypertensive crisis) – allow at least 14 days before starting a MAOI; avoid concomitant use with fluoxetine, allow 5 weeks between stopping fluoxetine and starting selegiline; allow 14 days between stopping selegiline and starting fluoxetine; increased CNS toxicity with tricyclics and vortioxetine.
- Oestrogens and progestogens: concentration of selegiline increased – avoid.
- Sympathomimetics: concomitant use is not recommended; risk of hypertensive crisis with dopamine.

**Administration**

**Reconstitution**
- 
**Route**
- Oral

**Rate of administration**
- 

**Other information**
- 1.25 mg oral lyophilisate is equivalent to a 10 mg tablet.
- Bioavailability is 10%.
Selexipag

Clinical use
Selective IP receptor agonist:
• Treatment of pulmonary arterial hypertension

Dose in normal renal function
200–1600 micrograms twice daily

Pharmacokinetics
Molecular weight (daltons) 496.6
% Protein binding 99
% Excreted unchanged in urine 12
Volume of distribution (L/kg) 11.7 Litres
Half-life — normal/ESRF (hrs) 0.8–2.5 (6.2–13.5 active metabolite)

Metabolism
Selexipag is rapidly absorbed and is hydrolysed by CES1 in the liver to its active metabolite. Oxidative metabolism catalysed by CYP3A4 and CYP2C8 leads to the formation of hydroxylated and dealkylated products. UGT1A3 and UGT2B7 are involved in the glucuronidation of the active metabolite. Excretion is mainly via the faeces (93%) and 12% via the urine.

Dose in renal impairment GFR (mL/min)
30–50 Dose as in normal renal function.
<30 Dose as in normal renal function. Titrate with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<30 mL/min.
HD Not dialysed. Dose as in GFR<30 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<30 mL/min.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Antibacterials: concentration possibly reduced by rifampicin – consider increasing selexipag dose.
• Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin – consider increasing selexipag dose.
• Clopidogrel: concentration of selexipag possibly increased – consider reducing dose of selexipag.
• Deferasirox: concentration of selexipag possibly increased – consider reducing dose of selexipag.
• Lipid-lowering drugs: concentration possibly increased by gemfibrozil – avoid.
• Teriflunomide: concentration of selexipag possibly increased – consider reducing dose of selexipag.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Use not advised by manufacturer in dialysis patients due to lack of data.
• Oral bioavailability is 49%.
• A 1.4- to 1.7-fold increase in exposure (maximum plasma concentration and area under the plasma concentration-time curve) to selexipag and its active metabolite was observed in subjects with severe renal impairment (eGFR<30 mL/min/1.73 m²).
### Clinical use
Constipation

### Dose in normal renal function
- Tablets: 15–30 mg (2–4 tablets) at night
- Granules: 5–10 mL with at least 150 mL water, juice, milk or a warm drink at night
- Syrup: 10–20 mL at night

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>862.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Systemic bioavailability less than 5%</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

### Metabolism
Absorbed senna is metabolised in the liver. Unabsorbed senna is hydrolysed in the colon by bacteria to release the active free anthraquinones.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unknown dialysability. Dose as in normal renal function.
- **HD**: Unknown dialysability. Dose as in normal renal function.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs
- None known

### Administration
**Reconstitution**
- **Route**: Oral

**Rate of administration**
- **Other information**
  - Acts in 8–12 hours.
  - Syrup available, 5 mL ≡ 1 tablet.
  - Granules available, 1 × 5 mL spoonful ≡ 2 tablets.
  - Diabetic patients should use the tablets as these have negligible sugar content.
Sertraline

Clinical use
SSRI:
- Antidepressant
- Post-traumatic stress disorder
- Obsessive compulsive disorder

Dose in normal renal function
25–200 mg daily depending on indication

Pharmacokinetics
Molecular weight (daltons) 342.7 (as hydrochloride)
% Protein binding >98
% Excreted unchanged in urine 0
Volume of distribution (L/kg) 25
Half-life — normal/ESRF (hrs) 26 / Probably unchanged

Metabolism
Sertraline undergoes extensive first-pass metabolism in the liver. The main pathway is demethylation to inactive N-desmethylsertraline, a process that appears to involve multiple cytochrome P450 isoenzymes; further metabolism and glucuronide conjugation occurs. Sertraline is excreted in about equal amounts in the urine and faeces, mainly as metabolites.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unknown dialysability. Dose as in normal renal function.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol; concentration of methadone possibly increased.
- Anticoagulants: effect of coumarins possibly enhanced; possibly increased risk of bleeding with dabigatran.
- Antidepressants: increased risk of toxic CNS effects of MAOIs and moclobemide; sertraline and MAOIs should not be prescribed within a 2 week period of each other; avoid with St John’s wort; possibly enhanced serotoninergic effects with duloxetine; can increase tricyclic antidepressant concentration; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: antagonism (lowered convulsive threshold); concentration possibly reduced by phenytoin, also concentration of phenytoin possibly increased.
- Antimalarials: avoid with artemether / lumefantrine and piperaquine with artenimol.
- Antipsychotics: concentration of clozapine increased; increased risk of ventricular arrhythmias with droperidol and possibly pimozide – avoid.
- Antivirals: concentration possibly reduced by darunavir; possibly increased concentration with ritonavir.
- Ciclosporin: may increase serotonin syndrome.
- Dapoxetine: possible increased risk of serotoninergic effects – avoid.
- Dopaminergics: increased risk of hypertension and CNS excitation with selegiline – avoid; increased risk of CNS toxicity with rasagiline – avoid.
- 5HT \textsubscript{1} agonist: increased risk of CNS toxicity with sumatriptan – avoid; possibly increased risk of serotoninergic effects with naratriptan.
- Linezolid: use with caution.
- Lithium: increased risk of CNS effects; lithium toxicity reported.
- Methylthioninium: risk of CNS toxicity – avoid if possible.

Administration
Reconstitution
Route Oral
Rate of administration —
**Sevelamer**

### Clinical use
Phosphate-binding agent

### Dose in normal renal function
1–5 tablets (average: 3–5) 3 times a day with meals; adjust according to serum phosphate level
Sevelamer carbonate sachets: 2.4 g 3 times a day with meals

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>Large</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

### Metabolism
Sevelamer is not systemically absorbed.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: reduces bioavailability of ciprofloxacin.
- Ciclosporin: possibly reduces ciclosporin concentration.
- Calcitriol: absorption may be impaired by sevelamer.
- Mycophenolate: may reduce mycophenolate levels.
- Tacrolimus: possibly reduces tacrolimus concentration.
- Thyroid hormones: possibly reduces levothyroxine concentration.

### Administration

#### Reconstitution
—

#### Route
Oral

#### Rate of administration
—

### Other information
- Do not use if the patient has swallowing disorders or untreated or severe gastroparesis.
- Available as hydrochloride and carbonate.
- One tablet = 800 mg of poly(allylamine hydrochloride or carbonate) polymer.
- Renagel tablets can be dispersed in 10 mL sodium bicarbonate 8.4% injection if patient is unable to take the tablets. (Information from the Royal Hospital for Sick Children, Yorkhill, Glasgow.)
- Sachets should be dispersed in 60 mL of water.
Sildenafil

**Clinical use**
- Treatment of erectile dysfunction (ED)
- To increase exercise ability in pulmonary arterial hypertension (PAH)

**Dose in normal renal function**
- ED: 25–100 mg 0.5–4 hours before sexual intercourse (ideally, about 1 hour); no more than 1 dose per day.
- PAH:
  - Oral: 20 mg 3 times daily
  - IV: 10 mg 3 times daily

**Pharmacokinetics**
- Molecular weight (daltons) 666.7 (as citrate)
- % Protein binding 96
- % Excreted unchanged in urine <2
- Volume of distribution (L/kg) 1–2
- Half-life — normal/ESRF (hrs) 4 / Increased

**Metabolism**
Sildenafil is metabolised in the liver mainly by cytochrome P450 isoenzymes CYP3A4 (the major route) and CYP2C9. The major metabolite, N-desmethylsildenafil also has some activity. Sildenafil is excreted as metabolites, mainly in the faeces, and to a lesser extent the urine.

**Dose in renal impairment GFR (mL/min)**
- 30–50 Dose as in normal renal function.
- 10–30 Dose as in normal renal function.
- <10 ED: Initial dose 25 mg and increase if required.
  - ED: Initial dose 25 mg and increase if required. See ‘Other information.’

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alpha-blockers: enhanced hypotensive effect – avoid for 4 hours after sildenafil.
- Antibacterials: concentration increased by clarithromycin and erythromycin – consider reducing sildenafil dose or frequency.
- Antifungals: concentration increased by ketoconazole – reduce initial dose for ED and avoid for PAH; concentration increased by itraconazole – reduce initial dose of sildenafil.
- Antivirals: ritonavir significantly increases sildenafil concentration – avoid; concentration possibly increased by saquinavir, fosamprenavir and indinavir – reduce dose of sildenafil; concentration reduced by etravirine; side effects possibly increased by atazanavir; risk of ventricular arrhythmias with saquinavir – avoid; avoid with telaprevir; avoid with tipranavir for PAH.
- Cobicistat: concentration of sildenafil possibly increased – reduce initial dose for ED and avoid for PAH.
- Nicorandil: enhanced hypotensive effect – avoid.
- Nitrates: enhanced hypotensive effect – absolutely contraindicated.
- Riociguat: enhanced hypotensive effect – avoid.

**Administration**

**Reconstitution**
- Route Oral, IV bolus

**Rate of administration**
- Other information
  - Oral bioavailability is 40%.
  - For PAH, the dose can be reduced to twice daily if there are problems with tolerability.
  - Dialysis is not expected to increase clearance as sildenafil is highly protein bound.
  - Patients should seek prompt medical advice if their erections last for more than 4 hours.
  - Recommend use on non-dialysis days due to hypotension. In peritoneal dialysis, treatment with sildenafil is well tolerated.
• Anecdotally it has been used at Guy’s Hospital, London for diabetic gastroparesis at a dose of 25 mg 3 times a day.
• The use of sildenafil is potentially hazardous in patients with active coronary ischaemia, those with congestive heart failure, and those with complicated multi-drug antihypertensive therapy regimens.
• In 9 patients on maintenance haemodialysis, sildenafil 50 mg appeared to produce firmer erections and greater sexual satisfaction, but the effects were prolonged for up to 48 hours after administration.
Siltuximab

Clinical use
Chimeric (human-murine) immunoglobulin G1κ (IgG1κ) monoclonal antibody:
• Treatment of multicentric Castleman's disease (MCD)

Dose in normal renal function
11 mg/kg every 3 weeks

Pharmacokinetics
Molecular weight (daltons) 145 000
% Protein binding No data
% Excreted unchanged in urine No data
Volume of distribution (L/kg) 4.5 Litres
Half-life — normal/ESRF (hrs) 12.1–20.5 days

Metabolism
As siltuximab is a monoclonal antibody, the expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptor-mediated clearance.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>12–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;12</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;12 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;12 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;12 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Live vaccines: risk of generalised infections – avoid.
• Ciclosporin and tacrolimus: monitor levels on initiation and discontinuation of siltuximab as it may reduce the activity of CYP450.

Administration
Reconstitution
—
Route
IV
Rate of administration
Over 60 minutes
Comments
• Dilute total dose to 250 mL with glucose 5%.
• Administer the diluted solution using administration sets lined with PVC, or polyurethane (PU), or PE, containing a 0.2-micron inline polyethersulfone (PES) filter.

Other information
• Manufacturer advises to use with caution in renal impairment due to lack of studies.
• Based on a population pharmacokinetic analysis using data from clinical trials in patients, no significant difference in siltuximab clearance was observed in patients with pre-existing renal impairment (CRCL≥12 mL/min) compared to patients with normal renal function.
**Clinical use**

HCV NS3/4A serine protease inhibitor:
- Treatment of hepatitis C in combination with other treatment

**Dose in normal renal function**

150 mg once daily for 12 weeks

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>749.9 (771.9 as sodium)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–13 / 24</td>
</tr>
</tbody>
</table>

**Metabolism**

Hepatically metabolised. *In vitro* experiments with human liver microsomes indicated that simeprevir primarily undergoes oxidative metabolism by the hepatic CYP3A4 system.

Elimination of simeprevir occurs via biliary excretion. Following a single oral administration of 200 mg [14C]-simeprevir to healthy subjects, on average 91% of the total radioactivity was recovered in faeces. Unchanged simeprevir in faeces accounted for on average 31% of the administered dose. Renal clearance plays an insignificant role in its elimination.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anti-arrhythmics: possible increased risk of bradycardia with amiodarone.
- Antibacterials: concentration possibly increased by clarithromycin – avoid; concentration of both drugs increased with erythromycin – avoid; concentration reduced by rifampicin and possibly rifabutin – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin and primidone – avoid.
- Antifungals: concentration possibly increased by fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole – avoid.
- Antivirals: concentration of both drugs increased with darunavir – avoid; concentration reduced by efavirenz; avoid with etravirine; concentration possibly reduced by nevirapine – avoid; concentration increased by ritonavir – avoid.
- Ciclosporin: avoid concomitant use, increased simeprevir concentration.
- Cobicistat: concentration possibly increased by cobicistat – avoid.

**Administration**

**Reconstitution**

**Route**

Oral

**Rate of administration**

**Other information**

- Simeprevir has not been studied in severe renal impairment (CRCL<30 mL/min). Exposure will be increased so manufacturer advises to use with caution.
- Compared to healthy subjects with normal renal function (classified using the Modification of Diet in Renal Disease [MDRD] eGFR formula; eGFR≥80 mL/min/1.73m²), the mean steady-state AUC of simeprevir was 1.62-fold higher in subjects with severe renal impairment (eGFR<30 mL/min/1.73m²).
- Oral bioavailability is 62%.
- A study looked at the pharmacokinetics in severe renal failure and concluded that there was not a
significant difference in pharmacokinetics and was well tolerated with most side effects being mild–moderate so simeprevir could be administered at the normal dose.¹

Reference:
Simvastatin

**Clinical use**

HMG CoA reductase inhibitor:
- Primary hypercholesterolaemia

**Dose in normal renal function**

5–80 mg at night

**Pharmacokinetics**

- Molecular weight (daltons) 418.6
- % Protein binding > 95
- % Excreted unchanged in urine 13
- Volume of distribution (L/kg) 54
- Half-life — normal/ESRF (hrs) 1.9 / –

**Metabolism**

Simvastatin is absorbed from the gastrointestinal tract and must be hydrolysed to its active β-hydroxyacid form. Other active metabolites have been detected and several inactive metabolites are also formed. Simvastatin is a substrate for the cytochrome P450 isoenzyme CYP3A4 and undergoes extensive first-pass metabolism in the liver, its primary site of action. Less than 5% of an oral dose has been reported to reach the circulation as active metabolites.

Simvastatin is mainly excreted in the faeces via the bile as metabolites. About 10–15% is recovered in the urine, mainly in inactive forms.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Doses above 10 mg should be used with caution (doses up to 40 mg have been used).</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anti-arrhythmics: increased risk of myopathy with amiodarone – do not exceed 20 mg of simvastatin; increased risk of myopathy with dronedarone.
- Antibacterials: increased risk of myopathy with clarithromycin, daptofycin, erythromycin and fusidic acid – avoid; possibly increased myopathy with azithromycin; concentration possibly reduced by rifampicin.
- Anticoagulants: effects of coumarins enhanced.
- Antiepileptics: concentration reduced by carbamazepine and eslicarbazepine.
- Antifungals: increased risk of myopathy with fluconazole, itraconazole, posaconazole, ketoconazole, voriconazole and possibly miconazole – avoid; possibly increased risk of myopathy with imidazoles.
- Antivirals: increased risk of myopathy with atazanavir, indinavir, lopinavir, ritonavir or saquinavir and possibly fosamprenavir, lopinavir or tipranavir – avoid; concentration reduced by efavirenz; avoid with boceprevir, dasabuvir, ombitasvir, paritaprevir and telaprevir; possible increased risk of myopathy with ledipasvir – reduce simvastatin dose; concentration increased by simeprevir – consider reducing simvastatin dose.
- Calcium-channel blockers: increased risk of myopathy with atazanavir, lopinavir, ritonavir and possibly saquinavir and possibly fosamprenavir, lopinavir or tipranavir – avoid; concentration reduced by efavirenz; avoid with boceprevir, dasabuvir, ombitasvir, paritaprevir and telaprevir; possible increased risk of myopathy with ledipasvir – reduce simvastatin dose; concentration increased by simeprevir – consider reducing simvastatin dose.
- Ciclosporin: increased risk of myopathy – avoid.
- Cobicistat: avoid with simvastatin.
- Colchicine: possible increased risk of myopathy.
- Grapefruit: increased risk of myopathy – avoid.
- Hormone antagonists: possibly increased risk of myopathy with danazol – avoid.
- Lipid-lowering agents: increased risk of myopathy with fibrates – do not exceed 10 mg of simvastatin except with fenofibrate; gemfibrozil – avoid; concentration increased by lomitapide – do not exceed 40 mg of simvastatin; increased risk of myopathy with nicotinic acid.
- Lipid-lowering agents: increased risk of myopathy with fibrates – do not exceed 10 mg of simvastatin except with fenofibrate; gemfibrozil – avoid; concentration increased by lomitapide – do not exceed 40 mg of simvastatin; increased risk of myopathy with nicotinic acid.
- Ranolazine: concentration increased by ranolazine, maximum dose of simvastatin is 20 mg.
- Ticagrelor: concentration of simvastatin increased; maximum dose of simvastatin is 40 mg.
<table>
<thead>
<tr>
<th>Administration</th>
<th>Other information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reconstitution</td>
<td>• <em>Drug Prescribing in Renal Failure</em>, 5th edition by</td>
</tr>
<tr>
<td>—</td>
<td>Aronoff et al. suggests that doses up to 40 mg are</td>
</tr>
<tr>
<td>Route</td>
<td>acceptable.</td>
</tr>
<tr>
<td>Oral</td>
<td>Reference:</td>
</tr>
<tr>
<td>Rate of administration</td>
<td>1. MHRA. <em>Drug Safety Update</em>. Statins: interactions</td>
</tr>
</tbody>
</table>
Sirolimus

**Clinical use**

Immunosuppressant:
- Prophylaxis of transplant allograft rejection

**Dose in normal renal function**

6 mg loading dose followed by 2 mg daily, adjusted according to levels – see 'Other information'.

**Pharmacokinetics**

- Molecular weight (daltons) 914.2
- % Protein binding 92
- % Excreted unchanged in urine 2.2
- Volume of distribution (L/kg) 4–20
- Half-life — normal/ESRF (hrs) 48–78 / Unchanged

**Metabolism**

Sirolimus is metabolised by the cytochrome P450 isoenzyme CYP3A4. Metabolism occurs by demethylation or hydroxylation, and the majority of a dose is excreted via the faeces.

**Dose in renal impairment GFR (mL/min)**

- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Not dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: concentration increased by clarithromycin – avoid; concentration of both drugs increased with erythromycin; concentration reduced by rifampicin and rifabutin – avoid.
- Antifungals: concentration increased byitraconazole, fluconazole, ketoconazole, miconafungin, miconazole, posaconazole and voriconazole – avoid with itraconazole, ketoconazole and voriconazole.
- Antivirals: concentration possibly increased by atazanavir, boceprevir and lopinavir; concentration of both drugs increased with telaprevir, reduce dose of sirolimus; concomitant use with dasabuvir plus ombitasvir/paritaprevir/ritonavir is not recommended unless the benefits outweigh the risks, if used together administer sirolimus 0.2 mg twice a week (every 3 or 4 days on the same two days each week). Sirolimus blood concentrations should be monitored every 4–7 days until 3 consecutive trough levels have shown stable concentrations of sirolimus. Sirolimus dose and/or dosing frequency should be adjusted as needed.
- Calcium-channel blockers: concentration increased by diltiazem; concentration of both drugs increased with verapamil.
- Ciclosporin: increased absorption of sirolimus – give sirolimus 4 hours after ciclosporin; sirolimus concentration increased; long-term concomitant administration may be associated with deterioration in renal function.
- Cytotoxics: use crizotinib with caution.
- Grapefruit juice: concentration of sirolimus increased – avoid.
- Mycophenolate: concomitant use of mycophenolate and sirolimus increases plasma levels of both sirolimus and mycophenolic acid.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Aim for trough levels of 4–12 ng/mL where sirolimus is used in combination with low dose ciclosporin.
- In cases of delayed graft function or where a calcineurin inhibitor is not tolerated or contraindicated, sirolimus may be used with steroids alone. A loading dose of 10–15 mg may be given, followed by maintenance dose of 3–6 mg daily and adjust according to levels. Aim for trough levels of 8–20 ng/mL.
• May be used in combination with MMF, but can lead to delayed wound healing post surgery. Sirolimus can increase levels of mycophenolate mofetil leading to anaemia.
• Some centres successfully using level-controlled sirolimus in conjunction with low dose tacrolimus.
• Anecdotally, has been used for encapsulating sclerosing peritonitis in a CAPD patient at Guy’s Hospital, London. Acts by interfering with various growth factors and their effect on impairing wound healing.

  • Pneumonitis appears to be more common with sirolimus than initially thought, especially if the trough levels are on the high side. (Glare J. Adverse effect report – pneumonitis with sirolimus. *Ann Intern Med.* 2006; 144: 505–9.)
• If changing from tablets to solution, give the same dose and monitor trough levels 1–2 weeks later.
• Tablet has a 27% increased bioavailability compared with the solution.
• Sirolimus has been associated with anaphylactic/anaphylactoid reactions, angioedema and hypersensitivity vasculitis.
Sitagliptin

Clinical use
Treatment of type 2 diabetes in combination with metformin or a thiazolidinedione

Dose in normal renal function
100 mg once daily

Pharmacokinetics
Molecular weight (daltons) 523.3 (as phosphate)
% Protein binding 38
% Excreted unchanged in urine 79
Volume of distribution (L/kg) 198 Litres
Half-life — normal/ESRF (hrs) 12.4 / Probably increased

Metabolism
Sitagliptin undergoes minimal metabolism, mainly by the cytochrome P450 isoenzyme CYP3A4, and to a lesser extent by CYP2C8. Renal excretion of sitagliptin involves active tubular secretion; it is a substrate for organic anion transporter-3 and P-glycoprotein.

Dose in renal impairment GFR (mL/min)
30–50 50 mg once daily.
<30 25 mg once daily.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<30 mL/min.
HD Not dialysed. Dose as in GFR<30 mL/min.
HDF/High flux Dialysed. Dose as in GFR<30 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR<30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• 13.5% of dose is removed during a 3–4 hour haemodialysis session.
• In severe renal impairment (GFR<30 mL/min) the AUC was increased 4-fold.
Sodium aurothiomalate

Clinical use
Active progressive rheumatoid arthritis in adults

Dose in normal renal function
10 mg as a test dose followed by 50–100 mg weekly, frequency is altered according to duration and response
See product literature for more information

Pharmacokinetics
<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>368.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>85–95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Majority</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–6 days / –</td>
</tr>
</tbody>
</table>

Metabolism
Mainly excreted in the urine with smaller amounts in the faeces.

Dose in renal impairment GFR (mL/min)
| 20–50 | Avoid. |
| 10–20 | Avoid. |
| <10   | Avoid. |

Dose in patients undergoing renal replacement therapies
| APD/CAPD | Unknown dialysability. Dose as in GFR<10 mL/min. |
| HD       | Not dialysed. Dose as in GFR<10 mL/min. |
| HDF/High flux | Unknown dialysability. Dose as in GFR<10 mL/min. |
| CAV/VVHD | Not dialysed. Dose as in GFR=10–20 mL/min. |

Important drug interactions
Potentially hazardous interactions with other drugs
- ACE-inhibitors: flushing and hypotension reported in combination.
- Penicillamine: increased risk of toxicity – avoid.

Administration
Reconstitution
—
Route
Deep IM
Rate of administration
—

Other information
- Warn patients to tell the doctor immediately if any of the following develop: sore throat, mouth ulcers, bruising, fever, malaise, rash, diarrhoea or nonspecific illness.
- Blood tests should be carried out monthly, and treatment should be withdrawn if the platelets fall below 100 000/mm$^3$, or if signs and symptoms suggestive of thrombocytopenia appear.
- Gold can produce nephrotic syndrome or less severe glomerular disease with proteinuria and haematuria, which are usually mild and transient. If persistent or clinically significant proteinuria develops, treatment with gold should be discontinued. Minor transient changes in renal function may also occur.
- Urine tests should be carried out pre-treatment and before each injection to test for proteinuria and haematuria.
- Gold may be found in the urine for up to 1 year or more owing to its presence in deep body compartments.
Sodium bicarbonate

**Clinical use**
- Metabolic acidosis
- Alkalisation of urine
- Renoprotection against contrast media

**Dose in normal renal function**
Oral: 0.5–1.5 g 3 times daily (or more may be required)
IV: 8.4%, 60–120 mL per hour; 4.2%, up to 120 mL per hour; 1.26% or 1.4% – see ‘Other information’

**Pharmacokinetics**
- Molecular weight (daltons): 84
- % Protein binding: 0
- % Excreted unchanged in urine: <1
- Volume of distribution (L/kg): Dependent on the physical state of the patient at the time.
- Half-life — normal/ESRF (hrs): No data

**Metabolism**
Oral bicarbonate, such as sodium bicarbonate, neutralises gastric acid with the production of carbon dioxide. Bicarbonate not involved in that reaction is absorbed and in the absence of a deficit of bicarbonate in the plasma, bicarbonate ions are excreted in the urine, which is rendered alkaline, and there is an accompanying diuresis.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Increases lithium excretion.

**Administration**

**Reconstitution**
—

**Route**
Oral, IV, central administration for undiluted 8.4% infusion

**Rate of administration**
—

**Other information**
- Caution – may result in sodium retention and oedema.
- Sodium bicarbonate 1.26% or 1.4% may be given IV to prevent the nephrotoxicity associated with scans or procedures involving radiological contrast media. A typical hydration regimen is 3 mL/kg/hour for 1 hour prior to the procedure, followed by 1 mL/kg/hour for 6 hours afterwards.
- 8.4% ≡ 1 mmol bicarbonate + 1 mmol sodium per mL
- 500 mg sodium bicarbonate tablet ≡ 6 mmol sodium + 6 mmol bicarbonate.
- Sodium bicarbonate reduces serum potassium concentrations by inducing a shift of potassium ions into the cell.
- A sugar free raspberry flavoured oral solution of 8.4% sodium bicarbonate is available from Martindale.
Sodium chloride

**Clinical use**

Treatment and prophylaxis of sodium chloride deficiency

**Dose in normal renal function**

Oral prophylaxis: 40–80 mmol sodium daily, up to a maximum of 200 mmol sodium daily
IV: in severe deficiency 2–3 Litres over 2–3 hours then reduce

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>58.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Dependent on the physiological state of the patient at the time</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

**Metabolism**

Excess sodium is mainly excreted by the kidney, and small amounts are lost in the faeces and sweat.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- May impair the efficacy of antihypertensive drugs in chronic renal failure.

**Administration**

**Reconstitution**
- 

**Route**
- Oral, IV

**Rate of administration**
- 

**Other information**

- Other regimens: for acute muscular cramps post haemodialysis, 10 mL sodium chloride 30% injection diluted in 100 mL sodium chloride 0.9%, and infused over 30 minutes or in dialysis washback.
- Sodium salts should be administered with caution to patients with congestive heart failure, peripheral or pulmonary oedema, or impaired renal function.
- Slow sodium® 600 mg tablet = approximately 10 mmol sodium and 10 mmol chloride.
Sodium clodronate

Clinical use
Bisphosphonate:
Management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast cancer or multiple myeloma

Dose in normal renal function
- 1.6–3.2 g daily in single or 2 divided doses
- Loron-520: 2–4 tablets daily

Pharmacokinetics
Molecular weight (daltons) 360.9 (as disodium salt)
% Protein binding 36
% Excreted unchanged in urine >70
Volume of distribution (L/kg) 0.3
Half-life — normal/ESRF (hrs) 1st phase: 2; 2nd phase: 13 / 51

Metabolism
Clodronate is not metabolised.
Over 70% of an intravenous dose is excreted unchanged in the urine within 24 hours, the remainder being sequestered to bone tissue. The substance which is bound to bone is excreted more slowly, and the renal clearance is about 75% of the plasma clearance.

Dose in renal impairment GFR (mL/min)
30–50 Loron: Dose as in normal renal function; Bonefos: 1200 mg daily.
10–30 Loron: 50% of normal dose; Bonefos: 800 mg daily.
<10 Avoid.

Important drug interactions
Potentially hazardous interactions with other drugs
- Cytotoxics: concentration of estramustine increased.

Administration
Reconstitution
Route
Oral
Rate of administration
—

Other information
- Reversible elevations of creatinine have been reported. Renal function should be monitored during treatment.
- Orally: avoid food for one hour before and after treatment, particularly calcium-containing products; also avoid iron, mineral supplements and antacids.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min.
Sodium fusidate

Clinical use
Antibacterial agent

Dose in normal renal function
- Oral: 0.5–1 g (as sodium fusidate) every 8 hours
- Suspension: 750 mg every 8 hours (as fusidic acid)

Pharmacokinetics
- Molecular weight (daltons): 538.7
- % Protein binding: 95
- % Excreted unchanged in urine: <1
- Volume of distribution (L/kg): 0.2
- Half-life — normal/ESRF (hrs): 10–15 / Unchanged

Metabolism
Fusidic acid is excreted in the bile, almost entirely as metabolites, some of which have weak antimicrobial activity.
Approximately 2% appears unchanged in the faeces.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antivirals: concentration of both drugs increased in combination with ritonavir and saquinavir – avoid with ritonavir.
- Statins: increased risk of myopathy with simvastatin and atorvastatin especially in diabetics. Avoid with simvastatin and for 7 days after last dose.¹

Administration
Reconstitution
- 
Route
- Oral
Rate of administration
- 

Other information
Reference:
# Sodium nitroprusside

## Clinical use
- Hypertensive crisis
- Heart failure
- Controlled hypotension in surgery

## Dose in normal renal function
- Hypertensive emergencies: 0.3–8 mcg/kg/minute
- Maintenance of blood pressure: 20–400 mcg/minute
- Heart failure: 10–200 mcg/minute
- Controlled blood pressure in surgery: maximum 1.5 mcg/kg/minute

## Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function. Avoid prolonged use.
- <10: Dose as in normal renal function. Avoid prolonged use.

## Pharmacokinetics
- Molecular weight (daltons) 297.9
- % Protein binding 0
- % Excreted unchanged in urine <10
- Volume of distribution (L/kg) 0.2
- Half-life — normal/ESRF (hrs) 2–10 minutes / Unchanged

## Metabolism
Sodium nitroprusside is rapidly metabolised to cyanide in erythrocytes and smooth muscle and, this is then followed by the release of nitric oxide, the active metabolite. Cyanide is further metabolised in the liver to thiocyanate, which is slowly excreted in the urine.

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.

## Administration
### Reconstitution
2–3 mL glucose 5%

### Route
IV

### Rate of administration
10–400 micrograms/minute, adjusted according to response

### Comments
- Dilute 50 mg in 250–1000 mL glucose 5% to give a concentration of 50–200 mcg/mL.
- Minimum volume is 1 mg/mL via central line. (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006.)
- Wrap syringes and lines in foil to protect from light.

## Other information
- Avoid prolonged use in renal impairment because accumulation of thiocyanate (which is dialysable) may cause seizures or a coma.
- Monitor thiocyanate and cyanide levels.
- Do not stop infusion abruptly – tail off over 10–30 minutes.
Sodium stibogluconate

Clinical use
Treatment of Leishmaniasis

Dose in normal renal function
- 20 mg/kg daily
- Maximum dose 850 mg

Pharmacokinetics
Molecular weight (daltons) 910.9
% Protein binding No data
% Excreted unchanged in urine 0.8
Volume of distribution (L/kg) 0.21
Half-life — normal/ESRF (hrs) Initial phase: 2; slower
terminal phase: 76

Metabolism
No data on possible metabolic pathways. Elimination occurs in two phases; a rapid initial phase, in which the majority of a dose is excreted via the kidneys within 12 hours, and a slower phase, possibly reflecting reduction to trivalent antimony.

Dose in renal impairment GFR (mL/min)
20–50 Avoid.
10–20 Avoid.
<10 Avoid.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Avoid.
HD Unknown dialysability. Avoid.
HDF/High flux Unknown dialysability. Avoid.
CAV/VVHD Unknown dialysability. Avoid.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antifungals: possible increased risk of arrhythmias with amphotericin – give 14 days apart.

Administration
Reconstitution
—
Route
IM, IV
Rate of administration
Over 5 minutes
Comments
Due to the presence of particulates (size range 20–300 microns) the solution should be drawn up through a filter immediately prior to administration.

Other information
- Has caused acute renal failure and accumulates in renal impairment therefore avoid use.

References:
Sodium valproate

Clinical use
All forms of epilepsy
Migraine prophylaxis (unlicensed)

Dose in normal renal function
- Oral: 600 mg – 2.5 g daily in divided doses
- IV: For continuation of existing oral therapy, IV and oral doses are equivalent, give the same dose.
- For initiation of new therapy: give a loading dose of 400–800 mg (up to 10 mg/kg), followed by either a constant infusion or intermittent doses up to a cumulative daily dose of 2.5 g.
- Migraine prophylaxis: 200 mg twice daily increasing to 1.2–1.5 g daily in divided doses if necessary.

Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>166.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90–95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>3–7</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.1–0.4*</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–15 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism
Valproic acid is extensively metabolised in the liver, a large part by glucuronidation (up to 60%) and the rest by a variety of complex pathways (up to 45%). It is excreted in the urine almost entirely in the form of its metabolites; small amounts are excreted in faeces and expired air.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism possibly inhibited by erythromycin; avoid with pivmecillinam; concentration reduced by carbapenems – avoid.
- Antidepressants: antagonise anticonvulsant effect; avoid with St John’s wort.
- Antiepileptics: concentration reduced by carbamazepine; concentration of active carbamazepine metabolite increased; increased concentration of lamotrigine, phenobarbital, rufinamide and possibly ethosuximide; sometimes reduces concentration of active metabolite of ocarbazepine; alters phenytoin concentration; phenytoin and phenobarbital reduce valproate concentration; hyperammonaemia and CNS toxicity with topiramate.
- Antimalarials: mefloquine antagonises anticonvulsant effect.
- Antipsychotics: antagonise anticonvulsant effect; increased neutropenia with olanzapine; possibly increases or decreases concentration of clozapine; possibly increases quetiapine concentration.
- Ciclosporin: variable ciclosporin blood level response.
- Orlistat: possibly increased risk of convulsions.
- Sodium oxybate: concentration of sodium oxybate increased.
- Ulcer-healing drugs: metabolism inhibited by cimetidine, increased concentration.

Administration
Reconstitution
Use solvent provided
Route
IV, oral, PR (unlicensed)
Rate of administration
3–5 minutes bolus, or continuous infusion

Other information
- Increases ketones in urine. May give false positive urine tests for ketones.
- Sodium valproate serum levels do not correlate with antiepileptic activity.
- Monitor serum levels to ensure not greater than 100 micrograms/mL, or if non-compliance is suspected.
- Suppositories are available on a named patient basis.

Reference:
Sofosbuvir

Clinical use
Pan-genotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase:
- Treatment of chronic hepatitis C infection in combination with other medication

Dose in normal renal function
400 mg once daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>529.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>85</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>3.5 (78% as metabolite)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.4 (GS-331007: 27)</td>
</tr>
</tbody>
</table>

Metabolism
Sofosbuvir is a nucleotide prodrug that is extensively metabolised. The active metabolite is formed in hepatocytes and not observed in plasma. The predominant (>90%) metabolite, GS-331007, is inactive. It is formed through sequential and parallel pathways to the formation of active metabolite. The metabolic pathway involves sequential hydrolysis of the carboxyl ester moiety catalysed by human cathepsin A or carboxylesterase 1 and phosphoramidate cleavage by histidine triad nucleotide binding protein followed by phosphorylation by the pyrimidine nucleotide biosynthesis pathway.
Dephosphorylation results in the formation of nucleoside metabolite GS-331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity in vitro. Following a single 400 mg oral dose of [14C]-sofosbuvir, mean total recovery of the dose was >92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, faeces, and expired air, respectively. This data indicate that renal clearance is the major elimination pathway for GS-331007 with a large part actively secreted.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>200 mg daily or 400 mg every 48 hours.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>18% dialysed. 200 mg daily, give at least 1 hour pre-dialysis. Use with caution. See 'Other Information'.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. 200 mg daily, give at least 1 hour pre-dialysis. Use with caution. See 'Other Information'.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min. See 'Other Information'.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: possibly increased risk of bradycardia with amiodarone.

Administration

Reconstitution

Route
Oral

Rate of administration

Other information
- Manufacturer has no information on the safety and efficacy of sofosbuvir in eGFR<30mL/min/1.73m2.
- From SPC: Relative to subjects with normal renal function (eGFR>80 mL/min/1.73m2), the sofosbuvir AUC0-inf was 61%, 107% and 171% higher in mild, moderate and severe renal impairment, while the GS-331007 AUC0-inf was 55%, 88% and 451% higher, respectively.
- In subjects with ESRD, relative to subjects with normal renal function, sofosbuvir and GS-331007
AUC_{0-inf} was 28% and 1280% higher when sofosbuvir was dosed 1 hour before hemodialysis compared with 60% and 2070% higher when sofosbuvir was dosed 1 hour after hemodialysis, respectively. A 4-hour haemodialysis session can remove 18% of sofosbuvir.

- One small study used 200 mg daily or 400 mg every 48 hours of sofosbuvir with simeprevir in patients with ESRD and on dialysis and found it to be well tolerated and efficacious.¹
- Another small study used full dose treatment in combination with simeprevir or ledipasvir with no adverse effects.²
- Another review paper showed suboptimal response with 200 mg daily and there are studies underway looking at giving 400 mg sofosbuvir to patients with severe renal impairment. They also reviewed another paper which used full dose sofosbuvir in severe renal impairment, they found an increase in adverse effects especially anaemia and recommend using full dose but monitoring closely.³
- Another single centre study looked at sofosbuvir in ESRD including haemodialysis patients. They initiated treatment at 200 mg daily but escalated up to 400 mg daily with good response and little side effects.⁴

References:
### Solifenacin succinate

**Clinical use**

- **Selective M₃ antimuscarinic**
  - Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency

**Dose in normal renal function**

5–10 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>480.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>11</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>600 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>45–68 / Increased by 60%</td>
</tr>
</tbody>
</table>

**Metabolism**

- Extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP3A4 and is excreted mainly as metabolites in urine and faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>5 mg once daily.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5 mg once daily.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**
  - Unlikely to be dialysed. Dose as in GFR<10 mL/min. Use with caution.
- **HD**
  - Unlikely to be dialysed. Dose as in GFR<10 mL/min. Use with caution.
- **HDF/High flux**
  - Unknown dialysability. Dose as in GFR<10 mL/min. Use with caution.
- **CAV/VVHD**
  - Unknown dialysability. Dose as in GFR=10–30 mL/min. Use with caution.

**Important drug interactions**

- Potentially hazardous interactions with other drugs
  - Avoid if GFR<30 mL/min if also taking itraconazole, ketoconazole or ritonavir.
  - Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Contraindicated by manufacturer in haemodialysis due to lack of data.
  - Bioavailability is 90%.
  - In patients with severe renal impairment (CRCL≤30 mL/min), exposure to solifenacin was significantly greater than in the controls, with increases in \( C_{max} \) of about 30%, AUC of more than 100% and half-life of more than 60%. A statistically significant relationship was observed between creatinine clearance and solifenacin clearance.
**Sorafenib**

**Clinical use**
Protein kinase inhibitor:
- Treatment of advanced renal cell carcinoma
- Treatment of hepatocellular carcinoma
- Treatment of thyroid cancer

**Dose in normal renal function**
400 mg twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>464.8 (637 as tosylate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99.5</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>25–48 / –</td>
</tr>
</tbody>
</table>

**Metabolism**
Sorafenib is metabolised primarily in the liver and undergoes oxidative metabolism mediated by CYP3A4, as well as glucuronidation mediated by UGT1A9. 8 metabolites have been identified, during in vitro studies one has been shown to have equal activity to sorafenib. About 96% of a dose is excreted within 14 days, with 77%, mostly as unchanged drug, recovered in the faeces, and 19% in the urine as glucuronidated metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: may enhance effect of coumarins.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Antivirals: avoid with boceprevir.

**Administration**

**Reconstitution**
- 

**Route**
Oral

**Rate of administration**
- 

**Comments**
Administer preferably without food.

**Other information**
- Increased amylase and lipase and hypophosphataemia are common.
- Most common side effects are diarrhoea and dermatological effects.
- May cause QT prolongation.
Sotalol hydrochloride

**Clinical use**

Beta-adrenoceptor blocker:
- Treatment of life-threatening ventricular arrhythmias
- Prophylaxis of SVT

**Dose in normal renal function**

- Oral: 80–640 mg per day in single or divided doses (480–640 mg under specialist supervision)
- IV: 20–120 mg every 6 hours

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>308.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&gt;90</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.6–2.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>10–20 / 56</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolism of sotalol is negligible, and it is excreted unchanged in the urine.

**Dose in renal impairment GFR (mL/min)**

- 30–60: 50% of normal dose.
- 10–30: 25% of normal dose.
- <10: 25% of normal dose and increase dosage interval. Use with caution.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapies</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonist hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of ventricular arrhythmias with amiodarone, dronedarone, disopyramide or procainamide – avoid; increased risk of myocardial depression and bradycardia with flecainide.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin – avoid; increased risk of ventricular arrhythmias with delamanid.
- Antidepressants: enhanced hypotensive effect with MAOIs; increased risk of ventricular arrhythmias with tricyclics; increased risk of ventricular arrhythmias with citalopram, escitalopram and venlafaxine – avoid.
- Antihistamines: increased risk of ventricular arrhythmias with mizolastine – avoid.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine; avoid with artemether and lumezantrine and piperazine with artenimol – increased risk of ventricular arrhythmias.
- Antimuscarinics: increased risk of ventricular arrhythmias with tolterodine.
- Antipsychotics: enhanced hypotensive effect with phenothiazines; increased risk of ventricular arrhythmias with amisulpride, droperidol, haloperidol, phenothiazines, pimozide, risperidone, sulpiride or zuclopenthixol – avoid with droperidol and zuclopenthixol.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir or telaprevir – avoid.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib; increased risk of ventricular arrhythmias with vandetanib – avoid; increased risk of ventricular arrhythmias with arsenic trioxide, bosutinib, ceritinib, panobinostat and vandetanib.
- Diuretics: enhanced hypotensive effect; increased risk of ventricular arrhythmias due to hypokalaemia.
- Fingolimod: possibly increased risk of bradycardia.
- Ivabradine: increased risk of ventricular arrhythmias.
• Moxisylyte: possible severe postural hypotension.
• Ranolazine: avoid concomitant use.
• Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

**Rate of administration**
- Slow IV bolus with ECG monitoring
- Over 10 minutes

**Other information**
- Oral bioavailability is >90%.
- Contraindicated in UK SPC but use with caution in US data sheet.
- Sotalol prolongs the QT interval, which predisposes to the development of torsades de pointes.
- If used in haemodialysis, give lowest possible dose, after dialysis.
**Clinical use**

Aldosterone antagonist, diuretic:
- Oedema
- Heart failure
- Ascites in liver and malignant cirrhosis
- Resistant hypertension (unlicensed)
- Treatment of primary hyperaldosteronism

**Dose in normal renal function**

25–400 mg daily, dose varies according to indication

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>416.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0 (47–57 as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.3–1.4 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Spironolactone is metabolised extensively to several metabolites including canrenone and 7α-thiomethylspirolactone, both of which are pharmacologically active. The major metabolite may be 7α-thiomethylspirolactone, although it is uncertain to what extent the actions of spironolactone are dependent on the parent compound or its metabolites. Spironolactone is excreted mainly in the urine and also in the faeces, in the form of metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>50% of normal dose.¹</td>
</tr>
<tr>
<td>10–20</td>
<td>50% of normal dose.¹</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- ACE inhibitors or angiotensin-II antagonists: enhanced hypotensive effect; risk of severe hyperkalaemia.
- Antibacterials: avoid with lymecycline.
- Antidepressants: increased risk of postural hypotension with tricyclics.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers.
- Cardiac glycosides: increased digoxin concentration.
- Ciclosporin: increased risk of hyperkalaemia.
- Cytotoxics: avoid with mitotane; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium: reduced lithium excretion.
- NSAIDs: increased risk of hyperkalaemia (especially with indometacin); increased risk of nephrotoxicity; diuretic effect of spironolactone antagonised by aspirin.
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Contraindicated by manufacturer in severe renal impairment.
• It can be used in renal patients but they are at an increased risk of hyperkalaemia and therefore spironolactone should be used with caution. It has active metabolites with long half-lives.

• Small studies have shown that doses of 25 mg of spironolactone 3 times a week can be safely used in haemodialysis patients although unknown whether that dose would be therapeutic – potassium levels should be monitored closely. (Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. *Nephrol Dial Transplant* 2003; 18(11): 2359–63.)

• Another small study used 25 mg daily but the potassium was monitored 3 times a week. (Hussain S, Dreyfuss, DE, Marcus RJ, et al. Is spironolactone safe for dialysis patients? *Nephrol Dial Transplant*. 2003; 18(11): 2364–8.)

Reference:
# Stavudine

## Clinical use

Nucleoside reverse transcriptase inhibitor:
- Treatment of HIV in combination with other antiretroviral drugs

## Dose in normal renal function

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;60</td>
<td>30 twice daily</td>
</tr>
<tr>
<td>&gt;60</td>
<td>40 twice daily</td>
</tr>
</tbody>
</table>

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>224.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;1</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.5</td>
</tr>
<tr>
<td>Half-life (hrs) normal/ESRF</td>
<td>1–1.5 / 5.5–8</td>
</tr>
</tbody>
</table>

## Metabolism

Stavudine is metabolised intracellularly to the active antiviral triphosphate. Following an oral 80-mg dose of [14C]-stavudine to healthy subjects, approximately 95% and 3% of the total radioactivity was recovered in urine and faeces, respectively. Approximately 70% of the orally administered stavudine dose was excreted as unchanged drug in urine. However, in HIV-infected patients, 42% (range: 13–87%) of the dose is excreted unchanged in the urine, by active tubular secretion andglomerular filtration.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>&lt;60 kg dose</th>
<th>&gt;60 kg dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>26–50</td>
<td>15 mg twice daily; 20 mg twice daily</td>
<td></td>
</tr>
<tr>
<td>&lt;25</td>
<td>15 mg daily; 20 mg daily</td>
<td></td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs:
- Antivirals: zidovudine may inhibit intracellular activation – avoid; increased risk of side effects with didanosine – avoid; increased risk of toxicity with ribavirin.
- Cytotoxics: effects possibly inhibited by doxorubicin; increased risk of toxicity with hydroxycarbamide – avoid.
- Orlistat: absorption of stavudine possibly reduced.

## Administration

### Reconstitution

- Route: Oral
- Rate of administration: 
- Comments:
  - Administer at least an hour before food.

## Other information

- Oral bioavailability is 86%.
- Clearance by haemodialysis is 120 mL/min.
- Lactic acidosis, sometimes fatal, has been reported with the use of nucleoside analogues.
- Patients with ESRF are more likely to develop peripheral neuropathy.
Streptokinase

Clinical use

Fibrinolytic:
- Thrombolysis in DVT, PE, acute arterial thromboembolism, acute MI, thrombosed A-V shunts

Dose in normal renal function

- Loading dose: 250 000 IU followed by 100 000 IU/hour for 12–72 hours (refer to SPC)
- Myocardial Infarction: 1.5 MIU followed by aspirin
- Thrombosed HD shunts: 10–25 000 IU sealed in shunt and repeated after 30–45 minutes

Pharmacokinetics

- Molecular weight (daltons): 47 408
- % Protein binding: No data
- % Excreted unchanged in urine: 0
- Volume of distribution (L/kg): 0.02–0.08
- Half-life — normal/ESRF (hrs): 18 minutes / –

Metabolism

A small proportion of the dose is bound to anti-streptokinase antibodies and metabolised with a half-life of 18 minutes, whilst most of it forms the streptokinase-plasminogen activator complex and is biotransformed with a half-life of about 80 minutes.

Dose in renal impairment GFR (mL/min)

- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unlikely to be dialysed. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

Important drug interactions

Potentially hazardous interactions with other drugs

- Anticoagulants should not be given with streptokinase.
- Heparin infusions should be stopped 4 hours before streptokinase infusion. If this is not possible, protamine sulphate should be used to neutralise the heparin; heparin infusions can be restarted 4 hours post streptokinase infusion followed by oral anticoagulants.

Administration

Reconstitution
See manufacturer’s literature.

Route
IV

Rate of administration

- Give loading dose of 250 000 IU in 100 mL fluid over 30 minutes, followed by an appropriate volume for the maintenance dose.
- Give 1.5 MIU for acute MI in 50–200 mL fluid over 1 hour.

Comments

- For occluded HD shunts, add 100 000 IU to 100 mL sodium chloride 0.9% and put 10–25 mL into the clotted portion of the shunt.

Other information

- There are no significant changes in pharmacokinetics in patients with renal insufficiency. Dosage reduction is therefore not necessary.
- Manufacturer advises to use in severe renal impairment only if benefit outweighs the risks.
Streptomycin (unlicensed)

Clinical use

Antibacterial agent:
- Tuberculosis, in combination with other drugs
- Adjunct to doxycycline in brucellosis
- Enterococcal endocarditis
- Streptococcal endocarditis

Dose in normal renal function

- TB: <40 years and weight >50 kg: 15 mg/kg (maximum 1 g) daily or 3 times a week
- TB: >40 years or weight <50 kg: 500–750 mg daily or 750 mg 3 times a week
- Doses of 25–30 mg/kg up to a maximum of 1.5 g twice weekly may be used
- Non-Tuberculosis infections: 1–2 g daily in divided doses
- Enterococcal endocarditis: 1 g twice daily for 2 weeks, then 500 mg twice daily for a further 4 weeks, in combination with penicillin
- Streptococcal endocarditis: 1 g twice daily for 1 week, then 500 mg twice daily for 1 week, in combination with penicillin. If >60 years, 500 mg twice daily for 2 weeks
- Adjust doses according to levels

Pharmacokinetics

Molecular weight (daltons) 581.6 (1457.4 as sulphate)
% Protein binding 34–35
% Excreted unchanged in urine 29–89
Volume of distribution (L/kg) 0.26
Half-life — normal/ESRF (hrs) 2.5 / 100

Metabolism

It is rapidly excreted by glomerular filtration and the concentration of streptomycin in the urine is often very high, with about 30–90% of a dose usually being excreted within 24 hours.

Dose in renal impairment GFR (mL/min)

- 50–80: 1 g loading dose then 7.5 mg/kg every 24 hours. Dose according to levels.
- 10–49: 1 g loading dose then 7.5 mg/kg every 24–72 hours. Dose according to levels.
- <10: 7.5 mg/kg every 72–96 hours. Dose according to levels.

Dose in patients undergoing renal replacement therapies

- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. 50–75% of loading dose after each dialysis.
- HDF/High flux: Dialysed. 50–75% of loading dose after each dialysis.
- CAV/VVHD: Dialysed. Dose as in GFR=10–49 mL/min. See ‘Other information’.

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of nephrotoxicity with colistimethate or polymyxins and possibly cephalosporins; increased risk of ototoxicity and nephrotoxicity with capreomycin or vancomycin.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxics: increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Loop diuretics: increased risk of ototoxicity.
- Muscle relaxants: enhanced effects of non-depolarising muscle relaxants and suxamethonium.
- Parasympathomimetics: neostigmine and pyridostigmine antagonised by aminoglycosides.
- Tacrolimus: increased risk of nephrotoxicity.

Administration

Reconstitution
Dissolve 1 g in 2 or 3 mL water for injection.

Route
IM, IV

Rate of administration
In 100 mL sodium chloride 0.9% or glucose 5% over 30 minutes

Comments
In patients who experience tingling sensations or dizziness during administration, increase the infusion time to 60 minutes.

Other information

- Available on a named patient basis from Pfizer.
- Peak level taken 1 hour post dose and should be in the range 15–40 mg/Litre; trough level (taken pre dose) should be <5 mg/Litre, or <1 mg/Litre in renal impairment or those over 50 years of age.
- May be less nephrotoxic than other aminoglycosides.
• PD peritonitis dose is 20–40 mg/Litre/day.
• Risk of side effects increases after a cumulative dose of 100 g.
• A study in 4 patients used IV streptomycin at a dose of 7–15 mg/kg over 30–60 minutes without any problems, although IV administration did increase risk of toxicity.
• Due to the efficacy of twice weekly therapy, it is recommended that tuberculosis patients with severe renal impairment be given a dose of 750 mg 2–3 times a week for the first 2 months of treatment; trough levels should not exceed 4 mg/L. (Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. *Am Rev Respir Dis*. 1993; 148(3): 650–5.)
• Peak serum concentrations in individuals with renal impairment should not exceed 20–25 mcg/mL.
• Risk of severe neurotoxicity, irreversible vestibular damage and cochlear reactions is greatly increased in patients with impaired renal function; optic nerve dysfunction, peripheral neuritis, arachnoiditis and encephalopathy may also occur.
• There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
**Clinical use**

Treatment of post menopausal osteoporosis and men at high risk of fractures

**Dose in normal renal function**

2 g once daily

**Pharmacokinetics**

- Molecular weight (daltons) 513.5
- % Protein binding 25
- % Excreted unchanged in urine 66
- Volume of distribution (L/kg) 1
- Half-life — normal/ESRF (hrs) 60 / Increased

**Metabolism**

Strontium ranelate has a high affinity for bone tissue. It is not metabolised, and excretion occurs via the kidneys and gastrointestinal tract.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>See ‘Other information’.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unknown dialysability. Dose as in GFR<10 mL/min
- HD: Unknown dialysability. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Calcium-containing compounds: separate administration by at least 2 hours.
- Antacids: separate administration by at least 2 hours.

**Other information**

- Manufacturer advises to use with caution in severe renal impairment due to lack of bone safety studies.
- Give between meals as the absorption of strontium is reduced by food and milk products.
- Interferes with colorimetric methods of blood and urinary calcium concentrations.
- Give with calcium and vitamin D supplements.
- Steady state strontium levels are approximately 50% higher in patients with a GFR<25 mL/min compared to patients with normal renal function. No specific treatment effect was detected in patients with renal impairment (Cohen-Solal ME, Augry F, Mauras Y, et al. Fluoride and strontium accumulation in bone does not correlate with osteoid tissue in dialysis patients. *Nephrol Dial Transplant*. 2002; 17(3): 449–54.)
- Another study found that haemodialysis patients with osteomalacia developed high bone-strontium levels. (D’Haese PC, Schrooten I, Goodman WG, et al. Increased bone strontium levels in hemodialysis patients with osteomalacia. *Kidney Int*. 2000; 57(3): 1107–14.)
- Oral bioavailability is about 25%.
- An increased incidence of nervous system disorders has been seen in patients with severe renal impairment (GFR<25 mL/min). Steady state strontium concentrations are increased by 50% in severe renal impairment. Prescribing should be balanced against the risks and benefits of using the medication. (UKMI. Is strontium ranelate safe to use for patients with renal impairment? *Clin Pharmacist*. September 2013. 5(7): 204.)
## Clinical use
- Treatment of peptic ulcer and chronic gastritis
- Prophylaxis of stress ulceration in seriously ill patients

## Dose in normal renal function
- 4 g daily in 2–4 divided doses
- Prophylaxis of stress ulceration: 1 g 6 times daily
- Maximum 8 g daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>2086.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>3.5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

## Metabolism
Sucralfate is only slightly absorbed from the gastrointestinal tract after oral doses. However, there can be some release of aluminium ions and of sucrose sulphate; small quantities of sucrose sulphate may then be absorbed and excreted, mainly in the urine; some absorption of aluminium may also occur.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>4 g daily</td>
</tr>
<tr>
<td>10–20</td>
<td>2–4 g daily</td>
</tr>
<tr>
<td>&lt;10</td>
<td>2–4 g daily</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

### Potentially hazardous interactions with other drugs
- Reduced absorption of digoxin, tetracyclines, quinolones, coumarins, fosphenytoin and phenytoin – give 2 hours after sucralfate.

## Administration
**Reconstitution**
—
**Route**
Oral
**Rate of administration**
—
**Comments**
- Sucralfate exerts its action at the site of the ulcer, and is minimally absorbed (3–5%) from the GI tract as sucrose sulphate.
- In normal renal function, any aluminium which is absorbed is excreted in the urine.
- Tablets may be dispersed in 10–15 mL of water.

## Other information
- Sucralfate should be used with caution in renal impairment as aluminium may be absorbed and accumulate.
- In severe renal impairment and patients receiving dialysis, sucralfate should be used with extreme caution and only for short periods.
- Absorbed aluminium is bound to plasma proteins and is not dialysable.
- Use of other aluminium-containing products with sucralfate can increase the total body burden of aluminium.
Sucroferric oxyhydroxide (Velphoro)

**Clinical use**
Phosphate binder

**Dose in normal renal function**
500–1000 mg three times a day with meals

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>866.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Not absorbed</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>No data</td>
</tr>
</tbody>
</table>

**Metabolism**
The active moiety of sucroferric oxyhydroxide, pn-FeOOH, is not metabolised. However, the degradation product of sucroferric oxyhydroxide, mononuclear iron species, can be released from the surface of polynuclear iron(III)-oxyhydroxide and be absorbed. Elimination is totally via the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: reduced absorption of 4-quinolones and tetracyclines.
- Dimercaprol: avoid concomitant use.
- Mycophenolate: may significantly reduce absorption of mycophenolate.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**

- In two Phase 1 studies, it was concluded that the potential for iron overload is minimal and no dose-dependent effects were observed in healthy volunteers.
- Less than 1% of the dose is absorbed.
- Sucroferric oxyhydroxide does not affect guaiac based (Haemoccult) or immunological based (iColo Rectal and Hexagon Obtri) faecal occult blood tests.
Sulfadiazine

Clinical use

Antimicrobial agent:
• Toxoplasmosis in AIDS patients (unlicensed indication)
• Prevention of rheumatic fever

Dose in normal renal function

Loading dose: 2–4 g
Maintenance dose: up to 4 g daily in divided doses

Pharmacokinetics

Molecular weight (daltons) 250.3; 272.3 (as sodium salt)
% Protein binding 20–55
% Excreted unchanged in urine 80
Volume of distribution (L/kg) 0.29
Half-life — normal/ESRF (hrs) 17 / Prolonged

Metabolism

Sulfadiazine is metabolised in the liver to the acetylated form, with elimination predominantly via the kidneys. Urinary excretion of sulfadiazine and its acetyl derivative is dependent on pH; when the urine is acidic about 30% is excreted unchanged in both fast and slow acetylators, whereas when the urine is alkaline about 75% is excreted unchanged by slow acetylators.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use 50% of dose and monitor levels.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use 25% of dose and monitor levels.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
• Antibacterials: increased risk of crystalluria with methenamine.
• Anticoagulants: effect of coumarins enhanced; metabolism of phenindione possibly inhibited.
• Antiepileptics: antifolate effect and concentration of phenytoin increased.
• Antimalarials: increased risk of antifolate effect with pyrimethamine.
• Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).
• Ciclosporin: reduced levels of ciclosporin; increased risk of nephrotoxicity.
• Cytotoxics: increase risk of methotrexate toxicity.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information

• Contraindicated by manufacturer in severe renal impairment.
• Doses estimated from evaluation of pharmacokinetic data.
• Penetrates into the CSF within 4 hours of oral administration to produce therapeutic concentrations which may be more than half those in the blood.
• Crystalluria may be avoided by adequate hydration and alkalinising the urine to a pH >7.15.
• Blood concentrations of 100–150 micrograms/mL are desirable.
• For treatment of toxoplasmosis, use sulfadiazine in conjunction with pyrimethamine 25–100 mg daily.
## Sulfasalazine (sulphasalazine)

### Clinical use
- Ulcerative colitis
- Crohn’s disease
- Rheumatoid arthritis

### Dose in normal renal function
- Oral: 1–2 g 4 times daily, reduced to 0.5 g 4 times daily
- Suppositories: 0.5–1 g twice daily
- Rheumatoid arthritis: 0.5 g daily, increased to 1.5 g twice daily

### Pharmacokinetics
- Molecular weight (daltons) 398.4
- % Protein binding 95–99
- % Excreted unchanged in urine 10–15
- Volume of distribution (L/kg) 5.9–9.1
- Half-life — normal/ESRF (hrs) 18 / –

### Metabolism
After cleavage of the sulfasalazine molecule about 60 to 80% of available sulfapyridine is absorbed, and undergoes extensive metabolism in the liver by acetylation, hydroxylation, and glucuronidation.

Most of a dose of sulfasalazine is excreted in the urine. Unchanged sulfasalazine accounts for 15% of the original dose, sulfapyridine and its metabolites 60%, and 5-ASA and its metabolites 20–33%.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start at very low dose and monitor. Use with caution.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=10–20 mL/min.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Ciclosporin: may reduce ciclosporin levels.

### Administration

**Reconstitution**
- —

**Route**
- Oral, rectal

**Rate of administration**
- —

### Other information
- 15% of a dose of sulfasalazine is absorbed in the small intestine and becomes highly bound to plasma proteins. The remainder is split into sulfapyridine and 5-ASA by colonic bacteria. Sulfapyridine is rapidly absorbed from the colon, whereas 5-ASA is poorly absorbed.
- Unabsorbed drug is excreted in the faeces.
- In patients with moderate to severe renal impairment, toxicity includes increased risk of crystalluria – ensure high fluid intake.
Sulfinpyrazone

**Clinical use**

- Gout prophylaxis
- Hyperuricaemia

**Dose in normal renal function**

100–200 mg daily with food (or milk); maximum dose 600–800 mg

**Pharmacokinetics**

- Molecular weight (daltons) 404.5
- % Protein binding 98
- % Excreted unchanged in urine 22–42
- Volume of distribution (L/kg) 0.06
- Half-life — normal/ESRF (hrs) 2–4 / Unchanged

**Metabolism**

Sulfinpyrazone is partly metabolised in the liver and some of the metabolites are active. On long-term therapy, sulfinpyrazone induces its own metabolism. Unchanged drug and metabolites are mainly excreted in the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Initially 50% of dose. Use lower dose range.</td>
</tr>
<tr>
<td>10–20</td>
<td>Initially 50% of dose. Use lower dose range.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Not dialysed. Avoid. See ‘Other information’.
- HD: Not dialysed. Avoid. See ‘Other information’.
- HDF/High flux: Unknown dialysability. Avoid. See ‘Other information’.
- CAV/VVHD: Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anticoagulants: increased risk of bleeding with apixaban; enhances anticoagulant effect of coumarins; possibly increased risk of bleeding with dabigatran.
- Antidiabetics: enhances effect of sulphonylureas.
- Antiepileptics: increases concentration of fosphenytoin and phenytoin.
- Ciclosporin: may reduce ciclosporin levels.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - An adequate fluid intake of 2–3 Litres daily should be taken to reduce risk of uric acid renal calculi.
  - Uricosuric effects are lost when GFR<10 mL/min.
  - Reversible acute renal failure may occur especially with high initial doses.
  - Can cause salt and water retention.
  - In combination with aspirin, has been shown to improve vascular access thrombosis in haemodialysis patients, but there was an increased occurrence of gastrointestinal bleeding (Domoto DT, Bauman JE, Joist JH. Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. *Throm Res.* 1991; 62(6): 737–43.)
  - Doses in renal impairment are from *Drug Prescribing in Renal Failure*, 5th edition by Aronoff *et al.*
Sulindac

**Clinical use**

NSAID and analgesic

**Dose in normal renal function**

200 mg twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>356.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>7</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7.8 / 16.4</td>
</tr>
</tbody>
</table>

**Metabolism**

Sulindac is metabolised by reversible reduction to the sulfide metabolite, which appears to be the active form, and by irreversible oxidation to the sulfone metabolite. About 50% is excreted in the urine mainly as the sulfone metabolite and its glucuronide conjugate, with smaller amounts of sulindac and its glucuronide conjugate; about 25% appears in the faeces, primarily as sulfone and sulfide metabolites. Sulindac and its metabolites are also excreted in bile and undergo extensive enterohepatic circulation.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Avoid if possible.</td>
</tr>
<tr>
<td>10–20</td>
<td>Give 50–100% of normal dose. Avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Give 50–100% of normal dose, but only use if on dialysis.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

Reconstitution

- Route
  - Oral

Rate of administration

- Other information

- Sulindac has become the NSAID of choice in some centres for patients with renal impairment because of reports of its renal sparing effects. There is evidence
that this sparing effect is dose-related and is lost if doses above 100 mg twice daily are used.

- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid NSAIDs if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if increased, discontinue therapy.
- Use normal doses in patients with CKD 5 on dialysis if they do not pass any urine.
- Use with caution in renal transplant recipients (can reduce intrarenal autocoid synthesis).
Sulpiride

Clinical use
Antipsychotic:
  • Acute and chronic schizophrenia

Dose in normal renal function
200–400 mg twice daily increasing to maximum 2.4 g daily

Pharmacokinetics
Molecular weight (daltons) 341.4
% Protein binding 40
% Excreted unchanged in urine 90–95
Volume of distribution (L/kg) 1.2–1.7
Half-life — normal/ESRF (hrs) 8–9 / 26

Metabolism
Sulpiride undergoes little metabolism.
95% of a dose is excreted in the urine and faeces, mainly as unchanged drug.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Give 66% of normal dose, or increase dosing interval by factor of 1.5.</td>
</tr>
<tr>
<td>10–20</td>
<td>Give 50% of normal dose, or increase dosing interval by factor of 2.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Give 30% of normal dose, or increase dosing interval by factor of 3.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Partly dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
  • Anaesthetics: enhanced hypotensive effect.
  • Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
  • Anti-arrhythmics increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide and amiodarone – avoid with amiodarone.
  • Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and parenteral erythromycin – avoid with moxifloxacin.
  • Antidepressants: possibly increased risk of ventricular arrhythmias and antimuscarinic side effects with tricyclics – avoid.
  • Antiepileptics: antagonism (convulsive threshold lowered).
  • Antimalarials: avoid with artemether/lumefantrine.
  • Antipsychotics: increased risk of ventricular arrhythmias with droperidol, haloperidol and pimozide – avoid; possible increased risk of ventricular arrhythmias with risperidone.
  • Antivirals: concentration possibly increased by ritonavir.
  • Anxiolytics and hypnotics: increased sedative effects.
  • Atomoxetine: increased risk of ventricular arrhythmias.
  • Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol.
  • Cytotoxics: increased risk of ventricular arrhythmias with vandetanib – avoid; increased risk of ventricular arrhythmias with arsenic trioxide.
  • Diuretics: enhanced hypotensive effect.
  • Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
  • Pentamidine: increased risk of ventricular arrhythmias.

Administration

Reconstitution
—

Route
Oral

Rate of administration
—

Other information
• Administer with caution and decrease the dose in renal impairment.
Sumatriptan

Clinical use
5HT₁ receptor agonist:
- Acute relief of migraine

Dose in normal renal function
- Oral: 50–100 mg; maximum 300 mg in 24 hours
- SC: 6 mg; maximum 12 mg in 24 hours
- Intranasally: 10–20 mg; maximum 40 mg in 24 hours

Pharmacokinetics
Molecular weight (daltons) 295.4; 413.5 (as succinate)
% Protein binding 14–21
% Excreted unchanged in urine <20
Volume of distribution (L/kg) 170 Litres
Half-life — normal/ESRF (hrs) 2 / Probably unchanged

Metabolism
Sumatriptan is extensively metabolised in the liver mainly by monoamine oxidase type A and is excreted mainly in the urine as the inactive indole acetic acid derivative and its glucuronide.

Non-renal clearance accounts for about 80% of the total clearance. The remaining 20% is excreted in urine, mainly as metabolites, by active renal tubular secretion. Sumatriptan and its metabolites also appear in the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function. Use with caution.
<10 Dose as in normal renal function. Use with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Unknown dialysability. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: increased risk of CNS toxicity with citalopram, escitalopram, fluoxetine and fluvoxamine – avoid with citalopram; risk of CNS toxicity with MAOIs, moclobemide, SSRIs, sertraline, St John's Wort – avoid; possibly increased serotonergic effects with duloxetine and venlafaxine.
- Dapoxetine: possible increased risk of serotonergic effects – avoid for 2 weeks after stopping 5HT₁ agonists.
- Ergot alkaloids: increased risk of vasospasm – avoid.

Administration
Reconstitution
Injection is pre-filled into syringes ready for administration.

Route
Oral, SC, nasal

Rate of administration
—

Other information
Oral bioavailability is 14%.
Sunitinib

Clinical use
Tyrosine kinase inhibitor:
• Treatment of metastatic renal cell carcinoma (MRCC), gastrointestinal stromal tumours (GIST) and pancreatic neuroendocrine tumours (pNET)

Dose in normal renal function
• MRCC and GIST: 25–75 mg daily with a 2 week treatment free period within 6-week cycle
• pNET: 37.5–50 mg daily
• Consult relevant local protocol

Pharmacokinetics
Molecular weight (daltons) 532.6 (as malate)
% Protein binding 95
% Excreted unchanged in urine 16 (unchanged drug + metabolites)
Volume of distribution (L/kg) 2230 Litres
Half-life — normal/ESRF (hrs) 40–60 / Unchanged

Metabolism
Metabolised mainly via the cytochrome P450 isoenzyme CYP3A4 to its primary active metabolite, which itself is then further metabolised via CYP3A4. Elimination is primarily via faeces. In a human mass balance study of [14C]sunitinib, 61% of the dose was eliminated in faeces and 16% by the renal route.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
• Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
• Antivirals: avoid concomitant use with boceprevir.
• Avoid concomitant use with other inhibitors or inducers of CYP3A4. Dose alterations may be required.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Systemic exposures after a single dose of sunitinib were similar in subjects with severe renal impairment (CRCL<30 mL/min) compared to subjects with normal renal function (CRCL>80 mL/min). Although sunitinib and its primary metabolite were not eliminated through haemodialysis in subjects with ESRD, the total systemic exposures were lower by 47% for sunitinib and 31% for its primary metabolite compared to subjects with normal renal function.
# Suxamethonium chloride

## Clinical use
Depolarising muscle relaxant used in short procedures and ECT.

## Dose in normal renal function
- IV injection: 1–1.5 mg/kg
- IV infusion: 2–5 mg/minute; maximum 500 mg/hour
- IM: 2.5 mg/kg, to a maximum of 150 mg
- Dose depends on preparation

## Pharmacokinetics
- **Molecular weight (daltons)**: 397.3
- **% Protein binding**: 70
- **% Excreted unchanged in urine**: <10
- **Volume of distribution (L/kg)**: No data
- **Half-life — normal/ESRF (hrs)**: 2–3 minutes / –

## Metabolism
Suxamethonium is rapidly hydrolysed to succinylmonocholine a weak neuro-muscular blocking drug. This is metabolised to succinic acid with only a small amount excreted in the urine.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution. See ‘Other information’.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: increased risk of myocardial depression and bradycardia with propofol; enhanced effect with volatile liquid general anaesthetics.
- Anti-arrhythmics: lidocaine and procainamide enhance muscle relaxant effect.
- Antibacterials: effect enhanced by aminoglycosides, clindamycin, polymyxins, vancomycin and piperacillin.
- Cardiac glycosides: increased risk of ventricular arrhythmias.

## Administration
### Reconstitution
- **Route**: IV

### Rate of administration
- Over 10–30 seconds
- Infusion: 2.5–4 mg/minute, maximum 500 mg/hour

### Comments
For continuous infusion add 10 mL to 500 mL glucose 5% or sodium chloride 0.9% = 0.1% solution.

## Other information
- Suxamethonium is predominantly excreted in the urine as active and inactive metabolites. Patients on dialysis may require a dose at the lower end of the range due to reduced plasma cholinesterase activity.
- Use with caution in hyperkalaemia as potassium is released from depolarised muscle.
- Hyperkalaemia may occur when suxamethonium is used in CKD 5.
Tacrolimus

**Clinical use**

Immunosuppressive agent:
- Prophylaxis and treatment of acute rejection in liver, heart and kidney transplantation
- Treatment of moderate to severe atopic eczema

**Dose in normal renal function**

Oral: Initially:
- Liver transplantation: 100–200 mcg/kg/day in 2 divided doses
- Kidney transplantation: 200–300 mcg/kg/day in 2 divided doses
- Heart transplantation: 75 mcg/kg/day in 2 divided doses
- Advagraf:
  - Liver transplantation: 100–200 mcg/kg once daily
  - Renal transplantation: 200–300 mcg/kg once daily
- Envarsus:
  - Liver transplantation: 110–130 mcg/kg once daily
  - Renal transplantation: 170 mcg/kg once daily

IV:
- Liver transplantation: 10–50 mcg/kg as a continuous 24 hour infusion, starting 6 hours post surgery
- Kidney transplantation: 50–100 mcg/kg as a continuous 24 hour infusion, starting within 24 hours of surgery
- Heart transplantation: 10–20 mcg/kg as a continuous 24 hour infusion

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>822</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1300 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12–16 / Probably unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Tacrolimus is extensively bound to erythrocytes in the blood, and variations in red cell binding account for much of the variability in pharmacokinetics. It is extensively metabolised in the liver, mainly by cytochrome P450 isoenzyme CYP3A4, and excreted, primarily in bile, almost entirely as metabolites. Considerable metabolism also occurs in the intestinal wall.

There are several metabolites identified. Only one of these has been shown in *vitro* to have immunosuppressive activity similar to that of tacrolimus. The other metabolites have only weak or no immunosuppressive activity. In systemic circulation only one of the inactive metabolites is present at low concentrations. Therefore, metabolites do not contribute to pharmacological activity of tacrolimus.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- Ciclosporin: may increase the half-life of ciclosporin and exacerbate any toxic effects. The two should not be prescribed concomitantly. Care should be taken when converting from ciclosporin to tacrolimus.
- Tacrolimus levels increased by: amlodipine, atazanavir, basiliximab, boceprevir, bromocriptine, chloramphenicol, cimetidine, cortisone, danazol, dapsone, diltiazem, ergotamine, ethinyloestradiol, felodipine, fosamprenavir, gestodene, grapefruit juice, imidazole and triazole antifungals, lidocaine, lansoprazole, possibly levofloxacin, macrolides, midazolam, nicardipine, nifedipine, norethisterone, omeprazole, pantoprazole, posaconazole, ranolazine; ritonavir, saquinavir, Chinese herbal remedies containing extracts of *Schisandra sphenanthera*, tamoxifen, theophylline, verapamil and voriconazole.
- Tacrolimus levels decreased by: carbamazepine, caspofungin, fosphenytoin, isoniazid, phenobarbital, phenytoin (fosphenytoin and phenytoin levels possibly increased), primidone, rifampicin, possibly rifabutin and St John’s wort.
• Increased nephrotoxicity with: aminoglycosides, amphotericin, NSAIDs, sulfamethoxazole, trimethoprim and vancomycin.
• Increased risk of hyperkalaemia with: potassium-sparing-diuretics and potassium salts.
• Anticoagulants: possibly increases concentration of dabigatran – avoid.
• Antipsychotics: avoid with droperidol, increased risk of ventricular arrhythmias.
• Antivirals: increased risk of nephrotoxicity with acyclovir, ganciclovir, valaciclovir and valganciclovir; concentration affected by efavirenz; concentration of both drugs increased with telaprevir; concomitant use with dasabuvir and ombitasvir/paritaprevir/ritonavir is not recommended unless the benefits outweigh the risks, if used concomitantly, tacrolimus should not be administered on the day dasabuvir and ombitasvir/paritaprevir/ritonavir are initiated. Beginning the day after dasabuvir and ombitasvir/paritaprevir/ritonavir are initiated; reinitiate tacrolimus at a reduced dose based on tacrolimus levels. The recommended tacrolimus dosing is 0.5 mg every 7 days, monitor levels at initiation and throughout treatment.
• Clotrimazole: more than doubles the bioavailability of tacrolimus (US-based researchers report that concomitant clotrimazole substantially increases the relative oral bioavailability of tacrolimus in renal transplant recipients. *Inpharma*. 2005 Dec 10; 1517: 15).
• Cytotoxics: concentration of afatinib possibly increased – separate dose by 6–12 hours; use crizotinib with caution; concentration increased by imatinib.

---

### Administration

**Reconstitution**

---

**Route**

IV, oral, topical

**Rate of administration**

Continuous infusion over 24 hours

**Comments**

- Dilute in glucose 5% or sodium chloride 0.9% to a concentration of 4–100 micrograms/mL, i.e. 5 mg in 50–1000 mL.

Incompatible with PVC:

- Use infusion fluids in polyethylene or glass containers.
- Use giving sets as used for the administration of taxol.
- Contains polyethoxylated castor oil which has been associated with anaphylaxis.

**Other information**

- When converting from oral to IV, give one fifth of the total daily dose over 24 hours and monitor levels. Since administration is as a 24-hour infusion, a true 12-hour trough level will not be measured. Levels will therefore be expected to be slightly above the quoted ranges for oral tacrolimus.
- The different brands of oral tacrolimus are not interchangeable. Patients should ONLY be switched between brands under the close supervision of a transplant/renal unit and monitored appropriately.
- Approximate ranges:
  - Initially: liver: 5–10 ng/mL, renal: 8–15 ng/mL
  - Maintenance: 5–15 ng/mL
  - Oral bioavailability is 20–25%.
  - Also available as a 0.03% and 0.1% ointment for eczema and anal Crohn’s disease.
Tadalafil

**Clinical use**

Treatment of erectile dysfunction (ED)
Benign prostate hyperplasia (BPH)
Pulmonary arterial hypertension (PAH)

**Dose in normal renal function**

- ED: 10–20 mg, 30 minutes to 12 hours before sexual activity; maximum 1 dose per day
- BPH: 5 mg once daily
- PAH: 40 mg once daily

**Pharmacokinetics**

Molecular weight (daltons) 389.4
% Protein binding 94
% Excreted unchanged in urine 36
Volume of distribution (L/kg) 63 Litres
Half-life — normal/ESRF (hrs) 17.5 / Increased

**Metabolism**

Tadalafil is metabolised in the liver mainly by the cytochrome P450 isoenzyme CYP3A4. The major metabolite, the methylcatechol glucuronide, is inactive. Tadalafil is excreted, mainly as metabolites, in the faeces (61% of the dose), and to a lesser extent the urine (36% of the dose).

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>ED</th>
<th>BPH</th>
<th>PAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>5–10 mg not more than every 48 hours</td>
<td>2.5–5 mg daily</td>
<td>20–40 mg daily</td>
</tr>
<tr>
<td>10–30</td>
<td>5–10 mg not more than every 72 hours and use with caution</td>
<td>Avoid</td>
<td>Avoid</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5–10 mg not more than every 72 hours and use with caution</td>
<td>Avoid</td>
<td>Avoid</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Alpha-blockers: enhanced hypotensive effect – avoid concomitant use.
- Antibacterials: concentration possibly increased by clarithromycin and erythromycin; concentration reduced by rifampin – avoid.
- Antifungals: concentration increased by ketoconazole – avoid; concentration possibly increased by itraconazole.
- Antivirals: concentration possibly increased by fosamprenavir and indinavir; increased by ritonavir – avoid; increased risk of ventricular arrhythmias with saquinavir – avoid; avoid high doses of tadalafil with telaprevir.
- Cobicistat: concentration of tadalafil possibly increased – reduce dose of tadalafil.
- Nicorandil: possibly enhanced hypotensive effect – avoid concomitant use.
- Nitrates: enhanced hypotensive effect – avoid concomitant use.
- Riociguat: enhanced hypotensive effect – avoid concomitant use.

**Administration**

**Reconstitution**

- Route Oral

**Rate of administration**

- Other information

- Due to lack of trial data, manufacturer recommends a maximum on-demand dose for ED of 10 mg in severe renal impairment; in practice a higher dose may be used with caution.
- Manufacturer contraindicates use in severe renal impairment for BPH and PAH due to lack of studies and increased AUC.
- Protein binding is not affected by renal impairment.
Tamoxifen

Clinical use
- Treatment of breast cancer
- Anovulatory infertility

Dose in normal renal function
- Breast cancer: 20 mg daily
- Anovulatory infertility: 20–80 mg daily on days 2–5 of menstrual cycle

Pharmacokinetics
- Molecular weight (daltons): 371.5; (563.6 as citrate)
- % Protein binding: >99
- % Excreted unchanged in urine: 0
- Volume of distribution (L/kg): 20
- Half-life — normal/ESRF (hrs): 7 days / Probably unchanged

Metabolism
Tamoxifen is extensively metabolised by cytochrome P450 isoenzymes, to active metabolites that include N-desmethyltamoxifen, 4-hydroxytamoxifen, and 4-hydroxy-N-desmethyltamoxifen (endoxifen). Metabolism is by hydroxylation, demethylation and conjugation. In-vitro studies suggest that both N-desmethyltamoxifen and 4-hydroxytamoxifen are further metabolised to endoxifen. Elimination occurs, chiefly as conjugates with practically no unchanged drug, principally through the faeces and to a lesser extent through the kidneys.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins enhanced.
- Antidepressants: metabolism of tamoxifen to active metabolite possibly inhibited by fluoxetine and paroxetine – avoid.
- Antipsychotics: increased risk of ventricular arrhythmias with droperidol – avoid.
- Buproprion: metabolism of tamoxifen to active metabolite possibly inhibited – avoid.
- Cinacalcet: metabolism of tamoxifen to active metabolite possibly inhibited – avoid.

Administration
Reconstitution —
Route Oral
Rate of administration —

Other information
- Tamoxifen has been used for the treatment of sclerosing encapsulating peritonitis, at a dose of 20 mg daily. (Eltoum MA, Wright S, Atchley J, et al. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int. 2006; 26(2): 203–6.)
### Tamsulosin hydrochloride

#### Clinical use
Treatment of benign prostatic hyperplasia

#### Dose in normal renal function
400 mcg in the morning after breakfast

#### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>445</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>9</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4–5.5 (M/R: 10–15)</td>
</tr>
</tbody>
</table>

**Increased**

#### Metabolism
Tamsulosin is metabolised slowly in the liver primarily by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4; it is excreted mainly in the urine as metabolites and some unchanged drug.

#### Dose in renal impairment GFR (mL/min)
- **20–50**: Dose as in normal renal function.
- **10–20**: Dose as in normal renal function.
- **<10**: Dose as in normal renal function. Use with caution.

#### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Not dialysed. Dose as in GFR < 10 mL/min.
- **HD**: Not dialysed. Dose as in GFR < 10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR < 10 mL/min.
- **CAV/VVHD**: Not dialysed. Dose as in GFR = 10–20 mL/min.

#### Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antifungals: concentration increased by ketoconazole.
- Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect, avoid concomitant use.
- Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Moxisylyte: possibly severe postural hypotension.

#### Administration
**Reconstitution**
- **Route**
  - Oral

**Rate of administration**
- **—**

#### Other information
- Manufacturer advises to use with caution if GFR < 10 mL/min due to lack of studies.
- Swallow whole with 150 mL of water while sitting or standing.
- Protein binding is increased in renal impairment.
Tapentadol hydrochloride

Clinical use
μ-opioid receptor agonist with additional noradrenaline reuptake inhibition properties:
• Treatment of moderate to severe acute pain

Dose in normal renal function
• 50 mg every 4–6 hours, maximum dose 600 mg daily (700 mg on 1st day)
• SR: Initially 50 mg twice daily, maximum 500 mg daily

Pharmacokinetics
Molecular weight (daltons) 257.8
% Protein binding 20
% Excreted unchanged in urine 3
Volume of distribution (L/kg) 442–638 Litres
Half-life — normal/ESRF (hrs) 4 (SR: 5–6) / Probably increased

Metabolism
Approximately 97% of the parent compound is metabolised by conjugation with glucuronic acid to produce glucuronides. It is also metabolised, to a lesser extent, via the cytochrome P450 isoenzymes CYP2C9, CYP2C19, and CYP2D6, before further conjugation. None of the metabolites have analgesic activity. Approximately 70% of the dose is excreted in the urine in the conjugated form and 3% as unchanged drug.

Important drug interactions
Potentially hazardous interactions with other drugs
• Analgesics: possible opioid withdrawal with buprenorphine and pentazocine.
• Antidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use, and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics.
• Antihistamines: increased sedative effects with sedating antihistamines.
• Antipsychotics: enhanced hypotensive and sedative effects.
• Dopaminergics: avoid with selegiline.
• Nalmefene: avoid concomitant use.
• Sodium oxybate: enhanced effect of sodium oxybate – avoid concomitant use.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Not recommended by manufacturer in severe renal impairment due to lack of studies.
• Extreme caution with all opiates in patients with impaired renal function.
• Bioavailability is 32%.
• AUC and Cmax of tapentadol were comparable in subjects with varying degrees of renal function (from normal to severely impaired). In people with mild, moderate, and severe renal impairment, the AUC of tapentadol-O-glucuronide are 1.5, 2.5, and 5.5-fold higher compared with normal renal function, respectively.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Use small doses, extended dosing intervals. Titrate according to response.

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Probably dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Probably dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Probably dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>
**Tazocin (piperacillin / tazobactam)**

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

4.5 g every 6–8 hours

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>Piperacillin: 539.5,</td>
</tr>
<tr>
<td></td>
<td>Tazobactam: 322.3</td>
</tr>
<tr>
<td></td>
<td>(as sodium)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Piperacillin: 20–30,</td>
</tr>
<tr>
<td></td>
<td>Tazobactam: 20–30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Piperacillin: 60–80,</td>
</tr>
<tr>
<td></td>
<td>Tazobactam: 80</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Piperacillin: 0.18–0.3,</td>
</tr>
<tr>
<td></td>
<td>Tazobactam: 0.18–0.33</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Piperacillin: 1 / 4–6,</td>
</tr>
<tr>
<td></td>
<td>Tazobactam: 1 / 7</td>
</tr>
</tbody>
</table>

**Metabolism**

Piperacillin is metabolised to a minor microbiologically active desethyl metabolite. Tazobactam is metabolised to a single metabolite that has been found to be microbiologically inactive.

Piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion. Piperacillin, tazobactam, and desethyl piperacillin are also secreted into the bile.

**Dose in renal impairment GFR (mL/min)**

- **40–50**: Dose as in normal renal function
- **20–40**: 4.5 g every 8 hours.
- **<20**: 4.5 g every 12 hours.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;20 mL/min.</td>
</tr>
<tr>
<td>CAV/VVH</td>
<td>Dialysed. Dose as in GFR=20–40 mL/min or 2.25 g every 6 hours¹ or 4.5 g every 12 hours.</td>
</tr>
<tr>
<td>CVVHD/HDF</td>
<td>Dialysed: Dose as in GFR=20–40 mL/min or 2.25–3.375 g every 6 hours¹. See ‘Other information.’</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Reduced excretion of methotrexate – monitor methotrexate levels during concomitant treatment.
- Enhanced action of vecuronium and similar neuromuscular blocking agents.

**Administration**

**Reconstitution**

Reconstitute each 4.5 g with 20 mL sterile water for injection or sodium chloride 0.9%.

**Route**

- IV

**Rate of administration**

- IV bolus over 3–5 minutes (unlicensed)
- IV infusion over 30 minutes

**Comments**

May be given as an infusion in glucose 5% or sodium chloride 0.9%.

**Other information**

- Change in administration was due to pharmacokinetic data showing an improved MIC with the infusion, not due to safety issues. (Personal communication with Pfizer, January 2014.)
- Sodium content is 2.79 mmol/g of injection.
- Has been used intraperitoneally for treatment of PD peritonitis at a concentration of 250 mg/L.
- Patients with renal impairment are at a greater risk of neuromuscular excitability or convulsions that are associated with overdose.
- May cause in vitro inactivation of aminoglycosides.
- 6–21% is removed by peritoneal dialysis and 30–50% by haemodialysis plus an extra 5% as the metabolite.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline:
  - The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be
according to the GFR rather than using the dialysis recommendations.

Reference:
Tedizolid phosphate

**Clinical use**
Reversible non-selective MAO inhibitor:
- Antibacterial agent

**Dose in normal renal function**
200 mg once daily for 6 days

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>450.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>70–90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;3 (18 active and metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>67–80 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**
Tedizolid phosphate is converted by endogenous plasma and tissue phosphatases to the microbiologically active moiety, tedizolid.
Tedizolid is eliminated in excreta, primarily as a non-circulating sulfate conjugate. Following single oral administration of [14C]-labelled tedizolid under fasted conditions, the majority of elimination occurred via the liver with 81.5% of the radioactive dose recovered in faeces and 18% in urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>&lt;10% dialysed.(^1) Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alcohol: some alcoholic and de-alcoholised drinks contain tyramine which can cause hypertensive crisis.
- Alpha-blockers: avoid concomitant use with indoramin; enhanced hypotensive effect.
- Analgesics: CNS excitation or depression with pethidine, other opioids and nefopam – avoid; increased risk of serotonergic effects and convulsions with tramadol – avoid.
- Antidepressants: enhancement of CNS effects and toxicity; avoid MAOIs, SSRIs and vortioxetine for 2 weeks after use; care with all antidepressants.
- Antiepileptics: antagonism of anticonvulsant effect; avoid carbamazepine with or within 2 weeks of MAOIs.
- Antimalarials: avoid concomitant use with artemether/lumefantrine and piperaquine with arteminol.
- Antipsychotics: effects enhanced by clozapine.
- Atomoxetine: possible increased risk of convulsions – avoid concomitant use and for 2 weeks after use.
- Bupropion: avoid with or for 2 weeks after MAOIs.
- Dapoxetine: increased risk of serotonergic effects, avoid with or for 2 weeks after MAOIs.
- Dexamfetamine and lisdexamfetamine: risk of hypertensive crisis, avoid with or for 2 weeks after MAOIs.
- Dopaminergics: avoid concomitant use with entacapone and tolcapone; hypertensive crisis with levodopa and rasagiline – avoid for at least 2 weeks after stopping MAOI; hypotension with selegiline.
- 5HT\(_1\) agonist: risk of CNS toxicity with sumatriptan, rizatriptan and zolmitriptan – avoid sumatriptan and rizatirptan for 2 weeks after MAOI.
- Metaraminol: risk of hypertensive crisis, avoid with or for 2 weeks after MAOIs.
- Methylpapine: avoid concomitant use.
- Opicapone: avoid concomitant use.
- Sympathomimetics: hypertensive crisis with sympathomimetics – avoid.
- Tetrabenazine: risk of CNS excitation and hypertension – avoid.
### Administration

<table>
<thead>
<tr>
<th>Reconstitution</th>
<th>4 mL water for injection</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Route</strong></td>
<td>Oral, IV infusion</td>
</tr>
<tr>
<td><strong>Rate of administration</strong></td>
<td>60 minutes</td>
</tr>
<tr>
<td><strong>Comments</strong></td>
<td>Further dilute in 250 mL sodium chloride 0.9%</td>
</tr>
</tbody>
</table>

### Other information

- Oral bioavailability >90%.

Reference:

Teduglutide

**Clinical use**

Human glucagon-like peptide-2 (GLP-2):
- Treatment of short bowel syndrome

**Dose in normal renal function**

0.05 mg/kg once daily

**Pharmacokinetics**

- Molecular weight (daltons): 3752.1
- % Protein binding: No data
- % Excreted unchanged in urine: Majority
- Volume of distribution (L/kg): 0.103

**Metabolism**

The metabolism of teduglutide is not fully known. Since teduglutide is a peptide it is likely that it follows the principal mechanism for peptide metabolism. See 'Other information'.

**Dose in renal impairment GFR (mL/min)**

- 20–50: Reduce dose by 50%.
- 10–20: Reduce dose by 50%.
- <10: Reduce dose by 50%.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Potential for increased absorption of some medications. Monitor narrow therapeutic index drugs carefully.

**Administration**

**Reconstitution**
0.5 mL with solvent provided

**Route**
SC

**Rate of administration**
—

**Other information**

- Bioavailability is 88%.
- Fluid overload has been seen as a side effect in clinical trials.
- In a phase 1 study, the effect of renal impairment on the pharmacokinetics of teduglutide following subcutaneous administration of 10 mg teduglutide was investigated. With progressive renal impairment up to and including end-stage renal disease the primary pharmacokinetic parameters of teduglutide increased up to a factor of 2.6 (AUC<sub>inf</sub>) and 2.1 (C<sub>max</sub>) compared to healthy subjects.
- Following intravenous administration teduglutide plasma clearance was approximately 127 mL/hr/kg which is equivalent to the glomerular filtration rate. Renal elimination was confirmed in a study investigating pharmacokinetics in subjects with renal impairment. No accumulation of teduglutide was observed following repeated subcutaneous administrations.
**Clinical use**

Antineoplastic agent:
- Metastatic colorectal cancer

**Dose in normal renal function**

- Tegafur: 300 mg/m$^2$ with uracil: 672 mg/m$^2$ daily in 3 divided doses for 28 days then nothing for 7 days
- Consult relevant local protocol

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Tegafur / Uracil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>200.2 / 112.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>52 / Negligible</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;20</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>59 / 474 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>11 / 20–40 minutes / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Tegafur is an oral prodrug of 5-FU and uracil reversibly inhibits DPD, the primary catabolic enzyme for 5-FU. Metabolism occurs in the liver. Conversion of tegafur to 5-FU occurs via C-5' oxidation (microsomal enzymes) and C-2' hydrolysis (cytosolic enzymes). Microsomal oxidation of tegafur is partially mediated by CYP2A6. The cytosolic enzymes responsible for the metabolism of tegafur are not known. Other metabolic products of tegafur include 3'-hydroxy tegafur, 4'-hydroxy tegafur, and dihydro tegafur which are all significantly less cytotoxic than 5-FU. The metabolism of 5-FU formed from tegafur follows the intrinsic de novo pathways for the naturally occurring pyrimidine, uracil.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhances effect of coumarins.
- Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis.
- Folic acid: toxicity of tegafur increased.
- Metronidazole and cimetidine inhibit metabolism (increased toxicity).

**Administration**

**Reconstitution**

- Route
  - Oral

- Rate of administration

**Other information**

- Tegafur with uracil has not been studied in renal impairment but due to low renal clearance no dose adjustment is recommended. Use with care.
Teicoplanin

**Clinical use**
Antibacterial agent.

**Dose in normal renal function**

Loading dose: 6–12 mg/kg or 400–800 mg every 12 hours for 3–5 doses (depends on indication), then 6–12 mg/kg/day

*C Difficile*: 100–200 mg twice daily orally for 10–14 days

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>1875–1891</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>90–95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&gt;97</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.94–1.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>150 / 62–230</td>
</tr>
</tbody>
</table>

**Metabolism**

Teicoplanin is excreted almost entirely by glomerular filtration in the urine, as unchanged drug. Two metabolites are formed probably by hydroxylation and represents 2–3% of the administered dose. Unchanged teicoplanin is mainly excreted by the urinary route while 2.7% of the administered dose is recovered in feces (via bile excretion) within 8 days following administration.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–80</td>
<td>Give normal loading dose, then reduce after 4th day to half of the dose daily or normal dose every 48 hours.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Give normal loading dose, then reduce after 4th day to a third of the dose daily or normal dose every 72 hours. See 'Other information'</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed.1 Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR&lt;30 mL/min. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- None known

**Administration**

**Reconstitution**

Use water for injection provided.

**Route**

IV, IM

**Rate of administration**

IV bolus: 2–3 minutes; IV infusion: 30 minutes

**Comments**

USE IN CAPD

- Give 6 mg/kg IV stat dose, then 20 mg/L/bag IP for 7 days, then 20 mg/L/alternate-bag for 7 days, then 20 mg/L/night-bag only for 7 days.

**Other information**

- Aim for troughs not less than 10 mg/L when measured by High Performance Liquid Chromatography (HPLC), or at least 15 mg/L when measured by Fluorescence Polarisation Immunoassay (FPIA) method. For endocarditis and other severe infections, teicoplanin trough levels of 15–30 mg/L when measured by HPLC, or 30–40 mg/L when measured by FPIA method should be aimed for.
- Long-term concurrent use of gentamicin and teicoplanin causes additive ototoxicity.
- Doses up to 600 mg three times a week have been used in HDF patients in severe infections.
- Teicoplanin is excreted almost entirely by glomerular filtration in the urine, as unchanged drug. No metabolites have been identified.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient's GFR is equated to the total fluid 'flux' within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Reference:

Telaprevir

**Clinical use**
HCV-protease inhibitor:
- Treatment of hepatitis C with compensated liver disease

**Dose in normal renal function**
750 mg every 8 hours or 1.125 g twice daily with food

**Pharmacokinetics**
Molecular weight (daltons) 679.8
% Protein binding 59–76
% Excreted unchanged in urine 1
Volume of distribution (L/kg) 252 Litres
Half-life — normal/ESRF (hrs) 9–11 / –

**Metabolism**
Extensively metabolised in the liver, involving hydrolysis, oxidation, and reduction.
Multiple metabolites were detected in faeces, plasma and urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Possibly dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Possibly dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Possibly dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Possibly dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alpha-blockers: avoid with alfuzosin.
- Analgesics: risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: risk of ventricular arrhythmias with amiodarone and disopyramide – avoid; risk of ventricular arrhythmias with flecainide and propafenone – use with caution; use IV lidocaine with caution.
- Antibacterials: concentration of both drugs increased with clarithromycin, erythromycin and telithromycin, increased risk of ventricular arrhythmias; avoid with rifabutin and rifampicin (concentration significantly reduced by rifampicin).
- Anticoagulants: concentration of warfarin possibly affected; avoid with apixaban; possibly increased dabigatran concentration.
- Antidepressants: possibly increased trazodone concentration; avoid with St John’s wort.
- Antiepileptics: avoid with carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: concentration of both drugs possibly increased with ketoconazole, increased risk of ventricular arrhythmias; possibly increased itraconazole concentration; possibly increased posaconazole concentration – increased risk of ventricular arrhythmias; possibly altered voriconazole concentration – increased risk of ventricular arrhythmias.
- Antipsychotics: avoid with pimozide; possibly increased lurasidone and quetiapine concentration – avoid.
- Antivirals: concentration possibly reduced by atazanavir; concentration of atazanavir possibly increased; avoid with darunavir, fosamprenavir and lopinavir; concentration of daclatasvir and possibly olaparib increased – reduce daclatasvir and olaparib dose; concentration reduced by efavirenz – increase telaprevir dose; concentration possibly reduced by ritonavir; concentration of tenofovir possibly increased.
- Anxiolytics and hypnotics: possibly increased midazolam concentration – risk of prolonged sedation, avoid concomitant use with oral midazolam.
- Beta-blockers: risk of ventricular arrhythmias with sotalol – avoid.
- Ciclosporin: concentration of both drugs increased, reduce ciclosporin dose.
- Cilostazol: possibly increases cilostazol concentration.
- Colchicine: possibly increased risk of colchicine toxicity – suspend or reduce colchicine dose, avoid in hepatic or renal impairment.
- Cytotoxics: possibly increases bosutinib concentration – avoid or consider reducing dose of bosutinib; reduce dose of ruxolitinib.
• Domperidone: possibly increased risk of ventricular arrhythmias – avoid.
• Ergot alkaloids: avoid concomitant use.
• Guanfacine: possibly increases guanfacine dose – halve dose of guanfacine.
• Lipid-regulating drugs: avoid with lomitapide, simvastatin and atorvastatin.
• Oestrogens: possibly reduced ethinylestradiol concentration and contraceptive effect.
• Sildenafil: avoid concomitant use.
• Sirolimus: concentration of both drugs increased, reduce sirolimus dose.
• Beta₂-sympathomimetics: avoid with salmeterol – risk of ventricular arrhythmias.
• Tacrolimus: concentration of both drugs increased, reduce tacrolimus dose.
• Tadalafil: avoid with high dose tadalafil.
• Vardenafil: avoid concomitant use.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

• The pharmacokinetics of telaprevir were assessed after administration of a single dose of 750 mg to HCV-negative subjects with severe renal impairment (CRCL<30 mL/min). The mean telaprevir $C_{\text{max}}$ and AUC were 10% and 21% greater, respectively, compared to healthy subjects.
Telavancin

**Clinical use**

Glycopeptide antibacterial agent:
- Treatment of MRSA hospital acquired pneumonia

**Dose in normal renal function**

- 10 mg/kg once daily for 7–21 days
- BMI > 30 kg/m²: 7.5 mg/kg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1755.7 (1792.1 as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>64–76</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.133</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8 / 14.5</td>
</tr>
</tbody>
</table>

**Metabolism**

*In vitro* studies have shown that CYP1A1, 1A2, 2B6, 2C18, 2C19, 2D6, 2E1, 2J2, 3A4, 3A5 and 4F12 are able to metabolise telavancin, resulting in hydroxylation at the 7, 8 and 9 position of the 2-(decylamino) ethyl side chain of telavancin.

In a mass balance study in male subjects using radiolabelled telavancin, 3 hydroxylated metabolites were identified with the predominant metabolite (THRX-651540) accounting for <10% of the radioactivity in urine and <2% of the radioactivity in plasma.

Renal excretion is the major route of elimination for telavancin in humans. In healthy young adults, after infusion of radiolabelled telavancin, approximately 76% of the administered dose was recovered from urine and less than 1% of the dose was recovered from faeces (collected for up to 9 days), based on total radioactivity.

Telavancin is mainly excreted unchanged accounting for approximately 82% of the total amount recovered over 48 hours in urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR range (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>7.5 mg/kg daily</td>
</tr>
<tr>
<td>10–30</td>
<td>10 mg/kg every 48 hours</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR &lt; 10 mL/min</td>
</tr>
<tr>
<td>HD</td>
<td>5.9% dialysed. Dose as in GFR &lt; 10 mL/min</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR &lt; 10 mL/min</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR = 10–30 mL/min. See 'Other information.'</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Vaccines: antibacterials inactivate oral typhoid vaccine.

**Administration**

**Reconstitution**
15 mL per 250 mg vial with glucose 5%, sodium chloride 0.9%, water for injection

**Route**
IV infusion

**Rate of administration**
Over 60 minutes

**Comments**
- Dilute 150–800 mg in 100–250 mL sodium chloride 0.9%, glucose 5%, Ringers solution.
- Doses > 800 mg dilute to a concentration of 0.6–8 mg/mL.

**Other information**

- 5.9% removed after 4 hours of haemodialysis.
- Contraindicated by UK manufacturer if CRCL < 30 mL/min or on dialysis. In the clinical studies, patients with pre-existing AKI receiving telavancin had an increased risk of mortality. All-cause mortality was 44% in the telavancin group and 25% in the vancomycin group, whereas in patients without AKI at baseline it was 17% and 18%, respectively.
- Dose in GFR = 10–30 mL/min is from US data sheet.
- Renal function should be measured daily for the first 3–5 days of treatment and every 48–72 hours thereafter.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline:
The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g., blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Telbivudine

Clinical use
Treatment of chronic Hepatitis B infection

Dose in normal renal function
600 mg daily

Pharmacokinetics
Molecular weight (daltons) 242.2
% Protein binding 3.3
% Excreted unchanged in urine 42
Volume of distribution (L/kg) No data
Half-life — normal/ESRF (hrs) 30–53.6 / Increased

Metabolism
Telbivudine is not metabolised. It is eliminated primarily by urinary excretion of unchanged substance.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Tablet</th>
<th>Oral solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>600 mg every 48 hours</td>
<td>400 mg daily</td>
</tr>
<tr>
<td>&lt;30</td>
<td>600 mg every 72 hours</td>
<td>200 mg daily</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Method</th>
<th>Tablet</th>
<th>Oral solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD Dialysed</td>
<td>600 mg every 96 hours</td>
<td>120 mg daily</td>
</tr>
<tr>
<td>HD Dialysed</td>
<td>600 mg every 96 hours</td>
<td>120 mg daily</td>
</tr>
<tr>
<td>HDF/High flux Dialysed</td>
<td>600 mg every 96 hours</td>
<td>120 mg daily</td>
</tr>
<tr>
<td>CAV/VVHD Dialysed</td>
<td>Dose as in GFR &lt; 30 mL/min</td>
<td>120 mg daily</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Interferons: increased risk of peripheral neuropathy.

Administration
Reconstitution

Route
Oral

Rate of administration

Other information
- Dosage guidelines are from the company and have not been tested so adjust the dose according to virological response and monitor for side effects.
- Has been associated with myopathy and myalgia.
- 4 hours of haemodialysis removes 23% of the dose.
## Telmisartan

### Clinical use
Angiotensin-II antagonist:
- Hypertension
- Prevention of cardiovascular events

### Dose in normal renal function
- Hypertension: 20–80 mg daily
- Prevention of cardiovascular events: 80 mg daily

### Pharmacokinetics
- Molecular weight (daltons) 514.6
- % Protein binding >99.5
- % Excreted unchanged in urine >1
- Volume of distribution (L/kg) 500 Litres
- Half-life — normal/ESRF (hrs) 24 / Unchanged

### Metabolism
Telmisartan is metabolised by conjugation to the glucuronide of the parent compound. No pharmacological activity has been shown for the conjugate. Telmisartan is excreted almost entirely in the faeces via bile, mainly as unchanged drug.

### Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Start with 20 mg and adjust according to response.

### Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal impairment with ACE-Is and aliskiren.
- Cardiac glycosides: concentration of digoxin increased.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

### Administration

#### Reconstitution
—

#### Route
Oral

#### Rate of administration
—

### Other information
- Hyperkalaemia and other side effects are more common in patients with impaired renal function.
- Close monitoring of renal function required during therapy in patients with renal insufficiency.
- Renal failure has been reported in association with angiotensin-II inhibitors in patients with renal artery stenosis, post renal transplant, and those with congestive heart failure.
- Oral bioavailability is 42–58% depending on dose.
**Clinical use**

Benzodiazepine:
- Insomnia (short-term use)
- Pre-med anxiolytic prior to minor procedures

**Dose in normal renal function**

- 10–40 mg at night
- Premedication: 20–40 mg, 60 minutes prior to procedure

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>300.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>96</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.3–1.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7–11 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Temazepam is metabolised mainly in the liver. It is excreted mainly in the urine in the form of its inactive glucuronide conjugate together with small amounts of the demethylated derivative, oxazepam, also in conjugated form.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Start with small doses.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with small doses.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- Antibacterials: metabolism possibly increased by rifampicin.
- Antipsychotics: increased sedative effects; risk of serious adverse effects in combination with clozapine.
- Antivirals: concentration possibly increased by ritonavir.
- Disulfiram: metabolism of temazepam inhibited (increased toxicity).
- Sodium oxybate: enhanced effects of sodium oxybate – avoid.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Increased CNS sensitivity in renal impairment.
- Long-term use may lead to dependence and withdrawal symptoms in certain patients.
- 80% of metabolites excreted in the urine.
Temocillin

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
1–2 g every 12 hours

**Pharmacokinetics**
- Molecular weight (daltons) 458.4 (as sodium salt)
- % Protein binding 75–85
- % Excreted unchanged in urine 90
- Volume of distribution (L/kg) 0.23
- Half-life — normal/ESRF (hrs) 3.1–5.4 / 28.2

**Metabolism**
Temocillin is excreted unchanged mainly in the kidney.

**Dose in renal impairment GFR (mL/min)**
- 30–60 1 g every 12 hours. See ‘Other information’.
- 10–30 1 g daily. See ‘Other information’.
- <10 1 g every 48 hours or 500 mg daily. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min. See ‘Other information’.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min. See ‘Other information’.
- CAV/VVHD Dialysed. Dose as in GFR=10–30 mL/min. See ‘Other information’.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Temocillin can reduce the excretion of methotrexate (increased risk of toxicity).

**Route**
IV, IM

**Rate of administration**
Slow IV bolus over 3–4 minutes
Infusion over 30–40 minutes

**Comments**
Incompatible with proteins, blood products, lipid emulsions and aminoglycosides.

**Other information**
- Bleeding has occurred in some patients (more likely in those with renal impairment).
- 20% is removed by haemodialysis and 17–26% by peritoneal dialysis.
- A study has shown that temocillin is efficacious when administered post dialysis at a dose of 2 g for the short break and 3 g before the long break between haemodialysis sessions. (Vandecasteele SJ, Bastos MAC, Capron A, et al. Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. *Int J Antimicrob Agents*. 2015; 46(6) 660–5.)
- A study in Dundee looked at the safety and effectiveness of temocillin for urinary sepsis in patients with renal impairment and found it a safe and effective treatment. (Oliver S, Kennedy H, Nathwan D, et al. Presented at the SRA 12th November 2011, Glasgow.)
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
- An alternative dosing regimen used by some units is:

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>1–2 g daily</td>
</tr>
<tr>
<td>&lt;10</td>
<td>1–2 g every 48 hours</td>
</tr>
</tbody>
</table>

**Administration**

**Reconstitution**
- IV: Dissolve in 20 mL water for injection.
- IV infusion: Dilute in 50–100 mL sodium chloride 0.9%.
- IM: Dissolve in 2 mL water for injection or lidocaine 0.5–1% (volume 2.7 mL).
Temozolomide

**Clinical use**

Antineoplastic agent:
- Glioblastoma multiforme
- Malignant glioma

**Dose in normal renal function**

- 75 mg/m² daily for 42 days with radiotherapy
- Adjuvant phase/monotherapy: 150–200 mg/m² once daily for 5 days
- Or according to local policy

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>194.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>10–20</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5–10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.3–0.5 (IV) (15–18 L/m² oral)</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.8 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Temozolomide undergoes spontaneous hydrolysis to its active metabolite 5-(3-methyl-triazen-1-yl)-imidazole-4-carboxamide (MTIC), which is then further hydrolysed to 5-amino-imidazole-4-carboxamide (AIC) and methylhydrazine. Temozolomide is largely eliminated by the kidneys, about 5–10% as unchanged drug.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Do not administer with food.</td>
</tr>
</tbody>
</table>

**Other information**

- Nadir for white cell count usually occurs 21–28 days after a dose, with recovery within 1–2 weeks.
- Rapidly and completely absorbed with 100% bioavailability and has extensive tissue distribution.
- Manufacturer advises to use with caution in severe renal failure due to lack of data but pharmacokinetics indicate that no dose change should be required.
Temsirilimus

Clinical use
Protein kinase inhibitor:
- Treatment of advanced renal cell carcinoma
- Treatment of mantle cell lymphoma

Dose in normal renal function
- Renal cell carcinoma: 25 mg once weekly
- Mantle cell lymphoma: 175 mg once weekly for 3 weeks then weekly doses of 75 mg

Pharmacokinetics
Molecular weight (daltons) 1030.3
% Protein binding 87
% Excreted unchanged in urine 4.6
Volume of distribution (L/kg) 172 Litres
Half-life — normal/ESRF (hrs) 17.7 / –

Metabolism
Mainly metabolised by cytochrome P450 isoenzyme CYP3A4 to 5 metabolites; sirolimus is the main active metabolite, there is increased exposure to sirolimus compared with temsirolium due to longer half-life of sirolimus.
Elimination is mainly in faeces; about 5% is recovered in the urine.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function. Use with caution.
<10 Use with caution.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration increased by clarithromycin and telithromycin – avoid; concentration of both drugs increased with erythromycin; concentration of active metabolite reduced by rifampicin and rifabutin – avoid.
- Antifungals: concentration increased of active metabolite increased by ketoconazole – avoid; concentration increased by fluconazole, itraconazole, miconazole, micafungin, posaconazole and voriconazole – avoid with itraconazole.
- Antipsychotics: increased risk of agranulocytosis with clozapine – avoid concomitant use.
- Antivirals: concentration possibly increased by atazanavir, boceprevir and lopinavir; concentration of both drugs increased with telaprevir.
- Calcium-channel blockers: concentration increased by diltiazem; concentration of both drugs increased with verapamil.
- Ciclosporin: increased absorption of temsirolium – give temsirolium 4 hours after ciclosporin; temsirolium concentration increased; long term concomitant administration may be associated with deterioration in renal function.
- Cytotoxics: use crizotinib with caution.
- Grapefruit juice: concentration of temsirolium increased – avoid.
- Mycophenolate: concomitant use of mycophenolate and sirolimus increases plasma levels of both temsirolium and mycophenolic acid.

Administration
Reconstitution
1.8 mL of diluent
Route
IV
Rate of administration
30–60 minutes
Comments
- Add to 250 mL sodium chloride 0.9% after dilution with diluent.
- Protect from light. Avoid PVC equipment.
- Administer through an infusion set with an in-line filter with a maximum pore size of 5 microns within 6 hours of being added to sodium chloride 0.9%.
Other information

- Use with caution as limited clinical experience of temsirolimus in renal impairment.
- Approximately 30 minutes before each dose patients should receive 25–50 mg of IV diphenhydramine or similar antihistamine.
- Associated with abnormal wound healing.
- May increase blood glucose levels.
- May commonly increase creatinine levels.
## Tenecteplase

### Clinical use

**Thrombolytic:**
- Acute myocardial infarction

### Dose in normal renal function

30–50 mg depending on patient weight (500–600 micrograms/kg)

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>70 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>6.1–9.1 Litres¹ (weight and dose related)</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>90–130 minutes / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Tenecteplase is cleared from circulation by binding to specific receptors in the liver followed by catabolism to small peptides.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs
- Drugs that affect coagulation or platelet function: increased risk of bleeding.

### Administration

**Reconstitution**
Water for injection

**Route**
IV

**Rate of administration**
Over 10 seconds

**Comments**
Incompatible with dextrose

### Other information

- It has an initial half-life of 20–24 minutes.
- Cleared mainly by hepatic metabolism.
- Re-administration is not recommended due to lack of experience.

### Reference

Tenofovir disoproxil

### Clinical use

Nucleoside reverse transcriptase inhibitor:
- Treatment of HIV in combination with other antiretroviral drugs
- Treatment of hepatitis B in compensated liver disease

### Dose in normal renal function

245 mg once daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>635.5 (as disoproxil fumarate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>0.7–7.2</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>IV: 70–80; oral: 32</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.8</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12–18 / Increased</td>
</tr>
</tbody>
</table>

### Metabolism

Tenofovir is excreted mainly in the urine by both active tubular secretion and glomerular filtration.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>245 mg every 48 hours or 132 mg (4 scoops) once daily.</td>
<td></td>
</tr>
<tr>
<td>20–30</td>
<td>245 mg every 72–96 hours or 66 mg (2 scoops) once daily.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>245 mg every 72–96 hours or 33 mg (1 scoop) once daily.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>245 mg every 72–96 hours or 33 mg (1 scoop) once daily.</td>
<td>Use with caution.1</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. 245 mg every 7 days or 16.5 mg (0.5 of a scoop) once daily.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. 245 mg every 7 days or after a total of 12 hours dialysis or 16.5 mg (0.5 of a scoop) once daily.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. 245 mg every 7 days or after a total of 12 hours dialysis or 16.5 mg (0.5 of a scoop) once daily.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=20–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antivirals: avoid with adefovir and cidofovir; reduces concentration of atazanavir, also concentration of tenofovir possibly increased; increased didanosine concentration resulting in increased toxicity (e.g. pancreatitis and lactic acidosis) – avoid; concentration increased by lopinavir and telaprevir.
- Co-administration with other drugs that are actively secreted via the tubular anionic transporter.
- Orlistat: absorption possibly reduced by orlistat.

### Administration

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

### Other information

- Manufacturer has no studies on the use of tenofovir in non-haemodialysis patients with GFR<10 mL/min. Use with caution as doses are based on limited data and may not be optimal.
- Lactic acidosis, sometimes fatal, and usually associated with severe hepatomegaly and steatosis, has been reported in patients receiving nucleoside reverse transcriptase inhibitors.
- Following a single 300 mg dose of tenofovir, subjects with a calculated CRCL<50 mL/min, and those with ESRF requiring dialysis, had substantial reductions in renal elimination of tenofovir, resulting in high systemic exposures necessitating an adjustment in dose.
- A 4-hour high-flux haemodialysis session was found to remove 10% of tenofovir from plasma.
- Renal impairment, which may include hypophosphataemia, has been reported with the use of tenofovir. The majority of these cases occurred in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents – monitor creatinine clearance and phosphate levels.

### Reference

Tenoxicam

Clinical use

NSAID and analgesic

Dose in normal renal function

20 mg once daily

Pharmacokinetics

Molecular weight (daltons) 337.4
% Protein binding 99
% Excreted unchanged in urine <1 (67% as metabolites and unchanged drug)
Volume of distribution (L/kg) 10–12 Litres
Half-life — normal/ESRF (hrs) 72 / –

Metabolism

Metabolised in the liver via cytochrome P450 2C9 to several pharmacologically inactive metabolites (mainly 5’-hydroxy-tenoxicam). Metabolites are excreted mainly in the urine; there is some biliary excretion of glucuronide conjugates of the metabolites.

Dose in renal impairment GFR (mL/min)

20–50 Dose as in normal renal function, but avoid if possible.
10–20 Dose as in normal renal function, but avoid if possible.
<10 Dose as in normal renal function, but only use if on dialysis.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min. See ‘Other information’.
HD Unlikely to be dialysed. Dose as in GFR<10 mL/min. See ‘Other information’.
HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min. See ‘Other information’.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs

- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

Administration

Reconstitution

—

Route

Oral, (IV, IM – unlicensed)

Rate of administration

—

Other information

- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine
984  Tenoxicam

48–72 hours after starting NSAID – if serum creatinine is increased, stop NSAID.
- Use normal doses in patients with CKD 5 if on dialysis and do not pass any urine.

- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
**Terazosin**

**Clinical use**

Alpha-adrenoceptor blocker:
- Hypertension
- Benign prostatic hyperplasia (BPH)

**Dose in normal renal function**

- Hypertension: 1–20 mg once daily
- BPH: 1–10 mg once daily

**Pharmacokinetics**

Molecular weight (daltons) 459.9
% Protein binding 90–94
% Excreted unchanged in urine 10
Volume of distribution (L/kg) 0.5–0.9
Half-life — normal/ESRF (hrs) 9–12 / Unchanged

**Metabolism**

Terazosin is metabolised in the liver; one of the metabolites has antihypertensive activity.
Terazosin is excreted in faeces via the bile, and in the urine, as unchanged drug and metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD** Not dialysed. Dose as in normal renal function.
- **HD** Not dialysed. Dose as in normal renal function.
- **HDF/High flux** Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD** Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect — avoid concomitant use.
- Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
- Moxisylyte: possibly severe postural hypotension when used in combination.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Therapy should be initiated with a single dose of 1 mg given at bedtime.
Terbinafine

Clinical use

Antifungal agent:
- Fungal infections of the skin and nails

Dose in normal renal function

250 mg daily
Topical: apply once or twice daily

Pharmacokinetics

Molecular weight (daltons) 291.4 (327.9 as hydrochloride)
% Protein binding 99
% Excreted unchanged in urine 0
Volume of distribution (L/kg) 6–11
Half-life — normal/ESRF (hrs) 17–36 / Increased

Metabolism

Terbinafine undergoes extensive first pass loss. It is hepatically metabolised to two major inactive metabolites, 80% of which are renally excreted.

Dose in renal impairment GFR (mL/min)

20–50 100% on alternate days.
10–20 100% on alternate days.
<10 100% on alternate days.

Dose in patients undergoing renal replacement therapies

APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: concentration reduced by rifampicin.

Administration

Reconstitution
—
Route
Oral, topical
Rate of administration
—

Other information

- Oral bioavailability is 40%.
- Manufacturer contraindicates use in severe renal impairment due to lack of studies in UK SPC but not US data sheet.
- Clearance is reduced by 50% if GFR<50 mL/min.
- In CKD 5 use with caution and monitor for side effects.

References:
Terbutaline sulphate

### Clinical use

Beta₂-adrenoceptor agonist:
- Reversible airways obstruction

### Dose in normal renal function

- Oral: 2.5–5 mg 3 times daily
- SC/IM/IV: 250–500 micrograms up to 4 times daily
- IV infusion: 90–300 micrograms/hour
- Turbohaler: 500 micrograms (1 inhalation) up to 4 times daily
- Nebulisation: 5–10 mg 2–4 times daily, or more frequently

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>548.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>15–25</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>55–60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.9–1.5</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>16–20 / –</td>
</tr>
</tbody>
</table>

### Metabolism

Terbutaline undergoes extensive first-pass metabolism by sulphate (and some glucuronide) conjugation in the liver and the gut wall. It is excreted in the urine and faeces partly as the inactive sulphate conjugate and partly as unchanged terbutaline, the ratio depending upon the route by which it is given.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

- APD/CAPD: Likely dialysability. Dose as in normal renal function.
- HD: Likely dialysability. Dose as in normal renal function.
- HDF/High flux: Likely dialysability. Dose as in normal renal function.
- CAV/VVHD: Likely dialysability. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs:
- Effect may be diminished by beta-blockers.
- Theophylline: increased risk of hypokalaemia.

### Administration

**Reconstitution**

**Route**

IV, SC, IM, oral, inhaled, nebulised

**Rate of administration**

1.5–5 mcg/minute

**Comments**

For IV infusion, add 1.5–2.5 mg to 500 mL glucose 5% or sodium chloride 0.9% (3–5 micrograms/mL).
Teriflunomide

Clinical use
Immunomodulating agent:
• Treatment of relapsing remitting multiple sclerosis

Dose in normal renal function
14 mg daily

Pharmacokinetics
Molecular weight (daltons) 270.2
% Protein binding >99
% Excreted unchanged in urine 22.6 (as metabolites)
Volume of distribution (L/kg) 11 Litres
Half-life — normal/ESRF (hrs) 18–19 days / Unchanged

Metabolism
Teriflunomide is the active metabolite of leflunomide. It is moderately metabolised and teriflunomide is the only component detected in plasma. The main biotransformation pathway is hydrolysis with oxidation being a minor pathway. Secondary pathways involve oxidation, N-acetylation and sulfate conjugation. Teriflunomide is excreted in the gastrointestinal tract mainly through the bile as unchanged drug and most likely by direct secretion.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Use with caution. See 'Other information'.
HD Unlikely to be dialysed. Use with caution. See 'Other information'.
HDF/High flux Unknown dialysability. Use with caution. See 'Other information'.
CAV/VVHD Unknown dialysability. Use with caution. See 'Other information'.

Important drug interactions
Potentially hazardous interactions with other drugs
• Lipid-lowering agents: effect significantly reduced by colestyramine – avoid; concentration of rosuvastatin increased – consider reducing rosuvastatin dose.
• Live vaccines: risk of generalised infections – avoid.

Administration
Reconstitution
Route Oral
Rate of administration

Other information
• Contraindicated by manufacturer in the UK in dialysis patients due to lack of data.
• Renal impairment had no effect on the pharmacokinetics of teriflunomide.
• Oral bioavailability is 100%.
• Takes about 3 months to reach steady state.
• A more rapid elimination of teriflunomide was observed in haemodialysis subjects which was not due to extraction of drug in the dialysate but instead to displacement of protein binding. (Australian SPC, Nov 2012.)
Teriparatide

**Clinical use**
Active fragment (1–34) of endogenous human parathyroid hormone:
- Treatment of osteoporosis in postmenopausal women and men at increased risk of fractures
- Treatment of corticosteroid-induced osteoporosis

**Dose in normal renal function**
20 mcg daily

**Pharmacokinetics**
- Molecular weight (daltons) 4117.8
- % Protein binding: No data
- % Excreted unchanged in urine: As metabolites
- Volume of distribution (L/kg) 1.7
- Half-life — normal/ESRF (hrs) 1 / Increased by 77%

**Metabolism**
No metabolism or excretion studies have been performed. Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver followed by excretion via the kidneys. The 24-hour urine excretion of calcium was reduced by a clinically unimportant amount (15%).

**Dose in renal impairment GFR (mL/min)**
- 30–50 Dose as in normal renal function.
- 10–30 Dose as in normal renal function. Use with caution.
- <10 Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HD Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
- 

**Route**
- SC

**Rate of administration**
- 

**Other information**
- Contraindicated by UK manufacturer in severe renal impairment.
- Use with caution due to patients with renal impairment having reduced calcaemic and calciuric responses to teriparatide.
- Bioavailability is 95%.
- No pharmacokinetic differences were identified in 11 patients with mild or moderate renal impairment [CRCL=30–72 mL/min] administered a single dose of teriparatide. In 5 patients with severe renal impairment (CRCL<30 mL/min), the AUC and half-life of teriparatide were increased by 73% and 77%, respectively. Maximum serum concentration of teriparatide was not increased. No studies have been performed in patients undergoing dialysis.
Terlipressin

Clinical use
Treatment of bleeding oesophageal varices

Dose in normal renal function
2 mg stat dose followed by 1–2 mg every 4–6 hours when required (until bleeding is controlled) for up to 72 hours. Doses are expressed as acetate.

Pharmacokinetics
Molecular weight (daltons) 1227.4 (1437.6 as acetate)
% Protein binding ~30
% Excreted unchanged in urine <2
Volume of distribution (L/kg) 0.6–0.9
Half-life — normal/ESRF (hrs) 50–70 minutes / –

Metabolism
Terlipressin is metabolised by tissue peptidases resulting in the slow release of lypressin. Terlipressin is almost completely metabolised in the kidneys and liver, with less than 1% of terlipressin and less than 0.1% of lypressin excreted in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose in renal function</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• None known

Administration
Reconstitution
With solvent provided
Route
IV
Rate of administration
—
Comments
Store reconstituted solution in the fridge and discard after 12 hours.

Other information
• 1 mg of terlipressin acetate is equivalent to about 0.85 mg of terlipressin.
• Maximum plasma levels are reached after 1–2 hours with a duration of action of 4–6 hours.
• Initial response within 25–40 minutes, duration 2–10 hours.
• Information from Martindale; some studies have found it can be used to improve renal function in hepatorenal syndrome, 1 mg every 6 hours, if the creatinine has not reduced by 30% after 3 days then the dose can be increased to 2 mg every 6 hours providing there is no cardiovascular disease.
• May cause hypertension.
• There is a case report of rhabdomyolysis.
# Tetracycline

## Clinical use
Antibacterial agent

## Dose in normal renal function
250–500 mg 4 times a day  
Acne: 500 mg twice daily

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>444.44</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>20–65</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>55–60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>&gt;0.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>6–12 / 57–120</td>
</tr>
</tbody>
</table>

## Metabolism
Tetracycline is excreted in the urine and in the faeces. Renal clearance is by glomerular filtration. Up to 60% of an intravenous dose of tetracycline, and up to 55% of an oral dose, is eliminated unchanged in the urine. The tetracyclines are excreted in the bile, where concentrations 5–25 times those in plasma can occur. There is some enterohepatic reabsorption and considerable quantities occur in the faeces after oral doses.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>250 mg 4 times a day</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- **Anticoagulants**: possibly enhance anticoagulant effect of coumarins and phenindione.
- **Oestrogens**: possibly reduce contraceptive effects of oestrogens (risk probably small).
- **Retinoids**: possible increased risk of benign intracranial hypertension with retinoids – avoid concomitant use.

## Administration
### Reconstitution
- 

### Route
- Oral

### Rate of administration
- 

## Other information
- 10% is removed by haemodialysis and 7% by peritoneal dialysis.
- Avoid if possible in renal impairment due to its potential nephrotoxicity and increased risk of azotaemia, hyperphosphataemia and acidosis.
- May cause an increase in blood urea which is dose related.
- Avoid in SLE.
Thalidomide

**Clinical use**
- Untreated multiple myeloma in patients >65 or who are ineligible for high dose chemotherapy, in combination with either melphalan and prednisone, or cyclophosphamide and dexamethasone
  (Unlicensed indications):
  - Erythema nodosum leprosum
  - Lupus erythematosus, aphthous ulceration, stomatitis, graft-versus-host disease, AIDS-associated waste syndrome, rheumatoid arthritis and other acute inflammatory conditions

**Dose in normal renal function**
200 mg daily
Unlicensed dose: 50–400 mg daily

**Pharmacokinetics**
<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>258.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>55–66</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;0.7</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>166 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–7 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**
Thalidomide is metabolised almost exclusively by non-enzymatic hydrolysis. In plasma, unchanged thalidomide represents 80% of the circulatory components. Unchanged thalidomide was a minor component (<3% of the dose) in urine. In addition to thalidomide, hydrolytic products N-(o-carboxybenzoyl) glutarimide and phthaloyl isoglutamine formed via non-enzymatic processes are also present in plasma and in urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Not dialysed. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Thalidomide enhances the effects of barbiturates, alcohol, chlorpromazine and reserpine.
- Use with caution with other drugs that can cause peripheral neuropathy.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- Major route of elimination is non-renal therefore normal doses may be given in renal failure.
- Manufacturer advises to monitor patients closely due to lack of studies.
Theophylline

Clinical use

- Reversible airways obstruction
- Acute severe asthma

Dose in normal renal function

Depends on preparation used

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>180.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>35–60</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>10</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.3–0.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3–12 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism

Theophylline is metabolised in the liver to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine. Demethylation to 3-methylxanthine (and possibly to 1-methylxanthine) is catalysed by the cytochrome P450 isoenzyme CYP1A2; hydroxylation to 1, 3-dimethyluric acid is catalysed by CYP2E1 and CYP3A3. Both the demethylation and hydroxylation pathways of theophylline metabolism are capacity-limited, resulting in non-linear elimination. The metabolites are excreted in the urine. In adults, about 10% of a dose of theophylline is excreted unchanged in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. See 'Other information'.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose/Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs

- Antibacterials: increased concentration with azithromycin, clarithromycin, erythromycin, ciprofloxacin, norfloxacin and isoniazid; decreased plasma levels of erythromycin if erythromycin taken orally; increased risk of convulsions if given with quinolones; rifampicin accelerates metabolism of theophylline.
- Antidepressants: concentration increased by fluvoxamine – avoid or halve theophylline dose and monitor levels; concentration reduced by St John’s wort – avoid.
- Antiepileptics: metabolism increased by carbamazepine, phenobarbital and primidone; concentration of both drugs increased with fosphenytoin and phenytoin.
- Antifungals: concentration increased by fluconazole and ketoconazole.
- Antivirals: metabolism of theophylline increased by ritonavir; concentration possibly increased by aciclovir.
- Calcium-channel blockers: concentration increased by diltiazem and verapamil and possibly other calcium-channel blockers.
- Deferasirox: concentration of theophylline increased.
- Febuxostat: use with caution.
- Interferons: reduced metabolism of theophylline.
- Tacrolimus: may increase tacrolimus levels.
- Ulcer-healing drugs: metabolism inhibited by cimetidine; absorption possibly reduced by sucralfate.

Administration

Reconstitution

Route

Oral

Rate of administration

Other information

- Therapeutic levels should be in the range 10–20 mg/Litre (55–110 micromols/Litre).
- 50% of dose is removed by haemodialysis.
- Studies have used it to protect against contrast nephropathy, with conflicting results.
Thiotepa

Clinical use
Alkylating antineoplastic agent

Dose in normal renal function
- Bladder, intravesical instillations: 30–60 mg
- Intracavitary instillation: 30–60 mg or 0.6–0.8 mg/kg
- IM: 15–30 mg
- Intrathecal: 10–15 mg
- Other doses depend on indication or local protocol

Pharmacokinetics
Molecular weight (daltons) 189.2
% Protein binding 10–40
% Excreted unchanged in urine <2
Volume of distribution (L/kg) 0.3–1.6
Half-life — normal/ESRF (hrs) 2.4 / –

Metabolism
Thiotepa is extensively metabolised to triethylenephosphoramide (TEPA), the primary metabolite, and some of the other metabolites have cytotoxic activity and are eliminated more slowly than the parent compound. It is excreted in the urine: less than 2% of a dose is reported to be present as unchanged drug or its primary metabolite.

Dose in renal impairment GFR (mL/min)
- 20–50 IM: Use a reduced dose with caution.
- 10–20 IM: Use a reduced dose with caution.
- <10 IM: Use a reduced dose with caution.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antipsychotics: avoid concomitant use with clozapine.
- Avoid concomitant use with other myelosuppressive agents.

Administration
Reconstitution
10 mL water for injection
Route
IV, IM, intrathecal (can be administered directly into pleural, pericardial or peritoneal cavities and as a bladder instillation)
Rate of administration
2–4 hours
Comments
For IV infusions: further dilute in 500 mL sodium chloride 0.9% (1000 mL if dose >500 mg)

Other information
- Manufacturer advises to use with caution due to lack of pharmacokinetic studies in renal impairment.
- Haemorrhagic cystitis has been reported.
Tiagabine

Clinical use
Antiepileptic

Dose in normal renal function
15–45 mg daily in 3 divided doses if dose >30 mg

Pharmacokinetics

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>412</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>96</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7–9 (2–3 in patients on enzyme inducing drugs) / –</td>
</tr>
</tbody>
</table>

Metabolism
Tiagabine has negligible renal clearance. Hepatic metabolism is the principle route for elimination of tiagabine. Less than 2% of the dose is excreted unchanged in urine and faeces. No active metabolites have been identified.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs

- Antidepressants: antagonism of anticonvulsant effect with SSRI, tricyclics and MAOIs (convulsive threshold lowered); avoid with St John’s wort.
- Antiepileptics: concentration reduced by phenytoin, carbamazepine and phenobarbital.
- Antimalarials: mefloquine antagonises anticonvulsant.
- Antipsychotics: anticonvulsant effect antagonised.
- Orlistat: possibly increased risk of convulsions.

Administration
Reconstitution

<table>
<thead>
<tr>
<th>Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of administration</td>
<td></td>
</tr>
</tbody>
</table>

Other information
- Although there is no evidence of withdrawal seizures, it is recommended to taper off treatment over a period of 2–3 weeks.
- Oral bioavailability is 89%.
**Tiaprofenic acid**

**Clinical use**

NSAID and analgesic

**Dose in normal renal function**

300 mg twice daily
Or 200 mg three times a day

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>260.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97–98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>50 (10% as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>5.4–6.7 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.5–2 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Sparingly metabolised in the liver to two inactive metabolites. Excretion of tiaprofenic acid and its metabolites are mainly in the urine in the form of acyl glucuronides; some is excreted in the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR range</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but avoid if possible.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but only use if on dialysis.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min. See ‘Other information’.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min. See ‘Other information’.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min. See ‘Other information’.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban – avoid long term use with edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

---

**Route**

Oral

**Rate of administration**

---

**Other information**

- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if serum creatinine is increased, stop NSAID.
- Use normal doses in patients with CKD 5 if on dialysis and do not pass any urine.
- Use with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.
Ticagrelor

**Clinical use**

Antiplatelet agent

**Dose in normal renal function**

180 mg loading dose followed by 60–90 mg twice daily in combination with aspirin

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>522.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt; 99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>87.5 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of the active metabolite and their interactions with other CYP3A substrates ranges from activation through to inhibition. The systemic exposure to the active metabolite is approximately 30–40% of that obtained for ticagrelor. The primary route of ticagrelor elimination is via hepatic metabolism. The primary route of elimination for the active metabolite is most likely via biliary secretion.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Antibacterials: concentration possibly increased by clarithromycin – avoid; concentration possibly increased by erythromycin; concentration reduced by rifampicin.
- Anticoagulants: concentration of dabigatran increased.
- Antifungals: concentration increased by ketoconazole – avoid.
- Antivirals: concentration possibly increased by atazanavir and ritonavir – avoid.
- Cardiac glycosides: concentration of digoxin increased.
- Ciclosporin: possibly increases ciclosporin concentration.
- Ergot alkaloids: concentration of ergot alkaloids possibly increased.
- Lipid-regulating drugs: concentration of simvastatin increased – increased risk of toxicity.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Manufacturer does not recommend use in dialysis patients due to lack of data.
- Oral bioavailability is 36%.
## Tigecycline

### Clinical use
Antibacterial agent

### Dose in normal renal function
Loading dose of 100 mg, then 50 mg twice daily

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>585.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>71–89</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>22</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>7–9</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>42 / Probably unchanged</td>
</tr>
</tbody>
</table>

### Metabolism
Tigecycline is not thought to be extensively metabolised, although some trace metabolites have been identified including a glucuronide, an N-acetyl metabolite, and a tigecycline epimer. Tigecycline is primarily eliminated (about 60%) via biliary excretion of unchanged drug and some metabolites.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs:
- **Anticoagulants**: possibly enhanced anticoagulant effect of coumarins.
- **Oestrogens**: possibly reduced contraceptive effects of oestrogens (risk probably small).

### Administration
**Reconstitution**
5.3 mL of sodium chloride 0.9% or glucose 5% (gently swirl to reconstitute)

**Route**
IV infusion

**Rate of administration**
30–60 minutes

**Comments**
Add required dose to 100 mL of sodium chloride 0.9% or glucose 5%.

### Other information
- AUC increased by 30% in CKD 5.
Timentin (ticarcillin / clavulanic acid)

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
3.2 g every 6–8 hours, increased to every 4 hours in severe infections

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Ticarcillin (as Na)</th>
<th>Clavulanic acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>428.4</td>
<td>199.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Ticarcillin 50,</td>
<td>Clavulanic acid 25</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Ticarcillin 85–90,</td>
<td>Clavulanic acid 40</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>Ticarcillin 0.14–0.21,</td>
<td>Clavulanic acid 0.3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>Ticarcillin 1.2 / 15,</td>
<td>Clavulanic acid 1 / 3–4</td>
</tr>
</tbody>
</table>

**Metabolism**
The major route of elimination for ticarcillin is in the urine via glomerular filtration and tubular secretion. Ticarcillin is also metabolised to a limited extent. Up to 90% of a dose is excreted unchanged in the urine, mostly within 6 hours after a dose. Plasma concentrations are enhanced by probenecid. Clavulanate is also excreted via the kidneys.

**Dose in renal impairment GFR (mL/min)**
- 30–60: 3.2 g every 8 hours.
- 10–30: 1.6 g every 8 hours.
- <10: 1.6 g every 12 hours.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVH: Dialysed. Dose as in GFR=10–30 mL/min or 2.4 g every 6–8 hours.1
- CVVHD/HDF: Dialysed. 3.2 g every 6 hours.2 See ‘Other information’.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins are potentially enhanced.
- Oral contraceptives: potentially reduced efficacy.
- Methotrexate: reduced excretion thereby increasing risk of toxicity.

**Administration**

**Reconstitution**
With 10 mL water for injection and add to 100 mL glucose 5%

**Route**
IV

**Rate of administration**
30–40 minutes

**Comments**
Each 3.2 g of ticarcillin/clavulanic acid contains 16 mmol of sodium and 1 mmol of potassium.

**Other information**
- CSM has advised that cholestatic jaundice may occur if treatment exceeds a period of 14 days and can present up to 6 weeks after treatment has been stopped. The incidence of cholestatic jaundice occurring with timentin is higher in males than in females and is particularly prevalent in men over the age of 65 years.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
Timolol maleate

**Clinical use**

Beta-adrenoceptor blocker:
- Hypertension
- Angina
- Glaucoma
- Migraine prophylaxis

**Dose in normal renal function**

- Hypertension: 10–60 mg daily, doses >30 mg in divided doses
- Angina: 5–30 mg twice daily
- Post MI: 5–10 mg twice daily
- Migraine: 10–20 mg daily in 1–2 divided doses

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>432.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>10</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Timolol undergoes significant hepatic metabolism, but first pass metabolism is low. The metabolites are excreted in the urine with some unchanged timolol.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Start with lowest dose and titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Start with lowest dose and titrate according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: NSAIDs antagonise hypotensive effect.
- Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
- Antidepressants: enhanced hypotensive effect with MAOIs.
- Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
- Antimalarials: increased risk of bradycardia with mefloquine.
- Antipsychotics: enhanced hypotensive effect with phenothiazines.
- Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
- Cytotoxics: possible increased risk of bradycardia with crizotinib.
- Diuretics: enhanced hypotensive effect.
- Fingolimod: possibly increased risk of bradycardia.
- Moxisylyte: possible severe postural hypotension.
- Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine; also response to adrenaline may be reduced.

**Administration**

**Reconstitution**

—

**Route**

Oral, topical

**Rate of administration**

—

**Other information**

- Timolol is more hydrophilic than lipophilic.
# Tinidazole

## Clinical use

Antibacterial agent

## Dose in normal renal function

1–2 g daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>247.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>8–12$^1$</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>20–25</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.61–0.67$^1$</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12–14 / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism

Tinidazole is excreted by the liver (up to 5%) and kidneys as unchanged drug and metabolites. An active hydroxy metabolite has been identified.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR range (mL/min)</th>
<th>Dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability, but likely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs

- Alcohol: disulfiram-like reaction.

## Administration

### Reconstitution

—

### Route

Oral

### Rate of administration

—

## Other information

- Dosage adjustment in renal failure is not necessary as a decrease in renal clearance is compensated for by increased faecal excretion of tinidazole.
- 43% can be removed during a 6-hour haemodialysis session.$^1$

Reference:

Tinzaparin sodium (LMWH)

Clinical use
- Peri- and postoperative surgical thromboprophylaxis
- Treatment of DVT and pulmonary embolism
- Prevention of thrombus formation in extracorporeal circulation during HD

Dose in normal renal function
- General surgery: (low-moderate risk) 3500 IU daily
- Orthopaedic surgery: (high risk) 50 IU/kg or 4500 IU daily
- DVT and PE: 175 IU/kg bodyweight once daily for at least 6 days and until adequate oral anticoagulation is established

Pharmacokinetics
Molecular weight (daltons) 5500–7500 (average 6500)
% Protein binding 14
% Excreted unchanged in urine 80–90
Volume of distribution (L/kg) 3.1–5 Litres
Half-life — normal/ESRF (hrs) 1.5 / 5.2 (detectable anti-Factor Xa activity persists for 24 hours)

Metabolism
Low molecular weight heparins are partially metabolised by desulphation and depolymerisation. The kidneys are the major site of tinzaparin excretion (approximately 70% based on animal studies).

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function. See 'Other information'.
- <20: Consider a dose reduction. See 'Other information'.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Not dialysed. Dose as in GFR < 20 mL/min.
- HD: Not dialysed. Dose as in GFR < 20 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR < 20 mL/min.
- CAV/VVHD: Not dialysed. Dose as in GFR = 20–50 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of bleeding with NSAIDs – avoid concomitant use with IV diclofenac; increased risk of haemorrhage with ketorolac – avoid concomitant use.
- Nitrates: anticoagulant effect reduced by infusions of glyceryl trinitrate.
- Use with care in patients receiving oral anticoagulants, platelet aggregation inhibitors, aspirin or dextran.

Administration
Reconstitution
- Route SC injection; IV bolus/infusion
- Rate of administration See 'Other information'.

Other information
- Tinzaparin is also indicated for prevention of clotting in the extracorporeal circulation during haemodialysis.
  - Dose for > 4 hr session: IV bolus (into arterial side of the dialyser or intravenously) of 3500–4500 IU
  - Dose for < 4 hr session: IV bolus of 2500 IU.
- Additional tinzaparin (500–1000 IU) may be given if concentrated RBCs or blood transfusions are given during dialysis, or additional treatment beyond the normal dialysis duration is employed.
- Determination of plasma anti-Xa levels may be used to monitor the tinzaparin dose during haemodialysis; plasma anti-Xa levels, one hour after dosing should be within the range 0.4–0.5 IU/mL.
- Additional doses may be required if using LMWHs for anticoagulation in intermittent HDF.
- Heparin can suppress adrenal secretion of aldosterone leading to hyperkalaemia particularly in patients with chronic renal impairment and diabetes mellitus.
- Low molecular weight heparins are renally excreted and hence accumulate in severe renal impairment. While the doses recommended for prophylaxis against DVT and prevention of thrombus formation in extracorporeal circuits are well tolerated in patients with CKD 5, the doses recommended for treatment of DVT and PE have not yet been verified as safe. LMWHs have been associated with severe, sometimes fatal, bleeding episodes in such patients. Hence the use of unfractionated heparin would be preferable in these instances.
- Information from Leo Pharma states that tinzaparin can safely be used in elderly patients with a GFR > 20 mL/min for 10 days without any accumulation (Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular weight heparin? *Arch Intern Med.* 2002; 162(22): 2605–9; Siguret V, Pautas E, Fevrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. *Thromb Haemostat.* 2000; 84(5): 800–4.)
- Some units routinely use a dose of 125 anti-Xa IU/kg in patients with GFR < 20 mL/min who require full anticoagulation.
- Use 1 mg of protamine for every 100 anti-Xa IU to neutralise the effects of tinzaparin. If prothrombin time is still raised 2–4 hours later, give 0.5 mg/kg infusion of protamine.
# Tioguanine

## Clinical use

Antineoplastic agent (antimetabolite):
- Acute leukaemia
- Chronic granulocytic leukaemia

## Dose in normal renal function

100–200 mg/m² daily

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>167.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Probably low</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.148</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>80 minutes / –</td>
</tr>
</tbody>
</table>

## Metabolism

Tioguanine undergoes extensive metabolism in the liver and other tissues to several active and inactive metabolites. Tioguanine is inactivated mainly by methylation to aminomethylthiopurine; small amounts are deaminated to thioxanthine, and may go on to be oxidised by xanthine oxidase to thiouric acid, but inactivation is essentially independent of xanthine oxidase and is not affected by inhibition of the enzyme. 24–46% of the dose is excreted in the urine within 24 hours. It is excreted in the urine almost entirely as metabolites.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function, use with care. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, use with care. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, use with care. See 'Other information'.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).

## Administration

### Reconstitution

- 

### Route

- Oral

### Rate of administration

- 

## Other information

- Variable and incomplete oral absorption with 14–46% bioavailability.
- *Drug Prescribing in Renal Failure, 5th edition* by Aronoff et al suggests using 100% of dose as tioguanine is hepatically metabolised.

Reference:
Tiotropium

**Clinical use**
Maintenance treatment of chronic obstructive pulmonary disease

**Dose in normal renal function**
18 micrograms once daily
Respimat: 5 micrograms once daily

**Pharmacokinetics**
- Molecular weight (daltons) 472.4 (as bromide)
- % Protein binding 72
- % Excreted unchanged in urine 14 (of inhaled dose)
- Volume of distribution (L/kg) 32
- Half-life — normal/ESRF (hrs) 5–6 days / Increased

**Metabolism**
Tiotropium is excreted largely unchanged in the urine, although it may undergo some metabolism by non-enzymatic cleavage and by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function. Use with caution.
- <10 Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in normal renal function. Use with caution.
- HD Unknown dialysability. Dose as in normal renal function. Use with caution.
- HDF/High flux Unknown dialysability. Dose as in normal renal function. Use with caution.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function. Use with caution.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Avoid administration with other anti-cholinergic drugs.
- Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.

**Administration**
- **Reconstitution** —
- **Route** Inhalation
- **Rate of administration** —

**Other information**
- Manufacturer advises to use with caution due to reduced renal clearance. In practice used in normal doses in renal impairment.
- Not to be used for acute episodes of bronchospasm.
Tipranavir

Clinical use
Protease inhibitor:
- Treatment of HIV infected patients in combination with ritonavir and other antiretroviral agents

Dose in normal renal function
500 mg twice daily in combination with ritonavir 200 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 602.7
% Protein binding >99.9
% Excreted unchanged in urine 0.5
Volume of distribution (L/kg) 7.7–10.2 Litres
Half-life — normal/ESRF (hrs) 5.5–6 / Unchanged

Metabolism
Tipranavir is metabolised by the cytochrome P450 system (mainly the isoenzyme CYP3A4), although when given with ritonavir metabolism is minimal with the majority of tipranavir being excreted unchanged in the faeces.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Not dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antacids: avoid giving for 2 hours after tipranavir administration.
- Antibacterials: plasma concentration of clarithromycin and other macrolides increased — reduce dose of clarithromycin in renal impairment; concentration increased by clarithromycin; rifabutin concentration increased (risk of uveitis) — reduce dose; concentration possibly reduced by rifampicin — avoid; avoid with telithromycin in severe renal and hepatic failure.
- Anticoagulants: avoid with apixaban and rivaroxaban.
- Antidepressants: concentration possibly reduced by St John’s wort — avoid.
- Antimalarials: use artemether/lumefantrine with caution; concentration of quinine increased.
- Antipsychotics: possibly increases aripiprazole concentration — reduce aripiprazole dose; possibly increases quetiapine concentration — avoid.
- Antivirals: reduces concentration of abacavir, dolutegravir, didanosine, fosamprenavir, lopinavir, saquinavir and zidovudine; concentration increased by atazanavir, also concentration of atazanavir reduced; concentration reduced by etravirine, also concentration of tipranavir increased — avoid.
- Beta-blockers: avoid with metoprolol for heart failure.
- Ciclosporin: levels possibly altered by tipranavir.
- Cobicistat: concentration of both drugs reduced — avoid.
- Lipid-lowering drugs: increased risk of myopathy with atorvastatin, max dose 10 mg; avoid with lomitapide; concentration of rosuvastatin increased — reduce rosuvastatin dose; concentration of simvastatin increased — avoid.
- Orlistat: absorption possibly reduced by orlistat.
- Ranolazine: possibly increases ranolazine concentration — avoid.
- Sirolimus: levels possibly altered by tipranavir.
- Tacrolimus: levels possibly altered by tipranavir.
- Ulcer-healing drugs: concentration of esomeprazole and omeprazole reduced.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Administer with food; enhanced bioavailability with high fat meals.

Reference:
**Clinical use**

Antiplatelet agent:
- Prevention of early myocardial infarction in patients with unstable angina or non-ST segment elevation myocardial infarction, and with last episode of chest pain within 12 hours

**Dose in normal renal function**

- Angiography planned for 4–48 hours after diagnosis: Initially 0.4 mcg/kg/minute for 30 minutes then 0.1 mcg/kg/minute for at least 48 hours
- Angiography within 4 hours of diagnosis: 25 mcg/kg over 3 minutes then 0.15 mcg/kg/minute for 12–24 hours. Max 48 hours

**Pharmacokinetics**

- Molecular weight (daltons) 495.1
- % Protein binding 65
- % Excreted unchanged in urine 66
- Volume of distribution (L/kg) 22–42 Litres
- Half-life — normal/ESRF (hrs) 1.5–2 / Increased

**Metabolism**

Tirofiban is eliminated largely unchanged in the urine, with some biliary excretion in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose details</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Give 50% of dose.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Give 50% of dose.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Iloprost: increased risk of bleeding.
- Heparin: increased risk of bleeding.

**Administration**

**Reconstitution**

- **Route** IV infusion

**Rate of administration**

- 0.1–0.4 mcg/kg/minute

**Comments**

Add 50 mL of the concentrate (250 mcg/mL) to 250 mL sodium chloride 0.9% or glucose 5%, to give a final concentration of 50 mcg/mL (remove 50 mL from bag first).

**Other information**

- Antiplatelet effect lasts for about 4–8 hours after stopping infusion.
- Main side effect is bleeding.
- Increased risk of bleeding once renal function falls to a GFR<60 mL/min – monitor carefully.
Tizanidine

**Clinical use**
Spasticity associated with multiple sclerosis or spinal cord injury/disease

**Dose in normal renal function**
2–24 mg daily in up to 3–4 divided doses (depending on response)
Max 36 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>290.2 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1[^1]</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2.4</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2.4 / Increased</td>
</tr>
</tbody>
</table>

**Metabolism**
Tizanidine undergoes rapid and extensive first pass metabolism in the liver mainly via the cytochrome P450 isoenzyme CYP1A2. The metabolites (mainly inactive) constitute 70% of the administered dose and are excreted via the renal route.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>25–50</td>
<td>Dose as in normal renal function. Initial dose 2 mg once daily and slowly increase by 2 mg increments. Increase daily dose before increasing frequency of administration.</td>
</tr>
<tr>
<td>&lt;25</td>
<td>Dose as in normal renal function. Initial dose 2 mg once daily and slowly increase by 2 mg increments. Increase daily dose before increasing frequency of administration.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;25 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;25 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;25 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=25–50 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: enhanced muscle relaxant effect with procainamide.
- Antibacterials: concentration increased by ciprofloxacin – avoid; concentration possibly increased by norfloxacin; concentration possibly reduced by rifampicin.
- Antidepressants: concentration increased by fluvoxamine – avoid.
- Antihypertensives: enhanced hypotensive effect.
- Oral contraceptives: clearance of tizanidine reduced by 50%.

**Reference:**
Tobramycin

**Clinical use**
Antibacterial agent

**Dose in normal renal function**
- IM/IV: 3 mg/kg/day in 3 divided doses; maximum 5 mg/kg/day in 3–4 divided doses
- Urinary tract infections: 2–3 mg/kg daily as a single dose (IM)

**Pharmacokinetics**
- Molecular weight (daltons) 467.5
- % Protein binding <5
- % Excreted unchanged in urine 90
- Volume of distribution (L/kg) 0.25
- Half-life — normal/ESRF (hrs) 2–3 / 5–70

**Metabolism**
Tobramycin is almost completely eliminated by the kidneys and the drug is eliminated unchanged almost entirely by glomerular filtration.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Give 1–2 mg/kg then dose according to serum levels.
- 10–20: Give 1 mg/kg then dose according to serum levels.
- <10: Give 1 mg/kg then dose according to serum levels.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. 1.5–2 mg/kg every 24 hours and monitor levels. See 'Other information'.

**Important drug interactions**
- Antibacterials: increased risk of nephrotoxicity with colistimethate or polymyxins and possibly cephalosporins; increased risk of ototoxicity and nephrotoxicity with capreomycin or vancomycin.
- Ciclosporin: increased risk of nephrotoxicity.
- Cytotoxics: increased risk of nephrotoxicity and possibly of ototoxicity with platinum compounds.
- Diuretics: increased risk of ototoxicity with loop diuretics.
- Muscle relaxants: enhanced effect of non-depolarising muscle relaxants and suxamethonium.
- Parasympathomimetics: antagonism of effect of neostigmine and pyridostigmine.
- Tacrolimus: increased risk of nephrotoxicity.

**Administration**

**Reconstitution**
Add to 50–100 mL sodium chloride 0.9% or glucose 5% for IV infusion.

**Route**
IV, IM, IP, nebulised

**Rate of administration**
20–60 minutes

**Comments**
Plasma concentrations should be measured frequently; trough ≤2 mg/L, peak 60 minutes post dose ≤10 mg/L; avoid prolonged peaks above 12 mg/L.

**Other information**
- 25–70% can be removed by haemodialysis.
- Used via nebuliser for chronic pulmonary *Pseudomonas aeruginosa* infection in cystic fibrosis: 300 mg every 12 hours for 28 days, repeat after 28 days.
- Can be used for peritonitis at doses of 6 mg/L intraperitoneally.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Tocilizumab

**Clinical use**

Interleukin inhibitor:
- Treatment of rheumatoid arthritis in combination with methotrexate

**Dose in normal renal function**

IV: 8 mg/kg every 4 weeks (maximum dose: 800 mg)
SC: 162 mg once weekly

**Pharmacokinetics**

- Molecular weight (daltons): 148,000
- % Protein binding: Not applicable
- % Excreted unchanged in urine: No data
- Volume of distribution (L/kg): 6.4 litres
- Half-life — normal/ESRF (hrs): 11-13 days (concentration dependent)

**Metabolism**

Tocilizumab undergoes biphasic elimination from the circulation. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear and non-linear clearance. The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations. Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance.

**Dose in renal impairment GFR (mL/min)**

- **20–50**: Dose as in normal renal function. Use with caution.
- **10–20**: Dose as in normal renal function. Use with caution.
- **<10**: Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**


**Important drug interactions**

Potentially hazardous interactions with other drugs
- Live vaccines: avoid concomitant administration.

**Administration**

**Reconstitution**

- **Route**: IV, SC
- **Rate of administration**: Over 60 minutes
- **Comments**: Final volume of 100 mL sodium chloride 0.9%

**Other information**

- There have been no studies in moderate to severe renal impairment. Manufacturer advises to monitor renal function closely.
- Bioavailability of subcutaneous formulation was 80%.
- Contains 1.17 mmol (26.55 mg) sodium per 1200 mg.
- There is a case report of tocilizumab being used safely and effectively in a patient with an eGFR of 26 mL/min. (Kato T, Koni I, Inoue R, et al. A case of active rheumatoid arthritis with renal dysfunction treated effectively with tocilizumab monotherapy. *Mod Rheumatol*. 2010; 20: 316–8.)
Tofacitinib citrate

**Clinical use**

Potent, selective inhibitor of the Janus kinase family:
- Treatment of moderate to severe active rheumatoid arthritis

**Dose in normal renal function**

5 mg twice daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>504.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>40</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>30</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>87 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3 / 3.8</td>
</tr>
</tbody>
</table>

**Metabolism**

70% metabolised in the liver by CYP3A4 (major) and CYP2C19 (minor). The 8 metabolites produced are inactive.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>5 mg once daily.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Minimal dialysability. Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>&lt;10% dialysed.¹ Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>&lt;10% dialysed.¹ Dose as in GFR&lt;30 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Minimal dialysability. Dose as in GFR=30–50 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: concentration of tofacitinib reduced by rifampicin – avoid.
- Antifungals: concentration of tofacitinib increased by fluconazole and ketoconazole – adjust tofacitinib dose.
- Antipsychotics: increased risk of agranulocytosis with clozapine – avoid.
- Ciclosporin: concentration of tofacitinib reduced – avoid.
- Tacrolimus: concentration of tofacitinib reduced – avoid.
- Vaccines: risk of generalised infections with live vaccines – avoid.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Oral bioavailability is 74%.
- Patients with CRCL=50–80 mL/min, 30–49 mL/min and <30 mL/min had 37%, 43% and 123% higher AUC, respectively, compared with healthy patients. In patients with end-stage renal disease the contribution of dialysis to the total clearance of tofacitinib was relatively small.

**Reference:**

**Tolbutamide**

**Clinical use**
Hypoglycaemic agent for non-insulin dependent diabetes

**Dose in normal renal function**
0.5–2 g daily in divided doses

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>270.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>95–97</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.1–0.15</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4–7 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**
Tolbutamide is metabolised in the liver by hydroxylation mediated by the cytochrome P450 isoenzyme CYP2C9. It is excreted in the urine chiefly as inactive metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose and caution</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose and caution</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: effects enhanced by NSAIDs – avoid with azapropazone.
- Antibacterials: effects enhanced by chloramphenicol, sulphonamides, tetracyclines and trimethoprim; effect reduced by rifamycins.
- Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR.
- Antifungals: concentration increased by fluconazole and miconazole, and possibly voriconazole.
- Lipid-regulating drugs: possibly additive hypoglycaemic effect with fibrates.
- Sulfinpyrazone: enhanced effect of sulphonylureas.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**

- Tolbutamide is not removed by dialysis. It is contraindicated in severe renal impairment, and should be started with a lower dose in mild to moderate renal impairment because of risk of hypoglycaemia.
- *Drug Prescribing in Renal Failure, 5th edition* by Aronoff et al suggest that 100% of dose can be used.
**Clinical use**

Catechol-o-methyltransferase inhibitor:
- Treatment of Parkinson's disease

**Dose in normal renal function**

100 mg three times daily, leave 6 hours between each dose
In exceptional circumstances can be increased to 200 mg three times daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>273.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0.5</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>9 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–3 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Extensively metabolised, mainly by conjugation to the inactive glucuronide, but methylation by catechol-O-methyltransferase to 3-O-methyltolcapone and metabolism by cytochrome P450 isoenzymes CYP3A4 and CYP2A6 also occurs.
Approximately 60% of a dose is excreted in the urine with the remainder appearing in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Unlikely to be dialysed. Dose as GFR < 10 mL/min.
- **HD**: Unlikely to be dialysed. Dose as GFR < 10 mL/min.
- **HDF/High flux**: Unlikely to be dialysed. Dose as GFR < 10 mL/min.
- **CAV/VVHD**: Use with caution. Dose as GFR = 10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antidepressants: avoid with MAOIs.

**Administration**

**Reconstitution**
- **Route**: Oral

**Rate of administration**
- **Other information**
  - Bioavailability is 65%.
  - Use with caution due to lack of data, although the pharmacokinetics are relatively unchanged in renal impairment.
**Clinical use**

**NSAID:**
- Treatment of migraine

**Dose in normal renal function**

200 mg when first symptoms appear; repeat once after 1–2 hours if satisfactory response is not obtained

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>261.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>8 (90% as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.16</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2.5 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Tolfenamic acid is metabolised in the liver; the metabolites and unchanged drug are conjugated with glucuronic acid.

About 90% of an ingested dose is excreted in the urine and the remainder in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function. Use with caution and monitor renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Avoid.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose/Use Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Removal unlikely. Use with caution.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Use with caution.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Use with caution.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Avoid if renal function potentially recoverable.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
- Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
- Antibacterials: possibly increased risk of convulsions with quinolones.
- Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban.
- Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
- Antidiabetic agents: effects of sulphonylureas enhanced.
- Antiepileptics: possibly increased phenytoin concentration.
- Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
- Ciclosporin: may potentiate nephrotoxicity.
- Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
- Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
- Lithium: excretion decreased.
- Pentoxifylline: increased risk of bleeding.
- Tacrolimus: increased risk of nephrotoxicity.
- Contraindicated in significantly impaired kidney or liver function.
- The urine may become a little more lemon-coloured due to coloured metabolites.
- Use only with extreme caution (or not at all) in haemodialysis patients with some degree of urine output, especially if other risk factors are present, e.g. nephrotic syndrome or diabetes mellitus or treatment with loop diuretics.
- Use normal doses in patients with CKD 5 on dialysis as long as they no longer pass any urine.
- Inhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid NSAIDs if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if increased, discontinue therapy.
- Use with caution in renal transplant recipients as can reduce intrarenal autacoid synthesis.
Tolterodine tartrate

**Clinical use**
Treatment of urinary frequency, urgency and incontinence

**Dose in normal renal function**
1–2 mg twice daily
M/R: 4 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>475.6</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>96</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.9–1.6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–3 (10 hours in poor metabolisers) / –</td>
</tr>
<tr>
<td></td>
<td>MR: 6 / –</td>
</tr>
</tbody>
</table>

**Metabolism**
Tolterodine is mainly metabolised in the liver by the cytochrome P450 isoenzyme CYP2D6 to the active 5-hydroxymethyl derivative; in a minority of poor metabolisers tolterodine is metabolised by CYP3A4 isoenzymes to its inactive N-dealkylated derivative. Tolterodine is excreted primarily in the urine with about 17% appearing in the faeces; less than 1% of a dose is excreted as unchanged drug.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td>1 mg twice daily. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>1 mg twice daily. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone, disopyramide and flecainide; increased risk of antimuscarinic side effects with disopyramide.
- Antifungals: avoid concomitant use with itraconazole and ketoconazole.
- Antivirals: avoid concomitant use with fosamprenavir, indinavir, lopinavir, ritonavir and saquinavir.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.

**Administration**

**Reconstitution**

**Route**
Oral

**Rate of administration**

**Other information**
- Active metabolites may accumulate in renal failure.
- Bioavailability is 17%.
- Use with caution in patients at risk of QT elongation.
Tolvaptan

**Clinical use**

Selective vasopressin V₂-receptor antagonist:
- Treatment of hyponatraemia secondary to SIADH
- To slow the progression of autosomal dominant polycystic kidney disease (ADPKD)

**Dose in normal renal function**

- SIADH: 15–60 mg once daily
- ADPKD: 60–120 mg daily in 2 divided doses taken 8 hours apart

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>448.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolised mainly by the cytochrome P450 isoenzyme CYP3A4.
Eliminated mainly by the faecal route.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with care. See ‘Other information’.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs:
- Grapefruit juice: avoid concomitant administration, exposure increased by a factor of 1.8.
- Doses for ADPKD need to be reduced if taken with CYP 3A4 inhibitors.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Contraindicated in anuric patients. Not recommended in severe renal impairment due to lack of studies.
  - If fluid restricted patients are treated with tolvaptan, care should be taken to ensure that patients do not become overly dehydrated.
  - Tolvaptan may cause a rapid increase in sodium levels.
  - Bioavailability is 56%.
  - Cases of severe hepatic failure have been seen in trials for the treatment of adult polycystic kidney disease where higher doses are used.
# Topiramate

## Clinical use
- Antiepileptic
- Prophylactic treatment of migraine

## Dose in normal renal function
- **Monotherapy: Epilepsy:** Initially, 25 mg at night increasing to 50–500 mg daily in 2 divided doses
- **Adjunctive treatment: Initially, 25–50 mg at night increasing to 200–400 mg daily in 2 divided doses**
- **Migraine:** Initially, 25 mg at night. Maintenance, 50–200 mg daily in 2 divided doses

## Pharmacokinetics
| Molecular weight (daltons) | 339.4 |
| % Protein binding | 9–17 |
| % Excreted unchanged in urine | 81 (as unchanged drug and metabolites) |
| Volume of distribution (L/kg) | 0.55–0.8 |
| Half-life — normal/ESRF (hrs) | 20–30 / 48–60 (12–15 hours if used with another enzyme-inducing antiepileptic drug) |

## Metabolism
Topiramate is not extensively metabolised (~20%) in healthy volunteers. It is metabolised up to 50% in patients receiving enzyme-inducing drugs. Six metabolites formed through hydroxylation, hydrolysis and glucuronidation have been identified but have little activity. It is eliminated chiefly in urine, as unchanged drug and metabolites.

## Dose in renal impairment GFR (mL/min)
- **20–50** Dose as in normal renal function.
- **10–20** Initially 50% of normal dose and increase according to response.
- **<10** Initially 50% of normal dose and increase according to response.

## Important drug interactions
Potentially hazardous interactions with other drugs
- **Antidepressants:** antagonism of anticonvulsant effect; avoid with St John’s wort.
- **Antiepileptics:** concentration reduced by fosphenytoin, phenytoin, carbamazepine and possibly phenobarbital; increases fosphenytoin and phenytoin concentration; reduces concentration of perampanel; hyperammonaemia and CNS toxicity reported with valproate.
- **Antimalarials:** mefloquine antagonises anticonvulsant effect.
- **Antipsychotics:** anticonvulsant effect antagonised.
- **Oestrogens and progestogens:** reduced contraceptive effect.
- **Orlistat:** possibly increased risk of convulsions.
- **Ulipristal:** reduced contraceptive effect – avoid.

## Administration
### Reconstitution
- **Route** Oral

### Rate of administration
- **Other information**
  - Patients with moderate to severe renal impairment may take 10–15 days to reach steady state, compared to 4–8 days in patients with normal renal function.
  - A higher frequency of renal stones has been noted in topiramate-treated patients, although the risk is not related to dose or duration of therapy. Adequate hydration is recommended to reduce this risk.
Topotecan

**Clinical use**

Antineoplastic agent:
- Treatment of metastatic ovarian, cervical and small cell lung cancer

**Dose in normal renal function**

- IV: 0.75–1.5 mg/m² for 5 days, repeated every 3 weeks
- Oral: 2.3 mg/m² for 5 days, repeated every 3 weeks

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>457.9 (as hydrochloride)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>35</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>51</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>132 Litres +/- 57</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2–3 / 4.9 (in moderate renal failure)</td>
</tr>
</tbody>
</table>

**Metabolism**

Topotecan undergoes reversible, pH-dependent hydrolysis of the active lactone moiety to the inactive hydroxycarboxamide (carboxylate) form. A relatively small amount of topotecan is metabolised by hepatic microsomal enzymes to an active metabolite, N-demethyltopotecan; the clinical significance of this metabolite is not known. Excretion is via biliary and renal routes with 20–60% excreted in the urine as topotecan or the open ring form.

**Dose in renal impairment GFR (mL/min)**

- **IV formulation:**
  - 40–60: Dose as in normal renal function. 0.75 mg/m²/day. See 'Other information'.
  - 20–39: Dose as in normal renal function. 0.75 mg/m²/day. See 'Other information'.
  - <20: Avoid. See 'Other information'.
- **Oral formulation:**
  - 30–49: Initially 1.9 mg/m²/day increasing to 2.3 mg/m²/day if tolerated.
  - <30: 0.6 mg/m²/day initially increasing if tolerated. See 'Other information'.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Unknown dialysability. IV: Dose as in GFR<20 mL/min. Oral: Dose as in GFR<30 mL/min.
- HD: Dialysed. IV: Dose as in GFR<20 mL/min. Oral: Dose as in GFR<30 mL/min.
- HDF/High flux: Dialysed. IV: Dose as in GFR<20 mL/min. Oral: Dose as in GFR<30 mL/min.
- CAV/VVHD: Dialysed. IV: Dose as in GFR=20–39 mL/min. Oral: Dose as in GFR=30–49 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
Add 4 mL of water for injection to each 4 mg vial.

**Route**
Oral, IV infusion

**Rate of administration**
Over 30 minutes

**Comments**
- Dilute further in sodium chloride 0.9% or glucose 5% to obtain a concentration of 25–50 mcg/mL.
- Once reconstituted use within 12 hours if stored at room temperature, and 24 hours if stored at 2–8°C if made under aseptic conditions.

**Other information**

- Oral dose in CRCL<30 mL/min is from US data sheet.
- If the patient has received extensive prior therapy it has been suggested that 1 mg/m²/day can be used in mild renal impairment and 0.5 mg/m²/day in moderate renal impairment. (Ormrod D, Spencer CM. Topotecan: a review of its efficacy in small cell lung cancer. Drugs. 1999; 58(3): 533–51.)
- In renal failure there is an increased risk of hematological toxicity (even at low doses, e.g. 0.5 mg/m²/day), therefore if it is to be used in severe renal failure, start at doses less than 0.5 mg/m²/day and monitor closely.
• No data for oral therapy in GFR<30 mL/min. Advice from SPC gives a dose of 1.9 mg/m²/day increasing to 2.3 mg/m² if tolerated for GFR=30–49 mL/min.

  - CRCL 60 mL/min: 80% of dose
  - CRCL 45 mL/min: 75% of dose
  - CRCL 30 mL/min: 70% of dose

• Drug Prescribing in Renal Failure, 5th edition by Aronoff et al. suggests:
  - GFR>50 mL/min: 75% of dose
  - GFR=10–50 mL/min: 50% of dose
  - GFR<10 mL/min: 25% of dose
Torsemide

Clinical use
Loop diuretic:
- Hypertension
- Oedema

Dose in normal renal function
2.5–40 mg once daily (varies according to indication)
Maximum dose: 200 mg daily in resistant oedema in renal patients

Pharmacokinetics
Molecular weight (daltons) 348.4
% Protein binding >99
% Excreted unchanged in urine 25
Volume of distribution (L/kg) 0.09–0.33
Half-life — normal/ESRF (hrs) 3–4 / Unchanged

Metabolism
Torsemide is metabolised by the cytochrome P450 isoenzyme CYP2C9 to three inactive metabolites, M1, M3 and M5 by stepwise oxidation, hydroxylation or ring hydroxylation. The inactive metabolites are excreted in the urine.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
HD Not dialysed. Dose as in normal renal function.
HDF/High flux Unlikely to be dialysed. Dose as in normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect with NSAIDs.
- Anti-arrhythmics: risk of cardiac toxicity with anti-arrhythmics if hypokalaemia occurs; effects of lidocaine and mexiletine antagonised.
- Antibacterials: increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid concomitant use with lymecycline.
- Antidpressants: increased risk of hypokalaemia with reboxetine; enhanced hyptensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hyponatraemia with carbamazepine.
- Antifungals: increased risk of hypokalaemia with amphotericin.
- Antihypertensives: enhanced hyptensive effect; increased risk of first dose hyptensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalaemia occurs.
- Antipsychotics: increased risk of ventricular arrhythmias with amisulpride or pimozide (avoid with pimozide) if hypokalaemia occurs; enhanced hyptensive effect with phenothiazines.
- Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium: risk of toxicity.

Administration
Reconstitution
—
Route Oral
Rate of administration —

Other information
- Torsemide 10 mg is equivalent to furosemide 20–40 mg.
- In patients with renal failure, the renal clearance is reduced but total plasma clearance is not significantly altered.
- Approximately 80% of dose is excreted renally as parent drug and metabolites.

Reference:
# Toremifene

## Clinical use
Hormone dependent metastatic breast cancer in post menopausal women

## Dose in normal renal function
60 mg daily

## Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>406</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99.5</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>10% as metabolites</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>580 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5 days / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
Toremifene is metabolised mainly by the cytochrome P450 isoenzyme CYP3A4. The main metabolite is N-demethyltoremifene and has similar anti-oestrogenic activity but weaker anti-tumour activity than toremifene. Toremifene is eliminated mainly as metabolites in the faeces.

## Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose / Dialysability</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. See ‘Other information’.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. See ‘Other information’.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. See ‘Other information’.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: enhanced anticoagulant effect of coumarins.
- Cytotoxics: possible increased risk of ventricular arrhythmias with vandetanib – avoid.

## Administration

### Reconstitution
- 

### Route
- Oral

### Rate of administration
- 

## Other information
- As it is not renally excreted, it may be possible to prescribe the normal dose in dialysis patients, although it has not previously been used in this population.
## Trabectedin

### Clinical use

**Antineoplastic agent:**
- Advanced soft tissue sarcoma
- Ovarian cancer

### Dose in normal renal function

- Soft tissue sarcoma: 1.5 mg/m²
- Ovarian cancer: 1.1 mg/m²
- Administered at 3 weekly intervals

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>761.8</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>94–98</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>&gt;5000 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>180 / Probably unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Metabolised in the liver, mainly by cytochrome P450 isoenzyme CYP3A4. Excreted mainly via the faeces.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–60</td>
<td>Dose as in normal renal function with monotherapy. Avoid with combination therapy.</td>
</tr>
<tr>
<td>&lt;30</td>
<td>Avoid. See 'Other information.'</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs:
- Alcohol: Avoid concomitant use.
- Antibacterials: concentration reduced by rifampicin.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
- Vaccines: risk of generalised infections – avoid.

### Administration

#### Reconstitution

- **Route:** IV infusion
- **Rate of administration:** 3–24 hours, rate depends on indication
- **Comments:** Dilute to 50 mL for central access and at least 1 Litre for peripheral access.

### Other information

- UK manufacturer advises to avoid if GFR<30 mL/min in monotherapy due to lack of studies although pharmacokinetics for mild to moderate renal impairment are unchanged compared to those with normal renal function.
- Corticosteroids should be administered 30 minutes before treatment to reduce hepatotoxicity and nausea.
Tramadol hydrochloride

Clinical use
Analgesic

Dose in normal renal function
Oral: 50–100 mg up to 4 hourly; maximum 400 mg daily
IM/IV: 50–100 mg every 4–6 hours; total daily dose 400 mg
MR: 50–200 mg twice daily
XL: 100–400 mg once daily

Pharmacokinetics
Molecular weight (daltons) 299.8
% Protein binding 20
% Excreted unchanged in urine 90
Volume of distribution (L/kg) 163–243 Litres
Half-life — normal/ESRF (hrs) 6 / 11

Metabolism
Tramadol is metabolised by N- and O-demethylation via the cytochrome P450 isoenzymes CYP3A4 and CYP2D6 and glucuronidation or sulfation in the liver. Only O-desmethyl-tramadol is pharmacologically active. Tramadol and its metabolites are almost completely excreted renally.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function
10–20 50–100 mg every 8 hours initially and titrate dose as tolerated.
<10 50 mg every 8 hours initially and titrate dose as tolerated.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: possible opioid withdrawal with buprenorphine and pentazocine.
- Anticoagulants: enhances effect of coumarins.
- Antidepressants: possibly increased serotonergic effects with duloxetine, mirtazapine or venlafaxine; possible CNS excitation or depression with MAOIs and moclobemide – avoid with MAOIs as increased risk of serotonergic effects and convulsions; increased risk of CNS toxicity with SSRIs or tricyclics.
- Antiepileptics: effect reduced by carbamazepine.
- Antihistamines: increased sedative effects with sedating antihistamines.
- Antipsychotics: enhanced hypotensive and sedative effects; increased risk of convulsions.
- Atomoxetine: increased risk of convulsions.
- Dapoxetine: possible increased risk of serotonergic effects – avoid.
- Dopaminergics: avoid with selegiline.
- Sodium oxybate: enhanced effect of sodium oxybate – avoid concomitant use.

Administration
Reconstitution
Route
IV, IM, oral
Rate of administration
Slow bolus or continuous IV infusion / PCA

Other information
- Tramadol is a centrally acting opioid agonist which also acts on inhibitory pain pathways.
- Bioavailability is 60–95%.
Trametinib

**Clinical use**

Protein kinase inhibitor:
- Monotherapy or in combination with dabrafenib for the treatment of unresectable or metastatic melanoma and non-small cell lung cancer (NSCLC) with a BRAF V600 mutation

**Dose in normal renal function**

2 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>615.4 (693.5 as dimethyl sulfoxide)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>97.4</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1200 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>127 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolised mainly by deacetylation alone or in combination with mono-oxygenation. The deacetylated metabolite was further metabolised by glucuronidation. CYP3A4 oxidation is considered a minor pathway of metabolism. The deacetylation is mediated by the carboxyl-esterases 1b, 1c and 2, with possible contributions by other hydrolytic enzymes.

Total dose recovery was low after a 10-day collection period (<50%) following administration of a single oral dose of radiolabelled trametinib, due to the long elimination half-life. Trametinib was excreted mainly in the faeces (>80% of recovered radioactivity) and to a minor extent in urine (≤19%).

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.

**Reference**

## Trandolapril

### Clinical use
Angiotensin converting enzyme inhibitor:
- Hypertension
- Heart failure
- After myocardial infarction

### Dose in normal renal function
0.5–4 mg once daily

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>430.5</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;80 (as trandolaprilat)</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>10–15</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>18 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>16–24 / – (as trandolaprilat)</td>
</tr>
</tbody>
</table>

### Metabolism
Trandolapril is metabolised in the liver to the active trandolaprilat and to some inactive metabolites. About 33% of an oral dose of trandolapril is excreted in the urine, mainly as trandolaprilat; the rest is excreted in the faeces.

### Dose in renal impairment GFR (mL/min)
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initial dose 500 mcg once daily, and increase according to response.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD**: Dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Dialysed. Dose as in GFR=10–20 mL/min.

### Important drug interactions
Potentially hazardous interactions with other drugs

- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
- Bee venom extract: possible severe anaphylactoid reactions when used together.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Cytotoxics: increased risk of angioedema with everolimus.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Gold: flushing and hypotension with sodium aurothiomalate.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

### Administration

#### Reconstitution

#### Route
Oral

#### Rate of administration

#### Other information
- Hyperkalaemia and other side effects are more common in patients with impaired renal function.
- Close monitoring of renal function required during therapy in patients with renal insufficiency.
- Renal failure has been reported in association with ACE inhibitors in patients with renal artery stenosis, post renal transplant and those with congestive heart failure.
- High incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor – this combination should therefore be avoided.
- Normal doses can be used in CKD 5.
Tranexamic acid

**Clinical use**

Haemostatic agent

**Dose in normal renal function**

- Oral: 1–1.5 g every 8–12 hours (15–25 mg/kg every 8–12 hours)
- IV: 0.5–1 g every 8 hours (25–50 mg/kg daily in divided doses)
- Dose depends on indication

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>157.2</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>3</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>90</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Tranexamic acid is excreted as unchanged drug mainly by urinary excretion via glomerular filtration.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>IV: mg/kg</th>
<th>Oral: mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>10–20</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>&lt;10</td>
<td>5</td>
<td>12.5</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD: Likely to be dialysed. Dose as in GFR<10 mL/min.
- HD: Likely to be dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Likely to be dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Likely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

- **Route**: IV, oral

**Rate of administration**

Slow bolus = 100 mg/minute or continuous IV infusion in glucose 5% or sodium chloride 0.9%

**Other information**

- Contraindicated by one manufacturer in the UK in severe renal impairment due to accumulation and increased risk of thrombus formation.
- A 5% topical solution can be made up using the IV preparation, mixed with water for injection. This can be used as a mouthwash to stop bleeding after dental surgery, or placed on a swab to reduce bleeding at fistula or other bleeding sites if conventional measures have not worked (anecdotal).
- Bioavailability is 45%.
**Tranylcypromine**

**Clinical use**
MAOI antidepressant

**Dose in normal renal function**
- Initially 10 mg twice daily, can be increased to 30 mg daily if required
- Maintenance: 10 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>364.5 (as sulphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Majority as metabolites</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3.09</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2</td>
</tr>
</tbody>
</table>

**Metabolism**
Tranylcypromine undergoes considerable hepatic metabolism, including breakdown of the side chain and probably conjugation. Excretion is renal mainly as metabolites.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dialysability</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

- Analgesics: CNS excitation or depression with pethidine, other opioids and nefopam – avoid; increased risk of serotonergic effects and convulsions with tramadol - avoid.
- Antibacterials: increased risk of hypertension and CNS excitation with linezolid and tedizolid – avoid for at least 2 weeks after stopping MAOIs.
- Antidepressants: enhancement of CNS effects and toxicity. Care with all antidepressants including drug free periods when changing therapies.
- Antidiabetics: possibly enhanced hypoglycaemic effect.
- Antiepileptics: antagonism of anticonvulsant effect; avoid carbamazepine with or within 2 weeks of MAOIs.
- Antihypertensives: enhanced hypotensive effect.
- Antimalarials: avoid with arteether/lumefantrine and piperaquine with artemimal.
- Antipsychotics: effects enhanced by clozapine.
- Anxiolytics: avoid buspirone with or within 2 weeks of MAOIs.
- Atomoxetine: avoid concomitant use and for 2 weeks after use; increased risk of convulsions.
- Bupropion: avoid with or for 2 weeks after MAOIs.
- Dapoxetine: risk of hypertensive crisis – avoid.
- Diuretics: enhanced hypotensive effect; avoid with indoramin.
- Dopaminergics: avoid with entacapone, safinamide and tolcapone; hypertensive crisis with levodopa and rasagline – avoid for at least 2 weeks after stopping MAOI; hypotension with selegiline.
- 5HT<sub>1</sub> agonist: risk of CNS toxicity with sumatriptan, rizatriptan and zolmitriptan – avoid sumatriptan and rizatriptan for 2 weeks after MAOI.
- Metaraminol: risk of hypertensive crisis – avoid for at least 2 weeks after stopping MAOIs.
- Methyldopa: avoid concomitant use.
- Opicapone: avoid concomitant use.
- Sympathomimetics: hypertensive crisis with sympathomimetics – avoid.
- Tetrabenazine: risk of CNS excitation and hypertension avoid.

**Administration**

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

---

**Tranylcypromine**

**Clinical use**

**Dose in normal renal function**

- Initially 10 mg twice daily, can be increased to 30 mg daily if required
- Maintenance: 10 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>364.5 (as sulphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Majority as metabolites</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3.09</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2</td>
</tr>
</tbody>
</table>

**Metabolism**
Tranylcypromine undergoes considerable hepatic metabolism, including breakdown of the side chain and probably conjugation. Excretion is renal mainly as metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dialysability</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

- Analgesics: CNS excitation or depression with pethidine, other opioids and nefopam – avoid; increased risk of serotonergic effects and convulsions with tramadol - avoid.
- Antibacterials: increased risk of hypertension and CNS excitation with linezolid and tedizolid – avoid for at least 2 weeks after stopping MAOIs.
- Antidepressants: enhancement of CNS effects and toxicity. Care with all antidepressants including drug free periods when changing therapies.
- Antidiabetics: possibly enhanced hypoglycaemic effect.
- Antiepileptics: antagonism of anticonvulsant effect; avoid carbamazepine with or within 2 weeks of MAOIs.
- Antihypertensives: enhanced hypotensive effect.
- Antimalarials: avoid with arteether/lumefantrine and piperaquine with artemimal.
- Antipsychotics: effects enhanced by clozapine.
- Anxiolytics: avoid buspirone with or within 2 weeks of MAOIs.
- Atomoxetine: avoid concomitant use and for 2 weeks after use; increased risk of convulsions.
- Bupropion: avoid with or for 2 weeks after MAOIs.
- Dapoxetine: risk of hypertensive crisis – avoid.
- Diuretics: enhanced hypotensive effect; avoid with indoramin.
- Dopaminergics: avoid with entacapone, safinamide and tolcapone; hypertensive crisis with levodopa and rasagline – avoid for at least 2 weeks after stopping MAOI; hypotension with selegiline.
- 5HT<sub>1</sub> agonist: risk of CNS toxicity with sumatriptan, rizatriptan and zolmitriptan – avoid sumatriptan and rizatriptan for 2 weeks after MAOI.
- Metaraminol: risk of hypertensive crisis – avoid for at least 2 weeks after stopping MAOIs.
- Methyldopa: avoid concomitant use.
- Opicapone: avoid concomitant use.
- Sympathomimetics: hypertensive crisis with sympathomimetics – avoid.
- Tetrabenazine: risk of CNS excitation and hypertension avoid.

---

**Tranylcypromine**

**Clinical use**

**Dose in normal renal function**

- Initially 10 mg twice daily, can be increased to 30 mg daily if required
- Maintenance: 10 mg daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>364.5 (as sulphate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Majority as metabolites</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3.09</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2</td>
</tr>
</tbody>
</table>

**Metabolism**
Tranylcypromine undergoes considerable hepatic metabolism, including breakdown of the side chain and probably conjugation. Excretion is renal mainly as metabolites.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dialysability</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

**Important drug interactions**

- Analgesics: CNS excitation or depression with pethidine, other opioids and nefopam – avoid; increased risk of serotonergic effects and convulsions with tramadol - avoid.
- Antibacterials: increased risk of hypertension and CNS excitation with linezolid and tedizolid – avoid for at least 2 weeks after stopping MAOIs.
- Antidepressants: enhancement of CNS effects and toxicity. Care with all antidepressants including drug free periods when changing therapies.
- Antidiabetics: possibly enhanced hypoglycaemic effect.
- Antiepileptics: antagonism of anticonvulsant effect; avoid carbamazepine with or within 2 weeks of MAOIs.
- Antihypertensives: enhanced hypotensive effect.
- Antimalarials: avoid with arteether/lumefantrine and piperaquine with artemimal.
- Antipsychotics: effects enhanced by clozapine.
- Anxiolytics: avoid buspirone with or within 2 weeks of MAOIs.
- Atomoxetine: avoid concomitant use and for 2 weeks after use; increased risk of convulsions.
- Bupropion: avoid with or for 2 weeks after MAOIs.
- Dapoxetine: risk of hypertensive crisis – avoid.
- Diuretics: enhanced hypotensive effect; avoid with indoramin.
- Dopaminergics: avoid with entacapone, safinamide and tolcapone; hypertensive crisis with levodopa and rasagline – avoid for at least 2 weeks after stopping MAOI; hypotension with selegiline.
- 5HT<sub>1</sub> agonist: risk of CNS toxicity with sumatriptan, rizatriptan and zolmitriptan – avoid sumatriptan and rizatriptan for 2 weeks after MAOI.
- Metaraminol: risk of hypertensive crisis – avoid for at least 2 weeks after stopping MAOIs.
- Methyldopa: avoid concomitant use.
- Opicapone: avoid concomitant use.
- Sympathomimetics: hypertensive crisis with sympathomimetics – avoid.
- Tetrabenazine: risk of CNS excitation and hypertension avoid.
Trastuzumab

### Clinical use

**Antineoplastic agent:**
- HER2-expressing breast cancer
- Metastatic gastric cancer

### Dose in normal renal function

<table>
<thead>
<tr>
<th>Dose</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 mg/kg then 2 mg/kg weekly</td>
<td></td>
</tr>
<tr>
<td>Or 8 mg/kg initially then 6 mg/kg every 3 weeks</td>
<td></td>
</tr>
<tr>
<td>Breast cancer only (SC): 600 mg every 3 weeks</td>
<td></td>
</tr>
<tr>
<td>Or according to local policy</td>
<td></td>
</tr>
</tbody>
</table>

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>148 000–185 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>No data</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.044</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>28–38 days / Probably unchanged</td>
</tr>
</tbody>
</table>

### Metabolism

Trastuzumab is most likely removed by opsonisation via the reticuloendothelial system.

### Important drug interactions

Potentially hazardous interactions with other drugs:
- Antipsychotics: avoid with clozapine – increased risk of agranulocytosis.
- Cytotoxics: possible increased risk of cardiotoxicity with daunorubicin, doxorubicin, epirubicin and idarubicin – avoid for up to 28 weeks after stopping trastuzumab.
- Vaccines: risk of generalised infections with live vaccines – avoid.

### Administration

#### Reconstitution

7.2 mL water for injection per 150 mg vial

#### Route

IV infusion, SC

#### Rate of administration

- 4 mg/kg over 90 minutes
- 2 mg/kg over 30 minutes
- SC: 2–5 minutes

#### Comments

- Allow to stand for 5 minutes after reconstitution.
- Dilute dose in 250 mL sodium chloride 0.9%.

### Other information

- Manufacturer has not done any studies in renal impairment but no dose reduction is probably required as trastuzumab does not require hepatic or renal metabolism for elimination.
- Distributes to normal cells, tumour cells and serum where HER2 antigens are found.
- Nadir for bone-marrow depression is 4 weeks with recovery within 6 weeks.
- Associated with cardiotoxicity.
- May remain in circulation for up to 27 weeks.
### Trazodone hydrochloride

#### Clinical use
Tricyclic-related antidepressant

#### Dose in normal renal function
- **Depression**: 100–300 mg daily; maximum 600 mg daily in divided doses for hospital patients
- **Anxiety**: 75–300 mg daily

#### Pharmacokinetics
- **Molecular weight (daltons)**: 408.3
- **% Protein binding**: 89–95
- **% Excreted unchanged in urine**: <5
- **Volume of distribution (L/kg)**: 1–2
- **Half-life — normal/ESRF (hrs)**: 5–13 / –

#### Metabolism
Trazodone is hepatically metabolised via the cytochrome P450 isoenzyme CYP3A4 by n-oxidation and hydroxylation. The metabolite m-chlorophenylpiperazine is active.

Trazodone is excreted in the urine almost entirely in the form of its metabolites.

#### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Start with small doses and increase gradually.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Start with small doses and increase gradually.</td>
</tr>
</tbody>
</table>

#### Dose in patients undergoing renal replacement therapies
- **APD/CAPD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=10–20 mL/min.

#### Important drug interactions
Potentially hazardous interactions with other drugs
- **Alcohol**: increased sedative effects.
- **Antidepressants**: avoid concomitant use with MAOIs and moclobemide.
- **Antiepileptics**: antagonism of anticonvulsant effect; concentration reduced by carbamazepine.
- **Antimalarials**: manufacturer advises avoid concomitant use with artemether and lumefantrine and piperaquine with arteminol.
- **Antivirals**: concentration increased by ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased by telaprevir.

#### Administration

##### Reconstitution
- —

##### Route
- Oral

##### Rate of administration
- —

#### Other information
- Use lower doses in elderly patients.
Treosulfan

**Clinical use**
Alkylating agent for ovarian cancer

**Dose in normal renal function**
- IV: 3–8 g/m² every 3–4 weeks
- Doses up to 1.5 g/m² have been given IP
- Oral: 400–600 mg/m²/day on days 1–28 then a 4-week rest period
- Or according to local protocol

**Pharmacokinetics**
- Molecular weight (daltons) 278.3
- % Protein binding No data
- % Excreted unchanged in urine 22–30
- Volume of distribution (L/kg) 44–88 Litres
- Half-life — normal/ESRF (hrs) 1.5–1.94 / –

**Metabolism**
Treosulfan is a prodrug of a bifunctional alkylating agent, converted *in vivo* to epoxide compounds. Approximately 30% of the substance is excreted unchanged in the urine within 24 hours, nearly 90% of which is within the first 6 hours after administration.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Use a reduced dose. See 'Other information'.
- 10–20 Use a reduced dose. See 'Other information'.
- <10 Use a reduced dose. See 'Other information'.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min.
- HD Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- None known

**Administration**
**Reconstitution**
20 or 100 mL water for injection for 1 g and 5 g vials respectively

**Route**
Oral, IV, IP

**Rate of administration**
15–30 minutes

**Comments**
Powder reconstitutes easier if water heated to 25–30°C

**Other information**
- Haemorrhagic cystitis has occurred after intravesical or intravenous administration.
**Clinical use**

Retinoid:
- Induction of remission in promyelocytic leukaemia (APL)
- Acne
- Photo-damage

**Dose in normal renal function**

APL: 45 mg/m² in 2 divided doses

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>300.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;95</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>60 (excreted as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.5–2 / –</td>
</tr>
</tbody>
</table>

**Metabolism**

Metabolised in the liver by the cytochrome P450 isoenzyme system to form isotretinoin, 4-oxo-trans-retinoic acid, and 4-oxo-cis-retinoic acid. Tretinoin is excreted in the bile and the urine.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR range (mL/min)</th>
<th>Dose (mg/m² daily)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>25</td>
</tr>
<tr>
<td>10–20</td>
<td>25</td>
</tr>
<tr>
<td>&lt;10</td>
<td>25</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapeutic modality</th>
<th>Dosing recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: possibly increased risk of benign intracranial hypertension with tetracyclines – avoid.
- Antifungals: possible increased risk of tretinoin toxicity with fluconazole, ketoconazole and voriconazole.
- Vitamin A: risk of hypervitaminosis – avoid.

**Administration**

**Reconstitution**

- **Route**
  - Oral, topical

**Rate of administration**

- **Other information**
  - Manufacturer recommends a reduced dose in renal impairment due to lack of data.
  - Oral bioavailability is 50%.
  - Monitor for signs of vitamin A toxicity.
  - There is a report of 2 patients who required dialysis during tretinoin treatment for acute promyelocytic leukaemia and who achieved remission; one was given a dose of 20 mg/m² daily in 2 divided doses and the other received 35 mg/m² daily in 3 divided doses. (Takitan K, Nagai K, Kanbe E, et al. Pharmacokinetics of all-trans retinoic acid in acute promyelocytic leukemia patients on dialysis. *Am J Hematol*. 2003; 74(2): 147–8.)
Triamcinolone

**Clinical use**
Corticosteroid

**Dose in normal renal function**
IM: 40 mg of acetone; maximum single dose 100 mg
Intra-articular: 2.5–40 mg of acetone, total max 80 mg
Intra-dermal: 2–3 mg, maximum 5 mg at any one site, total maximum 30 mg

**Pharmacokinetics**
Molecular weight (daltons) 394.4 (434.5 as acetone)
% Protein binding Low
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 1.4–2.1
Half-life — normal/ESRF (hrs) 2–5 / Unchanged

**Metabolism**
Triamcinolone is metabolised largely hepatically but also by the kidney and is excreted in urine. The main metabolic route is 6-beta-hydroxylation; no significant hydrolytic cleavage of the acetone occurs.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antibacterials: metabolism accelerated by rifamycins; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced.
- Anticoagulants: efficacy of coumarins and phenindione may be altered.
- Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
- Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited by itraconazole and ketoconazole.
- Antivirals: concentration possibly increased by ritonavir.
- Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids.
- Cobicistat: concentration of triamcinolone possibly increased.
- Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
- Vaccines: high dose corticosteroids can impair immune response to vaccines; avoid with live vaccines.

**Administration**

**Reconstitution**
—

**Route**
IM, intra-articular, topical, nasal, intradermal

**Rate of administration**
—

**Other information**
- Use with caution in severe renal impairment as sodium and water retention may occur.
- 4 mg is equivalent to 5 mg of prednisolone
**Triamterene**

### Clinical use
Diuretic (potassium-sparing)

### Dose in normal renal function
150–250 mg daily in divided doses; reduce to alternate days after 1 week

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>253</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>60%</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>5–10%</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2.2–3.7</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>2 / 10</td>
</tr>
</tbody>
</table>

### Metabolism
Triamterene is extensively metabolised apparently via the cytochrome P450 isoenzyme CYP1A2. It is mainly excreted in the urine in the form of metabolites with some unchanged triamterene; variable amounts are also excreted in the bile.

### Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Avoid. See 'Other information'.
- <10: Avoid. See 'Other information'.

### Dose in patients undergoing renal replacement therapies

### Important drug interactions
Potentially hazardous interactions with other drugs:
- ACE inhibitors and angiotensin-II antagonists: enhanced hypotensive effect (risk of severe hyperkalaemia).
- Analgesics: increased risk of nephrotoxicity with NSAIDs; increased risk of hyperkalaemia, especially with indometacin; antagonism of hypotensive effect.
- Antibacterials: avoid concomitant use with lymecycline.
- Antidepressants: enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antipsychotics: enhanced hypotensive effect with phenothiazines.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect of post-synaptic alpha-blockers, e.g. prazosin.
- Ciclosporin: increased risk of hyperkalaemia.
- Cytotoxics: increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium: reduced excretion of lithium (risk of lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia.

### Administration

#### Reconstitution
- —

#### Route
- Oral

#### Rate of administration
- —

### Other information
- Hyperkalaemia is common when GFR<30 mL/min. May cause acute kidney injury.
- Potassium-sparing diuretics are weak diuretics and are ineffective in moderate to severe renal failure.
- Bioavailability is 50%.
**Clinical use**
- Schizophrenia and other psychoses
- Anxiety
- Severe nausea and vomiting

**Dose in normal renal function**
- Schizophrenia: Initially 5 mg twice daily, increased by 5 mg after 1 week, then at intervals of 3 days according to response
- Anxiolytic and anti-emetic: 2–4 mg daily in divided doses; maximum 6 mg

**Pharmacokinetics**
- Molecular weight (daltons) 407.5
- % Protein binding >99
- % Excreted unchanged in urine <1
- Volume of distribution (L/kg) 160
- Half-life — normal/ESRF (hrs) 22 / –

**Metabolism**
Trifluoperazine undergoes extensive first pass metabolism. The major metabolite is the possibly active N-oxide; other metabolites include the sulfoxide and the 7-hydroxy derivative. Elimination occurs in the bile and urine.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function. Start with low dose.
- <10: Dose as in normal renal function. Start with low dose.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
- Potentially hazardous interactions with other drugs
  - Anaesthetics: enhanced hypotensive effect.
  - Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
  - Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide, drenedaron and amiodarone – avoid with amiodarone and drenedaron.
  - Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxac in – avoid with moxifloxacin.
  - Antidepressants: increased level of triclics; possibly increased risk of antimuscarinic side effects; risk of ventricular arrhythmias with citalopram and escitalopram – avoid; possible increased risk of convulsions with vortioxetine.
  - Antiepileptics: antagonism (convulsive threshold lowered).
  - Antimalarials: avoid with artemether/lumefantrine and piperaquine with arteminol.
  - Antipsychotics: increased risk of ventricular arrhythmias with droperidol and pimozide – avoid; possible increased risk of ventricular arrhythmias with risperidone.
  - Antivirals: concentration possibly increased with ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid.
  - Atomoxetine: increased risk of ventricular arrhythmias.
  - Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol.
  - Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
  - Diuretics: enhanced hypotensive effect.
  - Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
  - Pentamidine: increased risk of ventricular arrhythmias.

**Administration**

**Reconstitution**
- __

**Route**
- Oral

**Rate of administration**
- __

**Other information**
- Reduce starting dose in elderly or frail patients by at least half.
Trimethoprim

**Clinical use**

Antibacterial agent

**Dose in normal renal function**

Treatment: 200 mg every 12 hours  
Prophylaxis: 100 mg at night

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>290.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>45</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>40–60</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>1–2.2</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>8–10 / 20–49</td>
</tr>
</tbody>
</table>

**Metabolism**

About 10 to 20% of trimethoprim is metabolised in the liver and small amounts are excreted in the faeces via the bile, but most, about 40 to 60% of a dose, is excreted in urine, mainly as unchanged drug.  
Trimethoprim is excreted mainly by the kidneys through glomerular filtration and tubular secretion.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose as in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;25</td>
<td></td>
</tr>
<tr>
<td>15–25</td>
<td></td>
</tr>
<tr>
<td>&lt;15</td>
<td>50–100% of dose.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose in normal renal function.</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs

- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; concentration of procainamide increased.
- Antiepileptics: antifolate effect and concentration of fosphenytoin and phenytoin increased.
- Antimalarials: increased risk of antifolate effect with pyrimethamine.
- Ciclosporin: increased risk of nephrotoxicity; concentration of ciclosporin reduced by IV trimethoprim.
- Cytotoxics: increased risk of haematological toxicity with azathioprine, methotrexate and mercaptopurine; antifolate effect of methotrexate increased.
- Tacrolimus: possible increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

<table>
<thead>
<tr>
<th>Route</th>
<th>Oral</th>
</tr>
</thead>
</table>

**Rate of administration**

| — | — |

**Other information**

- Serum creatinine may rise due to competition for renal secretion.
- Hyperkalaemia is common in CKD 5 and transplant patients.
- New Zealand data sheet advises to use with caution if GFR<10 mL/min and monitor potassium.
- Short-term folic acid supplementation may be prescribed in patients with CKD 4–5 to cover antifolate effects of treatment dose.
Trimipramine

**Clinical use**
Tricyclic antidepressant

**Dose in normal renal function**
- 50–300 mg daily in divided doses
- Elderly: 10–25 mg 3 times daily; half the dose should be sufficient for maintenance

**Pharmacokinetics**
- Molecular weight (daltons) 410.5 (as maleate)
- % Protein binding 95
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) 31
- Half-life — normal/ESRF (hrs) 23 / –

**Metabolism**
Trimipramine is metabolised in the liver to its major metabolite desmethyltrimipramine, which is active. Trimipramine is excreted in the urine mainly in the form of its metabolites.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Alcohol: increased sedative effect.
- Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid; increased risk of ventricular arrhythmias with disopyramide, flecainide or propafenone; avoid with dronedarone.
- Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin and possibly telithromycin – avoid with delamanid and moxifloxacin.
- Anticoagulants: may alter anticoagulant effect of coumarins.
- Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide – avoid; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram – avoid; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, phenobarbital and possibly fosphenytoin, phenytoin and primidone.
- Antimalarials: avoid with artemether/lumefantrine and piperaquine with artemilor.
- Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, fluphenazine, haloperidol, pimozide, sulpiride and zuclopenthixol – avoid; increased risk of ventricular arrhythmias with risperidone; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.
- Antivirals: increased risk of ventricular arrhythmias with saquinavir – avoid; concentration possibly increased with ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
- Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.
- Dapoxetine: possibly increased risk of serotonergic effects – avoid.
- Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline.
- Pentamidine: increased risk of ventricular arrhythmias.
- Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.

**Administration**

**Reconstitution**
- **Route**: Oral
- **Rate of administration**
# Triptorelin

## Clinical use
- Advanced prostate cancer
- Endometriosis
- Precocious puberty
- Uterine fibroids prior to surgery

## Dose in normal renal function
- 3–3.75 mg every 4 weeks; depends on preparation
- 11.25 mg every 3 months

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>1311.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>3–14</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>92.4–115.8 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>7.5 / Unchanged</td>
</tr>
</tbody>
</table>

## Metabolism
The metabolism of triptorelin in humans is unknown, but it is thought to be hydrolysed in the plasma and excreted in the urine as inactive metabolites.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function, but monitor carefully.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function, but monitor carefully.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- None known

## Administration
**Reconstitution**
With 2 mL diluent provided
**Route**
SC, IM
**Rate of administration**
—

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min</td>
</tr>
</tbody>
</table>
Trospium chloride

**Clinical use**

**Antimuscarinic:**
- Symptomatic treatment of urinary incontinence, frequency or urgency

**Dose in normal renal function**
- 20 mg twice daily
- XL: 60 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons) 428
- % Protein binding 50–80
- % Excreted unchanged in urine 5.8
- Volume of distribution (L/kg) 395 Litres / XL: >600 Litres
- Half-life — normal/ESRF (hrs) 10–20 (XL: 38.5) / 20–40 (XL: 77)

**Metabolism**

The metabolic pathway of trospium in humans has not been fully defined. Of the 10% of the dose absorbed, metabolites account for approximately 40% of the excreted dose following oral administration. The major metabolic pathway is hypothesised as ester hydrolysis with subsequent conjugation of benzylic acid to form azoniaspironortropanol with glucuronic acid. The mean renal clearance for trospium (29 L/hour) is 4-fold higher than average glomerular filtration rate, indicating that active tubular secretion is a major route of elimination for trospium. There may be competition for elimination with other compounds that are also renally eliminated.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>20 mg daily or on alternate days. See 'Other information'.</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td>20 mg daily or on alternate days. See 'Other information'.</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>20 mg daily or on alternate days. See 'Other information'.</td>
<td></td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Probably dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Probably dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Probably dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Probably dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.

**Administration**

**Reconstitution**
- —

**Route**
- Oral

**Rate of administration**
- —

**Other information**
- Oral bioavailability is <10%.
- In a study conducted on patients with CRCL=8–32 mL/min the average AUC was increased 4-fold and the C<sub>max</sub> 2-fold.
- Avoid XL preparation patients with GFR<30 mL/min due to lack of data for dosage adjustments.
Urokinase

**Clinical use**

Fibrinolytic agent:
- Thrombosed arteriovenous shunts and intravenous cannulas
- Treatment of thromboembolic occlusive vascular disease, e.g. DVT, PE, peripheral vascular occlusion

**Dose in normal renal function**

- Lock: 5000–250 000 IU for 30 minutes – 2 hours
- Infusion: 5000–250 000 IU over 30 minutes – 48 hours, depending on local protocol
- Treatment of thromboembolic occlusive vascular disease: dose varies according to preparation and location of thrombus
- Consult product literature for more information

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>33 000–54 000</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>No data</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Low</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>No data</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>20 minutes / Increased</td>
</tr>
</tbody>
</table>

**Metabolism**

Urokinase is eliminated rapidly from the circulation by the liver.
The inactive degradation products are excreted mainly via the kidneys and also the bile.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**

2 mL of sodium chloride 0.9%

**Route**

—

**Rate of administration**

Various

**Other information**

- Can also be administered during dialysis.
- Care in patients with uraemic coagulopathies or bleeding diatheses.
- Some units mix 5000 IU of urokinase with 1.5 mL heparin 1000 u/mL.
Ursodeoxycholic acid

**Clinical use**
- Dissolution of gallstones
- Primary biliary cirrhosis

**Dose in normal renal function**
- Dissolution of gallstones: 8–12 mg/kg/day in 1–2 divided doses
- Primary biliary cirrhosis: 12–16 mg/kg in 3 divided doses

**Pharmacokinetics**
- Molecular weight (daltons) 392.6
- % Protein binding 96–98%
- % Excreted unchanged in urine 0
- Volume of distribution (L/kg) No data
- Half-life — normal/ESRF (hrs) No data

**Metabolism**
Ursodeoxycholic acid is absorbed from the gastrointestinal tract and undergoes enterohepatic recycling. It is partly conjugated in the liver before being excreted into the bile. Under the influence of intestinal bacteria the free and conjugated forms undergo 7α-dehydroxylation to lithocholic acid, some of which is excreted directly in the faeces and the rest absorbed and mainly conjugated and sulphated by the liver before excretion in the faeces.

**Dose in renal impairment GFR (mL/min)**
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD Unknown dialysability. Dose as in normal renal function.
- HD Unknown dialysability. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Ciclosporin: unpredictably increases the absorption of ciclosporin in some patients.

**Administration**
- Reconstitution —
- Route Oral
- Rate of administration —
Valaciclovir

Clinical use

Antiviral:
• Herpes zoster and simplex
• Prevention of cytomegalovirus (CMV) disease after renal transplantation

Dose in normal renal function

• Herpes simplex (HSV): 500 mg twice daily for 5–10 days
  (Immunocompromised: 1 g twice daily for 10 days)
• Herpes simplex suppression: 500 mg daily in 1–2 divided doses (500 mg twice daily in the immunocompromised)
• Herpes zoster: 1 g 3 times a day for 7 days
• Herpes labialis: 2 g stat then 2 g twice daily
• Prevention of CMV disease: 2 g 4 times a day for 90 days

Pharmacokinetics

Molecular weight (daltons) 360.8 (as hydrochloride)
% Protein binding 15
% Excreted unchanged in urine <1
Volume of distribution (L/kg) 0.7
Half-life — normal/ESRF (hrs) 3 / 14

Metabolism

Valaciclovir is readily absorbed from the gastrointestinal tract after oral doses, and is rapidly and almost completely converted to aciclovir and valine by first-pass intestinal or hepatic metabolism.
Aciclovir is converted to a small extent to the metabolites 9(carboxymethoxy)methylguanine (CMMG) by alcohol and aldehyde dehydrogenase and to 8-hydroxy-aciclovir (8-OH-ACV) by aldehyde oxidase. Approximately 88% of the total combined plasma exposure is attributable to aciclovir, 11% to CMMG and 1% to 8-OH-ACV.
Valaciclovir is eliminated mainly as aciclovir and its metabolite 9- CMMG; less than 1% of a dose of valaciclovir is excreted unchanged in the urine.

Dose in renal impairment GFR (mL/min)

For HSV and Herpes zoster:
50–75 Dose as in normal renal function.
30–50 HSV (treatment and suppression):
  HSV treatment: 500 mg daily.
  HSV (immunocompromised): 1 g daily
  HSV suppression: 250 mg daily
  HSV suppression
  (immunocompromised): 500 mg daily or 250 mg every 12 hours
  Herpes zoster: 1 g daily
  Herpes labialis: 500 mg stat then 500 mg twice daily
<10 HSV treatment:
  HSV treatment:
  HSV treatment
  (immunocompromised): 1 g daily
  HSV suppression:
  HSV suppression (immunocompromised): 500 mg daily or 250 mg every 12 hours
  Herpes zoster: 500 mg daily
  Herpes labialis: 500 mg stat dose

For CMV prophylaxis:
50–75 1.5 g every 6 hours
25–50 1.5 g every 8 hours
10–25 1.5 g every 12 hours
<10 1.5 g once daily

Dose in patients undergoing renal replacement therapies

APD/CAPD Not dialysed. Give 1g once daily and monitor for toxicity.
HD Dialysed. Dose as in GFR<10 mL/min post dialysis.
HDF/High flux Dialysed. Dose as in GFR<10 mL/min post dialysis.
CAV/VVHD Likely dialysability. Dose as in GFR=10–30 mL/min. See ‘Other information’.

Important drug interactions

Potentially hazardous interactions with other drugs
- Ciclosporin: may alter ciclosporin levels; possibly increased risk of nephrotoxicity.
- Mycophenolate: higher concentrations of both aciclovir and mycophenolic acid on concomitant administration.
- Tacrolimus: possibly increased risk of nephrotoxicity.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

- **Other information**
  - Bioavailability of aciclovir from 1 g oral dose of valaciclovir is 54%.
  - Mean peak aciclovir concentrations occur 1.5 hours post dose; peak plasma concentrations of valaciclovir are 4% of aciclovir levels, occur at a median of 30–60 minutes post dose, and are at or below the limit of quantification 3 hours post dose.
  - The dose quoted in the literature for CMV prophylaxis in transplant recipients is 2 g 4 times a day. However, in practice this results in severe aciclovir toxicity, especially in patients with poorly functioning grafts.
  - There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
Valganciclovir

**Clinical use**
- Induction and maintenance treatment of CMV retinitis in AIDS patients
- Treatment and prophylaxis of CMV disease in transplant patients

**Dose in normal renal function**
- Induction / Treatment: 900 mg twice daily for 21 days
- Maintenance / Prophylaxis: 900 mg once daily

**Pharmacokinetics**
- Molecular weight (daltons): 390.8 (as hydrochloride)
- % Protein binding: <2 (as ganciclovir)
- % Excreted unchanged in urine: 84.6–94.6 (as ganciclovir)
- Volume of distribution (L/kg): 0.519–0.841
- Half-life — normal/ESRF (hrs): 4.1 / 67.5

**Metabolism**
Valganciclovir is well absorbed from the gastrointestinal tract and rapidly and extensively metabolised in the intestinal wall and liver to ganciclovir. Valganciclovir is eliminated in the urine as unchanged ganciclovir, mainly by glomerular filtration and also active tubular secretion.

**Dose in renal impairment GFR (mL/min)**
- 10–24: Treatment: 450 mg every 48 hours. Prophylaxis: 450 mg twice weekly.
- <10: Treatment: 450 mg 2–3 times a week. Prophylaxis: 450 mg 1–2 times a week.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. See ‘Other information’.
- HD: Dialysed. See ‘Other information’.
- HDF/High flux: Dialysed. See ‘Other information’.
- CAV/VVHD: Dialysed. Dose as in GFR=10–24 mL/min. See ‘Other information’.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of convulsions with imipenem-cilastatin.
- Antivirals: possibly increased didanosine concentration; profound myelosuppression with zidovudine – avoid if possible.
- Mycophenolate: possibly increased concentrations of both mycophenolic acid and ganciclovir.
- Increased risk of myelosuppression with other myelosuppressive drugs.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- 900 mg valganciclovir twice daily is therapeutically equivalent to 5 mg/kg intravenous ganciclovir twice daily.
- Valganciclovir is a prodrug of ganciclovir.
- Take with food if possible.
- It is recommended that complete blood counts and platelet counts be monitored during therapy especially in patients with renal impairment.
- Approximately 50% of ganciclovir is removed by haemodialysis.
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, replacement rate = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.
- An alternative treatment regimen used in some units is:
<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;50</td>
<td>900 mg twice daily</td>
</tr>
<tr>
<td>25–50</td>
<td>450 mg twice daily</td>
</tr>
<tr>
<td>10–25</td>
<td>450 mg once daily</td>
</tr>
<tr>
<td>&lt;10</td>
<td>450 mg 3 times a week</td>
</tr>
</tbody>
</table>
Valproate semisodium

**Clinical use**
- Treatment of manic episodes associated with bipolar disorder
- Migraine prophylaxis (unlicensed)

**Dose in normal renal function**
- 750 mg–2 g daily in 2–3 divided doses
- Migraine prophylaxis: 250 mg twice daily increased to 1 g daily in divided doses if required

**Pharmacokinetics**
- Molecular weight (daltons) 310.4
- % Protein binding 85–94
- % Excreted unchanged in urine <3
- Volume of distribution (L/kg) 0.1–0.4
- Half-life — normal/ESRF (hrs) 14 / Increased

**Metabolism**
Valproic acid is extensively metabolised in the liver, a large part by glucuronidation (up to 60%) and the rest by a variety of complex pathways (up to 45%). It is excreted in the urine almost entirely in the form of its metabolites; small amounts are excreted in faeces and expired air.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Start with a low dose, adjust according to response.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism possibly inhibited by erythromycin; avoid with pivmecillinam; concentration reduced by carbapenems — avoid.
- Antidepressants: avoid with St John’s wort.
- Antiepileptics: concentration reduced by carbamazepine; concentration of active carbamazepine metabolite increased; increased concentration of lamotrigine, phenobarbital, rufinamide and possibly ethosuximide; sometimes reduces concentration of active metabolite of oxcarbazepine; alters phenytoin concentration; phenytoin and phenobarbital reduce valproate concentration; hyperammonaemia and CNS toxicity with topiramate.
- Antipsychotics: increased neutropenia with olanzapine; possibly increases or decreases concentration of clozapine; possibly increases quetiapine concentration.
- Ciclosporin: variable ciclosporin blood level response.
- Sodium oxybate: concentration of sodium oxybate increased.
- Ulcer-healing drugs: metabolism inhibited by cimetidine, increased concentration.

**Administration**

**Reconstitution**
- —

**Route**
- Oral

**Rate of administration**
- —

**Other information**
- May cause carnitine deficiency.
- Dialysis removes about 20% of dose.
- Tablets can be crushed but may result in increased gastrointestinal side effects.
Valsartan

**Clinical use**

Angiotensin-II antagonist:
- Hypertension
- Heart failure
- Myocardial infarction with left ventricular failure

**Dose in normal renal function**

- Hypertension: 40–320 mg daily in divided doses
- Heart failure: 40–160 mg twice daily
- Myocardial infarction: 20–160 mg twice daily

**Pharmacokinetics**

Molecular weight (daltons) 435.5
% Protein binding 94–97
% Excreted unchanged in urine 13
Volume of distribution (L/kg) 17 Litres
Half-life — normal/ESRF (hrs) 5–9 / Unchanged

**Metabolism**

Valsartan is not highly metabolised as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.

Valsartan is mainly eliminated by biliary excretion in faeces (about 83% of dose) and renally in urine (about 13% of dose), mainly as unchanged drug.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Initial dose 40 mg; titrate according to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Initial dose 40 mg; titrate according to response.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Method</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effect.
- Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
- Antihypertensives: increased risk of hyperkalaemia, hypotension and renal impairment with ACE-Is and aliskiren.
- Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
- Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
- ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
- Lithium: reduced excretion (possibility of enhanced lithium toxicity).
- Potassium salts: increased risk of hyperkalaemia.
- Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

**Administration**

**Reconstitution**

- **Route**
  - Oral

**Rate of administration**

**Other information**

- Bioavailability is 23%.
- Side effects (e.g. hyperkalaemia, metabolic acidosis) are more common in patients with impaired renal function.
- Close monitoring of renal function during therapy is necessary in those with renal insufficiency.
- Renal failure has been reported in association with angiotensin-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with severe congestive heart failure.
Vancomycin

Clinical use
Antibacterial agent

Dose in normal renal function
- IV: 1–1.5 g every 12 hours
- Or as per local protocol
- Oral: 125 mg up to 500 mg 4 times daily
  (Higher dose for resistant cases of Clostridium difficile)

Pharmacokinetics
Molecular weight (daltons) 1449.3 (1485.7 as hydrochloride)
% Protein binding 10–50 (19 CKD 5)
% Excreted unchanged in urine 80–90
Volume of distribution (L/kg) 0.47–1.1 (0.88 CKD 5)
Half-life — normal/ESRF (hrs) 6 / 120–216

Metabolism
Little or no metabolism of vancomycin is thought to take place. It is excreted unchanged by the kidneys, mostly by glomerular filtration. There is a small amount of non-renal clearance, although the mechanism for this has not been determined.

Dose in renal impairment GFR (mL/min)
See ‘Other information’ for alternative method in moderate and severe renal impairment.
20–50  IV: 0.5–1 g every 12–24 hours
  Oral: Dose as in normal renal function.
10–20  IV: 0.5–1 g every 24–48 hours or as per local protocol.
  Oral: Dose as in normal renal function.
<10  IV: 0.5–1 g every 48–96 hours or as per local protocol.
  Oral: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD  Not dialysed. Dose as in GFR<10 mL/min.
HD  Not dialysed. Dose as in GFR<10 mL/min.
HDF/High flux  Dialysed. See ‘Other information’.
CAV/VVH/HD:  Dialysed. 1 g every 48 hours. Or as per local protocol.
CVVHD/HDF  Dialysed. 1 g daily and see ‘Other information’. Or as per local protocol.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of nephrotoxicity and ototoxicity with aminoglycosides, capreomycin or colistimethate sodium; increased risk of nephrotoxicity with polymyxins.
- Ciclosporin: variable response; increased risk of nephrotoxicity.
- Diuretics: increased risk of ototoxicity with loop diuretics.
- Muscle relaxants: enhanced effects of suxamethonium.
- Tacrolimus: possible increased risk of nephrotoxicity.

Administration
Reconstitution
10 mL water for injection per 500 mg vial, then dilute 1 g to 250 mL with sodium chloride 0.9% (50 mL if giving centrally).

Route
IV, oral

Rate of administration
Not faster than 10 mg/minute

Comments
Usual dilution is 10–20 mg/mL. (UK Critical Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006.)

USE IN CAPD PERITONITIS:
- 12.5–25 mg/L per bag (See local protocol.)
- Various other regimens used in PD ranging from IV dosing to high dose stat IP use.
- Some units use the following:
  - Patient weight >60 kg: stat dose of 2 g IP on days 1, 7 and 14 in with a 6 hour dwell.
  - Patient weight <60 kg: 1.5 g IP on days 1, 7 and 14.

Other information
- Second line to metronidazole in treatment of pseudomembranous colitis.
- Not absorbed via oral route at low doses but monitor plasma levels at higher doses.
- Injection solution may be given orally; however, oral capsules available.
- Alternative dosage adjustment in moderate and severe renal impairment:
  - Give 1 g loading dose and monitor serum levels at 24 hour intervals. When level <10 mg/L give another 1 g dose. Peak levels, 2 hours after dose, should be in
range 18–26 mg/L. Some units use a 500 mg loading dose.

- Anephric/dialysis patients usually need 1 g once or twice weekly.
- In HDF higher doses are required; possible doses are 1 g initially followed by 500 mg every dialysis for 3 dialysis sessions. (Ariano RE, Fine A, Sitar DS, et al. Adequacy of a vancomycin dosing regimen in patients receiving high-flux haemodialysis. Am J Kidney Dis. 2005; 46(4): 681–7.)
- There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

Reference:
**Vandetanib**

### Clinical use

Tyrosine kinase inhibitor:
- Treatment of aggressive and symptomatic medullary thyroid cancer

### Dose in normal renal function

300 mg once daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>475.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>Approximately 90%</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>25</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>7450 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>19 days / Increased</td>
</tr>
</tbody>
</table>

### Metabolism

N-desmethyl-vandetanib is primarily produced by CYP3A4, and vandetanib-N-oxide is primarily produced by flavin–containing monoxygenase enzymes FMO1 and FMO3.

Unchanged vandentanib and metabolites vandetanib N-oxide and N-desmethyl vandetanib were detected in plasma, urine (25%) and faeces (44%).

### Dose in renal impairment GFR (mL/min)

- **30–50** Initially 200 mg daily. See ‘Other information’.
- **10–30** Initially 200 mg daily. See ‘Other information’.
- **<10** Initially 200 mg daily. See ‘Other information’.

### Dose in patients undergoing renal replacement therapies

- **APD/CAPD** Unlikely to be dialysed. Dose as in GFR< 10 mL/min. Use with caution.
- **HD** Unlikely to be dialysed. Dose as in GFR<10 mL/min. Use with caution.
- **HDF/High flux** Unlikely to be dialysed. Dose as in GFR<10 mL/min. Use with caution.
- **CAV/VVHD** Unlikely to be dialysed. Dose as in GFR=10–30 mL/min. Use with caution.

### Important drug interactions

Potentially hazardous interactions with other drugs
- **Analgesics**: possibly increased risk of ventricular arrhythmias with methadone – avoid.
- **Anti-arrhythmics**: possibly increased risk of ventricular arrhythmias with amiodarone or disopyramide – avoid.
- **Antibacterials**: possibly increased risk of ventricular arrhythmias with parenteral erythromycin and moxifloxacin – avoid; concentration reduced by rifampicin – avoid.
- **Antihistamines**: possibly increased risk of ventricular arrhythmias with mizolastine – avoid.
- **Antimalarials**: possibly increased risk of ventricular arrhythmias with artemether with lumefantrine – avoid.
- **Antipsychotics**: possibly increased risk of ventricular arrhythmias with amisulpiride, chlorpromazine, haloperidol, pimozide, sulpiride and zuclopenthixol – avoid; avoid concomitant use with clozapine, risk of agranulocytosis.
- **Beta-blockers**: possibly increased risk of ventricular arrhythmias with sotalol – avoid.
- **Cytotoxics**: possibly increased risk of ventricular arrhythmias with arsenic trioxide – avoid.
- **Hormone antagonist**: possibly increased risk of ventricular arrhythmias with toremifene – avoid.
- **5HT3-receptor antagonists**: possibly increased risk of ventricular arrhythmias with ondansetron – avoid.
- **Pentamidine**: possibly increased risk of ventricular arrhythmias – avoid.

### Administration

**Reconstitution**

- **Route** Oral

**Rate of administration**

- **Other information**
  - Although an initial dose of 200 mg has been recommended by the UK manufacturer in moderate renal impairment there is little safety or efficacy data for this dose. Not recommended in severe renal impairment due to lack of data.
  - Dosage in severe renal impairment from US data sheet.
• Vandetanib can prolong the QT interval so is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

• A pharmacokinetic study in volunteers with mild, moderate and severe renal impairment (GFR<30 mL/min) shows that exposure to vandetanib after a single dose is increased up to 1.5, 1.6 and 2-fold respectively.
Vardenafil

Clinical use
Treatment of erectile dysfunction

Dose in normal renal function
5–20 mg approximately 25–60 minutes before sexual activity, maximum 1 dose per day
Dose depends on preparation

Pharmacokinetics
Molecular weight (daltons) 488.6
% Protein binding 95
% Excreted unchanged in urine 2–6
Volume of distribution (L/kg) 208 Litres
Half-life — normal/ESRF (hrs) 4–5

Metabolism
Vardenafil is metabolised in the liver primarily by cytochrome P450 isoenzymes CYP3A4 (the major route) as well as CYP3A5 and CYP2C isoforms. The major metabolite produced by desethylaion of vardenafil also has some activity.
Vardenafil is excreted as metabolites mainly in the faeces (91 to 95%), and to a lesser extent in the urine.

Dose in renal impairment GFR (mL/min)
30–50 Dose as in normal renal function.
10–30 Initial dose 5 mg and adjust accordingly.
<10 Initial dose 5 mg and adjust accordingly.

Dose in patients undergoing renal replacement therapies
APD/CAPD Not dialysed. Dose as in GFR<10 mL/min. Use with caution.
HD Not dialysed. Dose as in GFR<10 mL/min. Use with caution.
HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min. Use with caution.
CAV/VVHD Not dialysed. Dose as in GFR=10–30 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Alpha-blockers: enhanced hypotensive effect – avoid for 6 hours after alpha-blockers (max dose 5 mg).
- Antifungals: concentration increased by ketoconazole, and itraconazole – avoid concomitant use.
- Antivirals: concentration increased by fosamprenavir, indinavir and ritonavir – avoid with indinavir and ritonavir; increased risk of ventricular arrhythmias with saquinavir – avoid; avoid with telaprevir, use tipranavir with caution.
- Cobicistat: concentration of vardenafil possibly increased – reduce dose of vardenafil.
- Grapefruit juice: concentration possibly increased – avoid concomitant use.
- Nicorandil: possibly enhanced hypotensive effect – avoid concomitant use.
- Nitrates: possibly enhanced hypotensive effect – avoid concomitant use.
- Riociguat: enhanced hypotensive effect – avoid concomitant use.

Administration
Reconstitution
Route
Oral
Rate of administration

Other information
- Contraindicated in dialysis patients due to lack of information, therefore suggest use with caution.
- Bioavailability is 15%.
## Varenicline

### Clinical use

Aid to smoking cessation

### Dose in normal renal function

0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, then 0.5–1 mg twice daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>361.3 (as tartrate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&lt;20</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>92</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>415</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>24 / Increased</td>
</tr>
</tbody>
</table>

### Metabolism

Varenicline undergoes minimal metabolism with less than 10% excreted as metabolites. About 92% of a dose is excreted unchanged in the urine. Minor metabolites in urine include varenicline N-carbamoylglucuronide, N-glucosylvarenicline and hydroxyvarenicline. In circulation, varenicline comprises 91% of drug-related material.

### Dose in renal impairment GFR (mL/min)

Initial doses as for normal renal function, then maintenance doses of:

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>1 mg once or twice daily.</td>
</tr>
<tr>
<td>10–30</td>
<td>0.5–1 mg daily.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>0.5–1 mg daily.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. 0.5 mg once daily.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. 0.5 mg once daily.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. 0.5 mg once daily.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- None known

### Administration

**Reconstitution**
- 

**Route**
- Oral

**Rate of administration**
- 

### Other information

- Contraindicated by manufacturer in end-stage renal disease in UK SPC, US data sheet advises a maximum dose of 0.5 mg once daily.
## Vecuronium bromide

### Clinical use
Non-depolarising muscle relaxant

### Dose in normal renal function
- **Intubation:** 80–100 micrograms/kg, with maintenance of 20–30 micrograms/kg
- **IV infusion:** 0.8–1.4 micrograms/kg/minute adjusted according to response

### Pharmacokinetics
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>637.7</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>25</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.18–0.27</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>0.5–1.3 / Unchanged</td>
</tr>
</tbody>
</table>

### Metabolism
Vecuronium partly metabolised by the liver; the metabolites have some neuromuscular blocking activity. It is excreted mainly in bile as unchanged drug and metabolites; some is also excreted in the urine.

### Dose in renal impairment GFR (mL/min)
- **20–50** Dose as in normal renal function.
- **10–20** Dose as in normal renal function.
- **<10** Dose as in normal renal function.

### Dose in patients undergoing renal replacement therapies
- **APD/CAPD** Unlikely to be dialysed. Dose as in normal renal function.
- **HD** Unlikely to be dialysed. Dose as in normal renal function.
- **HDF/High flux** Unknown dialysability. Dose as in normal renal function.
- **CAV/VVHD** Unknown dialysability. Dose as in normal renal function.

### Important drug interactions
Potentially hazardous interactions with other drugs
- **Anaesthetics:** enhanced muscle relaxant effect.
- **Anti-arrhythmics:** procainamide enhances muscle relaxant effect.
- **Antibacterials:** effect enhanced by aminoglycosides, clindamycin, polymyxins and piperacillin.
- **Antiepileptics:** muscle relaxant effects antagonised by carbamazepine; effects reduced by long-term use of fosphenytoin and phenytoin but might be increased by acute use.
- **Botulinum toxin:** neuromuscular block enhanced (risk of toxicity).

### Administration
**Reconstitution**
5 mL water for injection to reconstitute 10 mg vial; up to 10 mL sodium chloride 0.9% or glucose 5% may be used.

**Route**
- **IV**

**Rate of administration**
See dose.

**Comments**
May be added to sodium chloride 0.9%, glucose 5% or Ringer’s solution to give a final concentration of 40 mg/L.

### Other information
- Use normal doses with caution in renal failure as has active metabolites which may accumulate.
**Vedolizumab**

**Clinical use**

Monoclonal antibody:  
- Treatment of ulcerative colitis and Crohn’s disease

**Dose in normal renal function**

- 300 mg at 0, 2 and 6 weeks and every 8 weeks thereafter  
- Some patients may benefit from 300 mg every 4 weeks

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>147 000</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>0</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>Minimal</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>5 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>25 days / –</td>
</tr>
</tbody>
</table>

**Metabolism**

The expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptor-mediated clearance. The exact elimination route of vedolizumab is unknown although renal clearance is expected to be negligible.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>10–20</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Use with caution. See 'Other information'.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs  
- Live vaccines: risk of generalised infections – avoid.

**Administration**

**Reconstitution**

4.8 mL water for injection

**Route**

IV infusion

**Rate of administration**

Over 30 minutes

**Comments**

Add to 250 mL sodium chloride 0.9%

**Other information**

- Manufacturer has no data in renal impairment so therefore cannot advise on renal dosing.
Vemurafenib

**Clinical use**

BRAF kinase inhibitor:
- Treatment of metastatic melanoma

**Dose in normal renal function**

960 mg twice daily (doses 12 hours apart)

**Pharmacokinetics**

- Molecular weight (daltons) 489.9
- % Protein binding >99
- % Excreted unchanged in urine 1
- Volume of distribution (L/kg) 91–106 Litres
- Half-life — normal/ESRF (hrs) 51.6 / –

**Metabolism**

Only 5% of a dose of vemurafenib is metabolised. 94% of the dose is excreted in the faeces and 1% in the urine.

**Dose in renal impairment GFR (mL/min)**

- 40–50 Dose as in normal renal function.
- 10–40 Dose as in normal renal function. Use with caution.
- <10 Dose as in normal renal function. Use with caution.

**Dose in patients undergoing renal replacement therapies**

- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- HD Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- HDF/High flux Unlikely to be dialysed. Dose as in normal renal function. Use with caution.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function. Use with caution.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anticoagulants: possibly enhances anticoagulant effect of warfarin.
- Antipsychotics: avoid concomitant use with clozapine, risk of agranulocytosis.
- Oestrogens and progestogens: contraceptive effect possibly reduced.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Manufacturer advises to use with caution in severe renal impairment due to lack of data.
- Accumulation may occur in patients with renal impairment although there was no difference in clearance down to a GFR<40mL/min.
- May cause exposure dependent QT prolongation in which case the dose should be reduced.
- Renal toxicity, ranging from serum creatinine elevations to acute interstitial nephritis and acute tubular necrosis, has been reported with vemurafenib.
- Has been used in a patient on haemodiafiltration at normal dose with minimal side effects.
Venetoclax

Clinical use
Selective inhibitor of B-cell lymphoma protein:
- Treatment of chronic lymphocytic leukaemia

Dose in normal renal function
Initial dose: 20 mg daily increasing up to 400 mg daily over 5 weeks

Pharmacokinetics
Molecular weight (daltons) 868.4
% Protein binding Highly bound
% Excreted unchanged in urine <0.1
Volume of distribution (L/kg) 256–321 Litres
Half-life — normal/ESRF (hrs) 26

Metabolism
In vitro studies show that venetoclax is mainly metabolised by cytochrome P450 CYP3A4. M27 was identified as a major metabolite in plasma with an inhibitory activity against BCL-2 that is at least 58-fold lower than venetoclax in vitro.
Excretion is mainly by the faecal route (>99.9%; 20.8% unchanged).

Dose in renal impairment GFR (mL/min)
30–50 Dose as in normal renal function. See 'Other information'.
<30 Dose as in normal renal function. See 'Other information'.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in GFR<30 mL/min.
HD Unlikely to be dialysed. Dose as in GFR<30 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in GFR<30 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in GFR=30–50 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly increased by ciprofloxacin, clarithromycin and erythromycin – reduce venetoclax dose; avoid with rifampicin.
- Anticoagulants: avoid with dabigatran; concentration of warfarin increased.
- Antidepressants: avoid with St John’s wort.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin – avoid.
- Antifungals: concentration possibly increased by fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole – reduce venetoclax dose.
- Antipsychotics: increased risk of agranulocytosis with clozapine – avoid.
- Antivirals: concentration possibly reduced by efavirenz and etravirine – avoid; concentration possibly increased by ritonavir – reduce venetoclax dose.
- Bosentan: concentration of venetoclax possibly reduced by bosentan – avoid.
- Calcium channel blockers: concentration possibly increased by diltiazem and verapamil – reduce venetoclax dose.
- Cardiac glycosides: avoid with digoxin.
- Cytotoxics: avoid with everolimus.
- Grapefruit juice: avoid concomitant use.
- Modafinil: concentration of venetoclax possibly reduced – avoid.
- Sirolimus: avoid concomitant use.
- Vaccines: avoid with live vaccines.

Administration
Reconstitution
—
Route Oral
Rate of administration
—

Other information
- Manufacturer advises to use in severe renal impairment only if benefit outweighs risks due to lack of studies.
- Venetoclax exposure in people with mild or moderate renal impairment is similar to those with normal renal function.
- Patients with reduced renal function (CRCL<80 mL/min) may require more intensive prophylaxis and monitoring to reduce the risk of tumour lysis syndrome at initiation and during the dose-titration phase. Patients with severe renal impairment may be at more risk of tumour lysis syndrome.
Venlafaxine

Clinical use
Antidepressant:
• Depressive illness
• Generalised anxiety disorders
• Panic disorders

Dose in normal renal function
• 37.5–187.5 mg twice daily
• XL: 75–375 mg daily
• Generalised anxiety disorder: 75–225 mg once daily
• Panic disorders: 37.5–225 mg daily

Pharmacokinetics
Molecular weight (daltons) 277 (313.9 as hydrochloride)
% Protein binding 27
% Excreted unchanged in urine 5
Volume of distribution (L/kg) 7.5
Half-life — normal/ESRF (hrs) 5 / 6–8; XL: 9–21

Metabolism
Venlafaxine undergoes extensive first-pass metabolism in the liver mainly to the active metabolite O-desmethylvenlafaxine; this is mediated by the cytochrome P450 isoenzyme CYP2D6. The isoenzyme CYP3A4 is also involved in the metabolism of venlafaxine. Other metabolites include N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine. Peak plasma concentrations of venlafaxine and O-desmethylvenlafaxine occur about 2 and 4 hours after a dose, respectively. The majority of venlafaxine is excreted in the urine, mainly in the form of its metabolites, either free or in conjugated form.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–30</td>
<td>Reduce total dose by 50%.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Reduce total dose by 50%.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Analgesics: increased risk of bleeding with aspirin and NSAIDs; possibly increased serotonergic effects with tramadol.
• Anti-arrhythmics: risk of ventricular arrhythmias with amiodarone – avoid.
• Antibacterials: risk of ventricular arrhythmias with erythromycin, moxifloxacin – avoid.
• Anticoagulants: effects of warfarin possibly enhanced; possibly increased risk of bleeding with dabigatran.
• Antidepressants: avoid with MAOIs and moclobemide (increased risk of toxicity); possibly enhanced serotonergic effects with duloxetine, mirtazapine and St John’s wort; possible increased risk of convulsions with vortioxetine – avoid.
• Antimalarials: avoid concomitant use with artemether/lumefantrine and piperaquine with arteminol.
• Antipsychotics: increases concentration of clozapine and haloperidol.
• Beta-blockers: risk of ventricular arrhythmias with sotalol – avoid.
• Dapoxetine: possible increased risk of serotonergic effects – avoid.
• Dopaminergics: use entacapone with caution; increased risk of hypertension and CNS excitation with selegiline – avoid concomitant use.
• Methylthioninium: risk of CNS toxicity – avoid if possible.

Administration
Reconstitution

| Route         | Oral               |
Rate of administration

Other information

- Withhold dose until after haemodialysis to minimise nausea and any other side effects. (Personal information from Wyeth 19/01/2000.)

- May be used to treat peripheral diabetic neuropathy in haemodialysis patients; dose is up to 75 mg daily. www.medscape.com/viewarticle/440202

- An ECG is required before treatment.
Verapamil hydrochloride

**Clinical use**
Calcium-channel blocker:
- Supraventricular arrhythmias
- Angina
- Hypertension
- Cluster headaches (unlicensed)

**Dose in normal renal function**
Oral:
- Supraventricular arrhythmias: 40–120 mg 3 times daily
- Angina: 80–120 mg 3 times daily
- Hypertension: 240–480 mg daily in 2–3 divided doses
- Cluster headaches: 240–960 mg in 3-4 divided doses
IV:
- 5–10 mg followed by 5 mg, 5–10 minutes later if required

**Pharmacokinetics**
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>491.1</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>90</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>3–6</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>4.5–12 / Increased</td>
</tr>
</tbody>
</table>

**Metabolism**
Verapamil undergoes considerable first pass loss and is extensively metabolised in the liver. 12 metabolites have been identified. Of these only norverapamil has any significant activity (approximately 20% that of the parent compound). Norverapamil represents about 6% of the dose eliminated in urine and reaches steady-state plasma concentrations approximately equal to those of verapamil. About 70% of a dose is excreted by the kidneys in the form of its metabolites but about 16% is excreted in the bile into the faeces. Less than 4% is excreted unchanged.

**Dose in renal impairment GFR (mL/min)**
<table>
<thead>
<tr>
<th>GFR</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
<td>Monitor carefully</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
<td>Monitor carefully</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td>Monitor carefully</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in GFR<10 mL/min.
- HD: Not dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysability minimal. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Aminophylline and theophylline: enhanced effect of aminophylline and theophylline.
- Anaesthetics: increased hypotensive effect.
- Anti-arrhythmics: increased risk of amiodarone-induced bradycardia, AV block and myocardial depression; increased risk of myocardial depression and asystole with disopyramide and flecainide; increased risk of bradycardia and myocardial depression with dronedarone.
- Antibacterials: metabolism increased by rifampicin; metabolism possibly inhibited by erythromycin, clarithromycin and telithromycin (increased risk of toxicity).
- Anticoagulants: possibly increases dabigatran concentration – reduce dabigatran dose.
- Antidepressants: enhanced hypotensive effect with MAOIs; concentration of imipramine and possibly other tricyclics increased; concentration significantly reduced by St John’s wort.
- Antiepileptics: effect probably reduced by barbiturates, phenytoin and primidone; enhanced effect of carbamazepine.
- Antifungals: negative inotropic effect possibly increased with itraconazole.
- Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers.
- Antipsychotics: possibly increases concentration of lurasidone.
- Antivirals: concentration possibly increased by atazanavir and ritonavir; use telaprevir with caution.
- Avanafil: concentration of avanafil increased.
- Beta-blockers: enhanced hypotensive effect; risk of asystole, severe hypotension and heart failure if co-prescribed with beta-blockers.
- Cardiac glycosides: increased levels of digoxin. Increased AV block and bradycardia.
- Ciclosporin: variable reports of decreased nephrotoxicity and potentiated effect; may also increase ciclosporin levels.
- Colchicine: possibly increased risk of colchicine toxicity — suspend or reduce colchicine, avoid concomitant use in renal or hepatic failure.
- Cytotoxics: possibly increased bosutinib, doxorubicin, ibrutinib concentration — reduce dose of bosutinib and ibrutinib; possibly increased risk of bradycardia with crizotinib; concentration of both drugs may be increased in combination with everolimus — consider reducing everolimus dose; concentration of olaparib possibly increased — avoid or reduce olaparib dose.
- Fingolimod: increased risk of bradycardia.
- Grapefruit juice: concentration increased — avoid concomitant use.
- Ivabradine: concentration of ivabradine increased — avoid concomitant use.
- Lenalidomide: possibly increases lenalidomide concentration.
- Lipid-lowering agents: increased myopathy with atorvastatin and simvastatin — reduce dose of atorvastatin, do not exceed 20 mg of simvastatin¹, concentration of verapamil increased by atorvastatin; concentration of lomitapide increased — avoid.
- Sirolimus: concentration of both drugs increased.
- Tacrolimus: may increase tacrolimus levels.

## Administration

### Reconstitution

—

### Route

Oral, IV

### Rate of administration

Over 2 minutes (3 minutes in elderly)

### Other information

- Monitor BP and ECG.
- Active metabolites may accumulate in renal impairment.

## References:

Vigabatrin

Clinical use
Antiepileptic

Dose in normal renal function
1–3 g daily in single or divided doses

Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>129.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>Negligible</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>60–80</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.8</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>5–8 / 13–15</td>
</tr>
</tbody>
</table>

Metabolism
Vigabatrin is not significantly metabolised. About 60–80% of an oral dose is excreted in urine as unchanged drug.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>50–80</td>
<td>Give 75% of normal dose and titrate to response.</td>
</tr>
<tr>
<td>30–50</td>
<td>Give 50% of normal dose and titrate to response.</td>
</tr>
<tr>
<td>10–30</td>
<td>Give 25% of normal dose and titrate to response.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Give 25% of normal dose and titrate to response.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as for GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as for GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as for GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as for GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antidepressants: anticonvulsant effect antagonised, convulsive threshold lowered; avoid with St John’s wort.
- Antiepileptics: concentration of phenytoin reduced.
- Antimalarials: mefloquine antagonises anticonvulsant effect.
- Antipsychotics: anticonvulsant effect antagonised.
- Orlistat: increased risk of convulsions.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- UK SPC advises to use with caution if GFR<60 mL/min, doses in monograph are taken from US data sheet.
Vildagliptin

**Clinical use**

Dipeptidyl peptidase 4 inhibitor:
- Treatment of type 2 diabetes mellitus in combination with other antidiabetic drugs

**Dose in normal renal function**

50 mg twice daily
With a sulphonylurea: 50 mg in the morning

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>303.4</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>9.3</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>23</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>71 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3 / Increased</td>
</tr>
</tbody>
</table>

**Metabolism**

About 69% of a dose of vildagliptin is metabolised, mainly by hydrolysis in the kidney to inactive metabolites. About 85% of a dose is excreted in the urine (23% as unchanged drug), and 15% in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>50 mg</td>
</tr>
<tr>
<td>10–20</td>
<td>50 mg</td>
</tr>
<tr>
<td>&lt;10</td>
<td>50 mg</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HD**: Not dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Not dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- None known

**Administration**

**Reconstitution**
- —

**Route**
- Oral

**Rate of administration**
- —

**Other information**

- Cases of hepatic dysfunction have occasionally been reported.
- There is limited experience in patients with end-stage renal disease, use with caution.
- Oral bioavailability is 85%.
- Vildagliptin AUC increased on average 1.4, 1.7 and 2-fold in patients with mild, moderate and severe renal impairment, respectively, compared to normal healthy subjects. AUC of the metabolites LAY151 (the main metabolite) and BQS867 increased on average about 1.5, 3 and 7-fold in patients with mild, moderate and severe renal impairment, respectively. LAY151 concentrations were approximately 2–3-fold higher in patients with severe renal impairment.
- 3% of vildagliptin is removed after a 3–4 hour haemodialysis session.
- The main metabolite (LAY151) is also removed by haemodialysis.
Vinblastine sulphate

Clinical use
Antineoplastic agent

Dose in normal renal function
- 6 mg/m² (maximum of once a week)
- Testicular tumours: 0.2 mg/kg administered on each of two consecutive days every three weeks
- Or consult relevant local protocol

Pharmacokinetics
- Molecular weight (daltons) 909.1
- % Protein binding 99
- % Excreted unchanged in urine 14
- Volume of distribution (L/kg) 13–40
- Half-life — normal/ESRF (hrs) 25 / –

Metabolism
Vinblastine is extensively metabolised mainly in the liver by the CYP3A group of isoenzymes to desacetylvinblastine, which is more active than the parent compound. 33% of the drug is slowly excreted in the urine and 21% in the faeces within 72 hours.

Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function.
- 10–20 Dose as in normal renal function.
- <10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function.
- HD Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Aldesleukin: avoid concomitant use.
- Antibacterials: toxicity increased by erythromycin – avoid; possible increased risk of ventricular arrhythmias with delamanid.
- Antiepileptics: phenytoin levels may be reduced.
- Antifungals: possible increased risk of toxicity with itraconazole; metabolism possibly inhibited by posaconazole (increased risk of neurotoxicity).
- Antimalarials: avoid with piperaquine with arteminol.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).

Administration
Reconstitution
Add 10 mL of diluent to 10 mg vial. May be administered into fast-running drip of sodium chloride 0.9%.

Route
- IV

Rate of administration
- 1 minute

Comments
Do not dilute with large volumes (e.g. 100–250 mL) or give over long periods (30–60 minutes) as thrombophlebitis and extravasation may occur.
Vincristine sulphate

Clinical use
Antineoplastic agent

Dose in normal renal function
- IV: 1.4–1.5 mg/m² weekly; maximum 2 mg
- Consult relevant local protocol

Pharmacokinetics
Molecular weight (daltons) 923
% Protein binding 75
% Excreted unchanged in urine 10–20
Volume of distribution (L/kg) 5–11
Half-life — normal/ESRF (hrs) 15–155 / Unchanged

Metabolism
Vincristine is metabolised in the liver by the cytochrome P450 isoenzymes CYP3A4 and CYP3A5 and excreted mainly in the bile; about 70–80% of a dose is found in faeces, as unchanged drug and metabolites (40–50%), while 10–20% appears in the urine.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Type</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: possible increased risk of ventricular arrhythmias with delamanid.
- Antiepileptics: phenytoin levels may be reduced.
- Antifungals: metabolism possibly inhibited by itraconazole and posaconazole (increased risk of neurotoxicity).
- Antimalarials: avoid with piperaquine with arteminol.
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).
- Cytotoxics: toxicity possibly increased by asparaginase, crisantaspase and pegasparagase – give at least 3–24 hours before asparaginase, crisantaspase and pegasparagase; increased risk of hepatotoxicity with dactinomycin.

Administration
Reconstitution
- Route
  - IV
Rate of administration
- Slow bolus
Comments
- May be administered into fast running drip of sodium chloride 0.9% or glucose 5%.

Other information
- Most of an IV dose is excreted into the bile after rapid tissue binding.
Vindesine sulphate

**Clinical use**
Antineoplastic agent

**Dose in normal renal function**
3–4 mg/m² weekly

**Pharmacokinetics**
- Molecular weight (daltons) 852
- % Protein binding 65–75
- % Excreted unchanged in urine 13
- Volume of distribution (L/kg) 8
- Half-life — normal/ESRF (hrs) 20–24 / –

**Metabolism**
Vindesine is metabolised by cytochrome P450 (in the CYP 3A subfamily). Elimination is primarily via the biliary route, but 13% is excreted in urine in 24 hours.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in normal renal function.
- HD: Unlikely to be dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unlikely to be dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: possible increased risk of ventricular arrhythmias with delamanid.
- Antifungals: possible increased risk of toxicity with itraconazole.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).

**Administration**

**Reconstitution**
5 mL sodium chloride 0.9% per 5 mg vial

**Route**
IV

**Rate of administration**
1–3 minutes

**Comments**
- Can be injected into the tubing of a fast running infusion of sodium chloride 0.9%, glucose 5% or glucose/saline solutions, or directly into a vein.
- Reconstituted solution is stable for 24 hours if stored in a fridge.

**Other information**
- Nadir of the WCC occurs 3–5 days after dose with recovery after another 4–5 days.
Vinflunine

**Clinical use**
Antineoplastic agent (vinca alkaloid):
- Treatment of advanced or metastatic bladder cancer

**Dose in normal renal function**
- IV: 320 mg/m\(^2\) every 3 weeks
- Consult relevant local protocol

**Pharmacokinetics**
Molecular weight (daltons) 816.9 (1117.1 as tartrate)
% Protein binding 66.1–68.3
% Excreted unchanged in urine 33
Volume of distribution (L/kg) 35
Half-life — normal/ESRF (hrs) 40 / Increased

**Metabolism**
Metabolised by the cytochrome CYP3A4 isoenzyme, except for 4-O-deacetylvinflunine (DVFL), the only active metabolite and main metabolite in blood which is formed by multiple esterases. Excretion occurs via the faeces (about two-thirds) and the urine (about one-third).

**Dose in renal impairment GFR (mL/min)**
- 40–60: 280 mg/m\(^2\) every 3 weeks.
- 20–40: 250 mg/m\(^2\) every 3 weeks.
- <20: 250 mg/m\(^2\) every 3 weeks. Use with care.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Unlikely to be dialysed. Dose as in GFR<20 mL/min.
- HD: Unlikely to be dialysed. Dose as in GFR<20 mL/min.
- HDF/High flux: Unknown dialysability. Dose as in GFR<20 mL/min.
- CAV/VVHD: Unlikely to be dialysed. Dose as in GFR=20–40 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: possible increased risk of ventricular arrhythmias with delamanid; concentration possibly reduced by rifampicin – avoid.
- Antidepressants: concentration possibly reduced by St John’s wort – avoid.
- Antifungals: concentration increased by ketoconazole and possibly itraconazole (increased risk of neurotoxicity) – avoid.
- Antimalarials: avoid with piperaquine with artemimol.
- Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
- Antivirals: concentration possibly increased by ritonavir – avoid.
- Grapefruit juice: concentration of vinflunine increased – avoid.

**Administration**

- **Reconstitution**
  - IV infusion

- **Rate of administration**
  - Over 20 minutes

- **Comments**
  - Add to 100 mL of sodium chloride 0.9% or glucose 5%.
  - Protect from light.

**Other information**
- Vinflunine is eliminated following a multi-exponential concentration decay, with a terminal half-life close to 40 hours. DVFL is slowly formed and more slowly eliminated than vinflunine (half-life of approximately 120 hours).
## Vinorelbine

### Clinical use
- Treatment of advanced breast cancer (where other anthracyclines have failed)
- Non-small cell lung cancer

### Dose in normal renal function
- Oral: 60–80 mg/m² once weekly
- IV: 25–30 mg/m² once a week
- Maximum 60 mg per dose

### Pharmacokinetics
- Molecular weight (daltons) 1079.1 (as tartrate)
- % Protein binding 13.5 (78% bound to platelets)
- % Excreted unchanged in urine 18.5
- Volume of distribution (L/kg) >40
- Half-life — normal/ESRF (hrs) 28–44 / –

### Metabolism
Metabolism of vinorelbine appears to be hepatic. All metabolites of vinorelbine are formed by the CYP3A4 isoform of cytochromes P450, except 4-O-deacetylvinorelbine which is likely to be formed by carboxylesterases.
4-O-deacetylvinorelbine is the only active metabolite and the main one observed in blood. Excretion is mainly by the biliary route (18.5% appears in the urine).

### Dose in renal impairment GFR (mL/min)
- 20–50 Dose as in normal renal function and monitor closely.
- 10–20 Dose as in normal renal function and monitor closely.
- <10 Dose as in normal renal function and monitor closely.

### Dose in patients undergoing renal replacement therapies
- APD/CAPD Unlikely to be dialysed. Dose as in normal renal function and monitor closely.
- HD Unlikely to be dialysed. Dose as in normal renal function and monitor closely.
- HDF/High flux Unknown dialysability. Dose as in normal renal function and monitor closely.
- CAV/VVHD Unknown dialysability. Dose as in normal renal function and monitor closely.

### Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: increased risk of neutropenia with clarithromycin; possible increased risk of ventricular arrhythmias with delamanid.
- Antifungals: metabolism possibly inhibited by itraconazole, increased risk of neurotoxicity.
- Antimalarials: avoid with piperaquine with arteminol.
- Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis).

### Administration

#### Reconstitution
—

#### Route
Oral, IV bolus, infusion

#### Rate of administration
- Bolus: 5–10 minutes
- Infusion: 20–30 minutes

#### Comments
- Dilute bolus in 20–50 mL with sodium chloride 0.9%.
- Dilute infusion in 125 mL with sodium chloride 0.9%.
- Stable for 24 hours at 2–8°C.

### Other information
- Widely distributed in the body, mostly in spleen, liver, kidneys, lungs, thymus; moderately in heart, muscles; minimally in fat, brain, bone marrow. High levels are found in both normal and malignant lung tissues, with slow diffusion out of tumour tissue.
- Flush line with saline after infusion.
- Dose-limiting toxicity is mainly neutropenia.
- In patients where >75% of the liver volume has been replaced by metastases, it is empirically suggested that the dose be reduced by a third, with close haematological follow-up.
**Vismodegib**

### Clinical use

Antineoplastic agent:
- Treatment of basal cell carcinoma which is inappropriate for surgery or radiotherapy

### Dose in normal renal function

150 mg once daily

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>421.3</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>&gt;99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>4.4</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>16.4–26.6 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>12 days (single dose), 4 days (continuous)</td>
</tr>
</tbody>
</table>

### Metabolism

Vismodegib is hepatically metabolised by CYP2C9 and CYP3A4, however more than 98% of total systemic vismodegib is not metabolised. Metabolic pathways of vismodegib include oxidation, glucuronidation, and pyridine ring cleavage. The two most abundant oxidative metabolites recovered in faeces are produced in vitro by recombinant CYP2C9 and CYP3A4/5.

Vismodegib is slowly eliminated by a combination of metabolism and excretion of parent drug, the majority is recovered in the faeces (82%). Vismodegib and its metabolites are eliminated mainly by the hepatic route.

### Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>Dose as in normal renal function.</td>
<td></td>
</tr>
<tr>
<td>10–30</td>
<td>Dose as in normal renal function.</td>
<td>Monitor carefully.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
<td>Monitor carefully.</td>
</tr>
</tbody>
</table>

### Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in GFR=10–30 mL/min.</td>
</tr>
</tbody>
</table>

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: concentration possibly reduced by rifampicin — avoid.
- Antidepressants: concentration possibly reduced by St John’s wort — avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin — avoid.
- Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

### Administration

**Reconstitution**
- **Route**
  - Oral

**Rate of administration**
- **Other information**
  - Manufacturer has limited information in severe renal impairment and advises to monitor for adverse effects.
  - Pharmacokinetic data do not appear to be affected by renal impairment.
  - Teratogenic, double contraceptive measures are essential.
  - Oral bioavailability is 32%.
  - A case study used vismodegib in a patient on haemodialysis with good results and tolerability. (Maul LV, Kahler KC, Hauschild A. Effective and tolerable treatment of advanced basal cell carcinoma with vismodegib despite renal insufficiency. *JAMA Dermatol.* 2016; 152(12): 1387–8.)
Vitamin B and C preparations

Clinical use
Vitamin B and C supplementation

Dose in normal renal function
- Vitamin B Compound Strong: 1–2 tablets one to 3 times daily
- Pabrinex: Ampoules No 1 and No 2 every 8–12 hours depending on indication
- Post dialysis for vitamin supplementation: 1 pair every 2 weeks.

Pharmacokinetics
- Molecular weight (daltons): N/A
- % Protein binding: N/A
- % Excreted unchanged in urine: N/A
- Volume of distribution (L/kg): N/A
- Half-life — normal/ESRF (hrs): N/A

Metabolism
Metabolism is as per normal vitamin handling by the body.

Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
- APD/CAPD: Dialysed. Dose as in normal renal function.
- HD: Dialysed. Dose as in normal renal function.
- HDF/High flux: Dialysed. Dose as in normal renal function.
- CAV/VVHD: Dialysed. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- None known

Administration
Reconstitution
—
Route
Oral, IV, IM
Rate of administration
- Bolus: Max volume of 10 mL over 10 minutes
- Infusion: 15–30 minutes
Comments
Dilute in 50–100 mL sodium chloride or glucose 5%

Other information
- Supplement in HD patients due to loss on dialysis and poor diet.
- Available as Nephrovite® (Kimal) and Dialyvit® (Vitaline), Renavit® (Stanningley Pharma) — each tablet contains:
  - Vitamin B1 (Thiamine) 1.5 mg (Renavit 3 mg)
  - Vitamin B2 (Riboflavin) 1.7 mg
  - Vitamin B3 (niacinamide) 20 mg
  - Vitamin B6 (Pyridoxine) 10 mg
  - Vitamin B12 (cyanocobalamin) 6 mcg
  - Vitamin C 60 mg (Renavit 120 mg)
  - Biotin 300 mcg
  - Pantothenic Acid 10 mg
  - Folic Acid 800 mcg (Renavit 1 mg)
- Kevovite®, each tablet contains:
  - Vitamin B1 (Thiamine) 1 mg
  - Vitamin B2 (Riboflavin) 1 mg
  - Acetomenaphthone 500 mcg
  - Vitamin B6 (Pyridoxine) 330 mcg
  - Nicotinamide 3.3 mg
  - Vitamin C 16.6 mg
  - Biotin 170 mcg
  - Pantothenic Acid 1.16 mg
  - Alpha tocopheryl acetate 5 mg
  - Inositol 50 mg
  - Folic Acid 250 mcg
- Pabrinex:
  - Vitamin B1 (Thiamine) 250 mg
  - Vitamin B2 (Riboflavin) 4 mg
  - Vitamin B6 (Pyridoxine) 50 mg
  - Vitamin C 500 mg
  - Nicotinamide 160 mg
Voriconazole

**Clinical use**

Antifungal:
- Invasive aspergillosis
- Fluconazole-resistant serious invasive fungal infections
- Immunocompromised patients with progressive, possibly life-threatening infections

**Dose in normal renal function**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>6 mg/kg 12 hourly for 24 hours, then 3–4 mg/kg 12 hourly</td>
</tr>
<tr>
<td>Oral</td>
<td>400 mg 12 hourly for 24 hours, then 200–300 mg twice daily</td>
</tr>
</tbody>
</table>

**Pharmacokinetics**

- Molecular weight (daltons): 349.3
- % Protein binding: 58
- % Excreted unchanged in urine: <2
- Volume of distribution (L/kg): 4.6
- Half-life — normal/ESRF (hrs): 6 (depends on dose) / Unchanged

**Metabolism**

Voriconazole is metabolised by hepatic cytochrome P450 isoenzyme CYP2C19; the major metabolite is the inactive N-oxide. Metabolism via isoenzymes CYP2C9 and CYP3A4 has also been shown in vitro.

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Probably dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVH/HD/HDF</td>
<td>Dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Analgesics: concentration of diclofenac, ibuprofen, alfentanil, methadone and oxycodone increased, consider reducing alfentanil and methadone dose; concentration of fentanyl possibly increased.
- Anti-arrhythmics: avoid with dronedarone.
- Antibacterials: concentration reduced by rifabutin; increase dose of voriconazole from 200 to 350 mg and from 100 to 200 mg (depends on patient’s weight), and increase IV dose to 5 mg/kg if used in combination – avoid concomitant use if possible; increased rifabutin levels – monitor for toxicity; concentration reduced by rifampicin – avoid.
- Anticoagulants: avoid with apixaban and rivaroxaban; enhanced effect of coumarins.
- Antidepressants: avoid concomitant use with reboxetine; concentration reduced by St John’s wort – avoid.
- Antidiabetics: possibly increased concentration of sulphonylureas.
- Antiepileptics: concentration possibly reduced by carbamazepine, phenobarbital and primidone – avoid; fosphenytoin and phenytoin reduces voriconazole concentration and voriconazole increases fosphenytoin and phenytoin concentration – double oral voriconazole dose and increase IV to 5 mg/kg dose if using with phenytoin; avoid if possible.
- Antimalarials: avoid concomitant use with artemether/lumefantrine and piperaquine with artenimol.
- Antipsychotics: concentration of lurasidone increased – avoid concomitant use; increased risk of ventricular arrhythmias with pimozide – avoid concomitant use; possibly increased quetiapine levels – avoid concomitant use.
- Antivirals: concentration increased or decreased by atazanavir and concentration of atazanavir reduced; concentration of daclatasvir possibly increased – reduce daclatasvir dose; concentration possibly affected by darunavir; concentration reduced by efavirenz and ritonavir; also concentration of efavirenz increased – avoid with ritonavir; with efavirenz reduce dose by 50% and increase dose of voriconazole to 400 mg twice daily; concentration possibly increased by simeprevir – avoid; concentration possibly affected by telaprevir – increased risk of ventricular arrhythmias; possibly increased saquinavir levels; concentration of simeprevir possibly increased – avoid.
- Avanafil: possibly increased avanafil concentration – avoid.
- Benzodiazepines: may inhibit metabolism of diazepam and midazolam.
- Ciclosporin: AUC increased – reduce ciclosporin dose by 50% and monitor closely.
- Clopidogrel: possibly reduced antiplatelet effect.
- Cytotoxics: possibly increases bosutinib concentration – avoid or reduce dose of bosutinib; possibly increases crizotinib and everolimus concentration – avoid; possibly increases ibrutinib, pazopanib and ponatinib concentration – reduce dose of ibrutinib, pazopanib and ponatinib; avoid with ceritinib, lapatinib, nilotinib, cabazitaxel and docetaxel (or reduce dose of cabazitaxel, ceritinib and docetaxel); reduce dose of panobinostat and ruxolitinib.
- Domperidone: possible increased risk of arrhythmias – avoid.
- Ergot alkaloids: risk of ergotism – avoid.
- Ivacaftor and lumacaftor: possibly increase ivacaftor concentration – reduce dose of ivacaftor and ivacaftor with lumacaftor.
- Lipid-lowering drugs: possibly increased risk of myopathy with atorvastatin or simvastatin; avoid with lomitapide.
- Ranolazine: possibly increased ranolazine concentration – avoid.
- Retinoids: possibly increased risk of tretinoin toxicity.
- Sirolimus: increased sirolimus concentration – avoid.
- Tacrolimus: AUC increased – reduce tacrolimus dose to a third and monitor closely.
- Ulcer-healing drugs: esomeprazole and omeprazole concentration increased – reduce omeprazole dose by 50%.

**Administration**

**Reconstitution**
19 mL water for injection

**Route**
Oral, IV

**Rate of administration**
1–2 hours (3 mg/kg/hour)

**Comments**
- Not compatible with sodium bicarbonate or TPN solutions.
- Dilute to a concentration of 2–5 mg/mL with sodium chloride 0.9%, Hartman’s solution or glucose 5%.

**Other information**
- Haemodialysis clearance is 121 mL/min.
- Oral bioavailability is 96%.
- Only use IV in renal patients if patient is unable to tolerate oral, as intravenous vehicle (SBECD) accumulates in renal failure. The vehicle is dialysed at a rate of 55 mL/min.
- Take oral dose 1 hour before or an hour after meals.
- Monitor renal function as can enhance nephrotoxicity of other drugs and concurrent conditions.
- Rare reports of acute renal failure and discoid lupus erythematosus occurring.
- Also reports of haematuria, nephritis and tubular necrosis.
- In clinical trials, 30% of patients developed visual problems, usually with higher doses.
Vortioxetine

**Clinical use**
Antidepressant

**Dose in normal renal function**
5–20 mg once daily

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>298.4 (379.4 as hydrobromide)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>98–99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>59 (as metabolites)</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>2600 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>66</td>
</tr>
</tbody>
</table>

**Metabolism**

Vortioxetine is extensively metabolised in the liver, mainly by oxidation catalysed by CYP2D6 and to a minor extent CYP3A4/5 and CYP2C9, and subsequent glucuronic acid conjugation. The major metabolite of vortioxetine is pharmacologically inactive.

Approximately two thirds of the inactive vortioxetine metabolites are excreted in the urine and approximately one third in the faeces. Only negligible amounts of vortioxetine are excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR range</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in GFR=10–20 mL/min.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Antibacterials: avoid with linezolid; concentration reduced by rifampicin – consider increasing vortioxetine dose.
- Antidepressants: possible increased risk of convulsions with SSRIs and, tricyclics; avoid with moclobemide; increased risk of hypertension and CNS excitation with MAOIs – avoid.
- Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin – consider increasing vortioxetine dose.
- Antimalarials: possible increased risk of convulsions with mefloquine; avoid with artemether with lumefantrine and arteminol with piperaquine.
- Antipsychotics: possible increased risk of convulsions with butyrophenones, phenothiazines and thioxanthenes.
- Dopaminergics: risk of CNS excitation and hypertension with rasagiline and selegiline.

**Administration**

**Reconstitution**

—

**Route**

Oral

**Rate of administration**

—

**Other information**

- Manufacturer advises to use with caution in severe renal impairment due to lack of data.
- Following a single dose of 10 mg vortioxetine, renal impairment estimated using the Cockcroft-Gault formula (mild, moderate, or severe; n=8 per group) caused modest exposure increases (up to 30%), compared to healthy matched controls.
- Oral bioavailability is 75%.
Warfarin sodium

Clinical use
Anticoagulant

Dose in normal renal function
Depends on INR

Pharmacokinetics

<table>
<thead>
<tr>
<th>Molecular weight (daltons)</th>
<th>330.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Protein binding</td>
<td>99</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>0</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>0.14</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>37 / Unchanged</td>
</tr>
</tbody>
</table>

Metabolism
The R- and S-isomers are both metabolised in the liver. The S-isomer is metabolised more rapidly than the R-isomer, mainly by the cytochrome P450 isoenzyme CYP2C9, which shows genetic polymorphism. Other isoenzymes are also involved in the metabolism of the R-isomer. The metabolites, which have negligible or no anticoagulant activity, are excreted in the urine following reabsorption from the bile.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions

Potentially hazardous interactions with other drugs
There are many significant interactions with warfarin.
Prescribe with care with regard to the following:
- Anticoagulant effect enhanced by: alcohol, amiodarone, anabolic steroids, aspirin, aztreonam, bicalutamide, cefalosporins, chloramphenicol, cimetidine, ciprofloxacin, clopidogrel, cranberry juice, danazol, danthon, dipyridamole, dronedarone, disulfiram, entacapone, esomeprazole, exenatide, ezetimibe, fribates, fluconazole, fluotamide, fluvastatin, glucosamine, grapefruit juice,itraconazole, ketoconazole, levamisole, levofloxacin, macrolides, methylphenidate, metronidazole, miconazole, mirtazapine, nalidixic acid, neomycin, norfloxacin, NSAIDs, ofloxacin, omeprazole, pantoprazole, paracetamol, penicillins, progamil, propafenone, ritonavir, rosuvastatin, saquinavir, SSRls, simvastatin, sulfapyrazone, sulphonamides, tamoxifen, tegafur, testosterone, tetracyclines, thyroid hormones, ticaglycine, toremifene, trimadol, trimethoprim, valproate, venlafaxine, vitamin E and voriconazole.
- Anticoagulant effect decreased by: acitretin, atorvastatin, azathioprine, barbiturates, carbamazepine, enteral feeds, eslicarbazepine, enzalutamide, fosphenytoin, ginseng, griseofulvin, oral contraceptives, phenobarbital, phenytoin, primidone, rifamycins, St John’s wort (avoid concomitant use), sucralfate, vitamin K.
- Anticoagulant effects enhanced / reduced by: anion exchange resins, atazanavir, corticosteroids, dietary changes, disopyramide, efavirenz, fosamprenavir, nevirapine, ritonavir, telaprevir, tricyclics, trazodone.
- Analgesics: increased risk of bleeding with IV diclofenac and ketorolac – avoid concomitant use.
- Anticoagulants: increased risk of haemorrhage with apixaban, dabigatran, edoxaban and rivaroxaban – avoid concomitant use.
- Antidiabetic agents: enhanced hypoglycaemic effect with sulphonylureas; also possible changes to anticoagulant effect.
- Camomile: enhanced anticoagulation.
- Ciclosporin: there have been a few reports of altered anticoagulant effect; decreased ciclosporin levels have been seen rarely.
- Cytotoxics: increased risk of bleeding with erlotinib, imatinib and regorafenib; enhanced effect with capecitabine, etoposide, fluorouracil, ifosfamide, gefitinib, gemcitabine, sorafenib and vemurafenib; reduced effect with mercaptopurine and mitotane.
- Melatonin: possibly enhanced INR.

Administration

Reconstitution
- Route Oral
- Rate of administration —

Other information
- Reduced protein binding in renal impairment.
Xipamide

Clinical use
Thiazide diuretic:
- Hypertension
- Oedema

Dose in normal renal function
- Oedema: 40–80 mg in the morning
- Maintenance: 20 mg in the morning
- Hypertension: 20 mg in the morning

Pharmacokinetics
Molecular weight (daltons) 354.8
% Protein binding 99
% Excreted unchanged in urine 50
Volume of distribution (L/kg) 10–21 Litres
Half-life — normal/ESRF (hrs) 5–8 / 9–32

Metabolism
Xipamide is excreted in the urine, partly unchanged and partly in the form of the glucuronide metabolite. In patients with renal impairment excretion in the bile becomes more prominent.

Dose in renal impairment GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.

Dose in patients undergoing renal replacement therapies
APD/CAPD Unknown dialysability. Dose as in normal renal function.
HD Dialysed. Dose as in normal renal function.
HDF/High flux Dialysed. Dose as in normal renal function.
CAV/VVHD Unknown dialysability. Dose as in normal renal function.

Important drug interactions
Potentially hazardous interactions with other drugs
- Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect.
- Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised.

- Antibacterials: avoid administration with lymecycline.
- Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
- Antiepileptics: increased risk of hyponatraemia with carbamazepine.
- Antifungals: increased risk of hypokalaemia with ampheoterin.
- Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with post-synaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol.
- Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide – avoid concomitant use.
- Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
- Cardiac glycosides: increased toxicity if hypokalaemia occurs.
- Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia.
- Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
- Lithium excretion reduced (increased toxicity).

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
- Monitor for hypokalaemia.
- Diuresis starts within 1–2 hours, peaks at 4–6 hours and lasts for almost 24 hours.
- Manufacturer advises to avoid in severe renal impairment due to reduced clearance.
Zafirlukast

Clinical use
Leukotriene receptor antagonist:
• Prophylaxis of asthma

Dose in normal renal function
20 mg twice daily

Pharmacokinetics
Molecular weight (daltons) 575.7
% Protein binding 99
% Excreted unchanged in urine 0 (10% as metabolites)
Volume of distribution (L/kg) 70 Litres
Half-life — normal/ESRF (hrs) 10 / Possibly unchanged

Metabolism
Zafirlukast is extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP2C9. Following a radiolabelled dose the urinary excretion accounts for approximately 10% of the dose and faecal excretion for 89%. The metabolites identified in human plasma were found to be at least 90-fold less potent than zafirlukast in a standard in-vitro test of activity.

Dose in patients undergoing renal replacement therapies
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function, but use with care.</td>
</tr>
<tr>
<td>HD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function, but use with care.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function, but use with care.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function, but use with care.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Aminophylline: possibly increases aminophylline concentration; zafirlukast concentration reduced.
• Analgesics: concentration increased by aspirin.
• Antibacterials: concentration reduced by erythromycin.
• Anticoagulants: may enhance the effects of warfarin.
• Theophylline: possibly increases theophylline concentration; zafirlukast concentration reduced.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• UK SPC advises to use with caution due to lack of experience, no dose reduction is suggested in US data sheet or Drug Prescribing in Renal Failure, 5th edition by Aronoff et al.
• Do not take with food as it reduces bioavailability.
# Zanamivir

## Clinical use
- Treatment of influenza A and B within 48 hours after onset of symptoms
- Post exposure prophylaxis, up to 28 days during an epidemic

## Dose in normal renal function
Treatment: 10 mg twice daily for 5–10 days
Prophylaxis: 10 mg once daily for 10 days (for up to 28 days during an epidemic)

## Pharmacokinetics
- Molecular weight (daltons): 332.3
- % Protein binding: <10
- % Excreted unchanged in urine: 100
- Volume of distribution (L/kg): No data
- Half-life — normal/ESRF (hrs): 2.6–5 / Increased

## Metabolism
Zanamivir is renally excreted as unchanged drug, and does not undergo metabolism.

## Dose in renal impairment GFR (mL/min)
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function.
- <10: Dose as in normal renal function.

## Dose in patients undergoing renal replacement therapies
- APD/CAPD: Unknown dialysability. Dose as in normal renal function.
- HD: Unknown dialysability. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Unknown dialysability. Dose as in normal renal function.

## Important drug interactions
Potentially hazardous interactions with other drugs
- None known

## Administration

### Reconstitution
- —

### Route
- Inhalation

### Rate of administration
- —

## Other information
- 10–20% of dose is systemically absorbed.
Zepatier (elbasvir 50 mg / grazoprevir 100 mg)

Clinical use
Elbasvir is a HCV NS5A inhibitor, Grazoprevir is a HCV NS3/4A protease inhibitor
• Treatment of chronic hepatitis C

Dose in normal renal function
1 tablet daily

Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Elbasvir</th>
<th>Grazoprevir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>882;</td>
<td>766.9</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>99.9;</td>
<td>98.8</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
<td></td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>680 Litres;</td>
<td>1250 Litres</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>24;</td>
<td>31</td>
</tr>
</tbody>
</table>

Metabolism
Elbasvir and grazoprevir are partially eliminated by oxidative metabolism, mainly by CYP3A. No circulating metabolites of either elbasvir or grazoprevir were detected in human plasma. Excretion is mainly via the faeces (>90%).

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unlikely to be dialysed. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

Important drug interactions
Potentially hazardous interactions with other drugs
• Avoid with CYP3A4 and OATP1B inhibitors.
• Antibacterials: concentration of grazoprevir may be increased by rifampicin – avoid.
• Anticoagulants: concentration of dabigatran increased; monitor INR closely due to changes in liver function with coumarins.
• Antidepressants: avoid with St John’s wort.
• Antiepileptics: concentration of Zepatier may be reduced by carbamazepine, fosphenytoin and phenytoin – avoid.
• Antifungals: concentration of grazoprevir may be increased by ketoconazole – avoid.
• Antivirals: concentration of grazoprevir increased by atazanavir, darunavir, lopinavir and possibly saquinavir and tipranavir – avoid; concentration of Zepatier reduced by efavirenz – avoid; avoid with etravirine; concentration of Zepatier increased by ritonavir – avoid.
• Bosentan: concentration of Zepatier may be reduced – avoid.
• Ciclosporin: concentration of grazoprevir increased avoid.
• Cobicistat: concentration of Zepatier increased – avoid.
• Lipid lowering agents: maximum dose of atorvastatin, fluvastatin, lovastatin and simvastatin is 20 mg and rosuvastatin 10 mg when used in combination.
• Modafinil: avoid concomitant use.
• Tacrolimus: concentration of tacrolimus increased.

Administration
Reconstitution
—
Route
Oral
Rate of administration
—

Other information
• Less than 0.5 % of grazoprevir was recovered in dialysate over a 4-hour dialysis session.
• In population pharmacokinetic analysis in HCV-infected patients, elbasvir and grazoprevir AUCs
were 25% and 10% higher, respectively, in dialysis-dependent patients and 46% and 40% higher, respectively, in non-dialysis-dependent patients with severe renal impairment compared to elbasvir and grazoprevir AUC in patients without severe renal impairment.
# Zerbaxa (ceftolozane and tazobactam sodium)

## Clinical use
Antimicrobial agent

## Dose in normal renal function
1 g ceftolozane / 0.5 g tazobactam every 8 hours, duration depends on indication

## Pharmacokinetics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Ceftolozane</th>
<th>Tazobactam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>666.7</td>
<td>322.3</td>
</tr>
<tr>
<td>(as sodium)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Protein binding</td>
<td>16–21</td>
<td>20–30</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&gt;95</td>
<td>80</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>13.5</td>
<td>0.18–0.33</td>
</tr>
<tr>
<td>Litres, Tazobactam:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>3 / Increased,</td>
<td>1 / 7</td>
</tr>
</tbody>
</table>

## Metabolism
Ceftolozane is eliminated in the urine as unchanged parent substance and thus does not appear to be metabolised to any appreciable extent.

Tazobactam is metabolised to a single metabolite that has been found to be microbiologically inactive. More than 80% of tazobactam was excreted as the parent compound with the remaining amount excreted as the tazobactam M1 metabolite.

## Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Ceftolozane</th>
<th>Tazobactam</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–50</td>
<td>500 mg</td>
<td>250 mg</td>
</tr>
<tr>
<td></td>
<td>ceftolozane</td>
<td>tazobactam</td>
</tr>
<tr>
<td>15–29</td>
<td>250 mg</td>
<td>125 mg</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Loading dose: 500 mg ceftolozane / 250 mg tazobactam then 100 mg ceftolozane / 50 mg tazobactam every 8 hours.</td>
<td></td>
</tr>
</tbody>
</table>

## Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Dose details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Dialysed. Dose as in GFR&lt;15 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Dialysed. Dose as in GFR=15–29 mL/min. See 'Other information'.</td>
</tr>
</tbody>
</table>

## Important drug interactions
Potentially hazardous interactions with other drugs
- Anticoagulants: effects of coumarins may be enhanced.

## Administration

### Reconstitution
10 mL water for injection or sodium chloride 0.9%

### Route
IV infusion

### Rate of administration
Over 60 minutes

### Comments
Add appropriate volume to 100 mL sodium chloride 0.9% or glucose 5%.

## Other information
- Approximately 66% of ceftolozane, 56% of tazobactam, and 51% of the M1 metabolite of tazobactam were removed by dialysis.
- Each vial contains 10 mmol Na.
- A case study has given a patient with multidrug-resistant Pseudomonas aeruginosa pneumonia, bacteramia, and osteomyelitis 2 g ceftolozane / 1 g tazobactam every 8 hours while receiving CVVHDF. From pharmacokinetic data they concluded that giving 1 g ceftolozane / 0.5 g tazobactam to this patient would have given similar AUC profile as a patient with normal renal function given 2 g ceftolozane / 1 g tazobactam. Therefore they concluded that normal dosing may be used in CRRT but that more studies are required to confirm this data.\(^2\)
There are several methods of dosing drugs while a patient is undergoing continuous renal replacement therapy (CRRT) including the following guideline: The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid going through the filter circuit i.e. blood flow, citrate, dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL/minute, equated to a patient GFR. E.g. blood flow rate = 100 mL/min, filtration fluid flow rate = 1000 mL/hr, dialysis flow rate = 1000 mL/hr, replacement rate (post filter) = 200 mL/hr – this gives a CRRT dose of 2200 mL/hr. This is then divided by 60 to give an approximate GFR of 36.7 mL/min. Dose would then be according to the GFR rather than using the dialysis recommendations.

References:
Ziconotide (unlicensed)

**Clinical use**
Analgesia for intrathecal use

**Dose in normal renal function**
2.4–21.6 mcg daily; majority require <9.6 mcg/day

**Pharmacokinetics**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight (daltons)</td>
<td>2639.1 (2699.2 as acetate)</td>
</tr>
<tr>
<td>% Protein binding</td>
<td>53</td>
</tr>
<tr>
<td>% Excreted unchanged in urine</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Volume of distribution (L/kg)</td>
<td>30</td>
</tr>
<tr>
<td>Half-life — normal/ESRF (hrs)</td>
<td>1.3 / Unchanged</td>
</tr>
</tbody>
</table>

**Metabolism**

Ziconotide is a peptide consisting of 25 naturally-occurring amino acids and does not appear to be metabolised in the CSF. Once in the systemic circulation, ziconotide is expected to be mainly susceptible to proteolytic cleavage by various peptidases/proteases present in most organs (e.g., kidney, liver, lung, muscle, etc.), and then degraded to peptide fragments and its individual constituent free amino acids. These amino acids are expected to be taken up by cellular carrier systems and either subjected to normal intermediary metabolism or used as substrates for constitutive biosynthetic processes. Due to the wide distribution of these peptidases it is not expected that hepatic or renal impairment would affect the systemic clearance of ziconotide.

The biological activity of the various proteolytic degradation products has not been assessed although they are unlikely to have significant activity.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Dose as in normal renal function. Use with caution.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>CAV/VVHD</td>
<td>Unknown dialysability. Dose as in normal renal function.</td>
</tr>
</tbody>
</table>

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Contraindicated with IT chemotherapy.
- Can increase neuropsychiatric events with IT morphine.

**Administration**

**Reconstitution**

- **Route**
  Intrathecal

- **Rate of administration**
  Over 24 hours

**Comments**

- Dilute with preservative-free sodium chloride 0.9%; concentration should be no lower than 5 mcg/mL in an external pump and 25 mcg/mL in an internal pump.

**Other information**

- Use with caution in renal impairment due to lack of studies – start with the lower dose range.
- Has rarely caused rhabdomyolysis, myositis, acute kidney injury and urinary retention.
Zidovudine

Clinical use
Nucleoside reverse transcriptase inhibitor:
- Treatment of HIV in combination with other antiretroviral drugs
- Prevention of maternal-foetal HIV transmission

Dose in normal renal function
Oral: 250–300 mg twice daily
IV: 0.8–1 mg/kg every 4 hours
Prevention of maternal-foetal HIV transmission: 500 mg daily in divided doses

Pharmacokinetics
Molecular weight (daltons) 267.2
% Protein binding 34–38
% Excreted unchanged in urine 8–25
Volume of distribution (L/kg) 1.6
Half-life — normal/ESRF (hrs) 1.1 / 1.4–3

Metabolism
Zidovudine is metabolised intracellularly to the antiviral triphosphate. It is also metabolised in the liver, mainly to the inactive glucuronide, and is excreted in the urine as unchanged drug and metabolite. The 5’-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50–80% of the administered dose eliminated by renal excretion. There is substantial accumulation of this metabolite in renal failure. Renal clearance of zidovudine greatly exceeds creatinine clearance, indicating that significant tubular secretion takes place.

Dose in renal impairment GFR (mL/min)

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dosage Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–50</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>10–20</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>&lt;10</td>
<td>Give 50% of normal dose every 8 hours. i.e 300–400 mg daily in divided doses.¹</td>
</tr>
</tbody>
</table>

Dose in patients undergoing renal replacement therapies

<table>
<thead>
<tr>
<th>Renal Replacement Therapy</th>
<th>Dosage Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>APD/CAPD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min.</td>
</tr>
<tr>
<td>HD</td>
<td>Not dialysed. Dose as in GFR&lt;10 mL/min. Give post dialysis.</td>
</tr>
<tr>
<td>HDF/High flux</td>
<td>Unknown dialysability. Dose as in GFR&lt;10 mL/min. Give post dialysis.</td>
</tr>
</tbody>
</table>

CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

Important drug interactions
Potentially hazardous interactions with other drugs
- Antibacterials: absorption reduced by clarithromycin; avoid concomitant use with rifampicin.
- Antiepileptics: phenytoin levels may be raised or lowered; concentration possibly increased by valproate (increased risk of toxicity).
- Antifungals: concentration increased by fluconazole.
- Antivirals: profound myelosuppression with ganciclovir and valganciclovir – avoid if possible; increased risk of granulocytopenia with nevirapine; increased risk of anaemia with ribavirin – avoid; effects of stavudine inhibited – avoid concomitant use; concentration reduced by tipranavir.
- Orlistat: absorption possibly reduced by orlistat.
- Probenecid: excretion reduced by probenecid, increased risk of toxicity.

Administration
Reconstitution
—
Route
IV, oral
Rate of administration
1 hour
Comments
Dilute with glucose 5% infusion to give a final concentration of 2 mg/mL or 4 mg/mL.

Other information
- Dialysis has little effect on zidovudine, presumably because of rapid metabolism. The glucuronide metabolite (half-life = 1 hour) has no antiviral activity and will be significantly removed by dialysis.
- Patients with severe renal failure have 50% higher maximum plasma concentrations.
- Main risk in renal impairment is haematological toxicity.
- Oral bioavailability is 60–70%.

Reference:
Zoledronic acid

**Clinical use**
- Hypercalcaemia of malignancy
- Reduction of bone damage in advanced malignancies
- Paget's disease
- Osteoporosis

**Dose in normal renal function**

**Zometa:**
- Hypercalcaemia of malignancy: 4 mg as a single dose
- Reduction of bone damage in advanced malignancies: 4 mg every 3–4 weeks

**Aclasta:**
- Paget’s disease: 5 mg as a single dose
- Osteoporosis: 5 mg yearly

**Pharmacokinetics**
- Molecular weight (daltons): 272.1
- % Protein binding: 56
- % Excreted unchanged in urine: 39 +/− 16
- Volume of distribution (L/kg): 6.1–10.8 Litres
- Half-life — normal/ESRF (hrs): 146 / Increased

**Metabolism**
Zoledronic acid is not metabolised and is excreted unchanged via the kidney. Over the first 24 hours, 39 ± 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue.

**Dose in renal impairment GFR (mL/min)**

<table>
<thead>
<tr>
<th>GFR (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
<td>Dose as in normal renal function.</td>
</tr>
<tr>
<td>50–60</td>
<td>Zometa: 3.5 mg; Aclasta: Dose as in normal renal function.</td>
</tr>
<tr>
<td>40–49</td>
<td>Zometa: 3.3 mg; Aclasta: Dose as in normal renal function.</td>
</tr>
<tr>
<td>30–39</td>
<td>Zometa: 3 mg; Aclasta: avoid if GFR&lt;35 mL/min.</td>
</tr>
<tr>
<td>&lt;29</td>
<td>Avoid. Unless benefit outweighs risk.</td>
</tr>
</tbody>
</table>

**Dose in patients undergoing renal replacement therapies**

- **APD/CAPD**
  - Unknown dialysability. Dose as in GFR<29 mL/min.
- **HD**
  - Unknown dialysability. Dose as in GFR<29 mL/min.
- **HDF/High flux**
  - Unknown dialysability. Dose as in GFR<29 mL/min.
- **CAV/VVHD**
  - Unknown dialysability. Dose as in GFR=30–39 mL/min

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Other nephrotoxic drugs: use with caution as can enhance nephrotoxicity.

**Administration**

**Reconstitution**
Add 5 mL of water for injection to each 4 mg vial.

**Route**
IV

**Rate of administration**
15 minutes

**Comments**
- Add to 100 mL sodium chloride 0.9% or glucose 5%.
- Reconstituted solutions are stable for 24 hours at room temperature.

**Other information**
- Also administer a calcium supplement of 500 mg daily plus 400 IU of vitamin D daily with Zometa and 50,000 to 125,000 IU of vitamin D with Aclasta in patients with recent hip fractures. Renal impairment has been observed following the administration of Aclasta, especially in patients with pre-existing renal impairment. Other risk factors are: increasing age, repeated cycles of bisphosphonates, concomitant nephrotoxic medication, diuretic therapy or dehydration occurring after Aclasta administration.

- A small number of cases of renal failure requiring dialysis or with a fatal outcome have been reported.

- May cause osteonecrosis of the jaw.
**Zolmitriptan**

### Clinical use

5HT\_1 receptor agonist:
- Acute treatment of migraine
- Cluster headache

### Dose in normal renal function

Oral: 2.5–5 mg, repeated after 2 hours if required; maximum 10 mg in 24 hours
Intranasally for cluster headaches: 5 mg into 1 nostril as soon as possible after onset, repeated after not less than 2 hours, max 10 mg in 24 hours

### Pharmacokinetics

- Molecular weight (daltons) 287.4
- % Protein binding 25
- % Excreted unchanged in urine 60 (as metabolites)
- Volume of distribution (L/kg) 2.4
- Half-life — normal/ESRF (hrs) 2.5–3 / 3–3.5

### Metabolism

Zolmitriptan is eliminated largely by hepatic biotransformation followed by urinary excretion of the metabolites. There are three major metabolites: the indole acetic acid, (the major metabolite in plasma and urine), the N-oxide and N-desmethyl analogues. Only the N-desmethylated metabolite is active. The primary metabolism of zolmitriptan is mediated mainly by the cytochrome P450 isoenzyme CYP1A2 while monoamine oxidase type A is responsible for further metabolism of the N-desmethyl metabolite. Over 60% of a dose is excreted in the urine, mainly as the indole acetic acid, and about 30% appears in the faeces, mainly as unchanged drug.

### Dose in renal impairment GFR (mL/min)

- 20–50  Dose as in normal renal function.
- 10–20  Dose as in normal renal function.
- <10  Dose as in normal renal function.\(^1\)

### Dose in patients undergoing renal replacement therapies

- APD/CAPD  Unknown dialysability. Dose as in normal renal function.
- HD  Unknown dialysability. Dose as in normal renal function.
- HDF/High flux  Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD  Unknown dialysability. Dose as in normal renal function.

### Important drug interactions

Potentially hazardous interactions with other drugs
- Antibacterials: quinolones possibly inhibit metabolism — reduce dose of zolmitriptan.
- Antidepressants: increased risk of CNS toxicity with citalopram — avoid; risk of CNS toxicity with MAOIs and moclobemide — reduce dose of zolmitriptan to max 7.5 mg; SSRIs inhibit metabolism of zolmitriptan, reduce dose with fluvoxamine; possibly increased serotonergic effects with duloxetine and venlafaxine; increased serotonergic effects with St John’s wort — avoid concomitant use.
- Cimetidine: inhibits metabolism of zolmitriptan; maximum dose is 5 mg.
- Dapoxetine: possible increased risk of serotonergic effects — avoid for 2 weeks after stopping 5HT\_1 agonists.
- Ergot alkaloids: increased risk of vasospasm.
- Linezolid: risk of CNS toxicity — reduce dose of zolmitriptan.

### Administration

**Reconstitution**

- **Route** Oral

### Rate of administration

- **Other information**

- Oral bioavailability is 40%.
- Contraindicated if GFR<15 mL/min in UK SPC but not in US data sheet.
- One study showed that no dose reduction was required in patients not on dialysis. (Gillotin C, Bagnis C, Mamet JP, et al. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment in patients with renal failure not requiring dialysis. *Int J Clin Pharmacol Ther.* 1997; 35(11): 522–6).

**Reference:**

Zolpidem tartrate

**Clinical use**
Insomnia (short-term treatment)

**Dose in normal renal function**
5–10 mg at night.

**Pharmacokinetics**
- Molecular weight (daltons): 764.9
- % Protein binding: 92.5
- % Excreted unchanged in urine: Negligible (56% as active metabolites)
- Volume of distribution (L/kg): 0.34–0.54 (depends on age)
- Half-life — normal/ESRF (hrs): Average: 2.4 / Increased

**Metabolism**
Zolpidem tartrate is metabolised via several hepatic cytochrome P450 enzymes, the main enzyme being CYP3A4 with the contribution of CYP1A2. All metabolites are pharmacologically inactive and are eliminated in the urine (56%) and in the faeces (37%).

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Not dialysed. Dose as in normal renal function.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High flux: Unknown dialysability. Dose as in normal renal function.
- CAV/VVHD: Not dialysed. Dose as in normal renal function.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism accelerated by rifampicin.
- Antidepressants: increased sedative effects with sertraline.
- Antipsychotics: enhanced sedative effects.
- Antivirals: concentration increased by ritonavir (risk of extreme sedation and respiratory depression) – avoid concomitant use.

**Administration**

**Reconstitution**
- Route: Oral

**Rate of administration**
- Other information

- First pass metabolism by liver is 35%.
- Clearance is reduced in renal impairment.
- Oral bioavailability is 70%.
**Zonisamide**

**Clinical use**
Antiepileptic

**Dose in normal renal function**
- Monotherapy: Initially 100 mg once daily increasing to maximum 500 mg daily
- Initially: 25 mg twice daily, increasing to maintenance dose of 300–500 mg daily in 1 or 2 divided doses

**Pharmacokinetics**
- Molecular weight (daltons) 212.2
- % Protein binding 40–60
- % Excreted unchanged in urine 15–35
- Volume of distribution (L/kg) 0.8–1.6
- Half-life — normal/ESRF (hrs) 60–63 / Increased

**Metabolism**
Zonisamide is metabolised mainly by reductive cleavage of the benzisoxazole ring of the parent drug by CYP3A4 to form 2-sulphamoylacetylphenol (SMAP) and also by N-acetylation. Parent drug and SMAP can also be glucuronidated.
The metabolites, which could not be detected in plasma, are inactive. Excretion is mainly in the urine; about 15 to 30% appearing as unchanged drug, 15% as N-acetylzonisamide, and 50% as the glucuronide of SMAP.

**Dose in renal impairment GFR (mL/min)**
- 20–50: Dose as in normal renal function.
- 10–20: Dose as in normal renal function, titrate slowly. See ‘Other information’.
- <10: Dose as in normal renal function, titrate slowly. See ‘Other information’.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Probably dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antidepressants: anticonvulsant effect antagonised; avoid with St John's wort.
- Antimalarials: anticonvulsant effect antagonised by mefloquine.
- Antipsychotics: anticonvulsant effect antagonised.
- Orlistat: increased risk of convulsions.

**Administration**

**Reconstitution**
—

**Route**
Oral

**Rate of administration**
—

**Other information**
- AUC is increased by 35% in patients with a GFR<20 mL/min.
- Bioavailability is 100%.
- Increase dose at 2 weekly intervals in people with renal impairment and monitor more frequently.
Zopiclone

**Clinical use**
Hypnotic

**Dose in normal renal function**
3.75–7.5 mg at night

**Pharmacokinetics**
- Molecular weight (daltons): 388.8
- % Protein binding: 45–80
- % Excreted unchanged in urine: <5
- Volume of distribution (L/kg): 91.8–104.6 Litres
- Half-life — normal/ESRF (hrs): 3.5–6.5 / Unchanged

**Metabolism**
Zopiclone is extensively metabolised in the liver via the cytochrome P450 isoenzyme CYP3A4 and, to a lesser extent, CYP2C8; the 2 major metabolites, the less active zopiclone N-oxide and the inactive N-desmethylzopiclone, are excreted mainly in the urine. About 50% of a dose is converted by decarboxylation to inactive metabolites, which are partly eliminated via the lungs as carbon dioxide.

**Dose in patients undergoing renal replacement therapies**
- APD/CAPD: Dialysed. Dose as in GFR<10 mL/min.
- HD: Dialysed. Dose as in GFR<10 mL/min.
- HDF/High flux: Dialysed. Dose as in GFR<10 mL/min.
- CAV/VVHD: Dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**
Potentially hazardous interactions with other drugs
- Antibacterials: metabolism inhibited by erythromycin; concentration significantly reduced by rifampicin.
- Antipsychotics: enhanced sedative effects.
- Antivirals: concentration possibly increased by ritonavir.

**Administration**

**Reconstitution**
- **Route**: Oral
- **Rate of administration**: —

**Other information**
- It is recommended that elderly patients and those with severe renal disease should start treatment with 3.75 mg; however, accumulation has not been observed.
**Zuclopenthixol**

**Clinical use**

Antipsychotic for schizophrenia and other psychoses

**Dose in normal renal function**

Schizophrenia and paranoid psychoses:
- Oral: 20–30 mg daily in divided doses; maximum 150 mg daily
- Maintenance: 20–50 mg daily.
- Deep IM: 200–500 mg every 1–4 weeks. Maximum: 600 mg weekly

Acute psychoses: (Clopixol Acuphase)
- Deep IM: 50–150 mg, repeated if required after 2–3 days. Maximum 400 mg per course

**Pharmacokinetics**

Molecular weight (daltons) 401 (443 as acetate), (473.9 as hydrochloride), (555.2 as decanoate)

% Protein binding 98
% Excreted unchanged in urine Minimal (10–20% unchanged drug and metabolites)

Volume of distribution (L/kg) 10–20
Half-life — normal/ESRF (hrs) 20–24 / –

**Metabolism**

Metabolism of zuclopenthixol is by sulphoxidation, side-chain N-dealkylation and glucuronic acid conjugation. The sulphoxide metabolites are mainly excreted in the urine while unchanged drug and the dealkylated form tend to be excreted in the faeces.

**Dose in renal impairment GFR (mL/min)**

20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Start with 50% of the dose and titrate slowly.

**Dose in patients undergoing renal replacement therapies**

APD/CAPD Not dialysed. Dose as in GFR<10 mL/min.

HD Not dialysed. Dose as in GFR<10 mL/min.

HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min.

CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

**Important drug interactions**

Potentially hazardous interactions with other drugs
- Anaesthetics: enhanced hypotensive effects.
- Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone.
- Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval – avoid with amiodarone and disopyramide.
- Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and parenteral erythromycin – avoid
- Antidepressants: increased level of tricyclics; possible increased risk of convulsions with vortioxetine.
- Antiepileptics: anticonvulsant effect antagonised.
- Antimalarials: avoid concomitant use with artemether/lumefantrine.
- Antipsychotics: avoid concomitant use of clozapine with depot preparations in case of neutropenia; possible increased risk of ventricular arrhythmias with risperidone.
- Antivirals: concentration possibly increased with ritonavir.
- Atomoxetine: increased risk of ventricular arrhythmias.
- Anxiolytics and hypnotics: increased sedative effects.
- Beta-blockers: increased risk of ventricular arrhythmias with sotalol – avoid.
- Cytotoxics: increased risk of ventricular arrhythmias with vandetanib – avoid; increased risk of ventricular arrhythmias with arsenic trioxide.

**Administration**

**Reconstitution**

—

**Route**

Oral, IM

**Rate of administration**

—

**Other information**

- May cause hypotension and excessive sedation.
- Increased CNS sensitivity in renally impaired patients – start with small doses as can accumulate.
- Peak levels occur 3–6 hours after oral administration.
Drugs for malaria prophylaxis

The malaria prophylaxis regimens below reflect the guidelines agreed by UK malaria specialists, and are aimed at residents of the UK who travel to endemic areas. Because the drug sensitivities of malaria parasites change with time and place, the most up-to-date information on prophylaxis should always be obtained from an appropriate travel clinic.

**Mefloquine (Lariam®)**

- 250 mg (ONE tablet) ONCE a WEEK, starting 2–3 weeks prior to travelling and continuing for 4 weeks after returning.
- NO dose changes are required for patients with any degree of renal impairment.

**Doxycycline**

- 100 mg (ONE capsule) ONCE a DAY starting 1–2 days prior to travelling and continuing for 4 weeks after returning.
- CAPD or HAEMODIALYSIS patients – No dose adjustment required.
- TRANSPLANT patients – Doxycycline can DOUBLE the blood levels of Ciclosporin and Tacrolimus. Advise to commence taking the doxycycline at least 1 week prior to travelling to enable ciclosporin or tacrolimus levels to be monitored and adjusted as necessary.

**Chloroquine (Avloclor® or Nivaquine®) and Proguanil (Paludrine®)**

- CHLOROQUINE (base) 310 mg (TWO tablets) ONCE a WEEK, plus
- PROGUANIL 200 mg (TWO tablets) ONCE a DAY starting 1 week prior to travelling and continuing for 4 weeks after returning.

Chloroquine:

- Malaria prophylaxis: no dose adjustment necessary for renal impairment.
- Malaria treatment, i.e. full therapeutic dose: take the following into consideration:
  - TRANSPLANT patients: Chloroquine increases plasma Ciclosporin levels – monitor carefully.

Patients with renal insufficiency:

- GFR (mL/min) 20–59 100% dose.
- GFR (mL/min) 10–19 100% dose.
- GFR (mL/min) <10 50% dose.

Proguanil:

- TRANSPLANT patients: Dose according to the level of function of the renal transplant.
- CAPD and HAEMODIALYSIS patients: half a tablet (50 mg) once a week.

Patients with renal insufficiency:

- GFR (mL/min) >60 200 mg OD.
- GFR (mL/min) 20–59 100 mg OD.
- GFR (mL/min) 10–19 50 mg alt days.
- GFR (mL/min) <10 50 mg once a week.

Patients with renal insufficiency receiving proguanil should also be prescribed folic acid 5 mg daily to minimise side effects.

**Atovaquone 250 mg + Proguanil 100 mg (Malarone®)**

ONE tablet daily starting 1–2 days before travelling, and continuing for 7 days after returning.

Atovaquone + Proguanil dose

- GFR (mL/min) >30 Normal dose.
- GFR (mL/min) <30 Malarone not recommended, because with the combined preparation it is not possible to reduce the dose of proguanil but take the full dose of atovaquone. Use alternative therapy.
Live vaccines should NOT be administered to immunosuppressed patients – this includes both transplant patients, and those on dialysis.

Inactivated vaccines can be administered to immunosuppressed patients, although the response may be reduced, and further booster doses may be required as dictated by measuring antibody titres.

### Vaccines that are not recommended

- **BCG** (Bacillus Calmette-Guerin) vaccine
- **INFLUENZA** vaccine for intranasal use (Fluenz™)
- **MEASLES, MUMPS, RUBELLA** vaccine (MMrvaxPro®, Priorix®)
- **POLIO** Oral vaccine (Sabin) (OPV*), including household contacts of immunosuppressed patients as transmission of the live virus through faeces is possible.
- **ROTAVIRUS** vaccine (Rotarix®). For vaccination of children, but the rotavirus is excreted in the stool and may be transmitted to close contacts. However, vaccination of those with immunosuppressed close contacts may protect the contacts from wild-type rotavirus disease and outweigh any risk from transmission of vaccine virus.
- **TYPHOID** Oral vaccine (Vivotif®)
- **VARICELLA-ZOSTER** vaccine (Varilix®, Varivax®, Zostavax®)
- **YELLOW FEVER** vaccine (Stamaril™)

### Vaccines that may be administered

- **ANTHRAX** vaccine
- **CHOLERA** oral vaccine (Dukoral™)
- **DIPHTHERIA Adsorbed (low dose), TETANUS and INACTIVATED POLIOMYELITIS** vaccine (Revaxis®)
- **DIPHTHERIA Adsorbed (low dose), TETANUS, PERTUSSIS and INACTIVATED POLIOMYELITIS** vaccine (Infanrix-IPV®, Repevax®)
- **DIPHTHERIA Adsorbed, TETANUS, PERTUSSIS, POLIOMYELITIS (inactivated) and Haemophilus Type b Conjugate** (Adsorbed) vaccine (Infanrix-IPV+Hib®, Pediacel®)
- **HAEMOPHILUS INFLUENZAE type b & MENINGOCOCCAL Group C conjugate vaccine** (Menitorix®)
- **HEPATITIS A** vaccine (Avaxim®, Havrix Monodose®, VAQTA™)
- **HEPATITIS B** vaccine (Engerix B®, Fendrix®, HBvaxPRO®)
- **HEPATITIS A & B** vaccine (Ambirix®, Twinrix®)
- **HEPATITIS A & TYPHOID** vaccine (Hepatyx®, ViATIM®)
- **HUMAN PAPILLOMAVIRUS** vaccine (Cervarix®, Gardasil®)
- **INFLUENZA** Split Virion and Surface Antigen vaccines (Agrippal®, Enzira, Fluarix®, Imuvac®, Intanza®)
- **JAPANESE ENCEPHALITIS** vaccine (Ixiaro®)
- **MENINGOCOCCAL Group B Adsorbed** vaccine (Bexsero®)
- **MENINGOCOCCAL Group C Conjugate** vaccine (NeisVac-C®)
- **MENINGOCOCCAL A, C, W135 and Y, Polysaccharide** vaccine (ACWY Vax®) and **Conjugate** vaccine (Menveo®, Nimenrix®)
- **PNEUMOCOCCAL** Polysaccharide vaccine (Pneumovax II®) and **Conjugate** vaccine (Prevenar 13®, Synflorix®)
- **POLIO** Inactivated vaccine (Salk) (IPV®)
- **RABIES** vaccine (Rabipur®)
- **TICK-BORNE ENCEPHALITIS** vaccine (TicoVac®)
- **TYPHOID Vi Capsular Polysaccharide** vaccine (Typherix®, Typhim Vi®)